11284996
D009569_D006261 CID oxide-induced_6\JJ\1740|nitric (r_amod) headache_7\NN\5829480|during|oxide-induced|patients
D009569_D006261 CID oxide_6\NN\14818238|nitric|no (r_nmod:npmod) induced_10\JJ\1740|oxide (r_amod) headache_11\NN\5829480|induced|headaches
D009569_D006261 CID no_8\NN\7204911|(|) (r_appos) oxide_6\NN\14818238|nitric|no (r_nmod:npmod) induced_10\JJ\1740|oxide (r_amod) headache_11\NN\5829480|induced|headaches
D009569_D006261 CID no_17\NN\7204911| (r_compound) donor_18\NN\9608709|no (r_compound) trinitrate_20\NN\1740|by|the|donor|glyceryl|gtn (r_nmod) induced_14\VBN\1627355|trinitrate (r_acl) headache_13\NN\5829480|during|induced
D009569_D006261 CID no-induced_5\JJ\1740| (r_amod) headache_7\NN\5829480|no-induced|immediate
D009569_D018781 NONE oxide-induced_6\JJ\1740|nitric (r_amod) headache_7\NN\5829480|during|oxide-induced|patients (l_nmod) patients_9\NNS\9898892|in|headache (l_nmod) headache_13\NN\5829480|with|chronic|tension-type
D009569_D018781 NONE no_17\NN\7204911| (r_compound) donor_18\NN\9608709|no (r_compound) trinitrate_20\NN\1740|by|the|donor|glyceryl|gtn (r_nmod) induced_14\VBN\1627355|trinitrate (r_acl) headache_13\NN\5829480|during|induced (r_nmod) levels_9\NNS\4916342|plasma|cgrp|headache (r_dobj) investigate_7\VB\644583|to|levels|patients (l_nmod) patients_26\NNS\9898892|in|16|headache|and|controls (l_nmod) headache_30\NN\5829480|with|chronic|tension-type
D009569_D051270 NONE oxide_6\NN\14818238|nitric|no (r_nmod:npmod) induced_10\JJ\1740|oxide (r_amod) headache_11\NN\5829480|induced|headaches (l_nmod) headaches_14\NNS\5829480|in|primary
D009569_D051270 NONE no_8\NN\7204911|(|) (r_appos) oxide_6\NN\14818238|nitric|no (r_nmod:npmod) induced_10\JJ\1740|oxide (r_amod) headache_11\NN\5829480|induced|headaches (l_nmod) headaches_14\NNS\5829480|in|primary
D005996_D006261 CID trinitrate_20\NN\1740|by|the|donor|glyceryl|gtn (r_nmod) induced_14\VBN\1627355|trinitrate (r_acl) headache_13\NN\5829480|during|induced
D005996_D006261 CID gtn_22\NN\1740|(|) (r_appos) trinitrate_20\NN\1740|by|the|donor|glyceryl|gtn (r_nmod) induced_14\VBN\1627355|trinitrate (r_acl) headache_13\NN\5829480|during|induced
D005996_D006261 CID gtn_9\NN\1740|0.5|microg/kg/min|or|placebo (r_dobj) receive_6\VB\2210855|to|gtn|min|days (l_nmod) days_18\NNS\15140892|on|two|headache-free (l_nummod) headache-free_17\JJ\1740|
D005996_D006261 CID gtn_11\NN\1740| (r_compound) day_12\NN\15154774|on|the|gtn (r_nmod) developed_4\VBD\1753788|patients|headache|day|than|and|pronounced (l_dobj) headache_8\NN\5829480|stronger|immediate
D005996_D006261 CID gtn_11\NN\1740| (r_compound) day_12\NN\15154774|on|the|gtn (r_nmod) developed_4\VBD\1753788|patients|headache|day|than|and|pronounced (l_conj) pronounced_24\JJ\1740|headache|was|more|patients|than|. (l_nsubj) headache_20\NN\5829480|the
D005996_D018781 NONE trinitrate_20\NN\1740|by|the|donor|glyceryl|gtn (r_nmod) induced_14\VBN\1627355|trinitrate (r_acl) headache_13\NN\5829480|during|induced (r_nmod) levels_9\NNS\4916342|plasma|cgrp|headache (r_dobj) investigate_7\VB\644583|to|levels|patients (l_nmod) patients_26\NNS\9898892|in|16|headache|and|controls (l_nmod) headache_30\NN\5829480|with|chronic|tension-type
D005996_D018781 NONE gtn_22\NN\1740|(|) (r_appos) trinitrate_20\NN\1740|by|the|donor|glyceryl|gtn (r_nmod) induced_14\VBN\1627355|trinitrate (r_acl) headache_13\NN\5829480|during|induced (r_nmod) levels_9\NNS\4916342|plasma|cgrp|headache (r_dobj) investigate_7\VB\644583|to|levels|patients (l_nmod) patients_26\NNS\9898892|in|16|headache|and|controls (l_nmod) headache_30\NN\5829480|with|chronic|tension-type
2322844
D011453_D010146 NONE prostaglandins_6\NNS\5414534|of (r_nmod) administration_4\NN\1133281|of|intrathecal|prostaglandins (r_nmod) effects_1\NNS\13245626|the|administration|responses (l_nmod) responses_9\NNS\11410625|on|pain|mice (l_compound) pain_8\NN\14299637|
D019342_D010146 NONE acid_21\NN\14818238|acetic (r_conj) plate_18\NN\2797881|hot|and|acid|writhing (r_compound) tests_23\NNS\5798043|plate (r_dobj) using_16\VBG\1156834|by|tests (r_advcl) evaluated_14\VBN\670261|effects|were|using|. (l_nsubjpass) effects_1\NNS\13245626|the|administration|responses (l_nmod) responses_9\NNS\11410625|on|pain|mice (l_compound) pain_8\NN\14299637|
D015230_D006930 CID d2_1\NN\1740|prostaglandin|ng/mouse (r_nsubj) had_8\VBD\2108377|d2|action|response|period|. (l_dobj) action_11\NN\30358|a|hyperalgesic (l_amod) hyperalgesic_10\JJ\1740|
D015230_D006930 CID d2_30\NN\1740|of|prostaglandin (r_nmod) that_27\DT\1740|than|d2 (r_nmod) lasted_18\VBD\2704349|effect|shorter|min|that|. (r_conj) showed_2\VBD\2137132|e2|effect|doses|,|but|lasted (l_dobj) effect_5\NN\34213|a|hyperalgesic (l_amod) hyperalgesic_4\JJ\1740|
D015230_D006930 CID d2_5\NN\1740|of|prostaglandin (r_nmod) effect_2\NN\34213|the|hyperalgesic|d2 (l_amod) hyperalgesic_1\JJ\1740|
D015230_D006930 CID d2_6\NN\1740|both|prostaglandin|and|e2 (r_nsubj) exert_10\VBP\1158872|that|d2|hyperalgesia|cord (l_dobj) hyperalgesia_11\NN\1740|
D015232_D006930 CID e2_1\NN\1740|prostaglandin (r_nsubj) showed_2\VBD\2137132|e2|effect|doses|,|but|lasted (l_dobj) effect_5\NN\34213|a|hyperalgesic (l_amod) hyperalgesic_4\JJ\1740|
D015232_D006930 CID e2-induced_3\JJ\1740|prostaglandin (r_amod) hyperalgesia_4\NN\1740|e2-induced
D015232_D006930 CID e2_9\NN\1740|prostaglandin (r_conj) d2_6\NN\1740|both|prostaglandin|and|e2 (r_nsubj) exert_10\VBP\1158872|that|d2|hyperalgesia|cord (l_dobj) hyperalgesia_11\NN\1740|
D011453_D006930 NONE pg_10\NN\1740|1 (r_quantmod) 10_12\CD\13745420|pg|to (r_nummod) ng/mouse_13\NN\1740|of|10 (r_nmod) doses_7\NNS\3740161|at|ng/mouse (r_nmod) showed_2\VBD\2137132|e2|effect|doses|,|but|lasted (l_dobj) effect_5\NN\34213|a|hyperalgesic (l_amod) hyperalgesic_4\JJ\1740|
C053876_D006930 NONE ah6809_28\NN\1740|not|by|,|antagonist (r_conj) antagonist_15\NN\7846|of|a|substance|p|than|)|but|ah6809 (r_nmod) injection_10\NN\320852|by|simultaneous|antagonist (r_nmod) blocked_7\VBN\1476483|effect|was|injection|. (l_nsubjpass) effect_2\NN\34213|the|hyperalgesic|d2 (l_amod) hyperalgesic_1\JJ\1740|
C053876_D006930 NONE ah6809_8\NN\1740|by|(|than|to|ng|)|but|antagonist (r_nmod) blocked_6\VBN\1476483|conversely|,|hyperalgesia|was|ah6809|. (l_nsubjpass) hyperalgesia_4\NN\1740|e2-induced
D015237_D010146 NONE alpha_2\NN\6828818|prostaglandin|f2 (r_nsubj) had_3\VBD\2108377|alpha|effect|. (l_dobj) effect_5\NN\34213|little|responses (l_nmod) responses_8\NNS\11410625|on|pain (l_compound) pain_7\NN\14299637|
2790457
D002220_D012640 NONE carbamazepine_1\NN\1740|chronic (r_nsubj) inhibits_2\VBZ\2510337|carbamazepine|development|. (l_dobj) development_4\NN\248977|the|seizures (l_nmod) seizures_8\NNS\14081375|of|local|anesthetic|kindled
D002220_D012640 NONE carbamazepine_3\NN\1740|cbz (r_compound) treatment_7\NN\654885|of|carbamazepine (r_nmod) effects_1\NNS\13245626|the|treatment|seizures (l_nmod) seizures_11\NNS\14081375|on|local|anesthetic-kindled|and|lethality
D002220_D012640 NONE cbz_5\NN\1740|(|) (r_appos) carbamazepine_3\NN\1740|cbz (r_compound) treatment_7\NN\654885|of|carbamazepine (r_nmod) effects_1\NNS\13245626|the|treatment|seizures (l_nmod) seizures_11\NNS\14081375|on|local|anesthetic-kindled|and|lethality
D002220_D012640 NONE cbz_28\NN\1740| (r_compound) administration_29\NN\1133281|of|cbz (r_nmod) methods_26\NNS\5616786|under|different|administration (r_conj) stages_18\NNS\15113229|in|different|process|and|methods (r_nmod) evaluated_15\VBN\670261|effects|were|stages|. (l_nsubjpass) effects_1\NNS\13245626|the|treatment|seizures (l_nmod) seizures_11\NNS\14081375|on|local|anesthetic-kindled|and|lethality
D002220_D012640 NONE cbz_2\NN\1740|chronic|oral (r_nsubj) inhibited_3\VBD\2510337|cbz|development|,|but|had|. (l_dobj) development_5\NN\248977|the|seizures (l_nmod) seizures_11\NNS\14081375|of|lidocaine-
D002220_D012640 NONE cbz_2\NN\1740|chronic|oral (r_nsubj) inhibited_3\VBD\2510337|cbz|development|,|but|had|. (l_conj) had_14\VBD\2108377|effect (l_dobj) effect_16\NN\34213|little|seizures (l_nmod) seizures_23\NNS\14081375|on|the|developed|local|anesthetic
D002220_D012640 NONE cbz_1\NN\1740|chronic (r_nsubj) decreased_3\VBD\169651|cbz|also|incidence|. (l_dobj) incidence_5\NN\13821570|the|mortality (l_nmod) mortality_8\NN\5054863|of|seizure-related|rats (l_amod) seizure-related_7\JJ\1740|
D002220_D012640 NONE cbz_1\NN\1740|acute|range (r_nsubj) had_13\VBD\2108377|cbz|effect|. (l_dobj) effect_15\NN\34213|no|seizures (l_nmod) seizures_22\NNS\14081375|on|completed|lidocaine-kindled
D002220_D012640 NONE cbz_4\NN\1740|of|mg/kg (r_nmod) injection_2\NN\320852|repeated|i.p.|cbz (r_nsubj) effect_12\NN\34213|injection|also|was|without|development|. (l_nmod) development_15\NN\248977|on|the|seizures (l_nmod) seizures_20\NNS\14081375|of|lidocaine-
D002220_D012640 NONE cbz_4\NN\1740|of (r_nmod) effects_2\NNS\13245626|the|differential|cbz|depending (l_acl) depending_5\VBG\2604760|stage (l_nmod) stage_7\NN\15113229|upon|development (l_nmod) development_10\NN\248977|of|seizure (l_compound) seizure_9\NN\14081375|
D002220_D012640 NONE cbz_4\NN\1740|of (r_nmod) effects_2\NNS\13245626|the|differential|cbz|depending (r_nsubj) suggest_11\VBP\1010118|effects|underlie|. (l_ccomp) underlie_15\VBP\2604760|that|mechanisms|development (l_dobj) development_17\NN\248977|the|versus|maintenance|seizures (l_nmod) seizures_23\NNS\14081375|of|local|anesthetic-kindled
D003042_D012640 CID cocaine_11\NN\3492717|by|and|lidocaine (r_nmod) kindled_9\VBN\2764245|cocaine (r_acl) seizures_8\NNS\14081375|of|local|anesthetic|kindled
D003042_D012640 CID cocaine-induced_10\JJ\1740| (r_conj) lidocaine-_8\NN\1740|both|and|cocaine-induced (r_amod) seizures_11\NNS\14081375|of|lidocaine-
D003042_D012640 CID cocaine-induced_10\JJ\1740| (r_conj) lidocaine-_8\NN\1740|both|and|cocaine-induced (r_amod) seizures_11\NNS\14081375|of|lidocaine- (r_nmod) development_5\NN\248977|the|seizures (r_dobj) inhibited_3\VBD\2510337|cbz|development|,|but|had|. (l_conj) had_14\VBD\2108377|effect (l_dobj) effect_16\NN\34213|little|seizures (l_nmod) seizures_23\NNS\14081375|on|the|developed|local|anesthetic
D003042_D012640 CID cocaine-injected_11\JJ\1740| (r_amod) rats_12\NNS\2329401|in|the|cocaine-injected (r_nmod) mortality_8\NN\5054863|of|seizure-related|rats (l_amod) seizure-related_7\JJ\1740|
D003042_D012640 CID cocaine-induced_21\JJ\1740|acute (r_conj) lidocaine-kindled_18\JJ\1740|or|cocaine-induced (r_amod) seizures_22\NNS\14081375|on|completed|lidocaine-kindled
D003042_D012640 CID cocaine-kindled_19\JJ\1740| (r_conj) lidocaine-_17\NN\1740|or|cocaine-kindled (r_compound) seizures_20\NNS\14081375|of|lidocaine-
D008012_D012640 CID lidocaine_13\NN\3681148| (r_conj) cocaine_11\NN\3492717|by|and|lidocaine (r_nmod) kindled_9\VBN\2764245|cocaine (r_acl) seizures_8\NNS\14081375|of|local|anesthetic|kindled
D008012_D012640 CID lidocaine-_8\NN\1740|both|and|cocaine-induced (r_amod) seizures_11\NNS\14081375|of|lidocaine-
D008012_D012640 CID lidocaine-_8\NN\1740|both|and|cocaine-induced (r_amod) seizures_11\NNS\14081375|of|lidocaine- (r_nmod) development_5\NN\248977|the|seizures (r_dobj) inhibited_3\VBD\2510337|cbz|development|,|but|had|. (l_conj) had_14\VBD\2108377|effect (l_dobj) effect_16\NN\34213|little|seizures (l_nmod) seizures_23\NNS\14081375|on|the|developed|local|anesthetic
D008012_D012640 CID lidocaine-kindled_18\JJ\1740|or|cocaine-induced (r_amod) seizures_22\NNS\14081375|on|completed|lidocaine-kindled
D008012_D012640 CID lidocaine-_17\NN\1740|or|cocaine-kindled (r_compound) seizures_20\NNS\14081375|of|lidocaine-
2722224
D006854_D006973 CID hydrocortisone-induced_0\JJ\1740| (r_amod) hypertension_1\NN\14057371|hydrocortisone-induced|humans|:|responsiveness
D006854_D006973 CID hydrocortisone_7\NN\14751417|with (r_nmod) rise_1\NN\7324673|the|pressure|hydrocortisone (l_nmod) pressure_5\NN\11419404|in|resting|blood
D006854_D016534 NONE hydrocortisone_7\NN\14751417|with (r_nmod) rise_1\NN\7324673|the|pressure|hydrocortisone (r_nsubjpass) associated_9\VBN\628491|rise|is|output|)|. (l_nmod) output_14\NN\4007894|with|an|increased|cardiac|(|volume
12481039
D012964_D012640 NONE sodium_1\NN\14625458| (r_compound) channel_2\NN\6251781|sodium (r_compound) density_3\NN\4941325|reduced|channel|,|dependence|. (l_conj) dependence_7\NN\24720|altered|voltage|inactivation|,|and|susceptibility (l_conj) susceptibility_13\NN\13920835|increased|seizures|mice (l_nmod) seizures_15\NNS\14081375|to
D012964_D012640 NONE sodium_19\NN\14625458| (r_compound) 2-subunits_22\NNS\1740|sodium|channel|beta (r_dobj) lacking_18\VBG\1740|2-subunits (r_acl) mice_17\NNS\2329401|in|lacking (r_nmod) susceptibility_13\NN\13920835|increased|seizures|mice (l_nmod) seizures_15\NNS\14081375|to
D010862_D012640 CID pilocarpine-induced_17\JJ\1740| (r_amod) seizures_18\NNS\14081375|for|pilocarpine-induced (r_nmod) latency_13\NN\15269513|by|reduced|and|threshold|seizures (r_nmod) indicated_10\VBN\952524|as|latency (r_advcl) displayed_3\VBD\2137132|mice|susceptibility|,|indicated|,|but|seemed|. (l_dobj) susceptibility_5\NN\13920835|increased|seizures (l_nmod) seizures_7\NNS\14081375|to
D010862_D012640 CID pilocarpine-induced_17\JJ\1740| (r_amod) seizures_18\NNS\14081375|for|pilocarpine-induced
16960342
D019259_D006509 NONE lamivudine_15\NN\3834836| (r_compound) monotherapy_16\NN\1740|with|lamivudine (r_nmod) treatment_13\NN\654885|after|monotherapy (r_nmod) improvement_2\NN\7359599|sustained|clinical|patient|treatment|. (l_nmod) patient_5\NN\9898892|of|a|cirrhosis (l_nmod) cirrhosis_11\NN\14116321|with|decompensated|virus-related (l_amod) virus-related_10\JJ\1740|hepatitis|b (l_nmod:npmod) b_9\NN\1355326|
D019259_D005355 NONE lamivudine_15\NN\3834836| (r_compound) monotherapy_16\NN\1740|with|lamivudine (r_nmod) treatment_13\NN\654885|after|monotherapy (r_nmod) improvement_2\NN\7359599|sustained|clinical|patient|treatment|. (l_nmod) patient_5\NN\9898892|of|a|cirrhosis (l_nmod) cirrhosis_11\NN\14116321|with|decompensated|virus-related
D019259_D005355 NONE lamivudine_3\NN\3834836|of (r_nmod) administration_1\NN\1133281|the|lamivudine|patients (l_nmod) patients_5\NNS\9898892|to|cirrhosis (l_nmod) cirrhosis_8\NN\14116321|with|hbv-related
625456
D002119_D006934 CID carbon-ate-sodium_22\NN\1740| (r_compound) powders_24\NNS\15046900|of|calcium|carbon-ate-sodium|bicarbonate (r_nmod) amounts_19\NNS\13329641|large|powders (r_dobj) consumed_17\VBN\1168468|who|had|regularly|amounts|years (r_acl:relcl) patients_13\NNS\9898892|in|consumed (r_nmod) reported_11\VBN\831651|case|are|patients|. (l_nsubjpass) case_1\NN\7283608|one|hypercalcaemia|and|two (l_nmod) hypercalcaemia_4\NN\14299637|of|acute
D002119_D053040 CID carbon-ate-sodium_22\NN\1740| (r_compound) powders_24\NNS\15046900|of|calcium|carbon-ate-sodium|bicarbonate (r_nmod) amounts_19\NNS\13329641|large|powders (r_dobj) consumed_17\VBN\1168468|who|had|regularly|amounts|years (r_acl:relcl) patients_13\NNS\9898892|in|consumed (r_nmod) reported_11\VBN\831651|case|are|patients|. (l_nsubjpass) case_1\NN\7283608|one|hypercalcaemia|and|two (l_conj) two_6\CD\13741022|nephrolithiasis (l_nmod) nephrolithiasis_9\NN\14115914|of|recurrent
D017693_D006934 CID bicarbonate_23\NN\14798450| (r_compound) powders_24\NNS\15046900|of|calcium|carbon-ate-sodium|bicarbonate (r_nmod) amounts_19\NNS\13329641|large|powders (r_dobj) consumed_17\VBN\1168468|who|had|regularly|amounts|years (r_acl:relcl) patients_13\NNS\9898892|in|consumed (r_nmod) reported_11\VBN\831651|case|are|patients|. (l_nsubjpass) case_1\NN\7283608|one|hypercalcaemia|and|two (l_nmod) hypercalcaemia_4\NN\14299637|of|acute
D017693_D053040 CID bicarbonate_23\NN\14798450| (r_compound) powders_24\NNS\15046900|of|calcium|carbon-ate-sodium|bicarbonate (r_nmod) amounts_19\NNS\13329641|large|powders (r_dobj) consumed_17\VBN\1168468|who|had|regularly|amounts|years (r_acl:relcl) patients_13\NNS\9898892|in|consumed (r_nmod) reported_11\VBN\831651|case|are|patients|. (l_nsubjpass) case_1\NN\7283608|one|hypercalcaemia|and|two (l_conj) two_6\CD\13741022|nephrolithiasis (l_nmod) nephrolithiasis_9\NN\14115914|of|recurrent
12734532
D010665_D009203 CID dexatrim_3\NN\1740|phenylpropanolamine|cause (l_nmod) cause_9\NN\7323922|as|a|infarction (l_nmod) infarction_12\NN\14204950|of|myocardial
D010665_D009203 CID phenylpropanolamine_5\NN\2682038|(|) (r_appos) dexatrim_3\NN\1740|phenylpropanolamine|cause (l_nmod) cause_9\NN\7323922|as|a|infarction (l_nmod) infarction_12\NN\14204950|of|myocardial
D010665_D009202 NONE ppa_7\NN\1740|of (r_nmod) abuse_5\NN\418025|the|ppa (r_dobj) linked_3\VBN\628491|reports|have|abuse|injury|,|involved|. (l_nmod) injury_10\NN\14052046|with|myocardial
D010665_D009202 NONE dexatrim_7\NN\1740| (r_compound) (ppa)-induced_8\NN\1740|dexatrim (r_compound) injury_10\NN\14052046|of|(ppa)-induced|myocardial|woman
D010665_D009202 NONE (ppa)-induced_8\NN\1740|dexatrim (r_compound) injury_10\NN\14052046|of|(ppa)-induced|myocardial|woman
D010665_D009202 NONE ppa_10\NN\1740| (r_nmod:npmod) related_11\JJ\1740|ppa (r_amod) injury_13\NN\14052046|of|related|myocardial
D010665_D062787 NONE ppa_7\NN\1740|of (r_nmod) abuse_5\NN\418025|the|ppa (r_dobj) linked_3\VBN\628491|reports|have|abuse|injury|,|involved|. (l_advcl) involved_16\VBN\2676054|when|overdose|is (l_nsubjpass) overdose_14\NN\1740|
10533019
D004110_D013746 CID diltiazem-induced_4\NN\1740| (r_compound) tetany_5\NN\14304060|of|life-threatening|diltiazem-induced
D004110_D013746 CID diltiazem_16\NN\2938514|of|intravenous (r_nmod) infusion_13\NN\14589223|after|the|diltiazem (r_nmod) developed_5\VBD\1753788|who|tetany|infusion (l_dobj) tetany_6\NN\14304060|arrest
D004110_D013746 CID diltiazem_15\NN\2938514|of|intravenous (r_nmod) administration_12\NN\1133281|the|diltiazem (r_dobj) accompany_10\VB\1835496|that|tetany|may|administration|and|remedy (l_nsubj) tetany_8\NN\14304060|life-threatening
D002122_D013746 NONE chloride_8\NN\14818238|with|calcium (r_nmod) reversal_1\NN\199130|rapid|tetany|chloride|. (l_nmod) tetany_5\NN\14304060|of|life-threatening|diltiazem-induced
D002122_D013746 NONE chloride_4\NN\14818238|of|calcium (r_nmod) administration_1\NN\1133281|the|chloride (r_nsubj) resolved_6\VBD\352826|administration|rapidly|tetany|recovery|,|averting|. (l_dobj) tetany_10\NN\14304060|patient
D002122_D013746 NONE chloride_19\NN\14818238|calcium (r_nsubj) remedy_26\NN\258854|that|chloride|may|be|a|rapid (r_conj) accompany_10\VB\1835496|that|tetany|may|administration|and|remedy (l_nsubj) tetany_8\NN\14304060|life-threatening
D004110_D012131 NONE diltiazem_16\NN\2938514|of|intravenous (r_nmod) infusion_13\NN\14589223|after|the|diltiazem (r_nmod) developed_5\VBD\1753788|who|tetany|infusion (l_dobj) tetany_6\NN\14304060|arrest (l_nmod) arrest_10\NN\88481|with|sudden|respiratory
2750819
D008278_D020879 CID sulfate_4\NN\15010703|with|magnesium|and|nifedipine (r_nmod) blockade_1\NN\952963|neuromuscular|sulfate|.
D008278_D020879 CID sulfate_15\NN\15010703|of|magnesium (r_nmod) mg_12\NN\13717155|500|sulfate (r_nsubjpass) administered_17\VBN\2436349|after|mg|was (r_advcl) developed_7\VBD\1753788|patient|blockade|administered|. (l_dobj) blockade_9\NN\952963|neuromuscular
D009543_D020879 CID nifedipine_6\NN\2938514| (r_conj) sulfate_4\NN\15010703|with|magnesium|and|nifedipine (r_nmod) blockade_1\NN\952963|neuromuscular|sulfate|.
D009543_D020879 CID nifedipine_6\NN\2938514|with (r_nmod) tocolysis_4\NN\1740|nifedipine (r_dobj) received_3\VBD\2210855|who|tocolysis (r_acl:relcl) patient_1\NN\9898892|a|received (r_nsubj) developed_7\VBD\1753788|patient|blockade|administered|. (l_dobj) blockade_9\NN\952963|neuromuscular
D009543_D064420 NONE nifedipine_4\NN\2938514| (r_nsubj) potentiate_7\VB\229605|that|nifedipine|can|seriously|toxicity (l_dobj) toxicity_9\NN\13576101|the|magnesium
D008274_D064420 NONE magnesium_11\NN\14625458|of (r_nmod) toxicity_9\NN\13576101|the|magnesium
20552622
D000420_D013617 CID salbutamol_5\NN\1740|by (r_nmod) triggered_3\VBN\1641914|salbutamol (r_acl) tachyarrhythmia_2\NN\1740|swallowing-induced|atrial|triggered|:|report
D000420_D013617 CID salbutamol_2\NN\1740| (r_nsubjpass) presented_4\VBN\2137132|conclusion|:|salbutamol|is|here|trigger|. (l_nmod) trigger_9\NN\3659292|as|a|possible|siat (l_nmod) siat_11\NN\1740|for
D001262_D001145 NONE atenolol_6\NN\2832168|with (r_nmod) therapy_4\NN\657604|after|atenolol (r_nmod) resolved_2\VBD\352826|arrhythmia|therapy|,|but|recurred|. (l_nsubj) arrhythmia_1\NN\14103288|the
D001262_D001145 NONE atenolol_11\NN\2832168|with|the (r_nmod) week_8\NN\15113229|after|a|atenolol (r_conj) stopping_1\VBG\2452885|after|beta-agonist|,|and|week (r_advcl) disappeared_15\VBD\2609764|stopping|,|arrhythmia|. (l_nsubj) arrhythmia_14\NN\14103288|the
D000420_D013610 NONE salbutamol_21\NN\1740|like (r_nmod) beta-agonist_19\NN\1740|a|salbutamol|(|known|) (l_acl) known_23\VBN\2110220|induce (l_xcomp) induce_25\VB\1627355|to|tachycardia (l_dobj) tachycardia_26\NN\14110674|
D001262_D013610 NONE atenolol_47\NN\2832168|such|(|blocks|) (r_nmod) beta-blocker_44\NN\1740|a|atenolol (r_nsubj) relieve_56\VB\205885|that|beta-blocker|may|it (r_conj) trigger_31\NN\3659292|that|beta-agonist|may|be|the|reflexes|and|relieve (l_nsubj) beta-agonist_19\NN\1740|a|salbutamol|(|known|) (l_acl) known_23\VBN\2110220|induce (l_xcomp) induce_25\VB\1627355|to|tachycardia (l_dobj) tachycardia_26\NN\14110674|
11230490
D004317_D066126 NONE doxorubicin_8\NN\2716866|of|liposome-encapsulated|and|cyclophosphamide (r_nmod) efficacy_5\NN\5199286|preserved|antitumor|doxorubicin (r_conj) cardiotoxicity_1\NN\1740|reduced|and|efficacy|doxorubicin|trial|.
D004317_D066126 NONE doxorubicin_14\NN\2716866|compared|with|conventional|and|cyclophosphamide (r_nmod) cardiotoxicity_1\NN\1740|reduced|and|efficacy|doxorubicin|trial|.
D004317_D066126 NONE myocet_5\NN\1740|doxorubicin|combination (r_nsubj) reduces_26\VBZ\441445|whether|myocet|significantly|cardiotoxicity|providing (l_dobj) cardiotoxicity_28\NN\1740|doxorubicin
D004317_D066126 NONE doxorubicin_8\NN\2716866|(|liposome-encapsulated|;|company|) (r_appos) myocet_5\NN\1740|doxorubicin|combination (r_nsubj) reduces_26\VBZ\441445|whether|myocet|significantly|cardiotoxicity|providing (l_dobj) cardiotoxicity_28\NN\1740|doxorubicin
D004317_D066126 NONE doxorubicin_27\NN\2716866| (r_compound) cardiotoxicity_28\NN\1740|doxorubicin
D004317_D066126 NONE myocet_2\NN\1740| (r_nsubj) improves_3\VBZ\126264|:|myocet|index|reducing|and|provides (l_advcl) reducing_11\VBG\441445|by|significantly|cardiotoxicity (l_dobj) cardiotoxicity_12\NN\1740|and|neutropenia
D004317_D066126 NONE doxorubicin_8\NN\2716866|of (r_nmod) index_6\NN\13850304|the|therapeutic|doxorubicin (r_dobj) improves_3\VBZ\126264|:|myocet|index|reducing|and|provides (l_advcl) reducing_11\VBG\441445|by|significantly|cardiotoxicity (l_dobj) cardiotoxicity_12\NN\1740|and|neutropenia
D004317_D001943 NONE doxorubicin_8\NN\2716866|of|liposome-encapsulated|and|cyclophosphamide (r_nmod) efficacy_5\NN\5199286|preserved|antitumor|doxorubicin (r_conj) cardiotoxicity_1\NN\1740|reduced|and|efficacy|doxorubicin|trial|. (l_nmod) trial_22\NN\786195|in|a|multicenter|cancer (l_nmod) cancer_26\NN\14239425|of|metastatic|breast
D004317_D001943 NONE doxorubicin_14\NN\2716866|compared|with|conventional|and|cyclophosphamide (r_nmod) cardiotoxicity_1\NN\1740|reduced|and|efficacy|doxorubicin|trial|. (l_nmod) trial_22\NN\786195|in|a|multicenter|cancer (l_nmod) cancer_26\NN\14239425|of|metastatic|breast
D004317_D001943 NONE myocet_5\NN\1740|doxorubicin|combination (r_nsubj) reduces_26\VBZ\441445|whether|myocet|significantly|cardiotoxicity|providing (l_advcl) providing_30\VBG\2199590|while|efficacy|treatment (l_nmod) treatment_36\NN\654885|in|first-line|cancer (l_nmod) cancer_40\NN\14239425|of|metastatic|breast|mbc
D004317_D001943 NONE myocet_5\NN\1740|doxorubicin|combination (r_nsubj) reduces_26\VBZ\441445|whether|myocet|significantly|cardiotoxicity|providing (l_advcl) providing_30\VBG\2199590|while|efficacy|treatment (l_nmod) treatment_36\NN\654885|in|first-line|cancer (l_nmod) cancer_40\NN\14239425|of|metastatic|breast|mbc (l_appos) mbc_42\NN\1740|(|)
D004317_D001943 NONE doxorubicin_8\NN\2716866|(|liposome-encapsulated|;|company|) (r_appos) myocet_5\NN\1740|doxorubicin|combination (r_nsubj) reduces_26\VBZ\441445|whether|myocet|significantly|cardiotoxicity|providing (l_advcl) providing_30\VBG\2199590|while|efficacy|treatment (l_nmod) treatment_36\NN\654885|in|first-line|cancer (l_nmod) cancer_40\NN\14239425|of|metastatic|breast|mbc
D004317_D001943 NONE doxorubicin_8\NN\2716866|(|liposome-encapsulated|;|company|) (r_appos) myocet_5\NN\1740|doxorubicin|combination (r_nsubj) reduces_26\VBZ\441445|whether|myocet|significantly|cardiotoxicity|providing (l_advcl) providing_30\VBG\2199590|while|efficacy|treatment (l_nmod) treatment_36\NN\654885|in|first-line|cancer (l_nmod) cancer_40\NN\14239425|of|metastatic|breast|mbc (l_appos) mbc_42\NN\1740|(|)
D004317_D001943 NONE doxorubicin_27\NN\2716866| (r_compound) cardiotoxicity_28\NN\1740|doxorubicin (r_dobj) reduces_26\VBZ\441445|whether|myocet|significantly|cardiotoxicity|providing (l_advcl) providing_30\VBG\2199590|while|efficacy|treatment (l_nmod) treatment_36\NN\654885|in|first-line|cancer (l_nmod) cancer_40\NN\14239425|of|metastatic|breast|mbc
D004317_D001943 NONE doxorubicin_27\NN\2716866| (r_compound) cardiotoxicity_28\NN\1740|doxorubicin (r_dobj) reduces_26\VBZ\441445|whether|myocet|significantly|cardiotoxicity|providing (l_advcl) providing_30\VBG\2199590|while|efficacy|treatment (l_nmod) treatment_36\NN\654885|in|first-line|cancer (l_nmod) cancer_40\NN\14239425|of|metastatic|breast|mbc (l_appos) mbc_42\NN\1740|(|)
D004317_D001943 NONE myocet_26\NN\1740|of|m (r_nmod) mg/m(2_23\NN\1740|either|60|)|myocet|or|doxorubicin (r_dobj) receive_20\VB\2210855|to|mg/m(2|combination|,|weeks|progression (r_xcomp) randomized_18\VBN\278117|patients|patients|were|receive|. (l_nsubjpass) patients_7\NNS\9898892|ninety-seven|mbc (l_nmod) mbc_9\NN\1740|with|and|chemotherapy
D004317_D001943 NONE doxorubicin_32\NN\2716866|conventional|a|, (r_conj) mg/m(2_23\NN\1740|either|60|)|myocet|or|doxorubicin (r_dobj) receive_20\VB\2210855|to|mg/m(2|combination|,|weeks|progression (r_xcomp) randomized_18\VBN\278117|patients|patients|were|receive|. (l_nsubjpass) patients_7\NNS\9898892|ninety-seven|mbc (l_nmod) mbc_9\NN\1740|with|and|chemotherapy
D004317_D001943 NONE myocet_2\NN\1740| (r_nsubj) improves_3\VBZ\126264|:|myocet|index|reducing|and|provides (l_conj) provides_18\VBZ\2199590|efficacy|,|used (l_advcl) used_24\VBN\1156834|when|combination|therapy (l_nmod) therapy_31\NN\657604|as|first-line|mbc (l_nmod) mbc_33\NN\1740|for
D004317_D001943 NONE doxorubicin_8\NN\2716866|of (r_nmod) index_6\NN\13850304|the|therapeutic|doxorubicin (r_dobj) improves_3\VBZ\126264|:|myocet|index|reducing|and|provides (l_conj) provides_18\VBZ\2199590|efficacy|,|used (l_advcl) used_24\VBN\1156834|when|combination|therapy (l_nmod) therapy_31\NN\657604|as|first-line|mbc (l_nmod) mbc_33\NN\1740|for
D003520_D066126 NONE cyclophosphamide_10\NN\1740| (r_conj) doxorubicin_8\NN\2716866|of|liposome-encapsulated|and|cyclophosphamide (r_nmod) efficacy_5\NN\5199286|preserved|antitumor|doxorubicin (r_conj) cardiotoxicity_1\NN\1740|reduced|and|efficacy|doxorubicin|trial|.
D003520_D066126 NONE cyclophosphamide_16\NN\1740| (r_conj) doxorubicin_14\NN\2716866|compared|with|conventional|and|cyclophosphamide (r_nmod) cardiotoxicity_1\NN\1740|reduced|and|efficacy|doxorubicin|trial|.
D003520_D066126 NONE cyclophosphamide_24\NN\1740|with (r_nmod) combination_22\NN\7951464|in|cyclophosphamide (r_nmod) myocet_5\NN\1740|doxorubicin|combination (r_nsubj) reduces_26\VBZ\441445|whether|myocet|significantly|cardiotoxicity|providing (l_dobj) cardiotoxicity_28\NN\1740|doxorubicin
D003520_D066126 NONE cyclophosphamide_28\NN\1740|with (r_nmod) combination_26\NN\7951464|in|cyclophosphamide (r_nmod) used_24\VBN\1156834|when|combination|therapy (r_advcl) provides_18\VBZ\2199590|efficacy|,|used (r_conj) improves_3\VBZ\126264|:|myocet|index|reducing|and|provides (l_advcl) reducing_11\VBG\441445|by|significantly|cardiotoxicity (l_dobj) cardiotoxicity_12\NN\1740|and|neutropenia
D003520_D001943 NONE cyclophosphamide_10\NN\1740| (r_conj) doxorubicin_8\NN\2716866|of|liposome-encapsulated|and|cyclophosphamide (r_nmod) efficacy_5\NN\5199286|preserved|antitumor|doxorubicin (r_conj) cardiotoxicity_1\NN\1740|reduced|and|efficacy|doxorubicin|trial|. (l_nmod) trial_22\NN\786195|in|a|multicenter|cancer (l_nmod) cancer_26\NN\14239425|of|metastatic|breast
D003520_D001943 NONE cyclophosphamide_16\NN\1740| (r_conj) doxorubicin_14\NN\2716866|compared|with|conventional|and|cyclophosphamide (r_nmod) cardiotoxicity_1\NN\1740|reduced|and|efficacy|doxorubicin|trial|. (l_nmod) trial_22\NN\786195|in|a|multicenter|cancer (l_nmod) cancer_26\NN\14239425|of|metastatic|breast
D003520_D001943 NONE cyclophosphamide_24\NN\1740|with (r_nmod) combination_22\NN\7951464|in|cyclophosphamide (r_nmod) myocet_5\NN\1740|doxorubicin|combination (r_nsubj) reduces_26\VBZ\441445|whether|myocet|significantly|cardiotoxicity|providing (l_advcl) providing_30\VBG\2199590|while|efficacy|treatment (l_nmod) treatment_36\NN\654885|in|first-line|cancer (l_nmod) cancer_40\NN\14239425|of|metastatic|breast|mbc
D003520_D001943 NONE cyclophosphamide_24\NN\1740|with (r_nmod) combination_22\NN\7951464|in|cyclophosphamide (r_nmod) myocet_5\NN\1740|doxorubicin|combination (r_nsubj) reduces_26\VBZ\441445|whether|myocet|significantly|cardiotoxicity|providing (l_advcl) providing_30\VBG\2199590|while|efficacy|treatment (l_nmod) treatment_36\NN\654885|in|first-line|cancer (l_nmod) cancer_40\NN\14239425|of|metastatic|breast|mbc (l_appos) mbc_42\NN\1740|(|)
D003520_D001943 NONE cyclophosphamide_44\NN\1740|of|c (r_nmod) mg/m(2_41\NN\1740|with|600|)|cyclophosphamide (r_nmod) combination_38\NN\7951464|in|mg/m(2 (r_nmod) receive_20\VB\2210855|to|mg/m(2|combination|,|weeks|progression (r_xcomp) randomized_18\VBN\278117|patients|patients|were|receive|. (l_nsubjpass) patients_7\NNS\9898892|ninety-seven|mbc (l_nmod) mbc_9\NN\1740|with|and|chemotherapy
D003520_D001943 NONE cyclophosphamide_28\NN\1740|with (r_nmod) combination_26\NN\7951464|in|cyclophosphamide (r_nmod) used_24\VBN\1156834|when|combination|therapy (l_nmod) therapy_31\NN\657604|as|first-line|mbc (l_nmod) mbc_33\NN\1740|for
D004317_D064420 NONE myocet_26\NN\1740|of|m (r_nmod) mg/m(2_23\NN\1740|either|60|)|myocet|or|doxorubicin (r_dobj) receive_20\VB\2210855|to|mg/m(2|combination|,|weeks|progression (l_nmod) progression_54\NN\8457976|until|disease|or|toxicity (l_conj) toxicity_57\NN\13576101|unacceptable
D004317_D064420 NONE doxorubicin_32\NN\2716866|conventional|a|, (r_conj) mg/m(2_23\NN\1740|either|60|)|myocet|or|doxorubicin (r_dobj) receive_20\VB\2210855|to|mg/m(2|combination|,|weeks|progression (l_nmod) progression_54\NN\8457976|until|disease|or|toxicity (l_conj) toxicity_57\NN\13576101|unacceptable
D003520_D064420 NONE cyclophosphamide_44\NN\1740|of|c (r_nmod) mg/m(2_41\NN\1740|with|600|)|cyclophosphamide (r_nmod) combination_38\NN\7951464|in|mg/m(2 (r_nmod) receive_20\VB\2210855|to|mg/m(2|combination|,|weeks|progression (l_nmod) progression_54\NN\8457976|until|disease|or|toxicity (l_conj) toxicity_57\NN\13576101|unacceptable
D004317_D009503 CID myocet_2\NN\1740| (r_nsubj) improves_3\VBZ\126264|:|myocet|index|reducing|and|provides (l_advcl) reducing_11\VBG\441445|by|significantly|cardiotoxicity (l_dobj) cardiotoxicity_12\NN\1740|and|neutropenia (l_conj) neutropenia_16\NN\14196405|grade|4
D004317_D009503 CID doxorubicin_8\NN\2716866|of (r_nmod) index_6\NN\13850304|the|therapeutic|doxorubicin (r_dobj) improves_3\VBZ\126264|:|myocet|index|reducing|and|provides (l_advcl) reducing_11\VBG\441445|by|significantly|cardiotoxicity (l_dobj) cardiotoxicity_12\NN\1740|and|neutropenia (l_conj) neutropenia_16\NN\14196405|grade|4
D003520_D009503 CID cyclophosphamide_28\NN\1740|with (r_nmod) combination_26\NN\7951464|in|cyclophosphamide (r_nmod) used_24\VBN\1156834|when|combination|therapy (r_advcl) provides_18\VBZ\2199590|efficacy|,|used (r_conj) improves_3\VBZ\126264|:|myocet|index|reducing|and|provides (l_advcl) reducing_11\VBG\441445|by|significantly|cardiotoxicity (l_dobj) cardiotoxicity_12\NN\1740|and|neutropenia (l_conj) neutropenia_16\NN\14196405|grade|4
7843916
D003907_D009798 CID dexamethasone-induced_0\JJ\1740| (r_amod) hypertension_2\NN\14057371|dexamethasone-induced|ocular|eyes|.
D003907_D009798 CID dexamethasone-treated_4\JJ\1740| (r_amod) eyes_6\NNS\5945642|the|dexamethasone-treated|hypertensive
D003907_D009798 CID dexamethasone_2\NN\2721538| (r_compound) treatment_3\NN\654885|dexamethasone|eyes (r_nsubj) led_10\VBD\1752884|conclusion|treatment|generation|. (l_nmod) generation_13\NN\7942152|to|the|hypertension|% (l_nmod) hypertension_16\NN\14057371|of|ocular
D003907_D009798 CID dexamethasone-treated_23\JJ\1740| (r_amod) eyes_24\NNS\5945642|of|the|dexamethasone-treated (r_nmod) %_20\NN\1740|in|30|eyes (r_nmod) generation_13\NN\7942152|to|the|hypertension|% (l_nmod) hypertension_16\NN\14057371|of|ocular
D013256_D005901 NONE steroid_0\NN\14727670| (r_compound) treatment_1\NN\654885|steroid (r_nsubj) resulted_2\VBD\2633881|treatment|changes|. (l_nmod) changes_5\NNS\7283608|in|morphologic|meshwork|similar (l_amod) similar_10\JJ\1740|those (l_nmod) those_12\DT\1740|to|reported (l_acl) reported_13\VBN\831651|glaucoma (l_nmod) glaucoma_16\NN\14252864|for|corticosteroid|and|glaucoma
D013256_D005902 NONE steroid_0\NN\14727670| (r_compound) treatment_1\NN\654885|steroid (r_nsubj) resulted_2\VBD\2633881|treatment|changes|. (l_nmod) changes_5\NNS\7283608|in|morphologic|meshwork|similar (l_amod) similar_10\JJ\1740|those (l_nmod) those_12\DT\1740|to|reported (l_acl) reported_13\VBN\831651|glaucoma (l_nmod) glaucoma_16\NN\14252864|for|corticosteroid|and|glaucoma (l_conj) glaucoma_20\NN\14252864|angle
18541230
D011692_D009401 CID aminonucleoside_6\NN\1740| (r_compound) nephrosis_7\NN\14304060|on|puromycin|aminonucleoside|rats
D011692_D009401 CID aminonucleoside-induced_18\JJ\1740|puromycin (r_amod) nephrosis_19\NN\14304060|with|aminonucleoside-induced|,|model
D011692_D009404 NONE aminonucleoside-induced_18\JJ\1740|puromycin (r_amod) nephrosis_19\NN\14304060|with|aminonucleoside-induced|,|model (l_acl:relcl) model_25\NN\5888929|which|is|an|experimental|syndrome (l_nmod) syndrome_29\NN\5870365|of|human|nephrotic
D011692_D009404 NONE aminonucleoside-induced_14\JJ\1740| (r_amod) syndrome_16\NN\5870365|of|puromycin|aminonucleoside-induced|nephrotic
D011692_D006402 NONE aminonucleoside-induced_6\JJ\1740| (r_amod) abnormalities_8\NNS\14034177|the|puromycin|aminonucleoside-induced|hematological
D011692_D007674 NONE aminonucleoside-induced_1\JJ\1740| (r_amod) dysfunction_3\NN\14204950|puromycin|aminonucleoside-induced|renal|and|hyperlipidemia
D011692_D006949 NONE aminonucleoside-induced_1\JJ\1740| (r_amod) dysfunction_3\NN\14204950|puromycin|aminonucleoside-induced|renal|and|hyperlipidemia (l_conj) hyperlipidemia_5\NN\14299637|
17241657
D003042_D012640 CID cocaine_21\NN\3492717|of (r_nmod) actions_19\NNS\30358|the|convulsive|cocaine|mice (l_amod) convulsive_11\JJ\1740|,|lethal|and|rewarding
D003042_D012640 CID cocaine-induced_16\JJ\1740| (r_amod) convulsions_17\NNS\14081375|cocaine-induced|and|activity|,|not|lethality
C519696_D012640 NONE umb24_10\NN\1740|with|or|(+/-)-sm (r_nmod) pretreatment_4\NN\1740|mice|umb24 (r_nsubj) attenuated_15\VBD\224901|studies|,|pretreatment|significantly|convulsions|. (l_dobj) convulsions_17\NNS\14081375|cocaine-induced|and|activity|,|not|lethality
C107044_D012640 NONE 21_13\CD\13745420| (r_nummod) (+/-)-sm_12\NN\1740|21 (r_conj) umb24_10\NN\1740|with|or|(+/-)-sm (r_nmod) pretreatment_4\NN\1740|mice|umb24 (r_nsubj) attenuated_15\VBD\224901|studies|,|pretreatment|significantly|convulsions|. (l_dobj) convulsions_17\NNS\14081375|cocaine-induced|and|activity|,|not|lethality
15638391
D006220_D006966 CID haloperidol_16\NN\3713736|by (r_nmod) induced_14\VBN\1627355|haloperidol (r_acl) hyperprolactinemia_13\NN\1740|in|experimental|induced
D006220_D006966 CID haloperidol_15\NN\3713736|by|hal (r_nmod) induced_13\VBN\1627355|haloperidol|morphology (r_acl) hyperprolactinemia_11\NN\1740|of|,|induced
D006220_D006966 CID hal_17\NN\1740|(|) (r_appos) haloperidol_15\NN\3713736|by|hal (r_nmod) induced_13\VBN\1627355|haloperidol|morphology (r_acl) hyperprolactinemia_11\NN\1740|of|,|induced
7651879
D005442_D012640 CID flumazenil_2\NN\1740| (r_compound) administration_3\NN\1133281|after|flumazenil|patient (r_nmod) seizure_0\NN\14081375|administration|.
D005442_D012640 CID flumazenil_17\NN\1740|of (r_nmod) administration_15\NN\1133281|following|the|flumazenil (r_nmod) occurrence_3\NN\29378|the|seizure|administration (l_nmod) seizure_8\NN\14081375|of|a|generalized|tonic-clonic|patient
D005442_D012131 NONE flumazenil_0\NN\1740| (r_nsubj) antagonist_5\NN\7846|flumazenil|is|a|benzodiazepine|receptor|used|. (l_acl) used_6\VBN\1156834|reverse (l_xcomp) reverse_8\VB\109660|to|sedation (l_dobj) sedation_9\NN\14034177|and|depression|induced (l_conj) depression_12\NN\14373582|respiratory
D001569_D012131 NONE benzodiazepine_3\NN\3771443| (r_compound) antagonist_5\NN\7846|flumazenil|is|a|benzodiazepine|receptor|used|. (l_acl) used_6\VBN\1156834|reverse (l_xcomp) reverse_8\VB\109660|to|sedation (l_dobj) sedation_9\NN\14034177|and|depression|induced (l_conj) depression_12\NN\14373582|respiratory
D001569_D012131 NONE benzodiazepines_15\NNS\3771443|by (r_nmod) induced_13\VBN\1627355|benzodiazepines (r_acl) sedation_9\NN\14034177|and|depression|induced (l_conj) depression_12\NN\14373582|respiratory
19300240
D005472_D054549 CID flourouracil-induced_1\JJ\1740| (r_amod) syndrome_4\NN\5870365|5|flourouracil-induced|apical|ballooning|:|report
D005472_D015179 NONE fluorouracil_5\NN\2722166|with (r_nmod) chemotherapy_3\NN\661091|recent|fluorouracil|cancer (l_nmod) cancer_9\NN\14239425|for|metastatic|colorectal
D002395_D009369 NONE catecholamines_9\NNS\5407119|of|plasma|and|neuropeptides (l_conj) neuropeptides_13\NNS\1740|related|caused (l_acl) caused_14\VBN\1617192|diagnosis (l_nmod) diagnosis_17\NN\152018|by|cancer|as|chemotherapy (l_compound) cancer_16\NN\14239425|
D002395_D054549 NONE catecholamines_9\NNS\5407119|of|plasma|and|neuropeptides (r_nmod) levels_6\NNS\4916342|both|supraphysiologic|catecholamines (r_nsubj) contributed_24\VBN\126264|patient|,|levels|may|have|development|. (l_dobj) development_26\NN\248977|the|abs (l_nmod) abs_28\NNS\14592610|of
1141447
D008094_D003919 CID lithium-induced_7\JJ\1740| (r_amod) insipidus_9\NN\1740|of|lithium-induced|diabetes
D008094_D003919 CID lithium-induced_3\JJ\1740| (r_amod) insipidus_5\NN\1740|of|lithium-induced|diabetes
19642243
C096918_D058186 NONE tenofovir_8\NN\1740|on (r_nmod) failure_2\NN\66216|acute|renal|patients|tenofovir|receiving|.
C096918_D000163 NONE tenofovir_8\NN\1740|on (r_nmod) failure_2\NN\66216|acute|renal|patients|tenofovir|receiving|. (l_nmod) patients_4\NNS\9898892|in|aids (l_nmod) aids_6\NNP\13974317|with
C096918_D010019 NONE tenofovir_8\NN\1740|on (r_nmod) failure_2\NN\66216|acute|renal|patients|tenofovir|receiving|. (l_advcl) receiving_10\VBG\2210855|while|course (l_dobj) course_13\NN\883297|prolonged|vancomycin|osteomyelitis (l_nmod) osteomyelitis_15\NN\14351321|for
D014640_D058186 CID vancomycin_12\NN\2716866| (r_compound) course_13\NN\883297|prolonged|vancomycin|osteomyelitis (r_dobj) receiving_10\VBG\2210855|while|course (r_advcl) failure_2\NN\66216|acute|renal|patients|tenofovir|receiving|.
D014640_D000163 NONE vancomycin_12\NN\2716866| (r_compound) course_13\NN\883297|prolonged|vancomycin|osteomyelitis (r_dobj) receiving_10\VBG\2210855|while|course (r_advcl) failure_2\NN\66216|acute|renal|patients|tenofovir|receiving|. (l_nmod) patients_4\NNS\9898892|in|aids (l_nmod) aids_6\NNP\13974317|with
D014640_D010019 NONE vancomycin_12\NN\2716866| (r_compound) course_13\NN\883297|prolonged|vancomycin|osteomyelitis (l_nmod) osteomyelitis_15\NN\14351321|for
D014640_D051437 NONE vancomycin_8\NN\2716866| (r_compound) therapy_9\NN\657604|of|vancomycin (r_nmod) course_6\NN\883297|after|a|prolonged|therapy (r_nmod) developed_2\VBD\1753788|failure|course|patients|. (l_nsubj) failure_1\NN\66216|renal
D014640_D051437 NONE vancomycin_17\NN\2716866|of (r_nmod) administration_15\NN\1133281|during|prolonged|vancomycin (r_nmod) raise_7\VB\153263|that|tenofovir|may|risk|administration (l_dobj) risk_9\NN\14541044|the|failure (l_nmod) failure_12\NN\66216|of|renal
C418563_D051437 NONE fumarate_18\NN\1740|tenofovir|disoproxil (r_dobj) receiving_15\VBG\2210855|who|were|fumarate|part (r_acl:relcl) patients_12\NNS\9898892|in|2|receiving (r_nmod) developed_2\VBD\1753788|failure|course|patients|. (l_nsubj) failure_1\NN\66216|renal
C096918_D005198 NONE tenofovir_0\NN\1740| (r_nsubjpass) implicated_3\VBN\2677097|tenofovir|has|been|development|effects|. (l_nmod) development_6\NN\248977|in|the|syndrome (l_nmod) syndrome_9\NN\5870365|of|fanconi|and|insufficiency
C096918_D051437 NONE tenofovir_0\NN\1740| (r_nsubjpass) implicated_3\VBN\2677097|tenofovir|has|been|development|effects|. (l_nmod) development_6\NN\248977|in|the|syndrome (l_nmod) syndrome_9\NN\5870365|of|fanconi|and|insufficiency (l_conj) insufficiency_12\NN\14462946|renal
C096918_D051437 NONE tenofovir_5\NN\1740| (r_nsubj) raise_7\VB\153263|that|tenofovir|may|risk|administration (l_dobj) risk_9\NN\14541044|the|failure (l_nmod) failure_12\NN\66216|of|renal
D014640_D007674 NONE vancomycin_0\NN\2716866| (r_compound) nephrotoxicity_1\NN\1740|vancomycin
D014640_D007674 NONE vancomycin_0\NN\2716866| (r_compound) nephrotoxicity_1\NN\1740|vancomycin (r_nsubj) infrequent_3\JJ\1740|nephrotoxicity|is|but|result|. (l_conj) result_6\VB\2633881|may|coadministration (l_nmod) coadministration_8\NN\1740|from|agent (l_nmod) agent_12\NN\7347|with|a|nephrotoxic (l_amod) nephrotoxic_11\JJ\1740|
17263743
C009250_D006323 NONE sevoflurane_9\NN\1740| (r_compound) induction_10\NN\7450842|sevoflurane|anesthesia (r_dobj) undergoing_8\VBG\109660|induction|clonidine (r_acl) child_4\NN\9622049|in|a|palsy|undergoing (r_nmod) arrest_1\NN\88481|cardiac|child|.
C009250_D002547 NONE sevoflurane_9\NN\1740| (r_compound) induction_10\NN\7450842|sevoflurane|anesthesia (r_dobj) undergoing_8\VBG\109660|induction|clonidine (r_acl) child_4\NN\9622049|in|a|palsy|undergoing (l_nmod) palsy_7\NN\14557898|with|cerebral
D003000_D006323 CID clonidine_15\NN\2721160|after|preoperative (r_nmod) undergoing_8\VBG\109660|induction|clonidine (r_acl) child_4\NN\9622049|in|a|palsy|undergoing (r_nmod) arrest_1\NN\88481|cardiac|child|.
D003000_D006323 CID clonidine-associated_6\JJ\1740| (r_amod) arrest_8\NN\88481|of|clonidine-associated|cardiac|child
D003000_D002547 NONE clonidine_15\NN\2721160|after|preoperative (r_nmod) undergoing_8\VBG\109660|induction|clonidine (r_acl) child_4\NN\9622049|in|a|palsy|undergoing (l_nmod) palsy_7\NN\14557898|with|cerebral
D003000_D002547 NONE clonidine_16\NN\2721160| (r_dobj) receiving_15\VBG\2210855|clonidine|restlessness (r_acl) child_7\NN\9622049|of|a|5-year-old|palsy|,|receiving|,|presented (l_nmod) palsy_10\NN\14557898|with|cerebral|and|disorder
D003000_D004827 NONE clonidine_16\NN\2721160| (r_dobj) receiving_15\VBG\2210855|clonidine|restlessness (r_acl) child_7\NN\9622049|of|a|5-year-old|palsy|,|receiving|,|presented (l_nmod) palsy_10\NN\14557898|with|cerebral|and|disorder (l_conj) disorder_13\NN\14034177|seizure
D003000_D011595 NONE clonidine_16\NN\2721160| (r_dobj) receiving_15\VBG\2210855|clonidine|restlessness (l_nmod) restlessness_18\NN\4773351|for
D001418_D002547 NONE baclofen_26\NN\1740| (r_compound) pump_27\NN\3736970|of|a|baclofen (r_nmod) placement_23\NN\5074774|for|pump (r_nmod) presented_21\VBD\2137132|who|placement (r_acl:relcl) child_7\NN\9622049|of|a|5-year-old|palsy|,|receiving|,|presented (l_nmod) palsy_10\NN\14557898|with|cerebral|and|disorder
D001418_D004827 NONE baclofen_26\NN\1740| (r_compound) pump_27\NN\3736970|of|a|baclofen (r_nmod) placement_23\NN\5074774|for|pump (r_nmod) presented_21\VBD\2137132|who|placement (r_acl:relcl) child_7\NN\9622049|of|a|5-year-old|palsy|,|receiving|,|presented (l_nmod) palsy_10\NN\14557898|with|cerebral|and|disorder (l_conj) disorder_13\NN\14034177|seizure
D001418_D011595 NONE baclofen_26\NN\1740| (r_compound) pump_27\NN\3736970|of|a|baclofen (r_nmod) placement_23\NN\5074774|for|pump (r_nmod) presented_21\VBD\2137132|who|placement (r_acl:relcl) child_7\NN\9622049|of|a|5-year-old|palsy|,|receiving|,|presented (l_acl) receiving_15\VBG\2210855|clonidine|restlessness (l_nmod) restlessness_18\NN\4773351|for
D003000_D001008 NONE clonidine_16\NN\2721160|of (r_nmod) doses_14\NNS\3740161|three|clonidine (r_dobj) administered_12\VBD\2436349|knowledge|,|mother|doses|evening|reduce|. (l_advcl) reduce_26\VB\441445|to|anxiety (l_dobj) anxiety_27\NN\14373582|
11282081
D014700_D001281 CID verapamil_2\NN\2938514|of (r_nmod) effects_0\NNS\13245626|verapamil|fibrillation|. (l_nmod) fibrillation_5\NN\14361664|on|atrial|and|determinants
D014700_D001281 CID verapamil_19\NN\2938514| (r_dobj) administered_18\VBD\2436349|methods|evaluate|,|we|verapamil|dogs|. (l_advcl) evaluate_3\VB\670261|to|mechanisms (l_dobj) mechanisms_6\NNS\13446390|the|potential|promotion (l_nmod) promotion_9\NN\6598915|of|af|blockers (l_compound) af_8\NN\1740|
D014700_D001281 CID verapamil_2\NN\2938514| (r_nsubj) caused_3\VBD\1617192|verapamil|promotion|,|increasing|. (l_dobj) promotion_5\NN\6598915|af|dogs (l_compound) af_4\NN\1740|
D014700_D001281 CID verapamil_2\NN\2938514| (r_nsubj) caused_3\VBD\1617192|verapamil|promotion|,|increasing|. (l_advcl) increasing_10\VBG\169651|duration|,|s|s|dose (l_dobj) duration_12\NN\15113229|mean|af (l_nmod) af_14\NN\1740|of|induced
D014700_D001281 CID verapamil_4\NN\2938514| (r_nsubj) shortened_5\VBD\429060|experiments|,|verapamil|period|122+/-5|114+/-4|ms|length|,|decreased|accelerated|. (l_dep) accelerated_43\VBD\226566|heterogeneously|conduction|and|decreased (l_conj) decreased_47\VBD\169651|length|ms (l_dobj) length_50\NN\5093581|the|cycle|af (l_nmod) af_52\NN\1740|of
D014700_D001281 CID verapamil_22\NN\2938514|by (r_nmod) caused_20\VBN\1617192|verapamil (r_acl) that_19\DT\1740|to|caused (r_nmod) similar_17\JJ\1740|that|n=5 (r_amod) acceleration_16\NN\7296428|conduction|similar (r_dobj) produced_14\VBD\1617192|acceleration (r_conj) affect_3\VB\126264|diltiazem|did|not|erp|,|but|produced|. (l_dobj) erp_4\NN\1740|,|length|or|duration (l_conj) length_8\NN\5093581|af|cycle (l_compound) af_6\NN\1740|
D014700_D001281 CID verapamil_22\NN\2938514|by (r_nmod) caused_20\VBN\1617192|verapamil (r_acl) that_19\DT\1740|to|caused (r_nmod) similar_17\JJ\1740|that|n=5 (r_amod) acceleration_16\NN\7296428|conduction|similar (r_dobj) produced_14\VBD\1617192|acceleration (r_conj) affect_3\VB\126264|diltiazem|did|not|erp|,|but|produced|. (l_dobj) erp_4\NN\1740|,|length|or|duration (l_conj) duration_11\NN\15113229|af (l_compound) af_10\NN\1740|
D014700_D001281 CID verapamil_7\NN\2938514| (r_nsubj) failed_8\VBD\1798936|presence|,|verapamil|promote|. (l_xcomp) promote_10\VB\2556126|to|af (l_dobj) af_11\NN\1740|and|increased
D014700_D001281 CID verapamil_4\NN\2938514| (r_nsubj) promoted_5\VBD\2556126|that|verapamil|af|increasing (l_dobj) af_6\NN\1740|
D014700_D001281 CID verapamil_2\NN\2938514| (r_nsubj) promotes_3\VBZ\2556126|:|verapamil|af|dogs|promoting (l_dobj) af_4\NN\1740|
D002118_D013617 NONE ca(2_19\NN\1740| (r_compound) current_22\NN\11449002|l-type|ca(2|+|) (r_dobj) decreases_17\VBZ\169651|current (r_conj) promotes_5\VBZ\2556126|:|remodeling|occurrence|and|decreases (l_nsubj) remodeling_4\NN\1740|tachycardia-induced (l_amod) tachycardia-induced_3\JJ\1740|atrial
D002118_D001281 NONE ca(2_19\NN\1740| (r_compound) current_22\NN\11449002|l-type|ca(2|+|) (r_dobj) decreases_17\VBZ\169651|current (r_conj) promotes_5\VBZ\2556126|:|remodeling|occurrence|and|decreases (l_dobj) occurrence_7\NN\29378|the|and|maintenance|fibrillation (l_nmod) fibrillation_12\NN\14361664|of|atrial|af
D002118_D001281 NONE ca(2_19\NN\1740| (r_compound) current_22\NN\11449002|l-type|ca(2|+|) (r_dobj) decreases_17\VBZ\169651|current (r_conj) promotes_5\VBZ\2556126|:|remodeling|occurrence|and|decreases (l_dobj) occurrence_7\NN\29378|the|and|maintenance|fibrillation (l_nmod) fibrillation_12\NN\14361664|of|atrial|af (l_appos) af_14\NN\1740|(|)
D002118_D001281 NONE ca(2_9\NN\1740| (r_compound) blockade_12\NN\952963|acute|l-type|ca(2|)|channel (r_nsubj) promote_14\VB\2556126|that|blockade|can|af|,|consistent (l_dobj) af_15\NN\1740|
D002118_D001281 NONE ca(2_9\NN\1740| (r_compound) blockade_12\NN\952963|acute|l-type|ca(2|)|channel (r_nsubj) promote_14\VB\2556126|that|blockade|can|af|,|consistent (l_dep) consistent_17\JJ\1740|effect (l_nmod) effect_22\NN\34213|with|an|promoting|inhibition (l_amod) promoting_21\NN\1740|af (l_compound) af_20\NN\1740|
D002118_D001281 NONE ca(2_24\NN\1740| (r_compound) channel_27\NN\6251781|ca(2|+|) (r_compound) inhibition_28\NN\1068773|of|channel (r_nmod) effect_22\NN\34213|with|an|promoting|inhibition (r_nmod) consistent_17\JJ\1740|effect (r_dep) promote_14\VB\2556126|that|blockade|can|af|,|consistent (l_dobj) af_15\NN\1740|
D002118_D001281 NONE ca(2_24\NN\1740| (r_compound) channel_27\NN\6251781|ca(2|+|) (r_compound) inhibition_28\NN\1068773|of|channel (r_nmod) effect_22\NN\34213|with|an|promoting|inhibition (l_amod) promoting_21\NN\1740|af (l_compound) af_20\NN\1740|
D002118_D001281 NONE ca(2_11\NN\1740| (r_compound) blockers_15\NNS\10101634|by|ca(2|+|)|channel (r_nmod) promotion_9\NN\6598915|of|af|blockers (l_compound) af_8\NN\1740|
D009020_D001281 NONE morphine-chloralose_21\NN\1740| (r_nmod:npmod) anesthetized_22\JJ\1740|morphine-chloralose (r_amod) dogs_23\NNS\2083346|to|anesthetized (r_nmod) administered_18\VBD\2436349|methods|evaluate|,|we|verapamil|dogs|. (l_advcl) evaluate_3\VB\670261|to|mechanisms (l_dobj) mechanisms_6\NNS\13446390|the|potential|promotion (l_nmod) promotion_9\NN\6598915|of|af|blockers (l_compound) af_8\NN\1740|
D002698_D001281 NONE morphine-chloralose_21\NN\1740| (r_nmod:npmod) anesthetized_22\JJ\1740|morphine-chloralose (r_amod) dogs_23\NNS\2083346|to|anesthetized (r_nmod) administered_18\VBD\2436349|methods|evaluate|,|we|verapamil|dogs|. (l_advcl) evaluate_3\VB\670261|to|mechanisms (l_dobj) mechanisms_6\NNS\13446390|the|potential|promotion (l_nmod) promotion_9\NN\6598915|of|af|blockers (l_compound) af_8\NN\1740|
D004110_D001281 NONE diltiazem_0\NN\2938514| (r_nsubj) affect_3\VB\126264|diltiazem|did|not|erp|,|but|produced|. (l_dobj) erp_4\NN\1740|,|length|or|duration (l_conj) length_8\NN\5093581|af|cycle (l_compound) af_6\NN\1740|
D004110_D001281 NONE diltiazem_0\NN\2938514| (r_nsubj) affect_3\VB\126264|diltiazem|did|not|erp|,|but|produced|. (l_dobj) erp_4\NN\1740|,|length|or|duration (l_conj) duration_11\NN\15113229|af (l_compound) af_10\NN\1740|
D004110_D001281 NONE diltiazem_25\NN\2938514|by (r_nmod) shared_23\VBN\2660631|not|diltiazem (r_conj) dependent_16\JJ\1740|tone|and|shared (r_amod) effect_15\NN\34213|an|dependent (r_appos) reentry_12\NN\328015|multiple|circuit|,|effect (r_dobj) promoting_9\VBG\2556126|by|reentry (r_advcl) promotes_3\VBZ\2556126|:|verapamil|af|dogs|promoting (l_dobj) af_4\NN\1740|
14633084
D003907_D006470 NONE dexamethasone_2\NN\2721538|of (r_nmod) use_0\NN\407535|dexamethasone|mesna|prevention|. (l_nmod) prevention_7\NN\1073995|for|the|cystitis (l_nmod) cystitis_11\NN\14566129|of|ifosfamide-induced|hemorrhagic
D003907_D006470 NONE dexamethasone_11\NN\2721538|of (r_nmod) use_9\NN\407535|the|dexamethasone|combination|prevention (l_nmod) prevention_18\NN\1073995|for|the|hc (l_nmod) hc_21\NN\1740|of|ifs-induced
D003907_D006470 NONE dexamethasone_2\NN\2721538|combination (r_nsubj) efficient_8\JJ\1740|dexamethasone|was|blocking|. (l_advcl) blocking_10\VBG\1476483|in|hc (l_dobj) hc_12\NN\1740|ifs-induced
D003907_D006470 NONE dexamethasone_19\NN\2721538|with (r_nmod) all_13\DT\1740|doses|dexamethasone (r_conj) replacement_3\NN\196485|the|doses|saline|or|all (r_nsubj) prevent_22\VB\1740|however|,|replacement|did|not|hc|. (l_dobj) hc_23\NN\1740|
D003907_D003556 NONE dexamethasone_2\NN\2721538|of (r_nmod) use_0\NN\407535|dexamethasone|mesna|prevention|. (l_nmod) prevention_7\NN\1073995|for|the|cystitis (l_nmod) cystitis_11\NN\14566129|of|ifosfamide-induced|hemorrhagic
D003907_D003556 NONE dexamethasone_11\NN\2721538|of (r_nmod) use_9\NN\407535|the|dexamethasone|combination|prevention (l_nmod) prevention_18\NN\1073995|for|the|hc (l_nmod) hc_21\NN\1740|of|ifs-induced
D003907_D003556 NONE dexamethasone_2\NN\2721538|combination (r_nsubj) efficient_8\JJ\1740|dexamethasone|was|blocking|. (l_advcl) blocking_10\VBG\1476483|in|hc (l_dobj) hc_12\NN\1740|ifs-induced
D003907_D003556 NONE dexamethasone_19\NN\2721538|with (r_nmod) all_13\DT\1740|doses|dexamethasone (r_conj) replacement_3\NN\196485|the|doses|saline|or|all (r_nsubj) prevent_22\VB\1740|however|,|replacement|did|not|hc|. (l_dobj) hc_23\NN\1740|
D015080_D006470 NONE mesna_4\NN\1740|with (r_nmod) use_0\NN\407535|dexamethasone|mesna|prevention|. (l_nmod) prevention_7\NN\1073995|for|the|cystitis (l_nmod) cystitis_11\NN\14566129|of|ifosfamide-induced|hemorrhagic
D015080_D006470 NONE mesna_15\NN\1740|with (r_nmod) combination_13\NN\7951464|in|mesna (r_nmod) use_9\NN\407535|the|dexamethasone|combination|prevention (l_nmod) prevention_18\NN\1073995|for|the|hc (l_nmod) hc_21\NN\1740|of|ifs-induced
D015080_D006470 NONE mesna_6\NN\1740|with (r_nmod) combination_4\NN\7951464|in|mesna (r_nmod) dexamethasone_2\NN\2721538|combination (r_nsubj) efficient_8\JJ\1740|dexamethasone|was|blocking|. (l_advcl) blocking_10\VBG\1476483|in|hc (l_dobj) hc_12\NN\1740|ifs-induced
D015080_D006470 NONE mesna_9\NN\1740|of (r_nmod) doses_7\NNS\3740161|of|last|two|mesna (r_nmod) replacement_3\NN\196485|the|doses|saline|or|all (r_nsubj) prevent_22\VB\1740|however|,|replacement|did|not|hc|. (l_dobj) hc_23\NN\1740|
D015080_D006470 NONE mesna_16\NN\1740| (r_compound) doses_17\NNS\3740161|of|the|mesna (r_nmod) all_13\DT\1740|doses|dexamethasone (r_conj) replacement_3\NN\196485|the|doses|saline|or|all (r_nsubj) prevent_22\VB\1740|however|,|replacement|did|not|hc|. (l_dobj) hc_23\NN\1740|
D015080_D003556 NONE mesna_4\NN\1740|with (r_nmod) use_0\NN\407535|dexamethasone|mesna|prevention|. (l_nmod) prevention_7\NN\1073995|for|the|cystitis (l_nmod) cystitis_11\NN\14566129|of|ifosfamide-induced|hemorrhagic
D015080_D003556 NONE mesna_15\NN\1740|with (r_nmod) combination_13\NN\7951464|in|mesna (r_nmod) use_9\NN\407535|the|dexamethasone|combination|prevention (l_nmod) prevention_18\NN\1073995|for|the|hc (l_nmod) hc_21\NN\1740|of|ifs-induced
D015080_D003556 NONE mesna_6\NN\1740|with (r_nmod) combination_4\NN\7951464|in|mesna (r_nmod) dexamethasone_2\NN\2721538|combination (r_nsubj) efficient_8\JJ\1740|dexamethasone|was|blocking|. (l_advcl) blocking_10\VBG\1476483|in|hc (l_dobj) hc_12\NN\1740|ifs-induced
D015080_D003556 NONE mesna_9\NN\1740|of (r_nmod) doses_7\NNS\3740161|of|last|two|mesna (r_nmod) replacement_3\NN\196485|the|doses|saline|or|all (r_nsubj) prevent_22\VB\1740|however|,|replacement|did|not|hc|. (l_dobj) hc_23\NN\1740|
D015080_D003556 NONE mesna_16\NN\1740| (r_compound) doses_17\NNS\3740161|of|the|mesna (r_nmod) all_13\DT\1740|doses|dexamethasone (r_conj) replacement_3\NN\196485|the|doses|saline|or|all (r_nsubj) prevent_22\VB\1740|however|,|replacement|did|not|hc|. (l_dobj) hc_23\NN\1740|
D007069_D006470 CID ifosfamide-induced_9\JJ\1740| (r_amod) cystitis_11\NN\14566129|of|ifosfamide-induced|hemorrhagic
D007069_D006470 CID ifosfamide_14\NN\1740|with|ifs (r_nmod) chemotherapy_12\NN\661091|of|ifosfamide (r_nmod) side-effect_10\NN\1740|cystitis|is|a|limiting|chemotherapy (l_nsubj) cystitis_3\NN\14566129|hemorrhagic|hc
D007069_D006470 CID ifosfamide_14\NN\1740|with|ifs (r_nmod) chemotherapy_12\NN\661091|of|ifosfamide (r_nmod) side-effect_10\NN\1740|cystitis|is|a|limiting|chemotherapy (l_nsubj) cystitis_3\NN\14566129|hemorrhagic|hc (l_appos) hc_5\NN\1740|(|)
D007069_D006470 CID ifs_16\NN\1740|(|) (r_appos) ifosfamide_14\NN\1740|with|ifs (r_nmod) chemotherapy_12\NN\661091|of|ifosfamide (r_nmod) side-effect_10\NN\1740|cystitis|is|a|limiting|chemotherapy (l_nsubj) cystitis_3\NN\14566129|hemorrhagic|hc
D007069_D006470 CID ifs_16\NN\1740|(|) (r_appos) ifosfamide_14\NN\1740|with|ifs (r_nmod) chemotherapy_12\NN\661091|of|ifosfamide (r_nmod) side-effect_10\NN\1740|cystitis|is|a|limiting|chemotherapy (l_nsubj) cystitis_3\NN\14566129|hemorrhagic|hc (l_appos) hc_5\NN\1740|(|)
D007069_D006470 CID ifs-induced_20\JJ\1740| (r_amod) hc_21\NN\1740|of|ifs-induced
D007069_D006470 CID ifs-induced_11\JJ\1740| (r_amod) hc_12\NN\1740|ifs-induced
D007069_D003556 CID ifosfamide-induced_9\JJ\1740| (r_amod) cystitis_11\NN\14566129|of|ifosfamide-induced|hemorrhagic
D007069_D003556 CID ifosfamide_14\NN\1740|with|ifs (r_nmod) chemotherapy_12\NN\661091|of|ifosfamide (r_nmod) side-effect_10\NN\1740|cystitis|is|a|limiting|chemotherapy (l_nsubj) cystitis_3\NN\14566129|hemorrhagic|hc
D007069_D003556 CID ifosfamide_14\NN\1740|with|ifs (r_nmod) chemotherapy_12\NN\661091|of|ifosfamide (r_nmod) side-effect_10\NN\1740|cystitis|is|a|limiting|chemotherapy (l_nsubj) cystitis_3\NN\14566129|hemorrhagic|hc (l_appos) hc_5\NN\1740|(|)
D007069_D003556 CID ifs_16\NN\1740|(|) (r_appos) ifosfamide_14\NN\1740|with|ifs (r_nmod) chemotherapy_12\NN\661091|of|ifosfamide (r_nmod) side-effect_10\NN\1740|cystitis|is|a|limiting|chemotherapy (l_nsubj) cystitis_3\NN\14566129|hemorrhagic|hc
D007069_D003556 CID ifs_16\NN\1740|(|) (r_appos) ifosfamide_14\NN\1740|with|ifs (r_nmod) chemotherapy_12\NN\661091|of|ifosfamide (r_nmod) side-effect_10\NN\1740|cystitis|is|a|limiting|chemotherapy (l_nsubj) cystitis_3\NN\14566129|hemorrhagic|hc (l_appos) hc_5\NN\1740|(|)
D007069_D003556 CID ifs-induced_20\JJ\1740| (r_amod) hc_21\NN\1740|of|ifs-induced
D007069_D003556 CID ifs-induced_11\JJ\1740| (r_amod) hc_12\NN\1740|ifs-induced
343678
D006514_D006509 NONE antigen_39\NN\20090|hepatitis|b|surface (r_compound) (hbsag)-positive_40\NN\1740|antigen (r_nummod) donors_41\NNS\9608709|to|(hbsag)-positive (r_nmod) exposure_34\NN\5042871|after|needle-stick|donors (r_nmod) preventing_28\VBG\1740|in|hepatitis|exposure (r_advcl) efficacies_26\NNS\5199286|their|relative|preventing (r_dobj) assess_23\VB\670261|to|efficacies (r_acl) trial_21\NN\786195|in|a|randomized|,|double-blind|assess (r_nmod) examined_15\VBN\789138|globulin|were|trial|. (l_nsubjpass) globulin_3\NN\14736972|hepatitis|b|immune|hbig|and|globulin (l_compound) b_1\NN\1355326|
D006514_D006509 NONE antigen_39\NN\20090|hepatitis|b|surface (r_compound) (hbsag)-positive_40\NN\1740|antigen (r_nummod) donors_41\NNS\9608709|to|(hbsag)-positive (r_nmod) exposure_34\NN\5042871|after|needle-stick|donors (r_nmod) preventing_28\VBG\1740|in|hepatitis|exposure (l_dobj) hepatitis_31\NN\14127211|type|b
D006514_D006509 NONE (hbsag)-positive_40\NN\1740|antigen (r_nummod) donors_41\NNS\9608709|to|(hbsag)-positive (r_nmod) exposure_34\NN\5042871|after|needle-stick|donors (r_nmod) preventing_28\VBG\1740|in|hepatitis|exposure (r_advcl) efficacies_26\NNS\5199286|their|relative|preventing (r_dobj) assess_23\VB\670261|to|efficacies (r_acl) trial_21\NN\786195|in|a|randomized|,|double-blind|assess (r_nmod) examined_15\VBN\789138|globulin|were|trial|. (l_nsubjpass) globulin_3\NN\14736972|hepatitis|b|immune|hbig|and|globulin (l_compound) b_1\NN\1355326|
D006514_D006509 NONE (hbsag)-positive_40\NN\1740|antigen (r_nummod) donors_41\NNS\9608709|to|(hbsag)-positive (r_nmod) exposure_34\NN\5042871|after|needle-stick|donors (r_nmod) preventing_28\VBG\1740|in|hepatitis|exposure (l_dobj) hepatitis_31\NN\14127211|type|b
17975693
D002939_D001008 CID ciprofloxacin-_6\NN\1740|and|norfloxacin-treated (r_nummod) rats_9\NNS\2329401|ciprofloxacin- (r_nsubj) showed_10\VBD\2137132|that|rats|behaviour|comparison (l_dobj) behaviour_12\NN\14006945|anxious
D009643_D001008 CID norfloxacin-treated_8\JJ\1740| (r_conj) ciprofloxacin-_6\NN\1740|and|norfloxacin-treated (r_nummod) rats_9\NNS\2329401|ciprofloxacin- (r_nsubj) showed_10\VBD\2137132|that|rats|behaviour|comparison (l_dobj) behaviour_12\NN\14006945|anxious
3973521
9226773
D008094_D018500 CID lithium_5\NN\14625458| (r_compound) therapy_6\NN\657604|following|lithium (r_nmod) insipidus_3\NN\1740|persistent|nephrogenic|diabetes|therapy|.
D008094_D018500 CID lithium-induced_9\JJ\1740| (r_amod) insipidus_12\NN\1740|lithium-induced|nephrogenic|diabetes
D008094_D018500 CID lithium_15\NN\14625458| (r_compound) therapy_16\NN\657604|lithium (r_nsubjpass) discontinued_19\VBN\2609764|therapy|had|been|. (r_conj) diagnosed_6\VBN\644583|previously|he|had|been|have|,|and|discontinued (l_xcomp) have_8\VB\2108377|to|insipidus (l_dobj) insipidus_12\NN\1740|lithium-induced|nephrogenic|diabetes
D008094_D018500 CID lithium_8\NN\14625458|of (r_nmod) cessation_6\NN\7365849|despite|lithium (r_nmod) remained_1\VBD\2604760|he|thirsty|cessation|and|showed (l_conj) showed_13\VBD\2137132|investigations|him|have|. (l_xcomp) have_16\VB\2108377|to|thirst|,|evidence (l_nmod) evidence_26\NN\5816287|with|clear|insipidus (l_nmod) insipidus_30\NN\1740|of|nephrogenic|diabetes
D008094_D018500 CID lithium_0\NN\14625458| (r_nmod:npmod) induced_1\JJ\1740|lithium (r_amod) insipidus_4\NN\1740|induced|nephrogenic|diabetes
D008094_D018500 CID lithium_24\NN\14625458| (r_nsubjpass) stopped_26\VBN\2452885|after|lithium|was (r_advcl) persisted_16\VBD\118523|polyuria|patient|years|stopped|. (r_conj) considered_6\VBN\689344|insipidus|is|reversible|but|persisted (l_nsubjpass) insipidus_4\NN\1740|induced|nephrogenic|diabetes
D008094_D018500 CID lithium-induced_14\JJ\1740| (r_amod) insipidus_17\NN\1740|with|lithium-induced|nephrogenic|diabetes
D008094_D011141 CID lithium_8\NN\14625458|of (r_nmod) cessation_6\NN\7365849|despite|lithium (r_nmod) remained_1\VBD\2604760|he|thirsty|cessation|and|showed (l_xcomp) thirsty_2\JJ\1740|and|polyuric (l_conj) polyuric_4\JJ\1740|
D008094_D011141 CID lithium_0\NN\14625458| (r_nmod:npmod) induced_1\JJ\1740|lithium (r_amod) insipidus_4\NN\1740|induced|nephrogenic|diabetes (r_nsubjpass) considered_6\VBN\689344|insipidus|is|reversible|but|persisted (l_conj) persisted_16\VBD\118523|polyuria|patient|years|stopped|. (l_nsubj) polyuria_15\NN\14113228|
D008094_D011141 CID lithium_24\NN\14625458| (r_nsubjpass) stopped_26\VBN\2452885|after|lithium|was (r_advcl) persisted_16\VBD\118523|polyuria|patient|years|stopped|. (l_nsubj) polyuria_15\NN\14113228|
D014667_D011141 NONE vasopressin_21\NN\5407119| (r_compound) secretion_22\NN\13526110|vasopressin (r_conj) thirst_19\NN\14035298|normal|osmoregulated|and|secretion (r_dobj) have_16\VB\2108377|to|thirst|,|evidence (r_xcomp) showed_13\VBD\2137132|investigations|him|have|. (r_conj) remained_1\VBD\2604760|he|thirsty|cessation|and|showed (l_xcomp) thirsty_2\JJ\1740|and|polyuric (l_conj) polyuric_4\JJ\1740|
D014667_D018500 NONE vasopressin_21\NN\5407119| (r_compound) secretion_22\NN\13526110|vasopressin (r_conj) thirst_19\NN\14035298|normal|osmoregulated|and|secretion (r_dobj) have_16\VB\2108377|to|thirst|,|evidence (l_nmod) evidence_26\NN\5816287|with|clear|insipidus (l_nmod) insipidus_30\NN\1740|of|nephrogenic|diabetes
10074612
D008775_D007022 CID methylprednisolone_9\NN\1740|after|high-dose|intravenous (r_nmod) hypotension_0\NN\14057371|,|bradycardia|methylprednisolone|patient|.
D008775_D007022 CID methylprednisolone_16\NN\1740|of|high-dose (r_nmod) administration_13\NN\1133281|after|intravenous|methylprednisolone (r_nmod) hypotension_5\NN\14057371|of|,|bradycardia|administration|patient
D008775_D001919 CID methylprednisolone_9\NN\1740|after|high-dose|intravenous (r_nmod) hypotension_0\NN\14057371|,|bradycardia|methylprednisolone|patient|. (l_conj) bradycardia_2\NN\14110674|,|and|asystole
D008775_D001919 CID methylprednisolone_16\NN\1740|of|high-dose (r_nmod) administration_13\NN\1133281|after|intravenous|methylprednisolone (r_nmod) hypotension_5\NN\14057371|of|,|bradycardia|administration|patient (l_conj) bradycardia_7\NN\14110674|,|and|asystole
D008775_D006323 CID methylprednisolone_9\NN\1740|after|high-dose|intravenous (r_nmod) hypotension_0\NN\14057371|,|bradycardia|methylprednisolone|patient|. (l_conj) bradycardia_2\NN\14110674|,|and|asystole (l_conj) asystole_5\NN\14204950|
D008775_D006323 CID methylprednisolone_16\NN\1740|of|high-dose (r_nmod) administration_13\NN\1133281|after|intravenous|methylprednisolone (r_nmod) hypotension_5\NN\14057371|of|,|bradycardia|administration|patient (l_conj) bradycardia_7\NN\14110674|,|and|asystole (l_conj) asystole_10\NN\14204950|
D008775_D003645 NONE methylprednisolone_16\NN\1740|of|intravenous|ivmp (r_nmod) dose_13\NN\3740161|after|a|high|methylprednisolone (r_nmod) death_9\NN\7296428|of|sudden|dose
D008775_D003645 NONE ivmp_18\NN\1740|(|) (r_appos) methylprednisolone_16\NN\1740|of|intravenous|ivmp (r_nmod) dose_13\NN\3740161|after|a|high|methylprednisolone (r_nmod) death_9\NN\7296428|of|sudden|dose
18161408
D002996_D009203 CID citrate_7\NN\14850483|with|clomiphene|induction (r_nmod) associated_4\VBN\628491|citrate (r_acl) infarction_1\NN\14204950|myocardial|pregnancy|associated|:|report|.
D002996_D009203 CID cc_15\NN\13616054|between|and|infarction (l_conj) infarction_18\NN\14204950|myocardial
D002996_D013923 CID cc_15\NN\13616054|with (r_nmod) induction_13\NN\7450842|after|ovulation|cc (r_nmod) reported_10\VBN\831651|that|has|been|induction (r_acl:relcl) complication_6\NN\1073995|thromboembolism|is|a|rare|reported|. (l_nsubj) thromboembolism_0\NN\14100769|
D002996_D002637 NONE cc_12\NN\13616054| (r_dobj) received_11\VBN\2210855|woman|had|recently|cc|induction|and|presented|. (l_conj) presented_17\VBD\2137132|pain (l_nmod) pain_20\NN\14299637|with|chest
D002996_D013927 NONE cc_9\NN\13616054|of (r_nmod) complication_7\NN\1073995|thrombosis|might|be|a|rare|cc|. (l_nsubj) thrombosis_0\NN\14100769|
8643973
D017239_D010051 NONE paclitaxel_0\NN\1740| (r_nsubj) combined_1\VBN\2630189|paclitaxel|carboplatin|treatment|. (l_nmod) treatment_7\NN\654885|in|the|first-line|cancer (l_nmod) cancer_11\NN\14239425|of|advanced|ovarian
D017239_D010051 NONE paclitaxel_12\NN\1740|of|taxol (l_appos) taxol_14\NN\1740|(|;|company|,|princeton|)|given (l_acl) given_24\VBN\2327200|infusion|combination (l_nmod) combination_30\NN\7951464|in|carboplatin (l_nmod) carboplatin_32\NN\1740|with|administered (l_acl) administered_33\VBN\2436349|days|women (l_nmod) women_38\NNS\9605289|to|cancer (l_nmod) cancer_42\NN\14239425|with|advanced|ovarian
D017239_D010051 NONE taxol_14\NN\1740|(|;|company|,|princeton|)|given (l_acl) given_24\VBN\2327200|infusion|combination (l_nmod) combination_30\NN\7951464|in|carboplatin (l_nmod) carboplatin_32\NN\1740|with|administered (l_acl) administered_33\VBN\2436349|days|women (l_nmod) women_38\NNS\9605289|to|cancer (l_nmod) cancer_42\NN\14239425|with|advanced|ovarian
D017239_D010051 NONE paclitaxel_44\NN\1740| (r_compound) doses_45\NNS\3740161|paclitaxel (r_nsubjpass) escalated_47\VBN\153263|study|,|doses|were|follows|. (l_nmod) study_4\NN\635850|in|a|phase|i|determine (l_acl) determine_6\VB\1645601|to|dose (l_dobj) dose_10\NN\3740161|the|tolerated|paclitaxel (l_nmod) paclitaxel_12\NN\1740|of|taxol (l_appos) taxol_14\NN\1740|(|;|company|,|princeton|)|given (l_acl) given_24\VBN\2327200|infusion|combination (l_nmod) combination_30\NN\7951464|in|carboplatin (l_nmod) carboplatin_32\NN\1740|with|administered (l_acl) administered_33\VBN\2436349|days|women (l_nmod) women_38\NNS\9605289|to|cancer (l_nmod) cancer_42\NN\14239425|with|advanced|ovarian
D016190_D010051 NONE carboplatin_3\NN\1740|with (r_nmod) combined_1\VBN\2630189|paclitaxel|carboplatin|treatment|. (l_nmod) treatment_7\NN\654885|in|the|first-line|cancer (l_nmod) cancer_11\NN\14239425|of|advanced|ovarian
D016190_D010051 NONE carboplatin_32\NN\1740|with|administered (l_acl) administered_33\VBN\2436349|days|women (l_nmod) women_38\NNS\9605289|to|cancer (l_nmod) cancer_42\NN\14239425|with|advanced|ovarian
9952311
D004317_D028361 CID adriamycin-induced_7\JJ\1740| (r_amod) cardiomyopathy_8\NN\14103288|in|adriamycin-induced|mice (r_nmod) impairment_3\NN\7296428|structural|mitochondria|cardiomyopathy|:|suppression (l_nmod) mitochondria_5\NN\5445668|of
D004317_D028361 CID adr_21\NN\1740|of (r_nmod) effects_19\NNS\13245626|the|deteriorating|adr|function (r_nsubj) involve_25\VBP\2676054|that|effects|impairment (l_dobj) impairment_30\NN\7296428|mitochondrial|structural
D004317_D009202 NONE adriamycin-induced_7\JJ\1740| (r_amod) cardiomyopathy_8\NN\14103288|in|adriamycin-induced|mice
D004317_D009369 NONE adriamycin_3\NN\1740|of|adr (r_nmod) use_1\NN\407535|the|adriamycin|chemotherapy (l_nmod) chemotherapy_9\NN\661091|in|cancer (l_compound) cancer_8\NN\14239425|
D004317_D009369 NONE adr_5\NN\1740|(|) (r_appos) adriamycin_3\NN\1740|of|adr (r_nmod) use_1\NN\407535|the|adriamycin|chemotherapy (l_nmod) chemotherapy_9\NN\661091|in|cancer (l_compound) cancer_8\NN\14239425|
D004317_D002318 NONE adriamycin_3\NN\1740|of|adr (r_nmod) use_1\NN\407535|the|adriamycin|chemotherapy (r_nsubj) limited_12\JJ\1740|use|has|been|toxicity|. (l_nmod) toxicity_18\NN\13576101|due|its|cumulative|cardiovascular
D004317_D002318 NONE adr_5\NN\1740|(|) (r_appos) adriamycin_3\NN\1740|of|adr (r_nmod) use_1\NN\407535|the|adriamycin|chemotherapy (r_nsubj) limited_12\JJ\1740|use|has|been|toxicity|. (l_nmod) toxicity_18\NN\13576101|due|its|cumulative|cardiovascular
D004317_D001145 NONE adr_10\NN\1740|with (r_nmod) treatment_6\NN\654885|mice|adr (r_nsubj) caused_11\VBD\1617192|that|1|treatment|arrhythmias|;|underwent (l_dobj) arrhythmias_13\NNS\14103288|cardiovascular|characterized
D004317_D001919 CID adr_10\NN\1740|with (r_nmod) treatment_6\NN\654885|mice|adr (r_nsubj) caused_11\VBD\1617192|that|1|treatment|arrhythmias|;|underwent (l_dobj) arrhythmias_13\NNS\14103288|cardiovascular|characterized (l_acl) characterized_14\VBN\609683|bradycardia (l_nmod) bradycardia_16\NN\14110674|by|,|extension|,|and|failure|concentrations
D004317_D004487 NONE adr_10\NN\1740|with (r_nmod) treatment_6\NN\654885|mice|adr (r_nsubj) caused_11\VBD\1617192|that|1|treatment|arrhythmias|;|underwent (l_dep) underwent_50\VBD\109660|2|mitochondria|swelling|weeks (l_dobj) swelling_51\NN\14315071|,|fusion|,|dissolution|,|and/or|disruption
3780814
D010634_D063646 NONE phenobarbital_3\NN\2792049|of|given (r_nmod) action_1\NN\30358|anti-carcinogenic|phenobarbital|. (l_amod) anti-carcinogenic_0\JJ\1740|
D010634_D063646 NONE phenobarbital_13\NN\2792049|of|pb (l_dep) pb_15\NN\14625458|(|mg|carcinogenesis (l_nmod) carcinogenesis_26\NN\1740|on
D010634_D063646 NONE pb_15\NN\14625458|(|mg|carcinogenesis (l_nmod) carcinogenesis_26\NN\1740|on
D010634_D063646 NONE pb_15\NN\14625458| (r_conj) den_13\NN\8580803|by|+|pb (r_conj) den_9\NN\8580803|by|or|den|2 (r_nmod) treated_7\VBN\2376958|rats|were|den|weeks|schedule|. (l_nmod) schedule_26\NN\5898568|according|our|hepatocarcinogenesis (l_nmod) hepatocarcinogenesis_28\NN\1740|for
D010634_D063646 NONE pb_4\NN\14625458|,|promotes|, (l_acl:relcl) promotes_7\VBZ\2556126|which|carcinogenesis|administered (l_dobj) carcinogenesis_8\NN\1740|
D004052_D063646 NONE diethylnitrosamine_7\NN\1740|with|rat (r_nmod) given_4\VBN\2327200|simultaneously|diethylnitrosamine (r_acl) phenobarbital_3\NN\2792049|of|given (r_nmod) action_1\NN\30358|anti-carcinogenic|phenobarbital|. (l_amod) anti-carcinogenic_0\JJ\1740|
D004052_D063646 NONE diethylnitrosamine_33\NN\1740|with|den (r_nmod) administered_30\VBN\2436349|when|it|is|simultaneously|diethylnitrosamine (r_advcl) elucidate_9\VB\939277|to|effect|administered (l_dobj) effect_11\NN\34213|the|phenobarbital (l_nmod) phenobarbital_13\NN\2792049|of|pb (l_dep) pb_15\NN\14625458|(|mg|carcinogenesis (l_nmod) carcinogenesis_26\NN\1740|on
D004052_D063646 NONE den_35\NN\8580803|(|:|mg/kg/day (r_appos) diethylnitrosamine_33\NN\1740|with|den (r_nmod) administered_30\VBN\2436349|when|it|is|simultaneously|diethylnitrosamine (r_advcl) elucidate_9\VB\939277|to|effect|administered (l_dobj) effect_11\NN\34213|the|phenobarbital (l_nmod) phenobarbital_13\NN\2792049|of|pb (l_dep) pb_15\NN\14625458|(|mg|carcinogenesis (l_nmod) carcinogenesis_26\NN\1740|on
D004052_D063646 NONE den_9\NN\8580803|by|or|den|2 (r_nmod) treated_7\VBN\2376958|rats|were|den|weeks|schedule|. (l_nmod) schedule_26\NN\5898568|according|our|hepatocarcinogenesis (l_nmod) hepatocarcinogenesis_28\NN\1740|for
D004052_D063646 NONE den_13\NN\8580803|by|+|pb (r_conj) den_9\NN\8580803|by|or|den|2 (r_nmod) treated_7\VBN\2376958|rats|were|den|weeks|schedule|. (l_nmod) schedule_26\NN\5898568|according|our|hepatocarcinogenesis (l_nmod) hepatocarcinogenesis_28\NN\1740|for
D004052_D063646 NONE den_13\NN\8580803| (r_compound) treatment_14\NN\654885|after|the|den (r_nmod) administered_10\VBN\2436349|when|treatment (r_advcl) promotes_7\VBZ\2556126|which|carcinogenesis|administered (l_dobj) carcinogenesis_8\NN\1740|
D004052_D063646 NONE den_24\NN\8580803|with (r_nmod) given_21\VBN\2327200|when|simultaneously|den (r_advcl) reduces_16\VBZ\441445|that|pb|effect|given (l_nsubj) pb_4\NN\14625458|,|promotes|, (l_acl:relcl) promotes_7\VBZ\2556126|which|carcinogenesis|administered (l_dobj) carcinogenesis_8\NN\1740|
D010634_D011230 NONE pb_22\NN\14625458| (r_nsubjpass) given_24\VBN\2327200|when|pb|was|simultaneously|den|weeks (r_advcl) reduced_20\VBN\441445|end|,|number|was|significantly|given|. (l_nsubjpass) number_8\NN\5107765|the|and|size|foci (l_nmod) foci_17\NNS\5704266|of|induced|pas|positive|preneoplastic
D004052_D011230 CID den_27\NN\8580803|with (r_nmod) given_24\VBN\2327200|when|pb|was|simultaneously|den|weeks (r_advcl) reduced_20\VBN\441445|end|,|number|was|significantly|given|. (l_nsubjpass) number_8\NN\5107765|the|and|size|foci (l_nmod) foci_17\NNS\5704266|of|induced|pas|positive|preneoplastic
D004052_D009369 NONE den_1\NN\8580803|+|treated (r_compound) rats_5\NNS\2329401|in|den (r_nmod) prolonged_10\JJ\1740|rats|,|survival|was|and|decreased (l_conj) decreased_15\VBD\169651|incidence|compared (l_nsubj) incidence_14\NN\13821570|the|tumor (l_compound) tumor_13\NN\14234074|
D004052_D009369 NONE den_23\NN\8580803|by|alone (r_nmod) obtained_21\VBN\2210855|den (r_acl) results_20\NNS\34213|with|the|obtained|. (r_nmod) compared_17\VBN\644583|as|results (r_advcl) decreased_15\VBD\169651|incidence|compared (l_nsubj) incidence_14\NN\13821570|the|tumor (l_compound) tumor_13\NN\14234074|
D010634_D009369 NONE pb_3\NN\14625458| (r_nmod:npmod) treated_4\JJ\1740|pb (r_conj) den_1\NN\8580803|+|treated (r_compound) rats_5\NNS\2329401|in|den (r_nmod) prolonged_10\JJ\1740|rats|,|survival|was|and|decreased (l_conj) decreased_15\VBD\169651|incidence|compared (l_nsubj) incidence_14\NN\13821570|the|tumor (l_compound) tumor_13\NN\14234074|
6504332
D010634_D004409 CID phenobarbital-induced_0\JJ\1740| (r_amod) dyskinesia_1\NN\14084880|phenobarbital-induced|child|.
D010634_D004409 CID phenobarbital_13\NN\2792049| (r_compound) therapy_14\NN\657604|phenobarbital|seizures (r_dobj) starting_12\VBG\2009433|after|therapy (r_advcl) developed_7\VBD\1753788|child|dyskinesia|starting|. (l_dobj) dyskinesia_9\NN\14084880|a
D010634_D004409 CID phenobarbital_4\NN\2792049|with (r_nmod) challenge_2\NN\13927383|on|repeat|phenobarbital (r_nmod) recurred_8\VBD\339934|challenge|,|dyskinesia|. (l_nsubj) dyskinesia_7\NNS\14084880|the
D010634_D009422 NONE phenobarbital-induced_0\JJ\1740| (r_amod) dyskinesia_1\NN\14084880|phenobarbital-induced|child|. (l_nmod) child_5\NN\9622049|in|a|neurologically-impaired (l_amod) neurologically-impaired_4\RB\1740|
D010634_D009422 NONE phenobarbital_13\NN\2792049| (r_compound) therapy_14\NN\657604|phenobarbital|seizures (r_dobj) starting_12\VBG\2009433|after|therapy (r_advcl) developed_7\VBD\1753788|child|dyskinesia|starting|. (l_nsubj) child_2\NN\9622049|a|2-year-old|impairment (l_nmod) impairment_6\NN\7296428|with|known|neurologic
D010634_D012640 NONE phenobarbital_13\NN\2792049| (r_compound) therapy_14\NN\657604|phenobarbital|seizures (l_nmod) seizures_16\NNS\14081375|for
D010634_D009069 NONE phenobarbital_0\NN\2792049| (r_nsubjpass) added_3\VBN\156601|phenobarbital|should|be|list|. (l_nmod) list_6\NN\6637824|to|the|drugs (l_nmod) drugs_9\NNS\14778436|of|anticonvulsant|cause (l_acl:relcl) cause_12\VB\1617192|that|can|disorders (l_dobj) disorders_14\NNS\14034177|movement
3732088
D011188_D001145 NONE potassium_2\NN\14625458|and|arrhythmias (l_conj) arrhythmias_4\NNS\14103288|
D011188_D001145 NONE potassium_9\NN\14625458|in|plasma (r_nmod) changes_6\NNS\7283608|modest|potassium (r_nsubj) alter_11\VB\126264|that|changes|can|tendency (l_dobj) tendency_13\NN\6193203|the|arrhythmias (l_nmod) arrhythmias_16\NNS\14103288|towards|cardiac
D011188_D006973 NONE potassium_2\NN\14625458|and|arrhythmias (r_conj) diuretics_0\NNS\3247620|,|potassium|disease|. (l_nmod) disease_8\NN\14061805|in|hypertensive|coronary (l_amod) hypertensive_6\JJ\1740|
D011188_D006973 NONE potassium-conserving_25\JJ\1740| (r_amod) diuretic_26\NN\3247620|with|a|potassium-conserving|amiloride (r_nmod) treatment_22\NN\654885|of|diuretic (r_nmod) weeks_20\NNS\15113229|after|8|treatment|and|period (r_nmod) measured_6\VBN\697589|thus|,|excitability|was|patients|weeks|study|. (l_nmod) patients_8\NNS\9898892|in|hypertension (l_nmod) hypertension_12\NN\14057371|with|mild|essential|and|disease
D011188_D006973 NONE potassium-losing_36\JJ\1740| (r_amod) diuretic_37\NN\3247620|on|a|potassium-losing|chlorthalidone (r_nmod) period_33\NN\13575869|a|similar|diuretic (r_conj) weeks_20\NNS\15113229|after|8|treatment|and|period (r_nmod) measured_6\VBN\697589|thus|,|excitability|was|patients|weeks|study|. (l_nmod) patients_8\NNS\9898892|in|hypertension (l_nmod) hypertension_12\NN\14057371|with|mild|essential|and|disease
D011188_D003327 NONE potassium_2\NN\14625458|and|arrhythmias (r_conj) diuretics_0\NNS\3247620|,|potassium|disease|. (l_nmod) disease_8\NN\14061805|in|hypertensive|coronary
D011188_D003324 NONE potassium-conserving_25\JJ\1740| (r_amod) diuretic_26\NN\3247620|with|a|potassium-conserving|amiloride (r_nmod) treatment_22\NN\654885|of|diuretic (r_nmod) weeks_20\NNS\15113229|after|8|treatment|and|period (r_nmod) measured_6\VBN\697589|thus|,|excitability|was|patients|weeks|study|. (l_nmod) patients_8\NNS\9898892|in|hypertension (l_nmod) hypertension_12\NN\14057371|with|mild|essential|and|disease (l_conj) disease_17\NN\14061805|known|coronary|artery
D011188_D003324 NONE potassium-losing_36\JJ\1740| (r_amod) diuretic_37\NN\3247620|on|a|potassium-losing|chlorthalidone (r_nmod) period_33\NN\13575869|a|similar|diuretic (r_conj) weeks_20\NNS\15113229|after|8|treatment|and|period (r_nmod) measured_6\VBN\697589|thus|,|excitability|was|patients|weeks|study|. (l_nmod) patients_8\NNS\9898892|in|hypertension (l_nmod) hypertension_12\NN\14057371|with|mild|essential|and|disease (l_conj) disease_17\NN\14061805|known|coronary|artery
D000584_D006973 NONE amiloride_28\NN\1740|(|) (r_appos) diuretic_26\NN\3247620|with|a|potassium-conserving|amiloride (r_nmod) treatment_22\NN\654885|of|diuretic (r_nmod) weeks_20\NNS\15113229|after|8|treatment|and|period (r_nmod) measured_6\VBN\697589|thus|,|excitability|was|patients|weeks|study|. (l_nmod) patients_8\NNS\9898892|in|hypertension (l_nmod) hypertension_12\NN\14057371|with|mild|essential|and|disease
D000584_D003324 NONE amiloride_28\NN\1740|(|) (r_appos) diuretic_26\NN\3247620|with|a|potassium-conserving|amiloride (r_nmod) treatment_22\NN\654885|of|diuretic (r_nmod) weeks_20\NNS\15113229|after|8|treatment|and|period (r_nmod) measured_6\VBN\697589|thus|,|excitability|was|patients|weeks|study|. (l_nmod) patients_8\NNS\9898892|in|hypertension (l_nmod) hypertension_12\NN\14057371|with|mild|essential|and|disease (l_conj) disease_17\NN\14061805|known|coronary|artery
D002752_D006973 NONE chlorthalidone_39\NN\3214670|(|) (r_appos) diuretic_37\NN\3247620|on|a|potassium-losing|chlorthalidone (r_nmod) period_33\NN\13575869|a|similar|diuretic (r_conj) weeks_20\NNS\15113229|after|8|treatment|and|period (r_nmod) measured_6\VBN\697589|thus|,|excitability|was|patients|weeks|study|. (l_nmod) patients_8\NNS\9898892|in|hypertension (l_nmod) hypertension_12\NN\14057371|with|mild|essential|and|disease
D002752_D003324 NONE chlorthalidone_39\NN\3214670|(|) (r_appos) diuretic_37\NN\3247620|on|a|potassium-losing|chlorthalidone (r_nmod) period_33\NN\13575869|a|similar|diuretic (r_conj) weeks_20\NNS\15113229|after|8|treatment|and|period (r_nmod) measured_6\VBN\697589|thus|,|excitability|was|patients|weeks|study|. (l_nmod) patients_8\NNS\9898892|in|hypertension (l_nmod) hypertension_12\NN\14057371|with|mild|essential|and|disease (l_conj) disease_17\NN\14061805|known|coronary|artery
D000584_D018879 NONE amiloride_2\NN\1740| (r_compound) treatment_3\NN\654885|to|amiloride (r_nmod) compared_0\VBN\644583|treatment (r_prep) associated_9\VBN\628491|compared|,|phase|was|frequency|. (l_nmod) frequency_13\NN\15286249|with|an|increased|beats|monitoring|and|grading (l_nmod) beats_17\NNS\8289449|of|ventricular|ectopic
D002752_D018879 CID chlorthalidone_6\NN\3214670| (r_compound) phase_7\NN\15113229|the|chlorthalidone (r_nsubjpass) associated_9\VBN\628491|compared|,|phase|was|frequency|. (l_nmod) frequency_13\NN\15286249|with|an|increased|beats|monitoring|and|grading (l_nmod) beats_17\NNS\8289449|of|ventricular|ectopic
D011188_D017202 NONE potassium-losing_6\JJ\1740| (r_amod) therapy_8\NN\657604|potassium-losing|diuretic (r_nsubj) increase_10\VB\169651|because|therapy|can|excitability (l_dobj) excitability_13\NN\5653575|myocardial|electrical|patients (l_nmod) patients_15\NNS\9898892|in|disease (l_nmod) disease_19\NN\14061805|with|ischaemic|heart
D011188_D017202 NONE potassium_26\NN\14625458| (r_compound) concentrations_27\NNS\4916342|in|plasma|potassium (r_nmod) falls_23\NNS\11692265|minor|concentrations (r_nsubjpass) avoided_31\VBN\2452885|that|increase|,|falls|are|probably|best|patients (l_advcl) increase_10\VB\169651|because|therapy|can|excitability (l_dobj) excitability_13\NN\5653575|myocardial|electrical|patients (l_nmod) patients_15\NNS\9898892|in|disease (l_nmod) disease_19\NN\14061805|with|ischaemic|heart
8546130
D017291_D006212 CID clarithromycin-associated_0\NN\1740| (r_compound) hallucinations_2\NNS\14376855|clarithromycin-associated|visual|patient|.
D017291_D006212 CID clarithromycin_16\NN\1740| (r_appos) antibiotic_14\NN\2716205|with|the|new|macrolide|,|clarithromycin (r_nmod) association_9\NN\8008335|in|antibiotic (r_nmod) occurring_7\VBG\2623529|association (r_acl) hallucinations_6\NNS\14376855|is|visual|occurring
D017291_D007676 NONE clarithromycin-associated_0\NN\1740| (r_compound) hallucinations_2\NNS\14376855|clarithromycin-associated|visual|patient|. (l_nmod) patient_5\NN\9898892|in|a|failure (l_nmod) failure_9\NN\66216|with|chronic|renal|dialysis
D017291_D007676 NONE clarithromycin_8\NN\1740|of (r_nmod) dose_6\NN\3740161|of|a|high|clarithromycin (r_nmod) combination_1\NN\7951464|the|dose|face (l_nmod) face_10\NN\5225090|in|failure (l_nmod) failure_14\NN\66216|of|chronic|renal|patient
D018942_D006212 NONE macrolide_13\NN\1740| (r_compound) antibiotic_14\NN\2716205|with|the|new|macrolide|,|clarithromycin (r_nmod) association_9\NN\8008335|in|antibiotic (r_nmod) occurring_7\VBG\2623529|association (r_acl) hallucinations_6\NNS\14376855|is|visual|occurring
D017291_D020258 NONE clarithromycin_8\NN\1740|of (r_nmod) dose_6\NN\3740161|of|a|high|clarithromycin (r_nmod) combination_1\NN\7951464|the|dose|face (r_nsubj) facilitated_28\VBN\2547586|combination|,|may|have|appearance|. (l_dobj) appearance_30\NN\4723816|the|effect (l_nmod) effect_35\NN\34213|of|this|neurotoxic|side (l_amod) neurotoxic_33\JJ\1740|
D000535_D007676 NONE aluminum_23\NN\14625458| (r_compound) intoxication_24\NN\14034177|with|underlying|aluminum (r_nmod) patient_19\NN\9898892|in|a|anephric|,|intoxication (r_nmod) failure_14\NN\66216|of|chronic|renal|patient
D000535_D020258 NONE aluminum_23\NN\14625458| (r_compound) intoxication_24\NN\14034177|with|underlying|aluminum (r_nmod) patient_19\NN\9898892|in|a|anephric|,|intoxication (r_nmod) failure_14\NN\66216|of|chronic|renal|patient (r_nmod) face_10\NN\5225090|in|failure (r_nmod) combination_1\NN\7951464|the|dose|face (r_nsubj) facilitated_28\VBN\2547586|combination|,|may|have|appearance|. (l_dobj) appearance_30\NN\4723816|the|effect (l_nmod) effect_35\NN\34213|of|this|neurotoxic|side (l_amod) neurotoxic_33\JJ\1740|
8677458
D015080_D006470 CID mesna_4\NN\1740|of (r_nmod) administration_2\NN\1133281|continuous|subcutaneous|mesna|prevent|. (l_acl) prevent_6\VB\1740|to|cystitis (l_dobj) cystitis_9\NN\14566129|ifosfamide-induced|hemorrhagic
D015080_D006470 CID mesna_15\NN\1740| (r_dobj) administering_14\VBG\2436349|by|mesna|along|agent (r_advcl) prevented_12\VBN\1740|that|can|be|administering (r_acl:relcl) toxicity_6\NN\13576101|cystitis|is|a|major|potential|ifosfamide|prevented|. (l_nsubj) cystitis_1\NN\14566129|hemorrhagic
D015080_D003556 CID mesna_4\NN\1740|of (r_nmod) administration_2\NN\1133281|continuous|subcutaneous|mesna|prevent|. (l_acl) prevent_6\VB\1740|to|cystitis (l_dobj) cystitis_9\NN\14566129|ifosfamide-induced|hemorrhagic
D015080_D003556 CID mesna_15\NN\1740| (r_dobj) administering_14\VBG\2436349|by|mesna|along|agent (r_advcl) prevented_12\VBN\1740|that|can|be|administering (r_acl:relcl) toxicity_6\NN\13576101|cystitis|is|a|major|potential|ifosfamide|prevented|. (l_nsubj) cystitis_1\NN\14566129|hemorrhagic
D007069_D006470 CID ifosfamide-induced_7\JJ\1740| (r_amod) cystitis_9\NN\14566129|ifosfamide-induced|hemorrhagic
D007069_D006470 CID ifosfamide_8\NN\1740|of (r_nmod) toxicity_6\NN\13576101|cystitis|is|a|major|potential|ifosfamide|prevented|. (l_nsubj) cystitis_1\NN\14566129|hemorrhagic
D007069_D003556 CID ifosfamide-induced_7\JJ\1740| (r_amod) cystitis_9\NN\14566129|ifosfamide-induced|hemorrhagic
D007069_D003556 CID ifosfamide_8\NN\1740|of (r_nmod) toxicity_6\NN\13576101|cystitis|is|a|major|potential|ifosfamide|prevented|. (l_nsubj) cystitis_1\NN\14566129|hemorrhagic
D007069_D064420 NONE ifosfamide_8\NN\1740|of (r_nmod) toxicity_6\NN\13576101|cystitis|is|a|major|potential|ifosfamide|prevented|.
D015080_D064420 NONE mesna_15\NN\1740| (r_dobj) administering_14\VBG\2436349|by|mesna|along|agent (r_advcl) prevented_12\VBN\1740|that|can|be|administering (r_acl:relcl) toxicity_6\NN\13576101|cystitis|is|a|major|potential|ifosfamide|prevented|.
D015080_D014839 NONE mesna_19\NN\1740| (r_compound) concentrations_20\NNS\4916342|of|inadequate|urinary|mesna (r_nmod) risk_15\NN\14541044|with|the|concentrations (r_nmod) associated_12\VBN\628491|addition|,|delivery|will|not|be|risk|,|patient|. (l_nmod) patient_26\NN\9898892|such|in|a|taking|experiences (l_acl:relcl) experiences_31\VBZ\2108377|who|emesis|and|unable (l_dobj) emesis_34\NN\116687|severe|ifosfamide-induced
D015080_D014839 NONE mesna_29\NN\1740|oral (r_dobj) taking_27\VBG\2367363|mesna (r_acl) patient_26\NN\9898892|such|in|a|taking|experiences (l_acl:relcl) experiences_31\VBZ\2108377|who|emesis|and|unable (l_dobj) emesis_34\NN\116687|severe|ifosfamide-induced
D007069_D014839 NONE ifosfamide-induced_33\JJ\1740| (r_amod) emesis_34\NN\116687|severe|ifosfamide-induced
11999899
D012110_D009069 NONE reserpine_0\NN\2721160|mg/kg|,|administered|, (r_nsubj) produced_15\VBD\1617192|reserpine|increases|. (l_dobj) increases_16\NNS\13576355|dyskinesia (l_nmod) dyskinesia_19\NN\14084880|in|orofacial|,|protrusion|,|signs
D012110_D009069 NONE reserpine_0\NN\2721160|mg/kg|,|administered|, (r_nsubj) produce_29\VB\1617192|reserpine|did|not|dyskinesia|mice|. (l_dobj) dyskinesia_31\NN\14084880|oral
D012110_D004409 CID reserpine_0\NN\2721160|mg/kg|,|administered|, (r_nsubj) produced_15\VBD\1617192|reserpine|increases|. (l_dobj) increases_16\NNS\13576355|dyskinesia (l_nmod) dyskinesia_19\NN\14084880|in|orofacial|,|protrusion|,|signs (l_acl:relcl) signs_31\NNS\6643763|which|are|indicative (l_amod) indicative_32\JJ\1740|dyskinesia (l_nmod) dyskinesia_35\NNS\14084880|of|tardive
D012110_D004409 CID reserpine_4\NN\2721160| (r_nsubj) produces_5\VBZ\1617192|that|reserpine|movements (l_dobj) movements_9\NNS\191142|different|,|related
D012110_D004409 CID reserpine_4\NN\2721160| (r_nsubj) produces_5\VBZ\1617192|that|reserpine|movements (l_dobj) movements_9\NNS\191142|different|,|related (l_acl:relcl) related_13\JJ\1740|which|are|dose|and|considered (l_conj) considered_22\VBN\689344|can|be|signs (l_nmod) signs_28\NNS\6643763|as|parkinsonian-like|dsykinesia (l_compound) dsykinesia_27\NN\1740|
D012110_D014202 CID reserpine_0\NN\2721160| (r_nsubj) produced_2\VBD\1617192|reserpine|also|tremor|. (l_dobj) tremor_3\NN\345926|and|catalepsy|,|signs
D012110_D014202 CID reserpine-treated_11\JJ\1740| (r_amod) mice_12\NNS\2329401|in|reserpine-treated (r_nmod) increase_7\NN\13576355|a|significant|tremor|mice (l_nmod) tremor_9\NN\345926|of
D012110_D014202 CID reserpine_5\NN\2721160| (r_nsubj) induced_6\VBD\1627355|hand|,|reserpine|increases|mice|. (l_dobj) increases_7\NNS\13576355|tremor (l_nmod) tremor_9\NN\345926|in|and|catalepsy
D012110_D014202 CID reserpine_13\NN\2721160|by (r_nmod) induced_11\VBN\1627355|reserpine (r_acl) catalepsy_8\NN\14023236|the|and|tremor|induced (l_conj) tremor_10\NN\345926|
D012110_D014202 CID reserpine_2\NN\2721160|with|mg/kg (r_nmod) pretreatment_0\NN\1740|reserpine|test (r_nsubj) produced_13\VBD\1617192|pretreatment|increases|,|whereas|reversed|. (l_dobj) increases_14\NNS\13576355|movements|,|as|increases (l_conj) increases_26\NNS\13576355|tremor (l_nmod) tremor_28\NN\345926|in|and|catalepsy
D012110_D014202 CID reserpine_48\NN\2721160|of (r_nmod) effects_46\NNS\13245626|the|reserpine (r_dobj) reversed_44\VBD\109660|injection|effects (r_parataxis) produced_13\VBD\1617192|pretreatment|increases|,|whereas|reversed|. (l_dobj) increases_14\NNS\13576355|movements|,|as|increases (l_conj) increases_26\NNS\13576355|tremor (l_nmod) tremor_28\NN\345926|in|and|catalepsy
D012110_D002375 CID reserpine_0\NN\2721160| (r_nsubj) produced_2\VBD\1617192|reserpine|also|tremor|. (l_dobj) tremor_3\NN\345926|and|catalepsy|,|signs (l_conj) catalepsy_5\NN\14023236|
D012110_D002375 CID reserpine_26\NN\2721160|by (r_nmod) induced_24\VBN\1627355|reserpine (r_acl) catalepsy_23\NN\14023236|induced
D012110_D002375 CID reserpine_5\NN\2721160| (r_nsubj) induced_6\VBD\1627355|hand|,|reserpine|increases|mice|. (l_dobj) increases_7\NNS\13576355|tremor (l_nmod) tremor_9\NN\345926|in|and|catalepsy (l_conj) catalepsy_11\NN\14023236|
D012110_D002375 CID reserpine_13\NN\2721160|by (r_nmod) induced_11\VBN\1627355|reserpine (r_acl) catalepsy_8\NN\14023236|the|and|tremor|induced
D012110_D002375 CID reserpine_2\NN\2721160|with|mg/kg (r_nmod) pretreatment_0\NN\1740|reserpine|test (r_nsubj) produced_13\VBD\1617192|pretreatment|increases|,|whereas|reversed|. (l_dobj) increases_14\NNS\13576355|movements|,|as|increases (l_conj) increases_26\NNS\13576355|tremor (l_nmod) tremor_28\NN\345926|in|and|catalepsy (l_conj) catalepsy_30\NN\14023236|
D012110_D002375 CID reserpine_48\NN\2721160|of (r_nmod) effects_46\NNS\13245626|the|reserpine (r_dobj) reversed_44\VBD\109660|injection|effects (r_parataxis) produced_13\VBD\1617192|pretreatment|increases|,|whereas|reversed|. (l_dobj) increases_14\NNS\13576355|movements|,|as|increases (l_conj) increases_26\NNS\13576355|tremor (l_nmod) tremor_28\NN\345926|in|and|catalepsy (l_conj) catalepsy_30\NN\14023236|
D012110_D010300 NONE reserpine_0\NN\2721160| (r_nsubj) produced_2\VBD\1617192|reserpine|also|tremor|. (l_dobj) tremor_3\NN\345926|and|catalepsy|,|signs (l_appos) signs_9\NNS\6643763|which|are|suggestive (l_amod) suggestive_10\JJ\1740|disease (l_nmod) disease_14\NN\14061805|of|parkinson|'s
D012110_D010300 NONE reserpine_4\NN\2721160| (r_nsubj) produces_5\VBZ\1617192|that|reserpine|movements (l_dobj) movements_9\NNS\191142|different|,|related (l_acl:relcl) related_13\JJ\1740|which|are|dose|and|considered (l_conj) considered_22\VBN\689344|can|be|signs (l_nmod) signs_28\NNS\6643763|as|parkinsonian-like|dsykinesia (l_amod) parkinsonian-like_24\JJ\1740|and|tardive
D016291_D002375 NONE mk-801_0\NN\1740|mg/kg|,|administered|, (r_nsubj) prevented_14\VBD\1740|mk-801|movements|. (l_dobj) movements_18\NNS\191142|the|vacuous|chewing|,|protrusions|and|catalepsy (l_conj) catalepsy_23\NN\14023236|induced
D016291_D002375 NONE mk-801_0\NN\1740|mg/kg (r_compound) administration_5\NN\1133281|mk-801 (r_nsubj) attenuated_6\VBD\224901|administration|catalepsy|. (l_dobj) catalepsy_8\NN\14023236|the|and|tremor|induced
D016291_D002375 NONE mk-801_33\NN\1740| (r_compound) injection_38\NN\320852|mk-801|(|mg/kg|test (r_nsubj) reversed_44\VBD\109660|injection|effects (r_parataxis) produced_13\VBD\1617192|pretreatment|increases|,|whereas|reversed|. (l_dobj) increases_14\NNS\13576355|movements|,|as|increases (l_conj) increases_26\NNS\13576355|tremor (l_nmod) tremor_28\NN\345926|in|and|catalepsy (l_conj) catalepsy_30\NN\14023236|
D016291_D014202 NONE mk-801_2\NN\1740| (r_compound) injection_3\NN\320852|mk-801 (r_nsubj) produced_4\VBD\1617192|however|,|injection|increase|. (l_dobj) increase_7\NN\13576355|a|significant|tremor|mice (l_nmod) tremor_9\NN\345926|of
D016291_D014202 NONE mk-801_0\NN\1740|mg/kg (r_compound) administration_5\NN\1133281|mk-801 (r_nsubj) attenuated_6\VBD\224901|administration|catalepsy|. (l_dobj) catalepsy_8\NN\14023236|the|and|tremor|induced (l_conj) tremor_10\NN\345926|
D016291_D014202 NONE mk-801_33\NN\1740| (r_compound) injection_38\NN\320852|mk-801|(|mg/kg|test (r_nsubj) reversed_44\VBD\109660|injection|effects (r_parataxis) produced_13\VBD\1617192|pretreatment|increases|,|whereas|reversed|. (l_dobj) increases_14\NNS\13576355|movements|,|as|increases (l_conj) increases_26\NNS\13576355|tremor (l_nmod) tremor_28\NN\345926|in|and|catalepsy
D001058_D009069 NONE apomophine_15\NN\1740| (r_compound) injection_16\NN\320852|by|apomophine|mg/kg (r_nmod) followed_13\VBN\1835496|injection|test (r_conj) administered_6\VBN\2436349|test|and|followed (r_acl) reserpine_0\NN\2721160|mg/kg|,|administered|, (r_nsubj) produce_29\VB\1617192|reserpine|did|not|dyskinesia|mice|. (l_dobj) dyskinesia_31\NN\14084880|oral
D016202_D002375 NONE nmda_5\NN\1740|by (r_nmod) produced_3\VBN\1617192|nmda (r_acl) blockage_2\NN\14034177|the|glutamatergic|produced (r_nsubj) restore_7\VB\1631072|blockage|can|signs|model|. (l_dobj) signs_9\NNS\6643763|these|,|movements (l_nmod) movements_15\NNS\191142|such|vacuous|chewing|,|protrusions (l_conj) protrusions_18\NNS\13919685|tongue|,|catalepsy (l_conj) catalepsy_20\NN\14023236|and|tremor
D016202_D014202 NONE nmda_5\NN\1740|by (r_nmod) produced_3\VBN\1617192|nmda (r_acl) blockage_2\NN\14034177|the|glutamatergic|produced (r_nsubj) restore_7\VB\1631072|blockage|can|signs|model|. (l_dobj) signs_9\NNS\6643763|these|,|movements (l_nmod) movements_15\NNS\191142|such|vacuous|chewing|,|protrusions (l_conj) protrusions_18\NNS\13919685|tongue|,|catalepsy (l_conj) catalepsy_20\NN\14023236|and|tremor (l_conj) tremor_22\NN\345926|
12231232
D006220_D010300 NONE haloperidol_0\NN\3713736|mg/kg (r_nsubj) induced_6\VBD\1627355|haloperidol|rigidity|. (l_dobj) rigidity_9\NN\5023233|parkinsonian-like|muscle|,|measured (l_amod) parkinsonian-like_7\JJ\1740|
D006220_D009127 CID haloperidol_0\NN\3713736|mg/kg (r_nsubj) induced_6\VBD\1627355|haloperidol|rigidity|. (l_dobj) rigidity_9\NN\5023233|parkinsonian-like|muscle|,|measured
D006220_D009127 CID haloperidol-induced_11\JJ\1740| (r_amod) rigidity_13\NN\5023233|the|haloperidol-induced|muscle
C095756_D009127 NONE aida_0\NN\1740|doses (r_nsubj) diminished_9\VBD\169651|aida|rigidity|. (l_dobj) rigidity_13\NN\5023233|the|haloperidol-induced|muscle
12691807
D007980_D004421 CID levodopa-induced_0\JJ\1740| (r_amod) dystonia_2\NN\1740|levodopa-induced|oromandibular|palsy|.
D007980_D013494 NONE levodopa-induced_0\JJ\1740| (r_amod) dystonia_2\NN\1740|levodopa-induced|oromandibular|palsy|. (l_nmod) palsy_6\NN\14557898|in|progressive|supranuclear
D007980_D013494 NONE levodopa-induced_10\JJ\1740| (r_amod) dystonia_12\NN\1740|of|reversible|levodopa-induced|oromandibular|omd|patient (l_nmod) patient_19\NN\9898892|in|a|psp (l_compound) psp_18\NN\1740|
D007980_D013494 NONE levodopa-induced_10\JJ\1740| (r_amod) dystonia_12\NN\1740|of|reversible|levodopa-induced|oromandibular|omd|patient (r_nmod) case_7\NN\7283608|an|unusual|dystonia (r_dobj) describe_4\VBP\1001294|report|we|case|highlight|. (l_advcl) highlight_21\VB\514463|to|importance|,|and|discuss (l_dobj) importance_23\NN\5138488|the|recognizing (l_advcl) recognizing_25\VBG\686447|of|complication|management (l_nmod) management_32\NN\1123598|in|the|psp (l_nmod) psp_34\NN\1740|of
D007980_D004409 NONE levodopa-induced_0\JJ\1740| (r_amod) dyskinesias_1\NNS\14084880|levodopa-induced
D007980_D010300 NONE levodopa-induced_0\JJ\1740| (r_amod) dyskinesias_1\NNS\14084880|levodopa-induced (r_nsubjpass) reported_4\VBN\831651|dyskinesias|have|been|disease|. (l_nmod) disease_8\NN\14061805|in|parkinson|and|atrophy
D007980_D019578 NONE levodopa-induced_0\JJ\1740| (r_amod) dyskinesias_1\NNS\14084880|levodopa-induced (r_nsubjpass) reported_4\VBN\831651|dyskinesias|have|been|disease|. (l_nmod) disease_8\NN\14061805|in|parkinson|and|atrophy (l_conj) atrophy_12\NN\14299637|multiple|system
D007980_D008538 NONE levodopa-induced_10\JJ\1740| (r_amod) dystonia_12\NN\1740|of|reversible|levodopa-induced|oromandibular|omd|patient
D007980_D008538 NONE levodopa-induced_10\JJ\1740| (r_amod) dystonia_12\NN\1740|of|reversible|levodopa-induced|oromandibular|omd|patient (l_appos) omd_14\NN\1740|(|)
9305828
D010862_D004833 CID pilocarpine_4\NN\14712692| (r_compound) model_5\NN\5888929|in|the|pilocarpine|epilepsy (l_nmod) epilepsy_9\NN\14085708|of|lobe
D010862_D004833 CID pilo_30\NN\1740| (r_compound) model_31\NN\5888929|in|the|pilo|tle (l_nmod) tle_33\NN\1740|of
D010862_D004827 NONE pilocarpine_1\NN\14712692|pilo (r_compound) model_5\NN\5888929|the|pilocarpine|epilepsy (l_nmod) epilepsy_7\NN\14085708|of
D010862_D004827 NONE pilo_3\NN\1740|(|) (r_appos) pilocarpine_1\NN\14712692|pilo (r_compound) model_5\NN\5888929|the|pilocarpine|epilepsy (l_nmod) epilepsy_7\NN\14085708|of
D010862_D013226 NONE pilocarpine_1\NN\14712692|pilo (r_compound) model_5\NN\5888929|the|pilocarpine|epilepsy (r_nsubjpass) characterized_9\VBN\609683|model|is|period|. (l_nmod) period_13\NN\13575869|by|an|acute|epilepticus|followed (l_nmod) epilepticus_16\NN\1740|of|status
D010862_D013226 NONE pilo_3\NN\1740|(|) (r_appos) pilocarpine_1\NN\14712692|pilo (r_compound) model_5\NN\5888929|the|pilocarpine|epilepsy (r_nsubjpass) characterized_9\VBN\609683|model|is|period|. (l_nmod) period_13\NN\13575869|by|an|acute|epilepticus|followed (l_nmod) epilepticus_16\NN\1740|of|status
D010862_D012640 NONE pilocarpine_1\NN\14712692|pilo (r_compound) model_5\NN\5888929|the|pilocarpine|epilepsy (r_nsubjpass) characterized_9\VBN\609683|model|is|period|. (l_nmod) period_13\NN\13575869|by|an|acute|epilepticus|followed (l_acl) followed_17\VBN\1835496|seizures (l_nmod) seizures_21\NNS\14081375|by|spontaneous|recurrent|and|damage
D010862_D012640 NONE pilo_3\NN\1740|(|) (r_appos) pilocarpine_1\NN\14712692|pilo (r_compound) model_5\NN\5888929|the|pilocarpine|epilepsy (r_nsubjpass) characterized_9\VBN\609683|model|is|period|. (l_nmod) period_13\NN\13575869|by|an|acute|epilepticus|followed (l_acl) followed_17\VBN\1835496|seizures (l_nmod) seizures_21\NNS\14081375|by|spontaneous|recurrent|and|damage
D010862_D001930 NONE pilocarpine_1\NN\14712692|pilo (r_compound) model_5\NN\5888929|the|pilocarpine|epilepsy (r_nsubjpass) characterized_9\VBN\609683|model|is|period|. (l_nmod) period_13\NN\13575869|by|an|acute|epilepticus|followed (l_acl) followed_17\VBN\1835496|seizures (l_nmod) seizures_21\NNS\14081375|by|spontaneous|recurrent|and|damage (l_conj) damage_25\NN\7296428|related|brain
D010862_D001930 NONE pilo_3\NN\1740|(|) (r_appos) pilocarpine_1\NN\14712692|pilo (r_compound) model_5\NN\5888929|the|pilocarpine|epilepsy (r_nsubjpass) characterized_9\VBN\609683|model|is|period|. (l_nmod) period_13\NN\13575869|by|an|acute|epilepticus|followed (l_acl) followed_17\VBN\1835496|seizures (l_nmod) seizures_21\NNS\14081375|by|spontaneous|recurrent|and|damage (l_conj) damage_25\NN\7296428|related|brain
9326871
D017291_D017180 CID clarithromycin-induced_0\NN\1740| (r_compound) tachycardia_2\NN\14110674|clarithromycin-induced|ventricular|.
D004917_D005759 CID erythromycin_5\NN\2716866|of (r_nmod) profile_3\NN\6999802|the|side-effect|erythromycin (r_nsubjpass) established_7\VBN\2426171|although|profile|is|,|gastroenteritis (l_nmod) gastroenteritis_10\NN\14171682|including|and|interactions
D018942_D005759 NONE macrolides_27\NNS\1740|with|the|newer (r_nmod) experience_23\NN\5984287|macrolides (r_nsubjpass) recorded_31\VBN\2225492|established|,|experience|is|still|being|. (l_advcl) established_7\VBN\2426171|although|profile|is|,|gastroenteritis (l_nmod) gastroenteritis_10\NN\14171682|including|and|interactions
D004917_D066126 NONE erythromycin_11\NN\2716866|of (r_nmod) administration_9\NN\1133281|after|intravenous|erythromycin (r_nmod) demonstrated_3\VBN\2137132|cardiotoxicity|has|been|administration|but|reported|. (l_nsubjpass) cardiotoxicity_0\NN\1740|
D018942_D066126 NONE macrolides_20\NNS\1740|with|the|newer (r_nmod) reported_16\VBN\831651|has|never|been|macrolides (r_conj) demonstrated_3\VBN\2137132|cardiotoxicity|has|been|administration|but|reported|. (l_nsubjpass) cardiotoxicity_0\NN\1740|
D017291_D001145 NONE clarithromycin_14\NN\1740|of (r_nmod) doses_12\NNS\3740161|after|six|therapeutic|clarithromycin (r_nmod) occurred_8\VBD\2623529|that|doses (r_acl:relcl) dysrhythmias_6\NNS\1740|of|ventricular|occurred
19289093
D006493_D007022 NONE heparin_8\NN\2718259| (r_compound) products_9\NNS\3076708|of|heparin (r_nmod) lots_6\NNS\13757724|of|commercial|products (r_nmod) number_3\NN\5107765|a|lots (r_nsubjpass) found_11\VBN\2426171|recently|,|number|were|contaminated|. (l_xcomp) contaminated_14\VBN\1534147|to|be|derivative (l_nmod) derivative_23\NN\5802185|with|an|sulfate|elicit (l_acl:relcl) elicit_26\VB\1617192|that|could|response|infusion (l_dobj) response_29\NN\11410625|a|hypotensive|pigs (l_amod) hypotensive_28\JJ\1740|
D006493_D007022 NONE heparin_3\NN\2718259| (r_compound) products_4\NNS\3076708|both|contaminated|heparin|and|derivative (r_dobj) using_0\VBG\1156834|products (r_advcl) showed_12\VBD\2137132|using|,|we|produces|. (l_ccomp) produces_16\VBZ\1617192|that|oscs|hypotension (l_dobj) hypotension_18\NN\14057371|dose-dependent|pigs
D002809_D007022 CID sulfate_19\NN\15010703|oversulfated|chondroitin|oscs (r_compound) derivative_23\NN\5802185|with|an|sulfate|elicit (l_acl:relcl) elicit_26\VB\1617192|that|could|response|infusion (l_dobj) response_29\NN\11410625|a|hypotensive|pigs (l_amod) hypotensive_28\JJ\1740|
48362
D011802_D056486 CID quinidine_0\NN\2715941| (r_compound) hepatitis_1\NN\14127211|quinidine|.
D011802_D056486 CID quinidine_6\NN\2715941| (r_compound) hepatotoxicity_7\NN\1740|quinidine
1286498
D005442_D009325 CID flumazenil_11\NN\1740| (r_compound) group_12\NN\2137|in|the|flumazenil (r_nmod) nausea_6\NN\14299637|effects|were|and|vomiting|group|and|nausea|.
D005442_D009325 CID flumazenil_11\NN\1740| (r_compound) group_12\NN\2137|in|the|flumazenil (r_nmod) nausea_6\NN\14299637|effects|were|and|vomiting|group|and|nausea|. (l_conj) nausea_14\NN\14299637|and|pain|group
D005442_D014839 CID flumazenil_11\NN\1740| (r_compound) group_12\NN\2137|in|the|flumazenil (r_nmod) nausea_6\NN\14299637|effects|were|and|vomiting|group|and|nausea|. (l_conj) vomiting_8\NN\116687|
D005442_D010146 NONE flumazenil_11\NN\1740| (r_compound) group_12\NN\2137|in|the|flumazenil (r_nmod) nausea_6\NN\14299637|effects|were|and|vomiting|group|and|nausea|. (l_conj) nausea_14\NN\14299637|and|pain|group (l_conj) pain_17\NN\14299637|injection-site
9549528
D007980_D020734 NONE l-dopa-induced_7\JJ\1740| (r_amod) dyskinesia_9\NN\14084880|with|l-dopa-induced|peak-dose (r_nmod) patients_5\NNS\9898892|in|parkinsonian|dyskinesia (l_amod) parkinsonian_4\JJ\1740|
D007980_D020734 NONE l-dopa_36\NN\14604959| (r_compound) medication_37\NN\3247620|on|l-dopa (r_nmod) patients_34\NNS\9898892|of|parkinsonian|medication (l_amod) parkinsonian_33\JJ\1740|
D007980_D020734 NONE l-dopa_43\NN\14604959| (r_nmod:npmod) induced_44\JJ\1740|l-dopa (r_amod) dyskinesia_45\NN\14084880|without|induced (r_nmod) one_41\CD\13741022|the|first|dyskinesia|=|and|other (r_appos) groups_31\NNS\2137|of|two|patients|,|one (l_nmod) patients_34\NNS\9898892|of|parkinsonian|medication (l_amod) parkinsonian_33\JJ\1740|
D007980_D004409 CID l-dopa-induced_7\JJ\1740| (r_amod) dyskinesia_9\NN\14084880|with|l-dopa-induced|peak-dose
D007980_D004409 CID l-dopa_36\NN\14604959| (r_compound) medication_37\NN\3247620|on|l-dopa (r_nmod) patients_34\NNS\9898892|of|parkinsonian|medication (r_nmod) groups_31\NNS\2137|of|two|patients|,|one (l_appos) one_41\CD\13741022|the|first|dyskinesia|=|and|other (l_nmod) dyskinesia_45\NN\14084880|without|induced
D007980_D004409 CID l-dopa_36\NN\14604959| (r_compound) medication_37\NN\3247620|on|l-dopa (r_nmod) patients_34\NNS\9898892|of|parkinsonian|medication (r_nmod) groups_31\NNS\2137|of|two|patients|,|one (l_appos) one_41\CD\13741022|the|first|dyskinesia|=|and|other (l_conj) other_53\JJ\1740|the|dyskinesia|=|,|and|group (l_nmod) dyskinesia_57\NN\14084880|with|moderate|peak-dose
D007980_D004409 CID l-dopa_43\NN\14604959| (r_nmod:npmod) induced_44\JJ\1740|l-dopa (r_amod) dyskinesia_45\NN\14084880|without|induced
D007980_D004409 CID l-dopa_43\NN\14604959| (r_nmod:npmod) induced_44\JJ\1740|l-dopa (r_amod) dyskinesia_45\NN\14084880|without|induced (r_nmod) one_41\CD\13741022|the|first|dyskinesia|=|and|other (l_conj) other_53\JJ\1740|the|dyskinesia|=|,|and|group (l_nmod) dyskinesia_57\NN\14084880|with|moderate|peak-dose
D007980_D004409 CID l-dopa-induced_15\JJ\1740| (r_amod) dyskinesia_18\NN\14084880|like|l-dopa-induced|peak|dose (r_nmod) movement_12\NN\191142|an|hyperkinetic|abnormal|involuntary|,|dyskinesia|,
D007980_D004409 CID l-dopa-induced_15\JJ\1740| (r_amod) dyskinesia_18\NN\14084880|like|l-dopa-induced|peak|dose
D007980_D006948 NONE l-dopa-induced_15\JJ\1740| (r_amod) dyskinesia_18\NN\14084880|like|l-dopa-induced|peak|dose (r_nmod) movement_12\NN\191142|an|hyperkinetic|abnormal|involuntary|,|dyskinesia|, (l_amod) hyperkinetic_9\JJ\1740|
873132
D003840_D002779 NONE acid_7\NN\14818238|of|deoxycholic (r_nmod) sulfation_1\NN\1740|increased|and|7alpha-hydroxylation|acid|cholestasis|. (l_nmod) cholestasis_11\NN\14052403|in|estradiol-induced|rats
D004997_D002779 CID estradiol-induced_10\JJ\1740|ethinyl (r_amod) cholestasis_11\NN\14052403|in|estradiol-induced|rats
11694026
C012655_D014581 NONE nimesulide_2\NN\1740|of|and|paracetamol (r_nmod) tolerability_0\NN\1740|nimesulide|patients|. (l_nmod) patients_6\NNS\9898892|in|urticaria/angioedema (l_nmod) urticaria/angioedema_9\NN\1740|with|nsaid-induced
C012655_D014581 NONE nimesulide_9\NN\1740|of|and|paracetamol (r_nmod) tolerability_5\NN\1740|and|reliability|nimesulide (r_dobj) investigated_4\VBD\644583|study|we|tolerability|number|. (l_nmod) number_16\NN\5107765|in|a|large|patients (l_nmod) patients_18\NNS\9898892|of|history (l_nmod) history_23\NN\15120823|with|an|exclusive|urticaria/angioedema (l_nmod) urticaria/angioedema_26\NN\1740|of|nsaid-induced
C012655_D014581 NONE nimesulide_6\NN\1740|with|or|paracetamol (r_nmod) procedure_4\NN\407535|a|single-placebo-controlled|oral|challenge|nimesulide (r_nsubjpass) applied_10\VBN\2676054|procedure|was|patients|. (l_nmod) patients_13\NNS\9898892|to|829|history (l_nmod) history_16\NN\15120823|with|a|urticaria/angioedema (l_nmod) urticaria/angioedema_19\NN\1740|of|nsaid-induced
C012655_D014581 NONE nimesulide_10\NN\1740|of|and|paracetamol (r_nmod) tolerability_8\NN\1740|the|good|nimesulide|patients (l_nmod) patients_14\NNS\9898892|in|experienced (l_acl:relcl) experienced_16\VBD\2108377|who|urticaria/angioedema (l_dobj) urticaria/angioedema_17\NN\1740|caused
C012655_D000799 CID nimesulide_2\NN\1740|of|and|paracetamol (r_nmod) tolerability_0\NN\1740|nimesulide|patients|. (l_nmod) patients_6\NNS\9898892|in|urticaria/angioedema (l_nmod) urticaria/angioedema_9\NN\1740|with|nsaid-induced
C012655_D000799 CID nimesulide_9\NN\1740|of|and|paracetamol (r_nmod) tolerability_5\NN\1740|and|reliability|nimesulide (r_dobj) investigated_4\VBD\644583|study|we|tolerability|number|. (l_nmod) number_16\NN\5107765|in|a|large|patients (l_nmod) patients_18\NNS\9898892|of|history (l_nmod) history_23\NN\15120823|with|an|exclusive|urticaria/angioedema (l_nmod) urticaria/angioedema_26\NN\1740|of|nsaid-induced
C012655_D000799 CID nimesulide_6\NN\1740|with|or|paracetamol (r_nmod) procedure_4\NN\407535|a|single-placebo-controlled|oral|challenge|nimesulide (r_nsubjpass) applied_10\VBN\2676054|procedure|was|patients|. (l_nmod) patients_13\NNS\9898892|to|829|history (l_nmod) history_16\NN\15120823|with|a|urticaria/angioedema (l_nmod) urticaria/angioedema_19\NN\1740|of|nsaid-induced
C012655_D000799 CID nimesulide_10\NN\1740|of|and|paracetamol (r_nmod) tolerability_8\NN\1740|the|good|nimesulide|patients (l_nmod) patients_14\NNS\9898892|in|experienced (l_acl:relcl) experienced_16\VBD\2108377|who|urticaria/angioedema (l_dobj) urticaria/angioedema_17\NN\1740|caused
D000082_D014581 NONE paracetamol_4\NN\1740| (r_conj) nimesulide_2\NN\1740|of|and|paracetamol (r_nmod) tolerability_0\NN\1740|nimesulide|patients|. (l_nmod) patients_6\NNS\9898892|in|urticaria/angioedema (l_nmod) urticaria/angioedema_9\NN\1740|with|nsaid-induced
D000082_D014581 NONE paracetamol_11\NN\1740| (r_conj) nimesulide_9\NN\1740|of|and|paracetamol (r_nmod) tolerability_5\NN\1740|and|reliability|nimesulide (r_dobj) investigated_4\VBD\644583|study|we|tolerability|number|. (l_nmod) number_16\NN\5107765|in|a|large|patients (l_nmod) patients_18\NNS\9898892|of|history (l_nmod) history_23\NN\15120823|with|an|exclusive|urticaria/angioedema (l_nmod) urticaria/angioedema_26\NN\1740|of|nsaid-induced
D000082_D014581 NONE paracetamol_8\NN\1740| (r_conj) nimesulide_6\NN\1740|with|or|paracetamol (r_nmod) procedure_4\NN\407535|a|single-placebo-controlled|oral|challenge|nimesulide (r_nsubjpass) applied_10\VBN\2676054|procedure|was|patients|. (l_nmod) patients_13\NNS\9898892|to|829|history (l_nmod) history_16\NN\15120823|with|a|urticaria/angioedema (l_nmod) urticaria/angioedema_19\NN\1740|of|nsaid-induced
D000082_D014581 NONE paracetamol_12\NN\1740| (r_conj) nimesulide_10\NN\1740|of|and|paracetamol (r_nmod) tolerability_8\NN\1740|the|good|nimesulide|patients (l_nmod) patients_14\NNS\9898892|in|experienced (l_acl:relcl) experienced_16\VBD\2108377|who|urticaria/angioedema (l_dobj) urticaria/angioedema_17\NN\1740|caused
D000082_D000799 CID paracetamol_4\NN\1740| (r_conj) nimesulide_2\NN\1740|of|and|paracetamol (r_nmod) tolerability_0\NN\1740|nimesulide|patients|. (l_nmod) patients_6\NNS\9898892|in|urticaria/angioedema (l_nmod) urticaria/angioedema_9\NN\1740|with|nsaid-induced
D000082_D000799 CID paracetamol_11\NN\1740| (r_conj) nimesulide_9\NN\1740|of|and|paracetamol (r_nmod) tolerability_5\NN\1740|and|reliability|nimesulide (r_dobj) investigated_4\VBD\644583|study|we|tolerability|number|. (l_nmod) number_16\NN\5107765|in|a|large|patients (l_nmod) patients_18\NNS\9898892|of|history (l_nmod) history_23\NN\15120823|with|an|exclusive|urticaria/angioedema (l_nmod) urticaria/angioedema_26\NN\1740|of|nsaid-induced
D000082_D000799 CID paracetamol_8\NN\1740| (r_conj) nimesulide_6\NN\1740|with|or|paracetamol (r_nmod) procedure_4\NN\407535|a|single-placebo-controlled|oral|challenge|nimesulide (r_nsubjpass) applied_10\VBN\2676054|procedure|was|patients|. (l_nmod) patients_13\NNS\9898892|to|829|history (l_nmod) history_16\NN\15120823|with|a|urticaria/angioedema (l_nmod) urticaria/angioedema_19\NN\1740|of|nsaid-induced
D000082_D000799 CID paracetamol_12\NN\1740| (r_conj) nimesulide_10\NN\1740|of|and|paracetamol (r_nmod) tolerability_8\NN\1740|the|good|nimesulide|patients (l_nmod) patients_14\NNS\9898892|in|experienced (l_acl:relcl) experienced_16\VBD\2108377|who|urticaria/angioedema (l_dobj) urticaria/angioedema_17\NN\1740|caused
D000894_D014581 NONE nsaid-induced_8\JJ\1740| (r_amod) urticaria/angioedema_9\NN\1740|with|nsaid-induced
D000894_D014581 NONE nsaid-induced_25\JJ\1740| (r_amod) urticaria/angioedema_26\NN\1740|of|nsaid-induced
D000894_D014581 NONE nsaid-induced_18\JJ\1740| (r_amod) urticaria/angioedema_19\NN\1740|of|nsaid-induced
D000894_D014581 NONE nsaid-induced_21\JJ\1740| (r_amod) urticaria/angioedema_22\NN\1740|of|nsaid-induced|or|angioedema (r_nmod) history_19\NN\15120823|with|an|urticaria/angioedema (r_nmod) subjects_16\NNS\6598915|of|history (r_nmod) %_14\NN\1740|11.8|subjects (r_conj) %_3\NN\1740|18.28|patients|and|% (l_nmod) patients_5\NNS\9898892|of|history (l_nmod) history_8\NN\15120823|with|a|urticaria (l_nmod) urticaria_11\NN\14533203|of|chronic
D000894_D014581 NONE nsaid-induced_21\JJ\1740| (r_amod) urticaria/angioedema_22\NN\1740|of|nsaid-induced|or|angioedema
D000894_D014581 NONE nsaid-induced_21\JJ\1740| (r_amod) urticaria/angioedema_22\NN\1740|of|nsaid-induced|or|angioedema (l_conj) angioedema_24\NN\14316714|alone|(|with|urticaria|) (l_nmod) urticaria_31\NN\14533203|chronic
D000894_D014581 NONE nsaids_20\NNS\2721538|by (r_nmod) caused_18\VBN\1617192|nsaids (r_acl) urticaria/angioedema_17\NN\1740|caused
D000894_D014581 NONE nsaid-induced_29\JJ\1740| (r_amod) angioedema_30\NN\14316714|of|nsaid-induced (r_nmod) history_27\NN\15120823|by|a|angioedema (r_conj) history_16\NN\15120823|by|a|urticaria|and|,|all|,|history (l_nmod) urticaria_19\NN\14533203|of|chronic
D000894_D000799 CID nsaid-induced_8\JJ\1740| (r_amod) urticaria/angioedema_9\NN\1740|with|nsaid-induced
D000894_D000799 CID nsaid-induced_25\JJ\1740| (r_amod) urticaria/angioedema_26\NN\1740|of|nsaid-induced
D000894_D000799 CID nsaid-induced_18\JJ\1740| (r_amod) urticaria/angioedema_19\NN\1740|of|nsaid-induced
D000894_D000799 CID nsaid-induced_21\JJ\1740| (r_amod) urticaria/angioedema_22\NN\1740|of|nsaid-induced|or|angioedema
D000894_D000799 CID nsaid-induced_21\JJ\1740| (r_amod) urticaria/angioedema_22\NN\1740|of|nsaid-induced|or|angioedema (l_conj) angioedema_24\NN\14316714|alone|(|with|urticaria|)
D000894_D000799 CID nsaids_20\NNS\2721538|by (r_nmod) caused_18\VBN\1617192|nsaids (r_acl) urticaria/angioedema_17\NN\1740|caused
D000894_D000799 CID nsaid-induced_29\JJ\1740| (r_amod) angioedema_30\NN\14316714|of|nsaid-induced
18513945
D010121_D007022 CID oxytocin_0\NN\5407119| (r_nsubj) uterotonic_5\NN\1740|oxytocin|is|a|used|cause|. (l_acl:relcl) cause_8\VB\1617192|that|can|hypotension|,|given (l_dobj) hypotension_13\NN\14057371|significant
D010121_D007022 CID oxytocin-induced_0\JJ\1740| (r_amod) hypotension_1\NN\14057371|oxytocin-induced|delivery
D010121_D007022 CID oxytocin_4\NN\5407119|to (r_nmod) response_2\NN\11410625|in|oxytocin (r_nmod) hypotension_0\NN\14057371|response
D010121_D006473 NONE oxytocin-induced_0\JJ\1740| (r_amod) hypotension_1\NN\14057371|oxytocin-induced|delivery (r_nsubjpass) attributed_8\VBN\670261|hypotension|may|be|incorrectly|loss|. (l_nmod) loss_11\NN\13252973|to|blood
D010121_D020521 NONE oxytocin_4\NN\5407119|to (r_nmod) response_2\NN\11410625|in|oxytocin (r_nmod) hypotension_0\NN\14057371|response (r_nsubjpass) associated_6\VBN\628491|hypotension|was|decrease|. (l_nmod) decrease_9\NN\7296428|with|a|resistance|and|increase (l_conj) increase_17\NN\13576355|a|compensatory|volume (l_nmod) volume_20\NN\33615|in|stroke|,|rate|and|output (l_compound) stroke_19\NN\556313|
12745515
D016642_D012640 CID bupropion_7\NN\1740|sustained-release (r_conj) deprivation_4\NN\14493145|with|sleep|and|bupropion (r_nmod) associated_1\VBN\628491|deprivation (r_acl) seizure_0\NN\14081375|associated|.
D016642_D012640 CID bupropion_10\NN\1740| (r_compound) use_11\NN\407535|with|sustained-release|bupropion|and|deprivation (r_nmod) associated_7\VBN\628491|use (r_acl) seizure_6\NN\14081375|a|generalized|associated
D016642_D012640 CID bupropion_4\NN\1740| (r_compound) use_5\NN\407535|of|bupropion (r_nmod) weeks_2\NNS\15113229|after|5|use (r_nmod) experienced_9\VBD\2108377|weeks|,|subject|seizure|staying|. (l_dobj) seizure_14\NN\14081375|a|generalized|tonic|clonic
D016642_D012640 CID bupropion-associated_11\JJ\1740| (r_amod) seizures_12\NNS\14081375|of|bupropion-associated
D016642_D012892 NONE bupropion_7\NN\1740|sustained-release (r_conj) deprivation_4\NN\14493145|with|sleep|and|bupropion
D016642_D012892 NONE bupropion_10\NN\1740| (r_compound) use_11\NN\407535|with|sustained-release|bupropion|and|deprivation (l_conj) deprivation_14\NN\14493145|sleep
D016642_D012892 NONE bupropion-associated_11\JJ\1740| (r_amod) seizures_12\NNS\14081375|of|bupropion-associated (r_nmod) risk_9\NN\14541044|to|the|seizures (r_nmod) add_6\VB\156601|that|deprivation|may|risk (l_nsubj) deprivation_4\NN\14493145|sleep
326460
D001539_D007008 CID bendrofluazide-induced_2\JJ\1740| (r_amod) hypokalemia_3\NN\14299637|of|bendrofluazide-induced
D001539_D007008 CID bendrofluazide_15\NN\1740| (r_compound) treatment_16\NN\654885|of|short-term|bendrofluazide (r_nmod) hypokalemia_12\NN\14299637|the|treatment|subjects
D013999_D007008 NONE timolol_5\NN\2832168|by (r_nmod) amelioration_0\NN\248977|hypokalemia|timolol|. (l_nmod) hypokalemia_3\NN\14299637|of|bendrofluazide-induced
D013999_D007008 NONE timolol_6\NN\2832168| (r_appos) drug_4\NN\14778436|the|beta|adrenergic|blocking|,|timolol|, (r_nsubj) tended_8\VBD\2604760|drug|correct|and|significant (l_xcomp) correct_10\VB\138508|to|hypokalemia (l_dobj) hypokalemia_12\NN\14299637|the|treatment|subjects
6496797
D014196_D006327 CID trazodone_8\NN\3829085|of (r_nmod) dose_6\NN\3740161|following|a|single|trazodone (r_nmod) block_2\NN\21939|complete|heart|dose|.
D014196_D006327 CID trazodone_9\NN\3829085|of (r_nmod) dose_7\NN\3740161|a|single|starting|trazodone (r_dobj) receiving_3\VBG\2210855|after|dose (r_advcl) developed_13\VBD\1753788|receiving|,|patient|block|. (l_dobj) block_16\NN\21939|complete|heart
12851669
D017373_D054556 NONE acetate_12\NN\15010703|on|combined|cyproterone|and|ethinylestradiol (r_nmod) women_8\NNS\9605289|in|acetate (r_nmod) thromboembolism_6\NN\14100769|of|venous|women
D017373_D054556 NONE acetate_17\NN\15010703|on|cyproterone|plus|ethinylestradiol (r_nmod) women_14\NNS\9605289|among|acetate|,|and|women (r_nmod) achieve_3\VB\2524171|to|estimates|women (l_dobj) estimates_6\NNS\5802185|absolute|risk|thromboembolism (l_nmod) thromboembolism_9\NN\14100769|of|venous|vte
D017373_D054556 NONE acetate_17\NN\15010703|on|cyproterone|plus|ethinylestradiol (r_nmod) women_14\NNS\9605289|among|acetate|,|and|women (r_nmod) achieve_3\VB\2524171|to|estimates|women (l_dobj) estimates_6\NNS\5802185|absolute|risk|thromboembolism (l_nmod) thromboembolism_9\NN\14100769|of|venous|vte (l_appos) vte_11\NN\1740|(|)
D017373_D054556 NONE cpa/ee_21\NN\1740|(|) (r_appos) ethinylestradiol_19\NN\1740|cpa/ee (r_conj) acetate_17\NN\15010703|on|cyproterone|plus|ethinylestradiol (r_nmod) women_14\NNS\9605289|among|acetate|,|and|women (r_nmod) achieve_3\VB\2524171|to|estimates|women (l_dobj) estimates_6\NNS\5802185|absolute|risk|thromboembolism (l_nmod) thromboembolism_9\NN\14100769|of|venous|vte
D017373_D054556 NONE cpa/ee_21\NN\1740|(|) (r_appos) ethinylestradiol_19\NN\1740|cpa/ee (r_conj) acetate_17\NN\15010703|on|cyproterone|plus|ethinylestradiol (r_nmod) women_14\NNS\9605289|among|acetate|,|and|women (r_nmod) achieve_3\VB\2524171|to|estimates|women (l_dobj) estimates_6\NNS\5802185|absolute|risk|thromboembolism (l_nmod) thromboembolism_9\NN\14100769|of|venous|vte (l_appos) vte_11\NN\1740|(|)
D017373_D054556 NONE cpa/ee_63\NN\1740|on (r_nmod) women_61\NNS\9605289|among|the|cpa/ee (r_nmod) 3.1_46\CD\1740|1.3|years|women (r_conj) 4.2_26\CD\1740|3.2|years|,|and|3.1 (r_conj) 3.4_7\CD\1740|risk|was|3.8|years|women|,|4.2|. (l_nsubj) risk_3\NN\14541044|the|corresponding|absolute|vte (l_nmod) vte_5\NN\1740|of
D017373_D054556 NONE cpa/ee_22\NN\1740| (r_dobj) taking_21\VBG\2367363|cpa/ee (r_acl) women_20\NNS\9605289|among|taking (r_nmod) that_18\DT\1740|to|women (r_nmod) similar_16\JJ\1740|risk|is|that (l_nsubj) risk_7\NN\14541044|the|absolute|vte|women (l_nmod) vte_9\NN\1740|of
D004997_D054556 NONE ethinylestradiol_14\NN\1740| (r_conj) acetate_12\NN\15010703|on|combined|cyproterone|and|ethinylestradiol (r_nmod) women_8\NNS\9605289|in|acetate (r_nmod) thromboembolism_6\NN\14100769|of|venous|women
D004997_D054556 NONE ethinylestradiol_19\NN\1740|cpa/ee (r_conj) acetate_17\NN\15010703|on|cyproterone|plus|ethinylestradiol (r_nmod) women_14\NNS\9605289|among|acetate|,|and|women (r_nmod) achieve_3\VB\2524171|to|estimates|women (l_dobj) estimates_6\NNS\5802185|absolute|risk|thromboembolism (l_nmod) thromboembolism_9\NN\14100769|of|venous|vte
D004997_D054556 NONE ethinylestradiol_19\NN\1740|cpa/ee (r_conj) acetate_17\NN\15010703|on|cyproterone|plus|ethinylestradiol (r_nmod) women_14\NNS\9605289|among|acetate|,|and|women (r_nmod) achieve_3\VB\2524171|to|estimates|women (l_dobj) estimates_6\NNS\5802185|absolute|risk|thromboembolism (l_nmod) thromboembolism_9\NN\14100769|of|venous|vte (l_appos) vte_11\NN\1740|(|)
D004997_D054556 NONE cpa/ee_21\NN\1740|(|) (r_appos) ethinylestradiol_19\NN\1740|cpa/ee (r_conj) acetate_17\NN\15010703|on|cyproterone|plus|ethinylestradiol (r_nmod) women_14\NNS\9605289|among|acetate|,|and|women (r_nmod) achieve_3\VB\2524171|to|estimates|women (l_dobj) estimates_6\NNS\5802185|absolute|risk|thromboembolism (l_nmod) thromboembolism_9\NN\14100769|of|venous|vte
D004997_D054556 NONE cpa/ee_21\NN\1740|(|) (r_appos) ethinylestradiol_19\NN\1740|cpa/ee (r_conj) acetate_17\NN\15010703|on|cyproterone|plus|ethinylestradiol (r_nmod) women_14\NNS\9605289|among|acetate|,|and|women (r_nmod) achieve_3\VB\2524171|to|estimates|women (l_dobj) estimates_6\NNS\5802185|absolute|risk|thromboembolism (l_nmod) thromboembolism_9\NN\14100769|of|venous|vte (l_appos) vte_11\NN\1740|(|)
D004997_D054556 NONE cpa/ee_63\NN\1740|on (r_nmod) women_61\NNS\9605289|among|the|cpa/ee (r_nmod) 3.1_46\CD\1740|1.3|years|women (r_conj) 4.2_26\CD\1740|3.2|years|,|and|3.1 (r_conj) 3.4_7\CD\1740|risk|was|3.8|years|women|,|4.2|. (l_nsubj) risk_3\NN\14541044|the|corresponding|absolute|vte (l_nmod) vte_5\NN\1740|of
D004997_D054556 NONE cpa/ee_22\NN\1740| (r_dobj) taking_21\VBG\2367363|cpa/ee (r_acl) women_20\NNS\9605289|among|taking (r_nmod) that_18\DT\1740|to|women (r_nmod) similar_16\JJ\1740|risk|is|that (l_nsubj) risk_7\NN\14541044|the|absolute|vte|women (l_nmod) vte_9\NN\1740|of
D003277_D054556 CID contraceptives_30\NNS\3183080|on|combined|oral|cocs (r_nmod) women_26\NNS\9605289|among|contraceptives (r_conj) women_14\NNS\9605289|among|acetate|,|and|women (r_nmod) achieve_3\VB\2524171|to|estimates|women (l_dobj) estimates_6\NNS\5802185|absolute|risk|thromboembolism (l_nmod) thromboembolism_9\NN\14100769|of|venous|vte
D003277_D054556 CID contraceptives_30\NNS\3183080|on|combined|oral|cocs (r_nmod) women_26\NNS\9605289|among|contraceptives (r_conj) women_14\NNS\9605289|among|acetate|,|and|women (r_nmod) achieve_3\VB\2524171|to|estimates|women (l_dobj) estimates_6\NNS\5802185|absolute|risk|thromboembolism (l_nmod) thromboembolism_9\NN\14100769|of|venous|vte (l_appos) vte_11\NN\1740|(|)
D003277_D054556 CID cocs_32\NNS\1740|(|) (r_appos) contraceptives_30\NNS\3183080|on|combined|oral|cocs (r_nmod) women_26\NNS\9605289|among|contraceptives (r_conj) women_14\NNS\9605289|among|acetate|,|and|women (r_nmod) achieve_3\VB\2524171|to|estimates|women (l_dobj) estimates_6\NNS\5802185|absolute|risk|thromboembolism (l_nmod) thromboembolism_9\NN\14100769|of|venous|vte
D003277_D054556 CID cocs_32\NNS\1740|(|) (r_appos) contraceptives_30\NNS\3183080|on|combined|oral|cocs (r_nmod) women_26\NNS\9605289|among|contraceptives (r_conj) women_14\NNS\9605289|among|acetate|,|and|women (r_nmod) achieve_3\VB\2524171|to|estimates|women (l_dobj) estimates_6\NNS\5802185|absolute|risk|thromboembolism (l_nmod) thromboembolism_9\NN\14100769|of|venous|vte (l_appos) vte_11\NN\1740|(|)
D003277_D054556 CID cocs_20\NN\1740|on (r_nmod) while_18\IN\15122231|cocs (r_prep) had_16\VBN\2108377|to|have|vte|while (l_dobj) vte_17\NN\1740|
D003277_D054556 CID cocs_24\NNS\1740|on (r_nmod) women_22\NNS\9605289|among|the|cocs (r_nmod) 3.4_7\CD\1740|risk|was|3.8|years|women|,|4.2|. (l_nsubj) risk_3\NN\14541044|the|corresponding|absolute|vte (l_nmod) vte_5\NN\1740|of
D003277_D054556 CID cocs_43\NNS\1740|on|levonorgestrel-containing (r_nmod) women_40\NNS\9605289|among|cocs (r_nmod) years_38\NNS\15144371|per|000|women|women (r_nmod) 4.2_26\CD\1740|3.2|years|,|and|3.1 (r_conj) 3.4_7\CD\1740|risk|was|3.8|years|women|,|4.2|. (l_nsubj) risk_3\NN\14541044|the|corresponding|absolute|vte (l_nmod) vte_5\NN\1740|of
D003277_D054556 CID cocs_14\NNS\1740|on (r_nmod) women_12\NNS\9605289|among|danish|cocs (r_nmod) risk_7\NN\14541044|the|absolute|vte|women (l_nmod) vte_9\NN\1740|of
D016912_D054556 NONE levonorgestrel-containing_42\JJ\1740| (r_amod) cocs_43\NNS\1740|on|levonorgestrel-containing (r_nmod) women_40\NNS\9605289|among|cocs (r_nmod) years_38\NNS\15144371|per|000|women|women (r_nmod) 4.2_26\CD\1740|3.2|years|,|and|3.1 (r_conj) 3.4_7\CD\1740|risk|was|3.8|years|women|,|4.2|. (l_nsubj) risk_3\NN\14541044|the|corresponding|absolute|vte (l_nmod) vte_5\NN\1740|of
18201582
C084178_D006973 NONE telmisartan_28\NN\1740|of|and|amlodipine (r_nmod) combination_26\NN\7951464|of|a|fixed-dose|telmisartan|versus|monotherapy|adults (l_nmod) adults_36\NNS\7846|in|indian|hypertension (l_nmod) hypertension_40\NN\14057371|with|stage|ii
C084178_D006973 NONE telmisartan_23\NN\1740|of (r_compound) mg_25\NN\13717155|telmisartan|40|+|mg (r_dep) combination_18\NN\7951464|of|a|new|fixed-dose|fdc|mg|t+a (r_nmod) efficacy_11\NN\5199286|the|and|tolerability|combination (r_dobj) evaluate_9\VB\670261|to|efficacy|patients (l_nmod) patients_44\NNS\9898892|compared|in|adult|indian|hypertension (l_nmod) hypertension_48\NN\14057371|with|stage|ii
D017311_D006973 NONE amlodipine_30\NN\1740| (r_conj) telmisartan_28\NN\1740|of|and|amlodipine (r_nmod) combination_26\NN\7951464|of|a|fixed-dose|telmisartan|versus|monotherapy|adults (l_nmod) adults_36\NNS\7846|in|indian|hypertension (l_nmod) hypertension_40\NN\14057371|with|stage|ii
D017311_D006973 NONE amlodipine_32\NN\1740| (r_compound) monotherapy_33\NN\1740|amlodipine (r_conj) combination_26\NN\7951464|of|a|fixed-dose|telmisartan|versus|monotherapy|adults (l_nmod) adults_36\NNS\7846|in|indian|hypertension (l_nmod) hypertension_40\NN\14057371|with|stage|ii
D017311_D006973 NONE amlodipine_27\NN\1740| (r_compound) mg_29\NN\13717155|amlodipine|5 (r_conj) mg_25\NN\13717155|telmisartan|40|+|mg (r_dep) combination_18\NN\7951464|of|a|new|fixed-dose|fdc|mg|t+a (r_nmod) efficacy_11\NN\5199286|the|and|tolerability|combination (r_dobj) evaluate_9\VB\670261|to|efficacy|patients (l_nmod) patients_44\NNS\9898892|compared|in|adult|indian|hypertension (l_nmod) hypertension_48\NN\14057371|with|stage|ii
D017311_D006973 NONE amlodipine_35\NN\1740| (r_compound) monotherapy_37\NN\1740|with|amlodipine|5-mg|a (r_nmod) compared_33\VBN\644583|monotherapy (r_case) patients_44\NNS\9898892|compared|in|adult|indian|hypertension (l_nmod) hypertension_48\NN\14057371|with|stage|ii
19203554
D012460_D005921 NONE sulphasalazine_10\NN\1740| (r_compound) treatment_11\NN\654885|sulphasalazine (r_dobj) restarting_9\VBG\1857717|after|treatment (r_advcl) glomerulonephritis_7\NN\14113798|antibody-(pr3-anca|positive|necrotizing|restarting|.
D012460_D005921 NONE sulphasalazine_4\NN\1740| (r_nsubj) induce_6\VB\1627355|that|sulphasalazine|can|glomerulonephritis (l_dobj) glomerulonephritis_9\NN\14113798|pr3-anca-positive|necrotizing
D012460_D003093 NONE sulphasalazine_20\NN\1740| (r_compound) treatment_21\NN\654885|of|sulphasalazine (r_nmod) restarting_18\VBG\1857717|after|treatment (r_advcl) developed_6\VBD\1753788|woman|eyes|restarting|. (l_nsubj) woman_2\NN\9605289|a|59-year-old|colitis (l_nmod) colitis_5\NN\14336539|with|ulcerative
D012460_D005128 NONE sulphasalazine_20\NN\1740| (r_compound) treatment_21\NN\654885|of|sulphasalazine (r_nmod) restarting_18\VBG\1857717|after|treatment (r_advcl) developed_6\VBD\1753788|woman|eyes|restarting|. (l_dobj) eyes_8\NNS\5945642|red|,|effusion
D012460_D005128 NONE sulphasalazine_3\NN\1740| (r_compound) treatment_4\NN\654885|of|sulphasalazine (r_nmod) cessation_1\NN\7365849|treatment (r_nsubj) resulted_5\VBD\2633881|although|cessation|improvements (l_nmod) improvements_7\NNS\7359599|in|fever (l_nmod) fever_9\NN\14299637|in|,|eyes|,|pain|,|titer|and|volume (l_conj) eyes_12\NNS\5945642|red
D012460_D010996 CID sulphasalazine_20\NN\1740| (r_compound) treatment_21\NN\654885|of|sulphasalazine (r_nmod) restarting_18\VBG\1857717|after|treatment (r_advcl) developed_6\VBD\1753788|woman|eyes|restarting|. (l_dobj) eyes_8\NNS\5945642|red|,|effusion (l_conj) effusion_11\NN\6880249|pleural|,|eosinophilia
D012460_D010996 CID sulphasalazine_3\NN\1740| (r_compound) treatment_4\NN\654885|of|sulphasalazine (r_nmod) cessation_1\NN\7365849|treatment (r_nsubj) resulted_5\VBD\2633881|although|cessation|improvements (l_nmod) improvements_7\NNS\7359599|in|fever (l_nmod) fever_9\NN\14299637|in|,|eyes|,|pain|,|titer|and|volume (l_conj) volume_22\NN\33615|effusions (l_nmod) effusions_26\NNS\6880249|of|the|pleural
D012460_D010996 CID sulphasalazine_3\NN\1740| (r_compound) treatment_4\NN\654885|of|sulphasalazine (r_nmod) cessation_1\NN\7365849|treatment (r_nsubj) resulted_5\VBD\2633881|although|cessation|improvements (r_advcl) initiated_29\VBD\1617192|resulted|,|we|therapy|,|rose (l_advcl) rose_36\VBD\1835496|because|titer|eu|,|increased (l_conj) increased_43\VBD\169651|count|cells/microl|,|and|remained (l_conj) remained_52\VBD\2604760|effusion|. (l_nsubj) effusion_51\NN\6880249|the|pleural
D012460_D004802 NONE sulphasalazine_20\NN\1740| (r_compound) treatment_21\NN\654885|of|sulphasalazine (r_nmod) restarting_18\VBG\1857717|after|treatment (r_advcl) developed_6\VBD\1753788|woman|eyes|restarting|. (l_dobj) eyes_8\NNS\5945642|red|,|effusion (l_conj) effusion_11\NN\6880249|pleural|,|eosinophilia (l_conj) eosinophilia_13\NN\14299637|and|abnormalities
D012460_D001745 NONE sulphasalazine_20\NN\1740| (r_compound) treatment_21\NN\654885|of|sulphasalazine (r_nmod) restarting_18\VBG\1857717|after|treatment (r_advcl) developed_6\VBD\1753788|woman|eyes|restarting|. (l_dobj) eyes_8\NNS\5945642|red|,|effusion (l_conj) effusion_11\NN\6880249|pleural|,|eosinophilia (l_conj) eosinophilia_13\NN\14299637|and|abnormalities (l_conj) abnormalities_16\NNS\14034177|urinary
D012460_D005334 CID sulphasalazine_3\NN\1740| (r_compound) treatment_4\NN\654885|of|sulphasalazine (r_nmod) cessation_1\NN\7365849|treatment (r_nsubj) resulted_5\VBD\2633881|although|cessation|improvements (l_nmod) improvements_7\NNS\7359599|in|fever (l_nmod) fever_9\NN\14299637|in|,|eyes|,|pain|,|titer|and|volume
D012460_D002637 NONE sulphasalazine_3\NN\1740| (r_compound) treatment_4\NN\654885|of|sulphasalazine (r_nmod) cessation_1\NN\7365849|treatment (r_nsubj) resulted_5\VBD\2633881|although|cessation|improvements (l_nmod) improvements_7\NNS\7359599|in|fever (l_nmod) fever_9\NN\14299637|in|,|eyes|,|pain|,|titer|and|volume (l_conj) pain_15\NN\14299637|chest
D013256_D005334 NONE steroid_30\NN\14727670| (r_compound) therapy_31\NN\657604|steroid (r_dobj) initiated_29\VBD\1617192|resulted|,|we|therapy|,|rose (l_advcl) resulted_5\VBD\2633881|although|cessation|improvements (l_nmod) improvements_7\NNS\7359599|in|fever (l_nmod) fever_9\NN\14299637|in|,|eyes|,|pain|,|titer|and|volume
D013256_D005128 NONE steroid_30\NN\14727670| (r_compound) therapy_31\NN\657604|steroid (r_dobj) initiated_29\VBD\1617192|resulted|,|we|therapy|,|rose (l_advcl) resulted_5\VBD\2633881|although|cessation|improvements (l_nmod) improvements_7\NNS\7359599|in|fever (l_nmod) fever_9\NN\14299637|in|,|eyes|,|pain|,|titer|and|volume (l_conj) eyes_12\NNS\5945642|red
D013256_D002637 NONE steroid_30\NN\14727670| (r_compound) therapy_31\NN\657604|steroid (r_dobj) initiated_29\VBD\1617192|resulted|,|we|therapy|,|rose (l_advcl) resulted_5\VBD\2633881|although|cessation|improvements (l_nmod) improvements_7\NNS\7359599|in|fever (l_nmod) fever_9\NN\14299637|in|,|eyes|,|pain|,|titer|and|volume (l_conj) pain_15\NN\14299637|chest
D013256_D010996 NONE steroid_30\NN\14727670| (r_compound) therapy_31\NN\657604|steroid (r_dobj) initiated_29\VBD\1617192|resulted|,|we|therapy|,|rose (l_advcl) resulted_5\VBD\2633881|although|cessation|improvements (l_nmod) improvements_7\NNS\7359599|in|fever (l_nmod) fever_9\NN\14299637|in|,|eyes|,|pain|,|titer|and|volume (l_conj) volume_22\NN\33615|effusions (l_nmod) effusions_26\NNS\6880249|of|the|pleural
D013256_D010996 NONE steroid_30\NN\14727670| (r_compound) therapy_31\NN\657604|steroid (r_dobj) initiated_29\VBD\1617192|resulted|,|we|therapy|,|rose (l_advcl) rose_36\VBD\1835496|because|titer|eu|,|increased (l_conj) increased_43\VBD\169651|count|cells/microl|,|and|remained (l_conj) remained_52\VBD\2604760|effusion|. (l_nsubj) effusion_51\NN\6880249|the|pleural
D013256_D010996 NONE steroid_3\NN\14727670| (r_compound) therapy_4\NN\657604|after|steroid (r_nmod) month_1\NN\15113229|one|therapy (r_nmod:tmod) disappeared_9\VBD\2609764|month|,|effusion|,|and|normalized (l_nsubj) effusion_8\NN\6880249|the|pleural
2598570
D013496_D021501 CID suprofen_9\NNP\1740|from (r_nmod) syndrome_7\NN\5870365|of|the|acute|pain|suprofen (l_compound) pain_6\NN\14299637|flank
D000431_D006255 NONE alcohol_83\NN\7881800| (r_dobj) use_82\VB\1156834|to|alcohol|ratio (r_conj) ratio_53\NN\13815152|(|odds|,|5.9|;|interval|)|,|use|=|;|and|use (r_dep) participate_47\VB\2367363|to|exercise|ratio (r_xcomp) likely_4\JJ\1740|patients|were|more|men|participate|. (l_xcomp) men_7\NNS\8208016|to|be|ratio (l_dep) ratio_10\NN\13815152|(|odds|,|3.8|;|interval|)|,|suffer|ratio|; (l_conj) suffer_24\VB\2110220|fever (l_nmod) fever_27\NN\14299637|from|hay|and|asthma
D000431_D001249 NONE alcohol_83\NN\7881800| (r_dobj) use_82\VB\1156834|to|alcohol|ratio (r_conj) ratio_53\NN\13815152|(|odds|,|5.9|;|interval|)|,|use|=|;|and|use (r_dep) participate_47\VB\2367363|to|exercise|ratio (r_xcomp) likely_4\JJ\1740|patients|were|more|men|participate|. (l_xcomp) men_7\NNS\8208016|to|be|ratio (l_dep) ratio_10\NN\13815152|(|odds|,|3.8|;|interval|)|,|suffer|ratio|; (l_conj) suffer_24\VB\2110220|fever (l_nmod) fever_27\NN\14299637|from|hay|and|asthma (l_conj) asthma_29\NN\14145095|
D007052_D007674 NONE ibuprofen_15\NN\3828465|(|especially|) (r_appos) agents_12\NNS\7347|of|other|analgesic|ibuprofen (r_nmod) use_8\NN\407535|concurrent|agents|,|disease (l_conj) disease_20\NN\14061805|preexisting|renal|,|history
D007052_D007669 NONE ibuprofen_15\NN\3828465|(|especially|) (r_appos) agents_12\NNS\7347|of|other|analgesic|ibuprofen (r_nmod) use_8\NN\407535|concurrent|agents|,|disease (l_conj) disease_20\NN\14061805|preexisting|renal|,|history (l_conj) history_23\NN\15120823|a|stones|,|history (l_nmod) stones_26\NNS\19128|of|kidney
D007052_D006073 NONE ibuprofen_15\NN\3828465|(|especially|) (r_appos) agents_12\NNS\7347|of|other|analgesic|ibuprofen (r_nmod) use_8\NN\407535|concurrent|agents|,|disease (l_conj) disease_20\NN\14061805|preexisting|renal|,|history (l_conj) history_23\NN\15120823|a|stones|,|history (l_conj) history_29\NN\15120823|a|gout|,|increase (l_nmod) gout_31\NN\14186541|of
20510337
C024989_D007674 NONE q10_1\NN\1740|coenzyme (r_compound) treatment_2\NN\654885|q10 (r_nsubj) ameliorates_3\VBZ\126264|treatment|nephrotoxicity|. (l_dobj) nephrotoxicity_6\NN\1740|acute|cisplatin|mice
C024989_D007674 NONE q10_13\NN\1740| (r_compound) treatment_14\NN\654885|by|coenzyme|q10 (r_nmod) ameliorated_10\VBN\126264|also|,|damage|was|treatment|. (l_nsubjpass) damage_5\NN\7296428|histopathological|renal|tissue|mediated
C024989_D007674 NONE q10_5\NN\1740|coenzyme (r_nsubj) represents_6\VBZ\2664769|that|q10|option (l_dobj) option_10\NN\6480506|a|potential|therapeutic|protect (l_acl) protect_12\VB\1127795|to|nephrotoxicity (l_nmod) nephrotoxicity_16\NN\1740|against|acute|cisplatin|encountered
D002945_D007674 NONE cisplatin_5\NN\1740| (r_compound) nephrotoxicity_6\NN\1740|acute|cisplatin|mice
D002945_D007674 NONE cisplatin_8\NN\1740|by (r_nmod) mediated_6\VBN\761713|cisplatin (r_acl) damage_5\NN\7296428|histopathological|renal|tissue|mediated
D002945_D007674 NONE cisplatin_15\NN\1740| (r_compound) nephrotoxicity_16\NN\1740|against|acute|cisplatin|encountered
C024989_D058186 NONE q10_5\NN\1740|of|coenzyme (r_nmod) effect_2\NN\34213|the|nephroprotective|q10 (r_nsubjpass) investigated_7\VBN\644583|effect|was|mice|. (l_nmod) mice_9\NNS\2329401|in|injury (l_nmod) injury_13\NN\14052046|with|acute|renal|induced
D002945_D058186 CID cisplatin_21\NN\1740|of|mg/kg (r_nmod) injection_19\NN\320852|by|a|single|i.p.|cisplatin (r_nmod) induced_14\VBN\1627355|injection (r_acl) injury_13\NN\14052046|with|acute|renal|induced
C024989_D009369 NONE q10_1\NN\1740|coenzyme (r_nsubj) compensated_3\VBD\2673134|q10|significantly|deficits|,|suppressed|. (l_conj) suppressed_20\VBD\2510337|peroxidation|,|decreased (l_conj) decreased_24\VBD\169651|elevations|,|and|attenuated (l_dobj) elevations_26\NNS\7445480|the|factor-alpha (l_nmod) factor-alpha_30\NN\1740|of|tumor|necrosis|,|oxide|and|concentration (l_compound) tumor_28\NN\14234074|
C024989_D009336 NONE q10_1\NN\1740|coenzyme (r_nsubj) compensated_3\VBD\2673134|q10|significantly|deficits|,|suppressed|. (l_conj) suppressed_20\VBD\2510337|peroxidation|,|decreased (l_conj) decreased_24\VBD\169651|elevations|,|and|attenuated (l_dobj) elevations_26\NNS\7445480|the|factor-alpha (l_nmod) factor-alpha_30\NN\1740|of|tumor|necrosis|,|oxide|and|concentration (l_compound) necrosis_29\NN\11444117|
D005978_D009369 NONE glutathione_12\NN\1740| (r_compound) level_13\NN\4916342|(|reduced|glutathione|and|activity|) (r_dep) deficits_4\NNS\5113133|mechanisms|level (r_dobj) compensated_3\VBD\2673134|q10|significantly|deficits|,|suppressed|. (l_conj) suppressed_20\VBD\2510337|peroxidation|,|decreased (l_conj) decreased_24\VBD\169651|elevations|,|and|attenuated (l_dobj) elevations_26\NNS\7445480|the|factor-alpha (l_nmod) factor-alpha_30\NN\1740|of|tumor|necrosis|,|oxide|and|concentration (l_compound) tumor_28\NN\14234074|
D005978_D009336 NONE glutathione_12\NN\1740| (r_compound) level_13\NN\4916342|(|reduced|glutathione|and|activity|) (r_dep) deficits_4\NNS\5113133|mechanisms|level (r_dobj) compensated_3\VBD\2673134|q10|significantly|deficits|,|suppressed|. (l_conj) suppressed_20\VBD\2510337|peroxidation|,|decreased (l_conj) decreased_24\VBD\169651|elevations|,|and|attenuated (l_dobj) elevations_26\NNS\7445480|the|factor-alpha (l_nmod) factor-alpha_30\NN\1740|of|tumor|necrosis|,|oxide|and|concentration (l_compound) necrosis_29\NN\11444117|
D013481_D009369 NONE superoxide_15\NN\14971519| (r_compound) activity_17\NN\30358|superoxide|dismutase (r_conj) level_13\NN\4916342|(|reduced|glutathione|and|activity|) (r_dep) deficits_4\NNS\5113133|mechanisms|level (r_dobj) compensated_3\VBD\2673134|q10|significantly|deficits|,|suppressed|. (l_conj) suppressed_20\VBD\2510337|peroxidation|,|decreased (l_conj) decreased_24\VBD\169651|elevations|,|and|attenuated (l_dobj) elevations_26\NNS\7445480|the|factor-alpha (l_nmod) factor-alpha_30\NN\1740|of|tumor|necrosis|,|oxide|and|concentration (l_compound) tumor_28\NN\14234074|
D013481_D009336 NONE superoxide_15\NN\14971519| (r_compound) activity_17\NN\30358|superoxide|dismutase (r_conj) level_13\NN\4916342|(|reduced|glutathione|and|activity|) (r_dep) deficits_4\NNS\5113133|mechanisms|level (r_dobj) compensated_3\VBD\2673134|q10|significantly|deficits|,|suppressed|. (l_conj) suppressed_20\VBD\2510337|peroxidation|,|decreased (l_conj) decreased_24\VBD\169651|elevations|,|and|attenuated (l_dobj) elevations_26\NNS\7445480|the|factor-alpha (l_nmod) factor-alpha_30\NN\1740|of|tumor|necrosis|,|oxide|and|concentration (l_compound) necrosis_29\NN\11444117|
D009569_D009369 NONE oxide_33\NN\14818238|nitric (r_conj) factor-alpha_30\NN\1740|of|tumor|necrosis|,|oxide|and|concentration (l_compound) tumor_28\NN\14234074|
D009569_D009336 NONE oxide_33\NN\14818238|nitric (r_conj) factor-alpha_30\NN\1740|of|tumor|necrosis|,|oxide|and|concentration (l_compound) necrosis_29\NN\11444117|
D010984_D009369 NONE platinum_35\NN\14627081| (r_compound) ion_36\NN\9386422|platinum (r_compound) concentration_37\NN\4916342|ion (r_conj) factor-alpha_30\NN\1740|of|tumor|necrosis|,|oxide|and|concentration (l_compound) tumor_28\NN\14234074|
D010984_D009336 NONE platinum_35\NN\14627081| (r_compound) ion_36\NN\9386422|platinum (r_compound) concentration_37\NN\4916342|ion (r_conj) factor-alpha_30\NN\1740|of|tumor|necrosis|,|oxide|and|concentration (l_compound) necrosis_29\NN\11444117|
D012643_D009369 NONE selenium_44\NN\14724645|and|zinc (r_compound) ions_47\NNS\9386422|of|selenium (r_nmod) reductions_42\NNS\351485|the|ions|tissue (r_dobj) attenuated_40\VBD\224901|reductions (r_conj) decreased_24\VBD\169651|elevations|,|and|attenuated (l_dobj) elevations_26\NNS\7445480|the|factor-alpha (l_nmod) factor-alpha_30\NN\1740|of|tumor|necrosis|,|oxide|and|concentration (l_compound) tumor_28\NN\14234074|
D012643_D009336 NONE selenium_44\NN\14724645|and|zinc (r_compound) ions_47\NNS\9386422|of|selenium (r_nmod) reductions_42\NNS\351485|the|ions|tissue (r_dobj) attenuated_40\VBD\224901|reductions (r_conj) decreased_24\VBD\169651|elevations|,|and|attenuated (l_dobj) elevations_26\NNS\7445480|the|factor-alpha (l_nmod) factor-alpha_30\NN\1740|of|tumor|necrosis|,|oxide|and|concentration (l_compound) necrosis_29\NN\11444117|
D015032_D009369 NONE zinc_46\NN\14625458| (r_conj) selenium_44\NN\14724645|and|zinc (r_compound) ions_47\NNS\9386422|of|selenium (r_nmod) reductions_42\NNS\351485|the|ions|tissue (r_dobj) attenuated_40\VBD\224901|reductions (r_conj) decreased_24\VBD\169651|elevations|,|and|attenuated (l_dobj) elevations_26\NNS\7445480|the|factor-alpha (l_nmod) factor-alpha_30\NN\1740|of|tumor|necrosis|,|oxide|and|concentration (l_compound) tumor_28\NN\14234074|
D015032_D009336 NONE zinc_46\NN\14625458| (r_conj) selenium_44\NN\14724645|and|zinc (r_compound) ions_47\NNS\9386422|of|selenium (r_nmod) reductions_42\NNS\351485|the|ions|tissue (r_dobj) attenuated_40\VBD\224901|reductions (r_conj) decreased_24\VBD\169651|elevations|,|and|attenuated (l_dobj) elevations_26\NNS\7445480|the|factor-alpha (l_nmod) factor-alpha_30\NN\1740|of|tumor|necrosis|,|oxide|and|concentration (l_compound) necrosis_29\NN\11444117|
D002945_D009369 NONE cisplatin_53\NN\1740| (r_compound) administration_54\NN\1133281|from|cisplatin (r_nmod) resulted_51\VBD\2633881|administration (r_acl) tissue_50\NN\5220461|in|renal|resulted (r_nmod) reductions_42\NNS\351485|the|ions|tissue (r_dobj) attenuated_40\VBD\224901|reductions (r_conj) decreased_24\VBD\169651|elevations|,|and|attenuated (l_dobj) elevations_26\NNS\7445480|the|factor-alpha (l_nmod) factor-alpha_30\NN\1740|of|tumor|necrosis|,|oxide|and|concentration (l_compound) tumor_28\NN\14234074|
D002945_D009336 NONE cisplatin_53\NN\1740| (r_compound) administration_54\NN\1133281|from|cisplatin (r_nmod) resulted_51\VBD\2633881|administration (r_acl) tissue_50\NN\5220461|in|renal|resulted (r_nmod) reductions_42\NNS\351485|the|ions|tissue (r_dobj) attenuated_40\VBD\224901|reductions (r_conj) decreased_24\VBD\169651|elevations|,|and|attenuated (l_dobj) elevations_26\NNS\7445480|the|factor-alpha (l_nmod) factor-alpha_30\NN\1740|of|tumor|necrosis|,|oxide|and|concentration (l_compound) necrosis_29\NN\11444117|
19234905
D007980_D004409 CID levodopa-induced_53\JJ\1740| (r_amod) dyskinesias_54\NNS\14084880|levodopa-induced
D014635_D006423 NONE valproate_33\NN\1740|with|mg/day (r_nmod) improved_28\VBD\126264|which|partly|month|valproate (r_dep) developed_18\VBD\1753788|one|movements|subthalamotomy|improved (r_conj) had_8\VBD\2108377|one|hemianopsia|pallidotomy|and|developed|. (l_dobj) hemianopsia_12\NN\14552802|a|left|homonymous
19058474
D014859_D010490 NONE warfarin_13\NN\2718259|with (r_nmod) interaction_8\NN\37396|due|possible|juice|warfarin (r_nmod) haemopericardium_1\NN\1740|fatal|and|haemorrhage|interaction|.
D014859_D006471 CID warfarin_13\NN\2718259|with (r_nmod) interaction_8\NN\37396|due|possible|juice|warfarin (r_nmod) haemopericardium_1\NN\1740|fatal|and|haemorrhage|interaction|. (l_conj) haemorrhage_4\NN\14285662|gastrointestinal
D014859_D006470 NONE warfarin_26\NN\2718259|of (r_nmod) dosage_24\NN\13576355|his|usual|warfarin (r_dobj) maintaining_21\VBG\2202928|while|dosage (r_advcl) consumed_13\VBD\1168468|who|juice|weeks|maintaining (r_acl:relcl) man_11\NN\9605289|in|an|elderly|consumed (r_nmod) haemorrhage_7\NN\14285662|of|fatal|internal|man
11027904
D008691_D010146 NONE methadone-maintained_3\NN\1740| (r_compound) abusers_5\NNS\9633969|in|methadone-maintained|opioid (r_nmod) responses_1\NNS\11410625|pain|abusers|. (l_compound) pain_0\NN\14299637|
D008691_D010146 NONE methadone-maintenance_19\NN\1740|mm (r_compound) treatment_23\NN\654885|in|methadone-maintenance (r_nmod) stabilized_17\VBN\126264|treatment (r_acl) addicts_16\NNS\10059582|of|opioid|stabilized (r_nmod) sample_13\NN\5820620|in|a|addicts (r_nmod) tolerance_7\NN\5032565|pain|and|response|sample|n (l_compound) pain_6\NN\14299637|
D008691_D009293 NONE methadone-maintenance_19\NN\1740|mm (r_compound) treatment_23\NN\654885|in|methadone-maintenance (r_nmod) stabilized_17\VBN\126264|treatment (r_acl) addicts_16\NNS\10059582|of|opioid|stabilized
D004091_D010146 NONE hydromorphone_32\NN\2707683|(|mg (r_appos) opioid_30\NN\1740|common|hydromorphone|and|anti-inflammatory (r_compound) agents_45\NNS\7347|of|opioid|analgesic (r_nmod) doses_27\NNS\3740161|of|therapeutic|agents (r_nmod) administration_24\NN\1133281|before|oral|doses (r_nmod) examined_17\VBN\789138|using|,|tolerance|was|,|administration|. (l_nsubjpass) tolerance_9\NN\5032565|pain (l_nmod) pain_15\NN\14299637|to|cold-pressor
D020910_D010146 NONE ketorolac_40\NN\3828465| (r_compound) mg_42\NN\13717155|(|ketorolac|10|) (r_dep) anti-inflammatory_38\JJ\1740|nonsteroidal|mg (r_conj) opioid_30\NN\1740|common|hydromorphone|and|anti-inflammatory (r_compound) agents_45\NNS\7347|of|opioid|analgesic (r_nmod) doses_27\NNS\3740161|of|therapeutic|agents (r_nmod) administration_24\NN\1133281|before|oral|doses (r_nmod) examined_17\VBN\789138|using|,|tolerance|was|,|administration|. (l_nsubjpass) tolerance_9\NN\5032565|pain (l_nmod) pain_15\NN\14299637|to|cold-pressor
3431591
C031662_D064420 NONE 3717_1\CD\1740| (r_nummod) cb_0\NN\1740|3717|,|acid|, (r_nsubj) inhibitor_9\NN\20090|cb|is|a|tight-binding|synthase|. (l_nmod) synthase_12\NN\1740|of|thymidylate|ts|mediated (l_acl:relcl) mediated_19\VBN\761713|cytotoxicity|is|inhibition (l_nsubjpass) cytotoxicity_17\NN\13583478|whose
C031662_D064420 NONE acid_4\NN\14818238|n10-propargyl-5,8-dideazafolic (r_appos) cb_0\NN\1740|3717|,|acid|, (r_nsubj) inhibitor_9\NN\20090|cb|is|a|tight-binding|synthase|. (l_nmod) synthase_12\NN\1740|of|thymidylate|ts|mediated (l_acl:relcl) mediated_19\VBN\761713|cytotoxicity|is|inhibition (l_nsubjpass) cytotoxicity_17\NN\13583478|whose
C031662_D064420 NONE 3717_28\CD\1740| (r_nummod) cb_27\NN\1740|than|3717 (r_nmod) potent_25\JJ\1740|cb|,|respectively (r_dep) 26-_17\CD\1740|are|,|87-|,|119-|and|114-fold|more|potent (r_dep) di-_9\NN\1740|inhibitors|,|cb|,|tri-|,|tetra-|and|pentaglutamate|26-|,|and|determinant (l_conj) determinant_42\NN\5686481|formation|may|,|therefore|,|be|an|important|cytotoxicity|. (l_nmod) cytotoxicity_46\NN\13583478|of|3717
C031662_D064420 NONE 3717_45\NN\1740|cb (r_compound) cytotoxicity_46\NN\13583478|of|3717
C031662_D001943 NONE 3717_6\CD\1740| (r_nummod) cb_5\NN\1740|with|3717 (r_nmod) studies_3\NNS\635850|in|early|clinical|cb (r_nmod) seen_11\VBN\2106506|studies|,|activity|has|been|cancer|. (l_nmod) cancer_14\NN\14239425|in|breast|,|cancer
C031662_D010051 NONE 3717_6\CD\1740| (r_nummod) cb_5\NN\1740|with|3717 (r_nmod) studies_3\NNS\635850|in|early|clinical|cb (r_nmod) seen_11\VBN\2106506|studies|,|activity|has|been|cancer|. (l_nmod) cancer_14\NN\14239425|in|breast|,|cancer (l_conj) cancer_17\NN\14239425|ovarian|,|hepatoma
C031662_D006528 NONE 3717_6\CD\1740| (r_nummod) cb_5\NN\1740|with|3717 (r_nmod) studies_3\NNS\635850|in|early|clinical|cb (r_nmod) seen_11\VBN\2106506|studies|,|activity|has|been|cancer|. (l_nmod) cancer_14\NN\14239425|in|breast|,|cancer (l_conj) cancer_17\NN\14239425|ovarian|,|hepatoma (l_conj) hepatoma_19\NN\14242337|,|and|mesothelioma
C031662_D008654 NONE 3717_6\CD\1740| (r_nummod) cb_5\NN\1740|with|3717 (r_nmod) studies_3\NNS\635850|in|early|clinical|cb (r_nmod) seen_11\VBN\2106506|studies|,|activity|has|been|cancer|. (l_nmod) cancer_14\NN\14239425|in|breast|,|cancer (l_conj) cancer_17\NN\14239425|ovarian|,|hepatoma (l_conj) hepatoma_19\NN\14242337|,|and|mesothelioma (l_conj) mesothelioma_22\NN\14242337|
20705401
D012701_D011605 NONE serotonin_0\NN\14807737| (r_compound) gene_3\NN\8459252|serotonin|6|receptor (r_nsubjpass) associated_5\VBN\628491|gene|is|psychosis|. (l_nmod) psychosis_8\NN\14380140|with|methamphetamine-induced|population
D012701_D011605 NONE 5-ht6_20\NN\1740| (r_compound) receptors_21\NNS\5225602|altered|5-ht6 (r_nsubjpass) involved_23\VBN\2676054|that|receptors|are|pathophysiology (l_nmod) pathophysiology_26\NN\1740|in|the|disorders (l_nmod) disorders_29\NNS\14034177|of|psychotic
D012701_D011605 NONE 5-ht6_11\NN\1740| (r_compound) gene_12\NN\8459252|of|the|5-ht6|htr6 (r_nmod) association_8\NN\8008335|of|the|gene|psychosis (l_nmod) psychosis_18\NN\14380140|with|meth-induced
D008694_D011605 CID methamphetamine-induced_7\JJ\1740| (r_amod) psychosis_8\NN\14380140|with|methamphetamine-induced|population
D008694_D011605 CID methamphetamine_3\NN\2704153|(meth)-induced (r_compound) psychosis_5\NN\14380140|of|methamphetamine
D008694_D011605 CID (meth)-induced_4\NN\1740| (r_dep) methamphetamine_3\NN\2704153|(meth)-induced (r_compound) psychosis_5\NN\14380140|of|methamphetamine
D008694_D011605 CID meth-induced_17\JJ\1740| (r_amod) psychosis_18\NN\14380140|with|meth-induced
D008694_D011605 CID meth-induced_29\JJ\1740| (r_amod) patients_31\NNS\9898892|(|197|meth-induced|psychosis|and|controls|) (l_compound) psychosis_30\NN\14380140|
D008694_D011605 CID meth-induced_6\JJ\1740| (r_amod) patients_8\NNS\9898892|with|meth-induced|psychosis (l_compound) psychosis_7\NN\14380140|
D008694_D011605 CID meth-induced_30\JJ\1740| (r_amod) psychosis_31\NN\14380140|meth-induced
D008694_D011605 CID meth-induced_12\JJ\1740| (r_amod) psychosis_13\NN\14380140|of|meth-induced|population
D012701_D006948 NONE serotonin_1\NN\14807737| (r_compound) receptor_6\NN\5225602|the|serotonin|6|(|5-ht6|) (r_nsubjpass) targeted_9\VBN\1151110|receptor|is|therapeutically|antipsychotics|,|and|corrected (l_conj) corrected_28\VBN\138508|hyperactivity|is|use|. (l_nsubjpass) hyperactivity_24\NN\14052403|d-amphetamine-induced|rats
D012701_D006948 NONE 5-ht6_4\NN\1740| (r_compound) receptor_6\NN\5225602|the|serotonin|6|(|5-ht6|) (r_nsubjpass) targeted_9\VBN\1151110|receptor|is|therapeutically|antipsychotics|,|and|corrected (l_conj) corrected_28\VBN\138508|hyperactivity|is|use|. (l_nsubjpass) hyperactivity_24\NN\14052403|d-amphetamine-induced|rats
D012701_D006948 NONE 5-ht6_35\NN\1740| (r_compound) antagonist_37\NN\7846|of|a|selective|5-ht6|receptor (r_nmod) use_31\NN\407535|with|the|antagonist (r_nmod) corrected_28\VBN\138508|hyperactivity|is|use|. (l_nsubjpass) hyperactivity_24\NN\14052403|d-amphetamine-induced|rats
D003024_D006948 NONE clozapine_18\NN\3713736|such|and|olanzapine (r_nmod) antipsychotics_14\NNS\4470232|by|several|generation|,|clozapine (r_nmod) targeted_9\VBN\1151110|receptor|is|therapeutically|antipsychotics|,|and|corrected (l_conj) corrected_28\VBN\138508|hyperactivity|is|use|. (l_nsubjpass) hyperactivity_24\NN\14052403|d-amphetamine-induced|rats
C076029_D006948 NONE olanzapine_20\NN\1740| (r_conj) clozapine_18\NN\3713736|such|and|olanzapine (r_nmod) antipsychotics_14\NNS\4470232|by|several|generation|,|clozapine (r_nmod) targeted_9\VBN\1151110|receptor|is|therapeutically|antipsychotics|,|and|corrected (l_conj) corrected_28\VBN\138508|hyperactivity|is|use|. (l_nsubjpass) hyperactivity_24\NN\14052403|d-amphetamine-induced|rats
D003913_D006948 NONE d-amphetamine-induced_23\JJ\1740| (r_amod) hyperactivity_24\NN\14052403|d-amphetamine-induced|rats
D012701_D012559 NONE 5-ht6_20\NN\1740| (r_compound) receptors_21\NNS\5225602|altered|5-ht6 (r_nsubjpass) involved_23\VBN\2676054|that|receptors|are|pathophysiology (r_ccomp) suggests_17\VBZ\1010118|evidence|involved|. (r_conj) considered_4\VBN\689344|models|were|reflect|,|and|suggests (l_xcomp) reflect_6\VB\923793|to|symptoms (l_dobj) symptoms_9\NNS\5823932|the|positive|schizophrenia (l_nmod) schizophrenia_11\NN\14398067|of
D008694_D012563 NONE methamphetamine_3\NN\2704153|(meth)-induced (r_compound) psychosis_5\NN\14380140|of|methamphetamine (r_nmod) symptoms_1\NNS\5823932|the|psychosis (r_nsubj) similar_7\JJ\1740|symptoms|are|those|. (l_nmod) those_9\DT\1740|to|schizophrenia (l_nmod) schizophrenia_13\NN\14398067|of|type
D008694_D012563 NONE (meth)-induced_4\NN\1740| (r_dep) methamphetamine_3\NN\2704153|(meth)-induced (r_compound) psychosis_5\NN\14380140|of|methamphetamine (r_nmod) symptoms_1\NNS\5823932|the|psychosis (r_nsubj) similar_7\JJ\1740|symptoms|are|those|. (l_nmod) those_9\DT\1740|to|schizophrenia (l_nmod) schizophrenia_13\NN\14398067|of|type
16192988
D008694_D001523 CID methamphetamine_0\NN\2704153| (r_nsubj) causes_1\VBZ\1617192|methamphetamine|alterations|. (l_dobj) alterations_2\NNS\7283608|pathways (l_nmod) pathways_7\NNS\5483677|in|the|kinase-related|brains (l_nmod) brains_10\NNS\5462674|in|the|mice (l_nmod) mice_12\NNS\2329401|of|display (l_acl:relcl) display_14\VBP\2137132|that|aggressiveness (l_dobj) aggressiveness_16\NN\4835724|increased
D008694_D001523 CID methamphetamine_18\NN\2704153|meth (r_compound) abusers_22\NNS\9633969|in|methamphetamine (r_nmod) common_16\JJ\1740|are|abusers (r_conj) reported_4\VBN\831651|behaviors|have|been|patients|,|and|common|. (l_nsubjpass) behaviors_1\NNS\407535|aggressive
D008694_D001523 CID methamphetamine_18\NN\2704153|meth (r_compound) abusers_22\NNS\9633969|in|methamphetamine (r_nmod) common_16\JJ\1740|are|abusers (r_conj) reported_4\VBN\831651|behaviors|have|been|patients|,|and|common|. (l_nmod) patients_6\NNS\9898892|in|suffer (l_acl:relcl) suffer_8\VBP\2110220|who|disorders (l_nmod) disorders_12\NNS\14034177|from|some|psychiatric
D008694_D001523 CID meth_20\NN\2704153|(|) (r_appos) methamphetamine_18\NN\2704153|meth (r_compound) abusers_22\NNS\9633969|in|methamphetamine (r_nmod) common_16\JJ\1740|are|abusers (r_conj) reported_4\VBN\831651|behaviors|have|been|patients|,|and|common|. (l_nsubjpass) behaviors_1\NNS\407535|aggressive
D008694_D001523 CID meth_20\NN\2704153|(|) (r_appos) methamphetamine_18\NN\2704153|meth (r_compound) abusers_22\NNS\9633969|in|methamphetamine (r_nmod) common_16\JJ\1740|are|abusers (r_conj) reported_4\VBN\831651|behaviors|have|been|patients|,|and|common|. (l_nmod) patients_6\NNS\9898892|in|suffer (l_acl:relcl) suffer_8\VBP\2110220|who|disorders (l_nmod) disorders_12\NNS\14034177|from|some|psychiatric
D008694_D001523 CID meth_13\NN\2704153|of (r_nmod) injections_11\NNS\320852|multiple|meth (r_nsubj) increased_15\VBD\169651|that|injections|significantly|aggressiveness (l_dobj) aggressiveness_16\NN\4835724|mice
D008694_D001523 CID meth-induced_8\JJ\1740| (r_amod) hyperactivity_9\NN\14052403|to|meth-induced (r_nmod) secondary_6\JJ\1740|increase|was|not|hyperactivity|. (l_nsubj) increase_1\NN\13576355|this|aggressiveness (l_nmod) aggressiveness_3\NN\4835724|in
D008694_D006948 NONE meth-induced_8\JJ\1740| (r_amod) hyperactivity_9\NN\14052403|to|meth-induced
8643966
D017239_D002289 NONE paclitaxel_9\NN\1740|with (r_nmod) chemotherapy_0\NN\661091|cancer|paclitaxel|:|trial (l_nmod) cancer_7\NN\14239425|of|advanced|inoperable|non-small|cell|lung
D017239_D002289 NONE paclitaxel_6\NN\1740| (r_compound) infusions_7\NNS\14589223|of|24-hour|paclitaxel (r_nmod) trials_3\NNS\786195|two|phase|ii|infusions|patients (l_nmod) patients_10\NNS\9898892|in|chemotherapy-naive|cancer (l_nmod) cancer_19\NN\14239425|with|stage|non-small|cell|lung|nsclc
D017239_D002289 NONE paclitaxel_6\NN\1740| (r_compound) infusions_7\NNS\14589223|of|24-hour|paclitaxel (r_nmod) trials_3\NNS\786195|two|phase|ii|infusions|patients (l_nmod) patients_10\NNS\9898892|in|chemotherapy-naive|cancer (l_nmod) cancer_19\NN\14239425|with|stage|non-small|cell|lung|nsclc (l_appos) nsclc_21\NN\1740|(|)
D017239_D002289 NONE paclitaxel_9\NN\1740| (r_compound) infusion_10\NN\14589223|of|a|3-hour|paclitaxel (r_nmod) efficacy_3\NN\5199286|the|and|toxicity|infusion|trial (l_nmod) trial_15\NN\786195|in|a|phase|ii|patients (l_nmod) patients_17\NNS\9898892|in|nsclc (l_nmod) nsclc_24\NN\1740|with|stage
D017239_D002289 NONE paclitaxel_5\NN\1740|with|combined (l_acl) combined_6\VBN\2630189|drugs (l_nmod) drugs_9\NNS\14778436|with|other|active (l_amod) active_10\JJ\1740|nsclc (l_nmod) nsclc_12\NN\1740|against
D017239_D002289 NONE paclitaxel_21\NN\1740| (r_dobj) comparing_20\VBG\644583|paclitaxel|chemotherapy (r_acl) studies_19\NNS\635850|phase|comparing (r_nsubj) remain_25\VBP\2604760|studies|completed|. (r_conj) indicated_14\VBN\952524|studies|are|,|and|remain (l_nsubjpass) studies_3\NNS\635850|further|phase|paclitaxel (l_nmod) paclitaxel_5\NN\1740|with|combined (l_acl) combined_6\VBN\2630189|drugs (l_nmod) drugs_9\NNS\14778436|with|other|active (l_amod) active_10\JJ\1740|nsclc (l_nmod) nsclc_12\NN\1740|against
D017239_D009369 NONE paclitaxel_0\NN\1740|taxol (r_nsubj) demonstrated_13\VBN\2137132|paclitaxel|has|activity|. (l_dobj) activity_16\NN\30358|significant|antineoplastic|types (l_nmod) types_20\NNS\5839024|against|different|tumor|,|carcinoma (l_compound) tumor_19\NN\14234074|
D017239_D009369 NONE taxol_2\NN\1740|(|;|company (r_appos) paclitaxel_0\NN\1740|taxol (r_nsubj) demonstrated_13\VBN\2137132|paclitaxel|has|activity|. (l_dobj) activity_16\NN\30358|significant|antineoplastic|types (l_nmod) types_20\NNS\5839024|against|different|tumor|,|carcinoma (l_compound) tumor_19\NN\14234074|
D017239_D010051 NONE paclitaxel_0\NN\1740|taxol (r_nsubj) demonstrated_13\VBN\2137132|paclitaxel|has|activity|. (l_dobj) activity_16\NN\30358|significant|antineoplastic|types (l_nmod) types_20\NNS\5839024|against|different|tumor|,|carcinoma (l_appos) carcinoma_26\NN\14239918|ovarian
D017239_D010051 NONE taxol_2\NN\1740|(|;|company (r_appos) paclitaxel_0\NN\1740|taxol (r_nsubj) demonstrated_13\VBN\2137132|paclitaxel|has|activity|. (l_dobj) activity_16\NN\30358|significant|antineoplastic|types (l_nmod) types_20\NNS\5839024|against|different|tumor|,|carcinoma (l_appos) carcinoma_26\NN\14239918|ovarian
D017239_D001943 NONE paclitaxel_0\NN\1740|taxol (r_nsubj) demonstrated_13\VBN\2137132|paclitaxel|has|activity|. (l_dobj) activity_16\NN\30358|significant|antineoplastic|types (l_nmod) types_20\NNS\5839024|against|different|tumor|,|carcinoma (l_appos) carcinoma_26\NN\14239918|ovarian
D017239_D001943 NONE taxol_2\NN\1740|(|;|company (r_appos) paclitaxel_0\NN\1740|taxol (r_nsubj) demonstrated_13\VBN\2137132|paclitaxel|has|activity|. (l_dobj) activity_16\NN\30358|significant|antineoplastic|types (l_nmod) types_20\NNS\5839024|against|different|tumor|,|carcinoma (l_appos) carcinoma_26\NN\14239918|ovarian
D017239_D064420 NONE paclitaxel_9\NN\1740| (r_compound) infusion_10\NN\14589223|of|a|3-hour|paclitaxel (r_nmod) efficacy_3\NN\5199286|the|and|toxicity|infusion|trial (l_conj) toxicity_5\NN\13576101|
D017239_D064420 NONE paclitaxel_0\NN\1740| (r_nsubj) agent_6\NN\7347|paclitaxel|is|thus|an|active|single|population|,|proving|. (l_advcl) proving_16\VBG\2604760|with|infusion|effective|and|superior (l_conj) superior_24\JJ\1740|terms (l_nmod) terms_26\NNS\13945919|in|incidence (l_nmod) incidence_29\NN\13821570|of|the|toxicity (l_nmod) toxicity_34\NN\13576101|of|hematologic
9061311
D013481_D017114 NONE superoxide_1\NN\14971519|neutrophil|and|peroxide (r_compound) production_5\NN\30358|superoxide|patients|. (l_nmod) patients_7\NNS\9898892|in|failure (l_nmod) failure_11\NN\66216|with|acute|liver
D013481_D017114 NONE superoxide_2\NN\14971519|and|peroxide (r_compound) production_6\NN\30358|in|superoxide (r_nmod) defects_0\NNS\14462666|production (r_nsubjpass) implicated_9\VBN\2677097|defects|may|be|incidence|. (l_nmod) incidence_13\NN\13821570|in|the|high|infections (l_nmod) infections_16\NNS\14052046|of|bacterial|patients (l_nmod) patients_18\NNS\9898892|in|failure (l_nmod) failure_22\NN\66216|with|acute|liver|alf
D013481_D017114 NONE superoxide_2\NN\14971519|and|peroxide (r_compound) production_6\NN\30358|in|superoxide (r_nmod) defects_0\NNS\14462666|production (r_nsubjpass) implicated_9\VBN\2677097|defects|may|be|incidence|. (l_nmod) incidence_13\NN\13821570|in|the|high|infections (l_nmod) infections_16\NNS\14052046|of|bacterial|patients (l_nmod) patients_18\NNS\9898892|in|failure (l_nmod) failure_22\NN\66216|with|acute|liver|alf (l_appos) alf_24\NN\1740|(|)
D013481_D017114 NONE superoxide_0\NN\14971519|and|peroxide (r_compound) production_4\NN\30358|superoxide|neutrophils (l_nmod) neutrophils_7\NNS\5449959|by|alf|stimulated (l_compound) alf_6\NN\1740|
D013481_D017114 NONE superoxide_0\NN\14971519|and|peroxide (r_compound) production_4\NN\30358|superoxide|neutrophils (l_nmod) neutrophils_7\NNS\5449959|by|alf|stimulated (l_acl) stimulated_8\VBN\137313|zymosan (l_nmod) zymosan_10\NN\1740|with|opsonized (l_acl) opsonized_11\VBN\126264|serum (l_nmod) serum_14\NN\5397468|with|alf (l_compound) alf_13\NN\1740|
D013481_D017114 NONE superoxide_0\NN\14971519|and|peroxide (r_compound) production_4\NN\30358|superoxide|neutrophils (l_nmod) neutrophils_6\NNS\5449959|in|stimulated (l_acl) stimulated_7\VBN\137313|formyl-methionyl-leucyl-phenylalanine (l_nmod) formyl-methionyl-leucyl-phenylalanine_9\NN\1740|with|fmlp|patients (l_nmod) patients_18\NNS\9898892|from|a|further|18|alf (l_compound) alf_17\NN\1740|
D006861_D017114 NONE peroxide_4\NN\14780040|hydrogen (r_conj) superoxide_1\NN\14971519|neutrophil|and|peroxide (r_compound) production_5\NN\30358|superoxide|patients|. (l_nmod) patients_7\NNS\9898892|in|failure (l_nmod) failure_11\NN\66216|with|acute|liver
D006861_D017114 NONE peroxide_5\NN\14780040|hydrogen (r_conj) superoxide_2\NN\14971519|and|peroxide (r_compound) production_6\NN\30358|in|superoxide (r_nmod) defects_0\NNS\14462666|production (r_nsubjpass) implicated_9\VBN\2677097|defects|may|be|incidence|. (l_nmod) incidence_13\NN\13821570|in|the|high|infections (l_nmod) infections_16\NNS\14052046|of|bacterial|patients (l_nmod) patients_18\NNS\9898892|in|failure (l_nmod) failure_22\NN\66216|with|acute|liver|alf
D006861_D017114 NONE peroxide_5\NN\14780040|hydrogen (r_conj) superoxide_2\NN\14971519|and|peroxide (r_compound) production_6\NN\30358|in|superoxide (r_nmod) defects_0\NNS\14462666|production (r_nsubjpass) implicated_9\VBN\2677097|defects|may|be|incidence|. (l_nmod) incidence_13\NN\13821570|in|the|high|infections (l_nmod) infections_16\NNS\14052046|of|bacterial|patients (l_nmod) patients_18\NNS\9898892|in|failure (l_nmod) failure_22\NN\66216|with|acute|liver|alf (l_appos) alf_24\NN\1740|(|)
D006861_D017114 NONE peroxide_3\NN\14780040|hydrogen (r_conj) superoxide_0\NN\14971519|and|peroxide (r_compound) production_4\NN\30358|superoxide|neutrophils (l_nmod) neutrophils_7\NNS\5449959|by|alf|stimulated (l_compound) alf_6\NN\1740|
D006861_D017114 NONE peroxide_3\NN\14780040|hydrogen (r_conj) superoxide_0\NN\14971519|and|peroxide (r_compound) production_4\NN\30358|superoxide|neutrophils (l_nmod) neutrophils_7\NNS\5449959|by|alf|stimulated (l_acl) stimulated_8\VBN\137313|zymosan (l_nmod) zymosan_10\NN\1740|with|opsonized (l_acl) opsonized_11\VBN\126264|serum (l_nmod) serum_14\NN\5397468|with|alf (l_compound) alf_13\NN\1740|
D006861_D017114 NONE peroxide_3\NN\14780040|hydrogen (r_conj) superoxide_0\NN\14971519|and|peroxide (r_compound) production_4\NN\30358|superoxide|neutrophils (l_nmod) neutrophils_6\NNS\5449959|in|stimulated (l_acl) stimulated_7\VBN\137313|formyl-methionyl-leucyl-phenylalanine (l_nmod) formyl-methionyl-leucyl-phenylalanine_9\NN\1740|with|fmlp|patients (l_nmod) patients_18\NNS\9898892|from|a|further|18|alf (l_compound) alf_17\NN\1740|
D013481_D001424 NONE superoxide_2\NN\14971519|and|peroxide (r_compound) production_6\NN\30358|in|superoxide (r_nmod) defects_0\NNS\14462666|production (r_nsubjpass) implicated_9\VBN\2677097|defects|may|be|incidence|. (l_nmod) incidence_13\NN\13821570|in|the|high|infections (l_nmod) infections_16\NNS\14052046|of|bacterial|patients
D006861_D001424 NONE peroxide_5\NN\14780040|hydrogen (r_conj) superoxide_2\NN\14971519|and|peroxide (r_compound) production_6\NN\30358|in|superoxide (r_nmod) defects_0\NNS\14462666|production (r_nsubjpass) implicated_9\VBN\2677097|defects|may|be|incidence|. (l_nmod) incidence_13\NN\13821570|in|the|high|infections (l_nmod) infections_16\NNS\14052046|of|bacterial|patients
D010100_D017114 NONE oxygen_5\NN\14622893| (r_compound) production_7\NN\30358|oxygen|radical|patients (l_nmod) patients_9\NNS\9898892|in|alf|overdose (l_nmod) alf_11\NN\1740|with
D010100_D062787 NONE oxygen_5\NN\14622893| (r_compound) production_7\NN\30358|oxygen|radical|patients (l_nmod) patients_9\NNS\9898892|in|alf|overdose (l_nmod) overdose_15\NN\1740|due|paracetamol
D000082_D017114 CID paracetamol_14\NN\1740| (r_compound) overdose_15\NN\1740|due|paracetamol (r_nmod) patients_9\NNS\9898892|in|alf|overdose (l_nmod) alf_11\NN\1740|with
D000082_D017114 CID paracetamol_10\NN\1740| (r_compound) overdose_11\NN\1740|due|paracetamol (r_nmod) defect_5\NN\14462666|a|neutrophil|alf|overdose|,|dependent (l_nmod) alf_7\NN\1740|in
D000082_D062787 NONE paracetamol_14\NN\1740| (r_compound) overdose_15\NN\1740|due|paracetamol
D000082_D062787 NONE paracetamol_10\NN\1740| (r_compound) overdose_11\NN\1740|due|paracetamol
D009240_D017114 NONE formyl-methionyl-leucyl-phenylalanine_9\NN\1740|with|fmlp|patients (l_nmod) patients_18\NNS\9898892|from|a|further|18|alf (l_compound) alf_17\NN\1740|
D009240_D017114 NONE fmlp_11\NN\1740|(|) (r_appos) formyl-methionyl-leucyl-phenylalanine_9\NN\1740|with|fmlp|patients (l_nmod) patients_18\NNS\9898892|from|a|further|18|alf (l_compound) alf_17\NN\1740|
7437994
16006300
D002119_D064420 NONE carbonate_1\NN\15010703|calcium (r_compound) toxicity_2\NN\13576101|carbonate|:|syndrome|.
D002119_D006934 CID carbonate_1\NN\15010703|calcium (r_compound) toxicity_2\NN\13576101|carbonate|:|syndrome|. (l_appos) syndrome_7\NN\5870365|the|updated|milk-alkali|;|report
D002119_D006934 CID carbonate-induced_8\JJ\1740|calcium (r_amod) hypercalcemia_9\NN\14299637|with|carbonate-induced
D002119_D006934 CID carbonate-induced_8\JJ\1740|calcium (r_amod) hypercalcemia_9\NN\14299637|with|carbonate-induced (r_nmod) patients_5\NNS\9898892|3|hypercalcemia (r_dobj) describe_3\VB\1001294|to|patients|and|gain (l_conj) gain_11\VB\2238085|insights (l_dobj) insights_12\NNS\5710020|cause (l_nmod) cause_15\NN\7323922|into|the|and|management|syndrome (l_nmod) syndrome_21\NN\5870365|of|the|milk-alkali
D002119_D006934 CID carbonate_23\NN\15010703|of|ingested|calcium (r_nmod) amounts_18\NNS\13329641|by|small|carbonate|persons (r_nmod) precipitated_15\VBN\1642924|can|be|amounts (r_conj) cause_8\NN\7323922|:|syndrome|may|be|a|common|hypercalcemia|and|precipitated (l_nsubj) syndrome_3\NN\5870365|milk-alkali
D002119_D006934 CID carbonate_23\NN\15010703|of|ingested|calcium (r_nmod) amounts_18\NNS\13329641|by|small|carbonate|persons (r_nmod) precipitated_15\VBN\1642924|can|be|amounts (r_conj) cause_8\NN\7323922|:|syndrome|may|be|a|common|hypercalcemia|and|precipitated (l_nmod) hypercalcemia_11\NN\14299637|of|unexplained
D002118_D006934 NONE calcium_20\NN\14625458|(|corrected|serum|>|mg/dl|) (r_dep) hypercalcemia_16\NN\14299637|with|severe|calcium
D002118_D006934 NONE calcium_20\NN\14625458|(|corrected|serum|>|mg/dl|) (r_dep) hypercalcemia_16\NN\14299637|with|severe|calcium (r_nmod) presented_13\VBD\2137132|who|hypercalcemia (r_acl:relcl) patients_11\NNS\9898892|in|3|presented (r_nmod) report_3\VBP\831651|:|we|data|patients|and|review|. (l_conj) review_28\VBP\644583|literature (l_dobj) literature_31\NN\6362953|the|pertinent|syndrome (l_nmod) syndrome_34\NN\5870365|on|milk-alkali
C097949_D058186 NONE d_27\NN\15089472|1,25-dihydroxyvitamin (r_compound) concentrations_28\NNS\4916342|d (r_conj) hormone_17\NN\5404728|low|parathyroid|pth|,|peptide|,|and|concentrations (r_conj) insufficiency_8\NN\14462946|acute|renal|,|alkalosis|,|and|hormone
C097949_D000471 NONE d_27\NN\15089472|1,25-dihydroxyvitamin (r_compound) concentrations_28\NNS\4916342|d (r_conj) hormone_17\NN\5404728|low|parathyroid|pth|,|peptide|,|and|concentrations (r_conj) insufficiency_8\NN\14462946|acute|renal|,|alkalosis|,|and|hormone (l_conj) alkalosis_12\NN\14204950|relative|metabolic
D002118_D006996 NONE calcium_7\NN\14625458| (r_compound) concentrations_8\NNS\4916342|with|the|higher|serum|calcium (r_nmod) patients_2\NNS\9898892|the|2|concentrations (r_nsubj) received_9\VBD\2210855|patients|pamidronate|intravenously|mg|,|caused|. (l_advcl) caused_22\VBD\1617192|which|hypocalcemia (l_dobj) hypocalcemia_24\NN\14299637|severe
C019248_D006996 CID pamidronate_10\NN\1740| (r_dobj) received_9\VBD\2210855|patients|pamidronate|intravenously|mg|,|caused|. (l_advcl) caused_22\VBD\1617192|which|hypocalcemia (l_dobj) hypocalcemia_24\NN\14299637|severe
C019248_D006996 CID pamidronate_0\NN\1740| (r_compound) treatment_1\NN\654885|pamidronate (r_nsubjpass) associated_3\VBN\628491|treatment|is|risk|cases|. (l_nmod) risk_6\NN\14541044|with|considerable|hypocalcemia|, (l_nmod) hypocalcemia_8\NN\14299637|for
C019248_D006934 NONE pamidronate_0\NN\1740| (r_compound) treatment_1\NN\654885|pamidronate (r_nsubjpass) associated_3\VBN\628491|treatment|is|risk|cases|. (l_nmod) cases_12\NNS\7283608|in|hypercalcemia (l_nmod) hypercalcemia_16\NN\14299637|of|severe
8480959
D008148_D006937 NONE lovastatin_4\NN\3676175|of (r_nmod) efficacy_0\NN\5199286|and|tolerability|lovastatin|women|. (l_nmod) women_7\NNS\9605289|in|3390|hypercholesterolemia (l_nmod) hypercholesterolemia_10\NN\14299637|with|moderate
D008148_D006937 NONE lovastatin_9\NN\3676175|of (r_nmod) efficacy_5\NN\5199286|the|and|safety|lovastatin|women (l_nmod) women_11\NNS\9605289|in|hypercholesterolemia (l_nmod) hypercholesterolemia_14\NN\14299637|with|moderate
D008148_D006937 NONE lovastatin_2\NN\3676175| (r_nsubj) effective_5\JJ\1740|:|lovastatin|is|highly|and|tolerated|. (l_conj) tolerated_9\VBN\802318|well|therapy (l_nmod) therapy_11\NN\657604|as|hypercholesterolemia (l_nmod) hypercholesterolemia_14\NN\14299637|for|primary|women
D003401_D009135 NONE creatine_7\NN\14601829| (r_compound) kinase_8\NN\14732946|creatine (r_compound) elevations_9\NNS\7445480|with|kinase|greater (r_nmod) symptoms_5\NNS\5823932|as|muscle|elevations|limit (r_nmod) defined_2\VBN\2604760|symptoms (r_acl) myopathy_0\NN\14204950|,|defined|,
D008148_D009135 CID lovastatin_31\NN\3676175|of (r_nmod) dose_29\NN\3740161|with|the|recommended|daily|lovastatin|mg (r_nmod) associated_23\VBN\628491|dose (r_conj) rare_21\JJ\1740|myopathy|was|and|associated|. (l_nsubj) myopathy_0\NN\14204950|,|defined|,
8742498
D009243_D056486 NONE nad-precursors_5\NNS\1740|of (r_nmod) free_3\JJ\1740|nad-precursors (r_amod) diet_2\NN\7560652|of|free (r_nmod) influence_0\NN\5190804|diet|hepatotoxicity|. (l_nmod) hepatotoxicity_8\NN\1740|on|acetaminophen|mice
D009243_D056486 NONE nad_13\NN\14800277|of|,|substrate (r_nmod) precursors_11\NNS\14580897|of|nad (r_nmod) free_9\JJ\1740|precursors (r_amod) diet_8\NN\7560652|of|a|free (r_nmod) effects_5\NNS\13245626|the|diet|,|mice (l_nmod) mice_25\NNS\2329401|in|female|nmri|hepatitis (l_nmod) hepatitis_28\NN\14127211|with|aap
D009243_D056486 NONE nad_33\NN\14800277|of|enzyme|substrate (r_nmod) depletion_27\NN\351638|by|dietary|nad (r_conj) inhibition_19\NN\1068773|by|end-product|parp|naa|or|depletion (r_nmod) reduced_16\VBN\441445|that|hepatitis|can|either|be|inhibition (l_nsubjpass) hepatitis_7\NN\14127211|the|aap-induced|and|exacerbation
D000082_D056486 CID acetaminophen_7\NN\2707683| (r_compound) hepatotoxicity_8\NN\1740|on|acetaminophen|mice
D000082_D056486 CID acetaminophen_29\NN\2707683| (r_compound) (aap)-hepatitis_30\NN\1740|from|acetaminophen
D000082_D056486 CID acetaminophen_29\NN\2707683| (r_compound) (aap)-hepatitis_30\NN\1740|from|acetaminophen (r_nmod) suffering_27\VBG\2110220|(aap)-hepatitis (r_acl) mice_26\NNS\2329401|on|suffering (r_nmod) effects_6\NNS\13245626|the|hepatoprotective|amide|mice (r_dobj) demonstrated_3\VBD\2137132|recently|,|we|effects|,|suggesting|. (l_advcl) suggesting_32\VBG\1010118|involves (l_ccomp) involves_38\VBZ\2676054|that|injury|step (l_nsubj) injury_37\NN\14052046|the|aap-induced|liver
D000082_D056486 CID (aap)-hepatitis_30\NN\1740|from|acetaminophen
D000082_D056486 CID (aap)-hepatitis_30\NN\1740|from|acetaminophen (r_nmod) suffering_27\VBG\2110220|(aap)-hepatitis (r_acl) mice_26\NNS\2329401|on|suffering (r_nmod) effects_6\NNS\13245626|the|hepatoprotective|amide|mice (r_dobj) demonstrated_3\VBD\2137132|recently|,|we|effects|,|suggesting|. (l_advcl) suggesting_32\VBG\1010118|involves (l_ccomp) involves_38\VBZ\2676054|that|injury|step (l_nsubj) injury_37\NN\14052046|the|aap-induced|liver
D000082_D056486 CID aap-induced_35\JJ\1740| (r_amod) injury_37\NN\14052046|the|aap-induced|liver (r_nsubj) involves_38\VBZ\2676054|that|injury|step (r_ccomp) suggesting_32\VBG\1010118|involves (r_advcl) demonstrated_3\VBD\2137132|recently|,|we|effects|,|suggesting|. (l_dobj) effects_6\NNS\13245626|the|hepatoprotective|amide|mice (l_nmod) mice_26\NNS\2329401|on|suffering (l_acl) suffering_27\VBG\2110220|(aap)-hepatitis (l_nmod) (aap)-hepatitis_30\NN\1740|from|acetaminophen
D000082_D056486 CID aap-induced_35\JJ\1740| (r_amod) injury_37\NN\14052046|the|aap-induced|liver
D000082_D056486 CID aap_27\NN\1740| (r_compound) hepatitis_28\NN\14127211|with|aap
D000082_D056486 CID aap_17\NN\1740|presence|of (r_dobj) measured_12\VBN\697589|animals|,|increases|were|aap|,|and|inhibited (l_conj) inhibited_37\VBN\2510337|exacerbation|,|damage|was|%|ethanol|. (l_nsubjpass) damage_35\NN\7296428|the|liver
D000082_D056486 CID ethanol/aap-mice_15\NN\1740|to (r_nmod) given_13\VBN\2327200|when|naa|was|ethanol/aap-mice (r_advcl) observed_8\VBN\2163746|reduction|was|,|given|. (l_nsubjpass) reduction_4\NN\351485|a|further|%|hepatitis (l_nmod) hepatitis_6\NN\14127211|of
D000082_D056486 CID aap-induced_6\JJ\1740| (r_amod) hepatitis_7\NN\14127211|the|aap-induced|and|exacerbation
D000082_D056486 CID acetaminophen_16\NN\2707683|of (r_nmod) preparations_14\NNS\407535|in|pharmaceutical|acetaminophen (r_nmod) use_11\NN\407535|for|the|combinational|preparations (r_nmod) as_7\IN\14622893|use (r_prep) see_1\VBP\2106506|we|application|as|order|avoid|. (l_xcomp) avoid_20\VB\2452885|to|damage (l_dobj) damage_22\NN\7296428|hepatic|patients
D009536_D056486 NONE amide_10\NN\14727670|of|nicotinic|acid|,|inhibitor (r_nmod) effects_6\NNS\13245626|the|hepatoprotective|amide|mice (l_nmod) mice_26\NNS\2329401|on|suffering (l_acl) suffering_27\VBG\2110220|(aap)-hepatitis (l_nmod) (aap)-hepatitis_30\NN\1740|from|acetaminophen
D009536_D056486 NONE amide_10\NN\14727670|of|nicotinic|acid|,|inhibitor (r_nmod) effects_6\NNS\13245626|the|hepatoprotective|amide|mice (r_dobj) demonstrated_3\VBD\2137132|recently|,|we|effects|,|suggesting|. (l_advcl) suggesting_32\VBG\1010118|involves (l_ccomp) involves_38\VBZ\2676054|that|injury|step (l_nsubj) injury_37\NN\14052046|the|aap-induced|liver
D009536_D056486 NONE naa_11\NN\1740| (r_nsubjpass) given_13\VBN\2327200|when|naa|was|ethanol/aap-mice (r_advcl) observed_8\VBN\2163746|reduction|was|,|given|. (l_nsubjpass) reduction_4\NN\351485|a|further|%|hepatitis (l_nmod) hepatitis_6\NN\14127211|of
D009536_D056486 NONE naa_23\NN\1740|by (r_nmod) inhibition_19\NN\1068773|by|end-product|parp|naa|or|depletion (r_nmod) reduced_16\VBN\441445|that|hepatitis|can|either|be|inhibition (l_nsubjpass) hepatitis_7\NN\14127211|the|aap-induced|and|exacerbation
D009536_D056486 NONE naa_6\NN\1740|of (r_nmod) application_4\NN\947128|the|main|naa (r_dobj) see_1\VBP\2106506|we|application|as|order|avoid|. (l_xcomp) avoid_20\VB\2452885|to|damage (l_dobj) damage_22\NN\7296428|hepatic|patients
D011064_D056486 NONE )_17\-RRB-\1740| (r_punct) polymerase_18\NN\14732946|of|poly(adp-ribose|)|parp (r_nmod) inhibitor_14\NN\20090|a|selective|polymerase (r_appos) amide_10\NN\14727670|of|nicotinic|acid|,|inhibitor (r_nmod) effects_6\NNS\13245626|the|hepatoprotective|amide|mice (l_nmod) mice_26\NNS\2329401|on|suffering (l_acl) suffering_27\VBG\2110220|(aap)-hepatitis (l_nmod) (aap)-hepatitis_30\NN\1740|from|acetaminophen
D011064_D056486 NONE )_17\-RRB-\1740| (r_punct) polymerase_18\NN\14732946|of|poly(adp-ribose|)|parp (r_nmod) inhibitor_14\NN\20090|a|selective|polymerase (r_appos) amide_10\NN\14727670|of|nicotinic|acid|,|inhibitor (r_nmod) effects_6\NNS\13245626|the|hepatoprotective|amide|mice (r_dobj) demonstrated_3\VBD\2137132|recently|,|we|effects|,|suggesting|. (l_advcl) suggesting_32\VBG\1010118|involves (l_ccomp) involves_38\VBZ\2676054|that|injury|step (l_nsubj) injury_37\NN\14052046|the|aap-induced|liver
D000431_D056486 CID ethanol_35\NN\14708720| (r_compound) consumption_36\NN\13440063|of|simultaneous|ethanol|animals (r_nmod) influence_32\NN\5190804|the|consumption (r_dobj) evaluates_30\VBZ\670261|influence (r_conj) investigates_3\VBZ\644583|study|effects|and|evaluates|. (l_dobj) effects_5\NNS\13245626|the|diet|,|mice (l_nmod) mice_25\NNS\2329401|in|female|nmri|hepatitis (l_nmod) hepatitis_28\NN\14127211|with|aap
D000431_D056486 CID ethanol_25\NN\14708720|by|mice (r_nmod) caused_23\VBN\1617192|ethanol (r_acl) exacerbation_22\NN\374224|unlike|the|caused (r_nmod) inhibited_37\VBN\2510337|exacerbation|,|damage|was|%|ethanol|. (l_nsubjpass) damage_35\NN\7296428|the|liver
D000431_D056486 CID ethanol_42\NN\14708720|by (r_nmod) inhibited_37\VBN\2510337|exacerbation|,|damage|was|%|ethanol|. (l_nsubjpass) damage_35\NN\7296428|the|liver
D000431_D056486 CID ethanol/aap-mice_15\NN\1740|to (r_nmod) given_13\VBN\2327200|when|naa|was|ethanol/aap-mice (r_advcl) observed_8\VBN\2163746|reduction|was|,|given|. (l_nsubjpass) reduction_4\NN\351485|a|further|%|hepatitis (l_nmod) hepatitis_6\NN\14127211|of
D000431_D056486 CID ethanol_12\NN\14708720|by (r_nmod) exacerbation_10\NN\374224|its|ethanol (r_conj) hepatitis_7\NN\14127211|the|aap-induced|and|exacerbation
D018698_D056486 NONE glutamate-oxaloacetate_8\NN\1740| (r_compound) transaminase_9\NN\15077571|of|glutamate-oxaloacetate|got|and|transaminase (r_nmod) activities_6\NNS\30358|as|serum|transaminase (r_nmod) quantified_3\VBN\947077|injuries|were|activities|. (l_nsubjpass) injuries_1\NNS\14052046|liver
D018698_D056486 NONE glutamate-pyruvate_14\NN\1740| (r_compound) transaminase_15\NN\15077571|glutamate-pyruvate|gpt (r_conj) transaminase_9\NN\15077571|of|glutamate-oxaloacetate|got|and|transaminase (r_nmod) activities_6\NNS\30358|as|serum|transaminase (r_nmod) quantified_3\VBN\947077|injuries|were|activities|. (l_nsubjpass) injuries_1\NNS\14052046|liver
D062907_D056486 NONE glutamate-oxaloacetate_8\NN\1740| (r_compound) transaminase_9\NN\15077571|of|glutamate-oxaloacetate|got|and|transaminase (r_nmod) activities_6\NNS\30358|as|serum|transaminase (r_nmod) quantified_3\VBN\947077|injuries|were|activities|. (l_nsubjpass) injuries_1\NNS\14052046|liver
D019289_D056486 NONE glutamate-pyruvate_14\NN\1740| (r_compound) transaminase_15\NN\15077571|glutamate-pyruvate|gpt (r_conj) transaminase_9\NN\15077571|of|glutamate-oxaloacetate|got|and|transaminase (r_nmod) activities_6\NNS\30358|as|serum|transaminase (r_nmod) quantified_3\VBN\947077|injuries|were|activities|. (l_nsubjpass) injuries_1\NNS\14052046|liver
8988571
D003042_D003693 CID cocaine_4\NN\3492717| (r_compound) use_5\NN\407535|following|cocaine (r_nmod) delirium_2\NN\14391660|fatal|excited|use
D003042_D003693 CID cocaine_15\NN\3492717| (r_compound) toxicity_16\NN\13576101|of|cocaine (r_nmod) mechanisms_13\NNS\13446390|for|toxicity (r_nmod) evidence_11\NN\5816287|new|mechanisms (r_dobj) provide_9\VBP\2199590|delirium|:|findings|evidence|. (l_nsubj) delirium_2\NN\14391660|fatal|excited|use
D003042_D003693 CID cocaine-induced_7\JJ\1740| (r_amod) delirium_9\NN\14391660|from|cocaine-induced|excited|edds
D003042_D003693 CID cocaine-induced_7\JJ\1740| (r_amod) delirium_9\NN\14391660|from|cocaine-induced|excited|edds (l_appos) edds_11\NN\6702458|(|)
D003042_D003693 CID cocaine-related_5\JJ\1740| (r_amod) deaths_6\NNS\7296428|of|all|cocaine-related|county (r_nmod) registry_2\NN\6502378|from|a|deaths|,|1969 (r_nmod) compared_21\VBN\644583|registry|,|edds|were|victims|. (l_nsubjpass) edds_19\NNS\6702458|58
D003042_D003693 CID cocaine-related_5\JJ\1740| (r_amod) deaths_6\NNS\7296428|of|all|cocaine-related|county (r_nmod) registry_2\NN\6502378|from|a|deaths|,|1969 (r_nmod) compared_21\VBN\644583|registry|,|edds|were|victims|. (l_nmod) victims_24\NNS\9630641|with|125|overdose (l_nmod) overdose_28\NN\1740|of|accidental|cocaine|delirium (l_nmod) delirium_31\NN\14391660|without|excited
D003042_D003693 CID cocaine_27\NN\3492717| (r_compound) overdose_28\NN\1740|of|accidental|cocaine|delirium (r_nmod) victims_24\NNS\9630641|with|125|overdose (r_nmod) compared_21\VBN\644583|registry|,|edds|were|victims|. (l_nsubjpass) edds_19\NNS\6702458|58
D003042_D003693 CID cocaine_27\NN\3492717| (r_compound) overdose_28\NN\1740|of|accidental|cocaine|delirium (l_nmod) delirium_31\NN\14391660|without|excited
D003042_D003693 CID cocaine_4\NN\3492717|of|and|benzoylecgonine (r_nmod) concentrations_2\NNS\4916342|cocaine|blood|similar (r_dobj) had_1\VBD\2108377|edds|concentrations|. (l_nsubj) edds_0\NNS\6702458|
D003042_D003693 CID cocaine_11\NN\3492717| (r_compound) use_12\NN\407535|chronic|cocaine (r_nsubj) disrupts_13\VBZ\362348|that|use|function|and|,|precipitate (l_conj) precipitate_26\VB\1642924|coupled|,|may|agitation (l_dobj) agitation_27\NN\14373582|,|delirium (l_conj) delirium_29\NN\14391660|,|thermoregulation
D003042_D003693 CID cocaine_22\NN\3492717| (r_compound) use_23\NN\407535|with|recent|cocaine (r_nmod) coupled_19\VBN\1295275|when|use (r_advcl) precipitate_26\VB\1642924|coupled|,|may|agitation (l_dobj) agitation_27\NN\14373582|,|delirium (l_conj) delirium_29\NN\14391660|,|thermoregulation
D003042_D064420 NONE cocaine_4\NN\3492717| (r_compound) use_5\NN\407535|following|cocaine (r_nmod) delirium_2\NN\14391660|fatal|excited|use (r_nsubj) provide_9\VBP\2199590|delirium|:|findings|evidence|. (l_dobj) evidence_11\NN\5816287|new|mechanisms (l_nmod) mechanisms_13\NNS\13446390|for|toxicity (l_nmod) toxicity_16\NN\13576101|of|cocaine
D003042_D064420 NONE cocaine_15\NN\3492717| (r_compound) toxicity_16\NN\13576101|of|cocaine
D003042_D062787 NONE cocaine-related_5\JJ\1740| (r_amod) deaths_6\NNS\7296428|of|all|cocaine-related|county (r_nmod) registry_2\NN\6502378|from|a|deaths|,|1969 (r_nmod) compared_21\VBN\644583|registry|,|edds|were|victims|. (l_nmod) victims_24\NNS\9630641|with|125|overdose (l_nmod) overdose_28\NN\1740|of|accidental|cocaine|delirium
D003042_D062787 NONE cocaine_27\NN\3492717| (r_compound) overdose_28\NN\1740|of|accidental|cocaine|delirium
C005618_D003693 NONE benzoylecgonine_6\NN\1740| (r_conj) cocaine_4\NN\3492717|of|and|benzoylecgonine (r_nmod) concentrations_2\NNS\4916342|cocaine|blood|similar (r_dobj) had_1\VBD\2108377|edds|concentrations|. (l_nsubj) edds_0\NNS\6702458|
D003042_D011595 NONE cocaine_11\NN\3492717| (r_compound) use_12\NN\407535|chronic|cocaine (r_nsubj) disrupts_13\VBZ\362348|that|use|function|and|,|precipitate (l_conj) precipitate_26\VB\1642924|coupled|,|may|agitation (l_dobj) agitation_27\NN\14373582|,|delirium
D003042_D011595 NONE cocaine_22\NN\3492717| (r_compound) use_23\NN\407535|with|recent|cocaine (r_nmod) coupled_19\VBN\1295275|when|use (r_advcl) precipitate_26\VB\1642924|coupled|,|may|agitation (l_dobj) agitation_27\NN\14373582|,|delirium
D003042_D012206 CID cocaine_11\NN\3492717| (r_compound) use_12\NN\407535|chronic|cocaine (r_nsubj) disrupts_13\VBZ\362348|that|use|function|and|,|precipitate (l_conj) precipitate_26\VB\1642924|coupled|,|may|agitation (l_dobj) agitation_27\NN\14373582|,|delirium (l_conj) delirium_29\NN\14391660|,|thermoregulation (l_conj) thermoregulation_32\NN\1740|aberrant|,|rhabdomyolysis|and|death (l_conj) rhabdomyolysis_34\NN\1740|,
D003042_D012206 CID cocaine_22\NN\3492717| (r_compound) use_23\NN\407535|with|recent|cocaine (r_nmod) coupled_19\VBN\1295275|when|use (r_advcl) precipitate_26\VB\1642924|coupled|,|may|agitation (l_dobj) agitation_27\NN\14373582|,|delirium (l_conj) delirium_29\NN\14391660|,|thermoregulation (l_conj) thermoregulation_32\NN\1740|aberrant|,|rhabdomyolysis|and|death (l_conj) rhabdomyolysis_34\NN\1740|,
D003042_D003645 CID cocaine_11\NN\3492717| (r_compound) use_12\NN\407535|chronic|cocaine (r_nsubj) disrupts_13\VBZ\362348|that|use|function|and|,|precipitate (l_conj) precipitate_26\VB\1642924|coupled|,|may|agitation (l_dobj) agitation_27\NN\14373582|,|delirium (l_conj) delirium_29\NN\14391660|,|thermoregulation (l_conj) thermoregulation_32\NN\1740|aberrant|,|rhabdomyolysis|and|death (l_conj) death_38\NN\7296428|sudden
D003042_D003645 CID cocaine_22\NN\3492717| (r_compound) use_23\NN\407535|with|recent|cocaine (r_nmod) coupled_19\VBN\1295275|when|use (r_advcl) precipitate_26\VB\1642924|coupled|,|may|agitation (l_dobj) agitation_27\NN\14373582|,|delirium (l_conj) delirium_29\NN\14391660|,|thermoregulation (l_conj) thermoregulation_32\NN\1740|aberrant|,|rhabdomyolysis|and|death (l_conj) death_38\NN\7296428|sudden
2893236
D005680_D012133 NONE gaba_0\NN\14601829| (r_compound) involvement_1\NN\1080366|gaba|reversal|. (l_nmod) reversal_5\NN\199130|in|induced|paralysis (l_nmod) paralysis_8\NN\14557898|of|respiratory|produced
D005680_D012133 NONE gaba_13\NN\14601829| (r_conj) glutamate_11\NN\15010703|and|gaba (r_conj) paralysis_9\NN\14557898|respiratory|,|glutamate
D005680_D012133 NONE gaba_12\NN\14601829| (r_dobj) involves_11\VBZ\2676054|gaba|action (r_conj) reverses_4\VBZ\109660|naloxone|paralysis|and|involves (l_dobj) paralysis_6\NN\14557898|respiratory|produced
D009270_D012133 NONE naloxone_3\NN\3808977| (r_nmod:npmod) induced_4\JJ\1740|naloxone (r_amod) reversal_5\NN\199130|in|induced|paralysis (l_nmod) paralysis_8\NN\14557898|of|respiratory|produced
D009270_D012133 NONE naloxone_3\NN\3808977| (r_nsubj) reversed_4\VBD\109660|study|naloxone|paralysis|. (l_dobj) paralysis_6\NN\14557898|respiratory|induced
D009270_D012133 NONE naloxone_0\NN\3808977|mg/kg (r_nsubj) reversed_7\VBD\109660|naloxone|paralysis|levels|values|changes|. (l_dobj) paralysis_9\NN\14557898|respiratory|,|glutamate
D009270_D012133 NONE naloxone_3\NN\3808977| (r_nsubj) reverses_4\VBZ\109660|naloxone|paralysis|and|involves (l_dobj) paralysis_6\NN\14557898|respiratory|produced
D013874_D012133 CID thiopental_11\NN\2792049|by (r_nmod) produced_9\VBN\1617192|thiopental (r_acl) paralysis_8\NN\14557898|of|respiratory|produced
D013874_D012133 CID thiopental_9\NN\2792049|by (r_nmod) induced_7\VBN\1627355|thiopental|rats (r_acl) paralysis_6\NN\14557898|respiratory|induced
D013874_D012133 CID thiopental_9\NN\2792049|by (r_nmod) produced_7\VBN\1617192|thiopental (r_acl) paralysis_6\NN\14557898|respiratory|produced
D013874_D012131 NONE thiopental_4\NN\2792049|mg/kg|i.v. (r_nsubj) produced_5\VBD\1617192|thiopental|arrest|affecting|. (l_dobj) arrest_7\NN\88481|respiratory|increase
D005680_D012131 NONE gaba_12\NN\14601829|in (r_nmod) increase_10\NN\13576355|with|further|gaba|and|decrease|again|cortex (r_nmod) arrest_7\NN\88481|respiratory|increase
D018698_D012131 NONE glutamate_16\NN\15010703|in (r_nmod) decrease_14\NN\7296428|glutamate (r_conj) increase_10\NN\13576355|with|further|gaba|and|decrease|again|cortex (r_nmod) arrest_7\NN\88481|respiratory|increase
D000596_D012131 NONE acids_29\NNS\14818238|of|the|amino|studied (r_nmod) any_25\DT\1740|acids (r_dobj) affecting_24\VBG\126264|without|any (r_advcl) produced_5\VBD\1617192|thiopental|arrest|affecting|. (l_dobj) arrest_7\NN\88481|respiratory|increase
D018698_D012133 NONE glutamate_11\NN\15010703|and|gaba (r_conj) paralysis_9\NN\14557898|respiratory|,|glutamate
20683499
C029036_D000544 NONE crocin_9\NN\1740| (r_appos) constituents_3\NNS\3892891|of|active|l.|,|crocin (r_nmod) effects_0\NNS\13245626|constituents|model|. (l_nmod) model_12\NN\5888929|on|streptozocin-induced|disease|rats (l_nmod) disease_17\NN\14061805|of|alzheimer|'s
C029036_D000544 NONE crocins_8\NNS\1740|of (r_nmod) effect_6\NN\34213|the|crocins|disease (l_nmod) disease_13\NN\14061805|on|alzheimer|'s|induced
C029036_D000544 NONE crocin_10\NN\1740|of|mg/kg (r_nmod) effectiveness_8\NN\5190804|the|crocin|antagonizing|and|potential (l_conj) potential_27\NN\14481929|its|treatment (l_nmod) treatment_30\NN\654885|in|the|diseases (l_nmod) diseases_33\NNS\14061805|of|neurodegenerative|disease (l_nmod) disease_38\NN\14061805|such|alzheimer|'s
D013311_D000544 CID streptozocin-induced_11\JJ\1740| (r_amod) model_12\NN\5888929|on|streptozocin-induced|disease|rats (l_nmod) disease_17\NN\14061805|of|alzheimer|'s
D013311_D000544 CID streptozocin_20\NN\1740|by|intracerebroventricular|stz|rats (r_nmod) induced_14\VBN\1627355|streptozocin (r_acl) disease_13\NN\14061805|on|alzheimer|'s|induced
D013311_D000544 CID stz_22\NN\1740|(|) (r_appos) streptozocin_20\NN\1740|by|intracerebroventricular|stz|rats (r_nmod) induced_14\VBN\1627355|streptozocin (r_acl) disease_13\NN\14061805|on|alzheimer|'s|induced
D013311_D000544 CID stz-icv_10\NN\1740|with (r_nmod) injected_8\VBN\81072|groups|,|rats|were|stz-icv|bilaterally|mg/kg|day|and|later (l_nmod) groups_4\NNS\2137|in|alzheimer|disease (l_compound) disease_3\NN\14061805|'s
D013311_D000544 CID stz-icv_26\NN\1740| (r_compound) application_27\NN\947128|a|similar|stz-icv (r_nsubjpass) repeated_29\VBN\952524|injected|,|application|was|. (l_ccomp) injected_8\VBN\81072|groups|,|rats|were|stz-icv|bilaterally|mg/kg|day|and|later (l_nmod) groups_4\NNS\2137|in|alzheimer|disease (l_compound) disease_3\NN\14061805|'s
D013311_D000544 CID stz-icv_22\NN\1740|by|rats (r_nmod) caused_20\VBN\1617192|stz-icv (r_acl) deficits_19\NNS\5113133|the|cognitive|caused (r_dobj) antagonizing_16\VBG\1787955|in|deficits (r_advcl) effectiveness_8\NN\5190804|the|crocin|antagonizing|and|potential (l_conj) potential_27\NN\14481929|its|treatment (l_nmod) treatment_30\NN\654885|in|the|diseases (l_nmod) diseases_33\NNS\14061805|of|neurodegenerative|disease (l_nmod) disease_38\NN\14061805|such|alzheimer|'s
C029036_D007859 NONE crocin_3\NN\1740|dose (r_nsubj) attenuated_10\VB\224901|addition|,|crocin|could|significantly|impairment|test|. (l_dobj) impairment_14\NN\7296428|learning|group
C029036_D008569 NONE crocin_3\NN\1740|dose (r_nsubj) attenuated_10\VB\224901|addition|,|crocin|could|significantly|impairment|test|. (l_dobj) impairment_14\NN\7296428|learning|group
D013311_D007859 NONE stz-injected_17\JJ\1740| (r_amod) group_18\NN\2137|in|treated|stz-injected (r_nmod) impairment_14\NN\7296428|learning|group
D013311_D008569 NONE stz-injected_17\JJ\1740| (r_amod) group_18\NN\2137|in|treated|stz-injected (r_nmod) impairment_14\NN\7296428|learning|group
C029036_D003072 NONE crocin_10\NN\1740|of|mg/kg (r_nmod) effectiveness_8\NN\5190804|the|crocin|antagonizing|and|potential (l_advcl) antagonizing_16\VBG\1787955|in|deficits (l_dobj) deficits_19\NNS\5113133|the|cognitive|caused
C029036_D019636 NONE crocin_10\NN\1740|of|mg/kg (r_nmod) effectiveness_8\NN\5190804|the|crocin|antagonizing|and|potential (l_conj) potential_27\NN\14481929|its|treatment (l_nmod) treatment_30\NN\654885|in|the|diseases (l_nmod) diseases_33\NNS\14061805|of|neurodegenerative|disease
D013311_D003072 CID stz-icv_22\NN\1740|by|rats (r_nmod) caused_20\VBN\1617192|stz-icv (r_acl) deficits_19\NNS\5113133|the|cognitive|caused
D013311_D019636 NONE stz-icv_22\NN\1740|by|rats (r_nmod) caused_20\VBN\1617192|stz-icv (r_acl) deficits_19\NNS\5113133|the|cognitive|caused (r_dobj) antagonizing_16\VBG\1787955|in|deficits (r_advcl) effectiveness_8\NN\5190804|the|crocin|antagonizing|and|potential (l_conj) potential_27\NN\14481929|its|treatment (l_nmod) treatment_30\NN\654885|in|the|diseases (l_nmod) diseases_33\NNS\14061805|of|neurodegenerative|disease
15517007
D003520_D006331 CID cyclophosphamide_6\NN\1740|or|anthracyclines (r_nsubjpass) used_13\VBN\1156834|when|cyclophosphamide|are|patients (l_nmod) patients_15\NNS\9898892|in|damage|,|patients (l_nmod) damage_21\NN\7296428|with|a|possible|underlying|heart
D003520_D012595 NONE cyclophosphamide_6\NN\1740|or|anthracyclines (r_nsubjpass) used_13\VBN\1156834|when|cyclophosphamide|are|patients (l_nmod) patients_15\NNS\9898892|in|damage|,|patients (l_appos) patients_28\NNS\9898892|example|,|sclerosis (l_compound) sclerosis_27\NN\14204950|systemic
D018943_D006331 NONE anthracyclines_8\NNS\1740|mitoxantrone (r_conj) cyclophosphamide_6\NN\1740|or|anthracyclines (r_nsubjpass) used_13\VBN\1156834|when|cyclophosphamide|are|patients (l_nmod) patients_15\NNS\9898892|in|damage|,|patients (l_nmod) damage_21\NN\7296428|with|a|possible|underlying|heart
D018943_D012595 NONE anthracyclines_8\NNS\1740|mitoxantrone (r_conj) cyclophosphamide_6\NN\1740|or|anthracyclines (r_nsubjpass) used_13\VBN\1156834|when|cyclophosphamide|are|patients (l_nmod) patients_15\NNS\9898892|in|damage|,|patients (l_appos) patients_28\NNS\9898892|example|,|sclerosis (l_compound) sclerosis_27\NN\14204950|systemic
D008942_D006331 CID mitoxantrone_11\NN\1740|such (r_nmod) anthracyclines_8\NNS\1740|mitoxantrone (r_conj) cyclophosphamide_6\NN\1740|or|anthracyclines (r_nsubjpass) used_13\VBN\1156834|when|cyclophosphamide|are|patients (l_nmod) patients_15\NNS\9898892|in|damage|,|patients (l_nmod) damage_21\NN\7296428|with|a|possible|underlying|heart
D008942_D012595 NONE mitoxantrone_11\NN\1740|such (r_nmod) anthracyclines_8\NNS\1740|mitoxantrone (r_conj) cyclophosphamide_6\NN\1740|or|anthracyclines (r_nsubjpass) used_13\VBN\1156834|when|cyclophosphamide|are|patients (l_nmod) patients_15\NNS\9898892|in|damage|,|patients (l_appos) patients_28\NNS\9898892|example|,|sclerosis (l_compound) sclerosis_27\NN\14204950|systemic
8305357
D003630_D012514 NONE daunorubicin_1\NN\1740|liposomal|sarcoma|: (l_nmod) sarcoma_6\NN\14239918|in|advanced|kaposi|'s
D003630_D012514 NONE daunorubicin_16\NN\1740|of|liposomal|daunoxome (r_nmod) efficacy_11\NN\5199286|the|and|safety|daunorubicin|treatment (l_nmod) treatment_22\NN\654885|in|the|sarcoma (l_nmod) sarcoma_28\NN\14239918|of|related|kaposi|'s
D003630_D012514 NONE daunorubicin_7\NN\1740|liposomal (r_nsubj) agent_14\NN\7347|sample|,|daunorubicin|was|an|effective|treatment|. (l_nmod) treatment_17\NN\654885|in|the|sarcoma (l_nmod) sarcoma_21\NN\14239918|of|kaposi
D003630_D000163 NONE daunorubicin_16\NN\1740|of|liposomal|daunoxome (r_nmod) efficacy_11\NN\5199286|the|and|safety|daunorubicin|treatment (l_nmod) treatment_22\NN\654885|in|the|sarcoma (l_nmod) sarcoma_28\NN\14239918|of|related|kaposi|'s (l_amod) related_25\JJ\1740|aids (l_nmod:npmod) aids_24\NN\13974317|
3952818
D005472_D066126 NONE 5-fluorouracil_3\NN\1740|of (r_nmod) toxicity_1\NN\13576101|cardiac|5-fluorouracil|.
D005472_D066126 NONE 5-fu_14\NN\1740|due (r_nmod) cardiotoxicity_11\NN\1740|of|5-fu
D005472_D066126 NONE 5-fu_14\NN\1740|due (r_nmod) cardiotoxicity_11\NN\1740|of|5-fu (r_nmod) cause_9\NN\7323922|that|spasm|may|be|the|cardiotoxicity|,|and|used (l_conj) used_23\VBN\1156834|that|antagonists|may|probably|be|prevention (l_nmod) prevention_26\NN\1073995|in|the|or|treatment|cardiotoxicity (l_nmod) cardiotoxicity_31\NN\1740|of|5-fu
D005472_D066126 NONE 5-fu_30\NN\1740| (r_compound) cardiotoxicity_31\NN\1740|of|5-fu (r_nmod) prevention_26\NN\1073995|in|the|or|treatment|cardiotoxicity (r_nmod) used_23\VBN\1156834|that|antagonists|may|probably|be|prevention (r_conj) cause_9\NN\7323922|that|spasm|may|be|the|cardiotoxicity|,|and|used (l_nmod) cardiotoxicity_11\NN\1740|of|5-fu
D005472_D066126 NONE 5-fu_30\NN\1740| (r_compound) cardiotoxicity_31\NN\1740|of|5-fu
D005472_D003110 NONE 5-fluorouracil_18\NN\1740|5-fu (r_compound) administration_22\NN\1133281|after|5-fluorouracil (r_nmod) presented_14\VBD\2137132|who|pain|administration (r_acl:relcl) patient_6\NN\9898892|of|a|carcinoma|presented (l_nmod) carcinoma_9\NN\14239918|with|colon|and|metastasis
D005472_D003110 NONE 5-fu_20\NN\1740|(|) (r_appos) 5-fluorouracil_18\NN\1740|5-fu (r_compound) administration_22\NN\1133281|after|5-fluorouracil (r_nmod) presented_14\VBD\2137132|who|pain|administration (r_acl:relcl) patient_6\NN\9898892|of|a|carcinoma|presented (l_nmod) carcinoma_9\NN\14239918|with|colon|and|metastasis
D005472_D009362 NONE 5-fluorouracil_18\NN\1740|5-fu (r_compound) administration_22\NN\1133281|after|5-fluorouracil (r_nmod) presented_14\VBD\2137132|who|pain|administration (r_acl:relcl) patient_6\NN\9898892|of|a|carcinoma|presented (l_nmod) carcinoma_9\NN\14239918|with|colon|and|metastasis (l_conj) metastasis_12\NN\13533470|liver
D005472_D009362 NONE 5-fu_20\NN\1740|(|) (r_appos) 5-fluorouracil_18\NN\1740|5-fu (r_compound) administration_22\NN\1133281|after|5-fluorouracil (r_nmod) presented_14\VBD\2137132|who|pain|administration (r_acl:relcl) patient_6\NN\9898892|of|a|carcinoma|presented (l_nmod) carcinoma_9\NN\14239918|with|colon|and|metastasis (l_conj) metastasis_12\NN\13533470|liver
D005472_D002637 CID 5-fluorouracil_18\NN\1740|5-fu (r_compound) administration_22\NN\1133281|after|5-fluorouracil (r_nmod) presented_14\VBD\2137132|who|pain|administration (l_dobj) pain_16\NN\14299637|chest
D005472_D002637 CID 5-fu_20\NN\1740|(|) (r_appos) 5-fluorouracil_18\NN\1740|5-fu (r_compound) administration_22\NN\1133281|after|5-fluorouracil (r_nmod) presented_14\VBD\2137132|who|pain|administration (l_dobj) pain_16\NN\14299637|chest
D009543_D000788 NONE nifedipine_19\NN\2938514|with (r_nmod) resolved_17\VBD\352826|pain|promptly|nifedipine|. (r_conj) similar_4\JJ\1740|evolution|was|that|,|and|resolved (l_nmod) that_6\DT\1740|to|observed (l_acl) observed_7\VBN\2163746|angina (l_nmod) angina_11\NN\14171682|in|prinzmetal
D009543_D002637 NONE nifedipine_19\NN\2938514|with (r_nmod) resolved_17\VBD\352826|pain|promptly|nifedipine|. (l_nsubj) pain_15\NN\14299637|chest
D005472_D003329 NONE 5-fu_14\NN\1740|due (r_nmod) cardiotoxicity_11\NN\1740|of|5-fu (r_nmod) cause_9\NN\7323922|that|spasm|may|be|the|cardiotoxicity|,|and|used (l_nsubj) spasm_5\NN\14299637|coronary
D005472_D003329 NONE 5-fu_30\NN\1740| (r_compound) cardiotoxicity_31\NN\1740|of|5-fu (r_nmod) prevention_26\NN\1073995|in|the|or|treatment|cardiotoxicity (r_nmod) used_23\VBN\1156834|that|antagonists|may|probably|be|prevention (r_conj) cause_9\NN\7323922|that|spasm|may|be|the|cardiotoxicity|,|and|used (l_nsubj) spasm_5\NN\14299637|coronary
D002118_D003329 NONE calcium_18\NN\14625458| (r_compound) antagonists_19\NNS\7846|calcium (r_nsubjpass) used_23\VBN\1156834|that|antagonists|may|probably|be|prevention (r_conj) cause_9\NN\7323922|that|spasm|may|be|the|cardiotoxicity|,|and|used (l_nsubj) spasm_5\NN\14299637|coronary
D002118_D066126 NONE calcium_18\NN\14625458| (r_compound) antagonists_19\NNS\7846|calcium (r_nsubjpass) used_23\VBN\1156834|that|antagonists|may|probably|be|prevention (r_conj) cause_9\NN\7323922|that|spasm|may|be|the|cardiotoxicity|,|and|used (l_nmod) cardiotoxicity_11\NN\1740|of|5-fu
D002118_D066126 NONE calcium_18\NN\14625458| (r_compound) antagonists_19\NNS\7846|calcium (r_nsubjpass) used_23\VBN\1156834|that|antagonists|may|probably|be|prevention (l_nmod) prevention_26\NN\1073995|in|the|or|treatment|cardiotoxicity (l_nmod) cardiotoxicity_31\NN\1740|of|5-fu
16418614
D011441_D014657 CID ptu-associated_0\JJ\1740| (r_amod) vasculitis_1\NN\14336539|ptu-associated|girl|.
D011441_D014657 CID propylthiouracil_3\NN\14727670| (r_compound) (ptu)-associated_4\NN\1740|propylthiouracil (r_compound) vasculitis_5\NN\14336539|of|(ptu)-associated
D011441_D014657 CID (ptu)-associated_4\NN\1740|propylthiouracil (r_compound) vasculitis_5\NN\14336539|of|(ptu)-associated
D011441_D014657 CID ptu_36\NN\1740|of (r_nmod) withdrawal_34\NN\7206096|following|ptu (r_nmod) resolution_30\NN\6470073|the|observed|clinical|symptoms|withdrawal (r_conj) observation_9\NN\996969|by|features|,|and|resolution (r_nmod) made_7\VBN\126264|diagnosis|was|observation|. (l_nsubjpass) diagnosis_1\NN\152018|the|vasculitis (l_nmod) vasculitis_5\NN\14336539|of|(ptu)-associated
D011441_D014424 NONE ptu-associated_0\JJ\1740| (r_amod) vasculitis_1\NN\14336539|ptu-associated|girl|. (l_nmod) girl_4\NN\10787470|in|a|syndrome (l_nmod) syndrome_7\NN\5870365|with|turner|and|disease
D011441_D006111 NONE ptu-associated_0\JJ\1740| (r_amod) vasculitis_1\NN\14336539|ptu-associated|girl|. (l_nmod) girl_4\NN\10787470|in|a|syndrome (l_nmod) syndrome_7\NN\5870365|with|turner|and|disease (l_conj) disease_11\NN\14061805|graves
11208990
D009569_D007674 NONE oxide_3\NN\14818238|nitric (r_compound) production_4\NN\30358|of|oxide|and|apoptosis (r_nmod) association_0\NN\8008335|production|model|. (l_nmod) model_9\NN\5888929|in|a|nephropathy (l_nmod) nephropathy_12\NN\14573196|of|experimental
D009569_D009404 NONE no_6\NN\7204911|of (r_nmod) role_4\NN\719494|the|no|and|association|model (l_nmod) model_15\NN\5888929|in|an|experimental|syndrome (l_nmod) syndrome_18\NN\5870365|of|nephrotic|induced
D004317_D009404 CID adriamycin_25\NN\1740|of|adr (r_nmod) injection_23\NN\320852|by|a|single|adriamycin (r_nmod) induced_19\VBN\1627355|injection (r_acl) syndrome_18\NN\5870365|of|nephrotic|induced
D004317_D009404 CID adr_27\NN\1740|(|) (r_appos) adriamycin_25\NN\1740|of|adr (r_nmod) injection_23\NN\320852|by|a|single|adriamycin (r_nmod) induced_19\VBN\1627355|injection (r_acl) syndrome_18\NN\5870365|of|nephrotic|induced
D004317_D007674 NONE adr-induced_7\JJ\1740| (r_amod) nephropathy_8\NN\14573196|adr-induced
D004317_D007674 NONE adr-nephropathy_8\NN\1740|
D004317_D007674 NONE adr-nephropathy_13\JJ\1740|
D004317_D007674 NONE adr-nephropathy_4\NN\1740|
D004317_C537346 NONE adr_11\NN\1740|with (r_nmod) treated_9\VBN\2376958|adr (r_acl) rats_8\NNS\2329401|of|treated (r_nmod) kidneys_6\NNS\5333259|of|the|rats (r_nmod) examination_3\NN\633864|histopathological|kidneys (r_nsubj) revealed_12\VBD\2137132|results|examination|areas|. (l_dobj) areas_14\NNS\8630985|focal|proliferation|and|inflammation (l_nmod) proliferation_17\NN\13489037|of|mesangial
D004317_D009395 NONE adr_11\NN\1740|with (r_nmod) treated_9\VBN\2376958|adr (r_acl) rats_8\NNS\2329401|of|treated (r_nmod) kidneys_6\NNS\5333259|of|the|rats (r_nmod) examination_3\NN\633864|histopathological|kidneys (r_nsubj) revealed_12\VBD\2137132|results|examination|areas|. (l_dobj) areas_14\NNS\8630985|focal|proliferation|and|inflammation (l_conj) inflammation_21\NN\14299637|mild|tubulointerstitial
D009573_D007674 NONE nitrite_1\NN\14621446| (r_compound) levels_2\NNS\4916342|urine|nitrite (r_nsubjpass) increased_5\VBN\169651|levels|were|significantly|group|p|. (l_nmod) group_9\NN\2137|in|the|adr-nephropathy (l_compound) adr-nephropathy_8\NN\1740|
D010656_D007674 NONE phenylephrine_3\NN\2682038|and|acetylcholine (r_nmod:npmod) related_6\JJ\1740|phenylephrine (r_amod) responses_7\NNS\11410625|related (r_nsubj) impaired_10\JJ\1740|iprk|responses|were|significantly|group|. (l_nmod) group_14\NN\2137|in|the|adr-nephropathy (l_compound) adr-nephropathy_13\JJ\1740|
D000109_D007674 NONE acetylcholine_5\NN\14807558| (r_conj) phenylephrine_3\NN\2682038|and|acetylcholine (r_nmod:npmod) related_6\JJ\1740|phenylephrine (r_amod) responses_7\NNS\11410625|related (r_nsubj) impaired_10\JJ\1740|iprk|responses|were|significantly|group|. (l_nmod) group_14\NN\2137|in|the|adr-nephropathy (l_compound) adr-nephropathy_13\JJ\1740|
D009569_D009401 NONE no_7\NN\7204911|between|and|apoptosis (r_nmod) interactions_5\NNS\37396|no (r_nsubj) important_11\JJ\1740|that|interactions|are|pathogenesis (l_nmod) pathogenesis_14\NN\13533470|in|the|nephrosis (l_nmod) nephrosis_18\NN\14304060|of|the|adr-induced
D004317_D009401 NONE adr-induced_17\JJ\1740| (r_amod) nephrosis_18\NN\14304060|of|the|adr-induced
17786501
D004221_D009901 NONE disulfiram-induced_0\NN\1740| (r_compound) neuropathy_5\NN\14204950|disulfiram-induced|transient|optic|:|report
D004221_D009901 NONE disulfiram_15\NN\3740161|of (r_nmod) use_13\NN\407535|after|chronic|disulfiram|management (r_nmod) neuropathy_10\NN\14204950|of|optic|use
D004221_D010523 NONE disulfiram-induced_0\NN\1740| (r_compound) neuropathy_5\NN\14204950|disulfiram-induced|transient|optic|:|report
D004221_D010523 NONE disulfiram_15\NN\3740161|of (r_nmod) use_13\NN\407535|after|chronic|disulfiram|management (r_nmod) neuropathy_10\NN\14204950|of|optic|use
D004221_D000437 NONE disulfiram_15\NN\3740161|of (r_nmod) use_13\NN\407535|after|chronic|disulfiram|management (l_nmod) management_19\NN\1123598|for|dependence (l_compound) dependence_18\NN\24720|alcohol
D004221_D000437 NONE disulfiram_4\NN\3740161| (r_dobj) taking_3\VBG\2367363|he|had|been|disulfiram|dependence|years|. (l_nmod) dependence_7\NN\24720|for|alcohol
6127992
D014700_D017202 NONE verapamil_18\NN\2938514|with|and|drugs (r_nmod) therapy_16\NN\657604|during|combined|verapamil (r_nmod) developed_6\VBD\1753788|patients|failure|therapy|. (l_nsubj) patients_1\NNS\9898892|three|disease (l_nmod) disease_5\NN\14061805|with|ischaemic|heart
D014700_D006333 CID verapamil_18\NN\2938514|with|and|drugs (r_nmod) therapy_16\NN\657604|during|combined|verapamil (r_nmod) developed_6\VBD\1753788|patients|failure|therapy|. (l_dobj) failure_9\NN\66216|profound|cardiac|,|hypotension
D014700_D007022 CID verapamil_18\NN\2938514|with|and|drugs (r_nmod) therapy_16\NN\657604|during|combined|verapamil (r_nmod) developed_6\VBD\1753788|patients|failure|therapy|. (l_dobj) failure_9\NN\66216|profound|cardiac|,|hypotension (l_conj) hypotension_11\NN\14057371|and|bradycardia
D014700_D001919 CID verapamil_18\NN\2938514|with|and|drugs (r_nmod) therapy_16\NN\657604|during|combined|verapamil (r_nmod) developed_6\VBD\1753788|patients|failure|therapy|. (l_dobj) failure_9\NN\66216|profound|cardiac|,|hypotension (l_conj) hypotension_11\NN\14057371|and|bradycardia (l_conj) bradycardia_13\NN\14110674|
D000319_D017202 NONE drugs_22\NNS\14778436|beta-adrenergic|blocking (r_conj) verapamil_18\NN\2938514|with|and|drugs (r_nmod) therapy_16\NN\657604|during|combined|verapamil (r_nmod) developed_6\VBD\1753788|patients|failure|therapy|. (l_nsubj) patients_1\NNS\9898892|three|disease (l_nmod) disease_5\NN\14061805|with|ischaemic|heart
D000319_D006333 CID drugs_22\NNS\14778436|beta-adrenergic|blocking (r_conj) verapamil_18\NN\2938514|with|and|drugs (r_nmod) therapy_16\NN\657604|during|combined|verapamil (r_nmod) developed_6\VBD\1753788|patients|failure|therapy|. (l_dobj) failure_9\NN\66216|profound|cardiac|,|hypotension
D000319_D007022 CID drugs_22\NNS\14778436|beta-adrenergic|blocking (r_conj) verapamil_18\NN\2938514|with|and|drugs (r_nmod) therapy_16\NN\657604|during|combined|verapamil (r_nmod) developed_6\VBD\1753788|patients|failure|therapy|. (l_dobj) failure_9\NN\66216|profound|cardiac|,|hypotension (l_conj) hypotension_11\NN\14057371|and|bradycardia
D000319_D001919 CID drugs_22\NNS\14778436|beta-adrenergic|blocking (r_conj) verapamil_18\NN\2938514|with|and|drugs (r_nmod) therapy_16\NN\657604|during|combined|verapamil (r_nmod) developed_6\VBD\1753788|patients|failure|therapy|. (l_dobj) failure_9\NN\66216|profound|cardiac|,|hypotension (l_conj) hypotension_11\NN\14057371|and|bradycardia (l_conj) bradycardia_13\NN\14110674|
8492347
D005665_D013746 CID furosemide_6\NN\3214670|due|surreptitious (r_nmod) tetany_0\NN\14304060|and|rhabdomyolysis|furosemide
D005665_D012206 CID furosemide_6\NN\3214670|due|surreptitious (r_nmod) tetany_0\NN\14304060|and|rhabdomyolysis|furosemide (l_conj) rhabdomyolysis_2\NN\1740|
D008274_D013746 NONE magnesium_10\NN\14625458| (r_compound) supplementation_11\NN\5108947|of|magnesium (r_nmod) importance_8\NN\5138488|tetany|--|supplementation|. (l_compound) tetany_0\NN\14304060|and|rhabdomyolysis|furosemide
D008274_D012206 NONE magnesium_10\NN\14625458| (r_compound) supplementation_11\NN\5108947|of|magnesium (r_nmod) importance_8\NN\5138488|tetany|--|supplementation|. (l_compound) tetany_0\NN\14304060|and|rhabdomyolysis|furosemide (l_conj) rhabdomyolysis_2\NN\1740|
D011188_D007008 NONE potassium_23\NN\14625458|and|calcium (r_compound) supplementation_26\NN\5108947|by|potassium|alone|(|1,2 (r_nmod) corrected_21\VBN\138508|which|can|not|be|supplementation (r_acl:relcl) spasms_14\NNS\14299637|with|muscle|and|tetany|corrected (r_nmod) associated_11\VBN\628491|cause|,|hypomagnesemia|is|spasms|. (l_advcl) cause_4\VB\1617192|while|hypokalemia|may|weakness (l_nsubj) hypokalemia_2\NN\14299637|severe
D011188_D018908 NONE potassium_23\NN\14625458|and|calcium (r_compound) supplementation_26\NN\5108947|by|potassium|alone|(|1,2 (r_nmod) corrected_21\VBN\138508|which|can|not|be|supplementation (r_acl:relcl) spasms_14\NNS\14299637|with|muscle|and|tetany|corrected (r_nmod) associated_11\VBN\628491|cause|,|hypomagnesemia|is|spasms|. (l_advcl) cause_4\VB\1617192|while|hypokalemia|may|weakness (l_dobj) weakness_6\NN\14462666|muscle
D011188_C537153 NONE potassium_23\NN\14625458|and|calcium (r_compound) supplementation_26\NN\5108947|by|potassium|alone|(|1,2 (r_nmod) corrected_21\VBN\138508|which|can|not|be|supplementation (r_acl:relcl) spasms_14\NNS\14299637|with|muscle|and|tetany|corrected (r_nmod) associated_11\VBN\628491|cause|,|hypomagnesemia|is|spasms|. (l_nsubjpass) hypomagnesemia_9\NN\1740|severe
D011188_D013035 NONE potassium_23\NN\14625458|and|calcium (r_compound) supplementation_26\NN\5108947|by|potassium|alone|(|1,2 (r_nmod) corrected_21\VBN\138508|which|can|not|be|supplementation (r_acl:relcl) spasms_14\NNS\14299637|with|muscle|and|tetany|corrected
D011188_D013746 NONE potassium_23\NN\14625458|and|calcium (r_compound) supplementation_26\NN\5108947|by|potassium|alone|(|1,2 (r_nmod) corrected_21\VBN\138508|which|can|not|be|supplementation (r_acl:relcl) spasms_14\NNS\14299637|with|muscle|and|tetany|corrected (l_conj) tetany_16\NN\14304060|
D002118_D007008 NONE calcium_25\NN\14625458| (r_conj) potassium_23\NN\14625458|and|calcium (r_compound) supplementation_26\NN\5108947|by|potassium|alone|(|1,2 (r_nmod) corrected_21\VBN\138508|which|can|not|be|supplementation (r_acl:relcl) spasms_14\NNS\14299637|with|muscle|and|tetany|corrected (r_nmod) associated_11\VBN\628491|cause|,|hypomagnesemia|is|spasms|. (l_advcl) cause_4\VB\1617192|while|hypokalemia|may|weakness (l_nsubj) hypokalemia_2\NN\14299637|severe
D002118_D018908 NONE calcium_25\NN\14625458| (r_conj) potassium_23\NN\14625458|and|calcium (r_compound) supplementation_26\NN\5108947|by|potassium|alone|(|1,2 (r_nmod) corrected_21\VBN\138508|which|can|not|be|supplementation (r_acl:relcl) spasms_14\NNS\14299637|with|muscle|and|tetany|corrected (r_nmod) associated_11\VBN\628491|cause|,|hypomagnesemia|is|spasms|. (l_advcl) cause_4\VB\1617192|while|hypokalemia|may|weakness (l_dobj) weakness_6\NN\14462666|muscle
D002118_C537153 NONE calcium_25\NN\14625458| (r_conj) potassium_23\NN\14625458|and|calcium (r_compound) supplementation_26\NN\5108947|by|potassium|alone|(|1,2 (r_nmod) corrected_21\VBN\138508|which|can|not|be|supplementation (r_acl:relcl) spasms_14\NNS\14299637|with|muscle|and|tetany|corrected (r_nmod) associated_11\VBN\628491|cause|,|hypomagnesemia|is|spasms|. (l_nsubjpass) hypomagnesemia_9\NN\1740|severe
D002118_D013035 NONE calcium_25\NN\14625458| (r_conj) potassium_23\NN\14625458|and|calcium (r_compound) supplementation_26\NN\5108947|by|potassium|alone|(|1,2 (r_nmod) corrected_21\VBN\138508|which|can|not|be|supplementation (r_acl:relcl) spasms_14\NNS\14299637|with|muscle|and|tetany|corrected
D002118_D013746 NONE calcium_25\NN\14625458| (r_conj) potassium_23\NN\14625458|and|calcium (r_compound) supplementation_26\NN\5108947|by|potassium|alone|(|1,2 (r_nmod) corrected_21\VBN\138508|which|can|not|be|supplementation (r_acl:relcl) spasms_14\NNS\14299637|with|muscle|and|tetany|corrected (l_conj) tetany_16\NN\14304060|
D008274_D007008 NONE magnesium_27\NN\14625458| (r_compound) depletion_28\NN\351638|of|magnesium (r_nmod) effects_25\NNS\13245626|the|depletion (r_nsubjpass) noted_31\VBN\1009240|effects|were|not|patients|. (r_conj) reported_4\VBN\831651|hypokalemia|has|been|patients|(|3|and|observed|,|but|noted (l_nsubjpass) hypokalemia_1\NN\14299637|symptomatic
D008274_D006996 NONE magnesium_27\NN\14625458| (r_compound) depletion_28\NN\351638|of|magnesium (r_nmod) effects_25\NNS\13245626|the|depletion (r_nsubjpass) noted_31\VBN\1009240|effects|were|not|patients|. (r_conj) reported_4\VBN\831651|hypokalemia|has|been|patients|(|3|and|observed|,|but|noted (l_conj) observed_19\VBN\2163746|case|hypocalcemia|was|(|8) (l_nsubjpass) hypocalcemia_17\NN\14299637|
4069770
D005839_D007674 NONE gentamicin_0\NN\2716866| (r_compound) nephropathy_1\NN\14573196|gentamicin|neonate|.
D005839_D058186 CID gentamicin_18\NN\2716866|with|mg/kg/day|and|penicillin (r_nmod) therapy_16\NN\657604|after|gentamicin (r_nmod) died_10\VBD\146138|who|failure|therapy (l_nmod) failure_14\NN\66216|of|acute|renal
D010406_D058186 NONE penicillin_24\NN\2716866| (r_conj) gentamicin_18\NN\2716866|with|mg/kg/day|and|penicillin (r_nmod) therapy_16\NN\657604|after|gentamicin (r_nmod) died_10\VBD\146138|who|failure|therapy (l_nmod) failure_14\NN\66216|of|acute|renal
D005839_D001002 NONE gentamicin_2\NN\2716866| (r_compound) concentration_3\NN\4916342|the|serum|gentamicin (r_nsubj) reached_5\VBN\2005948|concentration|had|levels|developed|. (l_advcl) developed_10\VBD\1753788|when|anuria (l_nsubj) anuria_9\NN\14061805|
19707748
D064704_D012640 CID levofloxacin_3\NN\1740|with (r_nmod) associated_1\VBN\628491|levofloxacin (r_acl) seizures_0\NNS\14081375|associated|:|presentation
D064704_D012640 CID levofloxacin_17\NN\1740|with (r_nmod) treatment_15\NN\654885|levofloxacin (r_dobj) initiating_14\VBG\1617192|after|treatment (r_advcl) developed_10\VBD\1753788|who|seizures|initiating (l_dobj) seizures_11\NNS\14081375|
D064704_D012640 CID levofloxacin_17\NN\1740|with (r_nmod) treatment_15\NN\654885|levofloxacin (r_dobj) initiating_14\VBG\1617192|after|treatment (r_advcl) developed_10\VBD\1753788|who|seizures|initiating (r_acl:relcl) patient_8\NN\9898892|of|a|developed (r_nmod) case_5\NN\7283608|a|patient (r_dobj) present_3\VBP\2137132|:|we|case|and|discuss (l_conj) discuss_20\VB\1033527|to|interactions (l_dobj) interactions_24\NNS\37396|the|potential|drug-drug|related (l_amod) related_25\JJ\1740|inhibition (l_nmod) inhibition_28\NN\1068773|to|the|1a2|case (l_nmod) case_38\NN\7283608|in|this|,|as|cases (l_conj) cases_45\NNS\7283608|in|other|,|seizures (l_nmod) seizures_49\NNS\14081375|of|levofloxacin-induced
D064704_D012640 CID levofloxacin-induced_48\JJ\1740| (r_amod) seizures_49\NNS\14081375|of|levofloxacin-induced (r_nmod) cases_45\NNS\7283608|in|other|,|seizures (r_conj) case_38\NN\7283608|in|this|,|as|cases (r_nmod) inhibition_28\NN\1068773|to|the|1a2|case (r_nmod) related_25\JJ\1740|inhibition (r_amod) interactions_24\NNS\37396|the|potential|drug-drug|related (r_dobj) discuss_20\VB\1033527|to|interactions (r_conj) present_3\VBP\2137132|:|we|case|and|discuss (l_dobj) case_5\NN\7283608|a|patient (l_nmod) patient_8\NN\9898892|of|a|developed (l_acl:relcl) developed_10\VBD\1753788|who|seizures|initiating (l_dobj) seizures_11\NNS\14081375|
D064704_D012640 CID levofloxacin-induced_48\JJ\1740| (r_amod) seizures_49\NNS\14081375|of|levofloxacin-induced
D064704_D012640 CID levofloxacin-induced_5\JJ\1740| (r_amod) seizures_6\NNS\14081375|of|levofloxacin-induced
17965424
C422649_D001172 NONE etoricoxib_3\NN\1740|of (r_nmod) tolerability_1\NN\1740|gastrointestinal|etoricoxib|patients|:|results (l_nmod) patients_7\NNS\9898892|in|arthritis (l_compound) arthritis_6\NN\14171682|rheumatoid
C422649_D001172 NONE etoricoxib_12\NN\1740|vs|sodium (r_compound) tolerability_17\NN\1740|etoricoxib|gastrointestinal|and|effectiveness (r_compound) trial_20\NN\786195|of|the|tolerability|edge-ii (r_nmod) results_9\NNS\34213|trial|. (r_dep) tolerability_1\NN\1740|gastrointestinal|etoricoxib|patients|:|results (l_nmod) patients_7\NNS\9898892|in|arthritis (l_compound) arthritis_6\NN\14171682|rheumatoid
C422649_D001172 NONE etoricoxib_20\NN\1740|of|and|diclofenac (r_nmod) tolerability_14\NN\1740|the|gastrointestinal|,|safety|and|efficacy|etoricoxib|patients (l_nmod) patients_24\NNS\9898892|in|arthritis (l_nmod) arthritis_27\NN\14171682|with|rheumatoid|ra
C422649_D001172 NONE etoricoxib_20\NN\1740|of|and|diclofenac (r_nmod) tolerability_14\NN\1740|the|gastrointestinal|,|safety|and|efficacy|etoricoxib|patients (l_nmod) patients_24\NNS\9898892|in|arthritis (l_nmod) arthritis_27\NN\14171682|with|rheumatoid|ra (l_appos) ra_29\NN\14625458|(|)
C422649_D001172 NONE etoricoxib_22\NN\1740|mg|=|or|diclofenac|mg (r_dobj) received_21\VBD\2210855|etoricoxib|= (r_conj) enrolled_19\VBN\2471690|total|were|and|received|. (l_nsubjpass) total_5\NN\3553|a|patients (l_nmod) patients_8\NNS\9898892|of|4086|age|diagnosed (l_acl) diagnosed_15\VBN\644583|ra (l_nmod) ra_17\NN\14625458|with
D004008_D001172 NONE sodium_15\NN\14625458|diclofenac (r_conj) etoricoxib_12\NN\1740|vs|sodium (r_compound) tolerability_17\NN\1740|etoricoxib|gastrointestinal|and|effectiveness (r_compound) trial_20\NN\786195|of|the|tolerability|edge-ii (r_nmod) results_9\NNS\34213|trial|. (r_dep) tolerability_1\NN\1740|gastrointestinal|etoricoxib|patients|:|results (l_nmod) patients_7\NNS\9898892|in|arthritis (l_compound) arthritis_6\NN\14171682|rheumatoid
D004008_D001172 NONE diclofenac_22\NN\1740| (r_conj) etoricoxib_20\NN\1740|of|and|diclofenac (r_nmod) tolerability_14\NN\1740|the|gastrointestinal|,|safety|and|efficacy|etoricoxib|patients (l_nmod) patients_24\NNS\9898892|in|arthritis (l_nmod) arthritis_27\NN\14171682|with|rheumatoid|ra
D004008_D001172 NONE diclofenac_22\NN\1740| (r_conj) etoricoxib_20\NN\1740|of|and|diclofenac (r_nmod) tolerability_14\NN\1740|the|gastrointestinal|,|safety|and|efficacy|etoricoxib|patients (l_nmod) patients_24\NNS\9898892|in|arthritis (l_nmod) arthritis_27\NN\14171682|with|rheumatoid|ra (l_appos) ra_29\NN\14625458|(|)
D004008_D001172 NONE diclofenac_32\NN\1740| (r_conj) etoricoxib_22\NN\1740|mg|=|or|diclofenac|mg (r_dobj) received_21\VBD\2210855|etoricoxib|= (r_conj) enrolled_19\VBN\2471690|total|were|and|received|. (l_nsubjpass) total_5\NN\3553|a|patients (l_nmod) patients_8\NNS\9898892|of|4086|age|diagnosed (l_acl) diagnosed_15\VBN\644583|ra (l_nmod) ra_17\NN\14625458|with
C422649_D005767 NONE etoricoxib_12\NN\1740|with (r_nmod) lower_10\JJR\1740|rate|was|significantly|etoricoxib|diclofenac|events|. (l_nsubj) rate_3\NN\13815152|the|cumulative|discontinuation|aes (l_nmod) aes_7\NNS\1740|due|gi
C422649_D005767 NONE etoricoxib_2\NN\1740| (r_compound) mg_4\NN\13717155|etoricoxib|90 (r_nsubj) demonstrated_5\VBD\2137132|conclusions|mg|risk|higher|. (l_dobj) risk_9\NN\14541044|a|lower|discontinuing (l_advcl) discontinuing_11\VBG\2609764|for|treatment|aes|diclofenac (l_nmod) aes_16\NNS\1740|due|gi
C422649_D005767 NONE etoricoxib_2\NN\1740| (r_compound) mg_4\NN\13717155|etoricoxib|90 (r_nsubj) demonstrated_5\VBD\2137132|conclusions|mg|risk|higher|. (l_parataxis) higher_38\JJR\1740|discontinuations|,|were|significantly|etoricoxib (l_nsubj) discontinuations_22\NNS\209943|aes|,|common (l_advcl) common_29\JJ\1740|although|less|discontinuations (l_nmod) discontinuations_31\NNS\209943|than|aes (l_nmod) aes_34\NNS\1740|from|gi
C422649_D005767 NONE etoricoxib_40\NN\1740|with (r_nmod) higher_38\JJR\1740|discontinuations|,|were|significantly|etoricoxib (r_parataxis) demonstrated_5\VBD\2137132|conclusions|mg|risk|higher|. (l_dobj) risk_9\NN\14541044|a|lower|discontinuing (l_advcl) discontinuing_11\VBG\2609764|for|treatment|aes|diclofenac (l_nmod) aes_16\NNS\1740|due|gi
C422649_D005767 NONE etoricoxib_40\NN\1740|with (r_nmod) higher_38\JJR\1740|discontinuations|,|were|significantly|etoricoxib (l_nsubj) discontinuations_22\NNS\209943|aes|,|common (l_advcl) common_29\JJ\1740|although|less|discontinuations (l_nmod) discontinuations_31\NNS\209943|than|aes (l_nmod) aes_34\NNS\1740|from|gi
D004008_D005767 CID diclofenac_14\NN\1740|than (r_nmod) lower_10\JJR\1740|rate|was|significantly|etoricoxib|diclofenac|events|. (l_nsubj) rate_3\NN\13815152|the|cumulative|discontinuation|aes (l_nmod) aes_7\NNS\1740|due|gi
D004008_D005767 CID diclofenac_19\NN\1740|compared|with|mg. (r_nmod) discontinuing_11\VBG\2609764|for|treatment|aes|diclofenac (l_nmod) aes_16\NNS\1740|due|gi
D004008_D005767 CID diclofenac_19\NN\1740|compared|with|mg. (r_nmod) discontinuing_11\VBG\2609764|for|treatment|aes|diclofenac (r_advcl) risk_9\NN\14541044|a|lower|discontinuing (r_dobj) demonstrated_5\VBD\2137132|conclusions|mg|risk|higher|. (l_parataxis) higher_38\JJR\1740|discontinuations|,|were|significantly|etoricoxib (l_nsubj) discontinuations_22\NNS\209943|aes|,|common (l_advcl) common_29\JJ\1740|although|less|discontinuations (l_nmod) discontinuations_31\NNS\209943|than|aes (l_nmod) aes_34\NNS\1740|from|gi
C422649_D006973 CID etoricoxib_13\NN\1740|with (r_nmod) higher_11\JJR\1740|incidence|were|significantly|etoricoxib|%|diclofenac|. (l_nsubj) incidence_1\NN\13821570|the|discontinuations (l_nmod) discontinuations_3\NNS\209943|of|aes (l_nmod) aes_8\NNS\1740|for|hypertension-related (l_amod) hypertension-related_5\JJ\1740|and|oedema-related
C422649_D006973 CID etoricoxib_13\NN\1740|with (r_nmod) higher_11\JJR\1740|incidence|were|significantly|etoricoxib|%|diclofenac|. (l_advcl) diclofenac_24\NN\1740|compared|with|% (l_dep) %_27\NN\1740|(|1.5|and|%|respectively|;|p<0.001|and|p<0.01|) (l_amod) p<0.001_33\CD\1740|hypertension (l_nmod) hypertension_35\NN\14057371|for
C422649_D004487 CID etoricoxib_13\NN\1740|with (r_nmod) higher_11\JJR\1740|incidence|were|significantly|etoricoxib|%|diclofenac|. (l_nsubj) incidence_1\NN\13821570|the|discontinuations (l_nmod) discontinuations_3\NNS\209943|of|aes (l_nmod) aes_8\NNS\1740|for|hypertension-related (l_amod) hypertension-related_5\JJ\1740|and|oedema-related (l_conj) oedema-related_7\JJ\1740|
C422649_D004487 CID etoricoxib_13\NN\1740|with (r_nmod) higher_11\JJR\1740|incidence|were|significantly|etoricoxib|%|diclofenac|. (l_advcl) diclofenac_24\NN\1740|compared|with|% (l_dep) %_27\NN\1740|(|1.5|and|%|respectively|;|p<0.001|and|p<0.01|) (l_conj) p<0.01_37\CD\1740|oedema (l_nmod) oedema_39\NN\14315192|for
D004008_D006973 NONE diclofenac_24\NN\1740|compared|with|% (r_advcl) higher_11\JJR\1740|incidence|were|significantly|etoricoxib|%|diclofenac|. (l_nsubj) incidence_1\NN\13821570|the|discontinuations (l_nmod) discontinuations_3\NNS\209943|of|aes (l_nmod) aes_8\NNS\1740|for|hypertension-related (l_amod) hypertension-related_5\JJ\1740|and|oedema-related
D004008_D006973 NONE diclofenac_24\NN\1740|compared|with|% (l_dep) %_27\NN\1740|(|1.5|and|%|respectively|;|p<0.001|and|p<0.01|) (l_amod) p<0.001_33\CD\1740|hypertension (l_nmod) hypertension_35\NN\14057371|for
D004008_D004487 NONE diclofenac_24\NN\1740|compared|with|% (r_advcl) higher_11\JJR\1740|incidence|were|significantly|etoricoxib|%|diclofenac|. (l_nsubj) incidence_1\NN\13821570|the|discontinuations (l_nmod) discontinuations_3\NNS\209943|of|aes (l_nmod) aes_8\NNS\1740|for|hypertension-related (l_amod) hypertension-related_5\JJ\1740|and|oedema-related (l_conj) oedema-related_7\JJ\1740|
D004008_D004487 NONE diclofenac_24\NN\1740|compared|with|% (l_dep) %_27\NN\1740|(|1.5|and|%|respectively|;|p<0.001|and|p<0.01|) (l_conj) p<0.01_37\CD\1740|oedema (l_nmod) oedema_39\NN\14315192|for
20727411
-1_D011605 NONE s-ketamine_3\NN\1740| (r_nmod:npmod) induced_4\JJ\1740|s-ketamine (r_amod) psychosis_5\NN\14380140|of|induced
D016202_D012559 NONE n-methyl-d-aspartate_2\NN\1740| (r_compound) receptor_6\NN\5225602|the|glutamatergic|n-methyl-d-aspartate|(|nmda|) (r_nsubjpass) implicated_9\VBN\2677097|receptor|has|been|pathophysiology|. (l_nmod) pathophysiology_12\NN\1740|in|the|schizophrenia (l_nmod) schizophrenia_14\NN\14398067|of
D016202_D012559 NONE nmda_4\NN\1740| (r_compound) receptor_6\NN\5225602|the|glutamatergic|n-methyl-d-aspartate|(|nmda|) (r_nsubjpass) implicated_9\VBN\2677097|receptor|has|been|pathophysiology|. (l_nmod) pathophysiology_12\NN\1740|in|the|schizophrenia (l_nmod) schizophrenia_14\NN\14398067|of
D016202_D012559 NONE nmda_11\NN\1740| (r_compound) ketamine_14\NN\3054098|of|the|non-competitive|nmda|receptor|antagonist (r_nmod) dose_7\NN\3740161|a|subanesthetic|ketamine (r_nsubj) leads_15\VBZ\1752884|administered|,|dose|symptoms|. (l_nmod) symptoms_18\NNS\5823932|to|psychopathological|similar (l_amod) similar_19\JJ\1740|those (l_nmod) those_21\DT\1740|to|observed (l_acl) observed_22\VBN\2163746|schizophrenia (l_nmod) schizophrenia_24\NN\14398067|in
D016202_D012559 NONE nmda_10\NN\1740| (r_compound) receptor_11\NN\5225602|nmda (r_compound) dysfunction_12\NN\14204950|of|an|receptor|pathophysiology (l_nmod) pathophysiology_15\NN\1740|in|the|schizophrenia (l_nmod) schizophrenia_17\NN\14398067|of
D007649_D012559 NONE ketamine_14\NN\3054098|of|the|non-competitive|nmda|receptor|antagonist (r_nmod) dose_7\NN\3740161|a|subanesthetic|ketamine (r_nsubj) leads_15\VBZ\1752884|administered|,|dose|symptoms|. (l_nmod) symptoms_18\NNS\5823932|to|psychopathological|similar (l_amod) similar_19\JJ\1740|those (l_nmod) those_21\DT\1740|to|observed (l_acl) observed_22\VBN\2163746|schizophrenia (l_nmod) schizophrenia_24\NN\14398067|in
D007649_D012559 NONE ketamine_5\NN\3054098| (r_nsubj) exacerbates_6\VBZ\126264|patients|,|ketamine|symptoms|,|supporting|. (l_nmod) patients_1\NNS\9898892|in|schizophrenia (l_nmod) schizophrenia_3\NN\14398067|with
D007649_D012559 NONE ketamine_0\NN\3054098| (r_nsubj) induces_1\VBZ\1627355|ketamine|changes|. (l_dobj) changes_3\NNS\7283608|activation|subjects|similar (l_amod) similar_7\JJ\1740|those|,|regions (l_nmod) those_9\DT\1740|to|observed (l_acl) observed_10\VBN\2163746|patients (l_nmod) patients_12\NNS\9898892|in|schizophrenia (l_nmod) schizophrenia_14\NN\14398067|with
D007649_D018754 NONE ketamine_5\NN\3054098| (r_nsubj) exacerbates_6\VBZ\126264|patients|,|ketamine|symptoms|,|supporting|. (l_advcl) supporting_13\VBG\2199590|hypothesis (l_dobj) hypothesis_15\NN\7162194|the|dysfunction (l_nmod) dysfunction_19\NN\14204950|of|a|glutamatergic
D007649_D011605 CID ketamine_0\NN\3054098| (r_nsubj) elicited_1\VBD\1617192|ketamine|psychosis|. (l_dobj) psychosis_2\NN\14380140|psychopathology
8473723
D008728_D012640 CID levomepromazine-fluvoxamine_4\NN\1740| (r_compound) treatment_5\NN\654885|by|combined|levomepromazine-fluvoxamine (r_nmod) induced_1\VBN\1627355|treatment (r_acl) seizures_0\NNS\14081375|induced|.
D008728_D012640 CID levomepromazine-fluvoxamine_6\NN\1740| (r_nmod:npmod) treatment-induced_7\JJ\1740|levomepromazine-fluvoxamine (r_amod) seizures_8\NNS\14081375|of|combined|treatment-induced
D016666_D012640 CID levomepromazine-fluvoxamine_4\NN\1740| (r_compound) treatment_5\NN\654885|by|combined|levomepromazine-fluvoxamine (r_nmod) induced_1\VBN\1627355|treatment (r_acl) seizures_0\NNS\14081375|induced|.
D016666_D012640 CID levomepromazine-fluvoxamine_6\NN\1740| (r_nmod:npmod) treatment-induced_7\JJ\1740|levomepromazine-fluvoxamine (r_amod) seizures_8\NNS\14081375|of|combined|treatment-induced
3708922
D016572_D007674 CID cyclosporine_1\NN\1740| (r_compound) nephrotoxicity_2\NN\1740|experimental|cyclosporine|:|risk|.
D016572_D007674 CID cyclosporine_3\NN\1740|of|csa|or|combination (r_nmod) role_1\NN\719494|the|cyclosporine|development (l_nmod) development_16\NN\248977|in|the|toxicity (l_nmod) toxicity_19\NN\13576101|of|renal
D016572_D007674 CID csa_5\NN\1740|(|) (r_appos) cyclosporine_3\NN\1740|of|csa|or|combination (r_nmod) role_1\NN\719494|the|cyclosporine|development (l_nmod) development_16\NN\248977|in|the|toxicity (l_nmod) toxicity_19\NN\13576101|of|renal
D016572_D007674 CID csa_4\NN\1740|of|and|drugs (l_conj) drugs_8\NNS\14778436|various|chemotherapeutic|potential|,|gentamicin (l_nmod) potential_12\NN\14481929|with|a|nephrotoxic (l_amod) nephrotoxic_11\JJ\1740|
D016572_D007674 CID csa_40\NN\1740| (r_nmod:npmod) induced_41\JJ\1740|csa (r_amod) toxicity_42\NN\13576101|the|induced|model (r_dobj) aggravate_38\VB\126264|administration|did|not|toxicity|. (l_nsubj) administration_2\NN\1133281|the|combined|csa|, (l_nmod) csa_4\NN\1740|of|and|drugs (l_conj) drugs_8\NNS\14778436|various|chemotherapeutic|potential|,|gentamicin (l_nmod) potential_12\NN\14481929|with|a|nephrotoxic (l_amod) nephrotoxic_11\JJ\1740|
D016572_D007674 CID csa_8\NN\1740| (r_compound) nephrotoxicity_9\NN\1740|csa
D016572_D007674 CID csa_6\NN\1740|by (r_nmod) induced_4\VBN\1627355|csa (r_acl) nephrotoxicity_3\NN\1740|the|induced
D016572_D064420 NONE csa_4\NN\1740|of|and|drugs (r_nmod) administration_2\NN\1133281|the|combined|csa|, (r_nsubj) aggravate_38\VB\126264|administration|did|not|toxicity|. (l_dobj) toxicity_42\NN\13576101|the|induced|model
D016572_D064420 NONE csa_40\NN\1740| (r_nmod:npmod) induced_41\JJ\1740|csa (r_amod) toxicity_42\NN\13576101|the|induced|model
D005839_D007674 NONE gentamicin_16\NN\2716866|such|doses|,|b|,|used (r_nmod) drugs_8\NNS\14778436|various|chemotherapeutic|potential|,|gentamicin (l_nmod) potential_12\NN\14481929|with|a|nephrotoxic (l_amod) nephrotoxic_11\JJ\1740|
D005839_D007674 NONE gentamicin_0\NN\2716866|doses (r_nsubj) increased_7\VBD\169651|gentamicin|,|however|,|nephrotoxicity|. (l_dobj) nephrotoxicity_9\NN\1740|csa
D005839_D064420 NONE gentamicin_16\NN\2716866|such|doses|,|b|,|used (r_nmod) drugs_8\NNS\14778436|various|chemotherapeutic|potential|,|gentamicin (r_conj) csa_4\NN\1740|of|and|drugs (r_nmod) administration_2\NN\1133281|the|combined|csa|, (r_nsubj) aggravate_38\VB\126264|administration|did|not|toxicity|. (l_dobj) toxicity_42\NN\13576101|the|induced|model
D000666_D007674 NONE b_24\NN\1355326|amphothericin|and|ketoconazole (r_conj) gentamicin_16\NN\2716866|such|doses|,|b|,|used (r_nmod) drugs_8\NNS\14778436|various|chemotherapeutic|potential|,|gentamicin (l_nmod) potential_12\NN\14481929|with|a|nephrotoxic (l_amod) nephrotoxic_11\JJ\1740|
D000666_D064420 NONE b_24\NN\1355326|amphothericin|and|ketoconazole (r_conj) gentamicin_16\NN\2716866|such|doses|,|b|,|used (r_nmod) drugs_8\NNS\14778436|various|chemotherapeutic|potential|,|gentamicin (r_conj) csa_4\NN\1740|of|and|drugs (r_nmod) administration_2\NN\1133281|the|combined|csa|, (r_nsubj) aggravate_38\VB\126264|administration|did|not|toxicity|. (l_dobj) toxicity_42\NN\13576101|the|induced|model
D007654_D007674 NONE ketoconazole_26\NN\1740| (r_conj) b_24\NN\1355326|amphothericin|and|ketoconazole (r_conj) gentamicin_16\NN\2716866|such|doses|,|b|,|used (r_nmod) drugs_8\NNS\14778436|various|chemotherapeutic|potential|,|gentamicin (l_nmod) potential_12\NN\14481929|with|a|nephrotoxic (l_amod) nephrotoxic_11\JJ\1740|
D007654_D064420 NONE ketoconazole_26\NN\1740| (r_conj) b_24\NN\1355326|amphothericin|and|ketoconazole (r_conj) gentamicin_16\NN\2716866|such|doses|,|b|,|used (r_nmod) drugs_8\NNS\14778436|various|chemotherapeutic|potential|,|gentamicin (r_conj) csa_4\NN\1740|of|and|drugs (r_nmod) administration_2\NN\1133281|the|combined|csa|, (r_nsubj) aggravate_38\VB\126264|administration|did|not|toxicity|. (l_dobj) toxicity_42\NN\13576101|the|induced|model
10225068
D008012_D011128 CID lignocaine_10\NN\1740|with|hyperbaric|% (r_nmod) anaesthesia_5\NN\14034177|after|spinal|lignocaine (r_nmod) syndrome_2\NN\5870365|equina|anaesthesia|:|review
D008012_D011128 CID lignocaine_10\NN\1740|with|hyperbaric|% (r_nmod) anaesthesia_5\NN\14034177|after|spinal|lignocaine (r_nmod) syndrome_2\NN\5870365|equina|anaesthesia|:|review (l_appos) review_13\NN\5733583|a|cases|. (l_nmod) cases_16\NNS\7283608|of|six|syndrome|reported|1993 (l_nmod) syndrome_20\NN\5870365|of|cauda|equina
D008012_D020258 NONE lignocaine_15\NN\1740|of|hyperbaric|% (r_nmod) neurotoxicity_10\NN\1740|by|direct|lignocaine
1610717
D003042_D012640 CID cocaine-induced_0\JJ\1740| (r_amod) seizures_2\NNS\14081375|cocaine-induced|brainstem|and|behavior|.
16225977
C012052_D013981 CID amisulpride_0\NN\1740| (r_nmod:npmod) related_1\JJ\1740|amisulpride (r_amod) symptoms_3\NNS\5823932|related|tic-like|schizophrenic|.
C012052_D013981 CID amisulpride_11\NN\1740|of (r_nmod) dose_9\NN\3740161|the|amisulpride (r_dobj) reduced_7\VBD\441445|after|we|dose|down (r_advcl) resolved_3\VBD\352826|symptoms|completely|reduced|. (l_nsubj) symptoms_2\NNS\5823932|the|tic-like
C012052_D013981 CID amisulpride_30\NN\1740| (r_conj) quetiapine_25\NN\1740|such|,|clozapine|,|or|amisulpride (r_nmod) antipsychotics_22\NNS\4470232|with|atypical|quetiapine (r_nmod) treatment_19\NN\654885|during|antipsychotics (r_nmod) occur_13\VB\2623529|that|symptoms|might|individuals|treatment (l_nsubj) symptoms_11\NNS\5823932|tic-like
C012052_D012559 NONE amisulpride_0\NN\1740| (r_nmod:npmod) related_1\JJ\1740|amisulpride (r_amod) symptoms_3\NNS\5823932|related|tic-like|schizophrenic|. (l_nmod) schizophrenic_7\NN\10490141|in|an|adolescent
C012052_D012559 NONE amisulpride_16\NN\1740| (r_compound) treatment_17\NN\654885|of|amisulpride|mg (r_nmod) months_14\NNS\15113229|after|5|treatment (r_nmod) developed_7\VBD\1753788|who|movements|months (r_acl:relcl) girl_4\NN\10787470|a|15-year-old|schizophrenic|developed (l_appos) schizophrenic_5\JJ\1740|
D018967_D013981 NONE risperidone_11\NN\1740|such|,|olanzapine (r_nmod) antipsychotics_8\NNS\4470232|by|atypical|risperidone (r_nmod) treated_5\VBN\2376958|disorders|can|be|effectively|antipsychotics|. (l_nsubjpass) disorders_1\NNS\14034177|tic
C076029_D013981 NONE olanzapine_13\NN\1740|and|ziprasidone (r_conj) risperidone_11\NN\1740|such|,|olanzapine (r_nmod) antipsychotics_8\NNS\4470232|by|atypical|risperidone (r_nmod) treated_5\VBN\2376958|disorders|can|be|effectively|antipsychotics|. (l_nsubjpass) disorders_1\NNS\14034177|tic
C092292_D013981 NONE ziprasidone_15\NN\1740| (r_conj) olanzapine_13\NN\1740|and|ziprasidone (r_conj) risperidone_11\NN\1740|such|,|olanzapine (r_nmod) antipsychotics_8\NNS\4470232|by|atypical|risperidone (r_nmod) treated_5\VBN\2376958|disorders|can|be|effectively|antipsychotics|. (l_nsubjpass) disorders_1\NNS\14034177|tic
C069541_D013981 NONE quetiapine_22\NN\1740|with|or|clozapine (r_nmod) treatment_20\NN\654885|during|quetiapine (r_nmod) occurring_18\VBG\2623529|treatment (r_acl) symptoms_10\NNS\5823932|tic-like|,|variants|,|occurring
C069541_D013981 NONE quetiapine_25\NN\1740|such|,|clozapine|,|or|amisulpride (r_nmod) antipsychotics_22\NNS\4470232|with|atypical|quetiapine (r_nmod) treatment_19\NN\654885|during|antipsychotics (r_nmod) occur_13\VB\2623529|that|symptoms|might|individuals|treatment (l_nsubj) symptoms_11\NNS\5823932|tic-like
D003024_D013981 NONE clozapine_24\NN\3713736| (r_conj) quetiapine_22\NN\1740|with|or|clozapine (r_nmod) treatment_20\NN\654885|during|quetiapine (r_nmod) occurring_18\VBG\2623529|treatment (r_acl) symptoms_10\NNS\5823932|tic-like|,|variants|,|occurring
D003024_D013981 NONE clozapine_27\NN\3713736| (r_conj) quetiapine_25\NN\1740|such|,|clozapine|,|or|amisulpride (r_nmod) antipsychotics_22\NNS\4470232|with|atypical|quetiapine (r_nmod) treatment_19\NN\654885|during|antipsychotics (r_nmod) occur_13\VB\2623529|that|symptoms|might|individuals|treatment (l_nsubj) symptoms_11\NNS\5823932|tic-like
C012052_D020820 NONE amisulpride_16\NN\1740| (r_compound) treatment_17\NN\654885|of|amisulpride|mg (r_nmod) months_14\NNS\15113229|after|5|treatment (r_nmod) developed_7\VBD\1753788|who|movements|months (l_dobj) movements_11\NNS\191142|frequent|involuntary|eye-blinking
16820346
C065179_D006973 NONE atorvastatin_0\NN\3676175| (r_nsubj) prevented_1\VBD\1740|atorvastatin|and|reversed|. (l_conj) reversed_3\VBD\109660|hypertension (l_dobj) hypertension_5\NN\14057371|dexamethasone-induced|rat
C065179_D006973 NONE atorvastatin_6\NN\3676175|of|atorva (r_nmod) effects_4\NNS\13245626|the|antioxidant|atorvastatin|hypertension (l_nmod) hypertension_13\NN\14057371|on|(dex)-induced
C065179_D006973 NONE atorva_8\NN\1740|(|) (r_appos) atorvastatin_6\NN\3676175|of|atorva (r_nmod) effects_4\NNS\13245626|the|antioxidant|atorvastatin|hypertension (l_nmod) hypertension_13\NN\14057371|on|(dex)-induced
C065179_D006973 NONE atorva_22\NN\1740|with|mg/kg/day|or|water (r_nmod) treated_20\VBN\2376958|assess|,|rats|were|atorva|days|. (l_advcl) assess_1\VB\670261|to|effects (l_dobj) effects_4\NNS\13245626|the|antioxidant|atorvastatin|hypertension (l_nmod) hypertension_13\NN\14057371|on|(dex)-induced
C065179_D006973 NONE atorva_0\NN\1740| (r_nsubj) reversed_1\VBD\109660|atorva|hypertension|and|decreased|. (l_dobj) hypertension_3\NN\14057371|dex-induced|mmhg
C065179_D006973 NONE atorva_33\NN\1740|1187|+|dex (r_conj) dex_28\NN\1740|(|7931|,|atorva|,|0.0001|) (r_dep) superoxide_23\NN\14971519|plasma|dex (r_dobj) decreased_21\VBD\169651|superoxide (r_conj) reversed_1\VBD\109660|atorva|hypertension|and|decreased|. (l_dobj) hypertension_3\NN\14057371|dex-induced|mmhg
C065179_D006973 NONE atorvastatin_2\NN\3676175| (r_nsubj) prevented_3\VBD\1740|thus|,|atorvastatin|and|reversed|. (l_conj) reversed_5\VBD\109660|hypertension (l_dobj) hypertension_7\NN\14057371|dexamethasone-induced|rat
D003907_D006973 CID dexamethasone-induced_4\JJ\1740| (r_amod) hypertension_5\NN\14057371|dexamethasone-induced|rat
D003907_D006973 CID dexamethasone_11\NN\2721538| (r_compound) (dex)-induced_12\NN\1740|dexamethasone (r_nummod) hypertension_13\NN\14057371|on|(dex)-induced
D003907_D006973 CID (dex)-induced_12\NN\1740|dexamethasone (r_nummod) hypertension_13\NN\14057371|on|(dex)-induced
D003907_D006973 CID dex-induced_2\JJ\1740| (r_amod) hypertension_3\NN\14057371|dex-induced|mmhg
D003907_D006973 CID dex_28\NN\1740|(|7931|,|atorva|,|0.0001|) (r_dep) superoxide_23\NN\14971519|plasma|dex (r_dobj) decreased_21\VBD\169651|superoxide (r_conj) reversed_1\VBD\109660|atorva|hypertension|and|decreased|. (l_dobj) hypertension_3\NN\14057371|dex-induced|mmhg
D003907_D006973 CID dex_35\NN\1740| (r_conj) atorva_33\NN\1740|1187|+|dex (r_conj) dex_28\NN\1740|(|7931|,|atorva|,|0.0001|) (r_dep) superoxide_23\NN\14971519|plasma|dex (r_dobj) decreased_21\VBD\169651|superoxide (r_conj) reversed_1\VBD\109660|atorva|hypertension|and|decreased|. (l_dobj) hypertension_3\NN\14057371|dex-induced|mmhg
D003907_D006973 CID dexamethasone-induced_6\JJ\1740| (r_amod) hypertension_7\NN\14057371|dexamethasone-induced|rat
D013481_D006973 NONE superoxide_23\NN\14971519|plasma|dex (r_dobj) decreased_21\VBD\169651|superoxide (r_conj) reversed_1\VBD\109660|atorva|hypertension|and|decreased|. (l_dobj) hypertension_3\NN\14057371|dex-induced|mmhg
11079278
D008790_D017202 NONE metoprolol_3\NN\2832168|of|intravenous|or|metoprolol (r_nmod) effect_0\NN\34213|metoprolol|ischemia|. (l_nmod) ischemia_12\NN\14195315|on|dobutamine-induced|myocardial
D008790_D017202 NONE metoprolol_6\NN\2832168|intravenous|plus|glucagon (r_conj) metoprolol_3\NN\2832168|of|intravenous|or|metoprolol (r_nmod) effect_0\NN\34213|metoprolol|ischemia|. (l_nmod) ischemia_12\NN\14195315|on|dobutamine-induced|myocardial
D008790_D017202 NONE metoprolol_7\NN\2832168| (r_nsubj) attenuates_8\VBZ\224901|conclusion|:|testing|,|metoprolol|or|eliminates|. (l_conj) eliminates_10\VBZ\1619929|evidence (l_dobj) evidence_11\NN\5816287|ischemia (l_nmod) ischemia_14\NN\14195315|of|myocardial
D004280_D017202 CID dobutamine-induced_10\JJ\1740| (r_amod) ischemia_12\NN\14195315|on|dobutamine-induced|myocardial
D004280_D017202 CID dobutamine_3\NN\1740| (r_compound) testing_5\NN\639556|during|dobutamine|stress (r_nmod) attenuates_8\VBZ\224901|conclusion|:|testing|,|metoprolol|or|eliminates|. (l_conj) eliminates_10\VBZ\1619929|evidence (l_dobj) evidence_11\NN\5816287|ischemia (l_nmod) ischemia_14\NN\14195315|of|myocardial
6699841
D009288_D007681 CID naproxen_5\NN\3828465|due (r_nmod) necrosis_2\NN\11444117|renal|papillary|naproxen|.
D009288_D007681 CID naproxen_37\NN\3828465| (r_compound) therapy_38\NN\657604|of|naproxen (r_nmod) institution_35\NN\8008335|months|therapy (r_dobj) developed_25\VBD\1753788|man|,|necrosis|institution|. (l_dobj) necrosis_28\NN\11444117|renal|papillary|rpn
D009288_D007681 CID naproxen_37\NN\3828465| (r_compound) therapy_38\NN\657604|of|naproxen (r_nmod) institution_35\NN\8008335|months|therapy (r_dobj) developed_25\VBD\1753788|man|,|necrosis|institution|. (l_dobj) necrosis_28\NN\11444117|renal|papillary|rpn (l_appos) rpn_30\NN\1740|(|)
D013467_D001172 NONE sulindac_13\NN\3828465|with|,|calcium|,|salicylates|and|salts (r_nmod) treated_11\VBN\2376958|who|had|previously|been|sulindac (r_acl:relcl) man_2\NN\9605289|a|31-year-old|arthritis|,|treated (l_nmod) arthritis_5\NN\14171682|with|rheumatoid
D013467_D007681 NONE sulindac_13\NN\3828465|with|,|calcium|,|salicylates|and|salts (r_nmod) treated_11\VBN\2376958|who|had|previously|been|sulindac (r_acl:relcl) man_2\NN\9605289|a|31-year-old|arthritis|,|treated (r_nsubj) developed_25\VBD\1753788|man|,|necrosis|institution|. (l_dobj) necrosis_28\NN\11444117|renal|papillary|rpn
D013467_D007681 NONE sulindac_13\NN\3828465|with|,|calcium|,|salicylates|and|salts (r_nmod) treated_11\VBN\2376958|who|had|previously|been|sulindac (r_acl:relcl) man_2\NN\9605289|a|31-year-old|arthritis|,|treated (r_nsubj) developed_25\VBD\1753788|man|,|necrosis|institution|. (l_dobj) necrosis_28\NN\11444117|renal|papillary|rpn (l_appos) rpn_30\NN\1740|(|)
D013467_D007681 NONE sulindac_15\NN\3828465|of (r_nmod) advantages_13\NNS\5154517|possible|sulindac|patients (r_dobj) discuss_11\VBP\1033527|advantages (r_conj) review_1\VBP\644583|we|reports|and|discuss|. (l_dobj) reports_3\NNS\6470073|previous|linking (l_acl) linking_4\VBG\628491|rpn|use (l_dobj) rpn_5\NN\1740|
D005279_D001172 NONE calcium_16\NN\14625458|fenoprofen (r_conj) sulindac_13\NN\3828465|with|,|calcium|,|salicylates|and|salts (r_nmod) treated_11\VBN\2376958|who|had|previously|been|sulindac (r_acl:relcl) man_2\NN\9605289|a|31-year-old|arthritis|,|treated (l_nmod) arthritis_5\NN\14171682|with|rheumatoid
D005279_D007681 NONE calcium_16\NN\14625458|fenoprofen (r_conj) sulindac_13\NN\3828465|with|,|calcium|,|salicylates|and|salts (r_nmod) treated_11\VBN\2376958|who|had|previously|been|sulindac (r_acl:relcl) man_2\NN\9605289|a|31-year-old|arthritis|,|treated (r_nsubj) developed_25\VBD\1753788|man|,|necrosis|institution|. (l_dobj) necrosis_28\NN\11444117|renal|papillary|rpn
D005279_D007681 NONE calcium_16\NN\14625458|fenoprofen (r_conj) sulindac_13\NN\3828465|with|,|calcium|,|salicylates|and|salts (r_nmod) treated_11\VBN\2376958|who|had|previously|been|sulindac (r_acl:relcl) man_2\NN\9605289|a|31-year-old|arthritis|,|treated (r_nsubj) developed_25\VBD\1753788|man|,|necrosis|institution|. (l_dobj) necrosis_28\NN\11444117|renal|papillary|rpn (l_appos) rpn_30\NN\1740|(|)
D012459_D001172 NONE salicylates_20\NNS\3828465|dose (r_conj) sulindac_13\NN\3828465|with|,|calcium|,|salicylates|and|salts (r_nmod) treated_11\VBN\2376958|who|had|previously|been|sulindac (r_acl:relcl) man_2\NN\9605289|a|31-year-old|arthritis|,|treated (l_nmod) arthritis_5\NN\14171682|with|rheumatoid
D012459_D007681 NONE salicylates_20\NNS\3828465|dose (r_conj) sulindac_13\NN\3828465|with|,|calcium|,|salicylates|and|salts (r_nmod) treated_11\VBN\2376958|who|had|previously|been|sulindac (r_acl:relcl) man_2\NN\9605289|a|31-year-old|arthritis|,|treated (r_nsubj) developed_25\VBD\1753788|man|,|necrosis|institution|. (l_dobj) necrosis_28\NN\11444117|renal|papillary|rpn
D012459_D007681 NONE salicylates_20\NNS\3828465|dose (r_conj) sulindac_13\NN\3828465|with|,|calcium|,|salicylates|and|salts (r_nmod) treated_11\VBN\2376958|who|had|previously|been|sulindac (r_acl:relcl) man_2\NN\9605289|a|31-year-old|arthritis|,|treated (r_nsubj) developed_25\VBD\1753788|man|,|necrosis|institution|. (l_dobj) necrosis_28\NN\11444117|renal|papillary|rpn (l_appos) rpn_30\NN\1740|(|)
D006046_D001172 NONE gold_22\NN\13371489| (r_compound) salts_23\NNS\14818238|gold (r_conj) sulindac_13\NN\3828465|with|,|calcium|,|salicylates|and|salts (r_nmod) treated_11\VBN\2376958|who|had|previously|been|sulindac (r_acl:relcl) man_2\NN\9605289|a|31-year-old|arthritis|,|treated (l_nmod) arthritis_5\NN\14171682|with|rheumatoid
D006046_D007681 NONE gold_22\NN\13371489| (r_compound) salts_23\NNS\14818238|gold (r_conj) sulindac_13\NN\3828465|with|,|calcium|,|salicylates|and|salts (r_nmod) treated_11\VBN\2376958|who|had|previously|been|sulindac (r_acl:relcl) man_2\NN\9605289|a|31-year-old|arthritis|,|treated (r_nsubj) developed_25\VBD\1753788|man|,|necrosis|institution|. (l_dobj) necrosis_28\NN\11444117|renal|papillary|rpn
D006046_D007681 NONE gold_22\NN\13371489| (r_compound) salts_23\NNS\14818238|gold (r_conj) sulindac_13\NN\3828465|with|,|calcium|,|salicylates|and|salts (r_nmod) treated_11\VBN\2376958|who|had|previously|been|sulindac (r_acl:relcl) man_2\NN\9605289|a|31-year-old|arthritis|,|treated (r_nsubj) developed_25\VBD\1753788|man|,|necrosis|institution|. (l_dobj) necrosis_28\NN\11444117|renal|papillary|rpn (l_appos) rpn_30\NN\1740|(|)
D009288_D001172 NONE naproxen_37\NN\3828465| (r_compound) therapy_38\NN\657604|of|naproxen (r_nmod) institution_35\NN\8008335|months|therapy (r_dobj) developed_25\VBD\1753788|man|,|necrosis|institution|. (l_nsubj) man_2\NN\9605289|a|31-year-old|arthritis|,|treated (l_nmod) arthritis_5\NN\14171682|with|rheumatoid
D013467_D007674 NONE sulindac_15\NN\3828465|of (r_nmod) advantages_13\NNS\5154517|possible|sulindac|patients (l_nmod) patients_17\NNS\9898892|in|experienced (l_acl:relcl) experienced_20\VBN\2108377|who|have|toxicity (l_dobj) toxicity_22\NN\13576101|renal|agents
8599504
D004329_D000799 CID droperidol_3\NN\1740| (r_compound) administration_4\NN\1133281|with|droperidol (r_nmod) associated_1\VBN\628491|administration (r_acl) angioedema_0\NN\14316714|associated|.
D004329_D000799 CID droperidol_37\NN\1740|of (r_nmod) dose_35\NN\3740161|of|a|single|iv|droperidol (r_nmod) administration_30\NN\1133281|of|the|dose (r_nmod) minutes_27\NNS\6502378|within|10|administration (r_nmod) developed_24\VBD\1753788|whom|angioedema|minutes (l_nsubj) angioedema_17\NN\14316714|swelling
D004329_D004342 NONE droperidol_37\NN\1740|of (r_nmod) dose_35\NN\3740161|of|a|single|iv|droperidol (r_nmod) administration_30\NN\1133281|of|the|dose (r_nmod) minutes_27\NNS\6502378|within|10|administration (r_nmod) developed_24\VBD\1753788|whom|angioedema|minutes (r_acl:relcl) man_9\NN\9605289|of|a|healthy|19-year-old|allergies|developed (l_nmod) allergies_14\NNS\14533203|with|no|known|drug
D004329_D014060 NONE droperidol_37\NN\1740|of (r_nmod) dose_35\NN\3740161|of|a|single|iv|droperidol (r_nmod) administration_30\NN\1133281|of|the|dose (r_nmod) minutes_27\NNS\6502378|within|10|administration (r_nmod) developed_24\VBD\1753788|whom|angioedema|minutes (l_nsubj) angioedema_17\NN\14316714|swelling (l_nmod) swelling_21\NN\14315071|with|tongue|and|protrusion
D004329_D004487 NONE droperidol_37\NN\1740|of (r_nmod) dose_35\NN\3740161|of|a|single|iv|droperidol (r_nmod) administration_30\NN\1133281|of|the|dose (r_nmod) minutes_27\NNS\6502378|within|10|administration (r_nmod) developed_24\VBD\1753788|whom|angioedema|minutes (l_nsubj) angioedema_17\NN\14316714|swelling (l_nmod) swelling_21\NN\14315071|with|tongue|and|protrusion
16596970
D010862_D012640 NONE pilocarpine_0\JJ\1740| (r_amod) seizures_1\NNS\14081375|pilocarpine
D010862_D012640 NONE pilocarpine_0\NN\14712692|day (r_nsubj) induced_4\VBD\1627355|pilocarpine|epilepticus|;|resulted|. (l_parataxis) resulted_12\VBD\2633881|epilepticus|loss|,|whereas|had (l_nmod) loss_16\NN\13252973|in|ca3|cell|and|seizures (l_conj) seizures_19\NNS\14081375|spontaneous
D010862_D012640 NONE pilocarpine_0\NN\14712692|day (r_nsubj) induced_4\VBD\1627355|pilocarpine|epilepticus|;|resulted|. (l_parataxis) resulted_12\VBD\2633881|epilepticus|loss|,|whereas|had (l_ccomp) had_24\VBD\2108377|rats|loss (l_dobj) loss_27\NN\13252973|no|cell|or|seizures (l_conj) seizures_30\NNS\14081375|spontaneous
D010862_D001308 CID pilocarpine_0\JJ\1740| (r_amod) seizures_1\NNS\14081375|pilocarpine (r_nsubj) cause_2\VBP\1617192|seizures|impairment|. (l_dobj) impairment_4\NN\7296428|age-dependent|discrimination (l_nmod) discrimination_8\NN\1123598|in|location
D010862_D013226 CID pilocarpine_0\NN\14712692|day (r_nsubj) induced_4\VBD\1627355|pilocarpine|epilepticus|;|resulted|. (l_dobj) epilepticus_6\NN\1740|status
D010862_D013226 CID pilocarpine_0\NN\14712692|day (r_nsubj) induced_4\VBD\1627355|pilocarpine|epilepticus|;|resulted|. (l_parataxis) resulted_12\VBD\2633881|epilepticus|loss|,|whereas|had (l_nsubj) epilepticus_9\NN\1740|status|p45
8958188
C045894_D009369 NONE lometrexol_9\NN\1740| (r_nsubj) has_10\VBZ\2108377|that|lometrexol|activity (l_dobj) activity_11\NN\30358|tumours (l_nmod) tumours_13\NNS\14234074|against|refractory
D008727_D009369 NONE methotrexate_22\NN\2722166|notably (r_appos) drugs_19\NNS\14778436|to|other|,|methotrexate (r_nmod) refractory_16\JJ\1740|which|are|drugs (r_acl:relcl) tumours_13\NNS\14234074|against|refractory
C045894_D064420 NONE lometrexol_7\NN\1740|of (r_nmod) development_5\NN\248977|the|initial|clinical|lometrexol (r_nsubjpass) curtailed_9\VBN\235368|however|,|development|was|toxicities|. (l_nmod) toxicities_16\NNS\13576101|because|severe|antiproliferative
C045894_D064420 NONE lometrexol_8\NN\1740|of (r_nmod) toxicity_6\NN\13576101|the|lometrexol
C045894_D064420 NONE lometrexol_9\NN\1740|of|given (r_nmod) study_7\NN\635850|a|phase|i|clinical|lometrexol|confirmed (l_acl:relcl) confirmed_17\VBN\1011725|which|has|reduced (l_ccomp) reduced_26\VBN\441445|that|toxicity|can|be|markedly|supplementation (l_nsubjpass) toxicity_20\NN\13576101|the|lometrexol
C045894_D064420 NONE lometrexol_22\NN\1740|of (r_nmod) toxicity_20\NN\13576101|the|lometrexol
C045894_D064420 NONE lometrexol_4\NN\1740| (r_compound) pharmacokinetics_6\NNS\6054892|lometrexol|plasma (r_nsubjpass) altered_9\VBN\126264|that|pharmacokinetics|were|not|administration|indicating (l_advcl) indicating_14\VBG\952524|unlikely (l_ccomp) unlikely_18\JJ\1740|that|supplementation|is|reduce (l_xcomp) reduce_20\VB\441445|to|toxicity|enhancing (l_dobj) toxicity_21\NN\13576101|
C045894_D064420 NONE lometrexol_24\NN\1740| (r_compound) clearance_26\NN\5089947|lometrexol|plasma (r_dobj) enhancing_23\VBG\227165|by|clearance (r_advcl) reduce_20\VB\441445|to|toxicity|enhancing (l_dobj) toxicity_21\NN\13576101|
D005492_D064420 NONE acid_16\NN\14818238|folic (r_compound) administration_17\NN\1133281|by|dose|acid|, (r_nmod) prevented_11\VBN\1740|that|toxicity|can|be|administration|i.e.|days (l_nsubjpass) toxicity_6\NN\13576101|the|lometrexol
D005492_D064420 NONE acid_13\NN\14818238|folic (r_compound) supplementation_14\NN\5108947|with|acid (r_nmod) given_10\VBN\2327200|supplementation (r_acl) lometrexol_9\NN\1740|of|given (r_nmod) study_7\NN\635850|a|phase|i|clinical|lometrexol|confirmed (l_acl:relcl) confirmed_17\VBN\1011725|which|has|reduced (l_ccomp) reduced_26\VBN\441445|that|toxicity|can|be|markedly|supplementation (l_nsubjpass) toxicity_20\NN\13576101|the|lometrexol
D005492_D064420 NONE acid_29\NN\14818238| (r_compound) supplementation_30\NN\5108947|by|folic|acid (r_nmod) reduced_26\VBN\441445|that|toxicity|can|be|markedly|supplementation (l_nsubjpass) toxicity_20\NN\13576101|the|lometrexol
D005492_D064420 NONE folate_13\NN\15090742| (r_compound) elevation_14\NN\7445480|of|plasma|folate (r_nmod) extent_10\NN\13939892|the|elevation (r_conj) toxicity_7\NN\13576101|between|clinical|and|extent
D005492_D064420 NONE acid_12\NN\14818238| (r_compound) administration_13\NN\1133281|by|folic|acid (r_nmod) altered_9\VBN\126264|that|pharmacokinetics|were|not|administration|indicating (l_advcl) indicating_14\VBG\952524|unlikely (l_ccomp) unlikely_18\JJ\1740|that|supplementation|is|reduce (l_xcomp) reduce_20\VB\441445|to|toxicity|enhancing (l_dobj) toxicity_21\NN\13576101|
11861791
D011064_D006333 NONE )_3\-RRB-\1740| (r_punct) polymerase_4\NN\14732946|of|poly(adp-ribose|) (r_nmod) activation_0\NN\13561719|polymerase (r_nsubj) contributes_5\VBZ\126264|activation|development|. (l_nmod) development_7\NN\248977|to|failure (l_nmod) failure_11\NN\66216|of|doxorubicin-induced|heart
D004317_D006333 CID doxorubicin-induced_9\JJ\1740| (r_amod) failure_11\NN\66216|of|doxorubicin-induced|heart
D004317_D066126 NONE doxorubicin_12\NN\2716866|of|dox|,|antibiotic (r_nmod) cardiotoxicity_10\NN\1740|in|the|doxorubicin
D004317_D066126 NONE dox_14\NN\1740|(|) (r_appos) doxorubicin_12\NN\2716866|of|dox|,|antibiotic (r_nmod) cardiotoxicity_10\NN\1740|in|the|doxorubicin
D004317_D066126 NONE dox-induced_13\JJ\1740| (r_amod) cardiotoxicity_14\NN\1740|to|the|dox-induced
D004317_D066126 NONE dox_9\NN\1740|of (r_nmod) cardiotoxicity_7\NN\1740|to|the|dox
D018943_D066126 NONE anthracycline_21\NN\1740| (r_compound) antibiotic_22\NN\2716205|a|used|antitumor|anthracycline (r_appos) doxorubicin_12\NN\2716866|of|dox|,|antibiotic (r_nmod) cardiotoxicity_10\NN\1740|in|the|doxorubicin
C434926_D006331 NONE pj34_19\NN\1740|with|the|phenanthridinone|parp|inhibitor (r_nmod) inhibition_13\NN\1068773|pharmacological|pj34 (r_conj) deletion_10\NN\13508333|by|genetic|or|inhibition (r_nmod) approach_3\NN\940842|a|dual|suppression|,|deletion (r_dobj) using_0\VBG\1156834|approach (r_advcl) demonstrate_23\VBP\2137132|using|,|we|now|role|. (l_dobj) role_25\NN\719494|the|parp|development (l_nmod) development_30\NN\248977|in|the|dysfunction (l_nmod) dysfunction_33\NN\14204950|of|cardiac|induced
C434926_D006331 NONE pj34_3\NN\1740|with|a (r_nmod) treatment_0\NN\654885|pj34 (r_nsubj) improved_5\VBD\126264|treatment|significantly|dysfunction|and|increased|. (l_dobj) dysfunction_7\NN\14204950|cardiac
D004317_D006331 NONE dox_36\NN\1740|by (r_nmod) induced_34\VBN\1627355|dox (r_acl) dysfunction_33\NN\14204950|of|cardiac|induced
D004317_D005117 NONE dox_16\NN\1740| (r_compound) treatment_17\NN\654885|with|the|dox (r_nmod) associated_13\VBN\628491|treatment (r_acl) complications_12\NNS\1073995|of|severe|cardiac|associated
14982270
D008713_D041781 CID methimazole-induced_0\NN\1740| (r_amod) jaundice_2\NN\14299637|methimazole-induced|cholestatic|.
D008713_D007565 NONE methimazole_12\NN\1740|tid|and|propranolol (r_dobj) receiving_11\VBG\2210855|after|methimazole|treatment (r_advcl) had_3\VBD\2108377|woman|jaundice|receiving|. (l_dobj) jaundice_5\NN\14299637|severe|and|itching
D008713_D011537 CID methimazole_12\NN\1740|tid|and|propranolol (r_dobj) receiving_11\VBG\2210855|after|methimazole|treatment (r_advcl) had_3\VBD\2108377|woman|jaundice|receiving|. (l_dobj) jaundice_5\NN\14299637|severe|and|itching (l_conj) itching_7\NN\5723210|
D008713_D006980 NONE methimazole_12\NN\1740|tid|and|propranolol (r_dobj) receiving_11\VBG\2210855|after|methimazole|treatment (l_nmod) treatment_26\NN\654885|for|hyperthyroidism (l_nmod) hyperthyroidism_28\NN\14059928|of
D011433_D007565 NONE propranolol_19\NN\1740|tid (r_conj) methimazole_12\NN\1740|tid|and|propranolol (r_dobj) receiving_11\VBG\2210855|after|methimazole|treatment (r_advcl) had_3\VBD\2108377|woman|jaundice|receiving|. (l_dobj) jaundice_5\NN\14299637|severe|and|itching
D011433_D011537 NONE propranolol_19\NN\1740|tid (r_conj) methimazole_12\NN\1740|tid|and|propranolol (r_dobj) receiving_11\VBG\2210855|after|methimazole|treatment (r_advcl) had_3\VBD\2108377|woman|jaundice|receiving|. (l_dobj) jaundice_5\NN\14299637|severe|and|itching (l_conj) itching_7\NN\5723210|
D011433_D006980 NONE propranolol_19\NN\1740|tid (r_conj) methimazole_12\NN\1740|tid|and|propranolol (r_dobj) receiving_11\VBG\2210855|after|methimazole|treatment (l_nmod) treatment_26\NN\654885|for|hyperthyroidism (l_nmod) hyperthyroidism_28\NN\14059928|of
D008713_D002779 NONE methimazole-induced_0\JJ\1740| (r_amod) cholestasis_1\NN\14052403|methimazole-induced
D011433_D002779 NONE propranolol_6\NN\1740| (r_compound) therapy_7\NN\657604|propranolol (r_nsubjpass) resumed_9\VBN\2679899|therapy|was|. (r_conj) diagnosed_3\VBN\644583|cholestasis|was|,|and|resumed (l_nsubjpass) cholestasis_1\NN\14052403|methimazole-induced
7189975
D002045_D012640 CID bupivacaine-induced_21\JJ\1740| (r_amod) seizures_22\NNS\14081375|of|bupivacaine-induced (r_nmod) %_19\NN\1740|in|90|seizures|,|% (r_nmod) fatal_16\JJ\1740|dose|was|%|. (l_nsubj) dose_2\NN\3740161|a|cd50|anesthetic|causing (l_acl) causing_7\VBG\1617192|(|convulsions|%|) (l_dobj) convulsions_8\NNS\14081375|
D002045_D012640 CID bupivacaine-induced_21\JJ\1740| (r_amod) seizures_22\NNS\14081375|of|bupivacaine-induced
C004616_D012640 CID chloroprocaine_29\NN\1740| (r_compound) group_30\NN\2137|of|the|chloroprocaine (r_nmod) %_26\NN\1740|in|57|group|,|and|% (r_conj) %_19\NN\1740|in|90|seizures|,|% (r_nmod) fatal_16\JJ\1740|dose|was|%|. (l_nsubj) dose_2\NN\3740161|a|cd50|anesthetic|causing (l_acl) causing_7\VBG\1617192|(|convulsions|%|) (l_dobj) convulsions_8\NNS\14081375|
C004616_D012640 CID chloroprocaine_29\NN\1740| (r_compound) group_30\NN\2137|of|the|chloroprocaine (r_nmod) %_26\NN\1740|in|57|group|,|and|% (r_conj) %_19\NN\1740|in|90|seizures|,|% (l_nmod) seizures_22\NNS\14081375|of|bupivacaine-induced
D008012_D012640 CID lidocaine_38\NN\3681148| (r_compound) group_39\NN\2137|of|the|lidocaine (r_nmod) %_35\NN\1740|in|6|group (r_conj) %_26\NN\1740|in|57|group|,|and|% (r_conj) %_19\NN\1740|in|90|seizures|,|% (r_nmod) fatal_16\JJ\1740|dose|was|%|. (l_nsubj) dose_2\NN\3740161|a|cd50|anesthetic|causing (l_acl) causing_7\VBG\1617192|(|convulsions|%|) (l_dobj) convulsions_8\NNS\14081375|
D008012_D012640 CID lidocaine_38\NN\3681148| (r_compound) group_39\NN\2137|of|the|lidocaine (r_nmod) %_35\NN\1740|in|6|group (r_conj) %_26\NN\1740|in|57|group|,|and|% (r_conj) %_19\NN\1740|in|90|seizures|,|% (l_nmod) seizures_22\NNS\14081375|of|bupivacaine-induced
10523326
D009569_D006973 NONE oxide_1\NN\14818238| (r_compound) synthase_2\NN\1740|nitric|oxide (r_compound) expression_3\NN\4679549|synthase|course|. (l_nmod) course_6\NN\883297|in|the|hypertension (l_nmod) hypertension_9\NN\14057371|of|lead-induced
D009569_D006973 NONE no_15\NN\7204911| (r_compound) metabolites_16\NNS\20090|of|no|nox (r_nmod) excretion_13\NN\13466586|reduced|urinary|metabolites|,|and|sequestration (l_conj) sequestration_24\NN\1201021|increased|no|nitrotyrosine|tissues (l_nmod) tissues_29\NNS\5220461|in|various|rats (l_nmod) rats_31\NNS\2329401|in|hypertension (l_nmod) hypertension_34\NN\14057371|with|lead-induced
D009569_D006973 NONE no_23\NN\7204911| (r_compound) sequestration_24\NN\1201021|increased|no|nitrotyrosine|tissues (l_nmod) tissues_29\NNS\5220461|in|various|rats (l_nmod) rats_31\NNS\2329401|in|hypertension (l_nmod) hypertension_34\NN\14057371|with|lead-induced
D009569_D006973 NONE no_23\NN\7204911| (r_compound) synthase_24\NN\1740|no|nos (r_compound) expression_28\NN\4679549|due|depressed|synthase (l_case) due_20\JJ\1740|whether|reduction|is|,|part|,|to (l_nsubj) reduction_8\NN\351485|the|nox|hypertension (l_nmod) hypertension_14\NN\14057371|in|lead-induced
D009569_D006973 NONE no_9\NN\7204911| (r_compound) inactivation_10\NN\13518963|due|to|ros-mediated|no|,|inhibition|. (l_conj) inhibition_13\NN\1068773|lead-associated|activity|,|and|actions (l_conj) actions_21\NNS\30358|perhaps|stimulatory|stress (l_nmod) stress_25\NN\7083732|of|increased|shear|associated (l_acl) associated_26\VBN\628491|hypertension (l_nmod) hypertension_28\NN\14057371|with
D007854_D006973 CID lead-induced_8\JJ\1740| (r_amod) hypertension_9\NN\14057371|of|lead-induced
D007854_D006973 CID lead-induced_33\JJ\1740| (r_amod) hypertension_34\NN\14057371|with|lead-induced
D007854_D006973 CID lead-induced_13\JJ\1740| (r_amod) hypertension_14\NN\14057371|in|lead-induced
D007854_D006973 CID lead-induced_3\JJ\1740| (r_amod) hypertension_4\NN\14057371|lead-induced|model
D007854_D006973 CID lead-associated_12\JJ\1740| (r_amod) inhibition_13\NN\1068773|lead-associated|activity|,|and|actions (l_conj) actions_21\NNS\30358|perhaps|stimulatory|stress (l_nmod) stress_25\NN\7083732|of|increased|shear|associated (l_acl) associated_26\VBN\628491|hypertension (l_nmod) hypertension_28\NN\14057371|with
D010100_D006973 NONE oxygen_5\NN\14622893| (r_compound) species_6\NNS\7992450|elevated|reactive|oxygen|ros|,|excretion (l_conj) excretion_13\NN\13466586|reduced|urinary|metabolites|,|and|sequestration (l_conj) sequestration_24\NN\1201021|increased|no|nitrotyrosine|tissues (l_nmod) tissues_29\NNS\5220461|in|various|rats (l_nmod) rats_31\NNS\2329401|in|hypertension (l_nmod) hypertension_34\NN\14057371|with|lead-induced
C002744_D006973 NONE nitrotyrosine_26\NN\1740|as (r_nmod) sequestration_24\NN\1201021|increased|no|nitrotyrosine|tissues (l_nmod) tissues_29\NNS\5220461|in|various|rats (l_nmod) rats_31\NNS\2329401|in|hypertension (l_nmod) hypertension_34\NN\14057371|with|lead-induced
D014810_D006973 NONE e_1\NN\14724645|vitamin (r_compound) supplementation_2\NN\5108947|e (r_nsubj) ameliorated_3\VBD\126264|supplementation|hypertension|,|lowered|. (l_dobj) hypertension_4\NN\14057371|
D008315_D006973 NONE mda_8\NN\1740| (r_compound) concentration_9\NN\4916342|plasma|mda (r_dobj) lowered_6\VBD\1850315|concentration|,|and|raised (r_conj) ameliorated_3\VBD\126264|supplementation|hypertension|,|lowered|. (l_dobj) hypertension_4\NN\14057371|
19944333
C471405_D009203 NONE sorafenib-induced_0\NNP\1740| (r_compound) infarction_3\NN\14204950|sorafenib-induced|acute|myocardial|spasm|.
C471405_D003329 CID sorafenib-induced_0\NNP\1740| (r_compound) infarction_3\NN\14204950|sorafenib-induced|acute|myocardial|spasm|. (l_nmod) spasm_8\NN\14299637|due|coronary|artery
C471405_D003329 CID sorafenib-induced_6\JJ\1740| (r_amod) spasm_9\NN\14299637|of|sorafenib-induced|coronary|artery
D020108_D060050 NONE nicorandil_3\NN\1740|of|oral (r_nmod) addition_0\NN\3081021|nicorandil (r_nsubj) reduced_4\VBD\441445|addition|symptoms|and|maintained|. (l_conj) maintained_8\VBD\2202928|status (l_dobj) status_11\NN\24720|stable|angina (l_compound) angina_10\NN\14171682|
3108839
D016685_D006463 CID c_1\NN\13714184|mitomycin (r_nmod:npmod) associated_2\JJ\1740|c (r_amod) syndrome_5\NN\5870365|associated|hemolytic|uremic|.
D016685_D006463 CID c_1\NN\13714184|mitomycin (r_nmod:npmod) associated_2\JJ\1740|c (r_amod) syndrome_5\NN\5870365|associated|hemolytic|uremic|hus
D016685_D006463 CID c_1\NN\13714184|mitomycin (r_nmod:npmod) associated_2\JJ\1740|c (r_amod) syndrome_5\NN\5870365|associated|hemolytic|uremic|hus (l_appos) hus_7\NN\1740|(|)
D016685_D000743 NONE c_15\NN\13714184|mitomycin (r_compound) treatment_16\NN\654885|with|c (r_nmod) associated_12\VBN\628491|treatment (r_acl) anemia_5\NN\14189204|of|microangiopathic|hemolytic|,|thrombocytopenia|associated
D016685_D013921 NONE c_15\NN\13714184|mitomycin (r_compound) treatment_16\NN\654885|with|c (r_nmod) associated_12\VBN\628491|treatment (r_acl) anemia_5\NN\14189204|of|microangiopathic|hemolytic|,|thrombocytopenia|associated (l_conj) thrombocytopenia_7\NN\14189204|and|failure
D016685_D013921 NONE c_27\NN\13714184|with|mitomycin (r_nmod) treatment_24\NN\654885|while|on|c (r_nmod) developed_17\VBD\1753788|who|failure|treatment|and|died (l_dobj) failure_19\NN\66216|renal|and|thrombocytopenia (l_conj) thrombocytopenia_21\NN\14189204|
D016685_D051437 CID c_15\NN\13714184|mitomycin (r_compound) treatment_16\NN\654885|with|c (r_nmod) associated_12\VBN\628491|treatment (r_acl) anemia_5\NN\14189204|of|microangiopathic|hemolytic|,|thrombocytopenia|associated (l_conj) thrombocytopenia_7\NN\14189204|and|failure (l_conj) failure_11\NN\66216|progressive|renal
D016685_D051437 CID c_14\NN\13714184|mitomycin (r_compound) treatment_15\NN\654885|of|c (r_nmod) start_11\NN\7290905|after|treatment (r_nmod) develops_4\VBZ\1753788|failure|usually|start|and|% (l_nsubj) failure_2\NN\66216|the|renal
D016685_D051437 CID c_14\NN\13714184|mitomycin (r_compound) treatment_15\NN\654885|of|c (r_nmod) start_11\NN\7290905|after|treatment (r_nmod) develops_4\VBZ\1753788|failure|usually|start|and|% (l_conj) %_22\NN\1740|mortality|is|60|failure|. (l_nmod) failure_25\NN\66216|from|renal|or|edema
D016685_D051437 CID c_27\NN\13714184|with|mitomycin (r_nmod) treatment_24\NN\654885|while|on|c (r_nmod) developed_17\VBD\1753788|who|failure|treatment|and|died (l_dobj) failure_19\NN\66216|renal|and|thrombocytopenia
D016685_D011654 NONE c_14\NN\13714184|mitomycin (r_compound) treatment_15\NN\654885|of|c (r_nmod) start_11\NN\7290905|after|treatment (r_nmod) develops_4\VBZ\1753788|failure|usually|start|and|% (l_conj) %_22\NN\1740|mortality|is|60|failure|. (l_nmod) failure_25\NN\66216|from|renal|or|edema (l_conj) edema_28\NN\14315192|pulmonary
D016685_D011654 NONE c_27\NN\13714184|with|mitomycin (r_nmod) treatment_24\NN\654885|while|on|c (r_nmod) developed_17\VBD\1753788|who|failure|treatment|and|died (l_conj) died_29\VBD\146138|edema (l_nmod) edema_32\NN\14315192|in|pulmonary
D016685_D013274 NONE c_27\NN\13714184|with|mitomycin (r_nmod) treatment_24\NN\654885|while|on|c (r_nmod) developed_17\VBD\1753788|who|failure|treatment|and|died (r_acl:relcl) man_12\NN\9605289|in|a|yr-old|adenocarcinoma|developed (l_nmod) adenocarcinoma_15\NN\14242337|with|gastric
8586822
D002216_D006973 NONE captopril-treated_10\JJ\1740| (r_amod) rats_13\NNS\2329401|in|lifetime|captopril-treated|hypertensive (l_amod) hypertensive_12\JJ\1740|spontaneously
D002216_D006973 NONE captopril-treated_10\JJ\1740| (r_amod) rats_13\NNS\2329401|in|lifetime|captopril-treated|spontaneously|hypertensive|shr (l_amod) hypertensive_12\JJ\1740|
D002216_D006973 NONE captopril-treated_10\JJ\1740| (r_amod) rats_13\NNS\2329401|in|lifetime|captopril-treated|spontaneously|hypertensive|shr (r_nmod) contributes_22\VBZ\126264|that|,|rats|,|system|importantly|effect (l_nmod) effect_27\NN\34213|to|the|hypertensive|supplementation (l_amod) hypertensive_26\JJ\1740|
D017673_D006973 CID chloride_31\NN\14818238|dietary|sodium (r_compound) supplementation_32\NN\5108947|of|chloride (r_nmod) effect_27\NN\34213|to|the|hypertensive|supplementation (r_nmod) contributes_22\VBZ\126264|that|,|rats|,|system|importantly|effect (l_nmod) rats_13\NNS\2329401|in|lifetime|captopril-treated|spontaneously|hypertensive|shr (l_amod) hypertensive_12\JJ\1740|
D017673_D006973 CID chloride_31\NN\14818238|dietary|sodium (r_compound) supplementation_32\NN\5108947|of|chloride (r_nmod) effect_27\NN\34213|to|the|hypertensive|supplementation (l_amod) hypertensive_26\JJ\1740|
D017673_D006973 CID chloride-induced_19\JJ\1740|dietary|sodium (r_amod) increase_20\NN\13576355|the|chloride-induced|map|groups (l_nmod) map_22\NN\4076846|in
D018738_D006973 NONE hexamethonium_6\NN\1740|of|the|ganglionic|blocker (r_nmod) infusion_1\NN\14589223|intravenous|hexamethonium (r_nsubj) resulted_7\VBD\2633881|infusion|decline|. (l_nmod) decline_11\NN\13458571|in|a|rapid|map|eliminated (l_acl:relcl) eliminated_15\VBD\1619929|that|increase (l_dobj) increase_20\NN\13576355|the|chloride-induced|map|groups (l_nmod) map_22\NN\4076846|in
2569282
D020927_D009127 NONE dexmedetomidine_0\NN\1740|,|acting|, (r_nsubj) prevents_8\VBZ\1740|dexmedetomidine|rigidity|. (l_dobj) rigidity_11\NN\5023233|opiate-induced|muscle|rat
D020927_D009127 NONE d-med_11\NN\1740|with (r_nmod) treatment_9\NN\654885|d-med (r_nsubj) prevents_12\VBZ\1740|if|treatment|rigidity (l_dobj) rigidity_15\NN\5023233|the|muscle|caused
D020927_D009127 NONE d-med_3\NN\1740| (r_nsubj) prevented_4\VBD\1740|contrast|,|d-med|rigidity|fashion|. (l_dobj) rigidity_7\NN\5023233|alfentanil-induced|muscle
D020927_D009123 NONE dexmedetomidine_5\NN\1740|d-med (r_dep) agonist_4\NN\9613191|the|highly-selective|alpha-2|adrenergic|dexmedetomidine (r_nsubj) capable_10\JJ\1740|agonist|is|inducing|. (l_advcl) inducing_12\VBG\1627355|of|flaccidity|rats (l_dobj) flaccidity_14\NN\4938228|muscle|and|anesthesia
D020927_D009123 NONE d-med_7\NN\1740|(|) (r_appos) dexmedetomidine_5\NN\1740|d-med (r_dep) agonist_4\NN\9613191|the|highly-selective|alpha-2|adrenergic|dexmedetomidine (r_nsubj) capable_10\JJ\1740|agonist|is|inducing|. (l_advcl) inducing_12\VBG\1627355|of|flaccidity|rats (l_dobj) flaccidity_14\NN\4938228|muscle|and|anesthesia
D015760_D009127 CID alfentanil_19\NN\1740| (r_compound) anesthesia_20\NN\14034177|by|high-dose|alfentanil|rat (r_nmod) caused_16\VBN\1617192|anesthesia (r_acl) rigidity_15\NN\5023233|the|muscle|caused
D015760_D009127 CID alfentanil-induced_5\JJ\1740| (r_amod) rigidity_7\NN\5023233|alfentanil-induced|muscle
D020927_D018476 NONE d-med_2\NN\1740| (r_compound) animals_3\NNS\4475|the|high-dose|d-med (r_nsubj) flaccid_5\JJ\1740|animals|were|,|akinetic|and|lacked|. (l_conj) akinetic_7\JJ\1740|,
D020927_D012021 NONE d-med_2\NN\1740| (r_compound) animals_3\NNS\4475|the|high-dose|d-med (r_nsubj) flaccid_5\JJ\1740|animals|were|,|akinetic|and|lacked|. (l_conj) lacked_10\VBD\1740|response|period (l_dobj) response_13\NN\11410625|a|startle (l_compound) startle_12\NN\863513|
9579567
D013629_D001943 NONE tamoxifen_1\NN\2714883| (r_nsubjpass) used_4\VBN\1156834|since|tamoxifen|is|widely|treatment|and|proposed (l_nmod) treatment_8\NN\654885|in|cancer (l_compound) cancer_7\NN\14239425|breast
D013629_D001943 NONE tamoxifen_1\NN\2714883| (r_nsubjpass) used_4\VBN\1156834|since|tamoxifen|is|widely|treatment|and|proposed (l_conj) proposed_12\VBN\1010118|has|been|prevention (l_nmod) prevention_15\NN\1073995|for|the|cancer (l_nmod) cancer_18\NN\14239425|of|breast
D013629_D001943 NONE tamoxifen_9\NN\2714883| (r_compound) use_10\NN\407535|tamoxifen|or|treatments (r_conj) cancer_7\NN\14239425|between|endometrial|and|use|women (l_nmod) women_15\NNS\9605289|in|treated (l_acl) treated_16\VBN\2376958|cancer (l_nmod) cancer_19\NN\14239425|for|breast
D013629_D001943 NONE tamoxifen_7\NN\2714883|of (r_nmod) role_5\NN\719494|a|causal|tamoxifen|cancer|,|used (l_acl) used_14\VBN\1156834|when|proposed (l_advcl) proposed_17\VBN\1010118|as|currently|prevention (l_nmod) prevention_21\NN\1073995|for|breast|cancer (l_compound) cancer_20\NN\14239425|
D013629_D001943 NONE tamoxifen_3\NN\2714883|cancer (l_nmod) cancer_6\NN\14239425|for|breast
D013629_D001943 NONE tamoxifen_8\NN\2714883|of (r_nmod) ratio_6\NN\13815152|of|the|risk-benefit|tamoxifen|treatment (l_nmod) treatment_12\NN\654885|as|a|preventive|cancer (l_nmod) cancer_15\NN\14239425|for|breast
D013629_D016889 CID tamoxifen_9\NN\2714883| (r_compound) use_10\NN\407535|tamoxifen|or|treatments (r_conj) cancer_7\NN\14239425|between|endometrial|and|use|women
D013629_D016889 CID tamoxifen_4\NN\2714883| (r_dobj) received_3\VBN\2210855|who|had|tamoxifen (r_acl:relcl) women_0\NNS\9605289|received (r_nsubj) likely_8\JJ\1740|women|were|more|have|. (l_xcomp) have_10\VB\2108377|to|cancer (l_dobj) cancer_12\NN\14239425|endometrial|diagnosed|those
D013629_D016889 CID tamoxifen_8\NN\2714883| (r_dobj) received_7\VBN\2210855|had|tamoxifen (r_conj) had_2\VBD\2108377|who|cancer|and|received (l_dobj) cancer_4\NN\14239425|endometrial
D013629_D016889 CID tamoxifen_8\NN\2714883| (r_dobj) received_7\VBN\2210855|had|tamoxifen (r_conj) had_2\VBD\2108377|who|cancer|and|received (r_acl:relcl) women_0\NNS\9605289|had (r_nsubj) had_9\VBD\2108377|women|disease|those|. (l_nmod) those_17\DT\1740|than|cancer (l_nmod) cancer_20\NN\14239425|with|endometrial|received
D013629_D016889 CID tamoxifen_7\NN\2714883|of (r_nmod) role_5\NN\719494|a|causal|tamoxifen|cancer|,|used (l_nmod) cancer_10\NN\14239425|in|endometrial
D013629_D016889 CID tamoxifen_7\NN\2714883|with (r_nmod) treated_5\VBN\2376958|tamoxifen (r_acl) women_4\NNS\9605289|in|treated (r_nmod) diagnosed_2\VBN\644583|women (r_acl) cancers_1\NNS\14239425|endometrial|diagnosed
D013629_D020178 NONE tamoxifen_8\NN\2714883| (r_dobj) received_7\VBN\2210855|had|tamoxifen (r_conj) had_2\VBD\2108377|who|cancer|and|received (r_acl:relcl) women_0\NNS\9605289|had (r_nsubj) had_9\VBD\2108377|women|disease|those|. (l_dobj) disease_12\NN\14061805|advanced|and|prognosis
2343592
D015378_D012640 NONE imipenem_3\NN\1740| (r_compound) therapy_4\NN\657604|with|imipenem (r_nmod) activity_1\NN\30358|seizure|therapy|:|incidence (l_compound) seizure_0\NN\14081375|
C044650_D020521 NONE imipenem/cilastatin_30\NN\1740|of (r_nmod) doses_28\NNS\3740161|maximum|imipenem/cilastatin (r_dobj) receiving_26\VBG\2210855|while|doses (r_advcl) developed_23\VBD\1753788|patients|seizures|receiving|. (l_nsubj) patients_2\NNS\9898892|two|elderly|history (l_nmod) history_5\NN\15120823|with|a|accident (l_nmod) accident_10\NN\7314427|of|either|cerebral|vascular|cva|or|trauma|and|evidence
C044650_D020521 NONE imipenem/cilastatin_30\NN\1740|of (r_nmod) doses_28\NNS\3740161|maximum|imipenem/cilastatin (r_dobj) receiving_26\VBG\2210855|while|doses (r_advcl) developed_23\VBD\1753788|patients|seizures|receiving|. (l_nsubj) patients_2\NNS\9898892|two|elderly|history (l_nmod) history_5\NN\15120823|with|a|accident (l_nmod) accident_10\NN\7314427|of|either|cerebral|vascular|cva|or|trauma|and|evidence (l_appos) cva_12\NN\14081375|(|)
C044650_D006259 NONE imipenem/cilastatin_30\NN\1740|of (r_nmod) doses_28\NNS\3740161|maximum|imipenem/cilastatin (r_dobj) receiving_26\VBG\2210855|while|doses (r_advcl) developed_23\VBD\1753788|patients|seizures|receiving|. (l_nsubj) patients_2\NNS\9898892|two|elderly|history (l_nmod) history_5\NN\15120823|with|a|accident (l_nmod) accident_10\NN\7314427|of|either|cerebral|vascular|cva|or|trauma|and|evidence (l_conj) trauma_16\NN\14052046|head
C044650_D007674 NONE imipenem/cilastatin_30\NN\1740|of (r_nmod) doses_28\NNS\3740161|maximum|imipenem/cilastatin (r_dobj) receiving_26\VBG\2210855|while|doses (r_advcl) developed_23\VBD\1753788|patients|seizures|receiving|. (l_nsubj) patients_2\NNS\9898892|two|elderly|history (l_nmod) history_5\NN\15120823|with|a|accident (l_nmod) accident_10\NN\7314427|of|either|cerebral|vascular|cva|or|trauma|and|evidence (l_conj) evidence_19\NN\5816287|no|disease (l_nmod) disease_22\NN\14061805|of|renal
C044650_D012640 CID imipenem/cilastatin_30\NN\1740|of (r_nmod) doses_28\NNS\3740161|maximum|imipenem/cilastatin (r_dobj) receiving_26\VBG\2210855|while|doses (r_advcl) developed_23\VBD\1753788|patients|seizures|receiving|. (l_dobj) seizures_24\NNS\14081375|
D010672_D012640 NONE phenytoin_8\NN\3550533|of (r_nmod) doses_6\NNS\3740161|with|therapeutic|phenytoin (r_nmod) controlled_3\VBN\2422663|seizures|were|doses|. (l_nsubjpass) seizures_1\NNS\14081375|all
D047090_D012640 NONE beta-lactam_8\NN\1740| (r_compound) antibiotics_9\NNS\2716205|of|other|beta-lactam (r_nmod) doses_5\NNS\3740161|maximum|antibiotics (r_dobj) received_3\VBN\2210855|patients|had|doses|evidence|. (l_nmod) evidence_11\NN\5816287|without|activity (l_nmod) activity_14\NN\30358|of|seizure (l_compound) seizure_13\NN\14081375|
20466178
D016559_D003872 NONE tacrolimus_5\NN\1740| (r_compound) treatment_6\NN\654885|with|topical|tacrolimus (r_nmod) associated_2\VBN\628491|treatment (r_acl) dermatitis_1\NN\14226056|rosaceiform|associated|.
D016559_D003872 NONE tacrolimus_17\NN\1740| (r_compound) ointment_18\NN\4074482|%|tacrolimus (r_dobj) using_11\VBG\1156834|while|ointment|dermatitis (r_advcl) developed_6\VBD\1753788|who|eruptions|using (l_dobj) eruptions_9\NNS\7307754|rosacea-like|dermatitis (l_compound) dermatitis_8\NN\14226056|
D016559_D003872 NONE tacrolimus_7\NN\1740|such|or|pimecrolimus (r_nmod) immunomodulators_4\NNS\1740|of|tacrolimus (r_nmod) use_2\NN\407535|continuous|topical|immunomodulators (r_nsubjpass) regarded_12\VBN\689344|use|should|be|cause|,|reported|. (l_nmod) cause_16\NN\7323922|as|a|potential|dermatitis (l_nmod) dermatitis_19\NN\14226056|of|rosaceiform
D016559_D012393 NONE tacrolimus_17\NN\1740| (r_compound) ointment_18\NN\4074482|%|tacrolimus (r_dobj) using_11\VBG\1156834|while|ointment|dermatitis (r_advcl) developed_6\VBD\1753788|who|eruptions|using (l_dobj) eruptions_9\NNS\7307754|rosacea-like|dermatitis (l_amod) rosacea-like_7\NN\1740|
D016559_D003875 NONE tacrolimus_17\NN\1740| (r_compound) ointment_18\NN\4074482|%|tacrolimus (r_dobj) using_11\VBG\1156834|while|ointment|dermatitis (r_advcl) developed_6\VBD\1753788|who|eruptions|using (l_dobj) eruptions_9\NNS\7307754|rosacea-like|dermatitis
D016559_D005148 NONE tacrolimus_17\NN\1740| (r_compound) ointment_18\NN\4074482|%|tacrolimus (r_dobj) using_11\VBG\1156834|while|ointment|dermatitis (l_nmod) dermatitis_21\NN\14226056|for|facial
C117268_D003872 CID pimecrolimus_9\NN\1740| (r_conj) tacrolimus_7\NN\1740|such|or|pimecrolimus (r_nmod) immunomodulators_4\NNS\1740|of|tacrolimus (r_nmod) use_2\NN\407535|continuous|topical|immunomodulators (r_nsubjpass) regarded_12\VBN\689344|use|should|be|cause|,|reported|. (l_nmod) cause_16\NN\7323922|as|a|potential|dermatitis (l_nmod) dermatitis_19\NN\14226056|of|rosaceiform
6454943
D002216_D011507 NONE captopril_2\NN\2673637|of (r_nmod) effect_0\NN\34213|captopril|proteinuria|. (l_nmod) proteinuria_7\NN\14299637|on|pre-existing|rats
D002216_D011507 NONE captopril_6\NN\2673637| (r_compound) treatment_7\NN\654885|of|captopril|patients (r_nmod) effect_4\NN\34213|proteinuria|is|a|side|treatment|. (l_nsubj) proteinuria_0\NN\14299637|
D002216_D011507 NONE captopril_3\NN\2673637|of (r_nmod) administration_1\NN\1133281|oral|captopril|mg/kg|days (r_nsubj) failed_10\VBD\1798936|administration|aggravate|. (l_xcomp) aggravate_12\VB\126264|to|proteinuria (l_dobj) proteinuria_13\NN\14299637|pre-existing
D002216_D011507 NONE captopril_2\NN\2673637| (r_compound) treatment_3\NN\654885|captopril (r_nsubj) failed_4\VBD\1798936|also|,|treatment|potentiate|. (l_xcomp) potentiate_6\VB\229605|to|or|facilitate|development (l_dobj) development_9\NN\248977|proteinuria (l_nmod) proteinuria_12\NN\14299637|of|massive|invoked
D002216_D006973 NONE captopril_2\NN\2673637|of (r_nmod) effect_0\NN\34213|captopril|proteinuria|. (l_nmod) proteinuria_7\NN\14299637|on|pre-existing|rats (l_nmod) rats_11\NNS\2329401|in|hypertensive (l_amod) hypertensive_10\JJ\1740|spontaneously
D002216_D006973 NONE captopril_6\NN\2673637| (r_compound) treatment_7\NN\654885|of|captopril|patients (l_nmod) patients_10\NNS\9898892|in|hypertensive (l_amod) hypertensive_9\JJ\1740|
D011692_D011507 CID aminonucleoside-induced_6\JJ\1740| (r_conj) pre-existing_4\JJ\1740|and|aminonucleoside-induced (r_amod) proteinuria_7\NN\14299637|on|pre-existing|rats
D011692_D011507 CID aminonucleoside_16\NN\1740|by|puromycin|shr (r_nmod) invoked_13\VBN\1617192|aminonucleoside (r_acl) proteinuria_12\NN\14299637|of|massive|invoked
D011692_D006973 NONE aminonucleoside-induced_6\JJ\1740| (r_conj) pre-existing_4\JJ\1740|and|aminonucleoside-induced (r_amod) proteinuria_7\NN\14299637|on|pre-existing|rats (l_nmod) rats_11\NNS\2329401|in|hypertensive (l_amod) hypertensive_10\JJ\1740|spontaneously
D002216_D007674 NONE captopril_9\NN\2673637|with (r_nmod) reproducing_3\VBG\1621555|of|abnormality|captopril (l_dobj) abnormality_7\NN\14034177|the|same|renal
3780697
D005283_D009127 CID fentanyl_3\NN\2707683| (r_compound) administration_4\NN\1133281|after|fentanyl (r_nmod) rigidity_1\NN\5023233|post-operative|administration|.
D005283_D009127 CID fentanyl_25\NN\2707683|of (r_nmod) dose_23\NN\3740161|a|moderate|fentanyl (r_dobj) received_20\VBD\2210855|who|dose (r_acl:relcl) patient_18\NN\9898892|in|an|elderly|received (r_nmod) described_10\VBN\1001294|case|is|period|patient|. (l_nsubjpass) case_1\NN\7283608|a|rigidity (l_nmod) rigidity_4\NN\5023233|of|thoraco-abdominal|leading
D005283_D012131 NONE fentanyl_25\NN\2707683|of (r_nmod) dose_23\NN\3740161|a|moderate|fentanyl (r_dobj) received_20\VBD\2210855|who|dose (r_acl:relcl) patient_18\NN\9898892|in|an|elderly|received (r_nmod) described_10\VBN\1001294|case|is|period|patient|. (l_nsubjpass) case_1\NN\7283608|a|rigidity (l_nmod) rigidity_4\NN\5023233|of|thoraco-abdominal|leading (l_acl) leading_5\VBG\1752884|failure (l_nmod) failure_8\NN\66216|to|respiratory
19105845
D016642_D012640 CID hydrochloride-induced_8\JJ\1740|bupropion (r_amod) seizures_9\NNS\14081375|on|hydrochloride-induced|mice
D016642_D012640 CID bupropion-induced_17\JJ\1740| (r_amod) seizures_18\NNS\14081375|of|bupropion-induced
D016642_D012640 CID hcl_14\NN\1740|of|bupropion|mg/kg|,|dose (l_appos) dose_21\NN\3740161|a|known|convulsive|50|cd50 (l_amod) convulsive_20\JJ\1740|
D016642_D012640 CID hcl_14\NN\1740|of|bupropion|mg/kg|,|dose (r_nmod) rates_11\NNS\13308999|the|intraperitoneal|infusion|hcl (r_dobj) varying_7\VBG\2666239|of|rates|,|incidence (l_nmod) incidence_29\NN\13821570|on|the|and|severity|convulsions|mice (l_nmod) convulsions_34\NNS\14081375|of|bupropion-induced
D016642_D012640 CID bupropion-induced_33\JJ\1740| (r_amod) convulsions_34\NNS\14081375|of|bupropion-induced (r_nmod) incidence_29\NN\13821570|on|the|and|severity|convulsions|mice (r_nmod) varying_7\VBG\2666239|of|rates|,|incidence (l_dobj) rates_11\NNS\13308999|the|intraperitoneal|infusion|hcl (l_nmod) hcl_14\NN\1740|of|bupropion|mg/kg|,|dose (l_appos) dose_21\NN\3740161|a|known|convulsive|50|cd50 (l_amod) convulsive_20\JJ\1740|
D016642_D012640 CID bupropion-induced_33\JJ\1740| (r_amod) convulsions_34\NNS\14081375|of|bupropion-induced
D016642_D012640 CID hcl_10\NN\1740|of|bupropion|mg/kg (r_nmod) administration_7\NN\1133281|ip|hcl|injection (r_nsubj) induced_16\VBD\1627355|that|administration|convulsions|mice (l_dobj) convulsions_17\NNS\14081375|
D016642_D012640 CID hcl_27\NN\1740| (r_compound) mg/kg_29\NN\1740|of|bupropion|hcl|120 (r_nmod) time_24\NN\7308889|the|ip|infusion|mg/kg (r_dobj) increasing_20\VBG\169651|time (r_nsubjpass) associated_31\VBN\628491|increasing|was|odds|injection (l_nmod) odds_37\NNS\4756635|with|a|%|reduced|convulsions|times (l_nmod) convulsions_39\NNS\14081375|of
D016642_D012640 CID bupropion_21\NN\1740|of (r_nmod) dose_19\NN\3740161|of|a|fixed|bupropion (l_amod) fixed_16\JJ\1740|and|convulsive (l_conj) convulsive_18\JJ\1740|
D016642_D012640 CID bupropion_21\NN\1740|of (r_nmod) dose_19\NN\3740161|of|a|fixed|bupropion (r_nmod) time_13\NN\7308889|between|infusion|dose|and|risk|study (l_conj) risk_24\NN\14541044|the|convulsions (l_nmod) convulsions_26\NNS\14081375|of
14745746
C090450_D001943 NONE anastrozole_7\NN\1740|of|,|tamoxifen|alone|atac (r_nmod) trial_5\NN\786195|in|a|randomised|anastrozole (r_nmod) participating_1\VBG\2367363|trial (r_acl) patients_0\NNS\9898892|participating|n=94|and|group (l_conj) group_21\NN\2137|a|women|n=35 (l_nmod) women_23\NNS\9605289|of|cancer (l_nmod) cancer_26\NN\14239425|without|breast
D013629_D001943 NONE tamoxifen_9\NN\2714883| (r_conj) anastrozole_7\NN\1740|of|,|tamoxifen|alone|atac (r_nmod) trial_5\NN\786195|in|a|randomised|anastrozole (r_nmod) participating_1\VBG\2367363|trial (r_acl) patients_0\NNS\9898892|participating|n=94|and|group (l_conj) group_21\NN\2137|a|women|n=35 (l_nmod) women_23\NNS\9605289|of|cancer (l_nmod) cancer_26\NN\14239425|without|breast
16174948
D003042_D013345 CID cocaine-associated_6\JJ\1740| (r_amod) hemorrhage_8\NN\14285662|after|cocaine-associated|subarachnoid
D003042_D013345 CID cocaine-associated_12\JJ\1740| (r_amod) hemorrhage_14\NN\14285662|with|cocaine-associated|subarachnoid|sah
D003042_D013345 CID cocaine-associated_12\JJ\1740| (r_amod) hemorrhage_14\NN\14285662|with|cocaine-associated|subarachnoid|sah (l_appos) sah_16\NN\1740|(|)
D003042_D013345 CID cocaine_23\NN\3492717| (r_compound) use_24\NN\407535|after|cocaine (r_nmod) underwent_19\VBD\109660|who|angiography|use (r_acl:relcl) patients_10\NNS\9898892|of|hemorrhage|underwent (l_nmod) hemorrhage_14\NN\14285662|with|cocaine-associated|subarachnoid|sah
D003042_D013345 CID cocaine_23\NN\3492717| (r_compound) use_24\NN\407535|after|cocaine (r_nmod) underwent_19\VBD\109660|who|angiography|use (r_acl:relcl) patients_10\NNS\9898892|of|hemorrhage|underwent (l_nmod) hemorrhage_14\NN\14285662|with|cocaine-associated|subarachnoid|sah (l_appos) sah_16\NN\1740|(|)
D003042_D013345 CID cocaine_16\NN\3492717|for|or|metabolites (r_nmod) toxicology_14\NN\6054892|with|positive|urine|cocaine (r_nmod) those_10\DT\1740|toxicology (r_dobj) identified_9\VBD\699815|those (r_conj) screened_3\VBD\2533282|:|we|patients|retrospectively|and|identified|. (l_dobj) patients_4\NNS\9898892|sah (l_nmod) sah_6\NN\1740|with
D003042_D013345 CID cocaine_33\NN\3492717| (r_compound) use_34\NN\407535|with|cocaine (r_nmod) associated_31\VBN\628491|use (r_acl) sah_30\NN\1740|after|aneurysmal|associated
D003042_D013901 NONE cocaine_2\NN\3492717| (r_compound) use_3\NN\407535|cocaine (r_nsubjpass) associated_6\VBN\628491|:|use|has|been|complications|. (l_nmod) complications_9\NNS\1073995|with|neurovascular|,|vasoconstriction
D003042_D014657 NONE cocaine_2\NN\3492717| (r_compound) use_3\NN\407535|cocaine (r_nsubjpass) associated_6\VBN\628491|:|use|has|been|complications|. (l_nmod) complications_9\NNS\1073995|with|neurovascular|,|vasoconstriction (l_nmod) vasoconstriction_13\NN\1149911|including|arterial|and|vasculitis (l_conj) vasculitis_15\NN\14336539|
D003042_D014657 NONE cocaine_33\NN\3492717| (r_compound) use_34\NN\407535|with|cocaine (r_nmod) associated_31\VBN\628491|use (r_acl) sah_30\NN\1740|after|aneurysmal|associated (r_nmod) underwent_26\VBD\109660|who|angiography|sah (r_acl:relcl) patients_24\NNS\9898892|in|underwent (r_nmod) found_22\VBN\2426171|evidence|could|be|patients|. (l_nsubjpass) evidence_4\NN\5816287|no|quantitative|narrowing|or|evidence (l_conj) evidence_14\NN\5816287|qualitative|angiographic|narrowing (l_nmod) narrowing_17\NN\5064037|for|distal|or|vasculitis (l_conj) vasculitis_19\NN\14336539|
D003042_D017542 CID cocaine_33\NN\3492717| (r_compound) use_34\NN\407535|with|cocaine (r_nmod) associated_31\VBN\628491|use (r_acl) sah_30\NN\1740|after|aneurysmal|associated (l_amod) aneurysmal_29\JJ\1740|
8841157
C081489_D006973 NONE valsartan_0\NN\2712393|,|antagonist|:|study|. (l_appos) antagonist_6\NN\7846|a|new|angiotensin|ii|treatment (l_nmod) treatment_9\NN\654885|for|the|hypertension (l_nmod) hypertension_12\NN\14057371|of|essential
C081489_D006973 NONE valsartan_25\NN\2712393|mg|or|amlodipine (r_dobj) receive_22\VB\2210855|to|valsartan|weeks (r_xcomp) allocated_14\VBN\2228698|methods|were|randomly|fashion|and|number|receive|. (l_nsubjpass) methods_0\NNS\5616786|:|outpatients (l_appos) outpatients_6\NNS\10405694|sixty-eight|adult|hypertension (l_nmod) hypertension_11\NN\14057371|with|moderate
C081489_D006973 NONE valsartan_6\NN\2712393| (r_nsubj) effective_11\JJ\1740|that|valsartan|is|least|as|amlodipine|treatment (l_nmod) treatment_16\NN\654885|in|the|hypertension (l_nmod) hypertension_21\NN\14057371|of|moderate
D000804_D006973 NONE ii_5\CD\13741022| (r_nummod) antagonist_6\NN\7846|a|new|angiotensin|ii|treatment (l_nmod) treatment_9\NN\654885|for|the|hypertension (l_nmod) hypertension_12\NN\14057371|of|essential
D017311_D006973 NONE amlodipine_23\NN\1740|against (r_nmod) efficacy_19\NN\5199286|of|the|and|safety|amlodipine (r_nmod) study_16\NN\635850|a|comparative|efficacy (r_appos) valsartan_0\NN\2712393|,|antagonist|:|study|. (l_appos) antagonist_6\NN\7846|a|new|angiotensin|ii|treatment (l_nmod) treatment_9\NN\654885|for|the|hypertension (l_nmod) hypertension_12\NN\14057371|of|essential
D017311_D006973 NONE amlodipine_29\NN\1740|mg (r_conj) valsartan_25\NN\2712393|mg|or|amlodipine (r_dobj) receive_22\VB\2210855|to|valsartan|weeks (r_xcomp) allocated_14\VBN\2228698|methods|were|randomly|fashion|and|number|receive|. (l_nsubjpass) methods_0\NNS\5616786|:|outpatients (l_appos) outpatients_6\NNS\10405694|sixty-eight|adult|hypertension (l_nmod) hypertension_11\NN\14057371|with|moderate
D017311_D006973 NONE amlodipine_13\NN\1740|as (r_nmod) effective_11\JJ\1740|that|valsartan|is|least|as|amlodipine|treatment (l_nmod) treatment_16\NN\654885|in|the|hypertension (l_nmod) hypertension_21\NN\14057371|of|moderate
D017311_D004487 CID amlodipine_11\NN\1740| (r_compound) group_12\NN\2137|in|the|amlodipine (r_nmod) higher_8\JJR\1740|incidence|was|somewhat|group|,|dose|%|. (l_nsubj) incidence_1\NN\13821570|the|edema (l_nmod) edema_5\NN\14315192|of|drug-related|dependent
D017311_D004487 CID amlodipine_36\NN\1740|for|mg (r_nmod) %_32\NN\1740|3.6|amlodipine (r_appos) %_25\NN\1740|(|2.4|valsartan|;|%|;|%|;|%|) (r_dep) higher_8\JJR\1740|incidence|was|somewhat|group|,|dose|%|. (l_nsubj) incidence_1\NN\13821570|the|edema (l_nmod) edema_5\NN\14315192|of|drug-related|dependent
D017311_D004487 CID amlodipine_45\NN\1740|mg (r_conj) valsartan_41\NN\2712393|for|plus|amlodipine (r_nmod) %_39\NN\1740|0|valsartan (r_appos) %_25\NN\1740|(|2.4|valsartan|;|%|;|%|;|%|) (r_dep) higher_8\JJR\1740|incidence|was|somewhat|group|,|dose|%|. (l_nsubj) incidence_1\NN\13821570|the|edema (l_nmod) edema_5\NN\14315192|of|drug-related|dependent
D017311_D004487 CID amlodipine_52\NN\1740|for|mg (r_nmod) %_48\NN\1740|14.3|amlodipine (r_appos) %_25\NN\1740|(|2.4|valsartan|;|%|;|%|;|%|) (r_dep) higher_8\JJR\1740|incidence|was|somewhat|group|,|dose|%|. (l_nsubj) incidence_1\NN\13821570|the|edema (l_nmod) edema_5\NN\14315192|of|drug-related|dependent
C081489_D004487 CID valsartan_29\NN\2712393|for|mg (r_nmod) %_25\NN\1740|(|2.4|valsartan|;|%|;|%|;|%|) (r_dep) higher_8\JJR\1740|incidence|was|somewhat|group|,|dose|%|. (l_nsubj) incidence_1\NN\13821570|the|edema (l_nmod) edema_5\NN\14315192|of|drug-related|dependent
C081489_D004487 CID valsartan_41\NN\2712393|for|plus|amlodipine (r_nmod) %_39\NN\1740|0|valsartan (r_appos) %_25\NN\1740|(|2.4|valsartan|;|%|;|%|;|%|) (r_dep) higher_8\JJR\1740|incidence|was|somewhat|group|,|dose|%|. (l_nsubj) incidence_1\NN\13821570|the|edema (l_nmod) edema_5\NN\14315192|of|drug-related|dependent
6637851
D000638_D064420 NONE amiodarone_6\NN\2715941| (r_compound) therapy_7\NN\657604|of|high-dose|amiodarone|tachycardia (r_nmod) efficacy_1\NN\5199286|long-term|and|toxicity|therapy|. (l_conj) toxicity_3\NN\13576101|
D000638_D064420 NONE amiodarone_2\NN\2715941|large-dose (r_nsubj) effective_5\JJ\1740|although|amiodarone|is|highly|treatment (r_advcl) causes_21\VBZ\1617192|effective|,|it|toxicity|%|. (l_dobj) toxicity_23\NN\13576101|significant
D000638_D017180 NONE amiodarone_6\NN\2715941| (r_compound) therapy_7\NN\657604|of|high-dose|amiodarone|tachycardia (l_nmod) tachycardia_10\NN\14110674|for|ventricular|or|fibrillation
D000638_D017180 NONE amiodarone_0\NN\2715941| (r_nsubjpass) administered_2\VBN\2436349|amiodarone|was|patients|. (l_nmod) patients_5\NNS\9898892|to|154|had (l_acl:relcl) had_7\VBD\2108377|who|tachycardia (l_dobj) tachycardia_12\NN\14110674|sustained|,|symptomatic|ventricular|vt|=|or|arrest|and|refractory
D000638_D017180 NONE amiodarone_0\NN\2715941| (r_nsubjpass) administered_2\VBN\2436349|amiodarone|was|patients|. (l_nmod) patients_5\NNS\9898892|to|154|had (l_acl:relcl) had_7\VBD\2108377|who|tachycardia (l_dobj) tachycardia_12\NN\14110674|sustained|,|symptomatic|ventricular|vt|=|or|arrest|and|refractory (l_appos) vt_14\NN\1740|(|)
D000638_D017180 NONE amiodarone_7\NN\2715941|with (r_nmod) treatment_5\NN\654885|amiodarone (r_dobj) continued_4\VBD\2367363|percent|treatment|and|had|. (l_conj) had_9\VBD\2108377|recurrence|follow-up (l_dobj) recurrence_11\NN\7342049|no|vt (l_nmod) vt_14\NN\1740|of|symptomatic|or|fibrillation
D000638_D017180 NONE amiodarone_17\NN\2715941| (r_dobj) continuing_16\VBG\2367363|by|amiodarone|dose|or|addition (r_advcl) managed_14\VBN\2524171|were|successfully|continuing (r_conj) had_5\VBD\2108377|percent|recurrence|and|managed|. (l_dobj) recurrence_8\NN\7342049|a|nonfatal|vt (l_nmod) vt_10\NN\1740|of
D000638_D017180 NONE amiodarone_2\NN\2715941|large-dose (r_nsubj) effective_5\JJ\1740|although|amiodarone|is|highly|treatment (l_nmod) treatment_9\NN\654885|in|the|long-term|vt (l_nmod) vt_11\NN\1740|of|or|vf|refractory
D000638_D017180 NONE amiodarone_31\NN\2715941|with (r_nmod) managed_29\VBN\2524171|however|,|adjusted|,|%|can|be|successfully|amiodarone|. (l_nsubjpass) %_19\NN\1740|75|patients (l_nmod) patients_21\NNS\9898892|of|vt (l_nmod) vt_23\NN\1740|with|or|vf
D000638_D014693 NONE amiodarone_6\NN\2715941| (r_compound) therapy_7\NN\657604|of|high-dose|amiodarone|tachycardia (l_nmod) tachycardia_10\NN\14110674|for|ventricular|or|fibrillation (l_conj) fibrillation_13\NN\14361664|ventricular
D000638_D014693 NONE amiodarone_7\NN\2715941|with (r_nmod) treatment_5\NN\654885|amiodarone (r_dobj) continued_4\VBD\2367363|percent|treatment|and|had|. (l_conj) had_9\VBD\2108377|recurrence|follow-up (l_dobj) recurrence_11\NN\7342049|no|vt (l_nmod) vt_14\NN\1740|of|symptomatic|or|fibrillation (l_conj) fibrillation_17\NN\14361664|ventricular|vf
D000638_D014693 NONE amiodarone_7\NN\2715941|with (r_nmod) treatment_5\NN\654885|amiodarone (r_dobj) continued_4\VBD\2367363|percent|treatment|and|had|. (l_conj) had_9\VBD\2108377|recurrence|follow-up (l_dobj) recurrence_11\NN\7342049|no|vt (l_nmod) vt_14\NN\1740|of|symptomatic|or|fibrillation (l_conj) fibrillation_17\NN\14361664|ventricular|vf (l_appos) vf_19\NN\1740|(|)
D000638_D014693 NONE amiodarone_2\NN\2715941|large-dose (r_nsubj) effective_5\JJ\1740|although|amiodarone|is|highly|treatment (l_nmod) treatment_9\NN\654885|in|the|long-term|vt (l_nmod) vt_11\NN\1740|of|or|vf|refractory (l_conj) vf_13\NN\1740|
D000638_D014693 NONE amiodarone_31\NN\2715941|with (r_nmod) managed_29\VBN\2524171|however|,|adjusted|,|%|can|be|successfully|amiodarone|. (l_nsubjpass) %_19\NN\1740|75|patients (l_nmod) patients_21\NNS\9898892|of|vt (l_nmod) vt_23\NN\1740|with|or|vf (l_conj) vf_25\NN\1740|
D000638_D006323 NONE amiodarone_0\NN\2715941| (r_nsubjpass) administered_2\VBN\2436349|amiodarone|was|patients|. (l_nmod) patients_5\NNS\9898892|to|154|had (l_acl:relcl) had_7\VBD\2108377|who|tachycardia (l_dobj) tachycardia_12\NN\14110674|sustained|,|symptomatic|ventricular|vt|=|or|arrest|and|refractory (l_conj) arrest_24\NN\88481|a|cardiac|=
1969772
D018818_D007022 CID fenoldopam_9\NN\1740|with (r_nmod) induced_7\VBN\1627355|fenoldopam|dogs (r_acl) hypotension_6\NN\14057371|during|induced
D018818_D007022 CID fenoldopam_3\NN\1740| (r_nsubjpass) used_6\VBN\1156834|that|fenoldopam|could|be|induce (l_xcomp) induce_8\VB\1627355|to|hypotension|and|preserve (l_dobj) hypotension_9\NN\14057371|
D018818_D007022 CID fenoldopam-induced_8\JJ\1740| (r_amod) hypotension_9\NN\14057371|during|fenoldopam-induced
D018818_D007022 CID fenoldopam-induced_8\JJ\1740| (r_amod) hypotension_9\NN\14057371|during|fenoldopam-induced (r_nmod) increased_6\VBD\169651|flow|hypotension|cent|and|decreased|. (l_conj) decreased_16\VBD\169651|cent|hypotension|p (l_nmod) hypotension_25\NN\14057371|during|sodium|nitroprusside-induced
D012964_D007022 NONE sodium_23\NN\14625458| (r_compound) hypotension_25\NN\14057371|during|sodium|nitroprusside-induced (r_nmod) decreased_16\VBD\169651|cent|hypotension|p (r_conj) increased_6\VBD\169651|flow|hypotension|cent|and|decreased|. (l_nmod) hypotension_9\NN\14057371|during|fenoldopam-induced
D012964_D007022 NONE sodium_23\NN\14625458| (r_compound) hypotension_25\NN\14057371|during|sodium|nitroprusside-induced
D009599_D007022 CID nitroprusside-induced_24\JJ\1740| (r_amod) hypotension_25\NN\14057371|during|sodium|nitroprusside-induced (r_nmod) decreased_16\VBD\169651|cent|hypotension|p (r_conj) increased_6\VBD\169651|flow|hypotension|cent|and|decreased|. (l_nmod) hypotension_9\NN\14057371|during|fenoldopam-induced
D009599_D007022 CID nitroprusside-induced_24\JJ\1740| (r_amod) hypotension_25\NN\14057371|during|sodium|nitroprusside-induced
D009599_D007022 CID nitroprusside_1\NN\1740|sodium (r_nsubj) vasodilator_8\NN\3198383|nitroprusside|is|a|arteriolar|produce|. (l_acl:relcl) produce_11\VB\1617192|that|can|redistribution|away|hypotension (l_nmod) hypotension_22\NN\14057371|during|induced
D004298_D007022 NONE dopamine-1_4\NN\1740| (r_compound) agonist_9\NN\9613191|fenoldopam|is|a|selective|dopamine-1|(|da1|)|receptor|causes|. (l_acl:relcl) causes_11\VBZ\1617192|that|vasodilatation|and|preserves (l_conj) preserves_23\VBZ\2681795|flow|hypotension (l_nmod) hypotension_31\NN\14057371|during|induced
9545159
D020117_D008133 CID cisapride-diltiazem_7\NN\1740| (r_compound) interaction_8\NN\37396|to|cisapride-diltiazem (r_nmod) related_5\JJ\1740|interaction (r_acl) prolongation_0\NN\1017987|interval|related|. (l_nmod) interval_4\NN\33615|of|the|qt
D004110_D008133 CID cisapride-diltiazem_7\NN\1740| (r_compound) interaction_8\NN\37396|to|cisapride-diltiazem (r_nmod) related_5\JJ\1740|interaction (r_acl) prolongation_0\NN\1017987|interval|related|. (l_nmod) interval_4\NN\33615|of|the|qt
D020117_D015835 NONE cisapride_0\NN\1740|,|substrate|, (r_nsubjpass) prescribed_13\VBN\748282|cisapride|is|widely|treatment|. (l_nmod) treatment_16\NN\654885|for|the|disorders (l_nmod) disorders_20\NNS\14034177|of|gastrointestinal|motility
D004917_D008133 CID erythromycin_20\NN\2716866|with|or|agents|,|but|inhibitors (r_nmod) administration_18\NN\1133281|after|concomitant|erythromycin (r_nmod) reported_15\VBN\831651|prolongation|have|been|administration|. (l_nsubjpass) prolongation_0\NN\1017987|interval|,|pointes|,|and|death (l_nmod) interval_3\NN\33615|of|qt
D004917_D016171 CID erythromycin_20\NN\2716866|with|or|agents|,|but|inhibitors (r_nmod) administration_18\NN\1133281|after|concomitant|erythromycin (r_nmod) reported_15\VBN\831651|prolongation|have|been|administration|. (l_nsubjpass) prolongation_0\NN\1017987|interval|,|pointes|,|and|death (l_conj) pointes_7\NNS\1740|torsades|de
D004917_D016757 CID erythromycin_20\NN\2716866|with|or|agents|,|but|inhibitors (r_nmod) administration_18\NN\1133281|after|concomitant|erythromycin (r_nmod) reported_15\VBN\831651|prolongation|have|been|administration|. (l_nsubjpass) prolongation_0\NN\1017987|interval|,|pointes|,|and|death (l_conj) death_12\NN\7296428|sudden|cardiac
D001393_D008133 CID azole_22\NN\1740| (r_compound) agents_24\NNS\7347|azole|antifungal (r_conj) erythromycin_20\NN\2716866|with|or|agents|,|but|inhibitors (r_nmod) administration_18\NN\1133281|after|concomitant|erythromycin (r_nmod) reported_15\VBN\831651|prolongation|have|been|administration|. (l_nsubjpass) prolongation_0\NN\1017987|interval|,|pointes|,|and|death (l_nmod) interval_3\NN\33615|of|qt
D001393_D016171 CID azole_22\NN\1740| (r_compound) agents_24\NNS\7347|azole|antifungal (r_conj) erythromycin_20\NN\2716866|with|or|agents|,|but|inhibitors (r_nmod) administration_18\NN\1133281|after|concomitant|erythromycin (r_nmod) reported_15\VBN\831651|prolongation|have|been|administration|. (l_nsubjpass) prolongation_0\NN\1017987|interval|,|pointes|,|and|death (l_conj) pointes_7\NNS\1740|torsades|de
D001393_D016757 CID azole_22\NN\1740| (r_compound) agents_24\NNS\7347|azole|antifungal (r_conj) erythromycin_20\NN\2716866|with|or|agents|,|but|inhibitors (r_nmod) administration_18\NN\1133281|after|concomitant|erythromycin (r_nmod) reported_15\VBN\831651|prolongation|have|been|administration|. (l_nsubjpass) prolongation_0\NN\1017987|interval|,|pointes|,|and|death (l_conj) death_12\NN\7296428|sudden|cardiac
D020117_D005764 NONE cisapride_12\NN\1740| (r_dobj) taking_11\VBG\2367363|who|was|cisapride|disorder (l_nmod) disorder_16\NN\14034177|for|gastroesophageal|reflux
D020117_D006973 NONE cisapride_12\NN\1740| (r_dobj) taking_11\VBG\2367363|who|was|cisapride|disorder (r_acl:relcl) woman_8\NN\9605289|in|a|45-year-old|taking|and|diltiazem (l_conj) diltiazem_18\NN\2938514|,|agent|,|hypertension (l_nmod) hypertension_30\NN\14057371|for
D004110_D005764 NONE diltiazem_18\NN\2938514|,|agent|,|hypertension (r_conj) woman_8\NN\9605289|in|a|45-year-old|taking|and|diltiazem (l_acl:relcl) taking_11\VBG\2367363|who|was|cisapride|disorder (l_nmod) disorder_16\NN\14034177|for|gastroesophageal|reflux
D004110_D006973 NONE diltiazem_18\NN\2938514|,|agent|,|hypertension (l_nmod) hypertension_30\NN\14057371|for
1535072
D015016_D020018 NONE yohimbine_0\NN\1740| (r_compound) treatment_1\NN\654885|yohimbine|effects|. (l_nmod) effects_5\NNS\13245626|of|sexual|side|induced
D015016_D020018 NONE yohimbine_6\NN\1740| (r_nsubjpass) used_9\VBN\1156834|that|yohimbine|may|be|treat (l_xcomp) treat_11\VB\2376958|to|effects (l_dobj) effects_15\NNS\13245626|the|sexual|side|clomipramine
D015016_D020018 NONE yohimbine_3\NN\1740| (r_dobj) evaluated_2\VBD\670261|study|yohimbine|treatment|. (l_nmod) treatment_6\NN\654885|as|a|effects (l_nmod) effects_11\NNS\13245626|for|the|sexual|side|caused
D015016_D020018 NONE yohimbine_30\NN\1740| (r_dobj) given_29\VBN\2327200|patients|were|yohimbine|basis|trial|. (l_nsubjpass) patients_3\NNS\9898892|six|disorder (l_nmod) disorder_8\NN\14034177|with|either|obsessive|compulsive|,|trichotillomania|suffered (l_acl:relcl) suffered_18\VBD\2110220|who|effects|treatment (l_dobj) effects_21\NNS\13245626|sexual|side
D015016_D020018 NONE yohimbine_9\NN\1740| (r_nsubj) treatment_14\NN\654885|that|yohimbine|may|be|an|effective|effects (l_nmod) effects_19\NNS\13245626|for|the|sexual|side|caused
D012701_D020018 NONE serotonin_8\NN\14807737| (r_compound) blockers_10\NNS\10101634|by|serotonin|reuptake (r_nmod) induced_6\VBN\1627355|blockers (r_acl) effects_5\NNS\13245626|of|sexual|side|induced
D012701_D020018 NONE serotonin_14\NN\14807737| (r_compound) blockers_16\NNS\10101634|by|serotonin|reuptake (r_nmod) caused_12\VBN\1617192|blockers (r_acl) effects_11\NNS\13245626|for|the|sexual|side|caused
D012701_D020018 NONE serotonin_25\NN\14807737| (r_compound) blockers_27\NNS\10101634|with|serotonin|reuptake (r_nmod) treatment_23\NN\654885|after|blockers (r_nmod) suffered_18\VBD\2110220|who|effects|treatment (l_dobj) effects_21\NNS\13245626|sexual|side
D012701_D020018 NONE serotonin_22\NN\14807737| (r_compound) blockers_24\NNS\10101634|by|serotonin|reuptake (r_nmod) caused_20\VBN\1617192|blockers (r_acl) effects_19\NNS\13245626|for|the|sexual|side|caused
D015016_D007172 NONE yohimbine_8\NN\1740| (r_nsubj) facilitates_9\VBZ\2547586|that|yohimbine|behavior|and|helpful (l_conj) helpful_15\JJ\1740|may|be|treatment (l_nmod) treatment_18\NN\654885|in|the|impotence (l_nmod) impotence_21\NN\4723816|of|male
D002997_D020018 CID clomipramine_17\NN\4482543|of (r_nmod) effects_15\NNS\13245626|the|sexual|side|clomipramine
D012701_D009771 NONE serotonin_25\NN\14807737| (r_compound) blockers_27\NNS\10101634|with|serotonin|reuptake (r_nmod) treatment_23\NN\654885|after|blockers (r_nmod) suffered_18\VBD\2110220|who|effects|treatment (r_acl:relcl) disorder_8\NN\14034177|with|either|obsessive|compulsive|,|trichotillomania|suffered
D012701_D014256 NONE serotonin_25\NN\14807737| (r_compound) blockers_27\NNS\10101634|with|serotonin|reuptake (r_nmod) treatment_23\NN\654885|after|blockers (r_nmod) suffered_18\VBD\2110220|who|effects|treatment (r_acl:relcl) disorder_8\NN\14034177|with|either|obsessive|compulsive|,|trichotillomania|suffered (l_conj) trichotillomania_10\NN\9181557|,|anxiety|,|or|disorders
D012701_D001008 NONE serotonin_25\NN\14807737| (r_compound) blockers_27\NNS\10101634|with|serotonin|reuptake (r_nmod) treatment_23\NN\654885|after|blockers (r_nmod) suffered_18\VBD\2110220|who|effects|treatment (r_acl:relcl) disorder_8\NN\14034177|with|either|obsessive|compulsive|,|trichotillomania|suffered (l_conj) trichotillomania_10\NN\9181557|,|anxiety|,|or|disorders (l_conj) anxiety_12\NN\14373582|
D012701_D019964 NONE serotonin_25\NN\14807737| (r_compound) blockers_27\NNS\10101634|with|serotonin|reuptake (r_nmod) treatment_23\NN\654885|after|blockers (r_nmod) suffered_18\VBD\2110220|who|effects|treatment (r_acl:relcl) disorder_8\NN\14034177|with|either|obsessive|compulsive|,|trichotillomania|suffered (l_conj) trichotillomania_10\NN\9181557|,|anxiety|,|or|disorders (l_conj) disorders_16\NNS\14034177|affective
D015016_D009771 NONE yohimbine_30\NN\1740| (r_dobj) given_29\VBN\2327200|patients|were|yohimbine|basis|trial|. (l_nsubjpass) patients_3\NNS\9898892|six|disorder (l_nmod) disorder_8\NN\14034177|with|either|obsessive|compulsive|,|trichotillomania|suffered
D015016_D014256 NONE yohimbine_30\NN\1740| (r_dobj) given_29\VBN\2327200|patients|were|yohimbine|basis|trial|. (l_nsubjpass) patients_3\NNS\9898892|six|disorder (l_nmod) disorder_8\NN\14034177|with|either|obsessive|compulsive|,|trichotillomania|suffered (l_conj) trichotillomania_10\NN\9181557|,|anxiety|,|or|disorders
D015016_D001008 NONE yohimbine_30\NN\1740| (r_dobj) given_29\VBN\2327200|patients|were|yohimbine|basis|trial|. (l_nsubjpass) patients_3\NNS\9898892|six|disorder (l_nmod) disorder_8\NN\14034177|with|either|obsessive|compulsive|,|trichotillomania|suffered (l_conj) trichotillomania_10\NN\9181557|,|anxiety|,|or|disorders (l_conj) anxiety_12\NN\14373582|
D015016_D001008 NONE yohimbine_3\NN\1740|of (r_nmod) effects_1\NNS\13245626|side|yohimbine (r_nsubj) included_4\VBD\690614|effects|sweating|. (l_dobj) sweating_6\NN\13440063|excessive|,|anxiety (l_conj) anxiety_9\NN\14373582|increased|,|and|feeling
D015016_D019964 NONE yohimbine_30\NN\1740| (r_dobj) given_29\VBN\2327200|patients|were|yohimbine|basis|trial|. (l_nsubjpass) patients_3\NNS\9898892|six|disorder (l_nmod) disorder_8\NN\14034177|with|either|obsessive|compulsive|,|trichotillomania|suffered (l_conj) trichotillomania_10\NN\9181557|,|anxiety|,|or|disorders (l_conj) disorders_16\NNS\14034177|affective
1700207
C032151_D001145 NONE cibenzoline_6\NN\1740|of (r_nmod) isomers_4\NNS\14818238|of|optical|cibenzoline (r_nmod) effects_1\NNS\13245626|antiarrhythmic|isomers|arrhythmias|. (l_nmod) arrhythmias_10\NNS\14103288|on|canine|ventricular
C032151_D001145 NONE (+)-cibenzoline_3\NN\1740|of|and|(-)-cibenzoline (r_nmod) effects_1\NNS\13245626|antiarrhythmic|(+)-cibenzoline (r_nsubjpass) examined_7\VBN\789138|effects|were|using|. (l_xcomp) using_8\VBG\1156834|models (l_dobj) models_13\NNS\5888929|two|canine|ventricular|arrhythmia (l_compound) arrhythmia_12\NN\14103288|
C032151_D001145 NONE (-)-cibenzoline_5\NN\1740| (r_conj) (+)-cibenzoline_3\NN\1740|of|and|(-)-cibenzoline (r_nmod) effects_1\NNS\13245626|antiarrhythmic|(+)-cibenzoline (r_nsubjpass) examined_7\VBN\789138|effects|were|using|. (l_xcomp) using_8\VBG\1156834|models (l_dobj) models_13\NNS\5888929|two|canine|ventricular|arrhythmia (l_compound) arrhythmia_12\NN\14103288|
C032151_D001145 NONE (+)-cibenzoline_5\NN\1740|mg/kg|i.v. (r_nsubj) suppressed_6\VBD\2510337|(+)-cibenzoline|arrhythmias|,|respectively|. (l_dobj) arrhythmias_10\NNS\14103288|digitalis-
C032151_D001145 NONE (+)-cibenzoline_6\NN\1740|of (r_nmod) concentrations_4\NNS\4916342|the|minimum|effective|plasma|(+)-cibenzoline|arrhythmias (l_nmod) arrhythmias_11\NNS\14103288|for|digitalis-
C032151_D001145 NONE (-)-cibenzoline_8\NN\1740|of (r_nmod) i.v._6\NN\1740|(-)-cibenzoline (r_amod) mg/kg_5\NN\1740|of|1|i.v. (r_nmod) dose_2\NN\3740161|a|lower|mg/kg (r_nsubj) suppressed_9\VBD\2510337|dose|arrhythmia|,|whereas|needed|. (l_dobj) arrhythmia_12\NN\14103288|the|digitalis-induced
C032151_D001145 NONE (-)-cibenzoline_8\NN\1740|of (r_nmod) i.v._6\NN\1740|(-)-cibenzoline (r_amod) mg/kg_5\NN\1740|of|1|i.v. (r_nmod) dose_2\NN\3740161|a|lower|mg/kg (r_nsubj) suppressed_9\VBD\2510337|dose|arrhythmia|,|whereas|needed|. (l_parataxis) needed_19\VBN\2604760|mg/kg|was|suppress (l_xcomp) suppress_21\VB\2510337|to|arrhythmias (l_dobj) arrhythmias_23\NNS\14103288|adrenaline-induced
C032151_D001145 NONE (-)-cibenzoline_6\NN\1740|of (r_nmod) concentrations_4\NNS\4916342|the|minimum|effective|plasma|(-)-cibenzoline|arrhythmia (l_nmod) arrhythmia_11\NN\14103288|for|digitalis-
D004070_D001145 NONE digitalis_0\NN\15059939| (r_compound) arrhythmia_1\NN\14103288|digitalis|,|suppressed|,
D004070_D001145 NONE digitalis-_7\NN\1740|and|adrenaline-induced (r_amod) arrhythmias_10\NNS\14103288|digitalis-
D004070_D001145 NONE digitalis-_8\NN\1740|and|adrenaline-induced (r_amod) arrhythmias_11\NNS\14103288|for|digitalis-
D004070_D001145 NONE digitalis-induced_11\JJ\1740| (r_amod) arrhythmia_12\NN\14103288|the|digitalis-induced
D004070_D001145 NONE digitalis-induced_11\JJ\1740| (r_amod) arrhythmia_12\NN\14103288|the|digitalis-induced (r_dobj) suppressed_9\VBD\2510337|dose|arrhythmia|,|whereas|needed|. (l_parataxis) needed_19\VBN\2604760|mg/kg|was|suppress (l_xcomp) suppress_21\VB\2510337|to|arrhythmias (l_dobj) arrhythmias_23\NNS\14103288|adrenaline-induced
D004070_D001145 NONE digitalis-_8\NN\1740|and|adrenaline-induced (r_amod) arrhythmia_11\NN\14103288|for|digitalis-
D012964_D001145 NONE na_7\NN\14625458| (r_compound) blockers_9\NNS\10101634|by|na|channel (r_nmod) suppressed_5\VBN\2510337|which|is|blockers (r_acl:relcl) arrhythmia_1\NN\14103288|digitalis|,|suppressed|,
D010042_D001145 CID ouabain_21\NN\1740|of (r_nmod) injection_19\NN\320852|by|intravenous|ouabain|dogs (r_nmod) induced_12\VBN\1627355|arrhythmia|was|injection|. (l_nsubjpass) arrhythmia_1\NN\14103288|digitalis|,|suppressed|,
D010424_D001145 NONE pentobarbital-anesthetized_23\JJ\1740| (r_amod) dogs_24\NNS\2083346|in|pentobarbital-anesthetized (r_nmod) injection_19\NN\320852|by|intravenous|ouabain|dogs (r_nmod) induced_12\VBN\1627355|arrhythmia|was|injection|. (l_nsubjpass) arrhythmia_1\NN\14103288|digitalis|,|suppressed|,
D002118_D001145 NONE ca_7\NN\14625458| (r_compound) blockers_9\NNS\10101634|by|ca|channel (r_nmod) suppressed_5\VBN\2510337|which|is|blockers (r_acl:relcl) arrhythmia_1\NN\14103288|adrenaline|,|suppressed|,
D004837_D001145 CID adrenaline_14\NN\14807929| (r_compound) infusion_15\NN\14589223|by|adrenaline (r_nmod) induced_12\VBN\1627355|arrhythmia|was|infusion|dogs|. (l_nsubjpass) arrhythmia_1\NN\14103288|adrenaline|,|suppressed|,
D004837_D001145 CID adrenaline-induced_9\JJ\1740| (r_conj) digitalis-_7\NN\1740|and|adrenaline-induced (r_amod) arrhythmias_10\NNS\14103288|digitalis-
D004837_D001145 CID adrenaline-induced_10\JJ\1740| (r_conj) digitalis-_8\NN\1740|and|adrenaline-induced (r_amod) arrhythmias_11\NNS\14103288|for|digitalis-
D004837_D001145 CID adrenaline-induced_22\JJ\1740| (r_amod) arrhythmias_23\NNS\14103288|adrenaline-induced (r_dobj) suppress_21\VB\2510337|to|arrhythmias (r_xcomp) needed_19\VBN\2604760|mg/kg|was|suppress (r_parataxis) suppressed_9\VBD\2510337|dose|arrhythmia|,|whereas|needed|. (l_dobj) arrhythmia_12\NN\14103288|the|digitalis-induced
D004837_D001145 CID adrenaline-induced_22\JJ\1740| (r_amod) arrhythmias_23\NNS\14103288|adrenaline-induced
D004837_D001145 CID adrenaline-induced_10\JJ\1740| (r_conj) digitalis-_8\NN\1740|and|adrenaline-induced (r_amod) arrhythmia_11\NN\14103288|for|digitalis-
D006221_D001145 NONE halothane-anesthetized_17\JJ\1740| (r_amod) dogs_18\NNS\2083346|in|halothane-anesthetized (r_nmod) induced_12\VBN\1627355|arrhythmia|was|infusion|dogs|. (l_nsubjpass) arrhythmia_1\NN\14103288|adrenaline|,|suppressed|,
7161250
D006220_D010302 CID haloperidol_10\NN\3713736|of (r_nmod) doses_8\NNS\3740161|at|higher|haloperidol|and|patients (r_nmod) higher_5\JJR\1740|incidence|was|doses|. (l_nsubj) incidence_1\NN\13821570|the|parkinsonism (l_nmod) parkinsonism_3\NN\14085708|of
D001569_D017109 NONE benzodiazepine_5\NN\3771443| (r_compound) lorazepam_6\NN\2830852|by|the|benzodiazepine (r_nmod) controlled_2\VBN\2422663|akathisia|was|lorazepam|patients|,|ineffective|. (l_nsubjpass) akathisia_0\NN\1740|
D008140_D017109 NONE lorazepam_6\NN\2830852|by|the|benzodiazepine (r_nmod) controlled_2\VBN\2422663|akathisia|was|lorazepam|patients|,|ineffective|. (l_nsubjpass) akathisia_0\NN\1740|
19761039
D010936_D004409 NONE sinensis_7\FW\1740|of|hibiscus|rosa (r_nmod) extract_3\NN\14589223|of|methanolic|sinensis|mg/kg (r_nmod) effect_0\NN\34213|extract (r_nsubjpass) studied_15\VBN\630380|effect|was|dyskinesia|. (l_nmod) dyskinesia_19\NN\14084880|on|reserpine-induced|orofacial|and|alterations
D010936_D004409 NONE sinensis_10\FW\1740|hibiscus|rosa (r_nsubj) had_11\VBD\2108377|that|sinensis|role (l_dobj) role_14\NN\719494|a|protective|dyskinesia (l_nmod) dyskinesia_18\NN\14084880|against|reserpine-induced|orofacial|and|stress
D012110_D004409 CID reserpine-induced_17\JJ\1740| (r_amod) dyskinesia_19\NN\14084880|on|reserpine-induced|orofacial|and|alterations
D012110_D004409 CID reserpine-induced_16\JJ\1740| (r_amod) dyskinesia_18\NN\14084880|against|reserpine-induced|orofacial|and|stress
16574713
D018817_D020258 NONE 3,4-methylenedioxymethamphetamine_1\NN\1740|mdma (r_nsubjpass) shown_9\VBN\2137132|although|3,4-methylenedioxymethamphetamine|has|been|damage (r_advcl) known_26\VBN\2110220|shown|,|little|is|consequences|. (l_nmod) consequences_30\NNS\34213|about|the|long-term|lesions|functions (l_nmod) lesions_35\NNS\14204950|of|mdma-induced|5-ht|neurotoxic
D018817_D020258 NONE mdma_3\NN\3054098|(|or|ecstasy|) (r_appos) 3,4-methylenedioxymethamphetamine_1\NN\1740|mdma (r_nsubjpass) shown_9\VBN\2137132|although|3,4-methylenedioxymethamphetamine|has|been|damage (r_advcl) known_26\VBN\2110220|shown|,|little|is|consequences|. (l_nmod) consequences_30\NNS\34213|about|the|long-term|lesions|functions (l_nmod) lesions_35\NNS\14204950|of|mdma-induced|5-ht|neurotoxic
D018817_D020258 NONE ecstasy_5\NN\13985818| (r_conj) mdma_3\NN\3054098|(|or|ecstasy|) (r_appos) 3,4-methylenedioxymethamphetamine_1\NN\1740|mdma (r_nsubjpass) shown_9\VBN\2137132|although|3,4-methylenedioxymethamphetamine|has|been|damage (r_advcl) known_26\VBN\2110220|shown|,|little|is|consequences|. (l_nmod) consequences_30\NNS\34213|about|the|long-term|lesions|functions (l_nmod) lesions_35\NNS\14204950|of|mdma-induced|5-ht|neurotoxic
D018817_D020258 NONE mdma-induced_32\JJ\1740| (r_amod) lesions_35\NNS\14204950|of|mdma-induced|5-ht|neurotoxic
D012701_D020258 NONE serotonin_13\NN\14807737| (r_compound) neurons_17\NNS\5430628|brain|serotonin|(|5-ht|) (r_dobj) damage_11\VB\126264|to|neurons|animals (r_xcomp) shown_9\VBN\2137132|although|3,4-methylenedioxymethamphetamine|has|been|damage (r_advcl) known_26\VBN\2110220|shown|,|little|is|consequences|. (l_nmod) consequences_30\NNS\34213|about|the|long-term|lesions|functions (l_nmod) lesions_35\NNS\14204950|of|mdma-induced|5-ht|neurotoxic
D012701_D020258 NONE 5-ht_15\NN\1740| (r_compound) neurons_17\NNS\5430628|brain|serotonin|(|5-ht|) (r_dobj) damage_11\VB\126264|to|neurons|animals (r_xcomp) shown_9\VBN\2137132|although|3,4-methylenedioxymethamphetamine|has|been|damage (r_advcl) known_26\VBN\2110220|shown|,|little|is|consequences|. (l_nmod) consequences_30\NNS\34213|about|the|long-term|lesions|functions (l_nmod) lesions_35\NNS\14204950|of|mdma-induced|5-ht|neurotoxic
D012701_D020258 NONE 5-ht_33\NN\1740| (r_compound) lesions_35\NNS\14204950|of|mdma-induced|5-ht|neurotoxic
D012701_D020258 NONE 5-ht_40\NN\1740| (r_nsubjpass) involved_42\VBN\2676054|which|5-ht|is (r_acl:relcl) functions_37\NNS\13783581|on|involved|,|function (r_nmod) consequences_30\NNS\34213|about|the|long-term|lesions|functions (l_nmod) lesions_35\NNS\14204950|of|mdma-induced|5-ht|neurotoxic
D018817_D008569 CID mdma_12\NN\3054098| (r_compound) users_13\NNS\7846|in|moderate|mdma (r_nmod) observed_9\VBN\2163746|contrast|,|evidence|was|users|. (l_nsubjpass) evidence_4\NN\5816287|no|impairment (l_nmod) impairment_7\NN\7296428|of|memory
D018817_D008569 CID mdma_4\NN\3054098|of (r_nmod) use_2\NN\407535|the|mdma|quantities (r_nsubjpass) associated_16\VBN\628491|while|use|is|not|functioning (l_nmod) functioning_20\NN\29677|with|impaired|memory
D018817_D008569 CID mdma_4\NN\3054098|of (r_nmod) use_2\NN\407535|the|mdma|quantities (r_nsubjpass) associated_16\VBN\628491|while|use|is|not|functioning (r_advcl) lead_28\VB\1752884|associated|,|use|may|impairments|. (l_nmod) impairments_33\NNS\7296428|to|lasting|memory
D018817_D008569 CID mdma_25\NN\3054098| (r_compound) use_26\NN\407535|of|mdma (r_nmod) use_23\NN\407535|heavy|use (r_nsubj) lead_28\VB\1752884|associated|,|use|may|impairments|. (l_advcl) associated_16\VBN\628491|while|use|is|not|functioning (l_nmod) functioning_20\NN\29677|with|impaired|memory
D018817_D008569 CID mdma_25\NN\3054098| (r_compound) use_26\NN\407535|of|mdma (r_nmod) use_23\NN\407535|heavy|use (r_nsubj) lead_28\VB\1752884|associated|,|use|may|impairments|. (l_nmod) impairments_33\NNS\7296428|to|lasting|memory
15811908
C012052_D010673 NONE amisulpride_3\NN\1740|by|and|tiapride (r_nmod) unmasked_1\VBN\853195|amisulpride (r_acl) pheochromocytoma_0\NN\14235200|unmasked|.
C012052_D010673 NONE amisulpride_13\NN\1740|with|and|tiapride (r_nmod) treated_11\VBN\2376958|amisulpride (r_acl) patient_10\NN\9898892|in|a|treated (r_nmod) unmasking_5\NN\7215377|the|pheochromocytoma|patient (l_nmod) pheochromocytoma_7\NN\14235200|of
C012052_D010673 NONE amisulpride-_16\NN\1740|and|tiapride-induced (r_compound) crisis_20\NN\14411243|of|amisulpride-|hypertensive|patient (l_nmod) patient_23\NN\9898892|in|a|pheochromocytoma (l_nmod) pheochromocytoma_25\NN\14235200|with
D063325_D010673 NONE tiapride_5\NN\1740| (r_conj) amisulpride_3\NN\1740|by|and|tiapride (r_nmod) unmasked_1\VBN\853195|amisulpride (r_acl) pheochromocytoma_0\NN\14235200|unmasked|.
D063325_D010673 NONE tiapride_15\NN\1740| (r_conj) amisulpride_13\NN\1740|with|and|tiapride (r_nmod) treated_11\VBN\2376958|amisulpride (r_acl) patient_10\NN\9898892|in|a|treated (r_nmod) unmasking_5\NN\7215377|the|pheochromocytoma|patient (l_nmod) pheochromocytoma_7\NN\14235200|of
D063325_D010673 NONE tiapride-induced_18\JJ\1740| (r_conj) amisulpride-_16\NN\1740|and|tiapride-induced (r_compound) crisis_20\NN\14411243|of|amisulpride-|hypertensive|patient (l_nmod) patient_23\NN\9898892|in|a|pheochromocytoma (l_nmod) pheochromocytoma_25\NN\14235200|with
C012052_D006973 CID amisulpride_22\NN\1740|of|mg|and|tiapride (r_nmod) doses_20\NNS\3740161|the|first|amisulpride (r_dobj) developed_7\VBD\1753788|:|man|hypertension|after|doses|mg. (l_dobj) hypertension_9\NN\14057371|acute|headache
C012052_D006973 CID amisulpride_19\NN\1740|and|tiapride (r_compound) therapy_22\NN\657604|amisulpride (r_conj) crisis_17\NN\14411243|between|the|hypertensive|and|therapy (l_amod) hypertensive_16\JJ\1740|
C012052_D006973 CID amisulpride-_16\NN\1740|and|tiapride-induced (r_compound) crisis_20\NN\14411243|of|amisulpride-|hypertensive|patient (l_amod) hypertensive_19\JJ\1740|
C012052_D006261 CID amisulpride_22\NN\1740|of|mg|and|tiapride (r_nmod) doses_20\NNS\3740161|the|first|amisulpride (r_dobj) developed_7\VBD\1753788|:|man|hypertension|after|doses|mg. (l_dobj) hypertension_9\NN\14057371|acute|headache (l_nmod) headache_12\NN\5829480|with|severe|and|vomiting
C012052_D014839 CID amisulpride_22\NN\1740|of|mg|and|tiapride (r_nmod) doses_20\NNS\3740161|the|first|amisulpride (r_dobj) developed_7\VBD\1753788|:|man|hypertension|after|doses|mg. (l_dobj) hypertension_9\NN\14057371|acute|headache (l_nmod) headache_12\NN\5829480|with|severe|and|vomiting (l_conj) vomiting_14\NN\116687|
D063325_D006973 CID tiapride_26\NN\1740| (r_conj) amisulpride_22\NN\1740|of|mg|and|tiapride (r_nmod) doses_20\NNS\3740161|the|first|amisulpride (r_dobj) developed_7\VBD\1753788|:|man|hypertension|after|doses|mg. (l_dobj) hypertension_9\NN\14057371|acute|headache
D063325_D006973 CID tiapride_21\NN\1740| (r_conj) amisulpride_19\NN\1740|and|tiapride (r_compound) therapy_22\NN\657604|amisulpride (r_conj) crisis_17\NN\14411243|between|the|hypertensive|and|therapy (l_amod) hypertensive_16\JJ\1740|
D063325_D006973 CID tiapride-induced_18\JJ\1740| (r_conj) amisulpride-_16\NN\1740|and|tiapride-induced (r_compound) crisis_20\NN\14411243|of|amisulpride-|hypertensive|patient (l_amod) hypertensive_19\JJ\1740|
D063325_D006261 CID tiapride_26\NN\1740| (r_conj) amisulpride_22\NN\1740|of|mg|and|tiapride (r_nmod) doses_20\NNS\3740161|the|first|amisulpride (r_dobj) developed_7\VBD\1753788|:|man|hypertension|after|doses|mg. (l_dobj) hypertension_9\NN\14057371|acute|headache (l_nmod) headache_12\NN\5829480|with|severe|and|vomiting
D063325_D014839 CID tiapride_26\NN\1740| (r_conj) amisulpride_22\NN\1740|of|mg|and|tiapride (r_nmod) doses_20\NNS\3740161|the|first|amisulpride (r_dobj) developed_7\VBD\1753788|:|man|hypertension|after|doses|mg. (l_dobj) hypertension_9\NN\14057371|acute|headache (l_nmod) headache_12\NN\5829480|with|severe|and|vomiting (l_conj) vomiting_14\NN\116687|
D009529_D006973 NONE nicardipine_41\NN\1740|and|verapamil (r_compound) treatment_44\NN\654885|after|subsequent|nicardipine (r_nmod) recovered_38\VBD\2210855|patient|treatment|. (r_conj) discontinued_33\VBN\2609764|drugs|were|immediately|,|and|recovered (r_dep) summary_1\NN\6722453|case|developed|discontinued (l_dep) developed_7\VBD\1753788|:|man|hypertension|after|doses|mg. (l_dobj) hypertension_9\NN\14057371|acute|headache
D009529_D006261 NONE nicardipine_41\NN\1740|and|verapamil (r_compound) treatment_44\NN\654885|after|subsequent|nicardipine (r_nmod) recovered_38\VBD\2210855|patient|treatment|. (r_conj) discontinued_33\VBN\2609764|drugs|were|immediately|,|and|recovered (r_dep) summary_1\NN\6722453|case|developed|discontinued (l_dep) developed_7\VBD\1753788|:|man|hypertension|after|doses|mg. (l_dobj) hypertension_9\NN\14057371|acute|headache (l_nmod) headache_12\NN\5829480|with|severe|and|vomiting
D009529_D014839 NONE nicardipine_41\NN\1740|and|verapamil (r_compound) treatment_44\NN\654885|after|subsequent|nicardipine (r_nmod) recovered_38\VBD\2210855|patient|treatment|. (r_conj) discontinued_33\VBN\2609764|drugs|were|immediately|,|and|recovered (r_dep) summary_1\NN\6722453|case|developed|discontinued (l_dep) developed_7\VBD\1753788|:|man|hypertension|after|doses|mg. (l_dobj) hypertension_9\NN\14057371|acute|headache (l_nmod) headache_12\NN\5829480|with|severe|and|vomiting (l_conj) vomiting_14\NN\116687|
D014700_D006973 NONE verapamil_43\NN\2938514| (r_conj) nicardipine_41\NN\1740|and|verapamil (r_compound) treatment_44\NN\654885|after|subsequent|nicardipine (r_nmod) recovered_38\VBD\2210855|patient|treatment|. (r_conj) discontinued_33\VBN\2609764|drugs|were|immediately|,|and|recovered (r_dep) summary_1\NN\6722453|case|developed|discontinued (l_dep) developed_7\VBD\1753788|:|man|hypertension|after|doses|mg. (l_dobj) hypertension_9\NN\14057371|acute|headache
D014700_D006261 NONE verapamil_43\NN\2938514| (r_conj) nicardipine_41\NN\1740|and|verapamil (r_compound) treatment_44\NN\654885|after|subsequent|nicardipine (r_nmod) recovered_38\VBD\2210855|patient|treatment|. (r_conj) discontinued_33\VBN\2609764|drugs|were|immediately|,|and|recovered (r_dep) summary_1\NN\6722453|case|developed|discontinued (l_dep) developed_7\VBD\1753788|:|man|hypertension|after|doses|mg. (l_dobj) hypertension_9\NN\14057371|acute|headache (l_nmod) headache_12\NN\5829480|with|severe|and|vomiting
D014700_D014839 NONE verapamil_43\NN\2938514| (r_conj) nicardipine_41\NN\1740|and|verapamil (r_compound) treatment_44\NN\654885|after|subsequent|nicardipine (r_nmod) recovered_38\VBD\2210855|patient|treatment|. (r_conj) discontinued_33\VBN\2609764|drugs|were|immediately|,|and|recovered (r_dep) summary_1\NN\6722453|case|developed|discontinued (l_dep) developed_7\VBD\1753788|:|man|hypertension|after|doses|mg. (l_dobj) hypertension_9\NN\14057371|acute|headache (l_nmod) headache_12\NN\5829480|with|severe|and|vomiting (l_conj) vomiting_14\NN\116687|
C037689_D010673 NONE benzamide_14\NN\1740| (r_compound) drugs_15\NNS\14778436|of|substituted|benzamide (r_nmod) use_11\NN\407535|with|the|drugs (r_nmod) associated_8\VBN\628491|symptoms|are|often|use|,|but|unknown (l_nsubjpass) symptoms_3\NNS\5823932|drug-induced|pheochromocytoma (l_nmod) pheochromocytoma_5\NN\14235200|of
7066357
D011692_D009404 CID aminonucleoside_12\NN\1740|by|puromycin (r_nmod) induced_6\VBN\1627355|rat|aminonucleoside (r_acl) syndrome_5\NN\5870365|of|nephrotic|induced
D011692_D009404 CID aminonucleoside_19\NN\1740|by|puromycin (r_nmod) induced_16\VBN\1627355|aminonucleoside (r_acl) alterations_8\NNS\7283608|the|lipoproteins|found|induced (l_acl) found_12\VBN\2426171|syndrome (l_nmod) syndrome_15\NN\5870365|in|nephrotic
D011692_D009404 CID aminonucleoside_19\NN\1740|by|puromycin (r_nmod) induced_16\VBN\1627355|aminonucleoside (r_acl) alterations_8\NNS\7283608|the|lipoproteins|found|induced (r_nsubj) due_21\JJ\1740|whether|alterations|were|syndrome|aminonucleoside (l_nmod) syndrome_24\NN\5870365|to|nephrotic|se|,|or|part
D011692_D009404 CID aminonucleoside_37\NN\1740|to|the (r_nmod) due_21\JJ\1740|whether|alterations|were|syndrome|aminonucleoside (l_nsubj) alterations_8\NNS\7283608|the|lipoproteins|found|induced (l_acl) found_12\VBN\2426171|syndrome (l_nmod) syndrome_15\NN\5870365|in|nephrotic
D011692_D009404 CID aminonucleoside_37\NN\1740|to|the (r_nmod) due_21\JJ\1740|whether|alterations|were|syndrome|aminonucleoside (l_nmod) syndrome_24\NN\5870365|to|nephrotic|se|,|or|part
D011692_D009404 CID aminonucleoside_21\NN\1740|of|puromycin (r_nmod) administration_18\NN\1133281|during|the|aminonucleoside|mg/kg|and|development (l_conj) development_32\NN\248977|the|subsequent|syndrome (l_nmod) syndrome_35\NN\5870365|of|nephrotic
D005227_D009404 NONE acids_8\NNS\14818238|of|fatty|,|triacylglycerol|and|vldl (r_nmod) level_5\NN\4916342|the|plasma|acids (r_nsubj) decreased_13\VBD\169651|stage|level|remained|. (l_nmod) stage_2\NN\15113229|in|pre-nephrotic (l_amod) pre-nephrotic_1\JJ\1740|
D014280_D009404 NONE triacylglycerol_10\NN\1740| (r_conj) acids_8\NNS\14818238|of|fatty|,|triacylglycerol|and|vldl (r_nmod) level_5\NN\4916342|the|plasma|acids (r_nsubj) decreased_13\VBD\169651|stage|level|remained|. (l_nmod) stage_2\NN\15113229|in|pre-nephrotic (l_amod) pre-nephrotic_1\JJ\1740|
D002788_D009404 NONE esters_20\NNS\14727670|cholesteryl (r_conj) phospholipid_17\JJ\1740|of|,|esters|and|hdl (r_nmod) that_15\DT\1740|phospholipid (r_nsubj) remained_23\VBD\2604760|while|that|constant (r_advcl) decreased_13\VBD\169651|stage|level|remained|. (l_nmod) stage_2\NN\15113229|in|pre-nephrotic (l_amod) pre-nephrotic_1\JJ\1740|
15531665
D001205_D002318 CID c_3\NN\13714184|supplemental|vitamin (r_nsubj) increase_4\VB\169651|does|c|risk|? (l_dobj) risk_7\NN\14541044|cardiovascular|disease|women (l_compound) disease_6\NN\14061805|
D001205_D002318 CID c_11\NN\13714184|vitamin (r_compound) intake_12\NN\13440063|between|c|and|mortality (l_conj) mortality_14\NN\5054863|disease (l_nmod) disease_17\NN\14061805|from|cardiovascular
D001205_D002318 CID c_8\NN\13714184|vitamin (r_compound) intake_9\NN\13440063|between|c|and|mortality (l_conj) mortality_11\NN\5054863|disease (l_nmod) disease_15\NN\14061805|from|total|cardiovascular|=|,|disease
D001205_D002318 CID c_87\NN\13714184| (r_compound) intake_88\NN\13440063|of|total|vitamin|c|food (r_nmod) quintiles_83\NNS\1740|across|intake (r_nmod) 1.0_65\CD\1740|,|risks|were|,|0.97|,|1.11|,|1.47|,|and|1.84|p|quintiles (r_dep) results_24\NNS\34213|:|adjustment|1.0 (l_nmod) adjustment_27\NN\7357388|after|factors (l_nmod) factors_32\NNS\7326557|for|cardiovascular|disease|risk|,|type (l_compound) disease_30\NN\14061805|
D001205_D002318 CID c_87\NN\13714184| (r_compound) intake_88\NN\13440063|of|total|vitamin|c|food (r_nmod) quintiles_83\NNS\1740|across|intake (r_nmod) 1.0_65\CD\1740|,|risks|were|,|0.97|,|1.11|,|1.47|,|and|1.84|p|quintiles (l_nsubj) risks_58\NNS\14541044|the|adjusted|relative|mortality (l_nmod) mortality_63\NN\5054863|of|total|cardiovascular|disease (l_compound) disease_62\NN\14061805|
D001205_D002318 CID c_1\NN\13714184|vitamin (r_compound) intake_2\NN\13440063|c (r_nsubj) unrelated_4\JJ\1740|intake|was|mortality|. (l_nmod) mortality_6\NN\5054863|to|disease|baseline (l_nmod) disease_9\NN\14061805|from|cardiovascular|subjects
D001205_D002318 CID c_5\NN\13714184|high|vitamin (r_compound) intake_6\NN\13440063|a|c|supplements (r_nsubjpass) associated_10\VBN\628491|intake|is|risk (l_nmod) risk_14\NN\14541044|with|an|increased|mortality (l_nmod) mortality_18\NN\5054863|of|cardiovascular|disease|women (l_compound) disease_17\NN\14061805|
D001205_D003920 NONE c_3\NN\13714184|supplemental|vitamin (r_nsubj) increase_4\VB\169651|does|c|risk|? (l_dobj) risk_7\NN\14541044|cardiovascular|disease|women (l_nmod) women_9\NNS\9605289|in|diabetes (l_nmod) diabetes_11\NN\14075199|with
D001205_D003920 NONE c_12\NN\13714184|of|vitamin (r_nmod) intake_9\NN\13440063|a|high|c|persons (l_nmod) persons_15\NNS\7347|in|diabetic (l_amod) diabetic_14\JJ\1740|
D001205_D003920 NONE c_8\NN\13714184|vitamin (r_compound) intake_9\NN\13440063|between|c|and|mortality (r_nmod) relation_5\NN\2137|the|intake|women (l_nmod) women_41\NNS\9605289|in|1923|postmenopausal|reported (l_acl:relcl) reported_43\VBD\831651|who|diabetic (l_xcomp) diabetic_45\JJ\1740|being|baseline
D001205_D003920 NONE c_87\NN\13714184| (r_compound) intake_88\NN\13440063|of|total|vitamin|c|food (r_nmod) quintiles_83\NNS\1740|across|intake (r_nmod) 1.0_65\CD\1740|,|risks|were|,|0.97|,|1.11|,|1.47|,|and|1.84|p|quintiles (r_dep) results_24\NNS\34213|:|adjustment|1.0 (l_nmod) adjustment_27\NN\7357388|after|factors (l_nmod) factors_32\NNS\7326557|for|cardiovascular|disease|risk|,|type (l_conj) type_34\NN\5839024|medication|used|,|duration|,|and|intakes (l_nmod) medication_37\NN\3247620|of|diabetes (l_compound) diabetes_36\NN\14075199|
D001205_D003920 NONE c_87\NN\13714184| (r_compound) intake_88\NN\13440063|of|total|vitamin|c|food (r_nmod) quintiles_83\NNS\1740|across|intake (r_nmod) 1.0_65\CD\1740|,|risks|were|,|0.97|,|1.11|,|1.47|,|and|1.84|p|quintiles (r_dep) results_24\NNS\34213|:|adjustment|1.0 (l_nmod) adjustment_27\NN\7357388|after|factors (l_nmod) factors_32\NNS\7326557|for|cardiovascular|disease|risk|,|type (l_conj) type_34\NN\5839024|medication|used|,|duration|,|and|intakes (l_conj) duration_40\NN\15113229|diabetes (l_nmod) diabetes_42\NN\14075199|of
D001205_D003920 NONE c_5\NN\13714184|high|vitamin (r_compound) intake_6\NN\13440063|a|c|supplements (r_nsubjpass) associated_10\VBN\628491|intake|is|risk (l_nmod) risk_14\NN\14541044|with|an|increased|mortality (l_nmod) mortality_18\NN\5054863|of|cardiovascular|disease|women (l_nmod) women_21\NNS\9605289|in|postmenopausal|diabetes (l_nmod) diabetes_23\NN\14075199|with
D001205_D050197 NONE c_12\NN\13714184|of|vitamin (r_nmod) intake_9\NN\13440063|a|high|c|persons (r_nsubj) promote_17\VB\2556126|that|intake|might|atherosclerosis (l_dobj) atherosclerosis_18\NN\14108324|
D001205_D003324 NONE c_8\NN\13714184|vitamin (r_compound) intake_9\NN\13440063|between|c|and|mortality (l_conj) mortality_11\NN\5054863|disease (l_nmod) disease_15\NN\14061805|from|total|cardiovascular|=|,|disease (l_conj) disease_24\NN\14061805|coronary|artery|=|,|and|stroke
D001205_D003324 NONE c_87\NN\13714184| (r_compound) intake_88\NN\13440063|of|total|vitamin|c|food (r_nmod) quintiles_83\NNS\1740|across|intake (r_nmod) 1.0_65\CD\1740|,|risks|were|,|0.97|,|1.11|,|1.47|,|and|1.84|p|quintiles (r_dep) results_24\NNS\34213|:|adjustment|1.0 (r_dep) assessed_2\VBN\670261|diet|was|questionnaire|baseline|,|and|followed|results|. (l_conj) followed_20\VBN\1835496|subjects|were|prospectively|y. (l_nsubjpass) subjects_11\NNS\6598915|free (l_amod) free_13\JJ\1740|initially|disease (l_nmod) disease_17\NN\14061805|of|coronary|artery
D001205_D020521 NONE c_8\NN\13714184|vitamin (r_compound) intake_9\NN\13440063|between|c|and|mortality (l_conj) mortality_11\NN\5054863|disease (l_nmod) disease_15\NN\14061805|from|total|cardiovascular|=|,|disease (l_conj) disease_24\NN\14061805|coronary|artery|=|,|and|stroke (l_conj) stroke_32\NN\556313|=
D005492_D003324 NONE folate_47\NN\15090742|of|,|e|,|and|beta-carotene (r_nmod) intakes_45\NNS\13440063|folate (r_conj) type_34\NN\5839024|medication|used|,|duration|,|and|intakes (r_conj) factors_32\NNS\7326557|for|cardiovascular|disease|risk|,|type (r_nmod) adjustment_27\NN\7357388|after|factors (r_nmod) results_24\NNS\34213|:|adjustment|1.0 (r_dep) assessed_2\VBN\670261|diet|was|questionnaire|baseline|,|and|followed|results|. (l_conj) followed_20\VBN\1835496|subjects|were|prospectively|y. (l_nsubjpass) subjects_11\NNS\6598915|free (l_amod) free_13\JJ\1740|initially|disease (l_nmod) disease_17\NN\14061805|of|coronary|artery
D005492_D002318 NONE folate_47\NN\15090742|of|,|e|,|and|beta-carotene (r_nmod) intakes_45\NNS\13440063|folate (r_conj) type_34\NN\5839024|medication|used|,|duration|,|and|intakes (r_conj) factors_32\NNS\7326557|for|cardiovascular|disease|risk|,|type (l_compound) disease_30\NN\14061805|
D005492_D002318 NONE folate_47\NN\15090742|of|,|e|,|and|beta-carotene (r_nmod) intakes_45\NNS\13440063|folate (r_conj) type_34\NN\5839024|medication|used|,|duration|,|and|intakes (r_conj) factors_32\NNS\7326557|for|cardiovascular|disease|risk|,|type (r_nmod) adjustment_27\NN\7357388|after|factors (r_nmod) results_24\NNS\34213|:|adjustment|1.0 (l_dep) 1.0_65\CD\1740|,|risks|were|,|0.97|,|1.11|,|1.47|,|and|1.84|p|quintiles (l_nsubj) risks_58\NNS\14541044|the|adjusted|relative|mortality (l_nmod) mortality_63\NN\5054863|of|total|cardiovascular|disease (l_compound) disease_62\NN\14061805|
D005492_D003920 NONE folate_47\NN\15090742|of|,|e|,|and|beta-carotene (r_nmod) intakes_45\NNS\13440063|folate (r_conj) type_34\NN\5839024|medication|used|,|duration|,|and|intakes (l_nmod) medication_37\NN\3247620|of|diabetes (l_compound) diabetes_36\NN\14075199|
D005492_D003920 NONE folate_47\NN\15090742|of|,|e|,|and|beta-carotene (r_nmod) intakes_45\NNS\13440063|folate (r_conj) type_34\NN\5839024|medication|used|,|duration|,|and|intakes (l_conj) duration_40\NN\15113229|diabetes (l_nmod) diabetes_42\NN\14075199|of
D014810_D003324 NONE e_50\NN\14724645|vitamin (r_conj) folate_47\NN\15090742|of|,|e|,|and|beta-carotene (r_nmod) intakes_45\NNS\13440063|folate (r_conj) type_34\NN\5839024|medication|used|,|duration|,|and|intakes (r_conj) factors_32\NNS\7326557|for|cardiovascular|disease|risk|,|type (r_nmod) adjustment_27\NN\7357388|after|factors (r_nmod) results_24\NNS\34213|:|adjustment|1.0 (r_dep) assessed_2\VBN\670261|diet|was|questionnaire|baseline|,|and|followed|results|. (l_conj) followed_20\VBN\1835496|subjects|were|prospectively|y. (l_nsubjpass) subjects_11\NNS\6598915|free (l_amod) free_13\JJ\1740|initially|disease (l_nmod) disease_17\NN\14061805|of|coronary|artery
D014810_D002318 NONE e_50\NN\14724645|vitamin (r_conj) folate_47\NN\15090742|of|,|e|,|and|beta-carotene (r_nmod) intakes_45\NNS\13440063|folate (r_conj) type_34\NN\5839024|medication|used|,|duration|,|and|intakes (r_conj) factors_32\NNS\7326557|for|cardiovascular|disease|risk|,|type (l_compound) disease_30\NN\14061805|
D014810_D002318 NONE e_50\NN\14724645|vitamin (r_conj) folate_47\NN\15090742|of|,|e|,|and|beta-carotene (r_nmod) intakes_45\NNS\13440063|folate (r_conj) type_34\NN\5839024|medication|used|,|duration|,|and|intakes (r_conj) factors_32\NNS\7326557|for|cardiovascular|disease|risk|,|type (r_nmod) adjustment_27\NN\7357388|after|factors (r_nmod) results_24\NNS\34213|:|adjustment|1.0 (l_dep) 1.0_65\CD\1740|,|risks|were|,|0.97|,|1.11|,|1.47|,|and|1.84|p|quintiles (l_nsubj) risks_58\NNS\14541044|the|adjusted|relative|mortality (l_nmod) mortality_63\NN\5054863|of|total|cardiovascular|disease (l_compound) disease_62\NN\14061805|
D014810_D003920 NONE e_50\NN\14724645|vitamin (r_conj) folate_47\NN\15090742|of|,|e|,|and|beta-carotene (r_nmod) intakes_45\NNS\13440063|folate (r_conj) type_34\NN\5839024|medication|used|,|duration|,|and|intakes (l_nmod) medication_37\NN\3247620|of|diabetes (l_compound) diabetes_36\NN\14075199|
D014810_D003920 NONE e_50\NN\14724645|vitamin (r_conj) folate_47\NN\15090742|of|,|e|,|and|beta-carotene (r_nmod) intakes_45\NNS\13440063|folate (r_conj) type_34\NN\5839024|medication|used|,|duration|,|and|intakes (l_conj) duration_40\NN\15113229|diabetes (l_nmod) diabetes_42\NN\14075199|of
D019207_D003324 NONE beta-carotene_53\NN\14720962| (r_conj) folate_47\NN\15090742|of|,|e|,|and|beta-carotene (r_nmod) intakes_45\NNS\13440063|folate (r_conj) type_34\NN\5839024|medication|used|,|duration|,|and|intakes (r_conj) factors_32\NNS\7326557|for|cardiovascular|disease|risk|,|type (r_nmod) adjustment_27\NN\7357388|after|factors (r_nmod) results_24\NNS\34213|:|adjustment|1.0 (r_dep) assessed_2\VBN\670261|diet|was|questionnaire|baseline|,|and|followed|results|. (l_conj) followed_20\VBN\1835496|subjects|were|prospectively|y. (l_nsubjpass) subjects_11\NNS\6598915|free (l_amod) free_13\JJ\1740|initially|disease (l_nmod) disease_17\NN\14061805|of|coronary|artery
D019207_D002318 NONE beta-carotene_53\NN\14720962| (r_conj) folate_47\NN\15090742|of|,|e|,|and|beta-carotene (r_nmod) intakes_45\NNS\13440063|folate (r_conj) type_34\NN\5839024|medication|used|,|duration|,|and|intakes (r_conj) factors_32\NNS\7326557|for|cardiovascular|disease|risk|,|type (l_compound) disease_30\NN\14061805|
D019207_D002318 NONE beta-carotene_53\NN\14720962| (r_conj) folate_47\NN\15090742|of|,|e|,|and|beta-carotene (r_nmod) intakes_45\NNS\13440063|folate (r_conj) type_34\NN\5839024|medication|used|,|duration|,|and|intakes (r_conj) factors_32\NNS\7326557|for|cardiovascular|disease|risk|,|type (r_nmod) adjustment_27\NN\7357388|after|factors (r_nmod) results_24\NNS\34213|:|adjustment|1.0 (l_dep) 1.0_65\CD\1740|,|risks|were|,|0.97|,|1.11|,|1.47|,|and|1.84|p|quintiles (l_nsubj) risks_58\NNS\14541044|the|adjusted|relative|mortality (l_nmod) mortality_63\NN\5054863|of|total|cardiovascular|disease (l_compound) disease_62\NN\14061805|
D019207_D003920 NONE beta-carotene_53\NN\14720962| (r_conj) folate_47\NN\15090742|of|,|e|,|and|beta-carotene (r_nmod) intakes_45\NNS\13440063|folate (r_conj) type_34\NN\5839024|medication|used|,|duration|,|and|intakes (l_nmod) medication_37\NN\3247620|of|diabetes (l_compound) diabetes_36\NN\14075199|
D019207_D003920 NONE beta-carotene_53\NN\14720962| (r_conj) folate_47\NN\15090742|of|,|e|,|and|beta-carotene (r_nmod) intakes_45\NNS\13440063|folate (r_conj) type_34\NN\5839024|medication|used|,|duration|,|and|intakes (l_conj) duration_40\NN\15113229|diabetes (l_nmod) diabetes_42\NN\14075199|of
17702969
D005473_D005315 CID fluoxetine_3\NN\4169152|to (r_nmod) exposure_1\NN\5042871|prenatal|fluoxetine (r_nsubj) induces_4\VBZ\1627355|exposure|hypertension|. (l_dobj) hypertension_7\NN\14057371|fetal|pulmonary|rat
D005473_D005315 CID fluoxetine_5\NN\4169152| (r_compound) exposure_6\NN\5042871|fluoxetine (r_nsubj) resulted_7\VBD\2633881|compared|,|exposure|hypertension|evidenced|. (l_nmod) hypertension_11\NN\14057371|in|fetal|pulmonary
D005473_D006976 CID fluoxetine_3\NN\4169152|to (r_nmod) exposure_1\NN\5042871|prenatal|fluoxetine (r_nsubj) induces_4\VBZ\1627355|exposure|hypertension|. (l_dobj) hypertension_7\NN\14057371|fetal|pulmonary|rat
D005473_D006976 CID fluoxetine_4\NN\4169152| (r_compound) exposure_5\NN\5042871|fluoxetine (r_nsubj) increases_7\VBZ\169651|that|exposure|prenatally|prevalence (l_dobj) prevalence_9\NN\4764412|the|syndrome (l_nmod) syndrome_14\NN\5870365|of|persistent|pulmonary|hypertension|newborn
D005473_D006976 CID fluoxetine_20\NN\4169152| (r_compound) effect_21\NN\34213|of|a|hypertension|protective|fluoxetine|rodents (l_compound) hypertension_18\NN\14057371|pulmonary
D005473_D006976 CID fluoxetine_5\NN\4169152| (r_compound) exposure_6\NN\5042871|fluoxetine (r_nsubj) resulted_7\VBD\2633881|compared|,|exposure|hypertension|evidenced|. (l_nmod) hypertension_11\NN\14057371|in|fetal|pulmonary
D005473_D006976 CID fluoxetine_8\NN\4169152| (r_compound) exposure_9\NN\5042871|fluoxetine|utero (r_nsubj) induces_12\VBZ\1627355|contrast|,|exposure|hypertension|rat|result (l_dobj) hypertension_14\NN\14057371|pulmonary
3057041
C020976_D006255 NONE azelastine_12\NN\1740|of|,|chlorpheniramine|treatment (l_nmod) treatment_20\NN\654885|in|the|rhinitis (l_nmod) rhinitis_24\NN\14336539|of|spring|allergic
C020976_D006255 NONE azelastine_0\NN\1740|,|medication|, (r_nsubjpass) compared_8\VBN\644583|azelastine|was|maleate|efficacy|study|. (l_nmod) efficacy_15\NN\5199286|for|and|safety|treatment (l_nmod) treatment_20\NN\654885|in|the|rhinitis (l_nmod) rhinitis_24\NN\14336539|of|spring|allergic
C020976_D006255 NONE azelastine_0\NN\1740| (r_nsubj) appears_1\VBZ\2604760|azelastine|medication|. (l_xcomp) medication_8\NN\3247620|to|be|a|safe|,|efficacious|rhinitis (l_nmod) rhinitis_12\NN\14336539|for|seasonal|allergic
D002744_D006255 NONE chlorpheniramine_14\NN\1740|,|and|placebo (r_conj) azelastine_12\NN\1740|of|,|chlorpheniramine|treatment (l_nmod) treatment_20\NN\654885|in|the|rhinitis (l_nmod) rhinitis_24\NN\14336539|of|spring|allergic
D002744_D006255 NONE maleate_11\NN\2718811|with|chlorpheniramine|and|placebo (r_nmod) compared_8\VBN\644583|azelastine|was|maleate|efficacy|study|. (l_nmod) efficacy_15\NN\5199286|for|and|safety|treatment (l_nmod) treatment_20\NN\654885|in|the|rhinitis (l_nmod) rhinitis_24\NN\14336539|of|spring|allergic
C020976_D006970 CID azelastine_14\NN\1740| (r_compound) group_15\NN\2137|only|in|the|high-dose|azelastine (r_nmod) increased_6\VBN\169651|drowsiness|were|significantly|placebo|group|. (l_nsubjpass) drowsiness_0\NN\14015731|and|perception
C020976_D013651 CID azelastine_14\NN\1740| (r_compound) group_15\NN\2137|only|in|the|high-dose|azelastine (r_nmod) increased_6\VBN\169651|drowsiness|were|significantly|placebo|group|. (l_nsubjpass) drowsiness_0\NN\14015731|and|perception (l_conj) perception_4\NN\5926676|altered|taste
7604176
D017035_D009135 NONE pravastatin-associated_0\JJ\1740| (r_amod) myopathy_1\NN\14204950|pravastatin-associated|.|report
D017035_D009135 NONE pravastatin_17\NN\3676175| (r_compound) discontinuation_18\NN\209943|after|pravastatin (r_nmod) days_15\NNS\15140892|in|few|discontinuation (r_nmod) resolved_11\VBD\352826|which|days (r_acl:relcl) myopathy_5\NN\14204950|with|acute|limbs|resolved
D017035_D009135 NONE pravastatin-associated_11\JJ\1740| (r_amod) myopathy_12\NN\14204950|pravastatin-associated (r_nsubj) represent_14\VB\2664769|associated|,|myopathy|could|entity|. (l_advcl) associated_6\VBN\628491|while|lovastatin|have|been|myopathy (l_nmod) myopathy_9\NN\14204950|with|toxic
D017035_D009135 NONE pravastatin-associated_11\JJ\1740| (r_amod) myopathy_12\NN\14204950|pravastatin-associated
D017035_D009220 CID pravastatin_11\NN\3676175|of|,|inhibitor|, (r_nmod) use_9\NN\407535|with|the|pravastatin (r_nmod) associated_6\VBN\628491|use (r_acl) myopathy_5\NN\14204950|of|inflammatory|associated
D017035_D006937 NONE pravastatin_2\NN\3676175|mg/day (r_dobj) assumed_1\VBD\719734|he|pravastatin|hypercholesterolemia|. (l_nmod) hypercholesterolemia_9\NN\14299637|because
D008148_D009135 NONE lovastatin_1\NN\3676175|and|simvastatin (r_nsubjpass) associated_6\VBN\628491|while|lovastatin|have|been|myopathy (l_nmod) myopathy_9\NN\14204950|with|toxic
D008148_D009135 NONE lovastatin_1\NN\3676175|and|simvastatin (r_nsubjpass) associated_6\VBN\628491|while|lovastatin|have|been|myopathy (r_advcl) represent_14\VB\2664769|associated|,|myopathy|could|entity|. (l_nsubj) myopathy_12\NN\14204950|pravastatin-associated
D019821_D009135 NONE simvastatin_3\NN\3676175| (r_conj) lovastatin_1\NN\3676175|and|simvastatin (r_nsubjpass) associated_6\VBN\628491|while|lovastatin|have|been|myopathy (l_nmod) myopathy_9\NN\14204950|with|toxic
D019821_D009135 NONE simvastatin_3\NN\3676175| (r_conj) lovastatin_1\NN\3676175|and|simvastatin (r_nsubjpass) associated_6\VBN\628491|while|lovastatin|have|been|myopathy (r_advcl) represent_14\VB\2664769|associated|,|myopathy|could|entity|. (l_nsubj) myopathy_12\NN\14204950|pravastatin-associated
7416947
D004077_D020018 CID digoxin_11\NN\15060131|of (r_nmod) administration_9\NN\1133281|on|long-term|digoxin (r_nmod) patients_6\NNS\9898892|of|administration (r_nmod) dysfunction_4\NN\14204950|of|sexual|patients
D004077_D012214 NONE digoxin_10\NN\15060131|without (r_nmod) group_7\NN\2137|of|the|study|(|digoxin|) (r_nmod) patients_1\NNS\9898892|the|group (r_nsubj) capacity_17\NN\5202497|patients|were|of|similar|cardiac|functional|and|age|years|and|selected (l_conj) selected_29\VBN\697589|were|randomly|patients|. (l_nmod) patients_35\NNS\9898892|from|the|disease (l_compound) disease_34\NN\14061805|rheumatic|heart
3131282
C009166_D063646 NONE acetate_4\NN\15010703|of|retinyl (r_nmod) effect_1\NN\34213|co-carcinogenic|acetate|carcinogenesis|. (l_amod) co-carcinogenic_0\JJ\1740|
C009166_D013274 NONE acetate_4\NN\15010703|of|retinyl (r_nmod) effect_1\NN\34213|co-carcinogenic|acetate|carcinogenesis|. (l_nmod) carcinogenesis_7\NN\1740|on|forestomach|rats
C009166_D013274 NONE acetate_6\NN\15010703|of|retinyl|ra (r_nmod) effect_3\NN\34213|the|potential|modifying|acetate|tumorigenesis (l_nmod) tumorigenesis_16\NN\1740|on|(bha)-induced|rat|forestomach
C009166_D013274 NONE ra_8\NN\14625458|(|) (r_appos) acetate_6\NN\15010703|of|retinyl|ra (r_nmod) effect_3\NN\34213|the|potential|modifying|acetate|tumorigenesis (l_nmod) tumorigenesis_16\NN\1740|on|(bha)-induced|rat|forestomach
C009166_D013274 NONE ra_25\NN\14625458|of|% (r_nmod) co-administration_21\NN\1740|ra (r_nsubj) increased_33\VBD\169651|groups|,|observed|,|co-administration|significantly|(|p|incidence|%|%|group|. (l_dobj) incidence_35\NN\13821570|the|tumors (l_nmod) tumors_38\NNS\14234074|of|forestomach|papilloma
C009166_D013274 NONE ra-free_72\JJ\1740| (r_amod) water_73\NN\14618834|ra-free (r_dobj) given_71\VBN\2327200|water (r_acl) group_70\NN\2137|in|the|given (r_nmod) increased_33\VBD\169651|groups|,|observed|,|co-administration|significantly|(|p|incidence|%|%|group|. (l_dobj) incidence_35\NN\13821570|the|tumors (l_nmod) tumors_38\NNS\14234074|of|forestomach|papilloma
C009166_D013274 NONE ra_4\NN\14625458| (r_nsubj) acted_5\VBD\1619354|that|ra|co-carcinogen (l_nmod) co-carcinogen_8\NN\1740|as|a|carcinogenesis (l_nmod) carcinogenesis_13\NN\1740|in|the|bha|forestomach|rat
D002083_D063646 NONE hydroxyanisole_15\NN\1740|with|butylated (r_nmod) induced_12\VBN\1627355|hydroxyanisole (r_acl) rats_11\NNS\2329401|of|male|f344|induced (r_nmod) carcinogenesis_7\NN\1740|on|forestomach|rats (r_nmod) effect_1\NN\34213|co-carcinogenic|acetate|carcinogenesis|. (l_amod) co-carcinogenic_0\JJ\1740|
D002083_D013274 CID hydroxyanisole_15\NN\1740|with|butylated (r_nmod) induced_12\VBN\1627355|hydroxyanisole (r_acl) rats_11\NNS\2329401|of|male|f344|induced (r_nmod) carcinogenesis_7\NN\1740|on|forestomach|rats
D002083_D013274 CID hydroxyanisole_12\NN\1740|butylated (r_compound) (bha)-induced_13\NN\1740|hydroxyanisole (r_compound) tumorigenesis_16\NN\1740|on|(bha)-induced|rat|forestomach
D002083_D013274 CID (bha)-induced_13\NN\1740|hydroxyanisole (r_compound) tumorigenesis_16\NN\1740|on|(bha)-induced|rat|forestomach
D002083_D013274 CID bha_5\NN\1740|% (r_dobj) given_2\VBN\2327200|bha (r_acl) groups_1\NNS\2137|in|given (r_nmod) increased_33\VBD\169651|groups|,|observed|,|co-administration|significantly|(|p|incidence|%|%|group|. (l_dobj) incidence_35\NN\13821570|the|tumors (l_nmod) tumors_38\NNS\14234074|of|forestomach|papilloma
D002083_D013274 CID bha_11\NN\1740| (r_compound) carcinogenesis_13\NN\1740|in|the|bha|forestomach|rat
D002083_D010212 NONE bha_5\NN\1740|% (r_dobj) given_2\VBN\2327200|bha (r_acl) groups_1\NNS\2137|in|given (r_nmod) increased_33\VBD\169651|groups|,|observed|,|co-administration|significantly|(|p|incidence|%|%|group|. (l_dobj) incidence_35\NN\13821570|the|tumors (l_nmod) tumors_38\NNS\14234074|of|forestomach|papilloma (l_dep) papilloma_42\NN\14236226|(|squamous|cell|and|carcinoma|)
D002083_D002277 NONE bha_5\NN\1740|% (r_dobj) given_2\VBN\2327200|bha (r_acl) groups_1\NNS\2137|in|given (r_nmod) increased_33\VBD\169651|groups|,|observed|,|co-administration|significantly|(|p|incidence|%|%|group|. (l_dobj) incidence_35\NN\13821570|the|tumors (l_nmod) tumors_38\NNS\14234074|of|forestomach|papilloma (l_dep) papilloma_42\NN\14236226|(|squamous|cell|and|carcinoma|) (l_conj) carcinoma_44\NN\14239918|
D002083_D002277 NONE bha_5\NN\1740|% (r_dobj) given_2\VBN\2327200|bha (r_acl) groups_1\NNS\2137|in|given (r_nmod) increased_33\VBD\169651|groups|,|observed|,|co-administration|significantly|(|p|incidence|%|%|group|. (l_nmod) %_48\NN\1740|to|60|9/15 (l_appos) 9/15_50\CD\1740|(|,|rats|) (l_appos) rats_53\NNS\2329401|2|carcinoma (l_nmod) carcinoma_55\NN\14239918|with
D002083_D002277 NONE bha_5\NN\1740|% (r_dobj) given_2\VBN\2327200|bha (r_acl) groups_1\NNS\2137|in|given (r_nmod) increased_33\VBD\169651|groups|,|observed|,|co-administration|significantly|(|p|incidence|%|%|group|. (l_nmod) %_59\NN\1740|from|15|3/20 (l_appos) 3/20_61\CD\1740|(|,|rat|) (l_appos) rat_64\NN\2329401|one|carcinoma (l_nmod) carcinoma_66\NN\14239918|with
C009166_D010212 NONE ra_25\NN\14625458|of|% (r_nmod) co-administration_21\NN\1740|ra (r_nsubj) increased_33\VBD\169651|groups|,|observed|,|co-administration|significantly|(|p|incidence|%|%|group|. (l_dobj) incidence_35\NN\13821570|the|tumors (l_nmod) tumors_38\NNS\14234074|of|forestomach|papilloma (l_dep) papilloma_42\NN\14236226|(|squamous|cell|and|carcinoma|)
C009166_D010212 NONE ra-free_72\JJ\1740| (r_amod) water_73\NN\14618834|ra-free (r_dobj) given_71\VBN\2327200|water (r_acl) group_70\NN\2137|in|the|given (r_nmod) increased_33\VBD\169651|groups|,|observed|,|co-administration|significantly|(|p|incidence|%|%|group|. (l_dobj) incidence_35\NN\13821570|the|tumors (l_nmod) tumors_38\NNS\14234074|of|forestomach|papilloma (l_dep) papilloma_42\NN\14236226|(|squamous|cell|and|carcinoma|)
C009166_D010212 NONE ra_17\NN\14625458|with|% (r_nmod) rats_9\NNS\2329401|in|3|%|ra (r_nmod) induced_6\VBN\1627355|tumors|were|rats|and|rat|. (l_nsubjpass) tumors_0\NNS\14234074|,|papillomas|, (l_appos) papillomas_3\NNS\14236226|all
C009166_D010212 NONE ra_29\NN\14625458| (r_compound) co-administration_30\NN\1740|with|%|ra (r_nmod) rat_21\NN\2329401|in|one|%|co-administration (r_conj) induced_6\VBN\1627355|tumors|were|rats|and|rat|. (l_nsubjpass) tumors_0\NNS\14234074|,|papillomas|, (l_appos) papillomas_3\NNS\14236226|all
C009166_D002277 NONE ra_25\NN\14625458|of|% (r_nmod) co-administration_21\NN\1740|ra (r_nsubj) increased_33\VBD\169651|groups|,|observed|,|co-administration|significantly|(|p|incidence|%|%|group|. (l_dobj) incidence_35\NN\13821570|the|tumors (l_nmod) tumors_38\NNS\14234074|of|forestomach|papilloma (l_dep) papilloma_42\NN\14236226|(|squamous|cell|and|carcinoma|) (l_conj) carcinoma_44\NN\14239918|
C009166_D002277 NONE ra_25\NN\14625458|of|% (r_nmod) co-administration_21\NN\1740|ra (r_nsubj) increased_33\VBD\169651|groups|,|observed|,|co-administration|significantly|(|p|incidence|%|%|group|. (l_nmod) %_48\NN\1740|to|60|9/15 (l_appos) 9/15_50\CD\1740|(|,|rats|) (l_appos) rats_53\NNS\2329401|2|carcinoma (l_nmod) carcinoma_55\NN\14239918|with
C009166_D002277 NONE ra_25\NN\14625458|of|% (r_nmod) co-administration_21\NN\1740|ra (r_nsubj) increased_33\VBD\169651|groups|,|observed|,|co-administration|significantly|(|p|incidence|%|%|group|. (l_nmod) %_59\NN\1740|from|15|3/20 (l_appos) 3/20_61\CD\1740|(|,|rat|) (l_appos) rat_64\NN\2329401|one|carcinoma (l_nmod) carcinoma_66\NN\14239918|with
C009166_D002277 NONE ra-free_72\JJ\1740| (r_amod) water_73\NN\14618834|ra-free (r_dobj) given_71\VBN\2327200|water (r_acl) group_70\NN\2137|in|the|given (r_nmod) increased_33\VBD\169651|groups|,|observed|,|co-administration|significantly|(|p|incidence|%|%|group|. (l_dobj) incidence_35\NN\13821570|the|tumors (l_nmod) tumors_38\NNS\14234074|of|forestomach|papilloma (l_dep) papilloma_42\NN\14236226|(|squamous|cell|and|carcinoma|) (l_conj) carcinoma_44\NN\14239918|
C009166_D002277 NONE ra-free_72\JJ\1740| (r_amod) water_73\NN\14618834|ra-free (r_dobj) given_71\VBN\2327200|water (r_acl) group_70\NN\2137|in|the|given (r_nmod) increased_33\VBD\169651|groups|,|observed|,|co-administration|significantly|(|p|incidence|%|%|group|. (l_nmod) %_48\NN\1740|to|60|9/15 (l_appos) 9/15_50\CD\1740|(|,|rats|) (l_appos) rats_53\NNS\2329401|2|carcinoma (l_nmod) carcinoma_55\NN\14239918|with
C009166_D002277 NONE ra-free_72\JJ\1740| (r_amod) water_73\NN\14618834|ra-free (r_dobj) given_71\VBN\2327200|water (r_acl) group_70\NN\2137|in|the|given (r_nmod) increased_33\VBD\169651|groups|,|observed|,|co-administration|significantly|(|p|incidence|%|%|group|. (l_nmod) %_59\NN\1740|from|15|3/20 (l_appos) 3/20_61\CD\1740|(|,|rat|) (l_appos) rat_64\NN\2329401|one|carcinoma (l_nmod) carcinoma_66\NN\14239918|with
D002083_D017573 NONE bha_5\NN\1740|% (r_dobj) given_2\VBN\2327200|bha (r_acl) rats_1\NNS\2329401|in|given (r_nmod) showed_21\VBD\2137132|rats|,|ra|effect|. (l_dobj) effect_25\NN\34213|a|dose-dependent|enhancing|development (l_nmod) development_28\NN\248977|on|the|hyperplasia (l_nmod) hyperplasia_33\NN\14365950|of|the|bha-induced|epithelial
D002083_D017573 NONE bha-induced_31\JJ\1740| (r_amod) hyperplasia_33\NN\14365950|of|the|bha-induced|epithelial
C009166_D017573 NONE ra_7\NN\14625458|co-administered (r_nsubj) showed_21\VBD\2137132|rats|,|ra|effect|. (l_dobj) effect_25\NN\34213|a|dose-dependent|enhancing|development (l_nmod) development_28\NN\248977|on|the|hyperplasia (l_nmod) hyperplasia_33\NN\14365950|of|the|bha-induced|epithelial
C009166_D009369 NONE ra_17\NN\14625458|with|% (r_nmod) rats_9\NNS\2329401|in|3|%|ra (r_nmod) induced_6\VBN\1627355|tumors|were|rats|and|rat|. (l_nsubjpass) tumors_0\NNS\14234074|,|papillomas|,
C009166_D009369 NONE ra_29\NN\14625458| (r_compound) co-administration_30\NN\1740|with|%|ra (r_nmod) rat_21\NN\2329401|in|one|%|co-administration (r_conj) induced_6\VBN\1627355|tumors|were|rats|and|rat|. (l_nsubjpass) tumors_0\NNS\14234074|,|papillomas|,
8441146
D006046_D000741 CID gold_12\NN\13371489|by (r_nmod) caused_10\VBN\1617192|which|was|gold|case|and|d-penicillamine (r_acl:relcl) anemia_7\NN\14189204|severe|aplastic|caused
D010396_D000741 CID d-penicillamine_17\NN\1740|other (r_conj) caused_10\VBN\1617192|which|was|gold|case|and|d-penicillamine (r_acl:relcl) anemia_7\NN\14189204|severe|aplastic|caused
19940105
D018698_D010300 NONE glutamate_1\NN\15010703| (r_compound) subtype_4\NN\1740|metabotropic|glutamate|7|receptor (r_nsubj) modulates_5\VBZ\1724459|subtype|symptoms|. (l_dobj) symptoms_7\NNS\5823932|motor|models (l_nmod) models_10\NNS\5888929|in|rodent|disease (l_nmod) disease_14\NN\14061805|of|parkinson|'s
D018698_D010300 NONE glutamate_1\NN\15010703|metabotropic (r_compound) receptors_5\NNS\5225602|glutamate|mglu|) (r_nsubj) modulate_6\VBP\1724459|receptors|transmission|and|represent|. (l_conj) represent_15\VBP\2664769|targets (l_dobj) targets_18\NNS\7258332|promising|therapeutic|treatment (l_nmod) treatment_21\NN\654885|for|symptomatic|disease (l_nmod) disease_25\NN\14061805|of|parkinson|'s|pd
D018698_D010300 NONE glutamate_1\NN\15010703|metabotropic (r_compound) receptors_5\NNS\5225602|glutamate|mglu|) (r_nsubj) modulate_6\VBP\1724459|receptors|transmission|and|represent|. (l_conj) represent_15\VBP\2664769|targets (l_dobj) targets_18\NNS\7258332|promising|therapeutic|treatment (l_nmod) treatment_21\NN\654885|for|symptomatic|disease (l_nmod) disease_25\NN\14061805|of|parkinson|'s|pd (l_appos) pd_27\NN\14625458|(|)
C507346_D010300 NONE dihydrochloride_6\NN\1740|of|n|,|n'-dibenzhydrylethane-1,2-diamine|amn082|,|activator|, (r_nmod) effects_1\NNS\13245626|the|dihydrochloride (r_nsubjpass) tested_22\VBN\670261|effects|were|thus|models|. (l_nmod) models_26\NNS\5888929|in|different|rodent|pd (l_nmod) pd_28\NN\14625458|of
C507346_D010300 NONE amn082_8\NN\1740|(|) (r_appos) dihydrochloride_6\NN\1740|of|n|,|n'-dibenzhydrylethane-1,2-diamine|amn082|,|activator|, (r_nmod) effects_1\NNS\13245626|the|dihydrochloride (r_nsubjpass) tested_22\VBN\670261|effects|were|thus|models|. (l_nmod) models_26\NNS\5888929|in|different|rodent|pd (l_nmod) pd_28\NN\14625458|of
C507346_D010300 NONE amn082_18\NN\1740|mg/kg (r_nsubj) reverses_19\VBZ\109660|task|,|amn082|time|. (l_nmod) task_4\NN\575741|in|a|complex|used (l_acl) used_6\VBN\1156834|commonly|evaluate (l_xcomp) evaluate_8\VB\670261|to|symptoms (l_dobj) symptoms_11\NNS\5823932|major|akinetic|patients (l_nmod) patients_14\NNS\9898892|of|pd (l_compound) pd_13\NN\14625458|
C507346_D010300 NONE amn082_3\NN\1740|of (r_nmod) doses_1\NNS\3740161|higher|amn082|p.o. (r_nsubj) have_11\VBP\2108377|doses|effect|. (l_dobj) effect_13\NN\34213|no|models (l_nmod) models_17\NNS\5888929|on|the|same|pd (l_nmod) pd_19\NN\14625458|of
C507346_D002375 NONE amn082_20\NN\1740|of (r_nmod) administration_12\NN\1133281|intrastriatal|nmol|amn082 (r_conj) mg/kg_8\NN\1740|oral|(|5|)|or|administration (r_nsubj) reverses_21\VBZ\109660|that|mg/kg|catalepsy (l_dobj) catalepsy_23\NN\14023236|haloperidol-induced|rats
C507346_D002375 NONE amn082_3\NN\1740| (r_nsubj) reduces_4\VBZ\441445|addition|,|amn082|duration|manner|mice|. (l_dobj) duration_6\NN\15113229|the|catalepsy (l_nmod) catalepsy_9\NN\14023236|of|haloperidol-induced
D006220_D002375 CID haloperidol-induced_22\JJ\1740| (r_amod) catalepsy_23\NN\14023236|haloperidol-induced|rats
D006220_D002375 CID haloperidol-induced_8\JJ\1740| (r_amod) catalepsy_9\NN\14023236|of|haloperidol-induced
C507346_D018476 NONE amn082_18\NN\1740|mg/kg (r_nsubj) reverses_19\VBZ\109660|task|,|amn082|time|. (l_nmod) task_4\NN\575741|in|a|complex|used (l_acl) used_6\VBN\1156834|commonly|evaluate (l_xcomp) evaluate_8\VB\670261|to|symptoms (l_dobj) symptoms_11\NNS\5823932|major|akinetic|patients (l_amod) akinetic_10\JJ\1740|
D016627_D018476 NONE 6-ohda-lesioned_31\JJ\1740| (r_amod) rats_32\NNS\2329401|of|bilateral|6-ohda-lesioned (r_nmod) cue_28\NN\7010821|to|a|rats (r_nmod) respond_25\VB\2367363|to|cue (r_acl) time_23\NN\7308889|the|increased|reaction|respond (r_dobj) reverses_19\VBZ\109660|task|,|amn082|time|. (l_nmod) task_4\NN\575741|in|a|complex|used (l_acl) used_6\VBN\1156834|commonly|evaluate (l_xcomp) evaluate_8\VB\670261|to|symptoms (l_dobj) symptoms_11\NNS\5823932|major|akinetic|patients (l_amod) akinetic_10\JJ\1740|
D016627_D010300 NONE 6-ohda-lesioned_31\JJ\1740| (r_amod) rats_32\NNS\2329401|of|bilateral|6-ohda-lesioned (r_nmod) cue_28\NN\7010821|to|a|rats (r_nmod) respond_25\VB\2367363|to|cue (r_acl) time_23\NN\7308889|the|increased|reaction|respond (r_dobj) reverses_19\VBZ\109660|task|,|amn082|time|. (l_nmod) task_4\NN\575741|in|a|complex|used (l_acl) used_6\VBN\1156834|commonly|evaluate (l_xcomp) evaluate_8\VB\670261|to|symptoms (l_dobj) symptoms_11\NNS\5823932|major|akinetic|patients (l_nmod) patients_14\NNS\9898892|of|pd (l_compound) pd_13\NN\14625458|
804391
D012293_D011507 CID rifampin_8\NN\2716205| (r_nmod:npmod) treated_9\JJ\1740|rifampin (r_amod) patients_10\NNS\9898892|in|treated|tuberculosis (r_nmod) proteinuria_2\NN\14299637|chain|and|immunity|patients|.
D012293_D011507 CID rifampin_13\NN\2716205|with (r_nmod) treated_11\VBN\2376958|rifampin (r_acl) patients_10\NNS\9898892|in|17|tuberculosis|treated (r_nmod) found_4\VBN\2426171|proteinuria|was|patients|. (l_nsubjpass) proteinuria_2\NN\14299637|chain
D012293_D014376 NONE rifampin_8\NN\2716205| (r_nmod:npmod) treated_9\JJ\1740|rifampin (r_amod) patients_10\NNS\9898892|in|treated|tuberculosis (l_nmod) tuberculosis_12\NN\14127211|with
D012293_D014376 NONE rifampin_13\NN\2716205|with (r_nmod) treated_11\VBN\2376958|rifampin (r_acl) patients_10\NNS\9898892|in|17|tuberculosis|treated (l_compound) tuberculosis_9\NN\14127211|
11890511
7059267
D002747_D009901 CID chlorpropamide-induced_0\JJ\1740| (r_amod) neuropathy_2\NN\14204950|chlorpropamide-induced|optic|.
D002747_D009901 CID chlorpropamide_8\NN\1740|with|diabenese (r_nmod) treated_6\VBN\2376958|chlorpropamide (r_acl) woman_2\NN\9605289|a|65-year-old|diabetes|treated (r_nsubj) had_12\VBD\2108377|woman|neuropathy|. (l_dobj) neuropathy_16\NN\14204950|a|toxic|optic|resolved
D002747_D009901 CID diabenese_10\NN\1740|(|) (r_appos) chlorpropamide_8\NN\1740|with|diabenese (r_nmod) treated_6\VBN\2376958|chlorpropamide (r_acl) woman_2\NN\9605289|a|65-year-old|diabetes|treated (r_nsubj) had_12\VBD\2108377|woman|neuropathy|. (l_dobj) neuropathy_16\NN\14204950|a|toxic|optic|resolved
D002747_D009901 CID chlorpropamide_22\NN\1740| (r_compound) therapy_23\NN\657604|of|chlorpropamide (r_nmod) discontinuation_20\NN\209943|with|therapy (r_nmod) resolved_18\VBD\352826|that|discontinuation (r_acl:relcl) neuropathy_16\NN\14204950|a|toxic|optic|resolved
D002747_D003924 NONE chlorpropamide_8\NN\1740|with|diabenese (r_nmod) treated_6\VBN\2376958|chlorpropamide (r_acl) woman_2\NN\9605289|a|65-year-old|diabetes|treated (l_nmod) diabetes_5\NN\14075199|with|adult-onset
D002747_D003924 NONE diabenese_10\NN\1740|(|) (r_appos) chlorpropamide_8\NN\1740|with|diabenese (r_nmod) treated_6\VBN\2376958|chlorpropamide (r_acl) woman_2\NN\9605289|a|65-year-old|diabetes|treated (l_nmod) diabetes_5\NN\14075199|with|adult-onset
D002747_D003924 NONE chlorpropamide_22\NN\1740| (r_compound) therapy_23\NN\657604|of|chlorpropamide (r_nmod) discontinuation_20\NN\209943|with|therapy (r_nmod) resolved_18\VBD\352826|that|discontinuation (r_acl:relcl) neuropathy_16\NN\14204950|a|toxic|optic|resolved (r_dobj) had_12\VBD\2108377|woman|neuropathy|. (l_nsubj) woman_2\NN\9605289|a|65-year-old|diabetes|treated (l_nmod) diabetes_5\NN\14075199|with|adult-onset
8106150
D007980_D004409 NONE l-dopa-induced_5\JJ\1740| (r_amod) dyskinesias_6\NNS\14084880|on|l-dopa-induced|monkeys
D007980_D004409 NONE l-dopa_17\NN\14604959|with (r_nmod) combination_15\NN\7951464|in|l-dopa (r_nmod) tested_13\VBN\670261|series|were|then|combination|see|. (l_advcl) see_19\VB\2106506|to|modified (l_ccomp) modified_26\VBN\109660|if|movements|would|be (l_nsubjpass) movements_23\NNS\191142|the|dyskinetic (l_amod) dyskinetic_22\JJ\1740|
D015632_D004409 NONE mptp-treated_8\JJ\1740| (r_amod) monkeys_9\NNS\2469914|in|mptp-treated (r_nmod) dyskinesias_6\NNS\14084880|on|l-dopa-induced|monkeys
D015632_D020734 CID mptp_11\NN\1740|toxin (r_dep) rendered_6\VBN\120316|group|was|parkinsonian|mptp|. (l_xcomp) parkinsonian_7\JJ\1740|
D004298_D004409 NONE dopamine_10\NN\14807737|than (r_nmod) other_8\JJ\1740|dopamine (r_amod) neurotransmitters_7\NNS\14807410|primarily|on|other (r_nmod) acting_4\VBG\1619354|neurotransmitters (r_acl) agents_3\NNS\7347|of|acting (r_nmod) series_1\NN\8456993|a|agents (r_nsubjpass) tested_13\VBN\670261|series|were|then|combination|see|. (l_advcl) see_19\VB\2106506|to|modified (l_ccomp) modified_26\VBN\109660|if|movements|would|be (l_nsubjpass) movements_23\NNS\191142|the|dyskinetic (l_amod) dyskinetic_22\JJ\1740|
D003000_D004409 NONE clonidine_4\NN\2721160|including|,|physostigmine|,|methysergide|,|5-mdot|,|propranolol|,|and|mk-801 (r_nmod) drugs_1\NNS\14778436|several|,|clonidine|, (r_nsubj) reduced_18\VBD\441445|drugs|markedly|movements|but|cost|. (l_dobj) movements_21\NNS\191142|the|dyskinetic (l_amod) dyskinetic_20\JJ\1740|
D003000_D020734 NONE clonidine_4\NN\2721160|including|,|physostigmine|,|methysergide|,|5-mdot|,|propranolol|,|and|mk-801 (r_nmod) drugs_1\NNS\14778436|several|,|clonidine|, (r_nsubj) reduced_18\VBD\441445|drugs|markedly|movements|but|cost|. (l_conj) cost_25\NN\13275288|at|the|return (l_nmod) return_28\NN\6479665|of|a|symptomatology (l_nmod) symptomatology_31\NN\1740|of|parkinsonian (l_amod) parkinsonian_30\JJ\1740|
D010830_D004409 NONE physostigmine_6\NN\14712692| (r_conj) clonidine_4\NN\2721160|including|,|physostigmine|,|methysergide|,|5-mdot|,|propranolol|,|and|mk-801 (r_nmod) drugs_1\NNS\14778436|several|,|clonidine|, (r_nsubj) reduced_18\VBD\441445|drugs|markedly|movements|but|cost|. (l_dobj) movements_21\NNS\191142|the|dyskinetic (l_amod) dyskinetic_20\JJ\1740|
D010830_D020734 NONE physostigmine_6\NN\14712692| (r_conj) clonidine_4\NN\2721160|including|,|physostigmine|,|methysergide|,|5-mdot|,|propranolol|,|and|mk-801 (r_nmod) drugs_1\NNS\14778436|several|,|clonidine|, (r_nsubj) reduced_18\VBD\441445|drugs|markedly|movements|but|cost|. (l_conj) cost_25\NN\13275288|at|the|return (l_nmod) return_28\NN\6479665|of|a|symptomatology (l_nmod) symptomatology_31\NN\1740|of|parkinsonian (l_amod) parkinsonian_30\JJ\1740|
D008784_D004409 NONE methysergide_8\NN\1740| (r_conj) clonidine_4\NN\2721160|including|,|physostigmine|,|methysergide|,|5-mdot|,|propranolol|,|and|mk-801 (r_nmod) drugs_1\NNS\14778436|several|,|clonidine|, (r_nsubj) reduced_18\VBD\441445|drugs|markedly|movements|but|cost|. (l_dobj) movements_21\NNS\191142|the|dyskinetic (l_amod) dyskinetic_20\JJ\1740|
D008784_D020734 NONE methysergide_8\NN\1740| (r_conj) clonidine_4\NN\2721160|including|,|physostigmine|,|methysergide|,|5-mdot|,|propranolol|,|and|mk-801 (r_nmod) drugs_1\NNS\14778436|several|,|clonidine|, (r_nsubj) reduced_18\VBD\441445|drugs|markedly|movements|but|cost|. (l_conj) cost_25\NN\13275288|at|the|return (l_nmod) return_28\NN\6479665|of|a|symptomatology (l_nmod) symptomatology_31\NN\1740|of|parkinsonian (l_amod) parkinsonian_30\JJ\1740|
-1_D004409 NONE 5-mdot_10\NN\1740| (r_conj) clonidine_4\NN\2721160|including|,|physostigmine|,|methysergide|,|5-mdot|,|propranolol|,|and|mk-801 (r_nmod) drugs_1\NNS\14778436|several|,|clonidine|, (r_nsubj) reduced_18\VBD\441445|drugs|markedly|movements|but|cost|. (l_dobj) movements_21\NNS\191142|the|dyskinetic (l_amod) dyskinetic_20\JJ\1740|
-1_D020734 NONE 5-mdot_10\NN\1740| (r_conj) clonidine_4\NN\2721160|including|,|physostigmine|,|methysergide|,|5-mdot|,|propranolol|,|and|mk-801 (r_nmod) drugs_1\NNS\14778436|several|,|clonidine|, (r_nsubj) reduced_18\VBD\441445|drugs|markedly|movements|but|cost|. (l_conj) cost_25\NN\13275288|at|the|return (l_nmod) return_28\NN\6479665|of|a|symptomatology (l_nmod) symptomatology_31\NN\1740|of|parkinsonian (l_amod) parkinsonian_30\JJ\1740|
D011433_D004409 NONE propranolol_12\NN\1740| (r_conj) clonidine_4\NN\2721160|including|,|physostigmine|,|methysergide|,|5-mdot|,|propranolol|,|and|mk-801 (r_nmod) drugs_1\NNS\14778436|several|,|clonidine|, (r_nsubj) reduced_18\VBD\441445|drugs|markedly|movements|but|cost|. (l_dobj) movements_21\NNS\191142|the|dyskinetic (l_amod) dyskinetic_20\JJ\1740|
D011433_D020734 NONE propranolol_12\NN\1740| (r_conj) clonidine_4\NN\2721160|including|,|physostigmine|,|methysergide|,|5-mdot|,|propranolol|,|and|mk-801 (r_nmod) drugs_1\NNS\14778436|several|,|clonidine|, (r_nsubj) reduced_18\VBD\441445|drugs|markedly|movements|but|cost|. (l_conj) cost_25\NN\13275288|at|the|return (l_nmod) return_28\NN\6479665|of|a|symptomatology (l_nmod) symptomatology_31\NN\1740|of|parkinsonian (l_amod) parkinsonian_30\JJ\1740|
D016291_D004409 NONE mk-801_15\NN\1740| (r_conj) clonidine_4\NN\2721160|including|,|physostigmine|,|methysergide|,|5-mdot|,|propranolol|,|and|mk-801 (r_nmod) drugs_1\NNS\14778436|several|,|clonidine|, (r_nsubj) reduced_18\VBD\441445|drugs|markedly|movements|but|cost|. (l_dobj) movements_21\NNS\191142|the|dyskinetic (l_amod) dyskinetic_20\JJ\1740|
D016291_D020734 NONE mk-801_15\NN\1740| (r_conj) clonidine_4\NN\2721160|including|,|physostigmine|,|methysergide|,|5-mdot|,|propranolol|,|and|mk-801 (r_nmod) drugs_1\NNS\14778436|several|,|clonidine|, (r_nsubj) reduced_18\VBD\441445|drugs|markedly|movements|but|cost|. (l_conj) cost_25\NN\13275288|at|the|return (l_nmod) return_28\NN\6479665|of|a|symptomatology (l_nmod) symptomatology_31\NN\1740|of|parkinsonian (l_amod) parkinsonian_30\JJ\1740|
D015016_D004409 NONE yohimbine_2\NN\1740|and|meperidine (r_nsubj) reduced_5\VBD\441445|however|,|yohimbine|predominantly|movements|. (l_dobj) movements_9\NNS\191142|the|dyskinetic (l_amod) dyskinetic_8\JJ\1740|
D008614_D004409 NONE meperidine_4\NN\3808564| (r_conj) yohimbine_2\NN\1740|and|meperidine (r_nsubj) reduced_5\VBD\441445|however|,|yohimbine|predominantly|movements|. (l_dobj) movements_9\NNS\191142|the|dyskinetic (l_amod) dyskinetic_8\JJ\1740|
D001418_D020821 NONE baclofen_0\NN\1740| (r_nsubj) useful_3\JJ\1740|baclofen|was|also|monkey|form|. (l_nmod) form_11\NN\6286395|against|a|dystonic|dyskinesia (l_amod) dystonic_10\JJ\1740|more
D001418_D004409 NONE baclofen_0\NN\1740| (r_nsubj) useful_3\JJ\1740|baclofen|was|also|monkey|form|. (l_nmod) form_11\NN\6286395|against|a|dystonic|dyskinesia (l_nmod) dyskinesia_13\NN\14084880|of
D001285_D020821 NONE atropine_0\NN\14712692| (r_nsubj) converted_1\VBD\126264|atropine|movements|chorea|. (l_dobj) movements_4\NNS\191142|the|dystonic (l_amod) dystonic_3\JJ\1740|
D001285_D002819 NONE atropine_0\NN\14712692| (r_nsubj) converted_1\VBD\126264|atropine|movements|chorea|. (l_nmod) chorea_6\NN\14253124|into
6695415
D010665_D002543 CID phenylpropanolamine_4\NN\2682038|with (r_nmod) associated_2\VBN\628491|phenylpropanolamine|combination (r_acl) hemorrhage_1\NN\14285662|cerebral|associated|.
D010665_D002543 CID ppa/caffeine_4\NN\1740| (r_nsubj) lead_6\VB\1752884|that|ppa/caffeine|can|hemorrhage|administered (l_nmod) hemorrhage_9\NN\14285662|to|cerebral|animals
D002110_D002543 CID caffeine_8\NN\14712692|with (r_nmod) combination_6\NN\7951464|in|caffeine (r_nmod) associated_2\VBN\628491|phenylpropanolamine|combination (r_acl) hemorrhage_1\NN\14285662|cerebral|associated|.
D002110_D002543 CID ppa/caffeine_4\NN\1740| (r_nsubj) lead_6\VB\1752884|that|ppa/caffeine|can|hemorrhage|administered (l_nmod) hemorrhage_9\NN\14285662|to|cerebral|animals
D010665_D020521 CID phenylpropanolamine_0\NN\2682038|ppa (r_nsubj) drug_6\NN\14778436|phenylpropanolamine|is|a|associated|. (l_acl:relcl) associated_10\VBN\628491|that|has|been|effects (l_nmod) effects_14\NNS\13245626|with|serious|side|stroke (l_nmod) stroke_16\NN\556313|including
D010665_D020521 CID ppa_2\NN\1740|(|) (r_appos) phenylpropanolamine_0\NN\2682038|ppa (r_nsubj) drug_6\NN\14778436|phenylpropanolamine|is|a|associated|. (l_acl:relcl) associated_10\VBN\628491|that|has|been|effects (l_nmod) effects_14\NNS\13245626|with|serious|side|stroke (l_nmod) stroke_16\NN\556313|including
D010665_D020521 CID ppa/caffeine_5\NN\1740| (r_nsubj) lead_7\VB\1752884|if|ppa/caffeine|can|stroke (l_nmod) stroke_9\NN\556313|to|rats
D010665_D006973 CID ppa/caffeine_5\NN\1740| (r_nsubj) lead_7\VB\1752884|if|ppa/caffeine|can|stroke (l_nmod) stroke_9\NN\556313|to|rats (l_nmod) rats_14\NNS\2329401|in|normotensive (l_amod) normotensive_11\JJ\1740|and/or|hypertensive (l_conj) hypertensive_13\JJ\1740|
D010665_D006973 CID ppa/caffeine_2\NN\1740| (r_compound) administration_3\NN\1133281|a|single|ppa/caffeine|dose (r_nsubj) lead_8\VBP\1752884|administration|hypertension|. (l_nmod) hypertension_11\NN\14057371|to|acute|normotensive
D010665_D006973 CID ppa/caffeine_2\NN\1740| (r_compound) administration_3\NN\1133281|a|single|ppa/caffeine|dose (r_nsubj) lead_8\VBP\1752884|administration|hypertension|. (l_nmod) hypertension_11\NN\14057371|to|acute|normotensive (l_nmod) normotensive_15\JJ\1740|in|both|the|and|hypertensive|animals (l_conj) hypertensive_17\JJ\1740|
D010665_D006973 CID ppa/caffeine_4\NN\1740| (r_nsubj) lead_6\VB\1752884|that|ppa/caffeine|can|hemorrhage|administered (l_nmod) hemorrhage_9\NN\14285662|to|cerebral|animals (l_nmod) animals_13\NNS\4475|in|hypertensive (l_amod) hypertensive_12\JJ\1740|previously
D002110_D020521 NONE ppa/caffeine_5\NN\1740| (r_nsubj) lead_7\VB\1752884|if|ppa/caffeine|can|stroke (l_nmod) stroke_9\NN\556313|to|rats
D002110_D006973 CID ppa/caffeine_5\NN\1740| (r_nsubj) lead_7\VB\1752884|if|ppa/caffeine|can|stroke (l_nmod) stroke_9\NN\556313|to|rats (l_nmod) rats_14\NNS\2329401|in|normotensive (l_amod) normotensive_11\JJ\1740|and/or|hypertensive (l_conj) hypertensive_13\JJ\1740|
D002110_D006973 CID ppa/caffeine_2\NN\1740| (r_compound) administration_3\NN\1133281|a|single|ppa/caffeine|dose (r_nsubj) lead_8\VBP\1752884|administration|hypertension|. (l_nmod) hypertension_11\NN\14057371|to|acute|normotensive
D002110_D006973 CID ppa/caffeine_2\NN\1740| (r_compound) administration_3\NN\1133281|a|single|ppa/caffeine|dose (r_nsubj) lead_8\VBP\1752884|administration|hypertension|. (l_nmod) hypertension_11\NN\14057371|to|acute|normotensive (l_nmod) normotensive_15\JJ\1740|in|both|the|and|hypertensive|animals (l_conj) hypertensive_17\JJ\1740|
D002110_D006973 CID ppa/caffeine_4\NN\1740| (r_nsubj) lead_6\VB\1752884|that|ppa/caffeine|can|hemorrhage|administered (l_nmod) hemorrhage_9\NN\14285662|to|cerebral|animals (l_nmod) animals_13\NNS\4475|in|hypertensive (l_amod) hypertensive_12\JJ\1740|previously
1687392
D004298_D002375 NONE dopamine_6\NN\14807737| (r_compound) receptors_7\NNS\5225602|of|d-1|dopamine (r_nmod) blockade_0\NN\952963|receptors (r_nsubj) induce_9\VB\1627355|blockade|may|catalepsy|mice|. (l_dobj) catalepsy_10\NN\14023236|
D004298_D002375 NONE dopamine_6\NN\14807737| (r_compound) antagonists_7\NNS\7846|by|dopamine (r_nmod) induced_4\VBN\1627355|antagonists (r_acl) catalepsy_3\NN\14023236|the|induced
D004298_D002375 NONE dopamine_6\NN\14807737| (r_compound) antagonists_7\NNS\7846|by|dopamine (r_nmod) induced_4\VBN\1627355|antagonists (r_acl) catalepsy_3\NN\14023236|the|induced (r_nsubjpass) tested_10\VBN\670261|1|catalepsy|has|been|and|determined (l_conj) determined_20\VBN\1645601|subtypes|was|. (l_nsubjpass) subtypes_15\NNS\1740|the|possible|dopamine|involved (l_acl) involved_16\VBN\2676054|catalepsy (l_nmod) catalepsy_18\NN\14023236|in
D004298_D002375 NONE dopamine_14\NN\14807737| (r_compound) subtypes_15\NNS\1740|the|possible|dopamine|involved (r_nsubjpass) determined_20\VBN\1645601|subtypes|was|. (r_conj) tested_10\VBN\670261|1|catalepsy|has|been|and|determined (l_nsubjpass) catalepsy_3\NN\14023236|the|induced
D004298_D002375 NONE dopamine_14\NN\14807737| (r_compound) subtypes_15\NNS\1740|the|possible|dopamine|involved (l_acl) involved_16\VBN\2676054|catalepsy (l_nmod) catalepsy_18\NN\14023236|in
D004298_D002375 NONE dopamine_2\NN\14807737| (r_compound) fluphenazine_4\NN\3713736|2|dopamine|antagonist|,|23390|or|sulpiride (r_nsubj) induced_14\VBD\1627355|fluphenazine|catalepsy|. (l_dobj) catalepsy_15\NN\14023236|
D004298_D002375 NONE dopamine_18\NN\14807737| (r_compound) antagonists_19\NNS\7846|by|dopamine (r_nmod) induced_16\VBN\1627355|antagonists (r_acl) catalepsy_15\NN\14023236|on|induced
D005476_D002375 CID fluphenazine_4\NN\3713736|2|dopamine|antagonist|,|23390|or|sulpiride (r_nsubj) induced_14\VBD\1627355|fluphenazine|catalepsy|. (l_dobj) catalepsy_15\NN\14023236|
D005476_D002375 CID fluphenazine_15\NN\3713736|by|,|sch (r_nmod) induced_13\VBN\1627355|fluphenazine (r_acl) catalepsy_12\NN\14023236|the|induced
C534628_D002375 CID 23390_9\NN\1740|sch (r_conj) fluphenazine_4\NN\3713736|2|dopamine|antagonist|,|23390|or|sulpiride (r_nsubj) induced_14\VBD\1627355|fluphenazine|catalepsy|. (l_dobj) catalepsy_15\NN\14023236|
C534628_D002375 CID 23390_3\NN\1740| (r_nummod) sch_2\NN\1740|of|23390 (r_nmod) combination_0\NN\7951464|sch|sulpiride (r_nsubj) induce_8\VB\1627355|combination|did|not|potentiation|. (l_dobj) potentiation_10\NN\13564910|catalepsy (l_amod) catalepsy_9\JJ\1740|
C534628_D002375 CID 23390_18\NN\1740| (r_nummod) sch_17\NN\1740|23390|or|sulpiride (r_conj) fluphenazine_15\NN\3713736|by|,|sch (r_nmod) induced_13\VBN\1627355|fluphenazine (r_acl) catalepsy_12\NN\14023236|the|induced
D013469_D002375 CID sulpiride_13\NN\1740|d-2|antagonist (r_conj) fluphenazine_4\NN\3713736|2|dopamine|antagonist|,|23390|or|sulpiride (r_nsubj) induced_14\VBD\1627355|fluphenazine|catalepsy|. (l_dobj) catalepsy_15\NN\14023236|
D013469_D002375 CID sulpiride_5\NN\1740|with (r_nmod) combination_0\NN\7951464|sch|sulpiride (r_nsubj) induce_8\VB\1627355|combination|did|not|potentiation|. (l_dobj) potentiation_10\NN\13564910|catalepsy (l_amod) catalepsy_9\JJ\1740|
D013469_D002375 CID sulpiride_20\NN\1740| (r_conj) sch_17\NN\1740|23390|or|sulpiride (r_conj) fluphenazine_15\NN\3713736|by|,|sch (r_nmod) induced_13\VBN\1627355|fluphenazine (r_acl) catalepsy_12\NN\14023236|the|induced
D015647_D002375 NONE 38393_5\NN\1740| (r_dep) skf_4\NN\1740|d-1|agonist|38393|or|quinpirole (r_nsubj) decreased_10\VBD\169651|3|skf|catalepsy|. (l_dobj) catalepsy_12\NN\14023236|the|induced
D015647_D002375 NONE 38393_5\NN\1740| (r_nummod) skf_4\NN\1740|of|38393 (r_nmod) combination_2\NN\7951464|skf|quinpirole (r_nsubj) cause_10\VB\1617192|4|combination|did|not|effect|. (l_dobj) effect_13\NN\34213|potentiated|inhibitory|catalepsy (l_nmod) catalepsy_15\NN\14023236|on|induced
D019257_D002375 NONE quinpirole_9\NN\1740|d-2|agonist (r_conj) skf_4\NN\1740|d-1|agonist|38393|or|quinpirole (r_nsubj) decreased_10\VBD\169651|3|skf|catalepsy|. (l_dobj) catalepsy_12\NN\14023236|the|induced
D019257_D002375 NONE quinpirole_7\NN\1740|with (r_nmod) combination_2\NN\7951464|skf|quinpirole (r_nsubj) cause_10\VB\1617192|4|combination|did|not|effect|. (l_dobj) effect_13\NN\34213|potentiated|inhibitory|catalepsy (l_nmod) catalepsy_15\NN\14023236|on|induced
11245434
D003520_D000740 NONE cyclophosphamide_6\NN\1740| (r_compound) cytotoxicity_7\NN\13583478|in|cyclophosphamide|tumors (r_nmod) reduction_4\NN\351485|the|anemia-induced|cytotoxicity (l_amod) anemia-induced_3\JJ\1740|
D003520_D000740 NONE cyclophosphamide_25\NN\1740|of (r_nmod) cytotoxicity_23\NN\13583478|on|the|cyclophosphamide|tumors (r_nmod) impact_9\NN\7339329|the|prevention|cytotoxicity (l_nmod) prevention_12\NN\1073995|of|anemia|treatment (l_compound) anemia_11\NN\14189204|
D003520_D000740 NONE cyclophosphamide_9\NN\1740|of (r_nmod) cytotoxicity_7\NN\13583478|cyclophosphamide|tumors (r_dobj) reduces_6\VBZ\441445|that|anemia|cytotoxicity|,|whereas (l_nsubj) anemia_5\NN\14189204|chemotherapy-induced
D003520_D000740 NONE cyclophosphamide_9\NN\1740|of (r_nmod) cytotoxicity_7\NN\13583478|cyclophosphamide|tumors (r_dobj) reduces_6\VBZ\441445|that|anemia|cytotoxicity|,|whereas (r_ccomp) suggest_2\VBP\1010118|results|reduces|increases|. (l_ccomp) increases_24\VBZ\169651|correction|sensitivity|,|result (l_nsubj) correction_14\NN\248977|anemia|treatment (l_nmod) anemia_16\NN\14189204|of
D003520_D064420 NONE cyclophosphamide_6\NN\1740| (r_compound) cytotoxicity_7\NN\13583478|in|cyclophosphamide|tumors
D003520_D064420 NONE cyclophosphamide_25\NN\1740|of (r_nmod) cytotoxicity_23\NN\13583478|on|the|cyclophosphamide|tumors
D003520_D064420 NONE cyclophosphamide_9\NN\1740|of (r_nmod) cytotoxicity_7\NN\13583478|cyclophosphamide|tumors
D003520_D009369 NONE cyclophosphamide_6\NN\1740| (r_compound) cytotoxicity_7\NN\13583478|in|cyclophosphamide|tumors (l_nmod) tumors_10\NNS\14234074|in|rat
D003520_D009369 NONE cyclophosphamide_25\NN\1740|of (r_nmod) cytotoxicity_23\NN\13583478|on|the|cyclophosphamide|tumors (l_nmod) tumors_29\NNS\14234074|in|solid|experimental
D003520_D009369 NONE cyclophosphamide_9\NN\1740|of (r_nmod) dose_7\NN\3740161|with|a|single|cyclophosphamide|mg/kg (r_nmod) treated_3\VBN\2376958|when|tumors|were|dose|implantation (l_nsubjpass) tumors_1\NNS\14234074|
D003520_D009369 NONE cyclophosphamide_9\NN\1740|of (r_nmod) dose_7\NN\3740161|with|a|single|cyclophosphamide|mg/kg (r_nmod) treated_3\VBN\2376958|when|tumors|were|dose|implantation (r_advcl) observed_31\VBN\2163746|treated|,|delay|was|. (l_nsubjpass) delay_22\NN\15271008|a|growth|regrowth (l_nmod) regrowth_26\NN\1740|with|a|subsequent|tumors (l_nmod) tumors_29\NNS\14234074|of|the
D003520_D009369 NONE cyclophosphamide_9\NN\1740|of (r_nmod) cytotoxicity_7\NN\13583478|cyclophosphamide|tumors (l_nmod) tumors_11\NNS\14234074|in
D003520_D009369 NONE cyclophosphamide_9\NN\1740|of (r_nmod) cytotoxicity_7\NN\13583478|cyclophosphamide|tumors (r_dobj) reduces_6\VBZ\441445|that|anemia|cytotoxicity|,|whereas (r_ccomp) suggest_2\VBP\1010118|results|reduces|increases|. (l_ccomp) increases_24\VBZ\169651|correction|sensitivity|,|result (l_nmod) result_31\NN\34213|probably|as|a|supply (l_nmod) supply_36\NN\13576355|of|an|improved|oxygen|tissue (l_nmod) tissue_39\NN\5220461|to|tumor (l_compound) tumor_38\NN\14234074|
D016190_D000740 CID carboplatin_8\NN\1740|of|mg/kg (r_nmod) dose_6\NN\3740161|a|single|carboplatin|resulting (r_dobj) using_3\VBG\1156834|dose (r_xcomp) induced_2\VBN\1627355|anemia|was|using|. (l_nsubjpass) anemia_0\NN\14189204|
D016190_D000740 CID carboplatin_25\NN\1740| (r_compound) application_26\NN\947128|before|carboplatin (r_nmod) starting_21\VBG\2009433|days|application (r_advcl) administered_17\VBN\2436349|s.c.|times/week|starting (r_acl) rhuepo_12\NN\1740|by|iu/kg|administered (r_nmod) prevented_10\VBN\1740|group|,|development|was|rhuepo|. (l_nsubjpass) development_6\NN\248977|the|anemia (l_nmod) anemia_8\NN\14189204|of
D016190_D009369 NONE carboplatin_3\NN\1740| (r_compound) treatment_4\NN\654885|after|carboplatin (r_nmod) implanted_14\VBN\1421622|treatment|,|tumors|were|s.c.|dorsum|. (l_nsubjpass) tumors_6\NNS\14234074|ds-sarcoma
D016190_D009369 NONE carboplatin_1\NN\1740|neither|nor|rhuepo (r_compound) treatment_4\NN\654885|carboplatin (r_nsubj) influenced_5\VBD\137313|treatment|rate|se|. (l_dobj) rate_8\NN\13815152|tumor|growth (l_compound) tumor_6\NN\14234074|
D016190_D012509 NONE carboplatin_3\NN\1740| (r_compound) treatment_4\NN\654885|after|carboplatin (r_nmod) implanted_14\VBN\1421622|treatment|,|tumors|were|s.c.|dorsum|. (l_nsubjpass) tumors_6\NNS\14234074|ds-sarcoma (l_appos) ds-sarcoma_8\NN\1740|(|rat|)
D010100_D000740 NONE oxygen_35\NN\14622893| (r_compound) supply_36\NN\13576355|of|an|improved|oxygen|tissue (r_nmod) result_31\NN\34213|probably|as|a|supply (r_nmod) increases_24\VBZ\169651|correction|sensitivity|,|result (r_ccomp) suggest_2\VBP\1010118|results|reduces|increases|. (l_ccomp) reduces_6\VBZ\441445|that|anemia|cytotoxicity|,|whereas (l_nsubj) anemia_5\NN\14189204|chemotherapy-induced
D010100_D000740 NONE oxygen_35\NN\14622893| (r_compound) supply_36\NN\13576355|of|an|improved|oxygen|tissue (r_nmod) result_31\NN\34213|probably|as|a|supply (r_nmod) increases_24\VBZ\169651|correction|sensitivity|,|result (l_nsubj) correction_14\NN\248977|anemia|treatment (l_nmod) anemia_16\NN\14189204|of
D010100_D064420 NONE oxygen_35\NN\14622893| (r_compound) supply_36\NN\13576355|of|an|improved|oxygen|tissue (r_nmod) result_31\NN\34213|probably|as|a|supply (r_nmod) increases_24\VBZ\169651|correction|sensitivity|,|result (r_ccomp) suggest_2\VBP\1010118|results|reduces|increases|. (l_ccomp) reduces_6\VBZ\441445|that|anemia|cytotoxicity|,|whereas (l_dobj) cytotoxicity_7\NN\13583478|cyclophosphamide|tumors
D010100_D009369 NONE oxygen_35\NN\14622893| (r_compound) supply_36\NN\13576355|of|an|improved|oxygen|tissue (r_nmod) result_31\NN\34213|probably|as|a|supply (r_nmod) increases_24\VBZ\169651|correction|sensitivity|,|result (r_ccomp) suggest_2\VBP\1010118|results|reduces|increases|. (l_ccomp) reduces_6\VBZ\441445|that|anemia|cytotoxicity|,|whereas (l_dobj) cytotoxicity_7\NN\13583478|cyclophosphamide|tumors (l_nmod) tumors_11\NNS\14234074|in
D010100_D009369 NONE oxygen_35\NN\14622893| (r_compound) supply_36\NN\13576355|of|an|improved|oxygen|tissue (l_nmod) tissue_39\NN\5220461|to|tumor (l_compound) tumor_38\NN\14234074|
20304337
D003042_-1 NONE cocaine_8\NN\3492717|to (r_nmod) exposed_6\VBN\2110927|prenatally|cocaine (r_acl) infant_4\NN\9918248|in|an|exposed (r_nmod) dysgenesis_1\NN\14045507|brainstem|infant|.
7910951
D003473_D010243 NONE agents_7\NNS\7347|due|nondepolarizing|neuromuscular|blocking|and|corticosteroids (r_nmod) paralysis_1\NN\14557898|prolonged|agents|.
D000305_D010243 NONE corticosteroids_9\NNS\14745635| (r_conj) agents_7\NNS\7347|due|nondepolarizing|neuromuscular|blocking|and|corticosteroids (r_nmod) paralysis_1\NN\14557898|prolonged|agents|.
D003473_D018908 CID agents_7\NNS\7347|of|nondepolarizing|neuromuscular|blocking|nd-nmba (r_nmod) use_2\NN\407535|the|long-term|agents (r_nsubjpass) implicated_14\VBN\2677097|use|has|recently|been|cause|,|unclear|. (l_nmod) cause_17\NN\7323922|as|a|weakness (l_nmod) weakness_21\NN\14462666|of|prolonged|muscle
D003473_D018908 CID nd-nmba_9\NN\1740|(|) (r_appos) agents_7\NNS\7347|of|nondepolarizing|neuromuscular|blocking|nd-nmba (r_nmod) use_2\NN\407535|the|long-term|agents (r_nsubjpass) implicated_14\VBN\2677097|use|has|recently|been|cause|,|unclear|. (l_nmod) cause_17\NN\7323922|as|a|weakness (l_nmod) weakness_21\NN\14462666|of|prolonged|muscle
D003473_D018908 CID nd-nmbas_23\NN\1740|of (r_nmod) discontinuation_21\NN\209943|following|the|nd-nmbas (r_nmod) developed_16\VBD\1753788|who|weakness|discontinuation (l_dobj) weakness_18\NN\14462666|prolonged
D003473_D018908 CID nd-nmba_19\NN\1740|due (r_nmod) likely_16\RB\1740|most|nd-nmba (r_advmod) junction_13\NN\8664443|at|both|the|neuromuscular|(|likely|)|and|muscle (r_nmod) pathology_8\NN\6045562|weakness|is|due|junction|. (l_nsubj) weakness_1\NN\14462666|the|patients
D003473_D012131 NONE nd-nmbas_23\NN\1740|of (r_nmod) discontinuation_21\NN\209943|following|the|nd-nmbas (r_nmod) developed_16\VBD\1753788|who|weakness|discontinuation (r_acl:relcl) patients_3\NNS\9898892|3|age|insufficiency|developed (l_nmod) insufficiency_14\NN\14462946|with|acute|respiratory
D014673_D009135 NONE vecuronium_2\NN\1740| (r_compound) level_3\NN\4916342|the|serum|vecuronium|measured|discontinued (r_nsubj) ng/ml._18\NN\1740|level|was|172|showed (l_parataxis) showed_25\VBD\2137132|biopsy|loss|. (l_dobj) loss_26\NN\13252973|filaments (l_nmod) filaments_31\NNS\14866889|of|thick|,|myosin
D003473_D009468 CID nd-nmba_19\NN\1740|due (r_nmod) likely_16\RB\1740|most|nd-nmba (r_advmod) junction_13\NN\8664443|at|both|the|neuromuscular|(|likely|)|and|muscle
D000305_D018908 NONE corticosteroids_28\NNS\14745635|likely|due (r_appos) muscle_22\NN\5289601|(|corticosteroids|) (r_conj) junction_13\NN\8664443|at|both|the|neuromuscular|(|likely|)|and|muscle (r_nmod) pathology_8\NN\6045562|weakness|is|due|junction|. (l_nsubj) weakness_1\NN\14462666|the|patients
D000305_D009468 NONE corticosteroids_28\NNS\14745635|likely|due (r_appos) muscle_22\NN\5289601|(|corticosteroids|) (r_conj) junction_13\NN\8664443|at|both|the|neuromuscular|(|likely|)|and|muscle
15858223
D014635_D056486 CID acid_1\NN\14818238|valproic|i|: (r_compound) course_5\NN\883297|acid|time|biomarkers|,|toxicity|. (l_conj) toxicity_12\NN\13576101|liver|,|and|levels
D014635_D056486 CID acid_16\NN\14818238|valproic (r_compound) levels_18\NNS\4916342|acid|metabolite|rats (r_conj) toxicity_12\NN\13576101|liver|,|and|levels
D014635_D056486 CID vpa-associated_9\JJ\1740| (r_amod) stress_11\NN\7083732|between|vpa-associated|oxidative|and|hepatotoxicity (l_conj) hepatotoxicity_13\NN\1740|
D014635_D056486 CID vpa_23\NN\1740|with|mg/kg|or|saline (r_nmod) treated_20\VBN\2376958|determine|,|rats|were|ip|vpa|daily|2|days|. (l_advcl) determine_1\VB\1645601|to|was (l_ccomp) was_4\VBD\836236|whether|there|relationship (l_attr) relationship_7\NN\31921|a|temporal|stress (l_nmod) stress_11\NN\7083732|between|vpa-associated|oxidative|and|hepatotoxicity (l_conj) hepatotoxicity_13\NN\1740|
D005978_D056486 NONE alpha-glutathione_9\NN\1740| (r_compound) s-transferase_10\NN\1740|of|alpha-glutathione|alpha-gst (r_nmod) levels_7\NNS\4916342|based|on|serum|s-transferase|and|histology (r_nmod) evaluated_3\VBN\670261|toxicity|was|levels|. (l_nsubjpass) toxicity_1\NN\13576101|liver
D014635_D009336 CID vpa_6\NN\1740| (r_compound) treatment_7\NN\654885|vpa (r_nsubj) results_8\VBZ\2633881|that|treatment|stress|,|measured (l_advcl) measured_14\VBN\697589|as|levels (l_nmod) levels_16\NNS\4916342|by|15-f(2t)-isop|precedes (l_acl:relcl) precedes_21\VBZ\2690708|which|onset (l_dobj) onset_23\NN\7325190|the|necrosis (l_nmod) necrosis_25\NN\11444117|of|,|steatosis|,|and|levels
D014635_D005234 CID vpa_6\NN\1740| (r_compound) treatment_7\NN\654885|vpa (r_nsubj) results_8\VBZ\2633881|that|treatment|stress|,|measured (l_advcl) measured_14\VBN\697589|as|levels (l_nmod) levels_16\NNS\4916342|by|15-f(2t)-isop|precedes (l_acl:relcl) precedes_21\VBZ\2690708|which|onset (l_dobj) onset_23\NN\7325190|the|necrosis (l_nmod) necrosis_25\NN\11444117|of|,|steatosis|,|and|levels (l_conj) steatosis_27\NN\1740|
C075750_D009336 NONE 15-f(2t)-isop_18\NN\1740|of|, (r_nmod) levels_16\NNS\4916342|by|15-f(2t)-isop|precedes (l_acl:relcl) precedes_21\VBZ\2690708|which|onset (l_dobj) onset_23\NN\7325190|the|necrosis (l_nmod) necrosis_25\NN\11444117|of|,|steatosis|,|and|levels
C075750_D005234 NONE 15-f(2t)-isop_18\NN\1740|of|, (r_nmod) levels_16\NNS\4916342|by|15-f(2t)-isop|precedes (l_acl:relcl) precedes_21\VBZ\2690708|which|onset (l_dobj) onset_23\NN\7325190|the|necrosis (l_nmod) necrosis_25\NN\11444117|of|,|steatosis|,|and|levels (l_conj) steatosis_27\NN\1740|
21294084
D010406_D004827 NONE penicillin_12\NN\2716866| (r_nmod:npmod) -_13\JJ\1740|penicillin (r_amod) model_16\NN\5888929|in|-|induced|epilepsy|rats (r_nmod) discharges_10\NNS\7283608|on|cortical|epileptic|model (l_amod) epileptic_9\JJ\1740|
D010406_D004827 NONE penicillin_12\NN\2716866| (r_nmod:npmod) -_13\JJ\1740|penicillin (r_amod) model_16\NN\5888929|in|-|induced|epilepsy|rats (l_compound) epilepsy_15\NN\14085708|
D010406_D004827 NONE penicillin-induced_17\JJ\1740| (r_amod) model_19\NN\5888929|in|penicillin-induced|epilepsy (r_nmod) activity_15\NN\30358|on|cortical|epileptic|model (l_amod) epileptic_14\JJ\1740|
D010406_D004827 NONE penicillin-induced_17\JJ\1740| (r_amod) model_19\NN\5888929|in|penicillin-induced|epilepsy (l_compound) epilepsy_18\NN\14085708|
D010406_D004827 NONE penicillin-induced_9\JJ\1740| (r_amod) activity_12\NN\30358|the|acute|penicillin-induced|cortical|epileptic|independent (l_amod) epileptic_11\JJ\1740|
7905523
C059896_D015658 NONE n-butyl-deoxynojirimycin_6\NN\1740|of|combination|sc-48334|and|zidovudine|patients (l_nmod) patients_13\NNS\9898892|in|infection|cells/mm3 (l_nmod) infection_16\NN\14052046|with|hiv-1|and
C059896_D015658 NONE sc-48334_8\NN\1740|(|) (r_appos) n-butyl-deoxynojirimycin_6\NN\1740|of|combination|sc-48334|and|zidovudine|patients (l_nmod) patients_13\NNS\9898892|in|infection|cells/mm3 (l_nmod) infection_16\NN\14052046|with|hiv-1|and
D015215_D015658 NONE zidovudine_11\NN\3834836| (r_conj) n-butyl-deoxynojirimycin_6\NN\1740|of|combination|sc-48334|and|zidovudine|patients (l_nmod) patients_13\NNS\9898892|in|infection|cells/mm3 (l_nmod) infection_16\NN\14052046|with|hiv-1|and
C059896_D007153 NONE sc-48334_2\NN\1740| (r_compound) level_5\NN\4916342|the|mean|sc-48334|steady-state|trough|micrograms/ml (r_nsubj) concentration_18\NN\4916342|level|below|the|in|inhibitory|virus|. (l_nmod) virus_22\NN\9312843|for|human|immunodeficiency|hiv (l_compound) immunodeficiency_21\NN\13973990|
11900788
D009538_D002375 CID nicotine_0\NN\14712692| (r_compound) potentiation_1\NN\13564910|nicotine|catalepsy|. (l_nmod) catalepsy_4\NN\14023236|of|morphine-induced|mice
D009538_D002375 CID nicotine_7\NN\14712692|of (r_nmod) effects_5\NNS\13245626|nicotine|catalepsy (l_nmod) catalepsy_9\NN\14023236|on|induced
D009538_D002375 CID nicotine_3\NN\14712692| (r_conj) morphine_0\NN\2707683|not|nicotine (r_nsubj) induced_4\VBD\1627355|morphine|catalepsy|. (l_dobj) catalepsy_7\NN\14023236|a|dose-dependent
D009538_D002375 CID nicotine_22\NN\14712692|with (r_nmod) combination_18\NN\7951464|by|a|morphine|nicotine (r_nmod) induced_15\VBN\1627355|combination (r_acl) catalepsy_14\NN\14023236|induced
D009538_D002375 CID nicotine_16\NN\14712692| (r_conj) morphine_14\NN\2707683|by|plus|nicotine (r_nmod) induced_12\VBN\1627355|morphine (r_acl) catalepsy_11\NN\14023236|induced
D009538_D002375 CID nicotine_22\NN\14712692|by (r_nmod) induced_20\VBN\1627355|nicotine (r_acl) potentiation_17\NN\13564910|the|morphine|induced (r_nsubjpass) mediated_26\VBN\761713|potentiation|may|also|be|mechanisms (r_conj) elicited_8\VBN\1617192|that|catalepsy|can|be|receptors|,|and|mediated (l_nsubjpass) catalepsy_5\NN\14023236|morphine
D009020_D002375 CID morphine-induced_3\JJ\1740| (r_amod) catalepsy_4\NN\14023236|of|morphine-induced|mice
D009020_D002375 CID morphine_12\NN\2707683|by (r_nmod) induced_10\VBN\1627355|morphine|mice (r_acl) catalepsy_9\NN\14023236|on|induced
D009020_D002375 CID morphine_0\NN\2707683|not|nicotine (r_nsubj) induced_4\VBD\1627355|morphine|catalepsy|. (l_dobj) catalepsy_7\NN\14023236|a|dose-dependent
D009020_D002375 CID morphine_20\NN\2707683|of (r_nmod) combination_18\NN\7951464|by|a|morphine|nicotine (r_nmod) induced_15\VBN\1627355|combination (r_acl) catalepsy_14\NN\14023236|induced
D009020_D002375 CID morphine_14\NN\2707683|by|plus|nicotine (r_nmod) induced_12\VBN\1627355|morphine (r_acl) catalepsy_11\NN\14023236|induced
D009020_D002375 CID morphine_4\NN\2707683| (r_compound) catalepsy_5\NN\14023236|morphine
D009020_D002375 CID morphine_19\NN\2707683|of (r_nmod) potentiation_17\NN\13564910|the|morphine|induced (r_nsubjpass) mediated_26\VBN\761713|potentiation|may|also|be|mechanisms (r_conj) elicited_8\VBN\1617192|that|catalepsy|can|be|receptors|,|and|mediated (l_nsubjpass) catalepsy_5\NN\14023236|morphine
D001285_D002375 NONE atropine_3\NN\14712692|of|,|naloxone|,|mecamylamine|,|and|hexamethonium (r_nmod) administration_1\NN\1133281|intraperitoneal|atropine|mice (r_nsubj) reduced_13\VBD\441445|administration|catalepsy|. (l_dobj) catalepsy_14\NN\14023236|induced
D001285_D002375 NONE atropine_3\NN\14712692|of|,|hexamethonium|,|and|naloxone (r_nmod) injection_1\NN\320852|intracerebroventricular|atropine (r_nsubj) decreased_10\VBD\169651|injection|also|catalepsy|. (l_dobj) catalepsy_11\NN\14023236|induced
D009270_D002375 NONE naloxone_5\NN\3808977| (r_conj) atropine_3\NN\14712692|of|,|naloxone|,|mecamylamine|,|and|hexamethonium (r_nmod) administration_1\NN\1133281|intraperitoneal|atropine|mice (r_nsubj) reduced_13\VBD\441445|administration|catalepsy|. (l_dobj) catalepsy_14\NN\14023236|induced
D009270_D002375 NONE naloxone_8\NN\3808977| (r_conj) atropine_3\NN\14712692|of|,|hexamethonium|,|and|naloxone (r_nmod) injection_1\NN\320852|intracerebroventricular|atropine (r_nsubj) decreased_10\VBD\169651|injection|also|catalepsy|. (l_dobj) catalepsy_11\NN\14023236|induced
D008464_D002375 NONE mecamylamine_7\NN\1740| (r_conj) atropine_3\NN\14712692|of|,|naloxone|,|mecamylamine|,|and|hexamethonium (r_nmod) administration_1\NN\1133281|intraperitoneal|atropine|mice (r_nsubj) reduced_13\VBD\441445|administration|catalepsy|. (l_dobj) catalepsy_14\NN\14023236|induced
D018738_D002375 NONE hexamethonium_10\NN\1740| (r_conj) atropine_3\NN\14712692|of|,|naloxone|,|mecamylamine|,|and|hexamethonium (r_nmod) administration_1\NN\1133281|intraperitoneal|atropine|mice (r_nsubj) reduced_13\VBD\441445|administration|catalepsy|. (l_dobj) catalepsy_14\NN\14023236|induced
D018738_D002375 NONE hexamethonium_5\NN\1740| (r_conj) atropine_3\NN\14712692|of|,|hexamethonium|,|and|naloxone (r_nmod) injection_1\NN\320852|intracerebroventricular|atropine (r_nsubj) decreased_10\VBD\169651|injection|also|catalepsy|. (l_dobj) catalepsy_11\NN\14023236|induced
19721134
D010862_D001145 NONE pilocarpine_9\NN\14712692|of (r_nmod) effects_7\NNS\13245626|the|pilocarpine (r_dobj) evaluate_5\VB\670261|to|effects|and|explore (l_conj) explore_11\VB\789138|mechanism|,|using (l_advcl) using_17\VBG\1156834|rat|models (l_dobj) models_26\NNS\5888929|arrhythmia (l_compound) arrhythmia_25\NN\14103288|
D010862_D001145 NONE pilocarpine_5\NN\14712692| (r_nsubj) delayed_7\VBD\439958|that|pilocarpine|significantly|onset|,|decreased (l_dobj) onset_8\NN\7325190|arrhythmias (l_nmod) arrhythmias_10\NNS\14103288|of
D010862_D001145 NONE pilocarpine_5\NN\14712692| (r_nsubj) delayed_7\VBD\439958|that|pilocarpine|significantly|onset|,|decreased (l_conj) decreased_12\VBD\169651|course|,|reduced (l_conj) reduced_22\VBD\441445|score|,|and|increased (l_dobj) score_24\NN\5736149|arrhythmia (l_compound) arrhythmia_23\NN\14103288|
D010862_D001145 NONE pilocarpine_5\NN\14712692| (r_nsubj) delayed_7\VBD\439958|that|pilocarpine|significantly|onset|,|decreased (l_conj) decreased_12\VBD\169651|course|,|reduced (l_conj) reduced_22\VBD\441445|score|,|and|increased (l_conj) increased_27\VBD\169651|time (l_dobj) time_30\NN\7308889|the|survival|rats (l_nmod) rats_33\NNS\2329401|of|arrhythmic|and|pigs (l_amod) arrhythmic_32\JJ\1740|
D010862_D001145 NONE pilocarpine_4\NN\14712692| (r_nsubj) produced_5\VBD\1617192|that|pilocarpine|actions|stimulating (l_dobj) actions_7\NNS\30358|antiarrhythmic|models (l_nmod) models_14\NNS\5888929|on|rat|induced (l_compound) rat_10\NN\2329401|arrhythmic|and|pig (l_amod) arrhythmic_9\JJ\1740|
D000157_D001145 CID aconitine-induced_19\JJ\1740| (r_amod) rat_20\NN\2329401|both|aconitine-induced|and|pig (r_dobj) using_17\VBG\1156834|rat|models (l_dobj) models_26\NNS\5888929|arrhythmia (l_compound) arrhythmia_25\NN\14103288|
D000157_D001145 CID aconitine_17\NN\1740|by|or|ouabain (r_nmod) induced_15\VBN\1627355|aconitine (r_acl) models_14\NNS\5888929|on|rat|induced (l_compound) rat_10\NN\2329401|arrhythmic|and|pig (l_amod) arrhythmic_9\JJ\1740|
D010042_D001145 CID ouabain-induced_22\JJ\1740| (r_amod) pig_24\NN\2395003|ouabain-induced|guinea (r_conj) rat_20\NN\2329401|both|aconitine-induced|and|pig (r_dobj) using_17\VBG\1156834|rat|models (l_dobj) models_26\NNS\5888929|arrhythmia (l_compound) arrhythmia_25\NN\14103288|
D010042_D001145 CID ouabain_19\NN\1740| (r_conj) aconitine_17\NN\1740|by|or|ouabain (r_nmod) induced_15\VBN\1627355|aconitine (r_acl) models_14\NNS\5888929|on|rat|induced (l_compound) rat_10\NN\2329401|arrhythmic|and|pig (l_amod) arrhythmic_9\JJ\1740|
D010862_D017180 NONE pilocarpine_5\NN\14712692| (r_nsubj) delayed_7\VBD\439958|that|pilocarpine|significantly|onset|,|decreased (l_conj) decreased_12\VBD\169651|course|,|reduced (l_dobj) course_15\NN\883297|the|time|tachycardia (l_nmod) tachycardia_18\NN\14110674|of|ventricular|and|fibrillation (l_conj) fibrillation_20\NN\14361664|
D010862_D014693 NONE pilocarpine_5\NN\14712692| (r_nsubj) delayed_7\VBD\439958|that|pilocarpine|significantly|onset|,|decreased (l_conj) decreased_12\VBD\169651|course|,|reduced (l_dobj) course_15\NN\883297|the|time|tachycardia (l_nmod) tachycardia_18\NN\14110674|of|ventricular|and|fibrillation (l_conj) fibrillation_20\NN\14361664|
D002118_D001145 NONE ca(2_34\NN\1740| (r_compound) +_35\NN\1740|ca(2|) (r_compound) handling_37\NN\623162|of|+ (r_nmod) improvement_32\NN\7359599|to|the|handling (r_nmod) related_29\JJ\1740|mechanism|may|be|improvement (r_ccomp) suggest_2\VBP\1010118|data|produced|related|. (l_ccomp) produced_5\VBD\1617192|that|pilocarpine|actions|stimulating (l_dobj) actions_7\NNS\30358|antiarrhythmic|models (l_nmod) models_14\NNS\5888929|on|rat|induced (l_compound) rat_10\NN\2329401|arrhythmic|and|pig (l_amod) arrhythmic_9\JJ\1740|
8766220
D014147_D006212 CID tramadol_7\NN\1740|of|combined (r_nmod) intake_5\NN\13440063|after|long-term|tramadol (r_nmod) nightmares_0\NNS\14411243|and|hallucinations|intake|. (l_conj) hallucinations_2\NNS\14376855|
D014147_D006212 CID tramadol_21\NN\1740| (r_conj) drugs_19\NNS\14778436|of|psycho-active|and|tramadol (r_nmod) withdrawal_16\NN\7206096|after|the|drugs (r_nmod) stopped_13\VBD\2452885|that|only|withdrawal (r_acl:relcl) hallucinations_10\NNS\14376855|stopped
D014147_D009369 NONE tramadol_0\NN\1740| (r_nsubj) opioid_4\NN\1740|tramadol|is|a|weak|effects|used|. (l_acl:relcl) used_14\VBN\1156834|that|is|treat (l_xcomp) treat_16\VB\2376958|to|pain (l_dobj) pain_18\NN\14299637|cancer|and|pain (l_compound) cancer_17\NN\14239425|
D014147_D010146 NONE tramadol_0\NN\1740| (r_nsubj) opioid_4\NN\1740|tramadol|is|a|weak|effects|used|. (l_acl:relcl) used_14\VBN\1156834|that|is|treat (l_xcomp) treat_16\VB\2376958|to|pain (l_dobj) pain_18\NN\14299637|cancer|and|pain
D014147_D010146 NONE tramadol_0\NN\1740| (r_nsubj) opioid_4\NN\1740|tramadol|is|a|weak|effects|used|. (l_acl:relcl) used_14\VBN\1156834|that|is|treat (l_xcomp) treat_16\VB\2376958|to|pain (l_dobj) pain_18\NN\14299637|cancer|and|pain (l_conj) pain_23\NN\14299637|chronic|malignant
D017374_-1 NONE paroxetine_7\NN\1740|with|and|hydrochloride (r_nmod) association_5\NN\8008335|in|paroxetine (r_nmod) initiated_3\VBN\1617192|drug|was|association|patient|. (l_nmod) patient_14\NN\9898892|in|a|tetraparetic|pain (l_amod) tetraparetic_13\JJ\1740|
D017374_D059350 NONE paroxetine_7\NN\1740|with|and|hydrochloride (r_nmod) association_5\NN\8008335|in|paroxetine (r_nmod) initiated_3\VBN\1617192|drug|was|association|patient|. (l_nmod) patient_14\NN\9898892|in|a|tetraparetic|pain (l_nmod) pain_17\NN\14299637|with|chronic
D004308_-1 NONE hydrochloride_10\NN\14817592|dosulepine (r_conj) paroxetine_7\NN\1740|with|and|hydrochloride (r_nmod) association_5\NN\8008335|in|paroxetine (r_nmod) initiated_3\VBN\1617192|drug|was|association|patient|. (l_nmod) patient_14\NN\9898892|in|a|tetraparetic|pain (l_amod) tetraparetic_13\JJ\1740|
D004308_D059350 NONE hydrochloride_10\NN\14817592|dosulepine (r_conj) paroxetine_7\NN\1740|with|and|hydrochloride (r_nmod) association_5\NN\8008335|in|paroxetine (r_nmod) initiated_3\VBN\1617192|drug|was|association|patient|. (l_nmod) patient_14\NN\9898892|in|a|tetraparetic|pain (l_nmod) pain_17\NN\14299637|with|chronic
18006530
D015742_D010146 CID propofol_7\NN\1740|with|target-controlled|and|remifentanil (r_nmod) induction_4\NN\7450842|during|propofol (r_nmod) reduction_0\NN\351485|pain|induction|. (l_nmod) pain_2\NN\14299637|of
D015742_D010146 CID propofol_6\NN\1740|of (r_nmod) injection_4\NN\320852|on|propofol (r_nmod) pain_2\NN\14299637|injection
D015742_D010146 CID propofol_3\NN\1740| (r_compound) infusion_4\NN\14589223|propofol (r_compound) pain_5\NN\14299637|infusion
D015742_D010146 CID propofol_15\NN\1740| (r_compound) infusion_16\NN\14589223|the|propofol (r_dobj) starting_13\VBG\2009433|before|infusion|setting (r_advcl) infusing_10\VBG\606335|by|remifentanil|starting (r_advcl) prevented_8\VBN\1740|that|pain|might|be|infusing (l_nsubjpass) pain_5\NN\14299637|infusion
D015742_D010146 CID propofol_13\NN\1740|by (r_nmod) caused_11\VBN\1617192|propofol (r_acl) pain_10\NN\14299637|caused
D015742_D010146 CID propofol_22\NN\1740| (r_compound) infusion_23\NN\14589223|during|the|propofol (r_nmod) using_16\VBG\1156834|scale|infusion (r_xcomp) evaluated_15\VBN\670261|pain|was|using|. (l_nsubjpass) pain_10\NN\14299637|caused
D015742_D010146 CID propofol_9\NN\1740|of|and|remifentanil (r_nmod) tci_7\NN\1740|with|propofol (r_nmod) induction_3\NN\7450842|during|anaesthesia|tci (r_nmod) achieved_21\VBN\2524171|induction|,|reduction|was|complications|administration (l_nsubjpass) reduction_15\NN\351485|a|significant|pain (l_nmod) pain_19\NN\14299637|in|infusion
D015742_D010146 CID propofol_17\NN\1740| (r_compound) infusion_18\NN\14589223|propofol (r_compound) pain_19\NN\14299637|in|infusion
C071741_D010146 NONE remifentanil_9\NN\1740| (r_conj) propofol_7\NN\1740|with|target-controlled|and|remifentanil (r_nmod) induction_4\NN\7450842|during|propofol (r_nmod) reduction_0\NN\351485|pain|induction|. (l_nmod) pain_2\NN\14299637|of
C071741_D010146 NONE remifentanil_11\NN\1740| (r_dobj) infusing_10\VBG\606335|by|remifentanil|starting (r_advcl) prevented_8\VBN\1740|that|pain|might|be|infusing (l_nsubjpass) pain_5\NN\14299637|infusion
C071741_D010146 NONE remifentanil_20\NN\1740|of (r_nmod) concentration_15\NN\4916342|the|effect-site|ce|remifentanil|prevent (l_acl) prevent_22\VB\1740|to|pain|producing (l_dobj) pain_24\NN\14299637|the
C071741_D010146 NONE remifentanil-related_0\JJ\1740| (r_amod) complications_1\NNS\1073995|remifentanil-related (r_nsubjpass) assessed_3\VBN\670261|complications|were|infusion|,|and|evaluated (l_conj) evaluated_15\VBN\670261|pain|was|using|. (l_nsubjpass) pain_10\NN\14299637|caused
C071741_D010146 NONE remifentanil_6\NN\1740| (r_compound) infusion_7\NN\14589223|during|the|remifentanil (r_nmod) assessed_3\VBN\670261|complications|were|infusion|,|and|evaluated (l_conj) evaluated_15\VBN\670261|pain|was|using|. (l_nsubjpass) pain_10\NN\14299637|caused
C071741_D010146 NONE remifentanil_11\NN\1740| (r_conj) propofol_9\NN\1740|of|and|remifentanil (r_nmod) tci_7\NN\1740|with|propofol (r_nmod) induction_3\NN\7450842|during|anaesthesia|tci (r_nmod) achieved_21\VBN\2524171|induction|,|reduction|was|complications|administration (l_nsubjpass) reduction_15\NN\351485|a|significant|pain (l_nmod) pain_19\NN\14299637|in|infusion
C071741_D010146 NONE remifentanil_29\NN\1740|of (r_nmod) administration_27\NN\1133281|by|prior|remifentanil|ce (r_nmod) achieved_21\VBN\2524171|induction|,|reduction|was|complications|administration (l_nsubjpass) reduction_15\NN\351485|a|significant|pain (l_nmod) pain_19\NN\14299637|in|infusion
9848575
D018943_D009202 NONE anthracycline_6\NN\1740| (r_compound) derivative_7\NN\5802185|of|a|novel|synthetic|anthracycline|sm-5887 (r_nmod) effects_1\NNS\13245626|chronic|derivative|heart|. (l_nmod) heart_13\NN\5919034|on|normal|and|cardiomyopathy (l_conj) cardiomyopathy_16\NN\14103288|doxorubicin-induced|dogs
C055866_D009202 NONE sm-5887_9\NN\1740|(|) (r_appos) derivative_7\NN\5802185|of|a|novel|synthetic|anthracycline|sm-5887 (r_nmod) effects_1\NNS\13245626|chronic|derivative|heart|. (l_nmod) heart_13\NN\5919034|on|normal|and|cardiomyopathy (l_conj) cardiomyopathy_16\NN\14103288|doxorubicin-induced|dogs
C055866_D009202 NONE sm-5887_33\NN\1740| (r_compound) administration_34\NN\1133281|after|the|sm-5887 (r_nmod) sacrificed_30\VBN\2316304|which|were|terminally|administration (r_acl:relcl) animals_26\NNS\4475|sacrificed (r_nsubj) show_37\VB\2137132|while|animals|did|not|changes (r_advcl) demonstrated_8\VBD\2137132|animals|changes|,|show|. (l_dobj) changes_14\NNS\7283608|the|electrocardiogram|,|decrease|and|cardiomyopathy (l_conj) cardiomyopathy_23\NN\14103288|high-grade|histopathological
C055866_D009202 NONE sm-5887_8\NN\1740|of (r_nmod) effect_6\NN\34213|a|deteriorating|cardiotoxic|sm-5887 (r_dobj) examine_1\VB\789138|to|effect (r_advcl) induced_13\VBN\1627355|examine|,|cardiomyopathy|was|dogs|courses|. (l_nsubjpass) cardiomyopathy_11\NN\14103288|low-grade
C055866_D009202 NONE sm-5887_5\NN\1740| (r_compound) treatment_6\NN\654885|the|sm-5887 (r_nsubj) progress_9\VB\252019|contrary|,|treatment|did|not|grade|. (l_dobj) grade_11\NN\7975026|the|cardiomyopathy (l_nmod) cardiomyopathy_13\NN\14103288|of
D004317_D009202 CID doxorubicin-induced_15\JJ\1740| (r_amod) cardiomyopathy_16\NN\14103288|doxorubicin-induced|dogs
D004317_D009202 CID doxorubicin_7\NN\2716866|of (r_nmod) courses_5\NNS\883297|over|six|doxorubicin (r_nmod) received_2\VBD\2210855|which|courses (r_acl:relcl) animals_0\NNS\4475|received (r_nsubj) demonstrated_8\VBD\2137132|animals|changes|,|show|. (l_dobj) changes_14\NNS\7283608|the|electrocardiogram|,|decrease|and|cardiomyopathy (l_conj) cardiomyopathy_23\NN\14103288|high-grade|histopathological
D004317_D009202 CID doxorubicin_20\NN\2716866|of|mg/kg (r_nmod) courses_18\NNS\883297|by|four|doxorubicin (r_nmod) induced_13\VBN\1627355|examine|,|cardiomyopathy|was|dogs|courses|. (l_nsubjpass) cardiomyopathy_11\NN\14103288|low-grade
C055866_D066126 NONE sm-5887_11\NN\1740|of (r_nmod) potential_9\NN\14481929|the|chronic|cardiotoxic|sm-5887|and|effect (l_amod) cardiotoxic_8\JJ\1740|
C055866_D066126 NONE sm-5887_11\NN\1740|of (r_nmod) potential_9\NN\14481929|the|chronic|cardiotoxic|sm-5887|and|effect (l_conj) effect_16\NN\34213|a|possible|deteriorating|sm-5887|cardiotoxicity (l_nmod) cardiotoxicity_21\NN\1740|on|low-grade|pre-induced
C055866_D066126 NONE sm-5887_18\NN\1740|of (r_nmod) effect_16\NN\34213|a|possible|deteriorating|sm-5887|cardiotoxicity (r_conj) potential_9\NN\14481929|the|chronic|cardiotoxic|sm-5887|and|effect (l_amod) cardiotoxic_8\JJ\1740|
C055866_D066126 NONE sm-5887_18\NN\1740|of (r_nmod) effect_16\NN\34213|a|possible|deteriorating|sm-5887|cardiotoxicity (l_nmod) cardiotoxicity_21\NN\1740|on|low-grade|pre-induced
C055866_D066126 NONE sm-5887_8\NN\1740|of (r_nmod) effect_6\NN\34213|a|deteriorating|cardiotoxic|sm-5887 (l_amod) cardiotoxic_5\JJ\1740|
C055866_D066126 NONE sm-5887_3\NNP\1740| (r_nsubj) have_6\VB\2108377|conclusion|,|sm-5887|does|not|potential|. (l_dobj) potential_8\NN\14481929|any|cardiotoxicity (l_nmod) cardiotoxicity_11\NN\1740|of|chronic|and|effect
C055866_D066126 NONE sm-5887_3\NNP\1740| (r_nsubj) have_6\VB\2108377|conclusion|,|sm-5887|does|not|potential|. (l_dobj) potential_8\NN\14481929|any|cardiotoxicity (l_nmod) cardiotoxicity_11\NN\1740|of|chronic|and|effect (l_conj) effect_14\NN\34213|deteriorating|cardiotoxicity (l_nmod) cardiotoxicity_17\NN\1740|on|doxorubicin-induced|dogs
D004317_D066126 NONE doxorubicin_24\NN\2716866|by (r_nmod) pre-induced_22\JJ\1740|doxorubicin|dogs (r_acl) cardiotoxicity_21\NN\1740|on|low-grade|pre-induced (r_nmod) effect_16\NN\34213|a|possible|deteriorating|sm-5887|cardiotoxicity (r_conj) potential_9\NN\14481929|the|chronic|cardiotoxic|sm-5887|and|effect (l_amod) cardiotoxic_8\JJ\1740|
D004317_D066126 NONE doxorubicin_24\NN\2716866|by (r_nmod) pre-induced_22\JJ\1740|doxorubicin|dogs (r_acl) cardiotoxicity_21\NN\1740|on|low-grade|pre-induced
D004317_D066126 NONE doxorubicin_20\NN\2716866|of|mg/kg (r_nmod) courses_18\NNS\883297|by|four|doxorubicin (r_nmod) induced_13\VBN\1627355|examine|,|cardiomyopathy|was|dogs|courses|. (l_advcl) examine_1\VB\789138|to|effect (l_dobj) effect_6\NN\34213|a|deteriorating|cardiotoxic|sm-5887 (l_amod) cardiotoxic_5\JJ\1740|
D004317_D066126 NONE doxorubicin_9\NN\2716866| (r_compound) treatment_10\NN\654885|by|the|additional|doxorubicin (r_nmod) enhanced_5\VBN\227165|changes|were|treatment|. (l_nsubjpass) changes_3\NNS\7283608|the|low-grade|cardiotoxic (l_amod) cardiotoxic_2\JJ\1740|
D004317_D066126 NONE doxorubicin-induced_16\JJ\1740| (r_amod) cardiotoxicity_17\NN\1740|on|doxorubicin-induced|dogs (r_nmod) effect_14\NN\34213|deteriorating|cardiotoxicity (r_conj) cardiotoxicity_11\NN\1740|of|chronic|and|effect
D004317_D066126 NONE doxorubicin-induced_16\JJ\1740| (r_amod) cardiotoxicity_17\NN\1740|on|doxorubicin-induced|dogs
15579441
D011692_D000860 CID aminonucleoside-induced_15\JJ\1740| (r_amod) syndrome_17\NN\5870365|in|the|puromycin|aminonucleoside-induced|nephrotic (r_nmod) hypoxia_11\NN\14035298|diffuse|cortical|syndrome|and|hypoxia
D011692_D000860 CID aminonucleoside-induced_15\JJ\1740| (r_amod) syndrome_17\NN\5870365|in|the|puromycin|aminonucleoside-induced|nephrotic (r_nmod) hypoxia_11\NN\14035298|diffuse|cortical|syndrome|and|hypoxia (l_conj) hypoxia_22\NN\14035298|focal|model
D011692_D000860 CID aminonucleoside_19\NN\1740| (r_compound) model_20\NN\5888929|in|the|puromycin|aminonucleoside (r_nmod) weeks_15\NNS\15113229|at|2|model (r_nmod) reaching_11\VBG\2005948|2.2-fold|weeks|and|2.6-fold (r_advcl) increased_5\VBD\169651|expression|period|,|reaching|,|whereas|showed|. (l_nsubj) expression_0\NN\4679549|transgene (l_nmod) transgene_4\NN\5436752|of|the|hypoxia-responsive (l_amod) hypoxia-responsive_3\JJ\1740|
D011692_D009404 CID aminonucleoside-induced_15\JJ\1740| (r_amod) syndrome_17\NN\5870365|in|the|puromycin|aminonucleoside-induced|nephrotic
15266215
C406224_D013927 NONE valdecoxib_6\NN\3124700|of|the|inhibitor|versus|agents (r_nmod) effects_0\NNS\13245626|valdecoxib|events|. (l_nmod) events_16\NNS\23100|on|cardiovascular|thrombotic|patients (l_amod) thrombotic_15\JJ\1740|
C406224_D013927 NONE valdecoxib_23\NN\3124700|pooled|mg|,|nsaid|and|data (r_dobj) analyzing_21\VBG\78760|by|valdecoxib (r_advcl) determined_19\VBN\1645601|incidence|was|analyzing|. (l_nsubjpass) incidence_1\NN\13821570|the|events (l_nmod) events_5\NNS\23100|of|cardiovascular|thrombotic|cardiac (l_amod) thrombotic_4\JJ\1740|
C406224_D013927 NONE valdecoxib_23\NN\3124700|pooled|mg|,|nsaid|and|data (r_dobj) analyzing_21\VBG\78760|by|valdecoxib (r_advcl) determined_19\VBN\1645601|incidence|was|analyzing|. (l_nsubjpass) incidence_1\NN\13821570|the|events (l_nmod) events_5\NNS\23100|of|cardiovascular|thrombotic|cardiac (l_dep) cardiac_7\JJ\1740|(|,|cerebrovascular|,|or|thrombotic|) (l_conj) thrombotic_16\JJ\1740|arterial
C406224_D013927 NONE valdecoxib_10\NN\3124700|for|,|nsaids|,|and|placebo (r_nmod) similar_8\JJ\1740|incidences|were|valdecoxib|. (l_nsubj) incidences_3\NNS\13821570|crude|events (l_nmod) events_6\NNS\23100|of|thrombotic (l_amod) thrombotic_5\JJ\1740|
C406224_D013927 NONE valdecoxib_11\NN\3124700| (r_compound) dose_12\NN\3740161|for|each|valdecoxib (r_nmod) similar_8\JJ\1740|risk|was|also|dose|. (l_nsubj) risk_1\NN\14541044|the|events (l_nmod) events_5\NNS\23100|of|serious|thrombotic (l_amod) thrombotic_4\JJ\1740|
C406224_D013927 NONE valdecoxib_23\NN\3124700|,|%|; (r_dep) placebo_15\NN\3740161|(|,|%|;|valdecoxib|nsaids|) (r_dep) higher_4\JJR\1740|risk|was|consistently|users|nonusers|placebo|. (l_nsubj) risk_1\NN\14541044|thrombotic (l_amod) thrombotic_0\JJ\1740|
C406224_D013927 NONE valdecoxib_22\NN\3124700| (r_compound) doses_23\NNS\3740161|with|therapeutic|valdecoxib (r_nmod) treatment_3\NN\654885|short-|doses (r_nsubjpass) associated_26\VBN\628491|treatment|was|not|incidence|relative|. (l_nmod) incidence_30\NN\13821570|with|an|increased|events (l_nmod) events_33\NNS\23100|of|thrombotic (l_amod) thrombotic_32\JJ\1740|
C406224_D001168 NONE valdecoxib_6\NN\3124700|of|the|inhibitor|versus|agents (r_nmod) effects_0\NNS\13245626|valdecoxib|events|. (l_nmod) events_16\NNS\23100|on|cardiovascular|thrombotic|patients (l_nmod) patients_18\NNS\9898892|in|arthritis (l_nmod) arthritis_20\NN\14171682|with
C406224_D010003 NONE valdecoxib_6\NN\3124700|for|,|inhibitor|patients (l_nmod) patients_15\NNS\9898892|in|8000|osteoarthritis|treated (l_nmod) osteoarthritis_17\NN\14186541|with|and|arthritis
C406224_D010003 NONE valdecoxib_23\NN\3124700|pooled|mg|,|nsaid|and|data (l_conj) data_53\NNS\7951464|placebo|trials (l_nmod) trials_61\NNS\786195|from|10|osteoarthritis|weeks (l_compound) osteoarthritis_57\NN\14186541|randomized|and|arthritis
C406224_D010003 NONE valdecoxib_22\NN\3124700| (r_compound) doses_23\NNS\3740161|with|therapeutic|valdecoxib (r_nmod) treatment_3\NN\654885|short-|doses (r_nsubjpass) associated_26\VBN\628491|treatment|was|not|incidence|relative|. (l_advmod) relative_34\JJ\1740|nsaids|osteoarthritis (l_nmod) osteoarthritis_41\NN\14186541|in|and|patients|trials
C406224_D001172 NONE valdecoxib_6\NN\3124700|for|,|inhibitor|patients (l_nmod) patients_15\NNS\9898892|in|8000|osteoarthritis|treated (l_nmod) osteoarthritis_17\NN\14186541|with|and|arthritis (l_conj) arthritis_20\NN\14171682|rheumatoid
C406224_D001172 NONE valdecoxib_23\NN\3124700|pooled|mg|,|nsaid|and|data (l_conj) data_53\NNS\7951464|placebo|trials (l_nmod) trials_61\NNS\786195|from|10|osteoarthritis|weeks (l_compound) osteoarthritis_57\NN\14186541|randomized|and|arthritis (l_conj) arthritis_60\NN\14171682|rheumatoid
C406224_D001172 NONE valdecoxib_22\NN\3124700| (r_compound) doses_23\NNS\3740161|with|therapeutic|valdecoxib (r_nmod) treatment_3\NN\654885|short-|doses (r_nsubjpass) associated_26\VBN\628491|treatment|was|not|incidence|relative|. (l_advmod) relative_34\JJ\1740|nsaids|osteoarthritis (l_nmod) osteoarthritis_41\NN\14186541|in|and|patients|trials (l_conj) patients_45\NNS\9898892|arthritis (l_compound) arthritis_44\NN\14171682|rheumatoid
D004008_D013927 NONE diclofenac_35\NN\1740|(|bid|,|tid|,|or|naproxen|) (r_dep) nsaid_33\NN\2721538|nonselective|diclofenac (r_conj) valdecoxib_23\NN\3124700|pooled|mg|,|nsaid|and|data (r_dobj) analyzing_21\VBG\78760|by|valdecoxib (r_advcl) determined_19\VBN\1645601|incidence|was|analyzing|. (l_nsubjpass) incidence_1\NN\13821570|the|events (l_nmod) events_5\NNS\23100|of|cardiovascular|thrombotic|cardiac (l_amod) thrombotic_4\JJ\1740|
D004008_D013927 NONE diclofenac_35\NN\1740|(|bid|,|tid|,|or|naproxen|) (r_dep) nsaid_33\NN\2721538|nonselective|diclofenac (r_conj) valdecoxib_23\NN\3124700|pooled|mg|,|nsaid|and|data (r_dobj) analyzing_21\VBG\78760|by|valdecoxib (r_advcl) determined_19\VBN\1645601|incidence|was|analyzing|. (l_nsubjpass) incidence_1\NN\13821570|the|events (l_nmod) events_5\NNS\23100|of|cardiovascular|thrombotic|cardiac (l_dep) cardiac_7\JJ\1740|(|,|cerebrovascular|,|or|thrombotic|) (l_conj) thrombotic_16\JJ\1740|arterial
D004008_D010003 NONE diclofenac_35\NN\1740|(|bid|,|tid|,|or|naproxen|) (r_dep) nsaid_33\NN\2721538|nonselective|diclofenac (r_conj) valdecoxib_23\NN\3124700|pooled|mg|,|nsaid|and|data (l_conj) data_53\NNS\7951464|placebo|trials (l_nmod) trials_61\NNS\786195|from|10|osteoarthritis|weeks (l_compound) osteoarthritis_57\NN\14186541|randomized|and|arthritis
D004008_D001172 NONE diclofenac_35\NN\1740|(|bid|,|tid|,|or|naproxen|) (r_dep) nsaid_33\NN\2721538|nonselective|diclofenac (r_conj) valdecoxib_23\NN\3124700|pooled|mg|,|nsaid|and|data (l_conj) data_53\NNS\7951464|placebo|trials (l_nmod) trials_61\NNS\786195|from|10|osteoarthritis|weeks (l_compound) osteoarthritis_57\NN\14186541|randomized|and|arthritis (l_conj) arthritis_60\NN\14171682|rheumatoid
D007052_D013927 NONE ibuprofen_40\NN\3828465| (r_compound) tid_43\NN\1740|ibuprofen|mg (r_conj) diclofenac_35\NN\1740|(|bid|,|tid|,|or|naproxen|) (r_dep) nsaid_33\NN\2721538|nonselective|diclofenac (r_conj) valdecoxib_23\NN\3124700|pooled|mg|,|nsaid|and|data (r_dobj) analyzing_21\VBG\78760|by|valdecoxib (r_advcl) determined_19\VBN\1645601|incidence|was|analyzing|. (l_nsubjpass) incidence_1\NN\13821570|the|events (l_nmod) events_5\NNS\23100|of|cardiovascular|thrombotic|cardiac (l_amod) thrombotic_4\JJ\1740|
D007052_D013927 NONE ibuprofen_40\NN\3828465| (r_compound) tid_43\NN\1740|ibuprofen|mg (r_conj) diclofenac_35\NN\1740|(|bid|,|tid|,|or|naproxen|) (r_dep) nsaid_33\NN\2721538|nonselective|diclofenac (r_conj) valdecoxib_23\NN\3124700|pooled|mg|,|nsaid|and|data (r_dobj) analyzing_21\VBG\78760|by|valdecoxib (r_advcl) determined_19\VBN\1645601|incidence|was|analyzing|. (l_nsubjpass) incidence_1\NN\13821570|the|events (l_nmod) events_5\NNS\23100|of|cardiovascular|thrombotic|cardiac (l_dep) cardiac_7\JJ\1740|(|,|cerebrovascular|,|or|thrombotic|) (l_conj) thrombotic_16\JJ\1740|arterial
D007052_D010003 NONE ibuprofen_40\NN\3828465| (r_compound) tid_43\NN\1740|ibuprofen|mg (r_conj) diclofenac_35\NN\1740|(|bid|,|tid|,|or|naproxen|) (r_dep) nsaid_33\NN\2721538|nonselective|diclofenac (r_conj) valdecoxib_23\NN\3124700|pooled|mg|,|nsaid|and|data (l_conj) data_53\NNS\7951464|placebo|trials (l_nmod) trials_61\NNS\786195|from|10|osteoarthritis|weeks (l_compound) osteoarthritis_57\NN\14186541|randomized|and|arthritis
D007052_D001172 NONE ibuprofen_40\NN\3828465| (r_compound) tid_43\NN\1740|ibuprofen|mg (r_conj) diclofenac_35\NN\1740|(|bid|,|tid|,|or|naproxen|) (r_dep) nsaid_33\NN\2721538|nonselective|diclofenac (r_conj) valdecoxib_23\NN\3124700|pooled|mg|,|nsaid|and|data (l_conj) data_53\NNS\7951464|placebo|trials (l_nmod) trials_61\NNS\786195|from|10|osteoarthritis|weeks (l_compound) osteoarthritis_57\NN\14186541|randomized|and|arthritis (l_conj) arthritis_60\NN\14171682|rheumatoid
D009288_D013927 NONE naproxen_46\NN\3828465|bid (r_conj) diclofenac_35\NN\1740|(|bid|,|tid|,|or|naproxen|) (r_dep) nsaid_33\NN\2721538|nonselective|diclofenac (r_conj) valdecoxib_23\NN\3124700|pooled|mg|,|nsaid|and|data (r_dobj) analyzing_21\VBG\78760|by|valdecoxib (r_advcl) determined_19\VBN\1645601|incidence|was|analyzing|. (l_nsubjpass) incidence_1\NN\13821570|the|events (l_nmod) events_5\NNS\23100|of|cardiovascular|thrombotic|cardiac (l_amod) thrombotic_4\JJ\1740|
D009288_D013927 NONE naproxen_46\NN\3828465|bid (r_conj) diclofenac_35\NN\1740|(|bid|,|tid|,|or|naproxen|) (r_dep) nsaid_33\NN\2721538|nonselective|diclofenac (r_conj) valdecoxib_23\NN\3124700|pooled|mg|,|nsaid|and|data (r_dobj) analyzing_21\VBG\78760|by|valdecoxib (r_advcl) determined_19\VBN\1645601|incidence|was|analyzing|. (l_nsubjpass) incidence_1\NN\13821570|the|events (l_nmod) events_5\NNS\23100|of|cardiovascular|thrombotic|cardiac (l_dep) cardiac_7\JJ\1740|(|,|cerebrovascular|,|or|thrombotic|) (l_conj) thrombotic_16\JJ\1740|arterial
D009288_D010003 NONE naproxen_46\NN\3828465|bid (r_conj) diclofenac_35\NN\1740|(|bid|,|tid|,|or|naproxen|) (r_dep) nsaid_33\NN\2721538|nonselective|diclofenac (r_conj) valdecoxib_23\NN\3124700|pooled|mg|,|nsaid|and|data (l_conj) data_53\NNS\7951464|placebo|trials (l_nmod) trials_61\NNS\786195|from|10|osteoarthritis|weeks (l_compound) osteoarthritis_57\NN\14186541|randomized|and|arthritis
D009288_D001172 NONE naproxen_46\NN\3828465|bid (r_conj) diclofenac_35\NN\1740|(|bid|,|tid|,|or|naproxen|) (r_dep) nsaid_33\NN\2721538|nonselective|diclofenac (r_conj) valdecoxib_23\NN\3124700|pooled|mg|,|nsaid|and|data (l_conj) data_53\NNS\7951464|placebo|trials (l_nmod) trials_61\NNS\786195|from|10|osteoarthritis|weeks (l_compound) osteoarthritis_57\NN\14186541|randomized|and|arthritis (l_conj) arthritis_60\NN\14171682|rheumatoid
D001241_D013927 CID aspirin_8\NN\2707683| (r_compound) users_9\NNS\7846|of|aspirin (r_nmod) users_6\NNS\7846|for|users (r_nmod) higher_4\JJR\1740|risk|was|consistently|users|nonusers|placebo|. (l_nsubj) risk_1\NN\14541044|thrombotic (l_amod) thrombotic_0\JJ\1740|
D001241_D013927 CID aspirin_13\NN\2707683|of (r_nmod) nonusers_11\NNS\1740|than|aspirin (r_nmod) higher_4\JJR\1740|risk|was|consistently|users|nonusers|placebo|. (l_nsubj) risk_1\NN\14541044|thrombotic (l_amod) thrombotic_0\JJ\1740|
3088349
D000661_D009069 CID amphetamine_17\NN\3248958|by (r_nmod) exhaustion_15\NN\14016361|to|amphetamine (r_nmod) susceptibility_9\NN\13920835|system|exhaustion (r_dobj) reflects_8\VBZ\923793|rotation|susceptibility|. (l_nsubj) rotation_2\NN\331950|transient|contralateral|lesion
D000661_D009069 CID amphetamine-induced_26\JJ\1740| (r_amod) behavior_28\NN\407535|on|amphetamine-induced|rotational (r_nmod) effect_14\NN\34213|the|duration|,|behavior (r_dobj) examined_12\VBD\789138|clarify|we|effect|. (l_advcl) clarify_3\VB\939277|in|to|nature (l_dobj) nature_5\NN\4723816|the|rotation (l_nmod) rotation_10\NN\331950|of|this|initial|contralateral
D000661_D009069 CID amphetamine-induced_26\JJ\1740| (r_amod) behavior_28\NN\407535|on|amphetamine-induced|rotational
D000661_D009069 CID amphetamine_10\NN\3248958| (r_nsubjpass) administered_12\VBN\2436349|when|amphetamine|was|time|days|lesioning|,|indicating (l_xcomp) indicating_22\VBG\952524|involvement (l_dobj) involvement_23\NN\1080366|cells|rotation (l_nmod) rotation_30\NN\331950|in|the|contralateral
D000661_D009069 CID amphetamine_16\NN\3248958| (r_compound) dose_17\NN\3740161|amphetamine (r_conj) volume_14\NN\33615|of|either|lesion|,|dose|,|or|exercise (r_nmod) irrespective_10\RB\1740|volume (r_conj) duration_5\NN\15113229|of|the|recovery|(|and|irrespective (r_nmod) regardless_2\RB\1740|duration|) (r_advmod) tended_27\VBD\2604760|however|,|regardless|,|rotation|become|,|and|circled (l_nsubj) rotation_26\NN\331950|amphetamine-induced
D000661_D009069 CID amphetamine-induced_25\JJ\1740| (r_amod) rotation_26\NN\331950|amphetamine-induced
D000661_D009069 CID amphetamine_51\NN\3248958| (r_compound) injections_52\NNS\320852|to|further|amphetamine (r_nmod) response_48\NN\11410625|in|injections (r_nmod) circled_42\VBD\1835496|rats|ipsilaterally|lesion|response|. (r_conj) tended_27\VBD\2604760|however|,|regardless|,|rotation|become|,|and|circled (l_nsubj) rotation_26\NN\331950|amphetamine-induced
D000661_D009069 CID amphetamine_4\NN\3248958| (r_nsubj) has_5\VBZ\2108377|that|amphetamine|effect (l_dobj) effect_8\NN\34213|an|irreversible|pool (l_nmod) pool_13\NN\3302121|on|the|post-lesion|da|contributing (l_acl) contributing_14\VBG\126264|rotation (l_nmod) rotation_17\NN\331950|to|contralateral
D000661_-1 NONE amphetamine_17\NN\3248958|by (r_nmod) exhaustion_15\NN\14016361|to|amphetamine (r_nmod) susceptibility_9\NN\13920835|system|exhaustion (r_dobj) reflects_8\VBZ\923793|rotation|susceptibility|. (l_nsubj) rotation_2\NN\331950|transient|contralateral|lesion (l_nmod) lesion_7\NN\14204950|following|unilateral|nigra
D016627_-1 NONE 6-ohda_2\NN\1740| (r_nmod:npmod) induced_3\JJ\1740|6-ohda (r_amod) lesion_5\NN\14204950|following|unilateral|induced|sn
D016627_D009069 NONE 6-ohda_2\NN\1740| (r_nmod:npmod) induced_3\JJ\1740|6-ohda (r_amod) lesion_5\NN\14204950|following|unilateral|induced|sn (r_nmod) reported_15\VBN\831651|lesion|,|period|has|been|precede|. (l_nsubjpass) period_9\NN\13575869|a|transient|rotation (l_nmod) rotation_12\NN\331950|of|contralateral
D016627_D009069 NONE 6-ohda_2\NN\1740| (r_nmod:npmod) induced_3\JJ\1740|6-ohda (r_amod) lesion_5\NN\14204950|following|unilateral|induced|sn (r_nmod) reported_15\VBN\831651|lesion|,|period|has|been|precede|. (l_xcomp) precede_17\VB\2690708|to|circling (l_dobj) circling_21\NN\1740|the|predominant|ipsilateral
3413271
D004837_D017202 CID epinephrine_6\NN\14807929|by (r_nmod) induced_4\VBN\1627355|epinephrine (r_acl) ischemia_3\NN\14195315|of|myocardial|induced
D004837_D017202 CID epinephrine_3\NN\14807929|of (r_nmod) role_1\NN\719494|the|epinephrine|eliciting (l_advcl) eliciting_5\VBG\1617192|in|ischemia (l_dobj) ischemia_7\NN\14195315|myocardial
D004837_D017202 CID epinephrine_1\NN\14807929|both|and|exercise (r_nsubj) produced_4\VBD\1617192|epinephrine|ischemia|evidenced|. (l_dobj) ischemia_6\NN\14195315|myocardial
D004837_D017202 CID epinephrine_9\NN\14807929|by (r_nmod) induced_7\VBN\1627355|epinephrine (r_acl) ischemia_6\NN\14195315|of|myocardial|induced
D004837_D017202 CID epinephrine-induced_22\JJ\1740| (r_amod) ischemia_23\NN\14195315|epinephrine-induced (r_nsubjpass) characterized_25\VBN\609683|while|ischemia|was|increase (r_advcl) marked_4\VBN\1296462|ischemia|was|predominantly|rate|contribution|,|characterized|. (l_nsubjpass) ischemia_2\NN\14195315|exercise-induced|myocardial
D004837_D007511 NONE epinephrine_6\NN\14807929|by (r_nmod) induced_4\VBN\1627355|epinephrine (r_acl) ischemia_3\NN\14195315|of|myocardial|induced (r_nmod) mechanisms_0\NNS\13446390|ischemia|:|comparison|. (l_dep) comparison_8\NN\635850|ischemia (l_nmod) ischemia_11\NN\14195315|with|exercise-induced
D004837_D007511 NONE epinephrine_13\NN\14807929| (r_compound) infusion_14\NN\14589223|during|epinephrine|and|exercise (r_nmod) compared_11\VBN\644583|signs|were|infusion|. (l_nsubjpass) signs_1\NNS\6643763|objective|ischemia|and|factors (l_nmod) ischemia_3\NN\14195315|of
D004837_D007511 NONE epinephrine-induced_22\JJ\1740| (r_amod) ischemia_23\NN\14195315|epinephrine-induced
D004837_D007511 NONE epinephrine_7\NN\14807929|by (r_nmod) produced_5\VBN\1617192|epinephrine (r_acl) ischemia_4\NN\14195315|produced|,|occur
D004837_D003324 NONE epinephrine_3\NN\14807929|of (r_nmod) role_1\NN\719494|the|epinephrine|eliciting (r_nsubjpass) examined_9\VBN\789138|role|was|patients|. (l_nmod) patients_11\NNS\9898892|in|disease (l_nmod) disease_15\NN\14061805|with|coronary|artery
D010100_D007511 NONE oxygen_8\NN\14622893| (r_compound) consumption_9\NN\13440063|myocardial|oxygen (r_dobj) increasing_6\VBG\169651|consumption (r_acl) factors_5\NNS\7326557|increasing (r_conj) signs_1\NNS\6643763|objective|ischemia|and|factors (l_nmod) ischemia_3\NN\14195315|of
D004837_D003866 NONE epinephrine_1\NN\14807929|both|and|exercise (r_nsubj) produced_4\VBD\1617192|epinephrine|ischemia|evidenced|. (l_advcl) evidenced_8\VBN\1015244|as|depression (l_nmod) depression_12\NN\14373582|by|st|segment|and|angina
D004837_D000787 NONE epinephrine_1\NN\14807929|both|and|exercise (r_nsubj) produced_4\VBD\1617192|epinephrine|ischemia|evidenced|. (l_advcl) evidenced_8\VBN\1015244|as|depression (l_nmod) depression_12\NN\14373582|by|st|segment|and|angina (l_conj) angina_14\NN\14171682|
16629641
D007372_D006526 NONE interferon_12\NN\2725367|with|pegylated|and|ribavirin (r_nmod) therapy_9\NN\657604|treatment|is|combination|interferon|. (l_nsubj) treatment_3\NN\654885|the|current|best|infection (l_nmod) infection_6\NN\14052046|for|hcv
D012254_D006526 NONE ribavirin_14\NN\2725367| (r_conj) interferon_12\NN\2725367|with|pegylated|and|ribavirin (r_nmod) therapy_9\NN\657604|treatment|is|combination|interferon|. (l_nsubj) treatment_3\NN\654885|the|current|best|infection (l_nmod) infection_6\NN\14052046|for|hcv
D012254_D006526 NONE ribavirin-induced_8\JJ\1740| (r_amod) hemolysis_9\NN\13509528|of|ribavirin-induced (r_nmod) result_6\NN\34213|as|a|hemolysis (r_nmod) decrease_2\VBP\169651|concentrations|result|,|and|problematic (l_conj) problematic_16\JJ\1740|anemia|can|be|patients|. (l_nmod) patients_18\NNS\9898892|in|infection|,|those (l_nmod) infection_21\NN\14052046|with|hcv
D012254_D006461 NONE ribavirin-induced_8\JJ\1740| (r_amod) hemolysis_9\NN\13509528|of|ribavirin-induced
D012254_D000740 NONE ribavirin-induced_8\JJ\1740| (r_amod) hemolysis_9\NN\13509528|of|ribavirin-induced (r_nmod) result_6\NN\34213|as|a|hemolysis (r_nmod) decrease_2\VBP\169651|concentrations|result|,|and|problematic (l_conj) problematic_16\JJ\1740|anemia|can|be|patients|. (l_nsubj) anemia_13\NN\14189204|this
D012254_D000740 NONE ribavirin-associated_1\JJ\1740| (r_amod) anemia_2\NN\14189204|ribavirin-associated
D012254_D000740 NONE ribavirin-associated_8\JJ\1740| (r_amod) anemia_9\NN\14189204|ribavirin-associated
D012254_D007674 NONE ribavirin-induced_8\JJ\1740| (r_amod) hemolysis_9\NN\13509528|of|ribavirin-induced (r_nmod) result_6\NN\34213|as|a|hemolysis (r_nmod) decrease_2\VBP\169651|concentrations|result|,|and|problematic (l_conj) problematic_16\JJ\1740|anemia|can|be|patients|. (l_nmod) patients_18\NNS\9898892|in|infection|,|those (l_appos) those_24\DT\1740|especially|have (l_acl:relcl) have_26\VBP\2108377|who|disorders (l_dobj) disorders_31\NNS\14034177|comorbid|renal
D012254_D002318 NONE ribavirin-induced_8\JJ\1740| (r_amod) hemolysis_9\NN\13509528|of|ribavirin-induced (r_nmod) result_6\NN\34213|as|a|hemolysis (r_nmod) decrease_2\VBP\169651|concentrations|result|,|and|problematic (l_conj) problematic_16\JJ\1740|anemia|can|be|patients|. (l_nmod) patients_18\NNS\9898892|in|infection|,|those (l_appos) those_24\DT\1740|especially|have (l_acl:relcl) have_26\VBP\2108377|who|disorders (l_dobj) disorders_31\NNS\14034177|comorbid|renal
C026956_D000743 NONE viramidine_0\NN\1740|,|prodrug|, (r_nsubj) has_8\VBZ\2108377|viramidine|potential (l_dobj) potential_10\NN\14481929|the|maintain (l_acl) maintain_12\VB\2202928|to|efficacy|decreasing (l_advcl) decreasing_19\VBG\169651|while|risk (l_dobj) risk_21\NN\14541044|the|anemia (l_nmod) anemia_24\NN\14189204|of|hemolytic|patients
C026956_D019698 NONE viramidine_0\NN\1740|,|prodrug|, (r_nsubj) has_8\VBZ\2108377|viramidine|potential (l_dobj) potential_10\NN\14481929|the|maintain (l_acl) maintain_12\VB\2202928|to|efficacy|decreasing (l_advcl) decreasing_19\VBG\169651|while|risk (l_dobj) risk_21\NN\14541044|the|anemia (l_nmod) anemia_24\NN\14189204|of|hemolytic|patients (l_nmod) patients_26\NNS\9898892|in|c. (l_nmod) c._30\.\1740|with|chronic|hepatitis
D012254_D000743 CID ribavirin_6\NN\2725367|of (r_nmod) prodrug_4\NN\1740|a|liver-targeting|ribavirin (r_appos) viramidine_0\NN\1740|,|prodrug|, (r_nsubj) has_8\VBZ\2108377|viramidine|potential (l_dobj) potential_10\NN\14481929|the|maintain (l_acl) maintain_12\VB\2202928|to|efficacy|decreasing (l_advcl) decreasing_19\VBG\169651|while|risk (l_dobj) risk_21\NN\14541044|the|anemia (l_nmod) anemia_24\NN\14189204|of|hemolytic|patients
D012254_D000743 CID ribavirin_17\NN\2725367|of (r_nmod) efficacy_15\NN\5199286|the|virologic|ribavirin (r_dobj) maintain_12\VB\2202928|to|efficacy|decreasing (l_advcl) decreasing_19\VBG\169651|while|risk (l_dobj) risk_21\NN\14541044|the|anemia (l_nmod) anemia_24\NN\14189204|of|hemolytic|patients
D012254_D019698 NONE ribavirin_6\NN\2725367|of (r_nmod) prodrug_4\NN\1740|a|liver-targeting|ribavirin (r_appos) viramidine_0\NN\1740|,|prodrug|, (r_nsubj) has_8\VBZ\2108377|viramidine|potential (l_dobj) potential_10\NN\14481929|the|maintain (l_acl) maintain_12\VB\2202928|to|efficacy|decreasing (l_advcl) decreasing_19\VBG\169651|while|risk (l_dobj) risk_21\NN\14541044|the|anemia (l_nmod) anemia_24\NN\14189204|of|hemolytic|patients (l_nmod) patients_26\NNS\9898892|in|c. (l_nmod) c._30\.\1740|with|chronic|hepatitis
D012254_D019698 NONE ribavirin_17\NN\2725367|of (r_nmod) efficacy_15\NN\5199286|the|virologic|ribavirin (r_dobj) maintain_12\VB\2202928|to|efficacy|decreasing (l_advcl) decreasing_19\VBG\169651|while|risk (l_dobj) risk_21\NN\14541044|the|anemia (l_nmod) anemia_24\NN\14189204|of|hemolytic|patients (l_nmod) patients_26\NNS\9898892|in|c. (l_nmod) c._30\.\1740|with|chronic|hepatitis
16586083
D016861_D009203 CID inhibitors_25\NNS\20090|with|cyclooxygenase (r_nmod) treatment_22\NN\654885|during|inhibitors (r_nmod) risk_10\NN\14541044|an|increased|infarction|treatment (l_nmod) infarction_13\NN\14204950|of|myocardial|,|stroke
D016861_D020521 CID inhibitors_25\NNS\20090|with|cyclooxygenase (r_nmod) treatment_22\NN\654885|during|inhibitors (r_nmod) risk_10\NN\14541044|an|increased|infarction|treatment (l_nmod) infarction_13\NN\14204950|of|myocardial|,|stroke (l_conj) stroke_15\NN\556313|,|hypertension
D016861_D006973 CID inhibitors_25\NNS\20090|with|cyclooxygenase (r_nmod) treatment_22\NN\654885|during|inhibitors (r_nmod) risk_10\NN\14541044|an|increased|infarction|treatment (l_nmod) infarction_13\NN\14204950|of|myocardial|,|stroke (l_conj) stroke_15\NN\556313|,|hypertension (l_conj) hypertension_17\NN\14057371|and|failure
D016861_D006333 CID inhibitors_25\NNS\20090|with|cyclooxygenase (r_nmod) treatment_22\NN\654885|during|inhibitors (r_nmod) risk_10\NN\14541044|an|increased|infarction|treatment (l_nmod) infarction_13\NN\14204950|of|myocardial|,|stroke (l_conj) stroke_15\NN\556313|,|hypertension (l_conj) hypertension_17\NN\14057371|and|failure (l_conj) failure_20\NN\66216|heart
C109794_D002318 NONE peptide_8\NN\14724264|such|n-terminal|pro|brain|natriuretic|nt-probnp|or|protein (r_nmod) markers_1\NNS\21939|diagnostic|peptide (r_nsubj) help_17\VB\2556126|markers|might|identification|,|avoiding|. (l_advcl) avoiding_28\VBG\2452885|thus|occurrence (l_dobj) occurrence_30\NN\29378|the|toxicity (l_nmod) toxicity_34\NN\13576101|of|serious|cardiovascular
C109794_D002318 NONE nt-probnp_10\NN\1740|(|) (r_appos) peptide_8\NN\14724264|such|n-terminal|pro|brain|natriuretic|nt-probnp|or|protein (r_nmod) markers_1\NNS\21939|diagnostic|peptide (r_nsubj) help_17\VB\2556126|markers|might|identification|,|avoiding|. (l_advcl) avoiding_28\VBG\2452885|thus|occurrence (l_dobj) occurrence_30\NN\29378|the|toxicity (l_nmod) toxicity_34\NN\13576101|of|serious|cardiovascular
18363626
D020927_D001919 CID dexmedetomidine_1\NN\1740| (r_compound) sedation_2\NN\14034177|dexmedetomidine (r_nsubjpass) associated_4\VBN\628491|although|sedation|was|incidence|%|and|higher|. (l_nmod) incidence_9\NN\13821570|with|a|%|bradycardia (l_nmod) bradycardia_11\NN\14110674|of
D010100_D001919 NONE oxygen_28\NN\14622893| (r_compound) saturations_29\NNS\13534954|oxygen (r_nsubj) higher_34\JJR\1740|saturations|were|%|or (r_conj) associated_4\VBN\628491|although|sedation|was|incidence|%|and|higher|. (l_nmod) incidence_9\NN\13821570|with|a|%|bradycardia (l_nmod) bradycardia_11\NN\14110674|of
15673851
D016202_D020760 NONE n-methyl-d-aspartate_4\NN\1740| (r_compound) receptors_5\NNS\5225602|of|spinal|n-methyl-d-aspartate (r_nmod) activation_1\NN\13561719|the|receptors (r_nsubj) contribute_7\VB\126264|activation|may|degeneration|. (l_nmod) degeneration_9\NN\29677|to|neurons|induced (l_acl) induced_14\VBN\1627355|morphine|interval (l_nmod) interval_21\NN\33615|after|a|noninjurious|ischemia (l_nmod) ischemia_25\NN\14195315|of|spinal|cord
D016202_D020760 NONE nmda_15\NN\1740| (r_compound) receptor_16\NN\5225602|nmda (r_compound) activation_17\NN\13561719|via|receptor (r_nmod) neurotoxic_6\JJ\1740|that|opioids|may|be|setting|activation (l_nmod) setting_9\NN\8567235|in|the|ischemia (l_nmod) ischemia_13\NN\14195315|of|spinal|cord
D009020_D020760 NONE morphine_17\NN\2707683|by|neuraxial (r_nmod) induced_14\VBN\1627355|morphine|interval (l_nmod) interval_21\NN\33615|after|a|noninjurious|ischemia (l_nmod) ischemia_25\NN\14195315|of|spinal|cord
D016202_D001157 NONE n-methyl-d-aspartate_14\NN\1740| (r_compound) receptors_18\NNS\5225602|of|n-methyl-d-aspartate|nmda (r_nmod) activation_12\NN\13561719|receptors (r_conj) degeneration_6\NN\29677|between|the|neurons|and|activation|morphine|interval (l_nmod) interval_25\NN\33615|following|a|noninjurious|occlusion (l_nmod) occlusion_28\NN\14081375|of|aortic|rats
D016202_D001157 NONE nmda_16\NN\1740|(|) (r_compound) receptors_18\NNS\5225602|of|n-methyl-d-aspartate|nmda (r_nmod) activation_12\NN\13561719|receptors (r_conj) degeneration_6\NN\29677|between|the|neurons|and|activation|morphine|interval (l_nmod) interval_25\NN\33615|following|a|noninjurious|occlusion (l_nmod) occlusion_28\NN\14081375|of|aortic|rats
D009020_D001157 NONE morphine_21\NN\2707683|after|neuraxial (r_nmod) degeneration_6\NN\29677|between|the|neurons|and|activation|morphine|interval (l_nmod) interval_25\NN\33615|following|a|noninjurious|occlusion (l_nmod) occlusion_28\NN\14081375|of|aortic|rats
D016291_D020336 NONE mk-801_8\NN\1740|it|mug (r_appos) effect_5\NN\34213|the|mk-801|changes (l_nmod) changes_16\NNS\7283608|on|the|histopathologic|cord|paraparesis (l_nmod) paraparesis_24\NN\14558599|after|morphine-induced|spastic
D016291_D020336 NONE mk-801_1\NN\1740| (r_nsubj) reduced_3\VBD\441445|it|mk-801|significantly|number|group|. (l_dobj) number_5\NN\5107765|the|alpha-motoneurons|paraparesis (l_nmod) paraparesis_12\NN\14558599|after|morphine-induced|spastic
D009020_D020336 CID morphine-induced_22\JJ\1740| (r_amod) paraparesis_24\NN\14558599|after|morphine-induced|spastic
D009020_D020336 CID morphine-induced_10\JJ\1740| (r_amod) paraparesis_12\NN\14558599|after|morphine-induced|spastic
D009020_D020336 CID morphine_5\NN\2707683| (r_nsubj) induces_6\VBZ\1627355|that|it|morphine|paraparesis|increase (l_dobj) paraparesis_8\NN\14558599|spastic
D018698_D020336 NONE glutamate_15\NN\15010703|in|csf|,|involved (r_nmod) increase_12\NN\13576355|with|a|concomitant|glutamate (r_nmod) induces_6\VBZ\1627355|that|it|morphine|paraparesis|increase (l_dobj) paraparesis_8\NN\14558599|spastic
D016202_D020336 NONE nmda_21\NN\1740| (r_compound) receptor_22\NN\5225602|nmda (r_compound) activation_23\NN\13561719|in|receptor (r_nmod) involved_19\VBN\2676054|which|is|activation (r_acl:relcl) glutamate_15\NN\15010703|in|csf|,|involved (r_nmod) increase_12\NN\13576355|with|a|concomitant|glutamate (r_nmod) induces_6\VBZ\1627355|that|it|morphine|paraparesis|increase (l_dobj) paraparesis_8\NN\14558599|spastic
D016202_D020258 NONE nmda_15\NN\1740| (r_compound) receptor_16\NN\5225602|nmda (r_compound) activation_17\NN\13561719|via|receptor (r_nmod) neurotoxic_6\JJ\1740|that|opioids|may|be|setting|activation
7072798
D002701_D000741 CID chloramphenicol_8\NN\2716866|of|ophthalmic (r_nmod) administration_5\NN\1133281|following|topical|chloramphenicol (r_nmod) anemia_2\NN\14189204|fatal|aplastic|administration|.
D002701_D000741 CID chloramphenicol_20\NN\2716866|with (r_nmod) therapy_18\NN\657604|topical|chloramphenicol (r_dobj) beginning_16\VBG\941990|therapy (r_conj) undergoing_12\VBG\109660|after|extraction|and|beginning (r_advcl) died_3\VBD\146138|woman|anemia|undergoing|. (l_nmod) anemia_6\NN\14189204|of|aplastic
D002701_D000741 CID chloramphenicol_13\NN\2716866|to (r_nmod) response_11\NN\11410625|with|an|idiosyncratic|chloramphenicol (r_nmod) associated_7\VBN\628491|pattern|was|response|. (l_nsubjpass) pattern_1\NN\5726345|the|anemia (l_nmod) anemia_5\NN\14189204|of|the|aplastic
D002701_D000741 CID chloramphenicol_13\NN\2716866|with (r_nmod) treatment_11\NN\654885|after|topical|chloramphenicol|conditions (r_nmod) anemia_8\NN\14189204|of|fatal|aplastic|treatment
D002701_D002386 NONE chloramphenicol_20\NN\2716866|with (r_nmod) therapy_18\NN\657604|topical|chloramphenicol (r_dobj) beginning_16\VBG\941990|therapy (r_conj) undergoing_12\VBG\109660|after|extraction|and|beginning (l_dobj) extraction_14\NN\13518963|cataract (l_compound) cataract_13\NN\14252864|
D002701_D001855 NONE chloramphenicol_13\NN\2716866|with (r_nmod) treatment_11\NN\654885|after|topical|chloramphenicol|conditions (r_nmod) anemia_8\NN\14189204|of|fatal|aplastic|treatment (r_nmod) report_4\NN\6470073|this|was|the|second|anemia|,|reported|. (l_advcl) reported_29\VBN\831651|although|cases|have|also|been (l_nsubjpass) cases_20\NNS\7283608|two|hypoplasia (l_nmod) hypoplasia_25\NN\14365950|of|reversible|bone|marrow
D002701_D005128 NONE chloramphenicol_11\NN\2716866|with|applied (r_nmod) associated_7\VBN\628491|chloramphenicol (r_acl) toxicity_6\NN\13576101|of|ocular|associated
871943
D013390_D001049 CID succinylcholine_6\NN\3800001| (r_compound) apnoea_7\NN\1740|in|succinylcholine
D013390_D001049 CID succinylcholine_10\NN\3800001|after (r_nmod) lasting_6\VBG\2704349|succinylcholine (r_acl) apnoea_5\NN\1740|unexpected|prolonged|lasting
D013390_D001049 CID succinylcholine_6\NN\3800001| (r_compound) apnoea_7\NN\1740|in|succinylcholine
6150641
D002927_D007172 CID cimetidine_12\NN\14778019| (r_dobj) taking_11\VBG\2367363|while|cimetidine (r_advcl) developed_5\VBD\1753788|percent|changes|taking|and|disappeared (l_dobj) changes_7\NNS\7283608|breast|or|impotence (l_conj) impotence_9\NN\4723816|
D002927_D007172 CID cimetidine_21\NN\14778019| (r_nsubjpass) replaced_23\VBN\1631072|when|cimetidine|was|ranitidine (r_advcl) disappeared_19\VBD\2609764|cases|changes|replaced|. (r_conj) developed_5\VBD\1753788|percent|changes|taking|and|disappeared (l_dobj) changes_7\NNS\7283608|breast|or|impotence (l_conj) impotence_9\NN\4723816|
D011899_D007172 NONE ranitidine_25\NN\14778019|by (r_nmod) replaced_23\VBN\1631072|when|cimetidine|was|ranitidine (r_advcl) disappeared_19\VBD\2609764|cases|changes|replaced|. (r_conj) developed_5\VBD\1753788|percent|changes|taking|and|disappeared (l_dobj) changes_7\NNS\7283608|breast|or|impotence (l_conj) impotence_9\NN\4723816|
D002927_D056486 NONE cimetidine_5\NN\14778019|of|months|or|ranitidine (r_nmod) doses_3\NNS\3740161|with|high|cimetidine (r_nmod) treatment_0\NN\654885|doses (r_nsubjpass) associated_32\VBN\628491|treatment|was|not|toxicity|,|but|associated (l_nmod) toxicity_37\NN\13576101|with|hepatic|or|alterations
D002927_D056486 NONE cimetidine_60\NN\14778019| (r_compound) therapy_61\NN\657604|with|cimetidine (r_nmod) seen_58\VBN\2106506|than|therapy (r_acl) level_56\NN\4916342|with|a|lower|serum|creatinine|seen (r_nmod) associated_49\VBN\628491|therapy|was|level|. (r_conj) associated_32\VBN\628491|treatment|was|not|toxicity|,|but|associated (l_nmod) toxicity_37\NN\13576101|with|hepatic|or|alterations
D002927_D006402 NONE cimetidine_5\NN\14778019|of|months|or|ranitidine (r_nmod) doses_3\NNS\3740161|with|high|cimetidine (r_nmod) treatment_0\NN\654885|doses (r_nsubjpass) associated_32\VBN\628491|treatment|was|not|toxicity|,|but|associated (l_nmod) toxicity_37\NN\13576101|with|hepatic|or|alterations
D002927_D006402 NONE cimetidine_60\NN\14778019| (r_compound) therapy_61\NN\657604|with|cimetidine (r_nmod) seen_58\VBN\2106506|than|therapy (r_acl) level_56\NN\4916342|with|a|lower|serum|creatinine|seen (r_nmod) associated_49\VBN\628491|therapy|was|level|. (r_conj) associated_32\VBN\628491|treatment|was|not|toxicity|,|but|associated (l_nmod) toxicity_37\NN\13576101|with|hepatic|or|alterations
D011899_D056486 NONE ranitidine_18\NN\14778019|months (r_conj) cimetidine_5\NN\14778019|of|months|or|ranitidine (r_nmod) doses_3\NNS\3740161|with|high|cimetidine (r_nmod) treatment_0\NN\654885|doses (r_nsubjpass) associated_32\VBN\628491|treatment|was|not|toxicity|,|but|associated (l_nmod) toxicity_37\NN\13576101|with|hepatic|or|alterations
D011899_D056486 NONE ranitidine_46\NN\14778019| (r_compound) therapy_47\NN\657604|ranitidine (r_nsubjpass) associated_49\VBN\628491|therapy|was|level|. (r_conj) associated_32\VBN\628491|treatment|was|not|toxicity|,|but|associated (l_nmod) toxicity_37\NN\13576101|with|hepatic|or|alterations
D011899_D006402 NONE ranitidine_18\NN\14778019|months (r_conj) cimetidine_5\NN\14778019|of|months|or|ranitidine (r_nmod) doses_3\NNS\3740161|with|high|cimetidine (r_nmod) treatment_0\NN\654885|doses (r_nsubjpass) associated_32\VBN\628491|treatment|was|not|toxicity|,|but|associated (l_nmod) toxicity_37\NN\13576101|with|hepatic|or|alterations
D011899_D006402 NONE ranitidine_46\NN\14778019| (r_compound) therapy_47\NN\657604|ranitidine (r_nsubjpass) associated_49\VBN\628491|therapy|was|level|. (r_conj) associated_32\VBN\628491|treatment|was|not|toxicity|,|but|associated (l_nmod) toxicity_37\NN\13576101|with|hepatic|or|alterations
D003404_D056486 NONE creatinine_55\NN\1740| (r_compound) level_56\NN\4916342|with|a|lower|serum|creatinine|seen (r_nmod) associated_49\VBN\628491|therapy|was|level|. (r_conj) associated_32\VBN\628491|treatment|was|not|toxicity|,|but|associated (l_nmod) toxicity_37\NN\13576101|with|hepatic|or|alterations
D003404_D006402 NONE creatinine_55\NN\1740| (r_compound) level_56\NN\4916342|with|a|lower|serum|creatinine|seen (r_nmod) associated_49\VBN\628491|therapy|was|level|. (r_conj) associated_32\VBN\628491|treatment|was|not|toxicity|,|but|associated (l_nmod) toxicity_37\NN\13576101|with|hepatic|or|alterations
18483878
D003520_D003556 CID cyclophosphamide_15\NN\1740|(cyp)-induced (r_compound) cystitis_17\NN\14566129|with|cyclophosphamide
D003520_D003556 CID (cyp)-induced_16\NN\1740| (r_dep) cyclophosphamide_15\NN\1740|(cyp)-induced (r_compound) cystitis_17\NN\14566129|with|cyclophosphamide
D003520_D003556 CID cyclophosphamide_14\NN\1740|(cyp)-induced (r_compound) cystitis_16\NN\14566129|after|cyclophosphamide
D003520_D003556 CID (cyp)-induced_15\NN\1740| (r_dep) cyclophosphamide_14\NN\1740|(cyp)-induced (r_compound) cystitis_16\NN\14566129|after|cyclophosphamide
D003520_D003556 CID cyp-induced_32\JJ\1740| (r_amod) cystitis_33\NN\14566129|with|cyp-induced|mg/kg
D003520_D001745 NONE cyp_22\NN\1740|with (r_nmod) observed_18\VBN\2163746|wt|cyp (r_acl) that_17\DT\1740|above|observed (r_nmod) increased_15\VBN\169651|that|mice|,|mediators|are|that (l_nmod) mice_7\NNS\2329401|in|vip(-/-|inflammation (l_nmod) inflammation_10\NN\14299637|with|bladder
8607407
D002110_D006973 CID caffeine_5\NN\14712692|with (r_nmod) elevations_3\NNS\7445480|acute|pressure|caffeine|men|. (l_nmod) men_7\NNS\8208016|in|hypertension (l_nmod) hypertension_11\NN\14057371|with|borderline|systemic
D002110_D006973 CID caffeine_5\NN\14712692|of (r_nmod) actions_3\NNS\30358|the|vasoconstrictive|caffeine (r_nsubjpass) enhanced_7\VBN\227165|whether|actions|are|persons (l_nmod) persons_10\NNS\7347|in|hypertensive (l_amod) hypertensive_9\JJ\1740|
D002110_D006973 CID caffeine_24\NN\14712692| (r_compound) ingestion_25\NN\13440063|after|caffeine (r_nmod) achieved_19\VBD\2524171|consequently|,|exhibited|,|%|levels|ingestion|. (l_dobj) levels_22\NNS\4916342|hypertensive|bp (l_amod) hypertensive_20\JJ\1740|
D002110_D006973 CID caffeine_10\NN\14712692|to (r_nmod) responses_8\NNS\11410625|exaggerated|caffeine (r_nsubj) selective_13\JJ\1740|thus|,|men|,|responses|were|:|bp|,|consistent|. (l_nmod) men_5\NNS\8208016|in|borderline|hypertensive (l_amod) hypertensive_4\JJ\1740|
D002110_D006973 CID caffeine_10\NN\14712692|to (r_nmod) responses_8\NNS\11410625|exaggerated|caffeine (r_nsubj) selective_13\JJ\1740|thus|,|men|,|responses|were|:|bp|,|consistent|. (l_conj) consistent_18\JJ\1740|vasoconstriction|,|replicated|,|and|representative (l_conj) representative_29\JJ\1740|hypertensives (l_nmod) hypertensives_34\NNS\10405694|of|all|borderline
2894433
D003975_D001919 CID diazepam_0\NN\2830852| (r_nsubj) facilitates_1\VBZ\2547586|diazepam|bradycardia|. (l_dobj) bradycardia_3\NN\14110674|reflex|rats
D003975_D001919 CID diazepam_6\NN\2830852|with (r_nmod) pretreatment_1\NN\1740|intravenous|rats|diazepam|, (r_nsubj) enhance_19\VB\227165|pretreatment|causing|,|did|bradycardia|. (l_dobj) bradycardia_23\NN\14110674|the|adrenaline-induced|reflex
D003975_D001919 CID diazepam_3\NN\2830852| (r_compound) enhancement_4\NN\248977|the|diazepam|bradycardia (l_nmod) bradycardia_8\NN\14110674|of|adrenaline-induced|reflex
D003975_D001919 CID diazepam_4\NN\2830852| (r_nsubj) acts_5\VBZ\1619354|that|diazepam|complex|facilitate (l_xcomp) facilitate_18\VB\2547586|to|bradycardia (l_dobj) bradycardia_20\NN\14110674|reflex|mediated
D004837_D001919 CID adrenaline_12\NN\14807929|of|kg-1|) (r_nmod) infusion_10\NN\14589223|by|intravenous|adrenaline (r_nmod) produced_5\VBN\1617192|also|,|bradycardia|was|rats|infusion|. (l_nsubjpass) bradycardia_3\NN\14110674|reflex
D004837_D001919 CID adrenaline-induced_14\JJ\1740| (r_amod) effect_16\NN\34213|in|the|adrenaline-induced|pressor (r_nmod) change_11\NN\7283608|no|effect (r_dobj) causing_9\VBG\1617192|although|change (r_advcl) enhance_19\VB\227165|pretreatment|causing|,|did|bradycardia|. (l_dobj) bradycardia_23\NN\14110674|the|adrenaline-induced|reflex
D004837_D001919 CID adrenaline-induced_21\JJ\1740| (r_amod) bradycardia_23\NN\14110674|the|adrenaline-induced|reflex
D004837_D001919 CID adrenaline-induced_6\JJ\1740| (r_amod) bradycardia_8\NN\14110674|of|adrenaline-induced|reflex
D010852_D001919 NONE picrotoxin_20\NN\1740|of (r_nmod) dose_18\NN\3740161|with|an|intravenous|picrotoxin (r_nmod) pretreatment_12\NN\1740|by|rats|dose|blocks (r_nmod) antagonized_10\VBN\1787955|however|,|enhancement|was|pretreatment|. (l_nsubjpass) enhancement_4\NN\248977|the|diazepam|bradycardia (l_nmod) bradycardia_8\NN\14110674|of|adrenaline-induced|reflex
D002712_D001919 NONE chloride_25\NN\14818238| (r_compound) channels_26\NNS\6251781|chloride (r_dobj) blocks_24\VBZ\1476483|(|agent|channels|binding (r_dep) pretreatment_12\NN\1740|by|rats|dose|blocks (r_nmod) antagonized_10\VBN\1787955|however|,|enhancement|was|pretreatment|. (l_nsubjpass) enhancement_4\NN\248977|the|diazepam|bradycardia (l_nmod) bradycardia_8\NN\14110674|of|adrenaline-induced|reflex
D002712_D001919 NONE benzodiazepine-gaba-chloride_34\JJ\1740| (r_amod) complex_37\NN\5869584|with|the|benzodiazepine-gaba-chloride|channel|macromolecular (r_nmod) associated_31\VBN\628491|complex (r_acl) sites_30\NNS\8673395|to|associated|) (r_nmod) binding_28\VBG\1290422|by|sites (r_advcl) blocks_24\VBZ\1476483|(|agent|channels|binding (r_dep) pretreatment_12\NN\1740|by|rats|dose|blocks (r_nmod) antagonized_10\VBN\1787955|however|,|enhancement|was|pretreatment|. (l_nsubjpass) enhancement_4\NN\248977|the|diazepam|bradycardia (l_nmod) bradycardia_8\NN\14110674|of|adrenaline-induced|reflex
D002712_D001919 NONE benzodiazepine-gaba-chloride_8\JJ\1740| (r_amod) complex_11\NN\5869584|through|the|benzodiazepine-gaba-chloride|channel|macromolecular|system (r_nmod) acts_5\VBZ\1619354|that|diazepam|complex|facilitate (l_xcomp) facilitate_18\VB\2547586|to|bradycardia (l_dobj) bradycardia_20\NN\14110674|reflex|mediated
D001569_D001919 NONE benzodiazepine-gaba-chloride_34\JJ\1740| (r_amod) complex_37\NN\5869584|with|the|benzodiazepine-gaba-chloride|channel|macromolecular (r_nmod) associated_31\VBN\628491|complex (r_acl) sites_30\NNS\8673395|to|associated|) (r_nmod) binding_28\VBG\1290422|by|sites (r_advcl) blocks_24\VBZ\1476483|(|agent|channels|binding (r_dep) pretreatment_12\NN\1740|by|rats|dose|blocks (r_nmod) antagonized_10\VBN\1787955|however|,|enhancement|was|pretreatment|. (l_nsubjpass) enhancement_4\NN\248977|the|diazepam|bradycardia (l_nmod) bradycardia_8\NN\14110674|of|adrenaline-induced|reflex
D001569_D001919 NONE benzodiazepine-gaba-chloride_8\JJ\1740| (r_amod) complex_11\NN\5869584|through|the|benzodiazepine-gaba-chloride|channel|macromolecular|system (r_nmod) acts_5\VBZ\1619354|that|diazepam|complex|facilitate (l_xcomp) facilitate_18\VB\2547586|to|bradycardia (l_dobj) bradycardia_20\NN\14110674|reflex|mediated
D005680_D001919 NONE benzodiazepine-gaba-chloride_34\JJ\1740| (r_amod) complex_37\NN\5869584|with|the|benzodiazepine-gaba-chloride|channel|macromolecular (r_nmod) associated_31\VBN\628491|complex (r_acl) sites_30\NNS\8673395|to|associated|) (r_nmod) binding_28\VBG\1290422|by|sites (r_advcl) blocks_24\VBZ\1476483|(|agent|channels|binding (r_dep) pretreatment_12\NN\1740|by|rats|dose|blocks (r_nmod) antagonized_10\VBN\1787955|however|,|enhancement|was|pretreatment|. (l_nsubjpass) enhancement_4\NN\248977|the|diazepam|bradycardia (l_nmod) bradycardia_8\NN\14110674|of|adrenaline-induced|reflex
D005680_D001919 NONE benzodiazepine-gaba-chloride_8\JJ\1740| (r_amod) complex_11\NN\5869584|through|the|benzodiazepine-gaba-chloride|channel|macromolecular|system (r_nmod) acts_5\VBZ\1619354|that|diazepam|complex|facilitate (l_xcomp) facilitate_18\VB\2547586|to|bradycardia (l_dobj) bradycardia_20\NN\14110674|reflex|mediated
6732043
D000728_D020181 CID androgen_12\NN\14745635| (r_compound) administration_13\NN\1133281|by|exogenous|androgen (r_nmod) induction_0\NN\7450842|syndrome|woman|administration|. (l_nmod) syndrome_6\NN\5870365|of|the|obstructive|apnea
D000728_D020181 CID androgens_34\NNS\14745635|exogenous (r_dobj) administered_32\VBN\2436349|while|being|androgens (r_advcl) developed_20\VBN\1753788|who|had|changes|administered (l_dobj) changes_22\NNS\7283608|physical|and|syndrome (l_conj) syndrome_25\NN\5870365|the|apnea (l_nmod) apnea_29\NN\14299637|of|obstructive|sleep
D000728_D020181 CID androgen_3\NN\14745635|with (r_nmod) rechallenge_1\NN\1740|a|androgen (r_nsubj) produced_4\VBD\1617192|rechallenge|symptoms|. (l_dobj) symptoms_5\NNS\5823932|apnea|abated (l_nmod) apnea_9\NN\14299637|of|obstructive|sleep
D000728_D020181 CID androgen_15\NN\14745635| (r_compound) therapy_16\NN\657604|of|androgen (r_nmod) effect_13\NN\34213|a|possible|side|therapy (r_xcomp) considered_9\VBN\689344|development|must|be|effect|. (l_nsubjpass) development_0\NN\248977|syndrome (l_nmod) syndrome_6\NN\5870365|of|the|obstructive|apnea
D000728_D012891 NONE androgens_7\NNS\14745635|of (r_nmod) role_5\NN\719494|a|androgens|pathogenesis (l_nmod) pathogenesis_10\NN\13533470|in|the|apnea (l_nmod) apnea_13\NN\14299637|of|sleep
11847945
D007530_D002779 CID isoflurane_6\NN\3570838|to (r_nmod) exposure_4\NN\5042871|after|isoflurane (r_nmod) hepatitis_2\NN\14127211|acute|cholestatic|exposure|.
D007530_D002779 CID isoflurane_16\NN\3570838|to|the|anesthetic (r_nmod) exposure_11\NN\5042871|following|isoflurane (r_nmod) hepatitis_9\NN\14127211|of|acute|cholestatic|exposure
D007530_D002779 CID isoflurane_2\NN\3570838|,|agent|, (r_nsubj) cause_10\VB\1617192|isoflurane|can|hepatitis|. (l_dobj) hepatitis_13\NN\14127211|severe|cholestatic
D007530_D056486 CID isoflurane_6\NN\3570838|to (r_nmod) exposure_4\NN\5042871|after|isoflurane (r_nmod) hepatitis_2\NN\14127211|acute|cholestatic|exposure|.
D007530_D056486 CID isoflurane_16\NN\3570838|to|the|anesthetic (r_nmod) exposure_11\NN\5042871|following|isoflurane (r_nmod) hepatitis_9\NN\14127211|of|acute|cholestatic|exposure
D007530_D056486 CID isoflurane_2\NN\3570838|,|agent|, (r_nsubj) cause_10\VB\1617192|isoflurane|can|hepatitis|. (l_dobj) hepatitis_13\NN\14127211|severe|cholestatic
D004177_D000699 NONE dipyrone_7\NN\1740|except|for|analgesia (l_nmod) analgesia_9\NN\14034177|for
17344330
D008691_D013575 CID methadone_8\NN\3808564|with (r_nmod) treated_6\VBN\2376958|methadone|dependence|city (r_acl) patients_5\NNS\9898892|among|treated (r_nmod) syncope_0\NN\7478169|and|prolongation|patients|.
D008691_D013575 CID methadone_53\NN\3808564|of (r_nmod) effect_51\NN\34213|by|the|proarrhythmic|methadone (r_nmod) caused_47\VBN\1617192|mortality|may|,|part|,|be|effect|. (r_conj) attribute_12\VB\670261|faint|,|doctors|might|episodes|use|and|underestimate|,|and|caused (l_dobj) episodes_15\NNS\7283608|many|syncope (l_nmod) syncope_17\NN\7478169|of
D008691_D013575 CID methadone_9\NN\3808564| (r_compound) dose_10\NN\3740161|methadone|and|reporting (l_conj) reporting_12\NN\6681177|syncope (l_nmod) syncope_14\NN\7478169|of
D008691_D013575 CID methadone_4\NN\3808564| (r_compound) dose_5\NN\3740161|a|higher|methadone (r_nsubjpass) associated_7\VBN\628491|dose|was|odds|. (l_nmod) odds_21\NN\4756635|with|1.4|higher|syncope (l_nmod) syncope_23\NN\7478169|for
D008691_D013575 CID methadone_2\NN\3808564| (r_nsubjpass) associated_4\VBN\628491|:|methadone|is|prolongation (l_nmod) prolongation_7\NN\1017987|with|qt|and|reporting|population (l_conj) reporting_10\NN\6681177|higher|syncope (l_nmod) syncope_12\NN\7478169|of
D008691_D008133 CID methadone_8\NN\3808564|with (r_nmod) treated_6\VBN\2376958|methadone|dependence|city (r_acl) patients_5\NNS\9898892|among|treated (r_nmod) syncope_0\NN\7478169|and|prolongation|patients|. (l_conj) prolongation_3\NN\1017987|qt
D008691_D008133 CID methadone_5\NN\3808564|with (r_nmod) treated_3\VBN\2376958|methadone (r_acl) subjects_2\NNS\6598915|among|the|treated (r_nmod) had_14\VBD\2108377|subjects|,|men|interval|. (l_dobj) interval_17\NN\33615|prolonged|qtc
D008691_D008133 CID methadone_2\NN\3808564| (r_nsubjpass) associated_4\VBN\628491|:|methadone|is|prolongation (l_nmod) prolongation_7\NN\1017987|with|qt|and|reporting|population
D003932_D013575 NONE heroin_10\NN\3492717| (r_compound) dependence_11\NN\24720|for|heroin (r_nmod) treated_6\VBN\2376958|methadone|dependence|city (r_acl) patients_5\NNS\9898892|among|treated (r_nmod) syncope_0\NN\7478169|and|prolongation|patients|.
D003932_D013575 NONE heroin_1\NN\3492717| (r_compound) addicts_2\NNS\10059582|heroin (r_nsubj) faint_4\VBP\23868|as|addicts|sometimes|using (r_advcl) attribute_12\VB\670261|faint|,|doctors|might|episodes|use|and|underestimate|,|and|caused (l_dobj) episodes_15\NNS\7283608|many|syncope (l_nmod) syncope_17\NN\7478169|of
D003932_D013575 NONE heroin_17\NN\3492717| (r_compound) addicts_18\NNS\10059582|of|heroin (r_nmod) population_15\NN\7942152|in|a|addicts (r_nmod) prolongation_7\NN\1017987|with|qt|and|reporting|population (l_conj) reporting_10\NN\6681177|higher|syncope (l_nmod) syncope_12\NN\7478169|of
D003932_D008133 NONE heroin_10\NN\3492717| (r_compound) dependence_11\NN\24720|for|heroin (r_nmod) treated_6\VBN\2376958|methadone|dependence|city (r_acl) patients_5\NNS\9898892|among|treated (r_nmod) syncope_0\NN\7478169|and|prolongation|patients|. (l_conj) prolongation_3\NN\1017987|qt
D003932_D008133 NONE heroin_17\NN\3492717| (r_compound) addicts_18\NNS\10059582|of|heroin (r_nmod) population_15\NN\7942152|in|a|addicts (r_nmod) prolongation_7\NN\1017987|with|qt|and|reporting|population
D008691_D016171 NONE methadone_21\NN\3808564| (r_compound) users_22\NNS\7846|in|methadone (r_nmod) reported_19\VBN\831651|prolongation|has|been|users|. (l_nsubjpass) prolongation_0\NN\1017987|interval|ecg (l_nmod) ecg_7\NN\7000195|in|the|patients (l_nmod) patients_9\NNS\9898892|of|pointes (l_nmod) pointes_13\NNS\1740|with|torsade|de|tdp
D008691_D016171 NONE methadone_21\NN\3808564| (r_compound) users_22\NNS\7846|in|methadone (r_nmod) reported_19\VBN\831651|prolongation|has|been|users|. (l_nsubjpass) prolongation_0\NN\1017987|interval|ecg (l_nmod) ecg_7\NN\7000195|in|the|patients (l_nmod) patients_9\NNS\9898892|of|pointes (l_nmod) pointes_13\NNS\1740|with|torsade|de|tdp (l_appos) tdp_15\NN\1740|(|)
D008691_D016171 NONE methadone_53\NN\3808564|of (r_nmod) effect_51\NN\34213|by|the|proarrhythmic|methadone (r_nmod) caused_47\VBN\1617192|mortality|may|,|part|,|be|effect|. (r_conj) attribute_12\VB\670261|faint|,|doctors|might|episodes|use|and|underestimate|,|and|caused (l_conj) underestimate_24\VB\695226|thereby|incidence (l_dobj) incidence_26\NN\13821570|the|tdp|population (l_nmod) tdp_28\NN\1740|of
D003932_D016171 NONE heroin_1\NN\3492717| (r_compound) addicts_2\NNS\10059582|heroin (r_nsubj) faint_4\VBP\23868|as|addicts|sometimes|using (r_advcl) attribute_12\VB\670261|faint|,|doctors|might|episodes|use|and|underestimate|,|and|caused (l_conj) underestimate_24\VB\695226|thereby|incidence (l_dobj) incidence_26\NN\13821570|the|tdp|population (l_nmod) tdp_28\NN\1740|of
6942642
D049971_D007008 NONE thiazide_0\NN\3214670| (r_compound) diuretics_1\NNS\3247620|thiazide|,|hypokalemia|. (l_conj) hypokalemia_3\NN\14299637|and|arrhythmias
D049971_D007008 NONE thiazide_9\NN\3214670| (r_compound) therapy_10\NN\657604|of|chronic|thiazide (r_nmod) consequence_6\NN\34213|hypokalemia|is|a|encountered|metabolic|therapy|. (l_nsubj) hypokalemia_0\NN\14299637|
D049971_D007008 NONE thiazide_5\NN\3214670| (r_compound) diuretics_6\NNS\3247620|thiazide (r_nsubj) cause_7\VBP\1617192|that|diuretics|hypokalemia (l_dobj) hypokalemia_8\NN\14299637|and|depletion
D049971_D001145 NONE thiazide_0\NN\3214670| (r_compound) diuretics_1\NNS\3247620|thiazide|,|hypokalemia|. (l_conj) hypokalemia_3\NN\14299637|and|arrhythmias (l_conj) arrhythmias_6\NNS\14103288|cardiac
D006852_C563897 NONE hydrochlorothiazide_18\NN\4423288|with|hctc|administered (r_nmod) treated_1\VBD\2376958|we|patients|hydrochlorothiazide|. (l_dobj) patients_3\NNS\9898892|38|renin|hypertension (l_nmod) hypertension_16\NN\14057371|with|moderate|diastolic
D006852_C563897 NONE hctc_20\NN\1740|(|) (r_appos) hydrochlorothiazide_18\NN\4423288|with|hctc|administered (r_nmod) treated_1\VBD\2376958|we|patients|hydrochlorothiazide|. (l_dobj) patients_3\NNS\9898892|38|renin|hypertension (l_nmod) hypertension_16\NN\14057371|with|moderate|diastolic
D011188_D007008 NONE potassium_13\NN\14625458|of|body (r_nmod) depletion_10\NN\351638|potassium (r_conj) hypokalemia_8\NN\14299637|and|depletion
3084782
D008625_D009393 CID tiopronin_12\NN\1740|due|compound|and|antigens (r_nmod) dermatitis_9\NN\14226056|tiopronin (r_conj) nephritis_7\NN\14113228|between|and|dermatitis|,|and|dermatitis
D008625_D009393 CID tiopronin_17\NN\1740| (r_nmod:npmod) related_18\JJ\1740|tiopronin (r_amod) group_20\NN\2137|except|for|the|related|nephritis (l_compound) nephritis_19\NN\14113228|
D008625_D003872 CID tiopronin_12\NN\1740|due|compound|and|antigens (r_nmod) dermatitis_9\NN\14226056|tiopronin
D008625_D003872 CID tiopronin_12\NN\1740|due|compound|and|antigens (r_nmod) dermatitis_9\NN\14226056|tiopronin (r_conj) nephritis_7\NN\14113228|between|and|dermatitis|,|and|dermatitis (l_conj) dermatitis_27\NN\14226056|between|thiosulphate
D010396_D009393 NONE d-penicillamine_15\NN\1740|a (r_nmod:npmod) like_16\JJ\1740|d-penicillamine (r_amod) compound_17\NN\5869584|(|like|) (r_appos) tiopronin_12\NN\1740|due|compound|and|antigens (r_nmod) dermatitis_9\NN\14226056|tiopronin (r_conj) nephritis_7\NN\14113228|between|and|dermatitis|,|and|dermatitis
D010396_D003872 NONE d-penicillamine_15\NN\1740|a (r_nmod:npmod) like_16\JJ\1740|d-penicillamine (r_amod) compound_17\NN\5869584|(|like|) (r_appos) tiopronin_12\NN\1740|due|compound|and|antigens (r_nmod) dermatitis_9\NN\14226056|tiopronin
D010396_D003872 NONE d-penicillamine_15\NN\1740|a (r_nmod:npmod) like_16\JJ\1740|d-penicillamine (r_amod) compound_17\NN\5869584|(|like|) (r_appos) tiopronin_12\NN\1740|due|compound|and|antigens (r_nmod) dermatitis_9\NN\14226056|tiopronin (r_conj) nephritis_7\NN\14113228|between|and|dermatitis|,|and|dermatitis (l_conj) dermatitis_27\NN\14226056|between|thiosulphate
D006046_D009393 NONE gold_30\NN\13371489| (r_compound) thiosulphate_31\NN\1740|due|gold|and|b35 (r_nmod) dermatitis_27\NN\14226056|between|thiosulphate (r_conj) nephritis_7\NN\14113228|between|and|dermatitis|,|and|dermatitis
D006046_D003872 CID gold_30\NN\13371489| (r_compound) thiosulphate_31\NN\1740|due|gold|and|b35 (r_nmod) dermatitis_27\NN\14226056|between|thiosulphate (r_conj) nephritis_7\NN\14113228|between|and|dermatitis|,|and|dermatitis (l_conj) dermatitis_9\NN\14226056|tiopronin
D006046_D003872 CID gold_30\NN\13371489| (r_compound) thiosulphate_31\NN\1740|due|gold|and|b35 (r_nmod) dermatitis_27\NN\14226056|between|thiosulphate
-1_D009393 NONE thiosulphate_31\NN\1740|due|gold|and|b35 (r_nmod) dermatitis_27\NN\14226056|between|thiosulphate (r_conj) nephritis_7\NN\14113228|between|and|dermatitis|,|and|dermatitis
-1_D003872 NONE thiosulphate_31\NN\1740|due|gold|and|b35 (r_nmod) dermatitis_27\NN\14226056|between|thiosulphate (r_conj) nephritis_7\NN\14113228|between|and|dermatitis|,|and|dermatitis (l_conj) dermatitis_9\NN\14226056|tiopronin
-1_D003872 NONE thiosulphate_31\NN\1740|due|gold|and|b35 (r_nmod) dermatitis_27\NN\14226056|between|thiosulphate
D008625_D001172 NONE tiopronin_17\NN\1740| (r_nmod:npmod) related_18\JJ\1740|tiopronin (r_amod) group_20\NN\2137|except|for|the|related|nephritis (r_nmod) observed_9\VBN\2163746|compared|frequency|was|patients|group|. (l_nmod) patients_11\NNS\9898892|in|ra (l_nmod) ra_13\NN\14625458|with
4090988
D000082_D001749 CID paracetamol_2\NN\1740|by (r_nmod) induction_0\NN\7450842|paracetamol|tumours|. (l_nmod) tumours_7\NNS\14234074|of|bladder|rat
D000082_D001749 CID paracetamol-treated_11\JJ\1740| (r_amod) groups_12\NNS\2137|in|all|paracetamol-treated (r_nmod) developed_8\VBD\1753788|papillomas|groups|,|and|bore (l_conj) bore_17\VBD\1552519|rats|carcinomas|. (l_dobj) carcinomas_19\NNS\14239918|bladder
D000082_D008113 CID paracetamol_2\NN\1740|by (r_nmod) induction_0\NN\7450842|paracetamol|tumours|. (l_nmod) tumours_7\NNS\14234074|of|bladder|rat
D000082_D008113 CID paracetamol-treated_8\JJ\1740| (r_amod) rats_9\NNS\2329401|of|paracetamol-treated (r_nmod) livers_6\NNS\5298729|of|the|rats (r_nmod) study_3\NN\635850|an|electron|microscope|livers (r_nsubj) revealed_10\VBD\2137132|study|changes|. (l_dobj) changes_12\NNS\7283608|ultrastructural|hepatocytes|resemble (l_acl:relcl) resemble_17\VBP\2657219|that|those (l_dobj) those_18\DT\1740|result (l_acl:relcl) result_20\VBP\2633881|that|exposure (l_nmod) exposure_22\NN\5042871|from|variety (l_nmod) variety_25\NN\7951464|to|a|hepatocarcinogens (l_nmod) hepatocarcinogens_28\NNS\1740|of|known
D000082_D010212 NONE paracetamol-treated_11\JJ\1740| (r_amod) groups_12\NNS\2137|in|all|paracetamol-treated (r_nmod) developed_8\VBD\1753788|papillomas|groups|,|and|bore (l_nsubj) papillomas_0\NNS\14236226|epithelium
D000082_D006965 CID paracetamol-treated_7\JJ\1740| (r_amod) rats_8\NNS\2329401|of|paracetamol-treated (r_nmod) %_5\NN\1740|25|rats (r_nsubj) developed_9\VBD\1753788|additionally|,|%|hyperplasia|. (l_dobj) hyperplasia_10\NN\14365950|epithelium|,|coincident
D000082_D001744 NONE paracetamol-treated_7\JJ\1740| (r_amod) rats_8\NNS\2329401|of|paracetamol-treated (r_nmod) %_5\NN\1740|25|rats (r_nsubj) developed_9\VBD\1753788|additionally|,|%|hyperplasia|. (l_dobj) hyperplasia_10\NN\14365950|epithelium|,|coincident (l_acl:relcl) coincident_19\JJ\1740|which|was|not|presence (l_nmod) presence_22\NN\13954253|with|the|calculi (l_nmod) calculi_25\NNS\9416076|of|bladder
D000082_D009369 NONE paracetamol_12\NN\1740| (r_compound) feeding_13\NN\838098|following|paracetamol (r_nmod) arose_10\VBD\2623529|yield|also|feeding|. (l_nsubj) yield_2\NN\913705|a|low|tumours (l_nmod) tumours_4\NNS\14234074|of|sites
9514561
D002211_D010146 CID capsaicin_5\NN\15032661|by (r_nmod) elicited_3\VBN\1617192|capsaicin (r_acl) pain_2\NN\14299637|experimental|cranial|elicited|:|study
D002211_D010146 CID capsaicin_4\NN\15032661|of (r_nmod) amount_2\NN\13329641|a|small|capsaicin (r_nsubjpass) administered_6\VBN\2436349|amount|was|subcutaneously|forehead|evoke|. (l_advcl) evoke_13\VB\1617192|to|sensation (l_dobj) sensation_17\NN\5708432|a|burning|painful|division (l_amod) painful_16\JJ\1740|
20973483
D058915_D010300 NONE antagonist_9\NN\7846|of|a|dual|adenosine|a2a/a1|receptor|models (l_nmod) models_12\NNS\5888929|in|animal|disease (l_nmod) disease_16\NN\14061805|of|parkinson|'s
D058915_D010300 NONE antagonist_11\NN\7846|of|a|dual|adenosine|a(2a)/a(1|)|receptor|models (l_nmod) models_15\NNS\5888929|in|several|animal|disease (l_nmod) disease_19\NN\14061805|of|parkinson|'s
D006220_D010300 NONE haloperidol-induced_53\JJ\1740| (r_amod) catalepsy_54\NN\14023236|of|haloperidol-induced (r_nmod) models_51\NNS\5888929|including|mouse|catalepsy (r_nmod) models_42\NNS\5888929|of|animal|disease|models|,|model (l_nmod) disease_46\NN\14061805|of|parkinson|'s
D006220_D002375 CID haloperidol-induced_53\JJ\1740| (r_amod) catalepsy_54\NN\14023236|of|haloperidol-induced
D006220_D004409 NONE haloperidol-induced_53\JJ\1740| (r_amod) catalepsy_54\NN\14023236|of|haloperidol-induced (r_nmod) models_51\NNS\5888929|including|mouse|catalepsy (r_nmod) models_42\NNS\5888929|of|animal|disease|models|,|model (l_conj) model_57\NN\5888929|mouse|akinesia|,|model|,|and|model (l_nmod) akinesia_60\NN\14558226|of|reserpine-induced
D012110_D010300 NONE reserpine-induced_59\JJ\1740| (r_amod) akinesia_60\NN\14558226|of|reserpine-induced (r_nmod) model_57\NN\5888929|mouse|akinesia|,|model|,|and|model (r_conj) models_42\NNS\5888929|of|animal|disease|models|,|model (l_nmod) disease_46\NN\14061805|of|parkinson|'s
D012110_D002375 NONE reserpine-induced_59\JJ\1740| (r_amod) akinesia_60\NN\14558226|of|reserpine-induced (r_nmod) model_57\NN\5888929|mouse|akinesia|,|model|,|and|model (r_conj) models_42\NNS\5888929|of|animal|disease|models|,|model (l_nmod) models_51\NNS\5888929|including|mouse|catalepsy (l_nmod) catalepsy_54\NN\14023236|of|haloperidol-induced
D012110_D004409 CID reserpine-induced_59\JJ\1740| (r_amod) akinesia_60\NN\14558226|of|reserpine-induced
D016627_D010300 NONE 6-hydroxydopamine_63\NN\1740|6-ohda (r_compound) model_68\NN\5888929|rat|6-hydroxydopamine|lesion|rotation (r_conj) model_57\NN\5888929|mouse|akinesia|,|model|,|and|model (r_conj) models_42\NNS\5888929|of|animal|disease|models|,|model (l_nmod) disease_46\NN\14061805|of|parkinson|'s
D016627_D010300 NONE 6-ohda_65\NN\1740|(|) (r_appos) 6-hydroxydopamine_63\NN\1740|6-ohda (r_compound) model_68\NN\5888929|rat|6-hydroxydopamine|lesion|rotation (r_conj) model_57\NN\5888929|mouse|akinesia|,|model|,|and|model (r_conj) models_42\NNS\5888929|of|animal|disease|models|,|model (l_nmod) disease_46\NN\14061805|of|parkinson|'s
D016627_D002375 NONE 6-hydroxydopamine_63\NN\1740|6-ohda (r_compound) model_68\NN\5888929|rat|6-hydroxydopamine|lesion|rotation (r_conj) model_57\NN\5888929|mouse|akinesia|,|model|,|and|model (r_conj) models_42\NNS\5888929|of|animal|disease|models|,|model (l_nmod) models_51\NNS\5888929|including|mouse|catalepsy (l_nmod) catalepsy_54\NN\14023236|of|haloperidol-induced
D016627_D002375 NONE 6-ohda_65\NN\1740|(|) (r_appos) 6-hydroxydopamine_63\NN\1740|6-ohda (r_compound) model_68\NN\5888929|rat|6-hydroxydopamine|lesion|rotation (r_conj) model_57\NN\5888929|mouse|akinesia|,|model|,|and|model (r_conj) models_42\NNS\5888929|of|animal|disease|models|,|model (l_nmod) models_51\NNS\5888929|including|mouse|catalepsy (l_nmod) catalepsy_54\NN\14023236|of|haloperidol-induced
D016627_D004409 NONE 6-hydroxydopamine_63\NN\1740|6-ohda (r_compound) model_68\NN\5888929|rat|6-hydroxydopamine|lesion|rotation (r_conj) model_57\NN\5888929|mouse|akinesia|,|model|,|and|model (l_nmod) akinesia_60\NN\14558226|of|reserpine-induced
D016627_D004409 NONE 6-ohda_65\NN\1740|(|) (r_appos) 6-hydroxydopamine_63\NN\1740|6-ohda (r_compound) model_68\NN\5888929|rat|6-hydroxydopamine|lesion|rotation (r_conj) model_57\NN\5888929|mouse|akinesia|,|model|,|and|model (l_nmod) akinesia_60\NN\14558226|of|reserpine-induced
D015632_D010300 NONE mptp-treated_74\JJ\1740| (r_amod) model_77\NN\5888929|mptp-treated|primate (r_conj) model_57\NN\5888929|mouse|akinesia|,|model|,|and|model (r_conj) models_42\NNS\5888929|of|animal|disease|models|,|model (l_nmod) disease_46\NN\14061805|of|parkinson|'s
D015632_D002375 NONE mptp-treated_74\JJ\1740| (r_amod) model_77\NN\5888929|mptp-treated|primate (r_conj) model_57\NN\5888929|mouse|akinesia|,|model|,|and|model (r_conj) models_42\NNS\5888929|of|animal|disease|models|,|model (l_nmod) models_51\NNS\5888929|including|mouse|catalepsy (l_nmod) catalepsy_54\NN\14023236|of|haloperidol-induced
D015632_D004409 NONE mptp-treated_74\JJ\1740| (r_amod) model_77\NN\5888929|mptp-treated|primate (r_conj) model_57\NN\5888929|mouse|akinesia|,|model|,|and|model (l_nmod) akinesia_60\NN\14558226|of|reserpine-induced
11009181
D001058_D010300 NONE apomorphine_0\NN\3786417|:|therapy|. (l_appos) therapy_4\NN\657604|an|underutilized|disease (l_nmod) disease_8\NN\14061805|for|parkinson
D001058_D010300 NONE apomorphine_0\NN\3786417| (r_nsubj) drug_5\NN\14778436|apomorphine|was|the|first|dopaminergic|used|. (l_acl) used_7\VBN\1156834|ever|treat (l_xcomp) treat_9\VB\2376958|to|symptoms (l_dobj) symptoms_10\NNS\5823932|disease (l_nmod) disease_14\NN\14061805|of|parkinson
D001058_D010300 NONE apomorphine_24\NN\3786417|of (r_nmod) administration_22\NN\1133281|by|subcutaneous|apomorphine (r_nmod) treating_15\VBG\2376958|of|disease|administration (l_dobj) disease_19\NN\14061805|fluctuating|parkinson|'s
D001058_D010300 NONE apomorphine_8\NN\3786417| (r_compound) treatment_9\NN\654885|of|subcutaneous|apomorphine|disease (l_nmod) disease_14\NN\14061805|in|fluctuating|parkinson|'s
D001058_D004409 NONE apomorphine_13\NN\3786417| (r_compound) infusions_14\NNS\14589223|with|continuous|subcutaneous|apomorphine (r_nmod) monotherapy_9\NN\1740|infusions (r_nsubjpass) associated_16\VBN\628491|that|monotherapy|is|reductions (l_nmod) reductions_19\NNS\351485|with|marked|dyskinesias (l_nmod) dyskinesias_23\NNS\14084880|of|preexisting|levodopa-induced
D007980_D004409 CID levodopa-induced_22\JJ\1740| (r_amod) dyskinesias_23\NNS\14084880|of|preexisting|levodopa-induced
D001058_D001523 NONE apomorphine_6\NN\3786417| (r_compound) treatment_7\NN\654885|of|subcutaneous|apomorphine (r_nmod) effects_3\NNS\13245626|the|main|side|treatment (r_nsubj) related_9\JJ\1740|effects|are|problems|,|whereas|play (l_parataxis) play_20\VBP\1072262|sedation|role|. (l_nsubj) sedation_16\NN\14034177|and|complications (l_conj) complications_19\NNS\1073995|psychiatric (l_amod) psychiatric_18\JJ\1740|
15897593
D064730_D001855 NONE dexrazoxane_0\NN\1740| (r_nsubj) protects_1\VBZ\1127795|dexrazoxane|myelosuppression|. (l_nmod) myelosuppression_3\NN\1740|against|drugs
D064730_D001855 NONE dexrazoxane_5\NN\1740|of (r_nmod) doses_3\NNS\3740161|nontoxic|dexrazoxane (r_nsubj) reduced_6\VBD\441445|doses|myelosuppression|and|antagonized (l_dobj) myelosuppression_7\NN\1740|and|loss|daunorubicin|mice
D064730_D001855 NONE dexrazoxane_5\NN\1740|of (r_nmod) doses_3\NNS\3740161|nontoxic|dexrazoxane (r_nsubj) reduced_6\VBD\441445|doses|myelosuppression|and|antagonized (r_dep) results_0\NNS\34213|:|reduced (r_nsubj) reduced_31\VBD\441445|results|;|however|,|dexrazoxane|neither|myelosuppression|. (l_dobj) myelosuppression_32\NN\1740|,|loss|,|nor|cytotoxicity
D064730_D001855 NONE dexrazoxane_29\NN\1740| (r_nsubj) reduced_31\VBD\441445|results|;|however|,|dexrazoxane|neither|myelosuppression|. (l_nsubj) results_0\NNS\34213|:|reduced (l_dep) reduced_6\VBD\441445|doses|myelosuppression|and|antagonized (l_dobj) myelosuppression_7\NN\1740|and|loss|daunorubicin|mice
D064730_D001855 NONE dexrazoxane_29\NN\1740| (r_nsubj) reduced_31\VBD\441445|results|;|however|,|dexrazoxane|neither|myelosuppression|. (l_dobj) myelosuppression_32\NN\1740|,|loss|,|nor|cytotoxicity
D005047_D001855 NONE etoposide_9\NN\1740|and|daunorubicin (r_dep) drugs_8\NNS\14778436|from|the|dna|cleavage-enhancing|etoposide|not|doxorubicin (r_nmod) myelosuppression_3\NN\1740|against|drugs
D005047_D001855 NONE etoposide_10\NN\1740|the|epipodophyllotoxin (r_conj) anthracyclines_3\NNS\1740|the|daunorubicin|and|etoposide (r_nsubj) drugs_15\NNS\14778436|anthracyclines|are|potent|dna|cleavage-enhancing|used (r_appos) purpose_0\NN\5980875|:|drugs (r_nsubj) limit_30\VBP\2510337|purpose|;|however|,|myelosuppression|use|. (l_nsubj) myelosuppression_26\NN\1740|and|toxicity
D005047_D001855 NONE etoposide_14\NN\1740| (r_conj) daunorubicin_12\NN\1740|from|and|etoposide (r_nmod) myelosuppression_7\NN\1740|and|loss|daunorubicin|mice
D005047_D001855 NONE etoposide_14\NN\1740| (r_conj) daunorubicin_12\NN\1740|from|and|etoposide (r_nmod) myelosuppression_7\NN\1740|and|loss|daunorubicin|mice (r_dobj) reduced_6\VBD\441445|doses|myelosuppression|and|antagonized (r_dep) results_0\NNS\34213|:|reduced (r_nsubj) reduced_31\VBD\441445|results|;|however|,|dexrazoxane|neither|myelosuppression|. (l_dobj) myelosuppression_32\NN\1740|,|loss|,|nor|cytotoxicity
D003630_D001855 NONE daunorubicin_11\NN\1740| (r_conj) etoposide_9\NN\1740|and|daunorubicin (r_dep) drugs_8\NNS\14778436|from|the|dna|cleavage-enhancing|etoposide|not|doxorubicin (r_nmod) myelosuppression_3\NN\1740|against|drugs
D003630_D001855 NONE daunorubicin_4\NN\1740|and|doxorubicin (r_dep) anthracyclines_3\NNS\1740|the|daunorubicin|and|etoposide (r_nsubj) drugs_15\NNS\14778436|anthracyclines|are|potent|dna|cleavage-enhancing|used (r_appos) purpose_0\NN\5980875|:|drugs (r_nsubj) limit_30\VBP\2510337|purpose|;|however|,|myelosuppression|use|. (l_nsubj) myelosuppression_26\NN\1740|and|toxicity
D003630_D001855 NONE daunorubicin_12\NN\1740|from|and|etoposide (r_nmod) myelosuppression_7\NN\1740|and|loss|daunorubicin|mice
D003630_D001855 NONE daunorubicin_12\NN\1740|from|and|etoposide (r_nmod) myelosuppression_7\NN\1740|and|loss|daunorubicin|mice (r_dobj) reduced_6\VBD\441445|doses|myelosuppression|and|antagonized (r_dep) results_0\NNS\34213|:|reduced (r_nsubj) reduced_31\VBD\441445|results|;|however|,|dexrazoxane|neither|myelosuppression|. (l_dobj) myelosuppression_32\NN\1740|,|loss|,|nor|cytotoxicity
D004317_D001855 NONE doxorubicin_14\NN\2716866| (r_conj) drugs_8\NNS\14778436|from|the|dna|cleavage-enhancing|etoposide|not|doxorubicin (r_nmod) myelosuppression_3\NN\1740|against|drugs
D004317_D001855 NONE doxorubicin_6\NN\2716866| (r_conj) daunorubicin_4\NN\1740|and|doxorubicin (r_dep) anthracyclines_3\NNS\1740|the|daunorubicin|and|etoposide (r_nsubj) drugs_15\NNS\14778436|anthracyclines|are|potent|dna|cleavage-enhancing|used (r_appos) purpose_0\NN\5980875|:|drugs (r_nsubj) limit_30\VBP\2510337|purpose|;|however|,|myelosuppression|use|. (l_nsubj) myelosuppression_26\NN\1740|and|toxicity
D004317_D001855 NONE doxorubicin_43\NN\2716866|from (r_nmod) cytotoxicity_41\NN\13583478|the|in|doxorubicin (r_conj) myelosuppression_32\NN\1740|,|loss|,|nor|cytotoxicity (r_dobj) reduced_31\VBD\441445|results|;|however|,|dexrazoxane|neither|myelosuppression|. (l_nsubj) results_0\NNS\34213|:|reduced (l_dep) reduced_6\VBD\441445|doses|myelosuppression|and|antagonized (l_dobj) myelosuppression_7\NN\1740|and|loss|daunorubicin|mice
D004317_D001855 NONE doxorubicin_43\NN\2716866|from (r_nmod) cytotoxicity_41\NN\13583478|the|in|doxorubicin (r_conj) myelosuppression_32\NN\1740|,|loss|,|nor|cytotoxicity
D018943_D001855 NONE anthracyclines_3\NNS\1740|the|daunorubicin|and|etoposide (r_nsubj) drugs_15\NNS\14778436|anthracyclines|are|potent|dna|cleavage-enhancing|used (r_appos) purpose_0\NN\5980875|:|drugs (r_nsubj) limit_30\VBP\2510337|purpose|;|however|,|myelosuppression|use|. (l_nsubj) myelosuppression_26\NN\1740|and|toxicity
D018943_D066126 NONE anthracyclines_3\NNS\1740|the|daunorubicin|and|etoposide (r_nsubj) drugs_15\NNS\14778436|anthracyclines|are|potent|dna|cleavage-enhancing|used (r_appos) purpose_0\NN\5980875|:|drugs (r_nsubj) limit_30\VBP\2510337|purpose|;|however|,|myelosuppression|use|. (l_nsubj) myelosuppression_26\NN\1740|and|toxicity (l_conj) toxicity_29\NN\13576101|cardiac
D018943_D066126 NONE anthracycline-induced_9\JJ\1740| (r_amod) cardiotoxicity_10\NN\1740|against|anthracycline-induced
D003630_D066126 NONE daunorubicin_4\NN\1740|and|doxorubicin (r_dep) anthracyclines_3\NNS\1740|the|daunorubicin|and|etoposide (r_nsubj) drugs_15\NNS\14778436|anthracyclines|are|potent|dna|cleavage-enhancing|used (r_appos) purpose_0\NN\5980875|:|drugs (r_nsubj) limit_30\VBP\2510337|purpose|;|however|,|myelosuppression|use|. (l_nsubj) myelosuppression_26\NN\1740|and|toxicity (l_conj) toxicity_29\NN\13576101|cardiac
D004317_D066126 NONE doxorubicin_6\NN\2716866| (r_conj) daunorubicin_4\NN\1740|and|doxorubicin (r_dep) anthracyclines_3\NNS\1740|the|daunorubicin|and|etoposide (r_nsubj) drugs_15\NNS\14778436|anthracyclines|are|potent|dna|cleavage-enhancing|used (r_appos) purpose_0\NN\5980875|:|drugs (r_nsubj) limit_30\VBP\2510337|purpose|;|however|,|myelosuppression|use|. (l_nsubj) myelosuppression_26\NN\1740|and|toxicity (l_conj) toxicity_29\NN\13576101|cardiac
D011034_D001855 NONE epipodophyllotoxin_9\NN\1740| (r_compound) etoposide_10\NN\1740|the|epipodophyllotoxin (r_conj) anthracyclines_3\NNS\1740|the|daunorubicin|and|etoposide (r_nsubj) drugs_15\NNS\14778436|anthracyclines|are|potent|dna|cleavage-enhancing|used (r_appos) purpose_0\NN\5980875|:|drugs (r_nsubj) limit_30\VBP\2510337|purpose|;|however|,|myelosuppression|use|. (l_nsubj) myelosuppression_26\NN\1740|and|toxicity
D011034_D066126 NONE epipodophyllotoxin_9\NN\1740| (r_compound) etoposide_10\NN\1740|the|epipodophyllotoxin (r_conj) anthracyclines_3\NNS\1740|the|daunorubicin|and|etoposide (r_nsubj) drugs_15\NNS\14778436|anthracyclines|are|potent|dna|cleavage-enhancing|used (r_appos) purpose_0\NN\5980875|:|drugs (r_nsubj) limit_30\VBP\2510337|purpose|;|however|,|myelosuppression|use|. (l_nsubj) myelosuppression_26\NN\1740|and|toxicity (l_conj) toxicity_29\NN\13576101|cardiac
D005047_D066126 NONE etoposide_10\NN\1740|the|epipodophyllotoxin (r_conj) anthracyclines_3\NNS\1740|the|daunorubicin|and|etoposide (r_nsubj) drugs_15\NNS\14778436|anthracyclines|are|potent|dna|cleavage-enhancing|used (r_appos) purpose_0\NN\5980875|:|drugs (r_nsubj) limit_30\VBP\2510337|purpose|;|however|,|myelosuppression|use|. (l_nsubj) myelosuppression_26\NN\1740|and|toxicity (l_conj) toxicity_29\NN\13576101|cardiac
D064730_D066126 NONE dexrazoxane_0\NN\1740|icrf-187 (r_nsubjpass) recommended_5\VBN\875394|dexrazoxane|is|protection|. (l_nmod) protection_7\NN\407535|for|cardiotoxicity (l_nmod) cardiotoxicity_10\NN\1740|against|anthracycline-induced
D064730_D066126 NONE icrf-187_2\NN\1740|(|) (r_appos) dexrazoxane_0\NN\1740|icrf-187 (r_nsubjpass) recommended_5\VBN\875394|dexrazoxane|is|protection|. (l_nmod) protection_7\NN\407535|for|cardiotoxicity (l_nmod) cardiotoxicity_10\NN\1740|against|anthracycline-induced
D064730_D006402 NONE dexrazoxane_15\NN\1740|of|and|enhancers (r_nmod) coadministration_13\NN\1740|following|dexrazoxane (r_nmod) toxicity_11\NN\13576101|the|hematologic|coadministration
D064730_D006402 NONE dexrazoxane_43\NN\1740| (r_conj) doxorubicin_41\NN\2716866|+/-|dexrazoxane (r_conj) etoposide_36\NN\1740|to|,|daunorubicin|,|and|doxorubicin (r_nmod) sensitivity_27\NN\5651971|cells|etoposide (r_nsubjpass) determined_45\VBN\1645601|sensitivity|was|assays (r_parataxis) investigated_25\VBN\644583|use|,|toxicity|was|:|determined|. (l_nsubjpass) toxicity_11\NN\13576101|the|hematologic|coadministration
D064730_D006402 NONE dexrazoxane_8\NN\1740|and|doses (r_dobj) combining_7\VBG\2630189|dexrazoxane (r_acl) trials_1\NNS\786195|clinical|patients|combining (r_nsubj) ongoing_15\JJ\1740|trials|is|aim|. (l_nmod) aim_18\NN\5980875|with|the|improving (l_advcl) improving_20\VBG\126264|of|efficacy|aggravating (l_advcl) aggravating_23\VBG\126264|without|toxicity (l_dobj) toxicity_25\NN\13576101|hematologic
D005047_D006402 CID etoposide_36\NN\1740|to|,|daunorubicin|,|and|doxorubicin (r_nmod) sensitivity_27\NN\5651971|cells|etoposide (r_nsubjpass) determined_45\VBN\1645601|sensitivity|was|assays (r_parataxis) investigated_25\VBN\644583|use|,|toxicity|was|:|determined|. (l_nsubjpass) toxicity_11\NN\13576101|the|hematologic|coadministration
D005047_D006402 CID etoposide_13\NN\1740|of (r_nmod) doses_11\NNS\3740161|high|etoposide (r_conj) dexrazoxane_8\NN\1740|and|doses (r_dobj) combining_7\VBG\2630189|dexrazoxane (r_acl) trials_1\NNS\786195|clinical|patients|combining (r_nsubj) ongoing_15\JJ\1740|trials|is|aim|. (l_nmod) aim_18\NN\5980875|with|the|improving (l_advcl) improving_20\VBG\126264|of|efficacy|aggravating (l_advcl) aggravating_23\VBG\126264|without|toxicity (l_dobj) toxicity_25\NN\13576101|hematologic
D003630_D006402 CID daunorubicin_38\NN\1740| (r_conj) etoposide_36\NN\1740|to|,|daunorubicin|,|and|doxorubicin (r_nmod) sensitivity_27\NN\5651971|cells|etoposide (r_nsubjpass) determined_45\VBN\1645601|sensitivity|was|assays (r_parataxis) investigated_25\VBN\644583|use|,|toxicity|was|:|determined|. (l_nsubjpass) toxicity_11\NN\13576101|the|hematologic|coadministration
D004317_D006402 CID doxorubicin_41\NN\2716866|+/-|dexrazoxane (r_conj) etoposide_36\NN\1740|to|,|daunorubicin|,|and|doxorubicin (r_nmod) sensitivity_27\NN\5651971|cells|etoposide (r_nsubjpass) determined_45\VBN\1645601|sensitivity|was|assays (r_parataxis) investigated_25\VBN\644583|use|,|toxicity|was|:|determined|. (l_nsubjpass) toxicity_11\NN\13576101|the|hematologic|coadministration
D064730_D015431 NONE dexrazoxane_5\NN\1740|of (r_nmod) doses_3\NNS\3740161|nontoxic|dexrazoxane (r_nsubj) reduced_6\VBD\441445|doses|myelosuppression|and|antagonized (l_dobj) myelosuppression_7\NN\1740|and|loss|daunorubicin|mice (l_conj) loss_10\NN\13252973|weight
D064730_D015431 NONE dexrazoxane_5\NN\1740|of (r_nmod) doses_3\NNS\3740161|nontoxic|dexrazoxane (r_nsubj) reduced_6\VBD\441445|doses|myelosuppression|and|antagonized (r_dep) results_0\NNS\34213|:|reduced (r_nsubj) reduced_31\VBD\441445|results|;|however|,|dexrazoxane|neither|myelosuppression|. (l_dobj) myelosuppression_32\NN\1740|,|loss|,|nor|cytotoxicity (l_conj) loss_35\NN\13252973|weight
D064730_D015431 NONE dexrazoxane_29\NN\1740| (r_nsubj) reduced_31\VBD\441445|results|;|however|,|dexrazoxane|neither|myelosuppression|. (l_nsubj) results_0\NNS\34213|:|reduced (l_dep) reduced_6\VBD\441445|doses|myelosuppression|and|antagonized (l_dobj) myelosuppression_7\NN\1740|and|loss|daunorubicin|mice (l_conj) loss_10\NN\13252973|weight
D064730_D015431 NONE dexrazoxane_29\NN\1740| (r_nsubj) reduced_31\VBD\441445|results|;|however|,|dexrazoxane|neither|myelosuppression|. (l_dobj) myelosuppression_32\NN\1740|,|loss|,|nor|cytotoxicity (l_conj) loss_35\NN\13252973|weight
D064730_D064420 NONE dexrazoxane_5\NN\1740|of (r_nmod) doses_3\NNS\3740161|nontoxic|dexrazoxane (r_nsubj) reduced_6\VBD\441445|doses|myelosuppression|and|antagonized (r_dep) results_0\NNS\34213|:|reduced (r_nsubj) reduced_31\VBD\441445|results|;|however|,|dexrazoxane|neither|myelosuppression|. (l_dobj) myelosuppression_32\NN\1740|,|loss|,|nor|cytotoxicity (l_conj) cytotoxicity_41\NN\13583478|the|in|doxorubicin
D064730_D064420 NONE dexrazoxane_29\NN\1740| (r_nsubj) reduced_31\VBD\441445|results|;|however|,|dexrazoxane|neither|myelosuppression|. (l_dobj) myelosuppression_32\NN\1740|,|loss|,|nor|cytotoxicity (l_conj) cytotoxicity_41\NN\13583478|the|in|doxorubicin
D003630_D015431 CID daunorubicin_12\NN\1740|from|and|etoposide (r_nmod) myelosuppression_7\NN\1740|and|loss|daunorubicin|mice (l_conj) loss_10\NN\13252973|weight
D003630_D015431 CID daunorubicin_12\NN\1740|from|and|etoposide (r_nmod) myelosuppression_7\NN\1740|and|loss|daunorubicin|mice (r_dobj) reduced_6\VBD\441445|doses|myelosuppression|and|antagonized (r_dep) results_0\NNS\34213|:|reduced (r_nsubj) reduced_31\VBD\441445|results|;|however|,|dexrazoxane|neither|myelosuppression|. (l_dobj) myelosuppression_32\NN\1740|,|loss|,|nor|cytotoxicity (l_conj) loss_35\NN\13252973|weight
D003630_D064420 NONE daunorubicin_12\NN\1740|from|and|etoposide (r_nmod) myelosuppression_7\NN\1740|and|loss|daunorubicin|mice (r_dobj) reduced_6\VBD\441445|doses|myelosuppression|and|antagonized (r_dep) results_0\NNS\34213|:|reduced (r_nsubj) reduced_31\VBD\441445|results|;|however|,|dexrazoxane|neither|myelosuppression|. (l_dobj) myelosuppression_32\NN\1740|,|loss|,|nor|cytotoxicity (l_conj) cytotoxicity_41\NN\13583478|the|in|doxorubicin
D005047_D015431 CID etoposide_14\NN\1740| (r_conj) daunorubicin_12\NN\1740|from|and|etoposide (r_nmod) myelosuppression_7\NN\1740|and|loss|daunorubicin|mice (l_conj) loss_10\NN\13252973|weight
D005047_D015431 CID etoposide_14\NN\1740| (r_conj) daunorubicin_12\NN\1740|from|and|etoposide (r_nmod) myelosuppression_7\NN\1740|and|loss|daunorubicin|mice (r_dobj) reduced_6\VBD\441445|doses|myelosuppression|and|antagonized (r_dep) results_0\NNS\34213|:|reduced (r_nsubj) reduced_31\VBD\441445|results|;|however|,|dexrazoxane|neither|myelosuppression|. (l_dobj) myelosuppression_32\NN\1740|,|loss|,|nor|cytotoxicity (l_conj) loss_35\NN\13252973|weight
D005047_D064420 NONE etoposide_14\NN\1740| (r_conj) daunorubicin_12\NN\1740|from|and|etoposide (r_nmod) myelosuppression_7\NN\1740|and|loss|daunorubicin|mice (r_dobj) reduced_6\VBD\441445|doses|myelosuppression|and|antagonized (r_dep) results_0\NNS\34213|:|reduced (r_nsubj) reduced_31\VBD\441445|results|;|however|,|dexrazoxane|neither|myelosuppression|. (l_dobj) myelosuppression_32\NN\1740|,|loss|,|nor|cytotoxicity (l_conj) cytotoxicity_41\NN\13583478|the|in|doxorubicin
D004317_D015431 CID doxorubicin_43\NN\2716866|from (r_nmod) cytotoxicity_41\NN\13583478|the|in|doxorubicin (r_conj) myelosuppression_32\NN\1740|,|loss|,|nor|cytotoxicity (r_dobj) reduced_31\VBD\441445|results|;|however|,|dexrazoxane|neither|myelosuppression|. (l_nsubj) results_0\NNS\34213|:|reduced (l_dep) reduced_6\VBD\441445|doses|myelosuppression|and|antagonized (l_dobj) myelosuppression_7\NN\1740|and|loss|daunorubicin|mice (l_conj) loss_10\NN\13252973|weight
D004317_D015431 CID doxorubicin_43\NN\2716866|from (r_nmod) cytotoxicity_41\NN\13583478|the|in|doxorubicin (r_conj) myelosuppression_32\NN\1740|,|loss|,|nor|cytotoxicity (l_conj) loss_35\NN\13252973|weight
D004317_D064420 NONE doxorubicin_43\NN\2716866|from (r_nmod) cytotoxicity_41\NN\13583478|the|in|doxorubicin
D064730_D009362 NONE dexrazoxane_8\NN\1740|and|doses (r_dobj) combining_7\VBG\2630189|dexrazoxane (r_acl) trials_1\NNS\786195|clinical|patients|combining (l_nmod) patients_3\NNS\9898892|in|metastases (l_nmod) metastases_6\NNS\13533470|with|brain
D005047_D009362 NONE etoposide_13\NN\1740|of (r_nmod) doses_11\NNS\3740161|high|etoposide (r_conj) dexrazoxane_8\NN\1740|and|doses (r_dobj) combining_7\VBG\2630189|dexrazoxane (r_acl) trials_1\NNS\786195|clinical|patients|combining (l_nmod) patients_3\NNS\9898892|in|metastases (l_nmod) metastases_6\NNS\13533470|with|brain
8600333
C053519_D001859 NONE protocol_21\NN\6652242|,|doxorubicin (r_dep) treated_13\VBN\2376958|who|were|t5|protocol (r_acl:relcl) survivors_6\NNS\9630641|in|long-term|tumors|treated (l_nmod) tumors_10\NNS\14234074|of|malignant|bone
D004317_D001859 NONE doxorubicin_25\NN\2716866|both|including (r_appos) protocol_21\NN\6652242|,|doxorubicin (r_dep) treated_13\VBN\2376958|who|were|t5|protocol (r_acl:relcl) survivors_6\NNS\9630641|in|long-term|tumors|treated (l_nmod) tumors_10\NNS\14234074|of|malignant|bone
D004317_D066126 NONE doxorubicin-induced_3\JJ\1740| (r_amod) cardiotoxicity_4\NN\1740|of|doxorubicin-induced
10565806
C076029_D001714 CID olanzapine_4\NN\1740|by (r_nmod) induced_2\VBN\1627355|olanzapine (r_acl) syndrome_1\NN\5870365|hypomania-like|induced|. (l_amod) hypomania-like_0\JJ\1740|
C076029_D001714 CID olanzapine_26\NN\1740| (r_compound) treatment_27\NN\654885|of|olanzapine (r_nmod) introduction_24\NN\235435|after|the|treatment (r_nmod) developed_19\VBD\1753788|who|hypomania|introduction (l_dobj) hypomania_20\NN\1740|
C076029_D011618 NONE olanzapine_26\NN\1740| (r_compound) treatment_27\NN\654885|of|olanzapine (r_nmod) introduction_24\NN\235435|after|the|treatment (r_nmod) developed_19\VBD\1753788|who|hypomania|introduction (r_acl:relcl) diagnosis_7\NN\152018|with|a|disorder|developed (l_nmod) disorder_14\NN\14034177|of|a|not|specified|psychotic|dsm-iv
10539815
D000809_D051437 NONE angiotensin-converting_11\JJ\1740| (r_amod) therapy_14\NN\657604|during|angiotensin-converting|inhibitor (r_nmod) predictors_0\NNS\10756433|function|therapy|:|results (l_nmod) function_4\NN\13783581|of|decreased|renal|patients
D000809_D051437 NONE angiotensin-converting_3\JJ\1740| (r_amod) inhibitor_5\NN\20090|angiotensin-converting|enzyme (r_compound) therapy_6\NN\657604|inhibitor (r_nsubj) reduces_7\VBZ\441445|although|therapy|rates (r_advcl) cause_23\VB\1617192|background|reduces|,|it|may|also|function|. (l_dobj) function_26\NN\13783581|decreased|renal
D000809_D051437 NONE angiotensin-converting_19\JJ\1740| (r_amod) inhibitor_21\NN\20090|angiotensin-converting|enzyme (r_compound) therapy_22\NN\657604|inhibitor (r_dobj) prescribed_18\VBN\748282|who|are|therapy (r_acl:relcl) patients_13\NNS\9898892|in|chf|prescribed (r_nmod) predictors_6\NNS\10756433|specific|clinical|reduction|patients (l_nmod) reduction_8\NN\351485|of|function (l_nmod) function_11\NN\13783581|in|renal
D000809_D006333 NONE angiotensin-converting_11\JJ\1740| (r_amod) therapy_14\NN\657604|during|angiotensin-converting|inhibitor (r_nmod) predictors_0\NNS\10756433|function|therapy|:|results (l_nmod) function_4\NN\13783581|of|decreased|renal|patients (l_nmod) patients_6\NNS\9898892|in|failure (l_nmod) failure_9\NN\66216|with|heart
D000809_D006333 NONE angiotensin-converting_3\JJ\1740| (r_amod) inhibitor_5\NN\20090|angiotensin-converting|enzyme (r_compound) therapy_6\NN\657604|inhibitor (r_nsubj) reduces_7\VBZ\441445|although|therapy|rates (l_dobj) rates_9\NNS\13308999|mortality|patients (l_nmod) patients_11\NNS\9898892|in|failure (l_nmod) failure_15\NN\66216|with|congestive|heart|chf
D000809_D006333 NONE angiotensin-converting_3\JJ\1740| (r_amod) inhibitor_5\NN\20090|angiotensin-converting|enzyme (r_compound) therapy_6\NN\657604|inhibitor (r_nsubj) reduces_7\VBZ\441445|although|therapy|rates (l_dobj) rates_9\NNS\13308999|mortality|patients (l_nmod) patients_11\NNS\9898892|in|failure (l_nmod) failure_15\NN\66216|with|congestive|heart|chf (l_appos) chf_17\NN\1740|(|)
D000809_D006333 NONE angiotensin-converting_19\JJ\1740| (r_amod) inhibitor_21\NN\20090|angiotensin-converting|enzyme (r_compound) therapy_22\NN\657604|inhibitor (r_dobj) prescribed_18\VBN\748282|who|are|therapy (r_acl:relcl) patients_13\NNS\9898892|in|chf|prescribed (l_nmod) chf_15\NN\1740|with
D000809_D018487 NONE angiotensin-converting_11\JJ\1740| (r_amod) therapy_14\NN\657604|during|angiotensin-converting|inhibitor (r_nmod) predictors_0\NNS\10756433|function|therapy|:|results (l_dep) results_16\NNS\34213|studies|(|solvd|) (l_nmod) studies_19\NNS\635850|from|the|dysfunction (l_nmod) dysfunction_23\NN\14204950|of|ventricular
D004656_D018487 NONE enalapril_24\NN\2673637|of (r_nmod) trial_22\NN\786195|a|randomized|,|double-blind|,|placebo-controlled|enalapril|treatment (r_appos) studies_7\NNS\635850|from|the|dysfunction|solvd|,|trial (l_nmod) dysfunction_11\NN\14204950|of|left|ventricular
D004656_D006333 NONE enalapril_24\NN\2673637|of (r_nmod) trial_22\NN\786195|a|randomized|,|double-blind|,|placebo-controlled|enalapril|treatment (l_nmod) treatment_27\NN\654885|for|the|chf (l_nmod) chf_29\NN\1740|of
D004656_D006333 NONE enalapril_2\NN\2673637| (r_compound) use_3\NN\407535|enalapril (r_nsubj) caused_4\VBD\1617192|conclusions|use|increase|. (l_dobj) increase_8\NN\13576355|a|%|risk (l_nmod) risk_11\NN\14541044|in|the|function|patients (l_nmod) patients_17\NNS\9898892|in|chf (l_nmod) chf_19\NN\1740|with
D004656_D006333 NONE enalapril_23\NN\2673637| (r_compound) group_24\NN\2137|in|the|enalapril (r_nmod) reduced_20\VBN\441445|risk|was|group|group|. (r_conj) associated_2\VBN\628491|diabetes|was|risk|,|but|reduced (l_nmod) risk_6\NN\14541044|with|an|increased|impairment|patients (l_nmod) patients_12\NNS\9898892|in|all|chf (l_nmod) chf_14\NN\1740|with
D003404_D051437 NONE creatinine_10\NN\1740|in|serum|mg/dl (r_nmod) rise_7\NN\7324673|as|a|creatinine|baseline (r_nmod) defined_4\VBN\2604760|function|was|rise|. (l_nsubjpass) function_2\NN\13783581|decreased|renal
D003404_D006973 NONE creatinine_21\NN\1740|baseline (r_conj) age_14\NN\4916342|including|,|fraction|,|creatinine|,|pressure|,|history (l_conj) history_34\NN\15120823|hypertension (l_nmod) hypertension_36\NN\14057371|of|,|diabetes|,|and|use
D003404_D003920 NONE creatinine_21\NN\1740|baseline (r_conj) age_14\NN\4916342|including|,|fraction|,|creatinine|,|pressure|,|history (l_conj) history_34\NN\15120823|hypertension (l_nmod) hypertension_36\NN\14057371|of|,|diabetes|,|and|use (l_conj) diabetes_38\NN\14075199|
D004232_D006973 NONE diuretic_45\NN\3247620| (r_conj) antiplatelet_43\JJ\1740|,|diuretic|,|and|beta-blocker (r_amod) therapy_49\NN\657604|of|antiplatelet (r_nmod) use_41\NN\407535|therapy (r_conj) hypertension_36\NN\14057371|of|,|diabetes|,|and|use
D004232_D003920 NONE diuretic_45\NN\3247620| (r_conj) antiplatelet_43\JJ\1740|,|diuretic|,|and|beta-blocker (r_amod) therapy_49\NN\657604|of|antiplatelet (r_nmod) use_41\NN\407535|therapy (r_conj) hypertension_36\NN\14057371|of|,|diabetes|,|and|use (l_conj) diabetes_38\NN\14075199|
D004232_D003920 NONE diuretic_14\NN\3247620| (r_compound) therapy_15\NN\657604|diuretic (r_conj) age_12\NN\4916342|older|,|therapy|,|and|diabetes (l_conj) diabetes_18\NN\14075199|
D004656_D051437 CID enalapril_6\NN\2673637|to (r_nmod) assigned_4\VBN\2475922|randomly|enalapril (r_acl) patients_2\NNS\9898892|assigned (r_nsubj) had_7\VBD\2108377|results|patients|likelihood|. (l_dobj) likelihood_12\NN\4756172|a|greater|function|controls|= (l_nmod) function_16\NN\13783581|of|decreased|renal
D004656_D051437 CID enalapril_9\NN\2673637| (r_conj) placebo_7\NN\3740161|in|both|the|and|enalapril (r_compound) groups_10\NNS\2137|placebo (r_dep) associated_20\VBN\628491|analysis|,|groups|age|were|function|,|whereas|renoprotective (l_nmod) function_24\NN\13783581|with|decreased|renal
D004656_D051437 CID enalapril_23\NN\2673637| (r_compound) group_24\NN\2137|in|the|enalapril (r_nmod) so_20\RB\1740|more|group (r_conj) associated_3\VBN\628491|age|was|risk|,|but|so|enalapril (l_nmod) risk_7\NN\14541044|with|a|greater|developing (l_advcl) developing_9\VBG\1753788|of|function|groups (l_dobj) function_12\NN\13783581|decreased|renal
D004656_D051437 CID enalapril_26\NN\2673637|(|:|ratio|;|placebo|. (r_dep) associated_3\VBN\628491|age|was|risk|,|but|so|enalapril (l_nmod) risk_7\NN\14541044|with|a|greater|developing (l_advcl) developing_9\VBG\1753788|of|function|groups (l_dobj) function_12\NN\13783581|decreased|renal
D004656_D051437 CID enalapril_49\NN\2673637|with (r_nmod) rr_31\NN\1740|[|]|1.42|years|,|interval|1.52|enalapril (r_appos) ratio_29\NN\13815152|risk|rr (r_appos) enalapril_26\NN\2673637|(|:|ratio|;|placebo|. (r_dep) associated_3\VBN\628491|age|was|risk|,|but|so|enalapril (l_nmod) risk_7\NN\14541044|with|a|greater|developing (l_advcl) developing_9\VBG\1753788|of|function|groups (l_dobj) function_12\NN\13783581|decreased|renal
D004656_D051437 CID enalapril_15\NN\2673637| (r_compound) group_16\NN\2137|in|the|enalapril|rr (r_nmod) associated_4\VBN\628491|therapy|was|likewise|risk|group|than|. (l_nmod) risk_8\NN\14541044|with|a|greater|function (l_nmod) function_12\NN\13783581|of|decreased|renal
D004656_D051437 CID enalapril_2\NN\2673637| (r_compound) use_3\NN\407535|enalapril (r_nsubj) caused_4\VBD\1617192|conclusions|use|increase|. (l_dobj) increase_8\NN\13576355|a|%|risk (l_nmod) risk_11\NN\14541044|in|the|function|patients (l_nmod) function_15\NN\13783581|of|decreased|renal
D004656_D051437 CID enalapril_23\NN\2673637| (r_compound) group_24\NN\2137|in|the|enalapril (r_nmod) reduced_20\VBN\441445|risk|was|group|group|. (r_conj) associated_2\VBN\628491|diabetes|was|risk|,|but|reduced (l_nmod) risk_6\NN\14541044|with|an|increased|impairment|patients (l_nmod) impairment_9\NN\7296428|of|renal
D004656_D003920 NONE enalapril_9\NN\2673637| (r_conj) placebo_7\NN\3740161|in|both|the|and|enalapril (r_compound) groups_10\NNS\2137|placebo (r_dep) associated_20\VBN\628491|analysis|,|groups|age|were|function|,|whereas|renoprotective (l_nsubjpass) age_12\NN\4916342|older|,|therapy|,|and|diabetes (l_conj) diabetes_18\NN\14075199|
D004656_D003920 NONE enalapril_2\NN\2673637| (r_nsubj) had_3\VBD\2108377|conversely|,|enalapril|effect|placebo|. (l_nmod) placebo_21\NN\3740161|compared|with|rr|patients (l_nmod) patients_34\NNS\9898892|in|diabetes (l_nmod) diabetes_36\NN\14075199|with
D004656_D003920 NONE enalapril_23\NN\2673637| (r_compound) group_24\NN\2137|in|the|enalapril (r_nmod) reduced_20\VBN\441445|risk|was|group|group|. (r_conj) associated_2\VBN\628491|diabetes|was|risk|,|but|reduced (l_nsubjpass) diabetes_0\NN\14075199|
D004232_D051437 CID diuretic_14\NN\3247620| (r_compound) therapy_15\NN\657604|diuretic (r_conj) age_12\NN\4916342|older|,|therapy|,|and|diabetes (r_nsubjpass) associated_20\VBN\628491|analysis|,|groups|age|were|function|,|whereas|renoprotective (l_nmod) function_24\NN\13783581|with|decreased|renal
D004232_D051437 CID diuretic_0\NN\3247620| (r_compound) therapy_1\NN\657604|diuretic (r_nsubjpass) associated_4\VBN\628491|therapy|was|likewise|risk|group|than|. (l_nmod) risk_8\NN\14541044|with|a|greater|function (l_nmod) function_12\NN\13783581|of|decreased|renal
17194457
-1_D001523 NONE pcpa_3\NN\1740|to|alone (r_nmod) exposure_1\NN\5042871|chronic|pcpa (r_nsubj) decreased_6\VBD\169651|exposure|significantly|activity|increased|but|had|. (l_advcl) increased_10\VBD\169651|irritability (l_dobj) irritability_11\NN\7552087|
-1_D001523 NONE pcpa_3\NN\1740|to|alone (r_nmod) exposure_1\NN\5042871|chronic|pcpa (r_nsubj) decreased_6\VBD\169651|exposure|significantly|activity|increased|but|had|. (l_conj) had_13\VBD\2108377|effect (l_dobj) effect_15\NN\34213|no|behavior (l_nmod) behavior_18\NN\407535|on|sexual|,|preference (l_conj) preference_21\NN\7497473|partner|,|or|aggression (l_conj) aggression_24\NN\4657876|
D013739_D001523 CID t_0\NN\14999913|alone (r_nsubj) had_2\VBD\2108377|t|effect|but|increased|. (l_dobj) effect_4\NN\34213|no|locomotion (l_nmod) locomotion_6\NN\4773351|on|,|irritability (l_conj) irritability_8\NN\7552087|,|or|behavior
D013739_D001523 CID t_0\NN\14999913|alone (r_nsubj) had_2\VBD\2108377|t|effect|but|increased|. (l_conj) increased_14\VBD\169651|preference (l_dobj) preference_16\NN\7497473|partner|and|aggression (l_conj) aggression_18\NN\4657876|
D012701_D001523 NONE 5-ht_16\NN\1740|with|low|central (r_nmod) users_12\NNS\7846|pubertal|aas|5-ht (r_nsubj) prone_20\JJ\1740|that|users|may|be|especially|exhibit (l_xcomp) exhibit_22\VB\2632167|to|behavior (l_dobj) behavior_24\NN\407535|aggressive
20635749
D000638_D006333 NONE amiodarone_6\NN\2715941|on (r_nmod) patient_4\NN\9898892|failure|amiodarone|presenting|:|report (l_compound) failure_3\NN\66216|severe|congestive|heart
D000638_D006333 NONE amiodarone-induced_10\JJ\1740| (r_amod) hypothyroidism_11\NN\14059928|to|amiodarone-induced (r_nmod) secondary_8\JJ\1740|hypothyroidism|patient (l_nmod) patient_14\NN\9898892|in|a|failure (l_nmod) failure_19\NN\66216|with|severe|congestive|heart|chf
D000638_D006333 NONE amiodarone-induced_10\JJ\1740| (r_amod) hypothyroidism_11\NN\14059928|to|amiodarone-induced (r_nmod) secondary_8\JJ\1740|hypothyroidism|patient (l_nmod) patient_14\NN\9898892|in|a|failure (l_nmod) failure_19\NN\66216|with|severe|congestive|heart|chf (l_appos) chf_21\NN\1740|(|)
D000638_D006333 NONE amiodarone_4\NN\2715941|on (r_nmod) patients_0\NNS\9898892|chf|amiodarone (l_nmod) chf_2\NN\1740|with
D000638_D006333 NONE amiodarone_13\NN\2715941|of (r_nmod) usage_11\NN\407535|given|the|frequent|amiodarone|patients (l_nmod) patients_16\NNS\9898892|among|chf (l_compound) chf_15\NN\1740|
D000638_D009230 CID amiodarone_6\NN\2715941|on (r_nmod) patient_4\NN\9898892|failure|amiodarone|presenting|:|report (l_acl) presenting_7\VBG\2137132|coma (l_nmod) coma_10\NN\5678932|with|myxedemic
D000638_D009230 CID amiodarone-induced_10\JJ\1740| (r_amod) hypothyroidism_11\NN\14059928|to|amiodarone-induced (r_nmod) secondary_8\JJ\1740|hypothyroidism|patient (r_amod) coma_7\NN\5678932|of|myxedema|secondary
D000638_D009230 CID amiodarone_19\NN\2715941| (r_compound) therapy_20\NN\657604|during|term|amiodarone (r_nmod) report_12\NN\6470073|one|case|coma|therapy (l_nmod) coma_15\NN\5678932|of|myxedema
D000638_D003128 CID amiodarone_6\NN\2715941|on (r_nmod) patient_4\NN\9898892|failure|amiodarone|presenting|:|report (l_acl) presenting_7\VBG\2137132|coma (l_nmod) coma_10\NN\5678932|with|myxedemic
D000638_D003128 CID amiodarone-induced_10\JJ\1740| (r_amod) hypothyroidism_11\NN\14059928|to|amiodarone-induced (r_nmod) secondary_8\JJ\1740|hypothyroidism|patient (r_amod) coma_7\NN\5678932|of|myxedema|secondary
D000638_D003128 CID amiodarone_19\NN\2715941| (r_compound) therapy_20\NN\657604|during|term|amiodarone (r_nmod) report_12\NN\6470073|one|case|coma|therapy (l_nmod) coma_15\NN\5678932|of|myxedema
D000638_D007037 CID amiodarone-induced_10\JJ\1740| (r_amod) hypothyroidism_11\NN\14059928|to|amiodarone-induced
D000638_D007037 CID amiodarone_4\NN\2715941|on (r_nmod) patients_0\NNS\9898892|chf|amiodarone (r_nsubj) suffer_6\VB\2110220|patients|may|morbidity|hypothyroidism|,|and|deserve|. (l_nmod) hypothyroidism_12\NN\14059928|from
19370593
D004967_D054556 CID oestrogen-only_1\JJ\1740| (r_amod) ht_2\NN\1740|long-term|oestrogen-only (r_nsubj) increased_4\VBD\169651|ht|significantly|risk|(|years|,|but|increase|. (l_dobj) risk_6\NN\14541044|the|thrombo-embolism (l_nmod) thrombo-embolism_9\NN\1740|of|venous|,|stroke
D004967_D020521 CID oestrogen-only_1\JJ\1740| (r_amod) ht_2\NN\1740|long-term|oestrogen-only (r_nsubj) increased_4\VBD\169651|ht|significantly|risk|(|years|,|but|increase|. (l_dobj) risk_6\NN\14541044|the|thrombo-embolism (l_nmod) thrombo-embolism_9\NN\1740|of|venous|,|stroke (l_conj) stroke_11\NN\556313|and|disease
D004967_D005705 CID oestrogen-only_1\JJ\1740| (r_amod) ht_2\NN\1740|long-term|oestrogen-only (r_nsubj) increased_4\VBD\169651|ht|significantly|risk|(|years|,|but|increase|. (l_dobj) risk_6\NN\14541044|the|thrombo-embolism (l_nmod) thrombo-embolism_9\NN\1740|of|venous|,|stroke (l_conj) stroke_11\NN\556313|and|disease (l_conj) disease_14\NN\14061805|gallbladder
D004967_D001943 NONE oestrogen-only_1\JJ\1740| (r_amod) ht_2\NN\1740|long-term|oestrogen-only (r_nsubj) increased_4\VBD\169651|ht|significantly|risk|(|years|,|but|increase|. (l_conj) increase_36\VB\169651|did|not|significantly|risk (l_dobj) risk_38\NN\14541044|the|cancer (l_nmod) cancer_41\NN\14239425|of|breast
3961813
D003345_D009422 NONE corticosterone_7\NN\14752057|of|dietary (r_nmod) effects_4\NNS\13245626|dose-related|beneficial|corticosterone|neuropathy|. (l_nmod) neuropathy_11\NN\14204950|on|organophosphorus-induced|delayed|chickens
D003345_D009422 NONE corticosterone_13\NN\14752057|of (r_nmod) concentrations_2\NNS\4916342|low|than|)|corticosterone (r_nsubj) had_14\VBD\2108377|although|concentrations|effects|neuropathy (l_nmod) neuropathy_19\NN\14204950|on|totp-induced
D010755_D009422 NONE organophosphorus-induced_9\JJ\1740| (r_amod) neuropathy_11\NN\14204950|on|organophosphorus-induced|delayed|chickens
C025541_D009422 CID totp-induced_18\JJ\1740| (r_amod) neuropathy_19\NN\14204950|on|totp-induced
C025541_D009422 CID totp_35\NN\1740|either|or|dfp (r_dobj) given_33\VBN\2327200|totp (r_acl) chickens_32\NNS\7644706|in|given (r_nmod) exacerbated_28\VBD\126264|had|,|than|signs|chickens|. (l_advcl) had_14\VBD\2108377|although|concentrations|effects|neuropathy (l_nmod) neuropathy_19\NN\14204950|on|totp-induced
D007531_D009422 CID dfp_37\NN\1740| (r_conj) totp_35\NN\1740|either|or|dfp (r_dobj) given_33\VBN\2327200|totp (r_acl) chickens_32\NNS\7644706|in|given (r_nmod) exacerbated_28\VBD\126264|had|,|than|signs|chickens|. (l_advcl) had_14\VBD\2108377|although|concentrations|effects|neuropathy (l_nmod) neuropathy_19\NN\14204950|on|totp-induced
C025541_D020258 NONE totp_6\NN\1740|hr|or|dfp (r_appos) activities_2\NNS\30358|neurotoxic|esterase|totp (l_amod) neurotoxic_0\JJ\1740|
D007531_D020258 NONE dfp_8\NN\1740| (r_conj) totp_6\NN\1740|hr|or|dfp (r_appos) activities_2\NNS\30358|neurotoxic|esterase|totp (l_amod) neurotoxic_0\JJ\1740|
D010755_D020258 NONE organophosphorous_21\JJ\1740| (r_amod) compounds_22\NNS\5869584|organophosphorous (r_dobj) given_20\VBN\2327200|not|compounds (r_acl) chickens_18\NNS\7644706|in|given (r_nmod) measured_16\VBN\697589|chickens (r_acl) values_15\NNS\5941423|of|measured (r_nmod) %_13\NN\1740|activities|were|20|values|. (l_nsubj) activities_2\NNS\30358|neurotoxic|esterase|totp (l_amod) neurotoxic_0\JJ\1740|
C025541_D009410 CID totp_16\NN\1740|or|dfp (r_dobj) given_15\VBN\2327200|totp (r_acl) chickens_14\NNS\7644706|of|given (r_nmod) nerves_12\NNS\14373582|of|the|peripheral|chickens (r_nmod) levels_8\NNS\4916342|in|distal|nerves (r_nmod) evident_5\JJ\1740|fibers|were|also|levels|. (l_nsubj) fibers_2\NNS\14580897|degenerating|myelinated
D007531_D009410 CID dfp_18\NN\1740| (r_conj) totp_16\NN\1740|or|dfp (r_dobj) given_15\VBN\2327200|totp (r_acl) chickens_14\NNS\7644706|of|given (r_nmod) nerves_12\NNS\14373582|of|the|peripheral|chickens (r_nmod) levels_8\NNS\4916342|in|distal|nerves (r_nmod) evident_5\JJ\1740|fibers|were|also|levels|. (l_nsubj) fibers_2\NNS\14580897|degenerating|myelinated
2257294
C034753_D001855 NONE benzylacyclouridine_0\NN\1740| (r_nsubj) reverses_1\VBZ\109660|benzylacyclouridine|suppression|impairment|. (l_dobj) suppression_4\NN\13489037|azidothymidine-induced|marrow
C034753_D001855 NONE bau_11\NN\1740| (r_nsubj) reduced_12\VBD\441445|coadministered|,|bau|toxicity|. (l_dobj) toxicity_15\NN\13576101|azt-induced|marrow
C034753_D007153 NONE benzylacyclouridine_0\NN\1740| (r_nsubj) reverses_1\VBZ\109660|benzylacyclouridine|suppression|impairment|. (l_nmod) impairment_6\NN\7296428|without|activity (l_nmod) activity_11\NN\30358|of|virus (l_compound) virus_10\NN\9312843|anti-human|immunodeficiency (l_compound) immunodeficiency_9\NN\13973990|
D015215_D001855 CID azidothymidine-induced_2\JJ\1740| (r_amod) suppression_4\NN\13489037|azidothymidine-induced|marrow
D015215_D001855 CID azt_3\NN\3834836|with (r_nmod) coadministered_1\VBN\1740|when|azt|onset (r_advcl) reduced_12\VBD\441445|coadministered|,|bau|toxicity|. (l_dobj) toxicity_15\NN\13576101|azt-induced|marrow
D015215_D001855 CID azt-induced_13\JJ\1740| (r_amod) toxicity_15\NN\13576101|azt-induced|marrow
D015215_D007153 NONE azidothymidine-induced_2\JJ\1740| (r_amod) suppression_4\NN\13489037|azidothymidine-induced|marrow (r_dobj) reverses_1\VBZ\109660|benzylacyclouridine|suppression|impairment|. (l_nmod) impairment_6\NN\7296428|without|activity (l_nmod) activity_11\NN\30358|of|virus (l_compound) virus_10\NN\9312843|anti-human|immunodeficiency (l_compound) immunodeficiency_9\NN\13973990|
D015215_D007153 NONE azidothymidine_17\NN\1740| (r_compound) (azt)-induced_18\NN\1740|azidothymidine (r_nummod) inhibition_19\NN\1068773|(azt)-induced|cells (r_dobj) reduce_12\VB\441445|to|,|vitro|,|inhibition|impairment (l_nmod) impairment_26\NN\7296428|without|activity (l_nmod) activity_35\NN\30358|of|its|virus (l_compound) virus_31\NN\9312843|antihuman|immunodeficiency|hiv (l_compound) immunodeficiency_30\NN\13973990|
D015215_D007153 NONE (azt)-induced_18\NN\1740|azidothymidine (r_nummod) inhibition_19\NN\1068773|(azt)-induced|cells (r_dobj) reduce_12\VB\441445|to|,|vitro|,|inhibition|impairment (l_nmod) impairment_26\NN\7296428|without|activity (l_nmod) activity_35\NN\30358|of|its|virus (l_compound) virus_31\NN\9312843|antihuman|immunodeficiency|hiv (l_compound) immunodeficiency_30\NN\13973990|
D014529_D007153 NONE uridine_4\NN\1740|of|urd (r_nmod) concentrations_2\NNS\4916342|increased|extracellular|uridine (r_nsubjpass) reported_10\VBN\831651|concentrations|have|been|reduce|. (l_xcomp) reduce_12\VB\441445|to|,|vitro|,|inhibition|impairment (l_nmod) impairment_26\NN\7296428|without|activity (l_nmod) activity_35\NN\30358|of|its|virus (l_compound) virus_31\NN\9312843|antihuman|immunodeficiency|hiv (l_compound) immunodeficiency_30\NN\13973990|
D014529_D007153 NONE urd_6\NN\1740|(|) (r_appos) uridine_4\NN\1740|of|urd (r_nmod) concentrations_2\NNS\4916342|increased|extracellular|uridine (r_nsubjpass) reported_10\VBN\831651|concentrations|have|been|reduce|. (l_xcomp) reduce_12\VB\441445|to|,|vitro|,|inhibition|impairment (l_nmod) impairment_26\NN\7296428|without|activity (l_nmod) activity_35\NN\30358|of|its|virus (l_compound) virus_31\NN\9312843|antihuman|immunodeficiency|hiv (l_compound) immunodeficiency_30\NN\13973990|
D014529_D064420 NONE urd_8\NN\1740| (r_compound) administration_9\NN\1133281|with|chronic|urd (r_nmod) associated_5\VBN\628491|administration (r_acl) toxicities_4\NNS\13576101|because|the|clinical|associated
D014529_D064420 NONE urd_3\NN\1740| (r_compound) catabolism_4\NN\13526110|urd (r_dobj) inhibits_2\VBZ\2510337|agent|catabolism|and|,|vivo|,|increases|. (l_conj) increases_10\VBZ\169651|concentration|manner|,|toxicity (l_nmod) toxicity_23\NN\13576101|without|urd-related
D014529_D064420 NONE urd_15\NN\1740|of (r_nmod) concentration_13\NN\4916342|the|plasma|urd (r_dobj) increases_10\VBZ\169651|concentration|manner|,|toxicity (l_nmod) toxicity_23\NN\13576101|without|urd-related
D014529_D064420 NONE urd-related_22\JJ\1740| (r_amod) toxicity_23\NN\13576101|without|urd-related
D014529_D000740 NONE urd_8\NN\1740| (r_compound) administration_9\NN\1133281|with|chronic|urd (r_nmod) associated_5\VBN\628491|administration (r_acl) toxicities_4\NNS\13576101|because|the|clinical|associated (r_nmod) assessed_29\VBN\670261|toxicities|,|ability|was|. (l_nsubjpass) ability_12\NN\4723816|the|benzylacyclouridine|effect (l_acl) effect_19\VB\1645601|to|,|vivo|,|anemia (l_dobj) anemia_25\NN\14189204|azt-induced|and|leukopenia
D014529_D007970 NONE urd_8\NN\1740| (r_compound) administration_9\NN\1133281|with|chronic|urd (r_nmod) associated_5\VBN\628491|administration (r_acl) toxicities_4\NNS\13576101|because|the|clinical|associated (r_nmod) assessed_29\VBN\670261|toxicities|,|ability|was|. (l_nsubjpass) ability_12\NN\4723816|the|benzylacyclouridine|effect (l_acl) effect_19\VB\1645601|to|,|vivo|,|anemia (l_dobj) anemia_25\NN\14189204|azt-induced|and|leukopenia (l_conj) leukopenia_27\NN\14189204|
C034753_D064420 NONE benzylacyclouridine_14\NN\1740|of|bau (r_nmod) ability_12\NN\4723816|the|benzylacyclouridine|effect (r_nsubjpass) assessed_29\VBN\670261|toxicities|,|ability|was|. (l_nmod) toxicities_4\NNS\13576101|because|the|clinical|associated
C034753_D064420 NONE bau_16\NN\1740|(|) (r_appos) benzylacyclouridine_14\NN\1740|of|bau (r_nmod) ability_12\NN\4723816|the|benzylacyclouridine|effect (r_nsubjpass) assessed_29\VBN\670261|toxicities|,|ability|was|. (l_nmod) toxicities_4\NNS\13576101|because|the|clinical|associated
C034753_D000740 NONE benzylacyclouridine_14\NN\1740|of|bau (r_nmod) ability_12\NN\4723816|the|benzylacyclouridine|effect (l_acl) effect_19\VB\1645601|to|,|vivo|,|anemia (l_dobj) anemia_25\NN\14189204|azt-induced|and|leukopenia
C034753_D000740 NONE bau_16\NN\1740|(|) (r_appos) benzylacyclouridine_14\NN\1740|of|bau (r_nmod) ability_12\NN\4723816|the|benzylacyclouridine|effect (l_acl) effect_19\VB\1645601|to|,|vivo|,|anemia (l_dobj) anemia_25\NN\14189204|azt-induced|and|leukopenia
C034753_D000740 NONE bau_29\NN\1740|daily|mg/kg (r_conj) azt_26\NN\3834836|of|plus|bau (r_nmod) administration_24\NN\1133281|the|continued|azt (r_nsubj) reversed_37\VBD\109660|mice|,|administration|partially|anemia|,|increased|. (l_nmod) mice_1\NNS\2329401|in|rendered (l_acl) rendered_2\VBN\120316|anemic|administration (l_xcomp) anemic_3\JJ\1740|and|leukopenic
C034753_D000740 NONE bau_29\NN\1740|daily|mg/kg (r_conj) azt_26\NN\3834836|of|plus|bau (r_nmod) administration_24\NN\1133281|the|continued|azt (r_nsubj) reversed_37\VBD\109660|mice|,|administration|partially|anemia|,|increased|. (l_dobj) anemia_39\NN\14189204|azt-induced|and|leukopenia|p
C034753_D007970 NONE benzylacyclouridine_14\NN\1740|of|bau (r_nmod) ability_12\NN\4723816|the|benzylacyclouridine|effect (l_acl) effect_19\VB\1645601|to|,|vivo|,|anemia (l_dobj) anemia_25\NN\14189204|azt-induced|and|leukopenia (l_conj) leukopenia_27\NN\14189204|
C034753_D007970 NONE bau_16\NN\1740|(|) (r_appos) benzylacyclouridine_14\NN\1740|of|bau (r_nmod) ability_12\NN\4723816|the|benzylacyclouridine|effect (l_acl) effect_19\VB\1645601|to|,|vivo|,|anemia (l_dobj) anemia_25\NN\14189204|azt-induced|and|leukopenia (l_conj) leukopenia_27\NN\14189204|
C034753_D007970 NONE bau_29\NN\1740|daily|mg/kg (r_conj) azt_26\NN\3834836|of|plus|bau (r_nmod) administration_24\NN\1133281|the|continued|azt (r_nsubj) reversed_37\VBD\109660|mice|,|administration|partially|anemia|,|increased|. (l_nmod) mice_1\NNS\2329401|in|rendered (l_acl) rendered_2\VBN\120316|anemic|administration (l_xcomp) anemic_3\JJ\1740|and|leukopenic (l_conj) leukopenic_5\JJ\1740|
C034753_D007970 NONE bau_29\NN\1740|daily|mg/kg (r_conj) azt_26\NN\3834836|of|plus|bau (r_nmod) administration_24\NN\1133281|the|continued|azt (r_nsubj) reversed_37\VBD\109660|mice|,|administration|partially|anemia|,|increased|. (l_dobj) anemia_39\NN\14189204|azt-induced|and|leukopenia|p (l_conj) leukopenia_41\NN\14189204|
D015215_D064420 NONE azt-induced_24\JJ\1740| (r_amod) anemia_25\NN\14189204|azt-induced|and|leukopenia (r_dobj) effect_19\VB\1645601|to|,|vivo|,|anemia (r_acl) ability_12\NN\4723816|the|benzylacyclouridine|effect (r_nsubjpass) assessed_29\VBN\670261|toxicities|,|ability|was|. (l_nmod) toxicities_4\NNS\13576101|because|the|clinical|associated
D015215_D000740 CID azt-induced_24\JJ\1740| (r_amod) anemia_25\NN\14189204|azt-induced|and|leukopenia
D015215_D000740 CID azt_10\NN\3834836|of (r_nmod) administration_8\NN\1133281|by|the|azt|days|water (r_nmod) rendered_2\VBN\120316|anemic|administration (l_xcomp) anemic_3\JJ\1740|and|leukopenic
D015215_D000740 CID azt_10\NN\3834836|of (r_nmod) administration_8\NN\1133281|by|the|azt|days|water (r_nmod) rendered_2\VBN\120316|anemic|administration (r_acl) mice_1\NNS\2329401|in|rendered (r_nmod) reversed_37\VBD\109660|mice|,|administration|partially|anemia|,|increased|. (l_dobj) anemia_39\NN\14189204|azt-induced|and|leukopenia|p
D015215_D000740 CID azt_26\NN\3834836|of|plus|bau (r_nmod) administration_24\NN\1133281|the|continued|azt (r_nsubj) reversed_37\VBD\109660|mice|,|administration|partially|anemia|,|increased|. (l_nmod) mice_1\NNS\2329401|in|rendered (l_acl) rendered_2\VBN\120316|anemic|administration (l_xcomp) anemic_3\JJ\1740|and|leukopenic
D015215_D000740 CID azt_26\NN\3834836|of|plus|bau (r_nmod) administration_24\NN\1133281|the|continued|azt (r_nsubj) reversed_37\VBD\109660|mice|,|administration|partially|anemia|,|increased|. (l_dobj) anemia_39\NN\14189204|azt-induced|and|leukopenia|p
D015215_D000740 CID azt-induced_38\JJ\1740| (r_amod) anemia_39\NN\14189204|azt-induced|and|leukopenia|p (r_dobj) reversed_37\VBD\109660|mice|,|administration|partially|anemia|,|increased|. (l_nmod) mice_1\NNS\2329401|in|rendered (l_acl) rendered_2\VBN\120316|anemic|administration (l_xcomp) anemic_3\JJ\1740|and|leukopenic
D015215_D000740 CID azt-induced_38\JJ\1740| (r_amod) anemia_39\NN\14189204|azt-induced|and|leukopenia|p
D015215_D007970 CID azt-induced_24\JJ\1740| (r_amod) anemia_25\NN\14189204|azt-induced|and|leukopenia (l_conj) leukopenia_27\NN\14189204|
D015215_D007970 CID azt_10\NN\3834836|of (r_nmod) administration_8\NN\1133281|by|the|azt|days|water (r_nmod) rendered_2\VBN\120316|anemic|administration (l_xcomp) anemic_3\JJ\1740|and|leukopenic (l_conj) leukopenic_5\JJ\1740|
D015215_D007970 CID azt_10\NN\3834836|of (r_nmod) administration_8\NN\1133281|by|the|azt|days|water (r_nmod) rendered_2\VBN\120316|anemic|administration (r_acl) mice_1\NNS\2329401|in|rendered (r_nmod) reversed_37\VBD\109660|mice|,|administration|partially|anemia|,|increased|. (l_dobj) anemia_39\NN\14189204|azt-induced|and|leukopenia|p (l_conj) leukopenia_41\NN\14189204|
D015215_D007970 CID azt_26\NN\3834836|of|plus|bau (r_nmod) administration_24\NN\1133281|the|continued|azt (r_nsubj) reversed_37\VBD\109660|mice|,|administration|partially|anemia|,|increased|. (l_nmod) mice_1\NNS\2329401|in|rendered (l_acl) rendered_2\VBN\120316|anemic|administration (l_xcomp) anemic_3\JJ\1740|and|leukopenic (l_conj) leukopenic_5\JJ\1740|
D015215_D007970 CID azt_26\NN\3834836|of|plus|bau (r_nmod) administration_24\NN\1133281|the|continued|azt (r_nsubj) reversed_37\VBD\109660|mice|,|administration|partially|anemia|,|increased|. (l_dobj) anemia_39\NN\14189204|azt-induced|and|leukopenia|p (l_conj) leukopenia_41\NN\14189204|
D015215_D007970 CID azt-induced_38\JJ\1740| (r_amod) anemia_39\NN\14189204|azt-induced|and|leukopenia|p (r_dobj) reversed_37\VBD\109660|mice|,|administration|partially|anemia|,|increased|. (l_nmod) mice_1\NNS\2329401|in|rendered (l_acl) rendered_2\VBN\120316|anemic|administration (l_xcomp) anemic_3\JJ\1740|and|leukopenic (l_conj) leukopenic_5\JJ\1740|
D015215_D007970 CID azt-induced_38\JJ\1740| (r_amod) anemia_39\NN\14189204|azt-induced|and|leukopenia|p (l_conj) leukopenia_41\NN\14189204|
D015215_-1 NONE azt_10\NN\3834836|of (r_nmod) administration_8\NN\1133281|by|the|azt|days|water (r_nmod) rendered_2\VBN\120316|anemic|administration (r_acl) mice_1\NNS\2329401|in|rendered (r_nmod) reversed_37\VBD\109660|mice|,|administration|partially|anemia|,|increased|. (l_conj) increased_49\VBD\169651|reticulocytes|%|,|increased (l_conj) increased_63\VBD\169651|cellularity|,|and|improved (l_conj) improved_70\VBD\126264|megaloblastosis (l_dobj) megaloblastosis_71\NN\1740|
D015215_-1 NONE azt_26\NN\3834836|of|plus|bau (r_nmod) administration_24\NN\1133281|the|continued|azt (r_nsubj) reversed_37\VBD\109660|mice|,|administration|partially|anemia|,|increased|. (l_conj) increased_49\VBD\169651|reticulocytes|%|,|increased (l_conj) increased_63\VBD\169651|cellularity|,|and|improved (l_conj) improved_70\VBD\126264|megaloblastosis (l_dobj) megaloblastosis_71\NN\1740|
D015215_-1 NONE azt-induced_38\JJ\1740| (r_amod) anemia_39\NN\14189204|azt-induced|and|leukopenia|p (r_dobj) reversed_37\VBD\109660|mice|,|administration|partially|anemia|,|increased|. (l_conj) increased_49\VBD\169651|reticulocytes|%|,|increased (l_conj) increased_63\VBD\169651|cellularity|,|and|improved (l_conj) improved_70\VBD\126264|megaloblastosis (l_dobj) megaloblastosis_71\NN\1740|
C034753_-1 NONE bau_29\NN\1740|daily|mg/kg (r_conj) azt_26\NN\3834836|of|plus|bau (r_nmod) administration_24\NN\1133281|the|continued|azt (r_nsubj) reversed_37\VBD\109660|mice|,|administration|partially|anemia|,|increased|. (l_conj) increased_49\VBD\169651|reticulocytes|%|,|increased (l_conj) increased_63\VBD\169651|cellularity|,|and|improved (l_conj) improved_70\VBD\126264|megaloblastosis (l_dobj) megaloblastosis_71\NN\1740|
2886572
D004837_D006973 CID epinephrine-induced_5\JJ\1740| (r_amod) rats_7\NNS\2329401|in|epinephrine-induced|hypertensive (l_amod) hypertensive_6\JJ\1740|
18674790
D004041_D009765 CID fat_1\JJ\1740| (r_amod) diet-fed_2\JJ\1740|high|fat (r_amod) rats_4\NNS\2329401|diet-fed|obese (l_amod) obese_3\JJ\1740|
D004041_D009765 CID fat_16\JJ\1740| (r_amod) diet_17\NN\7560652|%|high|fat|hfd|,|induces (l_acl:relcl) induces_23\VBZ\1627355|which|obesity|rats (l_dobj) obesity_24\NN\4999401|
D004041_D066126 NONE fat_1\JJ\1740| (r_amod) diet-fed_2\JJ\1740|high|fat (r_amod) rats_4\NNS\2329401|diet-fed|obese (r_nsubj) sensitive_7\JJ\1740|rats|are|highly|cardiotoxicity|. (l_nmod) cardiotoxicity_10\NN\1740|to|doxorubicin-induced
D004041_D066126 NONE fat_16\JJ\1740| (r_amod) diet_17\NN\7560652|%|high|fat|hfd|,|induces (r_dobj) feeding_12\VBG\1182709|by|diet (r_acl) intervention_10\NN\1239064|a|physiological|feeding|, (r_nsubj) sensitizes_36\VBZ\126264|whether|intervention|cardiotoxicity (l_nmod) cardiotoxicity_39\NN\1740|to|doxorubicin-induced
D004317_D009765 NONE doxorubicin-induced_9\JJ\1740| (r_amod) cardiotoxicity_10\NN\1740|to|doxorubicin-induced (r_nmod) sensitive_7\JJ\1740|rats|are|highly|cardiotoxicity|. (l_nsubj) rats_4\NNS\2329401|diet-fed|obese (l_amod) obese_3\JJ\1740|
D004317_D009765 NONE doxorubicin-induced_38\JJ\1740| (r_amod) cardiotoxicity_39\NN\1740|to|doxorubicin-induced (r_nmod) sensitizes_36\VBZ\126264|whether|intervention|cardiotoxicity (l_nsubj) intervention_10\NN\1239064|a|physiological|feeding|, (l_acl) feeding_12\VBG\1182709|by|diet (l_dobj) diet_17\NN\7560652|%|high|fat|hfd|,|induces (l_acl:relcl) induces_23\VBZ\1627355|which|obesity|rats (l_dobj) obesity_24\NN\4999401|
D004317_D009765 NONE doxorubicin/kg_7\NN\1740|(|mg|,|ip|) (r_appos) dose_3\NN\3740161|a|ld(10|)|doxorubicin/kg|administered (r_nsubj) led_20\VBD\1752884|dose|cardiotoxicity|absence|. (l_nmod) cardiotoxicity_23\NN\1740|to|higher|,|dysfunction|,|peroxidation|,|and|mortality|rats (l_nmod) rats_41\NNS\2329401|in|the|obese|(|ob|) (l_amod) obese_37\JJ\1740|
D004317_D009765 NONE doxorubicin/kg_7\NN\1740|(|mg|,|ip|) (r_appos) dose_3\NN\3740161|a|ld(10|)|doxorubicin/kg|administered (r_nsubj) led_20\VBD\1752884|dose|cardiotoxicity|absence|. (l_nmod) cardiotoxicity_23\NN\1740|to|higher|,|dysfunction|,|peroxidation|,|and|mortality|rats (l_nmod) rats_41\NNS\2329401|in|the|obese|(|ob|) (l_compound) ob_39\NN\6043075|
D004317_D009765 NONE doxorubicin_0\NN\2716866| (r_compound) studies_2\NNS\635850|doxorubicin|toxicokinetics (r_nsubj) revealed_3\VBD\2137132|studies|change|. (l_dobj) change_5\NN\7283608|no|accumulation (l_nmod) accumulation_7\NN\13497135|in|doxorubicin|hearts (l_nmod) hearts_25\NNS\496167|in|the|diet-fed (l_amod) diet-fed_19\JJ\1740|normal|nd|and|ob (l_conj) ob_24\NN\6043075|
D004317_D009765 NONE doxorubicin_9\NN\2716866|of|and|doxorubicinol (r_nmod) accumulation_7\NN\13497135|in|doxorubicin|hearts (l_nmod) hearts_25\NNS\496167|in|the|diet-fed (l_amod) diet-fed_19\JJ\1740|normal|nd|and|ob (l_conj) ob_24\NN\6043075|
D004317_D009765 NONE doxorubicin_93\NN\2716866| (r_compound) administration_94\NN\1133281|after|doxorubicin (r_nmod) ratio_91\NN\13815152|by|decreased|atp/adp|administration (r_nmod) accompanied_87\VBN\1835496|ratio (r_acl) drop_82\NN\13899200|6|%|levels|accompanied (r_conj) stress_16\NN\7083732|due|:|1|higher|oxyradical|leading|,|downregulation|,|levels|,|oxidation|,|kinase|,|and|drop (r_nmod) sensitized_7\VBN\126264|that|rats|are|stress (l_nsubjpass) rats_5\NNS\2329401|ob (l_compound) ob_4\NN\6043075|
D004317_D009765 NONE doxorubicin_93\NN\2716866| (r_compound) administration_94\NN\1133281|after|doxorubicin (r_nmod) ratio_91\NN\13815152|by|decreased|atp/adp|administration (r_nmod) accompanied_87\VBN\1835496|ratio (r_acl) drop_82\NN\13899200|6|%|levels|accompanied (r_conj) stress_16\NN\7083732|due|:|1|higher|oxyradical|leading|,|downregulation|,|levels|,|oxidation|,|kinase|,|and|drop (l_conj) oxidation_52\NN\13447361|4|decreased|cardiac|fatty-acid|heart (l_dep) heart_56\NN\5919034|(|666.9+/-14.0|nmol/min/g|nd|versus|400.2+/-11.8|heart|) (l_conj) heart_62\NN\5919034|nmol/min/g|ob (l_nmod) ob_64\NN\6043075|in
D004317_D009765 NONE doxorubicin-induced_10\JJ\1740| (r_amod) cardiotoxicity_11\NN\1740|to|doxorubicin-induced (r_nmod) sensitized_8\VBN\126264|conclusion|,|rats|are|highly|cardiotoxicity|downregulating|. (l_nsubjpass) rats_5\NNS\2329401|hfd-induced|obese (l_amod) obese_4\JJ\1740|
D004317_D066126 NONE doxorubicin-induced_9\JJ\1740| (r_amod) cardiotoxicity_10\NN\1740|to|doxorubicin-induced
D004317_D066126 NONE doxorubicin_4\NN\2716866|by|adriamycin (r_nmod) chemotherapy_2\NN\661091|doxorubicin (r_nsubj) limited_9\JJ\1740|often|,|chemotherapy|is|cardiotoxicity|. (l_nmod) cardiotoxicity_14\NN\1740|due|threatening|patients
D004317_D066126 NONE adriamycin_6\NN\1740|(|) (r_appos) doxorubicin_4\NN\2716866|by|adriamycin (r_nmod) chemotherapy_2\NN\661091|doxorubicin (r_nsubj) limited_9\JJ\1740|often|,|chemotherapy|is|cardiotoxicity|. (l_nmod) cardiotoxicity_14\NN\1740|due|threatening|patients
D004317_D066126 NONE doxorubicin-induced_12\JJ\1740| (r_amod) cardiotoxicity_13\NN\1740|against|doxorubicin-induced
D004317_D066126 NONE doxorubicin-induced_38\JJ\1740| (r_amod) cardiotoxicity_39\NN\1740|to|doxorubicin-induced
D004317_D066126 NONE doxorubicin/kg_7\NN\1740|(|mg|,|ip|) (r_appos) dose_3\NN\3740161|a|ld(10|)|doxorubicin/kg|administered (r_nsubj) led_20\VBD\1752884|dose|cardiotoxicity|absence|. (l_nmod) cardiotoxicity_23\NN\1740|to|higher|,|dysfunction|,|peroxidation|,|and|mortality|rats
D004317_D066126 NONE doxorubicin-induced_10\JJ\1740| (r_amod) cardiotoxicity_11\NN\1740|to|doxorubicin-induced
D004317_D006331 CID doxorubicin/kg_7\NN\1740|(|mg|,|ip|) (r_appos) dose_3\NN\3740161|a|ld(10|)|doxorubicin/kg|administered (r_nsubj) led_20\VBD\1752884|dose|cardiotoxicity|absence|. (l_nmod) cardiotoxicity_23\NN\1740|to|higher|,|dysfunction|,|peroxidation|,|and|mortality|rats (l_conj) dysfunction_26\NN\14204950|cardiac
D004317_D007674 NONE doxorubicin/kg_7\NN\1740|(|mg|,|ip|) (r_appos) dose_3\NN\3740161|a|ld(10|)|doxorubicin/kg|administered (r_nsubj) led_20\VBD\1752884|dose|cardiotoxicity|absence|. (l_nmod) absence_44\NN\14449405|in|the|toxicity (l_nmod) toxicity_51\NN\13576101|of|any|renal
D004317_D056486 NONE doxorubicin/kg_7\NN\1740|(|mg|,|ip|) (r_appos) dose_3\NN\3740161|a|ld(10|)|doxorubicin/kg|administered (r_nsubj) led_20\VBD\1752884|dose|cardiotoxicity|absence|. (l_nmod) absence_44\NN\14449405|in|the|toxicity (l_nmod) toxicity_51\NN\13576101|of|any|renal
C010013_D009765 NONE doxorubicinol_11\NN\1740|metabolite (r_conj) doxorubicin_9\NN\2716866|of|and|doxorubicinol (r_nmod) accumulation_7\NN\13497135|in|doxorubicin|hearts (l_nmod) hearts_25\NNS\496167|in|the|diet-fed (l_amod) diet-fed_19\JJ\1740|normal|nd|and|ob (l_conj) ob_24\NN\6043075|
D000249_D009765 NONE amp-alpha2_72\NN\1740| (r_compound) kinase_74\NN\14732946|5|decreased|mitochondrial|amp-alpha2|protein (r_conj) stress_16\NN\7083732|due|:|1|higher|oxyradical|leading|,|downregulation|,|levels|,|oxidation|,|kinase|,|and|drop (r_nmod) sensitized_7\VBN\126264|that|rats|are|stress (l_nsubjpass) rats_5\NNS\2329401|ob (l_compound) ob_4\NN\6043075|
D000249_D009765 NONE amp-alpha2_72\NN\1740| (r_compound) kinase_74\NN\14732946|5|decreased|mitochondrial|amp-alpha2|protein (r_conj) stress_16\NN\7083732|due|:|1|higher|oxyradical|leading|,|downregulation|,|levels|,|oxidation|,|kinase|,|and|drop (l_conj) oxidation_52\NN\13447361|4|decreased|cardiac|fatty-acid|heart (l_dep) heart_56\NN\5919034|(|666.9+/-14.0|nmol/min/g|nd|versus|400.2+/-11.8|heart|) (l_conj) heart_62\NN\5919034|nmol/min/g|ob (l_nmod) ob_64\NN\6043075|in
D000255_D009765 NONE atp_85\NN\14964590| (r_compound) levels_86\NNS\4916342|in|cardiac|atp (r_nmod) drop_82\NN\13899200|6|%|levels|accompanied (r_conj) stress_16\NN\7083732|due|:|1|higher|oxyradical|leading|,|downregulation|,|levels|,|oxidation|,|kinase|,|and|drop (r_nmod) sensitized_7\VBN\126264|that|rats|are|stress (l_nsubjpass) rats_5\NNS\2329401|ob (l_compound) ob_4\NN\6043075|
D000255_D009765 NONE atp_85\NN\14964590| (r_compound) levels_86\NNS\4916342|in|cardiac|atp (r_nmod) drop_82\NN\13899200|6|%|levels|accompanied (r_conj) stress_16\NN\7083732|due|:|1|higher|oxyradical|leading|,|downregulation|,|levels|,|oxidation|,|kinase|,|and|drop (l_conj) oxidation_52\NN\13447361|4|decreased|cardiac|fatty-acid|heart (l_dep) heart_56\NN\5919034|(|666.9+/-14.0|nmol/min/g|nd|versus|400.2+/-11.8|heart|) (l_conj) heart_62\NN\5919034|nmol/min/g|ob (l_nmod) ob_64\NN\6043075|in
D000255_D009765 NONE atp/adp_90\NN\1740| (r_compound) ratio_91\NN\13815152|by|decreased|atp/adp|administration (r_nmod) accompanied_87\VBN\1835496|ratio (r_acl) drop_82\NN\13899200|6|%|levels|accompanied (r_conj) stress_16\NN\7083732|due|:|1|higher|oxyradical|leading|,|downregulation|,|levels|,|oxidation|,|kinase|,|and|drop (r_nmod) sensitized_7\VBN\126264|that|rats|are|stress (l_nsubjpass) rats_5\NNS\2329401|ob (l_compound) ob_4\NN\6043075|
D000255_D009765 NONE atp/adp_90\NN\1740| (r_compound) ratio_91\NN\13815152|by|decreased|atp/adp|administration (r_nmod) accompanied_87\VBN\1835496|ratio (r_acl) drop_82\NN\13899200|6|%|levels|accompanied (r_conj) stress_16\NN\7083732|due|:|1|higher|oxyradical|leading|,|downregulation|,|levels|,|oxidation|,|kinase|,|and|drop (l_conj) oxidation_52\NN\13447361|4|decreased|cardiac|fatty-acid|heart (l_dep) heart_56\NN\5919034|(|666.9+/-14.0|nmol/min/g|nd|versus|400.2+/-11.8|heart|) (l_conj) heart_62\NN\5919034|nmol/min/g|ob (l_nmod) ob_64\NN\6043075|in
D000255_D009765 NONE atp_17\NN\14964590| (r_compound) generation_18\NN\7942152|cardiac|mitochondrial|atp (r_dobj) downregulating_14\VBG\1740|by|substantially|generation|,|increasing (r_advcl) sensitized_8\VBN\126264|conclusion|,|rats|are|highly|cardiotoxicity|downregulating|. (l_nsubjpass) rats_5\NNS\2329401|hfd-induced|obese (l_amod) obese_4\JJ\1740|
D000244_D009765 NONE atp/adp_90\NN\1740| (r_compound) ratio_91\NN\13815152|by|decreased|atp/adp|administration (r_nmod) accompanied_87\VBN\1835496|ratio (r_acl) drop_82\NN\13899200|6|%|levels|accompanied (r_conj) stress_16\NN\7083732|due|:|1|higher|oxyradical|leading|,|downregulation|,|levels|,|oxidation|,|kinase|,|and|drop (r_nmod) sensitized_7\VBN\126264|that|rats|are|stress (l_nsubjpass) rats_5\NNS\2329401|ob (l_compound) ob_4\NN\6043075|
D000244_D009765 NONE atp/adp_90\NN\1740| (r_compound) ratio_91\NN\13815152|by|decreased|atp/adp|administration (r_nmod) accompanied_87\VBN\1835496|ratio (r_acl) drop_82\NN\13899200|6|%|levels|accompanied (r_conj) stress_16\NN\7083732|due|:|1|higher|oxyradical|leading|,|downregulation|,|levels|,|oxidation|,|kinase|,|and|drop (l_conj) oxidation_52\NN\13447361|4|decreased|cardiac|fatty-acid|heart (l_dep) heart_56\NN\5919034|(|666.9+/-14.0|nmol/min/g|nd|versus|400.2+/-11.8|heart|) (l_conj) heart_62\NN\5919034|nmol/min/g|ob (l_nmod) ob_64\NN\6043075|in
D000255_D066126 NONE atp_17\NN\14964590| (r_compound) generation_18\NN\7942152|cardiac|mitochondrial|atp (r_dobj) downregulating_14\VBG\1740|by|substantially|generation|,|increasing (r_advcl) sensitized_8\VBN\126264|conclusion|,|rats|are|highly|cardiotoxicity|downregulating|. (l_nmod) cardiotoxicity_11\NN\1740|to|doxorubicin-induced
2826064
D010096_D007008 NONE oxprenolol_6\NN\1740|by (r_nmod) abolishment_4\NN\209943|its|oxprenolol (r_conj) hypokalemia_1\NN\14299637|beta-2-adrenoceptor-mediated|and|abolishment|.
D010096_D007008 NONE oxprenolol_6\NN\1740|of (r_nmod) efficacy_4\NN\5199286|the|oxprenolol|antagonizing|,|together|interaction (l_advcl) antagonizing_8\VBG\1787955|in|hypokalemia (l_dobj) hypokalemia_10\NN\14299637|such
D010096_D007008 NONE oxprenolol_7\NN\1740| (r_compound) pretreatment_8\NN\1740|after|oxprenolol (r_nmod) concentrations_5\NNS\4916342|of|higher|terbutaline|pretreatment (r_nmod) spite_1\NN\7550369|in|concentrations (r_nmod) antagonized_15\VBN\1787955|spite|,|hypokalemia|was|completely|action|. (l_nsubjpass) hypokalemia_11\NN\14299637|the
D013726_D007008 CID terbutaline-induced_7\JJ\1740| (r_amod) hypokalemia_8\NN\14299637|of|terbutaline-induced
D013726_D007008 CID terbutaline_4\NN\1740| (r_compound) concentrations_5\NNS\4916342|of|higher|terbutaline|pretreatment (r_nmod) spite_1\NN\7550369|in|concentrations (r_nmod) antagonized_15\VBN\1787955|spite|,|hypokalemia|was|completely|action|. (l_nsubjpass) hypokalemia_11\NN\14299637|the
12091028
D003975_D006212 NONE diazepam_0\NN\2830852| (r_nsubj) remains_7\VBZ\2604760|diazepam|,|contraindicated|,|drug|buffers|. (l_advcl) buffers_17\VBZ\169806|as|it|response|and|decreases (l_conj) decreases_22\VBZ\169651|duration (l_dobj) duration_24\NN\15113229|the|and|intensity|hallucinations (l_nmod) hallucinations_31\NNS\14376855|of|operative
D007649_D006212 CID ketamine_14\NN\3054098|to (r_nmod) drug_12\NN\14778436|the|only|necessary|complementary|ketamine (r_xcomp) remains_7\VBZ\2604760|diazepam|,|contraindicated|,|drug|buffers|. (l_advcl) buffers_17\VBZ\169806|as|it|response|and|decreases (l_conj) decreases_22\VBZ\169651|duration (l_dobj) duration_24\NN\15113229|the|and|intensity|hallucinations (l_nmod) hallucinations_31\NNS\14376855|of|operative
15974569
D007608_D010146 NONE kainate_7\NN\1740| (r_compound) receptor_8\NN\5225602|glur5|kainate (r_compound) antagonists_9\NNS\7846|of|potent|receptor (r_nmod) prodrugs_1\NNS\1740|two|antagonists (r_nsubj) actives_10\NNS\14779550|prodrugs|models|. (l_nmod) models_14\NNS\5888929|in|three|animal|pain (l_nmod) pain_16\NN\14299637|of
D005557_D010146 NONE formalin-induced_17\JJ\1740| (r_amod) licking_19\NN\7291312|of|formalin-induced|paw (r_nmod) reversal_15\NN\199130|licking|,|hyperalgesia (r_dep) active_8\JJ\1740|prodrugs|were|orally|models|reversal|. (l_nmod) models_11\NNS\5888929|in|three|pain|: (l_nmod) pain_13\NN\14299637|of
D005557_D006930 NONE formalin-induced_17\JJ\1740| (r_amod) licking_19\NN\7291312|of|formalin-induced|paw (r_nmod) reversal_15\NN\199130|licking|,|hyperalgesia (l_conj) hyperalgesia_23\NN\1740|carrageenan-induced|thermal|,|and|hyperalgesia
D005557_D006930 NONE formalin-induced_17\JJ\1740| (r_amod) licking_19\NN\7291312|of|formalin-induced|paw (r_nmod) reversal_15\NN\199130|licking|,|hyperalgesia (l_conj) hyperalgesia_23\NN\1740|carrageenan-induced|thermal|,|and|hyperalgesia (l_conj) hyperalgesia_28\NN\1740|capsaicin-induced|mechanical
D002351_D010146 NONE carrageenan-induced_21\JJ\1740| (r_amod) hyperalgesia_23\NN\1740|carrageenan-induced|thermal|,|and|hyperalgesia (r_conj) reversal_15\NN\199130|licking|,|hyperalgesia (r_dep) active_8\JJ\1740|prodrugs|were|orally|models|reversal|. (l_nmod) models_11\NNS\5888929|in|three|pain|: (l_nmod) pain_13\NN\14299637|of
D002351_D006930 CID carrageenan-induced_21\JJ\1740| (r_amod) hyperalgesia_23\NN\1740|carrageenan-induced|thermal|,|and|hyperalgesia
D002351_D006930 CID carrageenan-induced_21\JJ\1740| (r_amod) hyperalgesia_23\NN\1740|carrageenan-induced|thermal|,|and|hyperalgesia (l_conj) hyperalgesia_28\NN\1740|capsaicin-induced|mechanical
D002211_D010146 NONE capsaicin-induced_26\JJ\1740| (r_amod) hyperalgesia_28\NN\1740|capsaicin-induced|mechanical (r_conj) hyperalgesia_23\NN\1740|carrageenan-induced|thermal|,|and|hyperalgesia (r_conj) reversal_15\NN\199130|licking|,|hyperalgesia (r_dep) active_8\JJ\1740|prodrugs|were|orally|models|reversal|. (l_nmod) models_11\NNS\5888929|in|three|pain|: (l_nmod) pain_13\NN\14299637|of
D002211_D006930 CID capsaicin-induced_26\JJ\1740| (r_amod) hyperalgesia_28\NN\1740|capsaicin-induced|mechanical (r_conj) hyperalgesia_23\NN\1740|carrageenan-induced|thermal|,|and|hyperalgesia
D002211_D006930 CID capsaicin-induced_26\JJ\1740| (r_amod) hyperalgesia_28\NN\1740|capsaicin-induced|mechanical
2055425
D013311_D003920 CID streptozotocin-induced_17\JJ\1740| (r_amod) mellitus_19\NN\1740|by|streptozotocin-induced|diabetes
D013311_D003920 CID streptozotocin-diabetic_17\JJ\1740|
D013311_D003920 CID streptozotocin-induced_9\JJ\1740| (r_amod) diabetes_10\NN\14075199|of|streptozotocin-induced
D000255_D003920 NONE atp_22\NN\14964590| (r_conj) stimulation_20\NN\242808|to|nerve|,|atp|,|and|bethanechol (r_nmod) responses_10\NNS\11410625|in|contractile|strips|stimulation (l_nmod) strips_14\NNS\9385911|of|bladder|body|rats (l_nmod) rats_17\NNS\2329401|from|diabetic (l_amod) diabetic_16\JJ\1740|
D000255_D003920 NONE atp_21\NN\14964590| (r_conj) stimulation_19\NN\242808|to|nerve|,|atp|,|and|bethanechol (r_nmod) responses_9\NNS\11410625|in|contractile|strips|stimulation (l_nmod) strips_13\NNS\9385911|of|bladder|body|rats (l_nmod) rats_16\NNS\2329401|from|diabetic (l_amod) diabetic_15\JJ\1740|
D018723_D003920 NONE bethanechol_25\NN\1740| (r_conj) stimulation_20\NN\242808|to|nerve|,|atp|,|and|bethanechol (r_nmod) responses_10\NNS\11410625|in|contractile|strips|stimulation (l_nmod) strips_14\NNS\9385911|of|bladder|body|rats (l_nmod) rats_17\NNS\2329401|from|diabetic (l_amod) diabetic_16\JJ\1740|
D018723_D003920 NONE bethanechol_24\NN\1740| (r_conj) stimulation_19\NN\242808|to|nerve|,|atp|,|and|bethanechol (r_nmod) responses_9\NNS\11410625|in|contractile|strips|stimulation (l_nmod) strips_13\NNS\9385911|of|bladder|body|rats (l_nmod) rats_16\NNS\2329401|from|diabetic (l_amod) diabetic_15\JJ\1740|
1504402
D007741_D004342 CID dilevalol-associated_7\JJ\1740| (r_amod) hepatitis_8\NN\14127211|for|dilevalol-associated (r_nmod) mechanism_5\NN\13446390|as|a|hepatitis (r_nmod) reaction_2\NN\13446390|hypersensitivity|immune|mechanism|. (l_compound) hypersensitivity_0\NN\14531772|
D007741_D056486 CID dilevalol-associated_7\JJ\1740| (r_amod) hepatitis_8\NN\14127211|for|dilevalol-associated
D007741_D056486 CID dilevalol_7\NN\1740|to|and|serum (r_nmod) reactivity_5\NN\5652926|lymphocyte|dilevalol (r_dobj) assess_3\VB\670261|to|reactivity|case (l_nmod) case_21\NN\7283608|in|a|injury (l_nmod) injury_25\NN\14052046|of|dilevalol-induced|liver
D007741_D056486 CID dilevalol_15\NN\1740| (r_compound) antigens_16\NNS\20090|putative|ex|dilevalol|or|metabolites (r_dobj) containing_11\VBG\2632940|antigens (r_acl) serum_10\NN\5397468|to|containing (r_conj) dilevalol_7\NN\1740|to|and|serum (r_nmod) reactivity_5\NN\5652926|lymphocyte|dilevalol (r_dobj) assess_3\VB\670261|to|reactivity|case (l_nmod) case_21\NN\7283608|in|a|injury (l_nmod) injury_25\NN\14052046|of|dilevalol-induced|liver
D007741_D056486 CID dilevalol-induced_23\JJ\1740| (r_amod) injury_25\NN\14052046|of|dilevalol-induced|liver
D007741_D056486 CID dilevalol-induced_10\JJ\1740| (r_amod) injury_12\NN\14052046|of|dilevalol-induced|liver
D007741_D056486 CID dilevalol_16\NN\1740| (r_compound) antigens_17\NNS\20090|ex|vivo-prepared|dilevalol (r_dobj) containing_13\VBG\2632940|antigens (r_acl) sera_12\NNS\5397468|to|containing (r_nmod) sensitization_10\NN\14531772|of|lymphocyte|sera (r_nmod) detection_7\NN\5708432|the|sensitization (r_dobj) allowed_5\VBD\797697|methodology|detection|,|suggesting (l_advcl) suggesting_19\VBG\1010118|involvement (l_dobj) involvement_21\NN\1080366|the|mechanism|injury (l_nmod) injury_29\NN\14052046|in|dilevalol-induced|liver
D007741_D056486 CID dilevalol-induced_27\JJ\1740| (r_amod) injury_29\NN\14052046|in|dilevalol-induced|liver
11860495
D013256_D000647 NONE steroid_0\NN\14727670| (r_compound) structure_1\NN\21939|steroid|and|properties (r_nsubj) determine_5\VBP\1645601|structure|effects|. (l_dobj) effects_8\NNS\13245626|the|anti-amnesic|sulphate|task (l_amod) anti-amnesic_7\JJ\1740|
C018370_D000647 NONE sulphate_11\NN\15010703|of|pregnenolone (r_nmod) effects_8\NNS\13245626|the|anti-amnesic|sulphate|task (l_amod) anti-amnesic_7\JJ\1740|
C018370_D000647 NONE pregs_2\NN\1740| (r_nsubj) able_4\JJ\1740|moreover|,|pregs|is|reverse|. (l_xcomp) reverse_6\VB\109660|to|effects (l_dobj) effects_9\NNS\13245626|the|amnesic-like|nmdar (l_amod) amnesic-like_8\JJ\1740|
C018370_D000647 NONE pregs_4\NNS\1740|of|and|analogs (r_nmod) effects_2\NNS\13245626|the|memory-enhancing|pregs (r_nsubjpass) tested_9\VBN\670261|effects|were|task|using|. (l_xcomp) using_15\VBG\1156834|model (l_dobj) model_17\NN\5888929|the|amnesia (l_nmod) amnesia_20\NN\5669934|of|scopolamine-induced
C018370_D000647 NONE pregs_10\NNS\1740|of|natural (r_nmod) ability_7\NN\4723816|by|the|pregs|effective (l_acl) effective_18\JJ\1740|to|order|more|enantiomer|reversing (l_advcl) reversing_24\VBG\109660|in|amnesia (l_dobj) amnesia_26\NN\5669934|scopolamine-induced
D005680_D000647 NONE gaba(a)r_13\NN\1740| (r_compound) ligands_14\NNS\20090|gaba(a)r (r_conj) nmdar_11\NN\1740|of|and|ligands (r_nmod) effects_9\NNS\13245626|the|amnesic-like|nmdar (l_amod) amnesic-like_8\JJ\1740|
D012601_D000647 CID scopolamine-induced_19\JJ\1740| (r_amod) amnesia_20\NN\5669934|of|scopolamine-induced
D012601_D000647 CID scopolamine-induced_25\JJ\1740| (r_amod) amnesia_26\NN\5669934|scopolamine-induced
1423339
D011433_D000647 CID propranolol_4\NN\1740| (r_compound) toxicity_5\NN\13576101|with|propranolol (r_nmod) associated_2\VBN\628491|toxicity (r_acl) syndrome_1\NN\5870365|amnestic|associated|:|report|.
D011433_D064420 NONE propranolol_4\NN\1740| (r_compound) toxicity_5\NN\13576101|with|propranolol
D011433_D064420 NONE propranolol_12\NN\1740| (r_compound) toxicity_13\NN\13576101|of|propranolol
D011433_D000544 NONE propranolol_12\NN\1740| (r_compound) toxicity_13\NN\13576101|of|propranolol (r_nmod) result_10\NN\34213|as|a|toxicity (r_nmod) developed_3\VBD\1753788|woman|dementia|result|. (l_dobj) dementia_7\NN\14395018|an|alzheimer-like|subacute (l_amod) alzheimer-like_5\JJ\1740|
D011433_D003704 NONE propranolol_12\NN\1740| (r_compound) toxicity_13\NN\13576101|of|propranolol (r_nmod) result_10\NN\34213|as|a|toxicity (r_nmod) developed_3\VBD\1753788|woman|dementia|result|. (l_dobj) dementia_7\NN\14395018|an|alzheimer-like|subacute
12760988
D013390_D010149 CID succinylcholine_3\NN\3800001|after (r_nmod) myalgia_1\NN\14322699|postoperative|succinylcholine|:|evidence|.
D013390_D010149 CID succinylcholine_6\NN\3800001|with (r_nmod) associated_4\VBN\628491|succinylcholine (r_acl) effect_3\NN\34213|a|common|side|associated (r_nsubj) myalgia_9\NN\14322699|effect|is|postoperative|.
D013390_D010149 CID succinylcholine_6\NN\3800001|before (r_nmod) administration_2\NN\1133281|dexamethasone|succinylcholine (r_nsubj) effective_9\JJ\1740|administration|was|not|decreasing (l_advcl) decreasing_11\VBG\169651|in|incidence (l_dobj) incidence_13\NN\13821570|the|or|severity|myalgia (l_nmod) myalgia_20\NN\14322699|of|succinylcholine-induced|postoperative
D013390_D010149 CID succinylcholine-induced_18\JJ\1740| (r_amod) myalgia_20\NN\14322699|of|succinylcholine-induced|postoperative
D013390_D010149 CID succinylcholine_11\NN\3800001|after (r_nmod) prevent_7\VB\1740|to|myalgia|succinylcholine (l_dobj) myalgia_9\NN\14322699|postoperative
D013390_D063806 CID succinylcholine-associated_5\JJ\1740| (r_amod) myalgia_6\NN\14322699|of|succinylcholine-associated
D013390_D063806 CID succinylcholine_18\NN\3800001|before (r_nmod) pretreated_12\VBN\1740|saline|succinylcholine (r_acl) patients_11\NNS\9898892|in|64|pretreated (r_nmod) determined_8\VBN\1645601|incidence|was|patients|=|. (l_nsubjpass) incidence_1\NN\13821570|the|and|severity|myalgia (l_nmod) myalgia_6\NN\14322699|of|succinylcholine-associated
D013390_D063806 CID succinylcholine-associated_12\JJ\1740| (r_amod) myalgia_13\NN\14322699|of|succinylcholine-associated
D003907_D063806 NONE dexamethasone_16\NN\2721538| (r_conj) saline_14\NN\14849367|with|or|dexamethasone (r_nmod) pretreated_12\VBN\1740|saline|succinylcholine (r_acl) patients_11\NNS\9898892|in|64|pretreated (r_nmod) determined_8\VBN\1645601|incidence|was|patients|=|. (l_nsubjpass) incidence_1\NN\13821570|the|and|severity|myalgia (l_nmod) myalgia_6\NN\14322699|of|succinylcholine-associated
D003907_D063806 NONE dexamethasone_18\NN\2721538| (r_compound) group_19\NN\2137|in|the|dexamethasone (r_nmod) patients_15\NNS\9898892|15|group (r_nsubj) complained_20\VBD\843959|patients|myalgia|patients|,|and|reported|. (r_parataxis) differ_7\VB\1740|incidence|did|not|significantly|groups|:|complained (l_nsubj) incidence_0\NN\13821570|and|severity|myalgia (l_nmod) myalgia_4\NN\14322699|of
D003907_D063806 NONE dexamethasone_18\NN\2721538| (r_compound) group_19\NN\2137|in|the|dexamethasone (r_nmod) patients_15\NNS\9898892|15|group (r_nsubj) complained_20\VBD\843959|patients|myalgia|patients|,|and|reported|. (l_nmod) myalgia_22\NN\14322699|of
D003907_D063806 NONE dexamethasone_18\NN\2721538| (r_compound) group_19\NN\2137|in|the|dexamethasone (r_nmod) patients_15\NNS\9898892|15|group (r_nsubj) complained_20\VBD\843959|patients|myalgia|patients|,|and|reported|. (l_conj) reported_36\VBN\831651|myalgia|was|patients|,|respectively|significant (l_nsubjpass) myalgia_34\NN\14322699|severe
D003907_D010149 NONE dexamethasone_4\NN\2721538|of (r_nmod) administration_2\NN\1133281|dexamethasone|succinylcholine (r_nsubj) effective_9\JJ\1740|administration|was|not|decreasing (l_advcl) decreasing_11\VBG\169651|in|incidence (l_dobj) incidence_13\NN\13821570|the|or|severity|myalgia (l_nmod) myalgia_20\NN\14322699|of|succinylcholine-induced|postoperative
D003907_D010149 NONE dexamethasone_2\NN\2721538|with (r_nmod) pretreatment_0\NN\1740|dexamethasone (r_nsubj) justified_5\JJ\1740|pretreatment|is|not|prevent|. (l_xcomp) prevent_7\VB\1740|to|myalgia|succinylcholine (l_dobj) myalgia_9\NN\14322699|postoperative
9205462
D013629_C537296 CID tamoxifen_9\NN\2714883| (r_compound) use_10\NN\407535|with|antecedent|tamoxifen (r_nmod) associated_6\VBN\628491|use (r_acl) tumor_2\NN\14234074|granulosa|cell|ovary|associated|. (l_nmod) ovary_5\NN\11675842|of|the
D013629_D009369 NONE tamoxifen_8\NN\2714883| (r_compound) use_9\NN\407535|between|tamoxifen|and|tumors (l_conj) tumors_12\NNS\14234074|gynecologic
D013629_D001943 NONE tamoxifen_9\NN\2714883|with (r_nmod) treated_7\VBN\2376958|case|woman|was|tamoxifen|carcinoma|. (l_nmod) carcinoma_16\NN\14239918|for|stage|ii|receptor-positive|breast
D004967_D001943 NONE estrogen_13\NN\14745635| (r_nmod:npmod) receptor-positive_14\JJ\1740|estrogen (r_amod) carcinoma_16\NN\14239918|for|stage|ii|receptor-positive|breast
D013629_D017093 CID tamoxifen-induced_4\JJ\1740| (r_amod) dysfunction_6\NN\14204950|with|tamoxifen-induced|liver
D013629_D017093 CID tamoxifen_20\NN\2714883| (r_compound) metabolism_21\NN\13526110|in|tamoxifen (r_nmod) alterations_18\NNS\7283608|because|metabolism (r_nmod) conclusion_0\NN\5837957|:|risk|alterations|. (l_appos) risk_11\NN\14541044|patients|may|be|at|increased|tumors (l_nsubj) patients_2\NNS\9898892|dysfunction (l_nmod) dysfunction_6\NN\14204950|with|tamoxifen-induced|liver
D013629_D006106 NONE tamoxifen-induced_4\JJ\1740| (r_amod) dysfunction_6\NN\14204950|with|tamoxifen-induced|liver (r_nmod) patients_2\NNS\9898892|dysfunction (r_nsubj) risk_11\NN\14541044|patients|may|be|at|increased|tumors (l_nmod) tumors_15\NNS\14234074|for|granulosa|cell
D013629_D006106 NONE tamoxifen_20\NN\2714883| (r_compound) metabolism_21\NN\13526110|in|tamoxifen (r_nmod) alterations_18\NNS\7283608|because|metabolism (r_nmod) conclusion_0\NN\5837957|:|risk|alterations|. (l_appos) risk_11\NN\14541044|patients|may|be|at|increased|tumors (l_nmod) tumors_15\NNS\14234074|for|granulosa|cell
3969369
D013739_D063646 NONE testosterone_3\NN\14747587|of|and|fat (r_nmod) effects_1\NNS\13245626|promotional|testosterone|carcinogenesis|. (l_nmod) carcinogenesis_9\NN\1740|on|prostate|rats
D013739_D011471 CID testosterone_6\NN\14747587|with (r_nmod) implanted_4\VBN\1421622|testosterone|age (r_acl) rats_2\NNS\2329401|conventional|lw|,|implanted|, (r_nsubj) developed_12\VBD\1753788|rats|incidence|interval|:|developed|. (l_dobj) incidence_15\NN\13821570|a|higher|cancer (l_nmod) cancer_18\NN\14239425|of|prostate
D013739_D011471 CID testosterone-treated_4\JJ\1740| (r_amod) rats_6\NNS\2329401|testosterone-treated|lw|fed (r_nsubj) developed_26\VBD\1753788|that|rats|cancer|intervals (l_dobj) cancer_28\NN\14239425|prostate
D013739_D009369 NONE testosterone_6\NN\14747587|with (r_nmod) implanted_4\VBN\1421622|testosterone|age (r_acl) rats_2\NNS\2329401|conventional|lw|,|implanted|, (r_nsubj) developed_12\VBD\1753788|rats|incidence|interval|:|developed|. (l_parataxis) developed_30\VBN\1753788|%|had|tumors|,|and|% (l_dobj) tumors_32\NNS\14234074|gross
D013739_D009369 NONE testosterone_6\NN\14747587|with (r_nmod) implanted_4\VBN\1421622|testosterone|age (r_acl) rats_2\NNS\2329401|conventional|lw|,|implanted|, (r_nsubj) developed_12\VBD\1753788|rats|incidence|interval|:|developed|. (l_parataxis) developed_30\VBN\1753788|%|had|tumors|,|and|% (l_conj) %_36\NN\1740|40|included (l_advcl) included_39\VBD\690614|when|it|tumors (l_dobj) tumors_41\NNS\14234074|microscopic
D013739_D011472 CID testosterone_9\NN\14747587|with (r_nmod) treated_7\VBN\2376958|testosterone (r_conj) fed_3\VBN\1182709|l-485|and|treated (r_acl) rats_2\NNS\2329401|conventional|sd|fed (r_nsubj) developed_10\VBD\1753788|rats|prostatitis|. (l_dobj) prostatitis_12\NN\14336539|only
8494478
D002939_D007674 NONE ciprofloxacin-induced_0\JJ\1740| (r_amod) nephrotoxicity_1\NN\1740|ciprofloxacin-induced|patients|.
D002939_D007674 NONE ciprofloxacin_3\NN\2716866|with (r_nmod) associated_1\VBN\628491|ciprofloxacin (r_acl) nephrotoxicity_0\NN\1740|associated
D002939_D009369 NONE ciprofloxacin-induced_0\JJ\1740| (r_amod) nephrotoxicity_1\NN\1740|ciprofloxacin-induced|patients|. (l_nmod) patients_3\NNS\9898892|in|cancer (l_nmod) cancer_5\NN\14239425|with
D002939_D009369 NONE ciprofloxacin_13\NN\2716866|with (r_nmod) treatment_11\NN\654885|ciprofloxacin (r_dobj) followed_10\VBD\1835496|that|treatment (r_acl:relcl) patients_1\NNS\9898892|five|cancer|developed|followed (l_nmod) cancer_3\NN\14239425|with
D002939_D058186 CID ciprofloxacin_13\NN\2716866|with (r_nmod) treatment_11\NN\654885|ciprofloxacin (r_dobj) followed_10\VBD\1835496|that|treatment (r_acl:relcl) patients_1\NNS\9898892|five|cancer|developed|followed (l_acl:relcl) developed_5\VBD\1753788|who|failure (l_dobj) failure_8\NN\66216|acute|renal
D002939_D058186 CID ciprofloxacin-induced_18\JJ\1740| (r_amod) failure_21\NN\66216|of|ciprofloxacin-induced|acute|renal
14648024
D014212_D004893 CID acid-induced_2\JJ\1740|all-|trans-retinoic (r_amod) nodosum_4\NN\1740|acid-induced|erythema|patients|.
D014212_D004893 CID acid_6\NN\14818238|with|all-|trans-retinoic|atra|leukemia (r_nmod) associated_2\VBN\628491|acid (r_acl) nodosum_1\NN\1740|erythema|associated
D014212_D004893 CID atra_8\NN\1740|(|) (r_appos) acid_6\NN\14818238|with|all-|trans-retinoic|atra|leukemia (r_nmod) associated_2\VBN\628491|acid (r_acl) nodosum_1\NN\1740|erythema|associated
D014212_D004893 CID atra_12\NN\1740| (r_compound) therapy_13\NN\657604|during|atra (r_nmod) developed_8\VBD\1753788|who|nodosum|therapy (l_dobj) nodosum_10\NN\1740|erythema
D014212_D004893 CID atra_23\NN\1740| (r_compound) therapy_24\NN\657604|after|atra (r_nmod) developed_9\VBD\1753788|fever|d11|,|therapy|. (l_nsubj) fever_0\NN\14299637|and|nodules (l_conj) nodules_6\NNS\5264913|subsequent|multiple|painful|erythematous|extremities
D014212_D004893 CID atra_0\NN\1740| (r_nsubj) seemed_1\VBD\2604760|atra|etiology|. (l_xcomp) etiology_7\NN\7326557|to|be|the|possible|nodosum (l_nmod) nodosum_10\NN\1740|of|erythema|patients
D014212_D004893 CID atra-induced_8\JJ\1740| (r_amod) nodosum_10\NN\1740|in|atra-induced|erythema
D014212_D015473 NONE acid-induced_2\JJ\1740|all-|trans-retinoic (r_amod) nodosum_4\NN\1740|acid-induced|erythema|patients|. (l_nmod) patients_6\NNS\9898892|in|leukemia (l_nmod) leukemia_10\NN\14239918|with|acute|promyelocytic
D014212_D015473 NONE acid_6\NN\14818238|with|all-|trans-retinoic|atra|leukemia (l_nmod) leukemia_13\NN\14239918|for|acute|promyelocytic|apl
D014212_D015473 NONE acid_6\NN\14818238|with|all-|trans-retinoic|atra|leukemia (l_nmod) leukemia_13\NN\14239918|for|acute|promyelocytic|apl (l_appos) apl_15\NN\1740|(|)
D014212_D015473 NONE atra_8\NN\1740|(|) (r_appos) acid_6\NN\14818238|with|all-|trans-retinoic|atra|leukemia (l_nmod) leukemia_13\NN\14239918|for|acute|promyelocytic|apl
D014212_D015473 NONE atra_8\NN\1740|(|) (r_appos) acid_6\NN\14818238|with|all-|trans-retinoic|atra|leukemia (l_nmod) leukemia_13\NN\14239918|for|acute|promyelocytic|apl (l_appos) apl_15\NN\1740|(|)
D014212_D015473 NONE atra_12\NN\1740| (r_compound) therapy_13\NN\657604|during|atra (r_nmod) developed_8\VBD\1753788|who|nodosum|therapy (r_acl:relcl) patients_3\NNS\9898892|four|apl|developed (l_nmod) apl_6\NN\1740|with|classic
D014212_D005334 CID atra_23\NN\1740| (r_compound) therapy_24\NN\657604|after|atra (r_nmod) developed_9\VBD\1753788|fever|d11|,|therapy|. (l_nsubj) fever_0\NN\14299637|and|nodules
D014212_D010146 NONE atra_23\NN\1740| (r_compound) therapy_24\NN\657604|after|atra (r_nmod) developed_9\VBD\1753788|fever|d11|,|therapy|. (l_nsubj) fever_0\NN\14299637|and|nodules (l_conj) nodules_6\NNS\5264913|subsequent|multiple|painful|erythematous|extremities (l_amod) painful_4\JJ\1740|
D013256_D004893 NONE steroid_3\NN\14727670|of (r_nmod) use_1\NN\407535|short-term|steroid (r_nsubj) effective_6\JJ\1740|use|is|very|nodosum|. (l_nmod) nodosum_10\NN\1740|in|atra-induced|erythema
12101159
D004110_D006323 CID diltiazem_5\NN\2938514| (r_compound) overdose_6\NN\1740|after|diltiazem (r_nmod) arrest_3\NN\88481|delayed|asystolic|cardiac|overdose|;|resuscitation|. (l_amod) asystolic_1\JJ\1740|
D004110_D006323 CID diltiazem_5\NN\2938514| (r_compound) overdose_6\NN\1740|after|diltiazem (r_nmod) arrest_3\NN\88481|delayed|asystolic|cardiac|overdose|;|resuscitation|.
D004110_D006323 CID diltiazem_16\NN\2938514| (r_compound) overdose_17\NN\1740|in|severe|diltiazem (r_nmod) role_6\NN\719494|a|therapy|overdose|,|onset (l_nmod) onset_22\NN\7325190|with|the|asystole (l_nmod) asystole_24\NN\14204950|of
D004110_D006323 CID diltiazem_11\NN\2938514| (r_compound) overdose_12\NN\1740|after|diltiazem (r_nmod) arrest_9\NN\88481|of|cardiac|overdose
D004110_D062787 CID diltiazem_5\NN\2938514| (r_compound) overdose_6\NN\1740|after|diltiazem
D004110_D062787 CID diltiazem_15\NN\2938514|of|,|paracetamol (r_nmod) g_13\NN\13717155|including|3.6|diltiazem (r_nmod) overdose_8\NN\1740|a|mixed|g
D004110_D062787 CID diltiazem_16\NN\2938514| (r_compound) overdose_17\NN\1740|in|severe|diltiazem
D004110_D062787 CID diltiazem_11\NN\2938514| (r_compound) overdose_12\NN\1740|after|diltiazem
D002118_D006323 NONE calcium_13\NN\14625458|with|dose|intravenous (r_nmod) resuscitation_8\NN\1047338|calcium (r_appos) arrest_3\NN\88481|delayed|asystolic|cardiac|overdose|;|resuscitation|. (l_amod) asystolic_1\JJ\1740|
D002118_D006323 NONE calcium_13\NN\14625458|with|dose|intravenous (r_nmod) resuscitation_8\NN\1047338|calcium (r_appos) arrest_3\NN\88481|delayed|asystolic|cardiac|overdose|;|resuscitation|.
D002118_D006323 NONE calcium_12\NN\14625458| (r_compound) therapy_13\NN\657604|for|aggressive|dose|intravenous|calcium (r_nmod) role_6\NN\719494|a|therapy|overdose|,|onset (l_nmod) onset_22\NN\7325190|with|the|asystole (l_nmod) asystole_24\NN\14204950|of
D002118_D062787 NONE calcium_13\NN\14625458|with|dose|intravenous (r_nmod) resuscitation_8\NN\1047338|calcium (r_appos) arrest_3\NN\88481|delayed|asystolic|cardiac|overdose|;|resuscitation|. (l_nmod) overdose_6\NN\1740|after|diltiazem
D002118_D062787 NONE calcium_12\NN\14625458| (r_compound) therapy_13\NN\657604|for|aggressive|dose|intravenous|calcium (r_nmod) role_6\NN\719494|a|therapy|overdose|,|onset (l_nmod) overdose_17\NN\1740|in|severe|diltiazem
D000082_D062787 NONE paracetamol_17\NN\1740|,|aspirin (r_conj) diltiazem_15\NN\2938514|of|,|paracetamol (r_nmod) g_13\NN\13717155|including|3.6|diltiazem (r_nmod) overdose_8\NN\1740|a|mixed|g
D001241_D062787 NONE aspirin_19\NN\2707683|,|nitrate (r_conj) paracetamol_17\NN\1740|,|aspirin (r_conj) diltiazem_15\NN\2938514|of|,|paracetamol (r_nmod) g_13\NN\13717155|including|3.6|diltiazem (r_nmod) overdose_8\NN\1740|a|mixed|g
D007547_D062787 NONE isosorbide_21\NN\3740161| (r_compound) nitrate_22\NN\14818238|isosorbide|,|and|alcohol (r_conj) aspirin_19\NN\2707683|,|nitrate (r_conj) paracetamol_17\NN\1740|,|aspirin (r_conj) diltiazem_15\NN\2938514|of|,|paracetamol (r_nmod) g_13\NN\13717155|including|3.6|diltiazem (r_nmod) overdose_8\NN\1740|a|mixed|g
D009566_D062787 NONE nitrate_22\NN\14818238|isosorbide|,|and|alcohol (r_conj) aspirin_19\NN\2707683|,|nitrate (r_conj) paracetamol_17\NN\1740|,|aspirin (r_conj) diltiazem_15\NN\2938514|of|,|paracetamol (r_nmod) g_13\NN\13717155|including|3.6|diltiazem (r_nmod) overdose_8\NN\1740|a|mixed|g
D000431_D062787 NONE alcohol_25\NN\7881800| (r_conj) nitrate_22\NN\14818238|isosorbide|,|and|alcohol (r_conj) aspirin_19\NN\2707683|,|nitrate (r_conj) paracetamol_17\NN\1740|,|aspirin (r_conj) diltiazem_15\NN\2938514|of|,|paracetamol (r_nmod) g_13\NN\13717155|including|3.6|diltiazem (r_nmod) overdose_8\NN\1740|a|mixed|g
20164825
D008687_D007674 NONE metformin_0\NN\2719105| (r_nsubj) prevents_1\VBZ\1740|metformin|nephropathy|pathway|. (l_dobj) nephropathy_4\NN\14573196|experimental|gentamicin-induced
D008687_D007674 NONE metformin_11\NN\2719105|by (r_nmod) correction_9\NN\248977|their|metformin (r_conj) markers_3\NNS\21939|these|in|dysfunction|and|correction (l_nmod) dysfunction_6\NN\14204950|of|kidney
D008687_D007674 NONE metformin_9\NN\2719105|of (r_nmod) effects_7\NNS\13245626|pleiotropic|metformin (r_nsubj) lessen_11\VB\169651|that|effects|can|nephrotoxicity|and|improve (l_dobj) nephrotoxicity_13\NN\1740|gentamicin
D005839_D007674 NONE gentamicin-induced_3\JJ\1740| (r_amod) nephropathy_4\NN\14573196|experimental|gentamicin-induced
D005839_D007674 NONE gentamicin_12\NN\2716866| (r_compound) nephrotoxicity_13\NN\1740|gentamicin
D008687_D014652 NONE metformin_3\NN\2719105|drug (r_nsubj) diminish_5\VB\169651|metformin|can|apoptosis|and|prevent|. (l_conj) prevent_15\VB\1740|dysfunction|patients (l_dobj) dysfunction_17\NN\14204950|vascular
D005839_D064420 NONE gentamicin_14\NN\2716866| (r_compound) toxicity_15\NN\13576101|of|gentamicin
D008687_D058186 NONE metformin_0\NN\2719105| (r_compound) treatment_1\NN\654885|metformin (r_nsubj) blocked_3\VBD\1476483|treatment|fully|failure|. (l_dobj) failure_7\NN\66216|gentamicin-mediated|acute|renal
D005839_D058186 CID gentamicin-mediated_4\JJ\1740| (r_amod) failure_7\NN\66216|gentamicin-mediated|acute|renal
12139551
D008787_D006323 CID metoclopramide_4\NN\1740|after|intravenous (r_nmod) arrest_1\NN\88481|cardiac|metoclopramide|-|case
D008787_D006323 CID metoclopramide_4\NN\1740|after|intravenous (r_nmod) arrest_1\NN\88481|cardiac|metoclopramide|-|case (l_appos) case_7\NN\7283608|a|injections|. (l_nmod) injections_11\NNS\320852|of|five|repeated|metoclopramide|causing (l_acl) causing_14\VBG\1617192|episodes (l_dobj) episodes_16\NNS\7283608|five|arrest (l_nmod) arrest_19\NN\88481|of|cardiac
D008787_D006323 CID metoclopramide_13\NN\1740|of (r_nmod) injections_11\NNS\320852|of|five|repeated|metoclopramide|causing (r_nmod) case_7\NN\7283608|a|injections|. (r_appos) arrest_1\NN\88481|cardiac|metoclopramide|-|case
D008787_D006323 CID metoclopramide_13\NN\1740|of (r_nmod) injections_11\NNS\320852|of|five|repeated|metoclopramide|causing (l_acl) causing_14\VBG\1617192|episodes (l_dobj) episodes_16\NNS\7283608|five|arrest (l_nmod) arrest_19\NN\88481|of|cardiac
D008787_D006323 CID metoclopramide_8\NN\1740|of (r_nmod) injection_6\NN\320852|intravenous|metoclopramide (r_nsubjpass) followed_11\VBN\1835496|where|injection|was|immediately|asystole|repeatedly (l_nmod) asystole_13\NN\14204950|by
D008787_D006323 CID metoclopramide_18\NN\1740|of (r_nmod) administration_16\NN\1133281|every|metoclopramide|s|) (r_nsubjpass) followed_25\VBN\1835496|that|administration|asystole (l_nmod) asystole_27\NN\14204950|by
D008787_D006323 CID metoclopramide_10\NN\1740|by (r_nmod) caused_8\VBN\1617192|metoclopramide (r_acl) arrest_7\NN\88481|of|cardiac|caused
14742097
D004809_D020018 NONE ephedrine_8\NN\14712692|of (r_nmod) study_6\NN\635850|a|randomized|,|placebo-controlled|,|crossover|ephedrine|dysfunction|. (l_nmod) dysfunction_13\NN\14204950|for|ssri-induced|female|sexual
D004809_D020018 NONE ephedrine_9\NN\14712692|,|agonist|, (r_nsubj) has_26\VBZ\2108377|whether|ephedrine|effects|reversing (l_advcl) reversing_30\VBG\109660|in|dysfunction (l_dobj) dysfunction_33\NN\14204950|antidepressant-induced|sexual
D004809_D020018 NONE ephedrine_27\NN\14712692|of|mg (r_nmod) effects_25\NNS\13245626|of|the|ephedrine|measures (r_nmod) study_22\NN\635850|in|an|eight-week|,|double-blind|,|placebo-controlled|,|cross-over|effects (r_nmod) participated_12\VBD\2367363|women|study|. (l_nsubj) women_3\NNS\9605289|nineteen|dysfunctional|receiving (l_amod) dysfunctional_2\JJ\1740|sexually
D005473_D020018 CID fluoxetine_6\NN\4169152|either|,|sertraline|,|or|paroxetine (r_dobj) receiving_4\VBG\2210855|fluoxetine (r_acl) women_3\NNS\9605289|nineteen|dysfunctional|receiving (l_amod) dysfunctional_2\JJ\1740|sexually
D020280_D020018 CID sertraline_8\NN\4169152| (r_conj) fluoxetine_6\NN\4169152|either|,|sertraline|,|or|paroxetine (r_dobj) receiving_4\VBG\2210855|fluoxetine (r_acl) women_3\NNS\9605289|nineteen|dysfunctional|receiving (l_amod) dysfunctional_2\JJ\1740|sexually
D017374_D020018 CID paroxetine_11\NN\1740| (r_conj) fluoxetine_6\NN\4169152|either|,|sertraline|,|or|paroxetine (r_dobj) receiving_4\VBG\2210855|fluoxetine (r_acl) women_3\NNS\9605289|nineteen|dysfunctional|receiving (l_amod) dysfunctional_2\JJ\1740|sexually
20103708
D013311_D003928 CID streptozotocin-induced_6\JJ\1740| (r_amod) nephropathy_8\NN\14573196|in|streptozotocin-induced|diabetic
D013311_D003928 CID streptozotocin-induced_26\JJ\1740| (r_amod) model_29\NN\5888929|a|streptozotocin-induced|nephropathy|mice|,|and|cells (r_conj) tissues_19\NNS\5220461|human|kidney|biopsy|patients|,|model (r_dobj) using_15\VBG\1156834|tissues (r_xcomp) explore_6\VBP\789138|:|we|role|using|. (l_dobj) role_9\NN\719494|the|protective|nrf2|nephropathy (l_nmod) nephropathy_14\NN\14573196|against|diabetic
D013311_D003928 CID streptozotocin-induced_26\JJ\1740| (r_amod) model_29\NN\5888929|a|streptozotocin-induced|nephropathy|mice|,|and|cells (r_conj) tissues_19\NNS\5220461|human|kidney|biopsy|patients|,|model (l_nmod) patients_23\NNS\9898892|from|diabetic|nephropathy (l_compound) nephropathy_22\NN\14573196|
D013311_D003928 CID streptozotocin-induced_26\JJ\1740| (r_amod) model_29\NN\5888929|a|streptozotocin-induced|nephropathy|mice|,|and|cells (l_compound) nephropathy_28\NN\14573196|diabetic
D010100_D003928 NONE oxygen_22\NN\14622893| (r_compound) species_23\NNS\7992450|of|reactive|oxygen|ros (r_nmod) production_19\NN\30358|by|the|species (r_nmod) accompanied_16\VBN\1835496|which|is|production (r_acl:relcl) causes_9\NNS\7323922|of|the|major|failure|,|accompanied (r_nmod) one_5\CD\13741022|objective|:|nephropathy|is|causes|. (l_nsubj) nephropathy_3\NN\14573196|diabetic
D010100_D051437 NONE oxygen_22\NN\14622893| (r_compound) species_23\NNS\7992450|of|reactive|oxygen|ros (r_nmod) production_19\NN\30358|by|the|species (r_nmod) accompanied_16\VBN\1835496|which|is|production (r_acl:relcl) causes_9\NNS\7323922|of|the|major|failure|,|accompanied (l_nmod) failure_12\NN\66216|of|renal
D013311_D058186 NONE streptozotocin-induced_13\JJ\1740| (r_amod) damage_15\NN\7296428|streptozotocin-induced|renal
6308526
C024224_D000699 NONE naloxazone_2\NN\1740|with (r_nmod) pretreatment_0\NN\1740|naloxazone (r_nsubj) blocked_4\VBD\1476483|pretreatment|significantly|analgesia|dose|. (l_dobj) analgesia_6\NN\14034177|morphine|,|catalepsy|and|hypothermia
C024224_D002375 NONE naloxazone_2\NN\1740|with (r_nmod) pretreatment_0\NN\1740|naloxazone (r_nsubj) blocked_4\VBD\1476483|pretreatment|significantly|analgesia|dose|. (l_dobj) analgesia_6\NN\14034177|morphine|,|catalepsy|and|hypothermia (l_conj) catalepsy_8\NN\14023236|
C024224_D007035 NONE naloxazone_2\NN\1740|with (r_nmod) pretreatment_0\NN\1740|naloxazone (r_nsubj) blocked_4\VBD\1476483|pretreatment|significantly|analgesia|dose|. (l_dobj) analgesia_6\NN\14034177|morphine|,|catalepsy|and|hypothermia (l_conj) hypothermia_10\NN\14034177|
D009020_D000699 NONE morphine_5\NN\2707683| (r_compound) analgesia_6\NN\14034177|morphine|,|catalepsy|and|hypothermia
D009020_D002375 CID morphine_5\NN\2707683| (r_compound) analgesia_6\NN\14034177|morphine|,|catalepsy|and|hypothermia (l_conj) catalepsy_8\NN\14023236|
D009020_D007035 CID morphine_5\NN\2707683| (r_compound) analgesia_6\NN\14034177|morphine|,|catalepsy|and|hypothermia (l_conj) hypothermia_10\NN\14034177|
C024224_D007022 NONE naloxazone_2\NN\1740| (r_nsubj) attenuated_4\VBD\224901|moreover|,|naloxazone|significantly|hypotension|,|whereas|affected (l_dobj) hypotension_7\NN\14057371|the|morphine-induced|and|depression
C024224_D012131 NONE naloxazone_2\NN\1740| (r_nsubj) attenuated_4\VBD\224901|moreover|,|naloxazone|significantly|hypotension|,|whereas|affected (l_dobj) hypotension_7\NN\14057371|the|morphine-induced|and|depression (l_conj) depression_10\NN\14373582|respiratory
C024224_D001919 NONE naloxazone_2\NN\1740| (r_nsubj) attenuated_4\VBD\224901|moreover|,|naloxazone|significantly|hypotension|,|whereas|affected (l_parataxis) affected_17\VBN\126264|bradycardia|was|less|. (l_nsubjpass) bradycardia_14\NN\14110674|morphine-induced
D009020_D007022 CID morphine-induced_6\JJ\1740| (r_amod) hypotension_7\NN\14057371|the|morphine-induced|and|depression
D009020_D007022 CID morphine-induced_13\JJ\1740| (r_amod) bradycardia_14\NN\14110674|morphine-induced (r_nsubjpass) affected_17\VBN\126264|bradycardia|was|less|. (r_parataxis) attenuated_4\VBD\224901|moreover|,|naloxazone|significantly|hypotension|,|whereas|affected (l_dobj) hypotension_7\NN\14057371|the|morphine-induced|and|depression
D009020_D012131 NONE morphine-induced_6\JJ\1740| (r_amod) hypotension_7\NN\14057371|the|morphine-induced|and|depression (l_conj) depression_10\NN\14373582|respiratory
D009020_D012131 NONE morphine-induced_13\JJ\1740| (r_amod) bradycardia_14\NN\14110674|morphine-induced (r_nsubjpass) affected_17\VBN\126264|bradycardia|was|less|. (r_parataxis) attenuated_4\VBD\224901|moreover|,|naloxazone|significantly|hypotension|,|whereas|affected (l_dobj) hypotension_7\NN\14057371|the|morphine-induced|and|depression (l_conj) depression_10\NN\14373582|respiratory
D009020_D001919 CID morphine-induced_6\JJ\1740| (r_amod) hypotension_7\NN\14057371|the|morphine-induced|and|depression (r_dobj) attenuated_4\VBD\224901|moreover|,|naloxazone|significantly|hypotension|,|whereas|affected (l_parataxis) affected_17\VBN\126264|bradycardia|was|less|. (l_nsubjpass) bradycardia_14\NN\14110674|morphine-induced
D009020_D001919 CID morphine-induced_13\JJ\1740| (r_amod) bradycardia_14\NN\14110674|morphine-induced
8475949
D010419_D017180 NONE pentamidine_3\NN\1740|and|tachycardia (l_conj) tachycardia_7\NN\14110674|polymorphic|ventricular
D010419_D017180 NONE isethionate_1\NN\1740|pentamidine (r_nsubjpass) associated_4\VBN\628491|isethionate|has|been|tachyarrhythmias|. (l_nmod) tachyarrhythmias_7\NNS\1740|with|ventricular|,|pointes
D010419_D016171 CID isethionate_1\NN\1740|pentamidine (r_nsubjpass) associated_4\VBN\628491|isethionate|has|been|tachyarrhythmias|. (l_nmod) tachyarrhythmias_7\NNS\1740|with|ventricular|,|pointes (l_nmod) pointes_12\NNS\1740|including|torsade|de
D010419_D016171 CID pentamidine-induced_0\JJ\1740| (r_amod) pointes_3\NNS\1740|pentamidine-induced|torsade|de
D010419_D016171 CID pentamidine_13\NN\1740|with (r_nmod) treatment_11\NN\654885|of|pentamidine (r_nmod) days_9\NNS\15140892|of|10|treatment (r_nmod) average_6\NN\6021499|after|an|days (r_nmod) occurred_3\VBD\2623529|pointes|average|. (l_nsubj) pointes_2\NNS\1740|torsade|de
D010419_D016171 CID pentamidine_14\NN\1740|of (r_nmod) discontinuation_12\NN\209943|without|pentamidine (r_nmod) recognized_7\VBN\686447|when|early|,|discontinuation (r_advcl) treated_5\VBN\2376958|pointes|can|be|recognized|. (l_nsubjpass) pointes_2\NNS\1740|torsade|de
D010419_C537153 NONE pentamidine-induced_0\JJ\1740| (r_amod) pointes_3\NNS\1740|pentamidine-induced|torsade|de (r_nsubj) related_6\JJ\1740|pointes|may|be|levels|and|induce (l_conj) induce_15\VB\1627355|hypomagnesemia|may|synergistically|torsade|. (l_nsubj) hypomagnesemia_12\NN\1740|
D008274_D016171 NONE magnesium_9\NN\14625458| (r_compound) levels_10\NNS\4916342|to|serum|magnesium (r_nmod) related_6\JJ\1740|pointes|may|be|levels|and|induce (l_nsubj) pointes_3\NNS\1740|pentamidine-induced|torsade|de
D008274_C537153 NONE magnesium_9\NN\14625458| (r_compound) levels_10\NNS\4916342|to|serum|magnesium (r_nmod) related_6\JJ\1740|pointes|may|be|levels|and|induce (l_conj) induce_15\VB\1627355|hypomagnesemia|may|synergistically|torsade|. (l_nsubj) hypomagnesemia_12\NN\1740|
D008274_D008133 NONE magnesium_8\NN\14625458| (r_compound) supplementation_9\NN\5108947|early|magnesium (r_nsubjpass) advocated_11\VBN\875394|observed|,|supplementation|is|. (l_advcl) observed_5\VBN\2163746|when|prolongation|is (l_nsubjpass) prolongation_3\NN\1017987|interval
8410199
D018698_D012640 NONE glutamate_2\NN\15010703| (r_nmod:npmod) mrna-containing_4\JJ\1740|glutamate|decarboxylase (r_amod) neurons_5\NNS\5430628|of|mrna-containing|gyrus (r_nmod) loss_0\NN\13252973|neurons|seizures|. (l_nmod) seizures_13\NNS\14081375|following|pilocarpine-induced
D018698_D012640 NONE acid_10\NN\14818238| (r_compound) neurons_16\NNS\5430628|glutamic|acid|decarboxylase|(|gad|)|mrna-containing|hilus (r_nsubj) vulnerable_25\JJ\1740|if|neurons|are|damage|model (l_nmod) damage_28\NN\7296428|to|seizure-induced (l_amod) seizure-induced_27\JJ\1740|
D018698_D012640 NONE acid_10\NN\14818238| (r_compound) neurons_16\NNS\5430628|glutamic|acid|decarboxylase|(|gad|)|mrna-containing|hilus (r_nsubj) vulnerable_25\JJ\1740|if|neurons|are|damage|model (l_nmod) model_31\NN\5888929|in|a|seizures (l_nmod) seizures_34\NNS\14081375|of|chronic
D010862_D012640 CID pilocarpine-induced_12\JJ\1740| (r_amod) seizures_13\NNS\14081375|following|pilocarpine-induced
D010862_D012640 CID pilocarpine_6\NN\14712692|with (r_nmod) injected_3\VBN\81072|rats|were|intraperitoneally|pilocarpine|,|and|studied (l_conj) studied_13\VBN\630380|formation|was|histologically|intervals|seizures|. (l_nmod) seizures_28\NNS\14081375|after|pilocarpine-induced
D010862_D012640 CID pilocarpine-induced_27\JJ\1740| (r_amod) seizures_28\NNS\14081375|after|pilocarpine-induced
C028911_D009410 NONE violet_6\JJ\1740| (r_amod) staining_7\NN\275424|including|cresyl|violet|,|methods|,|and|localization (l_conj) methods_11\NNS\5616786|neuronal|degeneration (l_compound) degeneration_10\NN\29677|
C028911_D009410 NONE violet_6\JJ\1740| (r_amod) staining_7\NN\275424|including|cresyl|violet|,|methods|,|and|localization (r_nmod) studies_2\NNS\635850|additional|neuronanatomical|,|staining|, (r_nsubj) suggested_22\VBD\1010118|studies|related|. (l_ccomp) related_34\JJ\1740|that|decrease|was|loss (l_nmod) loss_37\NN\13252973|to|neuronal|rather|decrease
9041081
D013256_D009798 NONE steroid-induced_11\JJ\1740| (r_amod) pressure_14\NN\11419404|steroid-induced|elevated|intraocular|iop|resolved
D013256_D009798 NONE steroid-induced_2\JJ\1740| (r_amod) rise_4\NN\7324673|the|transient|steroid-induced|iop
D000305_D009798 CID corticosteroid_21\NN\14745635| (r_compound) therapy_22\NN\657604|corticosteroid (r_nsubjpass) discontinued_24\VBN\2609764|after|therapy|was (r_advcl) resolved_19\VBD\352826|that|discontinued (r_acl:relcl) pressure_14\NN\11419404|steroid-induced|elevated|intraocular|iop|resolved
6817363
C036466_D007859 NONE aniracetam_5\NN\1740|ro (r_appos) compound_4\NN\5869584|of|the|novel|aniracetam (r_nmod) effects_0\NNS\13245626|compound|learning|. (l_nmod) learning_14\NN\5701944|upon|impaired|and|memory|rodents (l_conj) memory_16\NN\5926676|
C036466_D007859 NONE 5057_10\CD\1740| (r_nummod) ro_7\NN\6894544|(|13|-|5057|) (r_appos) aniracetam_5\NN\1740|ro (r_appos) compound_4\NN\5869584|of|the|novel|aniracetam (r_nmod) effects_0\NNS\13245626|compound|learning|. (l_nmod) learning_14\NN\5701944|upon|impaired|and|memory|rodents (l_conj) memory_16\NN\5926676|
C036466_D008569 NONE aniracetam_5\NN\1740|ro (r_appos) compound_4\NN\5869584|of|the|novel|aniracetam (r_nmod) effects_0\NNS\13245626|compound|learning|. (l_nmod) learning_14\NN\5701944|upon|impaired|and|memory|rodents (l_conj) memory_16\NN\5926676|
C036466_D008569 NONE 5057_10\CD\1740| (r_nummod) ro_7\NN\6894544|(|13|-|5057|) (r_appos) aniracetam_5\NN\1740|ro (r_appos) compound_4\NN\5869584|of|the|novel|aniracetam (r_nmod) effects_0\NNS\13245626|compound|learning|. (l_nmod) learning_14\NN\5701944|upon|impaired|and|memory|rodents (l_conj) memory_16\NN\5926676|
C036466_D003072 NONE aniracetam_3\NN\1740|of (r_nmod) effect_1\NN\34213|the|aniracetam (r_nsubjpass) studied_13\VBN\630380|effect|(|ro|was|forms|and|produced|. (l_nmod) forms_16\NNS\6286395|on|various|functions (l_nmod) functions_21\NNS\13783581|of|impaired|cognitive|learning|rodents
C036466_D003072 NONE 5057_8\NN\1740| (r_appos) ro_5\NN\6894544|-|5057|,|1-anisoyl-2-pyrrolidinone|) (r_nsubjpass) studied_13\VBN\630380|effect|(|ro|was|forms|and|produced|. (l_nmod) forms_16\NNS\6286395|on|various|functions (l_nmod) functions_21\NNS\13783581|of|impaired|cognitive|learning|rodents
C036466_D003072 NONE 1-anisoyl-2-pyrrolidinone_10\NN\1740| (r_appos) ro_5\NN\6894544|-|5057|,|1-anisoyl-2-pyrrolidinone|) (r_nsubjpass) studied_13\VBN\630380|effect|(|ro|was|forms|and|produced|. (l_nmod) forms_16\NNS\6286395|on|various|functions (l_nmod) functions_21\NNS\13783581|of|impaired|cognitive|learning|rodents
C036466_D003072 NONE aniracetam_12\NN\1740| (r_compound) doses_13\NNS\3740161|at|oral|aniracetam|mg/kg (r_nmod) seen_9\VBN\2106506|improvements|were|doses|. (l_nsubjpass) improvements_1\NNS\7359599|these|or|normalizations|functions (l_nmod) functions_7\NNS\13783581|of|impaired|cognitive
C036466_D006935 NONE aniracetam_3\NN\1740|of (r_nmod) effect_1\NN\34213|the|aniracetam (r_nsubjpass) studied_13\VBN\630380|effect|(|ro|was|forms|and|produced|. (l_conj) produced_30\VBD\1617192|effects (l_dobj) effects_33\NNS\13245626|the|following|:|prevention (l_dep) prevention_40\NN\1073995|1|complete|incapacity|;|prevention|protection|prevention (l_nmod) incapacity_43\NN\5644922|of|the|learn (l_acl) learn_45\VB\607114|to|response|rats (l_nmod) rats_51\NNS\2329401|in|exposed (l_acl) exposed_52\VBN\2110927|hypercapnia|session (l_nmod) hypercapnia_55\NN\14034177|to|sublethal
C036466_D006935 NONE aniracetam_3\NN\1740|of (r_nmod) effect_1\NN\34213|the|aniracetam (r_nsubjpass) studied_13\VBN\630380|effect|(|ro|was|forms|and|produced|. (l_conj) produced_30\VBD\1617192|effects (l_dobj) effects_33\NNS\13245626|the|following|:|prevention (l_dep) prevention_40\NN\1073995|1|complete|incapacity|;|prevention|protection|prevention (l_dep) prevention_178\NN\1073995|6|deficit|electroshock (l_nmod) electroshock_195\NN\662681|by|subconvulsant|or|hypercapnia|applied|h (l_conj) hypercapnia_197\NN\14034177|
C036466_D006935 NONE 5057_8\NN\1740| (r_appos) ro_5\NN\6894544|-|5057|,|1-anisoyl-2-pyrrolidinone|) (r_nsubjpass) studied_13\VBN\630380|effect|(|ro|was|forms|and|produced|. (l_conj) produced_30\VBD\1617192|effects (l_dobj) effects_33\NNS\13245626|the|following|:|prevention (l_dep) prevention_40\NN\1073995|1|complete|incapacity|;|prevention|protection|prevention (l_nmod) incapacity_43\NN\5644922|of|the|learn (l_acl) learn_45\VB\607114|to|response|rats (l_nmod) rats_51\NNS\2329401|in|exposed (l_acl) exposed_52\VBN\2110927|hypercapnia|session (l_nmod) hypercapnia_55\NN\14034177|to|sublethal
C036466_D006935 NONE 5057_8\NN\1740| (r_appos) ro_5\NN\6894544|-|5057|,|1-anisoyl-2-pyrrolidinone|) (r_nsubjpass) studied_13\VBN\630380|effect|(|ro|was|forms|and|produced|. (l_conj) produced_30\VBD\1617192|effects (l_dobj) effects_33\NNS\13245626|the|following|:|prevention (l_dep) prevention_40\NN\1073995|1|complete|incapacity|;|prevention|protection|prevention (l_dep) prevention_178\NN\1073995|6|deficit|electroshock (l_nmod) electroshock_195\NN\662681|by|subconvulsant|or|hypercapnia|applied|h (l_conj) hypercapnia_197\NN\14034177|
C036466_D006935 NONE 1-anisoyl-2-pyrrolidinone_10\NN\1740| (r_appos) ro_5\NN\6894544|-|5057|,|1-anisoyl-2-pyrrolidinone|) (r_nsubjpass) studied_13\VBN\630380|effect|(|ro|was|forms|and|produced|. (l_conj) produced_30\VBD\1617192|effects (l_dobj) effects_33\NNS\13245626|the|following|:|prevention (l_dep) prevention_40\NN\1073995|1|complete|incapacity|;|prevention|protection|prevention (l_nmod) incapacity_43\NN\5644922|of|the|learn (l_acl) learn_45\VB\607114|to|response|rats (l_nmod) rats_51\NNS\2329401|in|exposed (l_acl) exposed_52\VBN\2110927|hypercapnia|session (l_nmod) hypercapnia_55\NN\14034177|to|sublethal
C036466_D006935 NONE 1-anisoyl-2-pyrrolidinone_10\NN\1740| (r_appos) ro_5\NN\6894544|-|5057|,|1-anisoyl-2-pyrrolidinone|) (r_nsubjpass) studied_13\VBN\630380|effect|(|ro|was|forms|and|produced|. (l_conj) produced_30\VBD\1617192|effects (l_dobj) effects_33\NNS\13245626|the|following|:|prevention (l_dep) prevention_40\NN\1073995|1|complete|incapacity|;|prevention|protection|prevention (l_dep) prevention_178\NN\1073995|6|deficit|electroshock (l_nmod) electroshock_195\NN\662681|by|subconvulsant|or|hypercapnia|applied|h (l_conj) hypercapnia_197\NN\14034177|
C036466_D000647 NONE aniracetam_3\NN\1740|of (r_nmod) effect_1\NN\34213|the|aniracetam (r_nsubjpass) studied_13\VBN\630380|effect|(|ro|was|forms|and|produced|. (l_conj) produced_30\VBD\1617192|effects (l_dobj) effects_33\NNS\13245626|the|following|:|prevention (l_dep) prevention_40\NN\1073995|1|complete|incapacity|;|prevention|protection|prevention (l_conj) prevention_74\NN\1073995|2|partial|amnesia|; (l_nmod) amnesia_79\NN\5669934|of|the|scopolamine-induced|short-term|task
C036466_D000647 NONE aniracetam_3\NN\1740|of (r_nmod) effect_1\NN\34213|the|aniracetam (r_nsubjpass) studied_13\VBN\630380|effect|(|ro|was|forms|and|produced|. (l_conj) produced_30\VBD\1617192|effects (l_dobj) effects_33\NNS\13245626|the|following|:|prevention (l_dep) prevention_40\NN\1073995|1|complete|incapacity|;|prevention|protection|prevention (l_dep) protection_90\NN\407535|3|complete|amnesia|;|prevention (l_nmod) amnesia_92\NN\5669934|against|task
C036466_D000647 NONE 5057_8\NN\1740| (r_appos) ro_5\NN\6894544|-|5057|,|1-anisoyl-2-pyrrolidinone|) (r_nsubjpass) studied_13\VBN\630380|effect|(|ro|was|forms|and|produced|. (l_conj) produced_30\VBD\1617192|effects (l_dobj) effects_33\NNS\13245626|the|following|:|prevention (l_dep) prevention_40\NN\1073995|1|complete|incapacity|;|prevention|protection|prevention (l_conj) prevention_74\NN\1073995|2|partial|amnesia|; (l_nmod) amnesia_79\NN\5669934|of|the|scopolamine-induced|short-term|task
C036466_D000647 NONE 5057_8\NN\1740| (r_appos) ro_5\NN\6894544|-|5057|,|1-anisoyl-2-pyrrolidinone|) (r_nsubjpass) studied_13\VBN\630380|effect|(|ro|was|forms|and|produced|. (l_conj) produced_30\VBD\1617192|effects (l_dobj) effects_33\NNS\13245626|the|following|:|prevention (l_dep) prevention_40\NN\1073995|1|complete|incapacity|;|prevention|protection|prevention (l_dep) protection_90\NN\407535|3|complete|amnesia|;|prevention (l_nmod) amnesia_92\NN\5669934|against|task
C036466_D000647 NONE 1-anisoyl-2-pyrrolidinone_10\NN\1740| (r_appos) ro_5\NN\6894544|-|5057|,|1-anisoyl-2-pyrrolidinone|) (r_nsubjpass) studied_13\VBN\630380|effect|(|ro|was|forms|and|produced|. (l_conj) produced_30\VBD\1617192|effects (l_dobj) effects_33\NNS\13245626|the|following|:|prevention (l_dep) prevention_40\NN\1073995|1|complete|incapacity|;|prevention|protection|prevention (l_conj) prevention_74\NN\1073995|2|partial|amnesia|; (l_nmod) amnesia_79\NN\5669934|of|the|scopolamine-induced|short-term|task
C036466_D000647 NONE 1-anisoyl-2-pyrrolidinone_10\NN\1740| (r_appos) ro_5\NN\6894544|-|5057|,|1-anisoyl-2-pyrrolidinone|) (r_nsubjpass) studied_13\VBN\630380|effect|(|ro|was|forms|and|produced|. (l_conj) produced_30\VBD\1617192|effects (l_dobj) effects_33\NNS\13245626|the|following|:|prevention (l_dep) prevention_40\NN\1073995|1|complete|incapacity|;|prevention|protection|prevention (l_dep) protection_90\NN\407535|3|complete|amnesia|;|prevention (l_nmod) amnesia_92\NN\5669934|against|task
D012601_D003072 NONE scopolamine-induced_77\JJ\1740| (r_amod) amnesia_79\NN\5669934|of|the|scopolamine-induced|short-term|task (r_nmod) prevention_74\NN\1073995|2|partial|amnesia|; (r_conj) prevention_40\NN\1073995|1|complete|incapacity|;|prevention|protection|prevention (r_dep) effects_33\NNS\13245626|the|following|:|prevention (r_dobj) produced_30\VBD\1617192|effects (r_conj) studied_13\VBN\630380|effect|(|ro|was|forms|and|produced|. (l_nmod) forms_16\NNS\6286395|on|various|functions (l_nmod) functions_21\NNS\13783581|of|impaired|cognitive|learning|rodents
D012601_D006935 NONE scopolamine-induced_77\JJ\1740| (r_amod) amnesia_79\NN\5669934|of|the|scopolamine-induced|short-term|task (r_nmod) prevention_74\NN\1073995|2|partial|amnesia|; (r_conj) prevention_40\NN\1073995|1|complete|incapacity|;|prevention|protection|prevention (l_nmod) incapacity_43\NN\5644922|of|the|learn (l_acl) learn_45\VB\607114|to|response|rats (l_nmod) rats_51\NNS\2329401|in|exposed (l_acl) exposed_52\VBN\2110927|hypercapnia|session (l_nmod) hypercapnia_55\NN\14034177|to|sublethal
D012601_D006935 NONE scopolamine-induced_77\JJ\1740| (r_amod) amnesia_79\NN\5669934|of|the|scopolamine-induced|short-term|task (r_nmod) prevention_74\NN\1073995|2|partial|amnesia|; (r_conj) prevention_40\NN\1073995|1|complete|incapacity|;|prevention|protection|prevention (l_dep) prevention_178\NN\1073995|6|deficit|electroshock (l_nmod) electroshock_195\NN\662681|by|subconvulsant|or|hypercapnia|applied|h (l_conj) hypercapnia_197\NN\14034177|
D012601_D000647 CID scopolamine-induced_77\JJ\1740| (r_amod) amnesia_79\NN\5669934|of|the|scopolamine-induced|short-term|task
D012601_D000647 CID scopolamine-induced_77\JJ\1740| (r_amod) amnesia_79\NN\5669934|of|the|scopolamine-induced|short-term|task (r_nmod) prevention_74\NN\1073995|2|partial|amnesia|; (r_conj) prevention_40\NN\1073995|1|complete|incapacity|;|prevention|protection|prevention (l_dep) protection_90\NN\407535|3|complete|amnesia|;|prevention (l_nmod) amnesia_92\NN\5669934|against|task
D002701_D003072 NONE chloramphenicol_130\NN\2716866|by|or|cycloheximide|administered|; (r_nmod) prevention_112\NN\1073995|4|retention-|task|chloramphenicol|reversal (r_conj) protection_90\NN\407535|3|complete|amnesia|;|prevention (r_dep) prevention_40\NN\1073995|1|complete|incapacity|;|prevention|protection|prevention (r_dep) effects_33\NNS\13245626|the|following|:|prevention (r_dobj) produced_30\VBD\1617192|effects (r_conj) studied_13\VBN\630380|effect|(|ro|was|forms|and|produced|. (l_nmod) forms_16\NNS\6286395|on|various|functions (l_nmod) functions_21\NNS\13783581|of|impaired|cognitive|learning|rodents
D002701_D006935 NONE chloramphenicol_130\NN\2716866|by|or|cycloheximide|administered|; (r_nmod) prevention_112\NN\1073995|4|retention-|task|chloramphenicol|reversal (r_conj) protection_90\NN\407535|3|complete|amnesia|;|prevention (r_dep) prevention_40\NN\1073995|1|complete|incapacity|;|prevention|protection|prevention (l_nmod) incapacity_43\NN\5644922|of|the|learn (l_acl) learn_45\VB\607114|to|response|rats (l_nmod) rats_51\NNS\2329401|in|exposed (l_acl) exposed_52\VBN\2110927|hypercapnia|session (l_nmod) hypercapnia_55\NN\14034177|to|sublethal
D002701_D006935 NONE chloramphenicol_130\NN\2716866|by|or|cycloheximide|administered|; (r_nmod) prevention_112\NN\1073995|4|retention-|task|chloramphenicol|reversal (r_conj) protection_90\NN\407535|3|complete|amnesia|;|prevention (r_dep) prevention_40\NN\1073995|1|complete|incapacity|;|prevention|protection|prevention (l_dep) prevention_178\NN\1073995|6|deficit|electroshock (l_nmod) electroshock_195\NN\662681|by|subconvulsant|or|hypercapnia|applied|h (l_conj) hypercapnia_197\NN\14034177|
D002701_D000647 NONE chloramphenicol_130\NN\2716866|by|or|cycloheximide|administered|; (r_nmod) prevention_112\NN\1073995|4|retention-|task|chloramphenicol|reversal (r_conj) protection_90\NN\407535|3|complete|amnesia|;|prevention (r_dep) prevention_40\NN\1073995|1|complete|incapacity|;|prevention|protection|prevention (l_conj) prevention_74\NN\1073995|2|partial|amnesia|; (l_nmod) amnesia_79\NN\5669934|of|the|scopolamine-induced|short-term|task
D002701_D000647 NONE chloramphenicol_130\NN\2716866|by|or|cycloheximide|administered|; (r_nmod) prevention_112\NN\1073995|4|retention-|task|chloramphenicol|reversal (r_conj) protection_90\NN\407535|3|complete|amnesia|;|prevention (l_nmod) amnesia_92\NN\5669934|against|task
D003513_D003072 NONE cycloheximide_132\NN\1740| (r_conj) chloramphenicol_130\NN\2716866|by|or|cycloheximide|administered|; (r_nmod) prevention_112\NN\1073995|4|retention-|task|chloramphenicol|reversal (r_conj) protection_90\NN\407535|3|complete|amnesia|;|prevention (r_dep) prevention_40\NN\1073995|1|complete|incapacity|;|prevention|protection|prevention (r_dep) effects_33\NNS\13245626|the|following|:|prevention (r_dobj) produced_30\VBD\1617192|effects (r_conj) studied_13\VBN\630380|effect|(|ro|was|forms|and|produced|. (l_nmod) forms_16\NNS\6286395|on|various|functions (l_nmod) functions_21\NNS\13783581|of|impaired|cognitive|learning|rodents
D003513_D003072 NONE cycloheximide_169\NN\1740|by|injected (r_nmod) induced_167\VBN\1627355|cycloheximide (r_acl) task_166\NN\575741|of|a|passive|avoidance|induced (r_nmod) retention_159\NN\809465|in|or|retrieval|task (r_nmod) deficit_157\NN\5113133|of|the|retention (r_nmod) reversal_141\NN\199130|5|,|administered|,|deficit|; (r_dep) prevention_112\NN\1073995|4|retention-|task|chloramphenicol|reversal (r_conj) protection_90\NN\407535|3|complete|amnesia|;|prevention (r_dep) prevention_40\NN\1073995|1|complete|incapacity|;|prevention|protection|prevention (r_dep) effects_33\NNS\13245626|the|following|:|prevention (r_dobj) produced_30\VBD\1617192|effects (r_conj) studied_13\VBN\630380|effect|(|ro|was|forms|and|produced|. (l_nmod) forms_16\NNS\6286395|on|various|functions (l_nmod) functions_21\NNS\13783581|of|impaired|cognitive|learning|rodents
D003513_D006935 NONE cycloheximide_132\NN\1740| (r_conj) chloramphenicol_130\NN\2716866|by|or|cycloheximide|administered|; (r_nmod) prevention_112\NN\1073995|4|retention-|task|chloramphenicol|reversal (r_conj) protection_90\NN\407535|3|complete|amnesia|;|prevention (r_dep) prevention_40\NN\1073995|1|complete|incapacity|;|prevention|protection|prevention (l_nmod) incapacity_43\NN\5644922|of|the|learn (l_acl) learn_45\VB\607114|to|response|rats (l_nmod) rats_51\NNS\2329401|in|exposed (l_acl) exposed_52\VBN\2110927|hypercapnia|session (l_nmod) hypercapnia_55\NN\14034177|to|sublethal
D003513_D006935 NONE cycloheximide_132\NN\1740| (r_conj) chloramphenicol_130\NN\2716866|by|or|cycloheximide|administered|; (r_nmod) prevention_112\NN\1073995|4|retention-|task|chloramphenicol|reversal (r_conj) protection_90\NN\407535|3|complete|amnesia|;|prevention (r_dep) prevention_40\NN\1073995|1|complete|incapacity|;|prevention|protection|prevention (l_dep) prevention_178\NN\1073995|6|deficit|electroshock (l_nmod) electroshock_195\NN\662681|by|subconvulsant|or|hypercapnia|applied|h (l_conj) hypercapnia_197\NN\14034177|
D003513_D006935 NONE cycloheximide_169\NN\1740|by|injected (r_nmod) induced_167\VBN\1627355|cycloheximide (r_acl) task_166\NN\575741|of|a|passive|avoidance|induced (r_nmod) retention_159\NN\809465|in|or|retrieval|task (r_nmod) deficit_157\NN\5113133|of|the|retention (r_nmod) reversal_141\NN\199130|5|,|administered|,|deficit|; (r_dep) prevention_112\NN\1073995|4|retention-|task|chloramphenicol|reversal (r_conj) protection_90\NN\407535|3|complete|amnesia|;|prevention (r_dep) prevention_40\NN\1073995|1|complete|incapacity|;|prevention|protection|prevention (l_nmod) incapacity_43\NN\5644922|of|the|learn (l_acl) learn_45\VB\607114|to|response|rats (l_nmod) rats_51\NNS\2329401|in|exposed (l_acl) exposed_52\VBN\2110927|hypercapnia|session (l_nmod) hypercapnia_55\NN\14034177|to|sublethal
D003513_D006935 NONE cycloheximide_169\NN\1740|by|injected (r_nmod) induced_167\VBN\1627355|cycloheximide (r_acl) task_166\NN\575741|of|a|passive|avoidance|induced (r_nmod) retention_159\NN\809465|in|or|retrieval|task (r_nmod) deficit_157\NN\5113133|of|the|retention (r_nmod) reversal_141\NN\199130|5|,|administered|,|deficit|; (r_dep) prevention_112\NN\1073995|4|retention-|task|chloramphenicol|reversal (r_conj) protection_90\NN\407535|3|complete|amnesia|;|prevention (r_dep) prevention_40\NN\1073995|1|complete|incapacity|;|prevention|protection|prevention (l_dep) prevention_178\NN\1073995|6|deficit|electroshock (l_nmod) electroshock_195\NN\662681|by|subconvulsant|or|hypercapnia|applied|h (l_conj) hypercapnia_197\NN\14034177|
D003513_D000647 NONE cycloheximide_132\NN\1740| (r_conj) chloramphenicol_130\NN\2716866|by|or|cycloheximide|administered|; (r_nmod) prevention_112\NN\1073995|4|retention-|task|chloramphenicol|reversal (r_conj) protection_90\NN\407535|3|complete|amnesia|;|prevention (r_dep) prevention_40\NN\1073995|1|complete|incapacity|;|prevention|protection|prevention (l_conj) prevention_74\NN\1073995|2|partial|amnesia|; (l_nmod) amnesia_79\NN\5669934|of|the|scopolamine-induced|short-term|task
D003513_D000647 NONE cycloheximide_132\NN\1740| (r_conj) chloramphenicol_130\NN\2716866|by|or|cycloheximide|administered|; (r_nmod) prevention_112\NN\1073995|4|retention-|task|chloramphenicol|reversal (r_conj) protection_90\NN\407535|3|complete|amnesia|;|prevention (l_nmod) amnesia_92\NN\5669934|against|task
D003513_D000647 NONE cycloheximide_169\NN\1740|by|injected (r_nmod) induced_167\VBN\1627355|cycloheximide (r_acl) task_166\NN\575741|of|a|passive|avoidance|induced (r_nmod) retention_159\NN\809465|in|or|retrieval|task (r_nmod) deficit_157\NN\5113133|of|the|retention (r_nmod) reversal_141\NN\199130|5|,|administered|,|deficit|; (r_dep) prevention_112\NN\1073995|4|retention-|task|chloramphenicol|reversal (r_conj) protection_90\NN\407535|3|complete|amnesia|;|prevention (r_dep) prevention_40\NN\1073995|1|complete|incapacity|;|prevention|protection|prevention (l_conj) prevention_74\NN\1073995|2|partial|amnesia|; (l_nmod) amnesia_79\NN\5669934|of|the|scopolamine-induced|short-term|task
D003513_D000647 NONE cycloheximide_169\NN\1740|by|injected (r_nmod) induced_167\VBN\1627355|cycloheximide (r_acl) task_166\NN\575741|of|a|passive|avoidance|induced (r_nmod) retention_159\NN\809465|in|or|retrieval|task (r_nmod) deficit_157\NN\5113133|of|the|retention (r_nmod) reversal_141\NN\199130|5|,|administered|,|deficit|; (r_dep) prevention_112\NN\1073995|4|retention-|task|chloramphenicol|reversal (r_conj) protection_90\NN\407535|3|complete|amnesia|;|prevention (l_nmod) amnesia_92\NN\5669934|against|task
3411101
C033457_D056486 CID phenylethylbarbiturate-induced_1\JJ\1740| (r_amod) hepatitis_3\NN\14127211|quinidine|phenylethylbarbiturate-induced|fulminant|woman|.
C033457_D056486 CID phenylethylbarbiturate_26\NN\1740|of|quinidine (r_nmod) administration_23\NN\1133281|after|a|1-month|phenylethylbarbiturate (r_nmod) affected_9\VBN\126264|hepatitis|trimester|administration (l_nmod) hepatitis_12\NN\14127211|by|fulminant
C033457_D056486 CID phenylethylbarbiturate_3\NN\1740| (r_conj) quinidine_0\NN\2715941|itself|or|phenylethylbarbiturate (r_nsubj) responsible_6\JJ\1740|quinidine|may|be|hepatitis|. (l_nmod) hepatitis_9\NN\14127211|for|fulminant|patient
D011802_D056486 NONE quinidine_0\NN\2715941|itself|or|phenylethylbarbiturate (r_nsubj) responsible_6\JJ\1740|quinidine|may|be|hepatitis|. (l_nmod) hepatitis_9\NN\14127211|for|fulminant|patient
9875685
D014031_D064420 NONE tobramicyn_15\NN\1740|of (r_nmod) regimen_8\NN\5898568|of|dosage|once-daily|tobramicyn (r_nmod) effect_5\NN\34213|the|regimen|concentrations (l_nmod) concentrations_19\NNS\4916342|on|steady-state|serum|and|toxicity (l_conj) toxicity_21\NN\13576101|
D003404_D007674 NONE creatinine_2\NN\1740|increased|serum (r_nsubjpass) observed_4\VBN\2163746|creatinine|was|%|,|evidence|. (l_nmod) evidence_21\NN\5816287|without|nephrotoxicity (l_nmod) nephrotoxicity_23\NN\1740|of
6203632
D007545_D006332 CID isoproterenol-induced_2\JJ\1740| (r_amod) hypertrophy_4\NN\14365950|of|isoproterenol-induced|cardiac
D007545_D006332 CID isoproterenol_17\NN\3740161|of|iso (r_nmod) injections_15\NNS\320852|following|daily|subcutaneous|isoproterenol (r_nmod) studied_6\VBN\630380|development|was|rats|injections|. (l_nsubjpass) development_1\NN\248977|the|hypertrophy (l_nmod) hypertrophy_4\NN\14365950|of|cardiac
D007545_D006332 CID iso_19\NN\1740|(|)|weight|) (r_appos) isoproterenol_17\NN\3740161|of|iso (r_nmod) injections_15\NNS\320852|following|daily|subcutaneous|isoproterenol (r_nmod) studied_6\VBN\630380|development|was|rats|injections|. (l_nsubjpass) development_1\NN\248977|the|hypertrophy (l_nmod) hypertrophy_4\NN\14365950|of|cardiac
D007545_D006984 NONE iso_8\NN\1740|to (r_nmod) response_6\NN\11410625|the|adaptive|iso (r_nsubj) shows_9\VBZ\2137132|that|response|phase (l_dobj) phase_13\NN\15113229|an|early|hypertrophic|days|characterized (l_amod) hypertrophic_12\JJ\1740|
6540303
D000588_D002389 NONE amine_2\NN\14951377| (r_compound) pretreatment_3\NN\1740|of|amine (r_nmod) effects_0\NNS\13245626|pretreatment|catatonia|. (l_nmod) catatonia_6\NN\14544672|on|ketamine|animals
D007649_D002389 CID ketamine_5\NN\3054098| (r_compound) catatonia_6\NN\14544672|on|ketamine|animals
D007649_D002389 CID ketamine-induced_15\JJ\1740| (r_amod) catatonia_16\NN\14544672|on|ketamine-induced|chick
D007649_D002389 CID ketamine_17\NN\3054098|after (r_nmod) duration_10\NN\15113229|the|catatonia|ketamine (l_nmod) catatonia_12\NN\14544672|of|doc
D007649_D002389 CID ketamine_15\NN\3054098| (r_compound) catatonia_16\NN\14544672|of|ketamine
D002395_D002389 NONE catecholamines_10\NNS\5407119|of|and|idolamines (r_nmod) role_8\NN\719494|the|catecholamines|catatonia (l_nmod) catatonia_16\NN\14544672|on|ketamine-induced|chick
D004298_D002389 CID dopamine_7\NN\14807737|with (r_nmod) pretreatment_5\NN\1740|dopamine (r_nsubj) increased_8\VBD\169651|chick|,|pretreatment|duration|,|but|did (l_dobj) duration_10\NN\15113229|the|catatonia|ketamine (l_nmod) catatonia_12\NN\14544672|of|doc
D004298_D002389 CID dopamine_2\NN\14807737| (r_nsubj) appeared_3\VBD\2604760|furthermore|,|dopamine|act|. (l_xcomp) act_5\VB\1619354|to|systems (l_nmod) systems_7\NNS\3575240|on|involved|rather|directly|pituitary (l_amod) involved_10\VBN\2676054|closely|induction (l_nmod) induction_13\NN\7450842|with|the|catatonia (l_nmod) catatonia_16\NN\14544672|of|ketamine
D009638_D002389 NONE norepinephrine_22\NN\14807929|with (r_nmod) pretreatment_20\NN\1740|norepinephrine (r_nsubj) did_23\VBD\1640855|pretreatment|not|. (r_conj) increased_8\VBD\169651|chick|,|pretreatment|duration|,|but|did (l_dobj) duration_10\NN\15113229|the|catatonia|ketamine (l_nmod) catatonia_12\NN\14544672|of|doc
17511042
C417083_D063726 CID alpha-2b_16\NN\1740|during|pegylated|interferon|and|ribavirin (r_nmod) parasitosis_6\NN\1740|of|delusional|patient|alpha-2b
C417083_D063726 CID alpha-2b_15\NN\1740|with|pegylated|interferon|weekly|and|ribavirin (r_nmod) treatment_11\NN\654885|during|alpha-2b (r_nmod) developed_6\VBD\1753788|who|parasitosis|treatment (l_dobj) parasitosis_9\NN\1740|a|delusional
C417083_D019698 NONE alpha-2b_16\NN\1740|during|pegylated|interferon|and|ribavirin (r_nmod) parasitosis_6\NN\1740|of|delusional|patient|alpha-2b (l_nmod) patient_12\NN\9898892|in|a|chronic|hepatitis|c (l_compound) c_11\NN\13714184|
D012254_D063726 CID ribavirin_18\NN\2725367| (r_conj) alpha-2b_16\NN\1740|during|pegylated|interferon|and|ribavirin (r_nmod) parasitosis_6\NN\1740|of|delusional|patient|alpha-2b
D012254_D063726 CID ribavirin_18\NN\2725367| (r_conj) alpha-2b_15\NN\1740|with|pegylated|interferon|weekly|and|ribavirin (r_nmod) treatment_11\NN\654885|during|alpha-2b (r_nmod) developed_6\VBD\1753788|who|parasitosis|treatment (l_dobj) parasitosis_9\NN\1740|a|delusional
D012254_D019698 NONE ribavirin_18\NN\2725367| (r_conj) alpha-2b_16\NN\1740|during|pegylated|interferon|and|ribavirin (r_nmod) parasitosis_6\NN\1740|of|delusional|patient|alpha-2b (l_nmod) patient_12\NN\9898892|in|a|chronic|hepatitis|c (l_compound) c_11\NN\13714184|
D012254_D019698 NONE ribavirin_10\NN\2725367| (r_conj) interferon_8\NN\2725367|with|and|ribavirin (r_nmod) treatment_1\NN\654885|during|patients|interferon (l_nmod) patients_6\NNS\9898892|of|chronic|c (l_compound) c_5\NN\13714184|hepatitis
9270571
D004298_D020734 NONE dopamine_6\NN\14807737| (r_compound) agonist_9\NN\9613191|of|the|selective|dopamine|d1|receptor|,|a-86929 (r_nmod) use_2\NN\407535|potential|therapeutic|agonist|:|study (l_dep) study_15\NN\635850|an|acute|monkeys|. (l_nmod) monkeys_19\NNS\2469914|in|parkinsonian|levodopa-primed (l_amod) parkinsonian_17\JJ\1740|
C095427_D020734 NONE a-86929_11\NN\1740| (r_appos) agonist_9\NN\9613191|of|the|selective|dopamine|d1|receptor|,|a-86929 (r_nmod) use_2\NN\407535|potential|therapeutic|agonist|:|study (l_dep) study_15\NN\635850|an|acute|monkeys|. (l_nmod) monkeys_19\NNS\2469914|in|parkinsonian|levodopa-primed (l_amod) parkinsonian_17\JJ\1740|
C095427_D020734 NONE a-86929_3\NN\1740|of (r_nmod) administration_1\NN\1133281|acute|a-86929 (r_nsubj) efficacious_6\JJ\1740|administration|was|as|alleviating|,|but|likely|. (l_advcl) alleviating_8\VBG\205885|in|parkinsonism|levodopa (l_dobj) parkinsonism_10\NN\14085708|mptp-induced
D007980_D020734 NONE levodopa-primed_18\JJ\1740| (r_amod) monkeys_19\NNS\2469914|in|parkinsonian|levodopa-primed (l_amod) parkinsonian_17\JJ\1740|
D007980_D020734 NONE levodopa_12\NN\14604959|as|and|ly-171555 (r_nmod) alleviating_8\VBG\205885|in|parkinsonism|levodopa (l_dobj) parkinsonism_10\NN\14085708|mptp-induced
D007980_D020734 NONE levodopa-induced_23\JJ\1740| (r_amod) dyskinesias_24\NNS\14084880|the|levodopa-induced|animals (r_dobj) reproduce_21\VB\1621555|to|dyskinesias (r_xcomp) likely_19\JJ\1740|was|less|reproduce|than|ly-171555 (r_conj) efficacious_6\JJ\1740|administration|was|as|alleviating|,|but|likely|. (l_advcl) alleviating_8\VBG\205885|in|parkinsonism|levodopa (l_dobj) parkinsonism_10\NN\14085708|mptp-induced
D007980_D020734 NONE levodopa_36\NN\14604959|of (r_nmod) challenge_34\NN\13927383|subsequent|levodopa (r_conj) ly-171555_31\NN\1740|with|either|or|challenge (r_nmod) likely_19\JJ\1740|was|less|reproduce|than|ly-171555 (r_conj) efficacious_6\JJ\1740|administration|was|as|alleviating|,|but|likely|. (l_advcl) alleviating_8\VBG\205885|in|parkinsonism|levodopa (l_dobj) parkinsonism_10\NN\14085708|mptp-induced
D004298_D010300 NONE dopamine_4\NN\14807737| (r_compound) agonists_10\NNS\9613191|of|dopamine|(|da|)|d1|receptor (r_nmod) utility_2\NN\8186047|the|clinical|agonists|treatment (l_nmod) treatment_13\NN\654885|in|the|disease (l_nmod) disease_17\NN\14061805|of|parkinson|'s|pd
D004298_D010300 NONE dopamine_4\NN\14807737| (r_compound) agonists_10\NNS\9613191|of|dopamine|(|da|)|d1|receptor (r_nmod) utility_2\NN\8186047|the|clinical|agonists|treatment (l_nmod) treatment_13\NN\654885|in|the|disease (l_nmod) disease_17\NN\14061805|of|parkinson|'s|pd (l_appos) pd_19\NN\14625458|(|)
D004298_D010300 NONE da_6\NN\10484858| (r_compound) agonists_10\NNS\9613191|of|dopamine|(|da|)|d1|receptor (r_nmod) utility_2\NN\8186047|the|clinical|agonists|treatment (l_nmod) treatment_13\NN\654885|in|the|disease (l_nmod) disease_17\NN\14061805|of|parkinson|'s|pd
D004298_D010300 NONE da_6\NN\10484858| (r_compound) agonists_10\NNS\9613191|of|dopamine|(|da|)|d1|receptor (r_nmod) utility_2\NN\8186047|the|clinical|agonists|treatment (l_nmod) treatment_13\NN\654885|in|the|disease (l_nmod) disease_17\NN\14061805|of|parkinson|'s|pd (l_appos) pd_19\NN\14625458|(|)
D004298_D010300 NONE da_1\NN\10484858| (r_compound) agents_4\NNS\7347|potent|da|d1|receptor|duration (r_nsubj) tools_26\NNS\3563967|agents|are|potential|therapeutic|pd|and|merit|. (l_nmod) pd_28\NN\14625458|in
D015632_D004409 NONE 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine_10\NN\1740|(mptp)-exposed (r_compound) monkeys_13\NNS\2469914|in|four|1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine|cynomolgus|primed (l_acl) primed_14\VBN\406243|exhibit (l_xcomp) exhibit_16\VB\2632167|to|dyskinesias (l_dobj) dyskinesias_18\NNS\14084880|levodopa-induced
D015632_D004409 NONE 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine_10\NN\1740|(mptp)-exposed (r_compound) monkeys_13\NNS\2469914|in|four|1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine|cynomolgus|primed (r_nmod) conducted_2\VBD\2436349|we|therefore|study|monkeys|evaluate|. (l_advcl) evaluate_20\VB\670261|to|effects (l_dobj) effects_25\NNS\13245626|the|locomotor|challenge (l_amod) locomotor_22\JJ\1740|and|dyskinetic (l_conj) dyskinetic_24\JJ\1740|
D015632_D004409 NONE (mptp)-exposed_11\NN\1740| (r_dep) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine_10\NN\1740|(mptp)-exposed (r_compound) monkeys_13\NNS\2469914|in|four|1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine|cynomolgus|primed (l_acl) primed_14\VBN\406243|exhibit (l_xcomp) exhibit_16\VB\2632167|to|dyskinesias (l_dobj) dyskinesias_18\NNS\14084880|levodopa-induced
D015632_D004409 NONE (mptp)-exposed_11\NN\1740| (r_dep) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine_10\NN\1740|(mptp)-exposed (r_compound) monkeys_13\NNS\2469914|in|four|1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine|cynomolgus|primed (r_nmod) conducted_2\VBD\2436349|we|therefore|study|monkeys|evaluate|. (l_advcl) evaluate_20\VB\670261|to|effects (l_dobj) effects_25\NNS\13245626|the|locomotor|challenge (l_amod) locomotor_22\JJ\1740|and|dyskinetic (l_conj) dyskinetic_24\JJ\1740|
D015632_D004409 NONE mptp-induced_9\JJ\1740| (r_amod) parkinsonism_10\NN\14085708|mptp-induced (r_dobj) alleviating_8\VBG\205885|in|parkinsonism|levodopa (r_advcl) efficacious_6\JJ\1740|administration|was|as|alleviating|,|but|likely|. (l_conj) likely_19\JJ\1740|was|less|reproduce|than|ly-171555 (l_xcomp) reproduce_21\VB\1621555|to|dyskinesias (l_dobj) dyskinesias_24\NNS\14084880|the|levodopa-induced|animals
D007980_D004409 CID levodopa-induced_17\JJ\1740| (r_amod) dyskinesias_18\NNS\14084880|levodopa-induced
D007980_D004409 CID levodopa-induced_17\JJ\1740| (r_amod) dyskinesias_18\NNS\14084880|levodopa-induced (r_dobj) exhibit_16\VB\2632167|to|dyskinesias (r_xcomp) primed_14\VBN\406243|exhibit (r_acl) monkeys_13\NNS\2469914|in|four|1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine|cynomolgus|primed (r_nmod) conducted_2\VBD\2436349|we|therefore|study|monkeys|evaluate|. (l_advcl) evaluate_20\VB\670261|to|effects (l_dobj) effects_25\NNS\13245626|the|locomotor|challenge (l_amod) locomotor_22\JJ\1740|and|dyskinetic (l_conj) dyskinetic_24\JJ\1740|
D007980_D004409 CID levodopa_12\NN\14604959|as|and|ly-171555 (r_nmod) alleviating_8\VBG\205885|in|parkinsonism|levodopa (r_advcl) efficacious_6\JJ\1740|administration|was|as|alleviating|,|but|likely|. (l_conj) likely_19\JJ\1740|was|less|reproduce|than|ly-171555 (l_xcomp) reproduce_21\VB\1621555|to|dyskinesias (l_dobj) dyskinesias_24\NNS\14084880|the|levodopa-induced|animals
D007980_D004409 CID levodopa-induced_23\JJ\1740| (r_amod) dyskinesias_24\NNS\14084880|the|levodopa-induced|animals
D007980_D004409 CID levodopa_36\NN\14604959|of (r_nmod) challenge_34\NN\13927383|subsequent|levodopa (r_conj) ly-171555_31\NN\1740|with|either|or|challenge (r_nmod) likely_19\JJ\1740|was|less|reproduce|than|ly-171555 (l_xcomp) reproduce_21\VB\1621555|to|dyskinesias (l_dobj) dyskinesias_24\NNS\14084880|the|levodopa-induced|animals
C095427_D004409 NONE a-86929_39\NN\1740|of|10-diol|,|agonist (r_nmod) doses_30\NNS\3740161|with|four|(|mg/kg|)|a-86929 (r_nmod) challenge_27\NN\13927383|on|doses (r_nmod) effects_25\NNS\13245626|the|locomotor|challenge (r_dobj) evaluate_20\VB\670261|to|effects (r_advcl) conducted_2\VBD\2436349|we|therefore|study|monkeys|evaluate|. (l_nmod) monkeys_13\NNS\2469914|in|four|1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine|cynomolgus|primed (l_acl) primed_14\VBN\406243|exhibit (l_xcomp) exhibit_16\VB\2632167|to|dyskinesias (l_dobj) dyskinesias_18\NNS\14084880|levodopa-induced
C095427_D004409 NONE a-86929_39\NN\1740|of|10-diol|,|agonist (r_nmod) doses_30\NNS\3740161|with|four|(|mg/kg|)|a-86929 (r_nmod) challenge_27\NN\13927383|on|doses (r_nmod) effects_25\NNS\13245626|the|locomotor|challenge (l_amod) locomotor_22\JJ\1740|and|dyskinetic (l_conj) dyskinetic_24\JJ\1740|
C095427_D004409 NONE 10-diol_47\NN\1740|(|[-]-[5ar,11bs]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+|) (r_appos) a-86929_39\NN\1740|of|10-diol|,|agonist (r_nmod) doses_30\NNS\3740161|with|four|(|mg/kg|)|a-86929 (r_nmod) challenge_27\NN\13927383|on|doses (r_nmod) effects_25\NNS\13245626|the|locomotor|challenge (r_dobj) evaluate_20\VB\670261|to|effects (r_advcl) conducted_2\VBD\2436349|we|therefore|study|monkeys|evaluate|. (l_nmod) monkeys_13\NNS\2469914|in|four|1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine|cynomolgus|primed (l_acl) primed_14\VBN\406243|exhibit (l_xcomp) exhibit_16\VB\2632167|to|dyskinesias (l_dobj) dyskinesias_18\NNS\14084880|levodopa-induced
C095427_D004409 NONE 10-diol_47\NN\1740|(|[-]-[5ar,11bs]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+|) (r_appos) a-86929_39\NN\1740|of|10-diol|,|agonist (r_nmod) doses_30\NNS\3740161|with|four|(|mg/kg|)|a-86929 (r_nmod) challenge_27\NN\13927383|on|doses (r_nmod) effects_25\NNS\13245626|the|locomotor|challenge (l_amod) locomotor_22\JJ\1740|and|dyskinetic (l_conj) dyskinetic_24\JJ\1740|
C095427_D004409 NONE a-86929_3\NN\1740|of (r_nmod) administration_1\NN\1133281|acute|a-86929 (r_nsubj) efficacious_6\JJ\1740|administration|was|as|alleviating|,|but|likely|. (l_conj) likely_19\JJ\1740|was|less|reproduce|than|ly-171555 (l_xcomp) reproduce_21\VB\1621555|to|dyskinesias (l_dobj) dyskinesias_24\NNS\14084880|the|levodopa-induced|animals
D004298_D004409 NONE da_54\NN\10484858| (r_compound) agonist_57\NN\9613191|a|selective|da|d1-like|receptor|duration (r_appos) a-86929_39\NN\1740|of|10-diol|,|agonist (r_nmod) doses_30\NNS\3740161|with|four|(|mg/kg|)|a-86929 (r_nmod) challenge_27\NN\13927383|on|doses (r_nmod) effects_25\NNS\13245626|the|locomotor|challenge (r_dobj) evaluate_20\VB\670261|to|effects (r_advcl) conducted_2\VBD\2436349|we|therefore|study|monkeys|evaluate|. (l_nmod) monkeys_13\NNS\2469914|in|four|1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine|cynomolgus|primed (l_acl) primed_14\VBN\406243|exhibit (l_xcomp) exhibit_16\VB\2632167|to|dyskinesias (l_dobj) dyskinesias_18\NNS\14084880|levodopa-induced
D004298_D004409 NONE da_54\NN\10484858| (r_compound) agonist_57\NN\9613191|a|selective|da|d1-like|receptor|duration (r_appos) a-86929_39\NN\1740|of|10-diol|,|agonist (r_nmod) doses_30\NNS\3740161|with|four|(|mg/kg|)|a-86929 (r_nmod) challenge_27\NN\13927383|on|doses (r_nmod) effects_25\NNS\13245626|the|locomotor|challenge (l_amod) locomotor_22\JJ\1740|and|dyskinetic (l_conj) dyskinetic_24\JJ\1740|
D015632_D020734 CID mptp-induced_9\JJ\1740| (r_amod) parkinsonism_10\NN\14085708|mptp-induced
C416545_D020734 NONE ly-171555_14\NN\1740| (r_conj) levodopa_12\NN\14604959|as|and|ly-171555 (r_nmod) alleviating_8\VBG\205885|in|parkinsonism|levodopa (l_dobj) parkinsonism_10\NN\14085708|mptp-induced
C416545_D020734 NONE ly-171555_31\NN\1740|with|either|or|challenge (r_nmod) likely_19\JJ\1740|was|less|reproduce|than|ly-171555 (r_conj) efficacious_6\JJ\1740|administration|was|as|alleviating|,|but|likely|. (l_advcl) alleviating_8\VBG\205885|in|parkinsonism|levodopa (l_dobj) parkinsonism_10\NN\14085708|mptp-induced
C416545_D004409 NONE ly-171555_14\NN\1740| (r_conj) levodopa_12\NN\14604959|as|and|ly-171555 (r_nmod) alleviating_8\VBG\205885|in|parkinsonism|levodopa (r_advcl) efficacious_6\JJ\1740|administration|was|as|alleviating|,|but|likely|. (l_conj) likely_19\JJ\1740|was|less|reproduce|than|ly-171555 (l_xcomp) reproduce_21\VB\1621555|to|dyskinesias (l_dobj) dyskinesias_24\NNS\14084880|the|levodopa-induced|animals
C416545_D004409 NONE ly-171555_31\NN\1740|with|either|or|challenge (r_nmod) likely_19\JJ\1740|was|less|reproduce|than|ly-171555 (l_xcomp) reproduce_21\VB\1621555|to|dyskinesias (l_dobj) dyskinesias_24\NNS\14084880|the|levodopa-induced|animals
C095427_D010300 NONE a-86929_13\NN\1740|such|hr (r_nmod) duration_8\NN\15113229|with|an|intermediate|efficacy|a-86929 (r_nmod) agents_4\NNS\7347|potent|da|d1|receptor|duration (r_nsubj) tools_26\NNS\3563967|agents|are|potential|therapeutic|pd|and|merit|. (l_nmod) pd_28\NN\14625458|in
6794356
D016651_D014262 NONE carbonate_5\NN\15010703|lithium (r_compound) toxicity_6\NN\13576101|carbonate (r_conj) regurgitation_2\NN\7406350|valve|and|toxicity|infant|.
D016651_D064420 NONE carbonate_5\NN\15010703|lithium (r_compound) toxicity_6\NN\13576101|carbonate
D008094_D014262 NONE lithium_18\NN\14625458| (r_compound) level_19\NN\4916342|a|high|serum|lithium (r_conj) flutter_8\NN\331950|atrial|,|failure|,|and|level (r_conj) regurgitation_5\NN\7406350|with|massive|tricuspid|,|flutter
D008094_D014262 NONE lithium_26\NN\14625458| (r_compound) compounds_27\NNS\5869584|to|lithium (r_nmod) exposed_24\VBN\2110927|compounds|trimester (r_acl) infants_23\NNS\9918248|among|exposed (r_nmod) disease_21\NN\14061805|with|cardiac|infants (r_nmod) patient_18\NN\9898892|the|11th|described|disease (r_conj) patient_4\NN\9898892|this|is|the|first|manifest|,|and|patient|. (l_acl:relcl) manifest_7\VB\1015244|to|initially|regurgitation (l_dobj) regurgitation_9\NN\7406350|tricuspid|and|flutter
D008094_D001282 NONE lithium_18\NN\14625458| (r_compound) level_19\NN\4916342|a|high|serum|lithium (r_conj) flutter_8\NN\331950|atrial|,|failure|,|and|level
D008094_D001282 NONE lithium_26\NN\14625458| (r_compound) compounds_27\NNS\5869584|to|lithium (r_nmod) exposed_24\VBN\2110927|compounds|trimester (r_acl) infants_23\NNS\9918248|among|exposed (r_nmod) disease_21\NN\14061805|with|cardiac|infants (r_nmod) patient_18\NN\9898892|the|11th|described|disease (r_conj) patient_4\NN\9898892|this|is|the|first|manifest|,|and|patient|. (l_acl:relcl) manifest_7\VB\1015244|to|initially|regurgitation (l_dobj) regurgitation_9\NN\7406350|tricuspid|and|flutter (l_conj) flutter_12\NN\331950|atrial
D008094_D006333 NONE lithium_18\NN\14625458| (r_compound) level_19\NN\4916342|a|high|serum|lithium (r_conj) flutter_8\NN\331950|atrial|,|failure|,|and|level (l_conj) failure_12\NN\66216|congestive|heart
D008094_D006331 NONE lithium_26\NN\14625458| (r_compound) compounds_27\NNS\5869584|to|lithium (r_nmod) exposed_24\VBN\2110927|compounds|trimester (r_acl) infants_23\NNS\9918248|among|exposed (r_nmod) disease_21\NN\14061805|with|cardiac|infants
D016651_D006331 NONE carbonate_1\NN\15010703|lithium (r_nsubj) factor_5\NN\7326557|carbonate|may|be|a|incidence|taken|. (l_nmod) incidence_9\NN\13821570|in|the|increasing|disease (l_nmod) disease_13\NN\14061805|of|congenital|heart
7263204
D007213_D000741 CID indomethacin_5\NN\3828465| (r_compound) tests_9\NNS\5798043|due|indomethacin|--|lymphocyte|transformation|vitro (r_nmod) anemia_2\NN\14189204|fatal|aplastic|tests|.
D007213_D000741 CID indomethacin_1\NN\3828465| (r_nsubjpass) implicated_4\VBN\2677097|although|indomethacin|has|been|cause|basis (l_nmod) cause_8\NN\7323922|as|a|possible|anemia (l_nmod) anemia_11\NN\14189204|of|aplastic
D007213_D000741 CID indomethacin_16\NN\3828465| (r_conj) allopurinol_14\NN\3740161|than|and|indomethacin (r_nmod) other_12\JJ\1740|allopurinol (r_amod) drugs_11\NNS\14778436|no|other (r_nsubjpass) given_18\VBN\2327200|which|drugs|were (r_xcomp) described_7\VBN\1001294|case|is|given|. (l_nsubjpass) case_1\NN\7283608|a|anemia (l_nmod) anemia_5\NN\14189204|of|fatal|aplastic
D007213_D000741 CID indomethacin_6\NN\3828465|with (r_nmod) test_4\NN\5798043|a|positive|lymphocyte|transformation|indomethacin|vitro (r_nsubj) substantiates_10\VBZ\2604760|test|further|role|. (l_dobj) role_13\NN\719494|the|potential|drug|causing (l_advcl) causing_18\VBG\1617192|in|anemia (l_dobj) anemia_20\NN\14189204|aplastic|patient
D000493_D000741 NONE allopurinol_14\NN\3740161|than|and|indomethacin (r_nmod) other_12\JJ\1740|allopurinol (r_amod) drugs_11\NNS\14778436|no|other (r_nsubjpass) given_18\VBN\2327200|which|drugs|were (r_xcomp) described_7\VBN\1001294|case|is|given|. (l_nsubjpass) case_1\NN\7283608|a|anemia (l_nmod) anemia_5\NN\14189204|of|fatal|aplastic
14975762
D004317_D009369 NONE doxorubicin_0\NN\2716866| (r_nsubj) agent_4\NN\7347|doxorubicin|is|an|anti-tumor|represses|. (l_amod) anti-tumor_3\JJ\1740|
D004317_D006333 CID doxorubicin-induced_11\JJ\1740| (r_amod) apoptosis_12\NN\11486178|from|doxorubicin-induced (r_nmod) protects_7\VBZ\1127795|that|overexpression|myocytes|apoptosis|and|reduces (l_conj) reduces_14\VBZ\441445|extent|vivo (l_dobj) extent_16\NN\13939892|the|failure (l_nmod) failure_20\NN\66216|of|acute|heart|mice
188339
D003276_D008113 CID contraceptives_11\NNS\3183080|with|oral (r_nmod) associated_8\VBN\628491|contraceptives (r_acl) tumors_7\NNS\14234074|of|liver|associated
D003276_D008113 CID contraceptive_18\JJ\1740| (r_amod) steroids_19\NNS\14727670|oral|contraceptive (r_dobj) using_16\VBG\1156834|steroids (r_acl) women_15\NNS\9605289|in|young|using (r_nmod) seen_12\VBN\2106506|years|,|tumors|have|been|women|. (l_nsubjpass) tumors_9\NNS\14234074|rare|liver
D003276_D008113 CID contraceptives_8\NNS\3183080|with|oral (r_nmod) associated_5\VBN\628491|contraceptives|university (r_acl) tumors_4\NNS\14234074|for|liver|associated
D013256_D008113 NONE steroids_19\NNS\14727670|oral|contraceptive (r_dobj) using_16\VBG\1156834|steroids (r_acl) women_15\NNS\9605289|in|young|using (r_nmod) seen_12\VBN\2106506|years|,|tumors|have|been|women|. (l_nsubjpass) tumors_9\NNS\14234074|rare|liver
2557556
D015232_D006930 CID e2-induced_19\JJ\1740|prostaglandin (r_amod) hyperalgesia_20\NN\1740|of|e2-induced
D009020_D006930 NONE morphine_0\NN\2707683| (r_nsubj) alter_6\VB\126264|morphine|did|not|,|however|,|hyperalgesia|. (l_dobj) hyperalgesia_8\NN\1740|the|induced
D015124_D006930 CID monophosphate_14\NN\1740|by|8-bromo|cyclic|adenosine (r_nmod) induced_9\VBN\1627355|monophosphate (r_acl) hyperalgesia_8\NN\1740|the|induced
10328196
D020123_D064420 NONE sirolimus_5\NN\1740|of|rapamycin (r_nmod) administration_3\NN\1133281|following|sirolimus|psoriasis (r_nmod) toxicity_1\NN\13576101|systemic|administration|:|association|.
D020123_D064420 NONE rapamycin_8\NN\1740|(|formerly|) (r_appos) sirolimus_5\NN\1740|of|rapamycin (r_nmod) administration_3\NN\1133281|following|sirolimus|psoriasis (r_nmod) toxicity_1\NN\13576101|systemic|administration|:|association|.
D020123_D011565 NONE sirolimus_5\NN\1740|of|rapamycin (r_nmod) administration_3\NN\1133281|following|sirolimus|psoriasis (l_nmod) psoriasis_11\NN\14219661|for
D020123_D011565 NONE rapamycin_8\NN\1740|(|formerly|) (r_appos) sirolimus_5\NN\1740|of|rapamycin (r_nmod) administration_3\NN\1133281|following|sirolimus|psoriasis (l_nmod) psoriasis_11\NN\14219661|for
D020123_D011565 NONE sirolimus_14\NN\1740| (r_compound) cells_17\NNS\3080309|with|oral|sirolimus|lesional|skin|and|cells (r_nmod) treatment_11\NN\654885|following|cells (r_nmod) developed_5\VBD\1753788|after|individuals|syndrome|treatment (l_nsubj) individuals_2\NNS\7347|2|psoriasis (l_nmod) psoriasis_4\NN\14219661|with
D020123_D011565 NONE sirolimus-induced_10\JJ\1740| (r_amod) syndrome_13\NN\5870365|with|sirolimus-induced|capillary|leak (r_nmod) patient_8\NN\9898892|from|1|syndrome (r_nmod) specimen_5\NN\5820620|a|keratome|skin|patient (r_nsubj) had_14\VBD\2108377|specimen|increase|patient|. (l_nmod) patient_33\NN\9898892|compared|with|an|unaffected|sirolimus-treated|psoriasis|% (l_nmod) psoriasis_35\NN\14219661|with
D020123_D011565 NONE sirolimus-treated_32\JJ\1740| (r_amod) patient_33\NN\9898892|compared|with|an|unaffected|sirolimus-treated|psoriasis|% (l_nmod) psoriasis_35\NN\14219661|with
D020123_D011565 NONE sirolimus_28\NN\1740|of (r_nmod) presence_26\NN\13954253|in|the|sirolimus (r_nmod) did_18\VBD\1640855|than|cells|,|presence (r_advcl) exhibit_11\VB\2632167|to|apoptosis|did (r_xcomp) tended_9\VBD\2604760|cells|exhibit|. (l_nsubj) cells_4\NNS\3080309|activated|peripheral|blood|t|patients (l_nmod) patients_6\NNS\9898892|from|psoriasis (l_nmod) psoriasis_8\NN\14219661|with
D020123_D019559 CID sirolimus_5\NN\1740|of|rapamycin (r_nmod) administration_3\NN\1133281|following|sirolimus|psoriasis (r_nmod) toxicity_1\NN\13576101|systemic|administration|:|association|. (l_dep) association_13\NN\8008335|syndrome|apoptosis (l_nmod) syndrome_17\NN\5870365|of|capillary|leak
D020123_D019559 CID rapamycin_8\NN\1740|(|formerly|) (r_appos) sirolimus_5\NN\1740|of|rapamycin (r_nmod) administration_3\NN\1133281|following|sirolimus|psoriasis (r_nmod) toxicity_1\NN\13576101|systemic|administration|:|association|. (l_dep) association_13\NN\8008335|syndrome|apoptosis (l_nmod) syndrome_17\NN\5870365|of|capillary|leak
D020123_D019559 CID sirolimus_14\NN\1740| (r_compound) cells_17\NNS\3080309|with|oral|sirolimus|lesional|skin|and|cells (r_nmod) treatment_11\NN\654885|following|cells (r_nmod) developed_5\VBD\1753788|after|individuals|syndrome|treatment (l_dobj) syndrome_9\NN\5870365|a|leak
D020123_D019559 CID sirolimus-induced_10\JJ\1740| (r_amod) syndrome_13\NN\5870365|with|sirolimus-induced|capillary|leak
D020123_D019559 CID sirolimus-treated_32\JJ\1740| (r_amod) patient_33\NN\9898892|compared|with|an|unaffected|sirolimus-treated|psoriasis|% (r_nmod) had_14\VBD\2108377|specimen|increase|patient|. (l_nsubj) specimen_5\NN\5820620|a|keratome|skin|patient (l_nmod) patient_8\NN\9898892|from|1|syndrome (l_nmod) syndrome_13\NN\5870365|with|sirolimus-induced|capillary|leak
D020123_D019559 CID sirolimus_6\NN\1740|of (r_nmod) effects_4\NNS\13245626|severe|adverse|sirolimus (r_nsubj) include_7\VBP\690614|conclusions|effects|fever|. (l_dobj) fever_8\NN\14299637|,|anemia|,|and|syndrome (l_conj) syndrome_15\NN\5870365|leak
D003907_D011565 NONE dexamethasone-induced_15\JJ\1740| (r_conj) spontaneous_13\JJ\1740|or|dexamethasone-induced (r_amod) apoptosis_16\NN\11486178|greater|spontaneous (r_dobj) exhibit_11\VB\2632167|to|apoptosis|did (r_xcomp) tended_9\VBD\2604760|cells|exhibit|. (l_nsubj) cells_4\NNS\3080309|activated|peripheral|blood|t|patients (l_nmod) patients_6\NNS\9898892|from|psoriasis (l_nmod) psoriasis_8\NN\14219661|with
D020123_D005334 NONE sirolimus_6\NN\1740|of (r_nmod) effects_4\NNS\13245626|severe|adverse|sirolimus (r_nsubj) include_7\VBP\690614|conclusions|effects|fever|. (l_dobj) fever_8\NN\14299637|,|anemia|,|and|syndrome
D020123_D000740 NONE sirolimus_6\NN\1740|of (r_nmod) effects_4\NNS\13245626|severe|adverse|sirolimus (r_nsubj) include_7\VBP\690614|conclusions|effects|fever|. (l_dobj) fever_8\NN\14299637|,|anemia|,|and|syndrome (l_conj) anemia_10\NN\14189204|
12739036
D003401_D008180 NONE creatine_5\NN\14601829| (r_compound) kinase_6\NN\14732946|high|serum|creatine (r_compound) levels_7\NNS\4916342|of|kinase|erythematosus (l_nmod) erythematosus_11\NN\1740|in|systemic|lupus
D002738_D009135 NONE chloroquine-induced_13\JJ\1740| (r_amod) myopathy_14\NN\14204950|with|severe|chloroquine-induced
D002738_D009135 NONE chloroquine-induced_3\JJ\1740| (r_amod) myopathy_4\NN\14204950|chloroquine-induced
D001379_D008180 NONE azathioprine_23\NN\3740161|with|and|cyclophosphamide (r_nmod) treatment_21\NN\654885|of|azathioprine (r_nmod) periods_19\NNS\13575869|treatment (r_dobj) undergone_18\VBN\109660|periods (r_conj) suffering_6\VBG\2110220|1989|,|she|had|been|erythematosus|and|undergone|. (l_nmod) erythematosus_10\NN\1740|from|systemic|lupus|sle|involvement
D001379_D008180 NONE azathioprine_23\NN\3740161|with|and|cyclophosphamide (r_nmod) treatment_21\NN\654885|of|azathioprine (r_nmod) periods_19\NNS\13575869|treatment (r_dobj) undergone_18\VBN\109660|periods (r_conj) suffering_6\VBG\2110220|1989|,|she|had|been|erythematosus|and|undergone|. (l_nmod) erythematosus_10\NN\1740|from|systemic|lupus|sle|involvement (l_appos) sle_12\NN\14229912|(|)
D001379_D007674 NONE azathioprine_23\NN\3740161|with|and|cyclophosphamide (r_nmod) treatment_21\NN\654885|of|azathioprine (r_nmod) periods_19\NNS\13575869|treatment (r_dobj) undergone_18\VBN\109660|periods (r_conj) suffering_6\VBG\2110220|1989|,|she|had|been|erythematosus|and|undergone|. (l_nmod) erythematosus_10\NN\1740|from|systemic|lupus|sle|involvement (l_nmod) involvement_16\NN\1080366|with|renal
D003520_D008180 NONE cyclophosphamide_25\NN\1740| (r_conj) azathioprine_23\NN\3740161|with|and|cyclophosphamide (r_nmod) treatment_21\NN\654885|of|azathioprine (r_nmod) periods_19\NNS\13575869|treatment (r_dobj) undergone_18\VBN\109660|periods (r_conj) suffering_6\VBG\2110220|1989|,|she|had|been|erythematosus|and|undergone|. (l_nmod) erythematosus_10\NN\1740|from|systemic|lupus|sle|involvement
D003520_D008180 NONE cyclophosphamide_25\NN\1740| (r_conj) azathioprine_23\NN\3740161|with|and|cyclophosphamide (r_nmod) treatment_21\NN\654885|of|azathioprine (r_nmod) periods_19\NNS\13575869|treatment (r_dobj) undergone_18\VBN\109660|periods (r_conj) suffering_6\VBG\2110220|1989|,|she|had|been|erythematosus|and|undergone|. (l_nmod) erythematosus_10\NN\1740|from|systemic|lupus|sle|involvement (l_appos) sle_12\NN\14229912|(|)
D003520_D007674 NONE cyclophosphamide_25\NN\1740| (r_conj) azathioprine_23\NN\3740161|with|and|cyclophosphamide (r_nmod) treatment_21\NN\654885|of|azathioprine (r_nmod) periods_19\NNS\13575869|treatment (r_dobj) undergone_18\VBN\109660|periods (r_conj) suffering_6\VBG\2110220|1989|,|she|had|been|erythematosus|and|undergone|. (l_nmod) erythematosus_10\NN\1740|from|systemic|lupus|sle|involvement (l_nmod) involvement_16\NN\1080366|with|renal
D002738_D018771 NONE chloroquine_3\NN\2721948|with|cq (r_nmod) therapy_1\NN\657604|additional|chloroquine (r_nsubjpass) started_8\VBN\2009433|therapy|was|arthralgia|. (l_nmod) arthralgia_11\NN\14322699|because
D002738_D018771 NONE cq_5\NN\1740|(|) (r_appos) chloroquine_3\NN\2721948|with|cq (r_nmod) therapy_1\NN\657604|additional|chloroquine (r_nsubjpass) started_8\VBN\2009433|therapy|was|arthralgia|. (l_nmod) arthralgia_11\NN\14322699|because
D013256_D009220 NONE steroids_10\NNS\14727670|with (r_nmod) treated_8\VBN\2376958|patient|was|steroids|. (r_conj) suspected_2\VBN\916909|myositis|was|,|and|treated (l_nsubjpass) myositis_0\NN\14336539|
1928887
D009270_D007022 NONE naloxone_0\NN\3808977| (r_compound) reversal_1\NN\199130|naloxone|hypotension|. (l_nmod) hypotension_3\NN\14057371|of|overdose
D009270_D007022 NONE naloxone_3\NN\3808977|the|opioid|antagonist (r_nsubjpass) shown_6\VBN\2137132|naloxone|has|been|block|. (l_xcomp) block_8\VB\1476483|to|or|reverse (l_conj) reverse_10\VB\109660|actions (l_dobj) actions_13\NNS\30358|the|hypotensive|captopril (l_amod) hypotensive_12\JJ\1740|
D009270_D007022 NONE naloxone_22\NN\3808977|of (r_nmod) administration_20\NN\1133281|with|the|naloxone (r_nmod) resolved_16\VBD\352826|that|promptly|administration (r_acl:relcl) overdose_8\NN\1740|of|an|intentional|captopril|,|manifested|,|resolved (l_acl) manifested_10\VBN\1015244|hypotension (l_nmod) hypotension_13\NN\14057371|by|marked
D009270_D007022 NONE naloxone_15\NN\3808977|with (r_nmod) treated_13\VBN\2376958|naloxone (r_acl) hypotension_12\NN\14057371|of|captopril-induced|treated
D009270_D007022 NONE naloxone_7\NN\3808977|of (r_nmod) role_5\NN\719494|a|possible|naloxone|reversal (l_nmod) reversal_10\NN\199130|in|the|hypotension (l_nmod) hypotension_12\NN\14057371|of|resulting
D009270_D062787 NONE naloxone_0\NN\3808977| (r_compound) reversal_1\NN\199130|naloxone|hypotension|. (l_nmod) hypotension_3\NN\14057371|of|overdose (l_nmod) overdose_7\NN\1740|due|captopril
D009270_D062787 NONE naloxone_22\NN\3808977|of (r_nmod) administration_20\NN\1133281|with|the|naloxone (r_nmod) resolved_16\VBD\352826|that|promptly|administration (r_acl:relcl) overdose_8\NN\1740|of|an|intentional|captopril|,|manifested|,|resolved
D002216_D007022 NONE captopril_6\NN\2673637| (r_compound) overdose_7\NN\1740|due|captopril (r_nmod) hypotension_3\NN\14057371|of|overdose
D002216_D007022 NONE captopril_15\NN\2673637|of (r_nmod) actions_13\NNS\30358|the|hypotensive|captopril (l_amod) hypotensive_12\JJ\1740|
D002216_D007022 NONE captopril_7\NN\2673637| (r_compound) overdose_8\NN\1740|of|an|intentional|captopril|,|manifested|,|resolved (l_acl) manifested_10\VBN\1015244|hypotension (l_nmod) hypotension_13\NN\14057371|by|marked
D002216_D007022 NONE captopril-induced_11\JJ\1740| (r_amod) hypotension_12\NN\14057371|of|captopril-induced|treated
D002216_D007022 NONE captopril_15\NN\2673637|from (r_nmod) resulting_13\VBG\2633881|captopril (r_acl) hypotension_12\NN\14057371|of|resulting
D002216_D062787 NONE captopril_6\NN\2673637| (r_compound) overdose_7\NN\1740|due|captopril
D002216_D062787 NONE captopril_7\NN\2673637| (r_compound) overdose_8\NN\1740|of|an|intentional|captopril|,|manifested|,|resolved
20558148
D016202_D002375 NONE nmda_4\NN\1740| (r_compound) receptors_5\NNS\5225602|by|nmda|colliculus (r_nmod) mediated_2\VBN\761713|receptors (r_acl) neurotransmission_1\NN\1740|glutamatergic|mediated (r_nsubj) modulate_11\VB\1724459|neurotransmission|can|catalepsy|. (l_dobj) catalepsy_13\NN\14023236|haloperidol-induced
D016202_D002375 NONE nmda_10\NN\1740| (r_compound) antagonists_12\NNS\7846|of|glutamate|nmda|receptor|,|mk-801|,|or|n-methyl-d-aspartate (r_nmod) microinjections_7\NNS\1740|with|prior|intracollicular|antagonists (r_nmod) challenged_3\VBN\869596|catalepsy|was|microinjections|. (l_nsubjpass) catalepsy_1\NN\14023236|haloperidol-induced
D016202_D002375 NONE nmda_35\NN\1740| (r_compound) agonist_37\NN\9613191|nmda|receptor (r_compound) n-methyl-d-aspartate_38\NN\1740|of|the|agonist|nmda (r_conj) antagonists_12\NNS\7846|of|glutamate|nmda|receptor|,|mk-801|,|or|n-methyl-d-aspartate (r_nmod) microinjections_7\NNS\1740|with|prior|intracollicular|antagonists (r_nmod) challenged_3\VBN\869596|catalepsy|was|microinjections|. (l_nsubjpass) catalepsy_1\NN\14023236|haloperidol-induced
D016202_D002375 NONE n-methyl-d-aspartate_38\NN\1740|of|the|agonist|nmda (r_conj) antagonists_12\NNS\7846|of|glutamate|nmda|receptor|,|mk-801|,|or|n-methyl-d-aspartate (r_nmod) microinjections_7\NNS\1740|with|prior|intracollicular|antagonists (r_nmod) challenged_3\VBN\869596|catalepsy|was|microinjections|. (l_nsubjpass) catalepsy_1\NN\14023236|haloperidol-induced
D016202_D002375 NONE nmda_40\NN\1740|(|,|20|microl|) (r_dep) n-methyl-d-aspartate_38\NN\1740|of|the|agonist|nmda (r_conj) antagonists_12\NNS\7846|of|glutamate|nmda|receptor|,|mk-801|,|or|n-methyl-d-aspartate (r_nmod) microinjections_7\NNS\1740|with|prior|intracollicular|antagonists (r_nmod) challenged_3\VBN\869596|catalepsy|was|microinjections|. (l_nsubjpass) catalepsy_1\NN\14023236|haloperidol-induced
D006220_D002375 CID haloperidol-induced_12\JJ\1740| (r_amod) catalepsy_13\NN\14023236|haloperidol-induced
D006220_D002375 CID haloperidol_23\NN\3713736|by|the|blocker|administered (r_nmod) induced_17\VBN\1627355|haloperidol (r_acl) catalepsy_16\NN\14023236|on|the|induced
D006220_D002375 CID haloperidol-induced_0\JJ\1740| (r_amod) catalepsy_1\NN\14023236|haloperidol-induced
D006220_D002375 CID haloperidol_15\NN\3713736|of (r_nmod) injections_13\NNS\320852|to|systemic|haloperidol (r_nmod) previous_10\JJ\1740|injections (r_amod) microinjection_5\NN\1740|intracollicular|mk-801|previous (r_nsubj) attenuated_17\VBD\224901|that|microinjection|significantly|catalepsy|,|indicated (l_dobj) catalepsy_19\NN\14023236|the
D006220_D002375 CID haloperidol-induced_15\JJ\1740| (r_amod) catalepsy_16\NN\14023236|haloperidol-induced
D000596_D002375 NONE acid-mediated_9\JJ\1740|excitatory|amino (r_amod) mechanisms_10\NNS\13446390|of|acid-mediated|ic (r_nmod) influence_5\NN\5190804|the|mechanisms|catalepsy (l_nmod) catalepsy_16\NN\14023236|on|the|induced
D004298_D002375 NONE dopamine_20\NN\14807737| (r_compound) blocker_22\NN\10101634|dopamine|receptor (r_compound) haloperidol_23\NN\3713736|by|the|blocker|administered (r_nmod) induced_17\VBN\1627355|haloperidol (r_acl) catalepsy_16\NN\14023236|on|the|induced
D018698_D002375 NONE glutamate_9\NN\15010703| (r_compound) antagonists_12\NNS\7846|of|glutamate|nmda|receptor|,|mk-801|,|or|n-methyl-d-aspartate (r_nmod) microinjections_7\NNS\1740|with|prior|intracollicular|antagonists (r_nmod) challenged_3\VBN\869596|catalepsy|was|microinjections|. (l_nsubjpass) catalepsy_1\NN\14023236|haloperidol-induced
D018698_D002375 NONE glutamate-mediated_4\JJ\1740| (r_amod) mechanisms_5\NNS\13446390|glutamate-mediated|circuits (r_nsubj) influence_14\VBP\137313|that|mechanisms|catalepsy|and|participate (l_dobj) catalepsy_16\NN\14023236|haloperidol-induced
D016291_D002375 NONE mk-801_14\NN\1740|microl|)|and|ap7 (r_conj) antagonists_12\NNS\7846|of|glutamate|nmda|receptor|,|mk-801|,|or|n-methyl-d-aspartate (r_nmod) microinjections_7\NNS\1740|with|prior|intracollicular|antagonists (r_nmod) challenged_3\VBN\869596|catalepsy|was|microinjections|. (l_nsubjpass) catalepsy_1\NN\14023236|haloperidol-induced
D016291_D002375 NONE mk-801_7\NN\1740|of|and|ap7 (r_nmod) microinjection_5\NN\1740|intracollicular|mk-801|previous (r_nsubj) attenuated_17\VBD\224901|that|microinjection|significantly|catalepsy|,|indicated (l_dobj) catalepsy_19\NN\14023236|the
C031231_D002375 NONE ap7_23\NN\1740|microl|) (r_conj) mk-801_14\NN\1740|microl|)|and|ap7 (r_conj) antagonists_12\NNS\7846|of|glutamate|nmda|receptor|,|mk-801|,|or|n-methyl-d-aspartate (r_nmod) microinjections_7\NNS\1740|with|prior|intracollicular|antagonists (r_nmod) challenged_3\VBN\869596|catalepsy|was|microinjections|. (l_nsubjpass) catalepsy_1\NN\14023236|haloperidol-induced
C031231_D002375 NONE ap7_9\NN\1740| (r_conj) mk-801_7\NN\1740|of|and|ap7 (r_nmod) microinjection_5\NN\1740|intracollicular|mk-801|previous (r_nsubj) attenuated_17\VBD\224901|that|microinjection|significantly|catalepsy|,|indicated (l_dobj) catalepsy_19\NN\14023236|the
2435991
C032151_D001145 NONE cibenzoline_4\NN\1740|of (r_nmod) concentrations_2\NNS\4916342|antiarrhythmic|plasma|cibenzoline|arrhythmias|. (l_nmod) arrhythmias_8\NNS\14103288|on|canine|ventricular
C032151_D001145 NONE cibenzoline_16\NN\1740|of (r_nmod) effects_14\NNS\13245626|antiarrhythmic|cibenzoline (r_nsubjpass) examined_18\VBN\789138|using|,|effects|were|and|determined (l_advcl) using_0\VBG\1156834|ligation- (l_dobj) ligation-_3\NN\1740|two-stage|coronary|,|digitalis-|,|and|arrhythmias (l_conj) arrhythmias_11\NNS\14103288|adrenaline-induced|canine|ventricular
C032151_D001145 NONE cibenzoline_16\NN\1740|of (r_nmod) effects_14\NNS\13245626|antiarrhythmic|cibenzoline (r_nsubjpass) examined_18\VBN\789138|using|,|effects|were|and|determined (l_conj) determined_30\VBN\1645601|concentration|was|. (l_nsubjpass) concentration_24\NN\4916342|the|minimum|effective|plasma|model (l_nmod) model_28\NN\5888929|for|each|arrhythmia (l_compound) arrhythmia_27\NN\14103288|
C032151_D001145 NONE cibenzoline_0\NN\1740| (r_nsubj) suppressed_1\VBD\2510337|cibenzoline|arrhythmias|,|and|1.9 (l_dobj) arrhythmias_4\NNS\14103288|all|the
C032151_D001145 NONE cibenzoline_0\NN\1740| (r_nsubj) suppressed_1\VBD\2510337|cibenzoline|arrhythmias|,|and|1.9 (l_conj) 1.9_29\CD\1740|concentrations|were|+/-|0.9|mg/kg|,|1.6|mg/kg|,|0.6|,|and|3.5|micrograms/ml|,|respectively|=|. (l_nsubj) concentrations_11\NNS\4916342|the|minimum|effective|plasma|arrhythmias (l_nmod) arrhythmias_13\NNS\14103288|for|induced
C032151_D001145 NONE cibenzoline_1\NN\1740| (r_nsubj) had_2\VBD\2108377|because|cibenzoline|effects|and|found (l_conj) found_13\VBN\2426171|was|active|given (l_advcl) given_19\VBN\2327200|when|dogs (l_nmod) dogs_24\NNS\2083346|to|ligation|arrhythmia (l_compound) arrhythmia_23\NN\14103288|
D004071_D001145 CID digitalis-_5\NN\1740| (r_conj) ligation-_3\NN\1740|two-stage|coronary|,|digitalis-|,|and|arrhythmias (l_conj) arrhythmias_11\NNS\14103288|adrenaline-induced|canine|ventricular
D004071_D001145 CID digitalis-_5\NN\1740| (r_conj) ligation-_3\NN\1740|two-stage|coronary|,|digitalis-|,|and|arrhythmias (r_dobj) using_0\VBG\1156834|ligation- (r_advcl) examined_18\VBN\789138|using|,|effects|were|and|determined (l_conj) determined_30\VBN\1645601|concentration|was|. (l_nsubjpass) concentration_24\NN\4916342|the|minimum|effective|plasma|model (l_nmod) model_28\NN\5888929|for|each|arrhythmia (l_compound) arrhythmia_27\NN\14103288|
D004071_D001145 CID digitalis_24\NN\15059939| (r_conj) ligation_18\NN\149084|by|24-h|coronary|,|ligation|,|digitalis|,|and|adrenaline (r_nmod) induced_14\VBN\1627355|ligation (r_acl) arrhythmias_13\NNS\14103288|for|induced (r_nmod) concentrations_11\NNS\4916342|the|minimum|effective|plasma|arrhythmias (r_nsubj) 1.9_29\CD\1740|concentrations|were|+/-|0.9|mg/kg|,|1.6|mg/kg|,|0.6|,|and|3.5|micrograms/ml|,|respectively|=|. (r_conj) suppressed_1\VBD\2510337|cibenzoline|arrhythmias|,|and|1.9 (l_dobj) arrhythmias_4\NNS\14103288|all|the
D004071_D001145 CID digitalis_24\NN\15059939| (r_conj) ligation_18\NN\149084|by|24-h|coronary|,|ligation|,|digitalis|,|and|adrenaline (r_nmod) induced_14\VBN\1627355|ligation (r_acl) arrhythmias_13\NNS\14103288|for|induced
D004837_D001145 CID adrenaline-induced_8\JJ\1740| (r_amod) arrhythmias_11\NNS\14103288|adrenaline-induced|canine|ventricular
D004837_D001145 CID adrenaline-induced_8\JJ\1740| (r_amod) arrhythmias_11\NNS\14103288|adrenaline-induced|canine|ventricular (r_conj) ligation-_3\NN\1740|two-stage|coronary|,|digitalis-|,|and|arrhythmias (r_dobj) using_0\VBG\1156834|ligation- (r_advcl) examined_18\VBN\789138|using|,|effects|were|and|determined (l_conj) determined_30\VBN\1645601|concentration|was|. (l_nsubjpass) concentration_24\NN\4916342|the|minimum|effective|plasma|model (l_nmod) model_28\NN\5888929|for|each|arrhythmia (l_compound) arrhythmia_27\NN\14103288|
D004837_D001145 CID adrenaline_27\NN\14807929| (r_conj) ligation_18\NN\149084|by|24-h|coronary|,|ligation|,|digitalis|,|and|adrenaline (r_nmod) induced_14\VBN\1627355|ligation (r_acl) arrhythmias_13\NNS\14103288|for|induced (r_nmod) concentrations_11\NNS\4916342|the|minimum|effective|plasma|arrhythmias (r_nsubj) 1.9_29\CD\1740|concentrations|were|+/-|0.9|mg/kg|,|1.6|mg/kg|,|0.6|,|and|3.5|micrograms/ml|,|respectively|=|. (r_conj) suppressed_1\VBD\2510337|cibenzoline|arrhythmias|,|and|1.9 (l_dobj) arrhythmias_4\NNS\14103288|all|the
D004837_D001145 CID adrenaline_27\NN\14807929| (r_conj) ligation_18\NN\149084|by|24-h|coronary|,|ligation|,|digitalis|,|and|adrenaline (r_nmod) induced_14\VBN\1627355|ligation (r_acl) arrhythmias_13\NNS\14103288|for|induced
D004837_D001145 CID adrenaline-induced_3\JJ\1740| (r_amod) arrhythmia_4\NN\14103288|for|adrenaline-induced
D004837_D001145 CID adrenaline-induced_3\JJ\1740| (r_amod) arrhythmia_4\NN\14103288|for|adrenaline-induced (r_nmod) concentration_1\NN\4916342|the|arrhythmia (r_nsubj) higher_7\JJR\1740|concentration|was|significantly|those|. (l_nmod) those_9\DT\1740|than|types (l_nmod) types_13\NNS\5839024|for|the|other|arrhythmias (l_nmod) arrhythmias_15\NNS\14103288|of
C032151_D007022 NONE cibenzoline_1\NN\1740| (r_nsubj) had_2\VBD\2108377|because|cibenzoline|effects|and|found (l_dobj) effects_10\NNS\13245626|hypotensive (l_amod) hypotensive_5\JJ\1740|weak|and|node|depressive
C032151_D003866 NONE cibenzoline_1\NN\1740| (r_nsubj) had_2\VBD\2108377|because|cibenzoline|effects|and|found (l_dobj) effects_10\NNS\13245626|hypotensive (l_amod) hypotensive_5\JJ\1740|weak|and|node|depressive (l_dep) depressive_9\JJ\1740|
8384253
D014750_D008228 NONE vincristine_8\NN\3917455|with (r_nmod) treated_6\VBN\2376958|vincristine|1984 (r_acl) patients_1\NNS\9898892|forty|lymphoma|treated (l_nmod) lymphoma_5\NN\14239918|with|non-hodgkin
D014750_D008228 NONE vincristine_35\NN\3917455|of (r_nmod) effects_33\NNS\13245626|the|term|vincristine|system (r_dobj) evaluate_29\VB\670261|in|to|effects (r_advcl) investigated_25\VBN\644583|patients|were|evaluate|. (l_nsubjpass) patients_1\NNS\9898892|forty|lymphoma|treated (l_nmod) lymphoma_5\NN\14239918|with|non-hodgkin
D014750_D009422 NONE vincristine_8\NN\3917455| (r_compound) dose_9\NN\3740161|vincristine (r_compound) schedule_10\NN\5898568|with|the|mentioned|dose (r_nmod) reversible_18\JJ\1740|that|schedule|signs|are|deal|and|good (l_nsubj) signs_11\NNS\6643763|and|symptoms|neuropathy (l_nmod) neuropathy_16\NN\14204950|of|vincristine
D014750_D009422 NONE vincristine_15\NN\3917455| (r_compound) neuropathy_16\NN\14204950|of|vincristine
11099450
D007980_D010300 NONE levodopa-induced_33\JJ\1740| (r_amod) dyskinesias_34\NNS\14084880|levodopa-induced|lid (r_conj) signs_31\NNS\6643763|on|parkinsonian|off|'|and|dyskinesias (l_amod) parkinsonian_27\JJ\1740|
D007980_D010300 NONE levodopa_5\NN\14604959| (r_compound) responsiveness_6\NN\5652926|of|levodopa (r_nmod) value_3\NN\5856066|the|differential|predictive|responsiveness|outcome|and|correlations (l_nmod) outcome_9\NN\7291312|for|the|signs (l_nmod) signs_15\NNS\6643763|of|parkinsonian|off|'|and|lid (l_amod) parkinsonian_11\JJ\1740|
D007980_D010300 NONE levodopa_5\NN\14604959| (r_compound) responsiveness_6\NN\5652926|of|levodopa (r_nmod) value_3\NN\5856066|the|differential|predictive|responsiveness|outcome|and|correlations (l_conj) correlations_21\NNS\13841213|the|different|volume|dyskinesias (l_nmod) dyskinesias_27\NNS\14084880|with|and|signs (l_conj) signs_33\NNS\6643763|parkinsonian|'|off|' (l_amod) parkinsonian_29\JJ\1740|
D007980_D010300 NONE levodopa_5\NN\14604959| (r_compound) responsiveness_6\NN\5652926|of|levodopa (r_nmod) value_3\NN\5856066|the|differential|predictive|responsiveness|outcome|and|correlations (r_nsubj) indicate_34\VBP\952524|value|responsible|. (l_ccomp) responsible_43\JJ\1740|that|substrates|may|be|generation (l_nmod) generation_46\NN\7942152|for|the|signs (l_nmod) signs_52\NNS\6643763|of|parkinsonian|off|'|and|dyskinesias (l_amod) parkinsonian_48\JJ\1740|
D007980_D004409 CID levodopa-induced_33\JJ\1740| (r_amod) dyskinesias_34\NNS\14084880|levodopa-induced|lid
D007980_D004409 CID levodopa-induced_33\JJ\1740| (r_amod) dyskinesias_34\NNS\14084880|levodopa-induced|lid (l_appos) lid_36\NN\5313679|(|)
D007980_D004409 CID levodopa_8\NN\14604959| (r_compound) responsiveness_9\NN\5652926|between|the|preoperative|levodopa|signs|and|responsiveness (r_nmod) correlations_4\NNS\13841213|positive|responsiveness (r_dobj) found_1\VBD\2426171|we|correlations|,|whereas|was (l_parataxis) was_45\VBD\836236|there|correlation|. (l_attr) correlation_47\NN\13841213|no|improvement (l_nmod) improvement_50\NN\7359599|with|the|lid (l_nmod) lid_52\NN\5313679|in
D007980_D004409 CID levodopa_15\NN\14604959| (r_compound) responsiveness_16\NN\5652926|the|levodopa|scores|limbs|and|improvement (r_conj) responsiveness_9\NN\5652926|between|the|preoperative|levodopa|signs|and|responsiveness (r_nmod) correlations_4\NNS\13841213|positive|responsiveness (r_dobj) found_1\VBD\2426171|we|correlations|,|whereas|was (l_parataxis) was_45\VBD\836236|there|correlation|. (l_attr) correlation_47\NN\13841213|no|improvement (l_nmod) improvement_50\NN\7359599|with|the|lid (l_nmod) lid_52\NN\5313679|in
D007980_D004409 CID levodopa_5\NN\14604959| (r_compound) responsiveness_6\NN\5652926|of|levodopa (r_nmod) value_3\NN\5856066|the|differential|predictive|responsiveness|outcome|and|correlations (l_nmod) outcome_9\NN\7291312|for|the|signs (l_nmod) signs_15\NNS\6643763|of|parkinsonian|off|'|and|lid (l_conj) lid_17\NN\5313679|
D007980_D004409 CID levodopa_5\NN\14604959| (r_compound) responsiveness_6\NN\5652926|of|levodopa (r_nmod) value_3\NN\5856066|the|differential|predictive|responsiveness|outcome|and|correlations (l_conj) correlations_21\NNS\13841213|the|different|volume|dyskinesias (l_nmod) dyskinesias_27\NNS\14084880|with|and|signs
D007980_D004409 CID levodopa_5\NN\14604959| (r_compound) responsiveness_6\NN\5652926|of|levodopa (r_nmod) value_3\NN\5856066|the|differential|predictive|responsiveness|outcome|and|correlations (r_nsubj) indicate_34\VBP\952524|value|responsible|. (l_ccomp) responsible_43\JJ\1740|that|substrates|may|be|generation (l_nmod) generation_46\NN\7942152|for|the|signs (l_nmod) signs_52\NNS\6643763|of|parkinsonian|off|'|and|dyskinesias (l_conj) dyskinesias_54\NNS\14084880|
15042318
D004317_C535648 NONE doxorubicin-based_32\JJ\1740| (r_amod) chemotherapy_33\NN\661091|of|doxorubicin-based (r_nmod) cycle_30\NN\15269513|following|one|chemotherapy (r_nmod) fibrillation_27\NN\14361664|sudden|atrial|cycle|patient (r_conj) dystrophy_13\NN\14151139|myotonic|,|form|,|and|fibrillation (r_conj) lymphoma_10\NN\14239918|between|diffuse|b-cell|gastric|and|dystrophy
D004317_D009223 NONE doxorubicin-based_32\JJ\1740| (r_amod) chemotherapy_33\NN\661091|of|doxorubicin-based (r_nmod) cycle_30\NN\15269513|following|one|chemotherapy (r_nmod) fibrillation_27\NN\14361664|sudden|atrial|cycle|patient (r_conj) dystrophy_13\NN\14151139|myotonic|,|form|,|and|fibrillation
D004317_D009136 NONE doxorubicin-based_32\JJ\1740| (r_amod) chemotherapy_33\NN\661091|of|doxorubicin-based (r_nmod) cycle_30\NN\15269513|following|one|chemotherapy (r_nmod) fibrillation_27\NN\14361664|sudden|atrial|cycle|patient (r_conj) dystrophy_13\NN\14151139|myotonic|,|form|,|and|fibrillation (l_appos) form_18\NN\6286395|the|common|dystrophy (l_nmod) dystrophy_22\NN\14151139|of|adult|muscular
D004317_D001281 CID doxorubicin-based_32\JJ\1740| (r_amod) chemotherapy_33\NN\661091|of|doxorubicin-based (r_nmod) cycle_30\NN\15269513|following|one|chemotherapy (r_nmod) fibrillation_27\NN\14361664|sudden|atrial|cycle|patient
11860278
D004298_D004827 NONE dopamine_0\NN\14807737|da|,|signaling (r_nsubj) plays_10\VBZ\1072262|dopamine|,|role|control|. (l_nmod) control_16\NN\5190804|in|the|seizures (l_nmod) seizures_19\NNS\14081375|of|epileptic|arising
D004298_D004827 NONE da_2\NN\10484858|(|) (r_appos) dopamine_0\NN\14807737|da|,|signaling (r_nsubj) plays_10\VBZ\1072262|dopamine|,|role|control|. (l_nmod) control_16\NN\5190804|in|the|seizures (l_nmod) seizures_19\NNS\14081375|of|epileptic|arising
D004298_D004827 NONE da_11\NN\10484858| (r_compound) receptors_12\NNS\5225602|of|da (r_nmod) role_9\NN\719494|about|the|receptors|occurrence (l_nmod) occurrence_15\NN\29378|in|the|death (l_nmod) death_20\NN\7296428|of|epilepsy-induced|neuronal|cell (l_amod) epilepsy-induced_17\JJ\1740|
D010862_D012640 CID pilocarpine_18\NN\14712692|with|the|cholinergic|agonist (r_nmod) treated_13\VBN\2376958|pilocarpine (r_acl) mice_12\NNS\2329401|in|d2r|-/-|treated (r_nmod) occurrence_4\NN\29378|the|seizures|mice (l_nmod) seizures_6\NNS\14081375|of|and|neurotoxicity
D010862_D012640 CID pilocarpine-induced_2\JJ\1740| (r_amod) seizures_3\NNS\14081375|pilocarpine-induced
D010862_D020258 NONE pilocarpine_18\NN\14712692|with|the|cholinergic|agonist (r_nmod) treated_13\VBN\2376958|pilocarpine (r_acl) mice_12\NNS\2329401|in|d2r|-/-|treated (r_nmod) occurrence_4\NN\29378|the|seizures|mice (l_nmod) seizures_6\NNS\14081375|of|and|neurotoxicity (l_conj) neurotoxicity_8\NN\1740|
D007608_D012640 CID ka_21\NN\1740|to (r_nmod) comparison_19\NN\635850|in|ka (r_nmod) result_4\VBP\2633881|however|,|seizures|death|comparison|. (l_nsubj) seizures_3\NNS\14081375|pilocarpine-induced
D018698_D012640 NONE glutamate_14\NN\15010703|by|both|and|acetylcholine (r_nmod) induced_11\VBN\1627355|glutamate (r_acl) seizures_10\NNS\14081375|for|induced
D000109_D012640 NONE acetylcholine_16\NN\14807558| (r_conj) glutamate_14\NN\15010703|by|both|and|acetylcholine (r_nmod) induced_11\VBN\1627355|glutamate (r_acl) seizures_10\NNS\14081375|for|induced
2021202
D007530_D007022 CID isoflurane-induced_6\JJ\1740| (r_amod) hypotension_7\NN\14057371|during|prolonged|isoflurane-induced|humans
D007530_D007022 CID isoflurane-induced_3\JJ\1740| (r_amod) hypotension_4\NN\14057371|of|isoflurane-induced
D007530_D007022 CID isoflurane_11\NN\3570838| (r_nmod:npmod) inspired_12\JJ\1740|isoflurane (r_amod) concentration_13\NN\4916342|the|inspired (r_dobj) increasing_9\VBG\169651|by|concentration|maintain (r_advcl) induced_2\VBN\1627355|hypotension|was|min|increasing|. (l_nsubjpass) hypotension_0\NN\14057371|
D007530_D007022 CID isoflurane-induced_9\JJ\1740| (r_amod) hypotension_10\NN\14057371|during|isoflurane-induced
17923537
D005446_D014605 NONE acetonide_9\NN\1740| (r_compound) implants_10\NNS\4013729|with|fluocinolone|acetonide (r_nmod) treated_6\VBN\2376958|implants (r_acl) patients_3\NNS\9898892|in|uveitis|treated (l_nmod) uveitis_5\NN\14336539|with
D005446_D014605 NONE acetonide_23\NN\1740|fluocinolone|fa (r_compound) implant_28\NN\4013729|with|the|acetonide|intravitreal (r_nmod) treated_19\VBN\2376958|implant (r_acl) patients_16\NNS\9898892|in|uveitis|treated (l_nmod) uveitis_18\NN\14336539|with
D005446_D014605 NONE fa_25\NN\6868043|(|) (r_appos) acetonide_23\NN\1740|fluocinolone|fa (r_compound) implant_28\NN\4013729|with|the|acetonide|intravitreal (r_nmod) treated_19\VBN\2376958|implant (r_acl) patients_16\NNS\9898892|in|uveitis|treated (l_nmod) uveitis_18\NN\14336539|with
D005446_D009798 CID acetonide_23\NN\1740|fluocinolone|fa (r_compound) implant_28\NN\4013729|with|the|acetonide|intravitreal (r_nmod) treated_19\VBN\2376958|implant (r_acl) patients_16\NNS\9898892|in|uveitis|treated (r_nmod) incidence_5\NN\13821570|the|and|management|pressure|patients (l_nmod) pressure_11\NN\11419404|of|elevated|intraocular|iop
D005446_D009798 CID fa_25\NN\6868043|(|) (r_appos) acetonide_23\NN\1740|fluocinolone|fa (r_compound) implant_28\NN\4013729|with|the|acetonide|intravitreal (r_nmod) treated_19\VBN\2376958|implant (r_acl) patients_16\NNS\9898892|in|uveitis|treated (r_nmod) incidence_5\NN\13821570|the|and|management|pressure|patients (l_nmod) pressure_11\NN\11419404|of|elevated|intraocular|iop
2980315
C053571_D014693 NONE iopentol_14\NN\1740|after|%|and|iohexol (r_nmod) lower_6\JJR\1740|frequencies|were|significantly|p|iopentol|than|. (l_nsubj) frequencies_0\NNS\15286249|fibrillation (l_nmod) fibrillation_3\NN\14361664|of|ventricular
D007472_D014693 NONE iohexol_20\NN\1740|% (r_conj) iopentol_14\NN\1740|after|%|and|iohexol (r_nmod) lower_6\JJR\1740|frequencies|were|significantly|p|iopentol|than|. (l_nsubj) frequencies_0\NNS\15286249|fibrillation (l_nmod) fibrillation_3\NN\14361664|of|ventricular
D008794_D014693 CID metrizoate_27\NN\1740|after|% (r_nmod) than_25\IN\1740|metrizoate (r_prep) lower_6\JJR\1740|frequencies|were|significantly|p|iopentol|than|. (l_nsubj) frequencies_0\NNS\15286249|fibrillation (l_nmod) fibrillation_3\NN\14361664|of|ventricular
803783
D010121_D014869 CID oxytocin_4\NN\5407119| (r_compound) administration_5\NN\1133281|with|oxytocin|abortion (r_nmod) associated_2\VBN\628491|administration (r_acl) intoxication_1\NN\14034177|water|associated|.
D010121_D014869 CID oxytocin_8\NN\5407119| (r_compound) administration_9\NN\1133281|with|oxytocin|abortions (r_nmod) connection_6\NN\31921|in|administration (r_nmod) cases_1\NNS\7283608|four|intoxication|connection (l_nmod) intoxication_4\NN\14034177|of|water
D010121_D014869 CID oxytocin_0\NN\5407119| (r_compound) administration_1\NN\1133281|oxytocin|abortions (r_nsubjpass) advocated_6\VBN\875394|administration|is|carried|. (l_advcl) carried_12\VBN\1850315|only|if|it|can|be|out|observations (l_nmod) observations_16\NNS\996969|under|careful|staff (l_nmod) staff_21\NN\8208016|of|an|alert|nursing|,|aware|and|instructed (l_amod) aware_23\JJ\1740|symptoms (l_nmod) symptoms_26\NNS\5823932|of|the|intoxication (l_nmod) intoxication_29\NN\14034177|of|water
D010121_D000031 NONE oxytocin_4\NN\5407119| (r_compound) administration_5\NN\1133281|with|oxytocin|abortion (l_nmod) abortion_8\NN\209943|during|saline-induced
D010121_D000031 NONE oxytocin_8\NN\5407119| (r_compound) administration_9\NN\1133281|with|oxytocin|abortions (l_nmod) abortions_12\NNS\209943|during|saline-induced
D010121_D000031 NONE oxytocin_0\NN\5407119| (r_compound) administration_1\NN\1133281|oxytocin|abortions (l_nmod) abortions_4\NNS\209943|during|midtrimester-induced
D010121_D001247 NONE oxytocin_0\NN\5407119| (r_compound) administration_1\NN\1133281|oxytocin|abortions (r_nsubjpass) advocated_6\VBN\875394|administration|is|carried|. (l_advcl) carried_12\VBN\1850315|only|if|it|can|be|out|observations (l_nmod) observations_16\NNS\996969|under|careful|staff (l_nmod) staff_21\NN\8208016|of|an|alert|nursing|,|aware|and|instructed (l_conj) instructed_31\VBN\831651|watch (l_xcomp) watch_33\VB\661824|to|diuresis|and|report (l_conj) report_37\VB\831651|signs (l_dobj) signs_40\NNS\6643763|such|early|syndrome|asthenia (l_nmod) asthenia_45\NN\14547643|as|,|irritability
D010121_D001523 NONE oxytocin_0\NN\5407119| (r_compound) administration_1\NN\1133281|oxytocin|abortions (r_nsubjpass) advocated_6\VBN\875394|administration|is|carried|. (l_advcl) carried_12\VBN\1850315|only|if|it|can|be|out|observations (l_nmod) observations_16\NNS\996969|under|careful|staff (l_nmod) staff_21\NN\8208016|of|an|alert|nursing|,|aware|and|instructed (l_conj) instructed_31\VBN\831651|watch (l_xcomp) watch_33\VB\661824|to|diuresis|and|report (l_conj) report_37\VB\831651|signs (l_dobj) signs_40\NNS\6643763|such|early|syndrome|asthenia (l_nmod) asthenia_45\NN\14547643|as|,|irritability (l_conj) irritability_48\NN\7552087|muscular|,|or|headaches
D010121_D006261 NONE oxytocin_0\NN\5407119| (r_compound) administration_1\NN\1133281|oxytocin|abortions (r_nsubjpass) advocated_6\VBN\875394|administration|is|carried|. (l_advcl) carried_12\VBN\1850315|only|if|it|can|be|out|observations (l_nmod) observations_16\NNS\996969|under|careful|staff (l_nmod) staff_21\NN\8208016|of|an|alert|nursing|,|aware|and|instructed (l_conj) instructed_31\VBN\831651|watch (l_xcomp) watch_33\VB\661824|to|diuresis|and|report (l_conj) report_37\VB\831651|signs (l_dobj) signs_40\NNS\6643763|such|early|syndrome|asthenia (l_nmod) asthenia_45\NN\14547643|as|,|irritability (l_conj) irritability_48\NN\7552087|muscular|,|or|headaches (l_conj) headaches_51\NNS\5829480|
20735774
D000082_D017114 CID paracetamol-induced_6\NN\1740| (r_amod) failure_9\NN\66216|of|paracetamol-induced|acute|liver
D000082_D017114 CID paracetamol-induced_8\JJ\1740| (r_amod) failure_11\NN\66216|of|paracetamol-induced|acute|liver
D000082_D017114 CID paracetamol-induced_5\JJ\1740| (r_amod) failure_8\NN\66216|paracetamol-induced|acute|liver
D000082_D017114 CID paracetamol-induced_14\JJ\1740| (r_amod) injury_16\NN\14052046|whose|paracetamol-induced|liver (r_nsubj) caused_18\VBN\1617192|injury|had|failure (l_dobj) failure_22\NN\66216|an|acute|liver
D000082_D017114 CID paracetamol-induced_14\JJ\1740| (r_amod) injury_16\NN\14052046|whose|paracetamol-induced|liver (r_nsubj) caused_18\VBN\1617192|injury|had|failure (r_acl:relcl) patients_12\NNS\9898892|for|the|101|caused (r_nmod) higher_8\JJR\1740|on|,|rates|were|slightly|patients|=|,|but|age-dependent|frequent (l_conj) age-dependent_43\JJ\1740|association|was|,|and|died|,|whereas (l_conj) died_52\VBD\146138|survivors|disease (l_nsubj) survivors_47\NNS\9630641|no|failure (l_nmod) failure_51\NN\66216|of|acute|liver
D000082_D017114 CID paracetamol-induced_2\JJ\1740| (r_amod) failure_5\NN\66216|paracetamol-induced|acute|liver
D000082_D056486 NONE paracetamol-induced_9\JJ\1740| (r_amod) injury_12\NN\14052046|of|paracetamol-induced|acute|liver
D000082_D056486 NONE paracetamol-induced_14\JJ\1740| (r_amod) injury_16\NN\14052046|whose|paracetamol-induced|liver
D000082_D008107 NONE paracetamol-induced_14\JJ\1740| (r_amod) injury_16\NN\14052046|whose|paracetamol-induced|liver (r_nsubj) caused_18\VBN\1617192|injury|had|failure (r_acl:relcl) patients_12\NNS\9898892|for|the|101|caused (r_nmod) higher_8\JJR\1740|on|,|rates|were|slightly|patients|=|,|but|age-dependent|frequent (l_conj) age-dependent_43\JJ\1740|association|was|,|and|died|,|whereas (l_conj) died_52\VBD\146138|survivors|disease (l_nmod) disease_55\NN\14061805|of|liver
2220369
C015173_D020246 CID epinephrine_6\NN\14807929|topical|dipivalyl (r_conj) thrombosis_2\NN\14100769|vein|and|epinephrine|.
C015173_D020246 CID epinephrine_26\NN\14807929|with|dipivalyl (r_nmod) medication_23\NN\3247620|topical|epinephrine (r_dobj) started_21\VBN\2009433|after|having|medication|glaucoma (r_advcl) acquired_9\VBD\109660|who|thrombosis|eye|day|started (l_dobj) thrombosis_12\NN\14100769|vein
C015173_D005901 NONE epinephrine_26\NN\14807929|with|dipivalyl (r_nmod) medication_23\NN\3247620|topical|epinephrine (r_dobj) started_21\VBN\2009433|after|having|medication|glaucoma (l_nmod) glaucoma_29\NN\14252864|for|advanced|discovered
12600698
C005435_D015837 NONE edaravone_3\NN\1740|of (r_nmod) effect_1\NN\34213|protective|edaravone|vestibulotoxicity|. (l_nmod) vestibulotoxicity_6\NN\1740|against|streptomycin-induced|pig
C005435_D015837 NONE edaravone_8\NN\1740|by (r_nmod) alleviation_3\NN\7492516|vestibulotoxicity|edaravone|pigs (l_nmod) vestibulotoxicity_6\NN\1740|of|streptomycin-induced
C005435_D015837 NONE edaravone_4\NN\1740| (r_nsubj) suppresses_5\VBZ\2510337|that|edaravone|vestibulotoxicity (l_dobj) vestibulotoxicity_7\NN\1740|streptomycin-induced
D013307_D015837 CID streptomycin-induced_5\JJ\1740| (r_amod) vestibulotoxicity_6\NN\1740|against|streptomycin-induced|pig
D013307_D015837 CID streptomycin-induced_5\JJ\1740| (r_amod) vestibulotoxicity_6\NN\1740|of|streptomycin-induced
D013307_D015837 CID streptomycin-induced_6\JJ\1740| (r_amod) vestibulotoxicity_7\NN\1740|streptomycin-induced
C005435_D002544 NONE edaravone_0\NN\1740|,|scavenger|, (r_nsubj) has_7\VBZ\2108377|edaravone|action|and|used|. (l_conj) used_15\VBN\1156834|is|practice|treat (l_xcomp) treat_20\VB\2376958|to|infarction (l_dobj) infarction_22\NN\14204950|cerebral
10354657
D008094_D013959 NONE lithium_9\NN\14625458| (r_compound) therapy_10\NN\657604|of|lithium (r_nmod) duration_7\NN\15113229|to|the|therapy|,|age|(|had|) (l_acl:relcl) had_25\VBD\2108377|whether|not|patient|relative (l_dobj) relative_28\NN\7846|a|first-degree|disease (l_nmod) disease_31\NN\14061805|with|thyroid
D008094_D013959 NONE lithium_20\NN\14625458| (r_compound) therapy_21\NN\657604|of|lithium (r_nmod) onset_18\NN\7325190|after|therapy (r_nmod) years_16\NNS\15144371|(|3.7|onset|) (r_appos) onset_11\NN\7325190|patients|had|accelerated|hypothyroidism|years|patients|. (l_nsubj) patients_1\NNS\9898892|all|having (l_acl) having_2\VBG\2108377|relatives (l_dobj) relatives_4\NNS\7846|first-degree|affected (l_acl) affected_5\VBN\126264|illness (l_nmod) illness_8\NN\14052046|by|thyroid
D008094_D013959 NONE lithium_36\NN\14625458| (r_compound) therapy_37\NN\657604|of|lithium (r_nmod) onset_34\NN\7325190|after|therapy (r_nmod) years_32\NNS\15144371|(|8.6|onset|) (r_dep) patients_25\NNS\9898892|compared|with|history|years (r_nmod) onset_11\NN\7325190|patients|had|accelerated|hypothyroidism|years|patients|. (l_nsubj) patients_1\NNS\9898892|all|having (l_acl) having_2\VBG\2108377|relatives (l_dobj) relatives_4\NNS\7846|first-degree|affected (l_acl) affected_5\VBN\126264|illness (l_nmod) illness_8\NN\14052046|by|thyroid
D008094_D013959 NONE lithium_14\NN\14625458| (r_compound) therapy_15\NN\657604|during|lithium (r_nmod) factor_8\NN\7326557|:|illness|is|a|risk|hypothyroidism|therapy (l_nsubj) illness_4\NN\14052046|familial|thyroid
D008094_D001714 NONE lithium_18\NN\14625458| (r_compound) therapy_20\NN\657604|lithium|maintenance|ranging (r_dobj) receiving_17\VBG\2210855|therapy (r_acl) patients_6\NNS\9898892|hundred|(|men|)|disorder|receiving (l_nmod) disorder_16\NN\14034177|with|bipolar
D008094_D007037 CID lithium_20\NN\14625458| (r_compound) therapy_21\NN\657604|of|lithium (r_nmod) onset_18\NN\7325190|after|therapy (r_nmod) years_16\NNS\15144371|(|3.7|onset|) (r_appos) onset_11\NN\7325190|patients|had|accelerated|hypothyroidism|years|patients|. (l_nmod) hypothyroidism_13\NN\14059928|of
D008094_D007037 CID lithium_36\NN\14625458| (r_compound) therapy_37\NN\657604|of|lithium (r_nmod) onset_34\NN\7325190|after|therapy (r_nmod) years_32\NNS\15144371|(|8.6|onset|) (r_dep) patients_25\NNS\9898892|compared|with|history|years (r_nmod) onset_11\NN\7325190|patients|had|accelerated|hypothyroidism|years|patients|. (l_nmod) hypothyroidism_13\NN\14059928|of
D008094_D007037 CID lithium_14\NN\14625458| (r_compound) therapy_15\NN\657604|during|lithium (r_nmod) factor_8\NN\7326557|:|illness|is|a|risk|hypothyroidism|therapy (l_nmod) hypothyroidism_10\NN\14059928|for|and|hypercalcemia
D008094_D006934 NONE lithium_14\NN\14625458| (r_compound) therapy_15\NN\657604|during|lithium (r_nmod) factor_8\NN\7326557|:|illness|is|a|risk|hypothyroidism|therapy (l_nmod) hypothyroidism_10\NN\14059928|for|and|hypercalcemia (l_conj) hypercalcemia_12\NN\14299637|
15985056
D017963_D006606 CID azithromycin-associated_1\JJ\1740| (r_amod) hiccups_2\NNS\863513|possible|azithromycin-associated|.
D017963_D006606 CID azithromycin_11\NN\2716205| (r_compound) therapy_12\NN\657604|by|azithromycin (r_nmod) associated_9\VBN\628491|therapy (r_acl) hiccups_8\NNS\863513|of|persistent|associated
D017963_D006606 CID azithromycin_12\NN\2716205| (r_dobj) beginning_11\VBG\941990|after|azithromycin|treatment (r_advcl) presented_6\VBD\2137132|summary|:|man|hiccups|beginning|. (l_nmod) hiccups_9\NNS\863513|with|persistent
D017963_D006606 CID azithromycin_2\NN\2716205|of (r_nmod) discontinuation_0\NN\209943|azithromycin|and|therapy (r_nsubj) resolved_8\VBD\352826|discontinuation|finally|hiccups|. (l_dobj) hiccups_9\NNS\863513|
D017963_D006606 CID azithromycin_9\NN\2716205|by (r_nmod) mediated_7\VBN\761713|azithromycin (r_acl) mechanism_6\NN\13446390|a|vagal|mediated (r_nsubj) pathogenesis_13\NN\13533470|that|mechanism|could|be|the|hiccups (l_nmod) hiccups_15\NNS\863513|of|patient
D017963_D010612 NONE azithromycin_12\NN\2716205| (r_dobj) beginning_11\VBG\941990|after|azithromycin|treatment (l_nmod) treatment_15\NN\654885|for|the|pharyngitis (l_nmod) pharyngitis_17\NN\14171682|of
D001418_D006606 CID baclofen_6\NN\1740|with (r_nmod) therapy_4\NN\657604|baclofen (r_conj) discontinuation_0\NN\209943|azithromycin|and|therapy (r_nsubj) resolved_8\VBD\352826|discontinuation|finally|hiccups|. (l_dobj) hiccups_9\NNS\863513|
D003907_D006606 NONE dexamethasone_2\NN\2721538|(|and|methylprednisolone|) (r_appos) corticosteroids_0\NNS\14745635|dexamethasone|,|benzodiazepines (r_nsubj) agents_18\NNS\7347|corticosteroids|have|been|the|specific|mentioned|. (l_acl) mentioned_19\VBN\730052|frequently|literature|associated (l_advcl) associated_27\VBN\628491|as|being|development (l_nmod) development_30\NN\248977|with|the|hiccups (l_nmod) hiccups_32\NNS\863513|of
D008775_D006606 NONE methylprednisolone_4\NN\1740| (r_conj) dexamethasone_2\NN\2721538|(|and|methylprednisolone|) (r_appos) corticosteroids_0\NNS\14745635|dexamethasone|,|benzodiazepines (r_nsubj) agents_18\NNS\7347|corticosteroids|have|been|the|specific|mentioned|. (l_acl) mentioned_19\VBN\730052|frequently|literature|associated (l_advcl) associated_27\VBN\628491|as|being|development (l_nmod) development_30\NN\248977|with|the|hiccups (l_nmod) hiccups_32\NNS\863513|of
D001569_D006606 NONE benzodiazepines_7\NNS\3771443|midazolam|and|anaesthesia (r_conj) corticosteroids_0\NNS\14745635|dexamethasone|,|benzodiazepines (r_nsubj) agents_18\NNS\7347|corticosteroids|have|been|the|specific|mentioned|. (l_acl) mentioned_19\VBN\730052|frequently|literature|associated (l_advcl) associated_27\VBN\628491|as|being|development (l_nmod) development_30\NN\248977|with|the|hiccups (l_nmod) hiccups_32\NNS\863513|of
D008874_D006606 NONE midazolam_9\NN\2830852|(|) (r_appos) benzodiazepines_7\NNS\3771443|midazolam|and|anaesthesia (r_conj) corticosteroids_0\NNS\14745635|dexamethasone|,|benzodiazepines (r_nsubj) agents_18\NNS\7347|corticosteroids|have|been|the|specific|mentioned|. (l_acl) mentioned_19\VBN\730052|frequently|literature|associated (l_advcl) associated_27\VBN\628491|as|being|development (l_nmod) development_30\NN\248977|with|the|hiccups (l_nmod) hiccups_32\NNS\863513|of
D018942_D006606 NONE macrolide_10\NN\1740| (r_compound) antimicrobials_11\NNS\14778436|to|macrolide (r_nmod) related_8\JJ\1740|antimicrobials (r_xcomp) reported_7\VBN\831651|cases|have|been|related|. (l_nsubjpass) cases_1\NNS\7283608|few|hiccups (l_nmod) hiccups_4\NNS\863513|of|drug-induced
D018942_D006606 NONE macrolides_36\NNS\1740|with|other (r_nmod) reaction_33\NN\13446390|on|this|macrolides (r_nmod) reports_30\NNS\6470073|previous|reaction|and (r_conj) sequence_27\NN\8457976|mostly|because|the|close|temporal|,|reports (r_nmod) classified_12\VBN\657260|using|event|could|be|as|score|,|sequence|absence|. (l_dep) absence_39\NN\14449405|the|explanation (l_nmod) explanation_43\NN\6722453|of|any|alternative|hiccups (l_nmod) hiccups_45\NNS\863513|for
D018942_D006606 NONE macrolide_2\NN\1740| (r_compound) antimicrobials_3\NNS\14778436|macrolide (r_nsubjpass) reported_6\VBN\831651|however|,|antimicrobials|have|been|associated|and|explain (l_xcomp) associated_9\VBN\628491|to|be|hiccups (l_nmod) hiccups_11\NNS\863513|with
10728962
D014667_D007022 CID vasopressin_0\NN\5407119|treatment|. (l_nmod) treatment_3\NN\654885|in|the|hypotension (l_nmod) hypotension_6\NN\14057371|of|milrinone-induced|failure
D014667_D007022 CID vasopressin_16\NN\5407119|of (r_nmod) doses_14\NNS\3740161|low|vasopressin (r_nsubj) restored_17\VBD\1631072|patients|,|doses|pressure|inhibiting|. (l_nmod) patients_1\NNS\9898892|in|failure (l_nmod) failure_5\NN\66216|with|decompensated|heart|hypotension (l_nmod) hypotension_7\NN\14057371|with|treatment
D014667_D006333 NONE vasopressin_0\NN\5407119|treatment|. (l_nmod) treatment_3\NN\654885|in|the|hypotension (l_nmod) hypotension_6\NN\14057371|of|milrinone-induced|failure (l_nmod) failure_10\NN\66216|in|severe|heart
D014667_D006333 NONE vasopressin_16\NN\5407119|of (r_nmod) doses_14\NNS\3740161|low|vasopressin (r_nsubj) restored_17\VBD\1631072|patients|,|doses|pressure|inhibiting|. (l_nmod) patients_1\NNS\9898892|in|failure (l_nmod) failure_5\NN\66216|with|decompensated|heart|hypotension
D020105_D007022 CID milrinone-induced_5\JJ\1740| (r_amod) hypotension_6\NN\14057371|of|milrinone-induced|failure
D020105_D007022 CID milrinone_7\NN\1740|such (r_nmod) inhibitors_4\NNS\20090|of|phosphodiesterase|milrinone (r_nmod) use_1\NN\407535|the|inhibitors|treatment (r_nsubj) restricted_17\JJ\1740|use|is|frequently|cause|. (l_advcl) cause_20\VBP\1617192|because|they|vasodilation (l_dobj) vasodilation_21\NN\365995|and|hypotension (l_conj) hypotension_23\NN\14057371|
D020105_D007022 CID milrinone_11\NN\1740|with (r_nmod) treatment_9\NN\654885|after|milrinone (r_nmod) hypotension_7\NN\14057371|with|treatment
D020105_D007022 CID milrinone_26\NN\1740|of (r_nmod) effect_24\NN\34213|the|inotropic|milrinone (r_dobj) inhibiting_21\VBG\2510337|without|effect (r_advcl) restored_17\VBD\1631072|patients|,|doses|pressure|inhibiting|. (l_nmod) patients_1\NNS\9898892|in|failure (l_nmod) failure_5\NN\66216|with|decompensated|heart|hypotension (l_nmod) hypotension_7\NN\14057371|with|treatment
D020105_D006333 NONE milrinone-induced_5\JJ\1740| (r_amod) hypotension_6\NN\14057371|of|milrinone-induced|failure (l_nmod) failure_10\NN\66216|in|severe|heart
D020105_D006333 NONE milrinone_7\NN\1740|such (r_nmod) inhibitors_4\NNS\20090|of|phosphodiesterase|milrinone (r_nmod) use_1\NN\407535|the|inhibitors|treatment (l_nmod) treatment_10\NN\654885|in|the|failure (l_nmod) failure_14\NN\66216|of|severe|heart
D020105_D006333 NONE milrinone_11\NN\1740|with (r_nmod) treatment_9\NN\654885|after|milrinone (r_nmod) hypotension_7\NN\14057371|with|treatment (r_nmod) failure_5\NN\66216|with|decompensated|heart|hypotension
D020105_D006333 NONE milrinone_26\NN\1740|of (r_nmod) effect_24\NN\34213|the|inotropic|milrinone (r_dobj) inhibiting_21\VBG\2510337|without|effect (r_advcl) restored_17\VBD\1631072|patients|,|doses|pressure|inhibiting|. (l_nmod) patients_1\NNS\9898892|in|failure (l_nmod) failure_5\NN\66216|with|decompensated|heart|hypotension
2576810
D016666_D006948 CID fluvoxamine_4\NN\1740|with (r_nmod) treatment_2\NN\654885|a|repeated|fluvoxamine|daily|days|) (r_nsubj) potentiated_12\VBD\229605|treatment|mice|weaker|hyperactivity|. (l_dobj) hyperactivity_23\NN\14052403|the|amphetamine-induced
D016666_D006948 CID fluvoxamine_10\NN\1740|by (r_nmod) unaffected_8\JJ\1740|fluvoxamine (r_acomp) remained_7\VBD\2604760|hyperactivity|unaffected|. (l_nsubj) hyperactivity_1\NN\14052403|the|induced
D000661_D006948 CID amphetamine-induced_22\JJ\1740| (r_amod) hyperactivity_23\NN\14052403|the|amphetamine-induced
D009627_D006948 CID nomifensine_4\NN\1740|by (r_nmod) induced_2\VBN\1627355|nomifensine|mice (r_acl) hyperactivity_1\NN\14052403|the|induced
9523850
D008775_D018771 NONE methylprednisolone_2\NN\1740|of (r_nmod) value_0\NN\5856066|methylprednisolone|prevention|:|trial (l_nmod) prevention_4\NN\1073995|in|syndrome (l_nmod) syndrome_8\NN\5870365|of|the|arthralgia-myalgia|associated (l_compound) arthralgia-myalgia_7\NN\1740|
D008775_D018771 NONE mp_6\NN\10249459|of (r_nmod) administration_4\NN\1133281|mp|before (r_nsubj) reduces_11\VBZ\441445|that|administration|frequency (l_dobj) frequency_13\NN\15286249|the|and|severity|syndrome (l_nmod) syndrome_19\NN\5870365|of|the|arthralgia-myalgia (l_compound) arthralgia-myalgia_18\NN\1740|
D008775_D063806 NONE methylprednisolone_2\NN\1740|of (r_nmod) value_0\NN\5856066|methylprednisolone|prevention|:|trial (l_nmod) prevention_4\NN\1073995|in|syndrome (l_nmod) syndrome_8\NN\5870365|of|the|arthralgia-myalgia|associated (l_compound) arthralgia-myalgia_7\NN\1740|
D008775_D063806 NONE mp_6\NN\10249459|of (r_nmod) administration_4\NN\1133281|mp|before (r_nsubj) reduces_11\VBZ\441445|that|administration|frequency (l_dobj) frequency_13\NN\15286249|the|and|severity|syndrome (l_nmod) syndrome_19\NN\5870365|of|the|arthralgia-myalgia (l_compound) arthralgia-myalgia_18\NN\1740|
D007505_D018771 CID dextran_17\NN\1740|of|iron (r_nmod) infusion_14\NN\14589223|with|the|dose|dextran (r_nmod) associated_9\VBN\628491|infusion (r_acl) syndrome_8\NN\5870365|of|the|arthralgia-myalgia|associated (l_compound) arthralgia-myalgia_7\NN\1740|
D007505_D063806 NONE dextran_17\NN\1740|of|iron (r_nmod) infusion_14\NN\14589223|with|the|dose|dextran (r_nmod) associated_9\VBN\628491|infusion (r_acl) syndrome_8\NN\5870365|of|the|arthralgia-myalgia|associated (l_compound) arthralgia-myalgia_7\NN\1740|
15893386
D013390_D014313 CID succinylcholine-induced_0\JJ\1740| (r_amod) rigidity_3\NN\5023233|succinylcholine-induced|masseter|muscle|removal|.
D013390_D014313 CID succinylcholine_17\NN\3800001|sch (r_compound) administration_21\NN\1133281|after|succinylcholine|management (r_nmod) case_5\NN\7283608|a|rigidity|administration (l_nmod) rigidity_10\NN\5023233|of|severe|masseter|muscle|jaw
D013390_D014313 CID succinylcholine_17\NN\3800001|sch (r_compound) administration_21\NN\1133281|after|succinylcholine|management (r_nmod) case_5\NN\7283608|a|rigidity|administration (l_nmod) rigidity_10\NN\5023233|of|severe|masseter|muscle|jaw (l_appos) jaw_12\NN\5269901|(|steel|) (l_nmod) steel_14\NN\14586769|of
D013390_D014313 CID sch_19\NN\1740|(|) (r_appos) succinylcholine_17\NN\3800001|sch (r_compound) administration_21\NN\1133281|after|succinylcholine|management (r_nmod) case_5\NN\7283608|a|rigidity|administration (l_nmod) rigidity_10\NN\5023233|of|severe|masseter|muscle|jaw
D013390_D014313 CID sch_19\NN\1740|(|) (r_appos) succinylcholine_17\NN\3800001|sch (r_compound) administration_21\NN\1133281|after|succinylcholine|management (r_nmod) case_5\NN\7283608|a|rigidity|administration (l_nmod) rigidity_10\NN\5023233|of|severe|masseter|muscle|jaw (l_appos) jaw_12\NN\5269901|(|steel|) (l_nmod) steel_14\NN\14586769|of
D015742_D008305 NONE propofol_5\NN\1740| (r_compound) infusion_6\NN\14589223|with|propofol (r_nmod) continued_2\VBN\2367363|anesthesia|was|uneventfully|infusion|available|. (l_advcl) available_11\JJ\1740|while|facilities|were|detect (l_xcomp) detect_13\VB\2163746|to|and|treat (l_conj) treat_15\VB\2376958|hyperthermia (l_dobj) hyperthermia_17\NN\14034177|malignant
16710500
D004977_D009901 CID ethambutol-associated_0\NN\1740| (r_compound) neuropathy_2\NN\14204950|ethambutol-associated|optic|.
D004977_D009901 CID ethambutol-associated_6\NN\1740| (r_amod) neuropathy_9\NN\14204950|with|ethambutol-associated|toxic|optic
D004977_D014376 NONE ethambutol_2\NN\1740| (r_nsubjpass) used_4\VBN\1156834|:|ethambutol|is|treatment|. (l_nmod) treatment_7\NN\654885|in|the|tuberculosis (l_nmod) tuberculosis_9\NN\14127211|of|,|prevalent
D004977_D014786 CID ethambutol_2\NN\1740| (r_nsubjpass) used_4\VBN\1156834|:|ethambutol|is|treatment|. (l_nmod) treatment_7\NN\654885|in|the|tuberculosis (l_nmod) tuberculosis_9\NN\14127211|of|,|prevalent (l_acl:relcl) prevalent_14\JJ\1740|which|is|still|asia|,|and|associated (l_conj) associated_22\VBN\628491|can|be|loss (l_nmod) loss_26\NN\13252973|with|permanent|visual
D004977_D014786 CID ethambutol_2\NN\1740| (r_compound) usage_3\NN\407535|ethambutol (r_nsubjpass) associated_5\VBN\628491|usage|is|loss|and|avoided (l_nmod) loss_9\NN\13252973|with|permanent|visual
11858397
D008787_D016171 CID metoclopramide_5\NN\1740|by (r_nmod) induced_3\VBN\1627355|metoclopramide|woman (r_acl) pointes_2\NNS\1740|torsade|de|induced|.
D008787_D016171 CID metoclopramide_24\NN\1740|of (r_nmod) administration_22\NN\1133281|after|intravenous|metoclopramide (r_nmod) developed_14\VBD\1753788|who|pointes|administration (l_dobj) pointes_17\NNS\1740|torsade|de
D008787_D016171 CID metoclopramide_6\NN\1740| (r_nsubj) provokes_7\VBZ\1617192|that|metoclopramide|pointes|clinically (l_dobj) pointes_10\NNS\1740|torsade|de
D008787_D016171 CID metoclopramide_0\NN\1740| (r_nsubjpass) used_3\VBN\1156834|metoclopramide|should|be|cautiously|patients|. (l_nmod) patients_6\NNS\9898892|in|risk (l_nmod) risk_9\NN\14541044|with|a|pointes (l_nmod) pointes_13\NNS\1740|of|torsade|de
D008787_D002037 NONE metoclopramide_5\NN\1740|by (r_nmod) induced_3\VBN\1627355|metoclopramide|woman (l_nmod) woman_9\NN\9605289|in|an|elderly|block (l_nmod) block_16\NN\21939|with|preexisting|complete|left|bundle|branch
D008787_D002037 NONE metoclopramide_24\NN\1740|of (r_nmod) administration_22\NN\1133281|after|intravenous|metoclopramide (r_nmod) developed_14\VBD\1753788|who|pointes|administration (r_acl:relcl) woman_5\NN\9605289|on|a|92-year-old|block|developed (l_nmod) block_12\NN\21939|with|preexisting|complete|branch
D020117_D016171 CID cisapride_8\NN\1740|and|erythromycin (r_nsubjpass) given_12\VBN\2327200|when|cisapride|were|simultaneously (r_advcl) developed_3\VBD\1753788|patient|also|pointes|given|. (l_dobj) pointes_6\NNS\1740|torsade|de
D004917_D016171 CID erythromycin_10\NN\2716866| (r_conj) cisapride_8\NN\1740|and|erythromycin (r_nsubjpass) given_12\VBN\2327200|when|cisapride|were|simultaneously (r_advcl) developed_3\VBD\1753788|patient|also|pointes|given|. (l_dobj) pointes_6\NNS\1740|torsade|de
2051906
D001379_D002779 CID azathioprine_7\NN\3740161| (r_compound) therapy_8\NN\657604|following|azathioprine (r_nmod) cholestasis_1\NN\14052403|reversible|injury|therapy|.
D001379_D002779 CID azathioprine_7\NN\3740161| (r_compound) therapy_8\NN\657604|following|azathioprine (r_nmod) cholestasis_1\NN\14052403|reversible|injury|therapy|. (l_nmod) injury_5\NN\14052046|with|duct
D001379_D002779 CID azathioprine_28\NN\3740161| (r_compound) therapy_29\NN\657604|of|azathioprine (r_nmod) initiation_26\NN\7450842|months|therapy (r_dobj) developed_15\VBD\1753788|patient|,|features|initiation|. (l_dobj) features_19\NNS\5849040|clinical|cholestasis (l_nmod) cholestasis_22\NN\14052403|of|severe
D001379_D002779 CID azathioprine-induced_12\JJ\1740| (r_amod) cholestasis_13\NN\14052403|of|reversible|azathioprine-induced|associated
D001379_D002779 CID azathioprine-induced_12\JJ\1740| (r_amod) cholestasis_13\NN\14052403|of|reversible|azathioprine-induced|associated (l_acl) associated_14\VBN\628491|evidence (l_nmod) evidence_17\NN\5816287|with|histological|injury (l_nmod) injury_21\NN\14052046|of|duct
D001379_D017285 NONE azathioprine_28\NN\3740161| (r_compound) therapy_29\NN\657604|of|azathioprine (r_nmod) initiation_26\NN\7450842|months|therapy (r_dobj) developed_15\VBD\1753788|patient|,|features|initiation|. (l_nsubj) patient_2\NN\9898892|a|67-year-old|,|polymyositis (l_nmod) polymyositis_6\NN\14350292|with|primary|and|evidence
D001379_D008107 NONE azathioprine_28\NN\3740161| (r_compound) therapy_29\NN\657604|of|azathioprine (r_nmod) initiation_26\NN\7450842|months|therapy (r_dobj) developed_15\VBD\1753788|patient|,|features|initiation|. (l_nsubj) patient_2\NN\9898892|a|67-year-old|,|polymyositis (l_nmod) polymyositis_6\NN\14350292|with|primary|and|evidence (l_conj) evidence_10\NN\5816287|without|previous|disease (l_nmod) disease_13\NN\14061805|of|liver
15686794
D000638_D017116 CID amiodarone_8\NN\2715941|of (r_nmod) administration_6\NN\1133281|during|intravenous|amiodarone (r_nmod) pain_3\NN\14299637|acute|low|back|administration|:|report
D000638_D017116 CID amiodarone_26\NN\2715941| (r_compound) loading_27\NN\4571088|of|intravenous|amiodarone (r_nmod) initiation_23\NN\7450842|after|loading (r_nmod) experienced_12\VBD\2108377|who|pain|initiation (l_dobj) pain_18\NN\14299637|an|acute|devastating|low|back
D000638_D001281 NONE amiodarone_0\NN\2715941| (r_nsubj) represents_1\VBZ\2664769|amiodarone|drug|. (l_dobj) drug_5\NN\14778436|an|effective|antiarrhythmic|cardioversion (l_nmod) cardioversion_7\NN\1740|for|fibrillation|and|maintenance (l_nmod) fibrillation_11\NN\14361664|of|recent-onset|atrial|af
D000638_D001281 NONE amiodarone_0\NN\2715941| (r_nsubj) represents_1\VBZ\2664769|amiodarone|drug|. (l_dobj) drug_5\NN\14778436|an|effective|antiarrhythmic|cardioversion (l_nmod) cardioversion_7\NN\1740|for|fibrillation|and|maintenance (l_nmod) fibrillation_11\NN\14361664|of|recent-onset|atrial|af (l_appos) af_13\NN\1740|(|)
D000638_D001281 NONE amiodarone_26\NN\2715941| (r_compound) loading_27\NN\4571088|of|intravenous|amiodarone (r_nmod) initiation_23\NN\7450842|after|loading (r_nmod) experienced_12\VBD\2108377|who|pain|initiation (r_acl:relcl) patients_4\NNS\9898892|two|suffering|,|experienced (l_acl) suffering_5\VBG\2110220|fibrillation (l_nmod) fibrillation_9\NN\14361664|from|recent-onset|atrial
3703509
D011241_D053609 NONE prednisone_5\NN\2721538|to|oral (r_nmod) exposure_2\NN\5042871|following|short|prednisone (r_nmod) developed_9\VBD\1753788|exposure|,|boys|lethargy|,|increasing|. (l_dobj) lethargy_10\NN\14014621|
D011241_D006970 NONE prednisone_5\NN\2721538|to|oral (r_nmod) exposure_2\NN\5042871|following|short|prednisone (r_nmod) developed_9\VBD\1753788|exposure|,|boys|lethargy|,|increasing|. (l_advcl) increasing_12\VBG\169651|somnolence (l_dobj) somnolence_13\NN\14015731|,|polydipsia
D011241_D059606 NONE prednisone_5\NN\2721538|to|oral (r_nmod) exposure_2\NN\5042871|following|short|prednisone (r_nmod) developed_9\VBD\1753788|exposure|,|boys|lethargy|,|increasing|. (l_advcl) increasing_12\VBG\169651|somnolence (l_dobj) somnolence_13\NN\14015731|,|polydipsia (l_conj) polydipsia_15\NN\14040660|,|polyphagia
D011241_D006963 NONE prednisone_5\NN\2721538|to|oral (r_nmod) exposure_2\NN\5042871|following|short|prednisone (r_nmod) developed_9\VBD\1753788|exposure|,|boys|lethargy|,|increasing|. (l_advcl) increasing_12\VBG\169651|somnolence (l_dobj) somnolence_13\NN\14015731|,|polydipsia (l_conj) polydipsia_15\NN\14040660|,|polyphagia (l_conj) polyphagia_17\NN\1740|,|and|polyuria
D011241_D011141 NONE prednisone_5\NN\2721538|to|oral (r_nmod) exposure_2\NN\5042871|following|short|prednisone (r_nmod) developed_9\VBD\1753788|exposure|,|boys|lethargy|,|increasing|. (l_advcl) increasing_12\VBG\169651|somnolence (l_dobj) somnolence_13\NN\14015731|,|polydipsia (l_conj) polydipsia_15\NN\14040660|,|polyphagia (l_conj) polyphagia_17\NN\1740|,|and|polyuria (l_conj) polyuria_20\NN\14113228|
D019344_D000140 NONE lactate_13\NN\14850483| (r_compound) level_14\NN\4916342|without|a|known|serum|lactate (r_nmod) ketosis_8\NN\14299637|level (r_nsubj) present_16\JJ\1740|ketosis|was|other|. (r_conj) present_4\JJ\1740|acidosis|was|one|and|present (l_nsubj) acidosis_2\NN\14204950|nonketotic|lactic
D019344_D007662 NONE lactate_13\NN\14850483| (r_compound) level_14\NN\4916342|without|a|known|serum|lactate (r_nmod) ketosis_8\NN\14299637|level
12448656
D013792_D002292 NONE thalidomide_5\NN\4166841|of (r_nmod) study_3\NN\635850|a|phase|ii|thalidomide|carcinoma|. (l_nmod) carcinoma_11\NN\14239918|in|advanced|metastatic|renal|cell
D013792_D002292 NONE thalidomide_9\NN\4166841|of (r_nmod) toxicity_5\NN\13576101|the|and|activity|thalidomide|patients (l_nmod) patients_11\NNS\9898892|in|cancer (l_nmod) cancer_17\NN\14239425|with|advanced|metastatic|renal|cell
D013792_D002292 NONE thalidomide_13\NN\4166841|of (r_nmod) activity_11\NN\30358|of|thalidomide (r_nmod) level_9\NN\4916342|with|a|low|activity|carcinoma (l_nmod) carcinoma_17\NN\14239918|in|renal|cell
D013792_D002292 NONE thalidomide_8\NN\4166841|of (r_nmod) any_5\DT\1740|if|,|thalidomide|carcinoma (l_nmod) carcinoma_12\NN\14239918|for|renal|cell
D013792_D064420 NONE thalidomide_9\NN\4166841|of (r_nmod) toxicity_5\NN\13576101|the|and|activity|thalidomide|patients
9154656
D000809_D009404 NONE renin-angiotensin_7\JJ\1740| (r_amod) proteins_9\NNS\14944888|of|the|renin-angiotensin|system (r_nmod) concentration_1\NN\4916342|plasma|and|excretion|proteins (r_nsubjpass) altered_11\VBN\126264|concentration|are|rats|. (l_nmod) rats_13\NNS\2329401|in|syndrome (l_nmod) syndrome_16\NN\5870365|with|nephrotic|ns
D000809_D009404 NONE renin-angiotensin_7\JJ\1740| (r_amod) proteins_9\NNS\14944888|of|the|renin-angiotensin|system (r_nmod) concentration_1\NN\4916342|plasma|and|excretion|proteins (r_nsubjpass) altered_11\VBN\126264|concentration|are|rats|. (l_nmod) rats_13\NNS\2329401|in|syndrome (l_nmod) syndrome_16\NN\5870365|with|nephrotic|ns (l_appos) ns_18\NN\14622893|(|)
D011692_D009404 CID amino-nucleoside_9\NN\1740|of|puromycin|pan (r_nmod) injection_6\NN\320852|by|a|single|amino-nucleoside (r_nmod) induced_2\VBN\1627355|ns|was|injection|. (l_nsubjpass) ns_0\NN\14622893|
D011692_D009404 CID pan_11\NN\3101986|(|) (r_appos) amino-nucleoside_9\NN\1740|of|puromycin|pan (r_nmod) injection_6\NN\320852|by|a|single|amino-nucleoside (r_nmod) induced_2\VBN\1627355|ns|was|injection|. (l_nsubjpass) ns_0\NN\14622893|
D011692_D009404 CID pan_17\NN\3101986| (r_compound) injection_18\NN\320852|after|pan (r_nmod) day_14\NN\15154774|on|6|injection|,|established (l_acl:relcl) established_24\VBN\2426171|when|ns|was|clearly (l_nsubjpass) ns_21\NN\14622893|
D011692_D009404 CID pan_22\NN\3101986|by (r_nmod) induced_20\VBN\1627355|pan (r_acl) ns_19\NN\14622893|of|the|acute|induced
10027919
C051883_D006962 NONE 22-oxacalcitriol_0\NN\1740| (r_nsubj) suppresses_1\VBZ\2510337|22-oxacalcitriol|hyperparathyroidism|inducing|. (l_dobj) hyperparathyroidism_3\NN\14059928|secondary
C051883_D006962 NONE oct_5\NN\15209706|microg/kg (r_nsubj) stabilized_10\VBD\126264|hyperparathyroidism|,|oct|levels|months|. (l_nmod) hyperparathyroidism_3\NN\14059928|in|long-standing|secondary
C051883_D006962 NONE oct_8\NN\15209706| (r_nsubj) prevent_12\VB\1740|even|though|oct|does|not|completely|occurrence (r_advcl) use_28\NN\407535|that|prevent|,|it|may|be|of|management (l_nmod) management_31\NN\1123598|in|the|hyperparathyroidism (l_nmod) hyperparathyroidism_34\NN\14059928|of|secondary
C051883_D001851 NONE 22-oxacalcitriol_0\NN\1740| (r_nsubj) suppresses_1\VBZ\2510337|22-oxacalcitriol|hyperparathyroidism|inducing|. (l_advcl) inducing_5\VBG\1627355|without|turnover|dogs (l_dobj) turnover_8\NN\13819207|low|bone
C051883_D001851 NONE oct_8\NN\15209706| (r_nsubj) prevent_12\VB\1740|even|though|oct|does|not|completely|occurrence (r_advcl) use_28\NN\407535|that|prevent|,|it|may|be|of|management (r_ccomp) indicate_4\VBP\952524|results|use|induce (l_ccomp) induce_39\VB\1627355|because|it|does|not|turnover|and|,|therefore|,|increase (l_dobj) turnover_42\NN\13819207|low|bone
C051883_D001851 NONE oct_8\NN\15209706| (r_nsubj) prevent_12\VB\1740|even|though|oct|does|not|completely|occurrence (r_advcl) use_28\NN\407535|that|prevent|,|it|may|be|of|management (r_ccomp) indicate_4\VBP\952524|results|use|induce (l_ccomp) induce_39\VB\1627355|because|it|does|not|turnover|and|,|therefore|,|increase (l_conj) increase_49\VB\169651|does|not|risk (l_dobj) risk_51\NN\14541044|the|disease (l_nmod) disease_55\NN\14061805|of|adynamic|bone
C051883_D051437 NONE 22-oxacalcitriol_0\NN\1740| (r_nsubj) suppresses_1\VBZ\2510337|22-oxacalcitriol|hyperparathyroidism|inducing|. (l_advcl) inducing_5\VBG\1627355|without|turnover|dogs (l_nmod) dogs_10\NNS\2083346|in|failure (l_nmod) failure_13\NN\66216|with|renal
C051883_D051437 NONE oct_6\NN\15209706| (r_nsubj) decreased_8\VBD\169651|dogs|,|oct|significantly|levels|induction|. (l_nmod) induction_15\NN\7450842|soon|after|the|insufficiency (l_nmod) insufficiency_18\NN\14462946|of|renal
C051883_D051437 NONE oct_8\NN\15209706| (r_nsubj) prevent_12\VB\1740|even|though|oct|does|not|completely|occurrence (l_dobj) occurrence_14\NN\29378|the|hypercalcemia|dogs (l_nmod) dogs_19\NNS\2083346|in|experimental|insufficiency (l_nmod) insufficiency_22\NN\14462946|with|renal
D002117_D051437 NONE calcitriol_2\NN\1740| (r_compound) therapy_3\NN\657604|calcitriol (r_nsubj) suppresses_4\VBZ\2510337|therapy|levels|patients|but|has (l_nmod) patients_14\NNS\9898892|in|failure (l_nmod) failure_17\NN\66216|with|renal
D002117_D006934 CID calcitriol_2\NN\1740| (r_compound) therapy_3\NN\657604|calcitriol (r_nsubj) suppresses_4\VBZ\2510337|therapy|levels|patients|but|has (l_conj) has_19\VBZ\2108377|drawbacks (l_dobj) drawbacks_21\NNS\5161614|several|,|hypercalcemia (l_nmod) hypercalcemia_24\NN\14299637|including|and/or|suppression|,|lead
D002117_D001851 CID calcitriol_2\NN\1740| (r_compound) therapy_3\NN\657604|calcitriol (r_nsubj) suppresses_4\VBZ\2510337|therapy|levels|patients|but|has (l_conj) has_19\VBZ\2108377|drawbacks (l_dobj) drawbacks_21\NNS\5161614|several|,|hypercalcemia (l_nmod) hypercalcemia_24\NN\14299637|including|and/or|suppression|,|lead (l_conj) suppression_27\NN\13489037|marked|turnover (l_nmod) turnover_30\NN\13819207|of|bone
D002117_D001851 CID calcitriol_2\NN\1740| (r_compound) therapy_3\NN\657604|calcitriol (r_nsubj) suppresses_4\VBZ\2510337|therapy|levels|patients|but|has (l_conj) has_19\VBZ\2108377|drawbacks (l_dobj) drawbacks_21\NNS\5161614|several|,|hypercalcemia (l_nmod) hypercalcemia_24\NN\14299637|including|and/or|suppression|,|lead (l_acl:relcl) lead_34\VB\1752884|which|may|disease (l_nmod) disease_38\NN\14061805|to|adynamic|bone
C051883_D007674 NONE oct_9\NN\15209706|of (r_nmod) effects_7\NNS\13245626|the|oct|levels|states (l_nmod) states_18\NNS\8491826|in|function (l_nmod) function_24\NN\13783581|of|normal|renal
C051883_-1 NONE oct_4\NN\15209706| (r_nsubj) reversed_5\VBD\109660|dogs|,|oct|formation|,|but|alter|. (l_dobj) formation_8\NN\7938773|abnormal|bone|,|osteoid (l_nmod) osteoid_13\NN\1740|such|woven|and|fibrosis
C051883_D005355 NONE oct_4\NN\15209706| (r_nsubj) reversed_5\VBD\109660|dogs|,|oct|formation|,|but|alter|. (l_dobj) formation_8\NN\7938773|abnormal|bone|,|osteoid (l_nmod) osteoid_13\NN\1740|such|woven|and|fibrosis (l_conj) fibrosis_15\NN\14204950|
C051883_D006934 CID oct_8\NN\15209706| (r_nsubj) prevent_12\VB\1740|even|though|oct|does|not|completely|occurrence (l_dobj) occurrence_14\NN\29378|the|hypercalcemia|dogs (l_nmod) hypercalcemia_16\NN\14299637|of
7337133
D000082_D001929 CID acetaminophen_9\NN\2707683| (r_compound) overdose_10\NN\1740|in|acetaminophen (r_nmod) failure_7\NN\66216|with|fulminant|hepatic|overdose (r_nmod) associated_3\VBN\628491|failure (r_acl) edema_2\NN\14315192|massive|cerebral|associated|:|role|.
D000082_D001929 CID acetaminophen-induced_6\JJ\1740| (r_amod) failure_9\NN\66216|with|fatal|acetaminophen-induced|fulminant|hepatic|,|signs (l_nmod) signs_12\NNS\6643763|with|and|symptoms|edema|,|unresponsive (l_nmod) edema_17\NN\14315192|of|cerebral
D000082_D017093 CID acetaminophen_9\NN\2707683| (r_compound) overdose_10\NN\1740|in|acetaminophen (r_nmod) failure_7\NN\66216|with|fulminant|hepatic|overdose
D000082_D017093 CID acetaminophen-induced_6\JJ\1740| (r_amod) failure_9\NN\66216|with|fatal|acetaminophen-induced|fulminant|hepatic|,|signs
D000082_D062787 NONE acetaminophen_9\NN\2707683| (r_compound) overdose_10\NN\1740|in|acetaminophen
19274460
D003520_D009101 NONE cyclophosphamide_8\NN\1740|for|intravenous (r_nmod) definition_5\NN\6738281|dose|cyclophosphamide|combination (l_nmod) combination_10\NN\7951464|in|bortezomib/dexamethasone (l_nmod) bortezomib/dexamethasone_12\NN\1740|with|induction (l_nmod) induction_15\NN\7450842|for|remission|patients (l_nmod) patients_17\NNS\9898892|in|myeloma (l_nmod) myeloma_21\NN\14239425|with|diagnosed
D003520_D009101 NONE cyclophosphamide_11\NN\1740|of (r_nmod) dose_9\NN\3740161|the|recommended|cyclophosphamide|combination (r_dobj) evaluate_6\VB\670261|to|dose|treatment (l_nmod) treatment_20\NN\654885|as|induction|transplantation (l_nmod) transplantation_24\NN\671351|before|stem|cell|patients (l_nmod) patients_27\NNS\9898892|for|younger|myeloma (l_nmod) myeloma_32\NN\14239425|with|diagnosed|multiple|mm
D003520_D009101 NONE cyclophosphamide_11\NN\1740|of (r_nmod) dose_9\NN\3740161|the|recommended|cyclophosphamide|combination (r_dobj) evaluate_6\VB\670261|to|dose|treatment (l_nmod) treatment_20\NN\654885|as|induction|transplantation (l_nmod) transplantation_24\NN\671351|before|stem|cell|patients (l_nmod) patients_27\NNS\9898892|for|younger|myeloma (l_nmod) myeloma_32\NN\14239425|with|diagnosed|multiple|mm (l_appos) mm_34\NN\13649268|(|)
D003520_D009101 NONE cyclophosphamide_8\NN\1740|with|mg/m(2|)|and|dexamethasone (r_nmod) combination_6\NN\7951464|in|cyclophosphamide (r_nmod) bortezomib_4\NN\1740|combination (r_nsubj) treatment_19\NN\654885|that|bortezomib|is|an|effective|induction|patients|warrants (l_nmod) patients_21\NNS\9898892|for|mm (l_nmod) mm_25\NN\13649268|with|diagnosed
C400082_D009101 NONE bortezomib/dexamethasone_12\NN\1740|with|induction (l_nmod) induction_15\NN\7450842|for|remission|patients (l_nmod) patients_17\NNS\9898892|in|myeloma (l_nmod) myeloma_21\NN\14239425|with|diagnosed
C400082_D009101 NONE bortezomib_15\NN\1740|with|and|dexamethasone (r_nmod) combination_13\NN\7951464|in|bortezomib (r_nmod) dose_9\NN\3740161|the|recommended|cyclophosphamide|combination (r_dobj) evaluate_6\VB\670261|to|dose|treatment (l_nmod) treatment_20\NN\654885|as|induction|transplantation (l_nmod) transplantation_24\NN\671351|before|stem|cell|patients (l_nmod) patients_27\NNS\9898892|for|younger|myeloma (l_nmod) myeloma_32\NN\14239425|with|diagnosed|multiple|mm
C400082_D009101 NONE bortezomib_15\NN\1740|with|and|dexamethasone (r_nmod) combination_13\NN\7951464|in|bortezomib (r_nmod) dose_9\NN\3740161|the|recommended|cyclophosphamide|combination (r_dobj) evaluate_6\VB\670261|to|dose|treatment (l_nmod) treatment_20\NN\654885|as|induction|transplantation (l_nmod) transplantation_24\NN\671351|before|stem|cell|patients (l_nmod) patients_27\NNS\9898892|for|younger|myeloma (l_nmod) myeloma_32\NN\14239425|with|diagnosed|multiple|mm (l_appos) mm_34\NN\13649268|(|)
C400082_D009101 NONE bortezomib_4\NN\1740|combination (r_nsubj) treatment_19\NN\654885|that|bortezomib|is|an|effective|induction|patients|warrants (l_nmod) patients_21\NNS\9898892|for|mm (l_nmod) mm_25\NN\13649268|with|diagnosed
D003907_D009101 NONE bortezomib/dexamethasone_12\NN\1740|with|induction (l_nmod) induction_15\NN\7450842|for|remission|patients (l_nmod) patients_17\NNS\9898892|in|myeloma (l_nmod) myeloma_21\NN\14239425|with|diagnosed
D003907_D009101 NONE dexamethasone_17\NN\2721538| (r_conj) bortezomib_15\NN\1740|with|and|dexamethasone (r_nmod) combination_13\NN\7951464|in|bortezomib (r_nmod) dose_9\NN\3740161|the|recommended|cyclophosphamide|combination (r_dobj) evaluate_6\VB\670261|to|dose|treatment (l_nmod) treatment_20\NN\654885|as|induction|transplantation (l_nmod) transplantation_24\NN\671351|before|stem|cell|patients (l_nmod) patients_27\NNS\9898892|for|younger|myeloma (l_nmod) myeloma_32\NN\14239425|with|diagnosed|multiple|mm
D003907_D009101 NONE dexamethasone_17\NN\2721538| (r_conj) bortezomib_15\NN\1740|with|and|dexamethasone (r_nmod) combination_13\NN\7951464|in|bortezomib (r_nmod) dose_9\NN\3740161|the|recommended|cyclophosphamide|combination (r_dobj) evaluate_6\VB\670261|to|dose|treatment (l_nmod) treatment_20\NN\654885|as|induction|transplantation (l_nmod) transplantation_24\NN\671351|before|stem|cell|patients (l_nmod) patients_27\NNS\9898892|for|younger|myeloma (l_nmod) myeloma_32\NN\14239425|with|diagnosed|multiple|mm (l_appos) mm_34\NN\13649268|(|)
D003907_D009101 NONE dexamethasone_14\NN\2721538| (r_conj) cyclophosphamide_8\NN\1740|with|mg/m(2|)|and|dexamethasone (r_nmod) combination_6\NN\7951464|in|cyclophosphamide (r_nmod) bortezomib_4\NN\1740|combination (r_nsubj) treatment_19\NN\654885|that|bortezomib|is|an|effective|induction|patients|warrants (l_nmod) patients_21\NNS\9898892|for|mm (l_nmod) mm_25\NN\13649268|with|diagnosed
8888541
C047426_D020230 CID venlafaxine-tranylcypromine_3\NN\1740| (r_compound) interaction_4\NN\37396|from|venlafaxine-tranylcypromine (r_nmod) syndrome_1\NN\5870365|serotonin|interaction|.
C047426_D020230 CID venlafaxine-maoi_3\JJ\1740| (r_amod) interaction_4\NN\37396|a|venlafaxine-maoi|resulted (l_acl:relcl) resulted_6\VBD\2633881|that|syndrome (l_nmod) syndrome_10\NN\5870365|in|the|serotonin|male
D014191_D020230 CID venlafaxine-tranylcypromine_3\NN\1740| (r_compound) interaction_4\NN\37396|from|venlafaxine-tranylcypromine (r_nmod) syndrome_1\NN\5870365|serotonin|interaction|.
D014191_D020230 CID tranylcypromine_18\NN\3783017| (r_dobj) taking_17\VBG\2367363|who|was|tranylcypromine|depression (r_acl:relcl) male_14\NN\15388|in|a|23-y-old|taking (r_nmod) syndrome_10\NN\5870365|in|the|serotonin|male
D012701_D009127 NONE serotonin_3\NN\14807737| (r_compound) receptors_5\NNS\5225602|of|serotonin|5ht1a (r_nmod) stimulation_1\NN\242808|excessive|receptors (r_nsubj) causes_6\VBZ\1617192|stimulation|syndrome|. (l_dobj) syndrome_8\NN\5870365|a|excess|consists (l_acl:relcl) consists_13\VBZ\2603699|that|shivering (l_nmod) shivering_15\NN\14299637|of|,|rigidity|,|salivation (l_conj) rigidity_18\NN\5023233|muscle
D012701_D009127 NONE serotonin_10\NN\14807737| (r_compound) excess_11\NN\5119367|of|serotonin (r_nmod) syndrome_8\NN\5870365|a|excess|consists (l_acl:relcl) consists_13\VBZ\2603699|that|shivering (l_nmod) shivering_15\NN\14299637|of|,|rigidity|,|salivation (l_conj) rigidity_18\NN\5023233|muscle
D012701_D012798 NONE serotonin_3\NN\14807737| (r_compound) receptors_5\NNS\5225602|of|serotonin|5ht1a (r_nmod) stimulation_1\NN\242808|excessive|receptors (r_nsubj) causes_6\VBZ\1617192|stimulation|syndrome|. (l_dobj) syndrome_8\NN\5870365|a|excess|consists (l_acl:relcl) consists_13\VBZ\2603699|that|shivering (l_nmod) shivering_15\NN\14299637|of|,|rigidity|,|salivation (l_conj) salivation_20\NN\13553916|,|confusion
D012701_D012798 NONE serotonin_10\NN\14807737| (r_compound) excess_11\NN\5119367|of|serotonin (r_nmod) syndrome_8\NN\5870365|a|excess|consists (l_acl:relcl) consists_13\VBZ\2603699|that|shivering (l_nmod) shivering_15\NN\14299637|of|,|rigidity|,|salivation (l_conj) salivation_20\NN\13553916|,|confusion
D012701_D003221 NONE serotonin_3\NN\14807737| (r_compound) receptors_5\NNS\5225602|of|serotonin|5ht1a (r_nmod) stimulation_1\NN\242808|excessive|receptors (r_nsubj) causes_6\VBZ\1617192|stimulation|syndrome|. (l_dobj) syndrome_8\NN\5870365|a|excess|consists (l_acl:relcl) consists_13\VBZ\2603699|that|shivering (l_nmod) shivering_15\NN\14299637|of|,|rigidity|,|salivation (l_conj) salivation_20\NN\13553916|,|confusion (l_conj) confusion_22\NN\13972797|,|agitation
D012701_D003221 NONE serotonin_10\NN\14807737| (r_compound) excess_11\NN\5119367|of|serotonin (r_nmod) syndrome_8\NN\5870365|a|excess|consists (l_acl:relcl) consists_13\VBZ\2603699|that|shivering (l_nmod) shivering_15\NN\14299637|of|,|rigidity|,|salivation (l_conj) salivation_20\NN\13553916|,|confusion (l_conj) confusion_22\NN\13972797|,|agitation
D012701_D011595 NONE serotonin_3\NN\14807737| (r_compound) receptors_5\NNS\5225602|of|serotonin|5ht1a (r_nmod) stimulation_1\NN\242808|excessive|receptors (r_nsubj) causes_6\VBZ\1617192|stimulation|syndrome|. (l_dobj) syndrome_8\NN\5870365|a|excess|consists (l_acl:relcl) consists_13\VBZ\2603699|that|shivering (l_nmod) shivering_15\NN\14299637|of|,|rigidity|,|salivation (l_conj) salivation_20\NN\13553916|,|confusion (l_conj) confusion_22\NN\13972797|,|agitation (l_conj) agitation_24\NN\14373582|and|hyperthermia
D012701_D011595 NONE serotonin_10\NN\14807737| (r_compound) excess_11\NN\5119367|of|serotonin (r_nmod) syndrome_8\NN\5870365|a|excess|consists (l_acl:relcl) consists_13\VBZ\2603699|that|shivering (l_nmod) shivering_15\NN\14299637|of|,|rigidity|,|salivation (l_conj) salivation_20\NN\13553916|,|confusion (l_conj) confusion_22\NN\13972797|,|agitation (l_conj) agitation_24\NN\14373582|and|hyperthermia
D012701_D005334 NONE serotonin_3\NN\14807737| (r_compound) receptors_5\NNS\5225602|of|serotonin|5ht1a (r_nmod) stimulation_1\NN\242808|excessive|receptors (r_nsubj) causes_6\VBZ\1617192|stimulation|syndrome|. (l_dobj) syndrome_8\NN\5870365|a|excess|consists (l_acl:relcl) consists_13\VBZ\2603699|that|shivering (l_nmod) shivering_15\NN\14299637|of|,|rigidity|,|salivation (l_conj) salivation_20\NN\13553916|,|confusion (l_conj) confusion_22\NN\13972797|,|agitation (l_conj) agitation_24\NN\14373582|and|hyperthermia (l_conj) hyperthermia_26\NN\14034177|
D012701_D005334 NONE serotonin_10\NN\14807737| (r_compound) excess_11\NN\5119367|of|serotonin (r_nmod) syndrome_8\NN\5870365|a|excess|consists (l_acl:relcl) consists_13\VBZ\2603699|that|shivering (l_nmod) shivering_15\NN\14299637|of|,|rigidity|,|salivation (l_conj) salivation_20\NN\13553916|,|confusion (l_conj) confusion_22\NN\13972797|,|agitation (l_conj) agitation_24\NN\14373582|and|hyperthermia (l_conj) hyperthermia_26\NN\14034177|
C047426_D003866 NONE venlafaxine-maoi_3\JJ\1740| (r_amod) interaction_4\NN\37396|a|venlafaxine-maoi|resulted (l_acl:relcl) resulted_6\VBD\2633881|that|syndrome (l_nmod) syndrome_10\NN\5870365|in|the|serotonin|male (l_nmod) male_14\NN\15388|in|a|23-y-old|taking (l_acl:relcl) taking_17\VBG\2367363|who|was|tranylcypromine|depression (l_nmod) depression_20\NN\14373582|for
D014191_D003866 NONE tranylcypromine_18\NN\3783017| (r_dobj) taking_17\VBG\2367363|who|was|tranylcypromine|depression (l_nmod) depression_20\NN\14373582|for
D003975_D009127 NONE diazepam_26\NN\2830852|of (r_nmod) mg_24\NN\13717155|after|180|diazepam|i.v. (r_nmod) pressure_5\NN\11419404|signs|were|:|blood|hg|,|rate|,|and|temperature|f.|mg (r_nsubj) remained_29\VBD\2604760|pressure|he|tremulous|. (l_xcomp) tremulous_30\JJ\1740|rigidity (l_nmod) rigidity_33\NN\5023233|with|muscle|and|jaws
9636837
D016190_D020258 NONE carboplatin_6\NN\1740|'s (r_nmod:poss) advantages_8\NNS\5154517|of|carboplatin|cbdca (r_nmod) striking_4\JJ\1740|the|most|advantages|cisplatin (r_appos) background_0\NN\4921011|:|striking (r_compound) rate_21\NN\13815152|background|is|its|reduced|effects|. (l_nmod) effects_24\NNS\13245626|of|neurotoxic (l_amod) neurotoxic_23\JJ\1740|
D016190_D020258 NONE cbdca_10\NN\1740|(|) (r_appos) advantages_8\NNS\5154517|of|carboplatin|cbdca (r_nmod) striking_4\JJ\1740|the|most|advantages|cisplatin (r_appos) background_0\NN\4921011|:|striking (r_compound) rate_21\NN\13815152|background|is|its|reduced|effects|. (l_nmod) effects_24\NNS\13245626|of|neurotoxic (l_amod) neurotoxic_23\JJ\1740|
D016190_D020258 NONE cbdca_5\NN\1740| (r_compound) schedules_7\NNS\5898568|of|cbdca|higher-intensity (r_nmod) use_3\NN\407535|the|schedules|and|association (l_conj) association_10\NN\8008335|the|drugs|polychemotherapy (l_nmod) drugs_14\NNS\14778436|with|other|neurotoxic (l_amod) neurotoxic_13\JJ\1740|
D016190_D020258 NONE cbdca_2\NN\1740| (r_nsubj) neurotoxic_4\JJ\1740|cbdca|is|model|,|and|similar
D016190_D020258 NONE cbdca_2\NN\1740| (r_nsubj) neurotoxic_4\JJ\1740|cbdca|is|model|,|and|similar (r_acl:relcl) conclusions_0\NNS\5837957|:|neurotoxic|probable|. (l_dep) probable_29\JJ\1740|that|it|is|induced (l_ccomp) induced_33\VBN\1627355|that|neurotoxicity|is|drugs|mechanism (l_nsubjpass) neurotoxicity_31\NN\1740|
D002945_D020258 NONE cisplatin_13\NN\1740|over|cddp (r_nmod) striking_4\JJ\1740|the|most|advantages|cisplatin (r_appos) background_0\NN\4921011|:|striking (r_compound) rate_21\NN\13815152|background|is|its|reduced|effects|. (l_nmod) effects_24\NNS\13245626|of|neurotoxic (l_amod) neurotoxic_23\JJ\1740|
D002945_D020258 NONE cddp_15\NN\1740|(|) (r_appos) cisplatin_13\NN\1740|over|cddp (r_nmod) striking_4\JJ\1740|the|most|advantages|cisplatin (r_appos) background_0\NN\4921011|:|striking (r_compound) rate_21\NN\13815152|background|is|its|reduced|effects|. (l_nmod) effects_24\NNS\13245626|of|neurotoxic (l_amod) neurotoxic_23\JJ\1740|
D002945_D020258 NONE cddp_25\NN\1740|by (r_nmod) caused_23\VBN\1617192|cddp (r_acl) those_22\DT\1740|to|caused (r_nmod) similar_20\JJ\1740|type|are|closely|those (r_conj) neurotoxic_4\JJ\1740|cbdca|is|model|,|and|similar
D002945_D020258 NONE cddp_25\NN\1740|by (r_nmod) caused_23\VBN\1617192|cddp (r_acl) those_22\DT\1740|to|caused (r_nmod) similar_20\JJ\1740|type|are|closely|those (r_conj) neurotoxic_4\JJ\1740|cbdca|is|model|,|and|similar (r_acl:relcl) conclusions_0\NNS\5837957|:|neurotoxic|probable|. (l_dep) probable_29\JJ\1740|that|it|is|induced (l_ccomp) induced_33\VBN\1627355|that|neurotoxicity|is|drugs|mechanism (l_nsubjpass) neurotoxicity_31\NN\1740|
D016190_D010523 CID cbdca_5\NN\1740| (r_compound) schedules_7\NNS\5898568|of|cbdca|higher-intensity (r_nmod) use_3\NN\407535|the|schedules|and|association (r_nsubj) cause_18\VB\1617192|however|,|use|may|concern|. (l_dobj) concern_20\NN\5682950|some|safety|respect (l_nmod) respect_25\NN\5817845|with|damage (l_nmod) damage_30\NN\7296428|to|system
D016190_D010523 CID cbdca_2\NN\1740| (r_compound) administration_3\NN\1133281|cbdca (r_nsubj) induced_4\VBD\1627355|results|:|administration|neurotoxicity|. (l_dobj) neurotoxicity_7\NN\1740|dose-dependent|peripheral
16364460
D016713_D000647 NONE ritanserin_2\NN\1740|of (r_nmod) microinjection_0\NN\1740|ritanserin|region (r_nsubj) improves_9\VBZ\126264|microinjection|amnesia|. (l_dobj) amnesia_11\NN\5669934|scopolamine-induced|rats
D016713_D000647 NONE ritanserin_3\NN\1740|of|antagonist (r_nmod) effect_1\NN\34213|the|ritanserin|amnesia (l_nmod) amnesia_14\NN\5669934|on|scopolamine|maze
D016713_D000647 NONE ritanserin_6\NN\1740|of (r_nmod) microinjection_4\NN\1740|ritanserin|region (r_nsubj) improves_14\VBZ\126264|that|microinjection|amnesia (l_dobj) amnesia_17\NN\5669934|the|scopolamine-induced
D012601_D000647 CID scopolamine-induced_10\JJ\1740| (r_amod) amnesia_11\NN\5669934|scopolamine-induced|rats
D012601_D000647 CID scopolamine_9\NN\14712692|antagonist)-induced (r_compound) amnesia_14\NN\5669934|on|scopolamine|maze
D012601_D000647 CID scopolamine-induced_16\JJ\1740| (r_amod) amnesia_17\NN\5669934|the|scopolamine-induced
18177388
D000661_D054549 CID amphetamine_21\NN\3248958| (r_compound) use_22\NN\407535|of|amphetamine (r_nmod) setting_19\NN\8567235|in|the|use (r_nmod) syndrome_7\NN\5870365|reverse|left|ventricular|apical|ballooning|cardiomyopathy|woman|setting|.
D000661_D054549 CID amphetamine_21\NN\3248958| (r_compound) use_22\NN\407535|of|amphetamine (r_nmod) setting_19\NN\8567235|in|the|use (r_nmod) syndrome_7\NN\5870365|reverse|left|ventricular|apical|ballooning|cardiomyopathy|woman|setting|. (l_appos) cardiomyopathy_11\NN\14103288|(|reverse|takotsubo|)
D000661_D054549 CID amphetamine_26\NN\3248958| (r_compound) use_27\NN\407535|after|amphetamine (r_nmod) occurring_24\VBG\2623529|use (r_acl) type_18\NN\5839024|with|this|rare|syndrome|occurring (l_nmod) syndrome_23\NN\5870365|of|reverse|apical|ballooning
6728084
D000617_D007674 NONE aminoglycoside_3\NN\1740| (r_compound) treatment_4\NN\654885|of|aminoglycoside (r_nmod) effects_1\NNS\13245626|nephrotoxic|treatment|reabsorption|. (l_amod) nephrotoxic_0\JJ\1740|
D000617_D007674 NONE aminoglycosides_2\NNS\1740| (r_nsubj) act_4\VB\1619354|thus|,|aminoglycosides|may|nephrotoxicants|level|inducing|. (l_xcomp) inducing_12\VBG\1627355|impairment (l_dobj) impairment_13\NN\7296428|reabsorption (l_nmod) reabsorption_16\NN\13526110|of|renal|and|accumulation
7650771
D004456_D064420 NONE iodide_8\NN\14904359| (r_compound) drops_10\NNS\13899200|of|echothiophate|iodide|eye (r_nmod) instillation_5\NN\320852|from|ocular|drops (r_nmod) resulting_2\VBG\2633881|instillation (r_acl) toxicity_1\NN\13576101|cholinergic|resulting|.
D004456_D018908 CID iodide_12\NN\14904359| (r_compound) drops_14\NNS\13899200|of|echothiophate|iodide|ophthalmic (r_nmod) use_9\NN\407535|from|the|drops (r_nmod) developed_2\VBD\1753788|patient|syndrome|use|,|presented|. (l_conj) presented_16\VBD\2137132|weakness|and|given (l_nmod) weakness_20\NN\14462666|with|profound|muscle
D004456_D009157 NONE iodide_12\NN\14904359| (r_compound) drops_14\NNS\13899200|of|echothiophate|iodide|ophthalmic (r_nmod) use_9\NN\407535|from|the|drops (r_nmod) developed_2\VBD\1753788|patient|syndrome|use|,|presented|. (l_conj) presented_16\VBD\2137132|weakness|and|given (l_conj) given_24\VBN\2327200|was|initially|diagnosis (l_dobj) diagnosis_26\NN\152018|the|gravis (l_nmod) gravis_29\NN\1740|of|myasthenia
1255900
D006493_D013924 NONE heparin_8\NN\2718259| (r_compound) therapy_9\NN\657604|of|heparin|thrombophlebitis (l_nmod) thrombophlebitis_13\NN\14352890|for|suspected|pelvic
3461217
D008770_D011471 CID n-nitroso-n-methylurea_11\NN\1740|with|and|testosterone (r_nmod) treatments_9\NNS\654885|by|n-nitroso-n-methylurea (r_nmod) production_0\NN\30358|cancer|rats|treatments|. (l_nmod) cancer_4\NN\14239425|of|autochthonous|prostate
D008770_D011471 CID n-nitroso-n-methylurea_23\NN\1740|with|cas|and|propionate (r_nmod) treatments_21\NNS\654885|following|n-nitroso-n-methylurea (r_nmod) developed_11\VBD\1753788|%|adenocarcinomas|treatments|,|and|manifested (l_dobj) adenocarcinomas_16\NNS\14242337|large|,|palpable|prostate|pas
D008770_D011471 CID n-nitroso-n-methylurea_23\NN\1740|with|cas|and|propionate (r_nmod) treatments_21\NNS\654885|following|n-nitroso-n-methylurea (r_nmod) developed_11\VBD\1753788|%|adenocarcinomas|treatments|,|and|manifested (l_dobj) adenocarcinomas_16\NNS\14242337|large|,|palpable|prostate|pas (l_appos) pas_18\NNS\285557|(|)
D013739_D011471 NONE testosterone_13\NN\14747587| (r_conj) n-nitroso-n-methylurea_11\NN\1740|with|and|testosterone (r_nmod) treatments_9\NNS\654885|by|n-nitroso-n-methylurea (r_nmod) production_0\NN\30358|cancer|rats|treatments|. (l_nmod) cancer_4\NN\14239425|of|autochthonous|prostate
D008770_D009369 NONE n-nitroso-n-methylurea_23\NN\1740|with|cas|and|propionate (r_nmod) treatments_21\NNS\654885|following|n-nitroso-n-methylurea (r_nmod) developed_11\VBD\1753788|%|adenocarcinomas|treatments|,|and|manifested (l_conj) manifested_55\VBD\1015244|most|lesions|. (l_nsubj) most_50\JJS\1740|rats (l_nmod) rats_54\NNS\2329401|of|the|tumor-bearing (l_amod) tumor-bearing_53\JJ\1740|
D043343_D011471 CID propionate_35\NN\1740|testosterone|cas (r_conj) n-nitroso-n-methylurea_23\NN\1740|with|cas|and|propionate (r_nmod) treatments_21\NNS\654885|following|n-nitroso-n-methylurea (r_nmod) developed_11\VBD\1753788|%|adenocarcinomas|treatments|,|and|manifested (l_dobj) adenocarcinomas_16\NNS\14242337|large|,|palpable|prostate|pas
D043343_D011471 CID propionate_35\NN\1740|testosterone|cas (r_conj) n-nitroso-n-methylurea_23\NN\1740|with|cas|and|propionate (r_nmod) treatments_21\NNS\654885|following|n-nitroso-n-methylurea (r_nmod) developed_11\VBD\1753788|%|adenocarcinomas|treatments|,|and|manifested (l_dobj) adenocarcinomas_16\NNS\14242337|large|,|palpable|prostate|pas (l_appos) pas_18\NNS\285557|(|)
D043343_D011471 CID tp_38\NN\1740| (r_compound) cas_40\NN\14625458|[|(|tp|)|:|57|85|2|] (r_appos) propionate_35\NN\1740|testosterone|cas (r_conj) n-nitroso-n-methylurea_23\NN\1740|with|cas|and|propionate (r_nmod) treatments_21\NNS\654885|following|n-nitroso-n-methylurea (r_nmod) developed_11\VBD\1753788|%|adenocarcinomas|treatments|,|and|manifested (l_dobj) adenocarcinomas_16\NNS\14242337|large|,|palpable|prostate|pas
D043343_D011471 CID tp_38\NN\1740| (r_compound) cas_40\NN\14625458|[|(|tp|)|:|57|85|2|] (r_appos) propionate_35\NN\1740|testosterone|cas (r_conj) n-nitroso-n-methylurea_23\NN\1740|with|cas|and|propionate (r_nmod) treatments_21\NNS\654885|following|n-nitroso-n-methylurea (r_nmod) developed_11\VBD\1753788|%|adenocarcinomas|treatments|,|and|manifested (l_dobj) adenocarcinomas_16\NNS\14242337|large|,|palpable|prostate|pas (l_appos) pas_18\NNS\285557|(|)
D043343_D011471 CID tp_17\NN\1740|with (r_nmod) treated_14\VBN\2376958|when|tp (r_advcl) developed_8\VBD\1753788|timeframe|,|rat|pa|treated|. (l_dobj) pa_12\NN\10080869|a|similar|palpable
D043343_D011471 CID tp_4\NN\1740| (r_nsubj) acted_5\VBD\1619354|rats|,|tp|agent|,|emphasis|. (l_nmod) emphasis_14\NN\14434681|with|primary|development (l_nmod) development_17\NN\248977|on|the|cancer (l_nmod) cancer_20\NN\14239425|of|prostate
D043343_D009369 NONE propionate_35\NN\1740|testosterone|cas (r_conj) n-nitroso-n-methylurea_23\NN\1740|with|cas|and|propionate (r_nmod) treatments_21\NNS\654885|following|n-nitroso-n-methylurea (r_nmod) developed_11\VBD\1753788|%|adenocarcinomas|treatments|,|and|manifested (l_conj) manifested_55\VBD\1015244|most|lesions|. (l_nsubj) most_50\JJS\1740|rats (l_nmod) rats_54\NNS\2329401|of|the|tumor-bearing (l_amod) tumor-bearing_53\JJ\1740|
D043343_D009369 NONE tp_38\NN\1740| (r_compound) cas_40\NN\14625458|[|(|tp|)|:|57|85|2|] (r_appos) propionate_35\NN\1740|testosterone|cas (r_conj) n-nitroso-n-methylurea_23\NN\1740|with|cas|and|propionate (r_nmod) treatments_21\NNS\654885|following|n-nitroso-n-methylurea (r_nmod) developed_11\VBD\1753788|%|adenocarcinomas|treatments|,|and|manifested (l_conj) manifested_55\VBD\1015244|most|lesions|. (l_nsubj) most_50\JJS\1740|rats (l_nmod) rats_54\NNS\2329401|of|the|tumor-bearing (l_amod) tumor-bearing_53\JJ\1740|
D043343_D009369 NONE tp_4\NN\1740| (r_nsubj) acted_5\VBD\1619354|rats|,|tp|agent|,|emphasis|. (l_nmod) agent_10\NN\7347|as|a|tumor|enhancement (l_compound) tumor_8\NN\14234074|
430165
D010672_D010291 CID diphenylhydantoin_7\NN\3550533| (r_compound) toxicity_8\NN\13576101|of|diphenylhydantoin (r_nmod) manifestation_5\NN\7321772|a|rare|toxicity (r_appos) hemiparesis_1\NN\1740|transient|:|manifestation|.
D010672_D010291 CID dph_10\NN\6702458| (r_compound) overdose_11\NN\1740|due|dph (r_nmod) hemiparesis_7\NN\1740|progressive|overdose
D010672_D064420 NONE diphenylhydantoin_7\NN\3550533| (r_compound) toxicity_8\NN\13576101|of|diphenylhydantoin
D010672_D064420 NONE dph_13\NN\6702458| (r_compound) toxicity_14\NN\13576101|dph
D010672_D062787 CID diphenylhydantoin_6\NN\3550533|dph (r_compound) overdose_10\NN\1740|of|diphenylhydantoin
D010672_D062787 CID dph_8\NN\6702458|(|) (r_appos) diphenylhydantoin_6\NN\3550533|dph (r_compound) overdose_10\NN\1740|of|diphenylhydantoin
D010672_D062787 CID dph_10\NN\6702458| (r_compound) overdose_11\NN\1740|due|dph
D010672_D002526 CID diphenylhydantoin_6\NN\3550533|dph (r_compound) overdose_10\NN\1740|of|diphenylhydantoin (r_nmod) effects_4\NNS\13245626|among|the|common|side|overdose (r_nmod) those_19\DT\1740|effects|,|signs|are|dysfunction|. (l_nmod) dysfunction_22\NN\14204950|of|cerebellar
D010672_D002526 CID dph_8\NN\6702458|(|) (r_appos) diphenylhydantoin_6\NN\3550533|dph (r_compound) overdose_10\NN\1740|of|diphenylhydantoin (r_nmod) effects_4\NNS\13245626|among|the|common|side|overdose (r_nmod) those_19\DT\1740|effects|,|signs|are|dysfunction|. (l_nmod) dysfunction_22\NN\14204950|of|cerebellar
D010672_D001927 NONE dph_13\NN\6702458| (r_compound) toxicity_14\NN\13576101|dph (r_dobj) manifest_12\VB\1015244|to|toxicity|signs (r_xcomp) liable_10\JJ\1740|that|patients|are|manifest (l_nsubj) patients_4\NNS\9898892|damage (l_nmod) damage_8\NN\7296428|with|some|cerebral
85485
D001556_D006528 CID hexachloride_13\NN\1740|by|alpha-benzene (r_nmod) induced_10\VBN\1627355|hexachloride (r_acl) liver_5\NN\5298729|in|preneoplastic|and|hepatoma|mice|induced (l_conj) hepatoma_7\NN\14242337|
D001556_D006528 CID hexachloride_15\NN\1740|by|ppm|alpha-benzene (r_nmod) induced_8\VBN\1627355|mice|hexachloride (r_acl) lesions_7\NNS\14204950|hyperplastic|preneoplastic|liver|induced (r_conj) peroxisomes_0\NNS\1740|hepatomas|and|lesions (l_nmod) hepatomas_2\NNS\14242337|in
D001556_D017093 NONE hexachloride_15\NN\1740|by|ppm|alpha-benzene (r_nmod) induced_8\VBN\1627355|mice|hexachloride (r_acl) lesions_7\NNS\14204950|hyperplastic|preneoplastic|liver|induced
C012282_D006528 NONE ethyl-alpha-p-chlorophenoxyisobutyrate_23\NN\1740|to (r_nmod) respond_21\VB\2367363|tumors|,|cells|did|not|ethyl-alpha-p-chlorophenoxyisobutyrate|proliferation|. (l_advcl) tumors_7\NNS\14234074|although|most|were|well-differentiated|and|contained (l_nsubj) most_1\JJS\1740|hepatomas (l_nmod) hepatomas_4\NNS\14242337|of|the
C012282_D009369 NONE ethyl-alpha-p-chlorophenoxyisobutyrate_23\NN\1740|to (r_nmod) respond_21\VB\2367363|tumors|,|cells|did|not|ethyl-alpha-p-chlorophenoxyisobutyrate|proliferation|. (l_advcl) tumors_7\NNS\14234074|although|most|were|well-differentiated|and|contained
C012282_D009369 NONE ethyl-alpha-p-chlorophenoxyisobutyrate_23\NN\1740|to (r_nmod) respond_21\VB\2367363|tumors|,|cells|did|not|ethyl-alpha-p-chlorophenoxyisobutyrate|proliferation|. (l_nsubj) cells_18\NNS\3080309|the|tumor (l_compound) tumor_17\NN\14234074|
1636026
D013496_D058186 CID suprofen_1\NN\1740| (r_nsubjpass) associated_4\VBN\628491|although|suprofen|has|been|development (l_nmod) development_7\NN\248977|with|the|failure|subjects (l_nmod) failure_11\NN\66216|of|acute|renal
D013496_D058186 CID suprofen_3\NNP\1740| (r_nsubj) causes_4\VBZ\1617192|summary|,|suprofen|declines|,|likely|. (l_dobj) declines_6\NNS\13458571|acute|function (l_nmod) function_9\NN\13783581|in|renal
D013496_D007674 NONE suprofen_12\NN\1740|of (r_nmod) mg_10\NN\13717155|of|15|suprofen (r_nmod) dose_7\NN\3740161|of|a|single|mg (r_nmod) effects_3\NNS\13245626|the|direct|nephrotoxic|dose (l_amod) nephrotoxic_2\JJ\1740|
D014527_D007674 NONE acid_35\NN\14818238|of|uric (r_nmod) mg/dl_32\NN\1740|of|5|acid (r_nmod) addition_29\NN\3081021|with|the|mg/dl (r_nmod) perfused_21\VBN\454868|buffer|addition (r_acl) kidney_20\NN\5333259|in|the|recirculating|isolated|rat|perfused (r_nmod) compared_14\VBN\644583|effects|were|kidney|. (l_nsubjpass) effects_3\NNS\13245626|the|direct|nephrotoxic|dose (l_amod) nephrotoxic_2\JJ\1740|
D014527_D058186 NONE acid_21\NN\14818238|of|uric (r_nmod) distribution_18\NN\5726596|the|intrarenal|acid (r_dobj) altering_15\VBG\126264|by|directly|distribution (r_advcl) likely_12\RB\1740|most|altering (r_advmod) causes_4\VBZ\1617192|summary|,|suprofen|declines|,|likely|. (l_dobj) declines_6\NNS\13458571|acute|function (l_nmod) function_9\NN\13783581|in|renal
9022662
D010389_D002819 CID pemoline_0\NN\1740| (r_nmod:npmod) induced_1\JJ\1740|pemoline (r_amod) choreoathetosis_3\NN\1740|induced|acute|:|report
D010389_D002819 CID pemoline_9\NN\1740|with (r_nmod) poisoned_7\VBN\2579447|acutely|pemoline (r_acl) children_5\NNS\9622049|two|poisoned|experienced (l_acl:relcl) experienced_11\VBD\2108377|who|choreoathetosis (l_dobj) choreoathetosis_13\NN\1740|profound
D010389_D002819 CID pemoline_12\NN\1740| (r_compound) overdose_13\NN\1740|after|pemoline (r_nmod) presenting_10\VBG\2137132|overdose (r_acl) patients_9\NNS\9898892|in|presenting (r_nmod) considered_7\VBN\689344|possibility|should|be|patients|. (l_nsubjpass) possibility_1\NN\5944958|the|movements (l_nmod) movements_4\NNS\191142|of|choreoathetoid (l_amod) choreoathetoid_3\JJ\1740|
D010389_D001264 CID pemoline_0\NN\1740| (r_nmod:npmod) induced_1\JJ\1740|pemoline (r_amod) choreoathetosis_3\NN\1740|induced|acute|:|report
D010389_D001264 CID pemoline_9\NN\1740|with (r_nmod) poisoned_7\VBN\2579447|acutely|pemoline (r_acl) children_5\NNS\9622049|two|poisoned|experienced (l_acl:relcl) experienced_11\VBD\2108377|who|choreoathetosis (l_dobj) choreoathetosis_13\NN\1740|profound
D010389_D001264 CID pemoline_12\NN\1740| (r_compound) overdose_13\NN\1740|after|pemoline (r_nmod) presenting_10\VBG\2137132|overdose (r_acl) patients_9\NNS\9898892|in|presenting (r_nmod) considered_7\VBN\689344|possibility|should|be|patients|. (l_nsubjpass) possibility_1\NN\5944958|the|movements (l_nmod) movements_4\NNS\191142|of|choreoathetoid (l_amod) choreoathetoid_3\JJ\1740|
D010389_D001289 NONE pemoline_2\NN\1740| (r_nsubj) derivative_6\NN\5802185|:|pemoline|is|an|oxazolidine|different (l_acl:relcl) different_10\JJ\1740|that|is|structurally|amphetamines|and|used (l_conj) used_14\VBN\1156834|treatment (l_nmod) treatment_17\NN\654885|in|the|disorder (l_nmod) disorder_21\NN\14034177|of|attention|deficit
C064210_D001289 NONE oxazolidine_5\NN\1740| (r_compound) derivative_6\NN\5802185|:|pemoline|is|an|oxazolidine|different (l_acl:relcl) different_10\JJ\1740|that|is|structurally|amphetamines|and|used (l_conj) used_14\VBN\1156834|treatment (l_nmod) treatment_17\NN\654885|in|the|disorder (l_nmod) disorder_21\NN\14034177|of|attention|deficit
D000662_D001289 NONE amphetamines_12\NNS\3248958|from (r_nmod) different_10\JJ\1740|that|is|structurally|amphetamines|and|used (l_conj) used_14\VBN\1156834|treatment (l_nmod) treatment_17\NN\654885|in|the|disorder (l_nmod) disorder_21\NN\14034177|of|attention|deficit
D010389_D009069 NONE pemoline_0\NN\1740| (r_nsubjpass) associated_5\VBN\628491|pemoline|has|not|been|commonly|literature|cause|. (l_nmod) cause_11\NN\7323922|as|a|disorders (l_nmod) disorders_15\NNS\14034177|of|acute|movement
D010389_D009069 NONE pemoline_2\NN\1740| (r_nmod:npmod) associated_3\JJ\1740|pemoline (r_amod) disorder_5\NN\14034177|associated|movement
D008774_D001289 NONE methylphenidate_14\NN\4320126|with (r_nmod) treated_12\VBN\2376958|previously|methylphenidate|success (r_acl) disorder_10\NN\14034177|for|attention|deficit|treated
D001569_D002819 NONE benzodiazepines_10\NNS\3771443|of|intravenous (r_nmod) doses_7\NNS\3740161|high|benzodiazepines (r_conj) decontamination_4\NN\391599|gastrointestinal|and|doses (r_dobj) received_2\VBD\2210855|children|decontamination|attempt|. (l_nmod) attempt_13\NN\407535|in|an|control (l_acl) control_15\VB\2422663|to|movements (l_dobj) movements_18\NNS\191142|the|choreoathetoid (l_amod) choreoathetoid_17\JJ\1740|
D001569_D001264 NONE benzodiazepines_10\NNS\3771443|of|intravenous (r_nmod) doses_7\NNS\3740161|high|benzodiazepines (r_conj) decontamination_4\NN\391599|gastrointestinal|and|doses (r_dobj) received_2\VBD\2210855|children|decontamination|attempt|. (l_nmod) attempt_13\NN\407535|in|an|control (l_acl) control_15\VB\2422663|to|movements (l_dobj) movements_18\NNS\191142|the|choreoathetoid (l_amod) choreoathetoid_17\JJ\1740|
D010389_D062787 CID pemoline_12\NN\1740| (r_compound) overdose_13\NN\1740|after|pemoline
12013711
D018967_D010468 CID risperidone-associated_0\NN\1740| (r_compound) disturbances_5\NNS\407535|risperidone-associated|,|benign|transient|visual|patients|.
D018967_D010468 CID risperidone_17\NN\1740|with (r_nmod) treatment_15\NN\654885|risperidone (r_dobj) starting_14\VBG\2009433|immediately|after|treatment (r_advcl) appeared_11\VBD\2604760|which|starting (r_acl:relcl) episodes_4\NNS\7283608|short|disturbances|appeared (l_nmod) disturbances_8\NNS\407535|of|transient|visual|,
D018967_D010468 CID risperidone_0\NN\1740| (r_compound) administration_1\NN\1133281|risperidone (r_nsubjpass) continued_3\VBN\2367363|administration|was|and|wore (l_conj) wore_9\VBD\2630189|disturbances|gradually|off|. (l_nsubj) disturbances_7\NNS\407535|the|visual
D018967_D012559 NONE risperidone-associated_0\NN\1740| (r_compound) disturbances_5\NNS\407535|risperidone-associated|,|benign|transient|visual|patients|. (l_nmod) patients_8\NNS\9898892|in|schizophrenic|history (l_amod) schizophrenic_7\JJ\1740|
D018967_D012559 NONE risperidone_26\NN\1740|with (r_nmod) treated_24\VBN\2376958|patients|were|successfully|risperidone|. (l_nsubjpass) patients_2\NNS\9898892|two|schizophrenic|,|had|, (l_amod) schizophrenic_1\JJ\1740|
D008238_D010468 NONE lsd_14\NN\3097890| (r_compound) abuse_15\NN\418025|of|lsd (r_nmod) history_12\NN\15120823|with|a|past|abuse (r_nmod) patients_8\NNS\9898892|in|schizophrenic|history (r_nmod) disturbances_5\NNS\407535|risperidone-associated|,|benign|transient|visual|patients|.
D008238_D010468 NONE lsd_14\NN\3097890| (r_compound) consumption_15\NN\13440063|to|prior|lsd (r_nmod) related_11\VBN\628491|consumption (r_acl) flashbacks_9\NNS\6401328|as|"|"|related (r_nmod) experienced_6\VBN\2108377|previously|flashbacks (r_acl) disturbances_4\NNS\407535|visual|experienced
D008238_D012559 NONE lsd_14\NN\3097890| (r_compound) abuse_15\NN\418025|of|lsd (r_nmod) history_12\NN\15120823|with|a|past|abuse (r_nmod) patients_8\NNS\9898892|in|schizophrenic|history (l_amod) schizophrenic_7\JJ\1740|
D008238_D012559 NONE lsd_10\NN\3097890| (r_compound) abuse_11\NN\418025|of|lsd (r_nmod) history_8\NN\15120823|a|prior|abuse (r_dobj) had_5\VBD\2108377|who|history|and|developed (r_acl:relcl) patients_2\NNS\9898892|two|schizophrenic|,|had|, (l_amod) schizophrenic_1\JJ\1740|
D008238_D001480 NONE lsd_10\NN\3097890| (r_compound) abuse_11\NN\418025|of|lsd (r_nmod) history_8\NN\15120823|a|prior|abuse (r_dobj) had_5\VBD\2108377|who|history|and|developed (l_conj) developed_16\VBN\1753788|who|had|previously|eps (l_dobj) eps_17\NN\1740|antipsychotics
D018967_D001480 NONE risperidone_26\NN\1740|with (r_nmod) treated_24\VBN\2376958|patients|were|successfully|risperidone|. (l_nsubjpass) patients_2\NNS\9898892|two|schizophrenic|,|had|, (l_acl:relcl) had_5\VBD\2108377|who|history|and|developed (l_conj) developed_16\VBN\1753788|who|had|previously|eps (l_dobj) eps_17\NN\1740|antipsychotics
2709684
D010695_D006029 NONE phlorizin-induced_0\JJ\1740| (r_amod) glycosuria_1\NN\14299637|phlorizin-induced
D010695_D006029 NONE p_13\NN\14622893| (r_nmod:npmod) treated_14\JJ\1740|p (r_amod) animals_15\NNS\4475|of|the|treated (r_nmod) that_10\DT\1740|to|animals (r_nmod) similar_6\JJ\1740|(|degree|that|) (r_amod) glycosuria_4\NN\14299637|with|mild|similar
D010695_D006029 NONE p_1\NN\14622893| (r_nsubj) induced_2\VBD\1627355|,|p|glycosuria|. (l_dobj) glycosuria_7\NN\14299637|a|moderate|g/day|,|and|evidence
D010695_D007674 NONE phlorizin-induced_0\JJ\1740| (r_amod) glycosuria_1\NN\14299637|phlorizin-induced (r_nsubj) prevent_4\VB\1740|glycosuria|does|not|nephrotoxicity|. (l_dobj) nephrotoxicity_6\NN\1740|gentamicin|rats
D010695_D007674 NONE phlorizin_22\NN\1740|with|p (r_nmod) blockage_16\NN\14034177|by|reabsorption|phlorizin (r_nmod) induced_14\VBN\1627355|blockage (r_acl) diuresis_13\NN\14299637|with|chronic|solute|induced (r_nmod) rats_9\NNS\2329401|in|non-diabetic|diuresis (r_nmod) studied_6\VBN\630380|protection|was|rats|. (l_nsubjpass) protection_1\NN\407535|the|nephrotoxicity (l_nmod) nephrotoxicity_4\NN\1740|from|gentamicin
D010695_D007674 NONE p_24\NN\14622893|(|) (r_appos) phlorizin_22\NN\1740|with|p (r_nmod) blockage_16\NN\14034177|by|reabsorption|phlorizin (r_nmod) induced_14\VBN\1627355|blockage (r_acl) diuresis_13\NN\14299637|with|chronic|solute|induced (r_nmod) rats_9\NNS\2329401|in|non-diabetic|diuresis (r_nmod) studied_6\VBN\630380|protection|was|rats|. (l_nsubjpass) protection_1\NN\407535|the|nephrotoxicity (l_nmod) nephrotoxicity_4\NN\1740|from|gentamicin
D010695_D007674 NONE p_1\NN\14622893| (r_nsubj) induced_2\VBD\1627355|,|p|glycosuria|. (l_dobj) glycosuria_7\NN\14299637|a|moderate|g/day|,|and|evidence (l_conj) evidence_22\NN\5816287|no|functional|dysfunction (l_nmod) dysfunction_25\NN\14204950|of|renal|ccr|or|damage
D005839_D006029 NONE gentamicin_5\NN\2716866| (r_compound) nephrotoxicity_6\NN\1740|gentamicin|rats (r_dobj) prevent_4\VB\1740|glycosuria|does|not|nephrotoxicity|. (l_nsubj) glycosuria_1\NN\14299637|phlorizin-induced
D005839_D006029 NONE gentamicin-induced_37\JJ\1740| (r_amod) failure_40\NN\66216|to|gentamicin-induced|acute|renal|arf (r_nmod) resistance_35\NN\37396|for|their|failure (r_nmod) responsible_32\JJ\1740|that|this|may|part|be|resistance (r_ccomp) suggested_25\VBN\1010118|have|,|we|have|responsible|. (l_advcl) have_9\VBP\2108377|because|rats|diuresis (l_dobj) diuresis_13\NN\14299637|a|high|solute|glycosuria (l_appos) glycosuria_15\NN\14299637|(|g/day|)
D005839_D007674 NONE gentamicin_5\NN\2716866| (r_compound) nephrotoxicity_6\NN\1740|gentamicin|rats
D005839_D007674 NONE gentamicin_3\NN\2716866| (r_compound) nephrotoxicity_4\NN\1740|from|gentamicin
D005839_D007674 NONE gentamicin_9\NN\2716866|of (r_nmod) doses_1\NNS\3740161|nephrotoxic|wt/day|gentamicin (l_amod) nephrotoxic_0\JJ\1740|
D013311_D003920 CID streptozotocin-induced_3\JJ\1740| (r_amod) mellitus_5\NN\1740|with|streptozotocin-induced|diabetes|dm
D013311_D003920 CID streptozotocin-induced_3\JJ\1740| (r_amod) mellitus_5\NN\1740|with|streptozotocin-induced|diabetes|dm (l_appos) dm_7\NN\14117805|(|)
D013311_D006029 NONE streptozotocin-induced_3\JJ\1740| (r_amod) mellitus_5\NN\1740|with|streptozotocin-induced|diabetes|dm (r_nmod) rats_1\NNS\2329401|mellitus (r_nsubj) have_9\VBP\2108377|because|rats|diuresis (l_dobj) diuresis_13\NN\14299637|a|high|solute|glycosuria (l_appos) glycosuria_15\NN\14299637|(|g/day|)
D013311_D058186 NONE streptozotocin-induced_3\JJ\1740| (r_amod) mellitus_5\NN\1740|with|streptozotocin-induced|diabetes|dm (r_nmod) rats_1\NNS\2329401|mellitus (r_nsubj) have_9\VBP\2108377|because|rats|diuresis (r_advcl) suggested_25\VBN\1010118|have|,|we|have|responsible|. (l_ccomp) responsible_32\JJ\1740|that|this|may|part|be|resistance (l_nmod) resistance_35\NN\37396|for|their|failure (l_nmod) failure_40\NN\66216|to|gentamicin-induced|acute|renal|arf
D013311_D058186 NONE streptozotocin-induced_3\JJ\1740| (r_amod) mellitus_5\NN\1740|with|streptozotocin-induced|diabetes|dm (r_nmod) rats_1\NNS\2329401|mellitus (r_nsubj) have_9\VBP\2108377|because|rats|diuresis (r_advcl) suggested_25\VBN\1010118|have|,|we|have|responsible|. (l_ccomp) responsible_32\JJ\1740|that|this|may|part|be|resistance (l_nmod) resistance_35\NN\37396|for|their|failure (l_nmod) failure_40\NN\66216|to|gentamicin-induced|acute|renal|arf (l_appos) arf_42\NN\1740|(|)
D005839_D003920 NONE gentamicin-induced_37\JJ\1740| (r_amod) failure_40\NN\66216|to|gentamicin-induced|acute|renal|arf (r_nmod) resistance_35\NN\37396|for|their|failure (r_nmod) responsible_32\JJ\1740|that|this|may|part|be|resistance (r_ccomp) suggested_25\VBN\1010118|have|,|we|have|responsible|. (l_advcl) have_9\VBP\2108377|because|rats|diuresis (l_nsubj) rats_1\NNS\2329401|mellitus (l_nmod) mellitus_5\NN\1740|with|streptozotocin-induced|diabetes|dm
D005839_D003920 NONE gentamicin-induced_37\JJ\1740| (r_amod) failure_40\NN\66216|to|gentamicin-induced|acute|renal|arf (r_nmod) resistance_35\NN\37396|for|their|failure (r_nmod) responsible_32\JJ\1740|that|this|may|part|be|resistance (r_ccomp) suggested_25\VBN\1010118|have|,|we|have|responsible|. (l_advcl) have_9\VBP\2108377|because|rats|diuresis (l_nsubj) rats_1\NNS\2329401|mellitus (l_nmod) mellitus_5\NN\1740|with|streptozotocin-induced|diabetes|dm (l_appos) dm_7\NN\14117805|(|)
D005839_D003920 NONE gentamicin_3\NN\2716866| (r_compound) nephrotoxicity_4\NN\1740|from|gentamicin (r_nmod) protection_1\NN\407535|the|nephrotoxicity (r_nsubjpass) studied_6\VBN\630380|protection|was|rats|. (l_nmod) rats_9\NNS\2329401|in|non-diabetic|diuresis (l_amod) non-diabetic_8\JJ\1740|
D005839_D003920 NONE gentamicin_21\NN\2716866| (r_conj) p_19\NN\14622893|(|+|gentamicin|) (r_dep) group_16\NN\2137|ii|p|;|group|and|group (l_conj) group_31\NN\2137|iv|dm (l_dep) dm_35\NN\14117805|(|mild|+|gentamicin|)
D005839_D003920 NONE gentamicin_27\NN\2716866|(|alone|) (r_dep) group_24\NN\2137|iii|gentamicin (r_conj) group_16\NN\2137|ii|p|;|group|and|group (l_conj) group_31\NN\2137|iv|dm (l_dep) dm_35\NN\14117805|(|mild|+|gentamicin|)
D005839_D003920 NONE gentamicin_37\NN\2716866| (r_conj) dm_35\NN\14117805|(|mild|+|gentamicin|)
D005839_D058186 CID gentamicin-induced_37\JJ\1740| (r_amod) failure_40\NN\66216|to|gentamicin-induced|acute|renal|arf
D005839_D058186 CID gentamicin-induced_37\JJ\1740| (r_amod) failure_40\NN\66216|to|gentamicin-induced|acute|renal|arf (l_appos) arf_42\NN\1740|(|)
D005839_D058186 CID gentamicin-arf_8\NN\1740|
D005947_D007674 NONE glucose_19\NN\14710501| (r_compound) reabsorption_20\NN\13526110|of|tubular|glucose (r_nmod) blockage_16\NN\14034177|by|reabsorption|phlorizin (r_nmod) induced_14\VBN\1627355|blockage (r_acl) diuresis_13\NN\14299637|with|chronic|solute|induced (r_nmod) rats_9\NNS\2329401|in|non-diabetic|diuresis (r_nmod) studied_6\VBN\630380|protection|was|rats|. (l_nsubjpass) protection_1\NN\407535|the|nephrotoxicity (l_nmod) nephrotoxicity_4\NN\1740|from|gentamicin
D005947_D003920 NONE glucose_19\NN\14710501| (r_compound) reabsorption_20\NN\13526110|of|tubular|glucose (r_nmod) blockage_16\NN\14034177|by|reabsorption|phlorizin (r_nmod) induced_14\VBN\1627355|blockage (r_acl) diuresis_13\NN\14299637|with|chronic|solute|induced (r_nmod) rats_9\NNS\2329401|in|non-diabetic|diuresis (l_amod) non-diabetic_8\JJ\1740|
D010695_D003920 NONE phlorizin_22\NN\1740|with|p (r_nmod) blockage_16\NN\14034177|by|reabsorption|phlorizin (r_nmod) induced_14\VBN\1627355|blockage (r_acl) diuresis_13\NN\14299637|with|chronic|solute|induced (r_nmod) rats_9\NNS\2329401|in|non-diabetic|diuresis (l_amod) non-diabetic_8\JJ\1740|
D010695_D003920 NONE p_24\NN\14622893|(|) (r_appos) phlorizin_22\NN\1740|with|p (r_nmod) blockage_16\NN\14034177|by|reabsorption|phlorizin (r_nmod) induced_14\VBN\1627355|blockage (r_acl) diuresis_13\NN\14299637|with|chronic|solute|induced (r_nmod) rats_9\NNS\2329401|in|non-diabetic|diuresis (l_amod) non-diabetic_8\JJ\1740|
D010695_D003920 NONE p_13\NN\14622893| (r_nmod:npmod) treated_14\JJ\1740|p (r_amod) animals_15\NNS\4475|of|the|treated (r_nmod) that_10\DT\1740|to|animals (r_nmod) similar_6\JJ\1740|(|degree|that|) (r_amod) glycosuria_4\NN\14299637|with|mild|similar (r_nmod) rats_1\NNS\2329401|dm|glycosuria (l_compound) dm_0\NN\14117805|
D010695_D003920 NONE p_3\NN\14622893|(|alone|) (r_appos) group_0\NN\2137|1|p (r_nsubj) received_6\VBD\2210855|group|p|,|days|;|group|. (l_conj) group_16\NN\2137|ii|p|;|group|and|group (l_conj) group_31\NN\2137|iv|dm (l_dep) dm_35\NN\14117805|(|mild|+|gentamicin|)
D010695_D003920 NONE p_7\NN\14622893|,|mg/day (r_dobj) received_6\VBD\2210855|group|p|,|days|;|group|. (l_conj) group_16\NN\2137|ii|p|;|group|and|group (l_conj) group_31\NN\2137|iv|dm (l_dep) dm_35\NN\14117805|(|mild|+|gentamicin|)
D010695_D003920 NONE p_19\NN\14622893|(|+|gentamicin|) (r_dep) group_16\NN\2137|ii|p|;|group|and|group (l_conj) group_31\NN\2137|iv|dm (l_dep) dm_35\NN\14117805|(|mild|+|gentamicin|)
D010695_D009956 NONE p_1\NN\14622893| (r_nsubj) induced_2\VBD\1627355|,|p|glycosuria|. (l_dobj) glycosuria_7\NN\14299637|a|moderate|g/day|,|and|evidence (l_conj) evidence_22\NN\5816287|no|functional|dysfunction (l_nmod) dysfunction_25\NN\14204950|of|renal|ccr|or|damage (l_conj) damage_38\NN\7296428|score (l_appos) score_42\NN\5736149|(|tubular|necrosis|maximum|,|zero|) (l_compound) necrosis_41\NN\11444117|
D010695_D009956 NONE p_4\NN\14622893| (r_nsubj) prevent_7\VB\1740|group|,|p|did|not|gentamicin-arf|decrease (l_dep) decrease_11\NN\7296428|(|maximal|ccr|%|,|p|;|lysozymuria|. (l_conj) lysozymuria_25\NN\1740|peak|,|micrograms/day|;|and|score (l_conj) score_35\NN\5736149|tubular|necrosis|,|3.9|) (l_compound) necrosis_34\NN\11444117|
D010695_D009956 NONE p_19\NN\14622893|less (r_appos) decrease_11\NN\7296428|(|maximal|ccr|%|,|p|;|lysozymuria|. (l_conj) lysozymuria_25\NN\1740|peak|,|micrograms/day|;|and|score (l_conj) score_35\NN\5736149|tubular|necrosis|,|3.9|) (l_compound) necrosis_34\NN\11444117|
D010695_D009956 NONE p_18\NN\14622893|(|less|) (r_appos) decrease_12\NN\7296428|maximal|ccr|%|p|;|lysozymuria|score|. (l_dep) score_33\NN\5736149|tubular|necrosis|,|3.8 (l_compound) necrosis_32\NN\11444117|
D010695_D058186 NONE p_4\NN\14622893| (r_nsubj) prevent_7\VB\1740|group|,|p|did|not|gentamicin-arf|decrease (l_dobj) gentamicin-arf_8\NN\1740|
D010695_D058186 NONE p_19\NN\14622893|less (r_appos) decrease_11\NN\7296428|(|maximal|ccr|%|,|p|;|lysozymuria|. (r_dep) prevent_7\VB\1740|group|,|p|did|not|gentamicin-arf|decrease (l_dobj) gentamicin-arf_8\NN\1740|
D005839_D009956 NONE gentamicin-arf_8\NN\1740| (r_dobj) prevent_7\VB\1740|group|,|p|did|not|gentamicin-arf|decrease (l_dep) decrease_11\NN\7296428|(|maximal|ccr|%|,|p|;|lysozymuria|. (l_conj) lysozymuria_25\NN\1740|peak|,|micrograms/day|;|and|score (l_conj) score_35\NN\5736149|tubular|necrosis|,|3.9|) (l_compound) necrosis_34\NN\11444117|
7707116
D015474_D009447 NONE acid_5\NN\14818238|of|13-cis-retinoic|children (l_nmod) children_7\NNS\9622049|in|neuroblastoma (l_nmod) neuroblastoma_9\NN\14239425|with
D015474_D009447 NONE acid_9\NN\14818238|with|13-cis-retinoic|cis-ra (r_nmod) treatment_2\NN\654885|lines|acid (l_nmod) lines_6\NNS\8426461|of|neuroblastoma|cell (l_compound) neuroblastoma_4\NN\14239425|
D015474_D009447 NONE cis-ra_11\NN\1740|(|) (r_appos) acid_9\NN\14818238|with|13-cis-retinoic|cis-ra (r_nmod) treatment_2\NN\654885|lines|acid (l_nmod) lines_6\NNS\8426461|of|neuroblastoma|cell (l_compound) neuroblastoma_4\NN\14239425|
D015474_D009447 NONE cis-ra_1\NN\1740| (r_nsubj) demonstrated_3\VBN\2137132|since|cis-ra|has|responses|patients (l_nmod) patients_8\NNS\9898892|in|neuroblastoma (l_compound) neuroblastoma_7\NN\14239425|
D015474_D009447 NONE cis-ra_20\NN\1740|of|administered (l_acl) administered_21\VBN\2436349|schedule|children (l_nmod) children_27\NNS\9622049|in|neuroblastoma|transplantation (l_nmod) neuroblastoma_29\NN\14239425|with
D015474_D064420 NONE cis-ra_20\NN\1740|of|administered (r_nmod) dosage_10\NN\13576355|the|maximal-tolerated|mtd|,|toxicities|,|and|pharmacokinetics|cis-ra (l_conj) toxicities_15\NNS\13576101|
D015474_D064420 NONE cis-ra_4\NN\1740| (r_nsubjpass) discontinued_6\VBN\2609764|after|cis-ra|was (r_advcl) resolved_2\VBD\352826|toxicities|discontinued|. (l_nsubj) toxicities_1\NNS\13576101|all
D015474_D006934 CID cis-ra_11\NN\1740| (r_compound) levels_12\NNS\4916342|by|serum|cis-ra (r_nmod) predicted_8\VBN\916909|may|be|levels (r_conj) included_2\VBD\690614|dlt|hypercalcemia|,|and|predicted|. (l_dobj) hypercalcemia_3\NN\14299637|
1445986
D015313_D000743 CID cefotetan-induced_0\JJ\1740| (r_amod) anemia_3\NN\14189204|cefotetan-induced|immune|hemolytic|.
D010406_D000743 NONE penicillins_15\NNS\2716866|and|cephalosporins (r_dobj) receiving_14\VBG\2210855|penicillins (r_acl) patients_13\NNS\9898892|primarily|in|receiving (r_nmod) described_10\VBN\1001294|anemia|has|been|patients|. (l_nsubjpass) anemia_2\NN\14189204|immune|hemolytic|mechanism
D002511_D000743 NONE cephalosporins_18\NNS\2716866|first-generation (r_conj) penicillins_15\NNS\2716866|and|cephalosporins (r_dobj) receiving_14\VBG\2210855|penicillins (r_acl) patients_13\NNS\9898892|primarily|in|receiving (r_nmod) described_10\VBN\1001294|anemia|has|been|patients|. (l_nsubjpass) anemia_2\NN\14189204|immune|hemolytic|mechanism
D015313_D000740 NONE cefotetan_10\NN\1740|intravenous (r_dobj) receiving_8\VBG\2210855|while|cefotetan (r_advcl) developed_5\VBD\1753788|who|anemia|receiving (l_dobj) anemia_6\NN\14189204|
19719056
D019342_D010146 NONE acid_9\NN\14818238|acetic (r_nmod:npmod) induced_10\JJ\1740|acid (r_amod) model_12\NN\5888929|induced|writhing|mice|and|model|, (l_compound) writhing_11\NN\1740|
D019342_D004487 NONE acid_9\NN\14818238|acetic (r_nmod:npmod) induced_10\JJ\1740|acid (r_amod) model_12\NN\5888929|induced|writhing|mice|and|model|, (l_conj) model_21\NN\5888929|carrageenan-induced|rat|paw|edema (l_compound) edema_20\NN\14315192|
D002351_D010146 CID carrageenan-induced_17\JJ\1740| (r_amod) model_21\NN\5888929|carrageenan-induced|rat|paw|edema (r_conj) model_12\NN\5888929|induced|writhing|mice|and|model|, (l_compound) writhing_11\NN\1740|
D002351_D004487 CID carrageenan-induced_17\JJ\1740| (r_amod) model_21\NN\5888929|carrageenan-induced|rat|paw|edema (l_compound) edema_20\NN\14315192|
8911359
D003520_D001749 CID cyclophosphamide_0\NN\1740| (r_nmod:npmod) associated_1\JJ\1740|cyclophosphamide (r_amod) cancer_3\NN\14239425|associated|bladder|--|disease
D003520_D001749 CID cyclophosphamide_20\NN\1740| (r_nmod:npmod) associated_21\JJ\1740|cyclophosphamide (r_amod) cancer_23\NN\14239425|with|associated|bladder
D003520_D001749 CID cyclophosphamide_2\NN\1740| (r_nmod:npmod) associated_3\JJ\1740|cyclophosphamide (r_amod) tumor_5\NN\14234074|associated|bladder
D003520_D014523 NONE cyclophosphamide_13\NN\1740| (r_nmod:npmod) associated_14\JJ\1740|cyclophosphamide (r_amod) cancer_16\NN\14239425|of|associated|urothelial
11752998
D000241_D059787 NONE adenosine_6\NN\14964367|of|intrathecal (r_nmod) studies_3\NNS\635850|preclinical|adenosine (r_nsubj) suggest_7\VBP\1010118|studies|effective|,|and|suggests (l_ccomp) effective_11\JJ\1740|it|may|be|treatment (l_nmod) treatment_14\NN\654885|in|the|pain (l_nmod) pain_19\NN\14299637|of|acute|humans
D000241_D059787 NONE adenosine_35\NN\14964367|of (r_nmod) formulation_33\NN\14818238|with|a|swedish|adenosine (r_nmod) volunteers_27\NNS\10582746|in|and|patients|formulation (r_nmod) studies_25\NNS\635850|preliminary|volunteers (r_nsubj) suggests_36\VBZ\1010118|studies|effective|. (r_conj) suggest_7\VBP\1010118|studies|effective|,|and|suggests (l_ccomp) effective_11\JJ\1740|it|may|be|treatment (l_nmod) treatment_14\NN\654885|in|the|pain (l_nmod) pain_19\NN\14299637|of|acute|humans
D000241_D059350 NONE adenosine_6\NN\14964367|of|intrathecal (r_nmod) studies_3\NNS\635850|preclinical|adenosine (r_nsubj) suggest_7\VBP\1010118|studies|effective|,|and|suggests (l_ccomp) effective_11\JJ\1740|it|may|be|treatment (l_nmod) treatment_14\NN\654885|in|the|pain (l_nmod) pain_19\NN\14299637|of|acute|humans
D000241_D059350 NONE adenosine_35\NN\14964367|of (r_nmod) formulation_33\NN\14818238|with|a|swedish|adenosine (r_nmod) volunteers_27\NNS\10582746|in|and|patients|formulation (r_nmod) studies_25\NNS\635850|preliminary|volunteers (r_nsubj) suggests_36\VBZ\1010118|studies|effective|. (r_conj) suggest_7\VBP\1010118|studies|effective|,|and|suggests (l_ccomp) effective_11\JJ\1740|it|may|be|treatment (l_nmod) treatment_14\NN\654885|in|the|pain (l_nmod) pain_19\NN\14299637|of|acute|humans
D000241_D004342 NONE adenosine_6\NN\14964367|of|intrathecal (r_nmod) studies_3\NNS\635850|preclinical|adenosine (r_nsubj) suggest_7\VBP\1010118|studies|effective|,|and|suggests (l_conj) suggests_36\VBZ\1010118|studies|effective|. (l_ccomp) effective_40\JJ\1740|it|may|be|states (l_nmod) states_43\NNS\8491826|in|hypersensitivity|but|stimulation (l_compound) hypersensitivity_42\NN\14531772|
D000241_D004342 NONE adenosine_35\NN\14964367|of (r_nmod) formulation_33\NN\14818238|with|a|swedish|adenosine (r_nmod) volunteers_27\NNS\10582746|in|and|patients|formulation (r_nmod) studies_25\NNS\635850|preliminary|volunteers (r_nsubj) suggests_36\VBZ\1010118|studies|effective|. (l_ccomp) effective_40\JJ\1740|it|may|be|states (l_nmod) states_43\NNS\8491826|in|hypersensitivity|but|stimulation (l_compound) hypersensitivity_42\NN\14531772|
D000241_D004342 NONE adenosine_15\NN\14964367|of (r_nmod) formulation_13\NN\14818238|of|a|different|adenosine|marketed (r_nmod) efficacy_9\NN\5199286|for|formulation (r_nmod) screen_7\VB\2533282|to|efficacy|,|using (l_advcl) using_21\VBG\1156834|stimulation (l_dobj) stimulation_25\NN\242808|both|acute|noxious|and|hypersensitivity (l_conj) hypersensitivity_29\NN\14531772|capsaicin-evoked|mechanical
D000241_D004342 NONE adenosine_9\NN\14964367|by|intrathecal|hypersensitivity (l_nmod) hypersensitivity_11\NN\14531772|of|,|presumed
D002211_D004342 NONE capsaicin-evoked_27\JJ\1740| (r_amod) hypersensitivity_29\NN\14531772|capsaicin-evoked|mechanical
D002211_D004342 NONE capsaicin_22\NN\15032661| (r_compound) injection_23\NN\320852|after|peripheral|capsaicin (r_nmod) sensitization_17\NN\14531772|central|humans|injection (r_dobj) reflect_15\VB\923793|to|sensitization (r_xcomp) presumed_13\VBN\719734|reflect (r_acl) hypersensitivity_11\NN\14531772|of|,|presumed
D000241_D010146 NONE adenosine_32\NN\14964367| (r_compound) doses_33\NNS\3740161|with|intrathecal|adenosine|mg (r_nmod) trial_29\NN\786195|an|open-label|,|dose-escalating|doses|and|trial|obtained|,|and|determined|. (l_conj) determined_79\VBN\1645601|ratings|were (l_nsubjpass) ratings_60\NNS\5733583|pain|response (l_compound) pain_59\NN\14299637|
D000241_D010146 NONE adenosine_46\NN\14964367|of|,|mg. (r_nmod) trial_44\NN\786195|a|double-blind|,|placebo-controlled|adenosine (r_conj) trial_29\NN\786195|an|open-label|,|dose-escalating|doses|and|trial|obtained|,|and|determined|. (l_conj) determined_79\VBN\1645601|ratings|were (l_nsubjpass) ratings_60\NNS\5733583|pain|response (l_compound) pain_59\NN\14299637|
D000241_D010146 NONE adenosine_2\NN\14964367| (r_nsubj) produced_3\VBD\1617192|adenosine|effect|but|reduced|h. (l_dobj) effect_5\NN\34213|no|report (l_nmod) report_8\NN\6470073|on|pain|stimulation (l_compound) pain_7\NN\14299637|
D000241_D010146 NONE adenosine_37\NN\14964367|of (r_nmod) time_35\NN\7308889|residence|adenosine|fluid (r_nsubj) short_42\JJ\1740|,|time|was|h|. (r_dep) results_0\NNS\34213|:|produced|contrast|short (l_dep) produced_3\VBD\1617192|adenosine|effect|but|reduced|h. (l_dobj) effect_5\NN\34213|no|report (l_nmod) report_8\NN\6470073|on|pain|stimulation (l_compound) pain_7\NN\14299637|
D000241_D006930 NONE adenosine_32\NN\14964367| (r_compound) doses_33\NNS\3740161|with|intrathecal|adenosine|mg (r_nmod) trial_29\NN\786195|an|open-label|,|dose-escalating|doses|and|trial|obtained|,|and|determined|. (l_conj) determined_79\VBN\1645601|ratings|were (l_nsubjpass) ratings_60\NNS\5733583|pain|response (l_nmod) response_62\NN\11410625|in|stimuli (l_nmod) stimuli_66\NNS\5816287|to|acute|heat|and|areas (l_conj) areas_68\NNS\8630985|hyperalgesia (l_nmod) hyperalgesia_71\NN\1740|of|mechanical|and|allodynia|injection
D000241_D006930 NONE adenosine_32\NN\14964367| (r_compound) doses_33\NNS\3740161|with|intrathecal|adenosine|mg (r_nmod) trial_29\NN\786195|an|open-label|,|dose-escalating|doses|and|trial|obtained|,|and|determined|. (l_conj) determined_79\VBN\1645601|ratings|were (l_nsubjpass) ratings_60\NNS\5733583|pain|response (l_nmod) response_62\NN\11410625|in|stimuli (l_nmod) stimuli_66\NNS\5816287|to|acute|heat|and|areas (l_conj) areas_68\NNS\8630985|hyperalgesia (l_nmod) hyperalgesia_71\NN\1740|of|mechanical|and|allodynia|injection (l_conj) allodynia_73\NN\1740|
D000241_D006930 NONE adenosine_46\NN\14964367|of|,|mg. (r_nmod) trial_44\NN\786195|a|double-blind|,|placebo-controlled|adenosine (r_conj) trial_29\NN\786195|an|open-label|,|dose-escalating|doses|and|trial|obtained|,|and|determined|. (l_conj) determined_79\VBN\1645601|ratings|were (l_nsubjpass) ratings_60\NNS\5733583|pain|response (l_nmod) response_62\NN\11410625|in|stimuli (l_nmod) stimuli_66\NNS\5816287|to|acute|heat|and|areas (l_conj) areas_68\NNS\8630985|hyperalgesia (l_nmod) hyperalgesia_71\NN\1740|of|mechanical|and|allodynia|injection
D000241_D006930 NONE adenosine_46\NN\14964367|of|,|mg. (r_nmod) trial_44\NN\786195|a|double-blind|,|placebo-controlled|adenosine (r_conj) trial_29\NN\786195|an|open-label|,|dose-escalating|doses|and|trial|obtained|,|and|determined|. (l_conj) determined_79\VBN\1645601|ratings|were (l_nsubjpass) ratings_60\NNS\5733583|pain|response (l_nmod) response_62\NN\11410625|in|stimuli (l_nmod) stimuli_66\NNS\5816287|to|acute|heat|and|areas (l_conj) areas_68\NNS\8630985|hyperalgesia (l_nmod) hyperalgesia_71\NN\1740|of|mechanical|and|allodynia|injection (l_conj) allodynia_73\NN\1740|
D000241_D006930 NONE adenosine_2\NN\14964367| (r_nsubj) produced_3\VBD\1617192|adenosine|effect|but|reduced|h. (l_conj) reduced_17\VBD\441445|hyperalgesia (l_dobj) hyperalgesia_19\NN\1740|mechanical|and|allodynia|injection
D000241_D006930 NONE adenosine_2\NN\14964367| (r_nsubj) produced_3\VBD\1617192|adenosine|effect|but|reduced|h. (l_conj) reduced_17\VBD\441445|hyperalgesia (l_dobj) hyperalgesia_19\NN\1740|mechanical|and|allodynia|injection (l_conj) allodynia_21\NN\1740|
D000241_D006930 NONE adenosine_37\NN\14964367|of (r_nmod) time_35\NN\7308889|residence|adenosine|fluid (r_nsubj) short_42\JJ\1740|,|time|was|h|. (r_dep) results_0\NNS\34213|:|produced|contrast|short (l_dep) produced_3\VBD\1617192|adenosine|effect|but|reduced|h. (l_conj) reduced_17\VBD\441445|hyperalgesia (l_dobj) hyperalgesia_19\NN\1740|mechanical|and|allodynia|injection
D000241_D006930 NONE adenosine_37\NN\14964367|of (r_nmod) time_35\NN\7308889|residence|adenosine|fluid (r_nsubj) short_42\JJ\1740|,|time|was|h|. (r_dep) results_0\NNS\34213|:|produced|contrast|short (l_dep) produced_3\VBD\1617192|adenosine|effect|but|reduced|h. (l_conj) reduced_17\VBD\441445|hyperalgesia (l_dobj) hyperalgesia_19\NN\1740|mechanical|and|allodynia|injection (l_conj) allodynia_21\NN\1740|
D002211_D010146 NONE capsaicin_76\NN\15032661| (r_compound) injection_77\NN\320852|after|intradermal|capsaicin (r_nmod) hyperalgesia_71\NN\1740|of|mechanical|and|allodynia|injection (r_nmod) areas_68\NNS\8630985|hyperalgesia (r_conj) stimuli_66\NNS\5816287|to|acute|heat|and|areas (r_nmod) response_62\NN\11410625|in|stimuli (r_nmod) ratings_60\NNS\5733583|pain|response (l_compound) pain_59\NN\14299637|
D002211_D010146 NONE capsaicin_24\NN\15032661| (r_compound) injection_25\NN\320852|from|intradermal|capsaicin (r_nmod) hyperalgesia_19\NN\1740|mechanical|and|allodynia|injection (r_dobj) reduced_17\VBD\441445|hyperalgesia (r_conj) produced_3\VBD\1617192|adenosine|effect|but|reduced|h. (l_dobj) effect_5\NN\34213|no|report (l_nmod) report_8\NN\6470073|on|pain|stimulation (l_compound) pain_7\NN\14299637|
D002211_D006930 CID capsaicin_76\NN\15032661| (r_compound) injection_77\NN\320852|after|intradermal|capsaicin (r_nmod) hyperalgesia_71\NN\1740|of|mechanical|and|allodynia|injection
D002211_D006930 CID capsaicin_76\NN\15032661| (r_compound) injection_77\NN\320852|after|intradermal|capsaicin (r_nmod) hyperalgesia_71\NN\1740|of|mechanical|and|allodynia|injection (l_conj) allodynia_73\NN\1740|
D002211_D006930 CID capsaicin_24\NN\15032661| (r_compound) injection_25\NN\320852|from|intradermal|capsaicin (r_nmod) hyperalgesia_19\NN\1740|mechanical|and|allodynia|injection
D002211_D006930 CID capsaicin_24\NN\15032661| (r_compound) injection_25\NN\320852|from|intradermal|capsaicin (r_nmod) hyperalgesia_19\NN\1740|mechanical|and|allodynia|injection (l_conj) allodynia_21\NN\1740|
D000241_D009437 NONE adenosine_25\NN\14964367|of (r_nmod) residence_23\NN\8491027|due|prolonged|adenosine|fluid (r_conj) consistent_4\JJ\1740|effect|is|that|and|residence|. (l_nmod) that_6\DT\1740|with|observed (l_acl) observed_7\VBN\2163746|reports (l_nmod) reports_10\NNS\6470073|in|preliminary|patients (l_nmod) patients_12\NNS\9898892|of|pain (l_nmod) pain_16\NN\14299637|with|chronic|neuropathic
7724492
D004317_D007674 NONE doxorubicin_4\NN\2716866| (r_compound) (adriamycin)-loaded_5\NN\1740|doxorubicin (r_compound) nanoparticles_7\NNS\1740|of|(adriamycin)-loaded|cyanoacrylate (r_nmod) toxicity_2\NN\13576101|acute|renal|nanoparticles|.
D004317_D007674 NONE (adriamycin)-loaded_5\NN\1740|doxorubicin (r_compound) nanoparticles_7\NNS\1740|of|(adriamycin)-loaded|cyanoacrylate (r_nmod) toxicity_2\NN\13576101|acute|renal|nanoparticles|.
D004317_D007674 NONE doxorubicin-loaded_1\JJ\1740| (r_amod) nanoparticle_2\NN\1740|doxorubicin-loaded|dxnp (r_compound) toxicity_7\NN\13576101|acute|nanoparticle|renal
D004317_D007674 NONE dx_16\NN\1740|than|free (r_nmod) animals_13\NNS\4475|less|dx (r_dobj) killed_11\VBD\2473431|that|,|conditions|,|dxnp|animals|,|toxicity (l_nmod) toxicity_23\NN\13576101|despite|of|an|enhanced|renal|former
D003487_D007674 NONE cyanoacrylate_6\NN\1740| (r_compound) nanoparticles_7\NNS\1740|of|(adriamycin)-loaded|cyanoacrylate (r_nmod) toxicity_2\NN\13576101|acute|renal|nanoparticles|.
D004317_D005921 NONE doxorubicin-loaded_1\JJ\1740| (r_amod) nanoparticle_2\NN\1740|doxorubicin-loaded|dxnp (r_compound) toxicity_7\NN\13576101|acute|nanoparticle|renal (r_nsubjpass) explored_9\VBN\789138|toxicity|was|rats|. (l_nmod) rats_13\NNS\2329401|in|both|normal|and|rats (l_conj) rats_15\NNS\2329401|glomerulonephritis (l_nmod) glomerulonephritis_18\NN\14113798|with|experimental
D004317_D005921 NONE dx_10\NN\1740| (r_dobj) given_9\VBN\2327200|dx (r_acl) rats_8\NNS\2329401|5/6|given (r_nsubj) died_11\VBD\146138|rats|,|rats|days|,|contrast|. (l_nmod) rats_1\NNS\2329401|in|glomerulonephritis (l_nmod) glomerulonephritis_5\NN\14113798|with|immune|experimental
D004317_D011507 CID dx_16\NN\1740|with (r_nmod) treated_14\VBN\2376958|dx (r_acl) those_13\DT\1740|in|treated (r_nmod) than_11\IN\1740|those (r_dep) appeared_5\VBD\2604760|proteinuria|animals|than|. (l_nsubj) proteinuria_4\NN\14299637|a|higher
D004317_D011507 CID doxorubicin_22\NN\2716866| (r_compound) treatment_23\NN\654885|after|doxorubicin|mg/day (r_nmod) prolonged_20\JJ\1740|treatment (r_conj) intense_13\JJ\1740|was|more|0.001|and|prolonged|,|difference (r_conj) appeared_1\VBD\2604760|proteinuria|series|,|but|intense|. (l_nsubj) proteinuria_0\NN\14299637|
D004317_D011507 CID dx_37\NN\1740| (r_conj) dxnp_35\NN\1740|between|and|dx (r_nmod) difference_33\NN\4723816|without|significant|dxnp (r_nmod) intense_13\JJ\1740|was|more|0.001|and|prolonged|,|difference (r_conj) appeared_1\VBD\2604760|proteinuria|series|,|but|intense|. (l_nsubj) proteinuria_0\NN\14299637|
6293644
D006220_D002375 CID haloperidol-induced_7\JJ\1740| (r_amod) catalepsy_8\NN\14023236|of|haloperidol-induced
D006220_D006948 NONE haloperidol-induced_7\JJ\1740| (r_amod) catalepsy_8\NN\14023236|of|haloperidol-induced (r_nmod) potentiation_5\NN\13564910|in|a|catalepsy|and|prevention (l_conj) prevention_12\NN\1073995|a|partial|hyperactivity (l_nmod) hyperactivity_15\NN\14052403|of|apomorphine-induced
D001058_D002375 NONE apomorphine-induced_14\JJ\1740| (r_amod) hyperactivity_15\NN\14052403|of|apomorphine-induced (r_nmod) prevention_12\NN\1073995|a|partial|hyperactivity (r_conj) potentiation_5\NN\13564910|in|a|catalepsy|and|prevention (l_nmod) catalepsy_8\NN\14023236|of|haloperidol-induced
D001058_D006948 CID apomorphine-induced_14\JJ\1740| (r_amod) hyperactivity_15\NN\14052403|of|apomorphine-induced
8638876
D011374_D006261 NONE progesterone_22\NN\14747338|of|and|estradiol (r_nmod) use_20\NN\407535|after|parenteral|progesterone (r_nmod) developed_5\VBD\1753788|woman|headache|use|. (l_dobj) headache_6\NN\5829480|,|nausea|,|hemiparesis
D011374_D009325 NONE progesterone_22\NN\14747338|of|and|estradiol (r_nmod) use_20\NN\407535|after|parenteral|progesterone (r_nmod) developed_5\VBD\1753788|woman|headache|use|. (l_dobj) headache_6\NN\5829480|,|nausea|,|hemiparesis (l_conj) nausea_8\NN\14299637|and|vomiting
D011374_D014839 NONE progesterone_22\NN\14747338|of|and|estradiol (r_nmod) use_20\NN\407535|after|parenteral|progesterone (r_nmod) developed_5\VBD\1753788|woman|headache|use|. (l_dobj) headache_6\NN\5829480|,|nausea|,|hemiparesis (l_conj) nausea_8\NN\14299637|and|vomiting (l_conj) vomiting_10\NN\116687|
D011374_D010291 NONE progesterone_22\NN\14747338|of|and|estradiol (r_nmod) use_20\NN\407535|after|parenteral|progesterone (r_nmod) developed_5\VBD\1753788|woman|headache|use|. (l_dobj) headache_6\NN\5829480|,|nausea|,|hemiparesis (l_conj) hemiparesis_13\NN\1740|left|and|seizure
D011374_D012640 NONE progesterone_22\NN\14747338|of|and|estradiol (r_nmod) use_20\NN\407535|after|parenteral|progesterone (r_nmod) developed_5\VBD\1753788|woman|headache|use|. (l_dobj) headache_6\NN\5829480|,|nausea|,|hemiparesis (l_conj) hemiparesis_13\NN\1740|left|and|seizure (l_conj) seizure_15\NN\14081375|
D004958_D006261 NONE estradiol_24\NN\14749794| (r_conj) progesterone_22\NN\14747338|of|and|estradiol (r_nmod) use_20\NN\407535|after|parenteral|progesterone (r_nmod) developed_5\VBD\1753788|woman|headache|use|. (l_dobj) headache_6\NN\5829480|,|nausea|,|hemiparesis
D004958_D009325 NONE estradiol_24\NN\14749794| (r_conj) progesterone_22\NN\14747338|of|and|estradiol (r_nmod) use_20\NN\407535|after|parenteral|progesterone (r_nmod) developed_5\VBD\1753788|woman|headache|use|. (l_dobj) headache_6\NN\5829480|,|nausea|,|hemiparesis (l_conj) nausea_8\NN\14299637|and|vomiting
D004958_D014839 NONE estradiol_24\NN\14749794| (r_conj) progesterone_22\NN\14747338|of|and|estradiol (r_nmod) use_20\NN\407535|after|parenteral|progesterone (r_nmod) developed_5\VBD\1753788|woman|headache|use|. (l_dobj) headache_6\NN\5829480|,|nausea|,|hemiparesis (l_conj) nausea_8\NN\14299637|and|vomiting (l_conj) vomiting_10\NN\116687|
D004958_D010291 NONE estradiol_24\NN\14749794| (r_conj) progesterone_22\NN\14747338|of|and|estradiol (r_nmod) use_20\NN\407535|after|parenteral|progesterone (r_nmod) developed_5\VBD\1753788|woman|headache|use|. (l_dobj) headache_6\NN\5829480|,|nausea|,|hemiparesis (l_conj) hemiparesis_13\NN\1740|left|and|seizure
D004958_D012640 NONE estradiol_24\NN\14749794| (r_conj) progesterone_22\NN\14747338|of|and|estradiol (r_nmod) use_20\NN\407535|after|parenteral|progesterone (r_nmod) developed_5\VBD\1753788|woman|headache|use|. (l_dobj) headache_6\NN\5829480|,|nausea|,|hemiparesis (l_conj) hemiparesis_13\NN\1740|left|and|seizure (l_conj) seizure_15\NN\14081375|
D004958_D003920 NONE estradiol_11\NN\14749794|of|and|progesterone (r_nmod) use_9\NN\407535|the|estradiol|and|dm (l_conj) dm_17\NN\14117805|the|underlying
D004958_D002341 CID estradiol_11\NN\14749794|of|and|progesterone (r_nmod) use_9\NN\407535|the|estradiol|and|dm (r_nsubj) increased_18\VBD\169651|that|use|thrombogenicity|,|provided (l_advcl) provided_23\VBD\2199590|which|denominator (l_dobj) denominator_26\NN\13733167|a|common|thrombosis (l_nmod) thrombosis_28\NN\14100769|for|ica (l_nmod) ica_32\NN\1740|of|both|the|and|sinus (l_conj) sinus_36\NN\5248181|the|venous
D004958_D012851 CID estradiol_11\NN\14749794|of|and|progesterone (r_nmod) use_9\NN\407535|the|estradiol|and|dm (r_nsubj) increased_18\VBD\169651|that|use|thrombogenicity|,|provided (l_advcl) provided_23\VBD\2199590|which|denominator (l_dobj) denominator_26\NN\13733167|a|common|thrombosis (l_nmod) thrombosis_28\NN\14100769|for|ica (l_nmod) ica_32\NN\1740|of|both|the|and|sinus (l_conj) sinus_36\NN\5248181|the|venous
D011374_D003920 NONE progesterone_13\NN\14747338| (r_conj) estradiol_11\NN\14749794|of|and|progesterone (r_nmod) use_9\NN\407535|the|estradiol|and|dm (l_conj) dm_17\NN\14117805|the|underlying
D011374_D002341 CID progesterone_13\NN\14747338| (r_conj) estradiol_11\NN\14749794|of|and|progesterone (r_nmod) use_9\NN\407535|the|estradiol|and|dm (r_nsubj) increased_18\VBD\169651|that|use|thrombogenicity|,|provided (l_advcl) provided_23\VBD\2199590|which|denominator (l_dobj) denominator_26\NN\13733167|a|common|thrombosis (l_nmod) thrombosis_28\NN\14100769|for|ica (l_nmod) ica_32\NN\1740|of|both|the|and|sinus (l_conj) sinus_36\NN\5248181|the|venous
D011374_D012851 CID progesterone_13\NN\14747338| (r_conj) estradiol_11\NN\14749794|of|and|progesterone (r_nmod) use_9\NN\407535|the|estradiol|and|dm (r_nsubj) increased_18\VBD\169651|that|use|thrombogenicity|,|provided (l_advcl) provided_23\VBD\2199590|which|denominator (l_dobj) denominator_26\NN\13733167|a|common|thrombosis (l_nmod) thrombosis_28\NN\14100769|for|ica (l_nmod) ica_32\NN\1740|of|both|the|and|sinus (l_conj) sinus_36\NN\5248181|the|venous
15814210
D003907_D009422 CID dexamethasone_19\NN\2721538| (r_compound) treatment_20\NN\654885|after|dexamethasone|infants (r_nmod) age_12\NN\4916342|at|the|years|treatment (r_nmod) dysfunction_2\NN\14204950|minor|neurological|,|development|age|.
D003907_D009422 CID dexamethasone_19\NN\2721538| (r_compound) therapy_20\NN\657604|after|dexamethasone|infants (r_nmod) dysfunction_10\NN\14204950|minor|neurological|,|development|therapy
D003907_D009422 CID dexamethasone_1\NN\2721538| (r_compound) treatment_2\NN\654885|after|dexamethasone (r_nmod) showed_5\VBD\2137132|treatment|,|children|rate|. (l_dobj) rate_8\NN\13815152|a|higher|dysfunctions (l_nmod) dysfunctions_12\NNS\14204950|of|minor|neurological
11337188
D010068_D018366 CID oxacillin_5\NN\3910417|with (r_nmod) associated_3\VBN\628491|oxacillin (r_acl) vasculitis_2\NN\14336539|cutaneous|leucocytoclastic|associated|.
D010068_D018366 CID oxacillin_0\NN\3910417| (r_nsubjpass) included_3\VBN\690614|oxacillin|should|be|drugs|. (l_nmod) drugs_6\NNS\14778436|among|the|cause (l_acl:relcl) cause_9\VB\1617192|that|can|vasculitis (l_dobj) vasculitis_11\NN\14336539|leucocytoclastic
D010068_D013203 NONE oxacillin_7\NN\3910417|with (r_nmod) treated_5\VBN\2376958|who|was|oxacillin|week|bacteremia (l_nmod) bacteremia_15\NN\14204950|because|aureus
D010068_D016470 NONE oxacillin_7\NN\3910417|with (r_nmod) treated_5\VBN\2376958|who|was|oxacillin|week|bacteremia (l_nmod) bacteremia_15\NN\14204950|because|aureus
D010068_D051437 CID oxacillin_7\NN\3910417|with (r_nmod) treated_5\VBN\2376958|who|was|oxacillin|week|bacteremia (r_acl:relcl) man_2\NN\9605289|a|67-year-old|treated (r_nsubj) developed_17\VBD\1753788|man|,|failure|. (l_dobj) failure_19\NN\66216|renal|and|lesions
D010068_D011693 NONE oxacillin_7\NN\3910417|with (r_nmod) treated_5\VBN\2376958|who|was|oxacillin|week|bacteremia (r_acl:relcl) man_2\NN\9605289|a|67-year-old|treated (r_nsubj) developed_17\VBD\1753788|man|,|failure|. (l_dobj) failure_19\NN\66216|renal|and|lesions (l_conj) lesions_27\NNS\14204950|diffuse|,|symmetric|,|palpable|purpuric|feet
10411803
D015313_D000743 CID cefotetan_9\NN\1740|of (r_nmod) use_7\NN\407535|with|prophylactic|cefotetan|procedures (r_nmod) associated_4\VBN\628491|use (r_acl) anemia_3\NN\14189204|severe|immune|hemolytic|associated|.
D015313_D000743 CID cefotetan_6\NN\1740|especially (r_appos) cephalosporins_3\NNS\2716866|second-|,|cefotetan|, (r_nsubjpass) associated_10\VBN\628491|cephalosporins|are|increasingly|anemia|. (l_nmod) anemia_18\NN\14189204|with|fatal|immune|hemolytic
D015313_D000743 CID cefotetan-induced_9\JJ\1740| (r_amod) anemias_11\NNS\14189204|of|cefotetan-induced|hemolytic
D015313_D000743 CID cefotetan_18\NN\1740| (r_dobj) received_17\VBN\2210855|who|had|cefotetan|prophylactically|procedures (r_acl:relcl) patients_14\NNS\9898892|in|received (l_case) in_13\IN\13603305|10|were (l_nsubj) 10_3\CD\13745420|cases (l_nmod) cases_7\NNS\7283608|of|our|35|anemias (l_nmod) anemias_11\NNS\14189204|of|cefotetan-induced|hemolytic
D002511_D000743 NONE cephalosporins_3\NNS\2716866|second-|,|cefotetan|, (r_nsubjpass) associated_10\VBN\628491|cephalosporins|are|increasingly|anemia|. (l_nmod) anemia_18\NN\14189204|with|fatal|immune|hemolytic
12109865
6402369
D007069_D001745 CID ifosfamide-induced_2\JJ\1740| (r_amod) toxicity_4\NN\13576101|of|ifosfamide-induced|urothelial
D007069_D001745 CID ifosfamide_21\NN\1740|by|if (r_nmod) induced_19\VBN\1627355|ifosfamide (r_acl) toxicity_18\NN\13576101|against|urothelial|induced
D007069_D001745 CID if_23\NN\1740|(|) (r_appos) ifosfamide_21\NN\1740|by|if (r_nmod) induced_19\VBN\1627355|ifosfamide (r_acl) toxicity_18\NN\13576101|against|urothelial|induced
D007069_D001745 CID if_40\NN\1740|with (r_nmod) treatment_38\NN\654885|under|if|mg/m2 (r_nmod) group_29\NN\2137|in|a|patients|treatment (r_nmod) tested_26\VBN\670261|effect|was|group|part|. (l_nsubjpass) effect_2\NN\34213|the|protective|administration|toxicity (l_nmod) toxicity_18\NN\13576101|against|urothelial|induced
D007069_D008175 NONE ifosfamide-induced_2\JJ\1740| (r_amod) toxicity_4\NN\13576101|of|ifosfamide-induced|urothelial (r_nmod) treatment_0\NN\654885|toxicity|administration|. (l_nmod) administration_7\NN\1133281|by|oral|sulphonate|patients (l_nmod) patients_16\NNS\9898892|to|cancer (l_nmod) cancer_20\NN\14239425|with|inoperable|lung
D007069_D008175 NONE ifosfamide_21\NN\1740|by|if (r_nmod) induced_19\VBN\1627355|ifosfamide (r_acl) toxicity_18\NN\13576101|against|urothelial|induced (r_nmod) effect_2\NN\34213|the|protective|administration|toxicity (r_nsubjpass) tested_26\VBN\670261|effect|was|group|part|. (l_nmod) group_29\NN\2137|in|a|patients|treatment (l_nmod) patients_32\NNS\9898892|of|45|cancer (l_nmod) cancer_36\NN\14239425|with|inoperable|lung
D007069_D008175 NONE if_23\NN\1740|(|) (r_appos) ifosfamide_21\NN\1740|by|if (r_nmod) induced_19\VBN\1627355|ifosfamide (r_acl) toxicity_18\NN\13576101|against|urothelial|induced (r_nmod) effect_2\NN\34213|the|protective|administration|toxicity (r_nsubjpass) tested_26\VBN\670261|effect|was|group|part|. (l_nmod) group_29\NN\2137|in|a|patients|treatment (l_nmod) patients_32\NNS\9898892|of|45|cancer (l_nmod) cancer_36\NN\14239425|with|inoperable|lung
D007069_D008175 NONE if_40\NN\1740|with (r_nmod) treatment_38\NN\654885|under|if|mg/m2 (r_nmod) group_29\NN\2137|in|a|patients|treatment (l_nmod) patients_32\NNS\9898892|of|45|cancer (l_nmod) cancer_36\NN\14239425|with|inoperable|lung
D015080_D001745 NONE sulphonate_11\NN\1740|of|sodium|2-mercaptoethane|mesna (r_nmod) administration_7\NN\1133281|by|oral|sulphonate|patients (r_nmod) treatment_0\NN\654885|toxicity|administration|. (l_nmod) toxicity_4\NN\13576101|of|ifosfamide-induced|urothelial
D015080_D001745 NONE mesna_13\NN\1740|(|) (r_appos) sulphonate_11\NN\1740|of|sodium|2-mercaptoethane|mesna (r_nmod) administration_7\NN\1133281|by|oral|sulphonate|patients (r_nmod) treatment_0\NN\654885|toxicity|administration|. (l_nmod) toxicity_4\NN\13576101|of|ifosfamide-induced|urothelial
D015080_D001745 NONE sulphonate_12\NN\1740|sodium|2-mercaptoethane|mesna (r_dep) compound_9\NN\5869584|of|the|thiol|sulphonate (r_nmod) administration_5\NN\1133281|of|oral|compound (r_nmod) effect_2\NN\34213|the|protective|administration|toxicity (l_nmod) toxicity_18\NN\13576101|against|urothelial|induced
D015080_D001745 NONE mesna_14\NN\1740|(|) (r_appos) sulphonate_12\NN\1740|sodium|2-mercaptoethane|mesna (r_dep) compound_9\NN\5869584|of|the|thiol|sulphonate (r_nmod) administration_5\NN\1133281|of|oral|compound (r_nmod) effect_2\NN\34213|the|protective|administration|toxicity (l_nmod) toxicity_18\NN\13576101|against|urothelial|induced
D015080_D008175 NONE sulphonate_11\NN\1740|of|sodium|2-mercaptoethane|mesna (r_nmod) administration_7\NN\1133281|by|oral|sulphonate|patients (l_nmod) patients_16\NNS\9898892|to|cancer (l_nmod) cancer_20\NN\14239425|with|inoperable|lung
D015080_D008175 NONE mesna_13\NN\1740|(|) (r_appos) sulphonate_11\NN\1740|of|sodium|2-mercaptoethane|mesna (r_nmod) administration_7\NN\1133281|by|oral|sulphonate|patients (l_nmod) patients_16\NNS\9898892|to|cancer (l_nmod) cancer_20\NN\14239425|with|inoperable|lung
D015080_D008175 NONE sulphonate_12\NN\1740|sodium|2-mercaptoethane|mesna (r_dep) compound_9\NN\5869584|of|the|thiol|sulphonate (r_nmod) administration_5\NN\1133281|of|oral|compound (r_nmod) effect_2\NN\34213|the|protective|administration|toxicity (r_nsubjpass) tested_26\VBN\670261|effect|was|group|part|. (l_nmod) group_29\NN\2137|in|a|patients|treatment (l_nmod) patients_32\NNS\9898892|of|45|cancer (l_nmod) cancer_36\NN\14239425|with|inoperable|lung
D015080_D008175 NONE mesna_14\NN\1740|(|) (r_appos) sulphonate_12\NN\1740|sodium|2-mercaptoethane|mesna (r_dep) compound_9\NN\5869584|of|the|thiol|sulphonate (r_nmod) administration_5\NN\1133281|of|oral|compound (r_nmod) effect_2\NN\34213|the|protective|administration|toxicity (r_nsubjpass) tested_26\VBN\670261|effect|was|group|part|. (l_nmod) group_29\NN\2137|in|a|patients|treatment (l_nmod) patients_32\NNS\9898892|of|45|cancer (l_nmod) cancer_36\NN\14239425|with|inoperable|lung
D013438_D001745 NONE thiol_8\NN\1740| (r_compound) compound_9\NN\5869584|of|the|thiol|sulphonate (r_nmod) administration_5\NN\1133281|of|oral|compound (r_nmod) effect_2\NN\34213|the|protective|administration|toxicity (l_nmod) toxicity_18\NN\13576101|against|urothelial|induced
D013438_D008175 NONE thiol_8\NN\1740| (r_compound) compound_9\NN\5869584|of|the|thiol|sulphonate (r_nmod) administration_5\NN\1133281|of|oral|compound (r_nmod) effect_2\NN\34213|the|protective|administration|toxicity (r_nsubjpass) tested_26\VBN\670261|effect|was|group|part|. (l_nmod) group_29\NN\2137|in|a|patients|treatment (l_nmod) patients_32\NNS\9898892|of|45|cancer (l_nmod) cancer_36\NN\14239425|with|inoperable|lung
D015080_D064420 NONE mesna_7\NN\1740| (r_compound) series_8\NN\8456993|between|the|mesna|and|series (r_nmod) differences_4\NNS\4723816|no|appreciable|series (r_attr) were_1\VBD\836236|there|differences|respect|. (l_nmod) respect_15\NN\5817845|with|toxicity (l_nmod) toxicity_21\NN\13576101|to|haematological|treatment
19944736
D013619_D012640 CID tacrine_0\NN\1740|,|administered|, (r_nsubj) induces_8\VBZ\1627355|tacrine|seizures|. (l_dobj) seizures_10\NNS\14081375|electrocorticographic|and|damage
D013619_D001930 CID tacrine_0\NN\1740|,|administered|, (r_nsubj) induces_8\VBZ\1627355|tacrine|seizures|. (l_dobj) seizures_10\NNS\14081375|electrocorticographic|and|damage (l_conj) damage_14\NN\7296428|delayed|hippocampal
D013619_D001930 CID tacrine-loaded_3\JJ\1740| (r_amod) administration_5\NN\1133281|tacrine-loaded|nanoparticles (r_nsubj) induced_6\VBD\1627355|addition|,|administration|damage|animals|,|solution|. (l_dobj) damage_7\NN\7296428|cells (l_nmod) cells_10\NNS\3080309|of|neuronal|field
D013619_D001930 CID tacrine_27\NN\1740|of (r_nmod) solution_25\NN\14586258|while|the|saline|tacrine|% (r_nmod) induced_6\VBD\1627355|addition|,|administration|damage|animals|,|solution|. (l_dobj) damage_7\NN\7296428|cells (l_nmod) cells_10\NNS\3080309|of|neuronal|field
D018021_D012640 CID licl_4\NN\1740| (r_compound) rats_6\NNS\2329401|in|licl|pre-treated (r_nmod) administered_2\VBN\2436349|rats (r_acl) tacrine_0\NN\1740|,|administered|, (r_nsubj) induces_8\VBZ\1627355|tacrine|seizures|. (l_dobj) seizures_10\NNS\14081375|electrocorticographic|and|damage
D018021_D001930 CID licl_4\NN\1740| (r_compound) rats_6\NNS\2329401|in|licl|pre-treated (r_nmod) administered_2\VBN\2436349|rats (r_acl) tacrine_0\NN\1740|,|administered|, (r_nsubj) induces_8\VBZ\1627355|tacrine|seizures|. (l_dobj) seizures_10\NNS\14081375|electrocorticographic|and|damage (l_conj) damage_14\NN\7296428|delayed|hippocampal
D013619_D004827 NONE tacrine-loaded_5\JJ\1740| (r_amod) nanoparticles_6\NNS\1740|with|tacrine-loaded (r_nmod) treated_3\VBN\2376958|nanoparticles (r_acl) animals_2\NNS\4475|all|the|treated (r_nsubj) showed_7\VBD\2137132|animals|outcome|,|respect|. (l_dobj) outcome_10\NN\7291312|an|earlier|symptoms|onset (l_nmod) onset_18\NN\7325190|i.e.|epileptic (l_amod) epileptic_17\JJ\1740|
D013619_D004827 NONE tacrine-lithium_18\JJ\1740| (r_amod) model_19\NN\5888929|by|the|tacrine-lithium|epilepsy (l_nmod) epilepsy_21\NN\14085708|of|rat
D008094_D004827 NONE tacrine-lithium_18\JJ\1740| (r_amod) model_19\NN\5888929|by|the|tacrine-lithium|epilepsy (l_nmod) epilepsy_21\NN\14085708|of|rat
16563323
C071741_D009207 NONE remifentanil_0\NN\1740| (r_compound) pretreatment_1\NN\1740|remifentanil (r_nsubj) reduces_2\VBZ\441445|pretreatment|myoclonus|etomidate|. (l_dobj) myoclonus_3\NN\14360459|
C071741_D009207 NONE remifentanil_16\NN\1740|with (r_nmod) pretreatment_14\NN\1740|of|remifentanil (r_nmod) effect_12\NN\34213|the|pretreatment|microg/kg|and|effect (l_conj) effect_21\NN\34213|the|gender|incidence (l_nmod) incidence_26\NN\13821570|on|the|myoclonus|induction (l_nmod) myoclonus_28\NN\14360459|of
C071741_D009207 NONE remifentanil_12\NN\1740| (r_compound) group_13\NN\2137|in|the|remifentanil (r_nmod) lower_9\JJR\1740|incidence|was|significantly|group|%|than|%|p|. (l_nsubj) incidence_4\NN\13821570|the|myoclonus (l_nmod) myoclonus_6\NN\14360459|of
C071741_D009207 NONE remifentanil_4\NN\1740|with (r_compound) microg/kg_6\NN\1740|pretreatment|remifentanil|1 (r_appos) conclusion_0\NN\5837957|:|microg/kg (r_nsubj) reduced_7\VBD\441445|conclusion|myoclonus|induction|effects|. (l_dobj) myoclonus_8\NN\14360459|
D005045_D009207 CID etomidate_5\NN\1740|after (r_nmod) reduces_2\VBZ\441445|pretreatment|myoclonus|etomidate|. (l_dobj) myoclonus_3\NN\14360459|
D005045_D009207 CID etomidate_33\NN\1740|with (r_nmod) induction_31\NN\7450842|after|anesthesia|etomidate (r_nmod) incidence_26\NN\13821570|on|the|myoclonus|induction (l_nmod) myoclonus_28\NN\14360459|of
D005045_D009207 CID etomidate_16\NN\1740| (r_compound) administration_17\NN\1133281|after|etomidate (r_nmod) incidence_12\NN\13821570|with|increased|myoclonus|administration (l_nmod) myoclonus_14\NN\14360459|of
D005045_D009207 CID etomidate_10\NN\1740| (r_compound) induction_11\NN\7450842|after|etomidate (r_nmod) reduced_7\VBD\441445|conclusion|myoclonus|induction|effects|. (l_dobj) myoclonus_8\NN\14360459|
D005045_D009207 CID etomidate_9\NN\1740| (r_compound) administration_10\NN\1133281|after|etomidate (r_nmod) experience_1\VBP\2108377|men|incidence|administration|. (l_dobj) incidence_3\NN\13821570|increased|myoclonus|women (l_nmod) myoclonus_5\NN\14360459|of
C071741_D001049 NONE remifentanil_4\NN\1740|with (r_compound) microg/kg_6\NN\1740|pretreatment|remifentanil|1 (r_appos) conclusion_0\NN\5837957|:|microg/kg (r_nsubj) reduced_7\VBD\441445|conclusion|myoclonus|induction|effects|. (l_nmod) effects_14\NNS\13245626|without|side|sedation (l_nmod) sedation_17\NN\14034177|such|,|apnea (l_conj) apnea_19\NN\14299637|,|nausea
C071741_D009325 NONE remifentanil_4\NN\1740|with (r_compound) microg/kg_6\NN\1740|pretreatment|remifentanil|1 (r_appos) conclusion_0\NN\5837957|:|microg/kg (r_nsubj) reduced_7\VBD\441445|conclusion|myoclonus|induction|effects|. (l_nmod) effects_14\NNS\13245626|without|side|sedation (l_nmod) sedation_17\NN\14034177|such|,|apnea (l_conj) apnea_19\NN\14299637|,|nausea (l_conj) nausea_21\NN\14299637|,|or|pruritus
C071741_D011537 NONE remifentanil_4\NN\1740|with (r_compound) microg/kg_6\NN\1740|pretreatment|remifentanil|1 (r_appos) conclusion_0\NN\5837957|:|microg/kg (r_nsubj) reduced_7\VBD\441445|conclusion|myoclonus|induction|effects|. (l_nmod) effects_14\NNS\13245626|without|side|sedation (l_nmod) sedation_17\NN\14034177|such|,|apnea (l_conj) apnea_19\NN\14299637|,|nausea (l_conj) nausea_21\NN\14299637|,|or|pruritus (l_conj) pruritus_24\NN\5723563|
D005045_D001049 NONE etomidate_10\NN\1740| (r_compound) induction_11\NN\7450842|after|etomidate (r_nmod) reduced_7\VBD\441445|conclusion|myoclonus|induction|effects|. (l_nmod) effects_14\NNS\13245626|without|side|sedation (l_nmod) sedation_17\NN\14034177|such|,|apnea (l_conj) apnea_19\NN\14299637|,|nausea
D005045_D009325 NONE etomidate_10\NN\1740| (r_compound) induction_11\NN\7450842|after|etomidate (r_nmod) reduced_7\VBD\441445|conclusion|myoclonus|induction|effects|. (l_nmod) effects_14\NNS\13245626|without|side|sedation (l_nmod) sedation_17\NN\14034177|such|,|apnea (l_conj) apnea_19\NN\14299637|,|nausea (l_conj) nausea_21\NN\14299637|,|or|pruritus
D005045_D011537 NONE etomidate_10\NN\1740| (r_compound) induction_11\NN\7450842|after|etomidate (r_nmod) reduced_7\VBD\441445|conclusion|myoclonus|induction|effects|. (l_nmod) effects_14\NNS\13245626|without|side|sedation (l_nmod) sedation_17\NN\14034177|such|,|apnea (l_conj) apnea_19\NN\14299637|,|nausea (l_conj) nausea_21\NN\14299637|,|or|pruritus (l_conj) pruritus_24\NN\5723563|
10091616
D007980_D004409 CID levodopa-induced_2\JJ\1740| (r_amod) dyskinesias_3\NNS\14084880|of|levodopa-induced
D001058_D010300 NONE apomorphine_61\NN\3786417|of (r_nmod) dose_59\NN\3740161|of|an|effective|single|apomorphine (r_nmod) administration_54\NN\1133281|following|dose (r_nmod) worsening_49\NN\13457378|on|the|dyskinesia|administration (r_nmod) role_18\NN\719494|the|tasks|worsening (r_dobj) evaluate_16\VB\670261|to|role (r_advcl) included_11\VBN\690614|patients|were|study|evaluate|. (l_nsubjpass) patients_1\NNS\9898892|ten|had (l_acl:relcl) had_3\VBD\2108377|who|disease (l_dobj) disease_6\NN\14061805|parkinson|'s|dyskinesia
D001058_D004409 CID apomorphine_61\NN\3786417|of (r_nmod) dose_59\NN\3740161|of|an|effective|single|apomorphine (r_nmod) administration_54\NN\1133281|following|dose (r_nmod) worsening_49\NN\13457378|on|the|dyskinesia|administration (r_nmod) role_18\NN\719494|the|tasks|worsening (r_dobj) evaluate_16\VB\670261|to|role (r_advcl) included_11\VBN\690614|patients|were|study|evaluate|. (l_nsubjpass) patients_1\NNS\9898892|ten|had (l_acl:relcl) had_3\VBD\2108377|who|disease (l_dobj) disease_6\NN\14061805|parkinson|'s|dyskinesia (l_nmod) dyskinesia_9\NNS\14084880|with|disabling
D001058_D004409 CID apomorphine_61\NN\3786417|of (r_nmod) dose_59\NN\3740161|of|an|effective|single|apomorphine (r_nmod) administration_54\NN\1133281|following|dose (r_nmod) worsening_49\NN\13457378|on|the|dyskinesia|administration (l_nmod) dyskinesia_52\NN\14084880|of|peak-dose
11704023
D013999_D005901 NONE timolol_6\NN\2832168|of|aqueous|ophthalmic (r_nmod) comparison_0\NN\635850|timolol|placebo|response|. (l_nmod) response_14\NN\11410625|on|the|24-hour|rate|patients (l_nmod) patients_16\NNS\9898892|in|treatment (l_nmod) treatment_18\NN\654885|on|glaucoma (l_nmod) glaucoma_20\NN\14252864|for
D013999_D005901 NONE timolol_13\NN\2832168|%|aqueous|solution|and|suspension (r_conj) placebo_8\NN\3740161|of|,|timolol|gellan (r_nmod) effect_6\NN\34213|the|placebo|rate (l_nmod) rate_41\NN\13815152|on|the|24-hour|heart|patients (l_nmod) patients_43\NNS\9898892|in|treated (l_acl) treated_46\VBN\2376958|currently|being|glaucoma (l_nmod) glaucoma_48\NN\14252864|for
D013999_D005901 NONE timolol_15\NN\2832168| (r_compound) solution_16\NN\14586258|(|timolol|) (r_appos) timolol_13\NN\2832168|%|aqueous|solution|and|suspension (r_conj) placebo_8\NN\3740161|of|,|timolol|gellan (r_nmod) effect_6\NN\34213|the|placebo|rate (l_nmod) rate_41\NN\13815152|on|the|24-hour|heart|patients (l_nmod) patients_43\NNS\9898892|in|treated (l_acl) treated_46\VBN\2376958|currently|being|glaucoma (l_nmod) glaucoma_48\NN\14252864|for
D013999_D005901 NONE timolol_22\NN\2832168| (r_compound) suspension_23\NN\14586258|a|%|timolol|forms (r_conj) timolol_13\NN\2832168|%|aqueous|solution|and|suspension (r_conj) placebo_8\NN\3740161|of|,|timolol|gellan (r_nmod) effect_6\NN\34213|the|placebo|rate (l_nmod) rate_41\NN\13815152|on|the|24-hour|heart|patients (l_nmod) patients_43\NNS\9898892|in|treated (l_acl) treated_46\VBN\2376958|currently|being|glaucoma (l_nmod) glaucoma_48\NN\14252864|for
D013999_D005901 NONE timolol_34\NN\2832168| (r_compound) gellan_35\NN\1740|(|timolol|) (r_appos) placebo_8\NN\3740161|of|,|timolol|gellan (r_nmod) effect_6\NN\34213|the|placebo|rate (l_nmod) rate_41\NN\13815152|on|the|24-hour|heart|patients (l_nmod) patients_43\NNS\9898892|in|treated (l_acl) treated_46\VBN\2376958|currently|being|glaucoma (l_nmod) glaucoma_48\NN\14252864|for
D013999_D005902 NONE timolol_52\NN\2832168| (r_compound) solution_53\NN\14586258|timolol|morning|,|or|gellan (r_conj) placebo_42\NN\3740161|with|morning|,|solution (r_nmod) treatment_40\NN\654885|of|placebo (r_nmod) days_38\NNS\15140892|to|14|treatment (r_nmod) crossed_30\VBN\2050132|over|manner|days (r_conj) randomized_28\VBN\278117|methods|patients|were|and|crossed|. (l_nsubjpass) patients_4\NNS\9898892|forty-three|caucasian|glaucoma|age (l_nmod) glaucoma_8\NN\14252864|with|primary|open-angle|or|hypertension
D013999_D005902 NONE timolol_64\NN\2832168| (r_compound) gellan_65\NN\1740|timolol|morning (r_conj) solution_53\NN\14586258|timolol|morning|,|or|gellan (r_conj) placebo_42\NN\3740161|with|morning|,|solution (r_nmod) treatment_40\NN\654885|of|placebo (r_nmod) days_38\NNS\15140892|to|14|treatment (r_nmod) crossed_30\VBN\2050132|over|manner|days (r_conj) randomized_28\VBN\278117|methods|patients|were|and|crossed|. (l_nsubjpass) patients_4\NNS\9898892|forty-three|caucasian|glaucoma|age (l_nmod) glaucoma_8\NN\14252864|with|primary|open-angle|or|hypertension
D013999_D009798 NONE timolol_52\NN\2832168| (r_compound) solution_53\NN\14586258|timolol|morning|,|or|gellan (r_conj) placebo_42\NN\3740161|with|morning|,|solution (r_nmod) treatment_40\NN\654885|of|placebo (r_nmod) days_38\NNS\15140892|to|14|treatment (r_nmod) crossed_30\VBN\2050132|over|manner|days (r_conj) randomized_28\VBN\278117|methods|patients|were|and|crossed|. (l_nsubjpass) patients_4\NNS\9898892|forty-three|caucasian|glaucoma|age (l_nmod) glaucoma_8\NN\14252864|with|primary|open-angle|or|hypertension (l_conj) hypertension_11\NN\14057371|ocular
D013999_D009798 NONE timolol_64\NN\2832168| (r_compound) gellan_65\NN\1740|timolol|morning (r_conj) solution_53\NN\14586258|timolol|morning|,|or|gellan (r_conj) placebo_42\NN\3740161|with|morning|,|solution (r_nmod) treatment_40\NN\654885|of|placebo (r_nmod) days_38\NNS\15140892|to|14|treatment (r_nmod) crossed_30\VBN\2050132|over|manner|days (r_conj) randomized_28\VBN\278117|methods|patients|were|and|crossed|. (l_nsubjpass) patients_4\NNS\9898892|forty-three|caucasian|glaucoma|age (l_nmod) glaucoma_8\NN\14252864|with|primary|open-angle|or|hypertension (l_conj) hypertension_11\NN\14057371|ocular
15764424
D002395_D011605 NONE catecholamines_12\NNS\5407119|and|hyperkinesia (r_conj) severity_10\NN\5036394|to|symptom|,|catecholamines (r_nmod) relationship_7\NN\31921|severity|. (r_dep) levels_2\NNS\4916342|quantitative|drug|psychosis|:|relationship (l_nmod) psychosis_5\NN\14380140|in|stimulant
D002395_D011605 NONE catecholamines_10\NNS\5407119| (r_conj) levels_8\NNS\4916342|between|quantitative|stimulant|drug|,|catecholamines|,|and|symptoms (l_conj) symptoms_14\NNS\5823932|psychotic
D002395_D011605 NONE catecholamines_10\NNS\5407119| (r_conj) levels_8\NNS\4916342|between|quantitative|stimulant|drug|,|catecholamines|,|and|symptoms (r_nmod) relationship_3\NN\31921|the|levels (r_dobj) examine_1\VB\789138|to|relationship (r_advcl) interviewed_32\VBN\964694|examine|,|patients|were|,|and|collected (l_nsubjpass) patients_17\NNS\9898892|nineteen|service (l_nmod) service_22\NN\575741|in|a|psychiatric|emergency|diagnosis (l_nmod) diagnosis_25\NN\152018|with|a|psychosis (l_nmod) psychosis_30\NN\14380140|of|amphetamine-
D002395_D011605 NONE catecholamine_47\NN\5407119| (r_compound) metabolite_48\NN\20090|catecholamine (r_compound) levels_49\NNS\4916342|metabolite (r_conj) drug_45\NN\14778436|of|stimulant|and|levels (r_nmod) assays_42\NNS\5733583|for|quantitative|drug (r_nmod) collected_39\VBN\2281093|plasma|were|assays|. (r_conj) interviewed_32\VBN\964694|examine|,|patients|were|,|and|collected (l_advcl) examine_1\VB\789138|to|relationship (l_dobj) relationship_3\NN\31921|the|levels (l_nmod) levels_8\NNS\4916342|between|quantitative|stimulant|drug|,|catecholamines|,|and|symptoms (l_conj) symptoms_14\NNS\5823932|psychotic
D002395_D011605 NONE catecholamine_47\NN\5407119| (r_compound) metabolite_48\NN\20090|catecholamine (r_compound) levels_49\NNS\4916342|metabolite (r_conj) drug_45\NN\14778436|of|stimulant|and|levels (r_nmod) assays_42\NNS\5733583|for|quantitative|drug (r_nmod) collected_39\VBN\2281093|plasma|were|assays|. (r_conj) interviewed_32\VBN\964694|examine|,|patients|were|,|and|collected (l_nsubjpass) patients_17\NNS\9898892|nineteen|service (l_nmod) service_22\NN\575741|in|a|psychiatric|emergency|diagnosis (l_nmod) diagnosis_25\NN\152018|with|a|psychosis (l_nmod) psychosis_30\NN\14380140|of|amphetamine-
D002395_D006948 NONE catecholamines_12\NNS\5407119|and|hyperkinesia (l_conj) hyperkinesia_14\NN\1740|
D002395_D001523 NONE catecholamines_10\NNS\5407119| (r_conj) levels_8\NNS\4916342|between|quantitative|stimulant|drug|,|catecholamines|,|and|symptoms (r_nmod) relationship_3\NN\31921|the|levels (r_dobj) examine_1\VB\789138|to|relationship (r_advcl) interviewed_32\VBN\964694|examine|,|patients|were|,|and|collected (l_nsubjpass) patients_17\NNS\9898892|nineteen|service (l_nmod) service_22\NN\575741|in|a|psychiatric|emergency|diagnosis (l_amod) psychiatric_20\JJ\1740|
D002395_D001523 NONE catecholamine_47\NN\5407119| (r_compound) metabolite_48\NN\20090|catecholamine (r_compound) levels_49\NNS\4916342|metabolite (r_conj) drug_45\NN\14778436|of|stimulant|and|levels (r_nmod) assays_42\NNS\5733583|for|quantitative|drug (r_nmod) collected_39\VBN\2281093|plasma|were|assays|. (r_conj) interviewed_32\VBN\964694|examine|,|patients|were|,|and|collected (l_nsubjpass) patients_17\NNS\9898892|nineteen|service (l_nmod) service_22\NN\575741|in|a|psychiatric|emergency|diagnosis (l_amod) psychiatric_20\JJ\1740|
D000661_D011605 CID amphetamine-_27\NN\1740|or|cocaine-induced (r_amod) psychosis_30\NN\14380140|of|amphetamine- (r_nmod) diagnosis_25\NN\152018|with|a|psychosis (r_nmod) service_22\NN\575741|in|a|psychiatric|emergency|diagnosis (r_nmod) patients_17\NNS\9898892|nineteen|service (r_nsubjpass) interviewed_32\VBN\964694|examine|,|patients|were|,|and|collected (l_advcl) examine_1\VB\789138|to|relationship (l_dobj) relationship_3\NN\31921|the|levels (l_nmod) levels_8\NNS\4916342|between|quantitative|stimulant|drug|,|catecholamines|,|and|symptoms (l_conj) symptoms_14\NNS\5823932|psychotic
D000661_D011605 CID amphetamine-_27\NN\1740|or|cocaine-induced (r_amod) psychosis_30\NN\14380140|of|amphetamine-
D000661_D001523 NONE amphetamine-_27\NN\1740|or|cocaine-induced (r_amod) psychosis_30\NN\14380140|of|amphetamine- (r_nmod) diagnosis_25\NN\152018|with|a|psychosis (r_nmod) service_22\NN\575741|in|a|psychiatric|emergency|diagnosis (l_amod) psychiatric_20\JJ\1740|
D003042_D011605 CID cocaine-induced_29\JJ\1740| (r_conj) amphetamine-_27\NN\1740|or|cocaine-induced (r_amod) psychosis_30\NN\14380140|of|amphetamine- (r_nmod) diagnosis_25\NN\152018|with|a|psychosis (r_nmod) service_22\NN\575741|in|a|psychiatric|emergency|diagnosis (r_nmod) patients_17\NNS\9898892|nineteen|service (r_nsubjpass) interviewed_32\VBN\964694|examine|,|patients|were|,|and|collected (l_advcl) examine_1\VB\789138|to|relationship (l_dobj) relationship_3\NN\31921|the|levels (l_nmod) levels_8\NNS\4916342|between|quantitative|stimulant|drug|,|catecholamines|,|and|symptoms (l_conj) symptoms_14\NNS\5823932|psychotic
D003042_D011605 CID cocaine-induced_29\JJ\1740| (r_conj) amphetamine-_27\NN\1740|or|cocaine-induced (r_amod) psychosis_30\NN\14380140|of|amphetamine-
D003042_D001523 NONE cocaine-induced_29\JJ\1740| (r_conj) amphetamine-_27\NN\1740|or|cocaine-induced (r_amod) psychosis_30\NN\14380140|of|amphetamine- (r_nmod) diagnosis_25\NN\152018|with|a|psychosis (r_nmod) service_22\NN\575741|in|a|psychiatric|emergency|diagnosis (l_amod) psychiatric_20\JJ\1740|
D008694_D006948 CID methamphetamine_0\NN\2704153|or|amphetamine (r_compound) levels_3\NNS\4916342|methamphetamine (r_nsubjpass) related_5\VBN\628491|levels|were|scores|. (l_nmod) scores_9\NNS\13757724|to|several|psychopathology|and|rating (l_conj) rating_14\NN\5733583|the|global|hyperkinesia (l_compound) hyperkinesia_13\NN\1740|
D000661_D006948 CID amphetamine_2\NN\3248958| (r_conj) methamphetamine_0\NN\2704153|or|amphetamine (r_compound) levels_3\NNS\4916342|methamphetamine (r_nsubjpass) related_5\VBN\628491|levels|were|scores|. (l_nmod) scores_9\NNS\13757724|to|several|psychopathology|and|rating (l_conj) rating_14\NN\5733583|the|global|hyperkinesia (l_compound) hyperkinesia_13\NN\1740|
384871
D004977_D009901 CID ethambutol_6\NN\1740|combined|and|isoniazid (r_compound) treatment_9\NN\654885|due|ethambutol (r_nmod) neuropathy_2\NN\14204950|bilateral|optic|treatment|.
D007538_D009901 CID isoniazid_8\NN\2716205| (r_conj) ethambutol_6\NN\1740|combined|and|isoniazid (r_compound) treatment_9\NN\654885|due|ethambutol (r_nmod) neuropathy_2\NN\14204950|bilateral|optic|treatment|.
D004977_D064420 NONE ethambutol_8\NN\1740|due|to (r_nmod) toxicity_5\NN\13576101|of|nerve|ethambutol
3123611
D003276_D002819 CID contraception_4\NN\851994|with|oral (r_nmod) associated_1\VBN\628491|contraception (r_acl) chorea_0\NN\14253124|associated|.
D003276_D002819 CID contraceptives_7\NNS\3183080|oral (r_dobj) receiving_5\VBG\2210855|while|contraceptives (r_advcl) developed_2\VBD\1753788|patients|chorea|receiving|. (l_dobj) chorea_3\NN\14253124|
D003276_D002819 CID contraception_10\NN\851994|after|prolonged|oral (r_nmod) had_3\VBD\2108377|patient|chorea|contraception|. (l_dobj) chorea_6\NN\14253124|acute|amphetamine-induced
D000661_D002819 CID amphetamine-induced_5\JJ\1740| (r_amod) chorea_6\NN\14253124|acute|amphetamine-induced
11058428
D008775_D013119 NONE methylprednisolone_1\NN\1740|high-dose (r_nsubj) do_3\VB\1640855|methylprednisolone|may|harm|injury|. (l_nmod) injury_9\NN\14052046|for|cord
D008775_D013119 NONE methylprednisolone_14\NN\1740|high-dose (r_nsubj) became_15\VBD\146138|studies|,|methylprednisolone|standard|. (l_nmod) studies_8\NNPS\635850|because|the|national|acute|injury|(|nascis (l_compound) injury_7\NN\14052046|spinal|cord
D008775_D013119 NONE methylprednisolone_14\NN\1740|high-dose (r_nsubj) became_15\VBD\146138|studies|,|methylprednisolone|standard|. (l_attr) standard_17\NN\13577171|the|care|injury (l_nmod) injury_25\NN\14052046|for|the|acute|cord
D008775_D013119 NONE methylprednisolone_34\NN\1740| (r_nsubj) offers_35\VBZ\2327200|that|methylprednisolone|injury (l_nmod) injury_40\NN\14052046|to|the|cord
D000305_D009135 NONE corticosteroid_13\NN\14745635| (r_compound) myopathy_14\NN\14204950|of|acute|corticosteroid|cause
D000305_D009135 NONE corticosteroid_21\NN\14745635| (r_compound) myopathy_22\NN\14204950|acute|corticosteroid
D008775_D009135 CID methylprednisolone_17\NN\1740|high-dose (r_nsubj) cause_19\VB\1617192|that|methylprednisolone|may (r_acl:relcl) myopathy_14\NN\14204950|of|acute|corticosteroid|cause
D008775_D009135 CID methylprednisolone_34\NN\1740| (r_nsubj) offers_35\VBZ\2327200|that|methylprednisolone|injury (r_acl:relcl) protection_32\NN\407535|any|offers|. (r_conj) recording_18\NN\6791372|improvement|may|be|just|a|recovery|,|of|protection (r_conj) recovers_4\VBZ\2210855|further|,|myopathy|naturally|and|recording (l_nsubj) myopathy_3\NN\14204950|steroid
D008775_D009135 CID methylprednisolone_34\NN\1740| (r_nsubj) offers_35\VBZ\2327200|that|methylprednisolone|injury (r_acl:relcl) protection_32\NN\407535|any|offers|. (r_conj) recording_18\NN\6791372|improvement|may|be|just|a|recovery|,|of|protection (l_nmod) recovery_23\NN\7357388|of|this|natural|motor|myopathy (l_nmod) myopathy_27\NN\14204950|from|the|steroid
D008775_D009135 CID methylprednisolone_14\NN\1740|the|recommended (r_nsubj) cause_19\VB\1617192|that|methylprednisolone|may|myopathy (l_dobj) myopathy_22\NN\14204950|acute|corticosteroid
D013256_D009135 NONE steroid_2\NN\14727670| (r_compound) myopathy_3\NN\14204950|steroid
D013256_D009135 NONE steroid_2\NN\14727670| (r_compound) myopathy_3\NN\14204950|steroid (r_nsubj) recovers_4\VBZ\2210855|further|,|myopathy|naturally|and|recording (l_conj) recording_18\NN\6791372|improvement|may|be|just|a|recovery|,|of|protection (l_nmod) recovery_23\NN\7357388|of|this|natural|motor|myopathy (l_nmod) myopathy_27\NN\14204950|from|the|steroid
D013256_D009135 NONE steroid_26\NN\14727670| (r_compound) myopathy_27\NN\14204950|from|the|steroid (r_nmod) recovery_23\NN\7357388|of|this|natural|motor|myopathy (r_nmod) recording_18\NN\6791372|improvement|may|be|just|a|recovery|,|of|protection (r_conj) recovers_4\VBZ\2210855|further|,|myopathy|naturally|and|recording (l_nsubj) myopathy_3\NN\14204950|steroid
D013256_D009135 NONE steroid_26\NN\14727670| (r_compound) myopathy_27\NN\14204950|from|the|steroid
D013256_D013119 NONE steroid_2\NN\14727670| (r_compound) myopathy_3\NN\14204950|steroid (r_nsubj) recovers_4\VBZ\2210855|further|,|myopathy|naturally|and|recording (l_conj) recording_18\NN\6791372|improvement|may|be|just|a|recovery|,|of|protection (l_conj) protection_32\NN\407535|any|offers|. (l_acl:relcl) offers_35\VBZ\2327200|that|methylprednisolone|injury (l_nmod) injury_40\NN\14052046|to|the|cord
D013256_D013119 NONE steroid_26\NN\14727670| (r_compound) myopathy_27\NN\14204950|from|the|steroid (r_nmod) recovery_23\NN\7357388|of|this|natural|motor|myopathy (r_nmod) recording_18\NN\6791372|improvement|may|be|just|a|recovery|,|of|protection (l_conj) protection_32\NN\407535|any|offers|. (l_acl:relcl) offers_35\VBZ\2327200|that|methylprednisolone|injury (l_nmod) injury_40\NN\14052046|to|the|cord
1848636
D008790_D007008 NONE metoprolol_8\NN\2832168|by (r_nmod) antagonism_6\NN\24720|effect|was|the|metoprolol|hypokalemia|. (l_nmod) hypokalemia_11\NN\14299637|of|terbutaline-induced
D013726_D007008 CID terbutaline-induced_10\JJ\1740| (r_amod) hypokalemia_11\NN\14299637|of|terbutaline-induced
19139001
D000518_D015179 NONE difluoromethylornithine_13\NN\1740|of|and|sulindac (r_nmod) trial_11\NN\786195|in|a|phase|iii|clinical|difluoromethylornithine|prevention (l_nmod) prevention_17\NN\1073995|for|adenomas (l_nmod) adenomas_21\NNS\14236226|of|sporadic|colorectal
D013467_D015179 NONE sulindac_15\NN\3828465| (r_conj) difluoromethylornithine_13\NN\1740|of|and|sulindac (r_nmod) trial_11\NN\786195|in|a|phase|iii|clinical|difluoromethylornithine|prevention (l_nmod) prevention_17\NN\1073995|for|adenomas (l_nmod) adenomas_21\NNS\14236226|of|sporadic|colorectal
D000518_D018256 NONE difluoromethylornithine_17\NN\1740|with|dfmo|plus|sulindac|or|placebos (r_nmod) treatment_12\NN\654885|after|months|difluoromethylornithine (r_nmod) recurrence_7\NN\7342049|the|polyps|treatment (l_nmod) polyps_10\NNS\14234074|of|adenomatous
D000518_D018256 NONE dfmo_19\NN\1740|(|) (r_appos) difluoromethylornithine_17\NN\1740|with|dfmo|plus|sulindac|or|placebos (r_nmod) treatment_12\NN\654885|after|months|difluoromethylornithine (r_nmod) recurrence_7\NN\7342049|the|polyps|treatment (l_nmod) polyps_10\NNS\14234074|of|adenomatous
D013467_D018256 NONE sulindac_22\NN\3828465| (r_conj) difluoromethylornithine_17\NN\1740|with|dfmo|plus|sulindac|or|placebos (r_nmod) treatment_12\NN\654885|after|months|difluoromethylornithine (r_nmod) recurrence_7\NN\7342049|the|polyps|treatment (l_nmod) polyps_10\NNS\14234074|of|adenomatous
D000518_D034381 NONE dfmo_10\NN\1740|with (r_nmod) treatment_8\NN\654885|of|dfmo (r_nmod) toxicity_6\NN\13576101|loss|is|a|known|treatment (l_nsubj) loss_2\NN\13252973|temporary|hearing
D000518_D034381 NONE dfmo_12\NN\1740|plus|sulindac (r_compound) group_15\NN\2137|in|the|dfmo (r_nmod) subjects_9\NNS\6598915|of|group|experienced (l_acl:relcl) experienced_17\VBD\2108377|who|loss (l_dobj) loss_21\NN\13252973|significant|hearing
D000518_D064420 NONE dfmo_10\NN\1740|with (r_nmod) treatment_8\NN\654885|of|dfmo (r_nmod) toxicity_6\NN\13576101|loss|is|a|known|treatment
D013467_D034381 CID sulindac_14\NN\3828465| (r_conj) dfmo_12\NN\1740|plus|sulindac (r_compound) group_15\NN\2137|in|the|dfmo (r_nmod) subjects_9\NNS\6598915|of|group|experienced (l_acl:relcl) experienced_17\VBD\2108377|who|loss (l_dobj) loss_21\NN\13252973|significant|hearing
17574447
D010634_-1 NONE phenobarbital_6\NN\2792049| (r_compound) therapy_7\NN\657604|to|long-term|phenobarbital (r_nmod) related_3\JJ\1740|therapy (r_amod) hepatonecrosis_0\NN\1740|and|cholangitis|related|:|report|.
D010634_D002761 CID phenobarbital_6\NN\2792049| (r_compound) therapy_7\NN\657604|to|long-term|phenobarbital (r_nmod) related_3\JJ\1740|therapy (r_amod) hepatonecrosis_0\NN\1740|and|cholangitis|related|:|report|. (l_conj) cholangitis_2\NN\14336539|
D010634_D008107 CID phenobarbital_0\NN\2792049|pb (r_nsubj) has_4\VBZ\2108377|phenobarbital|reputation|,|and|believed (l_conj) believed_14\VBN\686447|it|is|commonly|indicate|. (l_ccomp) indicate_24\VB\952524|that|increases|do|not|or|predict|development (l_dobj) development_28\NN\248977|the|disease (l_nmod) disease_33\NN\14061805|of|significant|chronic|liver
D010634_D008107 CID pb_2\NN\14625458|(|) (r_appos) phenobarbital_0\NN\2792049|pb (r_nsubj) has_4\VBZ\2108377|phenobarbital|reputation|,|and|believed (l_conj) believed_14\VBN\686447|it|is|commonly|indicate|. (l_ccomp) indicate_24\VB\952524|that|increases|do|not|or|predict|development (l_dobj) development_28\NN\248977|the|disease (l_nmod) disease_33\NN\14061805|of|significant|chronic|liver
D010634_D008107 CID pb-related_16\JJ\1740| (r_amod) increases_17\NNS\13576355|pb-related|levels (r_nsubj) indicate_24\VB\952524|that|increases|do|not|or|predict|development (l_dobj) development_28\NN\248977|the|disease (l_nmod) disease_33\NN\14061805|of|significant|chronic|liver
D010634_D008107 CID pb_4\NN\14625458| (r_nsubjpass) associated_7\VBN\628491|that|pb|may|be|damage (l_nmod) damage_11\NN\7296428|with|chronic|liver|,|lead
D010634_D004827 NONE pb_15\NN\14625458|with (r_nmod) treated_13\VBN\2376958|pb (r_acl) patients_6\NNS\9898892|of|two|adult|history|treated|died (l_nmod) history_10\NN\15120823|with|a|long|epilepsy (l_nmod) epilepsy_12\NN\14085708|of
D010634_D006323 NONE pb_15\NN\14625458|with (r_nmod) treated_13\VBN\2376958|pb (r_acl) patients_6\NNS\9898892|of|two|adult|history|treated|died (l_acl:relcl) died_17\VBD\146138|who|suddenly|:|one (l_dep) one_20\CD\13741022|consequence|,|other (l_nmod) consequence_22\NN\34213|as|arrest (l_nmod) arrest_25\NN\88481|of|cardiac
D010634_D001996 NONE pb_15\NN\14625458|with (r_nmod) treated_13\VBN\2376958|pb (r_acl) patients_6\NNS\9898892|of|two|adult|history|treated|died (l_acl:relcl) died_17\VBD\146138|who|suddenly|:|one (l_dep) one_20\CD\13741022|consequence|,|other (l_appos) other_28\JJ\1740|the|bronchopneumonia (l_nmod) bronchopneumonia_31\NN\14147627|of|acute
D010634_D056487 NONE pb-related_15\JJ\1740| (r_amod) dysfunction_20\NN\14204950|of|pb-related|asymptomatic|chronic|hepatic|enzyme
6292680
D004317_D009202 CID doxorubicin_0\NN\2716866| (r_compound) cardiomyopathy_1\NN\14103288|doxorubicin|children|.
D004317_D009202 CID doxorubicin_23\NN\2716866|of (r_nmod) dosage_21\NN\13576355|conventional|doxorubicin (r_conj) irradiation_14\NN\13920835|after|bed|and|dosage (r_nmod) experienced_9\VBD\2108377|children|cardiomyopathy|irradiation|. (l_dobj) cardiomyopathy_12\NN\14103288|severe|anthracycline
D004317_D009202 CID doxorubicin_30\NN\2716866|of|and|irradiation (r_nmod) interaction_28\NN\37396|2|to|the|doxorubicin|muscle (r_conj) fact_8\NN\5816287|1|to|the|include|and|interaction (r_dobj) attributed_3\VBN\670261|cardiomyopathy|is|fact|. (l_nsubjpass) cardiomyopathy_1\NN\14103288|the
D004317_D009396 NONE doxorubicin_0\NN\2716866| (r_compound) cardiomyopathy_1\NN\14103288|doxorubicin|children|. (l_nmod) children_3\NNS\9622049|in|tumor (l_nmod) tumor_7\NN\14234074|with|left-sided|wilms
D004317_D009396 NONE doxorubicin_23\NN\2716866|of (r_nmod) dosage_21\NN\13576355|conventional|doxorubicin (r_conj) irradiation_14\NN\13920835|after|bed|and|dosage (r_nmod) experienced_9\VBD\2108377|children|cardiomyopathy|irradiation|. (l_nsubj) children_1\NNS\9622049|two|tumor (l_nmod) tumor_4\NN\14234074|with|wilms|kidney
D004317_D009396 NONE doxorubicin_30\NN\2716866|of|and|irradiation (r_nmod) interaction_28\NN\37396|2|to|the|doxorubicin|muscle (r_conj) fact_8\NN\5816287|1|to|the|include|and|interaction (l_acl) include_16\VBP\690614|that|fields|portion (l_nsubj) fields_11\NNS\8673395|radiation|tumor (l_nmod) tumor_15\NN\14234074|for|left|wilms
D004317_D009396 NONE doxorubicin_4\NN\2716866| (r_compound) dosage_5\NN\13576355|doxorubicin (r_nsubjpass) restricted_8\JJ\1740|that|dosage|be|sharply|children (l_nmod) children_10\NNS\9622049|in|tumor|receive (l_nmod) tumor_13\NN\14234074|with|wilms|kidney
D018943_D009396 NONE anthracycline_11\NN\1740| (r_compound) cardiomyopathy_12\NN\14103288|severe|anthracycline (r_dobj) experienced_9\VBD\2108377|children|cardiomyopathy|irradiation|. (l_nsubj) children_1\NNS\9622049|two|tumor (l_nmod) tumor_4\NN\14234074|with|wilms|kidney
D018943_D009202 NONE anthracycline_11\NN\1740| (r_compound) cardiomyopathy_12\NN\14103288|severe|anthracycline
D018943_D009369 NONE anthracycline_11\NN\1740| (r_compound) cardiomyopathy_12\NN\14103288|severe|anthracycline (r_dobj) experienced_9\VBD\2108377|children|cardiomyopathy|irradiation|. (l_nmod) irradiation_14\NN\13920835|after|bed|and|dosage (l_nmod) bed_18\NN\2821943|to|the|tumor (l_compound) tumor_17\NN\14234074|
D004317_D009369 NONE doxorubicin_23\NN\2716866|of (r_nmod) dosage_21\NN\13576355|conventional|doxorubicin (r_conj) irradiation_14\NN\13920835|after|bed|and|dosage (l_nmod) bed_18\NN\2821943|to|the|tumor (l_compound) tumor_17\NN\14234074|
7791169
D016595_D007674 NONE misoprostol_3\NN\1740|of (r_nmod) effect_1\NN\34213|protective|misoprostol|dysfunction|. (l_nmod) dysfunction_8\NN\14204950|on|induced|renal|patients
D016595_D007674 NONE misoprostol_2\NN\1740|of (r_nmod) addition_0\NN\3081021|misoprostol (r_nsubj) minimize_4\VB\441445|addition|can|impairment|affecting|. (l_dobj) impairment_7\NN\7296428|this|renal
D007213_D007674 CID indomethacin_5\NN\3828465| (r_nmod:npmod) induced_6\JJ\1740|indomethacin (r_amod) dysfunction_8\NN\14204950|on|induced|renal|patients
D007213_D007674 CID indomethacin_10\NN\3828465| (r_nmod:npmod) related_11\JJ\1740|indomethacin (r_amod) dysfunction_13\NN\14204950|related|renal
D016595_D010146 NONE misoprostol_2\NN\1740|of (r_nmod) addition_0\NN\3081021|misoprostol (r_nsubj) minimize_4\VB\441445|addition|can|impairment|affecting|. (l_advcl) affecting_9\VBG\126264|without|control (l_dobj) control_11\NN\5190804|pain (l_compound) pain_10\NN\14299637|
19917396
D016559_D006332 CID tacrolimus_5\NN\1740|by (r_nmod) induced_3\VBN\1627355|tacrolimus|recipient (r_acl) hypertrophy_2\NN\14365950|reversible|myocardial|induced|:|report|.
D016559_D006332 CID tacrolimus_8\NN\1740|by (r_nmod) induced_6\VBN\1627355|tacrolimus|transplantation (r_acl) hypertrophy_5\NN\14365950|transient|myocardial|induced
D016559_D006332 CID tacrolimus_10\NN\1740|of (r_nmod) concentration_8\NN\4916342|the|target|tacrolimus (r_dobj) reducing_5\VBG\441445|upon|concentration (r_advcl) resolved_3\VBD\352826|hypertrophy|completely|reducing|and|recur|. (l_nsubj) hypertrophy_1\NN\14365950|myocardial
D016559_D006332 CID tacrolimus_5\NN\1740| (r_nsubj) induces_6\VBZ\1627355|that|tacrolimus|hypertrophy (l_dobj) hypertrophy_9\NN\14365950|reversible|myocardial
9214597
D004967_D010911 NONE estrogen-induced_14\JJ\1740| (r_amod) tumors_17\NNS\14234074|of|estrogen-induced|rat|pituitary
D004967_D010911 NONE estrogen-initiated_20\JJ\1740| (r_amod) angiogenesis_22\NN\13489037|estrogen-initiated|tumor (r_dobj) mediate_19\VB\761713|expression|may|angiogenesis|. (l_nsubj) expression_1\NN\4679549|over|factor|development (l_nmod) development_12\NN\248977|during|the|tumors (l_nmod) tumors_17\NNS\14234074|of|estrogen-induced|rat|pituitary
D004967_D009369 NONE estrogen-induced_14\JJ\1740| (r_amod) tumors_17\NNS\14234074|of|estrogen-induced|rat|pituitary (r_nmod) development_12\NN\248977|during|the|tumors (r_nmod) expression_1\NN\4679549|over|factor|development (r_nsubj) mediate_19\VB\761713|expression|may|angiogenesis|. (l_dobj) angiogenesis_22\NN\13489037|estrogen-initiated|tumor (l_compound) tumor_21\NN\14234074|
D004967_D009369 NONE estrogen-initiated_20\JJ\1740| (r_amod) angiogenesis_22\NN\13489037|estrogen-initiated|tumor (l_compound) tumor_21\NN\14234074|
D004967_D009369 NONE estrogens_0\NNS\14745635|,|associated|, (l_acl:relcl) associated_5\VBN\628491|which|have|been|types (l_nmod) types_8\NNS\5839024|with|several|cancers (l_nmod) cancers_13\NNS\14239425|of|human
D004967_D009369 NONE estrogens_0\NNS\14745635|,|associated|, (r_nsubj) induce_16\VB\1627355|estrogens|can|angiogenesis|pituitary|. (l_dobj) angiogenesis_18\NN\13489037|tumor (l_compound) tumor_17\NN\14234074|
D004967_D009369 NONE estrogen_9\NN\14745635| (r_compound) carcinogenesis_10\NN\1740|during|estrogen (r_nmod) unknown_14\JJ\1740|details|,|carcinogenesis|,|are|still|. (l_nsubj) details_2\NNS\6634376|the|mechanistic|induction (l_nmod) induction_6\NN\7450842|of|tumor|angiogenesis (l_compound) tumor_4\NN\14234074|
D004967_D009369 NONE estrogen_5\NN\14745635|of (r_nmod) role_3\NN\719494|the|estrogen|regulation (l_nmod) regulation_8\NN\6652242|in|the|angiogenesis (l_nmod) angiogenesis_11\NN\13489037|of|tumor|pituitary (l_compound) tumor_10\NN\14234074|
D004967_D009369 NONE estrogen_27\NN\14745635| (r_nmod:npmod) induced_28\JJ\1740|estrogen (r_amod) angiogenesis_30\NN\13489037|of|induced|tumor|pituitary (l_compound) tumor_29\NN\14234074|
D004967_D063646 NONE estrogen_9\NN\14745635| (r_compound) carcinogenesis_10\NN\1740|during|estrogen
D004958_D009369 NONE e2_15\NN\1740| (r_nmod:npmod) exposed_16\JJ\1740|e2 (r_amod) pituitary_17\NN\5329735|in|the|exposed|rats (r_nmod) expression_12\NN\4679549|with|an|elevated|vegf/vpf|protein|pituitary (r_nmod) associated_6\VBN\628491|potential|was|expression|. (l_nsubjpass) potential_4\NN\14481929|the|high|tumor|angiogenic (l_compound) tumor_2\NN\14234074|
11583940
C063008_D007674 NONE mofetil_7\NN\1740|mycophenolate|and|sirolimus (r_appos) agents_4\NNS\7347|two|available|immunosuppressive|,|mofetil|, (r_nsubj) have_14\VBP\2108377|agents|nephrotoxicity|. (l_dobj) nephrotoxicity_16\NN\1740|no
D020123_D007674 NONE sirolimus_9\NN\1740|rapamycin (r_conj) mofetil_7\NN\1740|mycophenolate|and|sirolimus (r_appos) agents_4\NNS\7347|two|available|immunosuppressive|,|mofetil|, (r_nsubj) have_14\VBP\2108377|agents|nephrotoxicity|. (l_dobj) nephrotoxicity_16\NN\1740|no
D020123_D007674 NONE rapamycin_11\NN\1740|(|) (r_appos) sirolimus_9\NN\1740|rapamycin (r_conj) mofetil_7\NN\1740|mycophenolate|and|sirolimus (r_appos) agents_4\NNS\7347|two|available|immunosuppressive|,|mofetil|, (r_nsubj) have_14\VBP\2108377|agents|nephrotoxicity|. (l_dobj) nephrotoxicity_16\NN\1740|no
1300436
D005665_D007674 NONE furosemide_4\NN\3214670|of (r_nmod) effect_2\NN\34213|potential|deleterious|furosemide|nephropathy|. (l_nmod) nephropathy_7\NN\14573196|in|radiocontrast
D005665_D007674 NONE furosemide_11\NN\3214670|of (r_nmod) efficacy_9\NN\5199286|the|furosemide|addition|prevention (l_nmod) prevention_19\NN\1073995|in|the|nephropathy (l_nmod) nephropathy_22\NN\14573196|of|radiocontrast
D005665_D007674 NONE furosemide_0\NN\3214670| (r_nsubj) deleterious_3\JJ\1740|furosemide|may|be|prevention|. (l_nmod) prevention_6\NN\1073995|in|the|nephropathy (l_nmod) nephropathy_9\NN\14573196|of|radiocontrast
D005665_D058186 CID furosemide_30\NN\3214670|with (r_nmod) pretreated_28\VBN\1740|furosemide (r_acl) group_27\NN\2137|in|the|pretreated|< (r_nmod) deteriorated_24\VBD\208836|function|significantly|group|,|rise|,|occurred
D003404_D058186 NONE creatinine_44\NN\1740|in|serum (r_nmod) rise_41\NN\7324673|with|a|creatinine|145|h (r_nmod) deteriorated_24\VBD\208836|function|significantly|group|,|rise|,|occurred
D005665_D051437 NONE furosemide-treated_9\JJ\1740| (r_amod) group_10\NN\2137|in|the|furosemide-treated (r_nmod) associated_3\VBN\628491|failure|was|loss|group|. (l_nsubjpass) failure_1\NN\66216|renal
D005665_D015431 NONE furosemide-treated_9\JJ\1740| (r_amod) group_10\NN\2137|in|the|furosemide-treated (r_nmod) associated_3\VBN\628491|failure|was|loss|group|. (l_nmod) loss_6\NN\13252973|with|weight
12042105
C052342_D053040 CID topiramate-induced_0\JJ\1740| (r_amod) nephrolithiasis_1\NN\14115914|topiramate-induced|.
C052342_D053040 CID topiramate-induced_7\JJ\1740| (r_amod) nephrolithiasis_8\NN\14115914|of|topiramate-induced
C052342_D004827 NONE topiramate_0\NN\1740| (r_nsubj) medication_6\NN\3247620|topiramate|is|a|developed|antiepileptic|becoming|. (l_acl:relcl) becoming_9\VBG\146138|that|is|prescribed|efficacy (l_nmod) efficacy_16\NN\5199286|because|its|treating (l_advcl) treating_18\VBG\2376958|in|seizures (l_dobj) seizures_20\NNS\14081375|refractory
C020243_D053040 NONE phosphate_29\NN\15010703| (r_compound) nephrolithiasis_30\NN\14115914|of|calcium|phosphate
761833
D000641_D003128 NONE ammonia_2\NN\14940386| (r_compound) coma_3\NN\5678932|of|ammonia|rats
D000641_D003128 NONE ammonia_0\NN\14940386| (r_compound) coma_1\NN\5678932|ammonia
D000641_D003128 NONE ammonia_18\NN\14940386| (r_compound) coma_19\NN\5678932|the|ammonia
D000641_D003128 NONE ammonia_26\NN\14940386| (r_compound) concentrations_27\NNS\4916342|the|blood|ammonia (r_dobj) affect_21\VB\126264|concentrations (r_conj) prevent_16\VB\1740|infusion|did|not|coma|nor|affect|. (l_dobj) coma_19\NN\5678932|the|ammonia
D000641_D003128 NONE ammonia_12\NN\14940386|on|blood (r_nmod) effect_5\NN\34213|the|beneficial|l-dopa|ammonia (r_dobj) eliminated_2\VBD\1619929|nephrectomy|effect|and|prevented (l_conj) prevented_19\VBN\1740|coma|was|not|. (l_nsubjpass) coma_16\NN\5678932|the|ammonia
D000641_D003128 NONE ammonia_15\NN\14940386| (r_compound) coma_16\NN\5678932|the|ammonia
D000641_D003128 NONE ammonia_8\NN\14940386|in|blood (r_nmod) reduction_3\NN\351485|the|ammonia|and|prevention (l_conj) prevention_11\NN\1073995|the|coma|l-dopa (l_nmod) coma_14\NN\5678932|of|ammonia
D000641_D003128 NONE ammonia_13\NN\14940386| (r_compound) coma_14\NN\5678932|of|ammonia
D007980_D003128 NONE l-dopa_7\NN\14604959|by (r_nmod) reversal_0\NN\199130|coma|l-dopa|:|effect (l_nmod) coma_3\NN\5678932|of|ammonia|rats
D007980_D003128 NONE l-dopa_7\NN\14604959|with|mmol|given (r_nmod) prevented_3\VBN\1740|coma|was|l-dopa|. (l_nsubjpass) coma_1\NN\5678932|this
D007980_D003128 NONE l-dopa_7\NN\14604959|of (r_nmod) effect_5\NN\34213|the|beneficial|l-dopa|ammonia (r_dobj) eliminated_2\VBD\1619929|nephrectomy|effect|and|prevented (l_conj) prevented_19\VBN\1740|coma|was|not|. (l_nsubjpass) coma_16\NN\5678932|the|ammonia
D007980_D003128 NONE l-dopa_16\NN\14604959|after (r_nmod) prevention_11\NN\1073995|the|coma|l-dopa (l_nmod) coma_14\NN\5678932|of|ammonia
D000643_D003128 CID nh4cl_17\NN\1740|of|mmol (r_nmod) intraperitonealinjection_13\NN\1740|of|an|nh4cl (r_nmod) minutes_10\NNS\6502378|within|15|intraperitonealinjection (r_nmod) produced_3\VBN\1617192|coma|was|rats|minutes|. (l_nsubjpass) coma_1\NN\5678932|ammonia
D064751_D003128 NONE salt_17\NN\14818238|ammonium (r_compound) injection_18\NN\320852|before|the|salt (r_nmod) given_8\VBN\2327200|intubation|injection (r_acl) l-dopa_7\NN\14604959|with|mmol|given (r_nmod) prevented_3\VBN\1740|coma|was|l-dopa|. (l_nsubjpass) coma_1\NN\5678932|this
D004298_D003128 NONE dopamine_3\NN\14807737|of|sufficient (r_nmod) infusion_1\NN\14589223|intraventricular|dopamine (r_nsubj) prevent_16\VB\1740|infusion|did|not|coma|nor|affect|. (l_dobj) coma_19\NN\5678932|the|ammonia
D004298_D003128 NONE dopamine_9\NN\14807737|the|brain (r_dobj) raise_6\VB\153263|to|dopamine|extent (r_xcomp) sufficient_4\JJ\1740|raise (r_amod) dopamine_3\NN\14807737|of|sufficient (r_nmod) infusion_1\NN\14589223|intraventricular|dopamine (r_nsubj) prevent_16\VB\1740|infusion|did|not|coma|nor|affect|. (l_dobj) coma_19\NN\5678932|the|ammonia
D004298_D003128 NONE dopamine_27\NN\14807737|of (r_nmod) effect_25\NN\34213|by|the|peripheral|dopamine|function|rather|action (r_nmod) accounted_20\VBN\2604760|thus|,|reduction|,|can|be|for|effect|. (l_nsubjpass) reduction_3\NN\351485|the|ammonia|and|prevention (l_conj) prevention_11\NN\1073995|the|coma|l-dopa (l_nmod) coma_14\NN\5678932|of|ammonia
D007980_D001927 NONE l-dopa_16\NN\14604959| (r_dobj) receiving_15\VBG\2210855|l-dopa (r_acl) patients_14\NNS\9898892|in|some|encephalopathic|receiving (l_amod) encephalopathic_13\JJ\1740|
11302406
D015725_D016171 CID fluconazole-induced_0\NN\1740| (r_compound) pointes_3\NNS\1740|fluconazole-induced|torsade|de|.
D015725_D016171 CID fluconazole-associated_7\JJ\1740| (r_amod) pointes_10\NNS\1740|of|fluconazole-associated|torsade|de|tdp
D015725_D016171 CID fluconazole-associated_7\JJ\1740| (r_amod) pointes_10\NNS\1740|of|fluconazole-associated|torsade|de|tdp (l_appos) tdp_12\NN\1740|(|)
D015725_D016171 CID fluconazole-associated_7\JJ\1740| (r_amod) pointes_10\NNS\1740|of|fluconazole-associated|torsade|de|tdp (r_nmod) case_5\NN\7283608|a|pointes (r_dobj) present_3\VB\2137132|to|case|and|discuss (l_conj) discuss_15\VB\1033527|role (l_dobj) role_18\NN\719494|fluconazole|causing (l_advcl) causing_20\VBG\1617192|in|tdp (l_dobj) tdp_21\NN\1740|
D015725_D016171 CID fluconazole_16\NN\1740|'s (r_nmod:poss) role_18\NN\719494|fluconazole|causing (r_dobj) discuss_15\VB\1033527|role (r_conj) present_3\VB\2137132|to|case|and|discuss (l_dobj) case_5\NN\7283608|a|pointes (l_nmod) pointes_10\NNS\1740|of|fluconazole-associated|torsade|de|tdp
D015725_D016171 CID fluconazole_16\NN\1740|'s (r_nmod:poss) role_18\NN\719494|fluconazole|causing (r_dobj) discuss_15\VB\1033527|role (r_conj) present_3\VB\2137132|to|case|and|discuss (l_dobj) case_5\NN\7283608|a|pointes (l_nmod) pointes_10\NNS\1740|of|fluconazole-associated|torsade|de|tdp (l_appos) tdp_12\NN\1740|(|)
D015725_D016171 CID fluconazole_16\NN\1740|'s (r_nmod:poss) role_18\NN\719494|fluconazole|causing (l_advcl) causing_20\VBG\1617192|in|tdp (l_dobj) tdp_21\NN\1740|
D015725_D016171 CID fluconazole_22\NN\1740|oral (r_dobj) commencing_20\VBG\348746|fluconazole (r_advcl) developed_15\VBD\1753788|woman|tdp|after|commencing (l_dobj) tdp_16\NN\1740|
D015725_D016171 CID fluconazole_22\NN\1740|oral (r_dobj) commencing_20\VBG\348746|fluconazole (r_advcl) developed_15\VBD\1753788|woman|tdp|after|commencing (r_dep) summary_1\NN\6722453|case|:|developed|had (l_acl:relcl) had_25\VBD\2108377|patient|factors (l_dobj) factors_29\NNS\7326557|no|other|risk|tdp|,|disease (l_nmod) tdp_31\NN\1740|for
D015725_D016171 CID fluconazole_22\NN\1740|oral (r_dobj) commencing_20\VBG\348746|fluconazole (r_advcl) developed_15\VBD\1753788|woman|tdp|after|commencing (r_dep) summary_1\NN\6722453|case|:|developed|had (r_nsubj) was_48\VBD\836236|summary|there|association|. (l_nsubj) association_51\NN\8008335|a|temporal|initiation (l_nmod) initiation_54\NN\7450842|between|the|fluconazole|and|tdp (l_conj) tdp_58\NN\1740|
D015725_D016171 CID fluconazole_56\NN\1740|of (r_nmod) initiation_54\NN\7450842|between|the|fluconazole|and|tdp (r_nmod) association_51\NN\8008335|a|temporal|initiation (r_nsubj) was_48\VBD\836236|summary|there|association|. (l_nsubj) summary_1\NN\6722453|case|:|developed|had (l_dep) developed_15\VBD\1753788|woman|tdp|after|commencing (l_dobj) tdp_16\NN\1740|
D015725_D016171 CID fluconazole_56\NN\1740|of (r_nmod) initiation_54\NN\7450842|between|the|fluconazole|and|tdp (r_nmod) association_51\NN\8008335|a|temporal|initiation (r_nsubj) was_48\VBD\836236|summary|there|association|. (l_nsubj) summary_1\NN\6722453|case|:|developed|had (l_acl:relcl) had_25\VBD\2108377|patient|factors (l_dobj) factors_29\NNS\7326557|no|other|risk|tdp|,|disease (l_nmod) tdp_31\NN\1740|for
D015725_D016171 CID fluconazole_56\NN\1740|of (r_nmod) initiation_54\NN\7450842|between|the|fluconazole|and|tdp (l_conj) tdp_58\NN\1740|
D015725_D016171 CID fluconazole_4\NN\1740| (r_nsubjpass) discontinued_6\VBN\2609764|when|fluconazole|was (r_advcl) resolved_2\VBD\352826|tdp|discontinued (l_nsubj) tdp_1\NN\1740|the
D015725_D016171 CID fluconazole_4\NN\1740| (r_nsubjpass) discontinued_6\VBN\2609764|when|fluconazole|was (r_advcl) resolved_2\VBD\352826|tdp|discontinued (r_ccomp) continued_12\VBD\2367363|resolved|;|however|,|patient|have|:|indicates (l_parataxis) indicates_39\VBZ\952524|use|relationship|. (l_dobj) relationship_42\NN\31921|a|probable|use (l_nmod) use_45\NN\407535|between|the|fluconazole|and|development (l_conj) development_50\NN\248977|the|tdp (l_nmod) tdp_52\NN\1740|of
D015725_D016171 CID fluconazole_47\NN\1740|of (r_nmod) use_45\NN\407535|between|the|fluconazole|and|development (r_nmod) relationship_42\NN\31921|a|probable|use (r_dobj) indicates_39\VBZ\952524|use|relationship|. (r_parataxis) continued_12\VBD\2367363|resolved|;|however|,|patient|have|:|indicates (l_ccomp) resolved_2\VBD\352826|tdp|discontinued (l_nsubj) tdp_1\NN\1740|the
D015725_D016171 CID fluconazole_47\NN\1740|of (r_nmod) use_45\NN\407535|between|the|fluconazole|and|development (l_conj) development_50\NN\248977|the|tdp (l_nmod) tdp_52\NN\1740|of
D015725_D016171 CID fluconazole_39\NN\1740| (r_dobj) suggests_38\VBZ\1010118|was|strongly|fluconazole|etiology|. (l_ccomp) was_5\VBD\836236|patient|,|there|etiology|disappearance (l_attr) etiology_8\NN\7326557|no|other|identified|explain (l_acl:relcl) explain_12\VB\831651|that|could|prolongation (l_dobj) prolongation_14\NN\1017987|qt|or|tdp (l_conj) tdp_16\NN\1740|
D015725_D016171 CID fluconazole_7\NN\1740|,|doses (r_nsubj) cause_15\VB\1617192|that|fluconazole|,|may|prolongation (l_dobj) prolongation_16\NN\1017987|interval|,|leading (l_acl) leading_22\VBG\1752884|tdp (l_nmod) tdp_24\NN\1740|to
D015725_D003324 NONE fluconazole_22\NN\1740|oral (r_dobj) commencing_20\VBG\348746|fluconazole (r_advcl) developed_15\VBD\1753788|woman|tdp|after|commencing (r_dep) summary_1\NN\6722453|case|:|developed|had (l_acl:relcl) had_25\VBD\2108377|patient|factors (l_dobj) factors_29\NNS\7326557|no|other|risk|tdp|,|disease (l_nmod) disease_36\NN\14061805|including|coronary|artery|,|cardiomyopathy|,|failure|,|and|abnormalities
D015725_D003324 NONE fluconazole_56\NN\1740|of (r_nmod) initiation_54\NN\7450842|between|the|fluconazole|and|tdp (r_nmod) association_51\NN\8008335|a|temporal|initiation (r_nsubj) was_48\VBD\836236|summary|there|association|. (l_nsubj) summary_1\NN\6722453|case|:|developed|had (l_acl:relcl) had_25\VBD\2108377|patient|factors (l_dobj) factors_29\NNS\7326557|no|other|risk|tdp|,|disease (l_nmod) disease_36\NN\14061805|including|coronary|artery|,|cardiomyopathy|,|failure|,|and|abnormalities
D015725_D009202 NONE fluconazole_22\NN\1740|oral (r_dobj) commencing_20\VBG\348746|fluconazole (r_advcl) developed_15\VBD\1753788|woman|tdp|after|commencing (r_dep) summary_1\NN\6722453|case|:|developed|had (l_acl:relcl) had_25\VBD\2108377|patient|factors (l_dobj) factors_29\NNS\7326557|no|other|risk|tdp|,|disease (l_nmod) disease_36\NN\14061805|including|coronary|artery|,|cardiomyopathy|,|failure|,|and|abnormalities (l_conj) cardiomyopathy_38\NN\14103288|
D015725_D009202 NONE fluconazole_56\NN\1740|of (r_nmod) initiation_54\NN\7450842|between|the|fluconazole|and|tdp (r_nmod) association_51\NN\8008335|a|temporal|initiation (r_nsubj) was_48\VBD\836236|summary|there|association|. (l_nsubj) summary_1\NN\6722453|case|:|developed|had (l_acl:relcl) had_25\VBD\2108377|patient|factors (l_dobj) factors_29\NNS\7326557|no|other|risk|tdp|,|disease (l_nmod) disease_36\NN\14061805|including|coronary|artery|,|cardiomyopathy|,|failure|,|and|abnormalities (l_conj) cardiomyopathy_38\NN\14103288|
D015725_D006333 NONE fluconazole_22\NN\1740|oral (r_dobj) commencing_20\VBG\348746|fluconazole (r_advcl) developed_15\VBD\1753788|woman|tdp|after|commencing (r_dep) summary_1\NN\6722453|case|:|developed|had (l_acl:relcl) had_25\VBD\2108377|patient|factors (l_dobj) factors_29\NNS\7326557|no|other|risk|tdp|,|disease (l_nmod) disease_36\NN\14061805|including|coronary|artery|,|cardiomyopathy|,|failure|,|and|abnormalities (l_conj) failure_42\NN\66216|congestive|heart
D015725_D006333 NONE fluconazole_56\NN\1740|of (r_nmod) initiation_54\NN\7450842|between|the|fluconazole|and|tdp (r_nmod) association_51\NN\8008335|a|temporal|initiation (r_nsubj) was_48\VBD\836236|summary|there|association|. (l_nsubj) summary_1\NN\6722453|case|:|developed|had (l_acl:relcl) had_25\VBD\2108377|patient|factors (l_dobj) factors_29\NNS\7326557|no|other|risk|tdp|,|disease (l_nmod) disease_36\NN\14061805|including|coronary|artery|,|cardiomyopathy|,|failure|,|and|abnormalities (l_conj) failure_42\NN\66216|congestive|heart
D015725_D018879 NONE fluconazole_4\NN\1740| (r_nsubjpass) discontinued_6\VBN\2609764|when|fluconazole|was (r_advcl) resolved_2\VBD\352826|tdp|discontinued (r_ccomp) continued_12\VBD\2367363|resolved|;|however|,|patient|have|:|indicates (l_xcomp) have_14\VB\2108377|to|contractions|days (l_dobj) contractions_17\NNS\358931|premature|ventricular|and|tachycardia
D015725_D018879 NONE fluconazole_47\NN\1740|of (r_nmod) use_45\NN\407535|between|the|fluconazole|and|development (r_nmod) relationship_42\NN\31921|a|probable|use (r_dobj) indicates_39\VBZ\952524|use|relationship|. (r_parataxis) continued_12\VBD\2367363|resolved|;|however|,|patient|have|:|indicates (l_xcomp) have_14\VB\2108377|to|contractions|days (l_dobj) contractions_17\NNS\358931|premature|ventricular|and|tachycardia
D015725_D018879 NONE fluconazole_39\NN\1740| (r_dobj) suggests_38\VBZ\1010118|was|strongly|fluconazole|etiology|. (l_ccomp) was_5\VBD\836236|patient|,|there|etiology|disappearance (l_dep) disappearance_19\NN\42757|the|complete|nsvt|followed (l_nmod) nsvt_21\NN\1740|of|and|contractions (l_conj) contractions_25\NNS\358931|premature|ventricular
D015725_D017180 NONE fluconazole_4\NN\1740| (r_nsubjpass) discontinued_6\VBN\2609764|when|fluconazole|was (r_advcl) resolved_2\VBD\352826|tdp|discontinued (r_ccomp) continued_12\VBD\2367363|resolved|;|however|,|patient|have|:|indicates (l_xcomp) have_14\VB\2108377|to|contractions|days (l_dobj) contractions_17\NNS\358931|premature|ventricular|and|tachycardia (l_conj) tachycardia_21\NN\14110674|nonsustained|ventricular|nsvt
D015725_D017180 NONE fluconazole_4\NN\1740| (r_nsubjpass) discontinued_6\VBN\2609764|when|fluconazole|was (r_advcl) resolved_2\VBD\352826|tdp|discontinued (r_ccomp) continued_12\VBD\2367363|resolved|;|however|,|patient|have|:|indicates (l_xcomp) have_14\VB\2108377|to|contractions|days (l_dobj) contractions_17\NNS\358931|premature|ventricular|and|tachycardia (l_conj) tachycardia_21\NN\14110674|nonsustained|ventricular|nsvt (l_appos) nsvt_23\NN\1740|(|)
D015725_D017180 NONE fluconazole_47\NN\1740|of (r_nmod) use_45\NN\407535|between|the|fluconazole|and|development (r_nmod) relationship_42\NN\31921|a|probable|use (r_dobj) indicates_39\VBZ\952524|use|relationship|. (r_parataxis) continued_12\VBD\2367363|resolved|;|however|,|patient|have|:|indicates (l_xcomp) have_14\VB\2108377|to|contractions|days (l_dobj) contractions_17\NNS\358931|premature|ventricular|and|tachycardia (l_conj) tachycardia_21\NN\14110674|nonsustained|ventricular|nsvt
D015725_D017180 NONE fluconazole_47\NN\1740|of (r_nmod) use_45\NN\407535|between|the|fluconazole|and|development (r_nmod) relationship_42\NN\31921|a|probable|use (r_dobj) indicates_39\VBZ\952524|use|relationship|. (r_parataxis) continued_12\VBD\2367363|resolved|;|however|,|patient|have|:|indicates (l_xcomp) have_14\VB\2108377|to|contractions|days (l_dobj) contractions_17\NNS\358931|premature|ventricular|and|tachycardia (l_conj) tachycardia_21\NN\14110674|nonsustained|ventricular|nsvt (l_appos) nsvt_23\NN\1740|(|)
D015725_D017180 NONE fluconazole_39\NN\1740| (r_dobj) suggests_38\VBZ\1010118|was|strongly|fluconazole|etiology|. (l_ccomp) was_5\VBD\836236|patient|,|there|etiology|disappearance (l_dep) disappearance_19\NN\42757|the|complete|nsvt|followed (l_nmod) nsvt_21\NN\1740|of|and|contractions
D011188_D003866 NONE potassium_10\NN\14625458| (r_compound) currents_11\NNS\11449002|of|activating|rectifier|potassium (r_nmod) depression_4\NN\14373582|mechanism|is|currents|.
D015725_D008133 NONE fluconazole_39\NN\1740| (r_dobj) suggests_38\VBZ\1010118|was|strongly|fluconazole|etiology|. (l_ccomp) was_5\VBD\836236|patient|,|there|etiology|disappearance (l_attr) etiology_8\NN\7326557|no|other|identified|explain (l_acl:relcl) explain_12\VB\831651|that|could|prolongation (l_dobj) prolongation_14\NN\1017987|qt|or|tdp
D015725_D008133 NONE fluconazole_7\NN\1740|,|doses (r_nsubj) cause_15\VB\1617192|that|fluconazole|,|may|prolongation (l_dobj) prolongation_16\NN\1017987|interval|,|leading (l_nmod) interval_20\NN\33615|of|the|qt
D015725_D001145 NONE fluconazole_7\NN\1740| (r_nsubjpass) administered_9\VBN\2436349|when|fluconazole|is|patients (l_nmod) patients_11\NNS\9898892|in|risk (l_nmod) risk_15\NN\14541044|at|arrhythmias (l_nmod) arrhythmias_18\NNS\14103288|for|ventricular
17943461
D015215_D009202 CID azt-induced_7\JJ\1740| (r_amod) cardiomyopathy_8\NN\14103288|to|azt-induced
D015215_D002311 CID zidovudine_12\NN\3834836|3'-azido-2',3'-deoxythymidine (r_dep) component_11\NN\5867413|the|haart|zidovudine (r_nsubj) triggers_18\VBZ\1641914|whether|component|pathway|and|cause|tg|and|received (l_conj) cause_24\VBP\1617192|disruption|model (l_nmod) model_30\NN\5888929|in|a|murine|dcm (l_nmod) dcm_32\NN\1740|of
D015215_D002311 CID 3'-azido-2',3'-deoxythymidine_14\NN\1740|(|azt (r_appos) zidovudine_12\NN\3834836|3'-azido-2',3'-deoxythymidine (r_dep) component_11\NN\5867413|the|haart|zidovudine (r_nsubj) triggers_18\VBZ\1641914|whether|component|pathway|and|cause|tg|and|received (l_conj) cause_24\VBP\1617192|disruption|model (l_nmod) model_30\NN\5888929|in|a|murine|dcm (l_nmod) dcm_32\NN\1740|of
D015215_D002311 CID azt_16\NN\3834836|;|) (r_appos) 3'-azido-2',3'-deoxythymidine_14\NN\1740|(|azt (r_appos) zidovudine_12\NN\3834836|3'-azido-2',3'-deoxythymidine (r_dep) component_11\NN\5867413|the|haart|zidovudine (r_nsubj) triggers_18\VBZ\1641914|whether|component|pathway|and|cause|tg|and|received (l_conj) cause_24\VBP\1617192|disruption|model (l_nmod) model_30\NN\5888929|in|a|murine|dcm (l_nmod) dcm_32\NN\1740|of
D015215_D002311 CID azt_61\NN\3834836|of (r_nmod) concentrations_59\NNS\4916342|different|azt|mg/ml (r_dobj) containing_57\VBG\2632940|concentrations (r_xcomp) received_53\VBD\2210855|mice|water|ad|libitum|containing (r_conj) triggers_18\VBZ\1641914|whether|component|pathway|and|cause|tg|and|received (l_conj) cause_24\VBP\1617192|disruption|model (l_nmod) model_30\NN\5888929|in|a|murine|dcm (l_nmod) dcm_32\NN\1740|of
D015215_D002311 CID azt-treated_3\JJ\1740| (r_amod) mice_6\NNS\2329401|azt-treated|fasl|tg (r_nsubj) developed_7\VBD\1753788|contrast|,|mice|dilation|depressed|infiltration|. (l_dobj) dilation_9\NN\7138085|cardiac|and
6153967
D004737_D012640 CID enflurane_4\NN\3299929|administered (r_nsubj) resulted_10\VBD\2633881|patient|,|enflurane|seizures|. (l_nmod) seizures_15\NNS\14081375|in|unexpected|partial|motor
D004737_D012640 CID enflurane_6\NN\3299929|by (r_nmod) activated_4\VBN\1641914|enflurane (r_conj) delineated_2\VBN\2137132|and|activated (r_acl) foci_1\NNS\5704266|epileptic|delineated (r_nsubjpass) ablated_9\VBN\469382|foci|were|surgically|and|seizure-free (l_conj) seizure-free_15\JJ\1740|patients|are|now|.
D004737_D004827 NONE enflurane_6\NN\3299929|by (r_nmod) activated_4\VBN\1641914|enflurane (r_conj) delineated_2\VBN\2137132|and|activated (r_acl) foci_1\NNS\5704266|epileptic|delineated (l_amod) epileptic_0\JJ\1740|
D004737_D004827 NONE enflurane_5\NN\3299929| (r_nsubj) prove_7\VB\2604760|hand|,|enflurane|may|activator|. (l_xcomp) activator_14\NN\19613|to|be|a|safe|acting|foci|corticography (l_nmod) foci_17\NNS\5704266|of|epileptic (l_amod) epileptic_16\JJ\1740|
20533999
D004298_D020258 NONE dopamine_0\NN\14807737| (r_nsubj) essential_3\JJ\1740|dopamine|is|not|development|. (l_nmod) development_6\NN\248977|for|the|neurotoxicity (l_nmod) neurotoxicity_9\NN\1740|of|methamphetamine-induced
D004298_D020258 NONE da_19\NN\10484858| (r_compound) neurotoxicity_20\NN\1740|on|meth-induced|da
D004298_D020258 NONE da_13\NN\10484858|in|brain (r_nmod) deficient_10\JJ\1740|to|be|da (r_xcomp) engineered_7\VBN\1639714|genetically|deficient (r_acl) mice_5\NNS\2329401|engineered (r_nsubj) develop_14\VBP\1753788|that|mice|neurotoxicity|,|long (l_dobj) neurotoxicity_16\NN\1740|meth
D004298_D020258 NONE da_7\NN\10484858| (r_nsubj) essential_10\JJ\1740|that|da|is|not|development (l_nmod) development_13\NN\248977|for|the|neurotoxicity (l_nmod) neurotoxicity_17\NN\1740|of|meth-induced|dopaminergic
D004298_D020258 NONE da_24\NN\10484858|of (r_nmod) independent_22\JJ\1740|da (r_amod) mechanisms_21\NNS\13446390|independent (r_nsubj) warrant_25\VBP\1012073|that|mechanisms|investigation (r_ccomp) suggest_19\VBP\1010118|warrant (r_conj) demonstrate_5\VBP\2137132|taken|,|findings|essential|and|suggest|. (l_ccomp) essential_10\JJ\1740|that|da|is|not|development (l_nmod) development_13\NN\248977|for|the|neurotoxicity (l_nmod) neurotoxicity_17\NN\1740|of|meth-induced|dopaminergic
D008694_D020258 CID methamphetamine-induced_8\JJ\1740| (r_amod) neurotoxicity_9\NN\1740|of|methamphetamine-induced
D008694_D020258 CID meth-induced_18\JJ\1740| (r_amod) neurotoxicity_20\NN\1740|on|meth-induced|da
D008694_D020258 CID meth_15\NN\2704153| (r_compound) neurotoxicity_16\NN\1740|meth
D008694_D020258 CID meth_25\NN\2704153|of (r_nmod) effects_23\NNS\13245626|the|thermic|meth (r_nsubjpass) preserved_27\VBN\2681795|as|effects|are (r_advcl) long_19\RB\1740|as|preserved (r_advmod) develop_14\VBP\1753788|that|mice|neurotoxicity|,|long (l_dobj) neurotoxicity_16\NN\1740|meth
D008694_D020258 CID meth-induced_15\JJ\1740| (r_amod) neurotoxicity_17\NN\1740|of|meth-induced|dopaminergic
D004298_D064420 NONE dopamine_5\NN\14807737|da (r_nsubj) mediates_9\VBZ\761713|that|dopamine|toxicity|,|decrease (l_dobj) toxicity_12\NN\13576101|methamphetamine|neurons
D004298_D064420 NONE dopamine_5\NN\14807737|da (r_nsubj) mediates_9\VBZ\761713|that|dopamine|toxicity|,|decrease (l_advcl) decrease_25\VBP\169651|because|drugs|toxicity|,|whereas|enhance (l_dobj) toxicity_26\NN\13576101|
D004298_D064420 NONE dopamine_5\NN\14807737|da (r_nsubj) mediates_9\VBZ\761713|that|dopamine|toxicity|,|decrease (l_advcl) decrease_25\VBP\169651|because|drugs|toxicity|,|whereas|enhance (l_ccomp) enhance_34\VBP\227165|drugs|toxicity (l_dobj) toxicity_35\NN\13576101|
D004298_D064420 NONE da_7\NN\10484858|(|) (r_appos) dopamine_5\NN\14807737|da (r_nsubj) mediates_9\VBZ\761713|that|dopamine|toxicity|,|decrease (l_dobj) toxicity_12\NN\13576101|methamphetamine|neurons
D004298_D064420 NONE da_7\NN\10484858|(|) (r_appos) dopamine_5\NN\14807737|da (r_nsubj) mediates_9\VBZ\761713|that|dopamine|toxicity|,|decrease (l_advcl) decrease_25\VBP\169651|because|drugs|toxicity|,|whereas|enhance (l_dobj) toxicity_26\NN\13576101|
D004298_D064420 NONE da_7\NN\10484858|(|) (r_appos) dopamine_5\NN\14807737|da (r_nsubj) mediates_9\VBZ\761713|that|dopamine|toxicity|,|decrease (l_advcl) decrease_25\VBP\169651|because|drugs|toxicity|,|whereas|enhance (l_ccomp) enhance_34\VBP\227165|drugs|toxicity (l_dobj) toxicity_35\NN\13576101|
D004298_D064420 NONE da_23\NN\10484858| (r_compound) neurotransmission_24\NN\1740|with|da (r_nmod) interfere_21\VBP\2451370|that|neurotransmission (r_acl:relcl) drugs_19\NNS\14778436|interfere (r_nsubj) decrease_25\VBP\169651|because|drugs|toxicity|,|whereas|enhance (r_advcl) mediates_9\VBZ\761713|that|dopamine|toxicity|,|decrease (l_dobj) toxicity_12\NN\13576101|methamphetamine|neurons
D004298_D064420 NONE da_23\NN\10484858| (r_compound) neurotransmission_24\NN\1740|with|da (r_nmod) interfere_21\VBP\2451370|that|neurotransmission (r_acl:relcl) drugs_19\NNS\14778436|interfere (r_nsubj) decrease_25\VBP\169651|because|drugs|toxicity|,|whereas|enhance (l_dobj) toxicity_26\NN\13576101|
D004298_D064420 NONE da_23\NN\10484858| (r_compound) neurotransmission_24\NN\1740|with|da (r_nmod) interfere_21\VBP\2451370|that|neurotransmission (r_acl:relcl) drugs_19\NNS\14778436|interfere (r_nsubj) decrease_25\VBP\169651|because|drugs|toxicity|,|whereas|enhance (l_ccomp) enhance_34\VBP\227165|drugs|toxicity (l_dobj) toxicity_35\NN\13576101|
D004298_D064420 NONE da_32\NN\10484858| (r_compound) neurotransmission_33\NN\1740|da (r_dobj) increase_31\VBP\169651|that|neurotransmission (r_acl:relcl) drugs_29\NNS\14778436|increase (r_nsubj) enhance_34\VBP\227165|drugs|toxicity (r_ccomp) decrease_25\VBP\169651|because|drugs|toxicity|,|whereas|enhance (r_advcl) mediates_9\VBZ\761713|that|dopamine|toxicity|,|decrease (l_dobj) toxicity_12\NN\13576101|methamphetamine|neurons
D004298_D064420 NONE da_32\NN\10484858| (r_compound) neurotransmission_33\NN\1740|da (r_dobj) increase_31\VBP\169651|that|neurotransmission (r_acl:relcl) drugs_29\NNS\14778436|increase (r_nsubj) enhance_34\VBP\227165|drugs|toxicity (r_ccomp) decrease_25\VBP\169651|because|drugs|toxicity|,|whereas|enhance (l_dobj) toxicity_26\NN\13576101|
D004298_D064420 NONE da_32\NN\10484858| (r_compound) neurotransmission_33\NN\1740|da (r_dobj) increase_31\VBP\169651|that|neurotransmission (r_acl:relcl) drugs_29\NNS\14778436|increase (r_nsubj) enhance_34\VBP\227165|drugs|toxicity (l_dobj) toxicity_35\NN\13576101|
D008694_D064420 NONE methamphetamine_10\NN\2704153|(meth)-induced (r_compound) toxicity_12\NN\13576101|methamphetamine|neurons
D008694_D064420 NONE methamphetamine_10\NN\2704153|(meth)-induced (r_compound) toxicity_12\NN\13576101|methamphetamine|neurons (r_dobj) mediates_9\VBZ\761713|that|dopamine|toxicity|,|decrease (l_advcl) decrease_25\VBP\169651|because|drugs|toxicity|,|whereas|enhance (l_dobj) toxicity_26\NN\13576101|
D008694_D064420 NONE methamphetamine_10\NN\2704153|(meth)-induced (r_compound) toxicity_12\NN\13576101|methamphetamine|neurons (r_dobj) mediates_9\VBZ\761713|that|dopamine|toxicity|,|decrease (l_advcl) decrease_25\VBP\169651|because|drugs|toxicity|,|whereas|enhance (l_ccomp) enhance_34\VBP\227165|drugs|toxicity (l_dobj) toxicity_35\NN\13576101|
D008694_D064420 NONE (meth)-induced_11\JJ\1740| (r_dep) methamphetamine_10\NN\2704153|(meth)-induced (r_compound) toxicity_12\NN\13576101|methamphetamine|neurons
D008694_D064420 NONE (meth)-induced_11\JJ\1740| (r_dep) methamphetamine_10\NN\2704153|(meth)-induced (r_compound) toxicity_12\NN\13576101|methamphetamine|neurons (r_dobj) mediates_9\VBZ\761713|that|dopamine|toxicity|,|decrease (l_advcl) decrease_25\VBP\169651|because|drugs|toxicity|,|whereas|enhance (l_dobj) toxicity_26\NN\13576101|
D008694_D064420 NONE (meth)-induced_11\JJ\1740| (r_dep) methamphetamine_10\NN\2704153|(meth)-induced (r_compound) toxicity_12\NN\13576101|methamphetamine|neurons (r_dobj) mediates_9\VBZ\761713|that|dopamine|toxicity|,|decrease (l_advcl) decrease_25\VBP\169651|because|drugs|toxicity|,|whereas|enhance (l_ccomp) enhance_34\VBP\227165|drugs|toxicity (l_dobj) toxicity_35\NN\13576101|
D007980_D020258 NONE l-dihydroxyphenylalanine_9\NN\1740|of (r_nmod) ability_7\NN\4723816|the|reported|l-dihydroxyphenylalanine|reverse (l_acl) reverse_11\VB\109660|to|effect (l_dobj) effect_14\NN\34213|the|protective|alpha-methyl-para-tyrosine|neurotoxicity (l_nmod) neurotoxicity_20\NN\1740|on|meth-induced|da
D019805_D020258 NONE alpha-methyl-para-tyrosine_16\NN\1740|of (r_nmod) effect_14\NN\34213|the|protective|alpha-methyl-para-tyrosine|neurotoxicity (l_nmod) neurotoxicity_20\NN\1740|on|meth-induced|da
D004298_D009461 NONE da_13\NN\10484858| (r_compound) deficits_14\NNS\5113133|unilateral|brain|da (r_dobj) have_10\VB\2108377|to|deficits (r_xcomp) engineered_8\VBN\1639714|genetically|have (r_acl) mice_6\NNS\2329401|engineered (r_nsubj) develop_15\VBP\1753788|that|mice|deficits (l_dobj) deficits_18\NNS\5113133|meth-induced|dopaminergic|magnitude
D008694_D009461 NONE meth-induced_16\JJ\1740| (r_amod) deficits_18\NNS\5113133|meth-induced|dopaminergic|magnitude
7752389
D015232_D053201 CID e2-induced_1\JJ\1740|prostaglandin (r_amod) hyperactivity_3\NN\14052403|e2-induced|bladder|rats|:|involvement
D015320_D053201 NONE tachykinins_12\NNS\1740|of (r_nmod) involvement_10\NN\1080366|tachykinins|? (r_appos) hyperactivity_3\NN\14052403|e2-induced|bladder|rats|:|involvement
D015320_D053201 NONE tachykinins_6\NNS\1740|of (r_nmod) release_4\NN\3748886|via|tachykinins (r_nmod) contribute_8\VB\126264|prostanoids|may|,|release|,|hyperactivity|. (l_nmod) hyperactivity_14\NN\14052403|to|urge|seen
D011453_D053201 NONE prostanoids_0\NNS\1740| (r_nsubj) contribute_8\VB\126264|prostanoids|may|,|release|,|hyperactivity|. (l_nmod) hyperactivity_14\NN\14052403|to|urge|seen
9799166
D003042_D020521 CID cocaine_2\NN\3492717|or|amphetamine (r_compound) use_5\NN\407535|cocaine (r_conj) stroke_0\NN\556313|and|use|.
D003042_D020521 CID cocaine_3\NN\3492717|and|amphetamine (r_compound) use_6\NN\407535|of|cocaine (r_nmod) association_1\NN\8008335|the|use|stroke (l_nmod) stroke_11\NN\556313|with|hemorrhagic
D003042_D020521 CID cocaine_11\NN\3492717|of|and/or|amphetamine (r_nmod) use_9\NN\407535|cocaine (r_conj) number_2\NN\5107765|the|limited|studies|and|use (l_nmod) studies_5\NNS\635850|of|epidemiologic|stroke (l_nmod) stroke_7\NN\556313|of
D003042_D020521 CID cocaine_13\NN\3492717|and/or|amphetamine (r_dobj) using_12\VBG\1156834|to|cocaine (r_advcl) admitted_10\VBD\822367|who|using (r_acl:relcl) women_8\NNS\9605289|in|admitted (r_nmod) stroke_6\NN\556313|for|women
D003042_D020521 CID cocaine_3\NN\3492717|of|and/or|amphetamine (r_nmod) use_1\NN\407535|the|cocaine (r_nsubj) factor_10\NN\7326557|use|is|a|strong|risk|stroke|population|. (l_nmod) stroke_12\NN\556313|for
D000661_D020521 CID amphetamine_4\NN\3248958| (r_conj) cocaine_2\NN\3492717|or|amphetamine (r_compound) use_5\NN\407535|cocaine (r_conj) stroke_0\NN\556313|and|use|.
D000661_D020521 CID amphetamine_5\NN\3248958| (r_conj) cocaine_3\NN\3492717|and|amphetamine (r_compound) use_6\NN\407535|of|cocaine (r_nmod) association_1\NN\8008335|the|use|stroke (l_nmod) stroke_11\NN\556313|with|hemorrhagic
D000661_D020521 CID amphetamine_13\NN\3248958| (r_conj) cocaine_11\NN\3492717|of|and/or|amphetamine (r_nmod) use_9\NN\407535|cocaine (r_conj) number_2\NN\5107765|the|limited|studies|and|use (l_nmod) studies_5\NNS\635850|of|epidemiologic|stroke (l_nmod) stroke_7\NN\556313|of
D000661_D020521 CID amphetamine_15\NN\3248958| (r_conj) cocaine_13\NN\3492717|and/or|amphetamine (r_dobj) using_12\VBG\1156834|to|cocaine (r_advcl) admitted_10\VBD\822367|who|using (r_acl:relcl) women_8\NNS\9605289|in|admitted (r_nmod) stroke_6\NN\556313|for|women
D000661_D020521 CID amphetamine_5\NN\3248958| (r_conj) cocaine_3\NN\3492717|of|and/or|amphetamine (r_nmod) use_1\NN\407535|the|cocaine (r_nsubj) factor_10\NN\7326557|use|is|a|strong|risk|stroke|population|. (l_nmod) stroke_12\NN\556313|for
D003042_D007511 NONE cocaine_3\NN\3492717|and|amphetamine (r_compound) use_6\NN\407535|of|cocaine (r_nmod) association_1\NN\8008335|the|use|stroke (l_nmod) stroke_11\NN\556313|with|hemorrhagic (l_amod) hemorrhagic_8\JJ\1740|and|ischemic (l_conj) ischemic_10\JJ\1740|
D000661_D007511 NONE amphetamine_5\NN\3248958| (r_conj) cocaine_3\NN\3492717|and|amphetamine (r_compound) use_6\NN\407535|of|cocaine (r_nmod) association_1\NN\8008335|the|use|stroke (l_nmod) stroke_11\NN\556313|with|hemorrhagic (l_amod) hemorrhagic_8\JJ\1740|and|ischemic (l_conj) ischemic_10\JJ\1740|
10840460
D003520_D003556 CID cyclophosphamide-induced_0\JJ\1740| (r_amod) cystitis_1\NN\14566129|cyclophosphamide-induced|rats|:
D003520_D003556 CID cyclophosphamide_0\NN\1740|cp|,|agent|acrolein|, (r_nsubjpass) used_25\VBN\1156834|cyclophosphamide|was|induce|. (l_xcomp) induce_27\VB\1627355|to|cystitis (l_dobj) cystitis_28\NN\14566129|
D003520_D003556 CID cp_2\NN\1740|(|) (r_appos) cyclophosphamide_0\NN\1740|cp|,|agent|acrolein|, (r_nsubjpass) used_25\VBN\1156834|cyclophosphamide|was|induce|. (l_xcomp) induce_27\VB\1627355|to|cystitis (l_dobj) cystitis_28\NN\14566129|
D003520_D003556 CID cp-induced_12\JJ\1740| (r_amod) cystitis_13\NN\14566129|of|cp-induced
D003520_D059265 NONE cyclophosphamide-induced_0\JJ\1740| (r_amod) cystitis_1\NN\14566129|cyclophosphamide-induced|rats|: (r_compound) approach_8\NN\940842|cystitis|behavioral|model|. (l_nmod) model_12\NN\5888929|to|a|new|pain (l_nmod) pain_15\NN\14299637|of|visceral
D003520_D059265 NONE cp-induced_12\JJ\1740| (r_amod) cystitis_13\NN\14566129|of|cp-induced (r_nmod) model_10\NN\5888929|this|experimental|cystitis (r_nsubj) model_20\NN\5888929|that|model|may|be|an|interesting|new|behavioral|pain|,|allowing (l_nmod) pain_24\NN\14299637|of|inflammatory|visceral
D000171_D003556 NONE acrolein_22\NN\14584765|metabolite (r_appos) cyclophosphamide_0\NN\1740|cp|,|agent|acrolein|, (r_nsubjpass) used_25\VBN\1156834|cyclophosphamide|was|induce|. (l_xcomp) induce_27\VB\1627355|to|cystitis (l_dobj) cystitis_28\NN\14566129|
D009020_D001523 NONE morphine_0\NN\2707683| (r_nsubj) reversed_2\VBD\109660|morphine|dose-dependently|disorders|. (l_dobj) disorders_5\NNS\14034177|these|behavioral
D009020_D004487 NONE morphine_6\NN\2707683|of (r_nmod) administration_4\NN\1133281|of|morphine (r_nmod) time_2\NN\7308889|at|the|administration (r_nmod) observed_24\VBN\2163746|time|,|modifications|were|. (l_nsubjpass) modifications_9\NNS\191142|histological|wall|,|edema|, (l_nmod) edema_21\NN\14315192|such|chorionic|layer
D003520_D010146 CID cp-induced_12\JJ\1740| (r_amod) cystitis_13\NN\14566129|of|cp-induced (r_nmod) model_10\NN\5888929|this|experimental|cystitis (r_nsubj) model_20\NN\5888929|that|model|may|be|an|interesting|new|behavioral|pain|,|allowing (l_advcl) allowing_26\VBG\797697|understanding (l_dobj) understanding_29\NN\5804793|a|better|syndromes|and|thus|approach (l_nmod) syndromes_33\NNS\5870365|of|these|painful
3950060
D000583_D007674 CID amikacin_10\NN\1740| (r_dobj) receiving_9\VBG\2210855|amikacin (r_acl) patients_8\NNS\9898892|in|receiving (r_nmod) nephrotoxicity_3\NN\1740|with|and|outcome|patients
D000583_D007674 CID amikacin_6\NN\1740|with (r_nmod) treated_4\VBN\2376958|amikacin (r_acl) patients_3\NNS\9898892|from|60|treated (r_nmod) data_0\NNS\7951464|patients (r_nsubjpass) analyzed_8\VBN\78760|data|were|factors|. (l_nmod) factors_10\NNS\7326557|for|associated (l_acl) associated_11\VBN\628491|nephrotoxicity (l_nmod) nephrotoxicity_13\NN\1740|with
9067481
C013440_D056486 NONE hemisuccinate_12\NN\1740|cholesteryl|salt (r_compound) administration_19\NN\1133281|hemisuccinate (r_nsubjpass) shown_23\VBN\2137132|addition|,|administration|has|also|been|protect|. (l_xcomp) protect_25\VB\1127795|to|rats|effects (l_nmod) effects_30\NNS\13245626|from|the|hepatotoxic|tetrachloride (l_amod) hepatotoxic_29\JJ\1740|
-1_D056486 NONE salt_15\NN\14818238|,|tris|cs (r_appos) hemisuccinate_12\NN\1740|cholesteryl|salt (r_compound) administration_19\NN\1133281|hemisuccinate (r_nsubjpass) shown_23\VBN\2137132|addition|,|administration|has|also|been|protect|. (l_xcomp) protect_25\VB\1127795|to|rats|effects (l_nmod) effects_30\NNS\13245626|from|the|hepatotoxic|tetrachloride (l_amod) hepatotoxic_29\JJ\1740|
-1_D056486 NONE cs_17\NN\14625458|(|) (r_appos) salt_15\NN\14818238|,|tris|cs (r_appos) hemisuccinate_12\NN\1740|cholesteryl|salt (r_compound) administration_19\NN\1133281|hemisuccinate (r_nsubjpass) shown_23\VBN\2137132|addition|,|administration|has|also|been|protect|. (l_xcomp) protect_25\VB\1127795|to|rats|effects (l_nmod) effects_30\NNS\13245626|from|the|hepatotoxic|tetrachloride (l_amod) hepatotoxic_29\JJ\1740|
-1_D056486 NONE cs_13\NN\14625458|of (r_nmod) dose_11\NN\3740161|with|a|single|cs|100mg/kg (r_nmod) pretreatment_2\NN\1740|a|24-h|rats|dose (r_nsubj) resulted_20\VBD\2633881|pretreatment|,|protection|. (l_nmod) protection_23\NN\407535|in|significant|effects (l_nmod) effects_27\NNS\13245626|against|the|hepatotoxic|ccl4|and|effect (l_amod) hepatotoxic_26\JJ\1740|
-1_D056486 NONE cs_3\NN\14625458| (r_compound) protection_4\NN\407535|of|cs (r_nmod) mechanism_1\NN\13446390|the|protection (r_nsubj) appear_7\VB\2604760|mechanism|does|not|dependent|)|. (l_xcomp) dependent_10\JJ\1740|to|be|inhibition|(|light (l_nmod) light_24\NN\11421401|in|protection (l_nmod) protection_27\NN\407535|of|the|observed (l_acl) observed_28\VBN\2163746|hepatotoxicity (l_nmod) hepatotoxicity_31\NN\1740|against|galactosamine
D002251_D056486 CID tetrachloride_33\NN\14818238|of|carbon|ccl4 (r_nmod) effects_30\NNS\13245626|from|the|hepatotoxic|tetrachloride (l_amod) hepatotoxic_29\JJ\1740|
D002251_D056486 CID ccl4_35\NN\1740|(|) (r_appos) tetrachloride_33\NN\14818238|of|carbon|ccl4 (r_nmod) effects_30\NNS\13245626|from|the|hepatotoxic|tetrachloride (l_amod) hepatotoxic_29\JJ\1740|
D002251_D056486 CID ccl4_29\NN\1740|of|,|chcl3|,|acetaminophen|and|galactosamine (r_nmod) effects_27\NNS\13245626|against|the|hepatotoxic|ccl4|and|effect (l_amod) hepatotoxic_26\JJ\1740|
-1_D064420 NONE cs_8\NN\14625458| (r_compound) cytoprotection_9\NN\1740|of|cs (r_nmod) mechanism_6\NN\13446390|of|the|cytoprotection (r_nmod) understanding_3\NN\5804793|our|mechanism (r_dobj) further_1\VB\2554922|to|understanding (r_advcl) examined_12\VBD\789138|further|,|we|rats|abilities|. (l_dobj) abilities_19\NNS\4723816|the|protective|cs|toxicity (l_nmod) toxicity_49\NN\13576101|against|acetaminophen-
-1_D064420 NONE cs_21\NN\14625458|of|and|form (r_nmod) abilities_19\NNS\4723816|the|protective|cs|toxicity (l_nmod) toxicity_49\NN\13576101|against|acetaminophen-
-1_D064420 NONE cs_28\NN\14625458|of|, (r_nmod) form_26\NN\6286395|the|non-hydrolyzable|ether|cs|acid|,|salt (r_conj) cs_21\NN\14625458|of|and|form (r_nmod) abilities_19\NNS\4723816|the|protective|cs|toxicity (l_nmod) toxicity_49\NN\13576101|against|acetaminophen-
-1_D064420 NONE salt_34\NN\14818238|tris|cse (r_appos) form_26\NN\6286395|the|non-hydrolyzable|ether|cs|acid|,|salt (r_conj) cs_21\NN\14625458|of|and|form (r_nmod) abilities_19\NNS\4723816|the|protective|cs|toxicity (l_nmod) toxicity_49\NN\13576101|against|acetaminophen-
-1_D064420 NONE cse_36\NN\8342039|(|) (r_appos) salt_34\NN\14818238|tris|cse (r_appos) form_26\NN\6286395|the|non-hydrolyzable|ether|cs|acid|,|salt (r_conj) cs_21\NN\14625458|of|and|form (r_nmod) abilities_19\NNS\4723816|the|protective|cs|toxicity (l_nmod) toxicity_49\NN\13576101|against|acetaminophen-
C103872_D064420 NONE acid_31\NN\14818238|gamma-cholesteryloxybutyric (r_conj) form_26\NN\6286395|the|non-hydrolyzable|ether|cs|acid|,|salt (r_conj) cs_21\NN\14625458|of|and|form (r_nmod) abilities_19\NNS\4723816|the|protective|cs|toxicity (l_nmod) toxicity_49\NN\13576101|against|acetaminophen-
D000082_D064420 NONE acetaminophen-_39\NN\1740|,|adriamycin-|,|tetrachloride-|,|chloroform-|and|galactosamine-induced (r_compound) toxicity_49\NN\13576101|against|acetaminophen-
D004317_D064420 NONE adriamycin-_41\NN\1740| (r_conj) acetaminophen-_39\NN\1740|,|adriamycin-|,|tetrachloride-|,|chloroform-|and|galactosamine-induced (r_compound) toxicity_49\NN\13576101|against|acetaminophen-
D002251_D064420 NONE tetrachloride-_44\NN\1740|carbon (r_conj) acetaminophen-_39\NN\1740|,|adriamycin-|,|tetrachloride-|,|chloroform-|and|galactosamine-induced (r_compound) toxicity_49\NN\13576101|against|acetaminophen-
D002725_D064420 NONE chloroform-_46\NN\1740| (r_conj) acetaminophen-_39\NN\1740|,|adriamycin-|,|tetrachloride-|,|chloroform-|and|galactosamine-induced (r_compound) toxicity_49\NN\13576101|against|acetaminophen-
D005688_D064420 NONE galactosamine-induced_48\JJ\1740| (r_conj) acetaminophen-_39\NN\1740|,|adriamycin-|,|tetrachloride-|,|chloroform-|and|galactosamine-induced (r_compound) toxicity_49\NN\13576101|against|acetaminophen-
-1_D066126 NONE cs_13\NN\14625458|of (r_nmod) dose_11\NN\3740161|with|a|single|cs|100mg/kg (r_nmod) pretreatment_2\NN\1740|a|24-h|rats|dose (r_nsubj) resulted_20\VBD\2633881|pretreatment|,|protection|. (l_nmod) protection_23\NN\407535|in|significant|effects (l_nmod) effects_27\NNS\13245626|against|the|hepatotoxic|ccl4|and|effect (l_conj) effect_45\NN\34213|against|the|lethal|administration (l_amod) lethal_39\JJ\1740|(|and|cardiotoxic (l_conj) cardiotoxic_43\JJ\1740|presumably|)
D002251_D066126 NONE ccl4_29\NN\1740|of|,|chcl3|,|acetaminophen|and|galactosamine (r_nmod) effects_27\NNS\13245626|against|the|hepatotoxic|ccl4|and|effect (l_conj) effect_45\NN\34213|against|the|lethal|administration (l_amod) lethal_39\JJ\1740|(|and|cardiotoxic (l_conj) cardiotoxic_43\JJ\1740|presumably|)
D002725_D056486 CID chcl3_31\NN\1740| (r_conj) ccl4_29\NN\1740|of|,|chcl3|,|acetaminophen|and|galactosamine (r_nmod) effects_27\NNS\13245626|against|the|hepatotoxic|ccl4|and|effect (l_amod) hepatotoxic_26\JJ\1740|
D002725_D066126 NONE chcl3_31\NN\1740| (r_conj) ccl4_29\NN\1740|of|,|chcl3|,|acetaminophen|and|galactosamine (r_nmod) effects_27\NNS\13245626|against|the|hepatotoxic|ccl4|and|effect (l_conj) effect_45\NN\34213|against|the|lethal|administration (l_amod) lethal_39\JJ\1740|(|and|cardiotoxic (l_conj) cardiotoxic_43\JJ\1740|presumably|)
D000082_D056486 CID acetaminophen_33\NN\2707683| (r_conj) ccl4_29\NN\1740|of|,|chcl3|,|acetaminophen|and|galactosamine (r_nmod) effects_27\NNS\13245626|against|the|hepatotoxic|ccl4|and|effect (l_amod) hepatotoxic_26\JJ\1740|
D000082_D066126 NONE acetaminophen_33\NN\2707683| (r_conj) ccl4_29\NN\1740|of|,|chcl3|,|acetaminophen|and|galactosamine (r_nmod) effects_27\NNS\13245626|against|the|hepatotoxic|ccl4|and|effect (l_conj) effect_45\NN\34213|against|the|lethal|administration (l_amod) lethal_39\JJ\1740|(|and|cardiotoxic (l_conj) cardiotoxic_43\JJ\1740|presumably|)
D005688_D056486 CID galactosamine_35\NN\1740| (r_conj) ccl4_29\NN\1740|of|,|chcl3|,|acetaminophen|and|galactosamine (r_nmod) effects_27\NNS\13245626|against|the|hepatotoxic|ccl4|and|effect (l_amod) hepatotoxic_26\JJ\1740|
D005688_D056486 CID galactosamine_30\NN\1740| (r_compound) hepatotoxicity_31\NN\1740|against|galactosamine
D005688_D066126 NONE galactosamine_35\NN\1740| (r_conj) ccl4_29\NN\1740|of|,|chcl3|,|acetaminophen|and|galactosamine (r_nmod) effects_27\NNS\13245626|against|the|hepatotoxic|ccl4|and|effect (l_conj) effect_45\NN\34213|against|the|lethal|administration (l_amod) lethal_39\JJ\1740|(|and|cardiotoxic (l_conj) cardiotoxic_43\JJ\1740|presumably|)
D004317_D056486 NONE adriamycin_47\NN\1740| (r_compound) administration_48\NN\1133281|of|adriamycin (r_nmod) effect_45\NN\34213|against|the|lethal|administration (r_conj) effects_27\NNS\13245626|against|the|hepatotoxic|ccl4|and|effect (l_amod) hepatotoxic_26\JJ\1740|
D004317_D066126 CID adriamycin_47\NN\1740| (r_compound) administration_48\NN\1133281|of|adriamycin (r_nmod) effect_45\NN\34213|against|the|lethal|administration (l_amod) lethal_39\JJ\1740|(|and|cardiotoxic (l_conj) cardiotoxic_43\JJ\1740|presumably|)
19893084
D005839_D058186 CID gentamicin_12\NN\2716866|by (r_nmod) induced_10\VBN\1627355|gentamicin (r_acl) failure_9\NN\66216|during|acute|renal|induced
10910842
D011239_D018908 CID prednisolone-induced_0\JJ\1740| (r_amod) dysfunction_2\NN\14204950|prednisolone-induced|muscle
D011239_D001284 NONE prednisolone-induced_0\JJ\1740| (r_amod) dysfunction_2\NN\14204950|prednisolone-induced|muscle (r_nsubjpass) caused_4\VBN\1617192|dysfunction|is|atrophy|than|. (l_nmod) atrophy_7\NN\14299637|more|by
D000109_D018908 NONE acetylcholine_11\NN\14807558| (r_compound) receptor_12\NN\5225602|acetylcholine (r_compound) expression_13\NN\4679549|by|altered|receptor (r_nmod) than_8\IN\1740|expression (r_prep) caused_4\VBN\1617192|dysfunction|is|atrophy|than|. (l_nsubjpass) dysfunction_2\NN\14204950|prednisolone-induced|muscle
D000109_D001284 NONE acetylcholine_11\NN\14807558| (r_compound) receptor_12\NN\5225602|acetylcholine (r_compound) expression_13\NN\4679549|by|altered|receptor (r_nmod) than_8\IN\1740|expression (r_prep) caused_4\VBN\1617192|dysfunction|is|atrophy|than|. (l_nmod) atrophy_7\NN\14299637|more|by
D014403_D013746 NONE d-tubocurarine_21\NN\1740|of (r_nmod) curves_19\NNS\13863771|the|dose-response|d-tubocurarine|muscle (r_conj) tensions_8\NNS\14375890|the|nerve-evoked|peak|twitch|,|tensions|,|and|fatigability|,|and|curves (l_conj) tensions_11\NNS\14375890|tetanic (l_amod) tetanic_10\JJ\1740|
D011239_D009468 NONE prednisolone_8\NN\2721538|after (r_nmod) dysfunction_6\NN\14204950|the|neuromuscular|prednisolone
D011239_D009133 CID prednisolone_8\NN\2721538|after (r_nmod) dysfunction_6\NN\14204950|the|neuromuscular|prednisolone (r_nsubj) dose-dependent_10\JJ\1740|that|dysfunction|is|,|and|derives (l_conj) derives_13\VBZ\634472|primarily|atrophy|and|derives (l_nmod) atrophy_17\NN\14299637|from|muscle
D000109_D009133 NONE acetylcholine_20\NN\14807558| (r_compound) receptor_21\NN\5225602|acetylcholine (r_compound) expression_22\NN\4679549|in|receptor (r_nmod) changes_18\NNS\7283608|from|expression (r_nmod) derive_15\VBP\634472|less|changes (r_conj) derive_9\VBP\634472|primarily|atrophy|and|derive (l_nmod) atrophy_13\NN\14299637|from|muscle
19135948
C107135_D006086 NONE everolimus_4\NN\1740|with|and|tacrolimus (r_nmod) prophylaxis_2\NN\1077350|graft-versus-host|disease|everolimus (l_compound) disease_1\NN\14061805|
C107135_D006504 CID everolimus_4\NN\1740|with|and|tacrolimus (r_nmod) prophylaxis_2\NN\1077350|graft-versus-host|disease|everolimus (r_nsubjpass) associated_8\VBN\628491|prophylaxis|is|incidence|:|results|. (l_nmod) incidence_12\NN\13821570|with|a|high|syndrome (l_nmod) syndrome_16\NN\5870365|of|sinusoidal|obstruction|and|microangiopathy
C107135_D014652 CID everolimus_4\NN\1740|with|and|tacrolimus (r_nmod) prophylaxis_2\NN\1077350|graft-versus-host|disease|everolimus (r_nsubjpass) associated_8\VBN\628491|prophylaxis|is|incidence|:|results|. (l_nmod) incidence_12\NN\13821570|with|a|high|syndrome (l_nmod) syndrome_16\NN\5870365|of|sinusoidal|obstruction|and|microangiopathy (l_conj) microangiopathy_18\NN\1740|
D016559_D006086 NONE tacrolimus_6\NN\1740| (r_conj) everolimus_4\NN\1740|with|and|tacrolimus (r_nmod) prophylaxis_2\NN\1077350|graft-versus-host|disease|everolimus (l_compound) disease_1\NN\14061805|
D016559_D006504 CID tacrolimus_6\NN\1740| (r_conj) everolimus_4\NN\1740|with|and|tacrolimus (r_nmod) prophylaxis_2\NN\1077350|graft-versus-host|disease|everolimus (r_nsubjpass) associated_8\VBN\628491|prophylaxis|is|incidence|:|results|. (l_nmod) incidence_12\NN\13821570|with|a|high|syndrome (l_nmod) syndrome_16\NN\5870365|of|sinusoidal|obstruction|and|microangiopathy
D016559_D014652 CID tacrolimus_6\NN\1740| (r_conj) everolimus_4\NN\1740|with|and|tacrolimus (r_nmod) prophylaxis_2\NN\1077350|graft-versus-host|disease|everolimus (r_nsubjpass) associated_8\VBN\628491|prophylaxis|is|incidence|:|results|. (l_nmod) incidence_12\NN\13821570|with|a|high|syndrome (l_nmod) syndrome_16\NN\5870365|of|sinusoidal|obstruction|and|microangiopathy (l_conj) microangiopathy_18\NN\1740|
D008727_D006086 NONE methotrexate_5\NN\2722166|with (r_nmod) combined_3\VBN\2630189|methotrexate (r_acl) inhibitor_2\NN\20090|a|calcineurin|combined (r_nsubj) prophylaxis_9\NN\1077350|inhibitor|is|the|standard|disease|. (l_nmod) disease_12\NN\14061805|for|graft-versus-host|gvhd|transplantation
D008727_D006086 NONE methotrexate_5\NN\2722166|with (r_nmod) combined_3\VBN\2630189|methotrexate (r_acl) inhibitor_2\NN\20090|a|calcineurin|combined (r_nsubj) prophylaxis_9\NN\1077350|inhibitor|is|the|standard|disease|. (l_nmod) disease_12\NN\14061805|for|graft-versus-host|gvhd|transplantation (l_appos) gvhd_14\NN\1740|(|)
C107135_D009190 NONE everolimus_6\NN\1740|of|and|tacrolimus (r_nmod) combination_4\NN\7951464|on|a|everolimus|patients (l_nmod) patients_11\NNS\9898892|in|24|age|syndrome (l_nmod) syndrome_22\NN\5870365|with|either|myelodysplastic|mds|or|leukemia|undergoing
C107135_D009190 NONE everolimus_6\NN\1740|of|and|tacrolimus (r_nmod) combination_4\NN\7951464|on|a|everolimus|patients (l_nmod) patients_11\NNS\9898892|in|24|age|syndrome (l_nmod) syndrome_22\NN\5870365|with|either|myelodysplastic|mds|or|leukemia|undergoing (l_appos) mds_24\NN\14622893|(|;|=|)
C107135_D015470 NONE everolimus_6\NN\1740|of|and|tacrolimus (r_nmod) combination_4\NN\7951464|on|a|everolimus|patients (l_nmod) patients_11\NNS\9898892|in|24|age|syndrome (l_nmod) syndrome_22\NN\5870365|with|either|myelodysplastic|mds|or|leukemia|undergoing (l_conj) leukemia_33\NN\14239918|acute|myeloid|aml
C107135_D015470 NONE everolimus_6\NN\1740|of|and|tacrolimus (r_nmod) combination_4\NN\7951464|on|a|everolimus|patients (l_nmod) patients_11\NNS\9898892|in|24|age|syndrome (l_nmod) syndrome_22\NN\5870365|with|either|myelodysplastic|mds|or|leukemia|undergoing (l_conj) leukemia_33\NN\14239918|acute|myeloid|aml (l_appos) aml_35\NN\1740|(|;|=
D016559_D009190 NONE tacrolimus_8\NN\1740| (r_conj) everolimus_6\NN\1740|of|and|tacrolimus (r_nmod) combination_4\NN\7951464|on|a|everolimus|patients (l_nmod) patients_11\NNS\9898892|in|24|age|syndrome (l_nmod) syndrome_22\NN\5870365|with|either|myelodysplastic|mds|or|leukemia|undergoing
D016559_D009190 NONE tacrolimus_8\NN\1740| (r_conj) everolimus_6\NN\1740|of|and|tacrolimus (r_nmod) combination_4\NN\7951464|on|a|everolimus|patients (l_nmod) patients_11\NNS\9898892|in|24|age|syndrome (l_nmod) syndrome_22\NN\5870365|with|either|myelodysplastic|mds|or|leukemia|undergoing (l_appos) mds_24\NN\14622893|(|;|=|)
D016559_D015470 NONE tacrolimus_8\NN\1740| (r_conj) everolimus_6\NN\1740|of|and|tacrolimus (r_nmod) combination_4\NN\7951464|on|a|everolimus|patients (l_nmod) patients_11\NNS\9898892|in|24|age|syndrome (l_nmod) syndrome_22\NN\5870365|with|either|myelodysplastic|mds|or|leukemia|undergoing (l_conj) leukemia_33\NN\14239918|acute|myeloid|aml
D016559_D015470 NONE tacrolimus_8\NN\1740| (r_conj) everolimus_6\NN\1740|of|and|tacrolimus (r_nmod) combination_4\NN\7951464|on|a|everolimus|patients (l_nmod) patients_11\NNS\9898892|in|24|age|syndrome (l_nmod) syndrome_22\NN\5870365|with|either|myelodysplastic|mds|or|leukemia|undergoing (l_conj) leukemia_33\NN\14239918|acute|myeloid|aml (l_appos) aml_35\NN\1740|(|;|=
3015327
D007538_D009422 CID isoniazid_6\NN\2716205| (r_compound) neuropathy_7\NN\14204950|in|experimental|isoniazid|rat
D007538_D009422 CID isoniazid_8\NN\2716205|of (r_nmod) dose_6\NN\3740161|by|a|single|isoniazid|rats (r_nmod) caused_2\VBN\1617192|dose (r_acl) neuropathy_1\NN\14204950|the|caused
1732442
D004317_D009202 CID adriamycin-induced_8\JJ\1740| (r_amod) cardiomyopathy_9\NN\14103288|in|adriamycin-induced
D004317_D009202 CID adriamycin-induced_5\JJ\1740| (r_amod) cardiomyopathy_6\NN\14103288|of|adriamycin-induced
D004317_D009202 CID adriamycin-induced_5\JJ\1740| (r_amod) cardiomyopathy_6\NN\14103288|of|adriamycin-induced (r_nmod) model_3\NN\5888929|a|rat|cardiomyopathy (r_dobj) using_0\VBG\1156834|model (r_advcl) tested_9\VBD\670261|using|,|we|hypothesis|. (l_dobj) hypothesis_11\NN\7162194|the|appear (l_acl) appear_19\VB\2604760|that|activity|may|and|exacerbated (l_conj) exacerbated_22\JJ\1740|be|dose-dependently|cardiomyopathy (l_nmod) cardiomyopathy_26\NN\14103288|in|adriamycin
D004317_D009202 CID adriamycin_25\NN\1740| (r_compound) cardiomyopathy_26\NN\14103288|in|adriamycin (r_nmod) exacerbated_22\JJ\1740|be|dose-dependently|cardiomyopathy (r_conj) appear_19\VB\2604760|that|activity|may|and|exacerbated (r_acl) hypothesis_11\NN\7162194|the|appear (r_dobj) tested_9\VBD\670261|using|,|we|hypothesis|. (l_advcl) using_0\VBG\1156834|model (l_dobj) model_3\NN\5888929|a|rat|cardiomyopathy (l_nmod) cardiomyopathy_6\NN\14103288|of|adriamycin-induced
D004317_D009202 CID adriamycin_25\NN\1740| (r_compound) cardiomyopathy_26\NN\14103288|in|adriamycin
D004317_D009202 CID adriamycin-induced_34\JJ\1740| (r_amod) cardiomyopathy_35\NN\14103288|of|adriamycin-induced (r_nmod) detection_32\NN\5708432|for|cardiomyopathy (r_nmod) method_30\NN\5616786|that|scintigraphy|may|be|a|useful|detection (r_ccomp) indicates_22\VBZ\952524|appearance|method|. (l_nsubj) appearance_1\NN\4723816|the|activity|presence (l_nmod) presence_10\NN\13954253|in|the|impairment (l_nmod) impairment_14\NN\7296428|of|slight|myocardial|degeneration|)
D004317_D009202 CID adriamycin-induced_34\JJ\1740| (r_amod) cardiomyopathy_35\NN\14103288|of|adriamycin-induced
D019797_D009202 NONE iodine-125-metaiodobenzylguanidine_11\NN\1740|with (r_nmod) detection_0\NN\5708432|activity|iodine-125-metaiodobenzylguanidine|. (l_nmod) activity_6\NN\30358|of|abnormal|cardiac|adrenergic|neuron|cardiomyopathy (l_nmod) cardiomyopathy_9\NN\14103288|in|adriamycin-induced
D019797_D009202 NONE mibg_24\NN\1740| (r_compound) scintigraphy_25\NN\1740|mibg (r_nsubj) method_30\NN\5616786|that|scintigraphy|may|be|a|useful|detection (r_ccomp) indicates_22\VBZ\952524|appearance|method|. (l_nsubj) appearance_1\NN\4723816|the|activity|presence (l_nmod) presence_10\NN\13954253|in|the|impairment (l_nmod) impairment_14\NN\7296428|of|slight|myocardial|degeneration|)
D019797_D009202 NONE mibg_24\NN\1740| (r_compound) scintigraphy_25\NN\1740|mibg (r_nsubj) method_30\NN\5616786|that|scintigraphy|may|be|a|useful|detection (l_nmod) detection_32\NN\5708432|for|cardiomyopathy (l_nmod) cardiomyopathy_35\NN\14103288|of|adriamycin-induced
D004317_C536522 NONE adriamycin_16\NN\1740| (r_compound) treatment_17\NN\654885|of|adriamycin (r_nmod) duration_14\NN\15113229|to|the|treatment|mg/kg (r_nmod) relation_11\NN\2137|in|duration (r_nmod) analyzed_9\VBN\78760|degree|was|relation|. (l_nsubjpass) degree_1\NN\4916342|the|degeneration (l_nmod) degeneration_4\NN\29677|of|vacuolar|cells (l_nmod) cells_7\NNS\3080309|of|myocardial
D004317_C536522 NONE adriamycin-induced_34\JJ\1740| (r_amod) cardiomyopathy_35\NN\14103288|of|adriamycin-induced (r_nmod) detection_32\NN\5708432|for|cardiomyopathy (r_nmod) method_30\NN\5616786|that|scintigraphy|may|be|a|useful|detection (r_ccomp) indicates_22\VBZ\952524|appearance|method|. (l_nsubj) appearance_1\NN\4723816|the|activity|presence (l_nmod) presence_10\NN\13954253|in|the|impairment (l_nmod) impairment_14\NN\7296428|of|slight|myocardial|degeneration|) (l_dep) degeneration_20\NN\29677|scattered|vacuolar
D019797_C536522 NONE mibg_24\NN\1740| (r_compound) scintigraphy_25\NN\1740|mibg (r_nsubj) method_30\NN\5616786|that|scintigraphy|may|be|a|useful|detection (r_ccomp) indicates_22\VBZ\952524|appearance|method|. (l_nsubj) appearance_1\NN\4723816|the|activity|presence (l_nmod) presence_10\NN\13954253|in|the|impairment (l_nmod) impairment_14\NN\7296428|of|slight|myocardial|degeneration|) (l_dep) degeneration_20\NN\29677|scattered|vacuolar
6115999
D001539_D006973 NONE bendrofluazide_3\NN\1740|to|and|propranolol (r_nmod) reactions_1\NNS\13446390|adverse|bendrofluazide|treatment|. (l_nmod) treatment_8\NN\654885|for|the|hypertension (l_nmod) hypertension_11\NN\14057371|of|mild
D001539_D006973 NONE bendrofluazide_21\NN\1740|,|propranolol|,|or|placebo (r_appos) one_15\CD\13741022|to|groups|:|bendrofluazide (r_nmod) allocated_13\VBN\2228698|participants|are|randomly|one|. (l_nsubjpass) participants_0\NNS\9816771|trial (l_nmod) trial_7\NN\786195|in|the|council|treatment|hypertension (l_nmod) hypertension_10\NN\14057371|for|mild
D011433_D006973 NONE propranolol_5\NN\1740| (r_conj) bendrofluazide_3\NN\1740|to|and|propranolol (r_nmod) reactions_1\NNS\13446390|adverse|bendrofluazide|treatment|. (l_nmod) treatment_8\NN\654885|for|the|hypertension (l_nmod) hypertension_11\NN\14057371|of|mild
D011433_D006973 NONE propranolol_23\NN\1740| (r_conj) bendrofluazide_21\NN\1740|,|propranolol|,|or|placebo (r_appos) one_15\CD\13741022|to|groups|:|bendrofluazide (r_nmod) allocated_13\VBN\2228698|participants|are|randomly|one|. (l_nsubjpass) participants_0\NNS\9816771|trial (l_nmod) trial_7\NN\786195|in|the|council|treatment|hypertension (l_nmod) hypertension_10\NN\14057371|for|mild
D001539_D007172 CID bendrofluazide_6\NN\1740| (r_compound) treatment_7\NN\654885|between|bendrofluazide|and|impotence (l_conj) impotence_9\NN\4723816|
D001539_D007172 CID bendrofluazide_6\NN\1740| (r_compound) treatment_7\NN\654885|between|bendrofluazide|and|impotence (r_nmod) association_4\NN\8008335|an|treatment (r_dobj) show_2\VBP\2137132|results|association|,|and|occurred (l_conj) occurred_14\VBD\2623529|impotence|also|frequently|patients|than|. (l_nsubj) impotence_12\NN\4723816|
D011433_D007172 CID propranolol_20\NN\1740| (r_dobj) taking_19\VBG\2367363|propranolol (r_acl) patients_18\NNS\9898892|in|taking (r_nmod) occurred_14\VBD\2623529|impotence|also|frequently|patients|than|. (r_conj) show_2\VBP\2137132|results|association|,|and|occurred (l_dobj) association_4\NN\8008335|an|treatment (l_nmod) treatment_7\NN\654885|between|bendrofluazide|and|impotence (l_conj) impotence_9\NN\4723816|
D011433_D007172 CID propranolol_20\NN\1740| (r_dobj) taking_19\VBG\2367363|propranolol (r_acl) patients_18\NNS\9898892|in|taking (r_nmod) occurred_14\VBD\2623529|impotence|also|frequently|patients|than|. (l_nsubj) impotence_12\NN\4723816|
D001539_D018149 CID bendrofluazide_23\NN\1740| (r_compound) treatment_24\NN\654885|with|bendrofluazide (r_nmod) associated_21\VBN\628491|treatment (r_acl) gout_17\NN\14186541|men|,|associated (r_conj) tolerance_11\NN\5032565|impaired|glucose|men|and|gout|,|and|phenomenon
D001539_D006073 CID bendrofluazide_23\NN\1740| (r_compound) treatment_24\NN\654885|with|bendrofluazide (r_nmod) associated_21\VBN\628491|treatment (r_acl) gout_17\NN\14186541|men|,|associated
D001539_D011928 NONE bendrofluazide_23\NN\1740| (r_compound) treatment_24\NN\654885|with|bendrofluazide (r_nmod) associated_21\VBN\628491|treatment (r_acl) gout_17\NN\14186541|men|,|associated (r_conj) tolerance_11\NN\5032565|impaired|glucose|men|and|gout|,|and|phenomenon (l_conj) phenomenon_29\NN\29677|raynaud|and|dyspnoea
D001539_D004417 NONE bendrofluazide_23\NN\1740| (r_compound) treatment_24\NN\654885|with|bendrofluazide (r_nmod) associated_21\VBN\628491|treatment (r_acl) gout_17\NN\14186541|men|,|associated (r_conj) tolerance_11\NN\5032565|impaired|glucose|men|and|gout|,|and|phenomenon (l_conj) phenomenon_29\NN\29677|raynaud|and|dyspnoea (l_conj) dyspnoea_31\NN\14299637|men
D011433_D018149 NONE propranolol_37\NN\1740| (r_dobj) taking_36\VBG\2367363|propranolol (r_acl) men_33\NNS\8208016|in|and|women|taking (r_nmod) dyspnoea_31\NN\14299637|men (r_conj) phenomenon_29\NN\29677|raynaud|and|dyspnoea (r_conj) tolerance_11\NN\5032565|impaired|glucose|men|and|gout|,|and|phenomenon
D011433_D006073 NONE propranolol_37\NN\1740| (r_dobj) taking_36\VBG\2367363|propranolol (r_acl) men_33\NNS\8208016|in|and|women|taking (r_nmod) dyspnoea_31\NN\14299637|men (r_conj) phenomenon_29\NN\29677|raynaud|and|dyspnoea (r_conj) tolerance_11\NN\5032565|impaired|glucose|men|and|gout|,|and|phenomenon (l_conj) gout_17\NN\14186541|men|,|associated
D011433_D011928 CID propranolol_37\NN\1740| (r_dobj) taking_36\VBG\2367363|propranolol (r_acl) men_33\NNS\8208016|in|and|women|taking (r_nmod) dyspnoea_31\NN\14299637|men (r_conj) phenomenon_29\NN\29677|raynaud|and|dyspnoea
D011433_D004417 CID propranolol_37\NN\1740| (r_dobj) taking_36\VBG\2367363|propranolol (r_acl) men_33\NNS\8208016|in|and|women|taking (r_nmod) dyspnoea_31\NN\14299637|men
D011433_D003316 NONE propranolol_10\NN\1740| (r_compound) group_11\NN\2137|in|the|propranolol (r_nmod) occurred_7\VBN\2623529|to|have|group (r_xcomp) known_4\VBN\2110220|disease|is|occurred|. (l_nsubjpass) disease_2\NN\14061805|no|corneal
12180796
D009569_D009369 NONE oxide_7\NN\14818238|of|nitric|inos (r_nmod) type_4\NN\5839024|on|inducible|oxide|,|factor|and|factor-beta1|arteritis (l_conj) factor-beta1_22\NN\1740|tumor|growth|tgf-beta1 (l_compound) tumor_20\NN\14234074|
D009569_D009369 NONE oxide_21\NN\14818238| (r_compound) synthase_22\NN\1740|of|nitric|oxide|inos (r_nmod) type_18\NN\5839024|of|inducible|synthase|,|factor|and|factor-beta1 (l_conj) factor-beta1_37\NN\1740|tumor|growth|tgf-beta1 (l_compound) tumor_35\NN\14234074|
D009569_D001167 NONE oxide_7\NN\14818238|of|nitric|inos (r_nmod) type_4\NN\5839024|on|inducible|oxide|,|factor|and|factor-beta1|arteritis (l_nmod) arteritis_27\NN\14336539|in|induced
D009569_D001167 NONE oxide_21\NN\14818238| (r_compound) synthase_22\NN\1740|of|nitric|oxide|inos (r_nmod) type_18\NN\5839024|of|inducible|synthase|,|factor|and|factor-beta1 (r_nmod) expressions_15\NNS\4679549|for|type (r_nmod) examined_12\VBN\789138|arteritis|was|immunohistochemically|expressions|. (l_nsubjpass) arteritis_0\NN\14336539|induced|,
D018818_D009369 NONE fenoldopam_32\NN\1740|by|and|theophylline|,|vasodilators (r_nmod) induced_28\VBN\1627355|rats|fenoldopam (r_acl) arteritis_27\NN\14336539|in|induced (r_nmod) type_4\NN\5839024|on|inducible|oxide|,|factor|and|factor-beta1|arteritis (l_conj) factor-beta1_22\NN\1740|tumor|growth|tgf-beta1 (l_compound) tumor_20\NN\14234074|
D018818_D009369 NONE fenoldopam_7\NN\1740|and|theophylline (r_appos) vasodilators_5\NNS\3198383|by|,|fenoldopam (r_nmod) induced_1\VBN\1627355|rats|vasodilators (r_acl) arteritis_0\NN\14336539|induced|, (r_nsubjpass) examined_12\VBN\789138|arteritis|was|immunohistochemically|expressions|. (l_nmod) expressions_15\NNS\4679549|for|type (l_nmod) type_18\NN\5839024|of|inducible|synthase|,|factor|and|factor-beta1 (l_conj) factor-beta1_37\NN\1740|tumor|growth|tgf-beta1 (l_compound) tumor_35\NN\14234074|
D018818_D001167 CID fenoldopam_32\NN\1740|by|and|theophylline|,|vasodilators (r_nmod) induced_28\VBN\1627355|rats|fenoldopam (r_acl) arteritis_27\NN\14336539|in|induced
D018818_D001167 CID fenoldopam_7\NN\1740|and|theophylline (r_appos) vasodilators_5\NNS\3198383|by|,|fenoldopam (r_nmod) induced_1\VBN\1627355|rats|vasodilators (r_acl) arteritis_0\NN\14336539|induced|,
D013806_D009369 NONE theophylline_34\NN\2905612| (r_conj) fenoldopam_32\NN\1740|by|and|theophylline|,|vasodilators (r_nmod) induced_28\VBN\1627355|rats|fenoldopam (r_acl) arteritis_27\NN\14336539|in|induced (r_nmod) type_4\NN\5839024|on|inducible|oxide|,|factor|and|factor-beta1|arteritis (l_conj) factor-beta1_22\NN\1740|tumor|growth|tgf-beta1 (l_compound) tumor_20\NN\14234074|
D013806_D009369 NONE theophylline_9\NN\2905612| (r_conj) fenoldopam_7\NN\1740|and|theophylline (r_appos) vasodilators_5\NNS\3198383|by|,|fenoldopam (r_nmod) induced_1\VBN\1627355|rats|vasodilators (r_acl) arteritis_0\NN\14336539|induced|, (r_nsubjpass) examined_12\VBN\789138|arteritis|was|immunohistochemically|expressions|. (l_nmod) expressions_15\NNS\4679549|for|type (l_nmod) type_18\NN\5839024|of|inducible|synthase|,|factor|and|factor-beta1 (l_conj) factor-beta1_37\NN\1740|tumor|growth|tgf-beta1 (l_compound) tumor_35\NN\14234074|
D013806_D001167 CID theophylline_34\NN\2905612| (r_conj) fenoldopam_32\NN\1740|by|and|theophylline|,|vasodilators (r_nmod) induced_28\VBN\1627355|rats|fenoldopam (r_acl) arteritis_27\NN\14336539|in|induced
D013806_D001167 CID theophylline_9\NN\2905612| (r_conj) fenoldopam_7\NN\1740|and|theophylline (r_appos) vasodilators_5\NNS\3198383|by|,|fenoldopam (r_nmod) induced_1\VBN\1627355|rats|vasodilators (r_acl) arteritis_0\NN\14336539|induced|,
8045270
C081198_D002375 NONE kf17837_3\NN\1740|of|mg/kg (r_nmod) administration_1\NN\1133281|oral|kf17837 (r_nsubj) ameliorated_13\VBD\126264|administration|significantly|responses|,|manner|. (l_dobj) responses_16\NNS\11410625|the|cataleptic|induced (l_amod) cataleptic_15\JJ\1740|
C081198_D002375 NONE kf17837_0\NN\1740| (r_nsubj) reduced_2\VBD\441445|kf17837|also|catalepsy|. (l_dobj) catalepsy_4\NN\14023236|the|induced
D000241_D002375 NONE adenosine_23\NN\14964367| (r_compound) agonist_26\NN\9613191|of|an|adenosine|a2a|receptor|,|cgs (r_nmod) administration_20\NN\1133281|by|intracerebroventricular|agonist (r_nmod) induced_17\VBN\1627355|administration (r_acl) responses_16\NNS\11410625|the|cataleptic|induced (l_amod) cataleptic_15\JJ\1740|
C061282_D002375 CID 21680_29\CD\1740| (r_nummod) cgs_28\NN\13577934|21680|micrograms (r_appos) agonist_26\NN\9613191|of|an|adenosine|a2a|receptor|,|cgs (r_nmod) administration_20\NN\1133281|by|intracerebroventricular|agonist (r_nmod) induced_17\VBN\1627355|administration (r_acl) responses_16\NNS\11410625|the|cataleptic|induced (l_amod) cataleptic_15\JJ\1740|
D006220_D002375 CID haloperidol_7\NN\3713736|by|mg/kg|and|reserpine (r_nmod) induced_5\VBN\1627355|haloperidol (r_acl) catalepsy_4\NN\14023236|the|induced
D012110_D002375 CID reserpine_15\NN\2721160|by|mg/kg (r_conj) haloperidol_7\NN\3713736|by|mg/kg|and|reserpine (r_nmod) induced_5\VBN\1627355|haloperidol (r_acl) catalepsy_4\NN\14023236|the|induced
C081198_D010302 NONE kf17837_2\NN\1740| (r_nsubj) drug_7\NN\14778436|furthermore|,|kf17837|may|be|a|useful|treatment|. (l_nmod) treatment_10\NN\654885|in|the|parkinsonism (l_nmod) parkinsonism_12\NN\14085708|of
9105126
D013256_D018658 CID steroid_7\NN\14727670| (r_compound) therapy_8\NN\657604|with|long-term|steroid (r_nmod) associated_4\VBN\628491|therapy (r_acl) defect_3\NN\14462666|postinfarction|ventricular|septal|associated|.
D013256_D018658 CID steroid_11\NN\14727670| (r_compound) therapy_12\NN\657604|on|long-term|steroid (r_nmod) patients_8\NNS\9898892|in|therapy (r_nmod) rupture_6\NN\14285662|of|postinfarction|ventricular|septal|patients
D013256_D018658 CID steroid_4\NN\14727670| (r_compound) therapy_5\NN\657604|between|steroid|and|rupture (l_conj) rupture_10\NN\14285662|subsequent|postinfarction|septal
18657397
D010406_D004827 NONE penicillin-induced_5\JJ\1740| (r_amod) activity_7\NN\30358|of|penicillin-induced|epileptiform|rats
D010406_D004827 NONE penicillin_0\NN\2716866| (r_compound) model_1\NN\5888929|penicillin (r_nsubj) model_7\NN\5888929|model|is|a|used|experimental|research|. (l_nmod) research_10\NN\633864|for|epilepsy (l_compound) epilepsy_9\NN\14085708|
D010406_D004827 NONE penicillin-induced_13\JJ\1740| (r_amod) activity_15\NN\30358|of|penicillin-induced|epileptiform
D010406_D004827 NONE penicillin-induced_7\JJ\1740| (r_amod) periods_10\NNS\13575869|the|penicillin-induced|epileptiform|activity (l_compound) activity_9\NN\30358|
D010400_D004827 CID potassium_18\NN\14625458|400iu/2|microl|penicillin-g (r_dobj) injecting_14\VBG\81072|by|potassium|ventricle|recorded (r_advcl) induced_12\VBN\1627355|period|,|focus|was|injecting|. (l_nsubjpass) focus_10\NN\5704266|epileptic (l_amod) epileptic_9\JJ\1740|
16132524
D017239_D005909 NONE paclitaxel/carboplatin_3\NN\1740| (r_compound) phases_7\NNS\15113229|(|paclitaxel/carboplatin|liquid|crystalline|cubic|) (r_appos) chemotherapy_1\NN\661091|intracavitary|phases|glioblastoma|--|observations (l_nmod) glioblastoma_11\NN\14236743|for|recurrent
D017239_D005909 NONE paclitaxel_19\NN\1740|of|and|carboplatin|encapsulated (r_nmod) application_17\NN\947128|of|a|surgical|intracavitary|paclitaxel (r_nmod) feasibility_6\NN\5152150|the|,|safety|,|and|effects|application (r_nsubjpass) examined_29\VBN\789138|recurrences|,|feasibility|are|study|. (l_nmod) recurrences_3\NNS\7342049|for|human|glioblastoma (l_compound) glioblastoma_2\NN\14236743|
D017239_D005909 NONE paclitaxel_20\NN\1740|of|and|carboplatin (r_nmod) application_18\NN\947128|an|intracavitary|paclitaxel|phases (r_dobj) received_15\VBD\2210855|application|dosages (r_conj) underwent_12\VBD\109660|total|re-resection|and|received|. (l_nsubj) total_1\NN\3553|a|patients (l_nmod) patients_4\NNS\9898892|of|12|recurrence (l_nmod) recurrence_7\NN\7342049|with|a|multiforme (l_nmod) multiforme_11\NN\1740|of|a|glioblastoma (l_compound) glioblastoma_10\NN\14236743|
D016190_D005909 NONE paclitaxel/carboplatin_3\NN\1740| (r_compound) phases_7\NNS\15113229|(|paclitaxel/carboplatin|liquid|crystalline|cubic|) (r_appos) chemotherapy_1\NN\661091|intracavitary|phases|glioblastoma|--|observations (l_nmod) glioblastoma_11\NN\14236743|for|recurrent
D016190_D005909 NONE carboplatin_21\NN\1740| (r_conj) paclitaxel_19\NN\1740|of|and|carboplatin|encapsulated (r_nmod) application_17\NN\947128|of|a|surgical|intracavitary|paclitaxel (r_nmod) feasibility_6\NN\5152150|the|,|safety|,|and|effects|application (r_nsubjpass) examined_29\VBN\789138|recurrences|,|feasibility|are|study|. (l_nmod) recurrences_3\NNS\7342049|for|human|glioblastoma (l_compound) glioblastoma_2\NN\14236743|
D016190_D005909 NONE carboplatin_22\NN\1740| (r_conj) paclitaxel_20\NN\1740|of|and|carboplatin (r_nmod) application_18\NN\947128|an|intracavitary|paclitaxel|phases (r_dobj) received_15\VBD\2210855|application|dosages (r_conj) underwent_12\VBD\109660|total|re-resection|and|received|. (l_nsubj) total_1\NN\3553|a|patients (l_nmod) patients_4\NNS\9898892|of|12|recurrence (l_nmod) recurrence_7\NN\7342049|with|a|multiforme (l_nmod) multiforme_11\NN\1740|of|a|glioblastoma (l_compound) glioblastoma_10\NN\14236743|
D017239_D001929 CID paclitaxel_9\NN\1740|mg (r_dobj) received_4\VBD\2210855|six|paclitaxel|and|suffered|,|received|. (l_conj) suffered_11\VBD\2110220|edema (l_nmod) edema_17\NN\14315192|from|severe|brain
D017239_D001929 CID paclitaxel_30\NN\1740|of|mg (r_nmod) total_26\NN\3553|only|a|paclitaxel (r_dobj) received_23\VBD\2210855|while|patients|total (r_advcl) received_4\VBD\2210855|six|paclitaxel|and|suffered|,|received|. (l_conj) suffered_11\VBD\2110220|edema (l_nmod) edema_17\NN\14315192|from|severe|brain
3001299
D008094_D018500 NONE lithium_22\NN\14625458| (r_compound) treatment_23\NN\654885|during|lithium (r_nmod) hypothyroidism_20\NN\14059928|treatment (r_conj) insipidus_18\NN\1740|of|both|nephrogenic|diabetes|and|hypothyroidism
D008094_D007037 CID lithium_22\NN\14625458| (r_compound) treatment_23\NN\654885|during|lithium (r_nmod) hypothyroidism_20\NN\14059928|treatment
D008094_D007037 CID lithium_9\NN\14625458| (r_dobj) taking_8\VBG\2367363|while|they|were|lithium (r_advcl) developed_1\VBD\1753788|hypothyroidism|patients|taking|. (l_nsubj) hypothyroidism_0\NN\14059928|
1415380
D011803_D006463 CID quinine_6\NN\2721948|of (r_nmod) ingestion_4\NN\13440063|with|quinine (r_nmod) associated_2\VBN\628491|ingestion (r_acl) syndrome_1\NN\5870365|hemolytic-uremic|associated|.
D011803_D006463 CID quinine_3\NN\2721948| (r_compound) ingestion_4\NN\13440063|quinine (r_dobj) following_2\VBG\1835496|ingestion (r_acl) syndrome_1\NN\5870365|hemolytic-uremic|following
D011803_D006463 CID quinine-associated_0\JJ\1740| (r_amod) syndrome_2\NN\5870365|quinine-associated|hemolytic-uremic
6111982
D011433_D001145 NONE propranolol_6\NN\1740|of|and|pindolol|inhibiting (l_acl) inhibiting_9\VBG\2510337|arrhythmia|dogs (l_dobj) arrhythmia_12\NN\14103288|the|ouabain
D010869_D001145 NONE pindolol_8\NN\2832168| (r_conj) propranolol_6\NN\1740|of|and|pindolol|inhibiting (l_acl) inhibiting_9\VBG\2510337|arrhythmia|dogs (l_dobj) arrhythmia_12\NN\14103288|the|ouabain
D010042_D001145 CID ouabain_11\NN\1740| (r_compound) arrhythmia_12\NN\14103288|the|ouabain
11912119
D007980_D004409 CID levodopa-induced_3\JJ\1740| (r_amod) dyskinesias_4\NNS\14084880|levodopa-induced
D007980_D004409 CID levodopa_18\NN\14604959| (r_compound) therapy_19\NN\657604|of|levodopa (r_nmod) complications_16\NNS\1073995|to|motor|therapy|,|dyskinesias (l_nmod) dyskinesias_24\NNS\14084880|particularly|to|levodopa-induced|lid
D007980_D004409 CID levodopa_18\NN\14604959| (r_compound) therapy_19\NN\657604|of|levodopa (r_nmod) complications_16\NNS\1073995|to|motor|therapy|,|dyskinesias (l_nmod) dyskinesias_24\NNS\14084880|particularly|to|levodopa-induced|lid (l_appos) lid_26\NN\5313679|(|)
D007980_D004409 CID levodopa-induced_23\JJ\1740| (r_amod) dyskinesias_24\NNS\14084880|particularly|to|levodopa-induced|lid
D007980_D004409 CID levodopa-induced_23\JJ\1740| (r_amod) dyskinesias_24\NNS\14084880|particularly|to|levodopa-induced|lid (l_appos) lid_26\NN\5313679|(|)
D007980_D004409 CID levodopa-induced_23\JJ\1740| (r_amod) dyskinesias_24\NNS\14084880|levodopa-induced|disease (r_nmod) patients_8\NNS\9898892|of|parkinson|disease|with|dyskinesias (l_dep) with_9\IN\1740|disease (l_dep) disease_13\NN\14061805|(|parkinson|'s|+|lid|=|)|and|without (l_conj) lid_15\NN\5313679|,
D007980_D004409 CID levodopa-induced_23\JJ\1740| (r_amod) dyskinesias_24\NNS\14084880|levodopa-induced|disease
D007980_D004409 CID levodopa-induced_23\JJ\1740| (r_amod) dyskinesias_24\NNS\14084880|levodopa-induced|disease (l_dep) disease_28\NN\14061805|(|parkinson|'s|lid|,|and|controls (l_appos) lid_30\NN\5313679|-|,|=|)
D007980_D004409 CID levodopa_26\NN\14604959| (r_nmod) assessed_22\VBN\670261|score|were|on|levodopa|. (l_nsubjpass) score_2\NN\5736149|the|motor|scale|,|score (l_conj) score_14\NN\5736149|a|dyskinesia|and|force (l_compound) dyskinesia_13\NN\14084880|
D007980_D004409 CID levodopa_21\NN\14604959|by (r_nmod) increased_19\VBN\169651|disease|,|force|was|significantly|levodopa|%|. (l_nmod) disease_3\NN\14061805|in|parkinson|'s|+|lid (l_conj) lid_5\NN\5313679|
D007980_D010300 NONE levodopa-induced_3\JJ\1740| (r_amod) dyskinesias_4\NNS\14084880|levodopa-induced (r_conj) overflow_1\NN\329227|force|and|dyskinesias|disease|. (l_nmod) disease_8\NN\14061805|in|parkinson
D007980_D010300 NONE levodopa_18\NN\14604959| (r_compound) therapy_19\NN\657604|of|levodopa (r_nmod) complications_16\NNS\1073995|to|motor|therapy|,|dyskinesias (r_nmod) relationship_13\NN\31921|its|complications (r_conj) coordination_3\NN\5640433|force|hand|and|relationship (l_nmod) hand_6\NN\5566919|of|the|disease (l_nmod) disease_10\NN\14061805|in|parkinson|'s
D007980_D010300 NONE levodopa-induced_23\JJ\1740| (r_amod) dyskinesias_24\NNS\14084880|particularly|to|levodopa-induced|lid (r_nmod) complications_16\NNS\1073995|to|motor|therapy|,|dyskinesias (r_nmod) relationship_13\NN\31921|its|complications (r_conj) coordination_3\NN\5640433|force|hand|and|relationship (l_nmod) hand_6\NN\5566919|of|the|disease (l_nmod) disease_10\NN\14061805|in|parkinson|'s
D007980_D010300 NONE levodopa-induced_23\JJ\1740| (r_amod) dyskinesias_24\NNS\14084880|levodopa-induced|disease (r_nmod) patients_8\NNS\9898892|of|parkinson|disease|with|dyskinesias (l_compound) disease_7\NN\14061805|'s
D007980_D010300 NONE levodopa-induced_23\JJ\1740| (r_amod) dyskinesias_24\NNS\14084880|levodopa-induced|disease (r_nmod) patients_8\NNS\9898892|of|parkinson|disease|with|dyskinesias (l_dep) with_9\IN\1740|disease (l_dep) disease_13\NN\14061805|(|parkinson|'s|+|lid|=|)|and|without
D007980_D010300 NONE levodopa-induced_23\JJ\1740| (r_amod) dyskinesias_24\NNS\14084880|levodopa-induced|disease (l_dep) disease_28\NN\14061805|(|parkinson|'s|lid|,|and|controls
D007980_D010300 NONE levodopa_26\NN\14604959| (r_nmod) assessed_22\VBN\670261|score|were|on|levodopa|. (l_nsubjpass) score_2\NN\5736149|the|motor|scale|,|score (l_nmod) scale_10\NNP\7260623|of|the|unified|parkinson|disease|rating (l_compound) disease_8\NNP\14061805|
D007980_D010300 NONE levodopa_21\NN\14604959|by (r_nmod) increased_19\VBN\169651|disease|,|force|was|significantly|levodopa|%|. (l_nmod) disease_3\NN\14061805|in|parkinson|'s|+|lid
9201797
D002354_D002375 NONE hydrochloride_5\NN\14817592|of|carteolol|,|antagonist|,|catalepsy (l_nmod) catalepsy_13\NN\14023236|on|neuroleptic-induced|rats
D002354_D002375 NONE carteolol_5\NN\1740|of|,|antagonist|,|catalepsy (l_nmod) catalepsy_13\NN\14023236|on|haloperidol-induced|rats
D002354_D002375 NONE carteolol_0\NN\1740|,|as|propranolol|, (r_nsubj) inhibited_9\VBD\2510337|carteolol|catalepsy|. (l_dobj) catalepsy_12\NN\14023236|the|haloperidol-induced
D002354_D002375 NONE carteolol_5\NN\1740| (r_nsubj) improves_6\VBZ\126264|that|carteolol|catalepsy|activity|and|expected (l_dobj) catalepsy_8\NN\14023236|haloperidol-induced
D006220_D002375 CID haloperidol-induced_12\JJ\1740| (r_amod) catalepsy_13\NN\14023236|on|haloperidol-induced|rats
D006220_D002375 CID haloperidol-induced_11\JJ\1740| (r_amod) catalepsy_12\NN\14023236|the|haloperidol-induced
D006220_D002375 CID haloperidol-induced_7\JJ\1740| (r_amod) catalepsy_8\NN\14023236|haloperidol-induced
D011433_D002375 NONE propranolol_24\NN\1740|of|and|biperiden (r_nmod) those_22\DT\1740|with|propranolol (r_nmod) compared_20\VBN\644583|those (r_conj) studied_18\VBN\630380|therefore|,|effects|were|behaviorally|and|compared|. (l_nsubjpass) effects_3\NNS\13245626|the|carteolol (l_nmod) carteolol_5\NN\1740|of|,|antagonist|,|catalepsy (l_nmod) catalepsy_13\NN\14023236|on|haloperidol-induced|rats
D011433_D002375 NONE propranolol_5\NN\1740|and|biperiden (r_conj) carteolol_0\NN\1740|,|as|propranolol|, (r_nsubj) inhibited_9\VBD\2510337|carteolol|catalepsy|. (l_dobj) catalepsy_12\NN\14023236|the|haloperidol-induced
D001712_D002375 NONE biperiden_26\NN\1740|,|antagonist (r_conj) propranolol_24\NN\1740|of|and|biperiden (r_nmod) those_22\DT\1740|with|propranolol (r_nmod) compared_20\VBN\644583|those (r_conj) studied_18\VBN\630380|therefore|,|effects|were|behaviorally|and|compared|. (l_nsubjpass) effects_3\NNS\13245626|the|carteolol (l_nmod) carteolol_5\NN\1740|of|,|antagonist|,|catalepsy (l_nmod) catalepsy_13\NN\14023236|on|haloperidol-induced|rats
D001712_D002375 NONE biperiden_7\NN\1740| (r_conj) propranolol_5\NN\1740|and|biperiden (r_conj) carteolol_0\NN\1740|,|as|propranolol|, (r_nsubj) inhibited_9\VBD\2510337|carteolol|catalepsy|. (l_dobj) catalepsy_12\NN\14023236|the|haloperidol-induced
D002354_D009069 NONE carteolol_0\NN\1740| (r_nsubj) evoke_3\VB\1617192|carteolol|did|not|signs|. (l_dobj) signs_8\NNS\6643763|postsynaptic|dopamine|receptor-stimulating|behavioral|stereotypy (l_nmod) stereotypy_11\NN\1740|such|and|hyperlocomotion|rats (l_conj) hyperlocomotion_13\NN\1740|
D004298_D009069 NONE dopamine_5\NN\14807737| (r_compound) signs_8\NNS\6643763|postsynaptic|dopamine|receptor-stimulating|behavioral|stereotypy (l_nmod) stereotypy_11\NN\1740|such|and|hyperlocomotion|rats (l_conj) hyperlocomotion_13\NN\1740|
D002354_D017109 NONE carteolol_5\NN\1740| (r_nsubj) improves_6\VBZ\126264|that|carteolol|catalepsy|activity|and|expected (l_conj) expected_16\VBN\670261|is|effective (l_xcomp) effective_19\JJ\1740|to|be|treatment|attenuating (l_nmod) treatment_22\NN\654885|in|the|akathisia (l_nmod) akathisia_24\NN\1740|of
D006220_D017109 NONE haloperidol-induced_7\JJ\1740| (r_amod) catalepsy_8\NN\14023236|haloperidol-induced (r_dobj) improves_6\VBZ\126264|that|carteolol|catalepsy|activity|and|expected (l_conj) expected_16\VBN\670261|is|effective (l_xcomp) effective_19\JJ\1740|to|be|treatment|attenuating (l_nmod) treatment_22\NN\654885|in|the|akathisia (l_nmod) akathisia_24\NN\1740|of
D004298_D002375 NONE dopamine_34\NN\14807737| (r_compound) activity_37\NN\30358|due|its|postsynaptic|dopamine|receptor|antagonistic (r_nmod) attenuating_26\VBG\224901|without|effects|activity (r_advcl) effective_19\JJ\1740|to|be|treatment|attenuating (r_xcomp) expected_16\VBN\670261|is|effective (r_conj) improves_6\VBZ\126264|that|carteolol|catalepsy|activity|and|expected (l_dobj) catalepsy_8\NN\14023236|haloperidol-induced
D004298_D017109 NONE dopamine_34\NN\14807737| (r_compound) activity_37\NN\30358|due|its|postsynaptic|dopamine|receptor|antagonistic (r_nmod) attenuating_26\VBG\224901|without|effects|activity (r_advcl) effective_19\JJ\1740|to|be|treatment|attenuating (l_nmod) treatment_22\NN\654885|in|the|akathisia (l_nmod) akathisia_24\NN\1740|of
3762968
D014042_D014899 CID tolazamide-induced_3\JJ\1740| (r_amod) encephalopathy_6\NN\14084880|in|tolazamide-induced|wernicke
D014042_D014899 CID tolazamide_22\NN\4353189|with (r_nmod) treated_20\VBN\2376958|when|tolazamide (r_advcl) developed_15\VBD\1753788|who|encephalopathy|treated (l_dobj) encephalopathy_18\NN\14084880|wernicke
D014042_D014899 CID tolazamide-induced_13\JJ\1740| (r_amod) encephalopathy_16\NN\14084880|with|tolazamide-induced|wernicke|'s
D013831_D003920 NONE thiamine-dependent_3\JJ\1740| (r_amod) enzyme_4\NN\14723628|a|thiamine-dependent|,|transketolase|, (r_dobj) studied_1\VBD\630380|we|enzyme|fibroblasts|,|delineate|. (l_nmod) fibroblasts_9\NNS\5447757|from|patient (l_nmod) patient_13\NN\9898892|of|a|diabetic|developed (l_amod) diabetic_12\JJ\1740|
D013831_D014899 NONE thiamine-dependent_3\JJ\1740| (r_amod) enzyme_4\NN\14723628|a|thiamine-dependent|,|transketolase|, (r_dobj) studied_1\VBD\630380|we|enzyme|fibroblasts|,|delineate|. (l_nmod) fibroblasts_9\NNS\5447757|from|patient (l_nmod) patient_13\NN\9898892|of|a|diabetic|developed (l_acl:relcl) developed_15\VBD\1753788|who|encephalopathy|treated (l_dobj) encephalopathy_18\NN\14084880|wernicke
D013831_D020915 NONE thiamine-dependent_3\JJ\1740| (r_amod) enzyme_4\NN\14723628|a|thiamine-dependent|,|transketolase|, (r_dobj) studied_1\VBD\630380|we|enzyme|fibroblasts|,|delineate|. (l_advcl) delineate_27\VB\2137132|in|to|had|,|reported (l_advcl) reported_48\VBN\831651|as|previously|syndrome (l_nmod) syndrome_52\NN\5870365|in|postalcoholic|wernicke-korsakoff
D014042_D003920 NONE tolazamide_22\NN\4353189|with (r_nmod) treated_20\VBN\2376958|when|tolazamide (r_advcl) developed_15\VBD\1753788|who|encephalopathy|treated (r_acl:relcl) patient_13\NN\9898892|of|a|diabetic|developed (l_amod) diabetic_12\JJ\1740|
D014042_D020915 NONE tolazamide_22\NN\4353189|with (r_nmod) treated_20\VBN\2376958|when|tolazamide (r_advcl) developed_15\VBD\1753788|who|encephalopathy|treated (r_acl:relcl) patient_13\NN\9898892|of|a|diabetic|developed (r_nmod) fibroblasts_9\NNS\5447757|from|patient (r_nmod) studied_1\VBD\630380|we|enzyme|fibroblasts|,|delineate|. (l_advcl) delineate_27\VB\2137132|in|to|had|,|reported (l_advcl) reported_48\VBN\831651|as|previously|syndrome (l_nmod) syndrome_52\NN\5870365|in|postalcoholic|wernicke-korsakoff
D014042_D020915 NONE tolazamide-induced_13\JJ\1740| (r_amod) encephalopathy_16\NN\14084880|with|tolazamide-induced|wernicke|'s (r_nmod) patient_11\NN\9898892|the|encephalopathy (r_conj) syndrome_8\NN\5870365|between|postalcoholic|wernicke-korsakoff|and|patient
D013835_D003920 NONE pyrophosphate_40\NN\15010703|for|thiamine|tpp (r_nmod) km_37\NN\13649268|[|high|pyrophosphate|] (r_appos) abnormality_34\NN\14034177|transketolase|km (r_dobj) had_32\VBD\2108377|if|patient|also|abnormality (r_ccomp) delineate_27\VB\2137132|in|to|had|,|reported (r_advcl) studied_1\VBD\630380|we|enzyme|fibroblasts|,|delineate|. (l_nmod) fibroblasts_9\NNS\5447757|from|patient (l_nmod) patient_13\NN\9898892|of|a|diabetic|developed (l_amod) diabetic_12\JJ\1740|
D013835_D003920 NONE tpp_42\NN\1740|(|) (r_appos) pyrophosphate_40\NN\15010703|for|thiamine|tpp (r_nmod) km_37\NN\13649268|[|high|pyrophosphate|] (r_appos) abnormality_34\NN\14034177|transketolase|km (r_dobj) had_32\VBD\2108377|if|patient|also|abnormality (r_ccomp) delineate_27\VB\2137132|in|to|had|,|reported (r_advcl) studied_1\VBD\630380|we|enzyme|fibroblasts|,|delineate|. (l_nmod) fibroblasts_9\NNS\5447757|from|patient (l_nmod) patient_13\NN\9898892|of|a|diabetic|developed (l_amod) diabetic_12\JJ\1740|
D013835_D003920 NONE tpp_28\NN\1740|for (r_nmod) km_26\NN\13649268|by|its|tpp (r_nmod) determined_23\VBN\1645601|as|km (r_advcl) had_19\VBD\2108377|that|patient|transketolase|determined (l_nsubj) patient_5\NN\9898892|the|above-mentioned|and|one (l_conj) one_7\CD\13741022|kindreds|history (l_nmod) kindreds_11\NNS\7950920|of|the|diabetic (l_amod) diabetic_10\JJ\1740|
D013835_D014899 NONE pyrophosphate_40\NN\15010703|for|thiamine|tpp (r_nmod) km_37\NN\13649268|[|high|pyrophosphate|] (r_appos) abnormality_34\NN\14034177|transketolase|km (r_dobj) had_32\VBD\2108377|if|patient|also|abnormality (r_ccomp) delineate_27\VB\2137132|in|to|had|,|reported (r_advcl) studied_1\VBD\630380|we|enzyme|fibroblasts|,|delineate|. (l_nmod) fibroblasts_9\NNS\5447757|from|patient (l_nmod) patient_13\NN\9898892|of|a|diabetic|developed (l_acl:relcl) developed_15\VBD\1753788|who|encephalopathy|treated (l_dobj) encephalopathy_18\NN\14084880|wernicke
D013835_D014899 NONE tpp_42\NN\1740|(|) (r_appos) pyrophosphate_40\NN\15010703|for|thiamine|tpp (r_nmod) km_37\NN\13649268|[|high|pyrophosphate|] (r_appos) abnormality_34\NN\14034177|transketolase|km (r_dobj) had_32\VBD\2108377|if|patient|also|abnormality (r_ccomp) delineate_27\VB\2137132|in|to|had|,|reported (r_advcl) studied_1\VBD\630380|we|enzyme|fibroblasts|,|delineate|. (l_nmod) fibroblasts_9\NNS\5447757|from|patient (l_nmod) patient_13\NN\9898892|of|a|diabetic|developed (l_acl:relcl) developed_15\VBD\1753788|who|encephalopathy|treated (l_dobj) encephalopathy_18\NN\14084880|wernicke
D013835_D014899 NONE tpp_28\NN\1740|for (r_nmod) km_26\NN\13649268|by|its|tpp (r_nmod) determined_23\VBN\1645601|as|km (r_advcl) had_19\VBD\2108377|that|patient|transketolase|determined (l_nsubj) patient_5\NN\9898892|the|above-mentioned|and|one (l_conj) one_7\CD\13741022|kindreds|history (l_nmod) history_14\NN\15120823|with|no|encephalopathy (l_nmod) encephalopathy_18\NN\14084880|of|wernicke
D013835_D020915 NONE pyrophosphate_40\NN\15010703|for|thiamine|tpp (r_nmod) km_37\NN\13649268|[|high|pyrophosphate|] (r_appos) abnormality_34\NN\14034177|transketolase|km (r_dobj) had_32\VBD\2108377|if|patient|also|abnormality (r_ccomp) delineate_27\VB\2137132|in|to|had|,|reported (l_advcl) reported_48\VBN\831651|as|previously|syndrome (l_nmod) syndrome_52\NN\5870365|in|postalcoholic|wernicke-korsakoff
D013835_D020915 NONE tpp_42\NN\1740|(|) (r_appos) pyrophosphate_40\NN\15010703|for|thiamine|tpp (r_nmod) km_37\NN\13649268|[|high|pyrophosphate|] (r_appos) abnormality_34\NN\14034177|transketolase|km (r_dobj) had_32\VBD\2108377|if|patient|also|abnormality (r_ccomp) delineate_27\VB\2137132|in|to|had|,|reported (l_advcl) reported_48\VBN\831651|as|previously|syndrome (l_nmod) syndrome_52\NN\5870365|in|postalcoholic|wernicke-korsakoff
18441470
D008094_D054537 CID lithium_5\NN\14625458| (r_compound) therapy_6\NN\657604|to|lithium (r_nmod) secondary_3\JJ\1740|therapy (r_amod) block_2\NN\21939|complete|atrioventricular|secondary|.
D008094_D054537 CID lithium_17\NN\14625458| (r_compound) therapy_18\NN\657604|to|lithium (r_nmod) secondary_15\JJ\1740|therapy (r_advmod) developed_14\VBD\1753788|case|,|block|secondary|,|necessitating|. (l_nsubj) block_10\NN\21939|complete|atrioventricular|av|)|attacks
D008094_D012804 CID lithium_14\NN\14625458|of (r_nmod) effects_12\NNS\13245626|among|the|adverse|cardiovascular|lithium (r_nmod) reported_5\VBN\831651|dysfunction|has|been|frequently|effects|. (l_nsubjpass) dysfunction_2\NN\14204950|node
D008094_D013575 NONE lithium_17\NN\14625458| (r_compound) therapy_18\NN\657604|to|lithium (r_nmod) secondary_15\JJ\1740|therapy (r_advmod) developed_14\VBD\1753788|case|,|block|secondary|,|necessitating|. (l_nsubj) block_10\NN\21939|complete|atrioventricular|av|)|attacks (l_nmod) attacks_13\NNS\955060|with|syncopal
D008094_D013575 NONE lithium_1\NN\14625458| (r_compound) levels_2\NNS\4916342|serum|lithium (r_nsubj) remained_3\VBD\2604760|levels|under|range|attacks|. (l_nmod) attacks_13\NNS\955060|during|the|syncopal
2716967
D007649_D002375 CID ketamine_5\NN\3054098|of|and|morphine (r_nmod) combinations_3\NNS\7951464|by|ketamine (r_nmod) induced_1\VBN\1627355|combinations (r_acl) catalepsy_0\NN\14023236|induced|:|potentiation|.
D007649_D002375 CID ketamine_5\NN\3054098|both|and|morphine (r_nsubj) induced_8\VBD\1627355|that|ketamine|analgesia|rat (l_dobj) analgesia_9\NN\14034177|and|catalepsy (l_conj) catalepsy_11\NN\14023236|
D007649_D002375 CID ketamine_2\NN\3054098|with (r_nmod) pre-treatment_0\NN\1740|ketamine (r_nsubj) produced_3\VBD\1617192|pre-treatment|cross-tolerance|,|whereas|induce|attributed (l_dep) induce_14\VB\1627355|pretreatment|did|not|cross-tolerance|but|rather|augmented (l_conj) augmented_20\VBD\153263|response (l_dobj) response_23\NN\11410625|the|cataleptic (l_amod) cataleptic_22\JJ\1740|
D007649_D002375 CID ketamine_17\NN\3054098|to (r_nmod) cross-tolerance_15\NN\1740|ketamine (r_dobj) induce_14\VB\1627355|pretreatment|did|not|cross-tolerance|but|rather|augmented (l_conj) augmented_20\VBD\153263|response (l_dobj) response_23\NN\11410625|the|cataleptic (l_amod) cataleptic_22\JJ\1740|
D009020_D002375 CID morphine_7\NN\2707683| (r_conj) ketamine_5\NN\3054098|of|and|morphine (r_nmod) combinations_3\NNS\7951464|by|ketamine (r_nmod) induced_1\VBN\1627355|combinations (r_acl) catalepsy_0\NN\14023236|induced|:|potentiation|.
D009020_D002375 CID morphine_7\NN\2707683| (r_conj) ketamine_5\NN\3054098|both|and|morphine (r_nsubj) induced_8\VBD\1627355|that|ketamine|analgesia|rat (l_dobj) analgesia_9\NN\14034177|and|catalepsy (l_conj) catalepsy_11\NN\14023236|
D009020_D002375 CID morphine_6\NN\2707683|to (r_nmod) cross-tolerance_4\NN\1740|morphine (r_dobj) produced_3\VBD\1617192|pre-treatment|cross-tolerance|,|whereas|induce|attributed (l_dep) induce_14\VB\1627355|pretreatment|did|not|cross-tolerance|but|rather|augmented (l_conj) augmented_20\VBD\153263|response (l_dobj) response_23\NN\11410625|the|cataleptic (l_amod) cataleptic_22\JJ\1740|
D009020_D002375 CID morphine_11\NN\2707683|with (r_nmod) pretreatment_9\NN\1740|morphine (r_nsubj) induce_14\VB\1627355|pretreatment|did|not|cross-tolerance|but|rather|augmented (l_conj) augmented_20\VBD\153263|response (l_dobj) response_23\NN\11410625|the|cataleptic (l_amod) cataleptic_22\JJ\1740|
D009020_D002375 CID morphine_31\NN\2707683|to|residual|brain (r_nmod) attributed_28\VBN\670261|;|augmentation|was|morphine|. (r_parataxis) produced_3\VBD\1617192|pre-treatment|cross-tolerance|,|whereas|induce|attributed (l_dep) induce_14\VB\1627355|pretreatment|did|not|cross-tolerance|but|rather|augmented (l_conj) augmented_20\VBD\153263|response (l_dobj) response_23\NN\11410625|the|cataleptic (l_amod) cataleptic_22\JJ\1740|
D007649_D000699 NONE ketamine_5\NN\3054098|both|and|morphine (r_nsubj) induced_8\VBD\1627355|that|ketamine|analgesia|rat (l_dobj) analgesia_9\NN\14034177|and|catalepsy
D009020_D000699 NONE morphine_7\NN\2707683| (r_conj) ketamine_5\NN\3054098|both|and|morphine (r_nsubj) induced_8\VBD\1627355|that|ketamine|analgesia|rat (l_dobj) analgesia_9\NN\14034177|and|catalepsy
D007649_D009127 NONE ketamine_19\NN\3054098|of|or|morphine (r_nmod) predominance_17\NN\14441825|the|relative|ketamine|combination (r_dobj) reflected_14\VBD\923793|latency|,|predominance|. (l_nsubj) latency_0\NN\15269513|loss|rigidity (l_dep) rigidity_8\NN\5023233|and|behavior
D009020_D009127 NONE morphine_21\NN\2707683| (r_conj) ketamine_19\NN\3054098|of|or|morphine (r_nmod) predominance_17\NN\14441825|the|relative|ketamine|combination (r_dobj) reflected_14\VBD\923793|latency|,|predominance|. (l_nsubj) latency_0\NN\15269513|loss|rigidity (l_dep) rigidity_8\NN\5023233|and|behavior
D009270_D002375 NONE naloxone_0\NN\3808977| (r_nsubj) inhibited_1\VBD\2510337|naloxone|effects|. (l_dobj) effects_5\NNS\13245626|the|induced|cataleptic (l_amod) cataleptic_4\JJ\1740|
D009270_D002375 NONE naloxone_32\NN\3808977|for (r_nmod) id50_30\NN\1740|a|widely-different|naloxone (r_conj) asymmetry_24\NN\5062748|cross-tolerance|and|id50 (r_nsubj) argue_34\VB\772967|suggest|,|differences|,|asymmetry|would|action|. (l_advcl) suggest_8\VBP\1010118|while|potentiation|mechanisms (l_dobj) mechanisms_10\NNS\13446390|common|catalepsy (l_nmod) catalepsy_14\NN\14023236|for|the|induced
D009270_D009127 NONE naloxone_32\NN\3808977|for (r_nmod) id50_30\NN\1740|a|widely-different|naloxone (r_conj) asymmetry_24\NN\5062748|cross-tolerance|and|id50 (r_nsubj) argue_34\VB\772967|suggest|,|differences|,|asymmetry|would|action|. (l_nsubj) differences_16\NNS\4723816|latency (l_nmod) latency_18\NN\15269513|in|,|rigidity|and|behavior (l_conj) rigidity_20\NN\5023233|
28952
D011188_D007008 NONE potassium_1\NN\14625458| (r_compound) loss_2\NN\13252973|initial|potassium|and|hypokalaemia|administration|:|influence|. (l_conj) hypokalaemia_4\NN\1740|
D011188_D007008 NONE potassium_4\NN\14625458| (r_compound) loss_5\NN\13252973|the|initial|potassium|and|development|administration (l_conj) development_7\NN\248977|hypokalaemia (l_nmod) hypokalaemia_9\NN\1740|of
D011188_D007008 NONE potassium_4\NN\14625458| (r_compound) loss_5\NN\13252973|the|initial|potassium|and|development|administration (r_dobj) investigate_1\VB\644583|to|loss (r_advcl) performed_22\VBN\2367363|investigate|,|studies|were|patients|. (l_nmod) patients_25\NNS\9898892|in|ten|hypertension|shown (l_acl:relcl) shown_31\VBN\2137132|who|had|hypokalaemia|treatment (l_dobj) hypokalaemia_32\NN\1740|
D011188_D006973 NONE potassium_1\NN\14625458| (r_compound) loss_2\NN\13252973|initial|potassium|and|hypokalaemia|administration|:|influence|. (l_nmod) administration_7\NN\1133281|during|chlorthalidone|patients (l_nmod) patients_9\NNS\9898892|in|hypertension (l_nmod) hypertension_12\NN\14057371|with|essential
D011188_D006973 NONE potassium_4\NN\14625458| (r_compound) loss_5\NN\13252973|the|initial|potassium|and|development|administration (r_dobj) investigate_1\VB\644583|to|loss (r_advcl) performed_22\VBN\2367363|investigate|,|studies|were|patients|. (l_nmod) patients_25\NNS\9898892|in|ten|hypertension|shown (l_nmod) hypertension_28\NN\14057371|with|essential
D002752_D007008 CID chlorthalidone_6\NN\3214670| (r_compound) administration_7\NN\1133281|during|chlorthalidone|patients (r_nmod) loss_2\NN\13252973|initial|potassium|and|hypokalaemia|administration|:|influence|. (l_conj) hypokalaemia_4\NN\1740|
D002752_D006973 NONE chlorthalidone_6\NN\3214670| (r_compound) administration_7\NN\1133281|during|chlorthalidone|patients (l_nmod) patients_9\NNS\9898892|in|hypertension (l_nmod) hypertension_12\NN\14057371|with|essential
D012964_D007008 NONE sodium_18\NN\14625458| (r_compound) restriction_19\NN\5846054|of|dietary|sodium (r_nmod) influence_15\NN\5190804|the|restriction (r_appos) loss_2\NN\13252973|initial|potassium|and|hypokalaemia|administration|:|influence|. (l_conj) hypokalaemia_4\NN\1740|
D012964_D006973 NONE sodium_18\NN\14625458| (r_compound) restriction_19\NN\5846054|of|dietary|sodium (r_nmod) influence_15\NN\5190804|the|restriction (r_appos) loss_2\NN\13252973|initial|potassium|and|hypokalaemia|administration|:|influence|. (l_nmod) administration_7\NN\1133281|during|chlorthalidone|patients (l_nmod) patients_9\NNS\9898892|in|hypertension (l_nmod) hypertension_12\NN\14057371|with|essential
1079693
D000305_D014605 NONE corticosteroids_27\NNS\14745635|with|and|mydriatics (r_nmod) treatment_25\NN\654885|of|intensive|topical|corticosteroids (r_nmod) months_21\NNS\15113229|to|six|treatment (r_nmod) respond_16\VB\2367363|detection|,|%|did|not|months|. (l_nsubj) %_9\NN\1740|41|cases (l_nmod) cases_11\NNS\7283608|of|uveitis (l_nmod) uveitis_13\NN\14336539|of
D002738_D012164 NONE chloroquine_2\NN\2721948|or|hydroxychloroquine (r_dobj) used_1\VBD\1156834|we|chloroquine|cases|and|found|. (l_conj) found_11\VBD\2426171|case (l_dobj) case_14\NN\7283608|one|chorioretinopathy (l_nmod) chorioretinopathy_16\NN\1740|of|attributable
D006886_D012164 CID hydroxychloroquine_4\NN\2721538| (r_conj) chloroquine_2\NN\2721948|or|hydroxychloroquine (r_dobj) used_1\VBD\1156834|we|chloroquine|cases|and|found|. (l_conj) found_11\VBD\2426171|case (l_dobj) case_14\NN\7283608|one|chorioretinopathy (l_nmod) chorioretinopathy_16\NN\1740|of|attributable
D000305_D002386 NONE corticosteroids_2\NNS\14745635|administered (r_nsubjpass) used_4\VBN\1156834|corticosteroids|were|cases (r_ccomp) found_19\VBN\2426171|used|;|number|was|. (l_nsubjpass) number_13\NN\5107765|a|significant|cataracts (l_nmod) cataracts_17\NNS\14252864|of|posterior|subcapsular
8267029
D010396_D005921 CID penicillamine-induced_0\JJ\1740| (r_amod) glomerulonephritis_3\NN\14113798|penicillamine-induced|progressive|patient|.
D010396_D005921 CID d-penicillamine_17\NN\1740|mg/day (r_compound) treatment_22\NN\654885|of|d-penicillamine (r_nmod) months_15\NNS\15113229|after|5|treatment (r_nmod) presented_6\VBD\2137132|woman|glomerulonephritis|months|. (l_dobj) glomerulonephritis_9\NN\14113798|progressive|rpgn
D010396_D005921 CID d-penicillamine_17\NN\1740|mg/day (r_compound) treatment_22\NN\654885|of|d-penicillamine (r_nmod) months_15\NNS\15113229|after|5|treatment (r_nmod) presented_6\VBD\2137132|woman|glomerulonephritis|months|. (l_dobj) glomerulonephritis_9\NN\14113798|progressive|rpgn (l_appos) rpgn_11\NN\1740|(|)
D010396_D005921 CID d-penicillamine_9\NN\1740| (r_compound) treatment_10\NN\654885|of|d-penicillamine (r_nmod) course_7\NN\883297|in|the|treatment (r_nmod) case_2\NN\7283608|this|new|rpgn|course (l_nmod) rpgn_4\NN\1740|of
D010396_D001172 NONE penicillamine-induced_0\JJ\1740| (r_amod) glomerulonephritis_3\NN\14113798|penicillamine-induced|progressive|patient|. (l_nmod) patient_6\NN\9898892|in|a|arthritis (l_nmod) arthritis_9\NN\14171682|with|rheumatoid
D010396_D001172 NONE d-penicillamine_17\NN\1740|mg/day (r_compound) treatment_22\NN\654885|of|d-penicillamine (r_nmod) months_15\NNS\15113229|after|5|treatment (r_nmod) presented_6\VBD\2137132|woman|glomerulonephritis|months|. (l_nsubj) woman_2\NN\9605289|a|67-year-old|arthritis (l_nmod) arthritis_5\NN\14171682|with|rheumatoid
D010396_D011507 NONE d-penicillamine_9\NN\1740| (r_compound) treatment_10\NN\654885|of|d-penicillamine (r_nmod) course_7\NN\883297|in|the|treatment (r_nmod) case_2\NN\7283608|this|new|rpgn|course (r_nsubj) emphasizes_11\VBZ\943837|case|need|. (l_dobj) need_13\NN\13920835|the|monitoring (l_nmod) monitoring_16\NN\879759|for|frequent|function|and|evaluation (l_conj) evaluation_21\NN\874067|sediment (l_nmod) sediment_24\NN\20827|of|urinary|and|proteinuria|patients (l_conj) proteinuria_26\NN\14299637|
2466960
D005472_D066126 NONE fluorouracil_11\NN\2722166|5-fu (r_compound) therapy_15\NN\657604|with|fluorouracil (r_nmod) associated_9\VBN\628491|therapy (r_acl) toxicity_8\NN\13576101|of|cardiac|associated
D005472_D066126 NONE 5-fu_13\NN\1740|(|) (r_appos) fluorouracil_11\NN\2722166|5-fu (r_compound) therapy_15\NN\657604|with|fluorouracil (r_nmod) associated_9\VBN\628491|therapy (r_acl) toxicity_8\NN\13576101|of|cardiac|associated
D005472_D009369 NONE 5-fu_11\NN\1740| (r_compound) infusion_12\NN\14589223|5-fu|treatment (l_nmod) treatment_14\NN\654885|for|tumors (l_nmod) tumors_17\NNS\14234074|of|solid
D005472_D007511 CID 5-fu_11\NN\1740| (r_compound) infusion_12\NN\14589223|5-fu|treatment (r_dobj) undergoing_10\VBG\109660|infusion (r_acl) patients_9\NNS\9898892|on|25|undergoing (r_nmod) performed_2\VBD\2367363|we|prospectively|monitoring|patients|assess|. (l_advcl) assess_21\VB\670261|in|to|incidence (l_dobj) incidence_23\NN\13821570|the|changes (l_nmod) changes_27\NNS\7283608|of|ischemic|st (l_amod) ischemic_25\JJ\1740|
D005472_D007511 CID 5-fu_15\NN\1740| (r_compound) infusion_16\NN\14589223|5-fu (r_nmod) 0.05_10\CD\1740|incidence|was|+/-|0.02|prior|infusion|v|0.13|infusion|p|;|minutes|. (l_nsubj) incidence_1\NN\13821570|the|episodes (l_nmod) episodes_4\NNS\7283608|of|ischemic|patient (l_amod) ischemic_3\JJ\1740|
D005472_D007511 CID 5-fu_22\NN\1740| (r_compound) infusion_23\NN\14589223|during|5-fu (r_nmod) 0.05_10\CD\1740|incidence|was|+/-|0.02|prior|infusion|v|0.13|infusion|p|;|minutes|. (l_nsubj) incidence_1\NN\13821570|the|episodes (l_nmod) episodes_4\NNS\7283608|of|ischemic|patient (l_amod) ischemic_3\JJ\1740|
D005472_D007511 CID 5-fu_46\NN\1740|before (r_nmod) minutes_40\NNS\6502378|duration|was|0.6|patient|hour|5-fu|v|minutes|p (r_dep) 0.05_10\CD\1740|incidence|was|+/-|0.02|prior|infusion|v|0.13|infusion|p|;|minutes|. (l_nsubj) incidence_1\NN\13821570|the|episodes (l_nmod) episodes_4\NNS\7283608|of|ischemic|patient (l_amod) ischemic_3\JJ\1740|
D005472_D007511 CID 5-fu_57\NN\1740|during (r_nmod) minutes_51\NNS\6502378|1.9|patient|hour|5-fu (r_dep) minutes_40\NNS\6502378|duration|was|0.6|patient|hour|5-fu|v|minutes|p (r_dep) 0.05_10\CD\1740|incidence|was|+/-|0.02|prior|infusion|v|0.13|infusion|p|;|minutes|. (l_nsubj) incidence_1\NN\13821570|the|episodes (l_nmod) episodes_4\NNS\7283608|of|ischemic|patient (l_amod) ischemic_3\JJ\1740|
D005472_D007511 CID 5-fu_3\NN\1740| (r_compound) infusion_4\NN\14589223|5-fu (r_nsubjpass) associated_6\VBN\628491|that|infusion|is|increase (l_nmod) increase_10\NN\13576355|with|a|significant|deviation|patients (l_nmod) deviation_15\NN\7337390|in|silent|st|segment|suggestive (l_amod) suggestive_16\JJ\1740|ischemia|, (l_nmod) ischemia_18\NN\14195315|of
D005472_D000787 CID 5-fu_12\JJ\1740| (r_compound) infusion_13\NN\14589223|(|during|5-fu (r_appos) angina_9\NN\14171682|infusion (r_dobj) had_8\VBD\2108377|rare|:|patient|angina|)|. (l_ccomp) rare_3\JJ\1740|episodes|were (l_nsubj) episodes_1\NNS\7283608|anginal (l_amod) anginal_0\JJ\1740|
D005472_D000787 CID 5-fu_12\JJ\1740| (r_compound) infusion_13\NN\14589223|(|during|5-fu (r_appos) angina_9\NN\14171682|infusion
D005472_D003324 NONE 5-fu_3\NN\1740| (r_compound) infusion_4\NN\14589223|5-fu (r_nsubjpass) associated_6\VBN\628491|that|infusion|is|increase (l_nmod) increase_10\NN\13576355|with|a|significant|deviation|patients (l_nmod) patients_22\NNS\9898892|among|disease (l_nmod) disease_26\NN\14061805|with|coronary|artery
3300918
D008784_D014652 CID methysergide_20\NN\1740|of (r_nmod) ingestion_18\NN\13440063|to|the|methysergide|woman (r_nmod) secondary_15\JJ\1740|ingestion (r_xcomp) described_14\VBN\1001294|case|,|is|secondary|. (l_nsubjpass) case_2\NN\7283608|a|rare|vasospasm|,|together|findings (l_nmod) vasospasm_5\NN\1740|of|morbid
D004876_D005734 NONE ergot_6\NN\14276936|of (r_nmod) history_4\NN\15120823|of|the|ergot (r_nmod) discussion_1\NN\6252138|a|history (r_nsubj) includes_7\VBZ\690614|discussion|discovery|. (l_dobj) discovery_10\NN\30358|its|original|,|epidemics (l_appos) epidemics_13\NNS\7435273|the|gangrene (l_nmod) gangrene_15\NN\14204950|of|caused
D004876_D008881 CID ergot_6\NN\14276936|of (r_nmod) history_4\NN\15120823|of|the|ergot (r_nmod) discussion_1\NN\6252138|a|history (r_nsubj) includes_7\VBZ\690614|discussion|discovery|. (l_dobj) discovery_10\NN\30358|its|original|,|epidemics (l_appos) epidemics_13\NNS\7435273|the|gangrene (l_nmod) gangrene_15\NN\14204950|of|caused (l_acl:relcl) caused_19\VBN\1617192|that|it|has|ages|and|role (l_conj) role_28\NN\719494|its|past|management (l_nmod) management_31\NN\1123598|in|the|headache (l_nmod) headache_34\NN\5829480|of|migraine
D004876_D008881 CID ergot_11\NN\14276936| (r_compound) preparations_12\NNS\407535|ergot (r_nsubj) continue_13\VBP\2367363|advent|,|preparations|play|persists|. (l_xcomp) play_15\VB\1072262|to|role|, (l_dobj) role_18\NN\719494|a|major|therapy (l_nmod) therapy_21\NN\657604|in|migraine (l_compound) migraine_20\NN\14326607|
D002118_D008881 NONE calcium_4\NN\14625458| (r_compound) blockers_6\NNS\10101634|of|calcium|channel|and|antagonists (r_nmod) advent_2\NN\48225|despite|the|blockers (r_nmod) continue_13\VBP\2367363|advent|,|preparations|play|persists|. (l_xcomp) play_15\VB\1072262|to|role|, (l_dobj) role_18\NN\719494|a|major|therapy (l_nmod) therapy_21\NN\657604|in|migraine (l_compound) migraine_20\NN\14326607|
D002118_D004881 NONE calcium_4\NN\14625458| (r_compound) blockers_6\NNS\10101634|of|calcium|channel|and|antagonists (r_nmod) advent_2\NN\48225|despite|the|blockers (r_nmod) continue_13\VBP\2367363|advent|,|preparations|play|persists|. (l_advcl) persists_32\VBZ\118523|so|that|danger (l_nsubj) danger_26\NN\13920835|the|fire (l_nmod) fire_31\NN\7283608|of|anthony
D004876_D004881 NONE ergot_11\NN\14276936| (r_compound) preparations_12\NNS\407535|ergot (r_nsubj) continue_13\VBP\2367363|advent|,|preparations|play|persists|. (l_advcl) persists_32\VBZ\118523|so|that|danger (l_nsubj) danger_26\NN\13920835|the|fire (l_nmod) fire_31\NN\7283608|of|anthony
11185967
D003042_D012640 NONE cocaine_18\NN\3492717|for|or|amphetamine (r_nmod) screening_16\NN\6887726|of|positive|drug|cocaine (r_nmod) prevalence_11\NN\4764412|the|screening|patients (l_nmod) patients_26\NNS\9898892|in|adult|department|seizure (l_compound) seizure_25\NN\14081375|
D003042_D012640 NONE cocaine_11\NN\3492717|for|and|amphetamines|patients (l_nmod) patients_17\NNS\9898892|in|adult|seizure (l_compound) seizure_16\NN\14081375|
D000661_D012640 NONE amphetamine_20\NN\3248958| (r_conj) cocaine_18\NN\3492717|for|or|amphetamine (r_nmod) screening_16\NN\6887726|of|positive|drug|cocaine (r_nmod) prevalence_11\NN\4764412|the|screening|patients (l_nmod) patients_26\NNS\9898892|in|adult|department|seizure (l_compound) seizure_25\NN\14081375|
D000431_D012640 NONE alcohol-related_8\JJ\1740| (r_conj) drug_6\NN\14778436|or|alcohol-related (r_compound) disorder_10\NN\14034177|of|underlying|drug|seizure (l_compound) seizure_9\NN\14081375|
D000431_D012640 NONE alcohol-related_8\JJ\1740| (r_conj) drug_6\NN\14778436|or|alcohol-related (r_compound) disorder_10\NN\14034177|of|underlying|drug|seizure (r_nmod) history_3\NN\15120823|disorder|,|time|,|history|,|results|,|and|results (l_conj) time_13\NN\7308889|estimated|seizure|collection (l_nmod) seizure_15\NN\14081375|from
D000431_D019970 NONE alcohol-related_8\JJ\1740| (r_conj) drug_6\NN\14778436|or|alcohol-related (r_compound) disorder_10\NN\14034177|of|underlying|drug|seizure (r_nmod) history_3\NN\15120823|disorder|,|time|,|history|,|results|,|and|results (l_conj) history_20\NN\15120823|or|suspicion|abuse (l_nmod) abuse_27\NN\418025|of|cocaine
D000431_D019969 NONE alcohol-related_8\JJ\1740| (r_conj) drug_6\NN\14778436|or|alcohol-related (r_compound) disorder_10\NN\14034177|of|underlying|drug|seizure (r_nmod) history_3\NN\15120823|disorder|,|time|,|history|,|results|,|and|results (l_conj) history_20\NN\15120823|or|suspicion|abuse (l_nmod) abuse_27\NN\418025|of|cocaine
D000662_D012640 NONE amphetamines_13\NNS\3248958| (r_conj) cocaine_11\NN\3492717|for|and|amphetamines|patients (l_nmod) patients_17\NNS\9898892|in|adult|seizure (l_compound) seizure_16\NN\14081375|
9915601
D007538_D001919 CID isoniazid_10\NN\2716205|with (r_nmod) pretreated_8\VBN\1740|isoniazid (r_acl) rats_7\NNS\2329401|in|pretreated (r_nmod) induced_2\VBN\1627355|antagonists|rats (r_acl) bradycardia_1\NN\14110674|enhanced|induced|.
D007538_D001919 CID isoniazid_3\NN\2716205|of (r_nmod) doses_1\NNS\3740161|high|isoniazid (r_nsubj) increase_4\VBP\169651|doses|hypotension|and|change|. (l_conj) change_10\VBP\46534|tachycardia|bradycardia|,|interaction (l_nmod) bradycardia_16\NN\14110674|to
D007538_D001919 CID isoniazid_9\NN\2716205|by (r_nmod) enhancement_7\NN\248977|the|possible|isoniazid|bradycardia (l_nmod) bradycardia_11\NN\14110674|of|induced
D007538_D001919 CID isoniazid_0\NN\2716205| (r_nsubj) increased_2\VBD\169651|isoniazid|significantly|bradycardia|propranolol|. (l_dobj) bradycardia_3\NN\14110674|
D007538_D007022 CID isoniazid_3\NN\2716205|of (r_nmod) doses_1\NNS\3740161|high|isoniazid (r_nsubj) increase_4\VBP\169651|doses|hypotension|and|change|. (l_dobj) hypotension_5\NN\14057371|induced
D007538_D013610 NONE isoniazid_3\NN\2716205|of (r_nmod) doses_1\NNS\3740161|high|isoniazid (r_nsubj) increase_4\VBP\169651|doses|hypotension|and|change|. (l_conj) change_10\VBP\46534|tachycardia|bradycardia|,|interaction (l_dobj) tachycardia_14\NN\14110674|the|accompanying|reflex
D005680_D007022 NONE acid_27\NN\14818238|of|brain|gamma-aminobutyric|gaba (r_nmod) synthesis_23\NN\13446390|to|decreased|acid (r_nmod) attributed_20\VBN\670261|synthesis (r_acl) interaction_19\NN\37396|an|attributed (r_dobj) change_10\VBP\46534|tachycardia|bradycardia|,|interaction (r_conj) increase_4\VBP\169651|doses|hypotension|and|change|. (l_dobj) hypotension_5\NN\14057371|induced
D005680_D007022 NONE gaba_29\NN\14601829|(|) (r_appos) acid_27\NN\14818238|of|brain|gamma-aminobutyric|gaba (r_nmod) synthesis_23\NN\13446390|to|decreased|acid (r_nmod) attributed_20\VBN\670261|synthesis (r_acl) interaction_19\NN\37396|an|attributed (r_dobj) change_10\VBP\46534|tachycardia|bradycardia|,|interaction (r_conj) increase_4\VBP\169651|doses|hypotension|and|change|. (l_dobj) hypotension_5\NN\14057371|induced
D005680_D013610 NONE acid_27\NN\14818238|of|brain|gamma-aminobutyric|gaba (r_nmod) synthesis_23\NN\13446390|to|decreased|acid (r_nmod) attributed_20\VBN\670261|synthesis (r_acl) interaction_19\NN\37396|an|attributed (r_dobj) change_10\VBP\46534|tachycardia|bradycardia|,|interaction (l_dobj) tachycardia_14\NN\14110674|the|accompanying|reflex
D005680_D013610 NONE gaba_29\NN\14601829|(|) (r_appos) acid_27\NN\14818238|of|brain|gamma-aminobutyric|gaba (r_nmod) synthesis_23\NN\13446390|to|decreased|acid (r_nmod) attributed_20\VBN\670261|synthesis (r_acl) interaction_19\NN\37396|an|attributed (r_dobj) change_10\VBP\46534|tachycardia|bradycardia|,|interaction (l_dobj) tachycardia_14\NN\14110674|the|accompanying|reflex
D005680_D001919 NONE acid_27\NN\14818238|of|brain|gamma-aminobutyric|gaba (r_nmod) synthesis_23\NN\13446390|to|decreased|acid (r_nmod) attributed_20\VBN\670261|synthesis (r_acl) interaction_19\NN\37396|an|attributed (r_dobj) change_10\VBP\46534|tachycardia|bradycardia|,|interaction (l_nmod) bradycardia_16\NN\14110674|to
D005680_D001919 NONE gaba_29\NN\14601829|(|) (r_appos) acid_27\NN\14818238|of|brain|gamma-aminobutyric|gaba (r_nmod) synthesis_23\NN\13446390|to|decreased|acid (r_nmod) attributed_20\VBN\670261|synthesis (r_acl) interaction_19\NN\37396|an|attributed (r_dobj) change_10\VBP\46534|tachycardia|bradycardia|,|interaction (l_nmod) bradycardia_16\NN\14110674|to
D002698_D001919 NONE chloralose-urethane_22\NN\1740|with (r_nmod) anaesthetised_20\VBN\84738|chloralose-urethane (r_acl) rats_19\NNS\2329401|in|anaesthetised (r_nmod) determined_17\VBN\1645601|study|,|enhancement|was|rats|. (l_nsubjpass) enhancement_7\NN\248977|the|possible|isoniazid|bradycardia (l_nmod) bradycardia_11\NN\14110674|of|induced
D014520_D001919 NONE chloralose-urethane_22\NN\1740|with (r_nmod) anaesthetised_20\VBN\84738|chloralose-urethane (r_acl) rats_19\NNS\2329401|in|anaesthetised (r_nmod) determined_17\VBN\1645601|study|,|enhancement|was|rats|. (l_nsubjpass) enhancement_7\NN\248977|the|possible|isoniazid|bradycardia (l_nmod) bradycardia_11\NN\14110674|of|induced
D011433_D001919 NONE propranolol_5\NN\1740|after|,|pindolol|,|labetalol|and|atenolol|,|as|clonidine (r_nmod) increased_2\VBD\169651|isoniazid|significantly|bradycardia|propranolol|. (l_dobj) bradycardia_3\NN\14110674|
D010869_D001919 NONE pindolol_7\NN\2832168| (r_conj) propranolol_5\NN\1740|after|,|pindolol|,|labetalol|and|atenolol|,|as|clonidine (r_nmod) increased_2\VBD\169651|isoniazid|significantly|bradycardia|propranolol|. (l_dobj) bradycardia_3\NN\14110674|
D007741_D001919 NONE labetalol_9\NN\2721160| (r_conj) propranolol_5\NN\1740|after|,|pindolol|,|labetalol|and|atenolol|,|as|clonidine (r_nmod) increased_2\VBD\169651|isoniazid|significantly|bradycardia|propranolol|. (l_dobj) bradycardia_3\NN\14110674|
D001262_D001919 NONE atenolol_11\NN\2832168| (r_conj) propranolol_5\NN\1740|after|,|pindolol|,|labetalol|and|atenolol|,|as|clonidine (r_nmod) increased_2\VBD\169651|isoniazid|significantly|bradycardia|propranolol|. (l_dobj) bradycardia_3\NN\14110674|
D003000_D001919 NONE clonidine_17\NN\2721160|after|,|but|hexamethonium (r_conj) propranolol_5\NN\1740|after|,|pindolol|,|labetalol|and|atenolol|,|as|clonidine (r_nmod) increased_2\VBD\169651|isoniazid|significantly|bradycardia|propranolol|. (l_dobj) bradycardia_3\NN\14110674|
D018738_D001919 NONE hexamethonium_22\NN\1740|after|or|carbachol (r_conj) clonidine_17\NN\2721160|after|,|but|hexamethonium (r_conj) propranolol_5\NN\1740|after|,|pindolol|,|labetalol|and|atenolol|,|as|clonidine (r_nmod) increased_2\VBD\169651|isoniazid|significantly|bradycardia|propranolol|. (l_dobj) bradycardia_3\NN\14110674|
D002217_D001919 NONE carbachol_24\NN\1740| (r_conj) hexamethonium_22\NN\1740|after|or|carbachol (r_conj) clonidine_17\NN\2721160|after|,|but|hexamethonium (r_conj) propranolol_5\NN\1740|after|,|pindolol|,|labetalol|and|atenolol|,|as|clonidine (r_nmod) increased_2\VBD\169651|isoniazid|significantly|bradycardia|propranolol|. (l_dobj) bradycardia_3\NN\14110674|
10193809
D011692_D011507 CID aminonucleoside_3\NN\1740|puromycin|pan (r_nsubjpass) administered_8\VBN\2436349|methods|aminonucleoside|was|rats|induce|. (l_advcl) induce_14\VB\1627355|to|proteinuria (l_dobj) proteinuria_15\NN\14299637|
D011692_D011507 CID pan_5\NN\3101986|(|) (r_appos) aminonucleoside_3\NN\1740|puromycin|pan (r_nsubjpass) administered_8\VBN\2436349|methods|aminonucleoside|was|rats|induce|. (l_advcl) induce_14\VB\1627355|to|proteinuria (l_dobj) proteinuria_15\NN\14299637|
3769769
D014282_D001919 CID hydrochloride_4\NN\14817592|due|trihexyphenidyl (r_nmod) bradycardia_0\NN\14110674|hydrochloride|.
D014282_D012559 NONE hydrochloride_12\NN\14817592|trihexyphenidyl (r_appos) drug_9\NN\14778436|with|an|anticholinergic|,|hydrochloride (r_nmod) treated_5\VBN\2376958|patient|was|drug|. (l_nsubjpass) patient_3\NN\9898892|a|chronic|schizophrenic (l_amod) schizophrenic_2\JJ\1740|
6433367
D011453_D012640 NONE prostaglandin_2\NN\5414534| (r_compound) synthetase_3\NN\1740|prostaglandin (r_compound) inhibitors_4\NNS\20090|of|synthetase (r_nmod) effect_0\NN\34213|inhibitors|convulsions|. (l_nmod) convulsions_8\NNS\14081375|on|induced|rats
D011453_D012640 NONE prostaglandins_5\NNS\5414534|of|pgs (r_nmod) relationship_3\NN\31921|the|prostaglandins|induction (l_nmod) induction_11\NN\7450842|to|seizure (l_compound) seizure_10\NN\14081375|
D011453_D012640 NONE prostaglandins_5\NNS\5414534|of|pgs (r_nmod) relationship_3\NN\31921|the|prostaglandins|induction (r_dobj) investigate_1\VB\644583|to|relationship (r_advcl) evaluated_37\VBN\670261|investigate|,|effects|were|. (l_nsubjpass) effects_14\NNS\13245626|the|inhibitors|convulsions (l_nmod) convulsions_21\NNS\14081375|on|induced
D011453_D012640 NONE pgs_7\NNS\1740|(|) (r_appos) prostaglandins_5\NNS\5414534|of|pgs (r_nmod) relationship_3\NN\31921|the|prostaglandins|induction (l_nmod) induction_11\NN\7450842|to|seizure (l_compound) seizure_10\NN\14081375|
D011453_D012640 NONE pgs_7\NNS\1740|(|) (r_appos) prostaglandins_5\NNS\5414534|of|pgs (r_nmod) relationship_3\NN\31921|the|prostaglandins|induction (r_dobj) investigate_1\VB\644583|to|relationship (r_advcl) evaluated_37\VBN\670261|investigate|,|effects|were|. (l_nsubjpass) effects_14\NNS\13245626|the|inhibitors|convulsions (l_nmod) convulsions_21\NNS\14081375|on|induced
D011453_D012640 NONE pgs_4\NNS\1740| (r_nsubjpass) involved_6\VBN\2676054|that|pgs|are|mechanism(s|convulsions (l_nmod) mechanism(s_9\NN\1740|in|the|)|underlying (l_acl) underlying_11\VBG\2604760|convulsions|,|not|picrotoxin- (l_dobj) convulsions_15\NNS\14081375|fluorthyl-
D011453_D012640 NONE pgs_4\NNS\1740| (r_nsubjpass) involved_6\VBN\2676054|that|pgs|are|mechanism(s|convulsions (l_dep) convulsions_25\NNS\14081375|
D005481_D012640 CID flurothyl_24\NN\1740|by|,|picrotoxin|,|pentetrazol|,|electroshock|or|bicuculline (r_nmod) induced_22\VBN\1627355|flurothyl (r_acl) convulsions_21\NNS\14081375|on|induced (r_nmod) effects_14\NNS\13245626|the|inhibitors|convulsions (r_nsubjpass) evaluated_37\VBN\670261|investigate|,|effects|were|. (l_advcl) investigate_1\VB\644583|to|relationship (l_dobj) relationship_3\NN\31921|the|prostaglandins|induction (l_nmod) induction_11\NN\7450842|to|seizure (l_compound) seizure_10\NN\14081375|
D005481_D012640 CID flurothyl_24\NN\1740|by|,|picrotoxin|,|pentetrazol|,|electroshock|or|bicuculline (r_nmod) induced_22\VBN\1627355|flurothyl (r_acl) convulsions_21\NNS\14081375|on|induced
D005481_D012640 CID fluorthyl-_12\NN\1740|and|ptz-induced (r_amod) convulsions_15\NNS\14081375|fluorthyl-
D005481_D012640 CID fluorthyl-_12\NN\1740|and|ptz-induced (r_amod) convulsions_15\NNS\14081375|fluorthyl- (r_dobj) underlying_11\VBG\2604760|convulsions|,|not|picrotoxin- (r_acl) mechanism(s_9\NN\1740|in|the|)|underlying (r_nmod) involved_6\VBN\2676054|that|pgs|are|mechanism(s|convulsions (l_dep) convulsions_25\NNS\14081375|
D010852_D012640 CID picrotoxin_26\NN\1740| (r_conj) flurothyl_24\NN\1740|by|,|picrotoxin|,|pentetrazol|,|electroshock|or|bicuculline (r_nmod) induced_22\VBN\1627355|flurothyl (r_acl) convulsions_21\NNS\14081375|on|induced (r_nmod) effects_14\NNS\13245626|the|inhibitors|convulsions (r_nsubjpass) evaluated_37\VBN\670261|investigate|,|effects|were|. (l_advcl) investigate_1\VB\644583|to|relationship (l_dobj) relationship_3\NN\31921|the|prostaglandins|induction (l_nmod) induction_11\NN\7450842|to|seizure (l_compound) seizure_10\NN\14081375|
D010852_D012640 CID picrotoxin_26\NN\1740| (r_conj) flurothyl_24\NN\1740|by|,|picrotoxin|,|pentetrazol|,|electroshock|or|bicuculline (r_nmod) induced_22\VBN\1627355|flurothyl (r_acl) convulsions_21\NNS\14081375|on|induced
D010852_D012640 CID picrotoxin-_19\NN\1740|,|electroshock-|,|or|bicuculline-induced (r_conj) underlying_11\VBG\2604760|convulsions|,|not|picrotoxin- (l_dobj) convulsions_15\NNS\14081375|fluorthyl-
D010852_D012640 CID picrotoxin-_19\NN\1740|,|electroshock-|,|or|bicuculline-induced (r_conj) underlying_11\VBG\2604760|convulsions|,|not|picrotoxin- (r_acl) mechanism(s_9\NN\1740|in|the|)|underlying (r_nmod) involved_6\VBN\2676054|that|pgs|are|mechanism(s|convulsions (l_dep) convulsions_25\NNS\14081375|
D010433_D012640 CID pentetrazol_28\NN\1740|ptz (r_conj) flurothyl_24\NN\1740|by|,|picrotoxin|,|pentetrazol|,|electroshock|or|bicuculline (r_nmod) induced_22\VBN\1627355|flurothyl (r_acl) convulsions_21\NNS\14081375|on|induced (r_nmod) effects_14\NNS\13245626|the|inhibitors|convulsions (r_nsubjpass) evaluated_37\VBN\670261|investigate|,|effects|were|. (l_advcl) investigate_1\VB\644583|to|relationship (l_dobj) relationship_3\NN\31921|the|prostaglandins|induction (l_nmod) induction_11\NN\7450842|to|seizure (l_compound) seizure_10\NN\14081375|
D010433_D012640 CID pentetrazol_28\NN\1740|ptz (r_conj) flurothyl_24\NN\1740|by|,|picrotoxin|,|pentetrazol|,|electroshock|or|bicuculline (r_nmod) induced_22\VBN\1627355|flurothyl (r_acl) convulsions_21\NNS\14081375|on|induced
D010433_D012640 CID ptz_30\NN\1740|(|) (r_appos) pentetrazol_28\NN\1740|ptz (r_conj) flurothyl_24\NN\1740|by|,|picrotoxin|,|pentetrazol|,|electroshock|or|bicuculline (r_nmod) induced_22\VBN\1627355|flurothyl (r_acl) convulsions_21\NNS\14081375|on|induced (r_nmod) effects_14\NNS\13245626|the|inhibitors|convulsions (r_nsubjpass) evaluated_37\VBN\670261|investigate|,|effects|were|. (l_advcl) investigate_1\VB\644583|to|relationship (l_dobj) relationship_3\NN\31921|the|prostaglandins|induction (l_nmod) induction_11\NN\7450842|to|seizure (l_compound) seizure_10\NN\14081375|
D010433_D012640 CID ptz_30\NN\1740|(|) (r_appos) pentetrazol_28\NN\1740|ptz (r_conj) flurothyl_24\NN\1740|by|,|picrotoxin|,|pentetrazol|,|electroshock|or|bicuculline (r_nmod) induced_22\VBN\1627355|flurothyl (r_acl) convulsions_21\NNS\14081375|on|induced
D010433_D012640 CID ptz-induced_14\JJ\1740| (r_conj) fluorthyl-_12\NN\1740|and|ptz-induced (r_amod) convulsions_15\NNS\14081375|fluorthyl-
D010433_D012640 CID ptz-induced_14\JJ\1740| (r_conj) fluorthyl-_12\NN\1740|and|ptz-induced (r_amod) convulsions_15\NNS\14081375|fluorthyl- (r_dobj) underlying_11\VBG\2604760|convulsions|,|not|picrotoxin- (r_acl) mechanism(s_9\NN\1740|in|the|)|underlying (r_nmod) involved_6\VBN\2676054|that|pgs|are|mechanism(s|convulsions (l_dep) convulsions_25\NNS\14081375|
D001640_D012640 CID bicuculline_35\NN\1740| (r_conj) flurothyl_24\NN\1740|by|,|picrotoxin|,|pentetrazol|,|electroshock|or|bicuculline (r_nmod) induced_22\VBN\1627355|flurothyl (r_acl) convulsions_21\NNS\14081375|on|induced (r_nmod) effects_14\NNS\13245626|the|inhibitors|convulsions (r_nsubjpass) evaluated_37\VBN\670261|investigate|,|effects|were|. (l_advcl) investigate_1\VB\644583|to|relationship (l_dobj) relationship_3\NN\31921|the|prostaglandins|induction (l_nmod) induction_11\NN\7450842|to|seizure (l_compound) seizure_10\NN\14081375|
D001640_D012640 CID bicuculline_35\NN\1740| (r_conj) flurothyl_24\NN\1740|by|,|picrotoxin|,|pentetrazol|,|electroshock|or|bicuculline (r_nmod) induced_22\VBN\1627355|flurothyl (r_acl) convulsions_21\NNS\14081375|on|induced
D001640_D012640 CID bicuculline-induced_24\JJ\1740| (r_conj) picrotoxin-_19\NN\1740|,|electroshock-|,|or|bicuculline-induced (r_conj) underlying_11\VBG\2604760|convulsions|,|not|picrotoxin- (l_dobj) convulsions_15\NNS\14081375|fluorthyl-
D001640_D012640 CID bicuculline-induced_24\JJ\1740| (r_conj) picrotoxin-_19\NN\1740|,|electroshock-|,|or|bicuculline-induced (r_conj) underlying_11\VBG\2604760|convulsions|,|not|picrotoxin- (r_acl) mechanism(s_9\NN\1740|in|the|)|underlying (r_nmod) involved_6\VBN\2676054|that|pgs|are|mechanism(s|convulsions (l_dep) convulsions_25\NNS\14081375|
18239197
D014282_D003072 CID trihexyphenidyl_10\NN\1740| (r_compound) challenge_13\NN\13927383|after|trihexyphenidyl|oral|anticholinergic|elderly (r_nmod) associated_3\VBN\628491|allele|challenge (r_acl) slowing_2\NN\7296428|increased|mental|associated|.
D014282_D003072 CID trihexyphenidyl_7\NN\1740|of (r_nmod) dose_5\NN\3740161|a|2.0-mg|oral|trihexyphenidyl (r_nsubj) resulted_8\VBD\2633881|results|dose|ratings|. (l_nmod) ratings_12\NNS\5733583|in|increased|subjective|slowness|carriers (l_nmod) slowness_15\NN\5648247|of|mental
D014282_D003072 CID trihexyphenidyl_10\NN\1740|between|mg|and|placebo (r_nmod) scores_6\NNS\13757724|by|difference|trihexyphenidyl|ratings (l_nmod) ratings_14\NNS\5733583|on|slowness (l_nmod) slowness_17\NN\5648247|of|mental
D014282_D003072 CID trihexyphenidyl_16\JJ\1740| (r_amod) challenge_18\NN\13927383|after|trihexyphenidyl|anticholinergic (r_nmod) slowing_14\NN\7296428|with|increased|subjective|mental|challenge
D014282_D003221 NONE trihexyphenidyl_19\NN\1740|of (r_nmod) effects_17\NNS\13245626|subjective|trihexyphenidyl|measures (l_nmod) measures_21\NNS\168237|on|reflecting (l_acl) reflecting_22\VBG\923793|sedation (l_dobj) sedation_23\NN\14034177|and|confusion (l_conj) confusion_25\NN\13972797|
D014282_D003221 NONE trihexyphenidyl-induced_32\JJ\1740| (r_amod) effects_34\NNS\13245626|between|trihexyphenidyl-induced|subjective|and|performance (r_nmod) relationship_30\NN\31921|the|effects (r_dobj) investigate_28\VB\644583|to|relationship (r_conj) examine_9\VB\789138|to|relationship|and|investigate (l_dobj) relationship_11\NN\31921|the|epsilon4 (l_nmod) epsilon4_14\NN\1740|between|apoe|and|effects (l_conj) effects_17\NNS\13245626|subjective|trihexyphenidyl|measures (l_nmod) measures_21\NNS\168237|on|reflecting (l_acl) reflecting_22\VBG\923793|sedation (l_dobj) sedation_23\NN\14034177|and|confusion (l_conj) confusion_25\NN\13972797|
1728915
D002220_D006331 NONE carbamazepine-induced_0\NN\1740| (r_amod) dysfunction_2\NN\14204950|carbamazepine-induced|cardiac|.
D002220_D006331 NONE carbamazepine-associated_11\JJ\1740| (r_amod) dysfunction_13\NN\14204950|of|carbamazepine-associated|cardiac
D002220_D001919 CID carbamazepine_11\NN\1740|by (r_nmod) induced_9\VBN\1627355|carbamazepine (r_acl) bradycardia_4\NN\14110674|with|sinus|and|block|,|induced
D002220_D001919 CID carbamazepine_26\NN\1740| (r_compound) levels_28\NNS\4916342|with|therapeutic|carbamazepine|serum (r_nmod) associated_19\VBN\628491|levels (r_acl) bradyarrhythmias_13\NNS\1740|life-threatening|or|delay|,|associated
D002220_D054537 CID carbamazepine_11\NN\1740|by (r_nmod) induced_9\VBN\1627355|carbamazepine (r_acl) bradycardia_4\NN\14110674|with|sinus|and|block|,|induced (l_conj) block_7\NN\21939|atrioventricular
D002220_D054537 CID carbamazepine_26\NN\1740| (r_compound) levels_28\NNS\4916342|with|therapeutic|carbamazepine|serum (r_nmod) associated_19\VBN\628491|levels (r_acl) bradyarrhythmias_13\NNS\1740|life-threatening|or|delay|,|associated (l_conj) delay_17\NN\15271008|atrioventricular|conduction
D002220_D013616 CID carbamazepine_12\NN\1740| (r_compound) overdose_13\NN\1740|of|a|massive|carbamazepine (r_nmod) setting_8\NN\8567235|in|the|overdose (r_nmod) developed_3\VBD\1753788|group|tachycardias|setting|. (l_dobj) tachycardias_5\NNS\14110674|sinus
D002220_D062787 NONE carbamazepine_12\NN\1740| (r_compound) overdose_13\NN\1740|of|a|massive|carbamazepine
D002220_D001523 NONE carbamazepine_1\NN\1740| (r_nsubjpass) used_4\VBN\1156834|because|carbamazepine|is|widely|treatment (l_nmod) treatment_7\NN\654885|in|the|conditions (l_nmod) conditions_13\NNS\14512817|of|neurologic (l_amod) neurologic_10\JJ\1740|many|and|psychiatric (l_conj) psychiatric_12\JJ\1740|
15276120
D014859_D006470 CID warfarin-associated_3\JJ\1740| (r_nummod) hemorrhage_4\NN\14285662|in|warfarin-associated
D014859_D006470 CID warfarin-related_4\JJ\1740| (r_amod) bleeding_5\NN\14285662|of|warfarin-related|hospital
133615
D003276_D013923 NONE contraceptive_8\JJ\1740| (r_amod) therapy_9\NN\657604|of|oral|contraceptive (r_nmod) complications_5\NNS\1073995|therapy (r_dep) thromboembolic_2\JJ\1740|and|other|complications|relationship|:
D003276_D001778 CID contraceptive_8\JJ\1740| (r_amod) therapy_9\NN\657604|of|oral|contraceptive (r_nmod) complications_5\NNS\1073995|therapy (r_dep) thromboembolic_2\JJ\1740|and|other|complications|relationship|: (l_nmod) relationship_11\NN\31921|in|levels (l_nmod) levels_14\NNS\4916342|to|pretreatment|factors (l_nmod) factors_18\NNS\7326557|of|blood|coagulation (l_compound) coagulation_17\NN\13518963|
11467664
D008687_D041781 CID metformin_7\NN\2719105|of (r_nmod) use_5\NN\407535|with|the|metformin (r_nmod) associated_2\VBN\628491|use (r_acl) jaundice_1\NN\14299637|cholestatic|associated|.
D008687_D041781 CID hydrochloride_15\NN\14817592|with|metformin (r_nmod) treatment_12\NN\654885|of|hydrochloride (r_nmod) initiation_10\NN\7450842|after|treatment (r_nmod) developed_5\VBD\1753788|who|jaundice|initiation (l_dobj) jaundice_7\NN\14299637|cholestatic
D008687_D007565 NONE hydrochloride_1\NN\14817592|metformin (r_nsubjpass) discontinued_3\VBN\2609764|hydrochloride|was|,|and|resolved (l_conj) resolved_10\VBD\352826|jaundice|slowly|period|. (l_nsubj) jaundice_9\NN\14299637|patient
D008687_D007565 NONE metformin_12\NN\2719105|of (r_nmod) initiation_10\NN\7450842|after|the|metformin (r_nmod) onset_2\NN\7325190|given|the|jaundice|initiation (l_nmod) jaundice_5\NN\14299637|of|his
D008687_D007565 NONE metformin-associated_23\JJ\1740| (r_amod) hepatotoxicity_24\NN\1740|of|metformin-associated|,|case (r_nmod) example_21\NN\5816287|an|hepatotoxicity (r_dobj) represents_19\VBZ\2664769|that|case|example (r_ccomp) believe_15\VBP\686447|onset|,|we|represents|. (l_nmod) onset_2\NN\7325190|given|the|jaundice|initiation (l_nmod) jaundice_5\NN\14299637|of|his
D008687_D056486 NONE metformin_12\NN\2719105|of (r_nmod) initiation_10\NN\7450842|after|the|metformin (r_nmod) onset_2\NN\7325190|given|the|jaundice|initiation (r_nmod) believe_15\VBP\686447|onset|,|we|represents|. (l_ccomp) represents_19\VBZ\2664769|that|case|example (l_dobj) example_21\NN\5816287|an|hepatotoxicity (l_nmod) hepatotoxicity_24\NN\1740|of|metformin-associated|,|case
D008687_D056486 NONE metformin-associated_23\JJ\1740| (r_amod) hepatotoxicity_24\NN\1740|of|metformin-associated|,|case
9431903
D005996_D046628 NONE trinitrate_3\NN\1740|of|glyceryl (r_nmod) effect_0\NN\34213|trinitrate|spasm|. (l_nmod) spasm_9\NN\14299637|on|the|sphincter|of|oddi|evoked
D005996_D046628 NONE trinitrate_9\NN\1740|of|glyceryl (r_nmod) effect_6\NN\34213|the|trinitrate|spasm (l_nmod) spasm_16\NN\14299637|on|the|sphincter|of|oddi
D005996_D046628 NONE trinitrate_9\NN\1740|of|glyceryl (r_nmod) effect_6\NN\34213|the|trinitrate|spasm (r_nsubjpass) evaluated_18\VBN\670261|study|effect|was|patients|. (l_nmod) patients_22\NNS\9898892|in|nine|female|dyskinesia (l_nmod) dyskinesia_27\NN\14084880|with|sphincter|of|oddi
D005996_D046628 NONE trinitrate_13\NN\1740|of|glyceryl (r_nmod) effectiveness_10\NN\5190804|of|the|trinitrate|spasm (l_nmod) spasm_20\NN\14299637|on|the|sphincter|of|oddi|humans
D005996_D046628 NONE trinitrate_2\NN\1740|glyceryl (r_nsubj) able_4\JJ\1740|since|trinitrate|is|overcome (r_advcl) relevance_18\NN\13791389|able|,|it|might|be|of|treatment|. (l_nmod) treatment_21\NN\654885|in|the|dyskinesia (l_nmod) dyskinesia_26\NN\14084880|of|sphincter|of|oddi
D005996_D013035 NONE trinitrate_3\NN\1740|of|glyceryl (r_nmod) effect_0\NN\34213|trinitrate|spasm|. (l_nmod) spasm_9\NN\14299637|on|the|sphincter|of|oddi|evoked
D005996_D013035 NONE trinitrate_9\NN\1740|of|glyceryl (r_nmod) effect_6\NN\34213|the|trinitrate|spasm (l_nmod) spasm_16\NN\14299637|on|the|sphincter|of|oddi
D005996_D013035 NONE trinitrate_13\NN\1740|of|glyceryl (r_nmod) effectiveness_10\NN\5190804|of|the|trinitrate|spasm (l_nmod) spasm_20\NN\14299637|on|the|sphincter|of|oddi|humans
D009388_D046628 CID prostigmine-morphine_12\NN\1740| (r_compound) administration_13\NN\1133281|by|prostigmine-morphine (r_nmod) evoked_10\VBN\1617192|administration (r_acl) spasm_9\NN\14299637|on|the|sphincter|of|oddi|evoked
D009388_D046628 CID prostigmine-morphine-induced_12\JJ\1740| (r_amod) sphincter_13\NN\5289297|prostigmine-morphine-induced (r_compound) spasm_16\NN\14299637|on|the|sphincter|of|oddi
D009388_D046628 CID prostigmine-morphine-induced_12\JJ\1740| (r_amod) sphincter_13\NN\5289297|prostigmine-morphine-induced (r_compound) spasm_16\NN\14299637|on|the|sphincter|of|oddi (r_nmod) effect_6\NN\34213|the|trinitrate|spasm (r_nsubjpass) evaluated_18\VBN\670261|study|effect|was|patients|. (l_nmod) patients_22\NNS\9898892|in|nine|female|dyskinesia (l_nmod) dyskinesia_27\NN\14084880|with|sphincter|of|oddi
D009388_D046628 CID prostigmine-morphine_9\NN\1740| (r_compound) administration_10\NN\1133281|by|prostigmine-morphine|prostigmine (r_nmod) induced_7\VBN\1627355|spasm|was|administration|and|visualized|. (l_nsubjpass) spasm_5\NN\14299637|sphincter|of|oddi
D009388_D046628 CID prostigmine_14\NN\1740|(|mg|intramuscularly|and|morphine|) (r_dep) administration_10\NN\1133281|by|prostigmine-morphine|prostigmine (r_nmod) induced_7\VBN\1627355|spasm|was|administration|and|visualized|. (l_nsubjpass) spasm_5\NN\14299637|sphincter|of|oddi
D009388_D013035 CID prostigmine-morphine_12\NN\1740| (r_compound) administration_13\NN\1133281|by|prostigmine-morphine (r_nmod) evoked_10\VBN\1617192|administration (r_acl) spasm_9\NN\14299637|on|the|sphincter|of|oddi|evoked
D009388_D013035 CID prostigmine-morphine-induced_12\JJ\1740| (r_amod) sphincter_13\NN\5289297|prostigmine-morphine-induced (r_compound) spasm_16\NN\14299637|on|the|sphincter|of|oddi
D009388_D013035 CID prostigmine-morphine_9\NN\1740| (r_compound) administration_10\NN\1133281|by|prostigmine-morphine|prostigmine (r_nmod) induced_7\VBN\1627355|spasm|was|administration|and|visualized|. (l_nsubjpass) spasm_5\NN\14299637|sphincter|of|oddi
D009388_D013035 CID prostigmine_14\NN\1740|(|mg|intramuscularly|and|morphine|) (r_dep) administration_10\NN\1133281|by|prostigmine-morphine|prostigmine (r_nmod) induced_7\VBN\1627355|spasm|was|administration|and|visualized|. (l_nsubjpass) spasm_5\NN\14299637|sphincter|of|oddi
D009388_D013035 CID prostigmine-morphine_2\NN\1740| (r_compound) provocation_3\NN\1221611|prostigmine-morphine (r_nsubj) caused_4\VBD\1617192|provocation|increases|,|indicating (l_advcl) indicating_94\VBG\952524|spasm (l_dobj) spasm_97\NN\14299637|a|complete|level
D009020_D046628 CID prostigmine-morphine_12\NN\1740| (r_compound) administration_13\NN\1133281|by|prostigmine-morphine (r_nmod) evoked_10\VBN\1617192|administration (r_acl) spasm_9\NN\14299637|on|the|sphincter|of|oddi|evoked
D009020_D046628 CID prostigmine-morphine-induced_12\JJ\1740| (r_amod) sphincter_13\NN\5289297|prostigmine-morphine-induced (r_compound) spasm_16\NN\14299637|on|the|sphincter|of|oddi
D009020_D046628 CID prostigmine-morphine-induced_12\JJ\1740| (r_amod) sphincter_13\NN\5289297|prostigmine-morphine-induced (r_compound) spasm_16\NN\14299637|on|the|sphincter|of|oddi (r_nmod) effect_6\NN\34213|the|trinitrate|spasm (r_nsubjpass) evaluated_18\VBN\670261|study|effect|was|patients|. (l_nmod) patients_22\NNS\9898892|in|nine|female|dyskinesia (l_nmod) dyskinesia_27\NN\14084880|with|sphincter|of|oddi
D009020_D046628 CID prostigmine-morphine_9\NN\1740| (r_compound) administration_10\NN\1133281|by|prostigmine-morphine|prostigmine (r_nmod) induced_7\VBN\1627355|spasm|was|administration|and|visualized|. (l_nsubjpass) spasm_5\NN\14299637|sphincter|of|oddi
D009020_D046628 CID morphine_19\NN\2707683|mg|subcutaneously (r_conj) prostigmine_14\NN\1740|(|mg|intramuscularly|and|morphine|) (r_dep) administration_10\NN\1133281|by|prostigmine-morphine|prostigmine (r_nmod) induced_7\VBN\1627355|spasm|was|administration|and|visualized|. (l_nsubjpass) spasm_5\NN\14299637|sphincter|of|oddi
D009020_D046628 CID morphine-induced_16\JJ\1740| (r_amod) sphincter_17\NN\5289297|morphine-induced (r_compound) spasm_20\NN\14299637|on|the|sphincter|of|oddi|humans
D009020_D046628 CID morphine_12\NN\2707683|of (r_nmod) effect_10\NN\34213|even|the|drastic|morphine (r_dobj) overcome_6\VB\1101913|to|effect (r_xcomp) able_4\JJ\1740|since|trinitrate|is|overcome (r_advcl) relevance_18\NN\13791389|able|,|it|might|be|of|treatment|. (l_nmod) treatment_21\NN\654885|in|the|dyskinesia (l_nmod) dyskinesia_26\NN\14084880|of|sphincter|of|oddi
D009020_D013035 CID prostigmine-morphine_12\NN\1740| (r_compound) administration_13\NN\1133281|by|prostigmine-morphine (r_nmod) evoked_10\VBN\1617192|administration (r_acl) spasm_9\NN\14299637|on|the|sphincter|of|oddi|evoked
D009020_D013035 CID prostigmine-morphine-induced_12\JJ\1740| (r_amod) sphincter_13\NN\5289297|prostigmine-morphine-induced (r_compound) spasm_16\NN\14299637|on|the|sphincter|of|oddi
D009020_D013035 CID prostigmine-morphine_9\NN\1740| (r_compound) administration_10\NN\1133281|by|prostigmine-morphine|prostigmine (r_nmod) induced_7\VBN\1627355|spasm|was|administration|and|visualized|. (l_nsubjpass) spasm_5\NN\14299637|sphincter|of|oddi
D009020_D013035 CID morphine_19\NN\2707683|mg|subcutaneously (r_conj) prostigmine_14\NN\1740|(|mg|intramuscularly|and|morphine|) (r_dep) administration_10\NN\1133281|by|prostigmine-morphine|prostigmine (r_nmod) induced_7\VBN\1627355|spasm|was|administration|and|visualized|. (l_nsubjpass) spasm_5\NN\14299637|sphincter|of|oddi
D009020_D013035 CID prostigmine-morphine_2\NN\1740| (r_compound) provocation_3\NN\1221611|prostigmine-morphine (r_nsubj) caused_4\VBD\1617192|provocation|increases|,|indicating (l_advcl) indicating_94\VBG\952524|spasm (l_dobj) spasm_97\NN\14299637|a|complete|level
D009020_D013035 CID morphine-induced_16\JJ\1740| (r_amod) sphincter_17\NN\5289297|morphine-induced (r_compound) spasm_20\NN\14299637|on|the|sphincter|of|oddi|humans
17074608
D014635_D002819 CID valproate-induced_0\JJ\1740| (r_amod) chorea_1\NN\14253124|valproate-induced|and|encephalopathy|hyperglycinemia|.
D014635_D002819 CID valproate_32\NN\1740| (r_compound) therapy_33\NN\657604|of|valproate (r_nmod) initiation_30\NN\7450842|after|therapy (r_nmod) presentation_22\NN\1027379|following|her|encephalopathy|initiation (l_nmod) encephalopathy_25\NN\14084880|with|acute|and|chorea (l_conj) chorea_27\NN\14253124|
D014635_D001927 CID valproate-induced_0\JJ\1740| (r_amod) chorea_1\NN\14253124|valproate-induced|and|encephalopathy|hyperglycinemia|. (l_conj) encephalopathy_3\NN\14084880|
D014635_D001927 CID valproate_32\NN\1740| (r_compound) therapy_33\NN\657604|of|valproate (r_nmod) initiation_30\NN\7450842|after|therapy (r_nmod) presentation_22\NN\1027379|following|her|encephalopathy|initiation (l_nmod) encephalopathy_25\NN\14084880|with|acute|and|chorea
D014635_D020158 NONE valproate-induced_0\JJ\1740| (r_amod) chorea_1\NN\14253124|valproate-induced|and|encephalopathy|hyperglycinemia|. (l_nmod) hyperglycinemia_7\NN\1740|in|atypical|nonketotic
D014635_D020158 NONE valproate_32\NN\1740| (r_compound) therapy_33\NN\657604|of|valproate (r_nmod) initiation_30\NN\7450842|after|therapy (r_nmod) presentation_22\NN\1027379|following|her|encephalopathy|initiation (r_nmod) have_17\VB\2108377|to|hyperglycinemia|presentation (l_dobj) hyperglycinemia_19\NN\1740|nonketotic
D005998_D020158 NONE glycine_15\NN\14601829| (r_compound) system_17\NN\3575240|in|the|glycine|cleavage (r_nmod) defect_12\NN\14462666|a|system (r_nsubj) leads_18\VBZ\1752884|which|defect|accumulation (r_acl:relcl) disorder_4\NN\14034177|hyperglycinemia|is|a|metabolism|leads|. (l_nsubj) hyperglycinemia_1\NN\1740|nonketotic
D005998_D020158 NONE glycine_23\NN\14601829|of (r_nmod) accumulation_21\NN\13497135|to|an|glycine|brain (r_nmod) leads_18\VBZ\1752884|which|defect|accumulation (r_acl:relcl) disorder_4\NN\14034177|hyperglycinemia|is|a|metabolism|leads|. (l_nsubj) hyperglycinemia_1\NN\1740|nonketotic
D005998_D000592 NONE glycine_15\NN\14601829| (r_compound) system_17\NN\3575240|in|the|glycine|cleavage (r_nmod) defect_12\NN\14462666|a|system (r_nsubj) leads_18\VBZ\1752884|which|defect|accumulation (r_acl:relcl) disorder_4\NN\14034177|hyperglycinemia|is|a|metabolism|leads|. (l_nmod) metabolism_8\NN\13526110|of|amino|acid
D005998_D000592 NONE glycine_23\NN\14601829|of (r_nmod) accumulation_21\NN\13497135|to|an|glycine|brain (r_nmod) leads_18\VBZ\1752884|which|defect|accumulation (r_acl:relcl) disorder_4\NN\14034177|hyperglycinemia|is|a|metabolism|leads|. (l_nmod) metabolism_8\NN\13526110|of|amino|acid
D014635_D007805 NONE valproate_32\NN\1740| (r_compound) therapy_33\NN\657604|of|valproate (r_nmod) initiation_30\NN\7450842|after|therapy (r_nmod) presentation_22\NN\1027379|following|her|encephalopathy|initiation (r_nmod) have_17\VB\2108377|to|hyperglycinemia|presentation (r_xcomp) found_15\VBN\2426171|who|was|have (r_acl:relcl) patient_4\NN\9898892|a|delay|,|found (l_nmod) delay_8\NN\15271008|with|mild|language|and|retardation
D014635_D008607 NONE valproate_32\NN\1740| (r_compound) therapy_33\NN\657604|of|valproate (r_nmod) initiation_30\NN\7450842|after|therapy (r_nmod) presentation_22\NN\1027379|following|her|encephalopathy|initiation (r_nmod) have_17\VB\2108377|to|hyperglycinemia|presentation (r_xcomp) found_15\VBN\2426171|who|was|have (r_acl:relcl) patient_4\NN\9898892|a|delay|,|found (l_nmod) delay_8\NN\15271008|with|mild|language|and|retardation (l_conj) retardation_11\NN\7296428|mental
12907924
D008774_D009771 CID methylphenidate-induced_0\JJ\1740| (r_amod) symptoms_2\NNS\5823932|methylphenidate-induced|obsessive-compulsive|man|.
D008774_D009771 CID methylphenidate_10\NN\4320126| (r_nsubjpass) replaced_12\VBN\1631072|when|methylphenidate|was|fluvoxamine (r_advcl) diminished_5\VBD\169651|weeks|replaced (r_conj) ensued_3\VBD\2633881|behavior|but|diminished|. (l_nsubj) behavior_2\NN\407535|significant|obsessive-compulsive
D008774_D061218 NONE methylphenidate_14\NN\4320126|on (r_nmod) started_12\VBN\2009433|man|was|methylphenidate|. (l_nsubjpass) man_2\NN\9605289|an|82-year-old|depression (l_nmod) depression_5\NN\14373582|with|treatment-resistant|and|disease
D008774_D000544 NONE methylphenidate_14\NN\4320126|on (r_nmod) started_12\VBN\2009433|man|was|methylphenidate|. (l_nsubjpass) man_2\NN\9605289|an|82-year-old|depression (l_nmod) depression_5\NN\14373582|with|treatment-resistant|and|disease (l_conj) disease_10\NN\14061805|early|alzheimer|'s
D016666_D009771 NONE fluvoxamine_14\NN\1740|by (r_nmod) replaced_12\VBN\1631072|when|methylphenidate|was|fluvoxamine (r_advcl) diminished_5\VBD\169651|weeks|replaced (r_conj) ensued_3\VBD\2633881|behavior|but|diminished|. (l_nsubj) behavior_2\NN\407535|significant|obsessive-compulsive
8686832
D008012_D001416 CID lignocaine_11\NN\1740|hyperbaric|% (r_dobj) involving_7\VBG\2676054|lignocaine (r_acl) anaesthesia_6\NN\14034177|after|spinal|involving (r_nmod) pain_3\NN\14299637|leg|anaesthesia|.
D008012_D001416 CID lignocaine_14\NN\1740|of|hyperbaric|% (r_nmod) use_9\NN\407535|with|the|intrathecal|lignocaine (r_nmod) associated_5\VBN\628491|pain|is|use|. (l_nsubjpass) pain_3\NN\14299637|leg
D000431_D010146 NONE alcohol_27\NN\7881800| (r_compound) intake_28\NN\13440063|to|a|high|alcohol|,|factor (r_nmod) admitted_23\VBD\822367|five|intake|. (l_nsubj) five_0\CD\13741022|patients|and|seven (l_nmod) patients_4\NNS\9898892|of|the|13|%|pain (l_nmod) pain_10\NN\14299637|with
D000431_D010146 NONE alcohol_27\NN\7881800| (r_compound) intake_28\NN\13440063|to|a|high|alcohol|,|factor (r_nmod) admitted_23\VBD\822367|five|intake|. (l_nsubj) five_0\CD\13741022|patients|and|seven (l_conj) seven_12\CD\13741022|patients (l_nmod) patients_16\NNS\9898892|of|the|41|%|pain (l_nmod) pain_22\NN\14299637|without
9098464
D005473_D062788 CID hydrochloride_13\NN\14817592|by|fluoxetine|,|inhibitor|, (r_nmod) induced_10\VBN\1627355|hydrochloride (r_acl) hyperprolactinemia_9\NN\1740|of|induced (r_nmod) effects_7\NNS\13245626|the|hyperprolactinemia|induction (r_dep) model_2\NN\5888929|a|murine|adenomyosis|:|effects|. (l_nmod) adenomyosis_4\NN\14204950|of
D005473_D062788 CID hydrochloride_13\NN\14817592|by|fluoxetine|,|inhibitor|, (r_nmod) induced_10\VBN\1627355|hydrochloride (r_acl) hyperprolactinemia_9\NN\1740|of|induced (r_nmod) effects_7\NNS\13245626|the|hyperprolactinemia|induction (l_nmod) induction_23\NN\7450842|on|adenomyosis|rats (l_compound) adenomyosis_22\NN\14204950|
D005473_D062788 CID fluoxetine_11\NN\4169152|given (r_nsubj) caused_18\VBD\1617192|whether|fluoxetine|hyperprolactinemia|respect (l_nmod) respect_24\NN\5817845|with|adenomyosis (l_nmod) adenomyosis_26\NN\14204950|to
D005473_D062788 CID fluoxetine_14\NN\4169152| (r_dobj) receiving_13\VBG\2210855|fluoxetine (r_acl) group_12\NN\2137|within|the|noncastrated|receiving (r_nmod) all_8\DT\1740|group (r_amod) cases_4\NNS\7283608|11|adenomyosis|,|all (l_nmod) adenomyosis_6\NN\14204950|of
D005473_D006966 CID hydrochloride_13\NN\14817592|by|fluoxetine|,|inhibitor|, (r_nmod) induced_10\VBN\1627355|hydrochloride (r_acl) hyperprolactinemia_9\NN\1740|of|induced
D005473_D006966 CID fluoxetine_11\NN\4169152|given (r_nsubj) caused_18\VBD\1617192|whether|fluoxetine|hyperprolactinemia|respect (l_dobj) hyperprolactinemia_19\NN\1740|and|effects
D005473_D006966 CID fluoxetine_2\NN\4169152|,|inhibitor|, (r_nsubjpass) given_10\VBN\2327200|fluoxetine|was|rats|days|produce|. (l_advcl) produce_19\VB\1617192|to|hyperprolactinemia (l_dobj) hyperprolactinemia_20\NN\1740|
D012701_D062788 NONE serotonin_17\NN\14807737| (r_compound) inhibitor_19\NN\20090|a|selective|serotonin|reuptake (r_appos) hydrochloride_13\NN\14817592|by|fluoxetine|,|inhibitor|, (r_nmod) induced_10\VBN\1627355|hydrochloride (r_acl) hyperprolactinemia_9\NN\1740|of|induced (r_nmod) effects_7\NNS\13245626|the|hyperprolactinemia|induction (r_dep) model_2\NN\5888929|a|murine|adenomyosis|:|effects|. (l_nmod) adenomyosis_4\NN\14204950|of
D012701_D062788 NONE serotonin_17\NN\14807737| (r_compound) inhibitor_19\NN\20090|a|selective|serotonin|reuptake (r_appos) hydrochloride_13\NN\14817592|by|fluoxetine|,|inhibitor|, (r_nmod) induced_10\VBN\1627355|hydrochloride (r_acl) hyperprolactinemia_9\NN\1740|of|induced (r_nmod) effects_7\NNS\13245626|the|hyperprolactinemia|induction (l_nmod) induction_23\NN\7450842|on|adenomyosis|rats (l_compound) adenomyosis_22\NN\14204950|
D012701_D006966 NONE serotonin_17\NN\14807737| (r_compound) inhibitor_19\NN\20090|a|selective|serotonin|reuptake (r_appos) hydrochloride_13\NN\14817592|by|fluoxetine|,|inhibitor|, (r_nmod) induced_10\VBN\1627355|hydrochloride (r_acl) hyperprolactinemia_9\NN\1740|of|induced
D012701_D006966 NONE serotonin_5\NN\14807737| (r_compound) inhibitor_7\NN\20090|a|serotonin|reuptake (r_appos) fluoxetine_2\NN\4169152|,|inhibitor|, (r_nsubjpass) given_10\VBN\2327200|fluoxetine|was|rats|days|produce|. (l_advcl) produce_19\VB\1617192|to|hyperprolactinemia (l_dobj) hyperprolactinemia_20\NN\1740|
16720068
D017374_D009459 CID paroxetine_9\NN\1740|with|and|alprazolam (r_nmod) treatment_7\NN\654885|to|concomitant|paroxetine (r_nmod) related_4\JJ\1740|treatment (r_acl) syndrome_3\NN\5870365|possible|neuroleptic|malignant|related|.
D017374_D009459 CID paroxetine_22\NN\1740|combined|and|alprazolam (r_compound) treatment_25\NN\654885|after|paroxetine (r_nmod) occur_19\VB\2623529|that|symptoms|can|treatment (r_ccomp) demonstrating_14\VBG\2137132|thus|occur (r_advcl) presented_2\VBD\2137132|patient|symptoms|,|demonstrating|. (l_nmod) symptoms_4\NNS\5823932|with|syndrome (l_nmod) syndrome_8\NN\5870365|of|neuroleptic|malignant|nms
D017374_D009459 CID paroxetine_22\NN\1740|combined|and|alprazolam (r_compound) treatment_25\NN\654885|after|paroxetine (r_nmod) occur_19\VB\2623529|that|symptoms|can|treatment (r_ccomp) demonstrating_14\VBG\2137132|thus|occur (r_advcl) presented_2\VBD\2137132|patient|symptoms|,|demonstrating|. (l_nmod) symptoms_4\NNS\5823932|with|syndrome (l_nmod) syndrome_8\NN\5870365|of|neuroleptic|malignant|nms (l_appos) nms_10\NN\13649268|(|)
D017374_D009459 CID paroxetine_22\NN\1740|combined|and|alprazolam (r_compound) treatment_25\NN\654885|after|paroxetine (r_nmod) occur_19\VB\2623529|that|symptoms|can|treatment (l_nsubj) symptoms_17\NNS\5823932|nms-like (l_amod) nms-like_16\JJ\1740|
D000525_D009459 CID alprazolam_11\NN\2830852| (r_conj) paroxetine_9\NN\1740|with|and|alprazolam (r_nmod) treatment_7\NN\654885|to|concomitant|paroxetine (r_nmod) related_4\JJ\1740|treatment (r_acl) syndrome_3\NN\5870365|possible|neuroleptic|malignant|related|.
D000525_D009459 CID alprazolam_24\NN\2830852| (r_conj) paroxetine_22\NN\1740|combined|and|alprazolam (r_compound) treatment_25\NN\654885|after|paroxetine (r_nmod) occur_19\VB\2623529|that|symptoms|can|treatment (r_ccomp) demonstrating_14\VBG\2137132|thus|occur (r_advcl) presented_2\VBD\2137132|patient|symptoms|,|demonstrating|. (l_nmod) symptoms_4\NNS\5823932|with|syndrome (l_nmod) syndrome_8\NN\5870365|of|neuroleptic|malignant|nms
D000525_D009459 CID alprazolam_24\NN\2830852| (r_conj) paroxetine_22\NN\1740|combined|and|alprazolam (r_compound) treatment_25\NN\654885|after|paroxetine (r_nmod) occur_19\VB\2623529|that|symptoms|can|treatment (r_ccomp) demonstrating_14\VBG\2137132|thus|occur (r_advcl) presented_2\VBD\2137132|patient|symptoms|,|demonstrating|. (l_nmod) symptoms_4\NNS\5823932|with|syndrome (l_nmod) syndrome_8\NN\5870365|of|neuroleptic|malignant|nms (l_appos) nms_10\NN\13649268|(|)
D000525_D009459 CID alprazolam_24\NN\2830852| (r_conj) paroxetine_22\NN\1740|combined|and|alprazolam (r_compound) treatment_25\NN\654885|after|paroxetine (r_nmod) occur_19\VB\2623529|that|symptoms|can|treatment (l_nsubj) symptoms_17\NNS\5823932|nms-like (l_amod) nms-like_16\JJ\1740|
D017374_D011596 NONE paroxetine_5\NN\1740|and|alprazolam (r_compound) treatment_8\NN\654885|of|paroxetine (r_nmod) day_3\NN\15154774|on|the|10th|treatment (r_nmod) exhibited_12\VBD\2632167|day|,|patient|retardation|. (l_dobj) retardation_15\NN\7296428|marked|psychomotor|,|disorientation|rigidity
D017374_D009127 NONE paroxetine_5\NN\1740|and|alprazolam (r_compound) treatment_8\NN\654885|of|paroxetine (r_nmod) day_3\NN\15154774|on|the|10th|treatment (r_nmod) exhibited_12\VBD\2632167|day|,|patient|retardation|. (l_dobj) retardation_15\NN\7296428|marked|psychomotor|,|disorientation|rigidity (l_conj) rigidity_22\NN\5023233|severe|muscle|tremors
D017374_D014202 NONE paroxetine_5\NN\1740|and|alprazolam (r_compound) treatment_8\NN\654885|of|paroxetine (r_nmod) day_3\NN\15154774|on|the|10th|treatment (r_nmod) exhibited_12\VBD\2632167|day|,|patient|retardation|. (l_dobj) retardation_15\NN\7296428|marked|psychomotor|,|disorientation|rigidity (l_conj) rigidity_22\NN\5023233|severe|muscle|tremors (l_nmod) tremors_24\NNS\345926|with
D000525_D011596 NONE alprazolam_7\NN\2830852| (r_conj) paroxetine_5\NN\1740|and|alprazolam (r_compound) treatment_8\NN\654885|of|paroxetine (r_nmod) day_3\NN\15154774|on|the|10th|treatment (r_nmod) exhibited_12\VBD\2632167|day|,|patient|retardation|. (l_dobj) retardation_15\NN\7296428|marked|psychomotor|,|disorientation|rigidity
D000525_D009127 NONE alprazolam_7\NN\2830852| (r_conj) paroxetine_5\NN\1740|and|alprazolam (r_compound) treatment_8\NN\654885|of|paroxetine (r_nmod) day_3\NN\15154774|on|the|10th|treatment (r_nmod) exhibited_12\VBD\2632167|day|,|patient|retardation|. (l_dobj) retardation_15\NN\7296428|marked|psychomotor|,|disorientation|rigidity (l_conj) rigidity_22\NN\5023233|severe|muscle|tremors
D000525_D014202 NONE alprazolam_7\NN\2830852| (r_conj) paroxetine_5\NN\1740|and|alprazolam (r_compound) treatment_8\NN\654885|of|paroxetine (r_nmod) day_3\NN\15154774|on|the|10th|treatment (r_nmod) exhibited_12\VBD\2632167|day|,|patient|retardation|. (l_dobj) retardation_15\NN\7296428|marked|psychomotor|,|disorientation|rigidity (l_conj) rigidity_22\NN\5023233|severe|muscle|tremors (l_nmod) tremors_24\NNS\345926|with
921394
D007649_D003866 NONE ketamine_2\NN\3054098|of (r_nmod) injections_0\NNS\320852|ketamine|doses|artery (r_nsubj) produced_14\VBD\1617192|injections|depression|. (l_dobj) depression_16\NN\14373582|a|activity|action
D007649_D013610 CID ketamine-induced_18\JJ\1740| (r_amod) tachycardia_19\NN\14110674|of|the|ketamine-induced
7102237
D012601_D001049 NONE scopolamine_4\NN\14712692|with|+|morphine|(|+|nitrazepam (r_nmod) premedicated_2\VBN\1740|scopolamine (r_acl) patients_1\NNS\9898892|in|premedicated|evening|) (r_nmod) slower_28\JJR\1740|patients|,|effect|was|clearly|onset|that|i.v.|found (l_parataxis) found_45\VBN\2426171|sequelae|were|group|,|but|,|lasted|. (l_conj) lasted_63\VBD\2704349|occurred|it|longer (l_advcl) occurred_55\VBD\2623529|although|apnoea|often|group (l_nsubj) apnoea_54\NN\1740|
D009020_D001049 NONE morphine_6\NN\2707683| (r_conj) scopolamine_4\NN\14712692|with|+|morphine|(|+|nitrazepam (r_nmod) premedicated_2\VBN\1740|scopolamine (r_acl) patients_1\NNS\9898892|in|premedicated|evening|) (r_nmod) slower_28\JJR\1740|patients|,|effect|was|clearly|onset|that|i.v.|found (l_parataxis) found_45\VBN\2426171|sequelae|were|group|,|but|,|lasted|. (l_conj) lasted_63\VBD\2704349|occurred|it|longer (l_advcl) occurred_55\VBD\2623529|although|apnoea|often|group (l_nsubj) apnoea_54\NN\1740|
D009567_D001049 NONE nitrazepam_11\NN\2830852|mg (r_conj) scopolamine_4\NN\14712692|with|+|morphine|(|+|nitrazepam (r_nmod) premedicated_2\VBN\1740|scopolamine (r_acl) patients_1\NNS\9898892|in|premedicated|evening|) (r_nmod) slower_28\JJR\1740|patients|,|effect|was|clearly|onset|that|i.v.|found (l_parataxis) found_45\VBN\2426171|sequelae|were|group|,|but|,|lasted|. (l_conj) lasted_63\VBD\2704349|occurred|it|longer (l_advcl) occurred_55\VBD\2623529|although|apnoea|often|group (l_nsubj) apnoea_54\NN\1740|
D008874_D001049 CID midazolam_22\NN\2830852|of|mg/kg (r_nmod) effect_20\NN\34213|the|sleep-inducing|midazolam|i.v. (r_nsubj) slower_28\JJR\1740|patients|,|effect|was|clearly|onset|that|i.v.|found (l_parataxis) found_45\VBN\2426171|sequelae|were|group|,|but|,|lasted|. (l_conj) lasted_63\VBD\2704349|occurred|it|longer (l_advcl) occurred_55\VBD\2623529|although|apnoea|often|group (l_nsubj) apnoea_54\NN\1740|
D008874_D001049 CID midazolam_48\NN\2830852| (r_compound) group_49\NN\2137|in|the|midazolam (r_nmod) found_45\VBN\2426171|sequelae|were|group|,|but|,|lasted|. (l_conj) lasted_63\VBD\2704349|occurred|it|longer (l_advcl) occurred_55\VBD\2623529|although|apnoea|often|group (l_nsubj) apnoea_54\NN\1740|
D008874_D001049 CID midazolam_60\NN\2830852| (r_compound) group_61\NN\2137|in|the|midazolam (r_nmod) occurred_55\VBD\2623529|although|apnoea|often|group (l_nsubj) apnoea_54\NN\1740|
D013874_D001049 CID thiopentone_34\NN\1740|of|mg/kg (r_nmod) that_32\DT\1740|than|thiopentone (r_nmod) slower_28\JJR\1740|patients|,|effect|was|clearly|onset|that|i.v.|found (l_parataxis) found_45\VBN\2426171|sequelae|were|group|,|but|,|lasted|. (l_conj) lasted_63\VBD\2704349|occurred|it|longer (l_advcl) occurred_55\VBD\2623529|although|apnoea|often|group (l_nsubj) apnoea_54\NN\1740|
2339463
D015119_D020225 NONE acid_18\NN\14818238|epsilon-aminocaproic (r_compound) therapy_19\NN\657604|with|prolonged|acid|menorrhagia (r_nmod) associated_14\VBN\628491|therapy (r_acl) thrombosis_13\NN\14100769|sagittal|sinus|associated
D015119_D020227 NONE acid_18\NN\14818238|epsilon-aminocaproic (r_compound) therapy_19\NN\657604|with|prolonged|acid|menorrhagia (r_nmod) associated_14\VBN\628491|therapy (r_acl) thrombosis_13\NN\14100769|sagittal|sinus|associated
D015119_D008595 NONE acid_18\NN\14818238|epsilon-aminocaproic (r_compound) therapy_19\NN\657604|with|prolonged|acid|menorrhagia (l_nmod) menorrhagia_21\NN\13513747|for
D015119_D013923 NONE acid_13\NN\14818238|with|epsilon-aminocaproic (r_nmod) treatment_10\NN\654885|during|acid (r_nmod) reported_8\VBN\831651|although|risk|has|been|treatment (l_nsubjpass) risk_2\NN\14541044|increased|disease (l_nmod) disease_5\NN\14061805|of|thromboembolic
D015119_D012851 NONE acid_13\NN\14818238|with|epsilon-aminocaproic (r_nmod) treatment_10\NN\654885|during|acid (r_nmod) reported_8\VBN\831651|although|risk|has|been|treatment (r_advcl) described_22\VBN\1001294|reported|,|thrombosis|has|not|been|previously|. (l_nsubjpass) thrombosis_17\NN\14100769|cerebral|sinus
18997632
D002110_D017180 CID caffeine_7\NN\14712692| (r_compound) pretreatment_8\NN\1740|to|caffeine (r_nmod) related_5\JJ\1740|pretreatment (r_amod) tachycardia_4\NN\14110674|of|ventricular|related
D002110_D017180 CID caffeine_25\NN\14712692| (r_compound) administration_26\NN\1133281|after|caffeine (r_nmod) developed_14\VBD\1753788|who|bigeminy|administration (l_dobj) bigeminy_16\NN\1740|sustained|and|runs (l_conj) runs_20\NNS\186634|2|brief|tachycardia (l_nmod) tachycardia_23\NN\14110674|of|ventricular
D002110_D012640 CID caffeine_1\NN\14712692|intravenous (r_nsubjpass) used_4\VBN\1156834|caffeine|is|commonly|improve|and|tolerated|. (l_xcomp) improve_6\VB\126264|to|duration|patients (l_dobj) duration_8\NN\15113229|seizure|and|quality (l_compound) seizure_7\NN\14081375|
D002110_D018879 CID caffeine_1\NN\14712692|intravenous (r_nsubjpass) used_4\VBN\1156834|caffeine|is|commonly|improve|and|tolerated|. (l_conj) tolerated_18\VBN\802318|is|generally|well|aside (l_advmod) aside_19\RB\1740|reports (l_nmod) reports_22\NNS\6470073|from|occasional|ectopy (l_nmod) ectopy_27\NN\1740|of|benign|ventricular
D002110_D006331 NONE caffeine_25\NN\14712692| (r_compound) administration_26\NN\1133281|after|caffeine (r_nmod) developed_14\VBD\1753788|who|bigeminy|administration (r_acl:relcl) patient_3\NN\9898892|a|history|developed (l_nmod) history_7\NN\15120823|with|no|previous|disease (l_nmod) disease_10\NN\14061805|of|cardiac|or|arrhythmia
D002110_D001145 NONE caffeine_25\NN\14712692| (r_compound) administration_26\NN\1133281|after|caffeine (r_nmod) developed_14\VBD\1753788|who|bigeminy|administration (r_acl:relcl) patient_3\NN\9898892|a|history|developed (l_nmod) history_7\NN\15120823|with|no|previous|disease (l_nmod) disease_10\NN\14061805|of|cardiac|or|arrhythmia (l_conj) arrhythmia_12\NN\14103288|
D002110_D001145 NONE caffeine_2\NN\14712692|intravenous (r_nsubjpass) tolerated_6\VBN\802318|although|caffeine|is|generally|well (r_advcl) aware_12\JJ\1740|tolerated|,|clinician|should|be|potential|. (l_nmod) potential_15\NN\14481929|of|the|arrhythmias (l_nmod) arrhythmias_21\NNS\14103288|for|unpredictable|ventricular
2528969
8278214
D009020_D006930 CID morphine_11\NN\2707683|with|continuous|intravenous (r_nmod) treated_7\VBN\2376958|morphine (r_acl) patients_6\NNS\9898892|in|terminal|cancer|treated (r_nmod) hyperalgesia_0\NN\1740|and|myoclonus|patients|.
D009020_D006930 CID morphine_16\NN\2707683|of|intravenous (r_nmod) doses_13\NNS\3740161|with|high|morphine (r_nmod) treated_10\VBN\2376958|doses (r_acl) patients_2\NNS\9898892|eight|cancer|stages|treated (r_nsubj) developed_17\VBD\1753788|patients|hyperalgesia|. (l_dobj) hyperalgesia_18\NN\1740|
D009020_D006930 CID morphine_14\NN\2707683|of (r_nmod) doses_12\NNS\3740161|high|morphine (r_conj) hyperalgesia/myoclonus_9\NN\1740|between|and|doses
D009020_D006930 CID morphine_25\NN\2707683|,|or|metabolites|, (r_nsubj) plays_31\VBZ\1072262|that|morphine|role (r_ccomp) indicates_23\VBZ\952524|available|,|support|plays|. (l_advcl) available_16\JJ\1740|although|descriptions|are (l_nsubj) descriptions_4\NNS\6722453|few|clinical|relationship (l_nmod) relationship_7\NN\31921|of|the|hyperalgesia/myoclonus (l_nmod) hyperalgesia/myoclonus_9\NN\1740|between|and|doses
D009020_D009207 CID morphine_11\NN\2707683|with|continuous|intravenous (r_nmod) treated_7\VBN\2376958|morphine (r_acl) patients_6\NNS\9898892|in|terminal|cancer|treated (r_nmod) hyperalgesia_0\NN\1740|and|myoclonus|patients|. (l_conj) myoclonus_2\NN\14360459|
D009020_D009207 CID morphine_14\NN\2707683|of (r_nmod) doses_12\NNS\3740161|high|morphine (r_conj) hyperalgesia/myoclonus_9\NN\1740|between|and|doses
D009020_D009207 CID morphine_25\NN\2707683|,|or|metabolites|, (r_nsubj) plays_31\VBZ\1072262|that|morphine|role (r_ccomp) indicates_23\VBZ\952524|available|,|support|plays|. (l_advcl) available_16\JJ\1740|although|descriptions|are (l_nsubj) descriptions_4\NNS\6722453|few|clinical|relationship (l_nmod) relationship_7\NN\31921|of|the|hyperalgesia/myoclonus (l_nmod) hyperalgesia/myoclonus_9\NN\1740|between|and|doses
D009020_D009369 NONE morphine_11\NN\2707683|with|continuous|intravenous (r_nmod) treated_7\VBN\2376958|morphine (r_acl) patients_6\NNS\9898892|in|terminal|cancer|treated (l_compound) cancer_5\NN\14239425|
D009020_D009369 NONE morphine_16\NN\2707683|of|intravenous (r_nmod) doses_13\NNS\3740161|with|high|morphine (r_nmod) treated_10\VBN\2376958|doses (r_acl) patients_2\NNS\9898892|eight|cancer|stages|treated (l_compound) cancer_1\NN\14239425|
14704468
C066440_D012640 NONE loreclezole_0\NN\1740|mg/kg (r_nsubj) exerted_5\VBD\1158872|loreclezole|action|rats|,|reducing|. (l_advcl) reducing_14\VBG\441445|durations (l_dobj) durations_19\NNS\15113229|seizure (l_compound) seizure_16\NN\14081375|both|and|afterdischarge
9758264
D005492_D008180 CID acid_4\NN\14818238|of|folic (r_nmod) activity_1\NN\30358|epileptogenic|acid|drug (r_nsubj) induces_7\VBZ\1627355|activity|sle (l_dobj) sle_8\NN\14229912|acid
D005492_D008180 CID acid_11\NN\14818238|(|folic|and|epilepsy|) (r_appos) sle_8\NN\14229912|acid
D005492_D008180 CID acid_33\NN\14818238|of|folic (r_nmod) dose_23\NN\3740161|the|therapeutic|>|mg|acid (r_nsubj) triggered_34\VBD\1641914|conclusions|,|therefore|dose|cluster|. (l_nsubj) conclusions_0\NNS\5837957|:|damage (l_dep) damage_15\VB\126264|disease|could|barrier (l_nsubj) disease_8\NN\14061805|patient|autoimmune|lupus (l_appos) lupus_12\NN\14219661|(|probably|drug-induced|)
D005492_D004827 NONE acid_4\NN\14818238|of|folic (r_nmod) activity_1\NN\30358|epileptogenic|acid|drug (r_nsubj) induces_7\VBZ\1627355|activity|sle (l_dobj) sle_8\NN\14229912|acid (l_appos) acid_11\NN\14818238|(|folic|and|epilepsy|) (l_conj) epilepsy_13\NN\14085708|
D005492_D004827 NONE acid_11\NN\14818238|(|folic|and|epilepsy|) (l_conj) epilepsy_13\NN\14085708|
D005492_D004827 NONE acid-containing_8\JJ\1740|folic (r_amod) supplementation_10\NN\5108947|of|acid-containing|multivitamin (r_nmod) effect_5\NN\34213|the|supplementation|women|before|pregnancy (l_nmod) women_13\NNS\9605289|in|epileptic (l_amod) epileptic_12\JJ\1740|
D005492_D004827 NONE acid-containing_8\JJ\1740|folic (r_amod) supplementation_10\NN\5108947|of|acid-containing|multivitamin (r_nmod) effect_5\NN\34213|the|supplementation|women|before|pregnancy (r_dobj) study_3\VB\630380|to|effect|determine (l_advcl) determine_21\VB\1645601|in|to|rate (l_dobj) rate_23\NN\13815152|the|defects (l_nmod) defects_27\NNS\14462666|of|structural|birth|and|effects (l_conj) effects_31\NNS\13245626|epilepsy-related|side (l_amod) epilepsy-related_29\JJ\1740|
D005492_D004827 NONE acid_9\NN\14818238|folic|mg)-containing (r_compound) supplementation_14\NN\5108947|with|periconceptional|acid|multivitamin (r_nmod) women_5\NNS\9605289|of|60|epileptic|supplementation (l_amod) epileptic_4\JJ\1740|
D005492_D004827 NONE acid_9\NN\14818238|folic|mg)-containing (r_compound) supplementation_14\NN\5108947|with|periconceptional|acid|multivitamin (r_nmod) women_5\NNS\9605289|of|60|epileptic|supplementation (r_nmod) results_0\NNS\34213|:|women (r_nsubj) developed_18\VBD\1753788|results|,|one|effects|period|. (l_dobj) effects_21\NNS\13245626|epilepsy-related|side (l_amod) epilepsy-related_19\JJ\1740|
D005492_D004827 NONE acid_12\NN\14818238|folic|mg)-containing (r_compound) multivitamin_16\NN\7938149|a|acid (r_conj) carbamazepine_8\NN\1740|by|and|multivitamin (r_nmod) treated_5\VBN\2376958|woman|was|continuously|carbamazepine|week|. (l_nsubjpass) woman_3\NN\9605289|this|22-year-old|epileptic (l_amod) epileptic_2\JJ\1740|
D005492_D004827 NONE acid_33\NN\14818238|of|folic (r_nmod) dose_23\NN\3740161|the|therapeutic|>|mg|acid (r_nsubj) triggered_34\VBD\1641914|conclusions|,|therefore|dose|cluster|. (l_nsubj) conclusions_0\NNS\5837957|:|damage (l_dep) damage_15\VB\126264|disease|could|barrier (l_nsubj) disease_8\NN\14061805|patient|autoimmune|lupus (l_nmod:poss) patient_5\NN\9898892|the|epileptic|pregnant|'s (l_amod) epileptic_3\JJ\1740|
D005492_D004827 NONE acid_9\NN\14818238|of|folic (r_nmod) dose_1\NN\3740161|physiological|mg|acid|healthy|all|, (l_nmod) healthy_12\JJ\1740|in|and|women (l_conj) women_16\NNS\9605289|60|epileptic|, (l_amod) epileptic_15\JJ\1740|
D005492_D004827 NONE acid_9\NN\14818238|of|folic (r_nmod) dose_1\NN\3740161|physiological|mg|acid|healthy|all|, (r_nsubj) increase_26\VB\169651|dose|did|not|risk|. (l_dobj) risk_28\NN\14541044|the|seizures (l_nmod) seizures_31\NNS\14081375|for|epileptic
D005492_D000014 NONE acid-containing_8\JJ\1740|folic (r_amod) supplementation_10\NN\5108947|of|acid-containing|multivitamin (r_nmod) effect_5\NN\34213|the|supplementation|women|before|pregnancy (r_dobj) study_3\VB\630380|to|effect|determine (l_advcl) determine_21\VB\1645601|in|to|rate (l_dobj) rate_23\NN\13815152|the|defects (l_nmod) defects_27\NNS\14462666|of|structural|birth|and|effects
D002220_D004827 NONE carbamazepine_8\NN\1740|by|and|multivitamin (r_nmod) treated_5\VBN\2376958|woman|was|continuously|carbamazepine|week|. (l_nsubjpass) woman_3\NN\9605289|this|22-year-old|epileptic (l_amod) epileptic_2\JJ\1740|
D005492_D001327 NONE acid_33\NN\14818238|of|folic (r_nmod) dose_23\NN\3740161|the|therapeutic|>|mg|acid (r_nsubj) triggered_34\VBD\1641914|conclusions|,|therefore|dose|cluster|. (l_nsubj) conclusions_0\NNS\5837957|:|damage (l_dep) damage_15\VB\126264|disease|could|barrier (l_nsubj) disease_8\NN\14061805|patient|autoimmune|lupus
D005492_D001327 NONE acid_9\NN\14818238|of|folic (r_nmod) dose_1\NN\3740161|physiological|mg|acid|healthy|all|, (l_dep) all_18\DT\1740|disease (l_nmod) disease_22\NN\14061805|without|any|autoimmune
D005492_D012640 CID acid_33\NN\14818238|of|folic (r_nmod) dose_23\NN\3740161|the|therapeutic|>|mg|acid (r_nsubj) triggered_34\VBD\1641914|conclusions|,|therefore|dose|cluster|. (l_dobj) cluster_36\NN\7959269|a|seizures (l_nmod) seizures_38\NNS\14081375|of
12571256
C044834_D007674 NONE iodixanol_27\NN\1740| (r_appos) medium_25\NN\3575240|of|an|iso-osmolar|,|dimeric|,|nonionic|contrast|,|iodixanol|, (r_nmod) effects_16\NNS\13245626|the|nephrotoxic|medium|those (l_amod) nephrotoxic_15\JJ\1740|
C044834_D007674 NONE iodixanol_17\NN\1740| (r_nsubjpass) used_19\VBN\1156834|when|iodixanol|is|than|medium (r_advcl) likely_10\JJ\1740|nephropathy|may|be|less|develop|used|. (l_nsubj) nephropathy_2\NN\14573196|induced
D007472_D007674 CID iohexol_41\NN\1740| (r_appos) medium_39\NN\3575240|of|a|low-osmolar|,|nonionic|,|monomeric|contrast|,|iohexol (r_nmod) those_30\DT\1740|with|medium (r_nmod) effects_16\NNS\13245626|the|nephrotoxic|medium|those (l_amod) nephrotoxic_15\JJ\1740|
D003404_D003920 NONE creatinine_9\NN\1740| (r_compound) concentrations_10\NNS\4916342|with|serum|creatinine|mg (r_nmod) patients_4\NNS\9898892|129|diabetes|concentrations|underwent (l_nmod) diabetes_6\NN\14075199|with
16471092
C099041_D053201 NONE tolterodine_14\NN\1740| (r_compound) treatment_15\NN\654885|after|tolterodine (r_nmod) symptoms_1\NNS\5823932|urinary|and|changes|treatment|. (l_conj) changes_6\NNS\7283608|quality|women (l_nmod) women_9\NNS\9605289|in|thai|bladder (l_nmod) bladder_12\NN\5515670|with|overactive
C099041_D053201 NONE tolterodine_22\NN\1740| (r_compound) treatment_23\NN\654885|after|tolterodine (r_nmod) symptoms_6\NNS\5823932|the|urinary|and|changes|women|treatment (l_nmod) women_14\NNS\9605289|in|thai|bladder (l_nmod) bladder_17\NN\5515670|with|overactive|oab
C099041_D053201 NONE tolterodine_22\NN\1740| (r_compound) treatment_23\NN\654885|after|tolterodine (r_nmod) symptoms_6\NNS\5823932|the|urinary|and|changes|women|treatment (l_nmod) women_14\NNS\9605289|in|thai|bladder (l_nmod) bladder_17\NN\5515670|with|overactive|oab (l_appos) oab_19\NN\1740|(|)
C099041_D053201 NONE tolterodine_2\NN\1740| (r_nsubjpass) tolerated_5\VBN\802318|:|tolterodine|was|well|and|improved (l_conj) improved_9\VBD\126264|effects|quality|. (l_dobj) quality_11\NN\24264|the|life|women (l_nmod) women_16\NNS\9605289|in|thai|oab (l_nmod) oab_18\NN\1740|with
11022397
D014331_D008569 NONE tropicamide_11\NN\1740|of|and|pilocarpine (r_nmod) administration_9\NN\1133281|after|tropicamide (r_nmod) points_7\NNS\5868954|at|time|administration (r_nmod) size_4\NN\5090441|pupil|points|;|impairment (l_appos) impairment_16\NN\7296428|scopolamine-induced|recall (l_nmod) recall_19\NN\7185325|in|word
D010862_D008569 NONE pilocarpine_13\NN\14712692| (r_conj) tropicamide_11\NN\1740|of|and|pilocarpine (r_nmod) administration_9\NN\1133281|after|tropicamide (r_nmod) points_7\NNS\5868954|at|time|administration (r_nmod) size_4\NN\5090441|pupil|points|;|impairment (l_appos) impairment_16\NN\7296428|scopolamine-induced|recall (l_nmod) recall_19\NN\7185325|in|word
D012601_D008569 CID scopolamine-induced_15\JJ\1740| (r_amod) impairment_16\NN\7296428|scopolamine-induced|recall (l_nmod) recall_19\NN\7185325|in|word
D012601_D008569 CID scopolamine-induced_11\JJ\1740| (r_amod) impairment_12\NN\7296428|greater|scopolamine-induced|recall (l_nmod) recall_15\NN\7185325|in|word
3220106
D009538_D006948 CID nicotine-induced_3\JJ\1740| (r_amod) hyperactivity_5\NN\14052403|of|nicotine-induced|locomotor|rats
D009538_D006948 CID nicotine-treated_8\JJ\1740| (r_amod) rats_9\NNS\2329401|in|chronic|nicotine-treated (r_nmod) hyperactivity_5\NN\14052403|of|nicotine-induced|locomotor|rats
D009538_D006948 CID nicotine-treated_5\JJ\1740| (r_amod) rats_6\NNS\2329401|chronic|nicotine-treated (r_nsubj) develop_7\VBP\1753788|that|rats|hyperactivity|increases|,|followed (l_dobj) hyperactivity_9\NN\14052403|locomotor|response
D009538_D006948 CID nicotine_13\NN\14712692|to (r_nmod) response_11\NN\11410625|in|nicotine (r_nmod) hyperactivity_9\NN\14052403|locomotor|response
D004298_D006948 NONE da_26\NN\10484858| (r_compound) concentration_27\NN\4916342|da (r_conj) density_21\NN\4941325|of|both|the|receptors|and|concentration (r_nmod) increases_17\NNS\13576355|initially|due|density (r_nmod) develop_7\VBP\1753788|that|rats|hyperactivity|increases|,|followed (l_dobj) hyperactivity_9\NN\14052403|locomotor|response
D004298_D006948 NONE da_32\NN\10484858| (r_compound) supersensitivity_34\NN\1740|da|receptor (r_dobj) inducing_31\VBG\1627355|by|supersensitivity|striatum (r_advcl) followed_29\VBN\1835496|inducing (r_advcl) develop_7\VBP\1753788|that|rats|hyperactivity|increases|,|followed (l_dobj) hyperactivity_9\NN\14052403|locomotor|response
7007443
D000082_D017114 CID paracetamol_26\NN\1740| (r_compound) overdose_27\NN\1740|after|paracetamol (r_nmod) failure_24\NN\66216|fulminant|hepatic|overdose
D000082_D017114 CID paracetamol_26\NN\1740| (r_compound) overdose_27\NN\1740|after|paracetamol (r_nmod) failure_24\NN\66216|fulminant|hepatic|overdose (r_dobj) survived_21\VBD\1108148|who|failure (r_acl:relcl) those_19\DT\1740|in|survived (r_nmod) fourfold_17\RB\1740|nearly|those (r_conj) increased_8\VBN\169651|activity|was|tenfold|patients|and|fourfold|,|whereas|increased|. (l_parataxis) increased_32\VBN\169651|activities|were|equally|patients|survived (l_nmod) patients_35\NNS\9898892|in|failure (l_nmod) failure_39\NN\66216|with|fulminant|hepatic|hepatitis
D000082_D062787 NONE paracetamol_26\NN\1740| (r_compound) overdose_27\NN\1740|after|paracetamol
D000082_D006525 NONE paracetamol_26\NN\1740| (r_compound) overdose_27\NN\1740|after|paracetamol (r_nmod) failure_24\NN\66216|fulminant|hepatic|overdose (r_dobj) survived_21\VBD\1108148|who|failure (r_acl:relcl) those_19\DT\1740|in|survived (r_nmod) fourfold_17\RB\1740|nearly|those (r_conj) increased_8\VBN\169651|activity|was|tenfold|patients|and|fourfold|,|whereas|increased|. (l_parataxis) increased_32\VBN\169651|activities|were|equally|patients|survived (l_nmod) patients_35\NNS\9898892|in|failure (l_nmod) failure_39\NN\66216|with|fulminant|hepatic|hepatitis (l_nmod) hepatitis_43\NN\14127211|due|viral
11705128
D012254_D000743 CID ribavirin-induced_3\JJ\1740| (r_amod) anemia_5\NN\14189204|for|ribavirin-induced|hemolytic|treatment
D012254_D000743 CID ribavirin-induced_11\JJ\1740| (r_amod) anemia_13\NN\14189204|ribavirin-induced|hemolytic|riha
D012254_D000743 CID ribavirin-induced_11\JJ\1740| (r_amod) anemia_13\NN\14189204|ribavirin-induced|hemolytic|riha (l_appos) riha_15\NN\1740|(|)
D012254_D000743 CID ribavirin_14\NN\2725367| (r_compound) dosage_15\NN\13576355|of|the|ribavirin (r_nmod) reduction_9\NN\351485|standard|is|or|discontinuation|dosage|. (l_nsubj) standard_1\NN\13577171|the|care|management (l_nmod) management_5\NN\1123598|for|riha (l_nmod) riha_7\NN\1740|of
D012254_D000743 CID ribavirin_7\NN\2725367|of (r_nmod) dose_5\NN\3740161|about|the|optimal|ribavirin|and|incidence (l_conj) incidence_10\NN\13821570|the|riha|population (l_nmod) riha_12\NN\1740|of
D012254_D006526 NONE ribavirin-induced_3\JJ\1740| (r_amod) anemia_5\NN\14189204|for|ribavirin-induced|hemolytic|treatment (l_nmod) treatment_8\NN\654885|in|the|c (l_nmod) c_11\NN\13714184|of|hepatitis
D012254_D019698 NONE alpha-2b/ribavirin_17\NN\1740| (r_conj) interferon_15\NN\2725367|with|and|alpha-2b/ribavirin (r_nmod) therapy_13\NN\657604|of|combination|interferon (r_nmod) efficacy_8\NN\5199286|increased|and|cost-effectiveness|therapy|monotherapy|treatment (l_nmod) treatment_24\NN\654885|in|the|c (l_nmod) c_28\NN\13714184|of|chronic|hepatitis|chc
D012254_D019698 NONE alpha-2b/ribavirin_17\NN\1740| (r_conj) interferon_15\NN\2725367|with|and|alpha-2b/ribavirin (r_nmod) therapy_13\NN\657604|of|combination|interferon (r_nmod) efficacy_8\NN\5199286|increased|and|cost-effectiveness|therapy|monotherapy|treatment (l_nmod) treatment_24\NN\654885|in|the|c (l_nmod) c_28\NN\13714184|of|chronic|hepatitis|chc (l_appos) chc_30\NN\1740|(|)
D016898_D019698 NONE interferon-alpha_20\NN\1740| (r_compound) monotherapy_21\NN\1740|compared|with|interferon-alpha (r_nmod) efficacy_8\NN\5199286|increased|and|cost-effectiveness|therapy|monotherapy|treatment (l_nmod) treatment_24\NN\654885|in|the|c (l_nmod) c_28\NN\13714184|of|chronic|hepatitis|chc
D016898_D019698 NONE interferon-alpha_20\NN\1740| (r_compound) monotherapy_21\NN\1740|compared|with|interferon-alpha (r_nmod) efficacy_8\NN\5199286|increased|and|cost-effectiveness|therapy|monotherapy|treatment (l_nmod) treatment_24\NN\654885|in|the|c (l_nmod) c_28\NN\13714184|of|chronic|hepatitis|chc (l_appos) chc_30\NN\1740|(|)
17490790
D007505_D009410 CID dextran_2\NN\1740|peripheral|iron (r_nsubj) induced_3\VBD\1627355|dextran|degeneration|. (l_dobj) degeneration_4\NN\29677|neurons (l_nmod) neurons_7\NNS\5430628|of|dopaminergic|nigra
D007505_D009410 CID dextran_64\NN\1740| (r_nmod:npmod) overloaded_65\JJ\1740|dextran (r_amod) animals_66\NNS\4475|of|iron|overloaded (r_nmod) sn_61\NN\14625458|in|the|animals (r_nmod) content_58\NN\7951464|increased|iron|sn (r_conj) degeneration_51\NN\29677|the|neurons|and|content (l_nmod) neurons_54\NNS\5430628|of|dopaminergic
D007505_D009410 CID dextran_6\NN\1740|peripheral|iron (r_nsubj) increase_8\VB\169651|that|dextran|can|level (l_dobj) level_11\NN\4916342|the|iron|sn (l_nmod) sn_14\NN\14625458|in|the|,|causes (l_acl:relcl) causes_19\VBZ\1617192|where|iron|degeneration (l_dobj) degeneration_21\NN\29677|the|neurons (l_nmod) neurons_24\NNS\5430628|of|dopaminergic
D007501_D010300 NONE iron_0\NN\14625458| (r_compound) accumulation_1\NN\13497135|iron (r_nsubjpass) considered_3\VBN\689344|accumulation|is|involved|. (l_xcomp) involved_6\VBN\2676054|to|be|pathogenesis (l_nmod) pathogenesis_9\NN\13533470|in|the|disease (l_nmod) disease_13\NN\14061805|of|parkinson|'s
D007501_D009410 NONE iron_6\NN\14625458| (r_compound) overload_7\NN\3679986|between|peripheral|iron|and|loss|nigra (r_nmod) relationship_3\NN\31921|the|overload (r_dobj) demonstrate_1\VB\2137132|to|relationship (r_advcl) used_25\VBD\1156834|demonstrate|,|study|we|voltammetry|study|. (l_advcl) study_49\VB\630380|to|degeneration (l_dobj) degeneration_51\NN\29677|the|neurons|and|content (l_nmod) neurons_54\NNS\5430628|of|dopaminergic
D007501_D009410 NONE iron_39\NN\14625458| (r_compound) staining_40\NN\275424|perls|iron (r_conj) voltammetry_28\NN\1740|fast|cyclic|,|immunohistochemistry|,|staining|,|and|detection (r_dobj) used_25\VBD\1156834|demonstrate|,|study|we|voltammetry|study|. (l_advcl) study_49\VB\630380|to|degeneration (l_dobj) degeneration_51\NN\29677|the|neurons|and|content (l_nmod) neurons_54\NNS\5430628|of|dopaminergic
D007501_D009410 NONE iron_57\NN\14625458| (r_compound) content_58\NN\7951464|increased|iron|sn (r_conj) degeneration_51\NN\29677|the|neurons|and|content (l_nmod) neurons_54\NNS\5430628|of|dopaminergic
D007501_D009410 NONE iron_10\NN\14625458| (r_compound) level_11\NN\4916342|the|iron|sn (l_nmod) sn_14\NN\14625458|in|the|,|causes (l_acl:relcl) causes_19\VBZ\1617192|where|iron|degeneration (l_dobj) degeneration_21\NN\29677|the|neurons (l_nmod) neurons_24\NNS\5430628|of|dopaminergic
D007501_D009410 NONE iron_18\NN\14625458|excessive (r_nsubj) causes_19\VBZ\1617192|where|iron|degeneration (l_dobj) degeneration_21\NN\29677|the|neurons (l_nmod) neurons_24\NNS\5430628|of|dopaminergic
D014443_D009410 NONE tyrosine_30\NN\14601829| (r_compound) immunohistochemistry_35\NN\791527|tyrosine|hydroxylase|th (r_conj) voltammetry_28\NN\1740|fast|cyclic|,|immunohistochemistry|,|staining|,|and|detection (r_dobj) used_25\VBD\1156834|demonstrate|,|study|we|voltammetry|study|. (l_advcl) study_49\VB\630380|to|degeneration (l_dobj) degeneration_51\NN\29677|the|neurons|and|content (l_nmod) neurons_54\NNS\5430628|of|dopaminergic
2840807
D009074_D004421 CID msh/acth_6\NN\1740|(|) (r_appos) neuropeptide_4\NN\1740|msh/acth (r_compound) stimulation_8\NN\242808|after|neuropeptide|ceruleus (r_nmod) syndrome_2\NN\5870365|a|dystonia-like|stimulation|. (l_amod) dystonia-like_1\JJ\1740|
D000324_D004421 CID msh/acth_6\NN\1740|(|) (r_appos) neuropeptide_4\NN\1740|msh/acth (r_compound) stimulation_8\NN\242808|after|neuropeptide|ceruleus (r_nmod) syndrome_2\NN\5870365|a|dystonia-like|stimulation|. (l_amod) dystonia-like_1\JJ\1740|
D000324_D003866 NONE acth_20\NN\5407119| (r_compound) fragments_22\NNS\9385911|by|the|acth|n-terminal|lc|resulted (r_nmod) stimulated_17\VBN\137313|a|receptors|were|fragments|;|cause (l_conj) cause_53\VB\1617192|b|whether|ne|did|indeed|depression|; (l_dobj) depression_56\NN\14373582|the|long-term|synapses
D000324_D009069 NONE acth_20\NN\5407119| (r_compound) fragments_22\NNS\9385911|by|the|acth|n-terminal|lc|resulted (r_nmod) stimulated_17\VBN\137313|a|receptors|were|fragments|;|cause (l_conj) cause_53\VB\1617192|b|whether|ne|did|indeed|depression|; (l_dobj) depression_56\NN\14373582|the|long-term|synapses (l_nmod) synapses_60\NNS\13526110|at|purkinje|cell|described|resulted (l_acl:relcl) resulted_68\VBD\2633881|that|duration (l_nmod) duration_72\NN\15113229|in|the|long|disorder (l_nmod) disorder_76\NN\14034177|of|the|movement
7619765
D005047_D009203 CID etoposide-related_0\JJ\1740| (r_amod) infarction_2\NN\14204950|etoposide-related|myocardial|.
D005047_D009203 CID etoposide_11\NN\1740| (r_dobj) containing_10\VBG\2632940|etoposide (r_acl) chemotherapy_9\NN\661091|after|containing|, (r_nmod) reported_7\VBN\831651|occurrence|is|chemotherapy|man|. (l_nsubjpass) occurrence_1\NN\29378|the|infarction (l_nmod) infarction_5\NN\14204950|of|a|myocardial
D005047_D003327 NONE etoposide_11\NN\1740| (r_dobj) containing_10\VBG\2632940|etoposide (r_acl) chemotherapy_9\NN\661091|after|containing|, (r_nmod) reported_7\VBN\831651|occurrence|is|chemotherapy|man|. (l_nmod) man_15\NN\9605289|in|a|factors (l_nmod) factors_19\NNS\7326557|with|no|risk|disease (l_nmod) disease_23\NN\14061805|for|coronary|heart
2564649
D005283_D009127 CID fentanyl-induced_8\JJ\1740| (r_amod) rigidity_10\NN\5023233|in|fentanyl-induced|muscular|rat
D005283_D009127 CID fentanyl_13\NN\2707683| (r_compound) anesthesia_14\NN\14034177|with|high-dose|fentanyl (r_nmod) associated_10\VBN\628491|that|is|anesthesia (r_acl:relcl) effect_7\NN\34213|whereas|rigidity|is|a|well-known|side|associated (l_nsubj) rigidity_2\NN\5023233|muscular
D005283_D009127 CID fentanyl_10\NN\2707683|by (r_nmod) induction_5\NN\7450842|the|rigidity|fentanyl (l_nmod) rigidity_8\NN\5023233|of|muscular
D011224_D009127 NONE prazosin_30\NN\2698769| (r_appos) blocker_28\NN\10101634|with|the|alpha-adrenoceptor|,|prazosin (r_nmod) pretreatment_24\NN\1740|blocker (r_conj) lesions_18\NNS\14204950|by|prior|electrolytic|coeruleus|or|pretreatment (r_nmod) antagonized_11\VBN\1787955|rigidity|was|significantly|or|reduced|lesions|. (l_nsubjpass) rigidity_4\NN\5023233|such|an|induced|muscular|agent
1564236
D013793_D023921 NONE thallium-201_18\NN\1740| (r_compound) tomography_21\NN\900375|with|thallium-201|single-photon|emission (r_nmod) correlation_16\NN\13841213|tomography (r_dep) relation_0\NN\2137|defects|severity|:|correlation|. (l_nmod) severity_11\NN\5036394|to|the|stenosis (l_nmod) stenosis_14\NN\14204950|of|coronary
D004176_D006940 CID dipyridamole-induced_1\JJ\1740| (r_amod) hyperemia_2\NN\14320394|during|dipyridamole-induced
D004176_D006940 CID dipyridamole-induced_24\JJ\1740| (r_amod) hyperemia_25\NN\14320394|in|dipyridamole-induced
D004176_D006940 CID dipyridamole-induced_12\JJ\1740| (r_amod) hyperemia_13\NN\14320394|during|dipyridamole-induced
D004176_D023921 NONE dipyridamole-induced_1\JJ\1740| (r_amod) hyperemia_2\NN\14320394|during|dipyridamole-induced (r_nmod) had_14\VBD\2108377|hyperemia|,|12|area|echocardiography|. (l_nsubj) 12_4\CD\13745420|dogs (l_nmod) dogs_8\NNS\2083346|of|the|16|stenosis (l_nmod) stenosis_13\NN\14204950|with|a|partial|coronary
D013793_D006940 NONE thallium-201_0\NN\1740| (r_compound) spect_1\NN\1740|thallium-201 (r_nsubj) demonstrated_2\VBD\2137132|spect|defect|;|correlated (l_dobj) defect_5\NN\14462666|a|perfusion|dogs (l_nmod) dogs_9\NNS\2083346|in|all|14|analyzed (l_acl) analyzed_10\VBN\78760|hyperemia (l_nmod) hyperemia_13\NN\14320394|during|dipyridamole-induced
8424298
D007741_D007022 CID labetalol_6\NN\2721160|by (r_nmod) induced_4\VBN\1627355|labetalol|isoflurane (r_acl) hypotension_3\NN\14057371|of|deliberate|induced
D007741_D007022 CID labetalol_12\NN\2721160|by (r_nmod) induced_10\VBN\1627355|labetalol|isoflurane (r_acl) hypotension_9\NN\14057371|with|deliberate|induced
D007741_D007022 CID labetalol_12\NN\2721160|by (r_nmod) induced_10\VBN\1627355|labetalol|isoflurane (r_acl) hypotension_9\NN\14057371|with|deliberate|induced (r_nmod) anaesthetized_3\VBN\84738|patients|were|surgery|hypotension|group|. (l_appos) group_17\NN\2137|(|hypotensive|) (l_amod) hypotensive_16\JJ\1740|
D007741_D007022 CID labetalol_7\NN\2721160|by (r_nmod) induced_5\VBN\1627355|labetalol|isoflurane (r_acl) hypotension_4\NN\14057371|induced
D007530_D007022 CID isoflurane_8\NN\3570838|with (r_nmod) induced_4\VBN\1627355|labetalol|isoflurane (r_acl) hypotension_3\NN\14057371|of|deliberate|induced
D007530_D007022 CID isoflurane_14\NN\3570838|with (r_nmod) induced_10\VBN\1627355|labetalol|isoflurane (r_acl) hypotension_9\NN\14057371|with|deliberate|induced
D007530_D007022 CID isoflurane_14\NN\3570838|with (r_nmod) induced_10\VBN\1627355|labetalol|isoflurane (r_acl) hypotension_9\NN\14057371|with|deliberate|induced (r_nmod) anaesthetized_3\VBN\84738|patients|were|surgery|hypotension|group|. (l_appos) group_17\NN\2137|(|hypotensive|) (l_amod) hypotensive_16\JJ\1740|
D007530_D007022 CID isoflurane_9\NN\3570838|with (r_nmod) induced_5\VBN\1627355|labetalol|isoflurane (r_acl) hypotension_4\NN\14057371|induced
4038130
D008619_D009135 CID mepivacaine_19\NN\1740|to|and|lidocaine (r_nmod) exposure_17\NN\5042871|after|mepivacaine (r_nmod) seen_10\VBN\2106506|addition|,|damage|was|also|glands|,|exposure|. (l_nmod) addition_1\NN\3081021|in|damage (l_nmod) damage_4\NN\7296428|to|muscle
D008012_D009135 CID lidocaine_21\NN\3681148|plus|epinephrine (r_conj) mepivacaine_19\NN\1740|to|and|lidocaine (r_nmod) exposure_17\NN\5042871|after|mepivacaine (r_nmod) seen_10\VBN\2106506|addition|,|damage|was|also|glands|,|exposure|. (l_nmod) addition_1\NN\3081021|in|damage (l_nmod) damage_4\NN\7296428|to|muscle
D004837_D009135 NONE epinephrine_23\NN\14807929| (r_conj) lidocaine_21\NN\3681148|plus|epinephrine (r_conj) mepivacaine_19\NN\1740|to|and|lidocaine (r_nmod) exposure_17\NN\5042871|after|mepivacaine (r_nmod) seen_10\VBN\2106506|addition|,|damage|was|also|glands|,|exposure|. (l_nmod) addition_1\NN\3081021|in|damage (l_nmod) damage_4\NN\7296428|to|muscle
18086064
D020927_D009203 NONE dexmedetomidine_0\NN\1740| (r_nsubjpass) associated_2\VBN\628491|dexmedetomidine|was|trend|mortality|. (l_dep) mortality_12\NN\5054863|all-cause|or (l_dep) or_14\NN\3541091|(|0.27|,|ci|=|)|,|infarction|=|)|,|and|ischaemia (l_conj) infarction_31\NN\14204950|non-fatal|myocardial|or
D020927_D017202 NONE dexmedetomidine_0\NN\1740| (r_nsubjpass) associated_2\VBN\628491|dexmedetomidine|was|trend|mortality|. (l_dep) mortality_12\NN\5054863|all-cause|or (l_dep) or_14\NN\3541091|(|0.27|,|ci|=|)|,|infarction|=|)|,|and|ischaemia (l_conj) ischaemia_50\NN\14195315|myocardial|or
1628552
D002738_D006327 NONE chloroquine_0\NN\2721948| (r_nmod:npmod) related_1\JJ\1740|chloroquine (r_amod) block_4\NN\21939|related|complete|heart|blindness|:|report
D002738_D006327 NONE chloroquine_5\NN\2721948| (r_compound) retinopathy_6\NN\14252864|of|chloroquine (r_nmod) features_3\NNS\5849040|retinopathy (r_dobj) revealed_2\VBD\2137132|assessment|features (r_ccomp) revealed_10\VBD\2137132|revealed|,|assessment|features|. (l_dobj) features_11\NNS\5849040|failure|and|block (l_conj) block_19\NN\21939|a|complete|heart|pattern
D002738_D006327 NONE chloroquine_15\NN\2721948| (r_compound) discontinuation_16\NN\209943|following|chloroquine (r_nmod) resolved_12\VBD\352826|failure|spontaneously|discontinuation|. (r_conj) treated_4\VBN\2376958|block|was|insertion|and|resolved (l_nsubjpass) block_2\NN\21939|the|heart
D002738_D001766 CID chloroquine_0\NN\2721948| (r_nmod:npmod) related_1\JJ\1740|chloroquine (r_amod) block_4\NN\21939|related|complete|heart|blindness|:|report (l_nmod) blindness_6\NN\14552802|with
D002738_D015354 NONE chloroquine_9\NN\2721948| (r_compound) ingestion_10\NN\13440063|of|regular|chloroquine (r_nmod) history_6\NN\15120823|with|ingestion (r_nmod) woman_4\NN\9605289|a|old|african|history (r_nsubj) presented_11\VBD\2137132|woman|deterioration|. (l_nmod) deterioration_14\NN\14560612|with|progressive|vision|,|fatiguability|,|dyspnoea|,|dizziness (l_nmod) vision_16\NN\5767733|of
D002738_D005221 CID chloroquine_9\NN\2721948| (r_compound) ingestion_10\NN\13440063|of|regular|chloroquine (r_nmod) history_6\NN\15120823|with|ingestion (r_nmod) woman_4\NN\9605289|a|old|african|history (r_nsubj) presented_11\VBD\2137132|woman|deterioration|. (l_nmod) deterioration_14\NN\14560612|with|progressive|vision|,|fatiguability|,|dyspnoea|,|dizziness (l_appos) fatiguability_19\NN\1740|easy
D002738_D004417 CID chloroquine_9\NN\2721948| (r_compound) ingestion_10\NN\13440063|of|regular|chloroquine (r_nmod) history_6\NN\15120823|with|ingestion (r_nmod) woman_4\NN\9605289|a|old|african|history (r_nsubj) presented_11\VBD\2137132|woman|deterioration|. (l_nmod) deterioration_14\NN\14560612|with|progressive|vision|,|fatiguability|,|dyspnoea|,|dizziness (l_appos) dyspnoea_21\NN\14299637|
D002738_D004244 CID chloroquine_9\NN\2721948| (r_compound) ingestion_10\NN\13440063|of|regular|chloroquine (r_nmod) history_6\NN\15120823|with|ingestion (r_nmod) woman_4\NN\9605289|a|old|african|history (r_nsubj) presented_11\VBD\2137132|woman|deterioration|. (l_nmod) deterioration_14\NN\14560612|with|progressive|vision|,|fatiguability|,|dyspnoea|,|dizziness (l_appos) dizziness_23\NN\14299637|progressing
D002738_D013575 CID chloroquine_9\NN\2721948| (r_compound) ingestion_10\NN\13440063|of|regular|chloroquine (r_nmod) history_6\NN\15120823|with|ingestion (r_nmod) woman_4\NN\9605289|a|old|african|history (r_nsubj) presented_11\VBD\2137132|woman|deterioration|. (l_nmod) deterioration_14\NN\14560612|with|progressive|vision|,|fatiguability|,|dyspnoea|,|dizziness (l_appos) dizziness_23\NN\14299637|progressing (l_acl) progressing_24\VBG\252019|attacks (l_nmod) attacks_27\NNS\955060|to|syncopal
D002738_D012164 CID chloroquine_5\NN\2721948| (r_compound) retinopathy_6\NN\14252864|of|chloroquine
D002738_D006333 CID chloroquine_5\NN\2721948| (r_compound) retinopathy_6\NN\14252864|of|chloroquine (r_nmod) features_3\NNS\5849040|retinopathy (r_dobj) revealed_2\VBD\2137132|assessment|features (r_ccomp) revealed_10\VBD\2137132|revealed|,|assessment|features|. (l_dobj) features_11\NNS\5849040|failure|and|block (l_nmod) failure_14\NN\66216|of|heart
D002738_D006333 CID chloroquine_15\NN\2721948| (r_compound) discontinuation_16\NN\209943|following|chloroquine (r_nmod) resolved_12\VBD\352826|failure|spontaneously|discontinuation|. (l_nsubj) failure_11\NN\66216|the|heart
D002738_D002037 CID chloroquine_5\NN\2721948| (r_compound) retinopathy_6\NN\14252864|of|chloroquine (r_nmod) features_3\NNS\5849040|retinopathy (r_dobj) revealed_2\VBD\2137132|assessment|features (r_ccomp) revealed_10\VBD\2137132|revealed|,|assessment|features|. (l_dobj) features_11\NNS\5849040|failure|and|block (l_conj) block_19\NN\21939|a|complete|heart|pattern (l_nmod) pattern_25\NN\5726345|with|block (l_compound) block_24\NN\21939|right|bundle|branch
19923525
D009553_D008569 NONE nimodipine_0\NN\1740| (r_nsubj) prevents_1\VBZ\1740|nimodipine|impairment|. (l_dobj) impairment_3\NN\7296428|memory|caused
D009553_D007022 NONE nimodipine_0\NN\1740| (r_nsubj) prevents_1\VBZ\1740|nimodipine|impairment|. (l_dobj) impairment_3\NN\7296428|memory|caused (l_acl) caused_4\VBN\1617192|hypotension (l_nmod) hypotension_7\NN\14057371|by|nitroglycerin-induced|mice
D009553_D007022 NONE nimodipine_5\NN\1740|nimo|administered (l_acl) administered_9\VBN\2436349|onset (l_nmod) onset_12\NN\7325190|at|the|hypotension (l_nmod) hypotension_16\NN\14057371|of|(ntg)-induced
D009553_D007022 NONE nimo_7\NN\1740|(|) (r_appos) nimodipine_5\NN\1740|nimo|administered (l_acl) administered_9\VBN\2436349|onset (l_nmod) onset_12\NN\7325190|at|the|hypotension (l_nmod) hypotension_16\NN\14057371|of|(ntg)-induced
D009553_D007022 NONE nimo_27\NN\1740| (r_conj) ntg_25\NN\1740|+|nimo (r_conj) saline_23\NN\14849367|with|,|ntg|,|or|ntg|s (r_nmod) injected_21\VBN\81072|saline (r_acl) those_20\DT\1740|compared|with|injected (r_nmod) showed_5\VBD\2137132|mice|decrease|those|. (l_nsubj) mice_0\NNS\2329401|subjected (l_acl) subjected_1\VBN\137313|episodes (l_nmod) episodes_4\NNS\7283608|to|hypotensive (l_amod) hypotensive_3\JJ\1740|
D009553_D007022 NONE nimo_0\NN\1740| (r_nsubj) attenuated_1\VBD\224901|nimo|disruption|but|improve|. (l_conj) improve_15\VB\126264|did|not|latency|absence (l_nmod) absence_19\NN\14449405|in|the|hypotension (l_nmod) hypotension_21\NN\14057371|of
D009553_D007022 NONE nimo_4\NN\1740|of (r_nmod) effect_2\NN\34213|the|observed|nimo (r_nsubj) attributable_8\JJ\1740|effect|may|have|been|preservation|,|were|. (l_nmod) preservation_11\NN\817680|to|the|homeostasis|hypotension (l_nmod) hypotension_16\NN\14057371|during
D005996_D008569 CID nitroglycerin-induced_6\JJ\1740| (r_amod) hypotension_7\NN\14057371|by|nitroglycerin-induced|mice (r_nmod) caused_4\VBN\1617192|hypotension (r_acl) impairment_3\NN\7296428|memory|caused
D005996_D007022 CID nitroglycerin-induced_6\JJ\1740| (r_amod) hypotension_7\NN\14057371|by|nitroglycerin-induced|mice
D005996_D007022 CID nitroglycerin_14\NN\15015501| (r_compound) (ntg)-induced_15\NN\1740|nitroglycerin (r_compound) hypotension_16\NN\14057371|of|(ntg)-induced
D005996_D007022 CID (ntg)-induced_15\NN\1740|nitroglycerin (r_compound) hypotension_16\NN\14057371|of|(ntg)-induced
D005996_D007022 CID ntg_25\NN\1740|+|nimo (r_conj) saline_23\NN\14849367|with|,|ntg|,|or|ntg|s (r_nmod) injected_21\VBN\81072|saline (r_acl) those_20\DT\1740|compared|with|injected (r_nmod) showed_5\VBD\2137132|mice|decrease|those|. (l_nsubj) mice_0\NNS\2329401|subjected (l_acl) subjected_1\VBN\137313|episodes (l_nmod) episodes_4\NNS\7283608|to|hypotensive (l_amod) hypotensive_3\JJ\1740|
D005996_D007022 CID ntg_31\NN\1740|delayed (r_conj) saline_23\NN\14849367|with|,|ntg|,|or|ntg|s (r_nmod) injected_21\VBN\81072|saline (r_acl) those_20\DT\1740|compared|with|injected (r_nmod) showed_5\VBD\2137132|mice|decrease|those|. (l_nsubj) mice_0\NNS\2329401|subjected (l_acl) subjected_1\VBN\137313|episodes (l_nmod) episodes_4\NNS\7283608|to|hypotensive (l_amod) hypotensive_3\JJ\1740|
D005996_D007022 CID ntg_11\NN\1740|of (r_nmod) injection_9\NN\320852|the|ntg|learning (r_nsubj) produced_15\VBD\1617192|paradigm|,|injection|impairment|,|whereas (r_dep) conclusion_0\NN\5837957|:|produced (r_nsubj) had_30\VBD\2108377|conclusion|hypotension|effect|. (l_nsubj) hypotension_29\NN\14057371|induced
D005996_D007022 CID ntg_11\NN\1740|by (r_nmod) caused_9\VBN\1617192|ntg (r_acl) disruption_3\NN\1066163|the|consolidation|caused (r_dobj) attenuated_1\VBD\224901|nimo|disruption|but|improve|. (l_conj) improve_15\VB\126264|did|not|latency|absence (l_nmod) absence_19\NN\14449405|in|the|hypotension (l_nmod) hypotension_21\NN\14057371|of
D002118_D007022 NONE calcium_13\NN\14625458| (r_compound) homeostasis_14\NN\13934900|of|calcium (r_nmod) preservation_11\NN\817680|to|the|homeostasis|hypotension (l_nmod) hypotension_16\NN\14057371|during
2320800
D007069_D001002 CID ifosfamide_5\NN\1740| (r_compound) chemotherapy_6\NN\661091|dose|ifosfamide (r_dobj) complicating_2\VBG\126264|chemotherapy|patient (r_acl) anuria_1\NN\14061805|lethal|complicating|.
D007069_D001002 CID ifosfamide_28\NN\1740|after|bolus (r_nmod) day_23\NN\15154774|the|ifosfamide (r_appos) failure_18\NN\66216|an|irreversible|lethal|renal|anuria|,|day (l_nmod) anuria_20\NN\14061805|with
D007069_D001002 CID ifosfamide_11\NN\1740|that|anuria|due|,|occurring (l_nsubj) anuria_6\NN\14061805|this|lethal
D007069_D001943 NONE ifosfamide_5\NN\1740| (r_compound) chemotherapy_6\NN\661091|dose|ifosfamide (r_dobj) complicating_2\VBG\126264|chemotherapy|patient (l_nmod) patient_11\NN\9898892|in|a|breast|cancer|function (l_compound) cancer_10\NN\14239425|
D007069_D001943 NONE ifosfamide_28\NN\1740|after|bolus (r_nmod) day_23\NN\15154774|the|ifosfamide (r_appos) failure_18\NN\66216|an|irreversible|lethal|renal|anuria|,|day (r_dobj) developed_13\VBD\1753788|woman|,|failure|. (l_nsubj) woman_2\NN\9605289|a|sixty-year-old|cancer|,|treated (l_nmod) cancer_6\NN\14239425|with|advanced|breast
D007069_D007674 CID ifosfamide_5\NN\1740| (r_compound) chemotherapy_6\NN\661091|dose|ifosfamide (r_dobj) complicating_2\VBG\126264|chemotherapy|patient (l_nmod) patient_11\NN\9898892|in|a|breast|cancer|function (l_nmod) function_16\NN\13783581|with|an|impaired|renal
D007069_D007674 CID ifosfamide_0\NN\1740| (r_nsubj) drug_5\NN\14778436|ifosfamide|is|a|known|nephrotoxic|tubulopathies|. (l_amod) nephrotoxic_4\JJ\1740|
D007069_D007674 CID ifosfamide_0\NN\1740| (r_nsubj) drug_5\NN\14778436|ifosfamide|is|a|known|nephrotoxic|tubulopathies|. (l_nmod) tubulopathies_8\NNS\1740|with|demonstrated
D007069_D007674 CID ifosfamide_5\NN\1740|of (r_nmod) use_3\NN\407535|careful|ifosfamide|patients (l_nmod) patients_7\NNS\9898892|in|pretreated (l_acl) pretreated_8\VBN\1740|chemotherapy|and|perfusion (l_nmod) chemotherapy_11\NN\661091|with|nephrotoxic (l_amod) nephrotoxic_10\JJ\1740|
D002945_D001943 NONE cisplatin_11\NN\1740|with (r_nmod) treated_9\VBN\2376958|previously|cisplatin (r_acl) woman_2\NN\9605289|a|sixty-year-old|cancer|,|treated (l_nmod) cancer_6\NN\14239425|with|advanced|breast
D002945_D051437 NONE cisplatin_11\NN\1740|with (r_nmod) treated_9\VBN\2376958|previously|cisplatin (r_acl) woman_2\NN\9605289|a|sixty-year-old|cancer|,|treated (r_nsubj) developed_13\VBD\1753788|woman|,|failure|. (l_dobj) failure_18\NN\66216|an|irreversible|lethal|renal|anuria|,|day
D002945_D001002 NONE cisplatin_11\NN\1740|with (r_nmod) treated_9\VBN\2376958|previously|cisplatin (r_acl) woman_2\NN\9605289|a|sixty-year-old|cancer|,|treated (r_nsubj) developed_13\VBD\1753788|woman|,|failure|. (l_dobj) failure_18\NN\66216|an|irreversible|lethal|renal|anuria|,|day (l_nmod) anuria_20\NN\14061805|with
D002945_D001002 NONE cisplatin_20\NN\1740| (r_compound) chemotherapy_21\NN\661091|previous|cisplatin (r_dobj) received_18\VBN\2210855|having|chemotherapy|and|perfusion|hypotension (r_acl) patient_16\NN\9898892|in|a|received (r_nmod) occurring_13\VBG\2623529|patient (r_acl) ifosfamide_11\NN\1740|that|anuria|due|,|occurring (l_nsubj) anuria_6\NN\14061805|this|lethal
D007069_D051437 NONE ifosfamide_28\NN\1740|after|bolus (r_nmod) day_23\NN\15154774|the|ifosfamide (r_appos) failure_18\NN\66216|an|irreversible|lethal|renal|anuria|,|day
D007069_D007022 NONE ifosfamide_11\NN\1740|that|anuria|due|,|occurring (l_acl) occurring_13\VBG\2623529|patient (l_nmod) patient_16\NN\9898892|in|a|received (l_acl) received_18\VBN\2210855|having|chemotherapy|and|perfusion|hypotension (l_nmod) hypotension_30\NN\14057371|due|transient
D002945_D007022 NONE cisplatin_20\NN\1740| (r_compound) chemotherapy_21\NN\661091|previous|cisplatin (r_dobj) received_18\VBN\2210855|having|chemotherapy|and|perfusion|hypotension (l_nmod) hypotension_30\NN\14057371|due|transient
8854309
D003042_D011681 CID cocaine-induced_9\JJ\1740| (r_amod) paranoia_10\NN\14398067|of|cocaine-induced (r_nmod) marker_7\NN\21939|as|a|paranoia (r_nmod) measure_1\NN\168237|a|oscillation|marker|. (l_nmod) oscillation_4\NN\13518963|of|pupillary
D003042_D010259 CID cocaine-induced_9\JJ\1740| (r_amod) paranoia_10\NN\14398067|of|cocaine-induced
D003042_D010259 CID cocaine-induced_0\JJ\1740| (r_amod) paranoia_1\NN\14398067|cocaine-induced|cip
D003042_D010259 CID cocaine-induced_0\JJ\1740| (r_amod) paranoia_1\NN\14398067|cocaine-induced|cip (l_appos) cip_3\NN\1740|(|)
D003042_D010259 CID cocaine-induced_0\JJ\1740| (r_amod) paranoia_1\NN\14398067|cocaine-induced|cip (r_nsubj) remains_5\VBZ\2604760|paranoia|model|. (l_attr) model_9\NN\5888929|an|important|drug-induced|paranoia|emerged (l_nmod) paranoia_12\NN\14398067|of|idiopathic
D016578_D011681 NONE cocaine_14\NN\3492717|crack (r_compound) abusers_15\NNS\9633969|of|abstinent|cocaine|endorsing (r_nmod) group_10\NN\2137|a|abusers|n|group (r_dobj) distinguish_8\VB\618878|to|significantly|group (r_xcomp) able_5\JJ\1740|measures|were|distinguish|. (l_nsubj) measures_0\NNS\168237|oscillation (l_nmod) oscillation_3\NN\13518963|of|pupillary
D016578_D011681 NONE crack_28\NN\9379111| (r_compound) addicts_29\NNS\10059582|of|crack|denied (r_nmod) group_26\NN\2137|from|another|addicts (r_nmod) group_10\NN\2137|a|abusers|n|group (r_dobj) distinguish_8\VB\618878|to|significantly|group (r_xcomp) able_5\JJ\1740|measures|were|distinguish|. (l_nsubj) measures_0\NNS\168237|oscillation (l_nmod) oscillation_3\NN\13518963|of|pupillary
D016578_D010259 NONE cocaine_14\NN\3492717|crack (r_compound) abusers_15\NNS\9633969|of|abstinent|cocaine|endorsing (l_acl) endorsing_16\VBG\806502|cip (l_dobj) cip_18\NN\1740|past
D016578_D010259 NONE cocaine_14\NN\3492717|crack (r_compound) abusers_15\NNS\9633969|of|abstinent|cocaine|endorsing (r_nmod) group_10\NN\2137|a|abusers|n|group (l_nmod) group_26\NN\2137|from|another|addicts (l_nmod) addicts_29\NNS\10059582|of|crack|denied (l_acl:relcl) denied_31\VBD\823436|who|cip|= (l_dobj) cip_33\NN\1740|past
D016578_D010259 NONE crack_28\NN\9379111| (r_compound) addicts_29\NNS\10059582|of|crack|denied (r_nmod) group_26\NN\2137|from|another|addicts (r_nmod) group_10\NN\2137|a|abusers|n|group (l_nmod) abusers_15\NNS\9633969|of|abstinent|cocaine|endorsing (l_acl) endorsing_16\VBG\806502|cip (l_dobj) cip_18\NN\1740|past
D016578_D010259 NONE crack_28\NN\9379111| (r_compound) addicts_29\NNS\10059582|of|crack|denied (l_acl:relcl) denied_31\VBD\823436|who|cip|= (l_dobj) cip_33\NN\1740|past
2907585
-1_D002375 NONE aryl-piperazine_6\JJ\1740| (r_amod) drugs_8\NNS\14778436|by|novel|aryl-piperazine|anxiolytic (r_nmod) reversal_0\NN\199130|catalepsy|drugs|. (l_nmod) catalepsy_3\NN\14023236|of|neuroleptic-induced
-1_D002375 NONE aryl-piperazine_3\JJ\1740| (r_amod) analogues_4\NNS\4743605|of|aryl-piperazine|buspirone (r_nmod) series_1\NN\8456993|a|analogues (r_nsubjpass) tested_12\VBN\670261|series|were|ability|. (l_nmod) ability_15\NN\4723816|for|their|reverse (l_acl) reverse_17\VB\109660|to|catalepsy (l_dobj) catalepsy_20\NN\14023236|induced
D002065_D002375 NONE buspirone_5\NN\3771443| (r_appos) drug_3\NN\14778436|the|novel|anxiolytic|,|buspirone|, (r_nsubj) reverses_7\VBZ\109660|drug|catalepsy|. (l_dobj) catalepsy_8\NN\14023236|induced
D002065_D002375 NONE buspirone_6\NN\3771443|of|and|agonists (r_nmod) analogues_4\NNS\4743605|of|aryl-piperazine|buspirone (r_nmod) series_1\NN\8456993|a|analogues (r_nsubjpass) tested_12\VBN\670261|series|were|ability|. (l_nmod) ability_15\NN\4723816|for|their|reverse (l_acl) reverse_17\VB\109660|to|catalepsy (l_dobj) catalepsy_20\NN\14023236|induced
D006220_D002375 CID haloperidol_11\NN\3713736|by (r_nmod) induced_9\VBN\1627355|haloperidol (r_acl) catalepsy_8\NN\14023236|induced
D006220_D002375 CID haloperidol_18\NN\3713736| (r_nmod:npmod) induced_19\JJ\1740|haloperidol (r_amod) catalepsy_20\NN\14023236|induced
D058825_D002375 NONE agonists_10\NNS\9613191|other|5-hydroxytryptaminergic (r_conj) buspirone_6\NN\3771443|of|and|agonists (r_nmod) analogues_4\NNS\4743605|of|aryl-piperazine|buspirone (r_nmod) series_1\NN\8456993|a|analogues (r_nsubjpass) tested_12\VBN\670261|series|were|ability|. (l_nmod) ability_15\NN\4723816|for|their|reverse (l_acl) reverse_17\VB\109660|to|catalepsy (l_dobj) catalepsy_20\NN\14023236|induced
D012701_D002375 NONE 5-hydroxytryptamine1a_6\NN\1740| (r_compound) receptors_7\NNS\5225602|for|5-hydroxytryptamine1a (r_nmod) affinity_4\NN\11426530|with|strong|receptors (r_nmod) drugs_1\NNS\14778436|those|affinity (r_nsubj) able_9\JJ\1740|drugs|were|reverse|. (l_xcomp) reverse_11\VB\109660|to|catalepsy (l_dobj) catalepsy_12\NN\14023236|
D012701_D002375 NONE 5-ht_5\NN\1740| (r_compound) receptors_6\NNS\5225602|of|postsynaptic|5-ht (r_nmod) inhibition_2\NN\1068773|receptors (r_nsubj) inhibited_8\VBD\2510337|however|,|inhibition|neither|nor|potentiated|reversal|and|leaves|. (l_dobj) reversal_11\NN\199130|catalepsy (l_nmod) catalepsy_13\NN\14023236|of
9672273
D013629_D001943 NONE tamoxifen_5\NN\2714883|with (r_nmod) prevention_0\NN\1073995|cancer|tamoxifen (l_nmod) cancer_3\NN\14239425|of|breast
D013629_D001943 NONE tamoxifen_2\NN\2714883| (r_nsubj) agent_7\NN\7347|:|tamoxifen|is|a|chemopreventive|cancer|,|associated (l_nmod) cancer_10\NN\14239425|in|breast
D013629_D001943 NONE tamoxifen_16\NN\2714883|of (r_nmod) trial_14\NN\786195|a|double-blind|placebo-controlled|,|randomised|tamoxifen|women (l_nmod) women_18\NNS\9605289|in|(|italy|)|have (l_acl:relcl) have_27\VB\2108377|who|did|not|cancer|and|had (l_dobj) cancer_29\NN\14239425|breast
D013629_D001943 NONE tamoxifen_15\NN\2714883|19 (r_conj) placebo_9\NN\3740161|between|the|cases|and|tamoxifen (r_nmod) difference_3\NN\4723816|no|frequency|placebo (l_nmod) frequency_6\NN\15286249|in|breast-cancer (l_compound) breast-cancer_5\NN\1740|
D013629_D001943 NONE tamoxifen_12\NN\2714883| (r_dobj) receiving_11\VBG\2210855|tamoxifen (r_acl) women_10\NNS\9605289|among|receiving|used (r_nmod) reduction_5\NN\351485|a|significant|cancer|women (l_nmod) cancer_8\NN\14239425|of|breast
D013629_D001943 NONE tamoxifen_12\NN\2714883| (r_dobj) receiving_11\VBG\2210855|tamoxifen (r_acl) women_10\NNS\9605289|among|receiving|used (r_nmod) reduction_5\NN\351485|a|significant|cancer|women (r_attr) is_1\VBZ\836236|there|reduction (r_ccomp) found_34\VBD\2426171|is|:|women|,|we|cases|case|. (l_dobj) cases_36\NNS\7283608|eight|cancer (l_nmod) cancer_39\NN\14239425|of|breast
D013629_D001943 NONE tamoxifen_49\NN\2714883|to (r_nmod) allocated_47\VBN\2228698|tamoxifen (r_acl) women_46\NNS\9605289|among|362|allocated (r_nmod) case_43\NN\7283608|compared|with|one|women (r_nmod) found_34\VBD\2426171|is|:|women|,|we|cases|case|. (l_ccomp) is_1\VBZ\836236|there|reduction (l_attr) reduction_5\NN\351485|a|significant|cancer|women (l_nmod) cancer_8\NN\14239425|of|breast
D013629_D001943 NONE tamoxifen_49\NN\2714883|to (r_nmod) allocated_47\VBN\2228698|tamoxifen (r_acl) women_46\NNS\9605289|among|362|allocated (r_nmod) case_43\NN\7283608|compared|with|one|women (r_nmod) found_34\VBD\2426171|is|:|women|,|we|cases|case|. (l_dobj) cases_36\NNS\7283608|eight|cancer (l_nmod) cancer_39\NN\14239425|of|breast
D013629_D001943 NONE tamoxifen_27\NN\2714883|of (r_nmod) effects_25\NNS\13245626|the|postulated|protective|tamoxifen (r_nsubj) apparent_31\JJ\1740|has|,|cohort|,|effects|are|yet|. (l_nmod) cohort_12\NN\8184861|in|this|women (l_nmod) women_14\NNS\9605289|of|risk (l_nmod) risk_17\NN\14541044|at|cancer (l_nmod) cancer_20\NN\14239425|of|breast
D013629_D016889 NONE tamoxifen_2\NN\2714883| (r_nsubj) agent_7\NN\7347|:|tamoxifen|is|a|chemopreventive|cancer|,|associated (l_advcl) associated_17\VBN\628491|although|drug|may|be|development (l_nmod) development_20\NN\248977|with|the|cancer (l_nmod) cancer_23\NN\14239425|of|endometrial
D013629_D014652 CID tamoxifen_20\NN\2714883|on (r_nmod) women_18\NNS\9605289|among|tamoxifen (r_nmod) risk_11\NN\14541044|a|increased|events|women (l_nmod) events_14\NNS\23100|of|vascular|and|hypertriglyceridaemia
D013629_D015228 CID tamoxifen_20\NN\2714883|on (r_nmod) women_18\NNS\9605289|among|tamoxifen (r_nmod) risk_11\NN\14541044|a|increased|events|women (l_nmod) events_14\NNS\23100|of|vascular|and|hypertriglyceridaemia (l_conj) hypertriglyceridaemia_16\NN\1740|
10692744
D000086_D005862 CID acetazolamide-induced_0\JJ\1740| (r_amod) syndrome_2\NN\5870365|acetazolamide-induced|gerstmann|.
D000086_D005862 CID acetazolamide-induced_5\JJ\1740| (r_amod) syndrome_7\NN\5870365|of|acetazolamide-induced|gerstmann|patient
D000086_D003221 NONE acetazolamide_4\NN\1740|by (r_nmod) induced_2\VBN\1627355|acetazolamide (r_acl) confusion_1\NN\13972797|acute|induced
D000086_D007674 NONE acetazolamide_4\NN\1740|by (r_nmod) induced_2\VBN\1627355|acetazolamide (r_acl) confusion_1\NN\13972797|acute|induced (r_nsubj) reaction_11\NN\13446390|confusion|is|a|known|adverse|drug|patients|. (l_nmod) patients_13\NNS\9898892|in|impairment (l_nmod) impairment_16\NN\7296428|with|renal
9669632
D020117_D043183 NONE cisapride_2\NN\1740|of (r_nmod) effects_0\NNS\13245626|cisapride|symptoms|. (l_nmod) symptoms_4\NNS\5823932|on|and|function|patients (l_nmod) patients_11\NNS\9898892|in|syndrome (l_nmod) syndrome_15\NN\5870365|with|irritable|bowel
D020117_D043183 NONE cisapride_15\NN\1740| (r_appos) agent_13\NN\7347|with|a|prokinetic|,|cisapride|, (r_nmod) treatment_9\NN\654885|of|long-term|agent (r_nmod) effects_6\NNS\13245626|the|treatment|motility (l_nmod) motility_20\NN\4773351|on|postprandial|jejunal|and|symptoms (l_conj) symptoms_22\NNS\5823932|syndrome (l_nmod) syndrome_27\NN\5870365|in|the|irritable|bowel|ibs
D020117_D043183 NONE cisapride_15\NN\1740| (r_appos) agent_13\NN\7347|with|a|prokinetic|,|cisapride|, (r_nmod) treatment_9\NN\654885|of|long-term|agent (r_nmod) effects_6\NNS\13245626|the|treatment|motility (l_nmod) motility_20\NN\4773351|on|postprandial|jejunal|and|symptoms (l_conj) symptoms_22\NNS\5823932|syndrome (l_nmod) syndrome_27\NN\5870365|in|the|irritable|bowel|ibs (l_appos) ibs_29\NN\1740|(|)
D020117_D043183 NONE cisapride_32\NN\1740|,|mg|daily|=|or|placebo|] (r_dep) treatment_30\NN\654885|before|week|[|cisapride (r_nmod) underwent_19\VBD\109660|patients|manometry|treatment|. (l_nsubj) patients_3\NNS\9898892|thirty-eight|ibs|constipation-predominant (l_nmod) ibs_5\NN\1740|with
D020117_D043183 NONE cisapride-treated_11\JJ\1740| (r_amod) patients_14\NNS\9898892|in|cisapride-treated|constipation-predominant|ibs (l_compound) ibs_13\NN\1740|
D020117_D043183 NONE cisapride_27\NN\1740|versus|placebo (r_appos) score_16\NN\5736149|[|,|54|,|cisapride|p|;|pretreatment|] (r_dep) lower_9\JJR\1740|scores|were|patients|score|. (l_nmod) patients_14\NNS\9898892|in|cisapride-treated|constipation-predominant|ibs (l_compound) ibs_13\NN\1740|
D020117_D043183 NONE cisapride_9\NN\1740| (r_compound) therapy_10\NN\657604|after|cisapride (r_nmod) score_7\NN\5736149|a|higher|pain|therapy (r_dobj) had_3\VBD\2108377|patients|score|[|score|]|. (l_nsubj) patients_2\NNS\9898892|diarrhoea-predominant|ibs (l_compound) ibs_1\NN\1740|
D020117_D043183 NONE cisapride_23\NN\1740|versus|placebo (r_appos) score_12\NN\5736149|,|mm|,|cisapride|p|;|pretreatment (r_dobj) had_3\VBD\2108377|patients|score|[|score|]|. (l_nsubj) patients_2\NNS\9898892|diarrhoea-predominant|ibs (l_compound) ibs_1\NN\1740|
D020117_D043183 NONE cisapride_2\NN\1740| (r_nsubj) affects_3\VBZ\126264|conclusion|:|cisapride|characteristics|. (l_dobj) characteristics_6\NNS\5849040|contraction|and|symptoms (l_conj) symptoms_9\NNS\5823932|some|ibs (l_nmod) ibs_11\NN\1740|in
D020117_D003248 NONE cisapride_32\NN\1740|,|mg|daily|=|or|placebo|] (r_dep) treatment_30\NN\654885|before|week|[|cisapride (r_nmod) underwent_19\VBD\109660|patients|manometry|treatment|. (l_nsubj) patients_3\NNS\9898892|thirty-eight|ibs|constipation-predominant (l_dep) constipation-predominant_7\JJ\1740|(|,|=|;|diarrhoea-predominant|)
D020117_D003248 NONE cisapride-treated_11\JJ\1740| (r_amod) patients_14\NNS\9898892|in|cisapride-treated|constipation-predominant|ibs (r_nmod) lower_9\JJR\1740|scores|were|patients|score|. (l_nsubj) scores_1\NNS\13757724|symptom|relating (l_acl) relating_2\VBG\628491|severity (l_nmod) severity_5\NN\5036394|to|the|constipation (l_nmod) constipation_7\NN\14299637|of
D020117_D003248 NONE cisapride-treated_11\JJ\1740| (r_amod) patients_14\NNS\9898892|in|cisapride-treated|constipation-predominant|ibs (l_amod) constipation-predominant_12\JJ\1740|
D020117_D003248 NONE cisapride_27\NN\1740|versus|placebo (r_appos) score_16\NN\5736149|[|,|54|,|cisapride|p|;|pretreatment|] (r_dep) lower_9\JJR\1740|scores|were|patients|score|. (l_nsubj) scores_1\NNS\13757724|symptom|relating (l_acl) relating_2\VBG\628491|severity (l_nmod) severity_5\NN\5036394|to|the|constipation (l_nmod) constipation_7\NN\14299637|of
D020117_D003248 NONE cisapride_27\NN\1740|versus|placebo (r_appos) score_16\NN\5736149|[|,|54|,|cisapride|p|;|pretreatment|] (r_dep) lower_9\JJR\1740|scores|were|patients|score|. (l_nmod) patients_14\NNS\9898892|in|cisapride-treated|constipation-predominant|ibs (l_amod) constipation-predominant_12\JJ\1740|
D020117_D003967 NONE cisapride_32\NN\1740|,|mg|daily|=|or|placebo|] (r_dep) treatment_30\NN\654885|before|week|[|cisapride (r_nmod) underwent_19\VBD\109660|patients|manometry|treatment|. (l_nsubj) patients_3\NNS\9898892|thirty-eight|ibs|constipation-predominant (l_dep) constipation-predominant_7\JJ\1740|(|,|=|;|diarrhoea-predominant|) (l_dep) diarrhoea-predominant_13\JJ\1740|,|=
D020117_D003967 NONE cisapride_14\NN\1740|the|and|placebo (r_compound) groups_17\NNS\2137|between|cisapride (r_nmod) observed_11\VBN\2163746|differences|were|groups|. (r_dep) results_0\NNS\34213|:|patients|observed (l_nmod) patients_4\NNS\9898892|in|diarrhoea-predominant (l_amod) diarrhoea-predominant_3\JJ\1740|
D020117_D003967 NONE cisapride-treated_1\JJ\1740| (r_amod) patients_3\NNS\9898892|in|cisapride-treated|diarrhoea-predominant (l_amod) diarrhoea-predominant_2\JJ\1740|
D020117_D003967 NONE cisapride_21\NN\1740|versus|placebo (r_dep) hg_19\NN\14625458|(|29.3|mm|,|cisapride|<|;|pretreatment|,|duration (r_dep) higher_9\JJR\1740|patients|amplitude|was|hg|longer|,|cisapride|;|pretreatment|,|and|frequency|patients|. (l_nmod) patients_3\NNS\9898892|in|cisapride-treated|diarrhoea-predominant (l_amod) diarrhoea-predominant_2\JJ\1740|
D020117_D003967 NONE cisapride_54\NN\1740|versus|placebo|< (r_dep) higher_9\JJR\1740|patients|amplitude|was|hg|longer|,|cisapride|;|pretreatment|,|and|frequency|patients|. (l_nmod) patients_3\NNS\9898892|in|cisapride-treated|diarrhoea-predominant (l_amod) diarrhoea-predominant_2\JJ\1740|
D020117_D003967 NONE cisapride_87\NN\1740|versus|placebo (r_appos) cont./min_85\NN\1740|(|2.0|,|cisapride|0.001 (r_dobj) lower_76\JJR\1740|cont./min (r_acl) frequency_75\NN\15286249|the|mean|contraction|lower|;|pretreatment (r_conj) higher_9\JJR\1740|patients|amplitude|was|hg|longer|,|cisapride|;|pretreatment|,|and|frequency|patients|. (l_nmod) patients_3\NNS\9898892|in|cisapride-treated|diarrhoea-predominant (l_amod) diarrhoea-predominant_2\JJ\1740|
D020117_D003967 NONE cisapride_9\NN\1740| (r_compound) therapy_10\NN\657604|after|cisapride (r_nmod) score_7\NN\5736149|a|higher|pain|therapy (r_dobj) had_3\VBD\2108377|patients|score|[|score|]|. (l_nsubj) patients_2\NNS\9898892|diarrhoea-predominant|ibs (l_amod) diarrhoea-predominant_0\JJ\1740|
D020117_D003967 NONE cisapride_23\NN\1740|versus|placebo (r_appos) score_12\NN\5736149|,|mm|,|cisapride|p|;|pretreatment (r_dobj) had_3\VBD\2108377|patients|score|[|score|]|. (l_nsubj) patients_2\NNS\9898892|diarrhoea-predominant|ibs (l_amod) diarrhoea-predominant_0\JJ\1740|
D020117_D010146 NONE cisapride_9\NN\1740| (r_compound) therapy_10\NN\657604|after|cisapride (r_nmod) score_7\NN\5736149|a|higher|pain|therapy (l_compound) pain_6\NN\14299637|
D020117_D010146 NONE cisapride_23\NN\1740|versus|placebo (r_appos) score_12\NN\5736149|,|mm|,|cisapride|p|;|pretreatment (r_dobj) had_3\VBD\2108377|patients|score|[|score|]|. (l_dobj) score_7\NN\5736149|a|higher|pain|therapy (l_compound) pain_6\NN\14299637|
8665051
D000305_D009135 NONE corticosteroids_17\NNS\14745635|of (r_nmod) doses_15\NNS\3740161|with|massive|corticosteroids (r_nmod) treated_12\VBN\2376958|doses (r_acl) patients_11\NNS\9898892|in|treated (r_nmod) occur_9\VB\2623529|that|myopathy|may|patients (l_nsubj) myopathy_7\NN\14204950|acute
D013256_D000855 NONE steroid-treated_18\JJ\1740| (r_amod) groups_19\NNS\2137|in|the|steroid-treated (r_nmod) reduction_12\NN\351485|a|significant|intake|groups (l_nmod) intake_15\NN\13440063|of|food
D008775_D000855 CID m_26\NN\13649268|in|and|t (r_nmod) %_24\NN\1740|(|-50|m|,|respectively|) (r_dep) showed_9\VBD\2137132|intake|reduction|%|. (l_dobj) reduction_12\NN\351485|a|significant|intake|groups (l_nmod) intake_15\NN\13440063|of|food
D014221_D000855 CID t_28\NN\14999913| (r_conj) m_26\NN\13649268|in|and|t (r_nmod) %_24\NN\1740|(|-50|m|,|respectively|) (r_dep) showed_9\VBD\2137132|intake|reduction|%|. (l_dobj) reduction_12\NN\351485|a|significant|intake|groups (l_nmod) intake_15\NN\13440063|of|food
D013256_D013746 NONE steroid_6\NN\14727670| (r_compound) groups_7\NNS\2137|in|both|steroid (r_nmod) prolonged_3\JJ\1740|time|was|groups|,|and|longer|similar (l_parataxis) similar_23\JJ\1740|tensions|were|. (l_nsubj) tensions_21\NNS\14375890|tetanic (l_amod) tetanic_20\JJ\1740|
D008775_D013746 NONE m_17\NN\13649268|with (r_nmod) longer_15\JJR\1740|time|was|m|,|whereas (r_conj) prolonged_3\JJ\1740|time|was|groups|,|and|longer|similar (l_parataxis) similar_23\JJ\1740|tensions|were|. (l_nsubj) tensions_21\NNS\14375890|tetanic (l_amod) tetanic_20\JJ\1740|
D013256_D009133 NONE steroid_18\NN\14727670| (r_compound) groups_19\NNS\2137|in|the|steroid (r_nmod) atrophy_15\NN\14299637|type|iib|fiber|groups|and|also|atrophy
D013256_D009133 NONE steroid_18\NN\14727670| (r_compound) groups_19\NNS\2137|in|the|steroid (r_nmod) atrophy_15\NN\14299637|type|iib|fiber|groups|and|also|atrophy (l_conj) atrophy_25\NN\14299637|diaphragmatic|type|iia|t
D013256_D009133 NONE steroids_12\NNS\14727670|of (r_nmod) doses_10\NNS\3740161|with|massive|steroids (r_nmod) treatment_7\NN\654885|short-term|doses (r_nsubj) induced_13\VBD\1627355|that|1|treatment|wasting|;|induced|caused (l_dep) caused_61\VBN\1617192|4|atrophy|was|not|deprivation (l_nsubjpass) atrophy_58\NN\14299637|type|iib
D013256_D009133 NONE steroids_27\NNS\14727670|of (r_nmod) types_25\NNS\5839024|both|steroids (r_nsubj) induced_28\VBD\1627355|2|types|atrophy|,|resulting|;|caused (r_conj) induced_13\VBD\1627355|that|1|treatment|wasting|;|induced|caused (l_dep) caused_61\VBN\1617192|4|atrophy|was|not|deprivation (l_nsubjpass) atrophy_58\NN\14299637|type|iib
D013256_D009133 NONE steroid_48\NN\14727670|neither (r_nsubj) caused_49\VBD\1617192|3|steroid|necrosis|; (r_conj) induced_28\VBD\1627355|2|types|atrophy|,|resulting|;|caused (r_conj) induced_13\VBD\1627355|that|1|treatment|wasting|;|induced|caused (l_dep) caused_61\VBN\1617192|4|atrophy|was|not|deprivation (l_nsubjpass) atrophy_58\NN\14299637|type|iib
D013256_D009336 NONE steroid_18\NN\14727670| (r_compound) groups_19\NNS\2137|in|the|steroid (r_nmod) atrophy_15\NN\14299637|type|iib|fiber|groups|and|also|atrophy (r_dobj) showed_11\VBD\2137132|staining|atrophy|,|whereas|revealed (l_parataxis) revealed_32\VBD\2137132|examinations|pattern|. (l_dobj) pattern_36\NN\5726345|a|normal|muscular|absence (l_nmod) absence_38\NN\14449405|with|necrosis (l_nmod) necrosis_40\NN\11444117|of
D013256_D009336 NONE steroids_12\NNS\14727670|of (r_nmod) doses_10\NNS\3740161|with|massive|steroids (r_nmod) treatment_7\NN\654885|short-term|doses (r_nsubj) induced_13\VBD\1627355|that|1|treatment|wasting|;|induced|caused (l_conj) induced_28\VBD\1627355|2|types|atrophy|,|resulting|;|caused (l_conj) caused_49\VBD\1617192|3|steroid|necrosis|; (l_dobj) necrosis_51\NN\11444117|muscle
D013256_D009336 NONE steroids_27\NNS\14727670|of (r_nmod) types_25\NNS\5839024|both|steroids (r_nsubj) induced_28\VBD\1627355|2|types|atrophy|,|resulting|;|caused (l_conj) caused_49\VBD\1617192|3|steroid|necrosis|; (l_dobj) necrosis_51\NN\11444117|muscle
D013256_D009336 NONE steroid_48\NN\14727670|neither (r_nsubj) caused_49\VBD\1617192|3|steroid|necrosis|; (l_dobj) necrosis_51\NN\11444117|muscle
D014221_D009133 CID t_27\NN\14999913|with (r_nmod) atrophy_25\NN\14299637|diaphragmatic|type|iia|t (r_conj) atrophy_15\NN\14299637|type|iib|fiber|groups|and|also|atrophy
D014221_D009133 CID t_27\NN\14999913|with (r_nmod) atrophy_25\NN\14299637|diaphragmatic|type|iia|t
D014221_D009133 CID t_16\NN\14999913| (r_conj) c_14\NN\13714184|(|,|t|,|and|pf|) (r_dep) rats_12\NNS\2329401|in|18|c (r_nmod) performed_9\VBN\2367363|rats (r_acl) study_7\NN\635850|a|pair-fed|,|performed (r_nsubj) showed_22\VBD\2137132|finally|,|study|,|pronounced|. (l_ccomp) pronounced_29\JJ\1740|that|atrophy|was|less|animals|than (l_nsubj) atrophy_25\NN\14299637|muscle
D014221_D009133 CID t-treated_35\JJ\1740| (r_amod) animals_36\NNS\4475|in|t-treated (r_nmod) than_33\IN\1740|animals (r_prep) pronounced_29\JJ\1740|that|atrophy|was|less|animals|than (l_nsubj) atrophy_25\NN\14299637|muscle
D014221_D009336 NONE t_27\NN\14999913|with (r_nmod) atrophy_25\NN\14299637|diaphragmatic|type|iia|t (r_conj) atrophy_15\NN\14299637|type|iib|fiber|groups|and|also|atrophy (r_dobj) showed_11\VBD\2137132|staining|atrophy|,|whereas|revealed (l_parataxis) revealed_32\VBD\2137132|examinations|pattern|. (l_dobj) pattern_36\NN\5726345|a|normal|muscular|absence (l_nmod) absence_38\NN\14449405|with|necrosis (l_nmod) necrosis_40\NN\11444117|of
D013256_D001284 NONE steroids_12\NNS\14727670|of (r_nmod) doses_10\NNS\3740161|with|massive|steroids (r_nmod) treatment_7\NN\654885|short-term|doses (r_nsubj) induced_13\VBD\1627355|that|1|treatment|wasting|;|induced|caused (l_conj) induced_28\VBD\1627355|2|types|atrophy|,|resulting|;|caused (l_dobj) atrophy_32\NN\14299637|predominantly|type|iib
D013256_D001284 NONE steroids_27\NNS\14727670|of (r_nmod) types_25\NNS\5839024|both|steroids (r_nsubj) induced_28\VBD\1627355|2|types|atrophy|,|resulting|;|caused (l_dobj) atrophy_32\NN\14299637|predominantly|type|iib
D013256_D001284 NONE steroid_48\NN\14727670|neither (r_nsubj) caused_49\VBD\1617192|3|steroid|necrosis|; (r_conj) induced_28\VBD\1627355|2|types|atrophy|,|resulting|;|caused (l_dobj) atrophy_32\NN\14299637|predominantly|type|iib
16634859
D000431_D006130 CID alcohol-related_9\JJ\1740| (r_amod) impairment_12\NN\7296428|alcohol-related|fetal|growth
D000431_D006130 CID alcohol_1\NN\7881800| (r_compound) consumption_2\NN\13440063|alcohol (r_compound) recognition_4\NN\13932421|any|consumption|postpregnancy|drinkers (r_nsubj) resulted_9\VBD\2633881|recognition|growth|comparison|. (l_nmod) growth_13\NN\13526110|in|reduced|cerebellar|as|growth
D000431_D006130 CID alcohol_1\NN\7881800| (r_compound) consumption_2\NN\13440063|alcohol (r_compound) recognition_4\NN\13932421|any|consumption|postpregnancy|drinkers (r_nsubj) resulted_9\VBD\2633881|recognition|growth|comparison|. (l_nmod) growth_13\NN\13526110|in|reduced|cerebellar|as|growth (l_conj) growth_21\NN\13526110|decreased|cranial
1545575
D003520_D006470 CID cyclophosphamide_9\NN\1740| (r_compound) therapy_10\NN\657604|of|high-dose|cyclophosphamide|administered (r_nmod) complication_6\NN\1073995|cystitis|is|a|serious|therapy|. (l_nsubj) cystitis_1\NN\14566129|hemorrhagic
D003520_D006470 CID cyclophosphamide_27\NN\1740|of (r_nmod) metabolite_25\NN\20090|the|hepatic|cyclophosphamide|causes (l_acl:relcl) causes_29\VBZ\1617192|that|cystitis (l_dobj) cystitis_31\NN\14566129|hemorrhagic
D003520_D003556 CID cyclophosphamide_9\NN\1740| (r_compound) therapy_10\NN\657604|of|high-dose|cyclophosphamide|administered (r_nmod) complication_6\NN\1073995|cystitis|is|a|serious|therapy|. (l_nsubj) cystitis_1\NN\14566129|hemorrhagic
D003520_D003556 CID cyclophosphamide_27\NN\1740|of (r_nmod) metabolite_25\NN\20090|the|hepatic|cyclophosphamide|causes (l_acl:relcl) causes_29\VBZ\1617192|that|cystitis (l_dobj) cystitis_31\NN\14566129|hemorrhagic
D015080_D006470 NONE mesna_19\NN\1740|with|,|neutralizes (l_acl:relcl) neutralizes_22\VBZ\126264|which|metabolite (l_dobj) metabolite_25\NN\20090|the|hepatic|cyclophosphamide|causes (l_acl:relcl) causes_29\VBZ\1617192|that|cystitis (l_dobj) cystitis_31\NN\14566129|hemorrhagic
D015080_D006470 NONE mesna_10\NN\1740| (r_compound) uroprophylaxis_11\NN\1740|mesna (r_dobj) received_9\VBD\2210855|who|uroprophylaxis|transplantation (r_acl:relcl) patients_7\NNS\9898892|four|consecutive|received (r_nsubj) had_17\VBD\2108377|contrast|,|patients|cystitis|weeks|. (l_dobj) cystitis_20\NN\14566129|severe|hemorrhagic
D015080_D003556 NONE mesna_19\NN\1740|with|,|neutralizes (l_acl:relcl) neutralizes_22\VBZ\126264|which|metabolite (l_dobj) metabolite_25\NN\20090|the|hepatic|cyclophosphamide|causes (l_acl:relcl) causes_29\VBZ\1617192|that|cystitis (l_dobj) cystitis_31\NN\14566129|hemorrhagic
D015080_D003556 NONE mesna_10\NN\1740| (r_compound) uroprophylaxis_11\NN\1740|mesna (r_dobj) received_9\VBD\2210855|who|uroprophylaxis|transplantation (r_acl:relcl) patients_7\NNS\9898892|four|consecutive|received (r_nsubj) had_17\VBD\2108377|contrast|,|patients|cystitis|weeks|. (l_dobj) cystitis_20\NN\14566129|severe|hemorrhagic
18405372
D012460_D056486 CID sulfasalazine_3\NN\1740|with (r_nmod) associated_1\VBN\628491|sulfasalazine|arthritis (r_acl) hepatotoxicity_0\NN\1740|associated|:|series|.
D012460_D056486 CID sulfasalazine_7\NN\1740|on (r_nmod) hepatotoxicity_5\NN\1740|sulfasalazine
D012460_D056486 CID sulfasalazine_6\NN\1740|with (r_nmod) hepatotoxicity_4\NN\1740|of|sulfasalazine
D012460_D056486 CID sulfasalazine_7\NN\1740|with (r_nmod) hepatotoxicity_5\NN\1740|of|serious|sulfasalazine
D012460_D056486 CID sulfasalazine_6\NN\1740|with (r_nmod) associated_4\VBN\628491|sulfasalazine (r_acl) hepatotoxicity_3\NN\1740|serious|associated
D012460_D001168 NONE sulfasalazine_3\NN\1740|with (r_nmod) associated_1\VBN\628491|sulfasalazine|arthritis (l_nmod) arthritis_6\NN\14171682|in|inflammatory
16116131
D007980_D004409 CID levodopa-induced_7\JJ\1740| (r_amod) dyskinesia_8\NN\14084880|in|levodopa-induced
D001058_D010300 NONE apomorphine_46\NN\3786417| (r_compound) infusion_47\NN\14589223|by|continuous|apomorphine (r_nmod) induced_43\VBN\1627355|infusion (r_acl) state_42\NN\8491826|of|a|dyskinetic|induced (r_nmod) modification_38\NN\191142|in|a|state (r_nmod) result_35\VB\2633881|whether|modulation|may|modification (r_ccomp) investigated_28\VBD\644583|using|,|authors|result|. (l_advcl) using_0\VBG\1156834|stimulation|group (l_nmod) group_18\NN\2137|in|a|patients (l_nmod) patients_20\NNS\9898892|of|disease (l_nmod) disease_24\NN\14061805|with|advanced|parkinson
D001058_D004409 NONE apomorphine_46\NN\3786417| (r_compound) infusion_47\NN\14589223|by|continuous|apomorphine (r_nmod) induced_43\VBN\1627355|infusion (r_acl) state_42\NN\8491826|of|a|dyskinetic|induced (l_amod) dyskinetic_41\JJ\1740|
12452237
D008012_D010149 NONE lidocaine_1\NN\3681148| (r_nsubj) reduce_2\VB\441445|can|lidocaine|myalgia|? (l_dobj) myalgia_6\NN\14322699|induced|postoperative
D008012_D010149 NONE lidocaine_8\NN\3681148| (r_nsubjpass) proven_10\VBN\2604760|conclusion|,|used|,|lidocaine|is|agent|. (l_xcomp) agent_16\NN\7347|to|be|the|useful|pretreatment|reduction (l_nmod) reduction_19\NN\351485|for|the|myalgia (l_nmod) myalgia_22\NN\14322699|of|postoperative
D013390_D010149 CID succinylcholine_3\NN\3800001| (r_nmod:npmod) induced_4\JJ\1740|succinylcholine (r_amod) myalgia_6\NN\14322699|induced|postoperative
D013390_D010149 CID succinylcholine_4\NN\3800001| (r_nsubjpass) used_6\VBN\1156834|where|succinylcholine|is (r_advcl) proven_10\VBN\2604760|conclusion|,|used|,|lidocaine|is|agent|. (l_xcomp) agent_16\NN\7347|to|be|the|useful|pretreatment|reduction (l_nmod) reduction_19\NN\351485|for|the|myalgia (l_nmod) myalgia_22\NN\14322699|of|postoperative
D008012_D063806 NONE lidocaine_9\NN\3681148| (r_compound) pretreatment_10\NN\1740|of|lidocaine (r_nmod) effect_7\NN\34213|the|pretreatment|reduction (l_nmod) reduction_12\NN\351485|on|myalgia|patients (l_nmod) myalgia_15\NN\14322699|of|succinylcholine-induced
D013390_D063806 NONE succinylcholine-induced_14\JJ\1740| (r_amod) myalgia_15\NN\14322699|of|succinylcholine-induced
17049862
D010672_D007035 NONE phenytoin_1\NN\3550533| (r_compound) administration_2\NN\1133281|phenytoin (r_nsubj) safe_3\JJ\1740|is|administration|child|? (l_nmod) child_7\NN\9622049|in|a|hypothermic (l_amod) hypothermic_6\JJ\1740|
D010672_D007035 NONE phenytoin_5\NN\3550533|of|and|hypothermia (l_conj) hypothermia_7\NN\14034177|
D010672_D007035 NONE phenytoin_2\NN\3550533|of (r_nmod) administration_0\NN\1133281|phenytoin|presence (l_nmod) presence_5\NN\13954253|in|the|hypothermia (l_nmod) hypothermia_7\NN\14034177|of
D010672_D012640 NONE phenytoin_1\NN\3550533|intravenous (r_nsubjpass) administered_3\VBN\2436349|phenytoin|was|part|prophylaxis|. (l_nmod) prophylaxis_13\NN\1077350|for|seizure (l_compound) seizure_12\NN\14081375|
D010672_D001919 CID phenytoin_1\NN\3550533| (r_compound) administration_2\NN\1133281|following|phenytoin (r_nmod) developed_6\VBD\1753788|administration|,|patient|bradycardia|. (l_dobj) bradycardia_9\NN\14110674|acute|severe|,|refractory
D001285_D001919 NONE atropine_13\NN\14712692|to|and|adrenaline (r_nmod) refractory_11\JJ\1740|atropine (r_amod) bradycardia_9\NN\14110674|acute|severe|,|refractory
D004837_D001919 NONE adrenaline_15\NN\14807929| (r_conj) atropine_13\NN\14712692|to|and|adrenaline (r_nmod) refractory_11\JJ\1740|atropine (r_amod) bradycardia_9\NN\14110674|acute|severe|,|refractory
11063349
D020123_D064420 NONE rapa_13\NN\1740| (r_compound) conversion_14\NN\7359599|of|rapa (r_nmod) effects_11\NNS\13245626|the|conversion|patients (l_nmod) patients_16\NNS\9898892|in|undergoing (l_acl) undergoing_17\VBG\109660|toxicity (l_dobj) toxicity_27\NN\13576101|cyclosporine
D016572_D064420 NONE cyclosporine_18\NN\1740|csa|or|tacrolimus (r_compound) toxicity_27\NN\13576101|cyclosporine
D016572_D064420 NONE csa_20\NN\1740|(|) (r_appos) cyclosporine_18\NN\1740|csa|or|tacrolimus (r_compound) toxicity_27\NN\13576101|cyclosporine
D016572_D064420 NONE csa_6\NN\1740|or|tac (r_compound) nephrotoxicity_9\NN\1740|indications|were|chronic|csa|12|,|toxicity|. (l_conj) toxicity_18\NN\13576101|acute|csa|3|,|dysmorphism
D016572_D064420 NONE csa_15\NN\1740|or|tac (r_compound) toxicity_18\NN\13576101|acute|csa|3|,|dysmorphism
D016559_D064420 NONE tacrolimus_23\NN\1740|tac (r_conj) cyclosporine_18\NN\1740|csa|or|tacrolimus (r_compound) toxicity_27\NN\13576101|cyclosporine
D016559_D064420 NONE tac_25\NN\1740|(|) (r_appos) tacrolimus_23\NN\1740|tac (r_conj) cyclosporine_18\NN\1740|csa|or|tacrolimus (r_compound) toxicity_27\NN\13576101|cyclosporine
D016559_D064420 NONE tac_8\NN\1740| (r_conj) csa_6\NN\1740|or|tac (r_compound) nephrotoxicity_9\NN\1740|indications|were|chronic|csa|12|,|toxicity|. (l_conj) toxicity_18\NN\13576101|acute|csa|3|,|dysmorphism
D016559_D064420 NONE tac_17\NN\1740| (r_conj) csa_15\NN\1740|or|tac (r_compound) toxicity_18\NN\13576101|acute|csa|3|,|dysmorphism
D016572_D007674 CID csa_6\NN\1740|or|tac (r_compound) nephrotoxicity_9\NN\1740|indications|were|chronic|csa|12|,|toxicity|.
D016572_D007674 CID csa_15\NN\1740|or|tac (r_compound) toxicity_18\NN\13576101|acute|csa|3|,|dysmorphism (r_conj) nephrotoxicity_9\NN\1740|indications|were|chronic|csa|12|,|toxicity|.
D016572_-1 NONE csa_6\NN\1740|or|tac (r_compound) nephrotoxicity_9\NN\1740|indications|were|chronic|csa|12|,|toxicity|. (l_conj) toxicity_18\NN\13576101|acute|csa|3|,|dysmorphism (l_conj) dysmorphism_25\NN\1740|severe|facial|2|,|disorder
D016572_-1 NONE csa_15\NN\1740|or|tac (r_compound) toxicity_18\NN\13576101|acute|csa|3|,|dysmorphism (l_conj) dysmorphism_25\NN\1740|severe|facial|2|,|disorder
D016572_D008232 NONE csa_6\NN\1740|or|tac (r_compound) nephrotoxicity_9\NN\1740|indications|were|chronic|csa|12|,|toxicity|. (l_conj) toxicity_18\NN\13576101|acute|csa|3|,|dysmorphism (l_conj) dysmorphism_25\NN\1740|severe|facial|2|,|disorder (l_conj) disorder_32\NN\14034177|posttransplant|lymphoproliferative|ptld|remission|2|,|and|hepatotoxicity
D016572_D008232 NONE csa_6\NN\1740|or|tac (r_compound) nephrotoxicity_9\NN\1740|indications|were|chronic|csa|12|,|toxicity|. (l_conj) toxicity_18\NN\13576101|acute|csa|3|,|dysmorphism (l_conj) dysmorphism_25\NN\1740|severe|facial|2|,|disorder (l_conj) disorder_32\NN\14034177|posttransplant|lymphoproliferative|ptld|remission|2|,|and|hepatotoxicity (l_appos) ptld_34\NN\1740|(|)
D016572_D008232 NONE csa_15\NN\1740|or|tac (r_compound) toxicity_18\NN\13576101|acute|csa|3|,|dysmorphism (l_conj) dysmorphism_25\NN\1740|severe|facial|2|,|disorder (l_conj) disorder_32\NN\14034177|posttransplant|lymphoproliferative|ptld|remission|2|,|and|hepatotoxicity
D016572_D008232 NONE csa_15\NN\1740|or|tac (r_compound) toxicity_18\NN\13576101|acute|csa|3|,|dysmorphism (l_conj) dysmorphism_25\NN\1740|severe|facial|2|,|disorder (l_conj) disorder_32\NN\14034177|posttransplant|lymphoproliferative|ptld|remission|2|,|and|hepatotoxicity (l_appos) ptld_34\NN\1740|(|)
D016572_D056486 NONE csa_6\NN\1740|or|tac (r_compound) nephrotoxicity_9\NN\1740|indications|were|chronic|csa|12|,|toxicity|. (l_conj) toxicity_18\NN\13576101|acute|csa|3|,|dysmorphism (l_conj) dysmorphism_25\NN\1740|severe|facial|2|,|disorder (l_conj) disorder_32\NN\14034177|posttransplant|lymphoproliferative|ptld|remission|2|,|and|hepatotoxicity (l_conj) hepatotoxicity_43\NN\1740|1
D016572_D056486 NONE csa_15\NN\1740|or|tac (r_compound) toxicity_18\NN\13576101|acute|csa|3|,|dysmorphism (l_conj) dysmorphism_25\NN\1740|severe|facial|2|,|disorder (l_conj) disorder_32\NN\14034177|posttransplant|lymphoproliferative|ptld|remission|2|,|and|hepatotoxicity (l_conj) hepatotoxicity_43\NN\1740|1
D016559_D007674 CID tac_8\NN\1740| (r_conj) csa_6\NN\1740|or|tac (r_compound) nephrotoxicity_9\NN\1740|indications|were|chronic|csa|12|,|toxicity|.
D016559_D007674 CID tac_17\NN\1740| (r_conj) csa_15\NN\1740|or|tac (r_compound) toxicity_18\NN\13576101|acute|csa|3|,|dysmorphism (r_conj) nephrotoxicity_9\NN\1740|indications|were|chronic|csa|12|,|toxicity|.
D016559_-1 NONE tac_8\NN\1740| (r_conj) csa_6\NN\1740|or|tac (r_compound) nephrotoxicity_9\NN\1740|indications|were|chronic|csa|12|,|toxicity|. (l_conj) toxicity_18\NN\13576101|acute|csa|3|,|dysmorphism (l_conj) dysmorphism_25\NN\1740|severe|facial|2|,|disorder
D016559_-1 NONE tac_17\NN\1740| (r_conj) csa_15\NN\1740|or|tac (r_compound) toxicity_18\NN\13576101|acute|csa|3|,|dysmorphism (l_conj) dysmorphism_25\NN\1740|severe|facial|2|,|disorder
D016559_D008232 NONE tac_8\NN\1740| (r_conj) csa_6\NN\1740|or|tac (r_compound) nephrotoxicity_9\NN\1740|indications|were|chronic|csa|12|,|toxicity|. (l_conj) toxicity_18\NN\13576101|acute|csa|3|,|dysmorphism (l_conj) dysmorphism_25\NN\1740|severe|facial|2|,|disorder (l_conj) disorder_32\NN\14034177|posttransplant|lymphoproliferative|ptld|remission|2|,|and|hepatotoxicity
D016559_D008232 NONE tac_8\NN\1740| (r_conj) csa_6\NN\1740|or|tac (r_compound) nephrotoxicity_9\NN\1740|indications|were|chronic|csa|12|,|toxicity|. (l_conj) toxicity_18\NN\13576101|acute|csa|3|,|dysmorphism (l_conj) dysmorphism_25\NN\1740|severe|facial|2|,|disorder (l_conj) disorder_32\NN\14034177|posttransplant|lymphoproliferative|ptld|remission|2|,|and|hepatotoxicity (l_appos) ptld_34\NN\1740|(|)
D016559_D008232 NONE tac_17\NN\1740| (r_conj) csa_15\NN\1740|or|tac (r_compound) toxicity_18\NN\13576101|acute|csa|3|,|dysmorphism (l_conj) dysmorphism_25\NN\1740|severe|facial|2|,|disorder (l_conj) disorder_32\NN\14034177|posttransplant|lymphoproliferative|ptld|remission|2|,|and|hepatotoxicity
D016559_D008232 NONE tac_17\NN\1740| (r_conj) csa_15\NN\1740|or|tac (r_compound) toxicity_18\NN\13576101|acute|csa|3|,|dysmorphism (l_conj) dysmorphism_25\NN\1740|severe|facial|2|,|disorder (l_conj) disorder_32\NN\14034177|posttransplant|lymphoproliferative|ptld|remission|2|,|and|hepatotoxicity (l_appos) ptld_34\NN\1740|(|)
D016559_D056486 NONE tac_8\NN\1740| (r_conj) csa_6\NN\1740|or|tac (r_compound) nephrotoxicity_9\NN\1740|indications|were|chronic|csa|12|,|toxicity|. (l_conj) toxicity_18\NN\13576101|acute|csa|3|,|dysmorphism (l_conj) dysmorphism_25\NN\1740|severe|facial|2|,|disorder (l_conj) disorder_32\NN\14034177|posttransplant|lymphoproliferative|ptld|remission|2|,|and|hepatotoxicity (l_conj) hepatotoxicity_43\NN\1740|1
D016559_D056486 NONE tac_17\NN\1740| (r_conj) csa_15\NN\1740|or|tac (r_compound) toxicity_18\NN\13576101|acute|csa|3|,|dysmorphism (l_conj) dysmorphism_25\NN\1740|severe|facial|2|,|disorder (l_conj) disorder_32\NN\14034177|posttransplant|lymphoproliferative|ptld|remission|2|,|and|hepatotoxicity (l_conj) hepatotoxicity_43\NN\1740|1
D003404_D007674 NONE creatinine_18\NN\1740|in|serum (r_nmod) decrease_15\NN\7296428|a|significant|creatinine|micromol/liter (r_attr) was_12\VBD\836236|patients|there|decrease|. (l_nmod) patients_5\NNS\9898892|in|the|12|switched (l_acl) switched_6\VBN\138508|nephrotoxicity (l_nmod) nephrotoxicity_10\NN\1740|because|chronic
D020123_D011014 NONE rapa_0\NN\1740| (r_nsubjpass) discontinued_2\VBN\2609764|rapa|was|patients|,|pneumonia|. (l_nmod) pneumonia_9\NN\14145095|because|two|,|ptld
D020123_D008232 NONE rapa_0\NN\1740| (r_nsubjpass) discontinued_2\VBN\2609764|rapa|was|patients|,|pneumonia|. (l_nmod) pneumonia_9\NN\14145095|because|two|,|ptld (l_conj) ptld_13\NN\1740|one|,|and|ulcers
D020123_D013281 NONE rapa_0\NN\1740| (r_nsubjpass) discontinued_2\VBN\2609764|rapa|was|patients|,|pneumonia|. (l_nmod) pneumonia_9\NN\14145095|because|two|,|ptld (l_conj) ptld_13\NN\1740|one|,|and|ulcers (l_conj) ulcers_20\NNS\14211294|oral|aphtous|one
D020123_D011020 NONE rapa_6\NN\1740|to (r_nmod) converting_3\VBG\126264|when|patients|rapa (r_amod) levels_8\NNS\4916342|converting|drug (r_nsubjpass) monitored_11\VBN\2169352|however|,|levels|should|be|avoid|and|given (l_conj) given_25\VBN\2327200|prophylaxis|should|be|. (l_nsubjpass) prophylaxis_22\NN\1077350|adequate|antiviral|pneumonia (l_compound) pneumonia_21\NN\14145095|
16157917
C047781_D009207 CID lamotrigine_0\NN\1740|associated|. (l_acl) associated_1\VBN\628491|exacerbation (l_nmod) exacerbation_3\NN\374224|with|or|myoclonus|epilepsies (l_conj) myoclonus_7\NN\14360459|de
C047781_D009207 CID lamotrigine_11\NN\1740|with|ltg (r_nmod) treated_9\VBN\2376958|lamotrigine (r_acl) patients_1\NNS\9898892|five|epilepsies|treated (r_nsubj) experienced_15\VBD\2108377|patients|exacerbation|. (l_dobj) exacerbation_16\NN\374224|or|appearance (l_conj) appearance_20\NN\4723816|novo|jerks (l_nmod) jerks_23\NNS\10322238|of|myoclonic|mj
C047781_D009207 CID lamotrigine_11\NN\1740|with|ltg (r_nmod) treated_9\VBN\2376958|lamotrigine (r_acl) patients_1\NNS\9898892|five|epilepsies|treated (r_nsubj) experienced_15\VBD\2108377|patients|exacerbation|. (l_dobj) exacerbation_16\NN\374224|or|appearance (l_conj) appearance_20\NN\4723816|novo|jerks (l_nmod) jerks_23\NNS\10322238|of|myoclonic|mj (l_appos) mj_25\NN\1740|(|)
C047781_D009207 CID ltg_13\NN\1740|(|) (r_appos) lamotrigine_11\NN\1740|with|ltg (r_nmod) treated_9\VBN\2376958|lamotrigine (r_acl) patients_1\NNS\9898892|five|epilepsies|treated (r_nsubj) experienced_15\VBD\2108377|patients|exacerbation|. (l_dobj) exacerbation_16\NN\374224|or|appearance (l_conj) appearance_20\NN\4723816|novo|jerks (l_nmod) jerks_23\NNS\10322238|of|myoclonic|mj
C047781_D009207 CID ltg_13\NN\1740|(|) (r_appos) lamotrigine_11\NN\1740|with|ltg (r_nmod) treated_9\VBN\2376958|lamotrigine (r_acl) patients_1\NNS\9898892|five|epilepsies|treated (r_nsubj) experienced_15\VBD\2108377|patients|exacerbation|. (l_dobj) exacerbation_16\NN\374224|or|appearance (l_conj) appearance_20\NN\4723816|novo|jerks (l_nmod) jerks_23\NNS\10322238|of|myoclonic|mj (l_appos) mj_25\NN\1740|(|)
C047781_D009207 CID ltg_4\NN\1740| (r_nsubj) exacerbated_5\VBD\126264|patients|,|ltg|mj|manner|aggravation|. (l_dobj) mj_6\NNP\1740|
C047781_D009207 CID ltg_3\NN\1740| (r_compound) dose_4\NN\3740161|ltg (r_nsubjpass) decreased_6\VBN\169651|when|dose|was|% (r_advcl) disappeared_1\VBD\2609764|mj|decreased|. (l_nsubj) mj_0\NNP\1740|
C047781_D009207 CID ltg_4\NN\1740| (r_nsubj) exacerbated_5\VBD\126264|patients|,|ltg|mj|manner|,|status|. (l_dobj) mj_6\NN\1740|
C047781_D009207 CID ltg_4\NN\1740| (r_nsubj) exacerbated_5\VBD\126264|patients|,|ltg|mj|manner|,|status|. (l_nmod) status_17\NN\24720|with|myoclonic|ceased
C047781_D009207 CID ltg_22\NN\1740| (r_compound) withdrawal_23\NN\7206096|after|ltg (r_nmod) ceased_20\VBD\1740|that|only|withdrawal (r_acl:relcl) status_17\NN\24720|with|myoclonic|ceased (r_nmod) exacerbated_5\VBD\126264|patients|,|ltg|mj|manner|,|status|. (l_dobj) mj_6\NN\1740|
C047781_D009207 CID ltg_22\NN\1740| (r_compound) withdrawal_23\NN\7206096|after|ltg (r_nmod) ceased_20\VBD\1740|that|only|withdrawal (r_acl:relcl) status_17\NN\24720|with|myoclonic|ceased
C047781_C562694 NONE lamotrigine_0\NN\1740|associated|. (l_acl) associated_1\VBN\628491|exacerbation (l_nmod) exacerbation_3\NN\374224|with|or|myoclonus|epilepsies (l_nmod) epilepsies_11\NNS\14085708|in|idiopathic|generalized
C047781_C562694 NONE lamotrigine_11\NN\1740|with|ltg (r_nmod) treated_9\VBN\2376958|lamotrigine (r_acl) patients_1\NNS\9898892|five|epilepsies|treated (l_nmod) epilepsies_5\NNS\14085708|with|idiopathic|generalized|ige
C047781_C562694 NONE lamotrigine_11\NN\1740|with|ltg (r_nmod) treated_9\VBN\2376958|lamotrigine (r_acl) patients_1\NNS\9898892|five|epilepsies|treated (l_nmod) epilepsies_5\NNS\14085708|with|idiopathic|generalized|ige (l_appos) ige_7\NN\15030481|(|)
C047781_C562694 NONE ltg_13\NN\1740|(|) (r_appos) lamotrigine_11\NN\1740|with|ltg (r_nmod) treated_9\VBN\2376958|lamotrigine (r_acl) patients_1\NNS\9898892|five|epilepsies|treated (l_nmod) epilepsies_5\NNS\14085708|with|idiopathic|generalized|ige
C047781_C562694 NONE ltg_13\NN\1740|(|) (r_appos) lamotrigine_11\NN\1740|with|ltg (r_nmod) treated_9\VBN\2376958|lamotrigine (r_acl) patients_1\NNS\9898892|five|epilepsies|treated (l_nmod) epilepsies_5\NNS\14085708|with|idiopathic|generalized|ige (l_appos) ige_7\NN\15030481|(|)
3115150
D007650_D009127 NONE ketanserin_0\NN\1740| (r_compound) pretreatment_1\NN\1740|ketanserin (r_nsubj) reverses_2\VBZ\109660|pretreatment|rigidity|. (l_dobj) rigidity_5\NN\5023233|alfentanil-induced|muscle
D007650_D009127 NONE ketanserin_3\NN\1740|with|,|antagonist|, (r_nmod) pretreatment_1\NN\1740|systemic|ketanserin (r_nsubj) attenuated_14\VBD\224901|pretreatment|significantly|rigidity|alfentanil|. (l_dobj) rigidity_17\NN\5023233|the|muscle|produced
D007650_D009127 NONE ketanserin_9\NN\1740|(|greater|i.p.|)|followed (r_dobj) received_8\VBD\2210855|that|ketanserin (r_acl:relcl) animals_6\NNS\4475|received (r_nsubj) motionless_21\JJ\1740|absence|,|animals|were|,|flaccid|than|animals|. (l_nmod) absence_2\NN\14449405|despite|the|rigidity (l_nmod) rigidity_4\NN\5023233|of
D015760_D009127 CID alfentanil-induced_3\JJ\1740| (r_amod) rigidity_5\NN\5023233|alfentanil-induced|muscle
D015760_D009127 CID alfentanil_27\NN\1740|agonist (r_dobj) attenuated_14\VBD\224901|pretreatment|significantly|rigidity|alfentanil|. (l_dobj) rigidity_17\NN\5023233|the|muscle|produced
D015760_D009127 CID alfentanil_15\NN\1740|by (r_nmod) produced_13\VBN\1617192|alfentanil (r_acl) rigidity_12\NN\5023233|the|produced
D015760_D009127 CID alfentanil_19\NN\1740|by (r_nmod) followed_17\VBN\1835496|alfentanil (r_acl) ketanserin_9\NN\1740|(|greater|i.p.|)|followed (r_dobj) received_8\VBD\2210855|that|ketanserin (r_acl:relcl) animals_6\NNS\4475|received (r_nsubj) motionless_21\JJ\1740|absence|,|animals|were|,|flaccid|than|animals|. (l_nmod) absence_2\NN\14449405|despite|the|rigidity (l_nmod) rigidity_4\NN\5023233|of
D015760_D009127 CID alfentanil_35\NN\1740|alone (r_dobj) receiving_34\VBG\2210855|alfentanil (r_acl) animals_33\NNS\4475|were|receiving (r_nmod) motionless_21\JJ\1740|absence|,|animals|were|,|flaccid|than|animals|. (l_nmod) absence_2\NN\14449405|despite|the|rigidity (l_nmod) rigidity_4\NN\5023233|of
D012701_D009127 NONE serotonin_9\NN\14807737| (r_compound) antagonist_11\NN\7846|a|specific|type-2|serotonin|receptor (r_appos) ketanserin_3\NN\1740|with|,|antagonist|, (r_nmod) pretreatment_1\NN\1740|systemic|ketanserin (r_nsubj) attenuated_14\VBD\224901|pretreatment|significantly|rigidity|alfentanil|. (l_dobj) rigidity_17\NN\5023233|the|muscle|produced
D012701_D009127 NONE serotonin_3\NN\14807737| (r_compound) antagonists_4\NNS\7846|with|type-2|serotonin (r_nmod) pretreatment_0\NN\1740|antagonists (r_nsubj) useful_8\JJ\1740|pretreatment|may|be|clinically|attenuating|,|necessary|. (l_advcl) attenuating_10\VBG\224901|in|rigidity (l_dobj) rigidity_12\NN\5023233|opiate-induced
D002707_D009127 NONE chlordiazepoxide_0\NN\2830852|doses (r_nsubj) failed_7\VBD\1798936|chlordiazepoxide|influence|. (l_xcomp) influence_10\VB\137313|to|significantly|rigidity (l_dobj) rigidity_12\NN\5023233|the|produced
D012701_D002318 NONE serotonin_3\NN\14807737| (r_compound) antagonists_4\NNS\7846|with|type-2|serotonin (r_nmod) pretreatment_0\NN\1740|antagonists (r_nsubj) useful_8\JJ\1740|pretreatment|may|be|clinically|attenuating|,|necessary|. (l_advcl) necessary_19\JJ\1740|although|studies|will|be|assess (l_xcomp) assess_21\VB\670261|to|interaction (l_dobj) interaction_23\NN\37396|the|depression (l_nmod) depression_33\NN\14373582|of|cns
D012701_D012131 NONE serotonin_3\NN\14807737| (r_compound) antagonists_4\NNS\7846|with|type-2|serotonin (r_nmod) pretreatment_0\NN\1740|antagonists (r_nsubj) useful_8\JJ\1740|pretreatment|may|be|clinically|attenuating|,|necessary|. (l_advcl) necessary_19\JJ\1740|although|studies|will|be|assess (l_xcomp) assess_21\VB\670261|to|interaction (l_dobj) interaction_23\NN\37396|the|depression (l_nmod) depression_33\NN\14373582|of|cns
16600756
D011453_D053201 NONE prostaglandins_4\NNS\5414534| (r_conj) factor_2\NN\7326557|nerve|growth|and|prostaglandins|urine|. (l_nmod) urine_7\NN\14853947|in|the|patients (l_nmod) patients_10\NNS\9898892|of|female|bladder (l_nmod) bladder_13\NN\5515670|with|overactive
D011453_D053201 NONE pgs_7\NNS\1740| (r_conj) ngf_5\NN\14734348|in|urinary|and|pgs (r_nmod) changes_2\NNS\7283608|ngf|women (l_nmod) women_9\NNS\9605289|in|oab (l_nmod) oab_11\NN\1740|with
D011453_D053201 NONE pg_8\NN\1740| (r_conj) ngf_6\NN\14734348|between|urinary|and|pg|,|and|parameters (l_conj) parameters_12\NNS\5858936|urodynamic|patients (l_nmod) patients_14\NNS\9898892|in|oab (l_nmod) oab_16\NN\1740|with
D011453_D053201 NONE pgs_4\NNS\1740| (r_conj) ngf_2\NN\14734348|and|pgs (r_nsubj) have_5\VBP\2108377|ngf|roles|development (l_nmod) development_10\NN\248977|in|the|symptoms (l_nmod) symptoms_13\NNS\5823932|of|oab|patients (l_compound) oab_12\NN\1740|
D015232_D053201 CID pge2_5\NN\1740| (r_conj) ngf_3\NN\14734348|urinary|,|pge2|and|pgf2alpha (r_nsubjpass) increased_10\VBN\169651|results|ngf|were|significantly|patients|controls|. (l_nmod) patients_12\NNS\9898892|in|oab (l_nmod) oab_14\NN\1740|with
D015232_D053201 CID pge2_5\NN\1740|urinary (r_nsubj) correlated_7\VBD\2657219|patients|pge2|positively|volume|p|. (l_nmod) patients_1\NNS\9898892|in|oab (l_nmod) oab_3\NN\1740|with
D015237_D053201 CID pgf2alpha_7\NN\1740| (r_conj) ngf_3\NN\14734348|urinary|,|pge2|and|pgf2alpha (r_nsubjpass) increased_10\VBN\169651|results|ngf|were|significantly|patients|controls|. (l_nmod) patients_12\NNS\9898892|in|oab (l_nmod) oab_14\NN\1740|with
D015237_D053201 CID pgf2alpha_3\NN\1740| (r_conj) ngf_1\NN\14734348|urinary|,|pgf2alpha|and|pgi2 (r_nsubj) correlate_8\VB\2657219|ngf|did|not|parameters|. (l_nmod) parameters_11\NNS\5858936|with|urodynamic|patients (l_nmod) patients_13\NNS\9898892|in|oab (l_nmod) oab_15\NN\1740|with
D011464_D053201 NONE pgi2_3\NN\1740|urinary (r_nsubj) different_6\JJ\1740|however|,|pgi2|was|not|controls|. (l_nmod) controls_8\NNS\5190804|between|and|patients (l_conj) patients_10\NNS\9898892|oab (l_nmod) oab_12\NN\1740|with
D011464_D053201 NONE pgi2_5\NN\1740| (r_conj) ngf_1\NN\14734348|urinary|,|pgf2alpha|and|pgi2 (r_nsubj) correlate_8\VB\2657219|ngf|did|not|parameters|. (l_nmod) parameters_11\NNS\5858936|with|urodynamic|patients (l_nmod) patients_13\NNS\9898892|in|oab (l_nmod) oab_15\NN\1740|with
17042884
C069541_D001480 NONE quetiapine_9\NN\1740|with (r_nmod) symptoms_4\NNS\5823932|of|extrapyramidal|eps|quetiapine
C069541_D001480 NONE quetiapine_9\NN\1740|with (r_nmod) symptoms_4\NNS\5823932|of|extrapyramidal|eps|quetiapine (l_appos) eps_6\NNS\1740|(|)
C069541_D001480 NONE quetiapine_14\NN\1740|with (r_nmod) evaluate_3\VB\670261|to|symptoms|quetiapine|patients (l_dobj) symptoms_5\NNS\5823932|extrapyramidal|eps|,|akathisia|,
C069541_D001480 NONE quetiapine_14\NN\1740|with (r_nmod) evaluate_3\VB\670261|to|symptoms|quetiapine|patients (l_dobj) symptoms_5\NNS\5823932|extrapyramidal|eps|,|akathisia|, (l_appos) eps_7\NNS\1740|(|)
C069541_D001480 NONE quetiapine_16\NN\1740| (r_compound) monotherapy_17\NN\1740|with|quetiapine (r_nmod) different_14\JJ\1740|incidence|was|no|monotherapy|%|than|placebo|. (l_nsubj) incidence_3\NN\13821570|the|events|, (l_nmod) events_7\NNS\23100|of|eps-related|adverse|,|akathisia (l_amod) eps-related_5\JJ\1740|
C069541_D001480 NONE qtp_6\NN\1740|with|+|li/dvp|% (r_nmod) events_4\NNS\23100|eps-related|adverse|qtp (l_amod) eps-related_2\JJ\1740|
C069541_D001480 NONE quetiapine_41\NN\1740|than (r_nmod) incidence_5\NN\13821570|a|higher|p|akathisia|quetiapine (l_nmod) akathisia_12\NN\1740|of|%|,|tremor (l_conj) tremor_21\NN\345926|%|,|and|syndrome (l_conj) syndrome_32\NN\5870365|extrapyramidal|%
C069541_D001480 NONE quetiapine_15\NN\1740| (r_compound) therapy_16\NN\657604|with|quetiapine (r_nmod) eps_9\NNS\1740|of|,|akathisia|,|therapy
C069541_D001714 NONE quetiapine_9\NN\1740|with (r_nmod) symptoms_4\NNS\5823932|of|extrapyramidal|eps|quetiapine (r_nmod) incidence_1\NN\13821570|placebo-level|symptoms|studies|. (l_nmod) studies_12\NNS\635850|in|controlled|patients (l_nmod) patients_14\NNS\9898892|of|mania (l_nmod) mania_17\NN\9180259|with|bipolar
C069541_D001714 NONE quetiapine_14\NN\1740|with (r_nmod) evaluate_3\VB\670261|to|symptoms|quetiapine|patients (l_nmod) patients_16\NNS\9898892|in|mania (l_nmod) mania_19\NN\9180259|with|bipolar
C069541_D001714 NONE quetiapine_15\NN\1740| (r_compound) therapy_16\NN\657604|with|quetiapine (r_nmod) eps_9\NNS\1740|of|,|akathisia|,|therapy (r_nmod) incidence_7\NN\13821570|the|eps (r_nsubj) similar_18\JJ\1740|,|incidence|is|that (r_dep) conclusions_0\NNS\5837957|:|mania|similar|. (l_nmod) mania_4\NN\9180259|in|bipolar
C069541_D017109 NONE quetiapine_14\NN\1740|with (r_nmod) evaluate_3\VB\670261|to|symptoms|quetiapine|patients (l_dobj) symptoms_5\NNS\5823932|extrapyramidal|eps|,|akathisia|, (l_nmod) akathisia_11\NN\1740|including
C069541_D017109 NONE quetiapine_16\NN\1740| (r_compound) monotherapy_17\NN\1740|with|quetiapine (r_nmod) different_14\JJ\1740|incidence|was|no|monotherapy|%|than|placebo|. (l_nsubj) incidence_3\NN\13821570|the|events|, (l_nmod) events_7\NNS\23100|of|eps-related|adverse|,|akathisia (l_nmod) akathisia_10\NN\1740|including
C069541_D017109 NONE quetiapine_9\NN\1740| (r_compound) monotherapy_10\NN\1740|with|quetiapine|%|and|placebo|,|and|qtp (r_nmod) similar_7\JJ\1740|monotherapy (r_conj) low_5\JJ\1740|incidence|was|and|similar|. (l_nsubj) incidence_1\NN\13821570|the|akathisia (l_nmod) akathisia_3\NN\1740|of
C069541_D017109 NONE qtp_24\NN\1740|with|+|li/dvp|and|pbo (r_conj) monotherapy_10\NN\1740|with|quetiapine|%|and|placebo|,|and|qtp (r_nmod) similar_7\JJ\1740|monotherapy (r_conj) low_5\JJ\1740|incidence|was|and|similar|. (l_nsubj) incidence_1\NN\13821570|the|akathisia (l_nmod) akathisia_3\NN\1740|of
C069541_D017109 NONE quetiapine_41\NN\1740|than (r_nmod) incidence_5\NN\13821570|a|higher|p|akathisia|quetiapine (l_nmod) akathisia_12\NN\1740|of|%|,|tremor
C069541_D017109 NONE quetiapine_15\NN\1740| (r_compound) therapy_16\NN\657604|with|quetiapine (r_nmod) eps_9\NNS\1740|of|,|akathisia|,|therapy (l_nmod) akathisia_12\NN\1740|including
D008094_D001480 CID li/dvp_8\NN\1740| (r_conj) qtp_6\NN\1740|with|+|li/dvp|% (r_nmod) events_4\NNS\23100|eps-related|adverse|qtp (l_amod) eps-related_2\JJ\1740|
D008094_D001480 CID li/dvp_20\NN\1740| (r_conj) pbo_18\NN\1740|with|+|li/dvp (r_nmod) than_16\IN\1740|pbo (r_prep) different_15\JJ\1740|similarly|,|events|were|no|than|%|. (l_nsubj) events_4\NNS\23100|eps-related|adverse|qtp (l_amod) eps-related_2\JJ\1740|
D008094_D001480 CID lithium_28\NN\14625458| (r_compound) n_30\NN\14622893|lithium|( (r_nsubj) =_31\JJ\1740|with|n|98|) (r_advcl) treated_26\VBN\2376958|= (r_acl) patients_25\NNS\9898892|of|treated (r_nmod) %_23\NN\1740|26.5|patients|monotherapy (r_nsubj) experienced_35\VBD\2108377|%|events|. (r_parataxis) occurred_5\VBD\2623529|events|%|monotherapy|,|whereas|experienced (l_nsubj) events_1\NNS\23100|adverse|related (l_amod) related_2\JJ\1740|eps (l_nmod) eps_4\NN\1740|to
D008094_D001480 CID lithium_28\NN\14625458| (r_compound) n_30\NN\14622893|lithium|( (r_nsubj) =_31\JJ\1740|with|n|98|) (r_advcl) treated_26\VBN\2376958|= (r_acl) patients_25\NNS\9898892|of|treated (r_nmod) %_23\NN\1740|26.5|patients|monotherapy (r_nsubj) experienced_35\VBD\2108377|%|events|. (l_dobj) events_37\NNS\23100|adverse|related (l_amod) related_38\JJ\1740|eps (l_nmod) eps_40\NN\1740|to
D014635_D001480 NONE li/dvp_8\NN\1740| (r_conj) qtp_6\NN\1740|with|+|li/dvp|% (r_nmod) events_4\NNS\23100|eps-related|adverse|qtp (l_amod) eps-related_2\JJ\1740|
D014635_D001480 NONE li/dvp_20\NN\1740| (r_conj) pbo_18\NN\1740|with|+|li/dvp (r_nmod) than_16\IN\1740|pbo (r_prep) different_15\JJ\1740|similarly|,|events|were|no|than|%|. (l_nsubj) events_4\NNS\23100|eps-related|adverse|qtp (l_amod) eps-related_2\JJ\1740|
D006220_D001480 CID haloperidol_13\NN\3713736| (r_compound) n_15\NN\14622893|haloperidol|( (r_nsubj) =_16\JJ\1740|with|n|99|) (r_advcl) treated_11\VBN\2376958|= (r_acl) patients_10\NNS\9898892|of|treated (r_nmod) %_8\NN\1740|in|59.6|patients (r_nmod) occurred_5\VBD\2623529|events|%|monotherapy|,|whereas|experienced (l_nsubj) events_1\NNS\23100|adverse|related (l_amod) related_2\JJ\1740|eps (l_nmod) eps_4\NN\1740|to
D006220_D001480 CID haloperidol_13\NN\3713736| (r_compound) n_15\NN\14622893|haloperidol|( (r_nsubj) =_16\JJ\1740|with|n|99|) (r_advcl) treated_11\VBN\2376958|= (r_acl) patients_10\NNS\9898892|of|treated (r_nmod) %_8\NN\1740|in|59.6|patients (r_nmod) occurred_5\VBD\2623529|events|%|monotherapy|,|whereas|experienced (l_parataxis) experienced_35\VBD\2108377|%|events|. (l_dobj) events_37\NNS\23100|adverse|related (l_amod) related_38\JJ\1740|eps (l_nmod) eps_40\NN\1740|to
D006220_D001480 CID haloperidol_0\NN\3713736| (r_nsubj) induced_1\VBD\1627355|haloperidol|incidence|. (l_dobj) incidence_5\NN\13821570|a|higher|p|akathisia|quetiapine (l_nmod) akathisia_12\NN\1740|of|%|,|tremor (l_conj) tremor_21\NN\345926|%|,|and|syndrome (l_conj) syndrome_32\NN\5870365|extrapyramidal|%
D008094_D017109 NONE li/dvp_26\NN\1740|% (r_conj) qtp_24\NN\1740|with|+|li/dvp|and|pbo (r_conj) monotherapy_10\NN\1740|with|quetiapine|%|and|placebo|,|and|qtp (r_nmod) similar_7\JJ\1740|monotherapy (r_conj) low_5\JJ\1740|incidence|was|and|similar|. (l_nsubj) incidence_1\NN\13821570|the|akathisia (l_nmod) akathisia_3\NN\1740|of
D008094_D017109 NONE li/dvp_34\NN\1740|% (r_conj) pbo_32\NN\1740|+|li/dvp (r_conj) qtp_24\NN\1740|with|+|li/dvp|and|pbo (r_conj) monotherapy_10\NN\1740|with|quetiapine|%|and|placebo|,|and|qtp (r_nmod) similar_7\JJ\1740|monotherapy (r_conj) low_5\JJ\1740|incidence|was|and|similar|. (l_nsubj) incidence_1\NN\13821570|the|akathisia (l_nmod) akathisia_3\NN\1740|of
D014635_D017109 NONE li/dvp_26\NN\1740|% (r_conj) qtp_24\NN\1740|with|+|li/dvp|and|pbo (r_conj) monotherapy_10\NN\1740|with|quetiapine|%|and|placebo|,|and|qtp (r_nmod) similar_7\JJ\1740|monotherapy (r_conj) low_5\JJ\1740|incidence|was|and|similar|. (l_nsubj) incidence_1\NN\13821570|the|akathisia (l_nmod) akathisia_3\NN\1740|of
D014635_D017109 NONE li/dvp_34\NN\1740|% (r_conj) pbo_32\NN\1740|+|li/dvp (r_conj) qtp_24\NN\1740|with|+|li/dvp|and|pbo (r_conj) monotherapy_10\NN\1740|with|quetiapine|%|and|placebo|,|and|qtp (r_nmod) similar_7\JJ\1740|monotherapy (r_conj) low_5\JJ\1740|incidence|was|and|similar|. (l_nsubj) incidence_1\NN\13821570|the|akathisia (l_nmod) akathisia_3\NN\1740|of
D008094_D014202 CID lithium_0\NN\14625458| (r_nsubjpass) associated_2\VBN\628491|lithium|was|incidence|quetiapine|contributed (l_nmod) incidence_7\NN\13821570|with|a|higher|0.05|tremor|% (l_nmod) tremor_14\NN\345926|of
D008094_D014202 CID lithium_0\NN\14625458| (r_nsubjpass) associated_2\VBN\628491|lithium|was|incidence|quetiapine|contributed (l_parataxis) contributed_40\VBN\126264|;|tremor|may|have|rate|. (l_nsubj) tremor_27\NN\345926|cerebellar|,|effect|,
D008094_D014202 CID lithium_0\NN\14625458| (r_nsubjpass) associated_2\VBN\628491|lithium|was|incidence|quetiapine|contributed (l_parataxis) contributed_40\VBN\126264|;|tremor|may|have|rate|. (l_nmod) rate_44\NN\13815152|to|the|elevated|tremor (l_nmod) tremor_46\NN\345926|of|patients
D008094_D014202 CID lithium_36\NN\14625458|of (r_nmod) effect_34\NN\34213|which|is|a|known|adverse|lithium (r_acl:relcl) tremor_27\NN\345926|cerebellar|,|effect|, (r_nsubj) contributed_40\VBN\126264|;|tremor|may|have|rate|. (r_parataxis) associated_2\VBN\628491|lithium|was|incidence|quetiapine|contributed (l_nmod) incidence_7\NN\13821570|with|a|higher|0.05|tremor|% (l_nmod) tremor_14\NN\345926|of
D008094_D014202 CID lithium_36\NN\14625458|of (r_nmod) effect_34\NN\34213|which|is|a|known|adverse|lithium (r_acl:relcl) tremor_27\NN\345926|cerebellar|,|effect|,
D008094_D014202 CID lithium_36\NN\14625458|of (r_nmod) effect_34\NN\34213|which|is|a|known|adverse|lithium (r_acl:relcl) tremor_27\NN\345926|cerebellar|,|effect|, (r_nsubj) contributed_40\VBN\126264|;|tremor|may|have|rate|. (l_nmod) rate_44\NN\13815152|to|the|elevated|tremor (l_nmod) tremor_46\NN\345926|of|patients
D008094_D014202 CID lithium_50\NN\14625458| (r_compound) therapy_51\NN\657604|lithium (r_dobj) receiving_49\VBG\2210855|therapy (r_acl) patients_48\NNS\9898892|in|receiving (r_nmod) tremor_46\NN\345926|of|patients (r_nmod) rate_44\NN\13815152|to|the|elevated|tremor (r_nmod) contributed_40\VBN\126264|;|tremor|may|have|rate|. (r_parataxis) associated_2\VBN\628491|lithium|was|incidence|quetiapine|contributed (l_nmod) incidence_7\NN\13821570|with|a|higher|0.05|tremor|% (l_nmod) tremor_14\NN\345926|of
D008094_D014202 CID lithium_50\NN\14625458| (r_compound) therapy_51\NN\657604|lithium (r_dobj) receiving_49\VBG\2210855|therapy (r_acl) patients_48\NNS\9898892|in|receiving (r_nmod) tremor_46\NN\345926|of|patients (r_nmod) rate_44\NN\13815152|to|the|elevated|tremor (r_nmod) contributed_40\VBN\126264|;|tremor|may|have|rate|. (l_nsubj) tremor_27\NN\345926|cerebellar|,|effect|,
D008094_D014202 CID lithium_50\NN\14625458| (r_compound) therapy_51\NN\657604|lithium (r_dobj) receiving_49\VBG\2210855|therapy (r_acl) patients_48\NNS\9898892|in|receiving (r_nmod) tremor_46\NN\345926|of|patients
C069541_D014202 NONE quetiapine_20\NN\1740|than|% (r_nmod) associated_2\VBN\628491|lithium|was|incidence|quetiapine|contributed (l_nmod) incidence_7\NN\13821570|with|a|higher|0.05|tremor|% (l_nmod) tremor_14\NN\345926|of
C069541_D014202 NONE quetiapine_20\NN\1740|than|% (r_nmod) associated_2\VBN\628491|lithium|was|incidence|quetiapine|contributed (l_parataxis) contributed_40\VBN\126264|;|tremor|may|have|rate|. (l_nsubj) tremor_27\NN\345926|cerebellar|,|effect|,
C069541_D014202 NONE quetiapine_20\NN\1740|than|% (r_nmod) associated_2\VBN\628491|lithium|was|incidence|quetiapine|contributed (l_parataxis) contributed_40\VBN\126264|;|tremor|may|have|rate|. (l_nmod) rate_44\NN\13815152|to|the|elevated|tremor (l_nmod) tremor_46\NN\345926|of|patients
C069541_D014202 NONE quetiapine_41\NN\1740|than (r_nmod) incidence_5\NN\13821570|a|higher|p|akathisia|quetiapine (l_nmod) akathisia_12\NN\1740|of|%|,|tremor (l_conj) tremor_21\NN\345926|%|,|and|syndrome
D006220_D017109 CID haloperidol_0\NN\3713736| (r_nsubj) induced_1\VBD\1627355|haloperidol|incidence|. (l_dobj) incidence_5\NN\13821570|a|higher|p|akathisia|quetiapine (l_nmod) akathisia_12\NN\1740|of|%|,|tremor
D006220_D014202 CID haloperidol_0\NN\3713736| (r_nsubj) induced_1\VBD\1627355|haloperidol|incidence|. (l_dobj) incidence_5\NN\13821570|a|higher|p|akathisia|quetiapine (l_nmod) akathisia_12\NN\1740|of|%|,|tremor (l_conj) tremor_21\NN\345926|%|,|and|syndrome
19692487
D008094_D011141 NONE lithium-induced_6\JJ\1740| (r_amod) polyuria_7\NN\14113228|to|lithium-induced
D008094_D011141 NONE lithium-induced_8\JJ\1740| (r_amod) polyuria_9\NN\14113228|of|lithium-induced
D008094_D011141 NONE lithium-induced_7\JJ\1740| (r_amod) polyuria_8\NN\14113228|lithium-induced|mice
D008094_D011141 NONE lithium-induced_10\JJ\1740| (r_amod) polyuria_11\NN\14113228|to|lithium-induced|and|defect
D008094_D011141 NONE lithium-induced_7\JJ\1740| (r_amod) polyuria_8\NN\14113228|lithium-induced
D011458_D011141 NONE e_15\NN\14724645| (r_compound) synthase-1_16\NN\1740|in|microsomal|prostaglandin|e|mpges-1 (r_nmod) deficient_11\JJ\1740|synthase-1 (r_amod) mice_10\NNS\2329401|in|deficient (r_nmod) polyuria_8\NN\14113228|lithium-induced|mice
D018021_D011141 CID licl_4\NN\1740|of|mmol.kg(-1).day(-1 (r_nmod) administration_2\NN\1133281|a|2-wk|licl|ip|)|mice (r_nsubj) led_16\VBD\1752884|administration|polyuria|. (l_nmod) polyuria_20\NN\14113228|to|a|marked|urine
D015232_D011141 NONE )_27\-RRB-\1740| (r_punct) pge(2_26\NN\1740|of|urine|) (r_nmod) blockade_22\NN\952963|by|complete|pge(2|and|output (r_nmod) accompanied_18\VBN\1835496|blockade (r_advcl) resistant_8\JJ\1740|contrast|,|mice|were|largely|polyuria|,|accompanied|. (l_nmod) polyuria_11\NN\14113228|to|lithium-induced|and|defect
D015232_D011141 NONE )_5\-RRB-\1740| (r_punct) pge(2_4\NN\1740|that|mpges-1-derived|) (r_nmod) conclude_1\VBP\628491|we|pge(2|mediates|. (l_ccomp) mediates_6\VBZ\761713|polyuria|inhibition (l_dobj) polyuria_8\NN\14113228|lithium-induced
950631
D010396_D007674 CID penicillamine-induced_2\JJ\1740| (r_amod) disease_4\NN\14061805|of|penicillamine-induced|glomerular
D010396_D001172 NONE d-penicillamine_16\NN\1740|with (r_nmod) treatment_14\NN\654885|of|d-penicillamine (r_nmod) months_12\NNS\15113229|after|12|treatment (r_nmod) developed_5\VBD\1753788|patients|proteinuria|months|. (l_nsubj) patients_1\NNS\9898892|four|arthritis (l_nmod) arthritis_4\NN\14171682|with|rheumatoid
D010396_D011507 CID d-penicillamine_16\NN\1740|with (r_nmod) treatment_14\NN\654885|of|d-penicillamine (r_nmod) months_12\NNS\15113229|after|12|treatment (r_nmod) developed_5\VBD\1753788|patients|proteinuria|months|. (l_dobj) proteinuria_7\NN\14299637|heavy
2594614
C045856_D002318 NONE 52021_10\CD\1740| (r_nummod) bn_9\NN\1740|52021 (r_appos) antagonist_7\NN\7846|of|a|specific|platelet-activating|factor|,|bn|, (r_nmod) effect_1\NN\34213|protective|antagonist|impairments|. (l_nmod) impairments_15\NNS\7296428|on|bupivacaine-induced|cardiovascular|rats
C045856_D002318 NONE 52021_5\CD\1740| (r_nummod) bn_4\NN\1740|of|52021 (r_nmod) administration_2\NN\1133281|the|bn|, (r_nsubj) alter_14\VB\126264|since|administration|doses|,|did|not|mbp|doses (r_advcl) demonstrate_29\VBP\2137132|alter|,|bulk|clearly|action|. (l_dobj) action_32\NN\30358|a|protective|bn|toxicity (l_nmod) toxicity_46\NN\13576101|against|bupivacaine-induced|cardiovascular
C045856_D002318 NONE 52021_35\CD\1740| (r_nummod) bn_34\NN\1740|of|52021|,|antagonist|, (r_nmod) action_32\NN\30358|a|protective|bn|toxicity (l_nmod) toxicity_46\NN\13576101|against|bupivacaine-induced|cardiovascular
D002045_D002318 NONE bupivacaine-induced_13\JJ\1740| (r_amod) impairments_15\NNS\7296428|on|bupivacaine-induced|cardiovascular|rats
D002045_D002318 NONE bupivacaine-induced_44\JJ\1740| (r_amod) toxicity_46\NN\13576101|against|bupivacaine-induced|cardiovascular
D002045_D007022 CID bupivacaine_5\NN\1740|of|the|local|anaesthetic|mg/kg (r_nmod) administration_0\NN\1133281|bupivacaine|rats (r_nsubj) elicited_16\VBD\1617192|administration|decrease|. (l_dobj) decrease_19\NN\7296428|a|marked|pressure|leading (l_nmod) pressure_24\NN\11419404|of|mean|arterial|blood|mbp|and|rate (l_conj) rate_30\NN\13815152|heart|hr (l_appos) hr_32\NN\15154774|(|) (l_punct) )_33\-RRB-\1740|
D002045_D007022 CID bupivacaine_21\NN\1740| (r_compound) administration_22\NN\1133281|before|bupivacaine|mg/kg (r_nmod) injection_1\NN\320852|intravenous|bn|,|administration (r_nsubj) suppressed_28\VBD\2510337|injection|decrease|. (l_dobj) decrease_31\NN\7296428|both|the|mbp|and|hr (l_conj) hr_35\NN\15154774|
D002045_D007022 CID bupivacaine_12\NN\1740|after|mg/kg (r_nmod) injected_9\VBN\81072|when|bn|was|bupivacaine (r_advcl) observed_29\VBN\2163746|injected|,|reversion|was|,|whereas|ineffective (l_nsubjpass) reversion_20\NN\13286801|a|partial|decrease (l_nmod) decrease_23\NN\7296428|of|the|mbp (l_nmod) mbp_25\NN\1740|of|and|hr (l_conj) hr_27\NN\15154774|
D002045_D001919 CID bupivacaine_5\NN\1740|of|the|local|anaesthetic|mg/kg (r_nmod) administration_0\NN\1133281|bupivacaine|rats (r_nsubj) elicited_16\VBD\1617192|administration|decrease|. (l_dobj) decrease_19\NN\7296428|a|marked|pressure|leading (l_nmod) pressure_24\NN\11419404|of|mean|arterial|blood|mbp|and|rate (l_conj) rate_30\NN\13815152|heart|hr (l_appos) hr_32\NN\15154774|(|) (l_punct) )_33\-RRB-\1740|
D002045_D001919 CID bupivacaine_21\NN\1740| (r_compound) administration_22\NN\1133281|before|bupivacaine|mg/kg (r_nmod) injection_1\NN\320852|intravenous|bn|,|administration (r_nsubj) suppressed_28\VBD\2510337|injection|decrease|. (l_dobj) decrease_31\NN\7296428|both|the|mbp|and|hr (l_conj) hr_35\NN\15154774|
D002045_D001919 CID bupivacaine_12\NN\1740|after|mg/kg (r_nmod) injected_9\VBN\81072|when|bn|was|bupivacaine (r_advcl) observed_29\VBN\2163746|injected|,|reversion|was|,|whereas|ineffective (l_nsubjpass) reversion_20\NN\13286801|a|partial|decrease (l_nmod) decrease_23\NN\7296428|of|the|mbp (l_nmod) mbp_25\NN\1740|of|and|hr (l_conj) hr_27\NN\15154774|
C045856_D007022 NONE 52021_12\CD\1740| (r_nummod) bn_11\NN\1740|of|the|antagonist|52021|mg/kg (r_nmod) injection_1\NN\320852|intravenous|bn|,|administration (r_nsubj) suppressed_28\VBD\2510337|injection|decrease|. (l_dobj) decrease_31\NN\7296428|both|the|mbp|and|hr (l_conj) hr_35\NN\15154774|
C045856_D007022 NONE 52021_2\CD\1740| (r_appos) bn_1\NNP\1740|52021|mg/kg|i.v.|) (r_nsubjpass) injected_9\VBN\81072|when|bn|was|bupivacaine (r_advcl) observed_29\VBN\2163746|injected|,|reversion|was|,|whereas|ineffective (l_nsubjpass) reversion_20\NN\13286801|a|partial|decrease (l_nmod) decrease_23\NN\7296428|of|the|mbp (l_nmod) mbp_25\NN\1740|of|and|hr (l_conj) hr_27\NN\15154774|
C045856_D001919 NONE 52021_12\CD\1740| (r_nummod) bn_11\NN\1740|of|the|antagonist|52021|mg/kg (r_nmod) injection_1\NN\320852|intravenous|bn|,|administration (r_nsubj) suppressed_28\VBD\2510337|injection|decrease|. (l_dobj) decrease_31\NN\7296428|both|the|mbp|and|hr (l_conj) hr_35\NN\15154774|
C045856_D001919 NONE 52021_2\CD\1740| (r_appos) bn_1\NNP\1740|52021|mg/kg|i.v.|) (r_nsubjpass) injected_9\VBN\81072|when|bn|was|bupivacaine (r_advcl) observed_29\VBN\2163746|injected|,|reversion|was|,|whereas|ineffective (l_nsubjpass) reversion_20\NN\13286801|a|partial|decrease (l_nmod) decrease_23\NN\7296428|of|the|mbp (l_nmod) mbp_25\NN\1740|of|and|hr (l_conj) hr_27\NN\15154774|
D002045_D018376 NONE bupivacaine-induced_16\JJ\1740| (r_amod) alterations_18\NNS\7283608|in|bupivacaine-induced|cardiovascular
11827497
D006493_D013921 CID heparin-induced_1\JJ\1740| (r_amod) thrombocytopenia_2\NN\14189204|delayed-onset|heparin-induced|.
D006493_D013921 CID heparin-induced_2\JJ\1740| (r_amod) thrombocytopenia_3\NN\14189204|heparin-induced
D006493_D013921 CID heparin_10\NN\2718259| (r_compound) exposure_11\NN\5042871|days|heparin (r_dobj) presents_4\VBZ\2137132|thrombocytopenia|exposure|,|with|thromboemboli (l_nsubj) thrombocytopenia_3\NN\14189204|heparin-induced
D006493_D013921 CID heparin-induced_5\JJ\1740| (r_amod) thrombocytopenia_6\NN\14189204|of|heparin-induced
D006493_D013921 CID heparin-induced_18\JJ\1740| (r_amod) thrombocytopenia_19\NN\14189204|of|heparin-induced
D006493_D013921 CID heparin-induced_11\JJ\1740| (r_amod) thrombocytopenia_12\NN\14189204|heparin-induced
D006493_D013921 CID heparin_10\NN\2718259| (r_compound) exposure_11\NN\5042871|heparin|--|cases (l_nmod) cases_15\NNS\7283608|in|most|,|thrombocytopenia (l_nmod) thrombocytopenia_19\NN\14189204|with|no|recognized|--
D006493_D013921 CID heparin-induced_3\JJ\1740| (r_amod) thrombocytopenia_4\NN\14189204|delayed-onset|heparin-induced
D006493_D013921 CID heparin-induced_8\JJ\1740| (r_amod) thrombocytopenia_9\NN\14189204|heparin-induced
D006493_D013921 CID heparin_25\NN\2718259| (r_conj) anticoagulants_22\NNS\3740161|with|alternative|,|not|heparin (r_nmod) therapy_19\NN\657604|anticoagulants|, (r_nsubjpass) initiated_29\VBN\1617192|consider|;|therapy|should|be|. (l_advcl) consider_7\VB\689344|avoid|,|physicians|must|thrombocytopenia|returns (l_dobj) thrombocytopenia_9\NN\14189204|heparin-induced
D006493_D001157 CID heparin-induced_2\JJ\1740| (r_amod) thrombocytopenia_3\NN\14189204|heparin-induced (r_nsubj) presents_4\VBZ\2137132|thrombocytopenia|exposure|,|with|thromboemboli (l_nmod) thromboemboli_19\NNS\1740|arterial
D006493_D001157 CID heparin_10\NN\2718259| (r_compound) exposure_11\NN\5042871|days|heparin (r_dobj) presents_4\VBZ\2137132|thrombocytopenia|exposure|,|with|thromboemboli (l_nmod) thromboemboli_19\NNS\1740|arterial
D006493_D054556 CID heparin-induced_2\JJ\1740| (r_amod) thrombocytopenia_3\NN\14189204|heparin-induced (r_nsubj) presents_4\VBZ\2137132|thrombocytopenia|exposure|,|with|thromboemboli (l_nmod) thromboemboli_19\NNS\1740|arterial
D006493_D054556 CID heparin_10\NN\2718259| (r_compound) exposure_11\NN\5042871|days|heparin (r_dobj) presents_4\VBZ\2137132|thrombocytopenia|exposure|,|with|thromboemboli (l_nmod) thromboemboli_19\NNS\1740|arterial
D006493_D013923 NONE heparin-induced_11\JJ\1740| (r_amod) thrombocytopenia_12\NN\14189204|heparin-induced (r_nsubj) became_13\VBD\146138|whom|thrombocytopenia|apparent (l_xcomp) apparent_14\JJ\1740|presentation (l_nmod) presentation_17\NN\1027379|on|delayed|complications (l_nmod) complications_20\NNS\1073995|with|thromboembolic (l_amod) thromboembolic_19\JJ\1740|
D006493_D013923 NONE heparin-induced_13\JJ\1740| (r_amod) tests_18\NNS\5798043|of|heparin-induced|platelet|factor|antibody (r_nmod) results_11\NNS\34213|tests (r_conj) counts_3\NNS\13582013|platelet|,|onset|,|results|,|and|outcomes (l_conj) onset_5\NN\7325190|thromboembolism (l_nmod) thromboembolism_9\NN\14100769|of|determined
D006493_D013923 NONE heparin_10\NN\2718259| (r_compound) exposure_11\NN\5042871|heparin|--|cases (r_dobj) included_9\VBN\690614|that|had|exposure (r_acl:relcl) hospitalizations_6\NNS\15113229|after|included (r_nmod) went_3\VBD\2367363|patients|home|hospitalizations|only|return (l_advcl) return_24\VB\1835496|to|hospital|day|complications (l_nmod) complications_36\NNS\1073995|with|thromboembolic (l_amod) thromboembolic_35\JJ\1740|
D006493_D013923 NONE heparin-induced_8\JJ\1740| (r_amod) thrombocytopenia_9\NN\14189204|heparin-induced (r_dobj) consider_7\VB\689344|avoid|,|physicians|must|thrombocytopenia|returns (l_advcl) returns_15\VBZ\1835496|whenever|patient|thromboembolism (l_nmod) thromboembolism_17\NN\14100769|with
D006493_D013923 NONE heparin_25\NN\2718259| (r_conj) anticoagulants_22\NNS\3740161|with|alternative|,|not|heparin (r_nmod) therapy_19\NN\657604|anticoagulants|, (r_nsubjpass) initiated_29\VBN\1617192|consider|;|therapy|should|be|. (l_advcl) consider_7\VB\689344|avoid|,|physicians|must|thrombocytopenia|returns (l_advcl) returns_15\VBZ\1835496|whenever|patient|thromboembolism (l_nmod) thromboembolism_17\NN\14100769|with
20195852
D003287_D007674 CID media_8\NNS\3575240|of|nonionic|contrast (r_nmod) consumption_4\NN\13440063|after|media|children (r_nmod) risk_0\NN\14541044|nephropathy|consumption|:|study (l_nmod) nephropathy_2\NN\14573196|of
D003287_D007674 CID media-induced_6\JJ\1740|nonionic|contrast (r_amod) nephropathy_7\NN\14573196|on|media-induced|cin|patients|procedures
D003287_D007674 CID media-induced_6\JJ\1740|nonionic|contrast (r_amod) nephropathy_7\NN\14573196|on|media-induced|cin|patients|procedures (l_appos) cin_9\NN\1740|(|)
D003287_D007674 CID media_12\NNS\3575240|for|two|nonionic|contrast|cm|,|iopromide|,|patients (r_nmod) cin_7\NN\1740|of|media
D003287_D007674 CID cm_14\NNS\13649268|(|) (r_appos) media_12\NNS\3575240|for|two|nonionic|contrast|cm|,|iopromide|,|patients (r_nmod) cin_7\NN\1740|of|media
D003287_D007674 CID cm_43\NNS\13649268|of (r_nmod) type_39\NN\5839024|to|the|and|dosage|cm|and|presence (r_nmod) relation_36\NN\2137|in|type (r_nmod) compared_29\VBD\644583|rates|relation (r_conj) determined_3\VBD\1645601|study|incidence|and|compared|. (l_dobj) incidence_5\NN\13821570|the|cin (l_nmod) cin_7\NN\1740|of|media
D003287_D007674 CID cm_17\NN\13649268|of (r_nmod) dosage_15\NN\13576355|the|proper|cm (r_dobj) received_12\VBD\2210855|who|dosage (r_acl:relcl) those_10\DT\1740|%|were|among|received (l_nsubj) %_2\NN\1740|33.3|patients (l_nmod) patients_5\NNS\9898892|of|the|cin (l_nmod) cin_7\NN\1740|with
D003287_D007674 CID cm_17\NN\13649268|of (r_nmod) dosage_15\NN\13576355|the|proper|cm (r_dobj) received_12\VBD\2210855|who|dosage (r_acl:relcl) those_10\DT\1740|%|were|among|received (r_dep) whereas_0\IN\1740|those (r_advcl) increased_21\VBD\169651|whereas|,|percentage|%|,|difference|. (l_nmod) difference_35\NN\4723816|with|a|significant|incidence|related|= (l_nmod) incidence_38\NN\13821570|in|the|cin (l_nmod) cin_40\NN\1740|of
D003287_D007674 CID cm_47\NN\13649268|of (r_nmod) dosages_45\NNS\13576355|to|the|different|cm (r_nmod) related_41\JJ\1740|dosages (r_acl) difference_35\NN\4723816|with|a|significant|incidence|related|= (r_nmod) increased_21\VBD\169651|whereas|,|percentage|%|,|difference|. (l_advcl) whereas_0\IN\1740|those (l_dep) those_10\DT\1740|%|were|among|received (l_nsubj) %_2\NN\1740|33.3|patients (l_nmod) patients_5\NNS\9898892|of|the|cin (l_nmod) cin_7\NN\1740|with
D003287_D007674 CID cm_47\NN\13649268|of (r_nmod) dosages_45\NNS\13576355|to|the|different|cm (r_nmod) related_41\JJ\1740|dosages (r_acl) difference_35\NN\4723816|with|a|significant|incidence|related|= (l_nmod) incidence_38\NN\13821570|in|the|cin (l_nmod) cin_40\NN\1740|of
D003287_D007674 CID cm_13\NN\13649268|of|consumed|nonionic (r_nmod) type_9\NN\5839024|on|the|cm (r_conj) dosage_4\NN\13576355|on|but|type (r_nmod) depends_2\VBZ\2604760|incidence|dosage|,|nor|presence|,|and|needed (l_conj) needed_32\VBN\2604760|reversible|,|concern|is|prevention|. (l_advcl) reversible_27\JJ\1740|although|cin|usually|is (l_nsubj) cin_24\NN\1740|
D003287_D003490 NONE media_12\NNS\3575240|for|two|nonionic|contrast|cm|,|iopromide|,|patients (r_nmod) cin_7\NN\1740|of|media (r_nmod) incidence_5\NN\13821570|the|cin (r_dobj) determined_3\VBD\1645601|study|incidence|and|compared|. (l_conj) compared_29\VBD\644583|rates|relation (l_nmod) relation_36\NN\2137|in|type (l_nmod) type_39\NN\5839024|to|the|and|dosage|cm|and|presence (l_conj) presence_46\NN\13954253|the|cyanosis (l_nmod) cyanosis_48\NN\14299637|of
D003287_D003490 NONE cm_14\NNS\13649268|(|) (r_appos) media_12\NNS\3575240|for|two|nonionic|contrast|cm|,|iopromide|,|patients (r_nmod) cin_7\NN\1740|of|media (r_nmod) incidence_5\NN\13821570|the|cin (r_dobj) determined_3\VBD\1645601|study|incidence|and|compared|. (l_conj) compared_29\VBD\644583|rates|relation (l_nmod) relation_36\NN\2137|in|type (l_nmod) type_39\NN\5839024|to|the|and|dosage|cm|and|presence (l_conj) presence_46\NN\13954253|the|cyanosis (l_nmod) cyanosis_48\NN\14299637|of
D003287_D003490 NONE cm_43\NNS\13649268|of (r_nmod) type_39\NN\5839024|to|the|and|dosage|cm|and|presence (l_conj) presence_46\NN\13954253|the|cyanosis (l_nmod) cyanosis_48\NN\14299637|of
D003287_D003490 NONE cm_13\NN\13649268|of|consumed|nonionic (r_nmod) type_9\NN\5839024|on|the|cm (r_conj) dosage_4\NN\13576355|on|but|type (r_nmod) depends_2\VBZ\2604760|incidence|dosage|,|nor|presence|,|and|needed (l_conj) presence_18\NN\13954253|on|the|cyanosis (l_nmod) cyanosis_20\NN\14299637|of
C038192_D007674 CID iopromide_17\NN\1740|and|iohexol (r_appos) media_12\NNS\3575240|for|two|nonionic|contrast|cm|,|iopromide|,|patients (r_nmod) cin_7\NN\1740|of|media
C038192_D003490 NONE iopromide_17\NN\1740|and|iohexol (r_appos) media_12\NNS\3575240|for|two|nonionic|contrast|cm|,|iopromide|,|patients (r_nmod) cin_7\NN\1740|of|media (r_nmod) incidence_5\NN\13821570|the|cin (r_dobj) determined_3\VBD\1645601|study|incidence|and|compared|. (l_conj) compared_29\VBD\644583|rates|relation (l_nmod) relation_36\NN\2137|in|type (l_nmod) type_39\NN\5839024|to|the|and|dosage|cm|and|presence (l_conj) presence_46\NN\13954253|the|cyanosis (l_nmod) cyanosis_48\NN\14299637|of
D007472_D007674 CID iohexol_19\NN\1740| (r_conj) iopromide_17\NN\1740|and|iohexol (r_appos) media_12\NNS\3575240|for|two|nonionic|contrast|cm|,|iopromide|,|patients (r_nmod) cin_7\NN\1740|of|media
D007472_D003490 NONE iohexol_19\NN\1740| (r_conj) iopromide_17\NN\1740|and|iohexol (r_appos) media_12\NNS\3575240|for|two|nonionic|contrast|cm|,|iopromide|,|patients (r_nmod) cin_7\NN\1740|of|media (r_nmod) incidence_5\NN\13821570|the|cin (r_dobj) determined_3\VBD\1645601|study|incidence|and|compared|. (l_conj) compared_29\VBD\644583|rates|relation (l_nmod) relation_36\NN\2137|in|type (l_nmod) type_39\NN\5839024|to|the|and|dosage|cm|and|presence (l_conj) presence_46\NN\13954253|the|cyanosis (l_nmod) cyanosis_48\NN\14299637|of
1899352
D015080_D006417 NONE mesna_22\NN\1740| (r_dobj) adding_21\VBG\156601|mesna|infusate|patients (r_advcl) essential_19\JJ\1740|monitoring|is|,|adding|. (r_conj) precise_8\JJ\1740|frequency|are|not|,|and|essential (l_nsubj) frequency_1\NN\15286249|the|and|predictability|hematuria (l_nmod) hematuria_5\NN\14299637|of
D015080_D006417 NONE mesna_22\NN\1740| (r_dobj) adding_21\VBG\156601|mesna|infusate|patients (l_nmod) patients_27\NNS\9898892|in|hematuria (l_nmod) hematuria_30\NN\14299637|with|persistent
12549952
D016642_D017114 CID bupropion_5\NN\1740|concurrent|and|carbimazole (r_compound) therapy_8\NN\657604|with|bupropion (r_nmod) failure_2\NN\66216|acute|liver|therapy|.
D016642_D017114 CID bupropion_11\NN\1740|by (r_nmod) induced_9\VBN\1627355|bupropion (r_acl) hepatotoxicity_8\NN\1740|of|induced (r_nmod) evidence_6\NN\5816287|increasing|hepatotoxicity (r_attr) is_4\VBZ\836236|although|there|evidence (r_advcl) case_17\NN\7283608|is|,|this|is|the|first|fatality (l_nmod) fatality_19\NN\7355491|of|resulted (l_acl:relcl) resulted_23\VBN\2633881|that|could|have|failure (l_nmod) failure_27\NN\66216|from|acute|liver|patient
D016642_D017114 CID bupropion_32\NN\1740| (r_dobj) receiving_31\VBG\2210855|bupropion|treatment (r_acl) patient_30\NN\9898892|in|a|receiving (r_nmod) failure_27\NN\66216|from|acute|liver|patient
D016642_D017114 CID bupropion_15\NN\1740|by (r_nmod) induced_13\VBN\1627355|bupropion (r_acl) insult_12\NN\6714976|of|acute|liver|induced|given
D002231_D017114 CID carbimazole_7\NN\1740| (r_conj) bupropion_5\NN\1740|concurrent|and|carbimazole (r_compound) therapy_8\NN\657604|with|bupropion (r_nmod) failure_2\NN\66216|acute|liver|therapy|.
D002231_D017114 CID carbimazole_38\NN\1740|with (r_nmod) treatment_36\NN\654885|while|on|concomitant|carbimazole (r_nmod) receiving_31\VBG\2210855|bupropion|treatment (r_acl) patient_30\NN\9898892|in|a|receiving (r_nmod) failure_27\NN\66216|from|acute|liver|patient
D016642_D017093 NONE bupropion_16\NN\1740|of|and|carbimazole (r_nmod) use_14\NN\407535|with|concurrent|bupropion (r_nmod) associated_11\VBN\628491|possibly|use (r_acl) failure_9\NN\66216|of|fatal|liver|associated
D002231_D017093 NONE carbimazole_18\NN\1740| (r_conj) bupropion_16\NN\1740|of|and|carbimazole (r_nmod) use_14\NN\407535|with|concurrent|bupropion (r_nmod) associated_11\VBN\628491|possibly|use (r_acl) failure_9\NN\66216|of|fatal|liver|associated
D002231_D006980 NONE carbimazole_16\NN\1740|with|and|propranolol (r_nmod) treated_14\VBN\2376958|man|had|been|carbimazole|years|. (l_nsubjpass) man_6\NN\9605289|a|41-year-old|chinese|history (l_nmod) history_9\NN\15120823|with|a|hyperthyroidism (l_nmod) hyperthyroidism_11\NN\14059928|of
D011433_D006980 NONE propranolol_18\NN\1740| (r_conj) carbimazole_16\NN\1740|with|and|propranolol (r_nmod) treated_14\VBN\2376958|man|had|been|carbimazole|years|. (l_nsubjpass) man_6\NN\9605289|a|41-year-old|chinese|history (l_nmod) history_9\NN\15120823|with|a|hyperthyroidism (l_nmod) hyperthyroidism_11\NN\14059928|of
D016642_D056486 CID bupropion_3\NN\1740| (r_nmod:npmod) induced_4\JJ\1740|bupropion (r_amod) hepatotoxicity_5\NN\1740|induced|patient
D016642_D056486 CID bupropion_11\NN\1740|by (r_nmod) induced_9\VBN\1627355|bupropion (r_acl) hepatotoxicity_8\NN\1740|of|induced
D016642_D056486 CID bupropion_32\NN\1740| (r_dobj) receiving_31\VBG\2210855|bupropion|treatment (r_acl) patient_30\NN\9898892|in|a|receiving (r_nmod) failure_27\NN\66216|from|acute|liver|patient (r_nmod) resulted_23\VBN\2633881|that|could|have|failure (r_acl:relcl) fatality_19\NN\7355491|of|resulted (r_nmod) case_17\NN\7283608|is|,|this|is|the|first|fatality (l_advcl) is_4\VBZ\836236|although|there|evidence (l_attr) evidence_6\NN\5816287|increasing|hepatotoxicity (l_nmod) hepatotoxicity_8\NN\1740|of|induced
D016642_D056486 CID bupropion_15\NN\1740|by (r_nmod) induced_13\VBN\1627355|bupropion (r_acl) insult_12\NN\6714976|of|acute|liver|induced|given (l_acl) given_16\VBN\2327200|concurrently|drugs (l_nmod) drugs_21\NNS\14778436|with|other|hepatotoxic (l_amod) hepatotoxic_20\JJ\1740|
D002231_D056486 CID carbimazole_38\NN\1740|with (r_nmod) treatment_36\NN\654885|while|on|concomitant|carbimazole (r_nmod) receiving_31\VBG\2210855|bupropion|treatment (r_acl) patient_30\NN\9898892|in|a|receiving (r_nmod) failure_27\NN\66216|from|acute|liver|patient (r_nmod) resulted_23\VBN\2633881|that|could|have|failure (r_acl:relcl) fatality_19\NN\7355491|of|resulted (r_nmod) case_17\NN\7283608|is|,|this|is|the|first|fatality (l_advcl) is_4\VBZ\836236|although|there|evidence (l_attr) evidence_6\NN\5816287|increasing|hepatotoxicity (l_nmod) hepatotoxicity_8\NN\1740|of|induced
7197363
D001058_D012892 NONE apomorphine-induced_10\JJ\1740| (r_amod) aggressiveness_11\NN\4835724|on|apomorphine-induced|and|twitches|rats (r_nmod) effects_1\NNS\13245626|the|deprivation|aggressiveness (l_nmod) deprivation_5\NN\14493145|of|rem|sleep|remd
D001058_D012892 NONE apomorphine-induced_10\JJ\1740| (r_amod) aggressiveness_11\NN\4835724|on|apomorphine-induced|and|twitches|rats (r_nmod) effects_1\NNS\13245626|the|deprivation|aggressiveness (l_nmod) deprivation_5\NN\14493145|of|rem|sleep|remd (l_appos) remd_7\NN\1740|(|)
D001058_D012892 NONE apomorphine-induced_5\JJ\1740| (r_amod) aggressiveness_6\NN\4835724|apomorphine-induced (r_dobj) increased_4\VBD\169651|hr|aggressiveness|,|and|reduced|. (l_nsubj) hr_1\NN\15154774|forty-eight|remd (l_nmod) remd_3\NN\1740|of
D001058_D012892 NONE apomorphine-induced_5\JJ\1740| (r_amod) aggressiveness_6\NN\4835724|apomorphine-induced (r_dobj) increased_4\VBD\169651|hr|aggressiveness|,|and|reduced|. (l_conj) reduced_9\VBD\441445|(|completing|)|or|increased (l_advcl) completing_13\VBG\352826|after|remd (l_nmod) remd_15\NN\1740|of
D001058_D012892 NONE apomorphine-induced_5\JJ\1740| (r_amod) aggressiveness_6\NN\4835724|apomorphine-induced (r_dobj) increased_4\VBD\169651|hr|aggressiveness|,|and|reduced|. (l_conj) reduced_9\VBD\441445|(|completing|)|or|increased (l_conj) increased_18\VBD\169651|completing|twitches (l_dep) completing_23\VBG\352826|(|hr|remd|) (l_nmod) remd_25\NN\1740|of
D001058_D001523 CID apomorphine-induced_10\JJ\1740| (r_amod) aggressiveness_11\NN\4835724|on|apomorphine-induced|and|twitches|rats
D001058_D001523 CID apomorphine-induced_5\JJ\1740| (r_amod) aggressiveness_6\NN\4835724|apomorphine-induced
D001058_D009069 NONE apomorphine-induced_10\JJ\1740| (r_amod) aggressiveness_11\NN\4835724|on|apomorphine-induced|and|twitches|rats (l_conj) twitches_15\NNS\14360459|quipazine-induced|head
D001058_D009069 NONE apomorphine-induced_5\JJ\1740| (r_amod) aggressiveness_6\NN\4835724|apomorphine-induced (r_dobj) increased_4\VBD\169651|hr|aggressiveness|,|and|reduced|. (l_conj) reduced_9\VBD\441445|(|completing|)|or|increased (l_conj) increased_18\VBD\169651|completing|twitches (l_dobj) twitches_29\NNS\14360459|quipazine-induced|head
D011814_D012892 NONE quipazine-induced_13\JJ\1740| (r_amod) twitches_15\NNS\14360459|quipazine-induced|head (r_conj) aggressiveness_11\NN\4835724|on|apomorphine-induced|and|twitches|rats (r_nmod) effects_1\NNS\13245626|the|deprivation|aggressiveness (l_nmod) deprivation_5\NN\14493145|of|rem|sleep|remd
D011814_D012892 NONE quipazine-induced_13\JJ\1740| (r_amod) twitches_15\NNS\14360459|quipazine-induced|head (r_conj) aggressiveness_11\NN\4835724|on|apomorphine-induced|and|twitches|rats (r_nmod) effects_1\NNS\13245626|the|deprivation|aggressiveness (l_nmod) deprivation_5\NN\14493145|of|rem|sleep|remd (l_appos) remd_7\NN\1740|(|)
D011814_D012892 NONE quipazine-induced_27\JJ\1740| (r_amod) twitches_29\NNS\14360459|quipazine-induced|head (r_dobj) increased_18\VBD\169651|completing|twitches (r_conj) reduced_9\VBD\441445|(|completing|)|or|increased (r_conj) increased_4\VBD\169651|hr|aggressiveness|,|and|reduced|. (l_nsubj) hr_1\NN\15154774|forty-eight|remd (l_nmod) remd_3\NN\1740|of
D011814_D012892 NONE quipazine-induced_27\JJ\1740| (r_amod) twitches_29\NNS\14360459|quipazine-induced|head (r_dobj) increased_18\VBD\169651|completing|twitches (r_conj) reduced_9\VBD\441445|(|completing|)|or|increased (l_advcl) completing_13\VBG\352826|after|remd (l_nmod) remd_15\NN\1740|of
D011814_D012892 NONE quipazine-induced_27\JJ\1740| (r_amod) twitches_29\NNS\14360459|quipazine-induced|head (r_dobj) increased_18\VBD\169651|completing|twitches (l_dep) completing_23\VBG\352826|(|hr|remd|) (l_nmod) remd_25\NN\1740|of
D011814_D001523 NONE quipazine-induced_13\JJ\1740| (r_amod) twitches_15\NNS\14360459|quipazine-induced|head (r_conj) aggressiveness_11\NN\4835724|on|apomorphine-induced|and|twitches|rats
D011814_D001523 NONE quipazine-induced_27\JJ\1740| (r_amod) twitches_29\NNS\14360459|quipazine-induced|head (r_dobj) increased_18\VBD\169651|completing|twitches (r_conj) reduced_9\VBD\441445|(|completing|)|or|increased (r_conj) increased_4\VBD\169651|hr|aggressiveness|,|and|reduced|. (l_dobj) aggressiveness_6\NN\4835724|apomorphine-induced
D011814_D009069 CID quipazine-induced_13\JJ\1740| (r_amod) twitches_15\NNS\14360459|quipazine-induced|head
D011814_D009069 CID quipazine-induced_27\JJ\1740| (r_amod) twitches_29\NNS\14360459|quipazine-induced|head
17490864
D000661_D006948 CID amphetamine-induced_0\JJ\1740| (r_amod) hyperactivity_2\NN\14052403|amphetamine-induced|locomotor
3120485
2004015
D015215_C565469 NONE azidothymidine_8\NN\1740| (r_nmod:npmod) treated_9\JJ\1740|azidothymidine (r_amod) mice_11\NNS\2329401|in|treated|immunodeficient (l_amod) immunodeficient_10\JJ\1740|
D015215_D000740 CID 3'-azido-3'dideoxythymidine_4\NN\1740| (r_compound) azt_6\NN\3834836|by|3'-azido-3'dideoxythymidine|(|) (r_nmod) induced_2\VBN\1627355|azt (r_acl) anaemia_1\NN\14299637|the|induced
D015215_D000740 CID azt_6\NN\3834836|by|3'-azido-3'dideoxythymidine|(|) (r_nmod) induced_2\VBN\1627355|azt (r_acl) anaemia_1\NN\14299637|the|induced
D015215_D000740 CID azt-induced_26\JJ\1740| (r_amod) anaemia_27\NN\14299637|azt-induced
D015215_D000740 CID azt_0\NN\3834836| (r_nsubj) produced_1\VBD\1617192|azt|anaemia|groups|,|fashion|. (l_dobj) anaemia_2\NN\14299637|
D015215_D000740 CID azt_13\NN\3834836| (r_nmod:npmod) treated_14\JJ\1740|azt (r_amod) mice_15\NNS\2329401|in|treated (r_nmod) bfu-e_11\NN\1740|of|splenic|mice (r_nmod) number_5\NN\5107765|the|bfu-e (r_nsubj) increased_16\VBD\169651|anaemia|,|number|five-fold|levels|. (l_nmod) anaemia_2\NN\14299637|despite|the
D015215_D000740 CID azt_8\NN\3834836| (r_nmod:npmod) treated_9\JJ\1740|azt (r_amod) mice_10\NNS\2329401|in|treated (r_nmod) observed_6\VBN\2163746|mice (r_acl) levels_3\NNS\4916342|the|mean|plasma|epo|observed (r_nsubj) appropriate_12\JJ\1740|levels|were|degree|compared|. (l_nmod) degree_15\NN\4916342|for|the|anaemia (l_nmod) anaemia_17\NN\14299637|of|observed
D015215_D000740 CID azt_15\NN\3834836|and|phz (r_nmod:npmod) treated_18\JJ\1740|azt (r_amod) mice_19\NNS\2329401|in|treated|degrees (l_nmod) degrees_22\NNS\4916342|with|similar|anaemia (l_nmod) anaemia_24\NN\14299637|of
D015215_D000740 CID azt_12\NN\3834836| (r_nmod:npmod) treated_13\JJ\1740|azt (r_amod) mice_15\NNS\2329401|in|treated|infected (r_nmod) observed_10\VBN\2163746|mice (r_acl) anaemia_9\NN\14299637|of|observed
D015215_D000740 CID azt-induced_0\JJ\1740| (r_amod) anaemia_2\NN\14299637|azt-induced|peripheral|face
D015215_D000163 NONE azt-induced_26\JJ\1740| (r_amod) anaemia_27\NN\14299637|azt-induced (r_nsubj) due_29\JJ\1740|if|anaemia|is|, (r_case) responsiveness_36\NN\5652926|due|part|,|to|decreased|precursors|erythropoietin (r_nmod) determine_24\VB\1645601|to|responsiveness (r_advcl) used_2\VBN\1156834|we|have|model|determine|. (l_dobj) model_5\NN\5888929|a|murine|aids|,|infection|, (l_nmod) aids_7\NN\13974317|of
D015215_D007239 NONE azt-induced_26\JJ\1740| (r_amod) anaemia_27\NN\14299637|azt-induced (r_nsubj) due_29\JJ\1740|if|anaemia|is|, (r_case) responsiveness_36\NN\5652926|due|part|,|to|decreased|precursors|erythropoietin (r_nmod) determine_24\VB\1645601|to|responsiveness (r_advcl) used_2\VBN\1156834|we|have|model|determine|. (l_dobj) model_5\NN\5888929|a|murine|aids|,|infection|, (l_appos) infection_9\NN\14052046|mice|virus
D015215_D007938 NONE azt-induced_26\JJ\1740| (r_amod) anaemia_27\NN\14299637|azt-induced (r_nsubj) due_29\JJ\1740|if|anaemia|is|, (r_case) responsiveness_36\NN\5652926|due|part|,|to|decreased|precursors|erythropoietin (r_nmod) determine_24\VB\1645601|to|responsiveness (r_advcl) used_2\VBN\1156834|we|have|model|determine|. (l_dobj) model_5\NN\5888929|a|murine|aids|,|infection|, (l_appos) infection_9\NN\14052046|mice|virus (l_nmod) virus_21\NN\9312843|with|lp-bm5|murine|leukaemia|(|mulv|) (l_compound) leukaemia_17\NN\14239918|
C030299_D000740 NONE phenylhydrazine_22\NN\1740|phz (r_nmod:npmod) treated_26\JJ\1740|phenylhydrazine (r_amod) mice_27\NNS\2329401|with|treated (r_nmod) compared_20\VBN\644583|when|mice (r_advcl) appropriate_12\JJ\1740|levels|were|degree|compared|. (l_nmod) degree_15\NN\4916342|for|the|anaemia (l_nmod) anaemia_17\NN\14299637|of|observed
C030299_D000740 NONE phz_24\NN\1740|(|) (r_appos) phenylhydrazine_22\NN\1740|phz (r_nmod:npmod) treated_26\JJ\1740|phenylhydrazine (r_amod) mice_27\NNS\2329401|with|treated (r_nmod) compared_20\VBN\644583|when|mice (r_advcl) appropriate_12\JJ\1740|levels|were|degree|compared|. (l_nmod) degree_15\NN\4916342|for|the|anaemia (l_nmod) anaemia_17\NN\14299637|of|observed
C030299_D000740 NONE phz_17\NN\1740| (r_conj) azt_15\NN\3834836|and|phz (r_nmod:npmod) treated_18\JJ\1740|azt (r_amod) mice_19\NNS\2329401|in|treated|degrees (l_nmod) degrees_22\NNS\4916342|with|similar|anaemia (l_nmod) anaemia_24\NN\14299637|of
D015215_D045262 NONE azt_12\NN\3834836| (r_nmod:npmod) treated_13\JJ\1740|azt (r_amod) mice_15\NNS\2329401|in|treated|infected (r_nmod) observed_10\VBN\2163746|mice (r_acl) anaemia_9\NN\14299637|of|observed (r_nmod) degree_7\NN\4916342|for|the|anaemia (r_nmod) inappropriate_4\JJ\1740|however|,|reticulocytosis|was|degree|. (l_nsubj) reticulocytosis_2\NN\1740|
3670965
D012459_D012202 NONE salicylates_14\NNS\3828465|with|or|ingestion (r_nmod) association_12\NN\8008335|of|salicylates (r_nmod) lack_10\NN\14449126|despite|a|total|association (r_nmod) disappearing_4\VBG\2609764|syndrome|may|be|australia|lack|,|were|. (l_nsubj) syndrome_1\NN\5870365|reye
D001241_D012202 CID aspirin_16\NN\2707683| (r_compound) ingestion_17\NN\13440063|aspirin (r_conj) salicylates_14\NNS\3828465|with|or|ingestion (r_nmod) association_12\NN\8008335|of|salicylates (r_nmod) lack_10\NN\14449126|despite|a|total|association (r_nmod) disappearing_4\VBG\2609764|syndrome|may|be|australia|lack|,|were|. (l_nsubj) syndrome_1\NN\5870365|reye
15867025
D006514_D006509 CID antigen-positive_42\JJ\1740|b|surface (r_amod) mothers_43\NNS\10399491|to|hepatitis|antigen-positive (r_nmod) born_37\VBN\2630189|who|were|mothers (r_acl:relcl) infants_34\NNS\9918248|to|born (r_nmod) administration_27\NN\1133281|globulin|infants|,|immunity (r_conj) administration_15\NN\1133281|dose|infants|,|administration (r_conj) screening_8\NN\6887726|prenatal|b|,|administration (l_nmod) b_11\NN\1355326|for|hepatitis|and|rubella
D006514_D006509 CID antigen-positive_42\JJ\1740|b|surface (r_amod) mothers_43\NNS\10399491|to|hepatitis|antigen-positive (r_nmod) born_37\VBN\2630189|who|were|mothers (r_acl:relcl) infants_34\NNS\9918248|to|born (r_nmod) administration_27\NN\1133281|globulin|infants|,|immunity (r_conj) administration_15\NN\1133281|dose|infants|,|administration (l_nmod) dose_22\NN\3740161|of|the|vaccine|birth (l_compound) vaccine_20\NN\3562739|hepatitis|b (l_compound) b_19\NN\1355326|
D006514_D006509 CID antigen-positive_42\JJ\1740|b|surface (r_amod) mothers_43\NNS\10399491|to|hepatitis|antigen-positive (r_nmod) born_37\VBN\2630189|who|were|mothers (r_acl:relcl) infants_34\NNS\9918248|to|born (r_nmod) administration_27\NN\1133281|globulin|infants|,|immunity (l_nmod) globulin_32\NN\14736972|of|hepatitis|b|immune (l_compound) b_30\NN\1355326|
D006514_D006509 CID antigen-positive_9\JJ\1740|hepatitis|b|surface (r_amod) mothers_10\NNS\10399491|to|antigen-positive (r_nmod) born_4\VBN\2630189|who|were|mothers (r_acl:relcl) infants_1\NNS\9918248|all|born (r_nsubj) received_12\VBD\2210855|infants|also|globulin|. (l_dobj) globulin_16\NN\14736972|hepatitis|b|immune (l_compound) b_14\NN\1355326|
D006514_D012409 NONE antigen-positive_42\JJ\1740|b|surface (r_amod) mothers_43\NNS\10399491|to|hepatitis|antigen-positive (r_nmod) born_37\VBN\2630189|who|were|mothers (r_acl:relcl) infants_34\NNS\9918248|to|born (r_nmod) administration_27\NN\1133281|globulin|infants|,|immunity (r_conj) administration_15\NN\1133281|dose|infants|,|administration (r_conj) screening_8\NN\6887726|prenatal|b|,|administration (l_nmod) b_11\NN\1355326|for|hepatitis|and|rubella (l_conj) rubella_13\NN\14123044|
D006514_D012409 NONE antigen-positive_42\JJ\1740|b|surface (r_amod) mothers_43\NNS\10399491|to|hepatitis|antigen-positive (r_nmod) born_37\VBN\2630189|who|were|mothers (r_acl:relcl) infants_34\NNS\9918248|to|born (r_nmod) administration_27\NN\1133281|globulin|infants|,|immunity (l_conj) immunity_46\NN\13920835|rubella|,|and|administration (l_compound) rubella_45\NN\14123044|
D006514_D012409 NONE antigen-positive_42\JJ\1740|b|surface (r_amod) mothers_43\NNS\10399491|to|hepatitis|antigen-positive (r_nmod) born_37\VBN\2630189|who|were|mothers (r_acl:relcl) infants_34\NNS\9918248|to|born (r_nmod) administration_27\NN\1133281|globulin|infants|,|immunity (l_conj) immunity_46\NN\13920835|rubella|,|and|administration (l_conj) administration_49\NN\1133281|vaccine|women (l_nmod) vaccine_54\NN\3562739|of|in-hospital|postpartum|rubella (l_compound) rubella_53\NN\14123044|
D006514_D012409 NONE antigen-positive_42\JJ\1740|b|surface (r_amod) mothers_43\NNS\10399491|to|hepatitis|antigen-positive (r_nmod) born_37\VBN\2630189|who|were|mothers (r_acl:relcl) infants_34\NNS\9918248|to|born (r_nmod) administration_27\NN\1133281|globulin|infants|,|immunity (l_conj) immunity_46\NN\13920835|rubella|,|and|administration (l_conj) administration_49\NN\1133281|vaccine|women (l_nmod) women_58\NNS\9605289|to|rubella|nonimmune (l_compound) rubella_56\NN\14123044|
10743694
8514073
D008874_D014652 CID midazolam_3\NN\2830852|of|versus|diazepam (r_nmod) complications_1\NNS\1073995|venous|midazolam|.
D008874_D014652 CID midazolam_11\NN\2830852|with (r_nmod) associated_9\VBN\628491|complications|are|midazolam|than (l_nsubjpass) complications_7\NNS\1073995|fewer|venous
D008874_D014652 CID midazolam_14\NN\2830852| (r_conj) diazepam_12\NN\2830852|of|or|midazolam (r_nmod) injection_10\NN\320852|after|intravenous|diazepam|patients (r_nmod) incidence_4\NN\13821570|the|complications|injection (l_nmod) complications_7\NNS\1073995|of|venous
D008874_D014652 CID midazolam_17\NN\2830852|with|patients (r_nmod) than_15\IN\1740|midazolam (r_prep) frequent_6\JJ\1740|overall|,|complications|were|more|diazepam|patients|than|p|. (l_nsubj) complications_3\NNS\1073995|venous
D003975_D014652 CID diazepam_5\NN\2830852| (r_conj) midazolam_3\NN\2830852|of|versus|diazepam (r_nmod) complications_1\NNS\1073995|venous|midazolam|.
D003975_D014652 CID diazepam_14\NN\2830852|with|procedures (r_nmod) than_12\IN\1740|diazepam (r_prep) associated_9\VBN\628491|complications|are|midazolam|than (l_nsubjpass) complications_7\NNS\1073995|fewer|venous
D003975_D014652 CID diazepam_12\NN\2830852|of|or|midazolam (r_nmod) injection_10\NN\320852|after|intravenous|diazepam|patients (r_nmod) incidence_4\NN\13821570|the|complications|injection (l_nmod) complications_7\NNS\1073995|of|venous
D003975_D014652 CID diazepam_8\NN\2830852|with (r_nmod) frequent_6\JJ\1740|overall|,|complications|were|more|diazepam|patients|than|p|. (l_nsubj) complications_3\NNS\1073995|venous
D003975_D010146 NONE diazepam_18\NN\2830852| (r_compound) group_19\NN\2137|in|the|diazepam (r_nmod) patients_15\NNS\9898892|of|group (r_nmod) %_8\NN\1740|in|35|(|62|patients (r_nmod) occurred_5\VBD\2623529|pain|%|compared|. (l_nsubj) pain_0\NN\14299637|site
D008874_D010146 NONE midazolam_32\NN\2830852| (r_compound) group_33\NN\2137|in|the|midazolam (r_nmod) %_23\NN\1740|with|7|patients|group|p (r_nmod) compared_20\VBN\644583|% (r_prep) occurred_5\VBD\2623529|pain|%|compared|. (l_nsubj) pain_0\NN\14299637|site
D000431_D010146 NONE alcohol_17\NN\7881800| (r_compound) use_18\NN\407535|alcohol|,|and|pain (l_conj) pain_21\NN\14299637|injection
D000431_D014652 NONE alcohol_17\NN\7881800| (r_compound) use_18\NN\407535|alcohol|,|and|pain (r_conj) site_9\NN\8673395|intravenous|catheter|,|time|,|use (r_conj) use_5\NN\407535|nonsteroidal|anti-inflammatory|drug|,|site (r_conj) smoking_0\NN\831191|,|use (r_nsubj) had_25\VBD\2108377|smoking|effect|. (l_dobj) effect_27\NN\34213|no|incidence (l_nmod) incidence_30\NN\13821570|on|the|complications (l_nmod) complications_33\NNS\1073995|of|venous
9209318
D015215_D009190 CID azidothymidine_5\NN\1740|with|azt (r_nmod) treatment_1\NN\654885|lifetime|mice|azidothymidine (r_nsubj) produces_9\VBZ\1617192|treatment|myelodysplasia|. (l_dobj) myelodysplasia_10\NN\1740|
D015215_D009190 CID azt_7\NN\3834836|(|) (r_appos) azidothymidine_5\NN\1740|with|azt (r_nmod) treatment_1\NN\654885|lifetime|mice|azidothymidine (r_nsubj) produces_9\VBZ\1617192|treatment|myelodysplasia|. (l_dobj) myelodysplasia_10\NN\1740|
D015215_D009190 CID azt_2\NN\3834836| (r_compound) incorporation_3\NN\1237415|mentioned|azt (r_nsubj) induced_6\VBN\1627355|incorporation|may|have|hemopoiesis|. (l_dobj) hemopoiesis_9\NN\13526110|an|ineffective|cells|,|known (l_acl:relcl) known_19\VBN\2110220|which|is|seen (l_xcomp) seen_22\VBN\2106506|to|be|commonly|syndrome (l_nmod) syndrome_27\NN\5870365|in|the|myelodysplastic
D015215_D000748 CID azt_0\NN\3834836| (r_nsubj) induced_2\VBN\1627355|azt|has|anemia|therapy|. (l_dobj) anemia_5\NN\14189204|a|macrocytic|patients
D015215_D000748 CID azt_12\NN\3834836| (r_compound) therapy_13\NN\657604|on|term|azt (r_nmod) induced_2\VBN\1627355|azt|has|anemia|therapy|. (l_dobj) anemia_5\NN\14189204|a|macrocytic|patients
D015215_D000163 NONE azt_0\NN\3834836| (r_nsubj) induced_2\VBN\1627355|azt|has|anemia|therapy|. (l_dobj) anemia_5\NN\14189204|a|macrocytic|patients (l_nmod) patients_8\NNS\9898892|in|aids (l_compound) aids_7\NN\13974317|
D015215_D000163 NONE azt_12\NN\3834836| (r_compound) therapy_13\NN\657604|on|term|azt (r_nmod) induced_2\VBN\1627355|azt|has|anemia|therapy|. (l_dobj) anemia_5\NN\14189204|a|macrocytic|patients (l_nmod) patients_8\NNS\9898892|in|aids (l_compound) aids_7\NN\13974317|
11077455
D020888_D014786 CID vigabatrin-attributed_14\NN\1740| (r_nummod) constriction_17\NN\5071027|with|vigabatrin-attributed|visual|field
D020888_D014786 CID vigabatrin_11\NN\1740|with (r_nmod) associated_9\VBN\628491|to|be|vigabatrin (r_xcomp) thought_6\VBN\670261|associated (r_acl) constriction_5\NN\5071027|symptomatic|field|thought
D020888_D014786 CID vigabatrin-attributed_15\NN\1740| (r_amod) loss_18\NN\13252973|with|known|vigabatrin-attributed|visual|field
D020888_D014786 CID vigabatrin_11\NN\1740| (r_compound) therapy_12\NN\657604|with|vigabatrin (r_nmod) associated_9\VBN\628491|to|be|therapy (r_xcomp) appears_6\VBZ\2604760|conclusion|:|constriction|associated|. (l_nsubj) constriction_5\NN\5071027|marked|field
8617710
D020280_D003072 NONE sertraline_4\NN\4169152|of (r_nmod) effect_2\NN\34213|of|sertraline|sensitization (l_nmod) sensitization_7\NN\14531772|on|time-based|impairment|haloperidol (l_nmod) impairment_10\NN\7296428|of|cognitive
D020280_D003072 NONE sertraline_16\NN\4169152| (r_compound) administration_17\NN\1133281|by|concomitant|sertraline (r_nmod) worsened_13\VBN\146138|that|was|not|administration (r_acl:relcl) profile_6\NN\6999802|a|clear|impairment|worsened (l_nmod) impairment_9\NN\7296428|of|cognitive
D006220_D003072 CID haloperidol_12\NN\3713736|with (r_nmod) sensitization_7\NN\14531772|on|time-based|impairment|haloperidol (l_nmod) impairment_10\NN\7296428|of|cognitive
D006220_D003072 CID haloperidol_15\NN\3713736|of (r_nmod) administration_13\NN\1133281|hours|haloperidol (r_dobj) observed_7\VBN\2163746|impairment|was|administration|day|but|evident|. (l_nsubjpass) impairment_2\NN\7296428|function (l_nmod) function_5\NN\13783581|of|cognitive
D006220_D003072 CID haloperidol_2\NN\3713736| (r_nsubj) produced_3\VBD\1617192|conclusion|:|haloperidol|profile|. (l_dobj) profile_6\NN\6999802|a|clear|impairment|worsened (l_nmod) impairment_9\NN\7296428|of|cognitive
6892185
D002122_D015878 NONE chloride_4\NN\14818238|of|calcium|injected (l_acl) injected_5\VBN\81072|ventricles|vocalization (l_nmod) vocalization_15\NN\33020|upon|rage|,|fighting (l_conj) fighting_24\NN\958896|attack (l_dep) attack_26\NN\955060|(|paws|,|defense|and|biting|)|,|mydriasis|,|tremor|and|convulsions (l_conj) mydriasis_41\NN\365995|
D002122_D015878 NONE chloride_22\NN\14818238|by|calcium (r_nmod) changed_19\VBN\46534|hand|,|mydriasis|were|not|significantly|chloride|. (l_nsubjpass) mydriasis_5\NN\365995|,|tremor|and|convulsions|evoked
D002122_D015878 NONE chloride_5\NN\14818238|calcium (r_nsubj) dissociate_8\VB\2431320|that|chloride|can|"|"|vocalization|phenomena (l_nmod) phenomena_17\NNS\29677|from|autonomic|mydriasis (l_nmod) mydriasis_20\NN\365995|such|,|tremor|caused
D002122_D014202 NONE chloride_4\NN\14818238|of|calcium|injected (l_acl) injected_5\VBN\81072|ventricles|vocalization (l_nmod) vocalization_15\NN\33020|upon|rage|,|fighting (l_conj) fighting_24\NN\958896|attack (l_dep) attack_26\NN\955060|(|paws|,|defense|and|biting|)|,|mydriasis|,|tremor|and|convulsions (l_conj) tremor_43\NN\345926|
D002122_D014202 NONE chloride_22\NN\14818238|by|calcium (r_nmod) changed_19\VBN\46534|hand|,|mydriasis|were|not|significantly|chloride|. (l_nsubjpass) mydriasis_5\NN\365995|,|tremor|and|convulsions|evoked (l_conj) tremor_7\NN\345926|
D002122_D014202 NONE chloride_5\NN\14818238|calcium (r_nsubj) dissociate_8\VB\2431320|that|chloride|can|"|"|vocalization|phenomena (l_nmod) phenomena_17\NNS\29677|from|autonomic|mydriasis (l_nmod) mydriasis_20\NN\365995|such|,|tremor|caused (l_conj) tremor_22\NN\345926|and|convulsions
D002122_D004830 NONE chloride_4\NN\14818238|of|calcium|injected (l_acl) injected_5\VBN\81072|ventricles|vocalization (l_nmod) vocalization_15\NN\33020|upon|rage|,|fighting (l_conj) fighting_24\NN\958896|attack (l_dep) attack_26\NN\955060|(|paws|,|defense|and|biting|)|,|mydriasis|,|tremor|and|convulsions (l_conj) convulsions_46\NNS\14081375|clonic-tonic|produced
D002122_D004830 NONE chloride_22\NN\14818238|by|calcium (r_nmod) changed_19\VBN\46534|hand|,|mydriasis|were|not|significantly|chloride|. (l_nsubjpass) mydriasis_5\NN\365995|,|tremor|and|convulsions|evoked (l_conj) convulsions_10\NNS\14081375|clonic-tonic
D002122_D004830 NONE chloride_5\NN\14818238|calcium (r_nsubj) dissociate_8\VB\2431320|that|chloride|can|"|"|vocalization|phenomena (l_nmod) phenomena_17\NNS\29677|from|autonomic|mydriasis (l_nmod) mydriasis_20\NN\365995|such|,|tremor|caused (l_conj) tremor_22\NN\345926|and|convulsions (l_conj) convulsions_25\NNS\14081375|clonic-tonic
D002217_D015878 CID carbachol_49\NN\1740|by|and|eserine|injected (r_nmod) produced_47\VBN\1617192|carbachol (r_acl) convulsions_46\NNS\14081375|clonic-tonic|produced (r_conj) attack_26\NN\955060|(|paws|,|defense|and|biting|)|,|mydriasis|,|tremor|and|convulsions (l_conj) mydriasis_41\NN\365995|
D002217_D015878 CID carbachol_13\NN\1740|by|and|eserine (r_nmod) evoked_11\VBN\1617192|carbachol (r_acl) mydriasis_5\NN\365995|,|tremor|and|convulsions|evoked
D002217_D015878 CID carbachol_28\NN\1740|by|and|eserine (r_nmod) caused_26\VBN\1617192|carbachol (r_acl) mydriasis_20\NN\365995|such|,|tremor|caused
D002217_D014202 CID carbachol_49\NN\1740|by|and|eserine|injected (r_nmod) produced_47\VBN\1617192|carbachol (r_acl) convulsions_46\NNS\14081375|clonic-tonic|produced (r_conj) attack_26\NN\955060|(|paws|,|defense|and|biting|)|,|mydriasis|,|tremor|and|convulsions (l_conj) tremor_43\NN\345926|
D002217_D014202 CID carbachol_13\NN\1740|by|and|eserine (r_nmod) evoked_11\VBN\1617192|carbachol (r_acl) mydriasis_5\NN\365995|,|tremor|and|convulsions|evoked (l_conj) tremor_7\NN\345926|
D002217_D014202 CID carbachol_28\NN\1740|by|and|eserine (r_nmod) caused_26\VBN\1617192|carbachol (r_acl) mydriasis_20\NN\365995|such|,|tremor|caused (l_conj) tremor_22\NN\345926|and|convulsions
D002217_D004830 CID carbachol_49\NN\1740|by|and|eserine|injected (r_nmod) produced_47\VBN\1617192|carbachol (r_acl) convulsions_46\NNS\14081375|clonic-tonic|produced
D002217_D004830 CID carbachol_13\NN\1740|by|and|eserine (r_nmod) evoked_11\VBN\1617192|carbachol (r_acl) mydriasis_5\NN\365995|,|tremor|and|convulsions|evoked (l_conj) convulsions_10\NNS\14081375|clonic-tonic
D002217_D004830 CID carbachol_28\NN\1740|by|and|eserine (r_nmod) caused_26\VBN\1617192|carbachol (r_acl) mydriasis_20\NN\365995|such|,|tremor|caused (l_conj) tremor_22\NN\345926|and|convulsions (l_conj) convulsions_25\NNS\14081375|clonic-tonic
D010830_D015878 CID eserine_51\NN\1740| (r_conj) carbachol_49\NN\1740|by|and|eserine|injected (r_nmod) produced_47\VBN\1617192|carbachol (r_acl) convulsions_46\NNS\14081375|clonic-tonic|produced (r_conj) attack_26\NN\955060|(|paws|,|defense|and|biting|)|,|mydriasis|,|tremor|and|convulsions (l_conj) mydriasis_41\NN\365995|
D010830_D015878 CID eserine_15\NN\1740| (r_conj) carbachol_13\NN\1740|by|and|eserine (r_nmod) evoked_11\VBN\1617192|carbachol (r_acl) mydriasis_5\NN\365995|,|tremor|and|convulsions|evoked
D010830_D015878 CID eserine_30\NN\1740| (r_conj) carbachol_28\NN\1740|by|and|eserine (r_nmod) caused_26\VBN\1617192|carbachol (r_acl) mydriasis_20\NN\365995|such|,|tremor|caused
D010830_D014202 CID eserine_51\NN\1740| (r_conj) carbachol_49\NN\1740|by|and|eserine|injected (r_nmod) produced_47\VBN\1617192|carbachol (r_acl) convulsions_46\NNS\14081375|clonic-tonic|produced (r_conj) attack_26\NN\955060|(|paws|,|defense|and|biting|)|,|mydriasis|,|tremor|and|convulsions (l_conj) tremor_43\NN\345926|
D010830_D014202 CID eserine_15\NN\1740| (r_conj) carbachol_13\NN\1740|by|and|eserine (r_nmod) evoked_11\VBN\1617192|carbachol (r_acl) mydriasis_5\NN\365995|,|tremor|and|convulsions|evoked (l_conj) tremor_7\NN\345926|
D010830_D014202 CID eserine_30\NN\1740| (r_conj) carbachol_28\NN\1740|by|and|eserine (r_nmod) caused_26\VBN\1617192|carbachol (r_acl) mydriasis_20\NN\365995|such|,|tremor|caused (l_conj) tremor_22\NN\345926|and|convulsions
D010830_D004830 CID eserine_51\NN\1740| (r_conj) carbachol_49\NN\1740|by|and|eserine|injected (r_nmod) produced_47\VBN\1617192|carbachol (r_acl) convulsions_46\NNS\14081375|clonic-tonic|produced
D010830_D004830 CID eserine_15\NN\1740| (r_conj) carbachol_13\NN\1740|by|and|eserine (r_nmod) evoked_11\VBN\1617192|carbachol (r_acl) mydriasis_5\NN\365995|,|tremor|and|convulsions|evoked (l_conj) convulsions_10\NNS\14081375|clonic-tonic
D010830_D004830 CID eserine_30\NN\1740| (r_conj) carbachol_28\NN\1740|by|and|eserine (r_nmod) caused_26\VBN\1617192|carbachol (r_acl) mydriasis_20\NN\365995|such|,|tremor|caused (l_conj) tremor_22\NN\345926|and|convulsions (l_conj) convulsions_25\NNS\14081375|clonic-tonic
16725121
D009638_D012640 NONE norepinephrine_2\NN\14807929| (r_compound) transporter_3\NN\4490091|norepinephrine (r_compound) function_4\NN\13783581|of|transporter (r_nmod) down-regulation_0\NN\1740|function|induced|linking|. (l_acl) linking_11\VBG\628491|alteration (l_nmod) alteration_14\NN\7283608|to|the|sensitivity|and|counteraction (l_nmod) sensitivity_16\NN\5651971|of|convulsions (l_nmod) convulsions_19\NNS\14081375|of|local-anesthetics-induced
D009638_D012640 NONE norepinephrine_2\NN\14807929| (r_compound) transporter_3\NN\4490091|norepinephrine|net (r_compound) function_7\NN\13783581|of|transporter (r_nmod) alterations_0\NNS\7283608|function|inhibition|relation (l_nmod) relation_14\NN\2137|in|sensitization (l_nmod) sensitization_16\NN\14531772|to|seizures (l_nmod) seizures_18\NNS\14081375|to|induce
D003891_D012640 NONE desipramine_10\NN\4482543|of (r_nmod) administration_8\NN\1133281|by|chronic|desipramine (r_nmod) induced_5\VBN\1627355|administration (r_acl) down-regulation_0\NN\1740|function|induced|linking|. (l_acl) linking_11\VBG\628491|alteration (l_nmod) alteration_14\NN\7283608|to|the|sensitivity|and|counteraction (l_nmod) sensitivity_16\NN\5651971|of|convulsions (l_nmod) convulsions_19\NNS\14081375|of|local-anesthetics-induced
D003891_D012640 NONE desipramine_3\NN\4482543|of (r_nmod) administration_1\NN\1133281|daily|desipramine (r_nsubj) increased_4\VBD\169651|administration|incidence|and|decreased|. (l_dobj) incidence_6\NN\13821570|the|appearance (l_nmod) appearance_8\NN\4723816|of|convulsions (l_nmod) convulsions_11\NNS\14081375|of|lidocaine-induced
D003891_D012640 NONE desipramine_3\NN\4482543|of (r_nmod) administration_1\NN\1133281|daily|desipramine (r_nsubj) increased_4\VBD\169651|administration|incidence|and|decreased|. (l_conj) decreased_13\VBD\169651|that (l_dobj) that_14\DT\1740|convulsions (l_nmod) convulsions_17\NNS\14081375|of|cocaine-induced
D003891_D012640 NONE desipramine_4\NN\4482543|with (r_nmod) co-administration_0\NN\1740|lidocaine|desipramine (r_nsubj) reversed_5\VBD\109660|co-administration|changes|. (l_dobj) changes_7\NNS\7283608|the|activity|induced (l_nmod) activity_10\NN\30358|of|convulsive|lidocaine (l_amod) convulsive_9\JJ\1740|
D003891_D012640 NONE desipramine_20\NN\4482543|of (r_nmod) administration_18\NN\1133281|by|repeated|desipramine (r_nmod) induced_15\VBN\1627355|administration (r_acl) changes_7\NNS\7283608|the|activity|induced (l_nmod) activity_10\NN\30358|of|convulsive|lidocaine (l_amod) convulsive_9\JJ\1740|
D003891_D012640 NONE desipramine_13\NN\4482543|of (r_nmod) administration_11\NN\1133281|by|chronic|desipramine (r_nmod) induced_8\VBN\1627355|administration (r_acl) down-regulation_4\NN\1740|net|induced (r_nsubj) relevant_16\JJ\1740|that|down-regulation|may|be|sensitization (l_nmod) sensitization_19\NN\14531772|to|desipramine-induced|convulsions (l_nmod) convulsions_22\NNS\14081375|of|lidocaine
D003891_D012640 NONE desipramine-induced_18\JJ\1740| (r_amod) sensitization_19\NN\14531772|to|desipramine-induced|convulsions (l_nmod) convulsions_22\NNS\14081375|of|lidocaine
D003891_D012640 NONE desipramine-induced_0\JJ\1740| (r_amod) sensitization_1\NN\14531772|desipramine-induced|seizures (l_nmod) seizures_4\NNS\14081375|of|lidocaine
D003042_D012640 CID cocaine_21\NN\3492717|by|and|anesthetics (r_nmod) induce_19\VBN\1627355|cocaine (r_acl) seizures_18\NNS\14081375|to|induce
D003042_D012640 CID cocaine-induced_16\JJ\1740| (r_amod) convulsions_17\NNS\14081375|of|cocaine-induced (r_nmod) that_14\DT\1740|convulsions (r_dobj) decreased_13\VBD\169651|that (r_conj) increased_4\VBD\169651|administration|incidence|and|decreased|. (l_dobj) incidence_6\NN\13821570|the|appearance (l_nmod) appearance_8\NN\4723816|of|convulsions (l_nmod) convulsions_11\NNS\14081375|of|lidocaine-induced
D003042_D012640 CID cocaine-induced_16\JJ\1740| (r_amod) convulsions_17\NNS\14081375|of|cocaine-induced
D003042_D012640 CID cocaine_14\NN\3492717| (r_conj) lidocaine_12\NN\3681148|of|and|cocaine (r_nmod) activity_10\NN\30358|of|convulsive|lidocaine (l_amod) convulsive_9\JJ\1740|
D003042_D012640 CID cocaine_17\NN\3492717|of (r_nmod) administration_15\NN\1133281|from|repeated|cocaine (r_nmod) resulting_12\VBG\2633881|administration (r_acl) kindling_11\NN\15101361|from|resulting (r_nmod) distinct_9\JJ\1740|kindling (r_amod) mechanism_8\NN\13446390|a|distinct (r_dobj) have_6\VB\2108377|sensitization|may|mechanism|. (l_nsubj) sensitization_1\NN\14531772|desipramine-induced|seizures (l_nmod) seizures_4\NNS\14081375|of|lidocaine
D008012_D012640 CID lidocaine-induced_10\JJ\1740| (r_amod) convulsions_11\NNS\14081375|of|lidocaine-induced
D008012_D012640 CID lidocaine-induced_10\JJ\1740| (r_amod) convulsions_11\NNS\14081375|of|lidocaine-induced (r_nmod) appearance_8\NN\4723816|of|convulsions (r_nmod) incidence_6\NN\13821570|the|appearance (r_dobj) increased_4\VBD\169651|administration|incidence|and|decreased|. (l_conj) decreased_13\VBD\169651|that (l_dobj) that_14\DT\1740|convulsions (l_nmod) convulsions_17\NNS\14081375|of|cocaine-induced
D008012_D012640 CID lidocaine_2\NN\3681148|of (r_nmod) co-administration_0\NN\1740|lidocaine|desipramine (r_nsubj) reversed_5\VBD\109660|co-administration|changes|. (l_dobj) changes_7\NNS\7283608|the|activity|induced (l_nmod) activity_10\NN\30358|of|convulsive|lidocaine (l_amod) convulsive_9\JJ\1740|
D008012_D012640 CID lidocaine_12\NN\3681148|of|and|cocaine (r_nmod) activity_10\NN\30358|of|convulsive|lidocaine (l_amod) convulsive_9\JJ\1740|
D008012_D012640 CID lidocaine_21\NN\3681148| (r_compound) convulsions_22\NNS\14081375|of|lidocaine
D008012_D012640 CID lidocaine_3\NN\3681148| (r_compound) seizures_4\NNS\14081375|of|lidocaine
11078231
D004280_D017202 NONE dobutamine_8\NN\1740| (r_compound) echocardiography_10\NN\177127|during|dobutamine|stress (r_nmod) spasm_6\NN\14299637|due|artery|echocardiography (r_nmod) ischemia_1\NN\14195315|myocardial|spasm|.
D004280_D017202 NONE dobutamine_0\NN\1740| (r_compound) echocardiography_2\NN\177127|dobutamine|stress|dse (r_nsubj) test_12\NN\5798043|echocardiography|is|a|useful|provocation|ischemia|. (l_nmod) ischemia_15\NN\14195315|for|myocardial
D004280_D017202 NONE dobutamine_19\NN\1740|by (r_nmod) induced_17\VBN\1627355|whether|ischemia|is|dobutamine (l_nsubjpass) ischemia_11\NN\14195315|myocardial|due
D004280_D003329 CID dobutamine_8\NN\1740| (r_compound) echocardiography_10\NN\177127|during|dobutamine|stress (r_nmod) spasm_6\NN\14299637|due|artery|echocardiography
D004280_D003329 CID dobutamine_19\NN\1740|by (r_nmod) induced_17\VBN\1627355|whether|ischemia|is|dobutamine (l_nsubjpass) ischemia_11\NN\14195315|myocardial|due (l_amod) due_12\JJ\1740|spasm (l_nmod) spasm_15\NN\14299637|to|coronary
D004280_D003329 CID dobutamine_4\NN\1740| (r_nsubj) provoke_6\VB\1617192|that|dobutamine|can|spasm (l_dobj) spasm_8\NN\14299637|coronary|patients
D000109_D023921 NONE acetylcholine_8\NN\14807558|of (r_nmod) injection_6\NN\320852|by|intracoronary|acetylcholine (r_nmod) induced_3\VBN\1627355|spasm|was|injection|,|and|documented (l_conj) documented_17\VBN\1000214|stenosis|was|angiograms|. (l_nsubjpass) stenosis_15\NN\14204950|no|fixed|coronary|artery
D004280_D000788 CID dobutamine_4\NN\1740| (r_nsubj) provoke_6\VB\1617192|that|dobutamine|can|spasm (l_dobj) spasm_8\NN\14299637|coronary|patients (l_nmod) patients_11\NNS\9898892|in|some|angina (l_nmod) angina_15\NN\14171682|with|coronary|spastic
17019386
D008353_D005910 NONE mannitol_2\NN\3214670|of (r_nmod) passage_0\NN\199130|mannitol|brain|:|cause|. (l_nmod) brain_5\NN\5462674|into|the|gliomas (l_nmod) gliomas_7\NNS\14236743|around
D008353_D005910 NONE mannitol_2\NN\3214670|solution (r_nsubjpass) administered_12\VBN\2436349|methods|mannitol|was|bolus|patients (l_nmod) patients_17\NNS\9898892|to|had (l_dep) had_20\VBD\2108377|(|ten|glioma|)|before|craniotomy|. (l_dobj) glioma_22\NN\14236743|malignant|,|metastases|and|meningioma
D008353_D005910 NONE mannitol_7\NN\3214670| (r_compound) concentrations_8\NNS\4916342|mannitol|matter (r_nsubj) higher_17\JJR\1740|patients|,|concentrations|were|times|than|mean (l_nmod) patients_5\NNS\9898892|in|most|glioma (l_compound) glioma_4\NN\14236743|
D008353_D005910 NONE mannitol_15\NN\3214670| (r_nsubj) leak_17\VB\933821|that|bolus|,|mannitol|may|bbb|,|reversing (l_nmod) bbb_21\NN\1740|through|the|altered|gliomas (l_nmod) gliomas_23\NNS\14236743|near
D008353_D001929 NONE mannitol_5\NN\3214670|of (r_nmod) use_3\NN\407535|widespread|mannitol|reduce (l_acl) reduce_7\VB\441445|to|edema|patients (l_dobj) edema_9\NN\14315192|brain|and|icp
D008353_D019586 CID mannitol_5\NN\3214670|of (r_nmod) use_3\NN\407535|widespread|mannitol|reduce (l_acl) reduce_7\VB\441445|to|edema|patients (l_dobj) edema_9\NN\14315192|brain|and|icp (l_conj) icp_13\NN\1740|lower|elevated
D008353_D001932 NONE mannitol_5\NN\3214670|of (r_nmod) use_3\NN\407535|widespread|mannitol|reduce (l_acl) reduce_7\VB\441445|to|edema|patients (l_nmod) patients_17\NNS\9898892|in|tumor (l_compound) tumor_16\NN\14234074|brain
D008353_D001932 NONE mannitol_14\NN\3214670|of (r_nmod) passage_12\NN\199130|the|possible|mannitol|brain|administration (l_nmod) administration_19\NN\1133281|after|patients (l_nmod) patients_24\NNS\9898892|to|21|brain|tumor (l_compound) tumor_23\NN\14234074|
D008353_D009362 NONE mannitol_2\NN\3214670|solution (r_nsubjpass) administered_12\VBN\2436349|methods|mannitol|was|bolus|patients (l_nmod) patients_17\NNS\9898892|to|had (l_dep) had_20\VBD\2108377|(|ten|glioma|)|before|craniotomy|. (l_dobj) glioma_22\NN\14236743|malignant|,|metastases|and|meningioma (l_conj) metastases_26\NNS\13533470|seven|brain
D008353_D009362 NONE mannitol_8\NN\3214670|of (r_nmod) concentrations_6\NNS\4916342|plasma|mannitol (r_nsubj) higher_10\JJR\1740|patients|concentrations|were|concentrations|except|. (l_nsubj) patients_4\NNS\9898892|meningioma (l_compound) meningioma_1\NN\14235200|in|and|metastases (l_conj) metastases_3\NNS\13533470|
D008353_D008579 NONE mannitol_2\NN\3214670|solution (r_nsubjpass) administered_12\VBN\2436349|methods|mannitol|was|bolus|patients (l_nmod) patients_17\NNS\9898892|to|had (l_dep) had_20\VBD\2108377|(|ten|glioma|)|before|craniotomy|. (l_dobj) glioma_22\NN\14236743|malignant|,|metastases|and|meningioma (l_conj) meningioma_29\NN\14235200|four
D008353_D008579 NONE mannitol_8\NN\3214670|of (r_nmod) concentrations_6\NNS\4916342|plasma|mannitol (r_nsubj) higher_10\JJR\1740|patients|concentrations|were|concentrations|except|. (l_nsubj) patients_4\NNS\9898892|meningioma (l_compound) meningioma_1\NN\14235200|in|and|metastases
D008353_D004487 NONE mannitol_15\NN\3214670| (r_nsubj) leak_17\VB\933821|that|bolus|,|mannitol|may|bbb|,|reversing (l_advcl) reversing_25\VBG\109660|gradient|,|aggravating (l_conj) aggravating_32\VBG\126264|edema|and|promoting (l_dobj) edema_34\NN\14315192|peritumoral
2422478
D012701_D007022 NONE serotonin_2\NN\14807737| (r_compound) nerves_3\NNS\14373582|midline|b3|serotonin|medulla (r_nsubjpass) involved_8\VBN\2676054|nerves|are|effect|. (l_nmod) effect_11\NN\34213|in|hypotensive|methyldopa (l_amod) hypotensive_10\JJ\1740|
D012701_D007022 NONE serotonin_18\NN\14807737| (r_compound) neurons_19\NNS\5430628|of|the|b3|serotonin|medulla (r_nmod) cells_14\NNS\3080309|onto|the|ventrolateral|neurons (r_nmod) microinjection_8\NN\1740|methyldopa|cells (r_nsubj) elicits_23\VBZ\1617192|that|microinjection|response (l_dobj) response_26\NN\11410625|a|hypotensive|mediated (l_amod) hypotensive_25\JJ\1740|
D012701_D007022 NONE serotonin_17\NN\14807737| (r_compound) group_19\NN\2137|of|the|midline|b3|serotonin|cell|medulla (r_nmod) area_12\NN\8630985|into|the|group (r_nmod) microinjection_7\NN\1740|methyldopa|area (r_nsubj) caused_24\VBD\1617192|rats|,|microinjection|hypotension|. (l_dobj) hypotension_27\NN\14057371|a|potent|hg|,|maximal
D012701_D007022 NONE serotonin_49\NN\14807737| (r_compound) neurotoxin_50\NN\15034074|the|serotonin|5,7-dihydroxytryptamine (r_nsubj) injected_55\VBN\81072|by|neurotoxin|intracerebroventricularly (r_advcl) abolished_46\VBN\1740|was|injected (r_conj) maximal_37\JJ\1740|which|was|h|administration|and|abolished (r_acl:relcl) hypotension_27\NN\14057371|a|potent|hg|,|maximal
D012701_D007022 NONE serotonin_15\NN\14807737| (r_compound) projections_16\NNS\5775081|of|descending|serotonin|cord (r_nmod) lesion_11\NN\14204950|a|selective|projections (r_dobj) produce_7\VB\1617192|to|lesion (r_acl) injection_3\NN\320852|intraspinal|5,7-dht|produce (r_nsubj) affect_23\VB\126264|however|,|injection|did|not|hypotension|. (l_dobj) hypotension_25\NN\14057371|this
D012701_D007022 NONE serotonin_22\NN\14807737| (r_compound) cells_24\NNS\3080309|the|midline|serotonin|b3|medulla (r_nsubj) contribute_28\VBP\126264|that|,|cells|,|cells|action|,|projection (l_nmod) cells_10\NNS\3080309|unlike|the|ventrolateral|b3|mediate (l_acl:relcl) mediate_12\VBP\761713|which|hypotension|projections (l_dobj) hypotension_15\NN\14057371|a|methyldopa-induced
D012701_D007022 NONE serotonin_22\NN\14807737| (r_compound) cells_24\NNS\3080309|the|midline|serotonin|b3|medulla (r_nsubj) contribute_28\VBP\126264|that|,|cells|,|cells|action|,|projection (l_nmod) action_32\NN\30358|to|the|hypotensive|methyldopa (l_amod) hypotensive_31\JJ\1740|
D008750_D007022 CID methyldopa_13\NN\2721160|of (r_nmod) effect_11\NN\34213|in|hypotensive|methyldopa (l_amod) hypotensive_10\JJ\1740|
D008750_D007022 CID methyldopa_10\NN\2721160|of (r_nmod) microinjection_8\NN\1740|methyldopa|cells (r_nsubj) elicits_23\VBZ\1617192|that|microinjection|response (l_dobj) response_26\NN\11410625|a|hypotensive|mediated (l_amod) hypotensive_25\JJ\1740|
D008750_D007022 CID methyldopa_9\NN\2721160|of (r_nmod) microinjection_7\NN\1740|methyldopa|area (r_nsubj) caused_24\VBD\1617192|rats|,|microinjection|hypotension|. (l_dobj) hypotension_27\NN\14057371|a|potent|hg|,|maximal
D008750_D007022 CID methyldopa-induced_14\JJ\1740| (r_amod) hypotension_15\NN\14057371|a|methyldopa-induced
D008750_D007022 CID methyldopa-induced_14\JJ\1740| (r_amod) hypotension_15\NN\14057371|a|methyldopa-induced (r_dobj) mediate_12\VBP\761713|which|hypotension|projections (r_acl:relcl) cells_10\NNS\3080309|unlike|the|ventrolateral|b3|mediate (r_nmod) contribute_28\VBP\126264|that|,|cells|,|cells|action|,|projection (l_nmod) action_32\NN\30358|to|the|hypotensive|methyldopa (l_amod) hypotensive_31\JJ\1740|
D008750_D007022 CID methyldopa_34\NN\2721160|of (r_nmod) action_32\NN\30358|to|the|hypotensive|methyldopa (r_nmod) contribute_28\VBP\126264|that|,|cells|,|cells|action|,|projection (l_nmod) cells_10\NNS\3080309|unlike|the|ventrolateral|b3|mediate (l_acl:relcl) mediate_12\VBP\761713|which|hypotension|projections (l_dobj) hypotension_15\NN\14057371|a|methyldopa-induced
D008750_D007022 CID methyldopa_34\NN\2721160|of (r_nmod) action_32\NN\30358|to|the|hypotensive|methyldopa (l_amod) hypotensive_31\JJ\1740|
D008750_D006973 NONE methyldopa_9\NN\2721160|of (r_nmod) microinjection_7\NN\1740|methyldopa|area (r_nsubj) caused_24\VBD\1617192|rats|,|microinjection|hypotension|. (l_nmod) rats_5\NNS\2329401|in|hypertensive (l_amod) hypertensive_2\JJ\1740|spontaneously|stroke-prone
D008750_D020521 NONE methyldopa_9\NN\2721160|of (r_nmod) microinjection_7\NN\1740|methyldopa|area (r_nsubj) caused_24\VBD\1617192|rats|,|microinjection|hypotension|. (l_nmod) rats_5\NNS\2329401|in|hypertensive (l_amod) hypertensive_2\JJ\1740|spontaneously|stroke-prone (l_dep) stroke-prone_4\JJ\1740|,
D012701_D006973 NONE serotonin_17\NN\14807737| (r_compound) group_19\NN\2137|of|the|midline|b3|serotonin|cell|medulla (r_nmod) area_12\NN\8630985|into|the|group (r_nmod) microinjection_7\NN\1740|methyldopa|area (r_nsubj) caused_24\VBD\1617192|rats|,|microinjection|hypotension|. (l_nmod) rats_5\NNS\2329401|in|hypertensive (l_amod) hypertensive_2\JJ\1740|spontaneously|stroke-prone
D012701_D006973 NONE serotonin_49\NN\14807737| (r_compound) neurotoxin_50\NN\15034074|the|serotonin|5,7-dihydroxytryptamine (r_nsubj) injected_55\VBN\81072|by|neurotoxin|intracerebroventricularly (r_advcl) abolished_46\VBN\1740|was|injected (r_conj) maximal_37\JJ\1740|which|was|h|administration|and|abolished (r_acl:relcl) hypotension_27\NN\14057371|a|potent|hg|,|maximal (r_dobj) caused_24\VBD\1617192|rats|,|microinjection|hypotension|. (l_nmod) rats_5\NNS\2329401|in|hypertensive (l_amod) hypertensive_2\JJ\1740|spontaneously|stroke-prone
D012701_D020521 NONE serotonin_17\NN\14807737| (r_compound) group_19\NN\2137|of|the|midline|b3|serotonin|cell|medulla (r_nmod) area_12\NN\8630985|into|the|group (r_nmod) microinjection_7\NN\1740|methyldopa|area (r_nsubj) caused_24\VBD\1617192|rats|,|microinjection|hypotension|. (l_nmod) rats_5\NNS\2329401|in|hypertensive (l_amod) hypertensive_2\JJ\1740|spontaneously|stroke-prone (l_dep) stroke-prone_4\JJ\1740|,
D012701_D020521 NONE serotonin_49\NN\14807737| (r_compound) neurotoxin_50\NN\15034074|the|serotonin|5,7-dihydroxytryptamine (r_nsubj) injected_55\VBN\81072|by|neurotoxin|intracerebroventricularly (r_advcl) abolished_46\VBN\1740|was|injected (r_conj) maximal_37\JJ\1740|which|was|h|administration|and|abolished (r_acl:relcl) hypotension_27\NN\14057371|a|potent|hg|,|maximal (r_dobj) caused_24\VBD\1617192|rats|,|microinjection|hypotension|. (l_nmod) rats_5\NNS\2329401|in|hypertensive (l_amod) hypertensive_2\JJ\1740|spontaneously|stroke-prone (l_dep) stroke-prone_4\JJ\1740|,
D015116_D006973 NONE 5,7-dihydroxytryptamine_51\NN\1740|5,7-dht (r_dep) neurotoxin_50\NN\15034074|the|serotonin|5,7-dihydroxytryptamine (r_nsubj) injected_55\VBN\81072|by|neurotoxin|intracerebroventricularly (r_advcl) abolished_46\VBN\1740|was|injected (r_conj) maximal_37\JJ\1740|which|was|h|administration|and|abolished (r_acl:relcl) hypotension_27\NN\14057371|a|potent|hg|,|maximal (r_dobj) caused_24\VBD\1617192|rats|,|microinjection|hypotension|. (l_nmod) rats_5\NNS\2329401|in|hypertensive (l_amod) hypertensive_2\JJ\1740|spontaneously|stroke-prone
D015116_D006973 NONE 5,7-dht_53\NN\1740|(|) (r_appos) 5,7-dihydroxytryptamine_51\NN\1740|5,7-dht (r_dep) neurotoxin_50\NN\15034074|the|serotonin|5,7-dihydroxytryptamine (r_nsubj) injected_55\VBN\81072|by|neurotoxin|intracerebroventricularly (r_advcl) abolished_46\VBN\1740|was|injected (r_conj) maximal_37\JJ\1740|which|was|h|administration|and|abolished (r_acl:relcl) hypotension_27\NN\14057371|a|potent|hg|,|maximal (r_dobj) caused_24\VBD\1617192|rats|,|microinjection|hypotension|. (l_nmod) rats_5\NNS\2329401|in|hypertensive (l_amod) hypertensive_2\JJ\1740|spontaneously|stroke-prone
D015116_D020521 NONE 5,7-dihydroxytryptamine_51\NN\1740|5,7-dht (r_dep) neurotoxin_50\NN\15034074|the|serotonin|5,7-dihydroxytryptamine (r_nsubj) injected_55\VBN\81072|by|neurotoxin|intracerebroventricularly (r_advcl) abolished_46\VBN\1740|was|injected (r_conj) maximal_37\JJ\1740|which|was|h|administration|and|abolished (r_acl:relcl) hypotension_27\NN\14057371|a|potent|hg|,|maximal (r_dobj) caused_24\VBD\1617192|rats|,|microinjection|hypotension|. (l_nmod) rats_5\NNS\2329401|in|hypertensive (l_amod) hypertensive_2\JJ\1740|spontaneously|stroke-prone (l_dep) stroke-prone_4\JJ\1740|,
D015116_D020521 NONE 5,7-dht_53\NN\1740|(|) (r_appos) 5,7-dihydroxytryptamine_51\NN\1740|5,7-dht (r_dep) neurotoxin_50\NN\15034074|the|serotonin|5,7-dihydroxytryptamine (r_nsubj) injected_55\VBN\81072|by|neurotoxin|intracerebroventricularly (r_advcl) abolished_46\VBN\1740|was|injected (r_conj) maximal_37\JJ\1740|which|was|h|administration|and|abolished (r_acl:relcl) hypotension_27\NN\14057371|a|potent|hg|,|maximal (r_dobj) caused_24\VBD\1617192|rats|,|microinjection|hypotension|. (l_nmod) rats_5\NNS\2329401|in|hypertensive (l_amod) hypertensive_2\JJ\1740|spontaneously|stroke-prone (l_dep) stroke-prone_4\JJ\1740|,
D015116_D007022 NONE 5,7-dihydroxytryptamine_51\NN\1740|5,7-dht (r_dep) neurotoxin_50\NN\15034074|the|serotonin|5,7-dihydroxytryptamine (r_nsubj) injected_55\VBN\81072|by|neurotoxin|intracerebroventricularly (r_advcl) abolished_46\VBN\1740|was|injected (r_conj) maximal_37\JJ\1740|which|was|h|administration|and|abolished (r_acl:relcl) hypotension_27\NN\14057371|a|potent|hg|,|maximal
D015116_D007022 NONE 5,7-dht_53\NN\1740|(|) (r_appos) 5,7-dihydroxytryptamine_51\NN\1740|5,7-dht (r_dep) neurotoxin_50\NN\15034074|the|serotonin|5,7-dihydroxytryptamine (r_nsubj) injected_55\VBN\81072|by|neurotoxin|intracerebroventricularly (r_advcl) abolished_46\VBN\1740|was|injected (r_conj) maximal_37\JJ\1740|which|was|h|administration|and|abolished (r_acl:relcl) hypotension_27\NN\14057371|a|potent|hg|,|maximal
D015116_D007022 NONE 5,7-dht_5\NN\1740|of (r_nmod) injection_3\NN\320852|intraspinal|5,7-dht|produce (r_nsubj) affect_23\VB\126264|however|,|injection|did|not|hypotension|. (l_dobj) hypotension_25\NN\14057371|this
20331935
D018967_D006966 CID risperidone-induced_14\JJ\1740| (r_amod) hyperprolactinemia_15\NN\1740|of|risperidone-induced
D018967_D006966 CID risperidone_18\NN\1740|with (r_nmod) treated_16\VBN\2376958|risperidone|mean (r_acl) boys_10\NNS\9624168|of|83|=|treated (r_nmod) %_7\NN\1740|in|49|boys (r_nmod) present_4\JJ\1740|hyperprolactinemia|was|%|. (l_nsubj) hyperprolactinemia_2\NN\1740|
D018967_D006966 CID risperidone_8\NN\1740|and|ssris (r_nsubjpass) started_12\VBN\2009433|after|risperidone|were (r_advcl) occurred_6\VBD\2623529|fractures|,|3|started|,|and|occurred (l_conj) occurred_16\VBD\2623529|none|patients|. (l_nmod) patients_18\NNS\9898892|in|hyperprolactinemia (l_nmod) hyperprolactinemia_20\NN\1740|with
D018967_D006966 CID risperidone-induced_9\JJ\1740| (r_amod) hyperprolactinemia_10\NN\1740|risperidone-induced|and|treatment
D013739_D006966 NONE testosterone_1\NN\14747587| (r_compound) concentration_2\NN\4916342|serum|testosterone (r_nsubj) increased_3\VBD\169651|concentration|status|but|affected|. (l_conj) affected_10\VBN\126264|was|not|hyperprolactinemia (l_nmod) hyperprolactinemia_12\NN\1740|by
D018967_D050723 NONE risperidone_8\NN\1740|and|ssris (r_nsubjpass) started_12\VBN\2009433|after|risperidone|were (r_advcl) occurred_6\VBD\2623529|fractures|,|3|started|,|and|occurred (l_nmod) fractures_3\NNS\14285662|of|13|documented
15075188
D011692_D009404 CID aminonucleoside-induced_11\JJ\1740| (r_amod) syndrome_13\NN\5870365|in|puromycin|aminonucleoside-induced|nephrotic|rats
D011692_D009404 CID pan-induced_38\JJ\1740| (r_amod) syndrome_40\NN\5870365|with|pan-induced|nephrotic
D012964_D009404 NONE sodium_6\NN\14625458| (r_compound) retention_7\NN\809465|by|sodium|and|edema (r_nmod) accompanied_4\VBN\1835496|syndrome|is|often|retention|. (l_nsubjpass) syndrome_1\NN\5870365|nephrotic
D012964_D009404 NONE sodium_34\NN\14625458| (r_compound) retention_35\NN\809465|in|the|sodium|associated (l_acl) associated_36\VBN\628491|syndrome (l_nmod) syndrome_40\NN\5870365|with|pan-induced|nephrotic
D012964_D004487 NONE sodium_6\NN\14625458| (r_compound) retention_7\NN\809465|by|sodium|and|edema (l_conj) edema_10\NN\14315192|generalized
D011692_D011507 CID pan_4\NN\3101986| (r_compound) treatment_5\NN\654885|pan (r_nsubj) induced_6\VBD\1627355|days|,|treatment|proteinuria|. (l_dobj) proteinuria_8\NN\14299637|significant|,|hypoalbuminemia|,|excretion|,|and|ascites
D011692_D034141 CID pan_4\NN\3101986| (r_compound) treatment_5\NN\654885|pan (r_nsubj) induced_6\VBD\1627355|days|,|treatment|proteinuria|. (l_dobj) proteinuria_8\NN\14299637|significant|,|hypoalbuminemia|,|excretion|,|and|ascites (l_conj) hypoalbuminemia_10\NN\1740|
D011692_D001201 CID pan_4\NN\3101986| (r_compound) treatment_5\NN\654885|pan (r_nsubj) induced_6\VBD\1627355|days|,|treatment|proteinuria|. (l_dobj) proteinuria_8\NN\14299637|significant|,|hypoalbuminemia|,|excretion|,|and|ascites (l_conj) ascites_19\NN\14204950|extensive
D012964_D011507 NONE sodium_14\NN\14625458| (r_compound) excretion_15\NN\13466586|decreased|urinary|sodium (r_conj) proteinuria_8\NN\14299637|significant|,|hypoalbuminemia|,|excretion|,|and|ascites
D012964_D034141 NONE sodium_14\NN\14625458| (r_compound) excretion_15\NN\13466586|decreased|urinary|sodium (r_conj) proteinuria_8\NN\14299637|significant|,|hypoalbuminemia|,|excretion|,|and|ascites (l_conj) hypoalbuminemia_10\NN\1740|
D012964_D001201 NONE sodium_14\NN\14625458| (r_compound) excretion_15\NN\13466586|decreased|urinary|sodium (r_conj) proteinuria_8\NN\14299637|significant|,|hypoalbuminemia|,|excretion|,|and|ascites (l_conj) ascites_19\NN\14204950|extensive
7880714
7710775
D008315_D002545 CID malondialdehyde_4\NN\1740|of|plasma|,|oxypurines (r_nmod) dependence_1\NN\24720|time|malondialdehyde|ischemia|. (l_nmod) ischemia_13\NN\14195315|during|incomplete|cerebral|rat
-1_D002545 NONE oxypurines_6\NNS\1740|,|and|nucleosides (r_conj) malondialdehyde_4\NN\1740|of|plasma|,|oxypurines (r_nmod) dependence_1\NN\24720|time|malondialdehyde|ischemia|. (l_nmod) ischemia_13\NN\14195315|during|incomplete|cerebral|rat
D009705_D002545 NONE nucleosides_9\NNS\14887305| (r_conj) oxypurines_6\NNS\1740|,|and|nucleosides (r_conj) malondialdehyde_4\NN\1740|of|plasma|,|oxypurines (r_nmod) dependence_1\NN\24720|time|malondialdehyde|ischemia|. (l_nmod) ischemia_13\NN\14195315|during|incomplete|cerebral|rat
-1_D007511 NONE oxypurines_8\NNS\1740|of|plasma|and|nucleosides (r_nmod) increase_5\NN\13576355|a|time-dependent|oxypurines (r_nsubjpass) observed_12\VBN\2163746|ischemia|,|increase|was|. (l_nmod) ischemia_1\NN\14195315|during
-1_D007511 NONE oxypurines_10\NNS\1740| (r_conj) malondialdehyde_8\NN\1740|of|,|oxypurines|,|and|nucleosides|blood (r_nmod) determination_6\NN\43195|the|malondialdehyde|, (r_nsubjpass) used_20\VBN\1156834|that|determination|may|be|monitor (l_xcomp) monitor_22\VB\2169352|to|alterations (l_dobj) alterations_25\NNS\7283608|the|metabolic|tissues (l_nmod) tissues_27\NNS\5220461|of|occurring (l_acl) occurring_28\VBG\2623529|phenomena (l_nmod) phenomena_31\NNS\29677|during|ischemic (l_amod) ischemic_30\JJ\1740|
D009705_D007511 NONE nucleosides_10\NNS\14887305| (r_conj) oxypurines_8\NNS\1740|of|plasma|and|nucleosides (r_nmod) increase_5\NN\13576355|a|time-dependent|oxypurines (r_nsubjpass) observed_12\VBN\2163746|ischemia|,|increase|was|. (l_nmod) ischemia_1\NN\14195315|during
D009705_D007511 NONE nucleosides_13\NNS\14887305| (r_conj) malondialdehyde_8\NN\1740|of|,|oxypurines|,|and|nucleosides|blood (r_nmod) determination_6\NN\43195|the|malondialdehyde|, (r_nsubjpass) used_20\VBN\1156834|that|determination|may|be|monitor (l_xcomp) monitor_22\VB\2169352|to|alterations (l_dobj) alterations_25\NNS\7283608|the|metabolic|tissues (l_nmod) tissues_27\NNS\5220461|of|occurring (l_acl) occurring_28\VBG\2623529|phenomena (l_nmod) phenomena_31\NNS\29677|during|ischemic (l_amod) ischemic_30\JJ\1740|
D008315_D007511 NONE malondialdehyde_1\NN\1740|plasma|,|present|, (r_nsubj) increased_21\VBD\169651|malondialdehyde|min|,|resulting|. (l_nmod) min_24\NN\15154774|after|5|ischemia (l_nmod) ischemia_26\NN\14195315|of
D008315_D007511 NONE malondialdehyde_2\NN\1740|increased|plasma (r_nsubjpass) recorded_5\VBN\2225492|malondialdehyde|was|also|groups|,|higher|. (l_nmod) groups_9\NNS\2137|in|two|other|animals|,|one (l_appos) one_19\CD\13741022|receiving|,|other (l_acl) receiving_20\VBG\2210855|.|intravenously|ischemia (l_nmod) ischemia_33\NN\14195315|immediately|before
D008315_D007511 NONE malondialdehyde_2\NN\1740|increased|plasma (r_nsubjpass) recorded_5\VBN\2225492|malondialdehyde|was|also|groups|,|higher|. (l_nmod) groups_9\NNS\2137|in|two|other|animals|,|one (l_appos) one_19\CD\13741022|receiving|,|other (l_appos) other_36\JJ\1740|the|receiving (l_acl) receiving_37\VBG\2210855|.|rate|intravenously|ischemia (l_nmod) ischemia_56\NN\14195315|during
D008315_D007511 NONE malondialdehyde_63\NN\1740| (r_nsubj) higher_66\JJR\1740|although|group|malondialdehyde|was|significantly (r_advcl) recorded_5\VBN\2225492|malondialdehyde|was|also|groups|,|higher|. (l_nmod) groups_9\NNS\2137|in|two|other|animals|,|one (l_appos) one_19\CD\13741022|receiving|,|other (l_acl) receiving_20\VBG\2210855|.|intravenously|ischemia (l_nmod) ischemia_33\NN\14195315|immediately|before
D008315_D007511 NONE malondialdehyde_63\NN\1740| (r_nsubj) higher_66\JJR\1740|although|group|malondialdehyde|was|significantly (r_advcl) recorded_5\VBN\2225492|malondialdehyde|was|also|groups|,|higher|. (l_nmod) groups_9\NNS\2137|in|two|other|animals|,|one (l_appos) one_19\CD\13741022|receiving|,|other (l_appos) other_36\JJ\1740|the|receiving (l_acl) receiving_37\VBG\2210855|.|rate|intravenously|ischemia (l_nmod) ischemia_56\NN\14195315|during
D008315_D007511 NONE malondialdehyde_8\NN\1740|of|,|oxypurines|,|and|nucleosides|blood (r_nmod) determination_6\NN\43195|the|malondialdehyde|, (r_nsubjpass) used_20\VBN\1156834|that|determination|may|be|monitor (l_xcomp) monitor_22\VB\2169352|to|alterations (l_dobj) alterations_25\NNS\7283608|the|metabolic|tissues (l_nmod) tissues_27\NNS\5220461|of|occurring (l_acl) occurring_28\VBG\2623529|phenomena (l_nmod) phenomena_31\NNS\29677|during|ischemic (l_amod) ischemic_30\JJ\1740|
D008315_D007022 NONE malondialdehyde_2\NN\1740|increased|plasma (r_nsubjpass) recorded_5\VBN\2225492|malondialdehyde|was|also|groups|,|higher|. (l_nmod) groups_9\NNS\2137|in|two|other|animals|,|one (l_appos) one_19\CD\13741022|receiving|,|other (l_appos) other_36\JJ\1740|the|receiving (l_acl) receiving_37\VBG\2210855|.|rate|intravenously|ischemia (l_dobj) ._41\NN\1740|b.w|nitroprusside (l_nmod) nitroprusside_46\NN\1740|of|the|hypotensive|drug (l_amod) hypotensive_44\JJ\1740|
D008315_D007022 NONE malondialdehyde_63\NN\1740| (r_nsubj) higher_66\JJR\1740|although|group|malondialdehyde|was|significantly (r_advcl) recorded_5\VBN\2225492|malondialdehyde|was|also|groups|,|higher|. (l_nmod) groups_9\NNS\2137|in|two|other|animals|,|one (l_appos) one_19\CD\13741022|receiving|,|other (l_appos) other_36\JJ\1740|the|receiving (l_acl) receiving_37\VBG\2210855|.|rate|intravenously|ischemia (l_dobj) ._41\NN\1740|b.w|nitroprusside (l_nmod) nitroprusside_46\NN\1740|of|the|hypotensive|drug (l_amod) hypotensive_44\JJ\1740|
D001241_D007511 NONE acetylsalicylate_29\NN\1740|of|the|cyclooxygenase|inhibitor (r_nmod) ._24\NN\1740|b.w|acetylsalicylate (r_dobj) receiving_20\VBG\2210855|.|intravenously|ischemia (l_nmod) ischemia_33\NN\14195315|immediately|before
D001241_D007511 NONE acetylsalicylate_29\NN\1740|of|the|cyclooxygenase|inhibitor (r_nmod) ._24\NN\1740|b.w|acetylsalicylate (r_dobj) receiving_20\VBG\2210855|.|intravenously|ischemia (r_acl) one_19\CD\13741022|receiving|,|other (l_appos) other_36\JJ\1740|the|receiving (l_acl) receiving_37\VBG\2210855|.|rate|intravenously|ischemia (l_nmod) ischemia_56\NN\14195315|during
D001241_D007022 NONE acetylsalicylate_29\NN\1740|of|the|cyclooxygenase|inhibitor (r_nmod) ._24\NN\1740|b.w|acetylsalicylate (r_dobj) receiving_20\VBG\2210855|.|intravenously|ischemia (r_acl) one_19\CD\13741022|receiving|,|other (l_appos) other_36\JJ\1740|the|receiving (l_acl) receiving_37\VBG\2210855|.|rate|intravenously|ischemia (l_dobj) ._41\NN\1740|b.w|nitroprusside (l_nmod) nitroprusside_46\NN\1740|of|the|hypotensive|drug (l_amod) hypotensive_44\JJ\1740|
D009599_D007511 NONE nitroprusside_46\NN\1740|of|the|hypotensive|drug (r_nmod) ._41\NN\1740|b.w|nitroprusside (r_dobj) receiving_37\VBG\2210855|.|rate|intravenously|ischemia (r_acl) other_36\JJ\1740|the|receiving (r_appos) one_19\CD\13741022|receiving|,|other (l_acl) receiving_20\VBG\2210855|.|intravenously|ischemia (l_nmod) ischemia_33\NN\14195315|immediately|before
D009599_D007511 NONE nitroprusside_46\NN\1740|of|the|hypotensive|drug (r_nmod) ._41\NN\1740|b.w|nitroprusside (r_dobj) receiving_37\VBG\2210855|.|rate|intravenously|ischemia (l_nmod) ischemia_56\NN\14195315|during
D009599_D007022 NONE nitroprusside_46\NN\1740|of|the|hypotensive|drug (l_amod) hypotensive_44\JJ\1740|
6415512
D002220_D004831 CID carbamazepine_10\NN\1740| (r_compound) therapy_11\NN\657604|of|carbamazepine (r_nmod) institution_8\NN\8008335|following|therapy|children (r_nmod) seizures_6\NNS\14081375|myoclonic|institution|.
D002220_D004831 CID carbamazepine_11\NN\1740|with|epilepsy (r_nmod) treated_9\VBN\2376958|carbamazepine (r_acl) children_1\NNS\9622049|five|,|aged|,|treated|, (r_nsubj) had_15\VBD\2108377|children|reaction|. (l_dobj) reaction_19\NN\13446390|an|acute|aberrant|characterized (l_acl) characterized_20\VBN\609683|onset (l_nmod) onset_23\NN\7325190|by|the|absence|days (l_nmod) absence_28\NN\14449405|of|myoclonic|and/or|seizures (l_conj) seizures_35\NNS\14081375|atonic|motor
D002220_D004832 CID carbamazepine_10\NN\1740| (r_compound) therapy_11\NN\657604|of|carbamazepine (r_nmod) institution_8\NN\8008335|following|therapy|children (r_nmod) seizures_6\NNS\14081375|myoclonic|institution|.
D002220_D004832 CID carbamazepine_11\NN\1740|with|epilepsy (r_nmod) treated_9\VBN\2376958|carbamazepine (r_acl) children_1\NNS\9622049|five|,|aged|,|treated|, (r_nsubj) had_15\VBD\2108377|children|reaction|. (l_dobj) reaction_19\NN\13446390|an|acute|aberrant|characterized (l_acl) characterized_20\VBN\609683|onset (l_nmod) onset_23\NN\7325190|by|the|absence|days (l_nmod) absence_28\NN\14449405|of|myoclonic|and/or|seizures (l_conj) seizures_35\NNS\14081375|atonic|motor
D002220_D004827 NONE carbamazepine_11\NN\1740|with|epilepsy (l_nmod) epilepsy_13\NN\14085708|for
D002220_D012640 NONE carbamazepine_2\NN\1740|the (r_nsubjpass) discontinued_4\VBN\2609764|when|carbamazepine|was (r_advcl) returned_10\VBD\1835496|discontinued|,|two|state|quickly|,|had (l_conj) had_19\VBD\2108377|two|resolve|,|and|had (l_ccomp) resolve_24\VB\352826|seizures|months (l_nsubj) seizures_23\NNS\14081375|the|minor|motor
D002220_D012640 NONE carbamazepine_2\NN\1740|the (r_nsubjpass) discontinued_4\VBN\2609764|when|carbamazepine|was (r_advcl) returned_10\VBD\1835496|discontinued|,|two|state|quickly|,|had (l_conj) had_19\VBD\2108377|two|resolve|,|and|had (l_conj) had_33\VBD\2108377|one|persist|. (l_ccomp) persist_36\VB\118523|seizures (l_nsubj) seizures_35\NNS\14081375|the
11195262
D014635_D007177 CID valproate_3\NN\1740|of|sodium (r_nmod) contribution_0\NN\786195|valproate|syndrome|. (l_nmod) syndrome_6\NN\5870365|to|the|secretion (l_nmod) secretion_9\NN\13526110|of|inappropriate|hormone (l_nmod) hormone_12\NN\5404728|of|antidiuretic
D014635_D007177 CID valproate_12\NN\1740|sodium|vpa (r_dobj) administered_10\VBN\2436349|who|was|valproate|and|developed (l_conj) developed_19\VBD\1753788|who|subsequently|syndrome (l_dobj) syndrome_21\NN\5870365|the|secretion (l_nmod) secretion_24\NN\13526110|of|inappropriate|hormone (l_nmod) hormone_27\NN\5404728|of|antidiuretic|siadh
D014635_D007177 CID valproate_12\NN\1740|sodium|vpa (r_dobj) administered_10\VBN\2436349|who|was|valproate|and|developed (l_conj) developed_19\VBD\1753788|who|subsequently|syndrome (l_dobj) syndrome_21\NN\5870365|the|secretion (l_nmod) secretion_24\NN\13526110|of|inappropriate|hormone (l_nmod) hormone_27\NN\5404728|of|antidiuretic|siadh (l_appos) siadh_29\NN\1740|(|)
D014635_D007177 CID vpa_14\NN\1740|(|) (r_appos) valproate_12\NN\1740|sodium|vpa (r_dobj) administered_10\VBN\2436349|who|was|valproate|and|developed (l_conj) developed_19\VBD\1753788|who|subsequently|syndrome (l_dobj) syndrome_21\NN\5870365|the|secretion (l_nmod) secretion_24\NN\13526110|of|inappropriate|hormone (l_nmod) hormone_27\NN\5404728|of|antidiuretic|siadh
D014635_D007177 CID vpa_14\NN\1740|(|) (r_appos) valproate_12\NN\1740|sodium|vpa (r_dobj) administered_10\VBN\2436349|who|was|valproate|and|developed (l_conj) developed_19\VBD\1753788|who|subsequently|syndrome (l_dobj) syndrome_21\NN\5870365|the|secretion (l_nmod) secretion_24\NN\13526110|of|inappropriate|hormone (l_nmod) hormone_27\NN\5404728|of|antidiuretic|siadh (l_appos) siadh_29\NN\1740|(|)
D014635_D007177 CID vpa_28\NN\1740|of (r_nmod) administration_26\NN\1133281|the|long-term|vpa (r_conj) weakness_17\NN\14462666|including|a|system|and|administration (r_nmod) factors_14\NNS\7326557|of|weakness (r_nmod) combination_12\NN\7951464|of|a|factors (r_nmod) result_9\NN\34213|episode|to|be|the|combination (l_nsubj) episode_3\NN\7283608|this|siadh (l_nmod) siadh_5\NN\1740|of
D014635_D004830 NONE vpa_4\NN\1740| (r_dobj) taking_3\VBG\2367363|he|had|been|vpa|treatment|old|. (l_nmod) treatment_6\NN\654885|for|convulsions (l_nmod) convulsions_11\NNS\14081375|of|idiopathic|generalized|tonic-clonic
D014635_D002493 NONE vpa_28\NN\1740|of (r_nmod) administration_26\NN\1133281|the|long-term|vpa (r_conj) weakness_17\NN\14462666|including|a|system|and|administration (l_nmod) system_22\NN\3575240|of|the|central|nervous
18627295
D004317_D009202 CID doxorubicin_0\NN\2716866| (r_nmod:npmod) cardiomyopathy-induced_1\JJ\1740|doxorubicin
D004317_D009202 CID dox_17\NN\1740| (r_compound) cardiomyopathy_18\NN\14103288|of|dox
D004317_D009202 CID dox_17\NN\1740| (r_compound) cardiomyopathy_18\NN\14103288|of|dox (r_nmod) development_15\NN\248977|during|the|cardiomyopathy (r_nmod) role_4\NN\719494|the|possible|receptor|development (r_dobj) elucidate_1\VB\939277|to|role (r_advcl) studied_21\VBD\630380|elucidate|,|we|mice|investigating|. (l_advcl) investigating_30\VBG\644583|by|inflammation (l_dobj) inflammation_32\NN\14299637|cardiac|and|apoptosis|induction (l_nmod) induction_36\NN\7450842|after|cardiomyopathy (l_nmod) cardiomyopathy_39\NN\14103288|of|dox-induced
D004317_D009202 CID dox-induced_38\JJ\1740| (r_amod) cardiomyopathy_39\NN\14103288|of|dox-induced (r_nmod) induction_36\NN\7450842|after|cardiomyopathy (r_nmod) inflammation_32\NN\14299637|cardiac|and|apoptosis|induction (r_dobj) investigating_30\VBG\644583|by|inflammation (r_advcl) studied_21\VBD\630380|elucidate|,|we|mice|investigating|. (l_advcl) elucidate_1\VB\939277|to|role (l_dobj) role_4\NN\719494|the|possible|receptor|development (l_nmod) development_15\NN\248977|during|the|cardiomyopathy (l_nmod) cardiomyopathy_18\NN\14103288|of|dox
D004317_D009202 CID dox-induced_38\JJ\1740| (r_amod) cardiomyopathy_39\NN\14103288|of|dox-induced
D004317_D009202 CID dox_8\NN\1740| (r_compound) cardiomyopathy_9\NN\14103288|in|dox
D004317_D009202 CID dox_16\NN\1740| (r_compound) cardiomyopathy_17\NN\14103288|of|human|dox
D004317_D007249 NONE doxorubicin_0\NN\2716866| (r_nmod:npmod) cardiomyopathy-induced_1\JJ\1740|doxorubicin (r_amod) inflammation_2\NN\14299637|cardiomyopathy-induced|and|apoptosis
D004317_D007249 NONE dox_17\NN\1740| (r_compound) cardiomyopathy_18\NN\14103288|of|dox (r_nmod) development_15\NN\248977|during|the|cardiomyopathy (r_nmod) role_4\NN\719494|the|possible|receptor|development (r_dobj) elucidate_1\VB\939277|to|role (r_advcl) studied_21\VBD\630380|elucidate|,|we|mice|investigating|. (l_advcl) investigating_30\VBG\644583|by|inflammation (l_dobj) inflammation_32\NN\14299637|cardiac|and|apoptosis|induction
D004317_D007249 NONE dox-induced_38\JJ\1740| (r_amod) cardiomyopathy_39\NN\14103288|of|dox-induced (r_nmod) induction_36\NN\7450842|after|cardiomyopathy (r_nmod) inflammation_32\NN\14299637|cardiac|and|apoptosis|induction
D018943_D066126 NONE anthracycline_4\NN\1740| (r_compound) doxorubicin_5\NN\2716866|of|the|anthracycline|dox (r_nmod) use_1\NN\407535|clinical|doxorubicin (r_nsubjpass) limited_10\VBN\2510337|use|is|effects|. (l_nmod) effects_14\NNS\13245626|by|its|cardiotoxic|,|attributed (l_amod) cardiotoxic_13\JJ\1740|
D004317_D066126 NONE doxorubicin_5\NN\2716866|of|the|anthracycline|dox (r_nmod) use_1\NN\407535|clinical|doxorubicin (r_nsubjpass) limited_10\VBN\2510337|use|is|effects|. (l_nmod) effects_14\NNS\13245626|by|its|cardiotoxic|,|attributed (l_amod) cardiotoxic_13\JJ\1740|
D004317_D066126 NONE dox_7\NN\1740|(|) (r_appos) doxorubicin_5\NN\2716866|of|the|anthracycline|dox (r_nmod) use_1\NN\407535|clinical|doxorubicin (r_nsubjpass) limited_10\VBN\2510337|use|is|effects|. (l_nmod) effects_14\NNS\13245626|by|its|cardiotoxic|,|attributed (l_amod) cardiotoxic_13\JJ\1740|
D004317_D006331 NONE dox_0\NN\1740| (r_compound) mice_2\NNS\2329401|dox|control (r_nsubj) showed_3\VBD\2137132|mice|dysfunction|. (l_dobj) dysfunction_5\NN\14204950|cardiac|measured
D004317_D006331 NONE dox_1\NN\1740| (r_compound) mice_4\NNS\2329401|in|dox|b1r(-/- (r_nmod) improved_9\VBN\126264|mice|,|dysfunction|was|mice|associated|. (l_nsubjpass) dysfunction_7\NN\14204950|cardiac
D004317_D006331 NONE dox_12\NN\1740| (r_compound) mice_14\NNS\2329401|compared|to|dox|control|, (r_advcl) improved_9\VBN\126264|mice|,|dysfunction|was|mice|associated|. (l_nsubjpass) dysfunction_7\NN\14204950|cardiac
9228650
C049860_D000647 CID nik-247_2\NNP\1740|of (r_nmod) effects_0\NNS\13245626|nik-247|amnesia|. (l_nmod) amnesia_7\NN\5669934|on|cholinesterase
C049860_D000647 CID nik-247_3\NN\1740|of (r_nmod) effects_1\NNS\13245626|the|nik-247|cholinesterase (l_nmod) cholinesterase_5\NN\14732946|on|,|amnesia|and|movement (l_conj) amnesia_8\NN\5669934|scopolamine-induced
C049860_D000647 CID nik-247_4\NN\1740|dose (r_nsubj) improves_16\VBZ\126264|that|nik-247|amnesia|but|affect (l_dobj) amnesia_18\NN\5669934|scopolamine-induced
D012601_D000647 CID scopolamine-induced_6\JJ\1740| (r_conj) cholinesterase_4\NN\14732946|and|scopolamine-induced (r_compound) amnesia_7\NN\5669934|on|cholinesterase
D012601_D000647 CID scopolamine-induced_7\JJ\1740| (r_amod) amnesia_8\NN\5669934|scopolamine-induced
D012601_D000647 CID scopolamine_14\NN\14712692|by|mg/kg (r_nmod) induced_12\VBN\1627355|scopolamine (r_acl) amnesia_11\NN\5669934|the|induced|rats
D012601_D000647 CID scopolamine-induced_17\JJ\1740| (r_amod) amnesia_18\NN\5669934|scopolamine-induced
D013619_D000647 CID tacrine_23\NN\1740|and|e-2020 (r_dep) inhibitors_22\NNS\20090|of|the|well-known|cholinesterase|tacrine (r_nmod) those_17\DT\1740|with|inhibitors (r_nmod) compared_15\VBN\644583|those (r_conj) examined_13\VBN\789138|effects|were|and|compared|. (l_nsubjpass) effects_1\NNS\13245626|the|nik-247|cholinesterase (l_nmod) cholinesterase_5\NN\14732946|on|,|amnesia|and|movement (l_conj) amnesia_8\NN\5669934|scopolamine-induced
C076946_D000647 CID e-2020_25\NN\1740| (r_conj) tacrine_23\NN\1740|and|e-2020 (r_dep) inhibitors_22\NNS\20090|of|the|well-known|cholinesterase|tacrine (r_nmod) those_17\DT\1740|with|inhibitors (r_nmod) compared_15\VBN\644583|those (r_conj) examined_13\VBN\789138|effects|were|and|compared|. (l_nsubjpass) effects_1\NNS\13245626|the|nik-247|cholinesterase (l_nmod) cholinesterase_5\NN\14732946|on|,|amnesia|and|movement (l_conj) amnesia_8\NN\5669934|scopolamine-induced
C049860_D000544 NONE nik-247_4\NN\1740| (r_nsubj) drug_9\NN\14778436|that|nik-247|may|be|a|useful|treatment (l_nmod) treatment_12\NN\654885|for|the|disease (l_nmod) disease_16\NN\14061805|of|alzheimer|'s
9121607
D013256_D012640 NONE steroids_1\NNS\14727670|neuroactive (r_nsubj) protect_2\VBP\1127795|steroids|seizures|. (l_nmod) seizures_9\NNS\14081375|against|pilocarpine-|limbic|and|epilepticus
D013256_D012640 NONE steroids_0\NNS\14727670|group (r_nsubj) effective_17\JJ\1740|steroids|were|highly|protecting|. (l_advcl) protecting_19\VBG\1127795|in|seizures|values (l_nmod) seizures_29\NNS\14081375|against|pilocarpine|limbic|motor|and|epilepticus
D013256_D012640 NONE steroids_3\NNS\14727670|the|neuroactive (r_nsubj) potent_7\JJ\1740|although|steroids|were|less|clonazepam|protecting (l_advcl) protecting_13\VBG\1127795|in|seizures (l_nmod) seizures_16\NNS\14081375|against|pilocarpine
D013256_D012640 NONE steroids_3\NNS\14727670|the|neuroactive (r_nsubj) potent_7\JJ\1740|although|steroids|were|less|clonazepam|protecting (r_advcl) had_24\VBD\2108377|potent|,|steroids|values|clonazepam|,|indicating|. (l_dobj) values_30\NNS\5941423|comparable|protective|index|td50 (l_dep) td50_32\NN\1740|(|impairment|divided|) (l_acl) divided_36\VBN\140123|ed50 (l_nmod) ed50_38\NN\1740|by|protection (l_nmod) protection_41\NN\407535|for|seizure (l_compound) seizure_40\NN\14081375|
D013256_D012640 NONE steroids_18\NNS\14727670|alpha-configuration (r_nsubj) had_24\VBD\2108377|potent|,|steroids|values|clonazepam|,|indicating|. (l_advcl) potent_7\JJ\1740|although|steroids|were|less|clonazepam|protecting (l_advcl) protecting_13\VBG\1127795|in|seizures (l_nmod) seizures_16\NNS\14081375|against|pilocarpine
D013256_D012640 NONE steroids_18\NNS\14727670|alpha-configuration (r_nsubj) had_24\VBD\2108377|potent|,|steroids|values|clonazepam|,|indicating|. (l_dobj) values_30\NNS\5941423|comparable|protective|index|td50 (l_dep) td50_32\NN\1740|(|impairment|divided|) (l_acl) divided_36\VBN\140123|ed50 (l_nmod) ed50_38\NN\1740|by|protection (l_nmod) protection_41\NN\407535|for|seizure (l_compound) seizure_40\NN\14081375|
D013256_D012640 NONE steroids_50\NNS\14727670|some|neuroactive (r_nsubj) have_52\VB\2108377|that|steroids|may|toxicity (r_ccomp) indicating_46\VBG\952524|have (r_advcl) had_24\VBD\2108377|potent|,|steroids|values|clonazepam|,|indicating|. (l_advcl) potent_7\JJ\1740|although|steroids|were|less|clonazepam|protecting (l_advcl) protecting_13\VBG\1127795|in|seizures (l_nmod) seizures_16\NNS\14081375|against|pilocarpine
D013256_D012640 NONE steroids_50\NNS\14727670|some|neuroactive (r_nsubj) have_52\VB\2108377|that|steroids|may|toxicity (r_ccomp) indicating_46\VBG\952524|have (r_advcl) had_24\VBD\2108377|potent|,|steroids|values|clonazepam|,|indicating|. (l_dobj) values_30\NNS\5941423|comparable|protective|index|td50 (l_dep) td50_32\NN\1740|(|impairment|divided|) (l_acl) divided_36\VBN\140123|ed50 (l_nmod) ed50_38\NN\1740|by|protection (l_nmod) protection_41\NN\407535|for|seizure (l_compound) seizure_40\NN\14081375|
D013256_D012640 NONE steroids_0\NNS\14727670|alpha- (r_nsubj) produced_11\VBD\1617192|steroids|also|delay|,|but|protect|. (l_dobj) delay_14\NN\15271008|a|dose-dependent|onset (l_nmod) onset_17\NN\7325190|in|the|seizures (l_nmod) seizures_20\NNS\14081375|of|limbic|induced
D013256_D012640 NONE steroids_0\NNS\14727670|alpha- (r_nsubj) produced_11\VBD\1617192|steroids|also|delay|,|but|protect|. (l_conj) protect_36\VB\1127795|did|not|completely|seizures (l_nmod) seizures_39\NNS\14081375|against|the
D013256_D012640 NONE steroid_8\NN\14727670|of|the (r_nmod) dose_5\NN\3740161|a|second|steroid (r_nsubjpass) administered_10\VBN\2436349|when|dose|was|dose (r_advcl) obtained_30\VBN\2210855|however|,|administered|,|protection|was|. (l_nsubjpass) protection_19\NN\407535|complete|seizures (l_nmod) seizures_25\NNS\14081375|from|the|acid-induced|limbic|and|epilepticus
D013256_D012640 NONE steroids_1\NNS\14727670|the (r_nsubj) caused_3\VBD\1617192|steroids|also|delay|,|but|protect|. (l_conj) protect_20\VB\1127795|did|not|completely|seizures (l_nmod) seizures_23\NNS\14081375|against|nmda|or|lethality
D013256_D012640 NONE steroids_4\NNS\14727670|neuroactive (r_nsubj) effective_7\JJ\1740|that|steroids|are|highly|protecting|,|and|utility (l_advcl) protecting_9\VBG\1127795|in|seizures (l_nmod) seizures_15\NNS\14081375|against|pilocarpine-|and|epilepticus
D013256_D013226 NONE steroids_1\NNS\14727670|neuroactive (r_nsubj) protect_2\VBP\1127795|steroids|seizures|. (l_nmod) seizures_9\NNS\14081375|against|pilocarpine-|limbic|and|epilepticus (l_conj) epilepticus_12\NN\1740|status|mice
D013256_D013226 NONE steroids_0\NNS\14727670|group (r_nsubj) effective_17\JJ\1740|steroids|were|highly|protecting|. (l_advcl) protecting_19\VBG\1127795|in|seizures|values (l_nmod) seizures_29\NNS\14081375|against|pilocarpine|limbic|motor|and|epilepticus (l_conj) epilepticus_32\NN\1740|status
D013256_D013226 NONE steroid_8\NN\14727670|of|the (r_nmod) dose_5\NN\3740161|a|second|steroid (r_nsubjpass) administered_10\VBN\2436349|when|dose|was|dose (r_advcl) obtained_30\VBN\2210855|however|,|administered|,|protection|was|. (l_nsubjpass) protection_19\NN\407535|complete|seizures (l_nmod) seizures_25\NNS\14081375|from|the|acid-induced|limbic|and|epilepticus (l_conj) epilepticus_28\NN\1740|status
D013256_D013226 NONE steroids_4\NNS\14727670|neuroactive (r_nsubj) effective_7\JJ\1740|that|steroids|are|highly|protecting|,|and|utility (l_advcl) protecting_9\VBG\1127795|in|seizures (l_nmod) seizures_15\NNS\14081375|against|pilocarpine-|and|epilepticus (l_conj) epilepticus_18\NN\1740|status|mice
D013256_D013226 NONE steroids_4\NNS\14727670|neuroactive (r_nsubj) effective_7\JJ\1740|that|steroids|are|highly|protecting|,|and|utility (l_conj) utility_26\NN\8186047|may|be|of|treatment (l_nmod) treatment_29\NN\654885|in|the|forms (l_nmod) forms_32\NNS\6286395|of|some|epilepticus (l_nmod) epilepticus_35\NN\1740|of|status|humans
D010862_D012640 CID pilocarpine-_4\NN\1740|and|acid-induced (r_amod) seizures_9\NNS\14081375|against|pilocarpine-|limbic|and|epilepticus
D010862_D012640 CID pilocarpine-_28\NN\1740|,|acid-|and|n-methyl-d-aspartate|(nmda)-induced (r_compound) seizures_35\NNS\14081375|against|pilocarpine-|mice
D010862_D012640 CID pilocarpine_21\NN\14712692|mg/kg|s.c.)-induced (r_compound) seizures_29\NNS\14081375|against|pilocarpine|limbic|motor|and|epilepticus
D010862_D012640 CID pilocarpine_15\NN\14712692| (r_compound) seizures_16\NNS\14081375|against|pilocarpine
D010862_D012640 CID pilocarpine_15\NN\14712692| (r_compound) seizures_16\NNS\14081375|against|pilocarpine (r_nmod) protecting_13\VBG\1127795|in|seizures (r_advcl) potent_7\JJ\1740|although|steroids|were|less|clonazepam|protecting (r_advcl) had_24\VBD\2108377|potent|,|steroids|values|clonazepam|,|indicating|. (l_dobj) values_30\NNS\5941423|comparable|protective|index|td50 (l_dep) td50_32\NN\1740|(|impairment|divided|) (l_acl) divided_36\VBN\140123|ed50 (l_nmod) ed50_38\NN\1740|by|protection (l_nmod) protection_41\NN\407535|for|seizure (l_compound) seizure_40\NN\14081375|
D010862_D012640 CID pilocarpine-_11\NN\1740|and|acid-induced (r_amod) seizures_15\NNS\14081375|against|pilocarpine-|and|epilepticus
D010862_D013226 CID pilocarpine-_4\NN\1740|and|acid-induced (r_amod) seizures_9\NNS\14081375|against|pilocarpine-|limbic|and|epilepticus (l_conj) epilepticus_12\NN\1740|status|mice
D010862_D013226 CID pilocarpine_21\NN\14712692|mg/kg|s.c.)-induced (r_compound) seizures_29\NNS\14081375|against|pilocarpine|limbic|motor|and|epilepticus (l_conj) epilepticus_32\NN\1740|status
D010862_D013226 CID pilocarpine-_11\NN\1740|and|acid-induced (r_amod) seizures_15\NNS\14081375|against|pilocarpine-|and|epilepticus (l_conj) epilepticus_18\NN\1740|status|mice
D010862_D013226 CID pilocarpine-_11\NN\1740|and|acid-induced (r_amod) seizures_15\NNS\14081375|against|pilocarpine-|and|epilepticus (r_nmod) protecting_9\VBG\1127795|in|seizures (r_advcl) effective_7\JJ\1740|that|steroids|are|highly|protecting|,|and|utility (l_conj) utility_26\NN\8186047|may|be|of|treatment (l_nmod) treatment_29\NN\654885|in|the|forms (l_nmod) forms_32\NNS\6286395|of|some|epilepticus (l_nmod) epilepticus_35\NN\1740|of|status|humans
D007608_D012640 CID acid-induced_7\JJ\1740|kainic (r_conj) pilocarpine-_4\NN\1740|and|acid-induced (r_amod) seizures_9\NNS\14081375|against|pilocarpine-|limbic|and|epilepticus
D007608_D012640 CID acid-_31\NN\1740|kainic (r_conj) pilocarpine-_28\NN\1740|,|acid-|and|n-methyl-d-aspartate|(nmda)-induced (r_compound) seizures_35\NNS\14081375|against|pilocarpine-|mice
D007608_D012640 CID acid_24\NN\14818238|by|kainic|mg/kg (r_nmod) induced_21\VBN\1627355|acid (r_acl) seizures_20\NNS\14081375|of|limbic|induced
D007608_D012640 CID acid_24\NN\14818238|by|kainic|mg/kg (r_nmod) induced_21\VBN\1627355|acid (r_acl) seizures_20\NNS\14081375|of|limbic|induced (r_nmod) onset_17\NN\7325190|in|the|seizures (r_nmod) delay_14\NN\15271008|a|dose-dependent|onset (r_dobj) produced_11\VBD\1617192|steroids|also|delay|,|but|protect|. (l_conj) protect_36\VB\1127795|did|not|completely|seizures (l_nmod) seizures_39\NNS\14081375|against|the
D007608_D012640 CID acid-induced_23\JJ\1740|kainic (r_amod) seizures_25\NNS\14081375|from|the|acid-induced|limbic|and|epilepticus
D007608_D012640 CID acid-induced_14\JJ\1740|kainic (r_conj) pilocarpine-_11\NN\1740|and|acid-induced (r_amod) seizures_15\NNS\14081375|against|pilocarpine-|and|epilepticus
D007608_D013226 CID acid-induced_7\JJ\1740|kainic (r_conj) pilocarpine-_4\NN\1740|and|acid-induced (r_amod) seizures_9\NNS\14081375|against|pilocarpine-|limbic|and|epilepticus (l_conj) epilepticus_12\NN\1740|status|mice
D007608_D013226 CID acid-induced_23\JJ\1740|kainic (r_amod) seizures_25\NNS\14081375|from|the|acid-induced|limbic|and|epilepticus (l_conj) epilepticus_28\NN\1740|status
D007608_D013226 CID acid-induced_14\JJ\1740|kainic (r_conj) pilocarpine-_11\NN\1740|and|acid-induced (r_amod) seizures_15\NNS\14081375|against|pilocarpine-|and|epilepticus (l_conj) epilepticus_18\NN\1740|status|mice
D007608_D013226 CID acid-induced_14\JJ\1740|kainic (r_conj) pilocarpine-_11\NN\1740|and|acid-induced (r_amod) seizures_15\NNS\14081375|against|pilocarpine-|and|epilepticus (r_nmod) protecting_9\VBG\1127795|in|seizures (r_advcl) effective_7\JJ\1740|that|steroids|are|highly|protecting|,|and|utility (l_conj) utility_26\NN\8186047|may|be|of|treatment (l_nmod) treatment_29\NN\654885|in|the|forms (l_nmod) forms_32\NNS\6286395|of|some|epilepticus (l_nmod) epilepticus_35\NN\1740|of|status|humans
D011374_D012640 NONE progesterone_5\NN\14747338|of|pregnane-20-ones|and|deoxycorticosterone (r_nmod) metabolites_3\NNS\20090|several|related|progesterone (r_nsubjpass) evaluated_23\VBN\670261|metabolites|were|activity|. (l_nmod) activity_26\NN\30358|for|protective|seizures (l_nmod) seizures_35\NNS\14081375|against|pilocarpine-|mice
D011374_D012640 NONE pregnane-20-ones_9\NNS\1740|(|alpha-hydroxy|) (r_appos) progesterone_5\NN\14747338|of|pregnane-20-ones|and|deoxycorticosterone (r_nmod) metabolites_3\NNS\20090|several|related|progesterone (r_nsubjpass) evaluated_23\VBN\670261|metabolites|were|activity|. (l_nmod) activity_26\NN\30358|for|protective|seizures (l_nmod) seizures_35\NNS\14081375|against|pilocarpine-|mice
D003900_D012640 NONE deoxycorticosterone_12\NN\1740|pregnane-21-diol-20-ones|and|beta-epimers (r_conj) progesterone_5\NN\14747338|of|pregnane-20-ones|and|deoxycorticosterone (r_nmod) metabolites_3\NNS\20090|several|related|progesterone (r_nsubjpass) evaluated_23\VBN\670261|metabolites|were|activity|. (l_nmod) activity_26\NN\30358|for|protective|seizures (l_nmod) seizures_35\NNS\14081375|against|pilocarpine-|mice
D003900_D012640 NONE pregnane-21-diol-20-ones_16\NN\1740|(|alpha-hydroxy|) (r_appos) deoxycorticosterone_12\NN\1740|pregnane-21-diol-20-ones|and|beta-epimers (r_conj) progesterone_5\NN\14747338|of|pregnane-20-ones|and|deoxycorticosterone (r_nmod) metabolites_3\NNS\20090|several|related|progesterone (r_nsubjpass) evaluated_23\VBN\670261|metabolites|were|activity|. (l_nmod) activity_26\NN\30358|for|protective|seizures (l_nmod) seizures_35\NNS\14081375|against|pilocarpine-|mice
D016202_D012640 NONE n-methyl-d-aspartate_33\NN\1740| (r_conj) pilocarpine-_28\NN\1740|,|acid-|and|n-methyl-d-aspartate|(nmda)-induced (r_compound) seizures_35\NNS\14081375|against|pilocarpine-|mice
D016202_D012640 NONE (nmda)-induced_34\JJ\1740| (r_dep) pilocarpine-_28\NN\1740|,|acid-|and|n-methyl-d-aspartate|(nmda)-induced (r_compound) seizures_35\NNS\14081375|against|pilocarpine-|mice
D016202_D012640 NONE nmda_8\NN\1740|mg/kg (r_compound) lethality_14\NN\4790449|in|nmda (r_nmod) delay_6\NN\15271008|a|dose-dependent|lethality (r_dobj) caused_3\VBD\1617192|steroids|also|delay|,|but|protect|. (l_conj) protect_20\VB\1127795|did|not|completely|seizures (l_nmod) seizures_23\NNS\14081375|against|nmda|or|lethality
D016202_D012640 NONE nmda_22\NN\1740| (r_compound) seizures_23\NNS\14081375|against|nmda|or|lethality
D013256_D064420 NONE steroids_3\NNS\14727670|the|neuroactive (r_nsubj) potent_7\JJ\1740|although|steroids|were|less|clonazepam|protecting (r_advcl) had_24\VBD\2108377|potent|,|steroids|values|clonazepam|,|indicating|. (l_advcl) indicating_46\VBG\952524|have (l_ccomp) have_52\VB\2108377|that|steroids|may|toxicity (l_dobj) toxicity_55\NN\13576101|lower|relative
D013256_D064420 NONE steroids_18\NNS\14727670|alpha-configuration (r_nsubj) had_24\VBD\2108377|potent|,|steroids|values|clonazepam|,|indicating|. (l_advcl) indicating_46\VBG\952524|have (l_ccomp) have_52\VB\2108377|that|steroids|may|toxicity (l_dobj) toxicity_55\NN\13576101|lower|relative
D013256_D064420 NONE steroids_50\NNS\14727670|some|neuroactive (r_nsubj) have_52\VB\2108377|that|steroids|may|toxicity (l_dobj) toxicity_55\NN\13576101|lower|relative
D001569_D012640 NONE benzodiazepine_10\NN\3771443| (r_compound) clonazepam_11\NN\1740|than|the|benzodiazepine (r_nmod) potent_7\JJ\1740|although|steroids|were|less|clonazepam|protecting (l_advcl) protecting_13\VBG\1127795|in|seizures (l_nmod) seizures_16\NNS\14081375|against|pilocarpine
D001569_D012640 NONE benzodiazepine_10\NN\3771443| (r_compound) clonazepam_11\NN\1740|than|the|benzodiazepine (r_nmod) potent_7\JJ\1740|although|steroids|were|less|clonazepam|protecting (r_advcl) had_24\VBD\2108377|potent|,|steroids|values|clonazepam|,|indicating|. (l_dobj) values_30\NNS\5941423|comparable|protective|index|td50 (l_dep) td50_32\NN\1740|(|impairment|divided|) (l_acl) divided_36\VBN\140123|ed50 (l_nmod) ed50_38\NN\1740|by|protection (l_nmod) protection_41\NN\407535|for|seizure (l_compound) seizure_40\NN\14081375|
D001569_D064420 NONE benzodiazepine_10\NN\3771443| (r_compound) clonazepam_11\NN\1740|than|the|benzodiazepine (r_nmod) potent_7\JJ\1740|although|steroids|were|less|clonazepam|protecting (r_advcl) had_24\VBD\2108377|potent|,|steroids|values|clonazepam|,|indicating|. (l_advcl) indicating_46\VBG\952524|have (l_ccomp) have_52\VB\2108377|that|steroids|may|toxicity (l_dobj) toxicity_55\NN\13576101|lower|relative
D002998_D012640 NONE clonazepam_11\NN\1740|than|the|benzodiazepine (r_nmod) potent_7\JJ\1740|although|steroids|were|less|clonazepam|protecting (l_advcl) protecting_13\VBG\1127795|in|seizures (l_nmod) seizures_16\NNS\14081375|against|pilocarpine
D002998_D012640 NONE clonazepam_11\NN\1740|than|the|benzodiazepine (r_nmod) potent_7\JJ\1740|although|steroids|were|less|clonazepam|protecting (r_advcl) had_24\VBD\2108377|potent|,|steroids|values|clonazepam|,|indicating|. (l_dobj) values_30\NNS\5941423|comparable|protective|index|td50 (l_dep) td50_32\NN\1740|(|impairment|divided|) (l_acl) divided_36\VBN\140123|ed50 (l_nmod) ed50_38\NN\1740|by|protection (l_nmod) protection_41\NN\407535|for|seizure (l_compound) seizure_40\NN\14081375|
D002998_D012640 NONE clonazepam_44\NN\1740|than (r_nmod) had_24\VBD\2108377|potent|,|steroids|values|clonazepam|,|indicating|. (l_advcl) potent_7\JJ\1740|although|steroids|were|less|clonazepam|protecting (l_advcl) protecting_13\VBG\1127795|in|seizures (l_nmod) seizures_16\NNS\14081375|against|pilocarpine
D002998_D012640 NONE clonazepam_44\NN\1740|than (r_nmod) had_24\VBD\2108377|potent|,|steroids|values|clonazepam|,|indicating|. (l_dobj) values_30\NNS\5941423|comparable|protective|index|td50 (l_dep) td50_32\NN\1740|(|impairment|divided|) (l_acl) divided_36\VBN\140123|ed50 (l_nmod) ed50_38\NN\1740|by|protection (l_nmod) protection_41\NN\407535|for|seizure (l_compound) seizure_40\NN\14081375|
D002998_D064420 NONE clonazepam_11\NN\1740|than|the|benzodiazepine (r_nmod) potent_7\JJ\1740|although|steroids|were|less|clonazepam|protecting (r_advcl) had_24\VBD\2108377|potent|,|steroids|values|clonazepam|,|indicating|. (l_advcl) indicating_46\VBG\952524|have (l_ccomp) have_52\VB\2108377|that|steroids|may|toxicity (l_dobj) toxicity_55\NN\13576101|lower|relative
D002998_D064420 NONE clonazepam_44\NN\1740|than (r_nmod) had_24\VBD\2108377|potent|,|steroids|values|clonazepam|,|indicating|. (l_advcl) indicating_46\VBG\952524|have (l_ccomp) have_52\VB\2108377|that|steroids|may|toxicity (l_dobj) toxicity_55\NN\13576101|lower|relative
D010862_D064420 NONE pilocarpine_15\NN\14712692| (r_compound) seizures_16\NNS\14081375|against|pilocarpine (r_nmod) protecting_13\VBG\1127795|in|seizures (r_advcl) potent_7\JJ\1740|although|steroids|were|less|clonazepam|protecting (r_advcl) had_24\VBD\2108377|potent|,|steroids|values|clonazepam|,|indicating|. (l_advcl) indicating_46\VBG\952524|have (l_ccomp) have_52\VB\2108377|that|steroids|may|toxicity (l_dobj) toxicity_55\NN\13576101|lower|relative
19319147
D014859_D006470 NONE warfarin-associated_12\JJ\1740| (r_amod) hemorrhage_14\NN\14285662|of|warfarin-associated|intracerebral (r_nmod) model_10\NN\5888929|in|a|mouse|hemorrhage (r_nmod) reduces_4\VBZ\441445|reversal|volume|model|. (l_dobj) volume_6\NN\33615|hemorrhage (l_compound) hemorrhage_5\NN\14285662|
D014859_D002543 CID warfarin-associated_12\JJ\1740| (r_amod) hemorrhage_14\NN\14285662|of|warfarin-associated|intracerebral
D014859_D002543 CID warfarin-associated_0\JJ\1740| (r_amod) hemorrhage_2\NN\14285662|warfarin-associated|intracerebral|w-ich
D014859_D002543 CID warfarin-associated_0\JJ\1740| (r_amod) hemorrhage_2\NN\14285662|warfarin-associated|intracerebral|w-ich (l_appos) w-ich_4\NN\1740|(|)
D014859_D020521 NONE warfarin-associated_0\JJ\1740| (r_amod) hemorrhage_2\NN\14285662|warfarin-associated|intracerebral|w-ich (r_nsubj) type_9\NN\5839024|hemorrhage|is|a|severe|stroke|. (l_nmod) stroke_11\NN\556313|of
C025667_D002543 NONE pcc_5\NN\1740| (r_nsubj) treatment_11\NN\654885|pcc|to|be|an|effective|acute|w-ich|terms (l_nmod) w-ich_13\NN\1740|for
982002
D012293_D058186 CID rifampicin_8\NN\1740|of (r_nmod) administration_6\NN\1133281|to|the|rifampicin (r_nmod) subsequent_3\JJ\1740|administration (r_amod) failure_2\NN\66216|acute|renal|subsequent|.
D012293_D051437 NONE rifampicin_12\NN\1740|of (r_nmod) administration_10\NN\1133281|after|the|intermittent|rifampicin (r_nmod) developed_3\VBN\1753788|patients|had|failure|administration|. (l_dobj) failure_6\NN\66216|transient|renal
8251368
D009543_D013684 CID nifedipine-induced_1\JJ\1740| (r_amod) telangiectasia_3\NN\1740|photodistributed|nifedipine-induced|facial|.
D009543_D013684 CID nifedipine_4\NN\2938514|adalat (r_dobj) starting_3\VBG\2009433|after|nifedipine (r_advcl) developed_11\VBD\1753788|starting|,|patients|telangiectasia|. (l_dobj) telangiectasia_14\NN\1740|photodistributed|facial|,|became
D009543_D013684 CID adalat_6\NN\1740|(|) (r_appos) nifedipine_4\NN\2938514|adalat (r_dobj) starting_3\VBG\2009433|after|nifedipine (r_advcl) developed_11\VBD\1753788|starting|,|patients|telangiectasia|. (l_dobj) telangiectasia_14\NN\1740|photodistributed|facial|,|became
D017311_D013684 CID amlodipine_6\NN\1740|the|related|drug (r_dobj) commenced_1\VBD\348746|one|amlodipine|later|,|recurrence|. (l_nmod) recurrence_12\NN\7342049|with|telangiectasia (l_nmod) telangiectasia_14\NN\1740|of
2334179
D010396_D012594 NONE d-penicillamine_0\NN\1740|treatment|. (l_nmod) treatment_3\NN\654885|in|the|scleroderma (l_nmod) scleroderma_6\NN\14187378|of|localized
D010396_D012594 NONE d-penicillamine_15\NN\1740|with (r_nmod) treated_13\VBN\2376958|who|were|d-penicillamine (r_acl:relcl) patients_4\NNS\9898892|of|11|scleroderma|treated (l_nmod) scleroderma_10\NN\14187378|with|severe|,|extensive|localized
D010396_D012594 NONE d-penicillamine_4\NN\1740| (r_nsubj) effective_7\JJ\1740|that|d-penicillamine|may|be|cases (l_nmod) cases_10\NNS\7283608|in|severe|scleroderma (l_nmod) scleroderma_13\NN\14187378|of|localized
D010396_D009404 CID d-penicillamine_0\NN\1740| (r_nsubj) caused_1\VBD\1617192|d-penicillamine|syndrome (l_dobj) syndrome_3\NN\5870365|nephrotic|patient|and|proteinuria
D010396_D011507 CID d-penicillamine_0\NN\1740| (r_nsubj) caused_1\VBD\1617192|d-penicillamine|syndrome (l_dobj) syndrome_3\NN\5870365|nephrotic|patient|and|proteinuria (l_conj) proteinuria_10\NN\14299637|milder|reversible|patients
D010396_D051437 NONE d-penicillamine_0\NN\1740| (r_nsubj) caused_1\VBD\1617192|d-penicillamine|syndrome (r_ccomp) developed_17\VBD\1753788|caused|;|none|insufficiency|. (l_dobj) insufficiency_19\NN\14462946|renal
2533791
D017325_D006509 NONE vaccine_25\NN\3562739|of|derived|hepatitis|b (r_nmod) injections_19\NNS\320852|three|vaccine (r_conj) injections_6\NNS\320852|with|two|globulin|and|injections (l_nmod) globulin_11\NN\14736972|of|hepatitis|b|immune|hbig (l_compound) b_9\NN\1355326|
11226639
D008550_D053608 CID melatonin_3\NN\5407119|of (r_nmod) effects_1\NNS\13245626|dual|melatonin|narcosis|. (l_nmod) narcosis_6\NN\5678932|on|barbiturate-induced|rats
D008550_D053608 CID melatonin_0\NN\5407119| (r_nsubj) affects_1\VBZ\126264|melatonin|cycle|,|but|clear (l_conj) clear_11\JJ\1740|it|is|not|influence|. (l_ccomp) influence_15\VB\137313|whether|it|may|narcosis (l_dobj) narcosis_17\NN\5678932|drug-induced
D008550_D053608 CID melatonin_0\NN\5407119| (r_compound) pre-treatment_1\NN\1740|melatonin (r_nsubj) affected_2\VBD\126264|pre-treatment|manner|narcosis (l_dobj) narcosis_8\NN\5678932|barbiturate
D008550_D053608 CID melatonin_7\NN\5407119|of (r_nmod) dose_5\NN\3740161|the|highest|melatonin|mg/kg (r_nsubj) caused_12\VBD\1617192|contrast|,|dose|increase|and|produced|. (l_conj) produced_20\VBD\1617192|reduction (l_dobj) reduction_23\NN\351485|a|sustained|duration|,|and|reduction (l_nmod) duration_26\NN\15113229|of|the|narcosis (l_nmod) narcosis_28\NN\5678932|of
D008550_D053608 CID melatonin_0\NN\5407119|mg/kg (r_nsubj) influenced_5\VBD\137313|melatonin|duration|. (l_dobj) duration_7\NN\15113229|the|not|latency|ketamine-|narcosis (l_nmod) narcosis_16\NN\5678932|
D008550_D053608 CID melatonin_6\NN\5407119|of (r_nmod) action_4\NN\30358|the|dual|melatonin|narcosis (l_nmod) narcosis_9\NN\5678932|on|pharmacological
C032232_D053608 NONE barbiturate-induced_5\JJ\1740| (r_amod) narcosis_6\NN\5678932|on|barbiturate-induced|rats
C032232_D053608 NONE barbiturate_7\JJ\1740| (r_amod) narcosis_8\NN\5678932|barbiturate
C032232_D053608 NONE barbiturate_14\JJ\1740| (r_amod) narcosis_15\NN\5678932|of|barbiturate
C032232_D053608 NONE barbiturate_16\JJ\1740| (r_amod) mechanism_17\NN\13446390|for|the|barbiturate|action (r_nmod) specific_13\JJ\1740|to|be|mechanism (r_xcomp) seems_10\VBZ\2604760|thus|,|action|specific|. (l_nsubj) action_4\NN\30358|the|dual|melatonin|narcosis (l_nmod) narcosis_9\NN\5678932|on|pharmacological
D007649_D053608 CID ketamine-_13\NN\1740|of|or|diazepam-induced (r_nmod) duration_7\NN\15113229|the|not|latency|ketamine-|narcosis (l_nmod) narcosis_16\NN\5678932|
D003975_D053608 CID diazepam-induced_15\JJ\1740| (r_conj) ketamine-_13\NN\1740|of|or|diazepam-induced (r_nmod) duration_7\NN\15113229|the|not|latency|ketamine-|narcosis (l_nmod) narcosis_16\NN\5678932|
7596955
D000242_D001791 NONE camp_19\NN\3763727|of|intraplatelet (r_nmod) determination_16\NN\43195|camp (r_conj) examination_6\NN\633864|physical|and|collection|aggregation|and|determination (l_nmod) aggregation_14\NN\31264|for|ex|platelet
C045645_D006261 CID clz_25\NN\1740|of (r_nmod) ingestion_23\NN\13440063|after|clz (r_nmod) nausea_17\NN\14299637|one|,|ingestion (r_conj) flush_13\NN\15113229|facial|one|and|nausea (r_dobj) accompanying_11\VBG\1835496|flush (r_acl) headache_6\NN\5829480|duration|accompanying
C045645_D005483 CID clz_25\NN\1740|of (r_nmod) ingestion_23\NN\13440063|after|clz (r_nmod) nausea_17\NN\14299637|one|,|ingestion (r_conj) flush_13\NN\15113229|facial|one|and|nausea
C045645_D009325 CID clz_25\NN\1740|of (r_nmod) ingestion_23\NN\13440063|after|clz (r_nmod) nausea_17\NN\14299637|one|,|ingestion
3311455
D016572_D007674 CID cyclosporine_15\NN\1740|with (r_nmod) therapy_13\NN\657604|to|long-term|cyclosporine (r_nmod) secondary_10\JJ\1740|therapy (r_amod) nephrotoxicity_9\NN\1740|of|chronic|secondary
D016572_D007674 CID cyclosporine_8\NN\1740|of (r_nmod) dosages_6\NNS\13576355|even|these|lower|cyclosporine (r_nsubj) cause_10\VB\1617192|that|dosages|can|nephrotoxicity|and|required (l_dobj) nephrotoxicity_12\NN\1740|chronic
12093990
D012254_D000257 NONE ribavirin_1\NN\2725367| (r_compound) treatment_2\NN\654885|intravenous|ribavirin|disease|. (l_nmod) disease_6\NN\14061805|for|severe|adenovirus|children
D012254_D000257 NONE ribavirin_8\NN\2725367| (r_compound) therapy_9\NN\657604|with|intravenous|ribavirin|disease (l_nmod) disease_13\NN\14061805|for|severe|adenovirus
D012254_D000257 NONE ribavirin_14\NN\2725367|with|intravenous (r_nmod) treated_11\VBN\2376958|ribavirin|disease (l_nmod) disease_19\NN\14061805|for|documented|severe|adenovirus
D012254_D000257 NONE ribavirin_2\NN\2725367|intravenous (r_nsubj) effective_5\JJ\1740|although|ribavirin|was|not|children|series (l_nmod) children_8\NNS\9622049|for|all|disease (l_nmod) disease_12\NN\14061805|with|severe|adenovirus
D012254_D000257 NONE ribavirin_13\NN\2725367|with|intravenous (r_nmod) treated_10\VBN\2376958|ribavirin (r_acl) children_5\NNS\9622049|5|disease|treated (l_nmod) disease_9\NN\14061805|with|severe|adenovirus
D012254_D000257 NONE ribavirin_31\NN\2725367|such|intravenous (r_nmod) therapies_26\NNS\657604|of|useful|anti-adenoviral|,|ribavirin|, (r_nmod) trial_21\NN\786195|a|large|,|multicenter|clinical|therapies (r_nsubjpass) required_35\VBN\754942|seriousness|,|trial|is|clearly|demonstrate|. (l_nmod) seriousness_2\NN\7512147|given|the|and|prevalence|disease|hosts (l_nmod) disease_8\NN\14061805|of|adenovirus
D012254_D018357 NONE ribavirin_0\NN\2725367| (r_nsubjpass) licensed_2\JJ\1740|ribavirin|is|form|treatment|,|and|orally|c. (l_nmod) treatment_8\NN\654885|for|the|infection (l_nmod) infection_13\NN\14052046|of|virus
D012254_D006526 NONE ribavirin_0\NN\2725367| (r_nsubjpass) licensed_2\JJ\1740|ribavirin|is|form|treatment|,|and|orally|c. (l_punct) c._24\NN\1740|hepatitis
D012254_D006482 NONE ribavirin_1\NN\2725367|intravenous (r_nsubj) treatment_4\NN\654885|ribavirin|is|the|choice|infection|. (l_nmod) infection_8\NN\14052046|for|viruses (l_nmod) viruses_12\NNS\9312843|with|hemorrhagic|fever
D012254_D000740 NONE ribavirin_7\NN\2725367|of|intravenous (r_nmod) effect_4\NN\34213|the|common|adverse|ribavirin (r_nsubj) anemia_11\NN\14189204|effect|is|reversible|mild|.
C059262_D000257 NONE cidofovir_3\NN\1740|of (r_nmod) use_1\NN\407535|the|cidofovir|infection (l_nmod) infection_7\NN\14052046|in|severe|adenovirus
C059262_D007674 NONE cidofovir_3\NN\1740|of (r_nmod) use_1\NN\407535|the|cidofovir|infection (r_nsubjpass) limited_10\VBN\2510337|use|has|been|effects|. (l_nmod) effects_13\NNS\13245626|by|adverse|,|nephrotoxicity (l_appos) nephrotoxicity_21\NN\1740|significant|is
C059262_D058186 CID cidofovir_2\NN\1740|of (r_nmod) use_0\NN\407535|cidofovir|child (r_nsubjpass) associated_7\VBN\628491|use|was|failure|. (l_nmod) failure_11\NN\66216|with|progressive|renal|and|neutropenia
C059262_D009503 CID cidofovir_2\NN\1740|of (r_nmod) use_0\NN\407535|cidofovir|child (r_nsubjpass) associated_7\VBN\628491|use|was|failure|. (l_nmod) failure_11\NN\66216|with|progressive|renal|and|neutropenia (l_conj) neutropenia_13\NN\14196405|
D012254_D007239 NONE ribavirin_2\NN\2725367|intravenous (r_nsubj) effective_5\JJ\1740|although|ribavirin|was|not|children|series (r_advcl) unlikely_23\JJ\1740|effective|,|therapy|is|be|begun|. (l_advcl) begun_29\VBN\941990|if|late (l_advmod) late_30\RB\1740|course (l_nmod) course_33\NN\883297|in|the|infection (l_nmod) infection_36\NN\14052046|of|the
11838826
D018967_D006966 CID risperidone-induced_2\JJ\1740| (r_amod) hyperprolactinemia_3\NN\1740|of|risperidone-induced
D018967_D006966 CID risperidone_2\NN\1740|,|antagonist (r_nsubjpass) associated_18\VBN\628491|background|risperidone|is|hyperprolactinemia|. (l_nmod) hyperprolactinemia_20\NN\1740|with|adults
D018967_D006966 CID risperidone-induced_6\JJ\1740| (r_amod) hyperprolactinemia_7\NN\1740|of|risperidone-induced
D018967_D006966 CID risperidone-induced_12\JJ\1740| (r_amod) hyperprolactinemia_13\NN\1740|with|risperidone-induced
D018967_D006966 CID risperidone-induced_10\JJ\1740| (r_amod) hyperprolactinemia_11\NN\1740|of|risperidone-induced|youth
D004298_D006966 NONE dopamine_6\NN\14807737| (r_compound) agonist_7\NN\9613191|with|a|dopamine|children (r_nmod) treatment_0\NN\654885|hyperprolactinemia|agonist|. (l_nmod) hyperprolactinemia_3\NN\1740|of|risperidone-induced
C047047_D006966 NONE cabergoline_9\NN\1740|with (r_nmod) treatment_4\NN\654885|the|successful|hyperprolactinemia|cabergoline|youth (l_nmod) hyperprolactinemia_7\NN\1740|of|risperidone-induced
C047047_D006966 NONE cabergoline_16\NN\1740|with (r_nmod) treated_14\VBN\2376958|cabergoline (r_acl) children_10\NNS\9622049|of|four|hyperprolactinemia|treated (l_nmod) hyperprolactinemia_13\NN\1740|with|risperidone-induced
C047047_D006966 NONE cabergoline_2\NN\1740| (r_nsubj) useful_5\JJ\1740|cabergoline|may|be|treatment (l_nmod) treatment_8\NN\654885|for|the|hyperprolactinemia (l_nmod) hyperprolactinemia_11\NN\1740|of|risperidone-induced|youth
D018967_D001523 NONE risperidone-induced_29\JJ\1740| (r_amod) elevations_30\NNS\7445480|with|risperidone-induced|levels|ng/ml (r_nmod) males_3\NNS\15388|four|age|disorder|,|elevations (l_nmod) disorder_24\NN\14034177|with|manual|bipolar|or|psychoses (l_compound) manual_15\NNP\6421301|diagnostic|disorders|edition (l_nmod) disorders_18\NNPS\14034177|of|mental
D018967_D001714 NONE risperidone-induced_29\JJ\1740| (r_amod) elevations_30\NNS\7445480|with|risperidone-induced|levels|ng/ml (r_nmod) males_3\NNS\15388|four|age|disorder|,|elevations (l_nmod) disorder_24\NN\14034177|with|manual|bipolar|or|psychoses
D018967_D011605 NONE risperidone-induced_29\JJ\1740| (r_amod) elevations_30\NNS\7445480|with|risperidone-induced|levels|ng/ml (r_nmod) males_3\NNS\15388|four|age|disorder|,|elevations (l_nmod) disorder_24\NN\14034177|with|manual|bipolar|or|psychoses (l_conj) psychoses_26\NNS\14380140|
C047047_D001523 NONE cabergoline_51\NN\1740|with|dose (r_nmod) treated_49\VBN\2376958|males|,|were|cabergoline|. (l_nsubjpass) males_3\NNS\15388|four|age|disorder|,|elevations (l_nmod) disorder_24\NN\14034177|with|manual|bipolar|or|psychoses (l_compound) manual_15\NNP\6421301|diagnostic|disorders|edition (l_nmod) disorders_18\NNPS\14034177|of|mental
C047047_D001714 NONE cabergoline_51\NN\1740|with|dose (r_nmod) treated_49\VBN\2376958|males|,|were|cabergoline|. (l_nsubjpass) males_3\NNS\15388|four|age|disorder|,|elevations (l_nmod) disorder_24\NN\14034177|with|manual|bipolar|or|psychoses
C047047_D011605 NONE cabergoline_51\NN\1740|with|dose (r_nmod) treated_49\VBN\2376958|males|,|were|cabergoline|. (l_nsubjpass) males_3\NNS\15388|four|age|disorder|,|elevations (l_nmod) disorder_24\NN\14034177|with|manual|bipolar|or|psychoses (l_conj) psychoses_26\NNS\14380140|
1595783
D000638_D008171 NONE amiodarone_0\NN\2715941| (r_compound) toxicity_2\NN\13576101|amiodarone|pulmonary|.
D000638_D008171 NONE amiodarone_4\NN\2715941|of (r_nmod) toxicity_2\NN\13576101|the|pulmonary|amiodarone
D000638_D008171 NONE amiodarone-induced_6\JJ\1740| (r_amod) toxicity_8\NN\13576101|of|amiodarone-induced|pulmonary
D000638_D011014 CID amiodarone_0\NN\2715941| (r_nsubj) agent_5\NN\7347|amiodarone|is|an|antiarrhythmic|limited|. (l_acl:relcl) limited_9\VBN\2510337|utility|is|side-effects|,|pneumonitis (l_advcl) pneumonitis_18\NN\14336539|being
D000638_D004342 NONE amiodarone_4\NN\2715941|of (r_nmod) toxicity_2\NN\13576101|the|pulmonary|amiodarone (r_nsubjpass) thought_6\VBN\670261|toxicity|is|result|. (l_xcomp) result_8\VB\2633881|to|injury (l_nmod) injury_11\NN\14052046|from|direct|related (l_amod) related_12\JJ\1740|accumulation (l_nmod) accumulation_16\NN\13497135|to|the|intracellular|phospholipid (l_nmod) phospholipid_18\JJ\1740|of|and|pneumonitis (l_conj) pneumonitis_23\NN\14336539|cell-mediated|hypersensitivity
D000638_D000542 NONE amiodarone_4\NN\2715941|of (r_nmod) toxicity_2\NN\13576101|the|pulmonary|amiodarone (r_nsubjpass) thought_6\VBN\670261|toxicity|is|result|. (l_xcomp) result_8\VB\2633881|to|injury (l_nmod) injury_11\NN\14052046|from|direct|related (l_amod) related_12\JJ\1740|accumulation (l_nmod) accumulation_16\NN\13497135|to|the|intracellular|phospholipid (l_nmod) phospholipid_18\JJ\1740|of|and|pneumonitis (l_conj) pneumonitis_23\NN\14336539|cell-mediated|hypersensitivity
15565293
D004977_D009901 CID ethambutol-induced_10\JJ\1740| (r_amod) neuropathy_12\NN\14204950|with|ethambutol-induced|optic
D004977_D009901 CID ethambutol-induced_16\JJ\1740| (r_amod) neuropathy_18\NN\14204950|in|ethambutol-induced|optic
D004977_D009901 CID ethambutol_4\NN\1740|of (r_nmod) complication_2\NN\1073995|a|serious|ethambutol (r_nsubj) neuropathy_8\NN\14204950|complication|is|an|optic|impairs|.
D004977_D009901 CID ethambutol_8\NN\1740| (r_compound) (emb)-induced_9\NN\1740|ethambutol (r_nummod) neuropathy_11\NN\14204950|of|(emb)-induced|optic|deficits
D004977_D009901 CID (emb)-induced_9\NN\1740|ethambutol (r_nummod) neuropathy_11\NN\14204950|of|(emb)-induced|optic|deficits
D004977_D009901 CID emb-induced_6\JJ\1740| (r_amod) neuropathy_8\NN\14204950|of|emb-induced|optic
D004977_D009901 CID emb-induced_9\JJ\1740| (r_amod) neuropathy_11\NN\14204950|with|emb-induced|optic
D004977_D009901 CID emb-induced_7\JJ\1740| (r_amod) neuropathy_9\NN\14204950|of|emb-induced|optic
D004977_D009901 CID ethambutol_17\NN\1740| (r_compound) dosing_18\NN\1740|ethambutol|patients (r_dobj) manage_16\VB\2524171|to|properly|dosing|and|achieve (r_xcomp) important_13\JJ\1740|additionally|,|terms|,|it|is|manage|. (l_nmod) terms_3\NNS\13945919|in|management (l_nmod) management_5\NN\1123598|of|neuropathy (l_nmod) neuropathy_9\NN\14204950|of|emb-induced|optic
D004977_D009410 NONE ethambutol-induced_16\JJ\1740| (r_amod) neuropathy_18\NN\14204950|in|ethambutol-induced|optic (r_nmod) degeneration_14\NN\29677|of|axonal|neuropathy
D004977_D014376 NONE ethambutol_0\NN\1740| (r_nsubj) agent_4\NN\7347|ethambutol|is|an|antimycobacterial|used|. (l_acl) used_6\VBN\1156834|often|treat (l_xcomp) treat_8\VB\2376958|to|tuberculosis (l_dobj) tuberculosis_9\NN\14127211|
D004977_D014786 CID ethambutol_8\NN\1740| (r_compound) (emb)-induced_9\NN\1740|ethambutol (r_nummod) neuropathy_11\NN\14204950|of|(emb)-induced|optic|deficits (l_nmod) deficits_20\NNS\5113133|of|short-|visual
D004977_D014786 CID (emb)-induced_9\NN\1740|ethambutol (r_nummod) neuropathy_11\NN\14204950|of|(emb)-induced|optic|deficits (l_nmod) deficits_20\NNS\5113133|of|short-|visual
D004977_D014786 CID emb-induced_6\JJ\1740| (r_amod) neuropathy_8\NN\14204950|of|emb-induced|optic (r_nmod) history_4\NN\15120823|with|neuropathy (r_nmod) subjects_2\NNS\6598915|in|all|history (r_nmod) was_11\VBD\836236|subjects|,|there|loss|a (l_dep) a_28\NN\13649268|(|patient|,|recovery|,|loss|;|b|,|thickness|. (l_appos) b_44\NN\1355326|patient|,|deficits|,|loss|;|c (l_nmod) deficits_49\NNS\5113133|with|intermediate|visual
D004977_D014786 CID emb-induced_6\JJ\1740| (r_amod) neuropathy_8\NN\14204950|of|emb-induced|optic (r_nmod) history_4\NN\15120823|with|neuropathy (r_nmod) subjects_2\NNS\6598915|in|all|history (r_nmod) was_11\VBD\836236|subjects|,|there|loss|a (l_dep) a_28\NN\13649268|(|patient|,|recovery|,|loss|;|b|,|thickness|. (l_appos) b_44\NN\1355326|patient|,|deficits|,|loss|;|c (l_dep) c_56\NN\13714184|patient|,|deficits|,|loss|) (l_nmod) deficits_61\NNS\5113133|with|chronic|visual
D004977_D051437 NONE emb-induced_7\JJ\1740| (r_amod) neuropathy_9\NN\14204950|of|emb-induced|optic (r_nmod) management_5\NN\1123598|of|neuropathy (r_nmod) terms_3\NNS\13945919|in|management (r_nmod) important_13\JJ\1740|additionally|,|terms|,|it|is|manage|. (l_xcomp) manage_16\VB\2524171|to|properly|dosing|and|achieve (l_dobj) dosing_18\NN\1740|ethambutol|patients (l_nmod) patients_20\NNS\9898892|in|impairment (l_nmod) impairment_23\NN\7296428|with|renal
D004977_D051437 NONE ethambutol_17\NN\1740| (r_compound) dosing_18\NN\1740|ethambutol|patients (l_nmod) patients_20\NNS\9898892|in|impairment (l_nmod) impairment_23\NN\7296428|with|renal
1355091
D011224_D007024 CID prazosin-pretreated_9\JJ\1740| (r_amod) rats_13\NNS\2329401|in|chronic|prazosin-pretreated|conscious|hypertensive (r_nmod) blockade_6\NN\952963|following|alpha|2-adrenoceptor|rats (r_nmod) occurs_2\VBZ\2623529|hypotension|blockade|. (l_nsubj) hypotension_1\NN\14057371|orthostatic
D011224_D007024 CID prazosin_13\NN\2698769|with (r_nmod) treated_11\VBN\2376958|prazosin (r_acl) shr_10\NNP\1740|in|the|treated|map|,|but|shr (r_nmod) induced_5\VBD\1627355|however|,|tilt|hypotension|shr|. (l_dobj) hypotension_7\NN\14057371|orthostatic
D011224_D007024 CID prazosin_20\NN\2698769|of|kg-1 (r_nmod) dosing_18\NN\1740|prior|acute|prazosin|i.p. (r_nmod) performed_11\VBN\2367363|when|dosing|) (r_advcl) produce_7\VB\1617192|tilts|did|not|hypotension|performed|. (l_dobj) hypotension_9\NN\14057371|orthostatic
D011224_D006973 NONE prazosin-pretreated_9\JJ\1740| (r_amod) rats_13\NNS\2329401|in|chronic|prazosin-pretreated|conscious|hypertensive (l_amod) hypertensive_12\JJ\1740|spontaneously
D011224_D006973 NONE prazosin_9\NN\2698769| (r_compound) treatment_10\NN\654885|chronic|prazosin (r_nsubj) alters_11\VBZ\126264|whether|treatment|function (l_dobj) function_15\NN\13783581|the|alpha|2-adrenoceptor|control (l_nmod) control_18\NN\5190804|for|orthostatic|pressure|rats (l_nmod) rats_27\NNS\2329401|in|conscious|hypertensive|shr (l_amod) hypertensive_26\JJ\1740|spontaneously
D015016_D007024 NONE rauwolscine_31\NN\1740|with (r_nmod) treated_29\VBN\2376958|rauwolscine (r_acl) shr_28\NNP\1740|not|in|the|treated|map (r_conj) shr_10\NNP\1740|in|the|treated|map|,|but|shr (r_nmod) induced_5\VBD\1627355|however|,|tilt|hypotension|shr|. (l_dobj) hypotension_7\NN\14057371|orthostatic
C014282_D001919 CID cirazoline_11\NN\1740|to|the|1-agonist|kg-1|i.v.|)|,|abbott-53693|,|and|noradrenaline (r_nmod) responses_4\NNS\11410625|the|pressor|and|bradycardia|cirazoline (l_conj) bradycardia_6\NN\14110674|
C014282_D001919 CID cirazoline_7\NN\1740|of (r_nmod) effects_5\NNS\13245626|both|the|pressor|cirazoline (l_compound) pressor_2\NN\9190918|and|bradycardia (l_conj) bradycardia_4\NN\14110674|
C056299_D001919 CID abbott-53693_24\NN\1740|the|alpha|2-agonist|kg-1|i.v.|) (r_conj) cirazoline_11\NN\1740|to|the|1-agonist|kg-1|i.v.|)|,|abbott-53693|,|and|noradrenaline (r_nmod) responses_4\NNS\11410625|the|pressor|and|bradycardia|cirazoline (l_conj) bradycardia_6\NN\14110674|
C056299_D001919 CID abbott-53693_9\NN\1740|of (r_nmod) effects_7\NNS\13245626|the|pressor|abbott-53693 (r_nsubj) similar_11\JJ\1740|hand|,|effects|were|groups|,|but|greater (l_conj) greater_23\JJR\1740|bradycardia|was|shr|treatment|than|. (l_nsubj) bradycardia_21\NN\14110674|the|accompanying
D009638_D001919 CID noradrenaline_35\NN\14807929|kg-1|i.v.|) (r_conj) cirazoline_11\NN\1740|to|the|1-agonist|kg-1|i.v.|)|,|abbott-53693|,|and|noradrenaline (r_nmod) responses_4\NNS\11410625|the|pressor|and|bradycardia|cirazoline (l_conj) bradycardia_6\NN\14110674|
D009638_D001919 CID noradrenaline-induced_7\JJ\1740| (r_amod) effect_9\NN\34213|the|noradrenaline-induced|pressor|shr (r_dobj) accompanied_5\VBD\1835496|that|effect (r_acl:relcl) bradycardia_3\NN\14110674|the|accompanied
D011224_D001919 NONE prazosin_53\NN\2698769| (r_compound) pretreatment_54\NN\1740|with|chronic|prazosin (r_nmod) determined_45\VBN\1645601|4|responses|were|shr|pretreatment|. (l_nsubjpass) responses_4\NNS\11410625|the|pressor|and|bradycardia|cirazoline (l_conj) bradycardia_6\NN\14110674|
D011224_D001919 NONE prazosin_12\NN\2698769| (r_nmod:npmod) treated_13\JJ\1740|prazosin (r_amod) shr_14\NNS\1740|in|chronic|treated|= (r_nmod) abolished_9\VBN\1740|effects|were|shr|compared|. (l_nsubjpass) effects_5\NNS\13245626|both|the|pressor|cirazoline (l_compound) pressor_2\NN\9190918|and|bradycardia (l_conj) bradycardia_4\NN\14110674|
D011224_D001919 NONE prazosin_28\NN\2698769| (r_compound) treatment_29\NN\654885|with|chronic|prazosin (r_nmod) greater_23\JJR\1740|bradycardia|was|shr|treatment|than|. (l_nsubj) bradycardia_21\NN\14110674|the|accompanying
D011224_D001919 NONE prazosin_18\NN\2698769| (r_compound) treatment_19\NN\654885|with|chronic|prazosin (r_dobj) similar_13\JJ\1740|furthermore|,|bradycardia|was|treatment|reduction|shr.(abstract|truncated|) (l_nsubj) bradycardia_3\NN\14110674|the|accompanied
7647582
D004737_D056486 CID enflurane_4\NN\3299929|and|isoflurane (r_appos) anesthetics_2\NNS\3247620|two|halogenated|,|enflurane|, (r_nsubjpass) associated_10\VBN\628491|anesthetics|have|been|injury|both|. (l_nmod) injury_15\NN\14052046|with|an|allergic-type|hepatic
D004737_D056486 CID enflurane_11\NN\3299929|and/or|isoflurane (r_nsubj) produce_15\VB\1617192|which|enflurane|could|condition (l_dobj) condition_18\NN\24720|a|hypersensitivity|similar (l_amod) similar_19\JJ\1740|that|either (l_nmod) that_21\DT\1740|to|hepatitis (l_nmod) hepatitis_24\NN\14127211|of|halothane
D007530_D056486 CID isoflurane_6\NN\3570838| (r_conj) enflurane_4\NN\3299929|and|isoflurane (r_appos) anesthetics_2\NNS\3247620|two|halogenated|,|enflurane|, (r_nsubjpass) associated_10\VBN\628491|anesthetics|have|been|injury|both|. (l_nmod) injury_15\NN\14052046|with|an|allergic-type|hepatic
D007530_D056486 CID isoflurane_13\NN\3570838| (r_conj) enflurane_11\NN\3299929|and/or|isoflurane (r_nsubj) produce_15\VB\1617192|which|enflurane|could|condition (l_dobj) condition_18\NN\24720|a|hypersensitivity|similar (l_amod) similar_19\JJ\1740|that|either (l_nmod) that_21\DT\1740|to|hepatitis (l_nmod) hepatitis_24\NN\14127211|of|halothane
D006221_D056486 CID halothane_23\NN\3570838|to (r_nmod) exposure_21\NN\5042871|following|previous|halothane (r_conj) both_16\DT\1740|and|exposure (r_dep) associated_10\VBN\628491|anesthetics|have|been|injury|both|. (l_nmod) injury_15\NN\14052046|with|an|allergic-type|hepatic
D006221_D056486 CID halothane_0\NN\3570838| (r_compound) hepatitis_1\NN\14127211|halothane
D006221_D056486 CID halothane_16\NN\3570838| (r_compound) patients_18\NNS\9898892|on|halothane|hepatitis (l_compound) hepatitis_17\NN\14127211|
D006221_D056486 CID halothane_23\NN\3570838| (r_compound) hepatitis_24\NN\14127211|of|halothane
D006221_D056486 CID halothane_30\NN\3570838| (r_compound) administration_31\NN\1133281|to|halothane (r_nmod) subsequent_28\JJ\1740|administration (r_conj) either_25\CC\1740|alone|or|subsequent (r_dep) similar_19\JJ\1740|that|either (l_nmod) that_21\DT\1740|to|hepatitis (l_nmod) hepatitis_24\NN\14127211|of|halothane
D014269_D056486 NONE trifluoroacetyl_9\NN\1740| (r_compound) adduct_10\NN\14818238|(|trifluoroacetyl|) (r_appos) product_7\NN\3076708|to|a|protein-bound|biotransformation|adduct (r_nmod) response_2\NN\11410625|an|antibody|product (r_nsubjpass) detected_14\VBN\2163746|response|has|been|patients|. (l_nmod) patients_18\NNS\9898892|on|halothane|hepatitis (l_compound) hepatitis_17\NN\14127211|
D004737_D004342 NONE enflurane_8\NN\3299929|between|and|isoflurane (r_nmod) cross-reactivity_6\NN\1740|enflurane|hypersensitivity (l_nmod) hypersensitivity_13\NN\14531772|with|the|induced
D004737_D004342 NONE enflurane_11\NN\3299929|and/or|isoflurane (r_nsubj) produce_15\VB\1617192|which|enflurane|could|condition (l_dobj) condition_18\NN\24720|a|hypersensitivity|similar (l_compound) hypersensitivity_17\NN\14531772|
D007530_D004342 NONE isoflurane_10\NN\3570838| (r_conj) enflurane_8\NN\3299929|between|and|isoflurane (r_nmod) cross-reactivity_6\NN\1740|enflurane|hypersensitivity (l_nmod) hypersensitivity_13\NN\14531772|with|the|induced
D007530_D004342 NONE isoflurane_13\NN\3570838| (r_conj) enflurane_11\NN\3299929|and/or|isoflurane (r_nsubj) produce_15\VB\1617192|which|enflurane|could|condition (l_dobj) condition_18\NN\24720|a|hypersensitivity|similar (l_compound) hypersensitivity_17\NN\14531772|
D006221_D004342 NONE halothane_16\NN\3570838|by (r_nmod) induced_14\VBN\1627355|halothane (r_acl) hypersensitivity_13\NN\14531772|with|the|induced
D006221_D004342 NONE halothane_23\NN\3570838| (r_compound) hepatitis_24\NN\14127211|of|halothane (r_nmod) that_21\DT\1740|to|hepatitis (r_nmod) similar_19\JJ\1740|that|either (r_amod) condition_18\NN\24720|a|hypersensitivity|similar (l_compound) hypersensitivity_17\NN\14531772|
D006221_D004342 NONE halothane_30\NN\3570838| (r_compound) administration_31\NN\1133281|to|halothane (r_nmod) subsequent_28\JJ\1740|administration (r_conj) either_25\CC\1740|alone|or|subsequent (r_dep) similar_19\JJ\1740|that|either (r_amod) condition_18\NN\24720|a|hypersensitivity|similar (l_compound) hypersensitivity_17\NN\14531772|
2819587
7053705
D013866_D006504 CID 6-thioguanine_5\NN\1740|by (r_nmod) caused_3\VBN\1617192|6-thioguanine (r_acl) disease_2\NN\14061805|hepatic|veno-occlusive|caused|.
D013866_D006504 CID 6-thioguanine_23\NN\1740|with (r_nmod) therapy_21\NN\657604|of|maintenance|6-thioguanine (r_nmod) months_18\NNS\15113229|after|10|therapy (r_nmod) developed_7\VBD\1753788|disease|man|months|. (l_nsubj) disease_3\NN\14061805|reversible|veno-occlusive|liver (l_nmod) liver_6\NN\5298729|of|the
D013866_D006504 CID 6-thioguanine_31\NN\1740|to (r_nmod) related_28\JJ\1740|6-thioguanine (r_amod) veno-occlusive_27\JJ\1740|of|related (r_nmod) case_25\NN\7283608|may|be|the|first|veno-occlusive (r_conj) presented_2\VBD\2137132|case|opportunity|,|and|case|. (l_dobj) opportunity_5\NN\14481929|a|unique|observe (l_acl) observe_7\VB\2163746|to|features|time (l_dobj) features_10\NNS\5849040|the|histologic|disease (l_nmod) disease_16\NN\14061805|of|reversible|hepatic|veno-occlusive
D013866_D054198 NONE 6-thioguanine_23\NN\1740|with (r_nmod) therapy_21\NN\657604|of|maintenance|6-thioguanine (r_nmod) months_18\NNS\15113229|after|10|therapy (r_nmod) developed_7\VBD\1753788|disease|man|months|. (l_nmod) man_11\NN\9605289|in|a|23-year-old|leukemia (l_nmod) leukemia_15\NN\14239918|with|acute|lymphocytic
16826348
D003561_D010523 CID arabinoside_6\NN\1740| (r_compound) treatment_7\NN\654885|by|high-dose|cytosine|arabinoside (r_nmod) caused_2\VBN\1617192|treatment|patient (r_acl) neuropathy_1\NN\14204950|peripheral|caused|.
D003561_D010523 CID arabinoside_12\NN\1740|high-dose|cytosine (r_nsubj) therapy_15\NN\657604|unclear|,|arabinoside|is|a|toxic|,|and|play (l_advcl) unclear_8\JJ\1740|although|mechanisms|are|still (l_nsubj) mechanisms_2\NNS\13446390|the|neuropathy (l_nmod) neuropathy_5\NN\14204950|of|peripheral
D003561_D015470 NONE arabinoside_6\NN\1740| (r_compound) treatment_7\NN\654885|by|high-dose|cytosine|arabinoside (r_nmod) caused_2\VBN\1617192|treatment|patient (l_nmod) patient_10\NN\9898892|in|a|leukemia (l_nmod) leukemia_14\NN\14239918|with|acute|myeloid
D003561_D064420 NONE arabinoside_8\NN\1740|of|high-dose|cytosine (r_nmod) toxicity_4\NN\13576101|the|system|arabinoside
D003561_D064420 NONE arabinoside_8\NN\1740|of|high-dose|cytosine (r_nmod) toxicity_4\NN\13576101|the|system|arabinoside (r_nsubjpass) recognized_11\VBN\686447|toxicity|is|well|,|but|reported (l_conj) reported_27\VBN\831651|toxicity|has|been|infrequently|. (l_nsubjpass) toxicity_15\NN\13576101|the|arabinoside|system
D003561_D064420 NONE arabinoside_18\NN\1740|of|cytosine (r_nmod) toxicity_15\NN\13576101|the|arabinoside|system (r_nsubjpass) reported_27\VBN\831651|toxicity|has|been|infrequently|. (r_conj) recognized_11\VBN\686447|toxicity|is|well|,|but|reported (l_nsubjpass) toxicity_4\NN\13576101|the|system|arabinoside
D003561_D064420 NONE arabinoside_18\NN\1740|of|cytosine (r_nmod) toxicity_15\NN\13576101|the|arabinoside|system
D003561_D006987 NONE arabinoside_6\NN\1740|of|high-dose|cytosine (r_nmod) course_2\NN\883297|the|first|arabinoside (r_nsubj) resulted_7\VBD\2633881|course|symptoms|,|but|complained (l_conj) complained_26\VBD\843959|day|,|patient|numbness|. (l_nmod) numbness_28\NN\14299637|of|foot
D008775_D009422 NONE methylprednisolone_34\NN\1740|to (r_nmod) responded_32\VBD\2367363|symptoms|subsequently|methylprednisolone|. (r_conj) worsened_19\VBD\146138|resolving|however|,|received|,|symptoms|,|development|,|and|responded (l_ccomp) resolving_4\VBG\352826|neuropathy|was|gradually|; (l_nsubj) neuropathy_1\NN\14204950|this
D008775_D006086 NONE methylprednisolone_34\NN\1740|to (r_nmod) responded_32\VBD\2367363|symptoms|subsequently|methylprednisolone|. (r_conj) worsened_19\VBD\146138|resolving|however|,|received|,|symptoms|,|development|,|and|responded (l_nmod) development_23\NN\248977|with|the|disease (l_nmod) disease_26\NN\14061805|of|graft-versus-host
16844102
D024502_D020258 NONE alpha-tocopherol_2\NN\1740|of|and|deferoxamine (r_nmod) effect_0\NN\34213|alpha-tocopherol|neurotoxicity|. (l_nmod) neurotoxicity_7\NN\1740|on|methamphetamine-induced
D024502_D020258 NONE alpha-tocopherol_6\NN\1740|of|alpha-tc|,|scavenger|,|and|deferoxamine (r_nmod) effect_4\NN\34213|the|alpha-tocopherol|neurotoxicity (l_nmod) neurotoxicity_31\NN\1740|on|the|ma-induced
D024502_D020258 NONE alpha-tc_8\NN\1740|(|) (r_appos) alpha-tocopherol_6\NN\1740|of|alpha-tc|,|scavenger|,|and|deferoxamine (r_nmod) effect_4\NN\34213|the|alpha-tocopherol|neurotoxicity (l_nmod) neurotoxicity_31\NN\1740|on|the|ma-induced
D003676_D020258 NONE deferoxamine_4\NN\1740| (r_conj) alpha-tocopherol_2\NN\1740|of|and|deferoxamine (r_nmod) effect_0\NN\34213|alpha-tocopherol|neurotoxicity|. (l_nmod) neurotoxicity_7\NN\1740|on|methamphetamine-induced
D003676_D020258 NONE deferoxamine_19\NN\1740|dfo|,|chelator|, (r_conj) alpha-tocopherol_6\NN\1740|of|alpha-tc|,|scavenger|,|and|deferoxamine (r_nmod) effect_4\NN\34213|the|alpha-tocopherol|neurotoxicity (l_nmod) neurotoxicity_31\NN\1740|on|the|ma-induced
D003676_D020258 NONE dfo_21\NN\1740|(|) (r_appos) deferoxamine_19\NN\1740|dfo|,|chelator|, (r_conj) alpha-tocopherol_6\NN\1740|of|alpha-tc|,|scavenger|,|and|deferoxamine (r_nmod) effect_4\NN\34213|the|alpha-tocopherol|neurotoxicity (l_nmod) neurotoxicity_31\NN\1740|on|the|ma-induced
D008694_D020258 NONE methamphetamine-induced_6\JJ\1740| (r_amod) neurotoxicity_7\NN\1740|on|methamphetamine-induced
D008694_D020258 NONE methamphetamine_0\NN\2704153| (r_compound) (ma)-induced_1\NN\1740|methamphetamine (r_nummod) neurotoxicity_3\NN\1740|(ma)-induced|dopaminergic
D008694_D020258 NONE (ma)-induced_1\NN\1740|methamphetamine (r_nummod) neurotoxicity_3\NN\1740|(ma)-induced|dopaminergic
D008694_D020258 NONE ma-induced_30\JJ\1740| (r_amod) neurotoxicity_31\NN\1740|on|the|ma-induced
D010100_D020258 NONE oxygen_15\NN\14622893| (r_compound) species_16\NNS\7992450|of|reactive|oxygen (r_nmod) scavenger_12\NN\14779550|a|species (r_appos) alpha-tocopherol_6\NN\1740|of|alpha-tc|,|scavenger|,|and|deferoxamine (r_nmod) effect_4\NN\34213|the|alpha-tocopherol|neurotoxicity (l_nmod) neurotoxicity_31\NN\1740|on|the|ma-induced
D007501_D020258 NONE iron_25\NN\14625458| (r_compound) chelator_26\NN\1740|an|iron (r_appos) deferoxamine_19\NN\1740|dfo|,|chelator|, (r_conj) alpha-tocopherol_6\NN\1740|of|alpha-tc|,|scavenger|,|and|deferoxamine (r_nmod) effect_4\NN\34213|the|alpha-tocopherol|neurotoxicity (l_nmod) neurotoxicity_31\NN\1740|on|the|ma-induced
D024502_D005334 NONE alpha-tc_0\NN\1740|and|dfo (r_nsubj) attenuated_3\VBD\224901|alpha-tc|hyperthermia|. (l_dobj) hyperthermia_6\NN\14034177|the|ma-induced|as|alterations
D003676_D005334 NONE dfo_2\NN\1740| (r_conj) alpha-tc_0\NN\1740|and|dfo (r_nsubj) attenuated_3\VBD\224901|alpha-tc|hyperthermia|. (l_dobj) hyperthermia_6\NN\14034177|the|ma-induced|as|alterations
D008694_D005334 CID ma-induced_5\JJ\1740| (r_amod) hyperthermia_6\NN\14034177|the|ma-induced|as|alterations
D024502_D009422 NONE alpha-tc_3\NN\1740|and|dfo (r_nsubj) ameliorate_6\VBP\126264|that|alpha-tc|damage|decreasing (l_dobj) damage_10\NN\7296428|the|ma-induced|neuronal
D003676_D009422 NONE dfo_5\NN\1740| (r_conj) alpha-tc_3\NN\1740|and|dfo (r_nsubj) ameliorate_6\VBP\126264|that|alpha-tc|damage|decreasing (l_dobj) damage_10\NN\7296428|the|ma-induced|neuronal
D008694_D009422 CID ma-induced_8\JJ\1740| (r_amod) damage_10\NN\7296428|the|ma-induced|neuronal
19996135
D014148_D012640 CID acid_2\NN\14818238|high-dose|tranexamic (r_nsubjpass) associated_4\VBN\628491|acid|is|seizures|. (l_nmod) seizures_8\NNS\14081375|with|nonischemic|clinical|patients
D014148_D012640 CID txa_19\NN\1740| (r_compound) usage_20\NN\407535|between|txa|and|seizures (l_conj) seizures_22\NNS\14081375|surgery
D014148_D012640 CID txa_9\NN\1740|of (r_nmod) doses_7\NNS\3740161|high|txa (r_dobj) received_5\VBD\2210855|patients|doses|ranging|,|had (l_nsubj) patients_2\NNS\9898892|all|24|seizures (l_nmod) seizures_4\NNS\14081375|with
D014148_D012640 CID txa_9\NN\1740|of|high-dose (r_nmod) use_6\NN\407535|txa|patients|conjunction (r_nsubjpass) associated_23\VBN\628491|that|use|is|seizures (l_nmod) seizures_26\NNS\14081375|with|clinical|patients
6216862
D010396_D001172 NONE penicillamine_4\NN\3740161| (r_compound) therapy_5\NN\657604|of|penicillamine (r_nmod) effects_2\NNS\13245626|multiple|side|therapy|patient|. (l_nmod) patient_8\NN\9898892|in|one|arthritis (l_nmod) arthritis_11\NN\14171682|with|rheumatoid
D010396_D001172 NONE penicillamine_20\NN\3740161| (r_compound) therapy_21\NN\657604|of|penicillamine|patients (l_nmod) patients_23\NNS\9898892|in|arthritis (l_nmod) arthritis_26\NN\14171682|with|rheumatoid
D010396_D001172 NONE penicillamine_32\NN\3740161|with (r_nmod) treated_30\VBN\2376958|penicillamine (r_acl) arthritis_29\NN\14171682|with|rheumatoid|treated
D010396_D005076 CID penicillamine_20\NN\3740161| (r_compound) therapy_21\NN\657604|of|penicillamine|patients (r_nmod) complications_18\NNS\1073995|as|therapy (r_nmod) recorded_16\VBN\2225492|rashes|have|all|been|complications|. (l_nsubjpass) rashes_1\NNS\14321469|skin|,|proteinuria|,|erythematosus
D010396_D011507 CID penicillamine_20\NN\3740161| (r_compound) therapy_21\NN\657604|of|penicillamine|patients (r_nmod) complications_18\NNS\1073995|as|therapy (r_nmod) recorded_16\VBN\2225492|rashes|have|all|been|complications|. (l_nsubjpass) rashes_1\NNS\14321469|skin|,|proteinuria|,|erythematosus (l_conj) proteinuria_3\NN\14299637|
D010396_D008180 CID penicillamine_20\NN\3740161| (r_compound) therapy_21\NN\657604|of|penicillamine|patients (r_nmod) complications_18\NNS\1073995|as|therapy (r_nmod) recorded_16\VBN\2225492|rashes|have|all|been|complications|. (l_nsubjpass) rashes_1\NNS\14321469|skin|,|proteinuria|,|erythematosus (l_conj) erythematosus_7\NN\1740|systemic|lupus|,|polymyositis
D010396_D017285 CID penicillamine_20\NN\3740161| (r_compound) therapy_21\NN\657604|of|penicillamine|patients (r_nmod) complications_18\NNS\1073995|as|therapy (r_nmod) recorded_16\VBN\2225492|rashes|have|all|been|complications|. (l_nsubjpass) rashes_1\NNS\14321469|skin|,|proteinuria|,|erythematosus (l_conj) erythematosus_7\NN\1740|systemic|lupus|,|polymyositis (l_conj) polymyositis_9\NN\14350292|and|gravis
D010396_D009157 CID penicillamine_20\NN\3740161| (r_compound) therapy_21\NN\657604|of|penicillamine|patients (r_nmod) complications_18\NNS\1073995|as|therapy (r_nmod) recorded_16\VBN\2225492|rashes|have|all|been|complications|. (l_nsubjpass) rashes_1\NNS\14321469|skin|,|proteinuria|,|erythematosus (l_conj) erythematosus_7\NN\1740|systemic|lupus|,|polymyositis (l_conj) polymyositis_9\NN\14350292|and|gravis (l_conj) gravis_12\NN\1740|myasthenia
D010396_D012871 NONE penicillamine_32\NN\3740161|with (r_nmod) treated_30\VBN\2376958|penicillamine (r_acl) arthritis_29\NN\14171682|with|rheumatoid|treated (r_nmod) patients_26\NNS\9898892|not|in|arthritis (r_conj) patients_18\NNS\9898892|in|disease|but|patients (r_nmod) effect_16\NN\34213|as|a|rare|side|patients (r_nmod) reported_11\VBN\831651|which|has|been|effect (r_acl:relcl) serpiginosa_6\NN\1740|elastosis|perforans|,|reported (r_dobj) resembled_3\VBD\2657219|lesion|serpiginosa|. (l_nsubj) lesion_2\NN\14204950|the|skin
D010396_C536202 NONE penicillamine_32\NN\3740161|with (r_nmod) treated_30\VBN\2376958|penicillamine (r_acl) arthritis_29\NN\14171682|with|rheumatoid|treated (r_nmod) patients_26\NNS\9898892|not|in|arthritis (r_conj) patients_18\NNS\9898892|in|disease|but|patients (r_nmod) effect_16\NN\34213|as|a|rare|side|patients (r_nmod) reported_11\VBN\831651|which|has|been|effect (r_acl:relcl) serpiginosa_6\NN\1740|elastosis|perforans|,|reported
D010396_D006527 NONE penicillamine_32\NN\3740161|with (r_nmod) treated_30\VBN\2376958|penicillamine (r_acl) arthritis_29\NN\14171682|with|rheumatoid|treated (r_nmod) patients_26\NNS\9898892|not|in|arthritis (r_conj) patients_18\NNS\9898892|in|disease|but|patients (l_nmod) disease_22\NN\14061805|with|wilson|'s
20394767
D015016_D012021 CID yohimbine_2\NN\1740| (r_nsubj) increased_3\VBD\169651|furthermore|,|yohimbine|amplitude|,|suppressed|. (l_dobj) amplitude_6\NN\7444668|baseline|startle|les (l_compound) startle_5\NN\863513|
D015016_D012021 CID yohimbine_2\NN\1740| (r_nsubj) increased_3\VBD\169651|furthermore|,|yohimbine|amplitude|,|suppressed|. (l_advcl) suppressed_13\VBD\2510337|while|mcpp|startle|and|suppressed (l_dobj) startle_15\NN\863513|baseline|les
D015016_D012021 CID yohimbine_2\NN\1740| (r_nsubj) increased_3\VBD\169651|furthermore|,|yohimbine|amplitude|,|suppressed|. (l_advcl) suppressed_13\VBD\2510337|while|mcpp|startle|and|suppressed (l_conj) suppressed_24\VBD\2510337|ptz|startle (l_dobj) startle_26\NN\863513|baseline|fps
C015068_D012021 CID mcpp_12\NN\1740| (r_nsubj) suppressed_13\VBD\2510337|while|mcpp|startle|and|suppressed (r_advcl) increased_3\VBD\169651|furthermore|,|yohimbine|amplitude|,|suppressed|. (l_dobj) amplitude_6\NN\7444668|baseline|startle|les (l_compound) startle_5\NN\863513|
C015068_D012021 CID mcpp_12\NN\1740| (r_nsubj) suppressed_13\VBD\2510337|while|mcpp|startle|and|suppressed (l_dobj) startle_15\NN\863513|baseline|les
C015068_D012021 CID mcpp_12\NN\1740| (r_nsubj) suppressed_13\VBD\2510337|while|mcpp|startle|and|suppressed (l_conj) suppressed_24\VBD\2510337|ptz|startle (l_dobj) startle_26\NN\863513|baseline|fps
D010433_D012021 CID ptz_23\NN\1740| (r_nsubj) suppressed_24\VBD\2510337|ptz|startle (r_conj) suppressed_13\VBD\2510337|while|mcpp|startle|and|suppressed (r_advcl) increased_3\VBD\169651|furthermore|,|yohimbine|amplitude|,|suppressed|. (l_dobj) amplitude_6\NN\7444668|baseline|startle|les (l_compound) startle_5\NN\863513|
D010433_D012021 CID ptz_23\NN\1740| (r_nsubj) suppressed_24\VBD\2510337|ptz|startle (r_conj) suppressed_13\VBD\2510337|while|mcpp|startle|and|suppressed (l_dobj) startle_15\NN\863513|baseline|les
D010433_D012021 CID ptz_23\NN\1740| (r_nsubj) suppressed_24\VBD\2510337|ptz|startle (l_dobj) startle_26\NN\863513|baseline|fps
18808529
D007545_D009202 CID isoproterenol_0\NN\3740161| (r_nsubj) induces_1\VBZ\1627355|isoproterenol|loss|correlation|. (l_dep) correlation_10\NN\13841213|injury (l_nmod) injury_13\NN\14052046|with|myocardial
D007545_D009202 CID isoproterenol-induced_3\JJ\1740| (r_amod) damage_5\NN\7296428|of|isoproterenol-induced|myocardial
D007545_D009202 CID isoproterenol-induced_3\JJ\1740| (r_amod) damage_5\NN\7296428|of|isoproterenol-induced|myocardial (r_nmod) mechanism_1\NN\13446390|the|damage (r_nsubj) unknown_7\JJ\1740|mechanism|is|,|but|explanation (l_conj) explanation_26\NN\6722453|mismatch|is|the|best|alterations|. (l_nsubj) mismatch_11\NN\5695806|a|supply|hypotension (l_nmod) hypotension_19\NN\14057371|following|coronary|and|hyperactivity (l_conj) hyperactivity_22\NN\14052403|myocardial
D007545_D007022 NONE isoproterenol-induced_3\JJ\1740| (r_amod) damage_5\NN\7296428|of|isoproterenol-induced|myocardial (r_nmod) mechanism_1\NN\13446390|the|damage (r_nsubj) unknown_7\JJ\1740|mechanism|is|,|but|explanation (l_conj) explanation_26\NN\6722453|mismatch|is|the|best|alterations|. (l_nsubj) mismatch_11\NN\5695806|a|supply|hypotension (l_nmod) hypotension_19\NN\14057371|following|coronary|and|hyperactivity
D010100_D009202 NONE oxygen_13\NN\14622893| (r_compound) supply_14\NN\13576355|of|oxygen|vs.|demand (r_nmod) mismatch_11\NN\5695806|a|supply|hypotension (r_nsubj) explanation_26\NN\6722453|mismatch|is|the|best|alterations|. (r_conj) unknown_7\JJ\1740|mechanism|is|,|but|explanation (l_nsubj) mechanism_1\NN\13446390|the|damage (l_nmod) damage_5\NN\7296428|of|isoproterenol-induced|myocardial
D010100_D009202 NONE oxygen_13\NN\14622893| (r_compound) supply_14\NN\13576355|of|oxygen|vs.|demand (r_nmod) mismatch_11\NN\5695806|a|supply|hypotension (l_nmod) hypotension_19\NN\14057371|following|coronary|and|hyperactivity (l_conj) hyperactivity_22\NN\14052403|myocardial
D010100_D007022 NONE oxygen_13\NN\14622893| (r_compound) supply_14\NN\13576355|of|oxygen|vs.|demand (r_nmod) mismatch_11\NN\5695806|a|supply|hypotension (l_nmod) hypotension_19\NN\14057371|following|coronary|and|hyperactivity
D007545_D007511 CID isoproterenol_29\NN\3740161|by (r_nmod) induced_27\VBN\1627355|isoproterenol (r_acl) injury_26\NN\14052046|hence|severe|induced (r_conj) alterations_11\NNS\7283608|the|severe|integrity|and|injury (r_dobj) explain_8\VBP\831651|changes|,|alterations|. (l_nsubj) changes_1\NNS\7283608|these|,|related (l_acl) related_3\VBN\628491|injury (l_nmod) injury_6\NN\14052046|to|ischaemic
17682013
D008727_D056784 CID methotrexate_23\NN\2722166|of|intrathecal|leukaemia (r_nmod) recipients_20\NNS\9764201|in|methotrexate (r_nmod) described_10\VBN\1001294|leukoencephalopathy|has|been|complication|recipients (l_nsubjpass) leukoencephalopathy_4\NN\1740|a|transient|mimicking
D008727_D056784 CID methotrexate_13\NN\2722166|with|intrathecal|,|5-fluorouracil|,|and|capecitabine (r_nmod) treated_11\VBN\2376958|methotrexate (r_acl) patients_10\NNS\9898892|in|treated (r_nmod) leukoencephalopathy_8\NN\1740|of|toxic|patients
D008727_D002544 NONE methotrexate_23\NN\2722166|of|intrathecal|leukaemia (r_nmod) recipients_20\NNS\9764201|in|methotrexate (r_nmod) described_10\VBN\1001294|leukoencephalopathy|has|been|complication|recipients (l_nsubjpass) leukoencephalopathy_4\NN\1740|a|transient|mimicking (l_acl) mimicking_5\VBG\1742886|accident (l_dobj) accident_7\NN\7314427|cerebrovascular
D008727_D007938 NONE methotrexate_23\NN\2722166|of|intrathecal|leukaemia (l_nmod) leukaemia_26\NN\14239918|for|childhood
D005472_D056784 CID 5-fluorouracil_20\NN\1740|and|carmofur (r_conj) methotrexate_13\NN\2722166|with|intrathecal|,|5-fluorouracil|,|and|capecitabine (r_nmod) treated_11\VBN\2376958|methotrexate (r_acl) patients_10\NNS\9898892|in|treated (r_nmod) leukoencephalopathy_8\NN\1740|of|toxic|patients
C017367_D056784 CID carmofur_24\NN\1740|derivative (r_conj) 5-fluorouracil_20\NN\1740|and|carmofur (r_conj) methotrexate_13\NN\2722166|with|intrathecal|,|5-fluorouracil|,|and|capecitabine (r_nmod) treated_11\VBN\2376958|methotrexate (r_acl) patients_10\NNS\9898892|in|treated (r_nmod) leukoencephalopathy_8\NN\1740|of|toxic|patients
C110904_D056784 CID capecitabine_27\NN\1740| (r_conj) methotrexate_13\NN\2722166|with|intrathecal|,|5-fluorouracil|,|and|capecitabine (r_nmod) treated_11\VBN\2376958|methotrexate (r_acl) patients_10\NNS\9898892|in|treated (r_nmod) leukoencephalopathy_8\NN\1740|of|toxic|patients
9165568
D018967_D009459 CID risperidone_4\NN\1740|with (r_nmod) syndrome_2\NN\5870365|neuroleptic|malignant|risperidone|.
D018967_D009459 CID risperidone_10\NN\1740|with (r_nmod) monotherapy_8\NN\1740|after|risperidone (r_nmod) developed_3\VBD\1753788|woman|syndrome|monotherapy|. (l_dobj) syndrome_6\NN\5870365|neuroleptic|malignant
D018967_D009459 CID risperidone_11\NN\1740|with (r_nmod) observed_9\VBN\2163746|risperidone (r_acl) protection_4\NN\407535|the|effects|observed (r_nsubj) ensure_14\VB\664483|that|protection|does|not|protection (l_dobj) protection_15\NN\407535|syndrome (l_nmod) syndrome_19\NN\5870365|from|neuroleptic|malignant
D004298_D009459 NONE dopamine_10\NN\14807737| (r_compound) blockade_13\NN\952963|of|dopamine|receptor|striatum (r_nmod) result_8\NN\34213|to|be|a|blockade (r_xcomp) thought_4\VBN\670261|syndrome|is|result|. (l_nsubjpass) syndrome_2\NN\5870365|neuroleptic|malignant
D018967_D001480 NONE risperidone_14\NN\1740|with (r_nmod) impart_6\VB\952524|to|frequency|risperidone|dosages (l_dobj) frequency_9\NN\15286249|the|low|symptoms (l_nmod) symptoms_12\NNS\5823932|of|extrapyramidal
9321531
D007980_D010300 NONE levodopa-induced_11\JJ\1740| (r_amod) dyskinesias_12\NNS\14084880|levodopa-induced|and|disability (r_dobj) reduces_10\VBZ\441445|conclusions|,|pallidotomy|significantly|dyskinesias|. (l_nsubj) conclusions_0\NNS\5837957|:|disease (l_nmod) disease_6\NN\14061805|in|late-stage|parkinson|'s
D007980_D004409 CID levodopa-induced_11\JJ\1740| (r_amod) dyskinesias_12\NNS\14084880|levodopa-induced|and|disability
11573852
D000666_D012640 CID b-induced_1\JJ\1740|amphotericin (r_amod) seizures_2\NNS\14081375|b-induced|patient|.
D000666_D012640 CID b_18\NN\1355326|amphotericin (r_compound) infusion_19\NN\14589223|following|b (r_nmod) episodes_8\NNS\7283608|of|multiple|activity|patent|infusion (l_nmod) activity_11\NN\30358|of|seizure (l_compound) seizure_10\NN\14081375|
D000666_D012640 CID b_17\NN\1355326|of|amphotericin (r_nmod) infusion_14\NN\14589223|during|intravenous|b (r_nmod) experienced_7\VBD\2108377|:|man|seizures|infusion|,|then|seizures|. (l_conj) seizures_22\NNS\14081375|petit|mal|stopped
D000666_D012640 CID b_15\NN\1355326|amphotercin (r_compound) administration_16\NN\1133281|during|b (r_nmod) occurred_11\VBD\2623529|administration (r_conj) persisted_9\VBD\118523|administration|,|seizures|and|occurred|. (l_nsubj) seizures_8\NNS\14081375|the
D000666_D012640 CID b_8\NN\1355326|amphotericin (r_nsubj) cause_11\NN\7323922|that|b|was|the|seizures (l_nmod) seizures_14\NNS\14081375|of|the|patient
D000666_D012640 CID b_3\NN\1355326|amphotericin (r_nsubj) seems_4\VBZ\2604760|conclusions|:|b|cause|. (l_xcomp) cause_9\NN\7323922|to|be|the|probable|seizures (l_nmod) seizures_12\NNS\14081375|of|the
D000666_D012640 CID b_11\NN\1355326|with|amphotericin (r_nmod) associated_8\VBN\628491|b (r_acl) seizures_7\NNS\14081375|of|associated
D000666_D000163 NONE b-induced_1\JJ\1740|amphotericin (r_amod) seizures_2\NNS\14081375|b-induced|patient|. (l_nmod) patient_5\NN\9898892|in|a|aids (l_nmod) aids_7\NNP\13974317|with
D000666_D000163 NONE b_18\NN\1355326|amphotericin (r_compound) infusion_19\NN\14589223|following|b (r_nmod) episodes_8\NNS\7283608|of|multiple|activity|patent|infusion (l_nmod) patent_15\NN\6470073|in|an|aids (l_compound) aids_14\NN\13974317|
D000666_D000163 NONE b_8\NN\1355326|amphotericin (r_nsubj) cause_11\NN\7323922|that|b|was|the|seizures (l_nmod) seizures_14\NNS\14081375|of|the|patient (l_nmod) patient_18\NN\9898892|in|this|aids (l_compound) aids_17\NN\13974317|
D000666_D004830 NONE b_17\NN\1355326|of|amphotericin (r_nmod) infusion_14\NN\14589223|during|intravenous|b (r_nmod) experienced_7\VBD\2108377|:|man|seizures|infusion|,|then|seizures|. (l_dobj) seizures_11\NNS\14081375|recurrent|mal
D010672_D012640 NONE phenytoin_3\NN\3550533|of|and|lorazepam (r_nmod) administration_1\NN\1133281|despite|phenytoin (r_nmod) persisted_9\VBD\118523|administration|,|seizures|and|occurred|. (l_nsubj) seizures_8\NNS\14081375|the
D008140_D012640 NONE lorazepam_5\NN\2830852| (r_conj) phenytoin_3\NN\3550533|of|and|lorazepam (r_nmod) administration_1\NN\1133281|despite|phenytoin (r_nmod) persisted_9\VBD\118523|administration|,|seizures|and|occurred|. (l_nsubj) seizures_8\NNS\14081375|the
D000431_D000437 NONE alcohol_9\NN\7881800| (r_compound) intake_10\NN\13440063|alcohol|as|withdrawal (r_nsubj) cause_17\VB\1617192|had|;|intake|can|also|seizures|. (l_ccomp) had_2\VBD\2108377|patient|history (l_dobj) history_4\NN\15120823|a|abuse (l_nmod) abuse_7\NN\418025|of|alcohol
D000431_D012640 NONE alcohol_9\NN\7881800| (r_compound) intake_10\NN\13440063|alcohol|as|withdrawal (r_nsubj) cause_17\VB\1617192|had|;|intake|can|also|seizures|. (l_dobj) seizures_18\NNS\14081375|
D016049_D012640 NONE didanosine_0\NN\2725367| (r_nsubj) has_2\VBZ\2108377|didanosine|also|potential|. (l_dobj) potential_4\NN\14481929|a|inducing (l_advcl) inducing_6\VBG\1627355|for|seizures (l_dobj) seizures_7\NNS\14081375|
3962737
D000638_D056486 CID amiodarone_2\NN\2715941|of (r_nmod) hepatotoxicity_0\NN\1740|amiodarone|.
D000638_D056486 CID amiodarone_7\NN\2715941| (r_compound) treatment_8\NN\654885|due|amiodarone (r_nmod) hepatitis_4\NN\14127211|with|cholestatic|treatment
D000638_D056486 CID amiodarone_7\NN\2715941| (r_compound) treatment_8\NN\654885|due|amiodarone (r_nmod) hepatitis_4\NN\14127211|with|cholestatic|treatment (r_nmod) patient_1\NN\9898892|a|hepatitis (r_nsubjpass) presented_10\VBN\2137132|patient|is|below|and|given (l_conj) given_21\VBN\2327200|review|is|. (l_nsubjpass) review_14\NN\5733583|a|hepatotoxicity (l_nmod) hepatotoxicity_17\NN\1740|of|the|amiodarone
D000638_D056486 CID amiodarone_19\NN\2715941|of (r_nmod) hepatotoxicity_17\NN\1740|of|the|amiodarone (r_nmod) review_14\NN\5733583|a|hepatotoxicity (r_nsubjpass) given_21\VBN\2327200|review|is|. (r_conj) presented_10\VBN\2137132|patient|is|below|and|given (l_nsubjpass) patient_1\NN\9898892|a|hepatitis (l_nmod) hepatitis_4\NN\14127211|with|cholestatic|treatment
D000638_D056486 CID amiodarone_19\NN\2715941|of (r_nmod) hepatotoxicity_17\NN\1740|of|the|amiodarone
D000638_D056486 CID amiodarone_12\NN\2715941| (r_compound) treatment_13\NN\654885|due|amiodarone (r_nmod) injury_9\NN\14052046|of|hepatic|treatment|,|steatosis
D000638_D056486 CID amiodarone_12\NN\2715941| (r_compound) treatment_13\NN\654885|due|amiodarone (r_nmod) injury_9\NN\14052046|of|hepatic|treatment|,|steatosis (l_nmod) steatosis_16\NN\1740|including|,|alterations (l_conj) alterations_18\NNS\7283608|resembling (l_acl) resembling_19\VBG\2657219|hepatitis (l_xcomp) hepatitis_21\NN\14127211|alcoholic|,|hepatitis (l_conj) hepatitis_24\NN\14127211|cholestatic|and|cirrhosis
D000638_D013610 NONE amiodarone_0\NN\2715941| (r_nsubj) proved_2\VBN\2604760|amiodarone|has|effective|. (l_acomp) effective_4\JJ\1740|very|treatment (l_nmod) treatment_7\NN\654885|in|the|tachyarrhythmias (l_nmod) tachyarrhythmias_12\NNS\1740|of|resistant|cardiac
D000638_D002779 CID amiodarone_7\NN\2715941| (r_compound) treatment_8\NN\654885|due|amiodarone (r_nmod) hepatitis_4\NN\14127211|with|cholestatic|treatment
D000638_D002779 CID amiodarone_19\NN\2715941|of (r_nmod) hepatotoxicity_17\NN\1740|of|the|amiodarone (r_nmod) review_14\NN\5733583|a|hepatotoxicity (r_nsubjpass) given_21\VBN\2327200|review|is|. (r_conj) presented_10\VBN\2137132|patient|is|below|and|given (l_nsubjpass) patient_1\NN\9898892|a|hepatitis (l_nmod) hepatitis_4\NN\14127211|with|cholestatic|treatment
D000638_D002779 CID amiodarone_12\NN\2715941| (r_compound) treatment_13\NN\654885|due|amiodarone (r_nmod) injury_9\NN\14052046|of|hepatic|treatment|,|steatosis (l_nmod) steatosis_16\NN\1740|including|,|alterations (l_conj) alterations_18\NNS\7283608|resembling (l_acl) resembling_19\VBG\2657219|hepatitis (l_xcomp) hepatitis_21\NN\14127211|alcoholic|,|hepatitis (l_conj) hepatitis_24\NN\14127211|cholestatic|and|cirrhosis
D000638_D005234 CID amiodarone_12\NN\2715941| (r_compound) treatment_13\NN\654885|due|amiodarone (r_nmod) injury_9\NN\14052046|of|hepatic|treatment|,|steatosis (l_nmod) steatosis_16\NN\1740|including|,|alterations
D000638_D006519 NONE amiodarone_12\NN\2715941| (r_compound) treatment_13\NN\654885|due|amiodarone (r_nmod) injury_9\NN\14052046|of|hepatic|treatment|,|steatosis (l_nmod) steatosis_16\NN\1740|including|,|alterations (l_conj) alterations_18\NNS\7283608|resembling (l_acl) resembling_19\VBG\2657219|hepatitis (l_xcomp) hepatitis_21\NN\14127211|alcoholic|,|hepatitis
D000638_D008103 CID amiodarone_12\NN\2715941| (r_compound) treatment_13\NN\654885|due|amiodarone (r_nmod) injury_9\NN\14052046|of|hepatic|treatment|,|steatosis (l_nmod) steatosis_16\NN\1740|including|,|alterations (l_conj) alterations_18\NNS\7283608|resembling (l_acl) resembling_19\VBG\2657219|hepatitis (l_xcomp) hepatitis_21\NN\14127211|alcoholic|,|hepatitis (l_conj) hepatitis_24\NN\14127211|cholestatic|and|cirrhosis (l_conj) cirrhosis_27\NN\14116321|micronodular|liver (l_nmod) liver_30\NN\5298729|of|the
6436733
D014635_D004827 NONE acid_1\NN\14818238|valproic|vpa (r_nsubjpass) given_6\VBN\2327200|acid|was|patients|. (l_nmod) patients_10\NNS\9898892|to|24|epileptic|treated (l_amod) epileptic_9\JJ\1740|
D014635_D004827 NONE vpa_3\NN\1740|(|) (r_appos) acid_1\NN\14818238|valproic|vpa (r_nsubjpass) given_6\VBN\2327200|acid|was|patients|. (l_nmod) patients_10\NNS\9898892|to|24|epileptic|treated (l_amod) epileptic_9\JJ\1740|
D000641_D006970 CID ammonia_0\NN\14940386|nh3 (r_nsubj) higher_5\JJR\1740|ammonia|was|patients|,|similar|. (l_nmod) patients_7\NNS\9898892|in|complained|patients|than (l_acl:relcl) complained_14\VBD\843959|who|,|therapy|,|drowsiness (l_nmod) drowsiness_16\NN\14015731|of
D000641_D006970 CID nh3_2\NN\1740|(|) (r_appos) ammonia_0\NN\14940386|nh3 (r_nsubj) higher_5\JJR\1740|ammonia|was|patients|,|similar|. (l_nmod) patients_7\NNS\9898892|in|complained|patients|than (l_acl:relcl) complained_14\VBD\843959|who|,|therapy|,|drowsiness (l_nmod) drowsiness_16\NN\14015731|of
D014635_D006970 CID vpa_33\NN\1740| (r_compound) levels_35\NNS\4916342|vpa|plasma (r_nsubj) similar_37\JJ\1740|although|levels|were|groups (r_advcl) higher_5\JJR\1740|ammonia|was|patients|,|similar|. (l_nmod) patients_7\NNS\9898892|in|complained|patients|than (l_acl:relcl) complained_14\VBD\843959|who|,|therapy|,|drowsiness (l_nmod) drowsiness_16\NN\14015731|of
8012887
D006493_D013927 CID heparin-induced_7\JJ\1740| (r_amod) thrombosis_9\NN\14100769|of|heparin-induced|arterial
D006493_D013927 CID heparin-induced_6\JJ\1740| (r_amod) thrombosis_7\NN\14100769|with|heparin-induced
D006493_D013927 CID heparin_14\NN\2718259| (r_nmod:npmod) induced_15\JJ\1740|heparin (r_amod) aggregation_17\NN\31264|with|induced|platelet (r_nmod) patients_12\NNS\9898892|in|aggregation|require (r_nmod) development_8\NN\248977|against|thrombosis|patients (l_nmod) thrombosis_10\NN\14100769|of
D006493_D013927 CID heparin_14\NN\2718259| (r_nmod:npmod) induced_15\JJ\1740|heparin (r_amod) aggregation_17\NN\31264|with|induced|platelet (r_nmod) patients_12\NNS\9898892|in|aggregation|require (r_nmod) development_8\NN\248977|against|thrombosis|patients (r_nmod) prophylaxis_6\NN\1077350|for|development (r_nmod) used_3\VBN\1156834|ancrod|has|been|successfully|prophylaxis|,|but|defined (l_conj) defined_39\VBN\2604760|success|is|not|well|. (l_nsubjpass) success_27\NN\7283608|its|patients (l_nmod) patients_29\NNS\9898892|in|developed (l_acl:relcl) developed_32\VBN\1753788|who|have|syndrome (l_dobj) syndrome_35\NN\5870365|the|thrombosis (l_compound) thrombosis_34\NN\14100769|
D006493_D013927 CID heparin_23\NN\2718259|to (r_nmod) reexposure_21\NN\1740|brief|heparin (r_dobj) require_19\VBP\754942|who|reexposure (r_acl:relcl) patients_12\NNS\9898892|in|aggregation|require (r_nmod) development_8\NN\248977|against|thrombosis|patients (l_nmod) thrombosis_10\NN\14100769|of
D006493_D013927 CID heparin_23\NN\2718259|to (r_nmod) reexposure_21\NN\1740|brief|heparin (r_dobj) require_19\VBP\754942|who|reexposure (r_acl:relcl) patients_12\NNS\9898892|in|aggregation|require (r_nmod) development_8\NN\248977|against|thrombosis|patients (r_nmod) prophylaxis_6\NN\1077350|for|development (r_nmod) used_3\VBN\1156834|ancrod|has|been|successfully|prophylaxis|,|but|defined (l_conj) defined_39\VBN\2604760|success|is|not|well|. (l_nsubjpass) success_27\NN\7283608|its|patients (l_nmod) patients_29\NNS\9898892|in|developed (l_acl:relcl) developed_32\VBN\1753788|who|have|syndrome (l_dobj) syndrome_35\NN\5870365|the|thrombosis (l_compound) thrombosis_34\NN\14100769|
D006493_D013927 CID heparin-induced_14\JJ\1740| (r_amod) thrombosis_15\NN\14100769|with|heparin-induced
D006493_D001791 NONE heparin_14\NN\2718259| (r_nmod:npmod) induced_15\JJ\1740|heparin (r_amod) aggregation_17\NN\31264|with|induced|platelet
D006493_D001791 NONE heparin_23\NN\2718259|to (r_nmod) reexposure_21\NN\1740|brief|heparin (r_dobj) require_19\VBP\754942|who|reexposure (r_acl:relcl) patients_12\NNS\9898892|in|aggregation|require (l_nmod) aggregation_17\NN\31264|with|induced|platelet
663266
D003973_D014693 NONE diatrizoate_3\NN\1740|from (r_nmod) fibrillation_1\NN\14361664|ventricular|diatrizoate|with|agents|.
C027278_D064420 NONE %_5\NN\1740|renografin|76 (r_dobj) toxicity_1\NN\13576101|the|%
C027278_D064420 NONE %_13\NN\1740|hypaque|76 (r_dobj) that_9\DT\1740|with|% (r_nmod) compared_7\VBN\644583|toxicity|was|that|injection|. (l_nsubjpass) toxicity_1\NN\13576101|the|%
D003974_D014693 NONE renografin_7\NN\1740|with (r_nmod) occurred_2\VBD\2623529|fibrillation|often|renografin|,|suggesting|. (l_nsubj) fibrillation_1\NN\14361664|ventricular
D003974_D064420 NONE renografin_7\NN\1740|with (r_nmod) occurred_2\VBD\2623529|fibrillation|often|renografin|,|suggesting|. (l_advcl) suggesting_9\VBG\1010118|contribute (l_ccomp) contribute_13\VBP\126264|that|agents|toxicity (l_nmod) toxicity_15\NN\13576101|to|angiography
12852481
D001241_D000014 CID aspirin_0\NN\2707683|acid|,|inhibitor|, (r_nsubj) induces_17\VBZ\1627355|aspirin|anomalies|administered|ca|. (l_dobj) anomalies_19\NNS\14501726|developmental
D001241_D000014 CID acid_3\NN\14818238|(|acetylsalicylic|asa|) (r_appos) aspirin_0\NN\2707683|acid|,|inhibitor|, (r_nsubj) induces_17\VBZ\1627355|aspirin|anomalies|administered|ca|. (l_dobj) anomalies_19\NNS\14501726|developmental
D001241_D000014 CID asa_5\NN\1740|[|] (r_appos) acid_3\NN\14818238|(|acetylsalicylic|asa|) (r_appos) aspirin_0\NN\2707683|acid|,|inhibitor|, (r_nsubj) induces_17\VBZ\1627355|aspirin|anomalies|administered|ca|. (l_dobj) anomalies_19\NNS\14501726|developmental
D001241_D000014 CID asa_18\NN\1740| (r_nsubjpass) administered_20\VBN\2436349|when|asa|is|gd (r_advcl) compare_7\VB\644583|to|results|sprague-dawley|administered|;|compare (l_conj) compare_31\VB\644583|to|patterns|;|and|test (l_conj) test_48\VB\670261|to|hypothesis (l_dobj) hypothesis_50\NN\7162194|the|confounds (l_ccomp) confounds_55\VBZ\2604760|that|toxicity|detection|used (l_dobj) detection_57\NN\5708432|the|malformations (l_nmod) malformations_61\NNS\14213199|of|low|incidence|asa
D001241_D000014 CID asa_63\NN\1740|with (r_nmod) malformations_61\NNS\14213199|of|low|incidence|asa
D001241_D000014 CID asa_57\NN\1740| (r_nsubj) induces_58\VBZ\1627355|even|though|asa|malformations (r_advcl) focused_50\VBD\628491|results|hence|,|study|malformations|,|induces|. (l_nmod) malformations_53\NNS\14213199|on|these
D001241_D000014 CID asa_57\NN\1740| (r_nsubj) induces_58\VBZ\1627355|even|though|asa|malformations (l_dobj) malformations_62\NNS\14213199|several|other|low-incidence
D001241_D000014 CID asa_6\NN\1740| (r_nsubjpass) administered_8\VBN\2436349|when|asa|was|dose|or|period (r_advcl) similar_4\JJ\1740|variations|were|administered|. (l_nsubj) variations_0\NNS\7296428|and|malformations (l_conj) malformations_2\NNS\14213199|
D001241_D000014 CID asa_38\NN\1740|with|given (r_nmod) induced_36\VBN\1627355|that|,|titrating|,|malformations|could|also|be|asa (l_nsubjpass) malformations_17\NNS\14213199|occur|,|reported|,
D001241_D005767 NONE asa_18\NN\1740| (r_nsubjpass) administered_20\VBN\2436349|when|asa|is|gd (r_advcl) compare_7\VB\644583|to|results|sprague-dawley|administered|;|compare (l_conj) compare_31\VB\644583|to|patterns|;|and|test (l_conj) test_48\VB\670261|to|hypothesis (l_dobj) hypothesis_50\NN\7162194|the|confounds (l_ccomp) confounds_55\VBZ\2604760|that|toxicity|detection|used (l_nsubj) toxicity_54\NN\13576101|maternal|gastrointestinal
D001241_D005767 NONE asa_63\NN\1740|with (r_nmod) malformations_61\NNS\14213199|of|low|incidence|asa (r_nmod) detection_57\NN\5708432|the|malformations (r_dobj) confounds_55\VBZ\2604760|that|toxicity|detection|used (l_nsubj) toxicity_54\NN\13576101|maternal|gastrointestinal
D001241_D006345 CID asa_57\NN\1740| (r_nsubj) induces_58\VBZ\1627355|even|though|asa|malformations (r_advcl) focused_50\VBD\628491|results|hence|,|study|malformations|,|induces|. (l_nsubj) results_0\NNS\34213|:|suggested|jc|; (l_dep) suggested_5\VBD\1010118|evaluation|induce (l_ccomp) induce_8\VBP\1627355|that|nsaids|defects (l_dobj) defects_11\NNS\14462666|ventricular|septal|vsds|and|defects|rats|and|hernia
D001241_D006345 CID asa_57\NN\1740| (r_nsubj) induces_58\VBZ\1627355|even|though|asa|malformations (r_advcl) focused_50\VBD\628491|results|hence|,|study|malformations|,|induces|. (l_nsubj) results_0\NNS\34213|:|suggested|jc|; (l_dep) suggested_5\VBD\1010118|evaluation|induce (l_ccomp) induce_8\VBP\1627355|that|nsaids|defects (l_dobj) defects_11\NNS\14462666|ventricular|septal|vsds|and|defects|rats|and|hernia (l_appos) vsds_13\NNS\1740|(|)
D001241_D006345 CID asa_57\NN\1740| (r_nsubj) induces_58\VBZ\1627355|even|though|asa|malformations (r_advcl) focused_50\VBD\628491|results|hence|,|study|malformations|,|induces|. (l_nsubj) results_0\NNS\34213|:|suggested|jc|; (l_dep) suggested_5\VBD\1010118|evaluation|induce (l_ccomp) induce_8\VBP\1627355|that|nsaids|defects (l_dobj) defects_11\NNS\14462666|ventricular|septal|vsds|and|defects|rats|and|hernia (l_conj) hernia_25\NN\14295248|diaphragmatic|dh|,|mds|,|and|vsds|rabbits (l_conj) vsds_33\NNS\1740|
D001241_D009436 NONE asa_57\NN\1740| (r_nsubj) induces_58\VBZ\1627355|even|though|asa|malformations (r_advcl) focused_50\VBD\628491|results|hence|,|study|malformations|,|induces|. (l_nsubj) results_0\NNS\34213|:|suggested|jc|; (l_dep) suggested_5\VBD\1010118|evaluation|induce (l_ccomp) induce_8\VBP\1627355|that|nsaids|defects (l_dobj) defects_11\NNS\14462666|ventricular|septal|vsds|and|defects|rats|and|hernia (l_conj) defects_17\NNS\14462666|midline|mds
D001241_D009436 NONE asa_57\NN\1740| (r_nsubj) induces_58\VBZ\1627355|even|though|asa|malformations (r_advcl) focused_50\VBD\628491|results|hence|,|study|malformations|,|induces|. (l_nsubj) results_0\NNS\34213|:|suggested|jc|; (l_dep) suggested_5\VBD\1010118|evaluation|induce (l_ccomp) induce_8\VBP\1627355|that|nsaids|defects (l_dobj) defects_11\NNS\14462666|ventricular|septal|vsds|and|defects|rats|and|hernia (l_conj) defects_17\NNS\14462666|midline|mds (l_appos) mds_19\NNS\14622893|(|)
D001241_D009436 NONE asa_57\NN\1740| (r_nsubj) induces_58\VBZ\1627355|even|though|asa|malformations (r_advcl) focused_50\VBD\628491|results|hence|,|study|malformations|,|induces|. (l_nsubj) results_0\NNS\34213|:|suggested|jc|; (l_dep) suggested_5\VBD\1010118|evaluation|induce (l_ccomp) induce_8\VBP\1627355|that|nsaids|defects (l_dobj) defects_11\NNS\14462666|ventricular|septal|vsds|and|defects|rats|and|hernia (l_conj) hernia_25\NN\14295248|diaphragmatic|dh|,|mds|,|and|vsds|rabbits (l_conj) mds_30\NNS\14622893|
D001241_D065630 CID asa_57\NN\1740| (r_nsubj) induces_58\VBZ\1627355|even|though|asa|malformations (r_advcl) focused_50\VBD\628491|results|hence|,|study|malformations|,|induces|. (l_nsubj) results_0\NNS\34213|:|suggested|jc|; (l_dep) suggested_5\VBD\1010118|evaluation|induce (l_ccomp) induce_8\VBP\1627355|that|nsaids|defects (l_dobj) defects_11\NNS\14462666|ventricular|septal|vsds|and|defects|rats|and|hernia (l_conj) hernia_25\NN\14295248|diaphragmatic|dh|,|mds|,|and|vsds|rabbits
D001241_D065630 CID asa_57\NN\1740| (r_nsubj) induces_58\VBZ\1627355|even|though|asa|malformations (r_advcl) focused_50\VBD\628491|results|hence|,|study|malformations|,|induces|. (l_nsubj) results_0\NNS\34213|:|suggested|jc|; (l_dep) suggested_5\VBD\1010118|evaluation|induce (l_ccomp) induce_8\VBP\1627355|that|nsaids|defects (l_dobj) defects_11\NNS\14462666|ventricular|septal|vsds|and|defects|rats|and|hernia (l_conj) hernia_25\NN\14295248|diaphragmatic|dh|,|mds|,|and|vsds|rabbits (l_appos) dh_27\NN\1740|(|)
15580403
D012254_D006461 NONE ribavirin_3\NN\2725367| (r_compound) reduction_4\NN\351485|of|ribavirin|patients (l_nmod) patients_6\NNS\9898892|in|hemolysis (l_nmod) hemolysis_8\NN\13509528|with
D012254_D006461 NONE ribavirin_15\NN\2725367| (r_conj) interferon_13\NN\2725367|of|and|ribavirin (r_nmod) therapy_11\NN\657604|during|combination|interferon (r_nmod) timing_1\NN\5044673|adequate|reduction|therapy|c. (l_nmod) reduction_4\NN\351485|of|ribavirin|patients (l_nmod) patients_6\NNS\9898892|in|hemolysis (l_nmod) hemolysis_8\NN\13509528|with
D012254_D006461 NONE ribavirin_13\NN\2725367| (r_compound) reduction_14\NN\351485|of|ribavirin|patients (l_nmod) patients_16\NNS\9898892|in|hemolysis (l_nmod) hemolysis_18\NN\13509528|with|therapy
D012254_D019698 NONE ribavirin_3\NN\2725367| (r_compound) reduction_4\NN\351485|of|ribavirin|patients (r_nmod) timing_1\NN\5044673|adequate|reduction|therapy|c. (l_nmod) c._19\NN\1740|for|chronic|hepatitis
D012254_D019698 NONE ribavirin_15\NN\2725367| (r_conj) interferon_13\NN\2725367|of|and|ribavirin (r_nmod) therapy_11\NN\657604|during|combination|interferon (r_nmod) timing_1\NN\5044673|adequate|reduction|therapy|c. (l_nmod) c._19\NN\1740|for|chronic|hepatitis
D007372_D006461 NONE interferon_13\NN\2725367|of|and|ribavirin (r_nmod) therapy_11\NN\657604|during|combination|interferon (r_nmod) timing_1\NN\5044673|adequate|reduction|therapy|c. (l_nmod) reduction_4\NN\351485|of|ribavirin|patients (l_nmod) patients_6\NNS\9898892|in|hemolysis (l_nmod) hemolysis_8\NN\13509528|with
D007372_D019698 NONE interferon_13\NN\2725367|of|and|ribavirin (r_nmod) therapy_11\NN\657604|during|combination|interferon (r_nmod) timing_1\NN\5044673|adequate|reduction|therapy|c. (l_nmod) c._19\NN\1740|for|chronic|hepatitis
D007372_D000743 CID interferon_16\NN\2725367|of|and|ribavirin (r_nmod) therapy_14\NN\657604|of|the|combination|interferon (r_nmod) events_10\NNS\23100|of|the|major|adverse|therapy (r_nmod) one_5\CD\13741022|background|:|anemia|is|events|. (l_nsubj) anemia_3\NN\14189204|hemolytic
D012254_D000743 CID ribavirin_18\NN\2725367| (r_conj) interferon_16\NN\2725367|of|and|ribavirin (r_nmod) therapy_14\NN\657604|of|the|combination|interferon (r_nmod) events_10\NNS\23100|of|the|major|adverse|therapy (r_nmod) one_5\CD\13741022|background|:|anemia|is|events|. (l_nsubj) anemia_3\NN\14189204|hemolytic
D012254_D000743 CID ribavirin-related_2\JJ\1740| (r_amod) anemia_4\NN\14189204|because|ribavirin-related|hemolytic
D012254_D000740 NONE ribavirin_9\NN\2725367|of (r_nmod) reduction_7\NN\351485|with|ribavirin (r_nmod) patients_5\NNS\9898892|37|reduction (r_nsubj) continue_12\VB\2367363|however|,|patients|could|not|therapy|decreased|b|. (l_advcl) decreased_22\VBD\169651|because|values|to|or|occurred (l_conj) occurred_29\VBD\2623529|effects (l_nsubj) effects_28\NNS\13245626|anemia-related|severe|side (l_amod) anemia-related_25\JJ\1740|
15096016
D007980_D018476 NONE levodopa-induced_20\JJ\1740| (r_amod) dyskinesias_21\NNS\14084880|levodopa-induced (r_dobj) improving_19\VBG\126264|in|dyskinesias (r_advcl) to_16\TO\1740|be|improving (r_xcomp) seems_15\VBZ\2604760|however|strength|to|. (r_parataxis) improves_2\VBZ\126264|stimulation|bradykinesia|extent|;|seems (l_dobj) bradykinesia_3\NN\1740|and|rigidity
D007980_D009127 NONE levodopa-induced_20\JJ\1740| (r_amod) dyskinesias_21\NNS\14084880|levodopa-induced (r_dobj) improving_19\VBG\126264|in|dyskinesias (r_advcl) to_16\TO\1740|be|improving (r_xcomp) seems_15\VBZ\2604760|however|strength|to|. (r_parataxis) improves_2\VBZ\126264|stimulation|bradykinesia|extent|;|seems (l_dobj) bradykinesia_3\NN\1740|and|rigidity (l_conj) rigidity_5\NN\5023233|
D007980_D004409 CID levodopa-induced_20\JJ\1740| (r_amod) dyskinesias_21\NNS\14084880|levodopa-induced
7803371
D003915_D003072 CID dextromethorphan_6\NN\1740|of (r_nmod) abuse_4\NN\418025|from|long-term|dextromethorphan (r_nmod) deterioration_1\NN\14560612|cognitive|abuse|:|report
D003915_D003072 CID dm_13\NN\14117805|of (r_nmod) use_11\NN\407535|from|prolonged|dm (r_nmod) resulting_8\VBG\2633881|use (r_acl) deterioration_7\NN\14560612|of|cognitive|resulting
16584858
C013592_D009203 NONE mangiferin_2\NN\1740|of (r_nmod) role_0\NN\719494|mangiferin|alterations|. (l_nmod) alterations_5\NNS\7283608|on|biochemical|and|status|infarction (l_nmod) infarction_12\NN\14204950|in|isoproterenol-induced|myocardial|rats
C013592_D009203 NONE mangiferin_9\NN\1740|of|,|polyphenol (r_nmod) role_7\NN\719494|with|the|protective|mangiferin|,|infarction|mechanism (l_nmod) infarction_26\NN\14204950|on|(isph)-induced|myocardial|mi|rats
C013592_D009203 NONE mangiferin_9\NN\1740|of|,|polyphenol (r_nmod) role_7\NN\719494|with|the|protective|mangiferin|,|infarction|mechanism (l_nmod) infarction_26\NN\14204950|on|(isph)-induced|myocardial|mi|rats (l_appos) mi_28\NN\14207561|(|)
C013592_D009203 NONE mangiferin_3\NN\1740|with|(|weight|)|given (l_acl) given_17\VBN\2327200|intraperitoneally|days|rats (l_nmod) rats_24\NNS\2329401|to|mi (l_compound) mi_23\NN\14207561|
C013592_D009203 NONE mangiferin_14\NN\1740| (r_compound) administration_15\NN\1133281|upon|mangiferin (r_nmod) rose_11\VBD\1835496|activities|significantly|administration|compared|. (l_advcl) compared_17\VBN\644583|as|rats (l_nmod) rats_21\NNS\2329401|to|isph-induced|mi (l_compound) mi_20\NN\14207561|
C013592_D009203 NONE mangiferin_8\NN\1740| (r_nsubj) exerts_9\VBZ\1158872|that|mangiferin|effect|potential (l_dobj) effect_12\NN\34213|a|beneficial|mi (l_nmod) mi_15\NN\14207561|against|isph-induced
D007545_D009203 CID isoproterenol-induced_10\JJ\1740| (r_amod) infarction_12\NN\14204950|in|isoproterenol-induced|myocardial|rats
D007545_D009203 CID isoproterenol_23\NN\3740161| (r_compound) (isph)-induced_24\NN\1740|isoproterenol (r_compound) infarction_26\NN\14204950|on|(isph)-induced|myocardial|mi|rats
D007545_D009203 CID isoproterenol_23\NN\3740161| (r_compound) (isph)-induced_24\NN\1740|isoproterenol (r_compound) infarction_26\NN\14204950|on|(isph)-induced|myocardial|mi|rats (l_appos) mi_28\NN\14207561|(|)
D007545_D009203 CID (isph)-induced_24\NN\1740|isoproterenol (r_compound) infarction_26\NN\14204950|on|(isph)-induced|myocardial|mi|rats
D007545_D009203 CID (isph)-induced_24\NN\1740|isoproterenol (r_compound) infarction_26\NN\14204950|on|(isph)-induced|myocardial|mi|rats (l_appos) mi_28\NN\14207561|(|)
D007545_D009203 CID isph-induced_19\JJ\1740| (r_amod) rats_21\NNS\2329401|to|isph-induced|mi (l_compound) mi_20\NN\14207561|
D007545_D009203 CID isph-induced_14\JJ\1740| (r_amod) mi_15\NN\14207561|against|isph-induced
D059808_D009203 NONE polyphenol_12\NN\1740|a|linn (r_appos) mangiferin_9\NN\1740|of|,|polyphenol (r_nmod) role_7\NN\719494|with|the|protective|mangiferin|,|infarction|mechanism (l_nmod) infarction_26\NN\14204950|on|(isph)-induced|myocardial|mi|rats
D059808_D009203 NONE polyphenol_12\NN\1740|a|linn (r_appos) mangiferin_9\NN\1740|of|,|polyphenol (r_nmod) role_7\NN\719494|with|the|protective|mangiferin|,|infarction|mechanism (l_nmod) infarction_26\NN\14204950|on|(isph)-induced|myocardial|mi|rats (l_appos) mi_28\NN\14207561|(|)
D007545_D009202 NONE isph_3\NN\1740|of|weight (r_nmod) injection_1\NN\320852|subcutaneous|isph|rats|days (r_nsubj) caused_20\VBD\1617192|injection|damage|. (l_dobj) damage_22\NN\7296428|myocardial|heart|,|determined
D019344_D009202 NONE lactate_36\NN\14850483| (r_compound) dehydrogenase_37\NN\1740|of|serum|lactate|ldh|and|isoenzymes (r_nmod) activity_33\NN\30358|by|the|increased|dehydrogenase|,|level|and|capacity (r_nmod) determined_29\VBN\1645601|which|was|activity (r_acl:relcl) damage_22\NN\7296428|myocardial|heart|,|determined
D003401_D009202 NONE creatine_42\NN\14601829| (r_compound) isoenzymes_44\NNS\1740|creatine|phosphokinase|ck-mb (r_conj) dehydrogenase_37\NN\1740|of|serum|lactate|ldh|and|isoenzymes (r_nmod) activity_33\NN\30358|by|the|increased|dehydrogenase|,|level|and|capacity (r_nmod) determined_29\VBN\1645601|which|was|activity (r_acl:relcl) damage_22\NN\7296428|myocardial|heart|,|determined
D014527_D009202 NONE acid_51\NN\14818238| (r_compound) level_52\NN\4916342|increased|uric|acid (r_conj) activity_33\NN\30358|by|the|increased|dehydrogenase|,|level|and|capacity (r_nmod) determined_29\VBN\1645601|which|was|activity (r_acl:relcl) damage_22\NN\7296428|myocardial|heart|,|determined
D007501_D009202 NONE iron_56\NN\14625458| (r_compound) capacity_58\NN\5202497|reduced|plasma|iron|binding (r_conj) activity_33\NN\30358|by|the|increased|dehydrogenase|,|level|and|capacity (r_nmod) determined_29\VBN\1645601|which|was|activity (r_acl:relcl) damage_22\NN\7296428|myocardial|heart|,|determined
C013592_D017202 NONE mangiferin_4\NN\1740|of (r_nmod) role_2\NN\719494|the|protective|mangiferin (r_nsubjpass) analyzed_6\VBN\78760|role|was|test|. (l_nmod) test_14\NN\5798043|by|chloride|used (l_acl) used_15\VBN\1156834|assay (l_nmod) assay_20\NN\5733583|for|macroscopic|enzyme|mapping|myocardium (l_nmod) myocardium_24\NN\5389939|of|the|ischemic
C009591_D017202 NONE chloride_10\NN\14818238|triphenyl|tetrazolium|ttc (r_compound) test_14\NN\5798043|by|chloride|used (l_acl) used_15\VBN\1156834|assay (l_nmod) assay_20\NN\5733583|for|macroscopic|enzyme|mapping|myocardium (l_nmod) myocardium_24\NN\5389939|of|the|ischemic
C009591_D017202 NONE ttc_12\NN\1740|(|) (r_appos) chloride_10\NN\14818238|triphenyl|tetrazolium|ttc (r_compound) test_14\NN\5798043|by|chloride|used (l_acl) used_15\VBN\1156834|assay (l_nmod) assay_20\NN\5733583|for|macroscopic|enzyme|mapping|myocardium (l_nmod) myocardium_24\NN\5389939|of|the|ischemic
D013481_D009203 NONE superoxide_7\NN\14971519| (r_compound) dismutase_8\NN\1740|such|superoxide|,|catalase|,|peroxidase|,|transferase|and|reductase (r_nmod) enzymes_4\NNS\14723628|the|tissue|antioxidant|dismutase|activities|,|antioxidants (r_nsubjpass) altered_37\VBN\126264|enzymes|were|rats|. (l_nmod) rats_40\NNS\2329401|in|mi (l_compound) mi_39\NN\14207561|
D005978_D009203 NONE glutathione_12\NN\1740| (r_compound) peroxidase_13\NN\14971234|glutathione (r_conj) dismutase_8\NN\1740|such|superoxide|,|catalase|,|peroxidase|,|transferase|and|reductase (r_nmod) enzymes_4\NNS\14723628|the|tissue|antioxidant|dismutase|activities|,|antioxidants (r_nsubjpass) altered_37\VBN\126264|enzymes|were|rats|. (l_nmod) rats_40\NNS\2329401|in|mi (l_compound) mi_39\NN\14207561|
D005978_D009203 NONE glutathione_15\NN\1740| (r_compound) transferase_16\NN\14732946|glutathione (r_conj) dismutase_8\NN\1740|such|superoxide|,|catalase|,|peroxidase|,|transferase|and|reductase (r_nmod) enzymes_4\NNS\14723628|the|tissue|antioxidant|dismutase|activities|,|antioxidants (r_nsubjpass) altered_37\VBN\126264|enzymes|were|rats|. (l_nmod) rats_40\NNS\2329401|in|mi (l_compound) mi_39\NN\14207561|
D005978_D009203 NONE glutathione_18\NN\1740| (r_compound) reductase_19\NN\14732946|glutathione (r_conj) dismutase_8\NN\1740|such|superoxide|,|catalase|,|peroxidase|,|transferase|and|reductase (r_nmod) enzymes_4\NNS\14723628|the|tissue|antioxidant|dismutase|activities|,|antioxidants (r_nsubjpass) altered_37\VBN\126264|enzymes|were|rats|. (l_nmod) rats_40\NNS\2329401|in|mi (l_compound) mi_39\NN\14207561|
D005978_D009203 NONE glutathione_34\NN\1740| (r_compound) levels_35\NNS\4916342|glutathione (r_conj) cerruloplasmin_26\NN\1740|such|,|c|,|e|and|levels (r_nmod) antioxidants_23\NNS\14724436|non-enzymic|cerruloplasmin (r_dep) enzymes_4\NNS\14723628|the|tissue|antioxidant|dismutase|activities|,|antioxidants (r_nsubjpass) altered_37\VBN\126264|enzymes|were|rats|. (l_nmod) rats_40\NNS\2329401|in|mi (l_compound) mi_39\NN\14207561|
D001205_D009203 NONE c_29\NN\13714184|vitamin (r_conj) cerruloplasmin_26\NN\1740|such|,|c|,|e|and|levels (r_nmod) antioxidants_23\NNS\14724436|non-enzymic|cerruloplasmin (r_dep) enzymes_4\NNS\14723628|the|tissue|antioxidant|dismutase|activities|,|antioxidants (r_nsubjpass) altered_37\VBN\126264|enzymes|were|rats|. (l_nmod) rats_40\NNS\2329401|in|mi (l_compound) mi_39\NN\14207561|
D014810_D009203 NONE e_32\NN\14724645|vitamin (r_conj) cerruloplasmin_26\NN\1740|such|,|c|,|e|and|levels (r_nmod) antioxidants_23\NNS\14724436|non-enzymic|cerruloplasmin (r_dep) enzymes_4\NNS\14723628|the|tissue|antioxidant|dismutase|activities|,|antioxidants (r_nsubjpass) altered_37\VBN\126264|enzymes|were|rats|. (l_nmod) rats_40\NNS\2329401|in|mi (l_compound) mi_39\NN\14207561|
D004121_D009203 NONE sulphoxide_15\NN\1740|of|dimethyl (r_nmod) ml_12\NN\13616054|in|2|sulphoxide (r_nmod) suspended_9\VBN\1481360|ml (r_acl) weight_8\NN\5009170|mg/kg|body|suspended (r_appos) mangiferin_3\NN\1740|with|(|weight|)|given (l_acl) given_17\VBN\2327200|intraperitoneally|days|rats (l_nmod) rats_24\NNS\2329401|to|mi (l_compound) mi_23\NN\14207561|
C013592_D006331 NONE mangiferin_8\NN\1740| (r_nsubj) exerts_9\VBZ\1158872|that|mangiferin|effect|potential (l_nmod) potential_20\NN\14481929|due|its|antioxidant|,|regulated (l_acl:relcl) regulated_23\VBD\296178|which|system (l_dobj) system_27\NN\3575240|the|tissues|defense|damage (l_nmod) damage_30\NN\7296428|against|cardiac
D007545_D006331 NONE isph-induced_14\JJ\1740| (r_amod) mi_15\NN\14207561|against|isph-induced (r_nmod) effect_12\NN\34213|a|beneficial|mi (r_dobj) exerts_9\VBZ\1158872|that|mangiferin|effect|potential (l_nmod) potential_20\NN\14481929|due|its|antioxidant|,|regulated (l_acl:relcl) regulated_23\VBD\296178|which|system (l_dobj) system_27\NN\3575240|the|tissues|defense|damage (l_nmod) damage_30\NN\7296428|against|cardiac
2004
D013881_D017180 CID mellaril_8\NN\3713736|thioridazine (r_nsubj) appeared_12\VBD\2604760|receiving|,|mellaril|responsible|. (l_xcomp) responsible_15\JJ\1740|to|be|cases (l_nmod) cases_18\NNS\7283608|for|five|tachycardia|,|fatal (l_nmod) tachycardia_21\NN\14110674|of|ventricular
D013881_D017180 CID thioridazine_10\NN\3713736|(|) (r_appos) mellaril_8\NN\3713736|thioridazine (r_nsubj) appeared_12\VBD\2604760|receiving|,|mellaril|responsible|. (l_xcomp) responsible_15\JJ\1740|to|be|cases (l_nmod) cases_18\NNS\7283608|for|five|tachycardia|,|fatal (l_nmod) tachycardia_21\NN\14110674|of|ventricular
D002746_D013617 NONE thorazine_7\NN\3713736|chlorpromazine (r_dobj) receiving_6\VBG\2210855|thorazine (r_acl) patient_5\NN\9898892|in|one|receiving (r_nmod) developed_2\VBD\1753788|tachycardia|patient|. (l_nsubj) tachycardia_1\NN\14110674|supraventricular
D002746_D013617 NONE chlorpromazine_9\NN\3713736|(|) (r_appos) thorazine_7\NN\3713736|chlorpromazine (r_dobj) receiving_6\VBG\2210855|thorazine (r_acl) patient_5\NN\9898892|in|one|receiving (r_nmod) developed_2\VBD\1753788|tachycardia|patient|. (l_nsubj) tachycardia_1\NN\14110674|supraventricular
D009661_D002037 CID aventyl_0\NN\1740|nortriptyline|and|elavil|each (r_nsubj) produced_10\VBD\1617192|aventyl|block|. (l_dobj) block_14\NN\21939|left|bundle|branch|woman
D009661_D002037 CID nortriptyline_2\NN\4482543|(|) (r_appos) aventyl_0\NN\1740|nortriptyline|and|elavil|each (r_nsubj) produced_10\VBD\1617192|aventyl|block|. (l_dobj) block_14\NN\21939|left|bundle|branch|woman
D000639_D002037 CID elavil_5\NN\4482543|amitriptyline (r_conj) aventyl_0\NN\1740|nortriptyline|and|elavil|each (r_nsubj) produced_10\VBD\1617192|aventyl|block|. (l_dobj) block_14\NN\21939|left|bundle|branch|woman
D000639_D002037 CID amitriptyline_7\NN\4482543|(|) (r_appos) elavil_5\NN\4482543|amitriptyline (r_conj) aventyl_0\NN\1740|nortriptyline|and|elavil|each (r_nsubj) produced_10\VBD\1617192|aventyl|block|. (l_dobj) block_14\NN\21939|left|bundle|branch|woman
D008012_D001145 NONE lidocaine_8\NN\3681148|of (r_nmod) administration_6\NN\1133281|to|intravenous|lidocaine|and|shock|; (r_nmod) responded_3\VBD\2367363|arrhythmias|administration|required (l_nsubj) arrhythmias_2\NNS\14103288|the|ventricular
D011433_D001145 NONE propranolol_27\NN\1740|of (r_nmod) administration_25\NN\1133281|intravenous|propranolol (r_nsubj) combined_28\VBD\2630189|administration|pacing|one (r_conj) required_19\VBN\754942|pacing|was|instances|and|combined|. (r_parataxis) responded_3\VBD\2367363|arrhythmias|administration|required (l_nsubj) arrhythmias_2\NNS\14103288|the|ventricular
D010640_D005117 NONE phenothiazines_16\NNS\14771088|or|drugs (r_dobj) receiving_15\VBG\2210855|phenothiazines (r_acl) patients_14\NNS\9898892|to|receiving (r_nmod) complications_12\NNS\1073995|of|cardiac|patients
1711760
D007530_D006973 NONE isoflurane_1\NN\3570838| (r_compound) anesthesia_2\NN\14034177|under|isoflurane (r_nmod) occluded_12\VBN\2451370|anesthesia|,|mca|was|. (l_nsubjpass) mca_5\NN\1740|the|rats (l_nmod) rats_10\NNS\2329401|of|14|hypertensive (l_amod) hypertensive_9\JJ\1740|spontaneously
C009591_D009410 NONE 2,3,5-triphenyltetrazolium_8\NN\1740| (r_compound) staining_9\NN\275424|by|2,3,5-triphenyltetrazolium (r_nmod) determined_6\VBN\1645601|extent|was|staining|. (l_nsubjpass) extent_1\NN\13939892|the|injury (l_nmod) injury_4\NN\14052046|of|neuronal
D010656_D006973 CID phenylephrine-induced_4\JJ\1740| (r_amod) hypertension_5\NN\14057371|phenylephrine-induced|instituted
D010656_D020244 NONE phenylephrine-induced_4\JJ\1740| (r_amod) hypertension_5\NN\14057371|phenylephrine-induced|instituted (l_acl) instituted_6\VBN\1641914|h|mcao (l_dep) mcao_10\NN\1740|
D010656_D004487 NONE phenylephrine-induced_4\JJ\1740| (r_amod) hypertension_5\NN\14057371|phenylephrine-induced|instituted (r_nsubj) aggravate_13\VB\126264|that|hypertension|does|not|edema|,|improves (l_dobj) edema_14\NN\14315192|core
D010656_D004487 NONE phenylephrine-induced_4\JJ\1740| (r_amod) hypertension_5\NN\14057371|phenylephrine-induced|instituted (r_nsubj) aggravate_13\VB\126264|that|hypertension|does|not|edema|,|improves (l_conj) improves_22\VBZ\126264|that|it|edema|,|and|reduces (l_dobj) edema_23\NN\14315192|periphery
D010656_D007511 NONE phenylephrine-induced_4\JJ\1740| (r_amod) hypertension_5\NN\14057371|phenylephrine-induced|instituted (r_nsubj) aggravate_13\VB\126264|that|hypertension|does|not|edema|,|improves (l_dobj) edema_14\NN\14315192|core (l_nmod) core_18\NN\7996689|in|the|ischemic (l_amod) ischemic_17\JJ\1740|
D010656_D007511 NONE phenylephrine-induced_4\JJ\1740| (r_amod) hypertension_5\NN\14057371|phenylephrine-induced|instituted (r_nsubj) aggravate_13\VB\126264|that|hypertension|does|not|edema|,|improves (l_conj) improves_22\VBZ\126264|that|it|edema|,|and|reduces (l_dobj) edema_23\NN\14315192|periphery (l_nmod) periphery_26\NN\13903079|in|the|territory (l_nmod) territory_30\NN\8630985|of|the|ischemic (l_amod) ischemic_29\JJ\1740|
D010656_D009410 NONE phenylephrine-induced_4\JJ\1740| (r_amod) hypertension_5\NN\14057371|phenylephrine-induced|instituted (r_nsubj) aggravate_13\VB\126264|that|hypertension|does|not|edema|,|improves (l_conj) improves_22\VBZ\126264|that|it|edema|,|and|reduces (l_conj) reduces_35\VBZ\441445|that|it|area (l_dobj) area_37\NN\8630985|the|dysfunction (l_nmod) dysfunction_41\NN\14204950|of|histochemical|neuronal
10524660
D005996_D020326 CID trinitrate_1\NN\1740|glyceryl (r_nsubj) induces_2\VBZ\1627355|trinitrate|attacks|. (l_dobj) attacks_3\NNS\955060|migraine|sufferers (l_nmod) migraine_5\NN\14326607|of|aura (l_nmod) aura_7\NN\14299637|without
D005996_D020325 NONE trinitrate_1\NN\1740|glyceryl (r_nsubj) induces_2\VBZ\1627355|trinitrate|attacks|. (l_dobj) attacks_3\NNS\955060|migraine|sufferers (l_nmod) sufferers_9\NNS\9630641|in|migraine (l_nmod) migraine_11\NN\14326607|of|aura (l_nmod) aura_13\NN\14299637|with
D005996_D020325 NONE trinitrate_28\NN\1740|of|glyceryl|gtn|microg/kg/min (r_nmod) infusion_25\NN\14589223|to|intravenous|trinitrate (r_nmod) response_22\NN\11410625|the|headache|infusion|sufferers (r_dobj) examined_19\VBD\789138|clarify|,|study|we|response|. (l_advcl) clarify_3\VB\939277|in|to|true (l_ccomp) true_8\JJ\1740|whether|same|is|migraine (l_nmod) migraine_10\NN\14326607|for|aura (l_nmod) aura_12\NN\14299637|with
D005996_D020325 NONE trinitrate_28\NN\1740|of|glyceryl|gtn|microg/kg/min (r_nmod) infusion_25\NN\14589223|to|intravenous|trinitrate (r_nmod) response_22\NN\11410625|the|headache|infusion|sufferers (l_nmod) sufferers_41\NNS\9630641|in|12|migraine (l_nmod) migraine_43\NN\14326607|of|aura (l_nmod) aura_45\NN\14299637|with
D005996_D020325 NONE gtn_30\NN\1740|(|) (r_appos) trinitrate_28\NN\1740|of|glyceryl|gtn|microg/kg/min (r_nmod) infusion_25\NN\14589223|to|intravenous|trinitrate (r_nmod) response_22\NN\11410625|the|headache|infusion|sufferers (r_dobj) examined_19\VBD\789138|clarify|,|study|we|response|. (l_advcl) clarify_3\VB\939277|in|to|true (l_ccomp) true_8\JJ\1740|whether|same|is|migraine (l_nmod) migraine_10\NN\14326607|for|aura (l_nmod) aura_12\NN\14299637|with
D005996_D020325 NONE gtn_30\NN\1740|(|) (r_appos) trinitrate_28\NN\1740|of|glyceryl|gtn|microg/kg/min (r_nmod) infusion_25\NN\14589223|to|intravenous|trinitrate (r_nmod) response_22\NN\11410625|the|headache|infusion|sufferers (l_nmod) sufferers_41\NNS\9630641|in|12|migraine (l_nmod) migraine_43\NN\14326607|of|aura (l_nmod) aura_45\NN\14299637|with
D009569_D010146 NONE oxide_13\NN\14818238|nitric|no (r_dep) molecule_11\NN\9465459|the|messenger|oxide (r_nsubjpass) involved_18\VBN\2676054|that|molecule|is|mechanisms (l_nmod) mechanisms_21\NNS\13446390|in|pain|migraine (l_compound) pain_20\NN\14299637|
D009569_D010146 NONE no_15\NN\7204911|(|) (r_appos) oxide_13\NN\14818238|nitric|no (r_dep) molecule_11\NN\9465459|the|messenger|oxide (r_nsubjpass) involved_18\VBN\2676054|that|molecule|is|mechanisms (l_nmod) mechanisms_21\NNS\13446390|in|pain|migraine (l_compound) pain_20\NN\14299637|
D009569_D010146 NONE no_5\NN\7204911| (r_nsubjpass) involved_7\VBN\2676054|that|no|is|mechanisms (l_nmod) mechanisms_11\NNS\13446390|in|the|pain|migraine (l_compound) pain_10\NN\14299637|
D009569_D020326 CID oxide_13\NN\14818238|nitric|no (r_dep) molecule_11\NN\9465459|the|messenger|oxide (r_nsubjpass) involved_18\VBN\2676054|that|molecule|is|mechanisms (l_nmod) mechanisms_21\NNS\13446390|in|pain|migraine (l_nmod) migraine_23\NN\14326607|of|aura (l_nmod) aura_25\NN\14299637|without
D009569_D020326 CID no_15\NN\7204911|(|) (r_appos) oxide_13\NN\14818238|nitric|no (r_dep) molecule_11\NN\9465459|the|messenger|oxide (r_nsubjpass) involved_18\VBN\2676054|that|molecule|is|mechanisms (l_nmod) mechanisms_21\NNS\13446390|in|pain|migraine (l_nmod) migraine_23\NN\14326607|of|aura (l_nmod) aura_25\NN\14299637|without
D005996_D006261 NONE trinitrate_28\NN\1740|of|glyceryl|gtn|microg/kg/min (r_nmod) infusion_25\NN\14589223|to|intravenous|trinitrate (r_nmod) response_22\NN\11410625|the|headache|infusion|sufferers (l_compound) headache_21\NN\5829480|
D005996_D006261 NONE gtn_30\NN\1740|(|) (r_appos) trinitrate_28\NN\1740|of|glyceryl|gtn|microg/kg/min (r_nmod) infusion_25\NN\14589223|to|intravenous|trinitrate (r_nmod) response_22\NN\11410625|the|headache|infusion|sufferers (l_compound) headache_21\NN\5829480|
D005996_D006261 NONE gtn_14\NN\1740| (r_compound) infusion_15\NN\14589223|during|gtn|p=0.037 (r_nmod) severe_3\JJ\1740|headache|was|more|migraineurs|controls|infusion|as|h|. (l_nsubj) headache_0\NN\5829480|
D005996_D006261 NONE gtn-induced_5\JJ\1740| (r_amod) headache_6\NN\5829480|the|gtn-induced
D005996_D006261 NONE gtn-induced_5\JJ\1740| (r_amod) headache_6\NN\5829480|the|gtn-induced (r_nsubj) disappeared_8\VBD\2609764|controls|,|headache|gradually|,|occurred|. (l_advcl) occurred_16\VBD\2623529|whereas|migraineurs|intensity|time (l_nsubj) intensity_15\NN\5090441|peak|headache (l_compound) headache_14\NN\5829480|
D005996_D008881 NONE gtn_14\NN\1740| (r_compound) infusion_15\NN\14589223|during|gtn|p=0.037 (r_nmod) severe_3\JJ\1740|headache|was|more|migraineurs|controls|infusion|as|h|. (l_nmod) migraineurs_5\NNS\1740|in
D005996_D008881 NONE gtn-induced_5\JJ\1740| (r_amod) headache_6\NN\5829480|the|gtn-induced (r_nsubj) disappeared_8\VBD\2609764|controls|,|headache|gradually|,|occurred|. (l_advcl) occurred_16\VBD\2623529|whereas|migraineurs|intensity|time (l_nmod) migraineurs_12\NNS\1740|in
D009569_D020325 NONE no_5\NN\7204911| (r_nsubjpass) involved_7\VBN\2676054|that|no|is|mechanisms (l_nmod) mechanisms_11\NNS\13446390|in|the|pain|migraine (l_nmod) migraine_13\NN\14326607|of|aura (l_nmod) aura_15\NN\14299637|with
D009569_D020325 NONE no_9\NN\7204911| (r_dobj) liberate_8\VB\146138|to|no|animals (r_xcomp) shown_6\VBN\2137132|since|depression|has|been|liberate (r_advcl) help_16\VB\2556126|shown|,|finding|may|understanding|. (l_dobj) understanding_18\NN\5804793|our|coupling (l_nmod) coupling_21\NN\3091374|of|the|depression (l_nmod) depression_25\NN\14373582|between|cortical|spreading|and|headache (l_conj) headache_27\NN\5829480|migraine (l_nmod) migraine_29\NN\14326607|in|aura (l_nmod) aura_31\NN\14299637|with
D009569_D003866 NONE no_9\NN\7204911| (r_dobj) liberate_8\VB\146138|to|no|animals (r_xcomp) shown_6\VBN\2137132|since|depression|has|been|liberate (l_nsubjpass) depression_3\NN\14373582|cortical|spreading
D009569_D003866 NONE no_9\NN\7204911| (r_dobj) liberate_8\VB\146138|to|no|animals (r_xcomp) shown_6\VBN\2137132|since|depression|has|been|liberate (r_advcl) help_16\VB\2556126|shown|,|finding|may|understanding|. (l_dobj) understanding_18\NN\5804793|our|coupling (l_nmod) coupling_21\NN\3091374|of|the|depression (l_nmod) depression_25\NN\14373582|between|cortical|spreading|and|headache
D009569_D006261 NONE no_9\NN\7204911| (r_dobj) liberate_8\VB\146138|to|no|animals (r_xcomp) shown_6\VBN\2137132|since|depression|has|been|liberate (r_advcl) help_16\VB\2556126|shown|,|finding|may|understanding|. (l_dobj) understanding_18\NN\5804793|our|coupling (l_nmod) coupling_21\NN\3091374|of|the|depression (l_nmod) depression_25\NN\14373582|between|cortical|spreading|and|headache (l_conj) headache_27\NN\5829480|migraine
17285209
D017311_D006973 NONE amlodipine/benazapril_24\NN\1740| (r_compound) mg._26\NN\1740|of|amlodipine/benazapril|10/5 (r_nmod) started_18\VBN\2009433|who|was|pill|mg. (r_acl:relcl) female_10\NN\15388|on|a|old|african-american|hypertension|,|started (l_nmod) hypertension_14\NN\14057371|with|diagnosed
D017311_D015746 NONE amlodipine/benazapril_24\NN\1740| (r_compound) mg._26\NN\1740|of|amlodipine/benazapril|10/5 (r_nmod) started_18\VBN\2009433|who|was|pill|mg. (r_acl:relcl) female_10\NN\15388|on|a|old|african-american|hypertension|,|started (r_nmod) report_4\NN\6470073|this|is|a|case|female|presented (l_parataxis) presented_33\VBD\2137132|day|,|she|room|pain|. (l_nmod) pain_43\NN\14299637|with|abdominal|,|nausea|and|vomiting
D017311_D009325 NONE amlodipine/benazapril_24\NN\1740| (r_compound) mg._26\NN\1740|of|amlodipine/benazapril|10/5 (r_nmod) started_18\VBN\2009433|who|was|pill|mg. (r_acl:relcl) female_10\NN\15388|on|a|old|african-american|hypertension|,|started (r_nmod) report_4\NN\6470073|this|is|a|case|female|presented (l_parataxis) presented_33\VBD\2137132|day|,|she|room|pain|. (l_nmod) pain_43\NN\14299637|with|abdominal|,|nausea|and|vomiting (l_conj) nausea_45\NN\14299637|
D017311_D014839 NONE amlodipine/benazapril_24\NN\1740| (r_compound) mg._26\NN\1740|of|amlodipine/benazapril|10/5 (r_nmod) started_18\VBN\2009433|who|was|pill|mg. (r_acl:relcl) female_10\NN\15388|on|a|old|african-american|hypertension|,|started (r_nmod) report_4\NN\6470073|this|is|a|case|female|presented (l_parataxis) presented_33\VBD\2137132|day|,|she|room|pain|. (l_nmod) pain_43\NN\14299637|with|abdominal|,|nausea|and|vomiting (l_conj) vomiting_47\NN\116687|
C044946_D006973 NONE amlodipine/benazapril_24\NN\1740| (r_compound) mg._26\NN\1740|of|amlodipine/benazapril|10/5 (r_nmod) started_18\VBN\2009433|who|was|pill|mg. (r_acl:relcl) female_10\NN\15388|on|a|old|african-american|hypertension|,|started (l_nmod) hypertension_14\NN\14057371|with|diagnosed
C044946_D015746 NONE amlodipine/benazapril_24\NN\1740| (r_compound) mg._26\NN\1740|of|amlodipine/benazapril|10/5 (r_nmod) started_18\VBN\2009433|who|was|pill|mg. (r_acl:relcl) female_10\NN\15388|on|a|old|african-american|hypertension|,|started (r_nmod) report_4\NN\6470073|this|is|a|case|female|presented (l_parataxis) presented_33\VBD\2137132|day|,|she|room|pain|. (l_nmod) pain_43\NN\14299637|with|abdominal|,|nausea|and|vomiting
C044946_D009325 NONE amlodipine/benazapril_24\NN\1740| (r_compound) mg._26\NN\1740|of|amlodipine/benazapril|10/5 (r_nmod) started_18\VBN\2009433|who|was|pill|mg. (r_acl:relcl) female_10\NN\15388|on|a|old|african-american|hypertension|,|started (r_nmod) report_4\NN\6470073|this|is|a|case|female|presented (l_parataxis) presented_33\VBD\2137132|day|,|she|room|pain|. (l_nmod) pain_43\NN\14299637|with|abdominal|,|nausea|and|vomiting (l_conj) nausea_45\NN\14299637|
C044946_D014839 NONE amlodipine/benazapril_24\NN\1740| (r_compound) mg._26\NN\1740|of|amlodipine/benazapril|10/5 (r_nmod) started_18\VBN\2009433|who|was|pill|mg. (r_acl:relcl) female_10\NN\15388|on|a|old|african-american|hypertension|,|started (r_nmod) report_4\NN\6470073|this|is|a|case|female|presented (l_parataxis) presented_33\VBD\2137132|day|,|she|room|pain|. (l_nmod) pain_43\NN\14299637|with|abdominal|,|nausea|and|vomiting (l_conj) vomiting_47\NN\116687|
D000809_D007410 NONE angiotensin-converting_3\JJ\1740| (r_amod) enzyme_4\NN\14723628|angiotensin-converting|ace|and|blocker (r_compound) angioedema_16\NN\14316714|of|enzyme|intestinal
D000809_D007410 NONE angiotensin_9\NN\4522421| (r_compound) blocker_11\NN\10101634|angiotensin|receptor|arb (r_conj) enzyme_4\NN\14723628|angiotensin-converting|ace|and|blocker (r_compound) angioedema_16\NN\14316714|of|enzyme|intestinal
D000809_D000799 NONE angiotensin-converting_3\JJ\1740| (r_amod) enzyme_4\NN\14723628|angiotensin-converting|ace|and|blocker (r_compound) angioedema_16\NN\14316714|of|enzyme|intestinal
D000809_D000799 NONE angiotensin_9\NN\4522421| (r_compound) blocker_11\NN\10101634|angiotensin|receptor|arb (r_conj) enzyme_4\NN\14723628|angiotensin-converting|ace|and|blocker (r_compound) angioedema_16\NN\14316714|of|enzyme|intestinal
7421734
D004967_D010049 NONE estrogens_16\NNS\14745635|exogenous|,|treatment (r_dobj) received_14\VBD\2210855|estrogens (r_conj) had_1\VBD\2108377|she|failure|,|and|received|. (l_dobj) failure_3\NN\66216|ovarian|irradiation
D004967_D010049 NONE estrogens_4\NNS\14745635|on|replacement|failure (l_nmod) failure_7\NN\66216|for|ovarian|therapy
D004967_D006689 NONE estrogens_16\NNS\14745635|exogenous|,|treatment (r_dobj) received_14\VBD\2210855|estrogens (r_conj) had_1\VBD\2108377|she|failure|,|and|received|. (l_dobj) failure_3\NN\66216|ovarian|irradiation (l_nmod) irradiation_6\NN\13920835|after|abdominal|and|chemotherapy|disease (l_nmod) disease_11\NN\14061805|for|hodgkin
D004967_D016889 CID estrogens_16\NNS\14745635|exogenous|,|treatment (l_appos) treatment_19\NN\654885|a|implicated (l_acl) implicated_20\VBN\2677097|development (l_nmod) development_23\NN\248977|in|the|cancer (l_nmod) cancer_26\NN\14239425|of|endometrial|women
D004967_D016889 CID estrogens_4\NNS\14745635|on|replacement|failure (r_nmod) women_1\NNS\9605289|young|estrogens|risk|and|examined (l_nmod) risk_15\NN\14541044|may|also|have|increased|carcinoma (l_nmod) carcinoma_18\NN\14239918|of|endometrial
D004967_D009369 NONE estrogens_4\NNS\14745635|on|replacement|failure (l_nmod) failure_7\NN\66216|for|ovarian|therapy (l_nmod) therapy_10\NN\657604|after|cancer (l_compound) cancer_9\NN\14239425|
6769133
D004317_D066126 NONE adriamycin_6\NN\1740|of (r_nmod) effects_4\NNS\13245626|cardiotoxic|adriamycin|primates|. (l_amod) cardiotoxic_0\JJ\1740|and|leukemogenic
D004317_D006333 CID adriamycin_13\NN\1740| (r_compound) dose_14\NN\3740161|at|an|average|cumulative|adriamycin|mg/m2|that (r_nmod) developed_5\VBD\1753788|8|failure|dose|. (l_dobj) failure_8\NN\66216|congestive|heart
D018943_D001768 NONE anthracycline-induced_10\JJ\1740| (r_amod) cardiomyopathy_11\NN\14103288|in|human|anthracycline-induced (r_nmod) found_7\VBN\2426171|cardiomyopathy (r_acl) those_6\DT\1740|found (r_dobj) resembled_5\VBD\2657219|histologically|,|lesions|those|. (l_nsubj) lesions_4\NNS\14204950|the|myocardial
D018943_D009202 NONE anthracycline-induced_10\JJ\1740| (r_amod) cardiomyopathy_11\NN\14103288|in|human|anthracycline-induced
D004317_D015470 CID adriamycin_14\NN\1740|of (r_nmod) mg/m2_12\NN\1740|324|adriamycin (r_dobj) receiving_10\VBG\2210855|after|mg/m2 (r_advcl) developed_5\VBD\1753788|1|leukemia|receiving|alive (l_dobj) leukemia_8\NN\14239918|acute|myeloblastic
D004317_D007938 NONE adriamycin_4\NN\1740| (r_nsubj) cardiotoxin_9\NN\1740|that|adriamycin|is|a|potent|monkeys|than|,|and|consequence (l_conj) consequence_22\NN\34213|that|leukemia|may|be|a|treatment (l_nsubj) leukemia_18\NN\14239918|
3137399
D016685_D066126 NONE c._12\NN\1740|by|mitomycin (r_nmod) induced_9\VBN\1627355|c. (r_acl) cardiotoxicity_8\NN\1740|of|induced
D016685_D066126 NONE c_3\NN\13714184|mitomycin|mmc (r_nsubjpass) suggested_9\VBN\1010118|1975|c|has|been|cardiotoxic|. (l_xcomp) cardiotoxic_12\JJ\1740|to|be|,|combined
D016685_D066126 NONE mmc_5\NN\1740|(|) (r_appos) c_3\NN\13714184|mitomycin|mmc (r_nsubjpass) suggested_9\VBN\1010118|1975|c|has|been|cardiotoxic|. (l_xcomp) cardiotoxic_12\JJ\1740|to|be|,|combined
D016685_D066126 NONE mmc-related_16\JJ\1740| (r_amod) cardiotoxicity_17\NN\1740|mmc-related
D004317_D066126 NONE doxorubicin_21\NN\2716866| (r_dobj) combined_16\VBN\2630189|when|with|or|given|doxorubicin (r_advcl) cardiotoxic_12\JJ\1740|to|be|,|combined
D004317_D066126 NONE doxorubicin_45\NN\2716866|with (r_nmod) treated_43\VBN\2376958|doxorubicin (r_acl) patients_36\NNS\9898892|in|also|or|treated (r_nmod) occurring_22\VBG\2623529|levels|,|patients (r_dep) dependent_20\JJ\1740|that|cardiotoxicity|is|dose|,|occurring (l_nsubj) cardiotoxicity_17\NN\1740|mmc-related
D016685_D006333 CID mmc_11\NN\1740|after|mg|m-2|and|doxorubicin (r_nmod) developed_4\VBD\1753788|one|failure|mmc|. (l_dobj) failure_6\NN\66216|cardiac
D004317_D006333 CID doxorubicin_17\NN\2716866|mg|m-2 (r_conj) mmc_11\NN\1740|after|mg|m-2|and|doxorubicin (r_nmod) developed_4\VBD\1753788|one|failure|mmc|. (l_dobj) failure_6\NN\66216|cardiac
7785794
D014700_D012770 NONE verapamil_8\NN\2938514| (r_compound) sr_9\NN\14625458|after|verapamil|and|metoprolol (r_nmod) shock_2\NN\7510495|refractory|cardiogenic|and|block|sr|treatment|.
D014700_D006327 CID verapamil_8\NN\2938514| (r_compound) sr_9\NN\14625458|after|verapamil|and|metoprolol (r_nmod) shock_2\NN\7510495|refractory|cardiogenic|and|block|sr|treatment|. (l_conj) block_6\NN\21939|complete|heart
D014700_D006327 CID verapamil_19\NN\2938514|of|sustained-release (r_nmod) dose_16\NN\3740161|after|a|therapeutic|verapamil|use (r_nmod) presented_3\VBD\2137132|woman|block|dose|. (l_nmod) block_7\NN\21939|with|complete|heart|and|hypotension
D008790_D012770 NONE metoprolol_11\NN\2832168| (r_conj) sr_9\NN\14625458|after|verapamil|and|metoprolol (r_nmod) shock_2\NN\7510495|refractory|cardiogenic|and|block|sr|treatment|.
D008790_D006327 CID metoprolol_11\NN\2832168| (r_conj) sr_9\NN\14625458|after|verapamil|and|metoprolol (r_nmod) shock_2\NN\7510495|refractory|cardiogenic|and|block|sr|treatment|. (l_conj) block_6\NN\21939|complete|heart
D008790_D006327 CID metoprolol_24\NN\2832168|of (r_nmod) use_22\NN\407535|with|concomitant|metoprolol (r_nmod) dose_16\NN\3740161|after|a|therapeutic|verapamil|use (r_nmod) presented_3\VBD\2137132|woman|block|dose|. (l_nmod) block_7\NN\21939|with|complete|heart|and|hypotension
D014700_D007022 CID verapamil_19\NN\2938514|of|sustained-release (r_nmod) dose_16\NN\3740161|after|a|therapeutic|verapamil|use (r_nmod) presented_3\VBD\2137132|woman|block|dose|. (l_nmod) block_7\NN\21939|with|complete|heart|and|hypotension (l_conj) hypotension_10\NN\14057371|refractory
D008790_D007022 CID metoprolol_24\NN\2832168|of (r_nmod) use_22\NN\407535|with|concomitant|metoprolol (r_nmod) dose_16\NN\3740161|after|a|therapeutic|verapamil|use (r_nmod) presented_3\VBD\2137132|woman|block|dose|. (l_nmod) block_7\NN\21939|with|complete|heart|and|hypotension (l_conj) hypotension_10\NN\14057371|refractory
D001285_D007022 NONE atropine_17\NN\14712692|of|intravenous (r_nmod) uses_14\NNS\407535|with|multiple|atropine|as|doses (r_nmod) remain_4\VB\2604760|to|hypotensive|,|uses (l_acomp) hypotensive_5\JJ\1740|block
D001285_D006327 NONE atropine_17\NN\14712692|of|intravenous (r_nmod) uses_14\NNS\407535|with|multiple|atropine|as|doses (r_nmod) remain_4\VB\2604760|to|hypotensive|,|uses (l_acomp) hypotensive_5\JJ\1740|block (l_nmod) block_9\NN\21939|with|complete|heart
D004298_D007022 NONE dopamine_28\NN\14807737|such|and|dobutamine (r_nmod) agents_25\NNS\7347|of|pressor|dopamine (r_nmod) doses_22\NNS\3740161|high|agents (r_conj) uses_14\NNS\407535|with|multiple|atropine|as|doses (r_nmod) remain_4\VB\2604760|to|hypotensive|,|uses (l_acomp) hypotensive_5\JJ\1740|block
D004298_D006327 NONE dopamine_28\NN\14807737|such|and|dobutamine (r_nmod) agents_25\NNS\7347|of|pressor|dopamine (r_nmod) doses_22\NNS\3740161|high|agents (r_conj) uses_14\NNS\407535|with|multiple|atropine|as|doses (r_nmod) remain_4\VB\2604760|to|hypotensive|,|uses (l_acomp) hypotensive_5\JJ\1740|block (l_nmod) block_9\NN\21939|with|complete|heart
D004280_D007022 NONE dobutamine_30\NN\1740| (r_conj) dopamine_28\NN\14807737|such|and|dobutamine (r_nmod) agents_25\NNS\7347|of|pressor|dopamine (r_nmod) doses_22\NNS\3740161|high|agents (r_conj) uses_14\NNS\407535|with|multiple|atropine|as|doses (r_nmod) remain_4\VB\2604760|to|hypotensive|,|uses (l_acomp) hypotensive_5\JJ\1740|block
D004280_D006327 NONE dobutamine_30\NN\1740| (r_conj) dopamine_28\NN\14807737|such|and|dobutamine (r_nmod) agents_25\NNS\7347|of|pressor|dopamine (r_nmod) doses_22\NNS\3740161|high|agents (r_conj) uses_14\NNS\407535|with|multiple|atropine|as|doses (r_nmod) remain_4\VB\2604760|to|hypotensive|,|uses (l_acomp) hypotensive_5\JJ\1740|block (l_nmod) block_9\NN\21939|with|complete|heart
D002122_D007022 NONE chloride_9\NN\14818238|of|intravenous|calcium (r_nmod) use_5\NN\407535|after|the|chloride (r_nmod) resolved_18\VBD\352826|however|,|use|,|hypotension|. (l_nsubj) hypotension_13\NN\14057371|the|refractory|and|block
D002122_D006327 NONE chloride_9\NN\14818238|of|intravenous|calcium (r_nmod) use_5\NN\407535|after|the|chloride (r_nmod) resolved_18\VBD\352826|however|,|use|,|hypotension|. (l_nsubj) hypotension_13\NN\14057371|the|refractory|and|block (l_conj) block_17\NN\21939|complete|heart
6323692
C018824_D001259 CID acetate_3\NN\15010703|with|ammonium|nh4ac|mmol/kg (r_nmod) pretreatment_0\NN\1740|acetate (r_nsubj) doubled_13\VBD\247390|pretreatment|approximately|time|and|increased|,|but|had (l_conj) increased_25\VBD\169651|similarly|incoordination (l_dobj) incoordination_27\NN\5648247|muscular|diazepam
C018824_D001259 CID nh4ac_5\NN\1740|(|) (r_appos) acetate_3\NN\15010703|with|ammonium|nh4ac|mmol/kg (r_nmod) pretreatment_0\NN\1740|acetate (r_nsubj) doubled_13\VBD\247390|pretreatment|approximately|time|and|increased|,|but|had (l_conj) increased_25\VBD\169651|similarly|incoordination (l_dobj) incoordination_27\NN\5648247|muscular|diazepam
C018824_D001259 CID nh4ac_32\NN\1740| (r_compound) treatment_33\NN\654885|nh4ac|alone (r_nsubj) had_35\VBD\2108377|treatment|effect|. (r_conj) doubled_13\VBD\247390|pretreatment|approximately|time|and|increased|,|but|had (l_conj) increased_25\VBD\169651|similarly|incoordination (l_dobj) incoordination_27\NN\5648247|muscular|diazepam
C018824_D001259 CID nh4ac_8\NN\1740| (r_compound) pretreatment_9\NN\1740|nh4ac (r_conj) verapamil_1\NN\2938514|both|mg/kg|and|pretreatment (r_nsubj) enhanced_10\VBD\227165|verapamil|analgesia-|and|antagonized|,|and|affected (l_dobj) analgesia-_12\NN\1740|morphine|and|incoordination (l_conj) incoordination_16\NN\5648247|diazepam-induced|muscular
C018824_D001259 CID nh4ac_27\NN\1740| (r_conj) verapamil_25\NN\2938514|neither|nor|nh4ac (r_nsubj) affected_28\VBD\126264|verapamil|action|. (r_conj) enhanced_10\VBD\227165|verapamil|analgesia-|and|antagonized|,|and|affected (l_dobj) analgesia-_12\NN\1740|morphine|and|incoordination (l_conj) incoordination_16\NN\5648247|diazepam-induced|muscular
D009020_D001259 NONE morphine-treated_16\JJ\1740| (r_amod) mice_17\NNS\2329401|morphine-treated (r_nsubj) remained_18\VBD\2604760|mice|surface (r_acl:relcl) time_15\NN\7308889|the|remained (r_dobj) doubled_13\VBD\247390|pretreatment|approximately|time|and|increased|,|but|had (l_conj) increased_25\VBD\169651|similarly|incoordination (l_dobj) incoordination_27\NN\5648247|muscular|diazepam
D009020_D001259 NONE morphine_11\NN\2707683| (r_compound) analgesia-_12\NN\1740|morphine|and|incoordination (l_conj) incoordination_16\NN\5648247|diazepam-induced|muscular
D003975_D001259 CID diazepam_29\NN\2830852|by (r_nmod) incoordination_27\NN\5648247|muscular|diazepam
D003975_D001259 CID diazepam-induced_14\JJ\1740| (r_amod) incoordination_16\NN\5648247|diazepam-induced|muscular
D002118_D003866 NONE calcium_3\NN\14625458|of|excess (r_nmod) addition_0\NN\3081021|calcium (r_nsubj) reversed_4\VBD\109660|addition|depression|,|but|blocked (l_dobj) depression_6\NN\14373582|the|tissues
D002118_D003866 NONE calcium-independent_12\JJ\1740| (r_amod) release_14\NN\3748886|calcium-independent|catecholamine|acetaldehyde (r_nsubjpass) blocked_19\VBN\1476483|release|was|not|nh4ac|. (r_conj) reversed_4\VBD\109660|addition|depression|,|but|blocked (l_dobj) depression_6\NN\14373582|the|tissues
D002395_D003866 NONE catecholamine_13\NN\5407119| (r_compound) release_14\NN\3748886|calcium-independent|catecholamine|acetaldehyde (r_nsubjpass) blocked_19\VBN\1476483|release|was|not|nh4ac|. (r_conj) reversed_4\VBD\109660|addition|depression|,|but|blocked (l_dobj) depression_6\NN\14373582|the|tissues
D000079_D003866 NONE acetaldehyde_16\NN\14584765|by (r_nmod) release_14\NN\3748886|calcium-independent|catecholamine|acetaldehyde (r_nsubjpass) blocked_19\VBN\1476483|release|was|not|nh4ac|. (r_conj) reversed_4\VBD\109660|addition|depression|,|but|blocked (l_dobj) depression_6\NN\14373582|the|tissues
C018824_D003866 NONE nh4ac_21\NN\1740|by (r_nmod) blocked_19\VBN\1476483|release|was|not|nh4ac|. (r_conj) reversed_4\VBD\109660|addition|depression|,|but|blocked (l_dobj) depression_6\NN\14373582|the|tissues
D014700_D000699 NONE verapamil_1\NN\2938514|both|mg/kg|and|pretreatment (r_nsubj) enhanced_10\VBD\227165|verapamil|analgesia-|and|antagonized|,|and|affected (l_dobj) analgesia-_12\NN\1740|morphine|and|incoordination
D014700_D000699 NONE verapamil_25\NN\2938514|neither|nor|nh4ac (r_nsubj) affected_28\VBD\126264|verapamil|action|. (r_conj) enhanced_10\VBD\227165|verapamil|analgesia-|and|antagonized|,|and|affected (l_dobj) analgesia-_12\NN\1740|morphine|and|incoordination
D014700_D001259 NONE verapamil_1\NN\2938514|both|mg/kg|and|pretreatment (r_nsubj) enhanced_10\VBD\227165|verapamil|analgesia-|and|antagonized|,|and|affected (l_dobj) analgesia-_12\NN\1740|morphine|and|incoordination (l_conj) incoordination_16\NN\5648247|diazepam-induced|muscular
D014700_D001259 NONE verapamil_25\NN\2938514|neither|nor|nh4ac (r_nsubj) affected_28\VBD\126264|verapamil|action|. (r_conj) enhanced_10\VBD\227165|verapamil|analgesia-|and|antagonized|,|and|affected (l_dobj) analgesia-_12\NN\1740|morphine|and|incoordination (l_conj) incoordination_16\NN\5648247|diazepam-induced|muscular
C018824_D000699 NONE nh4ac_8\NN\1740| (r_compound) pretreatment_9\NN\1740|nh4ac (r_conj) verapamil_1\NN\2938514|both|mg/kg|and|pretreatment (r_nsubj) enhanced_10\VBD\227165|verapamil|analgesia-|and|antagonized|,|and|affected (l_dobj) analgesia-_12\NN\1740|morphine|and|incoordination
C018824_D000699 NONE nh4ac_27\NN\1740| (r_conj) verapamil_25\NN\2938514|neither|nor|nh4ac (r_nsubj) affected_28\VBD\126264|verapamil|action|. (r_conj) enhanced_10\VBD\227165|verapamil|analgesia-|and|antagonized|,|and|affected (l_dobj) analgesia-_12\NN\1740|morphine|and|incoordination
D009020_D000699 NONE morphine_11\NN\2707683| (r_compound) analgesia-_12\NN\1740|morphine|and|incoordination
D003975_D000699 NONE diazepam-induced_14\JJ\1740| (r_amod) incoordination_16\NN\5648247|diazepam-induced|muscular (r_conj) analgesia-_12\NN\1740|morphine|and|incoordination
D000661_D000699 NONE amphetamine-induced_19\JJ\1740| (r_amod) activity_21\NN\30358|amphetamine-induced|motor (r_dobj) antagonized_18\VBD\1787955|activity (r_conj) enhanced_10\VBD\227165|verapamil|analgesia-|and|antagonized|,|and|affected (l_dobj) analgesia-_12\NN\1740|morphine|and|incoordination
D000661_D001259 NONE amphetamine-induced_19\JJ\1740| (r_amod) activity_21\NN\30358|amphetamine-induced|motor (r_dobj) antagonized_18\VBD\1787955|activity (r_conj) enhanced_10\VBD\227165|verapamil|analgesia-|and|antagonized|,|and|affected (l_dobj) analgesia-_12\NN\1740|morphine|and|incoordination (l_conj) incoordination_16\NN\5648247|diazepam-induced|muscular
D010433_D000699 NONE metrazol_33\NN\3740161|of (r_nmod) action_31\NN\30358|the|convulsant|metrazol (r_dobj) affected_28\VBD\126264|verapamil|action|. (r_conj) enhanced_10\VBD\227165|verapamil|analgesia-|and|antagonized|,|and|affected (l_dobj) analgesia-_12\NN\1740|morphine|and|incoordination
D010433_D001259 NONE metrazol_33\NN\3740161|of (r_nmod) action_31\NN\30358|the|convulsant|metrazol (r_dobj) affected_28\VBD\126264|verapamil|action|. (r_conj) enhanced_10\VBD\227165|verapamil|analgesia-|and|antagonized|,|and|affected (l_dobj) analgesia-_12\NN\1740|morphine|and|incoordination (l_conj) incoordination_16\NN\5648247|diazepam-induced|muscular
D002118_D022124 NONE calcium_7\NN\14625458| (r_compound) action_10\NN\30358|a|calcium|channel|blocking|enhances (r_dobj) exerts_5\VBZ\1158872|that|hyperammonemia|action (l_nsubj) hyperammonemia_4\NN\1740|
11243580
D008012_D012640 CID lidocaine-induced_6\JJ\1740| (r_amod) convulsion_7\NN\14081375|in|lidocaine-induced|mouse
D008012_D012640 CID lidocaine-induced_26\JJ\1740| (r_amod) convulsions_27\NNS\14081375|on|lidocaine-induced
D008012_D012640 CID lidocaine_18\NN\3681148|mg/kg)-induced (r_compound) convulsions_22\NNS\14081375|of|lidocaine
D008012_D012640 CID lidocaine_10\NN\3681148|mg/kg|i.p.)-induced (r_compound) convulsions_16\NNS\14081375|of|lidocaine
D008012_D012640 CID lidocaine-induced_11\JJ\1740| (r_amod) convulsions_12\NNS\14081375|in|lidocaine-induced
D019331_D012640 NONE ester_4\NN\14727670|of|n-nitro-l-arginine-methyl|l-name|inhibitor|and|l-arginine (r_nmod) effects_1\NNS\13245626|the|ester (r_nsubjpass) investigated_24\VBN\644583|effects|were|convulsions|. (l_nmod) convulsions_27\NNS\14081375|on|lidocaine-induced
D019331_D012640 NONE l-name_6\NN\1740|(|) (r_appos) ester_4\NN\14727670|of|n-nitro-l-arginine-methyl|l-name|inhibitor|and|l-arginine (r_nmod) effects_1\NNS\13245626|the|ester (r_nsubjpass) investigated_24\VBN\644583|effects|were|convulsions|. (l_nmod) convulsions_27\NNS\14081375|on|lidocaine-induced
D019331_D012640 NONE l-name_0\NN\1740|mg/kg|and|diazepam (r_nsubj) decreased_14\VBD\169651|l-name|significantly|incidence|. (l_dobj) incidence_16\NN\13821570|the|convulsions (l_nmod) convulsions_22\NNS\14081375|of|lidocaine
D009569_D012640 NONE oxide_10\NN\14818238|nitric (r_compound) inhibitor_15\NN\20090|a|oxide|no|)|synthase (r_appos) ester_4\NN\14727670|of|n-nitro-l-arginine-methyl|l-name|inhibitor|and|l-arginine (r_nmod) effects_1\NNS\13245626|the|ester (r_nsubjpass) investigated_24\VBN\644583|effects|were|convulsions|. (l_nmod) convulsions_27\NNS\14081375|on|lidocaine-induced
D009569_D012640 NONE no_12\NN\7204911|( (r_compound) inhibitor_15\NN\20090|a|oxide|no|)|synthase (r_appos) ester_4\NN\14727670|of|n-nitro-l-arginine-methyl|l-name|inhibitor|and|l-arginine (r_nmod) effects_1\NNS\13245626|the|ester (r_nsubjpass) investigated_24\VBN\644583|effects|were|convulsions|. (l_nmod) convulsions_27\NNS\14081375|on|lidocaine-induced
D009569_D012640 NONE no_20\NN\7204911| (r_compound) precursor_21\NN\14580897|a|no (r_appos) l-arginine_17\NN\1740|,|precursor|, (r_conj) ester_4\NN\14727670|of|n-nitro-l-arginine-methyl|l-name|inhibitor|and|l-arginine (r_nmod) effects_1\NNS\13245626|the|ester (r_nsubjpass) investigated_24\VBN\644583|effects|were|convulsions|. (l_nmod) convulsions_27\NNS\14081375|on|lidocaine-induced
D009569_D012640 NONE no_5\NN\7204911| (r_nsubj) mediator_9\NN\10351874|that|no|is|a|proconvulsant|convulsions (l_nmod) convulsions_12\NNS\14081375|in|lidocaine-induced
D001120_D012640 NONE l-arginine_17\NN\1740|,|precursor|, (r_conj) ester_4\NN\14727670|of|n-nitro-l-arginine-methyl|l-name|inhibitor|and|l-arginine (r_nmod) effects_1\NNS\13245626|the|ester (r_nsubjpass) investigated_24\VBN\644583|effects|were|convulsions|. (l_nmod) convulsions_27\NNS\14081375|on|lidocaine-induced
D001120_D012640 NONE l-arginine_4\NN\1740| (r_compound) treatment_5\NN\654885|the|l-arginine (r_nsubj) increased_6\VBD\169651|contrast|,|treatment|incidence|significantly|. (l_dobj) incidence_8\NN\13821570|the|convulsions (l_nmod) convulsions_16\NNS\14081375|of|lidocaine
D003975_D012640 NONE diazepam_8\NN\2830852|mg/kg (r_conj) l-name_0\NN\1740|mg/kg|and|diazepam (r_nsubj) decreased_14\VBD\169651|l-name|significantly|incidence|. (l_dobj) incidence_16\NN\13821570|the|convulsions (l_nmod) convulsions_22\NNS\14081375|of|lidocaine
16047871
D014859_C535509 NONE warfarin-induced_0\JJ\1740| (r_nummod) vasculitis_2\NN\14336539|warfarin-induced|leukocytoclastic|.
D014859_C535509 NONE warfarin_10\NN\2718259|due (r_nmod) report_1\VBP\831651|we|patients|warfarin|. (l_dobj) patients_3\NNS\9898892|4|lv (l_nmod) lv_6\NN\1740|with|late-onset
D014859_C535509 NONE warfarin_9\NN\2718259| (r_compound) therapy_10\NN\657604|with|warfarin (r_nmod) associated_7\VBN\628491|therapy (r_acl) reaction_6\NN\13446390|lv|may|be|a|late-onset|adverse|associated|. (l_nsubj) lv_0\NN\1740|
D014859_D012871 NONE warfarin_11\NN\2718259| (r_dobj) receiving_10\VBG\2210855|after|warfarin|years (r_advcl) developed_8\VBD\1753788|that|receiving (r_acl:relcl) eruptions_6\NNS\7307754|with|skin|developed
D014859_D012871 NONE warfarin_21\NN\2718259| (r_nsubjpass) discontinued_23\VBN\2609764|after|warfarin|was (r_advcl) resolved_16\VBN\352826|lesions|patients|discontinued (r_ccomp) confirming_12\VBG\1011725|resolved (r_advcl) available_7\JJ\1740|results|were|patients|,|confirming|. (l_nsubj) results_1\NNS\34213|the|biopsies (l_nmod) biopsies_5\NNS\5739043|of|skin|lesion (l_compound) lesion_4\NN\14204950|
D014859_D018366 CID warfarin_21\NN\2718259| (r_nsubjpass) discontinued_23\VBN\2609764|after|warfarin|was (r_advcl) resolved_16\VBN\352826|lesions|patients|discontinued (l_nsubj) lesions_15\NNS\14204950|lv|cutaneous
33969
C084820_D010302 NONE ethopropazine_0\NN\1740|and|benztropine|parkinsonism|. (l_nmod) parkinsonism_5\NN\14085708|in|neuroleptic-induced
C084820_D010302 NONE ethopropazine_5\NN\1740| (r_nsubjpass) compared_7\VBN\644583|study|ethopropazine|was|benztropine|. (l_nmod) benztropine_9\NN\1740|to|treatment (l_nmod) treatment_12\NN\654885|in|the|parkinsonism (l_nmod) parkinsonism_14\NN\14085708|of|induced
C084820_D010302 NONE ethopropazine_0\NN\1740|and|benztropine (r_nsubjpass) found_4\VBN\2426171|ethopropazine|were|effective|and|efficacious|. (l_xcomp) effective_8\JJ\1740|to|be|equally|controlling (l_advcl) controlling_10\VBG\2422663|in|symptoms (l_dobj) symptoms_12\NNS\5823932|parkinsonian
D001590_D010302 NONE benztropine_2\NN\1740| (r_conj) ethopropazine_0\NN\1740|and|benztropine|parkinsonism|. (l_nmod) parkinsonism_5\NN\14085708|in|neuroleptic-induced
D001590_D010302 NONE benztropine_9\NN\1740|to|treatment (l_nmod) treatment_12\NN\654885|in|the|parkinsonism (l_nmod) parkinsonism_14\NN\14085708|of|induced
D001590_D010302 NONE benztropine_2\NN\1740| (r_conj) ethopropazine_0\NN\1740|and|benztropine (r_nsubjpass) found_4\VBN\2426171|ethopropazine|were|effective|and|efficacious|. (l_xcomp) effective_8\JJ\1740|to|be|equally|controlling (l_advcl) controlling_10\VBG\2422663|in|symptoms (l_dobj) symptoms_12\NNS\5823932|parkinsonian
D001590_D010302 NONE benztropine_3\NN\1740| (r_nsubj) drug_8\NN\14778436|that|benztropine|is|not|the|anticholinergic|choice|treatment|,|effect (l_nmod) treatment_13\NN\654885|in|the|symptoms (l_nmod) symptoms_17\NNS\5823932|of|neuroleptic-induced|parkinsonian
C084820_D012559 NONE ethopropazine_5\NN\1740| (r_nsubjpass) compared_7\VBN\644583|study|ethopropazine|was|benztropine|. (l_nmod) benztropine_9\NN\1740|to|treatment (l_nmod) treatment_12\NN\654885|in|the|parkinsonism (l_nmod) parkinsonism_14\NN\14085708|of|induced (l_acl) induced_15\VBN\1627355|enanthate|outpatients (l_nmod) outpatients_22\NNS\10405694|in|60|schizophrenic (l_amod) schizophrenic_21\JJ\1740|
D001590_D012559 NONE benztropine_9\NN\1740|to|treatment (l_nmod) treatment_12\NN\654885|in|the|parkinsonism (l_nmod) parkinsonism_14\NN\14085708|of|induced (l_acl) induced_15\VBN\1627355|enanthate|outpatients (l_nmod) outpatients_22\NNS\10405694|in|60|schizophrenic (l_amod) schizophrenic_21\JJ\1740|
C017610_D010302 CID enanthate_18\NN\1740|by|fluphenazine (r_nmod) induced_15\VBN\1627355|enanthate|outpatients (r_acl) parkinsonism_14\NN\14085708|of|induced
C017610_D012559 NONE enanthate_18\NN\1740|by|fluphenazine (r_nmod) induced_15\VBN\1627355|enanthate|outpatients (l_nmod) outpatients_22\NNS\10405694|in|60|schizophrenic (l_amod) schizophrenic_21\JJ\1740|
D011352_D010302 NONE procyclidine_18\NN\3800001|as|,|drug (r_nmod) efficacious_16\JJ\1740|were|as|procyclidine (r_conj) found_4\VBN\2426171|ethopropazine|were|effective|and|efficacious|. (l_xcomp) effective_8\JJ\1740|to|be|equally|controlling (l_advcl) controlling_10\VBG\2422663|in|symptoms (l_dobj) symptoms_12\NNS\5823932|parkinsonian
D001590_D004409 CID benztropine_2\NN\1740| (r_nmod:npmod) treated_3\JJ\1740|benztropine (r_amod) patients_4\NNS\9898892|treated (r_nsubj) had_5\VBD\2108377|however|,|patients|increase|. (l_dobj) increase_8\NN\13576355|a|significant|dyskinesia|condition|,|and|anxiety (l_nmod) dyskinesia_11\NN\14084880|in|tardive
D001590_D001008 CID benztropine_2\NN\1740| (r_nmod:npmod) treated_3\JJ\1740|benztropine (r_amod) patients_4\NNS\9898892|treated (r_nsubj) had_5\VBD\2108377|however|,|patients|increase|. (l_dobj) increase_8\NN\13576355|a|significant|dyskinesia|condition|,|and|anxiety (l_conj) anxiety_23\NN\14373582|more|and|depression|patients
D001590_D003866 CID benztropine_2\NN\1740| (r_nmod:npmod) treated_3\JJ\1740|benztropine (r_amod) patients_4\NNS\9898892|treated (r_nsubj) had_5\VBD\2108377|however|,|patients|increase|. (l_dobj) increase_8\NN\13576355|a|significant|dyskinesia|condition|,|and|anxiety (l_conj) anxiety_23\NN\14373582|more|and|depression|patients (l_conj) depression_25\NN\14373582|
D011352_D004409 NONE procyclindine_17\NN\1740| (r_compound) treatment_18\NN\654885|during|procyclindine (r_nmod) condition_15\NN\24720|compared|to|their|treatment (r_nmod) increase_8\NN\13576355|a|significant|dyskinesia|condition|,|and|anxiety (l_nmod) dyskinesia_11\NN\14084880|in|tardive
D011352_D001008 NONE procyclindine_17\NN\1740| (r_compound) treatment_18\NN\654885|during|procyclindine (r_nmod) condition_15\NN\24720|compared|to|their|treatment (r_nmod) increase_8\NN\13576355|a|significant|dyskinesia|condition|,|and|anxiety (l_conj) anxiety_23\NN\14373582|more|and|depression|patients
D011352_D003866 NONE procyclindine_17\NN\1740| (r_compound) treatment_18\NN\654885|during|procyclindine (r_nmod) condition_15\NN\24720|compared|to|their|treatment (r_nmod) increase_8\NN\13576355|a|significant|dyskinesia|condition|,|and|anxiety (l_conj) anxiety_23\NN\14373582|more|and|depression|patients (l_conj) depression_25\NN\14373582|
C084820_D004409 NONE ethopropazine_27\NN\1740| (r_nmod:npmod) treated_28\JJ\1740|ethopropazine (r_amod) patients_29\NNS\9898892|than|treated (r_nmod) anxiety_23\NN\14373582|more|and|depression|patients (r_conj) increase_8\NN\13576355|a|significant|dyskinesia|condition|,|and|anxiety (l_nmod) dyskinesia_11\NN\14084880|in|tardive
C084820_D001008 NONE ethopropazine_27\NN\1740| (r_nmod:npmod) treated_28\JJ\1740|ethopropazine (r_amod) patients_29\NNS\9898892|than|treated (r_nmod) anxiety_23\NN\14373582|more|and|depression|patients
C084820_D003866 NONE ethopropazine_27\NN\1740| (r_nmod:npmod) treated_28\JJ\1740|ethopropazine (r_amod) patients_29\NNS\9898892|than|treated (r_nmod) anxiety_23\NN\14373582|more|and|depression|patients (l_conj) depression_25\NN\14373582|
11868798
D013148_D007008 NONE spironolactone_0\NN\2721160|drug|? (l_dep) drug_6\NN\14778436|:|is|it|a|novel|prevention (l_nmod) prevention_9\NN\1073995|for|the|hypokalemia (l_nmod) hypokalemia_13\NN\14299637|of|b-related|patients
D013148_D007008 NONE spironolactone_43\NN\2721160|of (r_nmod) ability_41\NN\4723816|the|spironolactone|reduce (l_acl) reduce_45\VB\441445|to|requirements|and|prevent (l_conj) prevent_50\VB\1740|to|hypokalemia (l_dobj) hypokalemia_51\NN\14299637|patients
D013148_D007008 NONE spironolactone_6\NN\2721160| (r_nsubj) reduce_8\VB\441445|that|spironolactone|can|requirements|and|prevent (l_conj) prevent_12\VB\1740|hypokalemia|reducing (l_dobj) hypokalemia_13\NN\14299637|
D013148_D009369 NONE spironolactone_0\NN\2721160|drug|? (l_dep) drug_6\NN\14778436|:|is|it|a|novel|prevention (l_nmod) prevention_9\NN\1073995|for|the|hypokalemia (l_nmod) hypokalemia_13\NN\14299637|of|b-related|patients (l_nmod) patients_16\NNS\9898892|in|cancer (l_compound) cancer_15\NN\14239425|
D000666_D007008 CID b-related_12\JJ\1740|amphotericin (r_amod) hypokalemia_13\NN\14299637|of|b-related|patients
D000666_D007008 CID amb._24\NN\1740|with (r_nmod) effect_20\NN\34213|that|is|a|major|clinical|side|treatment|amb. (r_acl:relcl) wasting_13\NN\14547643|for|the|profound|potassium|effect (r_nmod) responsible_8\JJ\1740|to|be|wasting (r_xcomp) seems_5\VBZ\2604760|toxicity|responsible|potentiates|designed|. (l_parataxis) designed_37\VBN\1631534|study|was|assess (l_xcomp) assess_39\VB\670261|to|ability (l_dobj) ability_41\NN\4723816|the|spironolactone|reduce (l_acl) reduce_45\VB\441445|to|requirements|and|prevent (l_conj) prevent_50\VB\1740|to|hypokalemia (l_dobj) hypokalemia_51\NN\14299637|patients
D000666_D007008 CID amb._33\NN\1740|of (r_nmod) toxicity_31\NN\13576101|the|tubular|amb. (r_dobj) potentiates_28\VBZ\229605|depletion|also|toxicity (r_parataxis) seems_5\VBZ\2604760|toxicity|responsible|potentiates|designed|. (l_parataxis) designed_37\VBN\1631534|study|was|assess (l_xcomp) assess_39\VB\670261|to|ability (l_dobj) ability_41\NN\4723816|the|spironolactone|reduce (l_acl) reduce_45\VB\441445|to|requirements|and|prevent (l_conj) prevent_50\VB\1740|to|hypokalemia (l_dobj) hypokalemia_51\NN\14299637|patients
D000666_D007008 CID amb_56\NN\1740| (r_compound) treatment_57\NN\654885|on|amb (r_nmod) patients_54\NNS\9898892|in|neutropenic|treatment (r_nmod) hypokalemia_51\NN\14299637|patients
D000666_D007008 CID amb_23\NN\1740| (r_compound) treatment_24\NN\654885|on|amb (r_nmod) patients_21\NNS\9898892|in|neutropenic|treatment (r_nmod) loss_18\NN\13252973|urinary|potassium|patients (r_dobj) reducing_15\VBG\441445|by|loss (r_advcl) prevent_12\VB\1740|hypokalemia|reducing (l_dobj) hypokalemia_13\NN\14299637|
D000666_D009369 NONE b-related_12\JJ\1740|amphotericin (r_amod) hypokalemia_13\NN\14299637|of|b-related|patients (l_nmod) patients_16\NNS\9898892|in|cancer (l_compound) cancer_15\NN\14239425|
D000666_D007674 NONE b_10\NN\1355326|of|amphotericin|amb (r_nmod) effect_7\NN\34213|:|nephrotoxicity|is|the|major|adverse|b|,|limiting (l_nsubj) nephrotoxicity_2\NN\1740|
D000666_D007674 NONE amb_12\NN\1740|(|) (r_appos) b_10\NN\1355326|of|amphotericin|amb (r_nmod) effect_7\NN\34213|:|nephrotoxicity|is|the|major|adverse|b|,|limiting (l_nsubj) nephrotoxicity_2\NN\1740|
D011188_D064420 NONE potassium_12\NN\14625458| (r_compound) wasting_13\NN\14547643|for|the|profound|potassium|effect (r_nmod) responsible_8\JJ\1740|to|be|wasting (r_xcomp) seems_5\VBZ\2604760|toxicity|responsible|potentiates|designed|. (l_nsubj) toxicity_4\NN\13576101|selective|distal|tubular|epithelial
D011188_D064420 NONE potassium_12\NN\14625458| (r_compound) wasting_13\NN\14547643|for|the|profound|potassium|effect (r_nmod) responsible_8\JJ\1740|to|be|wasting (r_xcomp) seems_5\VBZ\2604760|toxicity|responsible|potentiates|designed|. (l_parataxis) potentiates_28\VBZ\229605|depletion|also|toxicity (l_dobj) toxicity_31\NN\13576101|the|tubular|amb.
D011188_D064420 NONE potassium_25\NN\14625458| (r_compound) depletion_26\NN\351638|potassium (r_nsubj) potentiates_28\VBZ\229605|depletion|also|toxicity (r_parataxis) seems_5\VBZ\2604760|toxicity|responsible|potentiates|designed|. (l_nsubj) toxicity_4\NN\13576101|selective|distal|tubular|epithelial
D011188_D064420 NONE potassium_25\NN\14625458| (r_compound) depletion_26\NN\351638|potassium (r_nsubj) potentiates_28\VBZ\229605|depletion|also|toxicity (l_dobj) toxicity_31\NN\13576101|the|tubular|amb.
D011188_D064420 NONE potassium_46\NN\14625458| (r_compound) requirements_47\NNS\1129920|potassium (r_dobj) reduce_45\VB\441445|to|requirements|and|prevent (r_acl) ability_41\NN\4723816|the|spironolactone|reduce (r_dobj) assess_39\VB\670261|to|ability (r_xcomp) designed_37\VBN\1631534|study|was|assess (r_parataxis) seems_5\VBZ\2604760|toxicity|responsible|potentiates|designed|. (l_nsubj) toxicity_4\NN\13576101|selective|distal|tubular|epithelial
D011188_D064420 NONE potassium_46\NN\14625458| (r_compound) requirements_47\NNS\1129920|potassium (r_dobj) reduce_45\VB\441445|to|requirements|and|prevent (r_acl) ability_41\NN\4723816|the|spironolactone|reduce (r_dobj) assess_39\VB\670261|to|ability (r_xcomp) designed_37\VBN\1631534|study|was|assess (r_parataxis) seems_5\VBZ\2604760|toxicity|responsible|potentiates|designed|. (l_parataxis) potentiates_28\VBZ\229605|depletion|also|toxicity (l_dobj) toxicity_31\NN\13576101|the|tubular|amb.
D011188_D007008 NONE potassium_12\NN\14625458| (r_compound) wasting_13\NN\14547643|for|the|profound|potassium|effect (r_nmod) responsible_8\JJ\1740|to|be|wasting (r_xcomp) seems_5\VBZ\2604760|toxicity|responsible|potentiates|designed|. (l_parataxis) designed_37\VBN\1631534|study|was|assess (l_xcomp) assess_39\VB\670261|to|ability (l_dobj) ability_41\NN\4723816|the|spironolactone|reduce (l_acl) reduce_45\VB\441445|to|requirements|and|prevent (l_conj) prevent_50\VB\1740|to|hypokalemia (l_dobj) hypokalemia_51\NN\14299637|patients
D011188_D007008 NONE potassium_25\NN\14625458| (r_compound) depletion_26\NN\351638|potassium (r_nsubj) potentiates_28\VBZ\229605|depletion|also|toxicity (r_parataxis) seems_5\VBZ\2604760|toxicity|responsible|potentiates|designed|. (l_parataxis) designed_37\VBN\1631534|study|was|assess (l_xcomp) assess_39\VB\670261|to|ability (l_dobj) ability_41\NN\4723816|the|spironolactone|reduce (l_acl) reduce_45\VB\441445|to|requirements|and|prevent (l_conj) prevent_50\VB\1740|to|hypokalemia (l_dobj) hypokalemia_51\NN\14299637|patients
D011188_D007008 NONE potassium_46\NN\14625458| (r_compound) requirements_47\NNS\1129920|potassium (r_dobj) reduce_45\VB\441445|to|requirements|and|prevent (l_conj) prevent_50\VB\1740|to|hypokalemia (l_dobj) hypokalemia_51\NN\14299637|patients
D011188_D007008 NONE potassium_9\NN\14625458| (r_compound) requirements_10\NNS\1129920|potassium (r_dobj) reduce_8\VB\441445|that|spironolactone|can|requirements|and|prevent (l_conj) prevent_12\VB\1740|hypokalemia|reducing (l_dobj) hypokalemia_13\NN\14299637|
D011188_D007008 NONE potassium_17\NN\14625458| (r_compound) loss_18\NN\13252973|urinary|potassium|patients (r_dobj) reducing_15\VBG\441445|by|loss (r_advcl) prevent_12\VB\1740|hypokalemia|reducing (l_dobj) hypokalemia_13\NN\14299637|
D011188_D009503 NONE potassium_12\NN\14625458| (r_compound) wasting_13\NN\14547643|for|the|profound|potassium|effect (r_nmod) responsible_8\JJ\1740|to|be|wasting (r_xcomp) seems_5\VBZ\2604760|toxicity|responsible|potentiates|designed|. (l_parataxis) designed_37\VBN\1631534|study|was|assess (l_xcomp) assess_39\VB\670261|to|ability (l_dobj) ability_41\NN\4723816|the|spironolactone|reduce (l_acl) reduce_45\VB\441445|to|requirements|and|prevent (l_conj) prevent_50\VB\1740|to|hypokalemia (l_dobj) hypokalemia_51\NN\14299637|patients (l_nmod) patients_54\NNS\9898892|in|neutropenic|treatment (l_amod) neutropenic_53\JJ\1740|
D011188_D009503 NONE potassium_25\NN\14625458| (r_compound) depletion_26\NN\351638|potassium (r_nsubj) potentiates_28\VBZ\229605|depletion|also|toxicity (r_parataxis) seems_5\VBZ\2604760|toxicity|responsible|potentiates|designed|. (l_parataxis) designed_37\VBN\1631534|study|was|assess (l_xcomp) assess_39\VB\670261|to|ability (l_dobj) ability_41\NN\4723816|the|spironolactone|reduce (l_acl) reduce_45\VB\441445|to|requirements|and|prevent (l_conj) prevent_50\VB\1740|to|hypokalemia (l_dobj) hypokalemia_51\NN\14299637|patients (l_nmod) patients_54\NNS\9898892|in|neutropenic|treatment (l_amod) neutropenic_53\JJ\1740|
D011188_D009503 NONE potassium_46\NN\14625458| (r_compound) requirements_47\NNS\1129920|potassium (r_dobj) reduce_45\VB\441445|to|requirements|and|prevent (l_conj) prevent_50\VB\1740|to|hypokalemia (l_dobj) hypokalemia_51\NN\14299637|patients (l_nmod) patients_54\NNS\9898892|in|neutropenic|treatment (l_amod) neutropenic_53\JJ\1740|
D011188_D009503 NONE potassium_9\NN\14625458| (r_compound) requirements_10\NNS\1129920|potassium (r_dobj) reduce_8\VB\441445|that|spironolactone|can|requirements|and|prevent (l_conj) prevent_12\VB\1740|hypokalemia|reducing (l_advcl) reducing_15\VBG\441445|by|loss (l_dobj) loss_18\NN\13252973|urinary|potassium|patients (l_nmod) patients_21\NNS\9898892|in|neutropenic|treatment (l_amod) neutropenic_20\JJ\1740|
D011188_D009503 NONE potassium_17\NN\14625458| (r_compound) loss_18\NN\13252973|urinary|potassium|patients (l_nmod) patients_21\NNS\9898892|in|neutropenic|treatment (l_amod) neutropenic_20\JJ\1740|
D000666_D064420 NONE amb._24\NN\1740|with (r_nmod) effect_20\NN\34213|that|is|a|major|clinical|side|treatment|amb. (r_acl:relcl) wasting_13\NN\14547643|for|the|profound|potassium|effect (r_nmod) responsible_8\JJ\1740|to|be|wasting (r_xcomp) seems_5\VBZ\2604760|toxicity|responsible|potentiates|designed|. (l_nsubj) toxicity_4\NN\13576101|selective|distal|tubular|epithelial
D000666_D064420 NONE amb._24\NN\1740|with (r_nmod) effect_20\NN\34213|that|is|a|major|clinical|side|treatment|amb. (r_acl:relcl) wasting_13\NN\14547643|for|the|profound|potassium|effect (r_nmod) responsible_8\JJ\1740|to|be|wasting (r_xcomp) seems_5\VBZ\2604760|toxicity|responsible|potentiates|designed|. (l_parataxis) potentiates_28\VBZ\229605|depletion|also|toxicity (l_dobj) toxicity_31\NN\13576101|the|tubular|amb.
D000666_D064420 NONE amb._33\NN\1740|of (r_nmod) toxicity_31\NN\13576101|the|tubular|amb. (r_dobj) potentiates_28\VBZ\229605|depletion|also|toxicity (r_parataxis) seems_5\VBZ\2604760|toxicity|responsible|potentiates|designed|. (l_nsubj) toxicity_4\NN\13576101|selective|distal|tubular|epithelial
D000666_D064420 NONE amb._33\NN\1740|of (r_nmod) toxicity_31\NN\13576101|the|tubular|amb.
D000666_D064420 NONE amb_56\NN\1740| (r_compound) treatment_57\NN\654885|on|amb (r_nmod) patients_54\NNS\9898892|in|neutropenic|treatment (r_nmod) hypokalemia_51\NN\14299637|patients (r_dobj) prevent_50\VB\1740|to|hypokalemia (r_conj) reduce_45\VB\441445|to|requirements|and|prevent (r_acl) ability_41\NN\4723816|the|spironolactone|reduce (r_dobj) assess_39\VB\670261|to|ability (r_xcomp) designed_37\VBN\1631534|study|was|assess (r_parataxis) seems_5\VBZ\2604760|toxicity|responsible|potentiates|designed|. (l_nsubj) toxicity_4\NN\13576101|selective|distal|tubular|epithelial
D000666_D064420 NONE amb_56\NN\1740| (r_compound) treatment_57\NN\654885|on|amb (r_nmod) patients_54\NNS\9898892|in|neutropenic|treatment (r_nmod) hypokalemia_51\NN\14299637|patients (r_dobj) prevent_50\VB\1740|to|hypokalemia (r_conj) reduce_45\VB\441445|to|requirements|and|prevent (r_acl) ability_41\NN\4723816|the|spironolactone|reduce (r_dobj) assess_39\VB\670261|to|ability (r_xcomp) designed_37\VBN\1631534|study|was|assess (r_parataxis) seems_5\VBZ\2604760|toxicity|responsible|potentiates|designed|. (l_parataxis) potentiates_28\VBZ\229605|depletion|also|toxicity (l_dobj) toxicity_31\NN\13576101|the|tubular|amb.
D000666_D009503 NONE amb._24\NN\1740|with (r_nmod) effect_20\NN\34213|that|is|a|major|clinical|side|treatment|amb. (r_acl:relcl) wasting_13\NN\14547643|for|the|profound|potassium|effect (r_nmod) responsible_8\JJ\1740|to|be|wasting (r_xcomp) seems_5\VBZ\2604760|toxicity|responsible|potentiates|designed|. (l_parataxis) designed_37\VBN\1631534|study|was|assess (l_xcomp) assess_39\VB\670261|to|ability (l_dobj) ability_41\NN\4723816|the|spironolactone|reduce (l_acl) reduce_45\VB\441445|to|requirements|and|prevent (l_conj) prevent_50\VB\1740|to|hypokalemia (l_dobj) hypokalemia_51\NN\14299637|patients (l_nmod) patients_54\NNS\9898892|in|neutropenic|treatment (l_amod) neutropenic_53\JJ\1740|
D000666_D009503 NONE amb._33\NN\1740|of (r_nmod) toxicity_31\NN\13576101|the|tubular|amb. (r_dobj) potentiates_28\VBZ\229605|depletion|also|toxicity (r_parataxis) seems_5\VBZ\2604760|toxicity|responsible|potentiates|designed|. (l_parataxis) designed_37\VBN\1631534|study|was|assess (l_xcomp) assess_39\VB\670261|to|ability (l_dobj) ability_41\NN\4723816|the|spironolactone|reduce (l_acl) reduce_45\VB\441445|to|requirements|and|prevent (l_conj) prevent_50\VB\1740|to|hypokalemia (l_dobj) hypokalemia_51\NN\14299637|patients (l_nmod) patients_54\NNS\9898892|in|neutropenic|treatment (l_amod) neutropenic_53\JJ\1740|
D000666_D009503 NONE amb_56\NN\1740| (r_compound) treatment_57\NN\654885|on|amb (r_nmod) patients_54\NNS\9898892|in|neutropenic|treatment (l_amod) neutropenic_53\JJ\1740|
D000666_D009503 NONE amb_23\NN\1740| (r_compound) treatment_24\NN\654885|on|amb (r_nmod) patients_21\NNS\9898892|in|neutropenic|treatment (l_amod) neutropenic_20\JJ\1740|
D013148_D064420 NONE spironolactone_43\NN\2721160|of (r_nmod) ability_41\NN\4723816|the|spironolactone|reduce (r_dobj) assess_39\VB\670261|to|ability (r_xcomp) designed_37\VBN\1631534|study|was|assess (r_parataxis) seems_5\VBZ\2604760|toxicity|responsible|potentiates|designed|. (l_nsubj) toxicity_4\NN\13576101|selective|distal|tubular|epithelial
D013148_D064420 NONE spironolactone_43\NN\2721160|of (r_nmod) ability_41\NN\4723816|the|spironolactone|reduce (r_dobj) assess_39\VB\670261|to|ability (r_xcomp) designed_37\VBN\1631534|study|was|assess (r_parataxis) seems_5\VBZ\2604760|toxicity|responsible|potentiates|designed|. (l_parataxis) potentiates_28\VBZ\229605|depletion|also|toxicity (l_dobj) toxicity_31\NN\13576101|the|tubular|amb.
D013148_D009503 NONE spironolactone_43\NN\2721160|of (r_nmod) ability_41\NN\4723816|the|spironolactone|reduce (l_acl) reduce_45\VB\441445|to|requirements|and|prevent (l_conj) prevent_50\VB\1740|to|hypokalemia (l_dobj) hypokalemia_51\NN\14299637|patients (l_nmod) patients_54\NNS\9898892|in|neutropenic|treatment (l_amod) neutropenic_53\JJ\1740|
D013148_D009503 NONE spironolactone_6\NN\2721160| (r_nsubj) reduce_8\VB\441445|that|spironolactone|can|requirements|and|prevent (l_conj) prevent_12\VB\1740|hypokalemia|reducing (l_advcl) reducing_15\VBG\441445|by|loss (l_dobj) loss_18\NN\13252973|urinary|potassium|patients (l_nmod) patients_21\NNS\9898892|in|neutropenic|treatment (l_amod) neutropenic_20\JJ\1740|
D000666_D006402 NONE amb_17\NN\1740|either|intravenous|alone|or|amb (r_dobj) receive_14\VB\2210855|to|amb|developing (r_xcomp) randomized_12\VBN\278117|methods|study|patients|were|receive|. (l_nsubjpass) patients_6\NNS\9898892|26|disorders (l_nmod) disorders_10\NNS\14034177|with|various|hematological
D000666_D006402 NONE amb_20\NN\1740|and|spironolactone|daily (r_conj) amb_17\NN\1740|either|intravenous|alone|or|amb (r_dobj) receive_14\VB\2210855|to|amb|developing (r_xcomp) randomized_12\VBN\278117|methods|study|patients|were|receive|. (l_nsubjpass) patients_6\NNS\9898892|26|disorders (l_nmod) disorders_10\NNS\14034177|with|various|hematological
D000666_D009181 NONE amb_17\NN\1740|either|intravenous|alone|or|amb (r_dobj) receive_14\VB\2210855|to|amb|developing (l_advcl) developing_29\VBG\1753788|when|infection (l_dobj) infection_35\NN\14052046|a|proven|fungal
D000666_D009181 NONE amb_20\NN\1740|and|spironolactone|daily (r_conj) amb_17\NN\1740|either|intravenous|alone|or|amb (r_dobj) receive_14\VB\2210855|to|amb|developing (l_advcl) developing_29\VBG\1753788|when|infection (l_dobj) infection_35\NN\14052046|a|proven|fungal
D013148_D006402 NONE spironolactone_23\NN\2721160|oral|mg (r_conj) amb_20\NN\1740|and|spironolactone|daily (r_conj) amb_17\NN\1740|either|intravenous|alone|or|amb (r_dobj) receive_14\VB\2210855|to|amb|developing (r_xcomp) randomized_12\VBN\278117|methods|study|patients|were|receive|. (l_nsubjpass) patients_6\NNS\9898892|26|disorders (l_nmod) disorders_10\NNS\14034177|with|various|hematological
D013148_D009181 NONE spironolactone_23\NN\2721160|oral|mg (r_conj) amb_20\NN\1740|and|spironolactone|daily (r_conj) amb_17\NN\1740|either|intravenous|alone|or|amb (r_dobj) receive_14\VB\2210855|to|amb|developing (l_advcl) developing_29\VBG\1753788|when|infection (l_dobj) infection_35\NN\14052046|a|proven|fungal
14736955
D004317_D009401 CID doxorubicin_10\NN\2716866| (r_compound) nephrosis_11\NN\14304060|in|doxorubicin
D004317_D007674 NONE doxorubicin_2\NN\2716866| (r_nsubj) induces_3\VBZ\1627355|background|:|doxorubicin|nephropathy|. (l_dobj) nephropathy_6\NN\14573196|a|self-perpetuating|characterized
D004317_D007674 NONE doxorubicin_2\NN\2716866| (r_nsubj) induces_3\VBZ\1627355|background|:|doxorubicin|nephropathy|. (l_dobj) nephropathy_6\NN\14573196|a|self-perpetuating|characterized (l_acl) characterized_7\VBN\609683|lesions (l_nmod) lesions_14\NNS\14204950|by|glomerular|tubular|rats
D004317_D007674 NONE doxorubicin-induced_27\JJ\1740| (r_amod) lesions_29\NNS\14204950|in|doxorubicin-induced|renal
C102006_D007674 NONE citrate_28\NN\14850483| (r_compound) synthase_29\NN\1740|citrate (r_compound) activity_30\NN\30358|increased|synthase (r_conj) lesions_12\NNS\14204950|glomerular|,|activities|and|activity
D013481_D007674 NONE superoxide_35\NN\14971519| (r_compound) production_36\NN\30358|with|superoxide|and|activities (r_nmod) correlated_33\VBN\2657219|injury|was|positively|production (r_parataxis) correlated_10\VBN\2657219|animals|,|injury|were|inversely|levels|cox-i.|correlated|. (l_nsubjpass) injury_7\NN\14052046|glomerular
D013481_D007674 NONE superoxide_25\NN\14971519|of (r_nmod) induction_23\NN\7450842|superoxide|lesions (l_nmod) lesions_29\NNS\14204950|in|doxorubicin-induced|renal
6381653
D007980_D004409 CID levodopa-induced_0\JJ\1740| (r_amod) dyskinesia_1\NN\14084880|levodopa-induced|and|thalamotomy|.
D007980_D004409 CID levodopa-induced_0\JJ\1740| (r_amod) dyskinesia_1\NN\14084880|levodopa-induced|limbs|cases|,
D007980_D004409 CID levodopa-induced_2\JJ\1740| (r_amod) dyskinesias_3\NNS\14084880|of|levodopa-induced
D007980_D010302 NONE levodopa-induced_0\JJ\1740| (r_amod) dyskinesia_1\NN\14084880|levodopa-induced|limbs|cases|, (l_nmod) cases_7\NNS\7283608|in|thirteen|parkinsonism|,|choreic (l_nmod) parkinsonism_9\NN\14085708|of
D007980_D010302 NONE levodopa-induced_2\JJ\1740| (r_amod) dyskinesias_3\NNS\14084880|of|levodopa-induced (r_nmod) control_0\NN\5190804|dyskinesias|lesions|course (l_nmod) course_9\NN\883297|in|the|treatment (l_nmod) treatment_12\NN\654885|of|routine|parkinsonism (l_nmod) parkinsonism_14\NN\14085708|of
D007980_D020821 NONE levodopa-induced_0\JJ\1740| (r_amod) dyskinesia_1\NN\14084880|levodopa-induced|limbs|cases|, (l_nmod) cases_7\NNS\7283608|in|thirteen|parkinsonism|,|choreic (l_acl:relcl) choreic_13\JJ\1740|which|was|,|ballistic (l_conj) ballistic_15\JJ\1740|or|dystonic (l_conj) dystonic_17\JJ\1740|type
D007980_D013786 NONE levodopa-induced_2\JJ\1740| (r_amod) dyskinesias_3\NNS\14084880|of|levodopa-induced (r_nmod) control_0\NN\5190804|dyskinesias|lesions|course (l_nmod) lesions_6\NNS\14204950|by|thalamic
9564988
D064704_D012852 NONE levofloxacin_3\NN\1740|of (r_nmod) assessment_1\NN\5732756|open-label|levofloxacin|treatment|. (l_nmod) treatment_6\NN\654885|for|the|sinusitis (l_nmod) sinusitis_10\NN\14336539|of|acute|bacterial|adults
D064704_D012852 NONE levofloxacin_9\NN\1740|of|mg (r_nmod) efficacy_5\NN\5199286|the|and|safety|levofloxacin|treating (l_advcl) treating_23\VBG\2376958|in|outpatients|sinusitis (l_nmod) sinusitis_29\NN\14336539|with|acute|bacterial
D064704_D012852 NONE levofloxacin_9\NN\1740|mg (r_nsubj) treatment_19\NN\654885|that|levofloxacin|is|an|effective|sinusitis (l_nmod) sinusitis_23\NN\14336539|for|acute|bacterial
9867728
D005277_D006349 NONE fenfluramine_8\NN\1740|of|and|dexfenfluramine (r_nmod) users_6\NNS\7846|among|fenfluramine|underwent (r_nmod) risk_0\NN\14541044|disease|users|. (l_nmod) disease_4\NN\14061805|for|valvular|heart
D005277_D006349 NONE fenfluramine_18\NN\1740|of|and|dexfenfluramine (r_nmod) users_16\NNS\7846|of|fenfluramine (r_nmod) %_14\NN\1740|38|users (r_nsubj) had_21\VBD\2108377|that|%|disease (l_dobj) disease_23\NN\14061805|valvular
D005277_D006349 NONE fenfluramine_15\NN\1740|of|or|dexfenfluramine (r_nmod) users_13\NNS\7846|among|fenfluramine|underwent (r_nmod) risk_5\NN\14541044|the|abnormalities|users (l_nmod) abnormalities_11\NNS\14034177|for|new|valvular
D005277_D006349 NONE fenfluramine-phentermine_20\NN\1740| (r_dobj) receiving_19\VBG\2210855|fenfluramine-phentermine (r_acl) ci_10\NN\13635336|[|95|%|,|%|]|)|receiving (r_appos) %_6\NN\1740|(|4.3|ci (r_appos) patients_3\NNS\9898892|two|% (r_nsubj) developed_21\VBD\1753788|patients|disease|. (l_dobj) disease_24\NN\14061805|valvular|heart
D020372_D006349 NONE dexfenfluramine_10\NN\1740| (r_conj) fenfluramine_8\NN\1740|of|and|dexfenfluramine (r_nmod) users_6\NNS\7846|among|fenfluramine|underwent (r_nmod) risk_0\NN\14541044|disease|users|. (l_nmod) disease_4\NN\14061805|for|valvular|heart
D020372_D006349 NONE dexfenfluramine_20\NN\1740| (r_conj) fenfluramine_18\NN\1740|of|and|dexfenfluramine (r_nmod) users_16\NNS\7846|of|fenfluramine (r_nmod) %_14\NN\1740|38|users (r_nsubj) had_21\VBD\2108377|that|%|disease (l_dobj) disease_23\NN\14061805|valvular
D020372_D006349 NONE dexfenfluramine_17\NN\1740| (r_conj) fenfluramine_15\NN\1740|of|or|dexfenfluramine (r_nmod) users_13\NNS\7846|among|fenfluramine|underwent (r_nmod) risk_5\NN\14541044|the|abnormalities|users (l_nmod) abnormalities_11\NNS\14034177|for|new|valvular
D010645_D006349 NONE fenfluramine-phentermine_20\NN\1740| (r_dobj) receiving_19\VBG\2210855|fenfluramine-phentermine (r_acl) ci_10\NN\13635336|[|95|%|,|%|]|)|receiving (r_appos) %_6\NN\1740|(|4.3|ci (r_appos) patients_3\NNS\9898892|two|% (r_nsubj) developed_21\VBD\1753788|patients|disease|. (l_dobj) disease_24\NN\14061805|valvular|heart
11524350
D002045_D064420 NONE bupivacaine-_5\NN\1740|,|levobupivacaine-|or|ropivacaine-infused (r_compound) rats_11\NNS\2329401|in|bupivacaine- (r_nmod) toxicity_1\NN\13576101|systemic|and|resuscitation|rats|.
D002045_D064420 NONE bupivacaine_6\NN\1740|of|,|levobupivacaine (r_nmod) toxicity_4\NN\13576101|the|systemic|bupivacaine|rats
D002045_D064420 NONE bupivacaine_15\NN\1740| (r_conj) ropivacaine_13\NN\1740|of|and|bupivacaine (r_nmod) that_11\DT\1740|between|ropivacaine (r_nmod) intermediate_9\JJ\1740|that|toxicity|is|that|administered|and|appears (l_nsubj) toxicity_5\NN\13576101|the|systemic|levobupivacaine
D002045_D064420 NONE bupivacaine_38\NN\1740|by|or|levobupivacaine (r_nmod) induced_36\VBN\1627355|bupivacaine (r_acl) that_35\DT\1740|than|induced (r_nmod) susceptible_31\JJ\1740|to|be|more|treatment|that (r_xcomp) appears_27\VBZ\2604760|that|arrest|susceptible (r_conj) intermediate_9\JJ\1740|that|toxicity|is|that|administered|and|appears (l_nsubj) toxicity_5\NN\13576101|the|systemic|levobupivacaine
C476513_D064420 NONE levobupivacaine-_7\NN\1740|, (r_conj) bupivacaine-_5\NN\1740|,|levobupivacaine-|or|ropivacaine-infused (r_compound) rats_11\NNS\2329401|in|bupivacaine- (r_nmod) toxicity_1\NN\13576101|systemic|and|resuscitation|rats|.
C476513_D064420 NONE levobupivacaine_8\NN\1740|,|and|ropivacaine (r_conj) bupivacaine_6\NN\1740|of|,|levobupivacaine (r_nmod) toxicity_4\NN\13576101|the|systemic|bupivacaine|rats
C476513_D064420 NONE levobupivacaine_7\NN\1740|of (r_nmod) toxicity_5\NN\13576101|the|systemic|levobupivacaine
C476513_D064420 NONE levobupivacaine_40\NN\1740| (r_conj) bupivacaine_38\NN\1740|by|or|levobupivacaine (r_nmod) induced_36\VBN\1627355|bupivacaine (r_acl) that_35\DT\1740|than|induced (r_nmod) susceptible_31\JJ\1740|to|be|more|treatment|that (r_xcomp) appears_27\VBZ\2604760|that|arrest|susceptible (r_conj) intermediate_9\JJ\1740|that|toxicity|is|that|administered|and|appears (l_nsubj) toxicity_5\NN\13576101|the|systemic|levobupivacaine
C037663_D064420 NONE ropivacaine-infused_10\NN\1740| (r_conj) bupivacaine-_5\NN\1740|,|levobupivacaine-|or|ropivacaine-infused (r_compound) rats_11\NNS\2329401|in|bupivacaine- (r_nmod) toxicity_1\NN\13576101|systemic|and|resuscitation|rats|.
C037663_D064420 NONE ropivacaine_11\NN\1740| (r_conj) levobupivacaine_8\NN\1740|,|and|ropivacaine (r_conj) bupivacaine_6\NN\1740|of|,|levobupivacaine (r_nmod) toxicity_4\NN\13576101|the|systemic|bupivacaine|rats
C037663_D064420 NONE ropivacaine_13\NN\1740|of|and|bupivacaine (r_nmod) that_11\DT\1740|between|ropivacaine (r_nmod) intermediate_9\JJ\1740|that|toxicity|is|that|administered|and|appears (l_nsubj) toxicity_5\NN\13576101|the|systemic|levobupivacaine
C037663_D064420 NONE ropivacaine-induced_24\JJ\1740| (r_amod) arrest_26\NN\88481|ropivacaine-induced|cardiac (r_nsubj) appears_27\VBZ\2604760|that|arrest|susceptible (r_conj) intermediate_9\JJ\1740|that|toxicity|is|that|administered|and|appears (l_nsubj) toxicity_5\NN\13576101|the|systemic|levobupivacaine
C476513_D012640 CID levobupivacaine_4\NN\1740|of|and|ropivacaine (r_nmod) doses_2\NNS\3740161|the|cumulative|levobupivacaine|produced (l_acl:relcl) produced_8\VBD\1617192|that|seizures (l_dobj) seizures_9\NNS\14081375|
C037663_D012640 CID ropivacaine_6\NN\1740| (r_conj) levobupivacaine_4\NN\1740|of|and|ropivacaine (r_nmod) doses_2\NNS\3740161|the|cumulative|levobupivacaine|produced (l_acl:relcl) produced_8\VBD\1617192|that|seizures (l_dobj) seizures_9\NNS\14081375|
D002045_D012640 NONE bupivacaine_18\NN\1740|of (r_nmod) those_16\DT\1740|than|bupivacaine (r_nmod) larger_14\JJR\1740|were|those (r_conj) similar_11\JJ\1740|doses|were|and|larger|. (l_nsubj) doses_2\NNS\3740161|the|cumulative|levobupivacaine|produced (l_acl:relcl) produced_8\VBD\1617192|that|seizures (l_dobj) seizures_9\NNS\14081375|
C476513_D001145 CID levobupivacaine_4\NN\1740|of (r_nmod) doses_2\NNS\3740161|the|cumulative|levobupivacaine|produced (l_acl:relcl) produced_6\VBD\1617192|that|dysrhythmias (l_dobj) dysrhythmias_7\NNS\1740|and|asystole
C476513_D006323 CID levobupivacaine_4\NN\1740|of (r_nmod) doses_2\NNS\3740161|the|cumulative|levobupivacaine|produced (l_acl:relcl) produced_6\VBD\1617192|that|dysrhythmias (l_dobj) dysrhythmias_7\NNS\1740|and|asystole (l_conj) asystole_9\NN\14204950|
C476513_D006323 CID levobupivacaine_7\NN\1740|of (r_nmod) toxicity_5\NN\13576101|the|systemic|levobupivacaine (r_nsubj) intermediate_9\JJ\1740|that|toxicity|is|that|administered|and|appears (l_conj) appears_27\VBZ\2604760|that|arrest|susceptible (l_nsubj) arrest_26\NN\88481|ropivacaine-induced|cardiac
C476513_D006323 CID levobupivacaine_40\NN\1740| (r_conj) bupivacaine_38\NN\1740|by|or|levobupivacaine (r_nmod) induced_36\VBN\1627355|bupivacaine (r_acl) that_35\DT\1740|than|induced (r_nmod) susceptible_31\JJ\1740|to|be|more|treatment|that (r_xcomp) appears_27\VBZ\2604760|that|arrest|susceptible (l_nsubj) arrest_26\NN\88481|ropivacaine-induced|cardiac
C037663_D001145 CID ropivacaine_17\NN\1740|of (r_nmod) doses_15\NNS\3740161|than|the|corresponding|ropivacaine (r_nmod) smaller_11\JJR\1740|doses|were|doses|,|but|larger (l_nsubj) doses_2\NNS\3740161|the|cumulative|levobupivacaine|produced (l_acl:relcl) produced_6\VBD\1617192|that|dysrhythmias (l_dobj) dysrhythmias_7\NNS\1740|and|asystole
C037663_D006323 CID ropivacaine_17\NN\1740|of (r_nmod) doses_15\NNS\3740161|than|the|corresponding|ropivacaine (r_nmod) smaller_11\JJR\1740|doses|were|doses|,|but|larger (l_nsubj) doses_2\NNS\3740161|the|cumulative|levobupivacaine|produced (l_acl:relcl) produced_6\VBD\1617192|that|dysrhythmias (l_dobj) dysrhythmias_7\NNS\1740|and|asystole (l_conj) asystole_9\NN\14204950|
C037663_D006323 CID ropivacaine_13\NN\1740|of|and|bupivacaine (r_nmod) that_11\DT\1740|between|ropivacaine (r_nmod) intermediate_9\JJ\1740|that|toxicity|is|that|administered|and|appears (l_conj) appears_27\VBZ\2604760|that|arrest|susceptible (l_nsubj) arrest_26\NN\88481|ropivacaine-induced|cardiac
C037663_D006323 CID ropivacaine-induced_24\JJ\1740| (r_amod) arrest_26\NN\88481|ropivacaine-induced|cardiac
D002045_D001145 NONE bupivacaine_26\NN\1740|of (r_nmod) those_24\DT\1740|than|bupivacaine (r_nmod) larger_22\JJR\1740|they|were|those|. (r_conj) smaller_11\JJR\1740|doses|were|doses|,|but|larger (l_nsubj) doses_2\NNS\3740161|the|cumulative|levobupivacaine|produced (l_acl:relcl) produced_6\VBD\1617192|that|dysrhythmias (l_dobj) dysrhythmias_7\NNS\1740|and|asystole
D002045_D006323 NONE bupivacaine_26\NN\1740|of (r_nmod) those_24\DT\1740|than|bupivacaine (r_nmod) larger_22\JJR\1740|they|were|those|. (r_conj) smaller_11\JJR\1740|doses|were|doses|,|but|larger (l_nsubj) doses_2\NNS\3740161|the|cumulative|levobupivacaine|produced (l_acl:relcl) produced_6\VBD\1617192|that|dysrhythmias (l_dobj) dysrhythmias_7\NNS\1740|and|asystole (l_conj) asystole_9\NN\14204950|
D002045_D006323 NONE bupivacaine_15\NN\1740| (r_conj) ropivacaine_13\NN\1740|of|and|bupivacaine (r_nmod) that_11\DT\1740|between|ropivacaine (r_nmod) intermediate_9\JJ\1740|that|toxicity|is|that|administered|and|appears (l_conj) appears_27\VBZ\2604760|that|arrest|susceptible (l_nsubj) arrest_26\NN\88481|ropivacaine-induced|cardiac
D002045_D006323 NONE bupivacaine_38\NN\1740|by|or|levobupivacaine (r_nmod) induced_36\VBN\1627355|bupivacaine (r_acl) that_35\DT\1740|than|induced (r_nmod) susceptible_31\JJ\1740|to|be|more|treatment|that (r_xcomp) appears_27\VBZ\2604760|that|arrest|susceptible (l_nsubj) arrest_26\NN\88481|ropivacaine-induced|cardiac
3183120
C033706_D001927 CID tiazofurin_5\NN\1740| (r_compound) usage_6\NN\407535|with|tiazofurin (r_nmod) associated_3\VBN\628491|usage (r_acl) lesions_2\NNS\14204950|reversible|cerebral|associated|:|demonstration
783197
D010042_D003324 NONE ouabain_2\NN\1740|of (r_nmod) effects_0\NNS\13245626|ouabain|supply|. (l_dep) supply_6\NN\13576355|oxygen|and|demand|patients (l_nmod) patients_10\NNS\9898892|in|disease (l_nmod) disease_15\NN\14061805|with|chronic|coronary|artery
D010042_D003324 NONE ouabain_5\NN\1740|of|weight (r_nmod) effects_3\NNS\13245626|the|ouabain|parameters (l_nmod) parameters_19\NNS\5858936|on|hemodynamic|patients (l_nmod) patients_22\NNS\9898892|in|11|disease (l_nmod) disease_28\NN\14061805|with|severe|chronic|coronary|artery|failure
D010042_D003324 NONE ouabain_24\NN\1740| (r_compound) administration_25\NN\1133281|after|ouabain (r_nmod) falls_22\VBZ\1835496|that|patients|volume|administration|normal (l_nmod) patients_4\NNS\9898892|in|disease|failure (l_nmod) disease_9\NN\14061805|with|chronic|coronary|artery
D010100_D003324 NONE oxygen_5\NN\14622893|on|myocardial (r_compound) supply_6\NN\13576355|oxygen|and|demand|patients (l_nmod) patients_10\NNS\9898892|in|disease (l_nmod) disease_15\NN\14061805|with|chronic|coronary|artery
D010100_D003324 NONE oxygen_7\NN\14622893|myocardial (r_compound) supply_8\NN\13576355|on|oxygen|and|demand (r_nmod) effects_1\NNS\13245626|the|glycosides|supply (r_nsubj) interest_14\NN\5682570|effects|are|of|particular|presence|,|but|measured (l_nmod) presence_17\NN\13954253|in|the|disease (l_nmod) disease_22\NN\14061805|of|obstructive|coronary|artery
D004071_D003324 NONE glycosides_4\NNS\14727670|of|digitalis (r_nmod) effects_1\NNS\13245626|the|glycosides|supply (r_nsubj) interest_14\NN\5682570|effects|are|of|particular|presence|,|but|measured (l_nmod) presence_17\NN\13954253|in|the|disease (l_nmod) disease_22\NN\14061805|of|obstructive|coronary|artery
D010042_D006333 NONE ouabain_5\NN\1740|of|weight (r_nmod) effects_3\NNS\13245626|the|ouabain|parameters (l_nmod) parameters_19\NNS\5858936|on|hemodynamic|patients (l_nmod) patients_22\NNS\9898892|in|11|disease (l_nmod) disease_28\NN\14061805|with|severe|chronic|coronary|artery|failure (l_nmod) failure_33\NN\66216|without|clinical|congestive|heart
D010042_D006333 NONE ouabain_24\NN\1740| (r_compound) administration_25\NN\1133281|after|ouabain (r_nmod) falls_22\VBZ\1835496|that|patients|volume|administration|normal (l_nmod) patients_4\NNS\9898892|in|disease|failure (l_nmod) failure_17\NN\66216|are|not|in|clinical|congestive|heart
D010042_D002303 CID ouabain_24\NN\1740| (r_compound) administration_25\NN\1133281|after|ouabain (r_nmod) falls_22\VBZ\1835496|that|patients|volume|administration|normal
6118280
D001569_D009207 NONE benzodiazepines_3\NNS\3771443|and|baclofen (r_conj) drugs_1\NNS\14778436|serotonergic|,|benzodiazepines (r_nsubj) block_6\VBP\1476483|drugs|jerks|. (l_dobj) jerks_9\NNS\10322238|muscimol-induced|myoclonic|strain
D001569_D009207 NONE benzodiazepines_2\NNS\3771443|of|the (r_nmod) found_12\VBN\2426171|benzodiazepines|,|clonazepam|was|potent|. (l_xcomp) potent_18\JJ\1740|to|be|more|diazepam|blocking (l_advcl) blocking_28\VBG\1476483|in|jerks (l_dobj) jerks_31\NNS\10322238|the|myoclonic
D001569_D009207 NONE benzodiazepines_7\NNS\3771443|the (r_conj) 5-htp_4\NN\1740|and|benzodiazepines (r_nsubjpass) found_10\VBN\2426171|fact|that|5-htp|have|been|beneficial (l_xcomp) beneficial_13\JJ\1740|to|be|management (l_nmod) management_16\NN\1123598|in|the|myoclonus (l_nmod) myoclonus_19\NN\14360459|of|clinical
D001569_D009207 NONE benzodiazepines_7\NNS\3771443|the (r_conj) 5-htp_4\NN\1740|and|benzodiazepines (r_nsubjpass) found_10\VBN\2426171|fact|that|5-htp|have|been|beneficial (r_ccomp) seems_24\VBZ\2604760|found|,|myoclonus|model|. (l_nsubj) myoclonus_23\NN\14360459|the|muscimol-induced
D001418_D009207 NONE baclofen_5\NN\1740| (r_conj) benzodiazepines_3\NNS\3771443|and|baclofen (r_conj) drugs_1\NNS\14778436|serotonergic|,|benzodiazepines (r_nsubj) block_6\VBP\1476483|drugs|jerks|. (l_dobj) jerks_9\NNS\10322238|muscimol-induced|myoclonic|strain
D001418_D009207 NONE (-)-baclofen_10\NN\1740| (r_conj) mk-212_8\NN\1740|of|and|(-)-baclofen (r_nmod) value_6\NN\5856066|the|possible|mk-212|management (l_nmod) management_13\NN\1123598|in|the|myoclonus (l_nmod) myoclonus_16\NN\14360459|of|clinical
D009118_D009207 CID muscimol-induced_7\JJ\1740| (r_amod) jerks_9\NNS\10322238|muscimol-induced|myoclonic|strain
D009118_D009207 CID muscimol_5\NN\1740| (r_nsubj) produced_6\VBD\1617192|mice|,|muscimol|jerks|. (l_dobj) jerks_8\NNS\10322238|myoclonic
D009118_D009207 CID muscimol-induced_22\JJ\1740| (r_amod) myoclonus_23\NN\14360459|the|muscimol-induced (r_nsubj) seems_24\VBZ\2604760|found|,|myoclonus|model|. (l_ccomp) found_10\VBN\2426171|fact|that|5-htp|have|been|beneficial (l_xcomp) beneficial_13\JJ\1740|to|be|management (l_nmod) management_16\NN\1123598|in|the|myoclonus (l_nmod) myoclonus_19\NN\14360459|of|clinical
D009118_D009207 CID muscimol-induced_22\JJ\1740| (r_amod) myoclonus_23\NN\14360459|the|muscimol-induced
D002998_D009207 NONE clonazepam_4\NN\1740|mg/kg (r_nsubjpass) found_12\VBN\2426171|benzodiazepines|,|clonazepam|was|potent|. (l_xcomp) potent_18\JJ\1740|to|be|more|diazepam|blocking (l_advcl) blocking_28\VBG\1476483|in|jerks (l_dobj) jerks_31\NNS\10322238|the|myoclonic
D003975_D009207 NONE diazepam_20\NN\2830852|than|mg/kg (r_nmod) potent_18\JJ\1740|to|be|more|diazepam|blocking (l_advcl) blocking_28\VBG\1476483|in|jerks (l_dobj) jerks_31\NNS\10322238|the|myoclonic
D006916_D009207 NONE 5-htp_4\NN\1740|and|benzodiazepines (r_nsubjpass) found_10\VBN\2426171|fact|that|5-htp|have|been|beneficial (l_xcomp) beneficial_13\JJ\1740|to|be|management (l_nmod) management_16\NN\1123598|in|the|myoclonus (l_nmod) myoclonus_19\NN\14360459|of|clinical
D006916_D009207 NONE 5-htp_4\NN\1740|and|benzodiazepines (r_nsubjpass) found_10\VBN\2426171|fact|that|5-htp|have|been|beneficial (r_ccomp) seems_24\VBZ\2604760|found|,|myoclonus|model|. (l_nsubj) myoclonus_23\NN\14360459|the|muscimol-induced
C014896_D009207 NONE mk-212_8\NN\1740|of|and|(-)-baclofen (r_nmod) value_6\NN\5856066|the|possible|mk-212|management (l_nmod) management_13\NN\1123598|in|the|myoclonus (l_nmod) myoclonus_16\NN\14360459|of|clinical
839274
D003276_D000236 CID contraceptives_14\NNS\3183080|on|oral (r_nmod) women_11\NNS\9605289|in|young|contraceptives (r_nmod) adenomas_1\NNS\14236226|hepatic|and|hyperplasia|women|:|reports
D003276_D000236 CID contraceptives_18\NNS\3183080|of|oral (r_nmod) use_15\NN\407535|with|the|contraceptives (r_nmod) associated_12\VBN\628491|presumably|use (r_acl) one_6\CD\13741022|hyperplasia|associated (r_conj) cases_1\NNS\7283608|two|adenoma|and|one (l_nmod) adenoma_4\NN\14236226|of|hepatic
D003276_D020518 CID contraceptives_14\NNS\3183080|on|oral (r_nmod) women_11\NNS\9605289|in|young|contraceptives (r_nmod) adenomas_1\NNS\14236226|hepatic|and|hyperplasia|women|:|reports (l_conj) hyperplasia_5\NN\14365950|focal|nodular|liver
D003276_D020518 CID contraceptives_18\NNS\3183080|of|oral (r_nmod) use_15\NN\407535|with|the|contraceptives (r_nmod) associated_12\VBN\628491|presumably|use (r_acl) one_6\CD\13741022|hyperplasia|associated (l_nmod) hyperplasia_10\NN\14365950|of|focal|nodular
8800187
D002122_D064420 NONE chloride_3\NN\14818238|of|calcium|and|therapy (r_nmod) effect_0\NN\34213|chloride|toxicity|. (l_nmod) toxicity_9\NN\13576101|on|desipramine|rats
D015761_D064420 NONE 4-aminopyridine_5\NN\1740| (r_compound) therapy_6\NN\657604|4-aminopyridine (r_conj) chloride_3\NN\14818238|of|calcium|and|therapy (r_nmod) effect_0\NN\34213|chloride|toxicity|. (l_nmod) toxicity_9\NN\13576101|on|desipramine|rats
D003891_D064420 NONE desipramine_8\NN\4482543| (r_compound) toxicity_9\NN\13576101|on|desipramine|rats
D002118_D007022 NONE calcium_7\NN\14625458| (r_compound) channel_8\NN\6251781|calcium (r_compound) blockade_9\NN\952963|of|channel (r_nmod) role_5\NN\719494|the|potential|blockade|hypotension (l_nmod) hypotension_13\NN\14057371|in|antidepressant-induced
D002118_D007022 NONE calcium_8\NN\14625458| (r_compound) channel_9\NN\6251781|calcium (r_compound) inhibition_10\NN\1068773|for|channel (r_nmod) role_6\NN\719494|a|inhibition|pathogenesis (l_nmod) pathogenesis_13\NN\13533470|in|the|hypotension (l_nmod) hypotension_17\NN\14057371|of|antidepressant-induced
D002118_D062787 NONE calcium_16\NN\14625458| (r_compound) channel_17\NN\6251781|calcium (r_compound) blocker_18\NN\10101634|channel (r_compound) overdose_19\NN\1740|with|blocker
D003891_D007022 CID desipramine_6\NN\4482543|the|antidepressant (r_dobj) received_2\VBD\2210855|rats|desipramine|ip|produce|. (l_advcl) produce_9\VB\1617192|to|hypotension (l_dobj) hypotension_10\NN\14057371|,|prolongation|,|and|bradycardia
D003891_D001919 CID desipramine_6\NN\4482543|the|antidepressant (r_dobj) received_2\VBD\2210855|rats|desipramine|ip|produce|. (l_advcl) produce_9\VB\1617192|to|hypotension (l_dobj) hypotension_10\NN\14057371|,|prolongation|,|and|bradycardia (l_conj) bradycardia_16\NN\14110674|
D017693_D007022 NONE nahco3_2\NN\1740|min (r_nsubj) reversed_8\VBD\109660|nahco3|hypotension|. (l_dobj) hypotension_9\NN\14057371|and|prolongation
D002122_D001145 CID cacl2_19\NN\1740| (r_compound) group_20\NN\2137|in|the|cacl2 (r_nmod) incidence_1\NN\13821570|the|arrhythmias|group (l_nmod) arrhythmias_4\NNS\14103288|of|ventricular|=|and|seizures
D002122_D012640 NONE cacl2_19\NN\1740| (r_compound) group_20\NN\2137|in|the|cacl2 (r_nmod) incidence_1\NN\13821570|the|arrhythmias|group (l_nmod) arrhythmias_4\NNS\14103288|of|ventricular|=|and|seizures (l_conj) seizures_11\NNS\14081375|=
D002122_D007022 NONE cacl2_5\NN\1740|of|or|4-aminopyridine (r_nmod) administration_3\NN\1133281|the|cacl2 (r_nsubj) reverse_10\VB\109660|administration|did|not|hypotension|. (l_dobj) hypotension_13\NN\14057371|antidepressant-induced|rats
D015761_D007022 NONE 4-aminopyridine_7\NN\1740| (r_conj) cacl2_5\NN\1740|of|or|4-aminopyridine (r_nmod) administration_3\NN\1133281|the|cacl2 (r_nsubj) reverse_10\VB\109660|administration|did|not|hypotension|. (l_dobj) hypotension_13\NN\14057371|antidepressant-induced|rats
D002122_D002318 NONE cacl2_0\NN\1740| (r_compound) therapy_1\NN\657604|cacl2 (r_nsubj) worsen_4\VB\146138|therapy|may|possibly|cardiovascular|. (l_dobj) cardiovascular_6\JJ\1740|both|and|toxicity (l_conj) toxicity_11\NN\13576101|system
D002122_D002493 NONE cacl2_0\NN\1740| (r_compound) therapy_1\NN\657604|cacl2 (r_nsubj) worsen_4\VB\146138|therapy|may|possibly|cardiovascular|. (l_dobj) cardiovascular_6\JJ\1740|both|and|toxicity (l_conj) toxicity_11\NN\13576101|system
17366349
C092292_D009459 CID ziprasidone_5\NN\1740|by (r_nmod) induced_3\VBN\1627355|ziprasidone|day (r_acl) syndrome_2\NN\5870365|neuroleptic|malignant|induced|.
C092292_D009459 CID ziprasidone_16\NN\1740|of (r_nmod) use_14\NN\407535|with|the|ziprasidone (r_nmod) associated_11\VBN\628491|use (r_acl) syndrome_7\NN\5870365|of|neuroleptic|malignant|nms|associated
C092292_D009459 CID ziprasidone_16\NN\1740|of (r_nmod) use_14\NN\407535|with|the|ziprasidone (r_nmod) associated_11\VBN\628491|use (r_acl) syndrome_7\NN\5870365|of|neuroleptic|malignant|nms|associated (l_appos) nms_9\NN\13649268|(|)
C092292_D009459 CID ziprasidone_14\NN\1740|like (r_nmod) drugs_12\NNS\14778436|atypical|antipsychotic|ziprasidone (r_nsubj) cause_19\NN\7323922|associated|,|drugs|may|also|be|a|. (l_advcl) associated_6\VBN\628491|although|neuroleptics|are|frequently|nms (l_nmod) nms_8\NN\13649268|with
C092292_D009459 CID ziprasidone_30\NN\1740|of|administrated (r_nmod) dose_26\NN\3740161|with|an|80-mg/day|ziprasidone (r_nmod) treatment_22\NN\654885|of|dose (r_nmod) days_20\NNS\15140892|after|2|treatment (r_nmod) developed_12\VBD\1753788|who|signs|days (l_dobj) signs_13\NNS\6643763|and|symptoms|nms (l_nmod) nms_17\NN\13649268|of
C092292_D009459 CID ziprasidone_14\NN\1740|due|reported (r_nmod) nms_11\NN\13649268|case|is|the|earliest|ziprasidone|.
C092292_D012559 NONE ziprasidone_30\NN\1740|of|administrated (r_nmod) dose_26\NN\3740161|with|an|80-mg/day|ziprasidone (r_nmod) treatment_22\NN\654885|of|dose (r_nmod) days_20\NNS\15140892|after|2|treatment (r_nmod) developed_12\VBD\1753788|who|signs|days (r_acl:relcl) male_5\NN\15388|patient|is|a|24-year-old|history|developed|. (l_nmod) history_8\NN\15120823|with|a|schizophrenia (l_nmod) schizophrenia_10\NN\14398067|of
9630698
D006220_D009127 CID haloperidol_5\NN\3713736|by|mg/kg (r_nmod) induced_3\VBN\1627355|rigidity|was|haloperidol|. (l_nsubjpass) rigidity_1\NN\5023233|muscle
D006220_D009127 CID haloperidol-induced_34\JJ\1740| (r_amod) rigidity_36\NN\5023233|both|the|haloperidol-induced|muscle|mmg|and|activity
C066192_D009127 NONE acid_1\NN\14818238|5,7-dichlorokynurenic|5,7-dcka|,|antagonist|,|injected|, (r_nsubj) decreased_31\VBD\169651|acid|rigidity|. (l_dobj) rigidity_36\NN\5023233|both|the|haloperidol-induced|muscle|mmg|and|activity
C066192_D009127 NONE 5,7-dcka_3\NN\1740|(|) (r_appos) acid_1\NN\14818238|5,7-dichlorokynurenic|5,7-dcka|,|antagonist|,|injected|, (r_nsubj) decreased_31\VBD\169651|acid|rigidity|. (l_dobj) rigidity_36\NN\5023233|both|the|haloperidol-induced|muscle|mmg|and|activity
D005998_D009127 NONE glycine_8\NN\14601829| (r_compound) antagonist_10\NN\7846|a|selective|glycine|site (r_appos) acid_1\NN\14818238|5,7-dichlorokynurenic|5,7-dcka|,|antagonist|,|injected|, (r_nsubj) decreased_31\VBD\169651|acid|rigidity|. (l_dobj) rigidity_36\NN\5023233|both|the|haloperidol-induced|muscle|mmg|and|activity
15930398
D015742_D000647 CID propofol_12\NN\1740|with (r_nmod) sedation_10\NN\14034177|during|procedural|propofol (r_nmod) onset_3\NN\7325190|of|the|and|persistence|amnesia|sedation (l_nmod) amnesia_7\NN\5669934|of
3653576
C001335_D058186 CID hexachloro-1:3-butadiene_24\NN\1740|of|hcbd|,|aminonucleoside|,|and|2-bromoethylamine|,|respectively (r_nmod) administration_22\NN\1133281|by|hexachloro-1:3-butadiene (r_nmod) produced_20\VBN\1617192|models|were|administration|. (l_nsubjpass) models_2\NNS\5888929|acute|experimental|damage (l_nmod) damage_5\NN\7296428|of|renal|regions
C001335_D058186 CID hcbd_26\NN\1740|(|) (r_appos) hexachloro-1:3-butadiene_24\NN\1740|of|hcbd|,|aminonucleoside|,|and|2-bromoethylamine|,|respectively (r_nmod) administration_22\NN\1133281|by|hexachloro-1:3-butadiene (r_nmod) produced_20\VBN\1617192|models|were|administration|. (l_nsubjpass) models_2\NNS\5888929|acute|experimental|damage (l_nmod) damage_5\NN\7296428|of|renal|regions
D011692_D058186 CID aminonucleoside_30\NN\1740|puromycin|pan (r_conj) hexachloro-1:3-butadiene_24\NN\1740|of|hcbd|,|aminonucleoside|,|and|2-bromoethylamine|,|respectively (r_nmod) administration_22\NN\1133281|by|hexachloro-1:3-butadiene (r_nmod) produced_20\VBN\1617192|models|were|administration|. (l_nsubjpass) models_2\NNS\5888929|acute|experimental|damage (l_nmod) damage_5\NN\7296428|of|renal|regions
D011692_D058186 CID pan_32\NN\3101986|(|) (r_appos) aminonucleoside_30\NN\1740|puromycin|pan (r_conj) hexachloro-1:3-butadiene_24\NN\1740|of|hcbd|,|aminonucleoside|,|and|2-bromoethylamine|,|respectively (r_nmod) administration_22\NN\1133281|by|hexachloro-1:3-butadiene (r_nmod) produced_20\VBN\1617192|models|were|administration|. (l_nsubjpass) models_2\NNS\5888929|acute|experimental|damage (l_nmod) damage_5\NN\7296428|of|renal|regions
C004504_D058186 CID 2-bromoethylamine_36\NN\1740|bea (r_conj) hexachloro-1:3-butadiene_24\NN\1740|of|hcbd|,|aminonucleoside|,|and|2-bromoethylamine|,|respectively (r_nmod) administration_22\NN\1133281|by|hexachloro-1:3-butadiene (r_nmod) produced_20\VBN\1617192|models|were|administration|. (l_nsubjpass) models_2\NNS\5888929|acute|experimental|damage (l_nmod) damage_5\NN\7296428|of|renal|regions
C004504_D058186 CID bea_38\NN\1740|(|) (r_appos) 2-bromoethylamine_36\NN\1740|bea (r_conj) hexachloro-1:3-butadiene_24\NN\1740|of|hcbd|,|aminonucleoside|,|and|2-bromoethylamine|,|respectively (r_nmod) administration_22\NN\1133281|by|hexachloro-1:3-butadiene (r_nmod) produced_20\VBN\1617192|models|were|administration|. (l_nsubjpass) models_2\NNS\5888929|acute|experimental|damage (l_nmod) damage_5\NN\7296428|of|renal|regions
C001335_D007674 NONE hcbd_4\NN\1740|by|or|bea (r_nmod) produced_2\VBN\1617192|hcbd (r_acl) damage_1\NN\7296428|tubular|produced (r_nsubjpass) discriminated_8\VBN\650353|damage|was|quantitatively|damage|. (l_nmod) damage_15\NN\7296428|from|glomerular|produced
C004504_D007674 NONE bea_6\NN\1740| (r_conj) hcbd_4\NN\1740|by|or|bea (r_nmod) produced_2\VBN\1617192|hcbd (r_acl) damage_1\NN\7296428|tubular|produced (r_nsubjpass) discriminated_8\VBN\650353|damage|was|quantitatively|damage|. (l_nmod) damage_15\NN\7296428|from|glomerular|produced
D011692_D007674 NONE pan_18\NN\3101986|by (r_nmod) produced_16\VBN\1617192|pan (r_acl) damage_15\NN\7296428|from|glomerular|produced
6674249
D015119_D009135 CID acid_3\NN\14818238|epsilon-aminocaproic|eaca (r_nsubj) induce_7\VB\1627355|why|may|acid|myopathy|? (l_dobj) myopathy_8\NN\14204950|man
D015119_D009135 CID eaca_5\NN\1740|(|) (r_appos) acid_3\NN\14818238|epsilon-aminocaproic|eaca (r_nsubj) induce_7\VB\1627355|why|may|acid|myopathy|? (l_dobj) myopathy_8\NN\14204950|man
D015119_D009135 CID acid_10\NN\14818238|short|epsilon-aminocaproic|eaca (r_compound) treatment_14\NN\654885|due|a|acid|patient (r_nmod) myopathy_4\NN\14204950|of|necrotizing|treatment
D015119_D009135 CID eaca_12\NN\1740|(|) (r_appos) acid_10\NN\14818238|short|epsilon-aminocaproic|eaca (r_compound) treatment_14\NN\654885|due|a|acid|patient (r_nmod) myopathy_4\NN\14204950|of|necrotizing|treatment
D015119_D009336 CID acid_10\NN\14818238|short|epsilon-aminocaproic|eaca (r_compound) treatment_14\NN\654885|due|a|acid|patient (r_nmod) myopathy_4\NN\14204950|of|necrotizing|treatment
D015119_D009336 CID eaca_12\NN\1740|(|) (r_appos) acid_10\NN\14818238|short|epsilon-aminocaproic|eaca (r_compound) treatment_14\NN\654885|due|a|acid|patient (r_nmod) myopathy_4\NN\14204950|of|necrotizing|treatment
D015119_D013345 NONE acid_10\NN\14818238|short|epsilon-aminocaproic|eaca (r_compound) treatment_14\NN\654885|due|a|acid|patient (l_nmod) patient_19\NN\9898892|in|a|year-old|haemorrhage (l_nmod) haemorrhage_22\NN\14285662|with|subarachnoid|sah
D015119_D013345 NONE acid_10\NN\14818238|short|epsilon-aminocaproic|eaca (r_compound) treatment_14\NN\654885|due|a|acid|patient (l_nmod) patient_19\NN\9898892|in|a|year-old|haemorrhage (l_nmod) haemorrhage_22\NN\14285662|with|subarachnoid|sah (l_appos) sah_24\NN\1740|(|)
D015119_D013345 NONE eaca_12\NN\1740|(|) (r_appos) acid_10\NN\14818238|short|epsilon-aminocaproic|eaca (r_compound) treatment_14\NN\654885|due|a|acid|patient (l_nmod) patient_19\NN\9898892|in|a|year-old|haemorrhage (l_nmod) haemorrhage_22\NN\14285662|with|subarachnoid|sah
D015119_D013345 NONE eaca_12\NN\1740|(|) (r_appos) acid_10\NN\14818238|short|epsilon-aminocaproic|eaca (r_compound) treatment_14\NN\654885|due|a|acid|patient (l_nmod) patient_19\NN\9898892|in|a|year-old|haemorrhage (l_nmod) haemorrhage_22\NN\14285662|with|subarachnoid|sah (l_appos) sah_24\NN\1740|(|)
21418164
D008130_D064420 NONE ccnu_0\NN\1740|lomustine (r_compound) toxicity_4\NN\13576101|ccnu|dogs|:|study
D008130_D064420 NONE lomustine_2\NN\2722458|(|) (r_appos) ccnu_0\NN\1740|lomustine (r_compound) toxicity_4\NN\13576101|ccnu|dogs|:|study
D008130_D064420 NONE ccnu_8\NN\1740|with (r_nmod) treated_6\VBN\2376958|ccnu (r_acl) dogs_5\NNS\2083346|of|the|206|treated (r_nmod) results_0\NNS\34213|:|dogs (r_nsubj) met_11\VBD\1182709|results|,|185|criteria|. (l_dobj) criteria_14\NNS\13577171|the|inclusion|class (l_nmod) class_19\NN\7951464|for|one|toxicity (l_nmod) toxicity_21\NN\13576101|of
D008130_D064420 NONE ccnu-associated_2\JJ\1740| (r_amod) toxicity_3\NN\13576101|ccnu-associated|dogs
D008130_D006402 NONE 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea_19\NN\1740|ccnu (r_dobj) receiving_18\VBG\2210855|1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (r_acl) dogs_17\NNS\2083346|in|tumour-bearing|receiving (r_nmod) toxicities_14\NNS\13576101|of|haematological|dogs
D008130_D006402 NONE ccnu_21\NN\1740|(|) (r_appos) 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea_19\NN\1740|ccnu (r_dobj) receiving_18\VBG\2210855|1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (r_acl) dogs_17\NNS\2083346|in|tumour-bearing|receiving (r_nmod) toxicities_14\NNS\13576101|of|haematological|dogs
D008130_D007674 NONE 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea_19\NN\1740|ccnu (r_dobj) receiving_18\VBG\2210855|1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (r_acl) dogs_17\NNS\2083346|in|tumour-bearing|receiving (r_nmod) toxicities_14\NNS\13576101|of|haematological|dogs
D008130_D007674 NONE ccnu_21\NN\1740|(|) (r_appos) 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea_19\NN\1740|ccnu (r_dobj) receiving_18\VBG\2210855|1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (r_acl) dogs_17\NNS\2083346|in|tumour-bearing|receiving (r_nmod) toxicities_14\NNS\13576101|of|haematological|dogs
D008130_D056486 NONE 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea_19\NN\1740|ccnu (r_dobj) receiving_18\VBG\2210855|1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (r_acl) dogs_17\NNS\2083346|in|tumour-bearing|receiving (r_nmod) toxicities_14\NNS\13576101|of|haematological|dogs
D008130_D056486 NONE ccnu_21\NN\1740|(|) (r_appos) 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea_19\NN\1740|ccnu (r_dobj) receiving_18\VBG\2210855|1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (r_acl) dogs_17\NNS\2083346|in|tumour-bearing|receiving (r_nmod) toxicities_14\NNS\13576101|of|haematological|dogs
D008130_D005767 NONE 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea_19\NN\1740|ccnu (r_dobj) receiving_18\VBG\2210855|1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (r_acl) dogs_17\NNS\2083346|in|tumour-bearing|receiving (r_nmod) toxicities_14\NNS\13576101|of|haematological|dogs
D008130_D005767 NONE ccnu_21\NN\1740|(|) (r_appos) 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea_19\NN\1740|ccnu (r_dobj) receiving_18\VBG\2210855|1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (r_acl) dogs_17\NNS\2083346|in|tumour-bearing|receiving (r_nmod) toxicities_14\NNS\13576101|of|haematological|dogs
D008130_D008223 NONE ccnu_0\NN\1740| (r_nsubjpass) used_2\VBN\1156834|ccnu|was|commonly|treatment|. (l_nmod) treatment_7\NN\654885|in|the|lymphoma (l_nmod) lymphoma_9\NN\14239918|of|,|tumour|,|tumour|,|tumours
D008130_D008223 NONE ccnu_0\NN\1740| (r_nsubjpass) used_2\VBN\1156834|ccnu|was|commonly|treatment|. (l_nmod) treatment_7\NN\654885|in|the|lymphoma (l_nmod) lymphoma_9\NN\14239918|of|,|tumour|,|tumour|,|tumours (l_conj) tumours_19\NNS\14234074|histiocytic|and|lymphoma (l_conj) lymphoma_22\NN\14239918|epitheliotropic
D008130_D034801 NONE ccnu_0\NN\1740| (r_nsubjpass) used_2\VBN\1156834|ccnu|was|commonly|treatment|. (l_nmod) treatment_7\NN\654885|in|the|lymphoma (l_nmod) lymphoma_9\NN\14239918|of|,|tumour|,|tumour|,|tumours (l_conj) tumour_13\NN\14234074|mast|cell
D008130_D001932 NONE ccnu_0\NN\1740| (r_nsubjpass) used_2\VBN\1156834|ccnu|was|commonly|treatment|. (l_nmod) treatment_7\NN\654885|in|the|lymphoma (l_nmod) lymphoma_9\NN\14239918|of|,|tumour|,|tumour|,|tumours (l_conj) tumour_16\NN\14234074|brain
D008130_D015620 NONE ccnu_0\NN\1740| (r_nsubjpass) used_2\VBN\1156834|ccnu|was|commonly|treatment|. (l_nmod) treatment_7\NN\654885|in|the|lymphoma (l_nmod) lymphoma_9\NN\14239918|of|,|tumour|,|tumour|,|tumours (l_conj) tumours_19\NNS\14234074|histiocytic|and|lymphoma
D000409_D064420 NONE alanine_5\NN\14601829| (r_compound) transaminase_6\NN\15077571|elevated|alanine|alt (r_compound) concentration_10\NN\4916342|transaminase (r_conj) toxicity_2\NN\13576101|potential|renal|and|concentration
18589141
D006493_D013921 CID heparin-induced_0\JJ\1740| (r_amod) thrombocytopenia_1\NN\14189204|heparin-induced|transplantation|.
D006493_D013921 CID heparin-induced_0\JJ\1740| (r_amod) thrombocytopenia_1\NN\14189204|heparin-induced|hit
D006493_D013921 CID heparin-induced_0\JJ\1740| (r_amod) thrombocytopenia_1\NN\14189204|heparin-induced|hit (l_appos) hit_3\NN\36762|(|)
D006493_D013921 CID heparin_11\NN\2718259|to (r_nmod) reaction_9\NN\13446390|thrombocytopenia|is|an|adverse|immune-mediated|heparin|,|resulting|. (l_nsubj) thrombocytopenia_1\NN\14189204|heparin-induced|hit
D006493_D013921 CID heparin_11\NN\2718259|to (r_nmod) reaction_9\NN\13446390|thrombocytopenia|is|an|adverse|immune-mediated|heparin|,|resulting|. (l_nsubj) thrombocytopenia_1\NN\14189204|heparin-induced|hit (l_appos) hit_3\NN\36762|(|)
D006493_D013921 CID 4/heparin-reactive_10\JJ\1740|factor (r_amod) antibody_11\NN\14728724|4/heparin-reactive|antibody (r_compound) positivity_16\NN\13856574|antibody|patients (r_conj) frequencies_1\NNS\15286249|the|hit|transplantation|and|positivity (l_nmod) hit_3\NN\36762|of
D006493_D013921 CID 4/heparin-reactive_10\JJ\1740|factor (r_amod) antibody_11\NN\14728724|4/heparin-reactive|antibody (l_appos) antibody_14\NN\14728724|(|hit|) (l_compound) hit_13\NN\36762|
D006493_D013921 CID ufh-related_5\JJ\1740| (r_amod) hit_6\NN\36762|ufh-related
D006493_D013927 NONE sodium_4\NN\14625458|unfractionated|heparin|ufh|or|heparin (r_nsubjpass) used_16\VBN\1156834|sodium|is|protocols|institutions|prevent (l_advcl) prevent_24\VB\1740|to|thrombosis (l_dobj) thrombosis_25\NN\14100769|transplantation
D006493_D013927 NONE ufh_6\NN\1740|(|) (r_appos) sodium_4\NN\14625458|unfractionated|heparin|ufh|or|heparin (r_nsubjpass) used_16\VBN\1156834|sodium|is|protocols|institutions|prevent (l_advcl) prevent_24\VB\1740|to|thrombosis (l_dobj) thrombosis_25\NN\14100769|transplantation
D006495_D013927 NONE heparin_11\NN\2718259|weight|lmwh (r_conj) sodium_4\NN\14625458|unfractionated|heparin|ufh|or|heparin (r_nsubjpass) used_16\VBN\1156834|sodium|is|protocols|institutions|prevent (l_advcl) prevent_24\VB\1740|to|thrombosis (l_dobj) thrombosis_25\NN\14100769|transplantation
D006493_D001791 NONE heparin-induced_1\JJ\1740| (r_amod) test_4\NN\5798043|the|heparin-induced|platelet|aggregation (l_compound) aggregation_3\NN\31264|
12911170
D002939_D009395 CID ciprofloxacin-induced_0\JJ\1740| (r_amod) nephritis_3\NN\14113228|ciprofloxacin-induced|acute|interstitial|and|anemia|.
D002939_D009395 CID ciprofloxacin_0\NN\2716866| (r_nsubjpass) associated_3\VBN\628491|ciprofloxacin|has|been|effects|. (l_nmod) effects_7\NNS\13245626|with|several|side|nephritis (l_nmod) nephritis_10\NN\14113228|including|interstitial|and|anemia
D002939_D009395 CID ciprofloxacin-induced_9\JJ\1740| (r_amod) nephritis_11\NN\14113228|of|ciprofloxacin-induced|interstitial|and|anemia
D002939_D000744 NONE ciprofloxacin-induced_0\JJ\1740| (r_amod) nephritis_3\NN\14113228|ciprofloxacin-induced|acute|interstitial|and|anemia|. (l_conj) anemia_7\NN\14189204|autoimmune|hemolytic
D002939_D000744 NONE ciprofloxacin-induced_9\JJ\1740| (r_amod) nephritis_11\NN\14113228|of|ciprofloxacin-induced|interstitial|and|anemia (l_conj) anemia_15\NN\14189204|autoimmune|hemolytic
D002939_D000743 CID ciprofloxacin_0\NN\2716866| (r_nsubjpass) associated_3\VBN\628491|ciprofloxacin|has|been|effects|. (l_nmod) effects_7\NNS\13245626|with|several|side|nephritis (l_nmod) nephritis_10\NN\14113228|including|interstitial|and|anemia (l_conj) anemia_13\NN\14189204|hemolytic
D013256_D000743 NONE steroid_10\NN\14727670| (r_compound) therapy_11\NN\657604|of|steroid (r_nmod) initiation_8\NN\7450842|therapy (r_conj) stopping_4\VBG\2452885|after|drug|and|initiation (r_advcl) improved_2\VBD\126264|anemia|stopping|. (l_nsubj) anemia_1\NN\14189204|hemolytic
591536
D006493_D013923 NONE heparin_6\NN\2718259| (r_compound) therapy_7\NN\657604|systemic|heparin (r_dobj) receiving_4\VBG\2210855|therapy (r_acl) patients_3\NNS\9898892|in|receiving (r_nmod) thromboembolism_1\NN\14100769|arterial|patients|:|complication
D006493_D013923 NONE heparin-induced_13\JJ\1740| (r_amod) thrombocytopenia_14\NN\14189204|with|heparin-induced (r_nmod) associated_11\VBN\628491|thrombocytopenia (r_acl) complication_10\NN\1073995|a|associated|. (r_dep) thromboembolism_1\NN\14100769|arterial|patients|:|complication
D006493_D013923 NONE heparin_8\NN\2718259| (r_compound) therapy_9\NN\657604|of|systemic|heparin (r_nmod) complication_5\NN\1073995|thromboembolism|is|a|recognized|therapy|. (l_nsubj) thromboembolism_1\NN\14100769|arterial
D006493_D013923 NONE heparin-induced_8\JJ\1740| (r_amod) aggregation_10\NN\31264|factor|is|heparin-induced|platelet|. (l_nsubj) factor_2\NN\7326557|the|common|relating (l_acl) relating_3\VBG\628491|thromboembolism (l_dobj) thromboembolism_4\NN\14100769|and|thrombocytopenia
D006493_D013921 CID heparin_6\NN\2718259| (r_compound) therapy_7\NN\657604|systemic|heparin (r_dobj) receiving_4\VBG\2210855|therapy (r_acl) patients_3\NNS\9898892|in|receiving (r_nmod) thromboembolism_1\NN\14100769|arterial|patients|:|complication (l_dep) complication_10\NN\1073995|a|associated|. (l_acl) associated_11\VBN\628491|thrombocytopenia (l_nmod) thrombocytopenia_14\NN\14189204|with|heparin-induced
D006493_D013921 CID heparin-induced_13\JJ\1740| (r_amod) thrombocytopenia_14\NN\14189204|with|heparin-induced
D006493_D013921 CID heparin_22\NN\2718259| (r_compound) therapy_23\NN\657604|of|heparin (r_nmod) initiation_20\NN\7450842|the|therapy (r_dobj) occurring_13\VBG\2623529|after|initiation (r_acl) ischemia_12\NN\14195315|with|distal|occurring (r_nmod) occlusion_6\NN\14081375|characteristic|is|arterial|thrombi|ischemia|,|preceded|. (l_acl) preceded_25\VBN\2690708|thrombocytopenia (l_nmod) thrombocytopenia_28\NN\14189204|by|profound|counts
D006493_D013921 CID heparin-induced_8\JJ\1740| (r_amod) aggregation_10\NN\31264|factor|is|heparin-induced|platelet|. (l_nsubj) factor_2\NN\7326557|the|common|relating (l_acl) relating_3\VBG\628491|thromboembolism (l_dobj) thromboembolism_4\NN\14100769|and|thrombocytopenia (l_conj) thrombocytopenia_6\NN\14189204|
D006493_D001157 CID heparin_22\NN\2718259| (r_compound) therapy_23\NN\657604|of|heparin (r_nmod) initiation_20\NN\7450842|the|therapy (r_dobj) occurring_13\VBG\2623529|after|initiation (r_acl) ischemia_12\NN\14195315|with|distal|occurring (r_nmod) occlusion_6\NN\14081375|characteristic|is|arterial|thrombi|ischemia|,|preceded|.
D006493_D013927 NONE heparin_22\NN\2718259| (r_compound) therapy_23\NN\657604|of|heparin (r_nmod) initiation_20\NN\7450842|the|therapy (r_dobj) occurring_13\VBG\2623529|after|initiation (r_acl) ischemia_12\NN\14195315|with|distal|occurring (r_nmod) occlusion_6\NN\14081375|characteristic|is|arterial|thrombi|ischemia|,|preceded|. (l_nmod) thrombi_9\NNS\5402091|by|platelet-fibrin
D006493_D007511 NONE heparin_22\NN\2718259| (r_compound) therapy_23\NN\657604|of|heparin (r_nmod) initiation_20\NN\7450842|the|therapy (r_dobj) occurring_13\VBG\2623529|after|initiation (r_acl) ischemia_12\NN\14195315|with|distal|occurring
D006493_D001791 NONE heparin-induced_8\JJ\1740| (r_amod) aggregation_10\NN\31264|factor|is|heparin-induced|platelet|.
19674115
D011718_D000857 CID pyrazinamide_4\NN\1740|by (r_nmod) induced_2\VBN\1627355|pyrazinamide (r_acl) dysosmia_1\NN\14052403|recurrent|induced|.
D011718_D000857 CID pyrazinamide_10\NN\1740|to (r_nmod) related_8\JJ\1740|pyrazinamide (r_amod) disorder_7\NN\14034177|of|reversible|olfactory|related
D011718_D000857 CID pyrazinamide_4\NN\1740| (r_compound) withdrawal_5\NN\7206096|after|pyrazinamide (r_nmod) disappeared_1\VBD\2609764|dysosmia|completely|withdrawal|and|recurred|. (l_nsubj) dysosmia_0\NN\14052403|
D011718_D056486 NONE pyrazinamide_0\NN\1740| (r_nsubj) have_2\VB\2108377|pyrazinamide|can|effects|. (l_dobj) effects_4\NNS\13245626|adverse|toxicity (l_nmod) toxicity_8\NN\13576101|such|hepatic|,|hyperuricemia
D011718_D033461 NONE pyrazinamide_0\NN\1740| (r_nsubj) have_2\VB\2108377|pyrazinamide|can|effects|. (l_dobj) effects_4\NNS\13245626|adverse|toxicity (l_nmod) toxicity_8\NN\13576101|such|hepatic|,|hyperuricemia (l_conj) hyperuricemia_10\NN\1740|or|disorders
6615052
D006493_D013921 CID heparin-induced_0\JJ\1740| (r_amod) thrombocytopenia_1\NN\14189204|heparin-induced|,|thrombosis|.
D006493_D013921 CID heparin-induced_4\JJ\1740| (r_amod) thrombocytopenia_5\NN\14189204|with|a|heparin-induced
D006493_D013927 NONE heparin-induced_0\JJ\1740| (r_amod) thrombocytopenia_1\NN\14189204|heparin-induced|,|thrombosis|. (l_conj) thrombosis_3\NN\14100769|,|and|hemorrhage
D006493_D006470 CID heparin-induced_0\JJ\1740| (r_amod) thrombocytopenia_1\NN\14189204|heparin-induced|,|thrombosis|. (l_conj) thrombosis_3\NN\14100769|,|and|hemorrhage (l_conj) hemorrhage_6\NN\14285662|
D006493_D006470 CID heparin_17\NN\2718259| (r_dobj) receiving_16\VBG\2210855|heparin (r_acl) patients_15\NNS\9898892|in|receiving (r_nmod) hemorrhage_6\NN\14285662|or|,|frequently|,|events|patients
D006493_D013923 CID heparin_17\NN\2718259| (r_dobj) receiving_16\VBG\2210855|heparin (r_acl) patients_15\NNS\9898892|in|receiving (r_nmod) hemorrhage_6\NN\14285662|or|,|frequently|,|events|patients (l_conj) events_13\NNS\23100|thromboembolic (l_amod) thromboembolic_12\JJ\1740|
D006493_D001791 NONE heparin_12\NN\2718259|to (r_nmod) resistance_10\NN\37396|increased|heparin|,|and|aggregation (r_conj) count_7\NN\13582013|a|falling|platelet|,|resistance
D006493_D001791 NONE heparin_24\NN\2718259| (r_nsubjpass) added_26\VBN\156601|when|heparin|is (r_advcl) revealed_3\VBN\2137132|testing|has|count|added|. (l_dobj) count_7\NN\13582013|a|falling|platelet|,|resistance
D006493_D001791 NONE heparin_15\NN\2718259| (r_dobj) receiving_14\VBG\2210855|while|patient|is|heparin (r_advcl) falls_4\VBZ\1835496|if|count|100,000/mm3|,|receiving (r_advcl) indicated_28\VBN\952524|falls|,|testing|,|is|. (l_nsubjpass) testing_19\NN\639556|platelet|aggregation|,|using (l_compound) aggregation_18\NN\31264|
8268147
D010396_D017285 CID d-penicillamine_13\NN\1740|with (r_nmod) treated_11\VBN\2376958|d-penicillamine (r_acl) patient_6\NN\9898892|in|a|cirrhosis|treated (r_nmod) polymyositis_3\NN\14350292|of|patient
D010396_D017285 CID d-penicillamine_10\NN\1740| (r_compound) treatment_11\NN\654885|of|d-penicillamine (r_nmod) complications_8\NNS\1073995|of|the|autoimmune|treatment (r_nmod) one_4\CD\13741022|as|complications (r_nmod) develop_2\VB\1753788|polymyositis/dermatomyositis|can|one|,|but|remains (l_nsubj) polymyositis/dermatomyositis_0\NN\1740|
D010396_D017285 CID d-penicillamine_14\NN\1740| (r_compound) therapy_15\NN\657604|d-penicillamine (r_dobj) receiving_13\VBG\2210855|while|therapy (r_advcl) developed_10\VBD\1753788|who|polymyositis|receiving (l_dobj) polymyositis_11\NN\14350292|
D010396_D017285 CID d-penicillamine_2\NN\1740| (r_compound) therapy_3\NN\657604|d-penicillamine (r_dobj) receiving_1\VBG\2210855|therapy (r_acl) patients_0\NNS\9898892|receiving (r_nsubjpass) followed_6\VBN\1835496|patients|should|be|carefully|development|. (l_nmod) development_10\NN\248977|for|the|complications (l_nmod) complications_13\NNS\1073995|of|autoimmune|polymyositis/dermatomyositis (l_nmod) polymyositis/dermatomyositis_15\NN\1740|like
D010396_D008105 NONE d-penicillamine_13\NN\1740|with (r_nmod) treated_11\VBN\2376958|d-penicillamine (r_acl) patient_6\NN\9898892|in|a|cirrhosis|treated (l_nmod) cirrhosis_10\NN\14116321|with|primary|biliary
D010396_D008105 NONE d-penicillamine_14\NN\1740| (r_compound) therapy_15\NN\657604|d-penicillamine (r_dobj) receiving_13\VBG\2210855|while|therapy (r_advcl) developed_10\VBD\1753788|who|polymyositis|receiving (r_acl:relcl) patient_3\NN\9898892|a|cirrhosis|,|developed (l_nmod) cirrhosis_7\NN\14116321|with|primary|biliary
D010396_D012216 NONE d-penicillamine_1\NN\1740| (r_nsubjpass) used_4\VBN\1156834|although|d-penicillamine|has|been|diseases (l_nmod) diseases_8\NNS\14061805|for|many|rheumatologic
D010396_D064420 NONE d-penicillamine_1\NN\1740| (r_nsubjpass) used_4\VBN\1156834|although|d-penicillamine|has|been|diseases (r_advcl) limits_11\VBZ\2510337|used|,|toxicity|usefulness|. (l_nsubj) toxicity_10\NN\13576101|
D010396_D003882 NONE d-penicillamine_10\NN\1740| (r_compound) treatment_11\NN\654885|of|d-penicillamine (r_nmod) complications_8\NNS\1073995|of|the|autoimmune|treatment (r_nmod) one_4\CD\13741022|as|complications (r_nmod) develop_2\VB\1753788|polymyositis/dermatomyositis|can|one|,|but|remains (l_nsubj) polymyositis/dermatomyositis_0\NN\1740|
D010396_D003882 NONE d-penicillamine_2\NN\1740| (r_compound) therapy_3\NN\657604|d-penicillamine (r_dobj) receiving_1\VBG\2210855|therapy (r_acl) patients_0\NNS\9898892|receiving (r_nsubjpass) followed_6\VBN\1835496|patients|should|be|carefully|development|. (l_nmod) development_10\NN\248977|for|the|complications (l_nmod) complications_13\NNS\1073995|of|autoimmune|polymyositis/dermatomyositis (l_nmod) polymyositis/dermatomyositis_15\NN\1740|like
3686155
D001971_D011605 CID bromocriptine_4\NN\1740|by (r_nmod) induced_2\VBN\1627355|bromocriptine (r_acl) psychosis_1\NN\14380140|postpartum|induced|.
D001971_D011605 CID bromocriptine_16\NN\1740| (r_dobj) received_15\VBN\2210855|having|bromocriptine|inhibition (r_advcl) seen_9\VBN\2106506|patients|were|psychosis|,|received|. (l_nmod) psychosis_12\NN\14380140|with|postpartum
D001971_D011605 CID bromocriptine_0\NN\1740|given (r_nsubjpass) associated_7\VBN\628491|bromocriptine|has|been|psychosis|. (l_nmod) psychosis_9\NN\14380140|with|patients
D001971_D011605 CID bromocriptine_4\NN\1740| (r_nsubj) cause_6\VB\1617192|that|bromocriptine|may|psychosis|given (l_dobj) psychosis_7\NN\14380140|
D001971_D001523 NONE bromocriptine_16\NN\1740| (r_dobj) received_15\VBN\2210855|having|bromocriptine|inhibition (r_advcl) seen_9\VBN\2106506|patients|were|psychosis|,|received|. (l_nsubjpass) patients_2\NNS\9898892|two|multigravida|history (l_nmod) history_7\NN\15120823|with|no|prior|psychiatric (l_amod) psychiatric_6\JJ\1740|
D001971_D007775 NONE bromocriptine_16\NN\1740| (r_dobj) received_15\VBN\2210855|having|bromocriptine|inhibition (l_nmod) inhibition_18\NN\1068773|for|lactation (l_nmod) lactation_20\NN\15113229|of
D001971_D010300 NONE bromocriptine_0\NN\1740|given (r_nsubjpass) associated_7\VBN\628491|bromocriptine|has|been|psychosis|. (l_nmod) psychosis_9\NN\14380140|with|patients (l_nmod) patients_11\NNS\9898892|in|receiving (l_acl) receiving_12\VBG\2210855|drug (l_dobj) drug_14\NN\14778436|the|disease (l_nmod) disease_18\NN\14061805|for|parkinson|'s
458486
D063325_D004409 NONE tiapride_0\NN\1740|movements|. (l_nmod) movements_4\NNS\191142|in|levodopa-induced|involuntary
D063325_D004409 NONE tiapride_0\NN\1740|,|derivative|, (r_nsubj) reduced_11\VBD\441445|tiapride|movements|patients|. (l_dobj) movements_16\NNS\191142|dose|involuntary
D007980_D004409 CID levodopa-induced_2\JJ\1740| (r_amod) movements_4\NNS\191142|in|levodopa-induced|involuntary
D007980_D004409 CID levodopa-induced_12\JJ\1740| (r_amod) dose_14\NN\3740161|levodopa-induced|peak (r_compound) movements_16\NNS\191142|dose|involuntary
D007980_D004409 CID levodopa-induced_8\JJ\1740| (r_amod) dyskinesias_9\NNS\14084880|levodopa-induced
D063325_D010300 NONE tiapride_0\NN\1740|,|derivative|, (r_nsubj) reduced_11\VBD\441445|tiapride|movements|patients|. (l_nmod) patients_19\NNS\9898892|in|16|disease (l_nmod) disease_24\NN\14061805|with|parkinson|'s
C037689_D004409 NONE benzamide_4\NN\1740| (r_compound) derivative_5\NN\5802185|a|substituted|benzamide|related (r_appos) tiapride_0\NN\1740|,|derivative|, (r_nsubj) reduced_11\VBD\441445|tiapride|movements|patients|. (l_dobj) movements_16\NNS\191142|dose|involuntary
C037689_D010300 NONE benzamide_4\NN\1740| (r_compound) derivative_5\NN\5802185|a|substituted|benzamide|related (r_appos) tiapride_0\NN\1740|,|derivative|, (r_nsubj) reduced_11\VBD\441445|tiapride|movements|patients|. (l_nmod) patients_19\NNS\9898892|in|16|disease (l_nmod) disease_24\NN\14061805|with|parkinson|'s
D008787_D004409 NONE metoclopramide_9\NN\1740|to (r_nmod) related_7\JJ\1740|closely|metoclopramide (r_amod) derivative_5\NN\5802185|a|substituted|benzamide|related (r_appos) tiapride_0\NN\1740|,|derivative|, (r_nsubj) reduced_11\VBD\441445|tiapride|movements|patients|. (l_dobj) movements_16\NNS\191142|dose|involuntary
D008787_D010300 NONE metoclopramide_9\NN\1740|to (r_nmod) related_7\JJ\1740|closely|metoclopramide (r_amod) derivative_5\NN\5802185|a|substituted|benzamide|related (r_appos) tiapride_0\NN\1740|,|derivative|, (r_nsubj) reduced_11\VBD\441445|tiapride|movements|patients|. (l_nmod) patients_19\NNS\9898892|in|16|disease (l_nmod) disease_24\NN\14061805|with|parkinson|'s
D007980_D010300 NONE levodopa-induced_12\JJ\1740| (r_amod) dose_14\NN\3740161|levodopa-induced|peak (r_compound) movements_16\NNS\191142|dose|involuntary (r_dobj) reduced_11\VBD\441445|tiapride|movements|patients|. (l_nmod) patients_19\NNS\9898892|in|16|disease (l_nmod) disease_24\NN\14061805|with|parkinson|'s
D063325_D004421 NONE tiapride_0\NN\1740| (r_nsubj) had_1\VBD\2108377|tiapride|effect|. (l_dobj) effect_3\NN\34213|no|morning (l_nmod) morning_7\NN\15113229|on|levodopa-induced|early|dystonia (l_nmod) dystonia_13\NN\1740|of|"|off-period|"|segmental
D007980_D004421 NONE levodopa-induced_5\JJ\1740| (r_amod) morning_7\NN\15113229|on|levodopa-induced|early|dystonia (l_nmod) dystonia_13\NN\1740|of|"|off-period|"|segmental
D004298_D004409 NONE dopamine_19\NN\14807737| (r_compound) receptors_20\NNS\5225602|of|dopamine (r_nmod) group_17\NN\2137|of|a|separate|receptors (r_nmod) overstimulation_13\NN\1740|by|group (r_nmod) caused_11\VBN\1617192|that|dyskinesias|are|overstimulation (l_nsubjpass) dyskinesias_9\NNS\14084880|levodopa-induced
3535719
D009428_D064420 NONE netilmicin_5\NN\1740|of|and|tobramycin (r_nmod) efficacy_1\NN\5199286|relative|and|toxicity|netilmicin|patients|. (l_conj) toxicity_3\NN\13576101|
D014031_D064420 NONE tobramycin_7\NN\2716866| (r_conj) netilmicin_5\NN\1740|of|and|tobramycin (r_nmod) efficacy_1\NN\5199286|relative|and|toxicity|netilmicin|patients|. (l_conj) toxicity_3\NN\13576101|
D009428_D007239 NONE sulfate_9\NN\15010703|of|netilmicin|or|sulfate (r_nmod) efficacy_4\NN\5199286|the|and|safety|sulfate|conjunction|patients (l_nmod) patients_21\NNS\9898892|in|118|immunocompromised|infections (l_nmod) infections_25\NNS\14052046|with|presumed|severe
D014031_D007239 NONE sulfate_12\NN\15010703|tobramycin (r_conj) sulfate_9\NN\15010703|of|netilmicin|or|sulfate (r_nmod) efficacy_4\NN\5199286|the|and|safety|sulfate|conjunction|patients (l_nmod) patients_21\NNS\9898892|in|118|immunocompromised|infections (l_nmod) infections_25\NNS\14052046|with|presumed|severe
D010878_D007239 NONE sodium_17\NN\14625458|with|piperacillin (r_nmod) conjunction_14\NN\5048123|in|sodium (r_nmod) efficacy_4\NN\5199286|the|and|safety|sulfate|conjunction|patients (l_nmod) patients_21\NNS\9898892|in|118|immunocompromised|infections (l_nmod) infections_25\NNS\14052046|with|presumed|severe
D009428_D007674 CID netilmicin_10\NN\1740|with|and|tobramycin (r_nmod) treated_8\VBN\2376958|netilmicin (r_acl) patients_7\NNS\9898892|in|treated (r_nmod) proportion_5\NN\13824815|in|a|similar|patients (r_nmod) occurred_1\VBD\2623529|nephrotoxicity|proportion|%|. (l_nsubj) nephrotoxicity_0\NN\1740|
D014031_D007674 CID tobramycin_12\NN\2716866| (r_conj) netilmicin_10\NN\1740|with|and|tobramycin (r_nmod) treated_8\VBN\2376958|netilmicin (r_acl) patients_7\NNS\9898892|in|treated (r_nmod) proportion_5\NN\13824815|in|a|similar|patients (r_nmod) occurred_1\VBD\2623529|nephrotoxicity|proportion|%|. (l_nsubj) nephrotoxicity_0\NN\1740|
D009428_D006311 CID netilmicin_10\NN\1740|of|42|and|piperacillin (r_nmod) four_3\CD\13741022|in|%|netilmicin|and|12 (r_nmod) occurred_1\VBD\2623529|ototoxicity|four|. (l_nsubj) ototoxicity_0\NN\1740|
D009428_D006311 CID netilmicin_13\NN\1740|with (r_nmod) reversible_11\JJ\1740|often|netilmicin|than (r_conj) severe_7\JJ\1740|that|ototoxicity|was|less|and|reversible (l_nsubj) ototoxicity_4\NN\1740|aminoglycoside-associated
D010878_D006311 CID piperacillin_12\NN\3910033| (r_conj) netilmicin_10\NN\1740|of|42|and|piperacillin (r_nmod) four_3\CD\13741022|in|%|netilmicin|and|12 (r_nmod) occurred_1\VBD\2623529|ototoxicity|four|. (l_nsubj) ototoxicity_0\NN\1740|
D010878_D006311 CID piperacillin-treated_24\JJ\1740| (r_conj) tobramycin_22\NN\2716866|and|piperacillin-treated (r_compound) patients_25\NNS\9898892|of|54|tobramycin (r_nmod) 12_15\CD\13745420|in|%|patients (r_conj) four_3\CD\13741022|in|%|netilmicin|and|12 (r_nmod) occurred_1\VBD\2623529|ototoxicity|four|. (l_nsubj) ototoxicity_0\NN\1740|
D014031_D006311 CID tobramycin_22\NN\2716866|and|piperacillin-treated (r_compound) patients_25\NNS\9898892|of|54|tobramycin (r_nmod) 12_15\CD\13745420|in|%|patients (r_conj) four_3\CD\13741022|in|%|netilmicin|and|12 (r_nmod) occurred_1\VBD\2623529|ototoxicity|four|. (l_nsubj) ototoxicity_0\NN\1740|
D014031_D006311 CID tobramycin_16\NN\2716866|with (r_nmod) than_14\IN\1740|tobramycin (r_prep) reversible_11\JJ\1740|often|netilmicin|than (r_conj) severe_7\JJ\1740|that|ototoxicity|was|less|and|reversible (l_nsubj) ototoxicity_4\NN\1740|aminoglycoside-associated
D000617_D006311 NONE aminoglycoside-associated_3\JJ\1740| (r_amod) ototoxicity_4\NN\1740|aminoglycoside-associated
16428827
C004742_D000647 NONE daidzein_0\NN\1740| (r_nsubj) activates_1\VBZ\1641914|daidzein|acetyltransferase|and|improves|. (l_conj) improves_8\VBZ\126264|amnesia (l_dobj) amnesia_10\NN\5669934|drug-induced
C004742_D000647 NONE daidzein_2\NN\1740|of|weight (r_nmod) administration_0\NN\1133281|daidzein|mice (r_nsubjpass) shown_12\VBN\2137132|administration|was|significantly|reverse|,|results|. (l_xcomp) reverse_15\VB\109660|to|amnesia (l_dobj) amnesia_17\NN\5669934|scopolamine-induced
C004742_D000647 NONE daidzein_4\NN\1740| (r_nsubj) play_6\VB\1072262|that|daidzein|might|role|activator|,|and|ameliorates (l_conj) ameliorates_21\VBZ\126264|that|it|also|amnesia (l_dobj) amnesia_23\NN\5669934|scopolamine-induced
D002794_D000647 NONE choline_2\NN\15090742| (r_compound) acetyltransferase_3\NN\1740|choline|cells (r_dobj) activates_1\VBZ\1641914|daidzein|acetyltransferase|and|improves|. (l_conj) improves_8\VBZ\126264|amnesia (l_dobj) amnesia_10\NN\5669934|drug-induced
D002794_D000544 NONE choline_1\NN\15090742| (r_compound) acetyltransferase_2\NN\1740|choline|chat (r_compound) activator_6\NN\19613|the|acetyltransferase|,|enhances|, (r_nsubj) factor_28\NN\7326557|activator|is|an|important|treatment|. (l_nmod) treatment_31\NN\654885|in|the|disease (l_nmod) disease_35\NN\14061805|of|alzheimer|'s|ad
D002794_D000544 NONE choline_1\NN\15090742| (r_compound) acetyltransferase_2\NN\1740|choline|chat (r_compound) activator_6\NN\19613|the|acetyltransferase|,|enhances|, (r_nsubj) factor_28\NN\7326557|activator|is|an|important|treatment|. (l_nmod) treatment_31\NN\654885|in|the|disease (l_nmod) disease_35\NN\14061805|of|alzheimer|'s|ad (l_appos) ad_37\NN\7247071|(|)
D000109_D000544 NONE acetylcholine_20\NN\14807558|of|ach (r_nmod) production_18\NN\30358|of|the|enzymatic|acetylcholine (r_nmod) augmentation_14\NN\7356676|via|an|production (r_nmod) enhances_9\VBZ\227165|which|transmission|augmentation (r_acl:relcl) activator_6\NN\19613|the|acetyltransferase|,|enhances|, (r_nsubj) factor_28\NN\7326557|activator|is|an|important|treatment|. (l_nmod) treatment_31\NN\654885|in|the|disease (l_nmod) disease_35\NN\14061805|of|alzheimer|'s|ad
D000109_D000544 NONE acetylcholine_20\NN\14807558|of|ach (r_nmod) production_18\NN\30358|of|the|enzymatic|acetylcholine (r_nmod) augmentation_14\NN\7356676|via|an|production (r_nmod) enhances_9\VBZ\227165|which|transmission|augmentation (r_acl:relcl) activator_6\NN\19613|the|acetyltransferase|,|enhances|, (r_nsubj) factor_28\NN\7326557|activator|is|an|important|treatment|. (l_nmod) treatment_31\NN\654885|in|the|disease (l_nmod) disease_35\NN\14061805|of|alzheimer|'s|ad (l_appos) ad_37\NN\7247071|(|)
D000109_D000544 NONE ach_22\NN\1740|(|) (r_appos) acetylcholine_20\NN\14807558|of|ach (r_nmod) production_18\NN\30358|of|the|enzymatic|acetylcholine (r_nmod) augmentation_14\NN\7356676|via|an|production (r_nmod) enhances_9\VBZ\227165|which|transmission|augmentation (r_acl:relcl) activator_6\NN\19613|the|acetyltransferase|,|enhances|, (r_nsubj) factor_28\NN\7326557|activator|is|an|important|treatment|. (l_nmod) treatment_31\NN\654885|in|the|disease (l_nmod) disease_35\NN\14061805|of|alzheimer|'s|ad
D000109_D000544 NONE ach_22\NN\1740|(|) (r_appos) acetylcholine_20\NN\14807558|of|ach (r_nmod) production_18\NN\30358|of|the|enzymatic|acetylcholine (r_nmod) augmentation_14\NN\7356676|via|an|production (r_nmod) enhances_9\VBZ\227165|which|transmission|augmentation (r_acl:relcl) activator_6\NN\19613|the|acetyltransferase|,|enhances|, (r_nsubj) factor_28\NN\7326557|activator|is|an|important|treatment|. (l_nmod) treatment_31\NN\654885|in|the|disease (l_nmod) disease_35\NN\14061805|of|alzheimer|'s|ad (l_appos) ad_37\NN\7247071|(|)
C004742_D007859 NONE daidzein_7\NN\1740|of|thunbergiana (r_nmod) effects_5\NNS\13245626|the|daidzein|impairments (l_nmod) impairments_13\NNS\7296428|on|scopolamine-induced|learning (l_nmod) learning_15\NN\5701944|of|and|memory (l_conj) memory_17\NN\5926676|
C004742_D008569 NONE daidzein_7\NN\1740|of|thunbergiana (r_nmod) effects_5\NNS\13245626|the|daidzein|impairments (l_nmod) impairments_13\NNS\7296428|on|scopolamine-induced|learning (l_nmod) learning_15\NN\5701944|of|and|memory (l_conj) memory_17\NN\5926676|
D012601_D007859 NONE scopolamine-induced_12\JJ\1740| (r_amod) impairments_13\NNS\7296428|on|scopolamine-induced|learning (l_nmod) learning_15\NN\5701944|of|and|memory (l_conj) memory_17\NN\5926676|
D012601_D008569 NONE scopolamine-induced_12\JJ\1740| (r_amod) impairments_13\NNS\7296428|on|scopolamine-induced|learning (l_nmod) learning_15\NN\5701944|of|and|memory (l_conj) memory_17\NN\5926676|
D012601_D000647 CID scopolamine-induced_16\JJ\1740| (r_amod) amnesia_17\NN\5669934|scopolamine-induced
D012601_D000647 CID scopolamine-induced_22\JJ\1740| (r_amod) amnesia_23\NN\5669934|scopolamine-induced
D000109_D000647 NONE acetylcholine_10\NN\14807558| (r_compound) biosynthesis_11\NN\13565379|in|acetylcholine (r_nmod) role_8\NN\719494|a|biosynthesis (r_dobj) play_6\VB\1072262|that|daidzein|might|role|activator|,|and|ameliorates (l_conj) ameliorates_21\VBZ\126264|that|it|also|amnesia (l_dobj) amnesia_23\NN\5669934|scopolamine-induced
8111719
D007069_D006212 CID ifosfamide-induced_2\JJ\1740| (r_amod) neurotoxicity_3\NN\1740|ifosfamide-induced (r_conj) hallucinations_0\NNS\14376855|and|neurotoxicity|.
D007069_D006212 CID ifosfamide_18\NN\1740|of (r_nmod) effect_16\NN\34213|hallucinations|are|a|known|side|ifosfamide (l_nsubj) hallucinations_2\NNS\14376855|symptom
D007069_D006212 CID ifosfamide-induced_3\JJ\1740| (r_amod) hallucinations_4\NNS\14376855|of|ifosfamide-induced
D007069_D006212 CID ifosfamide-induced_8\NN\1740| (r_amod) hallucinations_9\NNS\14376855|with|ifosfamide-induced
D007069_D006212 CID ifosfamide-induced_7\JJ\1740| (r_amod) hallucinations_8\NNS\14376855|for|possible|ifosfamide-induced|,|occur
D007069_D020258 NONE ifosfamide-induced_2\JJ\1740| (r_amod) neurotoxicity_3\NN\1740|ifosfamide-induced
D007069_D020258 NONE ifosfamide_18\NN\1740|of (r_nmod) effect_16\NN\34213|hallucinations|are|a|known|side|ifosfamide (l_nsubj) hallucinations_2\NNS\14376855|symptom (l_nmod) symptom_5\NN\5823932|as|a|neurotoxicity (l_nmod) neurotoxicity_8\NN\1740|of|central
D007069_D020258 NONE ifosfamide-induced_7\JJ\1740| (r_amod) hallucinations_8\NNS\14376855|for|possible|ifosfamide-induced|,|occur (l_acl:relcl) occur_12\VB\2623529|which|may|signs (l_nmod) signs_15\NNS\6643763|without|other|neurotoxicity (l_nmod) neurotoxicity_17\NN\1740|of
D006220_D011595 NONE haloperidol_10\NN\3713736|(|i.e.|,|) (r_appos) neuroleptics_6\NNS\4470232|high-potency|haloperidol (r_nsubj) effective_14\JJ\1740|becomes|,|neuroleptics|may|be|. (l_advcl) becomes_2\VBZ\146138|if|agitation|marked (l_nsubj) agitation_1\NN\14373582|
18356633
D000583_D007674 CID amikacin_3\NN\1740| (r_compound) nephrotoxicity_4\NN\1740|of|amikacin|population
D000583_D007674 CID amikacin-associated_2\JJ\1740| (r_amod) nephrotoxicity_3\NN\1740|amikacin-associated|population
D000583_D007674 CID amikacin_17\NN\1740| (r_compound) concentrations_19\NNS\4916342|via|amikacin|serum|pathogens (r_nmod) efficacy_15\NN\5199286|of|concentrations (r_nmod) evaluation_13\NN\874067|efficacy (r_conj) occurrence_1\NN\29378|the|nephrotoxicity|means|and|evaluation (l_nmod) nephrotoxicity_3\NN\1740|of
D000583_D009503 NONE amikacin_0\NN\1740| (r_nsubj) aminoglycoside_3\NN\1740|amikacin|is|an|used|. (l_acl) used_5\VBN\1156834|commonly|provide (l_xcomp) provide_7\VB\2199590|to|treatment (l_dobj) treatment_11\NN\654885|empirical|double|gram-negative|neutropenia (l_nmod) neutropenia_14\NN\14196405|for|febrile|and|infections
D000583_D007239 NONE amikacin_0\NN\1740| (r_nsubj) aminoglycoside_3\NN\1740|amikacin|is|an|used|. (l_acl) used_5\VBN\1156834|commonly|provide (l_xcomp) provide_7\VB\2199590|to|treatment (l_dobj) treatment_11\NN\654885|empirical|double|gram-negative|neutropenia (l_nmod) neutropenia_14\NN\14196405|for|febrile|and|infections (l_conj) infections_18\NNS\14052046|other|suspected
D000617_D009503 NONE aminoglycoside_3\NN\1740|amikacin|is|an|used|. (l_acl) used_5\VBN\1156834|commonly|provide (l_xcomp) provide_7\VB\2199590|to|treatment (l_dobj) treatment_11\NN\654885|empirical|double|gram-negative|neutropenia (l_nmod) neutropenia_14\NN\14196405|for|febrile|and|infections
D000617_D007239 NONE aminoglycoside_3\NN\1740|amikacin|is|an|used|. (l_acl) used_5\VBN\1156834|commonly|provide (l_xcomp) provide_7\VB\2199590|to|treatment (l_dobj) treatment_11\NN\654885|empirical|double|gram-negative|neutropenia (l_nmod) neutropenia_14\NN\14196405|for|febrile|and|infections (l_conj) infections_18\NNS\14052046|other|suspected
D000617_D006402 NONE aminoglycoside_15\NN\1740|with|an (r_nmod) treatment_12\NN\654885|aminoglycoside (r_dobj) required_11\VBD\754942|that|treatment (r_acl:relcl) diagnosis_4\NN\152018|with|a|consistent|required (l_amod) consistent_5\JJ\1740|disorder (l_nmod) disorder_9\NN\14034177|with|a|hematologic/oncologic
D000617_D009369 NONE aminoglycoside_15\NN\1740|with|an (r_nmod) treatment_12\NN\654885|aminoglycoside (r_dobj) required_11\VBD\754942|that|treatment (r_acl:relcl) diagnosis_4\NN\152018|with|a|consistent|required (l_amod) consistent_5\JJ\1740|disorder (l_nmod) disorder_9\NN\14034177|with|a|hematologic/oncologic
D000583_D006402 NONE amikacin_23\NN\1740|to|conventional (r_nmod) randomized_17\VBN\278117|patients|were|amikacin|. (l_nsubjpass) patients_1\NNS\9898892|forty|diagnosis (l_nmod) diagnosis_4\NN\152018|with|a|consistent|required (l_amod) consistent_5\JJ\1740|disorder (l_nmod) disorder_9\NN\14034177|with|a|hematologic/oncologic
D000583_D009369 NONE amikacin_23\NN\1740|to|conventional (r_nmod) randomized_17\VBN\278117|patients|were|amikacin|. (l_nsubjpass) patients_1\NNS\9898892|forty|diagnosis (l_nmod) diagnosis_4\NN\152018|with|a|consistent|required (l_amod) consistent_5\JJ\1740|disorder (l_nmod) disorder_9\NN\14034177|with|a|hematologic/oncologic
D003404_D007674 NONE creatinine_11\NN\1740|in|serum (r_nmod) increase_8\NN\13576355|of|an|creatinine (r_nmod) means_5\NNS\44150|by|increase (r_nmod) occurrence_1\NN\29378|the|nephrotoxicity|means|and|evaluation (l_nmod) nephrotoxicity_3\NN\1740|of
10414674
D007660_D013345 NONE ketoprofen_13\NN\3828465|either|,|mg|,|times|group|or|nsaid|starting (r_dobj) receive_11\VB\2210855|to|ketoprofen (r_xcomp) randomized_9\VBN\278117|patients|were|receive|. (l_nsubjpass) patients_0\NNS\9898892|hemorrhage (l_nmod) hemorrhage_4\NN\14285662|with|aneurysmal|subarachnoid|sah
D007660_D013345 NONE ketoprofen_13\NN\3828465|either|,|mg|,|times|group|or|nsaid|starting (r_dobj) receive_11\VB\2210855|to|ketoprofen (r_xcomp) randomized_9\VBN\278117|patients|were|receive|. (l_nsubjpass) patients_0\NNS\9898892|hemorrhage (l_nmod) hemorrhage_4\NN\14285662|with|aneurysmal|subarachnoid|sah (l_appos) sah_6\NN\1740|(|)
D007660_D013345 NONE ketoprofen_13\NN\3828465|either|,|mg|,|times|group|or|nsaid|starting (l_acl) starting_52\VBG\2009433|diagnosis (l_dobj) diagnosis_56\NN\152018|immediately|after|the|sah (l_nmod) sah_59\NN\1740|of|aneurysmal
D007660_D013345 NONE ketoprofen_23\NN\3828465| (r_compound) group_24\NN\2137|(|ketoprofen|,|=|) (r_dep) ketoprofen_13\NN\3828465|either|,|mg|,|times|group|or|nsaid|starting (r_dobj) receive_11\VB\2210855|to|ketoprofen (r_xcomp) randomized_9\VBN\278117|patients|were|receive|. (l_nsubjpass) patients_0\NNS\9898892|hemorrhage (l_nmod) hemorrhage_4\NN\14285662|with|aneurysmal|subarachnoid|sah
D007660_D013345 NONE ketoprofen_23\NN\3828465| (r_compound) group_24\NN\2137|(|ketoprofen|,|=|) (r_dep) ketoprofen_13\NN\3828465|either|,|mg|,|times|group|or|nsaid|starting (r_dobj) receive_11\VB\2210855|to|ketoprofen (r_xcomp) randomized_9\VBN\278117|patients|were|receive|. (l_nsubjpass) patients_0\NNS\9898892|hemorrhage (l_nmod) hemorrhage_4\NN\14285662|with|aneurysmal|subarachnoid|sah (l_appos) sah_6\NN\1740|(|)
D007660_D013345 NONE ketoprofen_23\NN\3828465| (r_compound) group_24\NN\2137|(|ketoprofen|,|=|) (r_dep) ketoprofen_13\NN\3828465|either|,|mg|,|times|group|or|nsaid|starting (l_acl) starting_52\VBG\2009433|diagnosis (l_dobj) diagnosis_56\NN\152018|immediately|after|the|sah (l_nmod) sah_59\NN\1740|of|aneurysmal
D007660_D013345 NONE ketoprofen_0\NN\3828465|not|acetaminophen (r_nsubj) impaired_4\VBD\258857|ketoprofen|function|. (l_dobj) function_6\NN\13783581|platelet|patients (l_nmod) patients_8\NNS\9898892|in|sah (l_nmod) sah_10\NN\1740|with
D007660_D017542 NONE ketoprofen_13\NN\3828465|either|,|mg|,|times|group|or|nsaid|starting (l_acl) starting_52\VBG\2009433|diagnosis (l_dobj) diagnosis_56\NN\152018|immediately|after|the|sah (l_nmod) sah_59\NN\1740|of|aneurysmal (l_amod) aneurysmal_58\JJ\1740|
D007660_D017542 NONE ketoprofen_23\NN\3828465| (r_compound) group_24\NN\2137|(|ketoprofen|,|=|) (r_dep) ketoprofen_13\NN\3828465|either|,|mg|,|times|group|or|nsaid|starting (l_acl) starting_52\VBG\2009433|diagnosis (l_dobj) diagnosis_56\NN\152018|immediately|after|the|sah (l_nmod) sah_59\NN\1740|of|aneurysmal (l_amod) aneurysmal_58\JJ\1740|
D000082_D013345 NONE acetaminophen_35\NN\2707683|,|g (r_appos) nsaid_33\NN\2721538|a|weak|,|acetaminophen|,|times|group (r_conj) ketoprofen_13\NN\3828465|either|,|mg|,|times|group|or|nsaid|starting (r_dobj) receive_11\VB\2210855|to|ketoprofen (r_xcomp) randomized_9\VBN\278117|patients|were|receive|. (l_nsubjpass) patients_0\NNS\9898892|hemorrhage (l_nmod) hemorrhage_4\NN\14285662|with|aneurysmal|subarachnoid|sah
D000082_D013345 NONE acetaminophen_35\NN\2707683|,|g (r_appos) nsaid_33\NN\2721538|a|weak|,|acetaminophen|,|times|group (r_conj) ketoprofen_13\NN\3828465|either|,|mg|,|times|group|or|nsaid|starting (r_dobj) receive_11\VB\2210855|to|ketoprofen (r_xcomp) randomized_9\VBN\278117|patients|were|receive|. (l_nsubjpass) patients_0\NNS\9898892|hemorrhage (l_nmod) hemorrhage_4\NN\14285662|with|aneurysmal|subarachnoid|sah (l_appos) sah_6\NN\1740|(|)
D000082_D013345 NONE acetaminophen_35\NN\2707683|,|g (r_appos) nsaid_33\NN\2721538|a|weak|,|acetaminophen|,|times|group (r_conj) ketoprofen_13\NN\3828465|either|,|mg|,|times|group|or|nsaid|starting (l_acl) starting_52\VBG\2009433|diagnosis (l_dobj) diagnosis_56\NN\152018|immediately|after|the|sah (l_nmod) sah_59\NN\1740|of|aneurysmal
D000082_D013345 NONE acetaminophen_45\NN\2707683| (r_compound) group_46\NN\2137|(|acetaminophen|,|= (r_dep) nsaid_33\NN\2721538|a|weak|,|acetaminophen|,|times|group (r_conj) ketoprofen_13\NN\3828465|either|,|mg|,|times|group|or|nsaid|starting (r_dobj) receive_11\VB\2210855|to|ketoprofen (r_xcomp) randomized_9\VBN\278117|patients|were|receive|. (l_nsubjpass) patients_0\NNS\9898892|hemorrhage (l_nmod) hemorrhage_4\NN\14285662|with|aneurysmal|subarachnoid|sah
D000082_D013345 NONE acetaminophen_45\NN\2707683| (r_compound) group_46\NN\2137|(|acetaminophen|,|= (r_dep) nsaid_33\NN\2721538|a|weak|,|acetaminophen|,|times|group (r_conj) ketoprofen_13\NN\3828465|either|,|mg|,|times|group|or|nsaid|starting (r_dobj) receive_11\VB\2210855|to|ketoprofen (r_xcomp) randomized_9\VBN\278117|patients|were|receive|. (l_nsubjpass) patients_0\NNS\9898892|hemorrhage (l_nmod) hemorrhage_4\NN\14285662|with|aneurysmal|subarachnoid|sah (l_appos) sah_6\NN\1740|(|)
D000082_D013345 NONE acetaminophen_45\NN\2707683| (r_compound) group_46\NN\2137|(|acetaminophen|,|= (r_dep) nsaid_33\NN\2721538|a|weak|,|acetaminophen|,|times|group (r_conj) ketoprofen_13\NN\3828465|either|,|mg|,|times|group|or|nsaid|starting (l_acl) starting_52\VBG\2009433|diagnosis (l_dobj) diagnosis_56\NN\152018|immediately|after|the|sah (l_nmod) sah_59\NN\1740|of|aneurysmal
D000082_D013345 NONE acetaminophen_3\NN\2707683| (r_conj) ketoprofen_0\NN\3828465|not|acetaminophen (r_nsubj) impaired_4\VBD\258857|ketoprofen|function|. (l_dobj) function_6\NN\13783581|platelet|patients (l_nmod) patients_8\NNS\9898892|in|sah (l_nmod) sah_10\NN\1740|with
D000082_D017542 NONE acetaminophen_35\NN\2707683|,|g (r_appos) nsaid_33\NN\2721538|a|weak|,|acetaminophen|,|times|group (r_conj) ketoprofen_13\NN\3828465|either|,|mg|,|times|group|or|nsaid|starting (l_acl) starting_52\VBG\2009433|diagnosis (l_dobj) diagnosis_56\NN\152018|immediately|after|the|sah (l_nmod) sah_59\NN\1740|of|aneurysmal (l_amod) aneurysmal_58\JJ\1740|
D000082_D017542 NONE acetaminophen_45\NN\2707683| (r_compound) group_46\NN\2137|(|acetaminophen|,|= (r_dep) nsaid_33\NN\2721538|a|weak|,|acetaminophen|,|times|group (r_conj) ketoprofen_13\NN\3828465|either|,|mg|,|times|group|or|nsaid|starting (l_acl) starting_52\VBG\2009433|diagnosis (l_dobj) diagnosis_56\NN\152018|immediately|after|the|sah (l_nmod) sah_59\NN\1740|of|aneurysmal (l_amod) aneurysmal_58\JJ\1740|
D000244_D001791 NONE diphosphate_9\NN\1740|of|adenosine (r_nmod) microm_6\NN\1740|by|6|diphosphate (r_nmod) induced_3\VBN\1627355|microm (r_acl) aggregation_2\NN\31264|maximal|platelet|induced
D007660_D001791 CID ketoprofen_14\NN\3828465|of (r_nmod) administration_12\NN\1133281|after|ketoprofen (r_nmod) decreased_10\VBD\169651|aggregation|administration|. (l_nsubj) aggregation_2\NN\31264|maximal|platelet|induced
D000082_D001791 NONE acetaminophen_9\NN\2707683| (r_compound) group_10\NN\2137|in|the|acetaminophen (r_nmod) increased_6\VBD\169651|contrast|,|aggregation|group|day|compared|p|. (l_nsubj) aggregation_5\NN\31264|maximal|platelet
D000082_D001791 NONE acetaminophen_9\NN\2707683| (r_compound) group_10\NN\2137|in|the|acetaminophen (r_nmod) increased_6\VBD\169651|contrast|,|aggregation|group|day|compared|p|. (l_advcl) compared_17\VBN\644583|as|results (l_nmod) results_23\NNS\34213|with|the|pretreatment|aggregation (l_compound) aggregation_22\NN\31264|platelet
D007660_D006406 CID ketoprofen_4\NN\3828465| (r_compound) group_5\NN\2137|in|the|ketoprofen (r_nmod) patient_1\NN\9898892|one|group (r_nsubj) developed_6\VBD\1753788|patient|hematoma|. (l_dobj) hematoma_10\NN\14317720|a|postoperative|intracranial
D007660_D002532 NONE ketoprofen_1\NN\3828465| (r_nsubjpass) used_3\VBN\1156834|if|ketoprofen|is|surgery (l_nmod) surgery_5\NN\6045562|before|aneurysms (l_nmod) aneurysms_9\NNS\14057371|on|cerebral|artery
D007660_D006470 NONE ketoprofen_1\NN\3828465| (r_nsubjpass) used_3\VBN\1156834|if|ketoprofen|is|surgery (r_advcl) pose_13\VB\2620587|used|,|it|may|factor|. (l_dobj) factor_17\NN\7326557|an|additional|risk|hemorrhage (l_nmod) hemorrhage_19\NN\14285662|for
20042557
D015742_D003693 CID propofol_40\NN\1740| (r_compound) sedation_41\NN\14034177|with|propofol (r_nmod) anesthesia_38\NN\14034177|under|spinal|sedation (r_nmod) underwent_32\VBD\109660|who|repair|anesthesia (r_acl:relcl) delirium_27\NN\14391660|without|preoperative|or|dementia|underwent
D015742_D003693 CID propofol_6\NN\1740| (r_compound) sedation_7\NN\14034177|of|light|propofol (r_nmod) use_3\NN\407535|the|sedation (r_nsubj) decreased_8\VBD\169651|use|prevalence|%|sedation|. (l_dobj) prevalence_10\NN\4764412|the|delirium (l_nmod) delirium_13\NN\14391660|of|postoperative
D015742_D003704 NONE propofol_40\NN\1740| (r_compound) sedation_41\NN\14034177|with|propofol (r_nmod) anesthesia_38\NN\14034177|under|spinal|sedation (r_nmod) underwent_32\VBD\109660|who|repair|anesthesia (r_acl:relcl) delirium_27\NN\14391660|without|preoperative|or|dementia|underwent (l_conj) dementia_30\NN\14395018|severe
D015742_D006620 NONE propofol_40\NN\1740| (r_compound) sedation_41\NN\14034177|with|propofol (r_nmod) anesthesia_38\NN\14034177|under|spinal|sedation (r_nmod) underwent_32\VBD\109660|who|repair|anesthesia (l_dobj) repair_35\NN\248977|hip|fracture (l_compound) fracture_34\NN\14285662|
D015742_D011183 CID propofol_6\NN\1740| (r_compound) sedation_7\NN\14034177|of|light|propofol (r_nmod) use_3\NN\407535|the|sedation (r_nsubj) decreased_8\VBD\169651|use|prevalence|%|sedation|. (l_dobj) prevalence_10\NN\4764412|the|delirium (l_nmod) delirium_13\NN\14391660|of|postoperative
7542793
D016572_D007674 CID a_3\NN\13649268|of|cyclosporin|and|fk506 (r_nmod) nephrotoxicity_0\NN\1740|a|:|inhibition|.
D016572_D007674 CID csa_8\NN\1740|of|and|fk506 (r_nmod) effects_6\NNS\13245626|the|nephrotoxic|csa (l_amod) nephrotoxic_5\JJ\1740|
D016559_D007674 CID fk506_5\NN\1740| (r_conj) a_3\NN\13649268|of|cyclosporin|and|fk506 (r_nmod) nephrotoxicity_0\NN\1740|a|:|inhibition|.
D016559_D007674 CID fk506_10\NN\1740| (r_conj) csa_8\NN\1740|of|and|fk506 (r_nmod) effects_6\NNS\13245626|the|nephrotoxic|csa (l_amod) nephrotoxic_5\JJ\1740|
D016572_D006984 NONE a_1\NN\13649268|cyclosporin|csa|, (r_nsubj) caused_29\VBD\1617192|a|reduction|. (l_dobj) reduction_31\NN\351485|a|rate|,|changes|,|and|hypertrophy|rats|given (l_conj) hypertrophy_45\NN\14365950|apparatus
D016572_D006984 NONE csa_3\NN\1740|(|;|mg/kg|)|and|fujimycine|,|not|rapamycin (r_appos) a_1\NN\13649268|cyclosporin|csa|, (r_nsubj) caused_29\VBD\1617192|a|reduction|. (l_dobj) reduction_31\NN\351485|a|rate|,|changes|,|and|hypertrophy|rats|given (l_conj) hypertrophy_45\NN\14365950|apparatus
D016559_D006984 NONE fujimycine_9\NN\1740|fk506 (r_conj) csa_3\NN\1740|(|;|mg/kg|)|and|fujimycine|,|not|rapamycin (r_appos) a_1\NN\13649268|cyclosporin|csa|, (r_nsubj) caused_29\VBD\1617192|a|reduction|. (l_dobj) reduction_31\NN\351485|a|rate|,|changes|,|and|hypertrophy|rats|given (l_conj) hypertrophy_45\NN\14365950|apparatus
D016559_D006984 NONE fk506_11\NN\1740|(|;|mg/kg|) (r_appos) fujimycine_9\NN\1740|fk506 (r_conj) csa_3\NN\1740|(|;|mg/kg|)|and|fujimycine|,|not|rapamycin (r_appos) a_1\NN\13649268|cyclosporin|csa|, (r_nsubj) caused_29\VBD\1617192|a|reduction|. (l_dobj) reduction_31\NN\351485|a|rate|,|changes|,|and|hypertrophy|rats|given (l_conj) hypertrophy_45\NN\14365950|apparatus
D018942_D006984 NONE macrolide_21\NN\1740|related|immunosuppressant (r_compound) rapamycin_23\NN\1740|the|macrolide|mg/kg (r_conj) csa_3\NN\1740|(|;|mg/kg|)|and|fujimycine|,|not|rapamycin (r_appos) a_1\NN\13649268|cyclosporin|csa|, (r_nsubj) caused_29\VBD\1617192|a|reduction|. (l_dobj) reduction_31\NN\351485|a|rate|,|changes|,|and|hypertrophy|rats|given (l_conj) hypertrophy_45\NN\14365950|apparatus
D020123_D006984 NONE rapamycin_23\NN\1740|the|macrolide|mg/kg (r_conj) csa_3\NN\1740|(|;|mg/kg|)|and|fujimycine|,|not|rapamycin (r_appos) a_1\NN\13649268|cyclosporin|csa|, (r_nsubj) caused_29\VBD\1617192|a|reduction|. (l_dobj) reduction_31\NN\351485|a|rate|,|changes|,|and|hypertrophy|rats|given (l_conj) hypertrophy_45\NN\14365950|apparatus
D016572_D064420 NONE csa_4\NN\1740|and|fk506 (r_compound) toxicity_7\NN\13576101|of|csa
D016559_D064420 NONE fk506_6\NN\1740| (r_conj) csa_4\NN\1740|and|fk506 (r_compound) toxicity_7\NN\13576101|of|csa
7282516
D004317_D009202 CID doxorubicin_5\NN\2716866| (r_compound) cardiomyopathy_6\NN\14103288|in|doxorubicin
D004317_D009202 CID doxorubicin_10\NN\2716866|dxr (r_dep) drug_9\NN\14778436|by|the|anticancer|doxorubicin (r_nmod) produced_5\VBN\1617192|drug (r_acl) cardiomyopathy_1\NN\14103288|the|cm|produced
D004317_D009202 CID doxorubicin_10\NN\2716866|dxr (r_dep) drug_9\NN\14778436|by|the|anticancer|doxorubicin (r_nmod) produced_5\VBN\1617192|drug (r_acl) cardiomyopathy_1\NN\14103288|the|cm|produced (l_appos) cm_3\NN\13649268|(|)
D004317_D009202 CID doxorubicin_10\NN\2716866|dxr (r_dep) drug_9\NN\14778436|by|the|anticancer|doxorubicin (r_nmod) produced_5\VBN\1617192|drug (r_acl) cardiomyopathy_1\NN\14103288|the|cm|produced (r_nsubj) provides_17\VBZ\2199590|cardiomyopathy|opportunity|. (l_dobj) opportunity_20\NN\14481929|a|unique|analyze (l_acl) analyze_22\VB\78760|to|relationships|development (l_nmod) development_28\NN\248977|during|disease (l_nmod) disease_31\NN\14061805|of|myocardial
D004317_D009202 CID dxr_12\NN\1740|(|)|adriamycin (r_appos) doxorubicin_10\NN\2716866|dxr (r_dep) drug_9\NN\14778436|by|the|anticancer|doxorubicin (r_nmod) produced_5\VBN\1617192|drug (r_acl) cardiomyopathy_1\NN\14103288|the|cm|produced
D004317_D009202 CID dxr_12\NN\1740|(|)|adriamycin (r_appos) doxorubicin_10\NN\2716866|dxr (r_dep) drug_9\NN\14778436|by|the|anticancer|doxorubicin (r_nmod) produced_5\VBN\1617192|drug (r_acl) cardiomyopathy_1\NN\14103288|the|cm|produced (l_appos) cm_3\NN\13649268|(|)
D004317_D009202 CID dxr_12\NN\1740|(|)|adriamycin (r_appos) doxorubicin_10\NN\2716866|dxr (r_dep) drug_9\NN\14778436|by|the|anticancer|doxorubicin (r_nmod) produced_5\VBN\1617192|drug (r_acl) cardiomyopathy_1\NN\14103288|the|cm|produced (r_nsubj) provides_17\VBZ\2199590|cardiomyopathy|opportunity|. (l_dobj) opportunity_20\NN\14481929|a|unique|analyze (l_acl) analyze_22\VB\78760|to|relationships|development (l_nmod) development_28\NN\248977|during|disease (l_nmod) disease_31\NN\14061805|of|myocardial
D004317_D009202 CID adriamycin_15\NN\1740|(|) (r_appos) dxr_12\NN\1740|(|)|adriamycin (r_appos) doxorubicin_10\NN\2716866|dxr (r_dep) drug_9\NN\14778436|by|the|anticancer|doxorubicin (r_nmod) produced_5\VBN\1617192|drug (r_acl) cardiomyopathy_1\NN\14103288|the|cm|produced
D004317_D009202 CID adriamycin_15\NN\1740|(|) (r_appos) dxr_12\NN\1740|(|)|adriamycin (r_appos) doxorubicin_10\NN\2716866|dxr (r_dep) drug_9\NN\14778436|by|the|anticancer|doxorubicin (r_nmod) produced_5\VBN\1617192|drug (r_acl) cardiomyopathy_1\NN\14103288|the|cm|produced (l_appos) cm_3\NN\13649268|(|)
D004317_D009202 CID adriamycin_15\NN\1740|(|) (r_appos) dxr_12\NN\1740|(|)|adriamycin (r_appos) doxorubicin_10\NN\2716866|dxr (r_dep) drug_9\NN\14778436|by|the|anticancer|doxorubicin (r_nmod) produced_5\VBN\1617192|drug (r_acl) cardiomyopathy_1\NN\14103288|the|cm|produced (r_nsubj) provides_17\VBZ\2199590|cardiomyopathy|opportunity|. (l_dobj) opportunity_20\NN\14481929|a|unique|analyze (l_acl) analyze_22\VB\78760|to|relationships|development (l_nmod) development_28\NN\248977|during|disease (l_nmod) disease_31\NN\14061805|of|myocardial
D004317_D009202 CID dxr-cm_1\NN\1740|
D004317_D009202 CID dxr-cm_1\NN\1740| (r_compound) damage_3\NN\7296428|in|dxr-cm|myocardial
D004317_D009202 CID dxr_13\NN\1740| (r_compound) dose_14\NN\3740161|(|dxr|) (r_appos) insult_11\NN\6714976|of|cytotoxic|dose (r_nmod) degree_8\NN\4916342|to|the|insult (r_nmod) proportional_5\JJ\1740|damage|is|degree|preserved|. (l_nsubj) damage_3\NN\7296428|in|dxr-cm|myocardial (l_compound) dxr-cm_1\NN\1740|
D004317_D009202 CID dxr_13\NN\1740| (r_compound) dose_14\NN\3740161|(|dxr|) (r_appos) insult_11\NN\6714976|of|cytotoxic|dose (r_nmod) degree_8\NN\4916342|to|the|insult (r_nmod) proportional_5\JJ\1740|damage|is|degree|preserved|. (l_nsubj) damage_3\NN\7296428|in|dxr-cm|myocardial
3934126
D014640_D007239 NONE vancomycin_0\NN\2716866| (r_nsubj) curative_2\JJ\1740|vancomycin|was|%|. (l_nmod) %_5\NN\1740|in|95|patients (l_nmod) patients_8\NNS\9898892|of|43|infection (l_nmod) infection_11\NN\14052046|with|proven
D014640_D007239 NONE vancomycin_3\NN\2716866|,|administered (r_nsubj) constitutes_8\VBZ\1647229|that|vancomycin|,|therapy (l_dobj) therapy_12\NN\657604|safe|,|effective|infections (l_nmod) infections_14\NNS\14052046|for|caused
D000617_D013924 NONE aminoglycoside_18\NN\1740|an|plus|vancomycin (r_dobj) receiving_16\VBG\2210855|aminoglycoside (r_acl) patients_15\NNS\9898892|to|receiving (r_nmod) confined_13\VBN\2510337|occurred|nephrotoxicity|were|patients|. (l_ccomp) occurred_1\VBD\2623529|thrombophlebitis|infusion|; (l_nsubj) thrombophlebitis_0\NN\14352890|
D000617_D007674 NONE aminoglycoside_18\NN\1740|an|plus|vancomycin (r_dobj) receiving_16\VBG\2210855|aminoglycoside (r_acl) patients_15\NNS\9898892|to|receiving (r_nmod) confined_13\VBN\2510337|occurred|nephrotoxicity|were|patients|. (l_nsubjpass) nephrotoxicity_9\NN\1740|and|ototoxicity
D000617_D006311 NONE aminoglycoside_18\NN\1740|an|plus|vancomycin (r_dobj) receiving_16\VBG\2210855|aminoglycoside (r_acl) patients_15\NNS\9898892|to|receiving (r_nmod) confined_13\VBN\2510337|occurred|nephrotoxicity|were|patients|. (l_nsubjpass) nephrotoxicity_9\NN\1740|and|ototoxicity (l_conj) ototoxicity_11\NN\1740|
D014640_D013924 CID vancomycin_20\NN\2716866| (r_conj) aminoglycoside_18\NN\1740|an|plus|vancomycin (r_dobj) receiving_16\VBG\2210855|aminoglycoside (r_acl) patients_15\NNS\9898892|to|receiving (r_nmod) confined_13\VBN\2510337|occurred|nephrotoxicity|were|patients|. (l_ccomp) occurred_1\VBD\2623529|thrombophlebitis|infusion|; (l_nsubj) thrombophlebitis_0\NN\14352890|
D014640_D007674 NONE vancomycin_20\NN\2716866| (r_conj) aminoglycoside_18\NN\1740|an|plus|vancomycin (r_dobj) receiving_16\VBG\2210855|aminoglycoside (r_acl) patients_15\NNS\9898892|to|receiving (r_nmod) confined_13\VBN\2510337|occurred|nephrotoxicity|were|patients|. (l_nsubjpass) nephrotoxicity_9\NN\1740|and|ototoxicity
D014640_D006311 CID vancomycin_20\NN\2716866| (r_conj) aminoglycoside_18\NN\1740|an|plus|vancomycin (r_dobj) receiving_16\VBG\2210855|aminoglycoside (r_acl) patients_15\NNS\9898892|to|receiving (r_nmod) confined_13\VBN\2510337|occurred|nephrotoxicity|were|patients|. (l_nsubjpass) nephrotoxicity_9\NN\1740|and|ototoxicity (l_conj) ototoxicity_11\NN\1740|
11271907
D003520_D006470 CID cyclophosphamide_5\NN\1740| (r_compound) therapy_6\NN\657604|to|cyclophosphamide (r_nmod) secondary_3\JJ\1740|therapy (r_amod) myocarditis_2\NN\14338942|fatal|haemorrhagic|secondary|.
D003520_D006470 CID cyclophosphamide_9\NN\1740| (r_compound) therapy_10\NN\657604|of|cyclophosphamide (r_nmod) complication_7\NN\1073995|myocarditis|is|a|rare|therapy|. (l_nsubj) myocarditis_1\NN\14338942|haemorrhagic
D003520_D009205 CID cyclophosphamide_5\NN\1740| (r_compound) therapy_6\NN\657604|to|cyclophosphamide (r_nmod) secondary_3\JJ\1740|therapy (r_amod) myocarditis_2\NN\14338942|fatal|haemorrhagic|secondary|.
D003520_D009205 CID cyclophosphamide_9\NN\1740| (r_compound) therapy_10\NN\657604|of|cyclophosphamide (r_nmod) complication_7\NN\1073995|myocarditis|is|a|rare|therapy|. (l_nsubj) myocarditis_1\NN\14338942|haemorrhagic
7565311
D016190_D058186 CID carboplatin_6\NN\1740| (r_compound) chemotherapy_7\NN\661091|in|dose|carboplatin (r_nmod) failure_2\NN\66216|acute|renal|chemotherapy|.
D016190_D058186 CID carboplatin_0\NN\1740| (r_nsubjpass) reported_3\VBN\831651|carboplatin|has|been|cause|. (l_xcomp) cause_5\VB\1617192|to|failure|administered (l_dobj) failure_8\NN\66216|acute|renal
D016190_D018233 NONE carboplatin_11\NN\1740|with|high-dose (r_nmod) treated_8\VBN\2376958|who|was|carboplatin|rhabdomyosarcoma (l_nmod) rhabdomyosarcoma_16\NN\14246359|for|metastatic|parameningeal|embryonal
2917114
D006024_D001919 NONE glycopyrronium_2\NN\1740|of|kg-1 (r_nmod) use_0\NN\407535|glycopyrronium (r_nsubj) provided_6\VBD\2199590|use|stability|and|,|given|,|sufficient|. (l_advcl) sufficient_20\JJ\1740|was|minimize (l_xcomp) minimize_22\VB\441445|to|bradycardias (l_dobj) bradycardias_26\NNS\14110674|early|,|edrophonium-induced
D004491_D001919 CID edrophonium_17\NN\1740|before|the (r_nmod) given_12\VBN\2327200|edrophonium (r_conj) provided_6\VBD\2199590|use|stability|and|,|given|,|sufficient|. (l_advcl) sufficient_20\JJ\1740|was|minimize (l_xcomp) minimize_22\VB\441445|to|bradycardias (l_dobj) bradycardias_26\NNS\14110674|early|,|edrophonium-induced
D004491_D001919 CID edrophonium-induced_25\JJ\1740| (r_amod) bradycardias_26\NNS\14110674|early|,|edrophonium-induced
12842176
D001556_D020258 NONE lindane_2\NN\14919948|of (r_nmod) effect_0\NN\34213|lindane|p450s|and|influence|. (l_conj) influence_10\NN\5190804|modulation|neurotoxicity (l_nmod) neurotoxicity_17\NN\1740|in|induced
D001556_D020258 NONE lindane_15\NN\14919948| (r_nmod:npmod) induced_16\JJ\1740|lindane (r_amod) neurotoxicity_17\NN\1740|in|induced
D008748_D012640 NONE 3-methylcholanthrene_9\NN\1740|of|mc|,|inducer (r_nmod) pretreatment_7\NN\1740|3-methylcholanthrene|, (r_nsubj) produce_21\VB\1617192|while|pretreatment|did|not|effect|incidence (l_nmod) incidence_27\NN\13821570|in|the|convulsions (l_nmod) convulsions_31\NNS\14081375|of|induced
D008748_D012640 NONE 3-methylcholanthrene_9\NN\1740|of|mc|,|inducer (r_nmod) pretreatment_7\NN\1740|3-methylcholanthrene|, (r_nsubj) produce_21\VB\1617192|while|pretreatment|did|not|effect|incidence (r_advcl) increased_57\VBD\169651|that|produce|,|pretreatment|significantly|incidence (l_dobj) incidence_59\NN\13821570|the|convulsions (l_nmod) convulsions_63\NNS\14081375|of|induced
D008748_D012640 NONE mc_11\NN\15286249|(|) (r_appos) 3-methylcholanthrene_9\NN\1740|of|mc|,|inducer (r_nmod) pretreatment_7\NN\1740|3-methylcholanthrene|, (r_nsubj) produce_21\VB\1617192|while|pretreatment|did|not|effect|incidence (l_nmod) incidence_27\NN\13821570|in|the|convulsions (l_nmod) convulsions_31\NNS\14081375|of|induced
D008748_D012640 NONE mc_11\NN\15286249|(|) (r_appos) 3-methylcholanthrene_9\NN\1740|of|mc|,|inducer (r_nmod) pretreatment_7\NN\1740|3-methylcholanthrene|, (r_nsubj) produce_21\VB\1617192|while|pretreatment|did|not|effect|incidence (r_advcl) increased_57\VBD\169651|that|produce|,|pretreatment|significantly|incidence (l_dobj) incidence_59\NN\13821570|the|convulsions (l_nmod) convulsions_63\NNS\14081375|of|induced
D001556_D012640 CID lindane_29\NN\14919948| (r_nmod:npmod) induced_30\JJ\1740|lindane (r_amod) convulsions_31\NNS\14081375|of|induced
D001556_D012640 CID lindane_29\NN\14919948| (r_nmod:npmod) induced_30\JJ\1740|lindane (r_amod) convulsions_31\NNS\14081375|of|induced (r_nmod) incidence_27\NN\13821570|in|the|convulsions (r_nmod) produce_21\VB\1617192|while|pretreatment|did|not|effect|incidence (r_advcl) increased_57\VBD\169651|that|produce|,|pretreatment|significantly|incidence (l_dobj) incidence_59\NN\13821570|the|convulsions (l_nmod) convulsions_63\NNS\14081375|of|induced
D001556_D012640 CID lindane_61\NN\14919948| (r_nmod:npmod) induced_62\JJ\1740|lindane (r_amod) convulsions_63\NNS\14081375|of|induced (r_nmod) incidence_59\NN\13821570|the|convulsions (r_dobj) increased_57\VBD\169651|that|produce|,|pretreatment|significantly|incidence (l_advcl) produce_21\VB\1617192|while|pretreatment|did|not|effect|incidence (l_nmod) incidence_27\NN\13821570|in|the|convulsions (l_nmod) convulsions_31\NNS\14081375|of|induced
D001556_D012640 CID lindane_61\NN\14919948| (r_nmod:npmod) induced_62\JJ\1740|lindane (r_amod) convulsions_63\NNS\14081375|of|induced
D001556_D012640 CID lindane_7\NN\14919948|of (r_nmod) metabolism_5\NN\13526110|the|p450-mediated|lindane (r_nsubjpass) blocked_9\VBN\1476483|when|metabolism|was|chloride (r_advcl) increased_17\VBN\169651|similarly|,|blocked|incidence|was|animals|indicating|. (l_nsubjpass) incidence_13\NN\13821570|convulsions (l_nmod) convulsions_15\NNS\14081375|of
D001556_D012640 CID lindane_22\NN\14919948|with (r_nmod) treated_20\VBN\2376958|lindane (r_acl) animals_19\NNS\4475|in|treated (r_nmod) increased_17\VBN\169651|similarly|,|blocked|incidence|was|animals|indicating|. (l_nsubjpass) incidence_13\NN\13821570|convulsions (l_nmod) convulsions_15\NNS\14081375|of
D001556_D012640 CID lindane_25\NN\14919948|se|metabolites (r_nsubjpass) involved_40\VBN\2676054|that|lindane|are|toxicity (r_ccomp) indicating_23\VBG\952524|involved (r_xcomp) increased_17\VBN\169651|similarly|,|blocked|incidence|was|animals|indicating|. (l_nsubjpass) incidence_13\NN\13821570|convulsions (l_nmod) convulsions_15\NNS\14081375|of
D010634_D012640 NONE phenobarbital_35\NN\2792049|with|pb|,|inducer|or|ethanol|, (r_nmod) pretreatment_33\NN\1740|phenobarbital (r_nsubj) increased_57\VBD\169651|that|produce|,|pretreatment|significantly|incidence (l_advcl) produce_21\VB\1617192|while|pretreatment|did|not|effect|incidence (l_nmod) incidence_27\NN\13821570|in|the|convulsions (l_nmod) convulsions_31\NNS\14081375|of|induced
D010634_D012640 NONE phenobarbital_35\NN\2792049|with|pb|,|inducer|or|ethanol|, (r_nmod) pretreatment_33\NN\1740|phenobarbital (r_nsubj) increased_57\VBD\169651|that|produce|,|pretreatment|significantly|incidence (l_dobj) incidence_59\NN\13821570|the|convulsions (l_nmod) convulsions_63\NNS\14081375|of|induced
D000431_D012640 NONE ethanol_46\NN\14708720|,|inducer (r_conj) phenobarbital_35\NN\2792049|with|pb|,|inducer|or|ethanol|, (r_nmod) pretreatment_33\NN\1740|phenobarbital (r_nsubj) increased_57\VBD\169651|that|produce|,|pretreatment|significantly|incidence (l_advcl) produce_21\VB\1617192|while|pretreatment|did|not|effect|incidence (l_nmod) incidence_27\NN\13821570|in|the|convulsions (l_nmod) convulsions_31\NNS\14081375|of|induced
D000431_D012640 NONE ethanol_46\NN\14708720|,|inducer (r_conj) phenobarbital_35\NN\2792049|with|pb|,|inducer|or|ethanol|, (r_nmod) pretreatment_33\NN\1740|phenobarbital (r_nsubj) increased_57\VBD\169651|that|produce|,|pretreatment|significantly|incidence (l_dobj) incidence_59\NN\13821570|the|convulsions (l_nmod) convulsions_63\NNS\14081375|of|induced
D000431_D012640 NONE ethanol_35\NN\14708720| (r_compound) isoenzymes_38\NNS\1740|ethanol|inducible|p450 (r_conj) pb_33\NN\14625458|by|or|isoenzymes (r_nmod) formed_31\VBN\1617192|pb (r_acl) metabolites_30\NNS\20090|its|formed (r_dep) lindane_25\NN\14919948|se|metabolites (r_nsubjpass) involved_40\VBN\2676054|that|lindane|are|toxicity (r_ccomp) indicating_23\VBG\952524|involved (r_xcomp) increased_17\VBN\169651|similarly|,|blocked|incidence|was|animals|indicating|. (l_nsubjpass) incidence_13\NN\13821570|convulsions (l_nmod) convulsions_15\NNS\14081375|of
D001556_D064420 NONE lindane_7\NN\14919948|of (r_nmod) metabolism_5\NN\13526110|the|p450-mediated|lindane (r_nsubjpass) blocked_9\VBN\1476483|when|metabolism|was|chloride (r_advcl) increased_17\VBN\169651|similarly|,|blocked|incidence|was|animals|indicating|. (l_xcomp) indicating_23\VBG\952524|involved (l_ccomp) involved_40\VBN\2676054|that|lindane|are|toxicity (l_nmod) toxicity_44\NN\13576101|in|its|neurobehavioral
D001556_D064420 NONE lindane_22\NN\14919948|with (r_nmod) treated_20\VBN\2376958|lindane (r_acl) animals_19\NNS\4475|in|treated (r_nmod) increased_17\VBN\169651|similarly|,|blocked|incidence|was|animals|indicating|. (l_xcomp) indicating_23\VBG\952524|involved (l_ccomp) involved_40\VBN\2676054|that|lindane|are|toxicity (l_nmod) toxicity_44\NN\13576101|in|its|neurobehavioral
D001556_D064420 NONE lindane_25\NN\14919948|se|metabolites (r_nsubjpass) involved_40\VBN\2676054|that|lindane|are|toxicity (l_nmod) toxicity_44\NN\13576101|in|its|neurobehavioral
C018021_D012640 NONE chloride_12\NN\14818238|by|cobalt (r_nmod) blocked_9\VBN\1476483|when|metabolism|was|chloride (r_advcl) increased_17\VBN\169651|similarly|,|blocked|incidence|was|animals|indicating|. (l_nsubjpass) incidence_13\NN\13821570|convulsions (l_nmod) convulsions_15\NNS\14081375|of
C018021_D064420 NONE chloride_12\NN\14818238|by|cobalt (r_nmod) blocked_9\VBN\1476483|when|metabolism|was|chloride (r_advcl) increased_17\VBN\169651|similarly|,|blocked|incidence|was|animals|indicating|. (l_xcomp) indicating_23\VBG\952524|involved (l_ccomp) involved_40\VBN\2676054|that|lindane|are|toxicity (l_nmod) toxicity_44\NN\13576101|in|its|neurobehavioral
D000431_D064420 NONE ethanol_35\NN\14708720| (r_compound) isoenzymes_38\NNS\1740|ethanol|inducible|p450 (r_conj) pb_33\NN\14625458|by|or|isoenzymes (r_nmod) formed_31\VBN\1617192|pb (r_acl) metabolites_30\NNS\20090|its|formed (r_dep) lindane_25\NN\14919948|se|metabolites (r_nsubjpass) involved_40\VBN\2676054|that|lindane|are|toxicity (l_nmod) toxicity_44\NN\13576101|in|its|neurobehavioral
15266362
D004280_D002312 NONE dobutamine_20\NN\1740| (r_compound) infusion_21\NN\14589223|with|dobutamine|and|drugs (r_nmod) managed_17\VBN\2524171|aggressively|infusion|assessed (r_conj) admitted_12\VBN\822367|patient|was|failure|and|managed|. (l_nsubjpass) patient_3\NN\9898892|the|47-year-old|female|,|known|, (l_acl) known_5\VBN\2110220|have (l_xcomp) have_7\VB\2108377|to|cardiomyopathy (l_dobj) cardiomyopathy_9\NN\14103288|hypertrophic
D004280_D018754 NONE dobutamine_20\NN\1740| (r_compound) infusion_21\NN\14589223|with|dobutamine|and|drugs (r_nmod) managed_17\VBN\2524171|aggressively|infusion|assessed (r_conj) admitted_12\VBN\822367|patient|was|failure|and|managed|. (l_nmod) failure_15\NN\66216|with|biventricular
D004280_D004342 CID dobutamine_13\NN\1740| (r_compound) therapy_15\NN\657604|to|dobutamine|infusion (r_nmod) related_11\JJ\1740|that|myocarditis|was|therapy (l_nsubj) myocarditis_9\NN\14338942|the|hypersensitivity|(|eosinophilic|) (l_compound) hypersensitivity_5\NN\14531772|
D004280_D004802 CID dobutamine_13\NN\1740| (r_compound) therapy_15\NN\657604|to|dobutamine|infusion (r_nmod) related_11\JJ\1740|that|myocarditis|was|therapy (l_nsubj) myocarditis_9\NN\14338942|the|hypersensitivity|(|eosinophilic|) (l_amod) eosinophilic_7\JJ\1740|
D004280_D009205 CID dobutamine_13\NN\1740| (r_compound) therapy_15\NN\657604|to|dobutamine|infusion (r_nmod) related_11\JJ\1740|that|myocarditis|was|therapy (l_nsubj) myocarditis_9\NN\14338942|the|hypersensitivity|(|eosinophilic|)
